PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Barbouche, R; Miquelis, R; Jones, IM; Fenouillet, E				Barbouche, R; Miquelis, R; Jones, IM; Fenouillet, E			Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MEMBRANE-FUSION; CHEMOKINE RECEPTORS; CD4; GP120; ENTRY; GLYCOSYLATION; SURFACE; CXCR4; IDENTIFICATION	The human immunodeficiency virus (HIV) envelope (Env) glycoprotein (gp) 120 is a highly disulfide-bonded molecule that attaches HIV to the lymphocyte surface receptors CD4 and CXCR4. Conformation changes within gp120 result from binding and trigger HIV/cell fusion. Inhibition of lymphocyte surface-associated protein-disulfide isomerase (PDI) blocks HIV/cell fusion, suggesting that redox changes within Env are required. Using a sensitive assay based on a thiol reagent, we show that (i) the thiol content of gp120, either secreted by mammalian cells or bound to a lymphocyte surface enabling CD4 but not CXCR4 binding, was 0.5-1 pmol SH/pmol gp120 (SH/gp120), whereas that of gp120 after its interaction with a surface enabling both CD4 and CXCR4 binding was raised to 4 SH/gp120; (ii) PDI inhibitors prevented this change; and (iii) gp120 displaying 2 SH/gp120 exhibited CD4 but not CXCR4 binding capacity. In addition, PDI inhibition did not impair gp120 binding to receptors. We conclude that on average two of the nine disulfides of gp120 are reduced during interaction with the lymphocyte surface after CXCR4 binding prior to fusion and that cell surface PDI catalyzes this process. Disulfide bond restructuring within Env may constitute the molecular basis of the post-receptor binding conformational changes that induce fusion competence.	Fac Med Nord, CNRS, F-13015 Marseille, France; Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Reading	Fenouillet, E (corresponding author), Fac Med Nord, CNRS, Blvd Pierre Dramard, F-13015 Marseille, France.	fenouillet.e@jean-roche.univ.mrs.fr						AVRIL LE, 1994, FEBS LETT, V345, P81, DOI 10.1016/0014-5793(94)00410-2; Barbouche R, 2000, VIROLOGY, V273, P169, DOI 10.1006/viro.2000.0368; Barbouche R, 2002, AIDS RES HUM RETROV, V18, P201, DOI 10.1089/08892220252781257; Barbouche R, 2000, FEMS MICROBIOL LETT, V183, P235, DOI 10.1111/j.1574-6968.2000.tb08964.x; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Couet J, 1996, BIOCHEMISTRY-US, V35, P14800, DOI 10.1021/bi961359w; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; Donoghue N, 2000, PROTEIN SCI, V9, P2436, DOI 10.1110/ps.9.12.2436; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Einfeld D, 1996, CURR TOP MICROBIOL, V214, P133; Fenouillet E, 2001, J INFECT DIS, V183, P744, DOI 10.1086/318823; FENOUILLET E, 1994, TRENDS BIOCHEM SCI, V19, P65, DOI 10.1016/0968-0004(94)90034-5; FENOUILLET E, 1989, J EXP MED, V169, P807, DOI 10.1084/jem.169.3.807; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Finnegan CM, 2001, J VIROL, V75, P11096, DOI 10.1128/JVI.75.22.11096-11105.2001; Gilbert HF, 1998, METHOD ENZYMOL, V290, P26, DOI 10.1016/S0076-6879(98)90005-2; Guthapfel R, 1996, EUR J BIOCHEM, V242, P315, DOI 10.1111/j.1432-1033.1996.0315r.x; Jiang XM, 1999, J BIOL CHEM, V274, P2416, DOI 10.1074/jbc.274.4.2416; KIDO H, 1991, FEBS LETT, V286, P233, DOI 10.1016/0014-5793(91)80981-8; KIENY MP, 1988, PROTEIN ENG, V2, P219; Kozak SL, 1999, J BIOL CHEM, V274, P23499, DOI 10.1074/jbc.274.33.23499; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; Matthias LJ, 2002, NAT IMMUNOL, V3, P727, DOI 10.1038/ni815; Mezghrani A, 2000, J BIOL CHEM, V275, P1920, DOI 10.1074/jbc.275.3.1920; Papandreou MJ, 2002, MOL PHARMACOL, V61, P186, DOI 10.1124/mol.61.1.186; Papandreou MJ, 1996, FEBS LETT, V379, P171, DOI 10.1016/0014-5793(95)01505-1; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Stathakis P, 1999, J BIOL CHEM, V274, P8910, DOI 10.1074/jbc.274.13.8910; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890; Zhou HP, 1999, ARCH BIOCHEM BIOPHYS, V369, P267, DOI 10.1006/abbi.1999.1368	40	133	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					3131	3136		10.1074/jbc.M205467200	http://dx.doi.org/10.1074/jbc.M205467200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12218052	hybrid			2022-12-25	WOS:000180915000047
J	Dormond, O; Bezzi, M; Mariotti, A; Ruegg, C				Dormond, O; Bezzi, M; Mariotti, A; Ruegg, C			Prostaglandin E-2 promotes integrin alpha(V)beta(3)-dependent endothelial cell adhesion, Rac-activation, and spreading through cAMP/PKA-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CANCER GROWTH; ANGIOGENESIS; MIGRATION; CYCLOOXYGENASE; INHIBITION; ALPHA-V-BETA-3; TRANSDUCTION; RECEPTORS; A(2)	We have recently reported that the inhibition of endothelial cell COX-2 by non-steroidal anti-inflammatory drugs suppresses alpha(V)beta(3)- (but not a(5)beta(1)-) dependent Rac activation, endothelial cell spreading, migration, and angiogenesis (Dormond, O., Foletti, A., Paroz, C., and Ruegg, C. (2001) Nat. MecL 7, 1041-1047). Here we investigated the role of the COX-2 metabolites PGE(2) and TXA2 in regulating human umbilical vein endothelial cell (HUVEC) adhesion and spreading. We report that PGE(2) accelerated alpha(V)beta(3)-mediated HUVEC adhesion and promoted Rac activation and cell spreading, whereas the TXA2 agonist U46619 retarded adhesion and inhibited spreading. We show that the cAMP level and the cAMP-regulated protein kinase A (PKA) activity are critical mediators of these PGE(2) effects. alpha(V)beta(3)-mediated adhesion induced a transient COX-2-dependent rise in cAMP levels, whereas the cell-permeable cAMP analogue 8-brcAMP accelerated adhesion, promoted Rac activation, and cell spreading in the presence of the COX-2 inhibitor NS-398. Pharmacological inhibition of PKA completely blocked alpha(V)beta(3)-mediated adhesion. A constitutively active Rac mutant (L61Rac) rescued alpha(V)beta(3)-dependent spreading in the presence of NS398 or U46691, but did not accelerate adhesion, whereas a dominant negative Rac mutant (N17Rac) suppressed spreading without affecting adhesion. alpha(5)beta(1)-mediated HUVEC adhesion, Rac activation, and spreading were not affected by PGE(2), U46691, 8-brcAAIEP, or the inhibition of PKA. In conclusion, these results demonstrate that PGE2 accelerates alpha(V)beta(3)-mediated endothelial cell adhesion through cAMP-dependent PKA activation and induces alpha(V)beta(3)-dependent spreading via cAMP- and PKA-dependent Rac activation and may contribute to the further understanding of the regulation of vascular integrins alpha(V)beta(3) by COX-2/PGE(2) during tumor angiogenesis and inflammation.	Univ Lausanne, Sch Med, CePO, CH-1011 Lausanne, Switzerland	University of Lausanne	Ruegg, C (corresponding author), Swiss Inst Expt Canc Res, Lab CePO, 155 Chemin Boveresses, CH-1066 Epalinges, Switzerland.	curzio.ruegg@isrec.unil.ch	Dormond, Olivier/B-5347-2017	Dormond, Olivier/0000-0002-6418-1782; Mariotti, Agnese/0000-0002-3704-7908				AUER KL, 1995, MOL BIOL CELL, V6, P1305, DOI 10.1091/mbc.6.10.1305; Bhattacharya S, 2001, AM J PHYSIOL-LUNG C, V280, pL1049, DOI 10.1152/ajplung.2001.280.5.L1049; Breyer MD, 2000, CURR OPIN NEPHROL HY, V9, P23, DOI 10.1097/00041552-200001000-00005; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Daniel TO, 1999, CANCER RES, V59, P4574; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FORM DM, 1983, P SOC EXP BIOL MED, V172, P214; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goldman AP, 1998, CARCINOGENESIS, V19, P2195, DOI 10.1093/carcin/19.12.2195; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; HALVORSON MJ, 1995, J IMMUNOL, V155, P4567; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; Jones MK, 1999, NAT MED, V5, P1418; Jones SL, 2002, J LEUKOCYTE BIOL, V71, P1042; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maier GD, 1996, CLIN EXP METASTAS, V14, P314; Masferrer JL, 2000, CANCER RES, V60, P1306; Max R, 1997, INT J CANCER, V71, P320, DOI 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.3.CO;2-3; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Plopper George E., 2000, Molecular Cell Biology Research Communications, V4, P129, DOI 10.1006/mcbr.2001.0267; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shiff SJ, 1999, J EXP MED, V190, P445, DOI 10.1084/jem.190.4.445; SHIMIZU Y, 1992, J EXP MED, V175, P577, DOI 10.1084/jem.175.2.577; Sipkins DA, 1998, NAT MED, V4, P623, DOI 10.1038/nm0598-623; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Whittard JD, 2001, J CELL SCI, V114, P3265; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	45	126	131	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45838	45846		10.1074/jbc.M209213200	http://dx.doi.org/10.1074/jbc.M209213200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237321	hybrid			2022-12-25	WOS:000179529300017
J	Gaudilliere, B; Shi, Y; Bonni, A				Gaudilliere, B; Shi, Y; Bonni, A			RNA interference reveals a requirement for myocyte enhancer factor 2A in activity-dependent neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; GRANULE CELLS; MEF2 GENES; EXPRESSION; DIFFERENTIATION; APOPTOSIS; PATHWAY	RNA interference (RNAi) provides a powerful method of gene silencing in eukaryotic cells, including proliferating mammalian cells. However, the utility of RNAi as a method of gene knock-down in primary postmitotic mammalian neurons remained unknown. Here, we asked if RNAi might be utilized to allow the assessment of the biological function of a specific gene in the nervous system. We employed a U6 promoter-driven DNA template approach to induce hairpin RNA-triggered RNAi to characterize the role of the transcription factor myocyte enhancer factor 2A (MEF2A) in the neuronal activity-dependent survival of granule neurons of the developing rat cerebellum. We found that the expression of MEF2A hairpin RNAs leads to the efficient and specific inhibition of endogenous MEF2A protein expression in primary cerebellar granule neurons. We also found that RNAi of NMF2A reduces significantly MEF2 response element-mediated transcription in granule neurons and inhibits activity-dependent granule neuron survival. Taken together, our RNAi experiments have revealed that MEF2A plays a critical role in activity-dependent neuronal survival. In addition, our findings indicate that RNAi does operate in postmitotic mammalian neurons and thus offers a rapid genetic method of studying gene function in the development and function of the mammalian nervous system.	Harvard Univ, Sch Med, Dept Pathol, Program Biol & Biomed Sci, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Bonni, A (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Program Biol & Biomed Sci, Boston, MA 02115 USA.			Gaudilliere, Brice/0000-0002-3475-5706	NIGMS NIH HHS [GM 53874] Funding Source: Medline; NINDS NIH HHS [R01-NS41021-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041021] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Harborth J, 2001, J CELL SCI, V114, P4557; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Lee JK, 2000, DEV DYNAM, V217, P361, DOI 10.1002/(SICI)1097-0177(200004)217:4<361::AID-DVDY3>3.0.CO;2-8; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Miller TM, 1996, J NEUROSCI, V16, P7487; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	27	85	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46442	46446		10.1074/jbc.M206653200	http://dx.doi.org/10.1074/jbc.M206653200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235147	hybrid			2022-12-25	WOS:000179529300096
J	Cheng, HF; Harris, RC				Cheng, HF; Harris, RC			Cyclooxygenase-2 expression in cultured cortical thick ascending limb of Henle increases in response to decreased extracellular ionic content by both transcriptional and post-transcriptional mechanisms - Role of p38-mediated pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; MACULA DENSA; MESSENGER-RNA; GENE-EXPRESSION; SIGNALING PATHWAYS; NUCLEAR-FACTOR; P38 MAPK; DIFFERENTIAL REGULATION	We showed previously that decreased extracellular salt or chloride up-regulates the cortical thick ascending limb of Henle (cTALH) COX-2 expression via a p38-dependent pathway. The present studies determined that low salt medium increased COX-2 mRNA expression 3.9-fold control by 6 h in cultured cTALH, which was blocked by actinomycin D pretreatment, suggesting transcriptional regulation. Luciferase activity (normalized to beta-galactosidase activity) of the full-length (-3400) COX-2 promoter in cTALH increased from 1.8 +/- 0.3 in control media to 5.8 +/- 0.7 in low salt (n = 9;p < 0.01). Low chloride medium had similar effects as low salt has on COX-2 promoter activity. Deletion constructs -815, -512, and -410 were similarly stimulated, but -385 could not be stimulated significantly by low salt (1.8 +/- 0.3 versus 2.4 +/- 0.5, n = 10). This suggested involvement of an NF-kappaB cis-element located in this region, which was confirmed by utilizing a construct with a point mutation of this NF-kappaB-binding site that was not stimulated by low salt medium. Co-incubation of the specific p38 inhibitor, SB203580 or PD169316, inhibited a low salt-induced increase in luciferase activity of the intact COX-2 promoter (5.8 +/- 0.7 versus 1.1 +/- 0.2, n = = 8 and 1.4 +/- 0.4, n = 4 respectively, p < 0.01). Mobility shift assays indicated that the low salt medium stimulated NF-kappaB binding activity, and this stimulation was inhibited by p38 inhibitors. To test whether p38 also increased COX-2 expression by increasing mRNA stability, cTALH were incubated in low salt for 2 h, and actinomycin was then added with or without SB203580. p38 inhibition led to a decreased half-life of COX-2 mRNA (from 68 to 18 min, n = 4-7, p < 0.05). Therefore, these studies indicate that p38 stimulates COX-2 expression in cTALH and macula densa by transcriptional regulation predominantly via a NF-kappaB-dependent pathway and by post-transcriptional increases in mRNA stability.	Vanderbilt Univ, Sch Med, Div Nephrol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, George M OBrien Kidney & Urol Dis Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Harris, RC (corresponding author), Vanderbilt Univ, Sch Med, Div Nephrol, S3322, Nashville, TN 37232 USA.				NIDDK NIH HHS [DK 39261] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN ML, 1988, AM J PHYSIOL, V255, pF704, DOI 10.1152/ajprenal.1988.255.4.F704; ARAKAWA T, 1995, FEBS LETT, V363, P105, DOI 10.1016/0014-5793(95)00293-I; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bartlett SR, 1999, J PHYSIOL-LONDON, V520, P399, DOI 10.1111/j.1469-7793.1999.00399.x; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Cheng HF, 2001, AM J PHYSIOL-RENAL, V280, pF449, DOI 10.1152/ajprenal.2001.280.3.F449; Cheng HF, 1999, J CLIN INVEST, V103, P953, DOI 10.1172/JCI5505; Cheng HF, 2000, J CLIN INVEST, V106, P681, DOI 10.1172/JCI10318; Cheng HF, 2000, AM J PHYSIOL-RENAL, V279, pF122, DOI 10.1152/ajprenal.2000.279.1.F122; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goebeler M, 2001, BLOOD, V97, P46, DOI 10.1182/blood.V97.1.46; Greger R, 1997, NEPHROL DIAL TRANSPL, V12, P2215, DOI 10.1093/ndt/12.11.2215; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; Han SW, 1999, MOL CELL ENDOCRINOL, V147, P7, DOI 10.1016/S0303-7207(98)00240-8; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; Ingram AJ, 2000, AM J PHYSIOL-RENAL, V279, pF243, DOI 10.1152/ajprenal.2000.279.2.F243; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; Jensen BL, 1997, KIDNEY INT, V52, P1242, DOI 10.1038/ki.1997.449; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LaPointe MC, 1999, HYPERTENSION, V33, P276, DOI 10.1161/01.HYP.33.1.276; Laporte JD, 2000, AM J PHYSIOL-LUNG C, V279, pL932, DOI 10.1152/ajplung.2000.279.5.L932; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Leonard M, 1999, KIDNEY INT, V56, P1366, DOI 10.1046/j.1523-1755.1999.00664.x; Lim JW, 2001, LAB INVEST, V81, P349, DOI 10.1038/labinvest.3780243; LORENZ JN, 1991, AM J PHYSIOL, V260, pF486, DOI 10.1152/ajprenal.1991.260.4.F486; LORENZ JN, 1990, AM J PHYSIOL, V259, pF186, DOI 10.1152/ajprenal.1990.259.1.F186; Mann B, 2001, KIDNEY INT, V59, P62, DOI 10.1046/j.1523-1755.2001.00466.x; MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mestre JR, 2001, J BIOL CHEM, V276, P3977, DOI 10.1074/jbc.M005077200; Nakao S, 2000, MOL CELL BIOCHEM, V209, P113, DOI 10.1023/A:1007155525020; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; Newton R, 1997, FEBS LETT, V418, P135, DOI 10.1016/S0014-5793(97)01362-8; Nielsen S, 1998, AM J PHYSIOL-RENAL, V275, pF885, DOI 10.1152/ajprenal.1998.275.6.F885; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; PERSSON AE, 1991, KIDNEY INT S, V32, P39; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Sakai T, 2000, CAN J ANAESTH, V47, P1019, DOI 10.1007/BF03024876; SALOMONSSON M, 1991, KIDNEY INT S, V32, P51; SCHLATTER E, 1989, PFLUG ARCH EUR J PHY, V414, P286, DOI 10.1007/BF00584628; Schnermann J, 1998, AM J PHYSIOL-REG I, V274, pR263, DOI 10.1152/ajpregu.1998.274.2.R263; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Tai H, 1997, ENDOCRINOLOGY, V138, P2372, DOI 10.1210/en.138.6.2372; Varghese J, 2001, J IMMUNOL, V166, P6570, DOI 10.4049/jimmunol.166.11.6570; von Knethen A, 1999, J IMMUNOL, V163, P2858; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wang JL, 2000, KIDNEY INT, V57, P2334, DOI 10.1046/j.1523-1755.2000.00093.x; Wang JL, 1999, HYPERTENSION, V34, P96, DOI 10.1161/01.HYP.34.1.96; Wolf K, 1999, HYPERTENSION, V34, P503, DOI 10.1161/01.HYP.34.3.503; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yang TX, 2000, J BIOL CHEM, V275, P37922, DOI 10.1074/jbc.M006218200; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhang X, 1997, BIOTECHNIQUES, V22, P848, DOI 10.2144/97225bm13	69	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45638	45643		10.1074/JBC.m206040200	http://dx.doi.org/10.1074/JBC.m206040200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237297	hybrid			2022-12-25	WOS:000179404800130
J	Crespo, PM; Zurita, AR; Daniotti, JL				Crespo, PM; Zurita, AR; Daniotti, JL			Effect of gangliosides on the distribution of a glycosylphosphatidylinositol-anchored protein in plasma membrane from Chinese hamster ovary-K1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR PHOSPHORYLATION; LIPID RAFTS; SIGNAL-TRANSDUCTION; GLYCOSPHINGOLIPID SYNTHESIS; GLUCOSYLCERAMIDE SYNTHASE; GM1 GANGLIOSIDE; TISSUE-CULTURE; GOLGI-COMPLEX; GD3 SYNTHASE; CHO-K1 CELLS	Glycosylphosphatidylinositol (GPI)-anchored proteins are clustered mainly in sphingolipid-cholesterol microdomains of the plasma membrane. The distribution of GPI-anchored fusion yellow fluorescent protein (GPI-YFP) in the plasma membrane of Chinese hamster ovary (CHO)-K1 cells with different glycolipid compositions was investigated. Cells depleted of glycosphingolipids by inhibiting glucosylceramide synthase activity or cell lines expressing different gangliosides caused by stable transfection of appropriate ganglioside glycosyltransferases or exposed to exogenous GM1 were transfected with GPI-YFP cDNA. The distribution of GPI-YFP fusion protein expressed at the plasma membrane was studied using the membrane-impermeable cross-linking agent bis(sulfosuccinimidyl)suberate. Results indicate that GPI-YFP forms clusters at the surface of cells expressing GM3, or cells depleted of glycolipids, or transfected cells expressing mainly GD3 and GT3, or GM1 and GDla, or mostly GM2, or highly expressing GM1. However, no significant changes in membrane microdomains of GPI-YFP were detected in the different glycolipid environments provided by the membranes of the cell lines under study. On the other hand, wild type CHO-K1 cells exposed to 100 muM GM1 before cross-linking with bis(sulfosuccinimidyl)suberate showed a dramatic reduction in the amount of GPI-YFP clusters. These findings clearly indicate that manipulating the glycolipid content of the cellular membrane, just by changing the ganglioside biosynthetic activity of the cell, did not significantly affect the association of GPI-YFP on the cell surface of CHO-K1 cells. The effect of exogenous GM1 gangliosides on GPI-YFP plasma membrane distribution might be a consequence of the ganglioside level reached in plasma membrane and/or the effect of particular ganglioside species (micelles) that lead to membrane architecture and/or dynamic modifications.	Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, Ctr Invest Quim Biol Cordoba, RA-5000 Cordoba, Argentina	National University of Cordoba	Daniotti, JL (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, Ctr Invest Quim Biol Cordoba, RA-5000 Cordoba, Argentina.							ABE A, 1995, J LIPID RES, V36, P611; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUSCH G, 1989, EUR J CELL BIOL, V50, P257; Chatterjee S, 2001, CELL MOL LIFE SCI, V58, P1969, DOI 10.1007/PL00000831; Chatterjee S, 2001, EMBO J, V20, P1583, DOI 10.1093/emboj/20.7.1583; Daniotti JL, 2000, J NEUROCHEM, V74, P1711, DOI 10.1046/j.1471-4159.2000.0741711.x; Dietrich C, 2001, P NATL ACAD SCI USA, V98, P10642, DOI 10.1073/pnas.191168698; El-Husseini AE, 2001, J BIOL CHEM, V276, P44984, DOI 10.1074/jbc.M103049200; Ferrari G, 1998, ANN NY ACAD SCI, V845, P263, DOI 10.1111/j.1749-6632.1998.tb09679.x; FOLCH J, 1951, J BIOL CHEM, V191, P819; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Fritz VMR, 1997, BBA-GENE STRUCT EXPR, V1354, P153, DOI 10.1016/S0167-4781(97)00117-6; FRITZ VMR, 1995, J NEUROCHEM, V65, P1859; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Giraudo CG, 1999, BIOCHEM J, V342, P633, DOI 10.1042/0264-6021:3420633; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; JI L, 1995, GLYCOBIOLOGY, V5, P343, DOI 10.1093/glycob/5.3.343; Kasahara K, 2000, J BIOL CHEM, V275, P34701, DOI 10.1074/jbc.M003163200; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; LESTER RL, 1993, J BIOL CHEM, V268, P845; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Meuillet EJ, 1999, CANCER RES, V59, P234; Mitsuda T, 2002, J BIOL CHEM, V277, P11239, DOI 10.1074/jbc.M107756200; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; Rodriguez JA, 2001, J NEUROSCI, V21, P8387, DOI 10.1523/JNEUROSCI.21-21-08387.2001; Rosner H, 1998, ANN NY ACAD SCI, V845, P200, DOI 10.1111/j.1749-6632.1998.tb09672.x; SAQR HE, 1993, J NEUROCHEM, V61, P395; SCHNEIDER JS, 1995, NEUROLOGY, V45, P1149, DOI 10.1212/WNL.45.6.1149; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1999, MOL BIOL CELL, V10, P3187, DOI 10.1091/mbc.10.10.3187; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Sprong H, 2001, J CELL BIOL, V155, P369, DOI 10.1083/jcb.200106104; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Tifft CJ, 2000, GLYCOBIOLOGY, V10, P1249, DOI 10.1093/glycob/10.12.1249; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vyas KA, 2001, BIOL CHEM, V382, P241, DOI 10.1515/BC.2001.031; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142; Zurita AR, 2001, BIOCHEM J, V355, P465, DOI 10.1042/0264-6021:3550465	50	35	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44731	44739		10.1074/jbc.M204604200	http://dx.doi.org/10.1074/jbc.M204604200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237294	hybrid			2022-12-25	WOS:000179404800019
J	Javaherian, K; Park, SY; Pickl, WF; LaMontagne, KR; Sjin, RTT; Gillies, S; Lo, KM				Javaherian, K; Park, SY; Pickl, WF; LaMontagne, KR; Sjin, RTT; Gillies, S; Lo, KM			Laminin modulates morphogenic properties of the collagen XVIII endostatin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS INHIBITOR ENDOSTATIN; HEPARAN-SULFATE; CAENORHABDITIS-ELEGANS; NC1/ENDOSTATIN DOMAIN; INTEGRINS; EXPRESSION; RECEPTORS; COMPONENT; BINDING; CELLS	We have shown previously that the oligomeric endostatin domain of collagen XVIII (NC1) functioned as a motility-inducing factor regulating the extracellular matrix-dependent morphogenesis of endothelial cells. This motogenic activity gave rise to structures resembling filipodia and lamellipodia and was dependent on Rac, Cdc42, and mitogen-activated protein kinase. Here, we demonstrate that these properties of endostatin are primarily mediated by laminin in the basement membrane and heparan sulfates on the cell surface. The sites of interaction between laminin and oligomeric endostain include the N-terminal regions of all three laminin chains (amino acids 204-1243 of the alpha chain, 932-1161 of the beta chain, and 150-965 of the gamma chain). A monoclonal antibody that blocks the interactions between endostatin and laminin was utilized to inhibit the motogenic activity of endostatin. In parallel, we have engineered selective point mutations and produced recombinant forms that lack binding to heparan sulfates on the cell surface. Our data are consistent with a model of endostatin with two binding sites: one mainly to laminin in the basement membrane and the other to heparan sulfates on the cell surface. The two binding domains on endostatin appear to be separate with the possibility of some overlap between the two sites.	Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Lexigen Pharmaceut Corp, Lexington, MA 02421 USA; Univ Vienna, Sch Med, Inst Immunol, A-1090 Vienna, Austria	Harvard University; Boston Children's Hospital; Harvard Medical School; University of Vienna	Javaherian, K (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Enders 470,320 Longwood Ave, Boston, MA 02115 USA.		Pickl, Winfried F/E-5682-2011	Pickl, Winfried F./0000-0003-0430-4952				Ackley BD, 2001, J CELL BIOL, V152, P1219, DOI 10.1083/jcb.152.6.1219; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Chang Z, 1999, AM J PATHOL, V155, P71, DOI 10.1016/S0002-9440(10)65101-2; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; DAUGHERTY BL, 1991, NUCLEIC ACIDS RES, V19, P2471, DOI 10.1093/nar/19.9.2471; Dhanabal M, 1999, CANCER RES, V59, P189; Ding YH, 1998, P NATL ACAD SCI USA, V95, P10443, DOI 10.1073/pnas.95.18.10443; Ghosh S, 2000, MICROSC RES TECHNIQ, V51, P238, DOI 10.1002/1097-0029(20001101)51:3<238::AID-JEMT4>3.0.CO;2-3; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404; Harlow E., 1988, ANTIBODIES LABORATOR, P310; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; Hopker VH, 1999, NATURE, V401, P69, DOI 10.1038/43441; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kuo CJ, 2001, J CELL BIOL, V152, P1233, DOI 10.1083/jcb.152.6.1233; Lim YS, 1999, J NEUROSCI, V19, P7048, DOI 10.1523/JNEUROSCI.19-16-07048.1999; Lo KM, 1998, PROTEIN ENG, V11, P495, DOI 10.1093/protein/11.6.495; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; Miosge N, 1999, FASEB J, V13, P1743, DOI 10.1096/fasebj.13.13.1743; OREILLY MS, 1997, CELL, V88, P227; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Sim B K, 1999, Angiogenesis, V3, P41, DOI 10.1023/A:1009058931769; TIMPL R, 1979, J BIOL CHEM, V254, P9933; Tunggal P, 2000, MICROSC RES TECHNIQ, V51, P214, DOI 10.1002/1097-0029(20001101)51:3<214::AID-JEMT2>3.0.CO;2-J	30	41	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45211	45218		10.1074/jbc.M206358200	http://dx.doi.org/10.1074/jbc.M206358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237301	hybrid			2022-12-25	WOS:000179404800080
J	Sasaki, H; Sato, H; Kuriyama-Matsumura, K; Sato, K; Maebara, K; Wang, HY; Tamba, M; Itoh, K; Yamamoto, M; Bannai, S				Sasaki, H; Sato, H; Kuriyama-Matsumura, K; Sato, K; Maebara, K; Wang, HY; Tamba, M; Itoh, K; Yamamoto, M; Bannai, S			Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; HUMAN-DIPLOID FIBROBLASTS; PLANAR AROMATIC-COMPOUNDS; YA-SUBUNIT GENE; INDUCIBLE EXPRESSION; BACTERIAL LIPOPOLYSACCHARIDE; OXIDATIVE STRESS; CYSTINE; GLUTATHIONE; NRF2	In mammalian cultured cells, the cystine/glutamate exchange transport mediated by system x(c)(-) is important to maintain intracellular GSH. levels. System x(c)(-) consists of two protein components, xCT and the heavy chain of 4F2 antigen. The activity of system x(c)(-) is induced by various stimuli, including electrophilic agents like diethyl maleate. In the present study, we have investigated the mechanism of the transcriptional regulation of xCT mRNA by diethyl maleate. The xCT gene consisted of twelve exons and sequence analysis identified four electrophile response element (EpRE)-like sequences between -230 and -1 in the W-flanking region, designated EpRE-1 to EpRE-4. To identify sequences mediating the constitutive and induced expression of xCT, a series of 5'-deletion mutants created from the 5'-flanking region were cloned into a luciferase reproter vector and transfected into BBR21 cells. The 5'-deletion analysis revealed that the sequence between -116 and -82 is essential for the basal expression and the sequence between -226 and -116 containing EpRE-1 is essential in response to diethyl maleate. Mutational analysis demonstrated that EpRE-1 is critically involved in the response to diethyl maleate. Other stress agents like arsenite, cadmium, and hydroquinone seemed to induce system xc- activity via the same sequence. Furthermore, the experiments using the mouse embryonic fibroblasts derived from the Nrf2-deficient mice revealed that the induction of xCT gene by electrophilic agents is mediated by Nrf2. EpRE occurs in a broad spectrum of genes for the proteins that are involved in the defense against xenobiotics and regulates their expression. The present results have demonstrated that xCT is a novel member of this protein family.	Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; University of Tsukuba	Sato, H (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaraki 3058575, Japan.		Itoh, Ken/B-9506-2013; Yamamoto, Masayuki/A-4873-2010	Itoh, Ken/0000-0002-5518-0729; Yamamoto, Masayuki/0000-0002-9073-9436				BANNAI S, 1986, J MEMBRANE BIOL, V89, P1, DOI 10.1007/BF01870891; BANNAI S, 1991, BIOCHIM BIOPHYS ACTA, V1092, P175, DOI 10.1016/0167-4889(91)90153-O; BANNAI S, 1980, J BIOL CHEM, V255, P2372; BANNAI S, 1982, J CELL PHYSIOL, V112, P265, DOI 10.1002/jcp.1041120216; Campagne MV, 2000, J NEUROSCI, V20, P5200, DOI 10.1523/JNEUROSCI.20-14-05200.2000; CHO Y, 1990, J NEUROCHEM, V55, P2091, DOI 10.1111/j.1471-4159.1990.tb05800.x; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; Erickson AM, 2002, J BIOL CHEM, V277, P30730, DOI 10.1074/jbc.M205225200; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SAGARA J, 1993, J NEUROCHEM, V61, P1667, DOI 10.1111/j.1471-4159.1993.tb09801.x; SATO H, 1995, BIOCHEM J, V310, P547, DOI 10.1042/bj3100547; SATO H, 1987, J BIOL CHEM, V262, P13015; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Sato H, 2001, J BIOL CHEM, V276, P10407, DOI 10.1074/jbc.M007216200; Sato H, 2000, ANTIOXID REDOX SIGN, V2, P665, DOI 10.1089/ars.2000.2.4-665; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WATANABE H, 1987, J EXP MED, V165, P628, DOI 10.1084/jem.165.3.628	29	368	375	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44765	44771		10.1074/jbc.M208704200	http://dx.doi.org/10.1074/jbc.M208704200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235164	hybrid			2022-12-25	WOS:000179404800024
J	Trotter, EW; Kao, CMF; Berenfeld, L; Botstein, D; Petsko, GA; Gray, JV				Trotter, EW; Kao, CMF; Berenfeld, L; Botstein, D; Petsko, GA; Gray, JV			Misfolded proteins are competent to mediate a subset of the responses to heat shock in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-AZETIDINE-2-CARBOXYLIC ACID RESIDUE; MAP KINASE PATHWAY; SIGNALING PATHWAY; STRESS-RESPONSE; YEAST; TRANSCRIPTION; CONFORMATION; DEGRADATION; EXPRESSION; REGULATOR	Cells may sense heat shock via the accumulation of thermally misfolded proteins. To explore this possibility, we determined the effect of protein misfolding on gene expression in the absence of temperature changes. The imino acid analog azetidine-2-carboxylic acid (AZC) is incorporated into protein competitively with proline and causes reduced thermal stability or misfolding. We found that adding AZC to yeast at sublethal concentrations sufficient to arrest proliferation selectively induced expression of heat shock factor-regulated genes to a maximum of 27-fold and that these inductions were dependent on heat shock factor. AZC treatment also selectively repressed expression of the ribosomal protein genes, another heat shock factor-dependent process, to a maximum of 20-fold. AZC treatment thus strongly and selectively activates heat shock factor. AZC treatment causes this activation by misfolding proteins. Induction of HSP42 by AZC treatment required protein synthesis; treatment with ethanol, which can also misfold proteins, activated heat shock factor, but treatment with canavanine, an arginine analog less potent than AZC at misfolding proteins, did not. However, misfolded proteins did not strongly induce the stress response element regulon. We conclude that misfolded proteins are competent to specifically trigger activation of heat shock factor in response to heat shock.	Univ Glasgow, Fac Biomed & Life Sci, Div Mol Genet, Glasgow G11 6NU, Lanark, Scotland; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	University of Glasgow; Stanford University; Stanford University; Brandeis University	Gray, JV (corresponding author), Univ Glasgow, Fac Biomed & Life Sci, Div Mol Genet, Anderson Coll Complex,54-56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.		Petsko, Gregory/AAO-7962-2020		NATIONAL CANCER INSTITUTE [R01CA077097] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000983] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046406, R01GM046406] Funding Source: NIH RePORTER; NCI NIH HHS [CA77097] Funding Source: Medline; NHGRI NIH HHS [HG00983] Funding Source: Medline; NIGMS NIH HHS [GM46406] Funding Source: Medline; DRS NIH HHS [RS19987] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); DRS NIH HHS		Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Boy-Marcotte E, 1999, MOL MICROBIOL, V33, P274, DOI 10.1046/j.1365-2958.1999.01467.x; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FOWDEN L, 1967, ADV ENZYMOL RAMB, V29, P89; FOWDEN L, 1963, BIOCHIM BIOPHYS ACTA, V71, P459, DOI 10.1016/0006-3002(63)91104-1; GRANT CM, 1989, MOL MICROBIOL, V3, P213; Gray JV, 1997, EMBO J, V16, P4924, DOI 10.1093/emboj/16.16.4924; HALLADAY JT, 1995, MOL CELL BIOL, V15, P4890; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; LANE JM, 1971, BIOCHIM BIOPHYS ACTA, V236, P528, DOI 10.1016/0005-2795(71)90236-4; Lopez N, 1999, J BACTERIOL, V181, P3136, DOI 10.1128/JB.181.10.3136-3143.1999; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PIPER PW, 1995, FEMS MICROBIOL LETT, V134, P121, DOI 10.1016/0378-1097(95)00431-9; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Trotter EW, 2001, P NATL ACAD SCI USA, V98, P7313, DOI 10.1073/pnas.121172998; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; ZAGARI A, 1990, BIOPOLYMERS, V30, P951, DOI 10.1002/bip.360300909; ZAGARI A, 1994, BIOPOLYMERS, V34, P51, DOI 10.1002/bip.360340107	30	124	132	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44817	44825		10.1074/jbc.M204686200	http://dx.doi.org/10.1074/jbc.M204686200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239211	hybrid			2022-12-25	WOS:000179404800031
J	Tseng, HM; Tomkinson, AE				Tseng, HM; Tomkinson, AE			A physical and functional interaction between yeast Pol4 and Dnl4-Lif1 links DNA synthesis and ligation in nonhomologous end joining	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; LIGASE-IV; HOMOLOGOUS RECOMBINATION; PROTEIN COMPLEX; DAMAGE RESPONSE; MAMMALIAN-CELLS; BETA-POLYMERASE; XRCC4 PROTEIN; MATING-TYPE	Genetic studies have implicated the Saccharomyces cerevisiae POL4 gene product in the repair of DNA double-strand breaks by nonhomologous end joining. Here we show that Pol4 preferentially catalyzes DNA synthesis on small gaps formed by the alignment of linear duplex DNA molecules with complementary ends, a DNA substrate specificity that is compatible with its predicted role in the repair of DNA double-strand breaks. Pol4 also interacts directly with the Dnl4 subunit of the Dnl4-Lif1 complex via its N-terminal BRCT domain. This interaction stimulates the DNA synthesis activity of Pol4 and, to a lesser extent, the DNA joining activity of Dnl4-Lif1. Notably, the joining of DNA substrates that require the combined action of Pol4 and Dnl4-Lif1 is much more efficient than the joining of similar DNA substrates that require only ligation. Thus, the physical and functional interactions between Pol4 and Dnl4-Lif1 provide a molecular mechanism for both the recruitment of Pol4 to in vivo DNA double-strand breaks and the coupling of the gap filling DNA synthesis and DNA joining reactions that complete the microhomology-mediated pathway of nonhomologous end joining.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Tomkinson, AE (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.				NCI NIH HHS [P01 CA81020, P30 CA54174] Funding Source: Medline; NIGMS NIH HHS [R01 GM47251] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA054174, P01CA081020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Frank-Vaillant M, 2001, GENE DEV, V15, P3005, DOI 10.1101/gad.206801; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Gilfillan S, 1995, IMMUNOL REV, V148, P201, DOI 10.1111/j.1600-065X.1995.tb00099.x; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; Kegel A, 2001, CURR BIOL, V11, P1611, DOI 10.1016/S0960-9822(01)00488-2; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KRAMER KM, 1994, MOL CELL BIOL, V14, P1293, DOI 10.1128/MCB.14.2.1293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Moreau S, 1999, MOL CELL BIOL, V19, P556; Ooi SL, 2001, SCIENCE, V294, P2552, DOI 10.1126/science.1065672; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; Ramos W, 1998, NUCLEIC ACIDS RES, V26, P5676, DOI 10.1093/nar/26.24.5676; RON D, 1992, BIOTECHNIQUES, V13, P866; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; SHIMIZU K, 1993, J BIOL CHEM, V268, P27148; Siede W, 1996, GENETICS, V142, P91; SOBEL RW, 1996, NATURE, V379, P183; Sobol RW, 2001, PROG NUCLEIC ACID RE, V68, P57; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Usui T, 2001, MOL CELL, V7, P1255, DOI 10.1016/S1097-2765(01)00270-2; Valencia M, 2001, NATURE, V414, P666, DOI 10.1038/414666a; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303	56	89	92	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45630	45637		10.1074/jbc.M206861200	http://dx.doi.org/10.1074/jbc.M206861200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235149	hybrid			2022-12-25	WOS:000179404800129
J	Foeger, N; Glaser, W; Skern, T				Foeger, N; Glaser, W; Skern, T			Recognition of eukaryotic initiation factor 4G isoforms by picornaviral proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUTH-DISEASE-VIRUS; TRANSLATION INITIATION; BINDING-PROTEIN; 2A PROTEINASE; LEADER PROTEINASE; P220 CLEAVAGE; FACTOR-III; EIF4G; RHINOVIRUS; SITE	The leader proteinase (L-pro) of foot and mouth disease virus is a papain-like cysteine proteinase. After processing itself from the polyprotein, L-pro then cleaves the host protein eukaryotic initiation factor (eIf) 4GI, thus preventing protein synthesis from capped mRNA in the infected cell. We have investigated L-pro interaction with eIF4GI and its isoform, eIF4GIL L-pro, expressed as a catalytically inactive fusion protein with glutathione S-transferase, binds specifically to eIF4G isomers in rabbit reticulocyte lysates. Deletion and specific mutagenesis were used to map the binding domain on L-pro to residues 183-195 of the C-terminal extension and to residue Cys(133). These residues of the C-terminal extension and Cys(133) are adjacent in the crystal structure but lie about 25 A from the active site. The region on eIF4GI recognized by the L-pro C-terminal extension was mapped to residues 640-669 using eIF4GI fragments generated by proteolysis or by in vitro translation. The L-pro cleavage site at Gly(674)down arrowArg(675) was not necessary for binding. Similar experiments with human rhinovirus 2A proteinase (2A(pro)), a chymotrypsin-like cysteine proteinase that also cleaves eIF4G isoforms, revealed that 2A(pro) can also bind to eIF4GI fragments lacking its cleavage site. These experiments strongly suggest a novel interaction between picornaviral proteinases and eIF4G isoforms.	Univ Vienna, Div Biochem, Inst Med Biochem, Vienna Bio Ctr, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Skern, T (corresponding author), Univ Vienna, Div Biochem, Inst Med Biochem, Vienna Bio Ctr, Dr Bohr Gasse 9-3, A-1030 Vienna, Austria.	timothy.skern@univie.ac.at	Skern, Tim/AAC-1732-2022; Foeger, Nicole/L-2620-2019	Skern, Tim/0000-0001-8865-5500; Foeger, Nicole/0000-0001-7775-7325				Belsham GJ, 2000, J VIROL, V74, P272, DOI 10.1128/JVI.74.1.272-280.2000; Belsham GJ, 2000, COLD SPRING HARBOR M, V39, P869; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; BERNSTEIN HD, 1985, MOL CELL BIOL, V5, P2913, DOI 10.1128/MCB.5.11.2913; Bovee ML, 1998, VIROLOGY, V245, P241, DOI 10.1006/viro.1998.9172; Bovee ML, 1998, VIROLOGY, V245, P229, DOI 10.1006/viro.1998.9171; Brown CC, 1996, J VIROL, V70, P5638, DOI 10.1128/JVI.70.8.5638-5641.1996; Byrd MP, 2002, MOL CELL BIOL, V22, P4499, DOI 10.1128/MCB.22.13.4499-4511.2002; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Glaser W, 2000, FEBS LETT, V480, P151, DOI 10.1016/S0014-5793(00)01928-1; Glaser W, 2001, J BIOL CHEM, V276, P35473, DOI 10.1074/jbc.M104192200; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Guarne A, 2000, J MOL BIOL, V302, P1227, DOI 10.1006/jmbi.2000.4115; Guarne A, 1998, EMBO J, V17, P7469, DOI 10.1093/emboj/17.24.7469; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hershey PEC, 1999, J BIOL CHEM, V274, P21297, DOI 10.1074/jbc.274.30.21297; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; Kanno T, 2001, VIRUS RES, V80, P101, DOI 10.1016/S0168-1702(01)00341-0; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; LLOYD RE, 1986, VIROLOGY, V150, P299, DOI 10.1016/0042-6822(86)90291-6; MADER S, 1995, MOL CELL BIOL, V15, P4990; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; MEDINA M, 1993, VIROLOGY, V194, P355, DOI 10.1006/viro.1993.1267; Morley SJ, 1997, RNA, V3, P1085; Ohlmann T, 1997, EMBO J, V16, P844, DOI 10.1093/emboj/16.4.844; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Petersen JFW, 1999, EMBO J, V18, P5463, DOI 10.1093/emboj/18.20.5463; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Sakoda Y, 2001, J VIROL, V75, P10643, DOI 10.1128/JVI.75.22.10643-10650.2001; SANGAR DV, 1987, NUCLEIC ACIDS RES, V15, P3305, DOI 10.1093/nar/15.8.3305; Seipelt J, 2000, J BIOL CHEM, V275, P20084, DOI 10.1074/jbc.275.26.20084; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Svitkin YV, 1999, J VIROL, V73, P3467, DOI 10.1128/JVI.73.4.3467-3472.1999; THOMAS AAM, 1992, EUR J BIOCHEM, V207, P471, DOI 10.1111/j.1432-1033.1992.tb17073.x; van Rensburg H, 2002, GENE, V289, P19, DOI 10.1016/S0378-1119(02)00471-7; Ventoso I, 1998, FEBS LETT, V435, P79, DOI 10.1016/S0014-5793(98)01027-8; WYCKOFF EE, 1992, J VIROL, V66, P2943, DOI 10.1128/JVI.66.5.2943-2951.1992; YAN RQ, 1992, J BIOL CHEM, V267, P23226; YU SF, 1991, VIROLOGY, V182, P615, DOI 10.1016/0042-6822(91)90602-8; Zamora M, 2002, J VIROL, V76, P165, DOI 10.1128/JVI.76.1.165-177.2002; ZIEGLER E, 1995, J VIROL, V69, P3465, DOI 10.1128/JVI.69.6.3465-3474.1995	54	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44300	44309		10.1074/jbc.M208006200	http://dx.doi.org/10.1074/jbc.M208006200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228254	hybrid			2022-12-25	WOS:000179272000100
J	Jeong, YJ; Kim, DE; Patel, SS				Jeong, YJ; Kim, DE; Patel, SS			Kinetic pathway of dTTP hydrolysis by hexameric T7 helicase-printase in the absence of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CHANGE MECHANISM; SEQUENTIAL HYDROLYSIS; OLIGOMERIC STRUCTURE; INORGANIC-PHOSPHATE; ATP HYDROLYSIS; PROTEIN; F1-ATPASE; RELEASE; SITES; RHO	Bacteriophage T7 gp4A' protein is a hexameric helicase-primase protein that separates the strands of a duplex DNA in a reaction coupled to dTTP hydrolysis. Here we reexamine in more detail the kinetic mechanism of dTTP hydrolysis by a preassembled T7 helicase hexamer in the absence of DNA. Pre-steady state dTTP hydrolysis kinetics showed a distinct burst whose amplitude indicated that a preformed hexamer of T7 helicase hydrolyzes on an average one dTTP per hexamer. The presteady state chase-time experiments provided evidence for sequential hydrolysis of two dTTPs. The medium [O-18]P-i exchange experiments failed to detect dTTP synthesis, indicating that the less than six-site hydrolysis observed is not due to reversible dTTP hydrolysis on the helicase active site. The P-i-release rate was measured directly using a stopped-flow fluorescence assay, and it was found that the rate of dTTP hydrolysis on the helicase active site is eight times faster than the P-i-release rate, which in turn is three times faster than the dTDP release rate. Thus, the rate-limiting step in the pathway of helicase-catalyzed deoxythymidine triphosphatase (dTTPase) reaction is the release of dTDP. Chase-time dTTPase kinetics in the steady state phase provided evidence for two to three slowly hydrolyzing dTTPase sites on the hexamer. The results of this study are therefore consistent with those reported earlier (Hingorani, M. M., Washington, M. T., Moore, K. C., and Patel, S. S. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 5012-5017), and they support a model of dTTP hydrolysis by T7 helicase hexamer that is similar to the binding change mechanism of F-1-ATPase with dTTP hydrolysis occurring sequentially at the catalytic sites.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Patel, SS (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.		Kim, Dong-Eun/D-8304-2011	Kim, Dong-Eun/0000-0001-6545-8387	NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; Baird CL, 2001, J BIOL CHEM, V276, P27893, DOI 10.1074/jbc.M102544200; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; COHN M, 1978, P NATL ACAD SCI USA, V75, P200, DOI 10.1073/pnas.75.1.200; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Hackney D D, 1980, Methods Enzymol, V64, P60; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; HUTTON RL, 1979, J BIOL CHEM, V254, P9990; Kim DE, 1999, J BIOL CHEM, V274, P32667, DOI 10.1074/jbc.274.46.32667; Kim DE, 2002, J MOL BIOL, V321, P807, DOI 10.1016/S0022-2836(02)00733-7; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; Morris PD, 1999, BIOCHEMISTRY-US, V38, P5164, DOI 10.1021/bi9822269; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Picha KM, 1998, J BIOL CHEM, V273, P27315, DOI 10.1074/jbc.273.42.27315; PIPER JM, 1981, ANAL BIOCHEM, V117, P70, DOI 10.1016/0003-2697(81)90693-X; Rajendran S, 2000, J MOL BIOL, V303, P773, DOI 10.1006/jmbi.2000.4124; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740	27	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43778	43784		10.1074/jbc.M208634200	http://dx.doi.org/10.1074/jbc.M208634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226105	hybrid			2022-12-25	WOS:000179272000033
J	Kashiwagi, T; Yokoyama, K; Ishikawa, K; Ono, K; Ejima, D; Matsui, H; Suzuki, E				Kashiwagi, T; Yokoyama, K; Ishikawa, K; Ono, K; Ejima, D; Matsui, H; Suzuki, E			Crystal structure of microbial transglutaminase from Streptoverticillium mobaraense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN FACTOR-XIII; ESCHERICHIA-COLI; CROSS-LINKING; PURIFICATION; PROTEIN; CLONING; CROSSLINKING; EXPRESSION; SUBSTRATE	The crystal structure of a microbial transglutaminase from Streptoverticillium mobaraense has been determined at 2.4 Angstrom resolution. The protein folds into a plate-like shape, and has one deep cleft at the edge of the molecule. Its overall structure is completely different from that of the factor XIII-like transglutaminase, which possesses a cysteine protease-like catalytic triad. The catalytic residue, Cys(64), exists at the bottom of the cleft. Asp(255) resides at the position nearest to Cys(64) and is also adjacent to His(274). Interestingly, Cys(64), Asp(255), and His(274) superimpose well on the catalytic triad "Cys-His-Asp" of the factor XIII-like transglutaminase, in this order. The secondary structure frameworks around these residues are also similar to each other. These results imply that both transglutaminases are related by convergent evolution; however, the microbial transglutaminase has developed a novel catalytic mechanism specialized for the cross-linking reaction. The structure accounts well for the catalytic mechanism, in which Asp(255) is considered to be enzymatically essential, as well as for the causes of the higher reaction rate, the broader substrate specificity, and the lower deamidation activity of this enzyme.	Ajinomoto Co Inc, Cent Res Labs, Kawasaki Ku, Kawasaki, Kanagawa 2108681, Japan	Ajinomoto Co Inc	Suzuki, E (corresponding author), Ajinomoto Co Inc, Cent Res Labs, Kawasaki Ku, 1-1 Suzuki Cho, Kawasaki, Kanagawa 2108681, Japan.							AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ANDO H, 1989, AGR BIOL CHEM TOKYO, V53, P2613, DOI 10.1080/00021369.1989.10869735; BAKER EN, 1980, ACTA CRYSTALLOGR A, V36, P559, DOI 10.1107/S0567739480001210; BEILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHUNG SI, 1972, P NATL ACAD SCI USA, V69, P303, DOI 10.1073/pnas.69.2.303; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; Duran R, 1998, BIOCHIMIE, V80, P313, DOI 10.1016/S0300-9084(98)80073-4; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; GLADNER JA, 1983, THROMB RES, V30, P273, DOI 10.1016/0049-3848(83)90081-6; GRANT FJ, 1994, BIOCHEM BIOPH RES CO, V203, P1117, DOI 10.1006/bbrc.1994.2298; HORNYAK TJ, 1989, BIOCHEMISTRY-US, V28, P7326, DOI 10.1021/bi00444a027; HORNYAK TJ, 1991, BIOCHEMISTRY-US, V30, P6175, DOI 10.1021/bi00239a014; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P6900, DOI 10.1021/bi00370a025; IKURA K, 1980, AGR BIOL CHEM TOKYO, V44, P1567, DOI 10.1080/00021369.1980.10864171; KANAJI T, 1993, J BIOL CHEM, V268, P11565; KLEIN JD, 1992, J BACTERIOL, V174, P2599, DOI 10.1128/jb.174.8.2599-2605.1992; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURTH L, 1984, J FOOD SCI, V49, P573, DOI 10.1111/j.1365-2621.1984.tb12471.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LORAND J, 1966, NATURE, V210, P1273, DOI 10.1038/2101273a0; MARGOSIAK SA, 1990, PLANT PHYSIOL, V92, P88, DOI 10.1104/pp.92.1.88; MOTOKI M, 1983, J FOOD SCI, V48, P561, DOI 10.1111/j.1365-2621.1983.tb10790.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Noguchi K, 2001, J BIOL CHEM, V276, P12055, DOI 10.1074/jbc.M009862200; Ohtsuka T, 2001, J FOOD SCI, V66, P25, DOI 10.1111/j.1365-2621.2001.tb15576.x; Ohtsuka T, 2000, BIOSCI BIOTECH BIOCH, V64, P2608, DOI 10.1271/bbb.64.2608; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paetzel M, 2002, J BIOL CHEM, V277, P9512, DOI 10.1074/jbc.M110983200; Pasternack R, 1998, EUR J BIOCHEM, V257, P570, DOI 10.1046/j.1432-1327.1998.2570570.x; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; Shimba N, 2002, FEBS LETT, V517, P175, DOI 10.1016/S0014-5793(02)02616-9; Shimba N, 2002, J AGR FOOD CHEM, V50, P1330, DOI 10.1021/jf010995k; SINGH RN, 1994, EUR J BIOCHEM, V225, P625, DOI 10.1111/j.1432-1033.1994.00625.x; TOKUNAGA F, 1993, J BIOL CHEM, V268, P262; Weiss MS, 1998, FEBS LETT, V423, P291, DOI 10.1016/S0014-5793(98)00098-2; WERAARCHAKULBOONMARK N, 1992, P NATL ACAD SCI USA, V89, P9804, DOI 10.1073/pnas.89.20.9804; WONG WSD, 1990, INT J BIOCHEM, V22, P53, DOI 10.1016/0020-711X(90)90077-G; WRIGHT CS, 1972, J MOL BIOL, V67, P151, DOI 10.1016/0022-2836(72)90391-9; YASUEDA H, 1995, EUR J BIOCHEM, V232, P411, DOI 10.1111/j.1432-1033.1995.tb20826.x; YEE VC, 1995, THROMB RES, V78, P389, DOI 10.1016/0049-3848(95)00072-Y; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Yokoyama K, 2000, BIOSCI BIOTECH BIOCH, V64, P1263, DOI 10.1271/bbb.64.1263; Zhu Y, 1995, APPL MICROBIOL BIOT, V44, P277, DOI 10.1007/s002530050554	47	179	205	6	80	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44252	44260		10.1074/jbc.M203933200	http://dx.doi.org/10.1074/jbc.M203933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221081	hybrid			2022-12-25	WOS:000179272000094
J	Mahajan, SS; Little, MM; Vazquez, R; Wilson, AC				Mahajan, SS; Little, MM; Vazquez, R; Wilson, AC			Interaction of HCF-1 with a cellular nuclear export factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; KAPPA-B-ALPHA; VP16 ACCESSORY PROTEIN; SUBCELLULAR-LOCALIZATION; VP16-INDUCED COMPLEX; ACTIVATION DOMAIN; TEGUMENT PROTEIN; BINDING PROTEIN; POTENTIAL ROLE; LEPTOMYCIN-B	HCF-1 is a cellular protein required by VP16 to activate the herpes simplex virus (HSV) immediate-early genes. VP16 is a component of the viral tegument and, after release into the cell, binds to HCF-1 and translocates to the nucleus to form a complex with the POU domain protein Oct-1 and a VP16-responsive DNA sequence. This VP16-induced complex boosts transcription of the viral immediate-early genes and initiates lytic replication. In uninfected cells, HCF-1 functions as a coactivator for the cellular transcription factors LZIP and GABP and also plays an essential role in cell proliferation. VP16 and LZIP share a tetrapeptide HCF-binding motif recognized by the beta-propeller domain of HCF-1. Here we describe a new cellular HCF-1 beta-propeller domain binding protein, termed HPIP, which contains a functional HCF-binding motif and a leucine-rich nuclear export sequence. We show that HPIP shuttles between the nucleus and cytoplasm in a CRM1-dependent manner and that overexpression of HPIP leads to accumulation of HCF-1 in the cytoplasm. These data suggest that HPIP regulates HCF-1 activity by modulating its subcellular localization. Furthermore, HPIP-mediated export may provide the pool of cytoplasmic HCF-1 required for import of virion-derived VP16 into the nucleus.	NYU, Med Ctr, Dept Microbiol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Wilson, AC (corresponding author), NYU, Med Ctr, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.		Wilson, Angus C/AAA-8153-2019	Wilson, Angus C/0000-0002-5016-4164	NIGMS NIH HHS [R01 GM061139, GM61139] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061139] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Donnelly M, 2001, J VIROL, V75, P2566, DOI 10.1128/JVI.75.6.2566-2574.2001; Elliott G, 2000, J VIROL, V74, P2131, DOI 10.1128/JVI.74.5.2131-2141.2000; Forgues M, 2001, J BIOL CHEM, V276, P22797, DOI 10.1074/jbc.M101259200; Fornerod M, 1997, CELL, V90, P1051; FRATTINI A, 1994, GENOMICS, V23, P30, DOI 10.1006/geno.1994.1455; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; GREAVES R, 1989, J VIROL, V63, P1641, DOI 10.1128/JVI.63.4.1641-1650.1989; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; Hughes TA, 1999, J BIOL CHEM, V274, P16437, DOI 10.1074/jbc.274.23.16437; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; Knopf CW, 2000, ACTA VIROL, V44, P289; Kristie TM, 1999, P NATL ACAD SCI USA, V96, P1229, DOI 10.1073/pnas.96.4.1229; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; La Boissiere S, 1999, EMBO J, V18, P480; LaBoissiere S, 1997, MOL CELL BIOL, V17, P7108, DOI 10.1128/MCB.17.12.7108; Lai JS, 1997, MOL CELL BIOL, V17, P3937, DOI 10.1128/MCB.17.7.3937; Lee SH, 2001, J BIOL CHEM, V276, P23599, DOI 10.1074/jbc.M011197200; Liu JL, 1997, J VIROL, V71, P3188, DOI 10.1128/JVI.71.4.3188-3196.1997; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, J VIROL, V74, P934, DOI 10.1128/JVI.74.2.934-943.2000; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Luciano RL, 2000, P NATL ACAD SCI USA, V97, P10757, DOI 10.1073/pnas.190062797; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; MORIUCHI H, 1995, J VIROL, V69, P4693, DOI 10.1128/JVI.69.8.4693-4701.1995; Morrison EE, 1998, J GEN VIROL, V79, P2517, DOI 10.1099/0022-1317-79-10-2517; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; OHARE P, 1993, SEMIN VIROL, V4, P145, DOI 10.1006/smvy.1993.1010; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; ROIZMAN B, 1996, FIELDS VIROLOGY, V2, P2231; Simmen KA, 1997, J VIROL, V71, P3886, DOI 10.1128/JVI.71.5.3886-3894.1997; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VARAGONA MJ, 1994, PLANT J, V5, P207, DOI 10.1046/j.1365-313X.1994.05020207.x; Vogel JL, 2000, P NATL ACAD SCI USA, V97, P9425, DOI 10.1073/pnas.160266697; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Williams SC, 1997, GENE EXPRESSION, V6, P371; Wilson AC, 2000, MOL CELL BIOL, V20, P6721, DOI 10.1128/MCB.20.18.6721-6730.2000; WILSON AC, 1995, GENOMICS, V25, P462, DOI 10.1016/0888-7543(95)80046-O; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; Ye GJ, 2000, J VIROL, V74, P1355, DOI 10.1128/JVI.74.3.1355-1363.2000	59	20	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44292	44299		10.1074/jbc.M205440200	http://dx.doi.org/10.1074/jbc.M205440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12235138	hybrid, Green Accepted			2022-12-25	WOS:000179272000099
J	Peng, J; Wu, ZJ; Wu, YQ; Hsu, M; Stevenson, FF; Boonplueang, R; Roffler-Tarlov, SK; Andersen, JK				Peng, J; Wu, ZJ; Wu, YQ; Hsu, M; Stevenson, FF; Boonplueang, R; Roffler-Tarlov, SK; Andersen, JK			Inhibition of caspases protects cerebellar granule cells of the weaver mouse from apoptosis and improves behavioral phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE MUTATION WEAVER; MUTANT MICE; K+ CHANNELS; NEURONAL APOPTOSIS; PURKINJE-CELLS; DEATH; ACTIVATION; GENE; GIRK2; DIFFERENTIATION	The homozygous mouse mutant weaver exhibits a massive loss of cerebellar granule neurons postnatally. The death of these cells is associated with a single amino acid mutation in the G protein-activated inwardly rectifying potassium channel, Girk2. Evidence suggests that both the mutated Girk2 channel and the calcium channel-associated N-methyl-D-aspartate receptor play important roles in the apoptotic death of weaver cerebellar granule cells, but the downstream events associated with this process are unknown. In this study, we demonstrate that the consequences of the mutation result in caspase activation. In addition, our results show that caspase inhibition in vivo decreases caspase activation and granule cell apoptosis and significantly improves behavioral deficits associated with the weaver's phenotype.	Buck Inst Age Res, Novato, CA 94945 USA; Univ So Calif, Dept Biol Sci, Program Mol Biol, Los Angeles, CA 90089 USA; Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Anat & Cell Biol, Boston, MA 02111 USA	Buck Institute for Research on Aging; University of Southern California; Tufts University; Tufts University	Andersen, JK (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.		wu, zhijin/J-2282-2014; wu, zhijin/J-4995-2016	wu, zhijin/0000-0002-9596-9134; Hsu, Mike/0000-0001-7086-1808; Andersen, Julie/0000-0003-1324-4875; Boonplueang, Rapee/0000-0002-4384-0363	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012141, R29AG012141] Funding Source: NIH RePORTER; NIA NIH HHS [AG51980, AG12141] Funding Source: Medline; NINDS NIH HHS [NS21461, NS20181] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bailly Y, 1996, J COMP NEUROL, V369, P150; BLATT GJ, 1985, J COMP NEUROL, V232, P117, DOI 10.1002/cne.902320110; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Ehrengruber MU, 1997, P NATL ACAD SCI USA, V94, P7070, DOI 10.1073/pnas.94.13.7070; GAO WQ, 1992, CELL, V68, P841, DOI 10.1016/0092-8674(92)90028-B; GRAYBIEL AM, 1990, J NEUROSCI, V10, P720; Harrison SMW, 1998, DEV BIOL, V195, P174, DOI 10.1006/dbio.1998.8848; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; Henderson CE, 1996, NEURON, V17, P579, DOI 10.1016/S0896-6273(00)80191-9; HERRUP K, 1987, NEUROSCIENCE, V23, P871, DOI 10.1016/0306-4522(87)90164-3; Jensen P, 1999, J NEUROSCI, V19, P7991; Kofuji P, 1996, NEURON, V16, P941, DOI 10.1016/S0896-6273(00)80117-8; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lauritzen I, 1997, BRAIN RES, V753, P8, DOI 10.1016/S0006-8993(96)01491-6; Maricich SM, 1997, J NEUROSCI, V17, P3675; Migheli A, 1999, AM J PATHOL, V155, P365, DOI 10.1016/S0002-9440(10)65133-4; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Namura S, 1998, J NEUROSCI, V18, P3659; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; RAKIC P, 1973, J COMP NEUROL, V152, P133, DOI 10.1002/cne.901520203; RAKIC P, 1973, J COMP NEUROL, V152, P103, DOI 10.1002/cne.901520202; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REZAI Z, 1972, DEV BIOL, V29, P17, DOI 10.1016/0012-1606(72)90039-5; RofflerTarlov S, 1996, J NEUROSCI, V16, P1819; ROFFLERTARLOV S, 1984, NATURE, V307, P62, DOI 10.1038/307062a0; Rossi P, 1998, J NEUROSCI, V18, P3537; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schein JC, 1998, DEV BIOL, V204, P432, DOI 10.1006/dbio.1998.9076; SCHMIDT MJ, 1982, J NEUROSCI, V2, P376; SIDMAN RL, 1965, CATALOG NEUROLOGICAL, P66; Silverman SK, 1996, P NATL ACAD SCI USA, V93, P15429, DOI 10.1073/pnas.93.26.15429; Slesinger PA, 1996, NEURON, V16, P321, DOI 10.1016/S0896-6273(00)80050-1; SMEYNE RJ, 1989, J NEUROSCI, V9, P1608; SMEYNE RJ, 1990, DEV BRAIN RES, V52, P211, DOI 10.1016/0165-3806(90)90237-S; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; Surmeier DJ, 1996, P NATL ACAD SCI USA, V93, P11191, DOI 10.1073/pnas.93.20.11191; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; TRIARHOU LC, 1988, EXP BRAIN RES, V70, P256; Viswanath V, 2000, P NATL ACAD SCI USA, V97, P2270, DOI 10.1073/pnas.030365297; Viswanath V, 2001, J NEUROSCI, V21, P9519, DOI 10.1523/JNEUROSCI.21-24-09519.2001; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wullner U, 1998, ACTA NEUROPATHOL, V96, P233, DOI 10.1007/s004010050889; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAMOTO M, 1990, J NEUROCYTOL, V19, P619, DOI 10.1007/BF01188031	50	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44285	44291		10.1074/jbc.M207407200	http://dx.doi.org/10.1074/jbc.M207407200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221097	hybrid			2022-12-25	WOS:000179272000098
J	Castellano, R; Van Lint, C; Peri, V; Veithen, E; Morel, Y; Costello, R; Olive, D; Collette, Y				Castellano, R; Van Lint, C; Peri, V; Veithen, E; Morel, Y; Costello, R; Olive, D; Collette, Y			Mechanisms regulating expression of the tumor necrosis factor-related light gene - Role of calcium-signaling pathway in the transcriptional control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; HERPESVIRUS ENTRY MEDIATOR; FACTOR-ALPHA GENE; TNF SUPERFAMILY; B-CELLS; NUCLEAR FACTOR; IN-VIVO; LIGAND; PROMOTER; NFAT	LIGHT (TNFSF14) is a newly identified tumor necrosis factor superfamily member involved in the regulation of immune responses by control of activation, maturation, and survival of immune effector cells. Despite the immunological relevance of the LIGHT protein, little knowledge is available as to how light gene expression is regulated. In T-lymphocytes, most LIGHT surface expression and transcript accumulation occurs after T cell activation. In this study, we have shown that these events are blocked at the transcriptional level by cyclosporin A, an immuno-suppressive drug. Besides, we identified a role for Ca2+-signaling pathways and NFAT transcription factors in T cell activation-induced LIGHT expression. To further investigate this process, we have identified, cloned, and characterized a 2.1-kilobase 5'-flanking DNA genomic fragment from the human light gene. We have shown the transcriptional activity of the herein-identified minimal 5' regulatory region of human light gene parallels the endogenous expression of light in T cells. Moreover, we demonstrated that induced LIGHT promoter activity can be equally blocked by cyclosporin A treatment or dominant negative NFAT overexpression and further identified by site-directed mutagenesis and electrophoretic mobility supershift analysis of a NFAT transcription factor binding site within the human light minimal promoter. Finally, Sp1 and Ets1 binding sites were identified and shown to regulate light basal promoter activity. Thus, the present study establishes a molecular basis to further understand the mechanisms governing human light gene expression and, consequently, could potentially lead to novel therapeutic manipulations that control the signaling cascade, resulting in LIGHT production in conditions characterized by immunopathologic activation of T cells.	INSERM, U119, Inst Cancerol & Immunol Marseille, F-13009 Marseille, France; Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, B-6041 Gosselies, Belgium; Inst J Paoli I Calmettes, Lab Immunol Tumeurs, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Collette, Y (corresponding author), INSERM, U119, Inst Cancerol & Immunol Marseille, 27 Blvd Lei Roure, F-13009 Marseille, France.		COLLETTE, Yves/F-2270-2013; Costello, Régis T/N-5079-2016; morel, yves/C-4757-2017	COLLETTE, Yves/0000-0001-5359-7099; Costello, Régis T/0000-0002-4086-1302; 				BAGNASCO M, 1989, EUR J IMMUNOL, V19, P823, DOI 10.1002/eji.1830190507; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; Benedict CA, 2001, IMMUNITY, V15, P617, DOI 10.1016/S1074-7613(01)00222-9; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Chou CF, 2000, J BIOMED SCI, V7, P136, DOI 10.1159/000025439; Chow CW, 1999, MOL CELL BIOL, V19, P2300; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COSTELLO R, 1993, EUR J IMMUNOL, V23, P608, DOI 10.1002/eji.1830230304; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; Granger SW, 2001, J IMMUNOL, V167, P5122, DOI 10.4049/jimmunol.167.9.5122; HAN J, 1991, J IMMUNOL, V146, P1843; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; KRAMER B, 1995, J BIOL CHEM, V270, P6577; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Luo C, 1996, J EXP MED, V184, P141, DOI 10.1084/jem.184.1.141; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Matsumoto Mitsuru, 1999, Journal of Medical Investigation, V46, P141; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; McClure RF, 1999, J BIOL CHEM, V274, P7756, DOI 10.1074/jbc.274.12.7756; Misawa K, 2000, CYTOGENET CELL GENET, V89, P89, DOI 10.1159/000015570; Morel Y, 2000, J IMMUNOL, V165, P4397, DOI 10.4049/jimmunol.165.8.4397; Morel Y, 2001, J IMMUNOL, V167, P2479, DOI 10.4049/jimmunol.167.5.2479; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Scheu S, 2002, J EXP MED, V195, P1613, DOI 10.1084/jem.20020215; SCHUBERT LA, 1995, J BIOL CHEM, V270, P29624; Shaikh RB, 2001, J IMMUNOL, V167, P6330, DOI 10.4049/jimmunol.167.11.6330; Sharma K, 2000, PHARMACOL THERAPEUT, V88, P333, DOI 10.1016/S0163-7258(00)00096-6; Tamada K, 2000, J IMMUNOL, V164, P4105, DOI 10.4049/jimmunol.164.8.4105; Tamada K, 2000, NAT MED, V6, P283; Tomaras GD, 1999, J LEUKOCYTE BIOL, V66, P183, DOI 10.1002/jlb.66.1.183; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Wang J, 2001, J CLIN INVEST, V108, P1771, DOI 10.1172/JCI200113827; Wang J, 2001, J IMMUNOL, V167, P5099, DOI 10.4049/jimmunol.167.9.5099; Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.3.CO;2-2; Xiao S, 2001, EUR J IMMUNOL, V31, P3339, DOI 10.1002/1521-4141(200111)31:11<3339::AID-IMMU3339>3.0.CO;2-U; Yang WC, 2000, INT IMMUNOL, V12, P1547, DOI 10.1093/intimm/12.11.1547; Ye QR, 2002, J EXP MED, V195, P795, DOI 10.1084/jem.20012088; Yu KY, 1999, J BIOL CHEM, V274, P13733, DOI 10.1074/jbc.274.20.13733; Zhai YF, 1998, J CLIN INVEST, V102, P1142, DOI 10.1172/JCI3492	46	20	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42841	42851		10.1074/jbc.M207689200	http://dx.doi.org/10.1074/jbc.M207689200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12215452	hybrid			2022-12-25	WOS:000179081200056
J	Massimi, I; Park, E; Rice, K; Muller-Esterl, W; Sauder, D; McGavin, MJ				Massimi, I; Park, E; Rice, K; Muller-Esterl, W; Sauder, D; McGavin, MJ			Identification of a novel maturation mechanism and restricted substrate specificity for the SspB cysteine protease of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; AMINO-ACID-SEQUENCE; INTRAMOLECULAR CHAPERONE; STREPTOCOCCUS-PYOGENES; PROTEOLYTIC ACTIVITY; PLASMA FIBRONECTIN; TERMINAL FRAGMENTS; BINDING-PROTEIN; SERINE-PROTEASE; CLEAVAGE SITES	The SspB cysteine protease of Staphylococcus aureus is expressed in an operon, flanked by the sspA serine protease, and sspC, encoding a 12.9-kDa protein of unknown function. SspB was expressed as a 40-kDa prepropeptide pSspB, which did not undergo autocatalytic maturation. Activity of pSspB was reduced compared with 22-kDa mature SspB, but it was equivalent to mature SspB after incubation with SspA, which specifically removed the pSspB N-terminal propeptide. SspC abrogated the activity of pSspB when incubated in a 1:1 complex but had no effect on SspA or papain. Activity of the pSspB-SspC complex was restored when incubated with SspA, and SspC was cleaved by SspA but not pSspB. Thus, SspC maintains pSspB as an inert zymogen, and SspA is required for removal of the propeptide and inactivation of SspC. Like the papain protease family, SspB cleaved substrates with a hydrophobic amino acid at P2 but had a strong preference for arginine at P1. It did not cleave casein, serum albumin, IgG, or IgA, but it promoted detachment of cultured keratinocytes and cleaved fibronectin and fibrinogen at sites recognized by urokinase plasminogen activator and plasmin, respectively. It also processed high molecular weight kininogen in a manner resembling plasma kallikrein. Thus, SspB exhibits a novel maturation mechanism and mimics the specificity of plasma serine proteases.	Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany; Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Dermatol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada	Goethe University Frankfurt; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto	McGavin, MJ (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Microbiol S112, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	martin.mcgavin@swchsc.on.ca		McGavin, Martin/0000-0001-5955-0689				Archer GL, 1998, CLIN INFECT DIS, V26, P1179, DOI 10.1086/520289; ASAKURA S, 1992, J CELL BIOL, V116, P465, DOI 10.1083/jcb.116.2.465; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Chavakis T, 2000, BLOOD, V96, P514; Collin M, 2001, INFECT IMMUN, V69, P7187, DOI 10.1128/IAI.69.11.7187-7189.2001; Colman RW, 2001, BIOL CHEM, V382, P65, DOI 10.1515/BC.2001.011; Coulter SN, 1998, MOL MICROBIOL, V30, P393, DOI 10.1046/j.1365-2958.1998.01075.x; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; Doran JD, 1999, EUR J BIOCHEM, V263, P145, DOI 10.1046/j.1432-1327.1999.00473.x; DRAPEAU GR, 1972, J BIOL CHEM, V247, P6720; DRAPEAU GR, 1978, J BACTERIOL, V136, P607, DOI 10.1128/JB.136.2.607-613.1978; Fitzgerald JR, 2001, P NATL ACAD SCI USA, V98, P8821, DOI 10.1073/pnas.161098098; Fu X, 2000, J BIOL CHEM, V275, P16871, DOI 10.1074/jbc.275.22.16871; GOLD LI, 1992, J CELL BIOCHEM, V50, P441, DOI 10.1002/jcb.240500412; GRINNELL F, 1980, CELL, V19, P517, DOI 10.1016/0092-8674(80)90526-7; HAMAGUCHI M, 1993, BLOOD, V81, P2348; Herwald H, 1998, NAT MED, V4, P298, DOI 10.1038/nm0398-298; Herwald H, 1996, J EXP MED, V184, P665, DOI 10.1084/jem.184.2.665; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HUFF S, 1994, J BIOL CHEM, V269, P15563; HURLETJENSEN A, 1983, THROMB RES, V29, P609, DOI 10.1016/0049-3848(83)90215-3; Jarraud S, 2002, INFECT IMMUN, V70, P631, DOI 10.1128/IAI.70.2.631-641.2002; KAPUR V, 1993, MICROB PATHOGENESIS, V15, P327, DOI 10.1006/mpat.1993.1083; Karlsson A, 2001, INFECT IMMUN, V69, P4742, DOI 10.1128/IAI.69.8.4742-4748.2001; KAUFMANN J, 1993, J BIOL CHEM, V268, P9079; Kim W, 1996, APPL ENVIRON MICROB, V62, P2482, DOI 10.1128/AEM.62.7.2482-2488.1996; KONDO S, 1993, J INVEST DERMATOL, V101, P690, DOI 10.1111/1523-1747.ep12371677; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; Lima APCA, 2002, J BIOL CHEM, V277, P5875, DOI 10.1074/jbc.M108518200; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Matsui T, 1998, EUR J BIOCHEM, V252, P569, DOI 10.1046/j.1432-1327.1998.2520569.x; Matsuka YV, 1999, INFECT IMMUN, V67, P4326, DOI 10.1128/IAI.67.9.4326-4333.1999; Matsuka YV, 1997, J PROTEIN CHEM, V16, P739, DOI 10.1023/A:1026307731751; McAleese FM, 2001, J BIOL CHEM, V276, P29969, DOI 10.1074/jbc.M102389200; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; McGavin MJ, 1997, INFECT IMMUN, V65, P2621, DOI 10.1128/IAI.65.7.2621-2628.1997; Motta G, 1998, BLOOD, V91, P516, DOI 10.1182/blood.V91.2.516.516_516_528; Musser JM, 1996, INFECT IMMUN, V64, P1913, DOI 10.1128/IAI.64.6.1913-1917.1996; Nomizu M, 2001, J BIOL CHEM, V276, P44551, DOI 10.1074/jbc.M106306200; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; Rice K, 2001, INFECT IMMUN, V69, P159, DOI 10.1128/IAI.69.1.159-169.2001; Sabat A, 2000, INFECT IMMUN, V68, P973, DOI 10.1128/IAI.68.2.973-976.2000; SCOTT CF, 1984, J CLIN INVEST, V73, P954, DOI 10.1172/JCI111319; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; Stockbauer KE, 1999, P NATL ACAD SCI USA, V96, P242, DOI 10.1073/pnas.96.1.242; STORER AC, 1994, METHOD ENZYMOL, V244, P486; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Yabuta Y, 2001, J BIOL CHEM, V276, P44427, DOI 10.1074/jbc.M107573200; YUEN SW, 1989, BIOTECHNIQUES, V7, P74; Ziebandt AK, 2001, PROTEOMICS, V1, P480, DOI 10.1002/1615-9861(200104)1:4<480::AID-PROT480>3.0.CO;2-O	53	79	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41770	41777		10.1074/jbc.M207162200	http://dx.doi.org/10.1074/jbc.M207162200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12207024	hybrid			2022-12-25	WOS:000178985300061
J	Ader, I; Toulas, C; Dalenc, F; Delmas, C; Bonnet, J; Cohen-Jonathan, E; Favre, G				Ader, I; Toulas, C; Dalenc, F; Delmas, C; Bonnet, J; Cohen-Jonathan, E; Favre, G			RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death	ONCOGENE			English	Article						radioresistance; farnesylation; Ras; RhoB	FIBROBLAST GROWTH-FACTOR; FARNESYLTRANSFERASE INHIBITORS; IN-VIVO; GERANYLGERANYLATED RHOB; ENDOTHELIAL-CELLS; RAS ONCOGENES; PROTEIN; RADIATION; PRENYLATION; FORMS	Farnesylated Ras oncoprotein induces a cellular resistance to ionizing radiation that can be reversed by farnesyltransferase inhibitors (FTI). We previously demonstrated that, expression of the 24 kDa FGF2 isoform in wild type ras bearing HeLa cells, induced radioresistance which was also reversed by FTI. We tested the hypothesis that wild type Ras or RhoB, which has been proposed as a potential FTI target, could control the FGF-2-induced radioresistance mechanisms. For this, we expressed inducible dominant negative forms of Ras (RasN17) and Rho (RhoBN19) in 24 kDa FGF2 transfected HeLa cells and analysed their survival after irradiation. While no cell survival modification was observed after RasN17 induction, the expression of RhoBN19 induced a radiosensitization of FGF2 radioresistant HeLa cells in the same range as the one observed after a 48 h treatment with the specific FTI, R115777. Moreover, we showed that activated RhoB but not RhoA induced radioresistance in NIH3T3 cells. The radiosensitizer effect of RhoBN19 expression was due to the induction of the radiation induced post-mitotic cell death. Taken together, these data demonstrate that 24 kDa FGF-2-induced radioresistance is controlled by Rho pathways and suggest that RhoB should be a major determinant in cellular resistance to ionizing radiation.	Ctr Lutte Contre Canc Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM U563, F-31052 Toulouse, France; Ctr Lutte Contre Canc Claudius Regaud, Dept Radiotherapie, F-31052 Toulouse, France	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Favre, G (corresponding author), Ctr Lutte Contre Canc Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM U563, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.		delmas, caroline/O-9241-2014; FAVRE, Gilles/K-9189-2014; Toulas, Christine/P-3838-2014; Moyal, Elizabeth/A-9802-2015; Ader-Perarnau, Isabelle/F-7160-2017	FAVRE, Gilles/0000-0002-2344-1883; Toulas, Christine/0000-0003-1261-1725; Moyal, Elizabeth/0000-0002-6593-9276; ADER, isabelle/0000-0001-5103-8509				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Baron R, 2000, P NATL ACAD SCI USA, V97, P11626, DOI 10.1073/pnas.97.21.11626; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1998, CANCER RES, V58, P1754; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BRUYNEEL EA, 1993, EUR J CANCER, V29A, P1958, DOI 10.1016/0959-8049(93)90452-L; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Cohen-Jonathan E, 1999, RADIAT RES, V152, P404, DOI 10.2307/3580225; Cohen-Jonathan E, 2000, RADIAT RES, V154, P125, DOI 10.1667/0033-7587(2000)154[0125:FIPTAE]2.0.CO;2; CohenJonathan E, 1997, CANCER RES, V57, P1364; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DECREMOUX P, 1994, INT J CANCER, V59, P408, DOI 10.1002/ijc.2910590320; Du W, 1999, MOL CELL BIOL, V19, P1831; End DW, 2001, CANCER RES, V61, P131; FERTIL B, 1984, RADIAT RES, V99, P73, DOI 10.2307/3576448; Fiorentini C, 1997, J BIOL CHEM, V272, P19532, DOI 10.1074/jbc.272.31.19532; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; FUKS Z, 1994, CANCER RES, V54, P2582; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; Lebowitz PF, 1998, CELL ADHES COMMUN, V6, P277, DOI 10.3109/15419069809010787; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MCKENNA WG, 1990, INT J RADIAT ONCOL, V18, P849, DOI 10.1016/0360-3016(90)90407-B; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Miquel K, 1997, CANCER RES, V57, P1846; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; VAN AL, 1997, GENE DEV, V11, P2295; WHITE JH, 1994, BIO-TECHNOL, V12, P1003, DOI 10.1038/nbt1094-1003	38	57	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					5998	6006		10.1038/sj.onc.1205746	http://dx.doi.org/10.1038/sj.onc.1205746			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203112				2022-12-25	WOS:000177671300003
J	Kato, K; Ito, H; Kamei, K; Iwamoto, I; Inaguma, Y				Kato, K; Ito, H; Kamei, K; Iwamoto, I; Inaguma, Y			Innervation-dependent phosphorylation and accumulation of crystallin and Hsp27 as insoluble complexes in disused muscle	FASEB JOURNAL			English	Article						molecular chaperone; phospho-specific antibodies; nerve activity	ALPHA-B-CRYSTALLIN; RAT SKELETAL-MUSCLE; HEAT-SHOCK PROTEIN; P38 MAP KINASE; ALEXANDERS-DISEASE; IDENTIFICATION; STRESS; GENE; PURIFICATION; CONTRACTION	Levels and phosphorylation states of the two small molecular chaperones, alphaB-crystallin and Hsp27, in disused rat soleus muscles were determined by Western blot analysis of extracts with antibodies recognizing each of the two proteins and their phosphorylated serine residues. Increased phosphorylation and relocalization to insoluble fractions were found within a few days of hindlimb suspension. High phosphorylation of alphaB-crystallin at Ser-59 (and to a certain extent, at Ser45) and of Hsp27 at Ser-15 and Ser-85, along with phosphorylated, active states of p38 and p44/42 mitogen-activated protein kinases were maintained during hind-limb suspension but promptly returned to control levels within a 5-day recovery period. These results are similar to those observed with U373 MG glioma cells exposed to proteasome inhibitors (16). However, the responses of alphaB-crystallin and Hsp27 in suspended soleus muscles did not appear with ipsilateral transection of the sciatic nerve trunk, indicating mediation by nerve activity. The fact that ubiquitinated proteins accumulated in the insoluble fractions of suspended soleus muscle further suggests participation of alphaB-crystallin and Hsp27 in quality control of proteins in disused soleus muscle, with involvement of nerve activity-dependent processes.	Aichi Human Serv ctr, Inst Dev Res, Dept Biochem, Kasugai, Aichi 4800392, Japan		Kato, K (corresponding author), Aichi Human Serv ctr, Inst Dev Res, Dept Biochem, 713-8 Kamiya, Kasugai, Aichi 4800392, Japan.	kato@inst-hsc.pref.aichi.jp		Ito, Hidenori/0000-0002-6527-477X				Aronson D, 1998, AM J PHYSIOL-CELL PH, V275, pC555, DOI 10.1152/ajpcell.1998.275.2.C555; Aronson D, 1997, J BIOL CHEM, V272, P25636, DOI 10.1074/jbc.272.41.25636; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; Beall AC, 1997, J BIOL CHEM, V272, P11283; BLOEMENDAL H, 1981, ANAL BIOCHEM, V117, P327, DOI 10.1016/0003-2697(81)90787-9; Boppart MD, 2001, AM J PHYSIOL-CELL PH, V280, pC352, DOI 10.1152/ajpcell.2001.280.2.C352; CHIESA R, 1987, J BIOL CHEM, V262, P1438; COOPER LF, 1994, J BIOL CHEM, V269, P7869; FURUNO K, 1990, J BIOL CHEM, V265, P8550; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; Goodyear LJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE403, DOI 10.1152/ajpendo.1996.271.2.E403; INAGUMA Y, 1993, J BIOCHEM-TOKYO, V114, P378, DOI 10.1093/oxfordjournals.jbchem.a124184; Inaguma Y, 2001, EUR J CELL BIOL, V80, P741, DOI 10.1078/0171-9335-00203; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; Ito H, 2002, J BIOCHEM, V131, P593, DOI 10.1093/oxfordjournals.jbchem.a003139; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; Kato K, 1998, J BIOL CHEM, V273, P28346, DOI 10.1074/jbc.273.43.28346; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; Kato K, 1996, J BIOL CHEM, V271, P26989, DOI 10.1074/jbc.271.43.26989; Kato K, 2001, J NEUROCHEM, V76, P730, DOI 10.1046/j.1471-4159.2001.00038.x; KATO K, 1994, J BIOL CHEM, V269, P15302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; QUAXJEUKEN Y, 1985, P NATL ACAD SCI USA, V82, P5819, DOI 10.1073/pnas.82.17.5819; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Sherwood DJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE870, DOI 10.1152/ajpendo.1999.276.5.E870; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Taillandier D, 1996, BIOCHEM J, V316, P65, DOI 10.1042/bj3160065; UOSHIMA K, 1993, BIOCHEM BIOPH RES CO, V197, P1388, DOI 10.1006/bbrc.1993.2631; Verschuure P, 2002, J MOL CELL CARDIOL, V34, P117, DOI 10.1006/jmcc.2001.1493; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; VOORTER CEM, 1986, EUR J BIOCHEM, V160, P203; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379	40	40	41	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1432	+		10.1096/fj.02-0129fje	http://dx.doi.org/10.1096/fj.02-0129fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205038				2022-12-25	WOS:000177813100008
J	Idicula, AM; Blatch, GL; Cooper, TG; Dorrington, RA				Idicula, AM; Blatch, GL; Cooper, TG; Dorrington, RA			Binding and activation by the zinc cluster transcription factors of Saccharomyces cerevisiae - Redefining the UAS(GABA) and its interaction with Uga3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; REGULATORY ELEMENTS; GENE-EXPRESSION; PROTEIN-BINDING; IN-VITRO; GAL4; RECOGNITION; REPRESSION; INDUCTION; PERMEASE	Uga3p, a member of zinc binuclear cluster transcription factor family, is required for gamma-aminobutyric aciddependent transcription of the UGA genes in Saccharomyces cerevisiae. Members of this family bind to CGG triplets with the spacer region between the triplets being an important specificity determinant. A conserved 19-nucleotide activation element in certain UGA gene promoter regions contains a CCGN(4)CGG-everted repeat proposed to be the binding site of Uga3p, UAS(GABA). The function of conserved nucleotides flanking the everted repeat has not been rigorously investigated. The interaction of Uga3p with UAS(GABA) was characterized in terms of binding in vitro and transcriptional activation of lacZ reporter genes in vivo. Electromobility shift assays using mutant UAS(GABA) sequences and heterologously produced full-length Uga3p demonstrated that UAS(GABA) consists of two independent Uga3p binding sites. Simultaneous occupation of both Uga3p binding sites of UASGABA with high affinity is essential for GABA-dependent transcriptional activation in vivo. We present evidence that the two Uga3p molecules bound to UASGABA probably interact with each other and show that Uga3p((1-124)), previously used for binding studies, is not functionally equivalent to the full-length protein with respect to binding in vitro. We propose that the Uga3p binding site is an asymmetric site of 5'-SGCGGN-WTTT-3' (S = G or C, W = A, or T and n = no nucleotide or G). However, UAS(GABA), is a palindrome containing two asymmetric Uga3p binding sites.	Rhodes Univ, Dept Biochem Microbiol & Biotechnol, ZA-6140 Grahamstown, South Africa; Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	Rhodes University; University of Tennessee System; University of Tennessee Health Science Center	Dorrington, RA (corresponding author), Rhodes Univ, Dept Biochem Microbiol & Biotechnol, POB 94, ZA-6140 Grahamstown, South Africa.	r.dorrington@ru.ac.za	Blatch, Gregory Lloyd/Q-5900-2019	Blatch, Gregory Lloyd/0000-0003-0778-8577; Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRE B, 1990, MOL GEN GENET, V220, P269; AXELROD JD, 1991, MOL CELL BIOL, V11, P564, DOI 10.1128/MCB.11.1.564; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; Coffman JA, 1997, J BACTERIOL, V179, P5609, DOI 10.1128/jb.179.17.5609-5613.1997; COFFMAN JA, 1994, J BACTERIOL, V176, P7476, DOI 10.1128/JB.176.24.7476-7483.1994; CUNNINGHAM TS, 1994, J BACTERIOL, V176, P4718, DOI 10.1128/JB.176.15.4718-4725.1994; DAUGHERTY JR, 1993, J BACTERIOL, V175, P64, DOI 10.1128/JB.175.1.64-73.1993; DHAWALE SS, 1993, NUCLEIC ACIDS RES, V21, P5537, DOI 10.1093/nar/21.24.5537; DORRINGTON RA, 1993, NUCLEIC ACIDS RES, V21, P3777, DOI 10.1093/nar/21.16.3777; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; IDICULA AM, 2002, THESIS RHODES U GRAH; KING DA, 1999, EUR J MORPHOL, V36, P86; KOVARI L, 1990, MOL CELL BIOL, V10, P5087, DOI 10.1128/MCB.10.10.5087; Lenouvel F, 1997, J BIOL CHEM, V272, P15521, DOI 10.1074/jbc.272.24.15521; Mamane Y, 1998, J BIOL CHEM, V273, P18556, DOI 10.1074/jbc.273.29.18556; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MCKELVEY J, 1990, YEAST, V6, P263, DOI 10.1002/yea.320060311; Moretti MB, 2001, INT J BIOCHEM CELL B, V33, P1202, DOI 10.1016/S1357-2725(01)00085-1; Noel J, 1998, J BIOL CHEM, V273, P17463, DOI 10.1074/jbc.273.28.17463; PAN T, 1989, P NATL ACAD SCI USA, V86, P3145, DOI 10.1073/pnas.86.9.3145; PARK HD, 1992, NUCLEIC ACIDS RES, V20, P1909, DOI 10.1093/nar/20.8.1909; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; SoussiBoudekou S, 1997, MOL MICROBIOL, V23, P1157, DOI 10.1046/j.1365-2958.1997.3021665.x; SZE JY, 1993, J BIOL CHEM, V268, P2505; TABOR S, 1990, CURRENT PROTOCOL MOL; TALIBI D, 1995, NUCLEIC ACIDS RES, V23, P550, DOI 10.1093/nar/23.4.550; VASHEE S, 1993, J BIOL CHEM, V268, P24699; VISSERS S, 1989, EUR J BIOCHEM, V181, P357, DOI 10.1111/j.1432-1033.1989.tb14732.x; Yu LH, 2000, PROTEIN SCI, V9, P2470, DOI 10.1110/ps.9.12.2470; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110	35	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45977	45983		10.1074/jbc.M201789200	http://dx.doi.org/10.1074/jbc.M201789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235130	hybrid, Green Accepted			2022-12-25	WOS:000179529300037
J	Iwamoto, S; Kumada, M; Kamesaki, T; Okuda, H; Kajii, E; Inagaki, T; Saikawa, D; Takeuchi, K; Ohkawara, S; Takahashi, R; Ueda, S; Inoue, S; Tahara, K; Hakamata, Y; Kobayashi, E				Iwamoto, S; Kumada, M; Kamesaki, T; Okuda, H; Kajii, E; Inagaki, T; Saikawa, D; Takeuchi, K; Ohkawara, S; Takahashi, R; Ueda, S; Inoue, S; Tahara, K; Hakamata, Y; Kobayashi, E			Rat encodes the paralogous gene equivalent of the human histo-blood group ABO gene - Association with antigen expression by overexpression of human ABO transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GALACTOSIDE 2-ALPHA-L-FUCOSYL-TRANSFERASE; CHEMICAL CARCINOGENESIS; DNA METHYLATION; LARGE-INTESTINE; HUMAN CANCER; GROUP-A; REGION; TRANSPLANTATION; HEPATOMA; LIVER	We cloned a rat ABO homologue and established human A- and B-transferase transgenic rats. A DNA fragment corresponding to exon 7 of the human ABO gene was amplified from Wistar rat genomic DNA and sequenced. Using the amplified fragments as a probe for Southern blotting, multiple hybridized bands appeared on both EcoRI- and BamHI-digested genomes of seven rat strains, which showed variations in the band numbers among the strains. Four cDNAs were cloned from a Wistar rat, three of which showed A-iransferase activity and one of which showed B-transferase activity. These activities were dependent on the equivalent residues at 266 and 268 of human ABO transferase. Wild Wistar rats expressed A-antigen in salivary gland, intestine, and urinary bladder tissue, but B-antigen was not stained in any organs studied, whereas a transcript from the ABO homologue with B-transferase activity was ubiquitous. Human A-transferase and B-transferase were transferred into Wistar rats. A-transgenic rats expressed A-antigen in ectopic tissue of the brain plexus, type II lung epithelium, pancreas, and epidermis. B-antigen in the B-transgenic rat was expressed in the same organs as A-transgenic rats. These results may shed light on the function and evolution of the ABO gene in primates.	Jichi Med Sch, Dept Legal Med & Human Genet, Minami Kawachi, Tochigi 32904, Japan; Jichi Med Sch, Dept Anat, Minami Kawachi, Tochigi 32904, Japan; YS New Technol Inst Inc, Minami Kawachi, Tochigi 32904, Japan; Jichi Med Sch, Ctr Mol Med, Minami Kawachi, Tochigi 3290498, Japan	Jichi Medical University; Jichi Medical University; Jichi Medical University	Iwamoto, S (corresponding author), Jichi Med Sch, Dept Legal Med & Human Genet, 3311-1 Minamikawachi Machi, Minami Kawachi, Tochigi 32904, Japan.	siwamoto@ms.jichi.ac.jp	Hakamata, Yoji/AAF-7759-2020; INAGAKI, Takeshi/N-2247-2016	INAGAKI, Takeshi/0000-0002-8720-2654; Hakamata, Yoji/0000-0002-0138-6692				ANGSTROM J, 1987, BIOCHIM BIOPHYS ACTA, V926, P79, DOI 10.1016/0304-4165(87)90184-X; BOUHOURS D, 1995, BBA-LIPID LIPID MET, V1255, P131, DOI 10.1016/0005-2760(94)00229-R; BOUHOURS JF, 1987, J BIOL CHEM, V262, P16370; BREIMER ME, 1979, BIOMED MASS SPECTROM, V6, P231, DOI 10.1002/bms.1200060603; COOPER DKC, 1990, J HEART TRANSPLANT, V9, P376; Hakamata Y, 2001, BIOCHEM BIOPH RES CO, V286, P779, DOI 10.1006/bbrc.2001.5452; Hakomori S, 1999, BBA-GEN SUBJECTS, V1473, P247, DOI 10.1016/S0304-4165(99)00183-X; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Hallouin F, 1997, GLYCOCONJUGATE J, V14, P801, DOI 10.1023/A:1018581719944; HOLMES EH, 1982, J BIOL CHEM, V257, P7698; HOLMES EH, 1983, J BIOL CHEM, V258, P3706; Ichikawa D, 1997, CANCER RES, V57, P3092; ISHIKAWA N, 1993, IMMUNOLOGY, V78, P303; Iwamoto S, 1998, INT J HEMATOL, V68, P257; Iwamoto S, 1999, GLYCOCONJUGATE J, V16, P659, DOI 10.1023/A:1007085202379; Koda Y, 1997, J BIOL CHEM, V272, P7501, DOI 10.1074/jbc.272.11.7501; Kominato Y, 1999, J BIOL CHEM, V274, P37240, DOI 10.1074/jbc.274.52.37240; KOMINATO Y, 1992, BIOCHEM BIOPH RES CO, V189, P154, DOI 10.1016/0006-291X(92)91538-2; Mak KM, 2000, ANAT RECORD, V259, P395; MIYAO N, 1993, CANCER RES, V53, P4066; Okuda H, 2000, BIOCHEM BIOPH RES CO, V274, P670, DOI 10.1006/bbrc.2000.3206; Olson FJ, 2002, J BIOL CHEM, V277, P15044, DOI 10.1074/jbc.M112287200; PIAU JP, 1994, BIOCHEM J, V300, P623, DOI 10.1042/bj3000623; Saitou N, 1997, MOL BIOL EVOL, V14, P399, DOI 10.1093/oxfordjournals.molbev.a025776; Sherwood AL, 1998, ARCH BIOCHEM BIOPHYS, V355, P215, DOI 10.1006/abbi.1998.0728; Soejima M, 1999, EUR J BIOCHEM, V266, P274, DOI 10.1046/j.1432-1327.1999.00865.x; Szulman A E, 1980, Curr Top Dev Biol, V14, P127; Tanabe K, 1996, TRANSFUS SCI, V17, P455; Wagner FF, 2000, BLOOD, V95, P3662; Watkins W.M., 1995, GLYCOPROTEINS, P313; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1995, GLYCOBIOLOGY, V5, P51, DOI 10.1093/glycob/5.1.51; Yamamoto M, 2001, J BIOL CHEM, V276, P13701, DOI 10.1074/jbc.M010805200	33	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46463	46469		10.1074/jbc.M206439200	http://dx.doi.org/10.1074/jbc.M206439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237302	hybrid			2022-12-25	WOS:000179529300099
J	Brandlin, I; Eiseler, T; Salowsky, R; Johannes, FJ				Brandlin, I; Eiseler, T; Salowsky, R; Johannes, FJ			Protein kinase C mu regulation of the JNK pathway is triggered via phosphoinositide-dependent kinase 1 and protein kinase C epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER DOMAIN; MOLECULAR-CLONING; PI 3-KINASE; IN-VITRO; KAPPA-B; PKC-MU; ACTIVATION; GOLGI; PHOSPHORYLATION; INTERACTS	The protein kinase C (PKC)-related enzyme PKCmu/PKD (protein kinase D) is activated by activation loop phosphorylation through PKCeta. Here we demonstrate that PKCmu is activated by the direct phosphorylation of PKC,E. PKCmu colocalizes with PKCepsilon in HEK293 and MCF7 cells as shown by confocal immunofluorescence analyses. PDK1, known as the upstream kinase for several PKC isozymes, associates intracellularly with PKCepsilon and PKCeta. PKCeta is phosphorylated by PDK1 in vitro, leading to kinase activation as similarly reported for PKCepsilon activation by PDK1. Coexpression of PDK1, PKCe and PKCmu in HEK293 cells results in PKCmu activation. In contrast, the coexpression of PDK1 and PKCeta with PKCmu does not activate PKCeta or consequently PKCmu. PDK1/PKCepsilon-triggered activation of PKCmu inhibits JNE a downstream effector of PKCmu, whereas upon transient expression of PDK1, PKCeta, and PKCmu, JNK is not affected. These data implicate PKCepsilon as the biologically important upstream kinase for PKCmu in HEK293 cells, regulating downstream effectors. Our results further indicate a PDK1/PKCeta/PKCmu controlled negative regulation of PKCeta kinase activity. In this study, we show that differentially activated kinase cascades involving PDK1 and novel PKC isotypes are responsible for the regulation of PKCmu activity and consequently inhibit the JNK pathway.	Fraunhofer Inst Interfacial Engn, D-70569 Stuttgart, Germany	Fraunhofer Gesellschaft	Johannes, FJ (corresponding author), Fraunhofer Inst Interfacial Engn, Nobelstr 12, D-70569 Stuttgart, Germany.	FJJ@IGB.FhG.de						Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; Cabodi S, 2000, MOL CELL, V6, P1121, DOI 10.1016/S1097-2765(00)00110-6; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hausser A, 2002, J CELL BIOL, V156, P65, DOI 10.1083/jcb.200110047; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Jones DH, 2000, J BIOL CHEM, V275, P13962, DOI 10.1074/jbc.C901019199; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; Li RCX, 2000, AM J PHYSIOL-HEART C, V279, pH1679, DOI 10.1152/ajpheart.2000.279.4.H1679; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; MEDEMA JP, 1994, MOL CELL BIOL, V14, P7078, DOI 10.1128/MCB.14.11.7078; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.3.CO;2-4; Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; Vertommen D, 2000, J BIOL CHEM, V275, P19567, DOI 10.1074/jbc.M001357200; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	39	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45451	45457		10.1074/jbc.M205299200	http://dx.doi.org/10.1074/jbc.M205299200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223477	hybrid			2022-12-25	WOS:000179404800109
J	Haeseleer, F; Jang, GF; Imanishi, Y; Driessen, CAGG; Matsumura, M; Nelson, PS; Palczewski, K				Haeseleer, F; Jang, GF; Imanishi, Y; Driessen, CAGG; Matsumura, M; Nelson, PS; Palczewski, K			Dual-substrate specificity short chain retinol dehydrogenases from the vertebrate retina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISUAL CYCLE; 11-CIS-RETINOL DEHYDROGENASE; FUNDUS-ALBIPUNCTATUS; 9-CIS-RETINOIC ACID; CRYSTAL-STRUCTURES; OUTER SEGMENTS; GENE; PIGMENT; IDENTIFICATION; EXPRESSION	Retinoids are chromophores involved in vision, transcriptional regulation, and cellular differentiation. Members of the short chain alcohol dehydrogenase/reductase superfamily catalyze the transformation of retinol to retinal. Here, we describe the identification and properties of three enzymes from a novel subfamily of four retinol dehydrogenases (RDH11-14) that display dual-substrate specificity, uniquely metabolizing all-trans- and cis-retinols with C-15 pro-R specificity. RDH11-14 could be involved in the first step of all-trans- and 9-cis-retinoic acid production in many tissues. RDH11-14 fill the gap in our understanding of 11-cis-retinal and all-trans-retinal transformations in photoreceptor (RDH12) and retinal pigment epithelial cells (RDH11). The dual-substrate specificity of RDH11 explains the minor phenotype associated with mutations in 11-cis-retinol dehydrogenase (RDH5) causing fundus albipunctatus in humans and engineered mice lacking RDH5. Furthermore, photoreceptor RDH12 could be involved in the production of 11-cis-retinal from 11-cisretinol during regeneration of the cone visual pigments. These newly identified enzymes add new elements to important retinoid metabolic pathways that have not been explained by previous genetic and biochemical studies.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Catholic Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Radboud University Nijmegen; Fred Hutchinson Cancer Center	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.		Imanishi, Yoshikazu/E-8178-2010	Imanishi, Yoshikazu/0000-0003-4696-4836	NATIONAL CANCER INSTITUTE [K08CA075173] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY008061, R01EY008061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059125] Funding Source: NIH RePORTER; NCI NIH HHS [CA75173] Funding Source: Medline; NEI NIH HHS [R01 EY008061, EY08061] Funding Source: Medline; NIDDK NIH HHS [DK59125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bennett MJ, 1996, BIOCHEMISTRY-US, V35, P10702, DOI 10.1021/bi9604688; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BLISS AF, 1951, ARCH BIOCHEM BIOPHYS, V31, P197, DOI 10.1016/0003-9861(51)90206-8; Chen P, 2001, NAT GENET, V28, P256, DOI 10.1038/90089; Chen P, 2001, J BIOL CHEM, V276, P21098, DOI 10.1074/jbc.M010441200; Chou CF, 2002, J BIOL CHEM, V277, P25209, DOI 10.1074/jbc.M201947200; Cideciyan AV, 2000, VISUAL NEUROSCI, V17, P667, DOI 10.1017/S0952523800175029; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Driessen CAGG, 1998, FEBS LETT, V428, P135, DOI 10.1016/S0014-5793(98)00473-6; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; Grimm C, 2000, J BIOL CHEM, V275, P41333, DOI 10.1074/jbc.M007559200; Haeseleer F, 2001, INVEST OPHTH VIS SCI, V42, P3294; Haeseleer F, 2000, METHOD ENZYMOL, V316, P372; Imanishi Y, 2002, EUR J NEUROSCI, V15, P63, DOI 10.1046/j.0953-816x.2001.01835.x; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; Jang GF, 2000, J BIOL CHEM, V275, P28128; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kedishvili NY, 2002, J BIOL CHEM, V277, P28909, DOI 10.1074/jbc.M202588200; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Lin BY, 2001, CANCER RES, V61, P1611; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MATSCHINSKY FM, 1968, J NEUROCHEM, V15, P643, DOI 10.1111/j.1471-4159.1968.tb08963.x; McBee JK, 2001, J BIOL CHEM, V276, P48483, DOI 10.1074/jbc.M105840200; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; MERCER EI, 1997, CONCISE ENCY BIOCH M; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; NAGAO A, 1994, FASEB J, V8, P968, DOI 10.1096/fasebj.8.12.8088462; Nakajima K, 1998, P NATL ACAD SCI USA, V95, P4876, DOI 10.1073/pnas.95.9.4876; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; Paik J, 2000, BIOCHEMISTRY-US, V39, P8073, DOI 10.1021/bi992152g; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Romert A, 2000, EXP CELL RES, V256, P338, DOI 10.1006/excr.2000.4817; Romert A, 1998, P NATL ACAD SCI USA, V95, P4404, DOI 10.1073/pnas.95.8.4404; Saari JC, 2000, METHOD ENZYMOL, V316, P359; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707	44	154	169	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45537	45546		10.1074/jbc.M208882200	http://dx.doi.org/10.1074/jbc.M208882200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12226107	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000179404800119
J	Schmidt, KH; Derry, KL; Kolodner, RD				Schmidt, KH; Derry, KL; Kolodner, RD			Saccharomyces cerevisiae RRM3, a 5 ' to 3 ' DNA helicase, physically interacts with proliferating cell nuclear antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FORK PROGRESSION; DNA-LIGASE-I; PCNA; PROTEINS; BINDING; REGION; INHERITANCE; CHROMATIN; FEN1	Proliferating cell nuclear antigen (PCNA) plays an essential role in eukaryotic DNA replication, and numerous DNA replication proteins have been found to interact with PCNA through a conserved eight-amino acid motif called the PIP-box. We have searched the genome of the yeast Saccharomyces cerevisiae for open reading frames that encode proteins with putative PIP-boxes and initiated testing of 135 novel candidates for their ability to interact with PCNA-conjugated agarose beads. The first new PCNA-binding protein identified in this manner is the 5' to 3' DNA helicase RRM3. Yeast two-hybrid tests show that N-terminal deletions of RRM3, which remove the PIP-box but leave the helicase motifs intact, abolish the interaction with PCNA. In addition, mutating the two phenylalanine residues in the PIP-box to alanine or aspartic acid reduces binding to PCNA, confirming that the PIP-box in RRM3 is responsible for interaction with PCNA. The results presented here suggest that the RRM3 helicase functions at the replication fork.	Univ Calif San Diego, Ludwig Inst Canc Res, Sch Med, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, Sch Med, Ctr Canc, CMME 3080,9500 Gilman Dr, La Jolla, CA 92093 USA.	rkolodner@ucsd.edu			NIGMS NIH HHS [GM27017] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amin NS, 1996, GENETICS, V144, P479; Bessler JB, 2001, TRENDS CELL BIOL, V11, P60, DOI 10.1016/S0962-8924(00)01877-8; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Ivessa AS, 2000, CELL, V100, P479, DOI 10.1016/S0092-8674(00)80683-2; Ivessa AS, 2002, GENE DEV, V16, P1383, DOI 10.1101/gad.982902; KEIL RL, 1993, GENETICS, V135, P711; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Koundrioukoff S, 2000, J BIOL CHEM, V275, P22882, DOI 10.1074/jbc.M001850200; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Krawitz DC, 2002, MOL CELL BIOL, V22, P614, DOI 10.1128/MCB.22.2.614-625.2002; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; Monson EK, 1997, P NATL ACAD SCI USA, V94, P13081, DOI 10.1073/pnas.94.24.13081; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Scholes DT, 2001, GENETICS, V159, P1449; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R	31	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45331	45337		10.1074/jbc.M207263200	http://dx.doi.org/10.1074/jbc.M207263200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239216	hybrid			2022-12-25	WOS:000179404800095
J	Stolz, J; Munro, S				Stolz, J; Munro, S			The components of the Saccharomyces cerevisiae mannosyltransferase complex M-Pol I have distinct functions in mannan synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; YEAST GOLGI-APPARATUS; PROTEIN GLYCOSYLATION; OUTER CHAIN; CATALYTIC DOMAIN; CANDIDA-ALBICANS; HEPARAN-SULFATE; MUTANTS; SYNTHASE; PATHWAY	The yeast Saccharomyces cerevisiae processes N-linked glycans in the Golgi apparatus in two different ways. Whereas most of the proteins of internal membranes receive a simple core-type structure, a long branched polymer termed mannan is attached to the glycans of many of the proteins destined for the cell wall. The first step in mannan synthesis is the initiation and extension of an alpha-1,6-linked polymannose backbone. This requires the sequential action of two enzyme complexes, mannan polymerases (M-Pol) I and II. M-Pol I contains the proteins Mnn9p and Van1p, although the stoichiometry and individual contributions to enzyme action are unclear. We report here that the two proteins are each present as a single copy in the complex. Both proteins contain a DXD motif found in the active site of many glycosyltransferases, and mutations in this motif in Mnn9p or Van1p reveal that both proteins contribute to mannose polymerization. However, the effects of these mutations on both the in vivo and in vitro activity are distinct, suggesting that the two proteins may have different roles in the complex. Finally, we show that a simple glycoprotein based on hen egg lysozyme can be used as a substrate for modification by purified M-Pol I in vitro.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Munro, S (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	sean@mrc-lmb.cam.ac.uk		Munro, Sean/0000-0001-6160-5773				ALVARADO E, 1990, BIOCHEMISTRY-US, V29, P2471, DOI 10.1021/bi00462a006; BALLOU L, 1995, P NATL ACAD SCI USA, V92, P2790, DOI 10.1073/pnas.92.7.2790; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BALLOU L, 1980, J BIOL CHEM, V255, P5986; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; Cullen PJ, 2000, GENETICS, V155, P1005; de Nobel H, 2000, TRENDS MICROBIOL, V8, P344, DOI 10.1016/S0966-842X(00)01805-9; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; Drickamer K, 1998, TRENDS BIOCHEM SCI, V23, P321, DOI 10.1016/S0968-0004(98)01246-8; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gibbons BJ, 2002, J MOL BIOL, V319, P463, DOI 10.1016/S0022-2836(02)00305-4; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Giraudo CG, 2001, P NATL ACAD SCI USA, V98, P1625, DOI 10.1073/pnas.031458398; GOPAL PK, 1987, P NATL ACAD SCI USA, V84, P8824, DOI 10.1073/pnas.84.24.8824; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Hashimoto H, 1997, BIOCHEM BIOPH RES CO, V241, P682, DOI 10.1006/bbrc.1997.7888; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; Horie T, 2001, YEAST, V18, P1493, DOI 10.1002/yea.790; HORST M, 1991, J BIOL CHEM, V266, P13914; Hummel M, 1997, EUR J BIOCHEM, V245, P428, DOI 10.1111/j.1432-1033.1997.00428.x; Ikuta K, 1997, BIOCHEM J, V323, P297, DOI 10.1042/bj3230297; JACKSON P, 1994, METHOD ENZYMOL, V230, P250; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Jungmann J, 1999, J BIOL CHEM, V274, P6579, DOI 10.1074/jbc.274.10.6579; KANIKENNULAT C, 1990, MOL CELL BIOL, V10, P898, DOI 10.1128/MCB.10.3.898; Kobayashi S, 2000, BIOCHEM BIOPH RES CO, V268, P860, DOI 10.1006/bbrc.2000.2219; Kojima H, 1999, BIOSCI BIOTECH BIOCH, V63, P1970, DOI 10.1271/bbb.63.1970; LEWIS MS, 1991, J BIOL CHEM, V266, P8255; Li JG, 2001, GLYCOBIOLOGY, V11, P217, DOI 10.1093/glycob/11.3.217; Lussier M, 1999, BBA-GEN SUBJECTS, V1426, P323, DOI 10.1016/S0304-4165(98)00133-0; Marks DL, 2001, J BIOL CHEM, V276, P26492, DOI 10.1074/jbc.M102612200; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Munro S, 2001, FEBS LETT, V498, P223, DOI 10.1016/S0014-5793(01)02488-7; Nacken V, 1996, GENE, V175, P253, DOI 10.1016/0378-1119(96)00171-0; NAKAMURA S, 1993, J BIOL CHEM, V268, P12706; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Neiman AM, 1997, GENETICS, V145, P637; Osmond BC, 1999, P NATL ACAD SCI USA, V96, P11206, DOI 10.1073/pnas.96.20.11206; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; Rayner JC, 1998, J BIOL CHEM, V273, P26836, DOI 10.1074/jbc.273.41.26836; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Saxena IM, 2000, CURR OPIN PLANT BIOL, V3, P523, DOI 10.1016/S1369-5266(00)00125-4; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; Southard SB, 1999, J BACTERIOL, V181, P7439, DOI 10.1128/JB.181.24.7439-7448.1999; Tessier DC, 2000, GLYCOBIOLOGY, V10, P403, DOI 10.1093/glycob/10.4.403; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wei G, 2000, J BIOL CHEM, V275, P27733; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723	62	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44801	44808		10.1074/jbc.M208023200	http://dx.doi.org/10.1074/jbc.M208023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235155	hybrid			2022-12-25	WOS:000179404800029
J	Inoshita, S; Takeda, K; Hatai, T; Terada, Y; Sano, M; Hata, J; Umezawa, A; Ichijo, H				Inoshita, S; Takeda, K; Hatai, T; Terada, Y; Sano, M; Hata, J; Umezawa, A; Ichijo, H			Phosphorylation and inactivation of myelbid cell leukemia 1 by JNK in response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HAMSTER OVARY CELLS; BCL-2 FAMILY; APOPTOSIS; MCL-1; PATHWAY; GENE; EXPRESSION; ASK1; MECHANISM	Oxidative stress induces JNK activation, which leads to apoptosis through mitochondria-dependent caspase activation. However, little is known about the mechanism by which JNK alters mitochondrial function. In this study, we investigated the role of phosphorylation of myeloid cell leukemia I (Mcl-1), an anti-apoptotic member of the Bcl-2 family, in oxidative stress-induced apoptosis. We found that JNK phosphorylated Ser-121 and Thr-163 of Mcl-1 in response to stimulation with H2O2 and that transfection of unphosphorylatable Mcl-1 resulted in an enhanced anti-apoptotic activity in response to stimulation with H2O2. JNK-dependent phosphorylation and thus inactivation of Mcl-1 may be one of the mechanisms through which oxidative stress induces cellular damage.	Tokyo Med & Dent Univ, Grad Sch, Lab Cell Signaling, Dept Hard Tissue Engn,Div Bio Matrix,Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Regulat & Internal Environm & Reprod, Div Syst Organ Regulat, Tokyo 1138549, Japan; Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1608582, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Keio University	Ichijo, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Cell Signaling, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.			Ichijo, Hidenori/0000-0002-5005-6438; Takeda, Kohsuke/0000-0002-8359-8399				Basu A, 1998, INT J ONCOL, V13, P659; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; GUIGLIANO D, 1996, DIABETES CARE, V19, P257; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Haldar S, 1998, CANCER RES, V58, P1609; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Muller I, 1997, BIOCHEM BIOPH RES CO, V230, P254, DOI 10.1006/bbrc.1996.5898; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SAITO I, 1985, J VIROL, V54, P711, DOI 10.1128/JVI.54.3.711-719.1985; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shigemasa K, 2002, JPN J CANCER RES, V93, P542, DOI 10.1111/j.1349-7006.2002.tb01289.x; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Umezawa A, 1996, CELL STRUCT FUNCT, V21, P143, DOI 10.1247/csf.21.143; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	37	189	194	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43730	43734		10.1074/jbc.M207951200	http://dx.doi.org/10.1074/jbc.M207951200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223490	hybrid			2022-12-25	WOS:000179272000026
J	Chouchane, S; Girotto, S; Yu, SW; Magliozzo, RS				Chouchane, S; Girotto, S; Yu, SW; Magliozzo, RS			Identification and characterization of tyrosyl radical formation in Mycobacterium tuberculosis catalase-peroxidase (KatG)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE-1; SITE-DIRECTED MUTAGENESIS; ELECTRON-PARAMAGNETIC-RESONANCE; RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; ISONIAZID ACTIVATION; COMPOUND-I; GHZ EPR; OXIDATION; GENE	The catalytic function of Mycobacterium tuberculosis catalase-peroxidase (KatG) and its role in activation of the anti-tuberculosis antibiotic isoniazid were investigated using rapid freeze-quench electron paramagnetic resonance (RFQ-EPR) experiments. The reaction of KatG with peroxyacetic acid was followed as a function of time using x-band EPR at 77 K. A doublet EPR signal appears within 6.4 ms after mixing and at time points through hundreds of milliseconds. Thereafter, a singlet signal develops and finally predominates after 1 s, with a total yield of radical similar to0.5 spin/heme. Simulation of the spectra provided EPR parameters consistent with those for tyrosyl radicals. Changes in the hyperfine splitting and/or line width in spectra for L-3,3-[H-2(2)]tyrosine-labeled, but not L-2,4,5,6,7-[H-2(5)]tryptophan-labeled KatG confirmed this assignment. The initial rate of radical formation was unchanged using a 3-fold or 10-fold excess of peroxyacetic acid, consistent with a rate-determining step involving an intermediate. Although Compound I is likely to be the precursor of tyrosyl radical in KatG, neither its EPR signal nor its reduction to Compound II during formation of the radical(s) could be observed. The tyrosyl radical doublet signal was rapidly quenched by addition of isoniazid and benzoic hydrazide, but not by iproniazid, which binds poorly to KatG.	CUNY Brooklyn Coll, Dept Chem, Brooklyn, NY 11210 USA; CUNY, Grad Ctr, Brooklyn, NY 11210 USA	City University of New York (CUNY) System; Brooklyn College (CUNY); City University of New York (CUNY) System	Chouchane, S (corresponding author), CUNY Brooklyn Coll, Dept Chem, 2900 Bedford Ave, Brooklyn, NY 11210 USA.		Girotto, Stefania/F-5997-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043582] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43582] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Collins DM, 1996, TRENDS MICROBIOL, V4, P426, DOI 10.1016/0966-842X(96)10066-4; Engleder M, 2000, BIOCHIMIE, V82, P211, DOI 10.1016/S0300-9084(00)00204-2; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GERFEN GJ, 1993, J AM CHEM SOC, V115, P6420, DOI 10.1021/ja00067a071; HEYM B, 1993, J BACTERIOL, V175, P4255, DOI 10.1128/JB.175.13.4255-4259.1993; Hillar A, 2000, BIOCHEMISTRY-US, V39, P5868, DOI 10.1021/bi0000059; HILLAR A, 1995, ARCH BIOCHEM BIOPHYS, V323, P438, DOI 10.1006/abbi.1995.0065; Ivancich A, 1999, J AM CHEM SOC, V121, P5743, DOI 10.1021/ja990562m; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Ivancich A, 2001, J AM CHEM SOC, V123, P5050, DOI 10.1021/ja0036514; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; Lei BF, 2000, J BIOL CHEM, V275, P2520, DOI 10.1074/jbc.275.4.2520; Lendzian F, 1996, J AM CHEM SOC, V118, P8111, DOI 10.1021/ja960917r; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; Magliozzo RS, 1996, J AM CHEM SOC, V118, P11303, DOI 10.1021/ja962047j; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; NEESE F, 1997, THESIS U KONSTANZ KO; NEESE F, 1995, QUANTUM CHEM PROGRAM, P5; Obinger C, 1999, FREE RADICAL RES, V31, pS243; Pym AS, 2001, MOL MICROBIOL, V40, P879, DOI 10.1046/j.1365-2958.2001.02427.x; Regelsberger G, 2000, J BIOL CHEM, V275, P22854, DOI 10.1074/jbc.M002371200; Regelsberger G, 1999, BIOCHEMISTRY-US, V38, P10480, DOI 10.1021/bi990886n; ROBITZEK EH, 1952, AM REV TUBERC PULM, V65, P402; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; SAHLIN M, 1982, J BIOL CHEM, V257, P366; Saint-Joanis B, 1999, BIOCHEM J, V338, P753, DOI 10.1042/0264-6021:3380753; Shi WJ, 2000, BIOCHEMISTRY-US, V39, P4112, DOI 10.1021/bi992561c; SINHA BK, 1983, J BIOL CHEM, V258, P796; SJOBERG BM, 1978, J BIOL CHEM, V253, P6863; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; SJOBERG BM, 1977, CIBA F SYMP, V60, P187; TSAI AL, 1994, J BIOL CHEM, V269, P5085; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; WELINDER KG, 1992, BIOCHEM SOC T, V20, P337, DOI 10.1042/bst0200337; Wengenack NL, 1999, J AM CHEM SOC, V121, P9748, DOI 10.1021/ja992590a; Wengenack NL, 2001, BIOCHEMISTRY-US, V40, P8990, DOI 10.1021/bi002614m; Yu SW, 2002, PROTEIN SCI, V11, P58, DOI 10.1110/ps.ps.09902; Zamocky M, 2001, FEBS LETT, V492, P177, DOI 10.1016/S0014-5793(01)02237-2; Zhang WH, 2001, BIOCHEMISTRY-US, V40, P4123, DOI 10.1021/bi002589k; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	46	59	59	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42633	42638		10.1074/jbc.M207916200	http://dx.doi.org/10.1074/jbc.M207916200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12205099	hybrid			2022-12-25	WOS:000179081200027
J	Denisov, IG; Makris, TM; Sligar, SG				Denisov, IG; Makris, TM; Sligar, SG			Formation and decay of hydroperoxo-ferric heme complex in horseradish peroxidase studied by cryoradiolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-ELECTRON REDUCTION; COMPOUND-I FORMATION; CYTOCHROME P450CAM; HYDROGEN-PEROXIDE; OXYGEN ACTIVATION; ELEMENTARY STEPS; RESIDUE; EPR; INTERMEDIATE; MECHANISM	Using radiolytic reduction of the oxy-ferrous horseradish peroxidase (HRP) at 77 K, we observed the formation and decay of the putative intermediate, the hydroperoxo-ferric heme complex, often called "Compound 0." This intermediate is common for several different enzyme systems as the precursor of the Compound I (ferryl-oxo pi-cation radical) intermediate. EPR and UV-visible absorption spectra show that protonation of the primary intermediate of radiolytic reduction, the peroxo-ferric complex, to form the hydroperoxo-ferric complex is completed only after annealing at temperatures 150-180 K. After further annealing at 195-205 K, this complex directly transforms to ferric HRP without any observable intervening species. The lack of Compound I formation is explained by inability of the enzyme to deliver the second proton to the distal oxygen atom of hydroperoxide ligand, shown to be necessary for dioxygen bond heterolysis on the "oxidase pathway," which is nonphysiological for HRP. Alternatively, the physiological substrate H2O2 brings both protons to the active site of HRP, and Compound I is subsequently formed via rearrangement of the proton from the proximal to the distal oxygen atom of the bound peroxide.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Sligar, SG (corresponding author), Univ Illinois, Dept Biochem, 505 S Goodwin Ave, Urbana, IL 61801 USA.		Denisov, Gleb S/J-6549-2013; Denisov, Ilia G/J-6590-2013; Makris, Thomas/W-9965-2019	Denisov, Gleb S/0000-0002-1246-0552; Denisov, Ilia G/0000-0002-7878-2626; Makris, Thomas/0000-0001-7927-620X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031756] Funding Source: NIH RePORTER; NCRR NIH HHS [P-41-RR01811] Funding Source: Medline; NIGMS NIH HHS [R37-GM31756] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEK HK, 1989, BIOCHEMISTRY-US, V28, P5714, DOI 10.1021/bi00440a003; BAEK HK, 1992, J AM CHEM SOC, V114, P718, DOI 10.1021/ja00028a046; Berglund GI, 2002, NATURE, V417, P463, DOI 10.1038/417463a; BLUMBERG WE, 1968, J BIOL CHEM, V243, P1854; Brittain T, 1997, BIOCHEM J, V326, P109, DOI 10.1042/bj3260109; Davydov R, 1999, J AM CHEM SOC, V121, P10654, DOI 10.1021/ja9918829; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; DAVYDOV R, 1991, FEBS LETT, V295, P113, DOI 10.1016/0014-5793(91)81398-R; Davydov RM, 1999, J AM CHEM SOC, V121, P10656, DOI 10.1021/ja992425v; DAVYDOV RM, 1980, BIOFIZIKA+, V25, P203; Denisov IG, 2001, J BIOL CHEM, V276, P11648, DOI 10.1074/jbc.M010219200; Denisov IG, 2001, J INORG BIOCHEM, V87, P215, DOI 10.1016/S0162-0134(01)00328-2; DUNFORD HB, 1999, HEME PEROXIDES; DUNFORD HB, 1991, PEROXIDASES CHEM BIO, V2, P2; Filizola M, 2000, J AM CHEM SOC, V122, P18, DOI 10.1021/ja992793z; GASYNA Z, 1979, FEBS LETT, V106, P213, DOI 10.1016/0014-5793(79)80730-9; GASYNA Z, 1988, BIOCHEMISTRY-US, V27, P2502; GERBER NC, 1994, J BIOL CHEM, V269, P4260; Groves John T., 1995, P3; Groves JT, 2000, CURR OPIN CHEM BIOL, V4, P687, DOI 10.1016/S1367-5931(00)00146-0; Harris DL, 1996, J AM CHEM SOC, V118, P10588, DOI 10.1021/ja9617247; Hiner ANP, 2002, J INORG BIOCHEM, V91, P27, DOI 10.1016/S0162-0134(02)00390-2; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; KAPPL R, 1985, BIOCHIM BIOPHYS ACTA, V827, P327, DOI 10.1016/0167-4838(85)90218-3; KOBAYASHI K, 1981, J BIOL CHEM, V256, P2350; Loew G, 1996, J AM CHEM SOC, V118, P10584, DOI 10.1021/ja961723e; MAGONOV S N, 1978, Molekulyarnaya Biologiya (Moscow), V12, P1182; MAGONOV S N, 1978, Molekulyarnaya Biologiya (Moscow), V12, P947; MAGONOV S N, 1978, Molekulyarnaya Biologiya (Moscow), V12, P1191; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; Mueller Ernest J., 1995, P83; Nicholls P, 2001, ADV INORG CHEM, V51, P51; POULOS TL, 1980, J BIOL CHEM, V255, P8199; Primus JL, 2002, J AM CHEM SOC, V124, P1214, DOI 10.1021/ja016907u; Rodriguez-Lopez JN, 2001, J AM CHEM SOC, V123, P11838, DOI 10.1021/ja011853+; RodriguezLopez JN, 1997, J BIOL CHEM, V272, P389; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Sjogren T, 2001, J BIOL CHEM, V276, P13072, DOI 10.1074/jbc.M011312200; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; SYMONS MCR, 1978, PROC R SOC SER B-BIO, V201, P285, DOI 10.1098/rspb.1978.0046; SYMONS MCR, 1978, BIOCHIM BIOPHYS ACTA, V535, P241, DOI 10.1016/0005-2795(78)90090-9; TAJIMA K, 1989, INORG CHIM ACTA, V163, P115, DOI 10.1016/S0020-1693(00)87150-9; Tanaka M, 1998, BIOCHEMISTRY-US, V37, P2629, DOI 10.1021/bi9725273; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9889, DOI 10.1021/bi970906q; Tsaprailis G., 1995, ADV INORG CHEM, V43, P79; Veeger C, 2002, J INORG BIOCHEM, V91, P35, DOI 10.1016/S0162-0134(02)00393-8; Veitch NC, 2001, ADV INORG CHEM, V51, P107; Vidakovic M, 1998, BIOCHEMISTRY-US, V37, P9211, DOI 10.1021/bi980189f; WATANABE Y, 1992, ENZYMES, V20, P405; Wirstam M, 1999, J AM CHEM SOC, V121, P10178, DOI 10.1021/ja991997c; Woods R.J., 1994, APPL RAD CHEM RAD PR; Woon DE, 1998, J PHYS CHEM A, V102, P10380, DOI 10.1021/jp9829896; Yeh HC, 2001, J BIOL INORG CHEM, V6, P770, DOI 10.1007/s007750100253	55	62	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42706	42710		10.1074/jbc.M207949200	http://dx.doi.org/10.1074/jbc.M207949200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12215454	hybrid			2022-12-25	WOS:000179081200037
J	Xu, H; Vavilin, D; Vermaas, W				Xu, H; Vavilin, D; Vermaas, W			The presence of chlorophyll b in Synechocystis sp PCC 6803 disturbs tetrapyrrole biosynthesis and enhances chlorophyll degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH-PROTOCHLOROPHYLLIDE OXIDOREDUCTASE; LIGHT-HARVESTING COMPLEX; PHOTOSYSTEM-I; HIGHER-PLANTS; GENE; PIGMENT; STRAIN; HEME; INVOLVEMENT; EXPRESSION	Both chlorophyll (Chl) a and b accumulate in the light in a Synechocystis sp. PCC 6803 strain that expresses higher plant genes coding for a light-harvesting complex 11 protein and Chl a oxygenase. This cyanobacterial strain also lacks photosystem (PS) I and cannot synthesize Chl in darkness because of the lack of chlL. When this PS I-less/chlL(-)/lhcb(+)/cao(+) strain was grown in darkness, small amounts of two unusual tetrapyrroles, protochlorophyllide (PChlide) b and pheophorbide (pheide) b, were identified. Accumulation of PChlide b trailed that of PChlide a by several days, suggesting that PChlide a is an inefficient substrate of Chl a oxygenase. The presence of pheide b in this organism suggests a breakdown of Chl b via a pathway that does not involve conversion to a-type pigments. When the PS I-less/chlL(-) control strain was grown in darkness, Chl degradation was much slower than in the PS I-less/chlL(-)/lhcb(+)/cao(+) strain, suggesting that the presence of Chl b leads to more rapid turnover of Chl-binding proteins and/or a more active Chl degradation pathway. Levels and biosynthesis kinetics of Chl and of its biosynthetic intermediates are very different in the PS I-less/chlL(-)/lhcb(+)/cao(+) strain versus in the control. Moreover, when grown in darkness for 14 days, upon the addition of 5-aminolevulinic acid, the level of magnesium-protoporphyrin IX increased 60-fold in the PS I-less/chlL(-)/lhcb(+)/cao(+) strain (only similar to2-fold in the PS I-less/chlL- control strain), whereas the PChlide and protoheme levels remained fairly constant. We propose that a b-type PChlide, Chl, or pheide in the PS I-less/chlL(-)/lhcb(+)/cao(+) strain may bind to tetrapyrrole biosynthesis regulatory protein(s) (for example, the small Cab-like proteins) and thus affect the regulation of this pathway.	Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynthesis, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Vermaas, W (corresponding author), Arizona State Univ, Dept Plant Biol, Box 871601, Tempe, AZ 85287 USA.	wim@asu.edu						ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; [Anonymous], MOL BIOL CHLOROPLAST; Beale S. I., 1990, BIOSYNTHESIS HEME CH, P287; BEDNARIK DP, 1985, ARCH BIOCHEM BIOPHYS, V240, P369, DOI 10.1016/0003-9861(85)90042-6; Espineda CE, 1999, P NATL ACAD SCI USA, V96, P10507, DOI 10.1073/pnas.96.18.10507; Folly P, 1999, J BIOL CHEM, V274, P21811, DOI 10.1074/jbc.274.31.21811; FUJITA Y, 1993, PLANT CELL PHYSIOL, V34, P305; FUJITA Y, 1992, PLANT CELL PHYSIOL, V33, P81; Funk C, 1999, BIOCHEMISTRY-US, V38, P9397, DOI 10.1021/bi990545+; He QF, 1998, EUR J BIOCHEM, V253, P161, DOI 10.1046/j.1432-1327.1998.2530161.x; He QF, 2001, J BIOL CHEM, V276, P306, DOI 10.1074/jbc.M008686200; Helfrich M, 1996, J AM CHEM SOC, V118, P2606, DOI 10.1021/ja953440c; Hortensteiner S, 1999, CELL MOL LIFE SCI, V56, P330, DOI 10.1007/s000180050434; HORTENSTEINER S, 1995, NEW PHYTOL, V129, P237, DOI 10.1111/j.1469-8137.1995.tb04293.x; Ito H, 1996, J BIOL CHEM, V271, P1475, DOI 10.1074/jbc.271.3.1475; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; JOHANNINGMEIER U, 1984, J BIOL CHEM, V259, P3541; Klement H, 1999, EUR J BIOCHEM, V265, P862, DOI 10.1046/j.1432-1327.1999.00627.x; Kruse E, 1997, PLANTA, V202, P235, DOI 10.1007/s004250050124; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Matile P, 1999, ANNU REV PLANT PHYS, V50, P67, DOI 10.1146/annurev.arplant.50.1.67; Oster U, 2000, PLANT J, V21, P305, DOI 10.1046/j.1365-313x.2000.00672.x; PORRA RJ, 1994, EUR J BIOCHEM, V219, P671, DOI 10.1111/j.1432-1033.1994.tb19983.x; Reinbothe C, 1999, NATURE, V397, P80, DOI 10.1038/16283; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Rudiger W., 1988, Plant pigments., P1; SAGER R, 1953, ANN NY ACAD SCI, V56, P831, DOI 10.1111/j.1749-6632.1953.tb30261.x; Scheumann V, 1999, PLANTA, V209, P364, DOI 10.1007/s004250050644; Scheumann V, 1999, FEBS LETT, V445, P445, DOI 10.1016/S0014-5793(99)00169-6; SCHNEEGURT MA, 1992, BIOCHEMISTRY-US, V31, P11677, DOI 10.1021/bi00162a002; SCHOCH S, 1995, EUR J BIOCHEM, V229, P291, DOI 10.1111/j.1432-1033.1995.tb20468.x; SHEDBALKAR VP, 1991, J BIOL CHEM, V266, P17151; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; STILLMAN LC, 1978, ANAL BIOCHEM, V91, P166, DOI 10.1016/0003-2697(78)90827-8; SUZUKI JY, 1992, PLANT CELL, V4, P929, DOI 10.1105/tpc.4.8.929; Takamiya K, 2000, TRENDS PLANT SCI, V5, P426, DOI 10.1016/S1360-1385(00)01735-0; Tanaka A, 1998, P NATL ACAD SCI USA, V95, P12719, DOI 10.1073/pnas.95.21.12719; THOMAS J, 1992, PLANT PHYSIOL BIOCH, V30, P285; Vavilin DV, 2002, PHYSIOL PLANTARUM, V115, P9, DOI 10.1034/j.1399-3054.2002.1150102.x; Vothknecht UC, 1998, PHYTOCHEMISTRY, V47, P513, DOI 10.1016/S0031-9422(97)00538-4; Wu QG, 1995, PLANT MOL BIOL, V29, P933, DOI 10.1007/BF00014967; Xu H, 2002, PLANT MOL BIOL, V49, P149, DOI 10.1023/A:1014900806905; Xu H, 2001, P NATL ACAD SCI USA, V98, P14168, DOI 10.1073/pnas.251530298	43	14	18	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42726	42732		10.1074/jbc.M205237200	http://dx.doi.org/10.1074/jbc.M205237200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12207014	hybrid			2022-12-25	WOS:000179081200040
J	Seidler, DG; Breuer, E; Grande-Allen, KJ; Hascall, VC; Kresse, H				Seidler, DG; Breuer, E; Grande-Allen, KJ; Hascall, VC; Kresse, H			Core protein dependence of epimerization of glucuronosyl residues in galactosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HEPARIN-COFACTOR-II; CULTURED HUMAN-FIBROBLASTS; IDURONIC ACID RESIDUES; DERMATAN SULFATE; CHONDROITIN SULFATE; HEPARIN/HEPARAN SULFATE; CAPSULAR POLYSACCHARIDE; PROTEODERMATAN SULFATE; STRUCTURAL FEATURES	Chondroitin sulfate and dermatan sulfate proteoglycans are distinguished by differences in their proportion of D-glucuronosyl and L-iduronosyl residues, the latter being formed by chondroitin-glucuronate 5-epimerase during or after glycosaminoglycan chain polymerization. To investigate the influence of the core protein on the extent of epimerization, we expressed chimeric proteins in 293 HEK cells constructed from intact or modified Met(1)-Gln(153) of decorin (DCN), which normally has a single dermatan sulfate chain at Ser(34), in combination with intact or modified Le -Ser CSF-1, which has a chondroitin sulfate attachment site at Ser(309). Transfected DCNM1-Q153, like full-length DCN, contained similar to20% L-iduronate. Conversely, transfected CSF-1(L241-S353), attached C-terminally on the DCN prepropeptide, contained almost exclusively D-glucuronate. Transfected intact chimeric DCNM1-Q153-CSF-1(L241.S353), with two glycosaminoglycan chains, also contained almost exclusively D-glucuronate in chains at both sites, as did chimeras in which alanine was substituted for serine at either of the glycosaminoglycan attachment sites. Nevertheless, undersulfated intact chimeric proteoglycan was an effective substrate for epimerization of glucuronate to iduronate residues when incubated with microsomal proteins and 3'-phosphoadenylylphosphosulfate. C-terminal truncation constructs were prepared from the full-length chimera with an alanine substitution at the CSF-1 glycosaminoglycan attachment site. Transfected truncations retaining the alanine-blocked site contained chains with essentially only glucuronate, whereas those further truncated by 49 or more amino acids and missing the modified attachment site contained chains with similar to15% iduronate. This 49-amino acid region contains a 7-amino acid motif that appears to be conserved in several chondroitin sulfate proteoglycans. The results are consistent with a model in which the core protein, possibly via this motif, is responsible for routing to subcellular compartments with or without sufficient access to chondroitin-glucuronate 5-epimerase for the addition of chains with or without iduronate residues, respectively.	Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany; Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44106 USA	University of Munster; Cleveland Clinic Foundation	Kresse, H (corresponding author), Univ Munster, Inst Physiol Chem & Pathobiochem, Waldeyerstr 15, D-48149 Munster, Germany.		Grande-Allen, Kathryn/P-4042-2014	Grande-Allen, Kathryn/0000-0003-1533-3767				Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; BEAVAN LA, 1993, J BIOL CHEM, V268, P9856; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; Boskey AL, 1997, CALCIFIED TISSUE INT, V61, P298, DOI 10.1007/s002239900339; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; CALABRO A, 2000, PROTEOGLYCANS STRUCT, P5; CHENG F, 1994, GLYCOBIOLOGY, V4, P685, DOI 10.1093/glycob/4.5.685; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FERRO DR, 1990, CARBOHYD RES, V195, P157, DOI 10.1016/0008-6215(90)84164-P; FRANSSON LA, 1991, GLYCOCONJUGATE J, V8, P108, DOI 10.1007/BF00731020; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; GREVE H, 1988, J BIOL CHEM, V263, P12886; Hagner-McWhirter A, 2000, GLYCOBIOLOGY, V10, P159, DOI 10.1093/glycob/10.2.159; Hamai A, 1997, J BIOL CHEM, V272, P9123; Hannesson HH, 1996, BIOCHEM J, V313, P589, DOI 10.1042/bj3130589; HAUSSER H, 1993, GLYCOBIOLOGY, V3, P557, DOI 10.1093/glycob/3.6.557; Hausser H, 1999, BIOCHEM J, V344, P827, DOI 10.1042/0264-6021:3440827; HIYAMA K, 1976, J BIOCHEM-TOKYO, V80, P1201, DOI 10.1093/oxfordjournals.jbchem.a131390; INOUE Y, 1990, BIOCHEM J, V265, P533, DOI 10.1042/bj2650533; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; KEARNS AE, 1993, J BIOL CHEM, V268, P11097; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; Kresse H, 2001, J BIOL CHEM, V276, P13411, DOI 10.1074/jbc.M009321200; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; LINHARDT RJ, 1991, BIOCHEM PHARMACOL, V42, P1609, DOI 10.1016/0006-2952(91)90431-4; MALMSTROM A, 1975, J BIOL CHEM, V250, P3419; MALMSTROM A, 1982, BIOCHEM J, V201, P489, DOI 10.1042/bj2010489; MALMSTROM A, 1981, BIOCHEM J, V198, P669, DOI 10.1042/bj1980669; MALMSTROM A, 1984, J BIOL CHEM, V259, P161; MASCELLANI G, 1993, BIOCHEM J, V296, P639, DOI 10.1042/bj2960639; MASCELLANI G, 1994, ANAL BIOCHEM, V223, P135, DOI 10.1006/abio.1994.1558; Mikhailov D, 1997, BIOCHEM J, V328, P51, DOI 10.1042/bj3280051; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; OTOTANI N, 1979, CARBOHYD RES, V70, P295, DOI 10.1016/S0008-6215(00)87109-8; PARTENHEIMER A, 1995, J IMMUNOL, V155, P5557; Pelham HRB, 2000, CELL, V102, P713, DOI 10.1016/S0092-8674(00)00060-X; Prydz K, 2000, J CELL SCI, V113, P193; RAO VSR, 1995, GLYCOBIOLOGY, V5, P273, DOI 10.1093/glycob/5.3.273; SCHWARZ K, 1990, J BIOL CHEM, V265, P22023; Shirk RA, 2000, J BIOL CHEM, V275, P18085, DOI 10.1074/jbc.M001659200; Silbert JE, 1996, GLYCOCONJUGATE J, V13, P907, DOI 10.1007/BF01053185; SUZU S, 1992, J BIOL CHEM, V267, P4345; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	47	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42409	42416		10.1074/jbc.M208442200	http://dx.doi.org/10.1074/jbc.M208442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12207034	hybrid			2022-12-25	WOS:000178985300139
J	Shi, H; Norman, AW; Okamura, WH; Sen, A; Zemel, MB				Shi, H; Norman, AW; Okamura, WH; Sen, A; Zemel, MB			1 alpha,25-dihydroxyvitamin D-3 inhibits uncoupling protein 2 expression in human adipocytes	FASEB JOURNAL			English	Article						intracellular calcium; membrane vitamin D receptor; nuclear vitamin D receptor; thermogenesis	CYTOSOLIC-FREE CALCIUM; VITAMIN-D-RECEPTOR; INSULIN-RESISTANCE; INTRACELLULAR CALCIUM; ADIPOSE DIFFERENTIATION; BIOLOGICAL RESPONSES; MEMBRANE-RECEPTOR; AGOUTI REGULATION; GENE; OBESITY	We recently demonstrated that suppressing 1alpha,25-(OH)(2)-D-3 by increasing dietary calcium decreases adipocyte intracellular Ca2+ ([Ca2+](i)), stimulates lipolysis, and inhibits lipogenesis. High calcium diets also increase core temperature and white adipose tissue uncoupling protein 2 (UCP2) expression in aP2-agouti transgenic mice. Accordingly, we have evaluated the role of 1alpha,25-(OH)(2)-D-3 in regulating human adipocyte UCP2 expression. Treatment of human adipocytes for 48 h with 1 nM 1alpha,25-(OH)(2)-D-3 inhibited UCP2 mRNA and protein levels by 50% (P<0.002) and completely blocked isoproterenol- or fatty acid-stimulated two- to threefold increases in UCP2 expression. However, a specific agonist for the membrane vitamin D receptor (mVDR), 1 alpha,25-dihydroxylumisterol(3), was unable to inhibit basal, isoproterenol-stimulated, or fatty acid-stimulated UCP2 expression, whereas a specific mVDR antagonist, 1 beta,25-dihydroxyvitamin D-3, was unable to prevent the 1 alpha,25-(OH)(2)-D-3 inhibition of UCP2 expression. In contrast, nuclear vitamin D receptor (nVDR) knockout via antisense oligodeoxynucleotide (ODN) prevented the inhibitory effect of 1 alpha,25-(OH)(2)-D-3 on adipocyte UCP2 expression and protein levels. These data indicate that 1 alpha,25-(OH)2-D3 exerts an inhibitory effect on adipocyte UCP2 expression via the nVDR. Thus, suppression of 1 alpha,25-(OH)(2)-D-3 and consequent up-regulation of UCP2 may contribute to our previous observation of increased thermogenesis in mice fed with high calcium diets.	Univ Tennessee, Knoxville, TN 37996 USA; Univ Calif Riverside, Riverside, CA 92521 USA; Zen Bio, Res Triangle Pk, NC 27709 USA	University of Tennessee System; University of Tennessee Knoxville; University of California System; University of California Riverside	Zemel, MB (corresponding author), Univ Tennessee, 1215 W Cumberland Ave,229, Knoxville, TN 37996 USA.	mzemel@utk.edu		Zemel, Michael/0000-0003-4104-5750				ANDERSEN T, 1988, METABOLISM, V37, P425, DOI 10.1016/0026-0495(88)90041-8; BARAN DT, 1991, J BONE MINER RES, V6, P1269; Baran DT, 2000, J CELL BIOCHEM, V78, P34, DOI 10.1002/(SICI)1097-4644(20000701)78:1<34::AID-JCB4>3.3.CO;2-Q; BARGERLUX MJ, 1995, CALCIFIED TISSUE INT, V57, P161, DOI 10.1007/BF00298438; BELL NH, 1985, J CLIN INVEST, V76, P370, DOI 10.1172/JCI111971; BYYNY RL, 1992, AM J HYPERTENS, V5, P459, DOI 10.1093/ajh/5.7.459; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; Dace A, 1997, BIOCHEM BIOPH RES CO, V232, P771, DOI 10.1006/bbrc.1997.6372; Davies KM, 2000, J CLIN ENDOCR METAB, V85, P4635, DOI 10.1210/jc.85.12.4635; DeLuca HF, 1998, NUTR REV, V56, pS4; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; Fleet JC, 1999, NUTR REV, V57, P60, DOI 10.1111/j.1753-4887.1999.tb01779.x; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Hida Y, 1998, LIFE SCI, V62, pPL205, DOI 10.1016/S0024-3205(98)00059-9; Kajikawa M, 1999, ENDOCRINOLOGY, V140, P4706, DOI 10.1210/en.140.10.4706; Kawada T, 1996, INT J OBESITY, V20, pS52; Kim JH, 1997, AM J PHYSIOL-ENDOC M, V272, pE379, DOI 10.1152/ajpendo.1997.272.3.E379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenoir C, 1996, ENDOCRINOLOGY, V137, P4268, DOI 10.1210/en.137.10.4268; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; LI YC, 1998, BONE, V23, pS263; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; Nemere I, 1998, J BONE MINER RES, V13, P1353, DOI 10.1359/jbmr.1998.13.9.1353; NEMERE I, 1994, J BIOL CHEM, V269, P23750; NORMAN AW, 1980, SCIENCE, V209, P823, DOI 10.1126/science.6250216; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; Norman AW, 1997, MOL ENDOCRINOL, V11, P1518, DOI 10.1210/me.11.10.1518; Norman AW, 1998, J BONE MINER RES, V13, P1360, DOI 10.1359/jbmr.1998.13.9.1360; Querfeld U, 1999, J AM SOC NEPHROL, V10, P2158; RESNICK L, 1999, PROG CARDIOVASC DIS, V4; Sanchez M, 1997, HYPERTENSION, V29, P531, DOI 10.1161/01.HYP.29.1.531; SHAN J, 1993, AM J HYPERTENS, V6, P983, DOI 10.1093/ajh/6.12.983; Shi H, 2001, FASEB J, V15, P2751, DOI 10.1096/fj.01-0584fje; Shi H, 2001, FASEB J, V15, P291; Shi H, 2000, PHYSIOL GENOMICS, V3, P75, DOI 10.1152/physiolgenomics.2000.3.2.75; Shi H, 1999, FASEB J, V13, P1833, DOI 10.1096/fasebj.13.13.1833; TANAKA Y, 1986, ENDOCRINOLOGY, V118, P1971, DOI 10.1210/endo-118-5-1971; TORNQUIST K, 1989, ENDOCRINOLOGY, V124, P2765, DOI 10.1210/endo-124-6-2765; TU M, 1999, BIOCHEM BIOPH RES CO, V265, P326; Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391; Yamada M, 1998, FEBS LETT, V432, P65, DOI 10.1016/S0014-5793(98)00835-7; YOSHIDA S, 1999, J PHYS MESOMECH, V2, P5; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733; Zemel MB, 2000, FASEB J, V14, P1132, DOI 10.1096/fasebj.14.9.1132	47	108	125	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1808	+		10.1096/fj.02-0255fje	http://dx.doi.org/10.1096/fj.02-0255fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223452				2022-12-25	WOS:000181189100011
J	Yamashita, M; Ukai-Tadenuma, M; Kimura, M; Omori, M; Inami, M; Taniguchi, M; Nakayama, T				Yamashita, M; Ukai-Tadenuma, M; Kimura, M; Omori, M; Inami, M; Taniguchi, M; Nakayama, T			Identification of a conserved GATA3 response element upstream proximal from the interleukin-13 gene locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL DIFFERENTIATION; TRANSCRIPTION FACTOR GATA-3; HISTONE ACETYLTRANSFERASE; COORDINATE REGULATOR; CYTOKINE EXPRESSION; IN-VIVO; TH1; ACTIVATION; RECEPTOR; BINDING	Differentiation of naive CD4 T cells into type 2 helper (Th2) cells is accompanied by chromatin remodeling of Th2 cytokine gene loci. Hyperacetylation of histone H3 on nucleosomes associated with the interleukin (IL)-4, IL-13 and IL-5 genes was observed in developing Th2 cells but not in Th1 cells. Histone hyperacetylation on IL-5 gene-associated nucleosomes was Th2-specific but occurred with delayed kinetics, and hyperacetylation on RAD50 gene-associated nucleosomes was T cell antigen receptor stimulation-dependent but not Th2-specific. The induction of the Th2-specific histone hyperacetylation was STAT6- and GATA3-dependent, and interestingly, it was accompanied by the expression of intergenic transcripts within the IL-13 and IL-4 gene loci. A conserved GATA3 response element (CGRE) containing four GATA consensus sequences was identified 1.6 kbp upstream from the IL-13 gene, corresponding with the 5'-border of the Th2-specific histone hyperacetylation region. The CGRE was shown to bind to GATA3, histone acetyltransferase complexes including CBP/p300, and RNA polymerase IL Also, the CGRE showed a significant enhancing effect on the Th2 cytokine gene promoters. Thus, the CGRE may play a crucial role for GATA3-mediated targeting and downstream spreading of core histone hyperacetylation within the IL-13 and IL-4 gene loci.	Chiba Univ, Dept Med Immunol M2, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Dept Mol Immunol, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan; Japan Sci & Technol Corp, PRESTO Project, Yokohama, Kanagawa 2300045, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Immune Regulat, Yokohama, Kanagawa 2300045, Japan	Chiba University; Chiba University; Japan Science & Technology Agency (JST); RIKEN	Nakayama, T (corresponding author), Chiba Univ, Dept Med Immunol M2, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	nakayama@med.m.chiba-u.ac.jp	Taniguchi, Masaru/N-7932-2015; Nakayama, Toshinori/E-1067-2017	Taniguchi, Masaru/0000-0001-7821-7179; Nakayama, Toshinori/0000-0002-1434-2007; Omori-Miyake, Miyuki/0000-0002-4643-4045				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agarwal S, 1998, CURR OPIN IMMUNOL, V10, P345, DOI 10.1016/S0952-7915(98)80174-X; Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Flavell RA, 1999, COLD SPRING HARB SYM, V64, P563, DOI 10.1101/sqb.1999.64.563; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Jones KA, 2000, GENE DEV, V14, P1992; Kimura M, 2001, IMMUNITY, V15, P275, DOI 10.1016/S1074-7613(01)00182-0; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Mohrs M, 2001, NAT IMMUNOL, V2, P842, DOI 10.1038/ni0901-842; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Reinke H, 2001, MOL CELL, V7, P529, DOI 10.1016/S1097-2765(01)00200-3; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takemoto N, 1998, INT IMMUNOL, V10, P1981, DOI 10.1093/intimm/10.12.1981; Travers A, 1999, P NATL ACAD SCI USA, V96, P13634, DOI 10.1073/pnas.96.24.13634; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Yamashita M, 1998, INT IMMUNOL, V10, P577, DOI 10.1093/intimm/10.5.577; Yamashita M, 1999, P NATL ACAD SCI USA, V96, P1024, DOI 10.1073/pnas.96.3.1024; Yamashita M, 2000, J EXP MED, V191, P1869, DOI 10.1084/jem.191.11.1869; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	40	147	151	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42399	42408		10.1074/jbc.M205876200	http://dx.doi.org/10.1074/jbc.M205876200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12205084	hybrid			2022-12-25	WOS:000178985300138
J	Udagawa, T; Fernandez, A; Achilles, EG; Folkman, J; D'Amato, RJ				Udagawa, T; Fernandez, A; Achilles, EG; Folkman, J; D'Amato, RJ			Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy	FASEB JOURNAL			English	Article						angiogenesis; dormant tumors; occult cancers	ENDOTHELIAL GROWTH-FACTOR; CARCINOMA-CELLS; BREAST-CANCER; IN-VIVO; INHIBITOR; RAS; EXPRESSION; METASTASES; INDUCTION; ONCOGENES	Some human tumor lines do not form visible tumors when inoculated into immunosuppressed mice. The fate of these human tumor lines was followed by transfecting them with green fluorescence protein before inoculating them into mice. Although the tumor lines failed to grow progressively, they formed small dormant microscopic foci maintained at constant mass by balanced proliferation and apoptosis. Transfecting the cells with either VEGF(165) or activated c-Ha-ras induced loss of dormancy, which correlated with a shift in the angiogenic balance toward increased vascularity with reduced tumor cell apoptosis. These results support a model in which loss of dormancy is controlled in part by a switch to an angiogenic phenotype. These tumor lines may serve as models for investigating the cellular mechanisms controlling dormancy and identifying those factors that promote the loss of balanced proliferation and apoptosis. Finally, these models may prove useful in the design and testing of therapies directed toward eradicating dormant tumors and preventing tumor recurrence.	Harvard Univ, Sch Med, Childrens Hosp, Dept Surg,Div Surg Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA; Hosp Leon, Unidad Invest, Leon 24071, Spain; Univ Hamburg, Univ Hamburg Hosp, Dept Hepatobiliary Surg, Hamburg, Germany	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Universidad de Leon; Hospital de Leon; University of Hamburg; University Medical Center Hamburg-Eppendorf	D'Amato, RJ (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Surg,Div Surg Res, Enders 1022,300 Longwood Ave, Boston, MA 02115 USA.	robert.damato@tch.harvard.edu			NATIONAL CANCER INSTITUTE [K01CA087013] Funding Source: NIH RePORTER; NCI NIH HHS [1 K01 CA87013-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achilles EG, 2001, J NATL CANCER I, V93, P1075, DOI 10.1093/jnci/93.14.1075; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Badgley CE, 1941, ARCH SURG-CHICAGO, V43, P541, DOI 10.1001/archsurg.1941.01210160002001; Barnhill RL, 1998, ARCH DERMATOL, V134, P991, DOI 10.1001/archderm.134.8.991; Bayko L, 1998, Angiogenesis, V2, P203, DOI 10.1023/A:1009275307663; BECKWITH JB, 1963, AM J PATHOL, V43, P1089; BILLIAU A, 1977, ANTIMICROB AGENTS CH, V12, P11, DOI 10.1128/AAC.12.1.11; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Califano J, 1999, J NATL CANCER I, V91, P599, DOI 10.1093/jnci/91.7.599; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CHOI BH, 1981, ACTA NEUROPATHOL, V254, P269; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; CROWLEY NJ, 1992, ARCH SURG-CHICAGO, V127, P1303; DEMICHELI R, 1994, J NATL CANCER I, V86, P45; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Galdemard C, 2000, J BIOL CHEM, V275, P17364, DOI 10.1074/jbc.M909316199; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HARACH HR, 1985, CANCER-AM CANCER SOC, V56, P531, DOI 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3; Holmgren L, 1998, ONCOGENE, V17, P819, DOI 10.1038/sj.onc.1201993; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Huntsman DG, 2001, NEW ENGL J MED, V344, P1904, DOI 10.1056/NEJM200106213442504; Kimura W, 1998, CANCER, V82, P1839, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1839::AID-CNCR5>3.0.CO;2-I; Lu KH, 2000, J CLIN ONCOL, V18, P2728, DOI 10.1200/JCO.2000.18.14.2728; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; Mizuno I, 1998, Rinsho Ketsueki, V39, P670; MONTIE JE, 1989, CANCER, V63, P381, DOI 10.1002/1097-0142(19890115)63:2<381::AID-CNCR2820630230>3.0.CO;2-O; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Orel SG, 1999, RADIOLOGY, V212, P543, DOI 10.1148/radiology.212.2.r99au40543; Rak J, 1996, EUR J CANCER, V32A, P2438, DOI 10.1016/S0959-8049(96)00396-6; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; Sheibani N, 1996, CANCER LETT, V107, P45, DOI 10.1016/0304-3835(96)04341-8; STOLL BA, 1982, PROLONGED ARREST CAN, V1, P59; SWEENEY TM, 1991, CANCER METAST REV, V10, P245, DOI 10.1007/BF00050795; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Tokunaga T, 1998, J NATL CANCER I, V90, P400, DOI 10.1093/jnci/90.5.400; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Yadav M, 1996, ANTICANCER RES, V16, P1787	48	103	107	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1361	1370		10.1096/fj.01-0813com	http://dx.doi.org/10.1096/fj.01-0813com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12205027				2022-12-25	WOS:000178441800010
J	Doolan, GK; Panchal, RG; Fonnes, EL; Clarke, AL; Williams, DA; Petrou, S				Doolan, GK; Panchal, RG; Fonnes, EL; Clarke, AL; Williams, DA; Petrou, S			Fatty acid augmentation of the cardiac slowly activating delayed rectifier current (I-Ks) is conferred by hminK	FASEB JOURNAL			English	Article						KvLQT1; free fatty acids; arrhythmias; electrophysiology	ARACHIDONIC-ACID; N-3; SUPPRESSION; MODULATION; K(V)LQT1; PROTEINS; CHANNELS; ADULT; FORM	The mechanism by which dietary fatty acids confer protection against cardiac arrhythmias and sudden cardiac death is not resolved. Here, we study the effects of several known cardioprotective and arrhythmogenic fatty acids on the slowly activating delayed rectifier potassium current (I-Ks), which is responsible for the repolarization phase of the cardiac action potential. cRNAs encoding either or both of the two subunits, KvLQT1 and hminK, that together produce I-Ks, were injected into Xenopus oocytes, and the effects of various fatty acids were determined. Docosahexaenoic acid (DHA) significantly augmented I-Ks as did the short-chained fully saturated lauric acid, and to a lesser extent the cis-unsaturated oleic acid. Eicosapentaenoic acid (EPA) was without significant effect on current magnitude, although it reduced the rate of activation. These results suggest that not all "antiarrhythmic" fatty acids target the same channel. To examine the role of hminK in this response, KvLQT1 was expressed alone. In this case, DHA, lauric acid, and oleic acid did not augment current, suggesting that hminK confers fatty acid sensitivity to I-Ks.	Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia	University of Melbourne	Petrou, S (corresponding author), Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia.	spetrou@unimelb.edu.au	Petrou, Steven/M-8332-2013; Panchal, Rekha/None	Petrou, Steven/0000-0002-4960-6375; Panchal, Rekha/0000-0001-8621-9078				AKHTAR M, 1990, CIRCULATION, V81, P1123, DOI 10.1161/01.CIR.81.3.1123; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Billman GE, 1997, LIPIDS, V32, P1161, DOI 10.1007/s11745-997-0149-2; Busch AE, 1997, BRIT J PHARMACOL, V122, P187, DOI 10.1038/sj.bjp.0701434; CHARNOCK JS, 1985, ANN NUTR METAB, V29, P279, DOI 10.1159/000176983; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Damron DS, 1997, AM J PHYSIOL-HEART C, V272, pH350, DOI 10.1152/ajpheart.1997.272.1.H350; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; HOCK CE, 1987, AM J PHYSIOL, V252, pH554, DOI 10.1152/ajpheart.1987.252.3.H554; Kang JX, 1997, P NATL ACAD SCI USA, V94, P2724, DOI 10.1073/pnas.94.6.2724; Kang JX, 2000, AM J CLIN NUTR, V71, p202S, DOI 10.1093/ajcn/71.1.202S; Leaf A, 2001, J MEMBRANE BIOL, V184, P263, DOI 10.1007/s00232-001-0095-0; Leifert WR, 1999, J PHYSIOL-LONDON, V520, P671, DOI 10.1111/j.1469-7793.1999.00671.x; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MCLENNAN PL, 1990, AM J CLIN NUTR, V51, P53, DOI 10.1093/ajcn/51.1.53; MCLENNAN PL, 1993, AM J CLIN NUTR, V58, P666, DOI 10.1093/ajcn/58.5.666; MCLENNAN PL, 1989, AUST NZ J MED, V19, P1, DOI 10.1111/j.1445-5994.1989.tb01662.x; MEVES H, 1994, PROG NEUROBIOL, V43, P175, DOI 10.1016/0301-0082(94)90012-4; Pepe S, 1996, J NUTR, V126, P34, DOI 10.1093/jn/126.1.34; PETROU S, 1994, J GEN PHYSIOL, V103, P471, DOI 10.1085/jgp.103.3.471; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Singh MP, 1999, IEEE INTERNET COMPUT, V3, P4, DOI 10.1109/MIC.1999.793453; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Unsold B, 2000, PFLUG ARCH EUR J PHY, V441, P368, DOI 10.1007/s004240000434; VanderVusse GJ, 1997, PROSTAG LEUKOTR ESS, V57, P85, DOI 10.1016/S0952-3278(97)90497-X; Wilde AAM, 1999, J AM COLL CARDIOL, V33, P327, DOI 10.1016/S0735-1097(98)00578-6; Xiao YF, 2000, AM J PHYSIOL-HEART C, V279, pH35, DOI 10.1152/ajpheart.2000.279.1.H35; Xiao YF, 1997, P NATL ACAD SCI USA, V94, P4182, DOI 10.1073/pnas.94.8.4182	28	37	37	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1662	+		10.1096/fj.02-0084fje	http://dx.doi.org/10.1096/fj.02-0084fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206993				2022-12-25	WOS:000177814000004
J	Hong, F; Lee, J; Song, JW; Lee, SJ; Ahn, H; Cho, JJ; Ha, J; Kim, SS				Hong, F; Lee, J; Song, JW; Lee, SJ; Ahn, H; Cho, JJ; Ha, J; Kim, SS			Cyclosporine blocks muscle differentiation by inducing oxidative stress and by inhibiting the peptidylprolyl-cis-trans-isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporine-induced cytotoxicity	FASEB JOURNAL			English	Article						reactive oxygen species (ROS); allogenic myoblast transplantation; FK-506; adaptive response; calcineurin	INDUCED NEPHROTOXICITY; IMMUNOPHILIN LIGAND; IN-VITRO; CELLS; ALLOTRANSPLANTATION; IMMUNOSUPPRESSION; TRANSPLANTATION; CYCLOPHOSPHAMIDE; EXPRESSION; MYOPATHY	Allogenic myoblast transplantation (AMT) is under investigation for treatment of severe genetic myopathies. Data regarding the role of cyclosporine (CsA) and FK-506 in AMT have shown that CsA is less effective than FK-506. For this study, we investigated mechanisms of CsA toxicity during AMT and showed that a high level of reactive oxygen species (ROS) generated by CsA, mediated partly by inhibition of the peptidylprolyl-cis-trans-isomerase (PPIase)-like activity of cyclophilin A (CypA), blocked differentiation and induced apoptosis at an early stage of muscle differentiation. Inhibition of the PPIase-like activity of CypA alone also blocked muscle differentiation. However, CsA toxicity did not depend on the inhibition of calcineurin activity during muscle differentiation. Together, these data suggest that CsA-mediated inhibition of the PPIase-like activity of CypA and the high level of ROS generation contributed to the low efficacy of CsA in AMT. In addition, we showed that a reduction of oxidative stress protected cells from CsA-induced apoptosis, and myoblasts that had survived after preexposure to CsA not only proliferated and differentiated reversibly but also gained resistance to subsequent CsA exposure. Thus, administration of antioxidants or overexpression of CypA either exogenously or endogenously during CsA treatment has the potential to improve the success of this treatment in AMT.	Kyung Hee Univ, Sch Med, Dept Mol Biol, Seoul 130701, South Korea; Kyung Hee Univ, Sch Med, Dept Anat, Seoul 130701, South Korea; Kyung Hee Univ, Sch Med, Dept Microbiol, Seoul 130701, South Korea; Dongseo Univ, Dept Biotechnol, Pusan 617716, South Korea; Korea Canc Ctr Hosp, Lab Radiat Effect, Seoul 139706, South Korea	Kyung Hee University; Kyung Hee University; Kyung Hee University; Dongseo University; National Cancer Center - Korea (NCC)	Kim, SS (corresponding author), Kyung Hee Univ, Sch Med, Dept Mol Biol, Seoul 130701, South Korea.	sgskim@khu.ac.kr	Kim, Sung Soo/S-2540-2017	Kim, Sung Soo/0000-0002-6817-7668				Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; ALEJANDRO DSJ, 1994, J AM SOC NEPHROL, V5, P153; Andreeva L, 1999, INT J EXP PATHOL, V80, P305, DOI 10.1046/j.1365-2613.1999.00128.x; ARELLANO F, 1991, LANCET, V337, P915, DOI 10.1016/0140-6736(91)90245-K; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; Biring MS, 1998, J APPL PHYSIOL, V84, P1967, DOI 10.1152/jappl.1998.84.6.1967; Buetler TM, 2000, TRENDS PHARMACOL SCI, V21, P288, DOI 10.1016/S0165-6147(00)01508-X; de Lema GP, 1998, LIFE SCI, V62, P1745, DOI 10.1016/S0024-3205(98)00136-2; Doyle V, 1999, BIOCHEM J, V341, P127, DOI 10.1042/0264-6021:3410127; FERNANDEZSOLA J, 1990, LANCET, V335, P362; Friday BB, 2000, J CELL BIOL, V149, P657, DOI 10.1083/jcb.149.3.657; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GILL RG, 1995, CELL TRANSPLANT, V4, P361, DOI 10.1016/0963-6897(95)00019-T; GOY JJ, 1989, LANCET, V1, P1446; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hamilton GS, 1998, J MED CHEM, V41, P5119, DOI 10.1021/jm980307x; HARDIMAN O, 1993, NEUROLOGY, V43, P1432, DOI 10.1212/WNL.43.7.1432; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; HOKANSON JF, 1995, AM J RESP CRIT CARE, V151, P1848, DOI 10.1164/ajrccm.151.6.7767529; Hovland AR, 1999, NEUROCHEM INT, V35, P229, DOI 10.1016/S0197-0186(99)00065-0; Jaschke A, 1998, J MOL BIOL, V277, P763, DOI 10.1006/jmbi.1998.1644; KARPATI G, 1993, ANN NEUROL, V34, P8, DOI 10.1002/ana.410340105; KINOSHITA I, 1995, MUSCLE NERVE, V18, P1217; KINOSHITA I, 1994, MUSCLE NERVE, V17, P1407, DOI 10.1002/mus.880171210; Kumar KV, 1999, TRANSPLANTATION, V67, P1065, DOI 10.1097/00007890-199904150-00022; LABRECQUE C, 1992, TRANSPLANT P, V24, P2889; LAW PK, 1988, MUSCLE NERVE, V11, P525, DOI 10.1002/mus.880110602; Lee JP, 1999, P NATL ACAD SCI USA, V96, P3251, DOI 10.1073/pnas.96.6.3251; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Leonardi A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1512; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Longoni B, 2001, FASEB J, V15, P731, DOI 10.1096/fj.00-0163com; Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162-3109(00)00192-2; Naidu MUR, 1999, NEPHRON, V81, P60, DOI 10.1159/000045247; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; RUSH DN, 1991, CLIN BIOCHEM, V24, P101, DOI 10.1016/0009-9120(91)90399-Y; SHAW LM, 1990, CLIN CHEM, V36, P1841; Skuk D, 2000, MICROSC RES TECHNIQ, V48, P213, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<213::AID-JEMT9>3.0.CO;2-Z; SZABO I, 1991, J BIOL CHEM, V266, P3376; TEGZESS AM, 1988, TRANSPLANT P, V20, P530; Tran TT, 2000, J BIOL CHEM, V275, P35708, DOI 10.1074/jbc.M005636200; VILQUIN JT, 1995, NEUROMUSCULAR DISORD, V5, P511, DOI 10.1016/0960-8966(95)00011-B; WANG CY, 1994, TRANSPLANTATION, V58, P940, DOI 10.1097/00007890-199410270-00014; Wolf A, 1997, J PHARMACOL EXP THER, V280, P1328; Zhong Z, 1999, MOL PHARMACOL, V56, P455, DOI 10.1124/mol.56.3.455; Zhong Z, 1998, AM J PHYSIOL-RENAL, V275, pF595, DOI 10.1152/ajprenal.1998.275.4.F595; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	48	96	99	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10					1633	+		10.1096/fj.02-0060fje	http://dx.doi.org/10.1096/fj.02-0060fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207006				2022-12-25	WOS:000177814000022
J	Duquette, M; Laneuville, O				Duquette, M; Laneuville, O			Translational regulation of prostaglandin endoperoxide H synthase-1 mRNA in megakaryocytic MEG-01 cells - Specific protein binding to a conserved 20-nucleotide cis element in the 3 '-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA; EXPRESSION; LINE; ACID; CYCLOOXYGENASE-1; DIFFERENTIATION; DEGRADATION; INDUCTION; SEQUENCE	Prostaglandin endoperoxide H synthase-1 (PGHS-1) is an abundant enzyme in platelets, where it plays a key role in the cascade of prostanoid formation. In platelets, the primary site of PGHS-1 synthesis is in precursor megakaryocytic cells. We have previously shown that in megakaryocytic MEG-01 cells, TPA induces an increase of PGHS-1 mRNA within a few hours, whereas protein increase occurs after several days of treatment. We now report that the delayed increase in PGHS-1 protein is caused by translational regulation. De novo PGHS-1 synthesis, measured using [S-35]methionine pulse labeling followed by immunoprecipitation, was detected at day 4 after TPA treatment but not at day 1. To identify a potential element of PGHS-1 mRNA controlling translation, we compared the 3'-untranslated region from different species and identified a 20-nt segment perfectly conserved. The 20-nt segment was used as a probe in RNA gel mobility-shift assays using MEG-01 extracts from control cells or from TPA-treated cells. Four complexes were formed with extracts from control cells or cells treated with TPA for 1 day but were not observed with extracts from cells treated for 4 days. Of the 4 complexes, one was sequence-specific and binding involved uridylate residues and interactions with a 45-kDa protein and a protein doublet of 116 kDa. Binding of this 45/116-kDa complex to the 20-nt conserved cis element most likely regulates negatively PGHS-1 protein accumulation. We have provided evidence that the PGHS-1 gene is regulated at the translational level.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Laneuville, O (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	olaneuvi@uottawa.ca						Amara FM, 1996, BIOCHEM BIOPH RES CO, V228, P347, DOI 10.1006/bbrc.1996.1664; BRANNON TS, 1994, J CLIN INVEST, V93, P2230, DOI 10.1172/JCI117220; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Fraboulet S, 1998, ENDOCRINOLOGY, V139, P894, DOI 10.1210/en.139.3.894; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Kroll SL, 2001, J BIOL CHEM, V276, P49410, DOI 10.1074/jbc.M109577200; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; MATIJEVICALEKSIC N, 1995, BBA-MOL CELL RES, V1269, P167, DOI 10.1016/0167-4889(95)00116-A; Mroske C, 2000, EXP HEMATOL, V28, P411, DOI 10.1016/S0301-472X(00)00125-9; OGURA M, 1988, BLOOD, V72, P49; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; Plant MH, 1999, BIOCHEM J, V344, P677, DOI 10.1042/0264-6021:3440677; Schneider N, 2001, J NEUROCHEM, V77, P416, DOI 10.1046/j.1471-4159.2001.00264.x; Smith CJ, 1997, ADV EXP MED BIOL, V400, P99; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Taniura S, 2002, J BIOL CHEM, V277, P16823, DOI 10.1074/jbc.M200527200; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931	24	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44631	44637		10.1074/jbc.M207007200	http://dx.doi.org/10.1074/jbc.M207007200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237309	hybrid			2022-12-25	WOS:000179404800007
J	Lee, TH; Lwu, S; Kim, J; Pelletier, J				Lee, TH; Lwu, S; Kim, J; Pelletier, J			Inhibition of Wilms tumor 1 transactivation by bone marrow zinc finger 2, a novel transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR GENE; DNA-BINDING; SUBNUCLEAR LOCALIZATION; MOLECULAR-CLONING; WT1 GENE; DIFFERENTIATION; PROTEIN; EXPRESSION; PRODUCT; DOMAINS	The Wilms tumor suppressor gene, wt1, encodes a zinc finger transcription factor that has been implicated in the regulation of a number of genes. Protein-protein interactions are known to modulate the transcription regulatory functions of Wilms tumor (WT1) and have also implicated WT1 in splicing. In this report, we identify a novel WT1-interacting protein, bone marrow zinc finger 2 (BMZF2), by affinity chromatography utilizing immobilized WT1 protein. BMZF2 is a potential transcription factor with 18 zinc fingers. The BMZF2 mRNA is mainly expressed in fetal tissues, and the protein is predominantly nuclear. Co-immunoprecipitation experiments are consistent with an in vivo association between WT1 and BMZF2. Glutathione S-transferase pulldown assays and far Western blots revealed that zinc fingers VI-X (amino acids 231-370) are required for interaction with the zinc finger region of WT1. Functionally, BMZF2 inhibits transcriptional activation by WT1. Moreover, a chimeric protein generated by fusion of BMZF2 to the GAL4 DNA-binding domain significantly decreases promoter activity of a reporter containing GAL4 DNA-binding sites, suggesting the presence of an active repressor domain within BMZF2. Our results suggest that BMZF2 interferes with the transactivation potential of WT1.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Sogang Univ, Dept Life Sci, Mapo Gu, Seoul 121742, South Korea	McGill University; McGill University; Sogang University	Pelletier, J (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,Rm 810,3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.		Lee, Tae Ho/AAT-1721-2020					Baird PN, 1997, EXP HEMATOL, V25, P312; Bardeesy N, 1998, NUCLEIC ACIDS RES, V26, P1784, DOI 10.1093/nar/26.7.1784; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Han ZG, 1999, J BIOL CHEM, V274, P35741, DOI 10.1074/jbc.274.50.35741; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Kim J, 1999, MOL CELL BIOL, V19, P2289; Laity JH, 2000, P NATL ACAD SCI USA, V97, P11932, DOI 10.1073/pnas.97.22.11932; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee JK, 2001, MET MATER-KOREA, V7, P187, DOI 10.1007/BF03026974; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; MATSUNAGA E, 1981, HUM GENET, V57, P231; Maurer U, 1997, EXP HEMATOL, V25, P945; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MESSEN HD, 1997, BLOOD, V89, P3486; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PritchardJones K, 1997, LEUKEMIA LYMPHOMA, V27, P207, DOI 10.3109/10428199709059677; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Sambrook J., 2002, MOL CLONING LAB MANU; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; SEKIYA M, 1994, BLOOD, V83, P1867; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Smith SI, 2000, CANCER RES, V60, P808; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1995, ONCOGENE, V10, P415; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944	44	26	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44826	44837		10.1074/jbc.M205667200	http://dx.doi.org/10.1074/jbc.M205667200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239212	hybrid			2022-12-25	WOS:000179404800032
J	Maynard, CJ; Cappai, R; Volitakis, I; Cherny, RA; White, AR; Beyreuther, K; Masters, CL; Bush, AI; Li, QX				Maynard, CJ; Cappai, R; Volitakis, I; Cherny, RA; White, AR; Beyreuther, K; Masters, CL; Bush, AI; Li, QX			Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA; TRANSGENIC MICE; TRACE-ELEMENTS; PRECURSOR PROTEIN; OXIDATIVE STRESS; CEREBROSPINAL-FLUID; CATALYZED OXIDATION; BINDING-SITE; SERUM ZINC; CONSEQUENCES	Increased brain metal levels have been associated with normal aging and a variety of diseases, including Alzheimer's disease (AD). Copper and iron levels both show marked increases with age and may adversely interact with the amyloid-beta (Abeta) peptide causing its aggregation and the production of neurotoxic hydrogen peroxide (H2O2), contributing to the pathogenesis of AD. Amyloid precursor protein (APP) possesses copper/zinc binding sites in its amino-terminal domain and in the Abeta domain. Here we demonstrate that overexpression of the carboxyl-terminal fragment of APP, containing Abeta, results in significantly reduced copper and iron levels in transgenic mouse brain, while overexpression of the APP in Tg2576 transgenic mice results in significantly reduced copper, but not iron, levels prior to the appearance of amyloid neuropathology and throughout the lifespan of the mouse. Concomitant increases in brain manganese levels were observed with both transgenic strains. These findings, complemented by our previous findings of elevated copper levels in APP knock-out mice, support roles for APP and Abeta in physiological metal regulation.	Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Univ Heidelberg, Zentrum Mol Biol Heidelberg, D-69120 Heidelberg, Germany; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lab Oxidat Biol Genet & Aging Res Unit, Charlestown, MA 02129 USA	Ruprecht Karls University Heidelberg; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Li, QX (corresponding author), Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.		Bush, Ashley I/A-1186-2007; Bush, Ashley/Y-2457-2019; Cappai, Roberto/B-3347-2010; White, Anthony/P-5596-2016	Bush, Ashley I/0000-0001-8259-9069; Bush, Ashley/0000-0001-8259-9069; Volitakis, Irene/0000-0003-0766-817X; Cappai, Roberto/0000-0002-9505-8496; White, Anthony/0000-0003-1802-9891	NIA NIH HHS [R01AG12656] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Atwood CS, 1999, MET IONS BIOL SYST, V36, P309; Bartzokis G, 1997, MAGN RESON IMAGING, V15, P29, DOI 10.1016/S0730-725X(96)00234-2; BASUN H, 1991, J NEURAL TRANSM-PARK, V3, P231; BOHNEN N, 1994, Z GERONTOL, V27, P324; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; BUSH AI, 1993, J BIOL CHEM, V268, P16109; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; CONNOR JR, 1992, J NEUROSCI RES, V31, P327, DOI 10.1002/jnr.490310214; Cornett CR, 1998, NEUROTOXICOLOGY, V19, P339; Cuajungco MP, 2000, J BIOL CHEM, V275, P19439, DOI 10.1074/jbc.C000165200; Deibel MA, 1996, J NEUROL SCI, V143, P137, DOI 10.1016/S0022-510X(96)00203-1; Del Corso L, 2000, PANMINERVA MED, V42, P273; DRAYER B, 1986, AM J ROENTGENOL, V147, P103, DOI 10.2214/ajr.147.1.103; Frederickson CJ, 2001, BIOMETALS, V14, P353, DOI 10.1023/A:1012934207456; Gonzalez C, 1999, EUR J CLIN INVEST, V29, P637; HARTTER DE, 1988, J BIOL CHEM, V263, P799; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kontush A, 2001, FREE RADICAL BIO MED, V30, P119, DOI 10.1016/S0891-5849(00)00458-5; Lee JY, 1999, J NEUROSCI, V19, DOI 10.1523/jneurosci.19-11-j0002.1999; Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699; Li QX, 1999, J NEUROCHEM, V72, P2479, DOI 10.1046/j.1471-4159.1999.0722479.x; Loeffler DA, 1996, BRAIN RES, V738, P265, DOI 10.1016/S0006-8993(96)00782-2; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; MARKESBERY WR, 1984, NEUROBIOL AGING, V5, P19, DOI 10.1016/0197-4580(84)90081-2; Martin WRW, 1998, MOVEMENT DISORD, V13, P281; MASSIE HR, 1979, MECH AGEING DEV, V10, P93, DOI 10.1016/0047-6374(79)90073-3; MASTERS CL, 2002, 7 INT GEN SPRINGF AL; McLoughlin DM, 2001, J BIOL CHEM, V276, P9303, DOI 10.1074/jbc.M010023200; MORITA A, 1994, BIOL TRACE ELEM RES, V42, P165, DOI 10.1007/BF02785387; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; PAPPOLLA MA, 1992, AM J PATHOL, V140, P621; PLANTIN LO, 1987, BIOL TRACE ELEM RES, V13, P69, DOI 10.1007/BF02796622; Rao KSJ, 1999, ALZHEIMERS REP, V2, P241; SAMUDRALWAR DL, 1995, J NEUROL SCI, V130, P139, DOI 10.1016/0022-510X(95)00018-W; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Smith MA, 1995, J NEUROL SCI, V134, P92, DOI 10.1016/0022-510X(95)00213-L; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; Squitti R, 2002, EUR J CLIN INVEST, V32, P51, DOI 10.1046/j.1365-2362.2002.00933.x; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; THOMAS LO, 1993, AM J NEURORADIOL, V14, P1043; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; WOODWARD WD, 1984, J GERONTOL, V39, P521, DOI 10.1093/geronj/39.5.521; Wu SM, 1997, J BIOL CHEM, V272, P20627, DOI 10.1074/jbc.272.33.20627; Yassin MS, 2000, J NEUROL SCI, V173, P40, DOI 10.1016/S0022-510X(99)00297-X; Zecca L, 2001, J NEUROCHEM, V76, P1766, DOI 10.1046/j.1471-4159.2001.00186.x	59	300	309	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44670	44676		10.1074/jbc.M204379200	http://dx.doi.org/10.1074/jbc.M204379200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12215434	hybrid			2022-12-25	WOS:000179404800011
J	Piccininni, S; Varaklioti, A; Nardelli, M; Dave, B; Raney, KD; McCarthy, JEG				Piccininni, S; Varaklioti, A; Nardelli, M; Dave, B; Raney, KD; McCarthy, JEG			Modulation of the hepatitis C virus RNA-dependent RNA polymerase activity by the non-structural (NS) 3 helicase and the NS4B membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; CRYSTAL-STRUCTURE; VIRAL-RNA; REPLICATION; IDENTIFICATION; REQUIREMENTS; MECHANISM; TEMPLATE; COMPLEX; REGION	The hepatitis C virus (HCV) nonstructural protein 5B (NS5B) is believed to be the central catalytic enzyme responsible for HCV replication but there are many unanswered questions about how its activity is controlled. In this study we reveal that two other HCV proteins, NS3 (a protease/helicase) and NS4B (a hydrophobic protein of unknown function), physically and functionally interact with the NS5B polymerase. We describe a new procedure for generating highly pure NS4B, and use this protein in biochemical studies together with NS5B and NS3. To study the functional effects of the protein-protein interactions, we have developed an in vitro replication assay using the natural noncoding 3' regions of the respective positive ((+)-3'-untranslated region) and negative ((-)-3'-terminal region) RNA strands of the HCV genome. Our studies show that NS3 dramatically modulates template recognition by NS5B and changes the synthetic products generated by this enzyme. The use of an NTPase-deficient mutant form of NS3 demonstrates that the NTPase activity (and thus helicase activity) of this protein is specifically required for these effects. Moreover, NS4B is found to be a negative regulator of the NS3-NS5B replication complex. Overall, these results reveal that NS3, NS4B, and NS5B can interact to form a regulatory complex that could feature in the process of HCV replication.	Univ Manchester, Dept Biomol Sci, Posttranscript Control Grp, Manchester M60 1QD, Lancs, England; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Manchester; University of Arkansas System; University of Arkansas Medical Sciences	McCarthy, JEG (corresponding author), Univ Manchester, Dept Biomol Sci, Posttranscript Control Grp, POB 88, Manchester M60 1QD, Lancs, England.	J.McCarthy@umist.ac.uk	Dave, Bhuvanesh/ABF-8334-2020; Varaklioti, Agoritsa/AAP-7116-2020	Dave, Bhuvanesh/0000-0001-6741-1363; Varaklioti, Agoritsa/0000-0002-3897-819X	NIAID NIH HHS [AI47350] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047350] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; Harlow E., 1988, ANTIBODIES LAB MANUA; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Hugle T, 2001, VIROLOGY, V284, P70, DOI 10.1006/viro.2001.0873; Hwang SB, 1997, VIROLOGY, V227, P439, DOI 10.1006/viro.1996.8357; Ishido S, 1998, BIOCHEM BIOPH RES CO, V244, P35, DOI 10.1006/bbrc.1998.8202; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; Kato J, 2002, J MED VIROL, V66, P187, DOI 10.1002/jmv.2129; Khu YL, 2001, J VIROL, V75, P205, DOI 10.1128/JVI.75.1.205-214.2001; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Lavanchy D, 1999, J VIRAL HEPATITIS, V6, P35; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Lin C, 1997, J VIROL, V71, P6465, DOI 10.1128/JVI.71.9.6465-6471.1997; Lohmann V, 1999, J BIOL CHEM, V274, P10807, DOI 10.1074/jbc.274.16.10807; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Macnaughton TB, 2002, J VIROL, V76, P3920, DOI 10.1128/JVI.76.8.3920-3927.2002; Matsumoto M, 1996, VIROLOGY, V218, P43, DOI 10.1006/viro.1996.0164; Moradpour D, 2002, J BIOL CHEM, V277, P593, DOI 10.1074/jbc.M108748200; Neddermann P, 1999, J VIROL, V73, P9984, DOI 10.1128/JVI.73.12.9984-9991.1999; Oh JW, 2000, J BIOL CHEM, V275, P17710, DOI 10.1074/jbc.M908781199; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Park C, 2002, J VIROL METHODS, V101, P211, DOI 10.1016/S0166-0934(01)00443-8; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Qin WP, 2001, HEPATOLOGY, V33, P728, DOI 10.1053/jhep.2001.22765; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Reigadas S, 2001, EUR J BIOCHEM, V268, P5857, DOI 10.1046/j.0014-2956.2001.02532.x; Rosenberg S, 2001, J MOL BIOL, V313, P451, DOI 10.1006/jmbi.2001.5055; Sarbah SA, 2000, J CLIN GASTROENTEROL, V30, P125, DOI 10.1097/00004836-200003000-00005; Schmidt-Mende J, 2001, J BIOL CHEM, V276, P44052, DOI 10.1074/jbc.M103358200; Shimotohno K, 2000, SEMIN CANCER BIOL, V10, P233, DOI 10.1006/scbi.2000.0322; Shirota Y, 2002, J BIOL CHEM, V277, P11149, DOI 10.1074/jbc.M111392200; Tackett AJ, 2001, NUCLEIC ACIDS RES, V29, P565, DOI 10.1093/nar/29.2.565; Tomei L, 2000, J GEN VIROL, V81, P759, DOI 10.1099/0022-1317-81-3-759; Wang QM, 2002, J VIROL, V76, P3865, DOI 10.1128/JVI.76.8.3865-3872.2002; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	46	121	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45670	45679		10.1074/jbc.M204124200	http://dx.doi.org/10.1074/jbc.M204124200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235135	hybrid			2022-12-25	WOS:000179404800134
J	Honsho, M; Hiroshige, T; Fujiki, Y				Honsho, M; Hiroshige, T; Fujiki, Y			The membrane biogenesis peroxin Pex16p - Topogenesis and functional roles in peroxisomal membrane assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARY CELL MUTANTS; COMPLEMENTATION GROUP; ZELLWEGER-SYNDROME; TARGETING SIGNALS; CDNA CLONING; MUTATION ANALYSIS; PROTEIN; GENE; IMPORT; PEX3P	Previously we isolated human PEX16 encoding 336-amino acid-long peroxin Pex16p and showed that its dysfunction was responsible for Zellweger syndrome of complementation group D (group 9). Here we have determined the membrane topology of Pex16p by differential permeabilization method: both N- and C-terminal parts are exposed to the cytosol. In the search for Pex16p topogenic sequence, basic amino acids clustered sequence, RKELRKKLPVSLSQQK, at positions 66-81 and the first transmembrane segment locating far downstream, nearly by 40 amino acids, of this basic region were defined to be essential for integration into peroxisome membranes. Localization to peroxisomes of membrane proteins such as Pex14p, Pex13p, and PMP70 was interfered with in CHO-K1 cells by a higher level expression of the pex16 patient-derived dysfunctional but topogenically active Pex16pR176ter comprising resides 1-176 or of the C-terminal cytoplasmic part starting from residues at 244 to the C terminus. Furthermore, Pex16p C-terminal cytoplasmic part severely abrogated peroxisome restoration in pex mutants such as matrix protein import-defective pex12 and membrane assembly impaired pex3 by respective PEX12 and PEX3 expression, whereas the N-terminal cytosolic region did not affect restoration. These results imply that Pex16p functions in peroxisome membrane assembly, more likely upstream of Pex3p.	Kyushu Univ, Grad Sch, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Japan Sci & Technol Corp, SORST, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Grad Sch, Fac Sci, Dept Biol, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	yfujiscb@mbox.nc.kyushu-u.ac.jp		Honsho, Masanori/0000-0001-6165-4516				Abe I, 1998, FEBS LETT, V431, P468, DOI 10.1016/S0014-5793(98)00815-1; Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Brosius U, 2002, J BIOL CHEM, V277, P774, DOI 10.1074/jbc.M108155200; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Fujiki Y, 2000, FEBS LETT, V476, P42, DOI 10.1016/S0014-5793(00)01667-7; Fujiki Y, 1997, BBA-MOL BASIS DIS, V1361, P235, DOI 10.1016/S0925-4439(97)00051-3; Ghaedi K, 2000, AM J HUM GENET, V67, P976, DOI 10.1086/303086; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; Ghaedi K, 1999, EXP CELL RES, V248, P489, DOI 10.1006/excr.1999.4413; Gotte K, 1998, MOL CELL BIOL, V18, P616; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Honsho M, 2001, J BIOL CHEM, V276, P9375, DOI 10.1074/jbc.M003304200; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; Kinoshita N, 1998, J BIOL CHEM, V273, P24122, DOI 10.1074/jbc.273.37.24122; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Mukai S, 2002, J BIOL CHEM, V277, P9548, DOI 10.1074/jbc.M108635200; Muntau AC, 2000, AM J HUM GENET, V67, P967, DOI 10.1086/303071; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; Okumoto K, 1997, EXP CELL RES, V233, P11, DOI 10.1006/excr.1997.3552; Okumoto K, 1998, HUM MOL GENET, V7, P1399, DOI 10.1093/hmg/7.9.1399; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Otera H, 2001, J BIOL CHEM, V276, P2858, DOI 10.1074/jbc.M007730200; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; SAKAI Y, 1995, J BACTERIOL, V177, P6773, DOI 10.1128/jb.177.23.6773-6781.1995; Schrader M, 1998, J BIOL CHEM, V273, P29607, DOI 10.1074/jbc.273.45.29607; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Shimozawa N, 2000, HUM MOL GENET, V9, P1995, DOI 10.1093/hmg/9.13.1995; Shimozawa N, 2002, BIOCHEM BIOPH RES CO, V292, P109, DOI 10.1006/bbrc.2002.6642; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; Soukupova M, 1999, EUR J CELL BIOL, V78, P357, DOI 10.1016/S0171-9335(99)80078-8; South ST, 2000, J CELL BIOL, V149, P1345, DOI 10.1083/jcb.149.7.1345; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Subramani S, 1997, NAT GENET, V15, P331, DOI 10.1038/ng0497-331; Titorenko VI, 1998, TRENDS BIOCHEM SCI, V23, P231, DOI 10.1016/S0968-0004(98)01226-2; Titorenko VI, 2001, NAT REV MOL CELL BIO, V2, P357, DOI 10.1038/35073063; Toyama R, 1999, HUM MOL GENET, V8, P1673, DOI 10.1093/hmg/8.9.1673; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; Voorn-Brouwer T, 2001, J CELL SCI, V114, P2199; Wang XD, 2001, J BIOL CHEM, V276, P10897, DOI 10.1074/jbc.M010883200; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Yamasaki M., 1998, BIOIMAGES, V6, P1	57	65	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44513	44524		10.1074/jbc.M206139200	http://dx.doi.org/10.1074/jbc.M206139200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223482	hybrid			2022-12-25	WOS:000179272000123
J	Rontein, D; Dieuaide-Noubhani, M; Dufourc, EJ; Raymond, P; Rolin, D				Rontein, D; Dieuaide-Noubhani, M; Dufourc, EJ; Raymond, P; Rolin, D			The metabolic architecture of plant cells - Stability of central metabolism and flexibility of anabolic pathways during the growth cycle of tomato cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC POTATO PLANTS; PHOSPHOENOLPYRUVATE CARBOXYLASE; CARBOHYDRATE-METABOLISM; SUSPENSION CULTURES; PENTOSE-PHOSPHATE; PYRUVATE-KINASE; ACID CYCLE; GLUCOSE; FLUXES; SUCROSE	The changes in the intermediary metabolism of plant cells were quantified according to growth conditions at three different stages of the growth cycle of tomato cell suspension. Eighteen fluxes of central metabolism were calculated from C-13 enrichments after near steady-state labeling by a metabolic model similar to that described in Dieuaide-Noubhani et aL (Dieuaide-Noubhani, M., Raffard, G., Canioni, P., Pradet, A., and Raymond, P. (1995) J. BioL Chem 270,13147-13159), and 10 net fluxes were obtained directly from end-product accumulation rates. The absolute flux values of central metabolic pathways gradually slowed down with the decrease of glucose influx into the cells. However, the relative fluxes of glycolysis, the pentose-P pathway, and the tricarboxylic acid cycle remained unchanged during the culture cycle at 70, 28, and 40% of glucose influx, respectively, and the futile cycle of sucrose remained high at about 6-fold the glucose influx, independently from carbon nutritional conditions. This natural resistance to flux alterations is referred to as metabolic stability. The numerous anabolic pathways, including starch synthesis, hexose accumulation, biosynthesis of wall polysaccharides, and amino and organic acid biosynthesis were comparatively low and variable. The phosphoenolpyruvate carboxylase flux decreased 5-fold in absolute terms and 2-fold in relation to the glucose influx rate during the culture cycle. We conclude that anabolic fluxes constitute the flexible part of plant cell metabolism that can fluctuate in relation to cell demands for growth.	INRA, UMR 619, Inst Biol Vegetale & Mol, F-33883 Villenave Dornon, France; Ecole Polytech, Inst Europeen Chim & Biol, F-33402 Talence, France	INRAE	Rolin, D (corresponding author), INRA, UMR 619, Inst Biol Vegetale & Mol, BP 81, F-33883 Villenave Dornon, France.	rolin@bordeaux.inra.fr	DUFOURC, Erick Joel/AAA-4992-2020	DUFOURC, Erick Joel/0000-0002-8221-9326; RONTEIN, Denis/0000-0002-3288-3800				ADAMS CA, 1982, PLANT CELL PHYSIOL, V23, P959; Botha FC, 1998, PHYSIOL PLANTARUM, V102, P429, DOI 10.1034/j.1399-3054.1998.1020311.x; Bouzier AK, 1998, J BIOL CHEM, V273, P27162, DOI 10.1074/jbc.273.42.27162; BROUQUISSE R, 1992, PLANTA, V188, P384, DOI 10.1007/BF00192806; BROUQUISSE R, 1991, PLANT PHYSIOL, V96, P619, DOI 10.1104/pp.96.2.619; BRYAN JK, 1992, BIOCH PLANTS COMP TR, V5, P403; COHEN SA, 1994, J CHROMATOGR A, V661, P25, DOI 10.1016/0021-9673(93)E0821-B; CORTEZ S, 2002, IN PRESS PLANT PHYSL; DANCER J, 1990, PLANTA, V182, P223, DOI 10.1007/BF00197115; DAVIES SEC, 1992, BIOCHEMISTRY-US, V31, P4729, DOI 10.1021/bi00134a028; DAVIS BM, 1982, J INT ASS MATH GEOL, V14, P189, DOI 10.1007/BF01083951; Dieuaide-Noubhani M, 1997, PLANT PHYSIOL, V115, P1505, DOI 10.1104/pp.115.4.1505; DIEUAIDENOUBHANI M, 1995, J BIOL CHEM, V270, P13147, DOI 10.1074/jbc.270.22.13147; Edwards S, 1998, PLANT PHYSIOL, V116, P1073, DOI 10.1104/pp.116.3.1073; Flugge UI, 1998, CURR OPIN PLANT BIOL, V1, P201, DOI 10.1016/S1369-5266(98)80105-2; GOTTLOBMCHUGH SG, 1992, PLANT PHYSIOL, V100, P820, DOI 10.1104/pp.100.2.820; HAJIREZAEI M, 1994, PLANTA, V192, P16; HATZFELD WD, 1990, PLANTA, V180, P198, DOI 10.1007/BF00193996; Herbers K, 1996, TRENDS BIOTECHNOL, V14, P198, DOI 10.1016/0167-7799(96)10027-5; HILL SA, 1994, PLANTA, V192, P52, DOI 10.1007/BF00198692; Ireland R.J., 1997, PLANT METABOLISM, P478; KANABUS J, 1986, PLANT PHYSIOL, V82, P363, DOI 10.1104/pp.82.2.363; KATZ J, 1967, BIOCHEMISTRY-US, V6, P2227, DOI 10.1021/bi00859a046; Krook J, 1998, J EXP BOT, V49, P1917, DOI 10.1093/jexbot/49.329.1917; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; Lozovaya VV, 1996, PLANT PHYSIOL, V111, P921, DOI 10.1104/pp.111.3.921; Macnicol PK, 1998, PHYSIOL PLANTARUM, V103, P132, DOI 10.1034/j.1399-3054.1998.1030116.x; MACRAE E, 1992, PLANTA, V188, P314, DOI 10.1007/BF00192797; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; Martin F, 1998, PLANT PHYSIOL, V118, P627, DOI 10.1104/pp.118.2.627; Marx A, 1996, BIOTECHNOL BIOENG, V49, P111, DOI 10.1002/(SICI)1097-0290(19960120)49:2<111::AID-BIT1>3.0.CO;2-T; McNeil SD, 2000, PLANT PHYSIOL, V124, P153, DOI 10.1104/pp.124.1.153; MOELLERING H, 1966, ANAL BIOCHEM, V17, P369, DOI 10.1016/0003-2697(66)90172-2; MOING A, 1994, PLANT PHYSIOL, V106, P591, DOI 10.1104/pp.106.2.591; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nuccio ML, 1998, PLANT J, V16, P487, DOI 10.1046/j.1365-313x.1998.00316.x; Plaxton WC, 1996, ANNU REV PLANT PHYS, V47, P185, DOI 10.1146/annurev.arplant.47.1.185; RANCE M, 1983, J MAGN RESON, V52, P221, DOI 10.1016/0022-2364(83)90190-7; REES TA, 1994, PLANT CELL ENVIRON, V17, P587; Roscher A, 1998, J BIOL CHEM, V273, P25053, DOI 10.1074/jbc.273.39.25053; Roscher A, 2000, J BIOTECHNOL, V77, P81, DOI 10.1016/S0168-1656(99)00209-6; SALON C, 1988, J BIOL CHEM, V263, P12278; SCHAAFF I, 1989, YEAST, V5, P285, DOI 10.1002/yea.320050408; SMIRNOFF N, 1995, ENV PLANT B, P1; STEPHANOPOULOS G, 1991, SCIENCE, V252, P1675, DOI 10.1126/science.1904627; STITT M, 1995, ANNU REV PLANT PHYS, V46, P341, DOI 10.1146/annurev.pp.46.060195.002013; STITT M, 1978, PHYTOCHEMISTRY, V17, P1251, DOI 10.1016/S0031-9422(00)94566-7; Stitt Mark, 1994, Current Opinion in Biotechnology, V5, P137, DOI 10.1016/S0958-1669(05)80026-6; Weber A, 2000, PLANT CELL, V12, P787, DOI 10.1105/tpc.12.5.787; WENDLER R, 1991, PLANTA, V183, P31, DOI 10.1007/BF00197564; Zrenner R, 1996, PLANT J, V9, P671, DOI 10.1046/j.1365-313X.1996.9050671.x	51	157	166	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43948	43960		10.1074/jbc.M206366200	http://dx.doi.org/10.1074/jbc.M206366200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226084	hybrid, Green Published			2022-12-25	WOS:000179272000055
J	Scheinfeld, MH; Ghersi, E; Laky, K; Fowlkes, BJ; D'Adamio, L				Scheinfeld, MH; Ghersi, E; Laky, K; Fowlkes, BJ; D'Adamio, L			Processing of beta-amyloid precursor-like protein-1 and-2 by gamma-secretase regulates transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; INTRAMEMBRANE CLEAVAGE; FE65 PROTEIN; FAMILY; NOTCH; APLP2; GENE; PRESENILIN-1; INHIBITORS	The familial Alzheimer's disease gene product beta-amyloid (Abeta) precursor protein (APP) is processed by the beta-and gamma-secretases to produce Abeta as well as AID (APP Intracellular Domain) which is derived from the extreme carboxyl terminus of APP. AID was originally shown to lower the cellular threshold to apoptosis and more recently has been shown to modulate gene expression such that it represses Notch-dependent gene expression while in combination with Fe65 it enhances gene activation. Here we report that the two other members of the APP family, beta-amyloid precursor-like protein-1 and -2 (APLP1 and APLP2), are also processed by the gamma-secretase in a Presenilin 1-dependent manner. Furthermore, the extreme carboxyl-terminal fragments produced by this processing (here termed APP-like Intracellular Domain or ALID1 and ALID2) are able to enhance Fe65-dependent gene activation, similar to what has been reported for AID. Considering that only APP and not the APLPs have been linked to familial Alzheimer's disease (AD), this data should help in understanding the physiologic roles of the APP family members and in differentiating these functions from the pathologic role of APP in Alzheimer's disease.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; NIAID, Cellular & Mol Immunol Lab, NIH, Bethesda, MD 20892 USA	Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	D'Adamio, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	ldadamio@aecom.yu.edu		Scheinfeld, Meir H/0000-0001-8880-4318; D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM07288] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cappai R, 1999, FEBS LETT, V442, P95, DOI 10.1016/S0014-5793(98)01635-4; Cowan CM, 2001, J NEUROSCI, V21, P7099, DOI 10.1523/JNEUROSCI.21-18-07099.2001; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; D'Adamio L, 2002, RES PER ALZ, P101; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Galvan V, 2002, J NEUROCHEM, V82, P283, DOI 10.1046/j.1471-4159.2002.00970.x; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Heber S, 2000, J NEUROSCI, V20, P7951; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; KIM TW, 1995, MOL BRAIN RES, V32, P36, DOI 10.1016/0169-328X(95)00328-P; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lenkkeri U, 1998, HUM GENET, V102, P192, DOI 10.1007/s004390050676; LO ACY, 1995, J BIOL CHEM, V270, P12641, DOI 10.1074/jbc.270.21.12641; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; McNamara MJ, 1998, BRAIN RES, V804, P45, DOI 10.1016/S0006-8993(98)00653-2; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Paliga K, 1997, EUR J BIOCHEM, V250, P354, DOI 10.1111/j.1432-1033.1997.0354a.x; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; VONDERKAMMER H, 1994, GENOMICS, V20, P308, DOI 10.1006/geno.1994.1174; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xu KP, 2001, AM J PHYSIOL-CELL PH, V281, pC603, DOI 10.1152/ajpcell.2001.281.2.C603	41	132	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44195	44201		10.1074/jbc.M208110200	http://dx.doi.org/10.1074/jbc.M208110200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228233	hybrid			2022-12-25	WOS:000179272000086
J	Ge, WW; Wu, JJ; Zhai, JB; Nie, ZY; Lin, H; Schlaepfer, WW; Canete-Soler, R				Ge, WW; Wu, JJ; Zhai, JB; Nie, ZY; Lin, H; Schlaepfer, WW; Canete-Soler, R			Binding of p190RhoGEF to a destabilizing element on the light neurofilament mRNA is competed by BC1 RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; SINGLE-STRANDED-DNA; MOLECULAR-CLONING; DENDRITIC LOCATION; PUR ALPHA; RAT CDNAS; EXPRESSION; GENE; PROTEIN; IDENTIFICATION	The enhancement of RNA-mediated motor neuron degeneration in transgenic mice by mutating a major mRNA instability determinant in a light neurofilament (NF-L) transgene implicates cognate RNA binding factors in the pathogenesis of motor neuron degeneration. p190RhoGEF is a neuron-enriched guanine exchange factor (GEF) that binds to the NF-L-destabilizing element, to c-Jun N-terminal kinase-interactive protein-1 (JIP-1), and to 14-3-3 and may link neurofilament expression to pathways affecting neuronal homeostasis. This study was undertaken to identify additional RNA species that bind p190RhoGEF and could affect interactions of the exchange factor with NF-L transcripts. The C-terminal domain of p190RhoGEF, containing the RNA-binding site, was expressed as a glutathione S-transferase fusion protein and was used as an affinity probe to isolate interactive RNAs in rat brain extracts. As expected, NF-L mRNA was identified as an RNA specie eluted from the affinity column. In addition, BC1 RNA was also found enriched in the bound RNA fraction. BC1 is a 152-nucleotide RNA that is highly expressed but untranslated in differentiated neurons. We show that BC1 and NF-L mRNA bind to a similar site in the C-terminal domain of p190RhoGEF, and their bindings to p190RhoGEF are readily cross-competed. Moreover, we identify a novel binding site in BC1 to account for its interaction with p190RhoGEF. The findings suggest a novel role of BC1 in differentiated neurons involving RNA-protein interactions of p190RhoGEF.	Univ Penn, Ctr Med, Stellar Chance Labs 609C, Div Neuropathol, Philadelphia, PA 19104 USA	University of Pennsylvania	Ge, WW (corresponding author), Univ Penn, Ctr Med, Stellar Chance Labs 609C, Div Neuropathol, 422 Curie Blvd, Philadelphia, PA 19104 USA.	wws435jp@mail.med.upenn.edu						Brosius J, 1999, GENE, V238, P115, DOI 10.1016/S0378-1119(99)00227-9; Canete-Soler R, 1999, J NEUROSCI, V19, P1273; Canete-Soler R, 2001, J BIOL CHEM, V276, P32046, DOI 10.1074/jbc.M104104200; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DECHIARA TM, 1987, P NATL ACAD SCI USA, V84, P2624, DOI 10.1073/pnas.84.9.2624; Deininger PL, 1996, PROG NUCLEIC ACID RE, V52, P67, DOI 10.1016/S0079-6603(08)60964-2; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; KIM J, 1995, NUCLEIC ACIDS RES, V23, P2245, DOI 10.1093/nar/23.12.2245; Kobayashi S, 2000, BIOCHEM BIOPH RES CO, V277, P341, DOI 10.1006/bbrc.2000.3683; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; Lee SY, 2000, J CELL SCI, V113, P1883; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; MARTIGNETTI JA, 1993, P NATL ACAD SCI USA, V90, P9698, DOI 10.1073/pnas.90.20.9698; MCKINNON RD, 1987, MOL CELL BIOL, V7, P2148, DOI 10.1128/MCB.7.6.2148; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Muslimov IA, 2002, J NEUROSCI, V22, P4293, DOI 10.1523/JNEUROSCI.22-11-04293.2002; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Nie ZY, 2002, J NEUROSCI, V22, P7662; Ohashi S, 2000, J NEUROCHEM, V75, P1781, DOI 10.1046/j.1471-4159.2000.0751781.x; Pellet JB, 2000, EUR J NEUROSCI, V12, P621, DOI 10.1046/j.1460-9568.2000.00945.x; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Roy AM, 2000, GENOME RES, V10, P1485, DOI 10.1101/gr.152300; SCHLAEPFER WW, 1990, J NEUROCHEM, V55, P453, DOI 10.1111/j.1471-4159.1990.tb04157.x; Steggerda SM, 2002, INT REV CYTOL, V217, P41; TIEDGE H, 1991, P NATL ACAD SCI USA, V88, P2093, DOI 10.1073/pnas.88.6.2093; TIEDGE H, 1993, J NEUROSCI, V13, P2382, DOI 10.1523/JNEUROSCI.13-06-02382.1993; Tomilin NV, 1999, INT REV CYTOL, V186, P1; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; WATANABE M, 1991, MOL BRAIN RES, V10, P151, DOI 10.1016/0169-328X(91)90105-7; WATANABE M, 1993, MOL BRAIN RES, V17, P135, DOI 10.1016/0169-328X(93)90082-Z; WATANABE M, 1994, MOL BRAIN RES, V25, P113, DOI 10.1016/0169-328X(94)90285-2; WONG PC, 1995, J CELL BIOL, V130, P1413, DOI 10.1083/jcb.130.6.1413; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Zhai JB, 2001, J BIOL CHEM, V276, P41318, DOI 10.1074/jbc.M107709200	41	18	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42701	42705		10.1074/jbc.M206635200	http://dx.doi.org/10.1074/jbc.M206635200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12215442	hybrid			2022-12-25	WOS:000179081200036
J	Ruban, AV; Pascal, A; Lee, PJ; Robert, B; Horton, P				Ruban, AV; Pascal, A; Lee, PJ; Robert, B; Horton, P			Molecular configuration of xanthophyll cycle carotenoids in photosystem II antenna complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; PLANTS; PHOTOPROTECTION; MEMBRANE; DYNAMICS; BINDING	The molecular configuration of the xanthophyll cycle carotenoids, violaxanthin and zeaxanthin, was studied in various isolated photosystem II antenna components in comparison to intact photosystem II membranes using resonance Raman combined with low-temperature absorption spectroscopy. The molecular configurations of zeaxanthin and violaxanthin in thylakoids and isolated photosystem II membranes were found to be the same within an isolated oligomeric LHCII antenna, confirming our recent conclusion that these molecules are not freely located in photosynthetic membranes (Ruban, A V., Pascal, A. A., Robert, B., and Horton, P. (2001) J. Biol. Chem. 276, 24862-24870). In contrast, xanthophyll cycle carotenoids bound to LHCII trimers had largely lost their in vivo configuration, suggesting their partial dissociation from the binding locus. Violaxanthin and zeaxanthin associated with the minor antenna complexes, CP26 and CP29, were also found to be in a relaxed configuration, similar to that of free pigment. The origin of the characteristic C-H vibrational bands of violaxanthin and zeaxanthin in vivo is discussed by comparison with those of neoxanthin and lutein in oligomeric and trimeric LHCII respectively.	Univ Sheffield, Dept Mol Biol & Biotechnol, Robert Hill Inst, Sheffield S10 2TN, S Yorkshire, England; Ecole Normale Super, CNRS, Dept Biol, Unite Mixte Rech 8543, F-75230 Paris 05, France; CEA Saclay, Serv Biophys Fonct Membranaires, F-91191 Gif Sur Yvette, France; CEA Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France	University of Sheffield; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS)	Ruban, AV (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Robert Hill Inst, Sheffield S10 2TN, S Yorkshire, England.	a.ruban@sheffield.ac.uk	Robert, Bruno/D-1264-2012; Horton, Peter/A-3958-2012; pascal, andrew a/B-6186-2014	Robert, Bruno/0000-0001-5999-4538; Horton, Peter/0000-0002-6095-1460; pascal, andrew a/0000-0002-1844-6065				Baker NR, 1994, PHOTOINHIBITION PHOT; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Boekema EJ, 2000, J MOL BIOL, V301, P1123, DOI 10.1006/jmbi.2000.4037; Boekema EJ, 1998, FEBS LETT, V424, P95, DOI 10.1016/S0014-5793(98)00147-1; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; Gilmore AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/j.1399-3054.1997.990127.x; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Horton P, 2000, PHILOS T R SOC B, V355, P1361, DOI 10.1098/rstb.2000.0698; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; JOHNSON GN, 1993, PLANT CELL ENVIRON, V16, P681, DOI 10.1111/j.1365-3040.1993.tb00486.x; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; LEE AL, 1995, PLANT PHYSIOL, V85, P495; OWENS TG, 1992, RES PHOTOSYNTHESIS, V4, P179; PETER GF, 1991, J BIOL CHEM, V266, P16745; Peterman EJG, 1997, CHEM PHYS LETT, V264, P279, DOI 10.1016/S0009-2614(96)01334-6; Robert B, 1999, ADV PHOTOSYNTH, V8, P189; Ruban AV, 2000, FEBS LETT, V477, P181, DOI 10.1016/S0014-5793(00)01799-3; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; Ruban AV, 2001, J BIOL CHEM, V276, P24862, DOI 10.1074/jbc.M103263200; SAITO S, 1983, J RAMAN SPECTROSC, V14, P310, DOI 10.1002/jrs.1250140504; STURGIS JN, 1994, J MOL BIOL, V238, P445, DOI 10.1006/jmbi.1994.1303; Verhoeven AS, 1999, PLANT PHYSIOL, V120, P727, DOI 10.1104/pp.120.3.727; YAKUSHEVSKA AE, EUR J BIOCH, V268, P6020	24	61	62	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42937	42942		10.1074/jbc.M207823200	http://dx.doi.org/10.1074/jbc.M207823200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12207030	hybrid			2022-12-25	WOS:000179081200067
J	Tanimoto, T; Jin, ZG; Berk, BC				Tanimoto, T; Jin, ZG; Berk, BC			Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SMOOTH-MUSCLE CELLS; ANGIOTENSIN-II; EGF RECEPTOR; SIGNAL-TRANSDUCTION; ACTIVATION; ANGIOGENESIS; SPHINGOSINE-1-PHOSPHATE; CONVERGENCE; CAVEOLIN-1	Sphingosine 1-phosphate (S1P) and vascular endothelial growth factor (VEGF) elicit numerous biological responses including cell survival, growth, migration, and differentiation in endothelial cells mediated by the endothelial differentiation gene, a family of G-protein-coupled receptors, and fetal liver kinase-1/kinase-insert domain-containing receptor (Flk-1/KDR), one of VEGF receptors, respectively. Recently, it was reported that SIP or VEGF treatment of endothelial cells leads to phosphorylation at Ser-1179 in bovine endothelial nitric oxide synthase (eNOS), and this phosphorylation is critical for eNOS activation. SIP stimulation of eNOS phosphorylation was shown to involve G(i) protein, phosphoinositide 3-kinase, and Akt. VEGF also activates eNOS through Flk-1/KDR, phosphoinositide 3-kinase, and Akt, which suggested that SIP and VEGF may share upstream signaling mediators. We now report that SIP treatment of bovine aortic endothelial cells acutely increases the tyrosine phosphorylation of Flk-1/KDR, similar to VEGF treatment. S1P-mediated phosphorylation of Flk-1/KDR, Akt, and eNOS were all inhibited by VEGF receptor tyrosine kinase inhibitors and by antisense Flk-1/KDR oligonucleotides. Our study suggests that SIP activation of eNOS involves Gi, calcium, and Src family kinase-dependent transactivation of Flk-1/KDR. These data are the first to establish a critical role of Flk-1/KDR in S1P-stimulated eNOS phosphorylation and activation.	Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA	University of Rochester	Berk, BC (corresponding author), Univ Rochester, Cardiovasc Res Ctr, 601 Elmwood Ave,Box 679, Rochester, NY 14642 USA.			Berk, Bradford/0000-0002-2767-4115	NHLBI NIH HHS [HV64839, HV49192] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Igarashi J, 2001, J BIOL CHEM, V276, P36281, DOI 10.1074/jbc.M105628200; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Kim JH, 2000, IUBMB LIFE, V50, P119, DOI 10.1080/713803698; Kroll J, 1999, BIOCHEM BIOPH RES CO, V265, P636, DOI 10.1006/bbrc.1999.1729; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Peterson TE, 1999, CIRC RES, V85, P29; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Rikitake Y, 2002, ARTERIOSCL THROM VAS, V22, P108, DOI 10.1161/hq0102.101843; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	41	179	184	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42997	43001		10.1074/jbc.M204764200	http://dx.doi.org/10.1074/jbc.M204764200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12226078	hybrid			2022-12-25	WOS:000179081200075
J	Ward, DG; Cornes, MP; Trayer, IP				Ward, DG; Cornes, MP; Trayer, IP			Structural consequences of cardiac troponin I phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MUSCLE TROPONIN; REGULATORY DOMAIN; MOLECULAR-CLONING; ESCHERICHIA-COLI; PROTEIN-KINASE; LIGHT CHAIN; RESOLUTION; BINDING; MUTANTS	beta-Adrenergic stimulation of the heart results in bisphosphorylation of the N-terminal extension of cardiac troponin I (TnI). Bisphosphorylation of TnI reduces the affinity of the regulatory site on troponin C (TnC) for Ca2+ by increasing the rate of Ca2+ dissociation. What remains unclear is how the phosphorylation signal is transmitted from one subunit of troponin to another. We have produced a series of mutations in the N-terminal extension of TnI designed to further our understanding of the mechanisms involved. The ability of phosphorylation of the mutant TnIs to affect Ca2+ sensitivity has been assessed. We find that the Pro residues found in a conserved (Xaa-Pro)(4) motif N-terminal to the phosphorylation sites are not required for the effect of the N-terminal extension on Ca2+ binding in the presence or absence of phosphorylation. Our experiments also reveal that the full effects of phosphorylation are seen even when residues 1-15 of TnI are deleted. If further residues are removed, not only does the effect of phosphorylation diminish but deletion of the N-terminal extension mimics phosphorylation. We propose that TnI residues 16-29 bind to TnC stabilizing the "open" Ca2+. bound state. Phosphorylation (or deletion) prevents this binding, accelerating Ca2+ release.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Trayer, IP (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	I.P.trayer@bham.ac.uk	Cornes, Mike/K-3166-2019	Ward, Douglas/0000-0002-2328-1445				Abbott MB, 2001, BIOCHEMISTRY-US, V40, P5992, DOI 10.1021/bi0100642; ALHILLAWI E, 1994, EUR J BIOCHEM, V225, P1195, DOI 10.1111/j.1432-1033.1994.1195b.x; AUSONI S, 1994, J BIOL CHEM, V269, P339; BHANDARI DG, 1986, EUR J BIOCHEM, V160, P349, DOI 10.1111/j.1432-1033.1986.tb09978.x; Bilmen JG, 2001, EUR J BIOCHEM, V268, P6318, DOI 10.1046/j.0014-2956.2001.02589.x; BREWER S, 1990, J MOL BIOL, V216, P883, DOI 10.1016/S0022-2836(99)80008-4; CALVERT MJ, 1999, J MUSCLE RES CELL M, V20, P830; Chandra M, 1999, BIOCHEM BIOPH RES CO, V263, P219, DOI 10.1006/bbrc.1999.1341; Dohet C, 1995, FEBS LETT, V377, P131, DOI 10.1016/0014-5793(95)01319-9; Dong WJ, 2000, PROTEINS, V41, P438, DOI 10.1002/1097-0134(20001201)41:4<438::AID-PROT20>3.0.CO;2-E; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6754, DOI 10.1021/bi9622276; Dong WJ, 1997, BIOPHYS J, V72, P850, DOI 10.1016/S0006-3495(97)78719-8; FARAH CS, 1994, J BIOL CHEM, V269, P5230; Ferrieres G, 2000, FEBS LETT, V479, P99, DOI 10.1016/S0014-5793(00)01881-0; Finley N, 1999, FEBS LETT, V453, P107, DOI 10.1016/S0014-5793(99)00693-6; Gaponenko V, 1999, J BIOL CHEM, V274, P16681, DOI 10.1074/jbc.274.24.16681; Gasmi-Seabrook GMC, 1999, BIOCHEMISTRY-US, V38, P8313, DOI 10.1021/bi9902642; GRAND RJA, 1976, BIOCHEM J, V159, P633, DOI 10.1042/bj1590633; GUO XD, 1994, J BIOL CHEM, V269, P15210; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; IKEBE M, 1991, J BIOL CHEM, V266, P21339; JAQUET K, 1993, BIOCHEMISTRY-US, V32, P13873, DOI 10.1021/bi00213a016; Jaquet K, 1998, J MUSCLE RES CELL M, V19, P647, DOI 10.1023/A:1005381131102; Keane NE, 1997, EUR J BIOCHEM, V248, P329, DOI 10.1111/j.1432-1033.1997.00329.x; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P2821, DOI 10.1021/bi00408a024; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LIAO RL, 1992, BIOPHYS J, V63, P986, DOI 10.1016/S0006-3495(92)81685-5; LIAO RL, 1994, BIOCHEMISTRY-US, V33, P12729, DOI 10.1021/bi00208a026; Maytum R, 2001, BIOCHEMISTRY-US, V40, P7334, DOI 10.1021/bi010072i; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; NOLAND TA, 1995, J BIOL CHEM, V270, P25445, DOI 10.1074/jbc.270.43.25445; RAY KP, 1976, FEBS LETT, V70, P11, DOI 10.1016/0014-5793(76)80716-8; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TRAYER IP, 1966, BIOCHEM Z, V345, P87; VALLINS WJ, 1990, FEBS LETT, V270, P57, DOI 10.1016/0014-5793(90)81234-F; VANEERD JP, 1976, BIOCHEMISTRY-US, V15, P1171, DOI 10.1021/bi00650a033; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; Ward DG, 2001, EUR J BIOCHEM, V268, P179, DOI 10.1046/j.1432-1327.2001.01871.x; WARD DG, 2000, J MUSCLE RES CELL M, V21, P808; WATTANAPERMPOOL J, 1995, J MOL CELL CARDIOL, V27, P1383, DOI 10.1006/jmcc.1995.0131; ZHANG R, 1995, CIRC RES, V76, P1028, DOI 10.1161/01.RES.76.6.1028	46	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41795	41801		10.1074/jbc.M206744200	http://dx.doi.org/10.1074/jbc.M206744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12207022	hybrid			2022-12-25	WOS:000178985300064
J	Wu, CH; Nusse, R				Wu, CH; Nusse, R			Ligand receptor interactions in the Wnt signaling pathway in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WINGLESS MORPHOGEN GRADIENT; HEDGEHOG RECEPTOR; SPEMANN ORGANIZER; FRIZZLED FAMILY; POLARITY GENES; CELL-SURFACE; PROTEIN; ENCODES; EXPRESSION; MUTATIONS	Secreted Wnt proteins have numerous signaling functions during development, mediated by Frizzled molecules that act as Wnt receptors on the cell surface. In the genome of Drosophila, seven Writ genes (including wingless; wg), and five frizzled genes have been identified. Relatively little is known about signaling and binding specificities of different Wnt and Frizzled proteins. We have developed an assay to determine the strength of binding between membrane-tethered Wnts and ligand binding domains of the Frizzled receptors. We found a wide spectrum of binding affinities, reflecting known genetic interactions. Most Wnt proteins can bind to multiple Frizzleds and vice versa, suggesting redundancy in vivo. In an extension of these experiments, we tested whether two different subdomains of the Wg protein would by themselves bind to Frizzled and generate a biological response. Whereas these two separate domains are secreted from cells, suggesting that they form independently folded parts of the protein, they were only able to evoke a response when co-transfected, indicating that both are required for function. In addition to the Frizzleds, members of the LRP family (represented by the arrow gene in Drosophila) are also necessary for Wnt signal transduction and have been postulated to act as co-receptors. We have therefore examined whether a soluble form of the Arrow molecule can bind to Wingless and Frizzled, but no interactions were detected.	Stanford Univ, Sch Med, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Nusse, R (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060388] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01GM/CA60388-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; BAKER NE, 1988, DEVELOPMENT, V102, P489; BARTHALAY Y, 1990, EMBO J, V9, P3603, DOI 10.1002/j.1460-2075.1990.tb07571.x; BEJSOVEC A, 1995, GENETICS, V139, P309; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhanot P, 1999, DEVELOPMENT, V126, P4175; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Chen CM, 1999, DEVELOPMENT, V126, P5441; Chen Y, 1998, DEVELOPMENT, V125, P4943; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; Cohen ED, 2002, DEV CELL, V2, P437, DOI 10.1016/S1534-5807(02)00142-9; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; DELAESCALERA S, 1990, EMBO J, V9, P3593, DOI 10.1002/j.1460-2075.1990.tb07570.x; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Dierick HA, 1998, DEVELOPMENT, V125, P4729; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FRADKIN LG, 1995, DEV BIOL, V168, P202, DOI 10.1006/dbio.1995.1072; Hays R, 1997, DEVELOPMENT, V124, P3727; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Ingham PW, 2000, CURR BIOL, V10, P1315, DOI 10.1016/S0960-9822(00)00755-7; Janson K, 2001, MECH DEVELOP, V103, P117, DOI 10.1016/S0925-4773(01)00323-9; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kozopas KM, 1998, GENE DEV, V12, P1155, DOI 10.1101/gad.12.8.1155; Kozopas KM, 2002, DEV BIOL, V243, P312, DOI 10.1006/dbio.2002.0572; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Rulifson EJ, 2000, MOL CELL, V6, P117, DOI 10.1016/S1097-2765(00)00013-7; RUSSELL J, 1992, DEVELOPMENT, V115, P475; Sato A, 1999, DEVELOPMENT, V126, P4421; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Shibamoto S, 1998, GENES CELLS, V3, P659; Sivasankaran R, 2000, MECH DEVELOP, V91, P427, DOI 10.1016/S0925-4773(99)00313-5; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Willert K, 1999, DEVELOPMENT, V126, P4165; WONG LL, 1993, J CELL BIOL, V123, P209, DOI 10.1083/jcb.123.1.209; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	57	143	163	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41762	41769		10.1074/jbc.M207850200	http://dx.doi.org/10.1074/jbc.M207850200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12205098	hybrid			2022-12-25	WOS:000178985300060
J	Graille, M; Harrison, S; Crump, MP; Findlow, SC; Housden, NG; Muller, BH; Battail-Poirot, N; Sibai, G; Sutton, BJ; Taussig, MJ; Jolivet-Reynaud, C; Gore, MG; Stura, EA				Graille, M; Harrison, S; Crump, MP; Findlow, SC; Housden, NG; Muller, BH; Battail-Poirot, N; Sibai, G; Sutton, BJ; Taussig, MJ; Jolivet-Reynaud, C; Gore, MG; Stura, EA			Evidence for plasticity and structural mimicry at the immunoglobulin light chain-protein L interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; X-RAY-DIFFRACTION; PEPTOSTREPTOCOCCUS-MAGNUS; CRYSTAL-STRUCTURE; BINDING DOMAIN; STAPHYLOCOCCUS-AUREUS; EXTRACELLULAR DOMAIN; FAB FRAGMENT; EPO RECEPTOR; HUMAN-IGG	The multidomain bacterial surface protein L (PpL) is a virulence factor expressed by only 10% of Peptostreptococcus magnus strains, and its expression is correlated with bacterial vaginosis. The molecular basis for its ability to recognize 60% of mammalian immunoglobulin light chain variable regions (V-L) has been described recently by x-ray crystallography, which suggested the presence of two V-L binding sites on each protein L domain (Graille, M., Stura, E. A., Housden, N.G., Beekingham, J.A., Bottomley, S. P., Beale, D., Taussig, M.J., Sutton, B.J., Gore, M. G., and Charbonnier, J. (2001) Structure, 679-687). Here, we report the crystal structure at 2.1 Angstrom resolution of a protein L mutant complexed to an Fab' fragment with only 50% of the VL residues interacting with PpL site 1 conserved. Comparison of the site 1 interface from both structures shows how protein L is able to accommodate these sequence differences and therefore bind to a large repertoire of Ig. The x-ray structure and NMR results confirm the existence of two V-L binding sites on a single protein L domain. These sites exhibit a remarkable structural mimicry of growth factors binding to their receptors. This could explain the protein L superantigenic activity on human B lymphocytes.	Univ Southampton, Inst Biomol Sci, Dept Biochem, Southampton SO16 7PX, Hants, England; CEA, Ctr Etud Saclay, Lab Struct Prot, F-91191 Gif Sur Yvette, France; CEA, Ctr Etud Saclay, UMR CEA Biomerieux, DIEP, F-91191 Gif Sur Yvette, France; Biomerieux, Dept R&D Immunoessais & Proteom, F-69280 Marcy Letoile, France; Kings Coll London, Randall Ctr, London SE1 1UL, England; Babraham Inst, Technol Res Grp, Cambridge CB2 4AT, England	University of Southampton; CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; bioMerieux; University of London; King's College London; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Gore, MG (corresponding author), Univ Southampton, Inst Biomol Sci, Dept Biochem, Bassett Crescent E, Southampton SO16 7PX, Hants, England.	M.G.Gore@soton.ac.uk; estura@cea.fr	GRAILLE, Marc/D-3242-2014; Stura, Enrico A./A-2793-2010	GRAILLE, Marc/0000-0002-7853-5852; Stura, Enrico A./0000-0001-6718-2118; Housden, Nicholas/0000-0002-4706-8278; Crump, Matthew/0000-0002-7868-5818				AKERSTROM B, 1989, J BIOL CHEM, V264, P19740; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beckingham JA, 2001, BIOCHEM J, V353, P395, DOI 10.1042/0264-6021:3530395; Beckingham JA, 1999, BIOCHEM J, V340, P193, DOI 10.1042/0264-6021:3400193; Bettsworth F, 2001, J MOL RECOGNIT, V14, P99, DOI 10.1002/jmr.525; BJORCK L, 1988, J IMMUNOL, V140, P1194; BJORCK L, 1984, J IMMUNOL, V133, P969; Bottomley SP, 1995, BIOSEPARATION, V5, P359; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DERRICK JP, 1992, NATURE, V359, P752, DOI 10.1038/359752a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Genovese A, 2000, INFECT IMMUN, V68, P5517, DOI 10.1128/IAI.68.10.5517-5524.2000; Graille M, 2001, STRUCTURE, V9, P679, DOI 10.1016/S0969-2126(01)00630-X; Graille M, 2000, P NATL ACAD SCI USA, V97, P5399, DOI 10.1073/pnas.97.10.5399; Jolivet-Reynaud C, 1998, J MED VIROL, V56, P300, DOI 10.1002/(SICI)1096-9071(199812)56:4&lt;300::AID-JMV3&gt;3.0.CO;2-8; KASTERN W, 1992, J BIOL CHEM, V267, P12820; KASTERN W, 1990, INFECT IMMUN, V58, P1217, DOI 10.1128/IAI.58.5.1217-1222.1990; LANGONE JJ, 1982, ADV IMMUNOL, V32, P157; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MURPHY JP, 1994, MOL MICROBIOL, V12, P911, DOI 10.1111/j.1365-2958.1994.tb01079.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NILSON BHK, 1992, J BIOL CHEM, V267, P2234; O'Neill JW, 2001, ACTA CRYSTALLOGR D, V57, P480, DOI 10.1107/S0907444901000373; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; Ricci S, 2001, MICROB PATHOGENESIS, V30, P229, DOI 10.1006/mpat.2000.0427; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; RUBERTI F, 1994, J IMMUNOL METHODS, V173, P33, DOI 10.1016/0022-1759(94)90280-1; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; STURA EA, 1991, J CRYST GROWTH, V110, P270, DOI 10.1016/0022-0248(91)90896-D; Stura EA, 2002, ACTA CRYSTALLOGR D, V58, P1744, DOI 10.1107/S0907444902012805; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; WIKSTROM M, 1994, BIOCHEMISTRY-US, V33, P14011, DOI 10.1021/bi00251a008; Wikstrom M, 1996, EUR J BIOCHEM, V235, P543, DOI 10.1111/j.1432-1033.1996.00543.x; WIKSTROM M, 1995, J MOL BIOL, V250, P128, DOI 10.1006/jmbi.1995.0364	41	34	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47500	47506		10.1074/jbc.M206105200	http://dx.doi.org/10.1074/jbc.M206105200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12221088	hybrid, Green Published			2022-12-25	WOS:000179663700087
J	Pasta, SY; Raman, B; Ramakrishna, T; Rao, CM				Pasta, SY; Raman, B; Ramakrishna, T; Rao, CM			Role of the C-terminal extensions of alpha-crystallins - Swapping the C-terminal extension of alpha A-crystallin to alpha B-crystallin results in enhanced chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MOLTEN-GLOBULE STATE; DESMIN-RELATED MYOPATHY; MOLECULAR CHAPERONE; QUATERNARY STRUCTURE; MISSENSE MUTATION; THERMAL-STRESS; LENS; DOMAIN; IDENTIFICATION	Several small heat shock proteins contain a well conserved a-crystallin domain, flanked by an N-terminal domain and a C-terminal extension, both of which vary in length and sequence. The structural and functional role of the C-terminal extension of small heat shock proteins, particularly of alphaA- and alphaB-crystallins, is not well understood. We have swapped the C-terminal extensions between alphaA- and alphaB-crystallins and generated two novel chimeric proteins, alphaABc and alphaBAc. We have investigated the domain-swapped chimeras for structural and functional alterations. We have used thermal and non-thermal models of protein aggregation and found that the chimeric alphaB with the C-terminal extension of alphaA-crystallin, alphaBAc, exhibits dramatically enhanced chaperone-like activity. Interestingly, however, the chimeric alphaA with the C-terminal extension of alphaB-crystallin, alphaABc, has almost lost its activity. Pyrene solubilization and bis-1-anilino-8-naphthalenesulfonate binding studies show that alphaBAc exhibits more solvent-exposed hydrophobic pockets than alphaA, alphaB, or alphaABc. Significant tertiary structural changes are revealed by tryptophan fluorescence and near-UV CD studies upon swapping the C-terminal extensions. The far-UV CD spectrum of alphaBAc differs from that of alphaB-crystallin whereas that of alphaABc overlaps with that of alphaA-crystallin. Gel filtration chromatography shows alteration in the size of the proteins upon swapping the C-terminal extensions. Our study demonstrates that the unstructured C-terminal extensions play a crucial role in the structure and chaperone activity, in addition to generally believed electrostatic "solubilizer" function.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Rao, CM (corresponding author), Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.							Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; Andley UP, 2002, J BIOL CHEM, V277, P10178, DOI 10.1074/jbc.M109211200; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BHAT SP, 1991, EUR J BIOCHEM, V202, P775, DOI 10.1111/j.1432-1033.1991.tb16432.x; Bloemendal H, 1981, MOL CELLULAR BIOL EY, P1; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; Carver JA, 1998, INT J BIOL MACROMOL, V22, P197, DOI 10.1016/S0141-8130(98)00017-8; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Clark JI, 2000, CURR OPIN STRUC BIOL, V10, P52, DOI 10.1016/S0959-440X(99)00048-2; Das BK, 1997, BIOCHEM BIOPH RES CO, V236, P370, DOI 10.1006/bbrc.1997.6950; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Feil IK, 2001, J BIOL CHEM, V276, P12024, DOI 10.1074/jbc.M010856200; Fernando P, 2000, CELL STRESS CHAPERON, V5, P148, DOI 10.1379/1466-1268(2000)005<0148:FCOXSH>2.0.CO;2; Goenka S, 2001, BIOCHEM J, V359, P547, DOI 10.1042/0264-6021:3590547; Hess J F, 1998, Mol Vis, V4, P29; Hook DWA, 1997, EUR J BIOCHEM, V247, P380, DOI 10.1111/j.1432-1033.1997.00380.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Kumar LVS, 2000, J BIOL CHEM, V275, P22009, DOI 10.1074/jbc.M003307200; Kumar LVS, 1999, J BIOL CHEM, V274, P24137, DOI 10.1074/jbc.274.34.24137; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; LI LK, 1973, EXP EYE RES, V15, P179, DOI 10.1016/0014-4835(73)90117-6; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; Marini I, 2000, J BIOL CHEM, V275, P32559, DOI 10.1074/jbc.M006133200; Martin JL, 1997, CIRCULATION, V96, P4343; Mornon JP, 1998, INT J BIOL MACROMOL, V22, P219, DOI 10.1016/S0141-8130(98)00019-1; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; QUAXJEUKEN Y, 1985, P NATL ACAD SCI USA, V82, P5819, DOI 10.1073/pnas.82.17.5819; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; Rajaraman K, 1998, BIOCHEM BIOPH RES CO, V249, P917, DOI 10.1006/bbrc.1998.9242; Rajaraman K, 2001, FEBS LETT, V497, P118, DOI 10.1016/S0014-5793(01)02451-6; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; Rao CM, 1998, INT J BIOL MACROMOL, V22, P271; RAO PV, 1991, ARCH BIOCHEM BIOPHYS, V284, P181, DOI 10.1016/0003-9861(91)90281-M; Rawat U, 1998, J BIOL CHEM, V273, P9415, DOI 10.1074/jbc.273.16.9415; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma KK, 2000, J BIOL CHEM, V275, P3767, DOI 10.1074/jbc.275.6.3767; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; Smith JB, 1996, EXP EYE RES, V63, P125, DOI 10.1006/exer.1996.0100; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; Studer S, 2002, EUR J BIOCHEM, V269, P3578, DOI 10.1046/j.1432-1033.2002.03049.x; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; van Rijk AF, 2000, FEBS LETT, V480, P79, DOI 10.1016/S0014-5793(00)01908-6; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang KY, 2000, EUR J BIOCHEM, V267, P4705, DOI 10.1046/j.1432-1327.2000.01521.x	66	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45821	45828		10.1074/jbc.M206499200	http://dx.doi.org/10.1074/jbc.M206499200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235146	hybrid			2022-12-25	WOS:000179529300015
J	van Rossenberg, SMW; Sliedregt-Bol, KM; Meeuwenoord, NJ; van Berkel, TJC; van Boom, JH; van der Marel, GA; Biessen, EAL				van Rossenberg, SMW; Sliedregt-Bol, KM; Meeuwenoord, NJ; van Berkel, TJC; van Boom, JH; van der Marel, GA; Biessen, EAL			Targeted lysosome disruptive elements for improvement of parenchymal liver cell-specific gene delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-INDUCED FUSION; ASIALOGLYCOPROTEIN RECEPTOR; MEMBRANE-FUSION; IN-VITRO; INTRACELLULAR DELIVERY; FUSOGENIC PEPTIDE; MAMMALIAN-CELLS; DNA COMPLEXES; EXPRESSION; HEPATOCYTES	The transfection ability of nonviral gene therapy vehicles is generally hampered by untimely lysosomal degradation of internalized DNA. In this study we describe the development of a targeted lysosome disruptive element to facilitate the escape of DNA from the lysosomal compartment, thus enhancing the transfection efficacy, in a cell-specific fashion. Two peptides (INF7 and JTS-1) were tested for their capacity to disrupt liposomes. In contrast to JTS-1, INF7 induced rapid cholesterol-independent leakage (EC50, 1.3 mum). INF7 was therefore selected for coupling to a high affinity ligand for the asialoglycoprotein receptor (ASGPr), K(GalNAc)(2) to improve its uptake by parenchymal liver cells. Although the parent peptide disrupted both cholesterol-rich and -poor liposomes, the conjugate, INF7-K(GalNAc)(2) only induced leakage of cholesterol-poor liposomes. Given that endosomal membranes of eukaryotic cells contain <5% cholesterol, this implies that the conjugate will display a higher selectivity toward endosomal membranes. Although both INF7 and INF7-K(GalNAc)(2) were found to increase the transfection efficiency on polyplex-mediated gene transfer to parenchymal liver cells by 30-fold, only INF7-K(GaINAc)(2) appeared to do so in an ASGPr-specific manner. In mice, INF7-K(GaINAc)(2) was specifically targeted to the liver, whereas INF7 was distributed evenly over various organs. In summary, we have prepared a nontoxic cell-specific lysosome disruptive element that improves gene delivery to parenchymal liver cells via the ASGPr. Its high cell specificity and preference to lyse intracellular membranes make this conjugate a promising lead in hepatocyte-specific drug/gene delivery protocols.	Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands; Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	van Rossenberg, SMW (corresponding author), Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Gorlaeus Labs, PO Box 9502, NL-2300 RA Leiden, Netherlands.	rossenbe@lacdr.leidenuniv.nl	Van Berkel, Theo/ABD-7677-2021					Akhtar S, 2000, ADV DRUG DELIVER REV, V44, P3, DOI 10.1016/S0169-409X(00)00080-6; ALBERTS B, 1983, MOL BIOL CELL, P260; ARAR K, 1995, BIOCONJUGATE CHEM, V6, P573, DOI 10.1021/bc00035a011; Beck NB, 2000, GENE THER, V7, P1274, DOI 10.1038/sj.gt.3301246; Biessen EAL, 1999, BIOCHEM J, V340, P783, DOI 10.1042/0264-6021:3400783; Biessen EAL, 2002, BIOCONJUGATE CHEM, V13, P295, DOI 10.1021/bc015550g; Chowdhury NR, 1996, J BIOL CHEM, V271, P2341, DOI 10.1074/jbc.271.4.2341; COTTEN M, 1993, METHOD ENZYMOL, V217, P618; Decout A, 1998, BBA-BIOMEMBRANES, V1372, P102, DOI 10.1016/S0005-2736(98)00050-9; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Gottschalk S, 1996, GENE THER, V3, P448; Huang H, 1999, J PEPT RES, V53, P548, DOI 10.1034/j.1399-3011.1999.00059.x; Kickler A, 1997, BIOCONJUGATE CHEM, V8, P213, DOI 10.1021/bc970009z; Kobayashi T, 2001, SEMIN CELL DEV BIOL, V12, P173, DOI 10.1006/scdb.2000.0234; Lim DW, 2000, BIOCONJUGATE CHEM, V11, P688, DOI 10.1021/bc000014u; Martin I, 1999, BIOCHEMISTRY-US, V38, P9337, DOI 10.1021/bi9829534; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; McKenzie DL, 1999, J PEPT RES, V54, P311, DOI 10.1034/j.1399-3011.1999.00104.x; Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730; Niidome T, 2000, BIOMATERIALS, V21, P1811, DOI 10.1016/S0142-9612(00)00076-4; Nishikawa M, 2000, GENE THER, V7, P548, DOI 10.1038/sj.gt.3301140; PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8720, DOI 10.1021/bi00489a031; Pecheur EI, 2000, J BIOL CHEM, V275, P3936, DOI 10.1074/jbc.275.6.3936; Pecheur EI, 1999, J MEMBRANE BIOL, V167, P1, DOI 10.1007/s002329900466; Pecheur EI, 1999, BIOCHEMISTRY-US, V38, P364, DOI 10.1021/bi981389u; Pecheur EI, 1998, BIOCHEMISTRY-US, V37, P2361, DOI 10.1021/bi972697f; PLANK C, 1994, J BIOL CHEM, V269, P12918; Plourde R, 1996, BIOCONJUGATE CHEM, V7, P131, DOI 10.1021/bc950083m; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Rensen PCN, 1997, MOL PHARMACOL, V52, P445, DOI 10.1124/mol.52.3.445; Rensen PCN, 2001, J BIOL CHEM, V276, P37577, DOI 10.1074/jbc.M101786200; Schoen P, 1999, GENE THER, V6, P823, DOI 10.1038/sj.gt.3300919; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Simoes S, 1999, GENE THER, V6, P1798, DOI 10.1038/sj.gt.3301015; Sliedregt LAJM, 1999, J MED CHEM, V42, P609, DOI 10.1021/jm981078h; Smith LC, 1998, ADV DRUG DELIVER REV, V30, P115, DOI 10.1016/S0169-409X(97)00111-7; Sugano M, 1996, J BIOL CHEM, V271, P19080, DOI 10.1074/jbc.271.32.19080; Terpstra V, 2000, ARTERIOSCL THROM VAS, V20, P1860, DOI 10.1161/01.ATV.20.8.1860; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Valentijn ARPM, 1997, TETRAHEDRON, V53, P759, DOI 10.1016/S0040-4020(96)01018-6; VAYSSE L, 2000, BIOCHIM BIOPHYS ACTA, V26, P369; Wadhwa MS, 1997, BIOCONJUGATE CHEM, V8, P81, DOI 10.1021/bc960079q; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WATABE A, 1999, BIOCH BIOPHYS ACTA B, V12, P1; Wolfert MA, 1998, GENE THER, V5, P409, DOI 10.1038/sj.gt.3300606; Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91; Zhang X, 2001, BIOORG MED CHEM LETT, V11, P1269, DOI 10.1016/S0960-894X(01)00198-6	49	31	36	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45803	45810		10.1074/jbc.M203510200	http://dx.doi.org/10.1074/jbc.M203510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237290	Green Published, hybrid			2022-12-25	WOS:000179529300013
J	Kang, SJ; Cresswell, P				Kang, SJ; Cresswell, P			Calnexin, calreticulin, and ERp57 cooperate in disulfide bond formation in human CD1d heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECOGNITION; CLASS-I MOLECULES; ENDOPLASMIC-RETICULUM; BIOCHEMICAL-CHARACTERIZATION; ALPHA-GALACTOSYLCERAMIDE; SURFACE EXPRESSION; SELF-GLYCOLIPIDS; LOADING COMPLEX; QUALITY-CONTROL; LYMPHOCYTES-T	Members of the CD1 family of membrane glycoproteins can present antigenic lipids to T lymphocytes. Like major histocompatibility complex class I molecules, they form a heterodimeric complex of a heavy chain and beta(2)-microglobulin (beta(2)m) in the endoplasmic reticulum (ER). Binding of lipid antigens, however, takes place in endosomal compartments, similar to class II molecules, and on the plasma membrane. Unlike major histocompatibility complex class I or CD1b molecules, which need beta(2)m to exit the ER, CD1d can be expressed on the cell surface as either a free heavy chain or associated with beta(2)m. These differences led us to investigate early events of CD1d biosynthesis and maturation and the role of ER chaperones in its assembly. Here we show that CD1d associates in the ER with both calnexin and calreticulin and with the thiol oxidoreductase ERp57 in a manner dependent on glucose trimming of its N-linked glycans. Complete disulfide bond formation in the CD1d heavy chain was substantially impaired if the chaperone interactions were blocked by the glucosidase inhibitors castanospermine or N-butyldeoxynojirimycin. The formation of at least one of the disulfide bonds in the CD1d heavy chain is coupled to its glucose trimming-dependent association with ERp57, calnexin, and calreticulin.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University	Cresswell, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.		Kang, Suk-Jo/C-1796-2011		NIAID NIH HHS [AI23081] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023081, R01AI023081] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amano M, 1998, J IMMUNOL, V161, P1710; ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; Bai A, 2000, J IMMUNOL, V165, P7025, DOI 10.4049/jimmunol.165.12.7025; Bai A, 1998, IMMUNITY, V9, P413, DOI 10.1016/S1074-7613(00)80624-X; BALK SP, 1994, SCIENCE, V265, P259, DOI 10.1126/science.7517575; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87; Briken V, 2002, EMBO J, V21, P825, DOI 10.1093/emboj/21.4.825; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Brossay L, 1998, J IMMUNOL, V160, P3681; Brossay L, 1998, J IMMUNOL, V161, P5124; BRUTKIEWICZ RR, 1995, J EXP MED, V182, P1913, DOI 10.1084/jem.182.6.1913; Burdin N, 1998, J IMMUNOL, V161, P3271; Cannon KS, 2001, EMBO J, V20, P2443, DOI 10.1093/emboj/20.10.2443; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; Chiu NM, 1999, J EXP MED, V190, P423, DOI 10.1084/jem.190.3.423; Chun T, 2001, J IMMUNOL, V167, P1507, DOI 10.4049/jimmunol.167.3.1507; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; De Silva AD, 2002, J IMMUNOL, V168, P723, DOI 10.4049/jimmunol.168.2.723; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Diedrich G, 2001, J IMMUNOL, V166, P1703, DOI 10.4049/jimmunol.166.3.1703; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109; Exley M, 2000, IMMUNOLOGY, V100, P37, DOI 10.1046/j.1365-2567.2000.00001.x; Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6; Gumperz JE, 2000, IMMUNITY, V12, P211, DOI 10.1016/S1074-7613(00)80174-0; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; Huttinger R, 1999, INT IMMUNOL, V11, P1615, DOI 10.1093/intimm/11.10.1615; Joyce S, 1998, SCIENCE, V279, P1541, DOI 10.1126/science.279.5356.1541; Kang SJ, 2002, EMBO J, V21, P1650, DOI 10.1093/emboj/21.7.1650; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kim HS, 1999, J BIOL CHEM, V274, P9289, DOI 10.1074/jbc.274.14.9289; Lee N, 1998, J IMMUNOL, V160, P4951; Lybarger L, 2001, J IMMUNOL, V167, P2097, DOI 10.4049/jimmunol.167.4.2097; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Moody DB, 2000, NATURE, V404, P884, DOI 10.1038/35009119; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; Porcelli SA, 1999, ANNU REV IMMUNOL, V17, P297, DOI 10.1146/annurev.immunol.17.1.297; Rodionov DG, 1999, J IMMUNOL, V162, P1488; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Shamshiev A, 2000, IMMUNITY, V13, P255, DOI 10.1016/S1074-7613(00)00025-X; Shamshiev A, 2002, J EXP MED, V195, P1013, DOI 10.1084/jem.20011963; Shamshiev A, 1999, EUR J IMMUNOL, V29, P1667, DOI 10.1002/(SICI)1521-4141(199905)29:05<1667::AID-IMMU1667>3.0.CO;2-U; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; STAM NJ, 1986, J IMMUNOL, V137, P2299; SUGITA M, 1994, J EXP MED, V180, P2163, DOI 10.1084/jem.180.6.2163; Sugita M, 1997, J IMMUNOL, V159, P2358; Teitell M, 1997, J IMMUNOL, V158, P2143; Van der Wal FJ, 1998, EUR J BIOCHEM, V256, P51, DOI 10.1046/j.1432-1327.1998.2560051.x; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	58	89	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44838	44844		10.1074/jbc.M207831200	http://dx.doi.org/10.1074/jbc.M207831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239218	hybrid			2022-12-25	WOS:000179404800033
J	Shah, M; Patel, K; Fried, VA; Sehgal, PB				Shah, M; Patel, K; Fried, VA; Sehgal, PB			Interactions of STAT3 with caveolin-1 and heat shock protein 90 in plasma membrane raft and cytosolic complexes - Preservation of cytokine signaling during fever	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS PYROGEN; IFN-GAMMA; IN-VITRO; ACTIVATION; INTERLEUKIN-6; RECEPTOR; COMPONENTS; PATHWAYS; CELLS; LOCALIZATION	Interleukin-6 (IL-6) initiates STAT3 signaling in plasma membrane rafts with the subsequent transit of Tyr-phosphorylated STAT3 (PY-STAT3) through the cytoplasmic compartment to the nucleus in association with accessory proteins. We initially identified caveolin-1 (cav-1) as a candidate STAT3-associated accessory protein due to its co-localization with STAT3 and PY-STAT3 in flotation raft fractions, and heat shock protein 90 (HSP90) due to its inclusion in cytosolic STAT3-containing 200-400-kDa complexes. Subsequent immuno-magnetic bead pullout assays showed that STAT3, PY-STAT3, cav-1, and HSP90 interacted in plasma membrane and cytoplasmic complexes derived from uninduced and stimulated Hep3B cells. This was a general property of STAT3 in that these interactions were also observed in alveolar epithelial type II-like cells, lung fibroblasts, and pulmonary arterial endothelial cells. Exposure of Hep3B cells to the raft disrupter methyl-beta-cyclodextrin for 1-10 min followed by IL-6 stimulation for 15 min preferentially inhibited the appearance of PY-STAT3 in the cav-1-enriched sedimentable cytoplasmic fraction, suggesting that these complexes may represent a trafficking intermediate immediately downstream from the raft. Because IL-6 is known to function in the body in the context of fever, the possibility that HSP90 may help preserve IL-6-induced STAT3 signaling at elevated temperature was investigated. Geldanamycin, an HSP90 inhibitor, markedly inhibited IL-6-stimulated STAT3 signaling in Hep3B hepatocytes cultured overnight at 39.5 degreesC as evaluated by DNA-shift assays, trafficking of PY-STAT3 to the nucleus, cross-precipitation of HSP90 by anti-STAT3 polyclonal antibody, and reporter/luciferase construct experiments. Taken together, the data show that IL-6/raft/STAT3 signaling is a chaperoned pathway that involves cav-1 and HSP90 as accessory proteins and suggest a mechanism for the preservation of this signaling during fever.	New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Sehgal, PB (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Rm 201,Basic Sci Bldg, Valhalla, NY 10595 USA.				NCI NIH HHS [CA-82647] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082647] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1989, Ann N Y Acad Sci, V557, P1; Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DINARELLO CA, 1991, BRAIN RES, V562, P199, DOI 10.1016/0006-8993(91)90622-3; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Guo GG, 2002, J INTERF CYTOK RES, V22, P555, DOI 10.1089/10799900252982034; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HELFGOTT DC, 1989, J IMMUNOL, V142, P948; Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257; Kone BC, 2000, ACTA PHYSIOL SCAND, V168, P27; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; LEMAY LG, 1990, AM J PHYSIOL, V258, P798; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; MACKIEWICZ A, 1995, ANN NY ACAD SCI, V762, P1; Marmor MD, 2001, BLOOD, V98, P1489, DOI 10.1182/blood.V98.5.1489; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Predescu SA, 2001, MOL BIOL CELL, V12, P1019, DOI 10.1091/mbc.12.4.1019; Rayanade RJ, 1997, J BIOL CHEM, V272, P4659, DOI 10.1074/jbc.272.8.4659; Rayanade RJ, 1998, J IMMUNOL, V161, P325; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROTHWELL NJ, 1991, CAN J PHYSIOL PHARM, V69, P1465, DOI 10.1139/y91-219; Sadir R, 2001, CYTOKINE, V14, P19, DOI 10.1006/cyto.2000.0854; Sehgal PB, 2000, CELL SIGNAL, V12, P525, DOI 10.1016/S0898-6568(00)00098-X; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stephanou A, 1998, BIOCHEM J, V330, P189, DOI 10.1042/bj3300189; Stephanou A, 1999, GENE EXPRESSION, V7, P311; Subramaniam PS, 2002, J IMMUNOL, V169, P1959, DOI 10.4049/jimmunol.169.4.1959; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; Teixeira A, 1999, J NEUROCHEM, V72, P120, DOI 10.1046/j.1471-4159.1999.0720120.x; WANG L, 1995, J BIOL CHEM, V270, P23159, DOI 10.1074/jbc.270.39.23159; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128	39	94	94	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45662	45669		10.1074/jbc.M205935200	http://dx.doi.org/10.1074/jbc.M205935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235142	hybrid			2022-12-25	WOS:000179404800133
J	Grantcharova, E; Furkert, J; Reusch, HP; Krell, HW; Papsdorf, G; Beyermann, M; Schulein, R; Rosenthal, W; Oksche, A				Grantcharova, E; Furkert, J; Reusch, HP; Krell, HW; Papsdorf, G; Beyermann, M; Schulein, R; Rosenthal, W; Oksche, A			The extracellular N terminus of the endothelin B (ETB) receptor is cleaved by a metalloprotease in an agonist-dependent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; ET(B) RECEPTORS; CIRCULATING ENDOTHELIN-1; DOWN-REGULATION; INSECT CELLS; L-SELECTIN; MEMBRANE; PROTEIN; LIGAND; ECTODOMAIN	The extracellular N terminus of the endothelin B (ETB) receptor is susceptible to limited proteolysis (cleavage at R64 down arrow S65), but the regulation and the functional consequences of the proteolysis remain elusive. We analyzed the ETB receptor or an ETB-GFP fusion protein stably or transiently expressed in HEK293 cells. After incubation of cells at 4 degreesC, only the full-length ETB receptor was detected at the cell surface. However, when cells were incubated at 37 degreesC, N-terminal cleavage was observed, provided endothelin 1 was present during the incubation. Cleavage was not inhibited by internalization inhibitors (sucrose, phenylarsine oxide). However, in cells incubated with both internalization inhibitors and metalloprotease inhibitors (batimastat, inhibitor of TNFalpha-convertase) or metal chelators (EDTA, phenanthroline), the cleavage was blocked, indicating that metalloproteases cleave the agonist-occupied ETB receptor at the cell surface. Functional analysis of a mutant ETB receptor lacking the first 64 amino acids ([Delta2-64]ETB receptor) revealed normal functional properties, but a 15-fold reduced cell surface expression. The results suggest a role of the N-terminal proteolysis in the regulation of cell surface expression of the ETB receptor. This is the first example of a multispanning membrane protein, which is cleaved by a metalloprotease, but retains its functional activity and overall structure.	Free Univ Berlin, Inst Klin Pharmakol & Toxikol, D-14195 Berlin, Germany; Roche Diagnost GmbH, Pharma Res Penzberg, D-82372 Penzberg, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Forsch Inst Mol Pharmakol, D-13125 Berlin, Germany	Free University of Berlin; Roche Holding; Free University of Berlin	Oksche, A (corresponding author), Thiellallee 67-73, D-14195 Berlin, Germany.		Oksche, Alexander/M-6678-2019	Oksche, Alexander/0000-0003-4592-1770				AKIYAMA N, 1992, PROTEIN EXPRES PURIF, V3, P427, DOI 10.1016/S1046-5928(05)80046-4; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BELDENT V, 1993, J BIOL CHEM, V268, P26428; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; Couet J, 1996, J BIOL CHEM, V271, P4545; Cramer H, 2001, EUR J BIOCHEM, V268, P5449, DOI 10.1046/j.0014-2956.2001.02486.x; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; Doi T, 1997, EUR J BIOCHEM, V248, P139, DOI 10.1111/j.1432-1033.1997.00139.x; Dupuis J, 1996, J APPL PHYSIOL, V81, P1510, DOI 10.1152/jappl.1996.81.4.1510; EGUCHI S, 1993, J CARDIOVASC PHARM, V22, pS161, DOI 10.1097/00005344-199322008-00043; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FUKURODA T, 1994, BIOCHEM BIOPH RES CO, V199, P1461, DOI 10.1006/bbrc.1994.1395; Gomis-Ruth FX, 1998, PROTEIN SCI, V7, P283; HAGIWARA H, 1991, J CARDIOVASC PHARM, V17, pS117, DOI 10.1097/00005344-199100177-00030; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Kochl R, 2002, J BIOL CHEM, V277, P16131, DOI 10.1074/jbc.M111674200; KOJRO E, 1995, J BIOL CHEM, V270, P6476, DOI 10.1074/jbc.270.12.6476; Krause G, 2000, MOL PHARMACOL, V57, P232; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Mizuguchi T, 1997, BRIT J PHARMACOL, V120, P1427, DOI 10.1038/sj.bjp.0701054; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Oksche A, 2000, MOL PHARMACOL, V57, P1104; Oksche A, 2002, MOL ENDOCRINOL, V16, P799, DOI 10.1210/me.16.4.799; Oksche A, 2000, J CARDIOVASC PHARM, V36, pS44; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; ROBINSON PJ, 1987, P NATL ACAD SCI USA, V84, P527, DOI 10.1073/pnas.84.2.527; SAITO Y, 1991, J BIOL CHEM, V266, P23433; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Satoh M, 1997, EUR J BIOCHEM, V249, P803, DOI 10.1111/j.1432-1033.1997.00803.x; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schmidlin Fabien, 2001, Current Opinion in Pharmacology, V1, P575, DOI 10.1016/S1471-4892(01)00099-6; SEO B, 1994, CIRCULATION, V89, P1203, DOI 10.1161/01.CIR.89.3.1203; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SMITH BJ, 1993, APPL BIOCHEM BIOTECH, V41, P189, DOI 10.1007/BF02916422; SOKOLOVSKY M, 1992, J BIOL CHEM, V267, P20551; TAKASUKA T, 1994, J BIOL CHEM, V269, P7509; TAKASUKA T, 1991, J CARDIOVASC PHARM, V17, pS109; TAKAYANAGI R, 1991, REGUL PEPTIDES, V32, P23, DOI 10.1016/0167-0115(91)90004-Z; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAGGONER WG, 1992, LIFE SCI, V51, P1869, DOI 10.1016/0024-3205(92)90038-Q; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132	52	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43933	43941		10.1074/jbc.M208407200	http://dx.doi.org/10.1074/jbc.M208407200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226103	hybrid			2022-12-25	WOS:000179272000053
J	Jarvis, SE; Barr, W; Feng, ZP; Hamid, J; Zamponi, GW				Jarvis, SE; Barr, W; Feng, ZP; Hamid, J; Zamponi, GW			Molecular determinants of syntaxin 1 modulation of N-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN MODULATION; G-BETA-GAMMA; CA2+ CHANNELS; SNARE COMPLEX; NEUROTRANSMITTER RELEASE; 3-DIMENSIONAL STRUCTURE; FUNCTIONAL INTERACTION; BINDING; 1A; SUBUNIT	We have previously reported that syntaxin 1A, a component of the presynaptic SNARE complex, directly modulates N-type calcium channel gating in addition to promoting tonic G-protein inhibition of the channels, whereas syntaxin 1B affects channel gating but does not support G-protein modulation (Jarvis, S. E., and Zamponi, G. W. (2001) J. Neurosci. 21, 2939 -2948). Here, we have investigated the molecular determinants that govern the action of syntaxin 1 isoforms on N-type calcium channel function. In vitro evidence shows that both syntaxin 1 isoforms physically interact with the G-protein beta subunit and the synaptic protein interaction (synprint) site contained within the N-type calcium channel domain H-Ill linker region. Moreover, in vitro evidence suggests that distinct domains of syntaxin participate in each interaction, with the COOH-terminal SNARE domain (residues 183-230) binding to Gbeta and the N-terminal (residues 1-69) binding to the synprint motif of the channel. Electrophysiological analysis of chimeric syntaxin 1A/1B constructs reveals that the variable NH2-terminal domains of syntaxin 1 are responsible for the differential effects of syntaxin 1A and 1B on N-type calcium channel function. Because syntaxin 1 exists in both "open" and "closed" conformations during exocytosis, we produced a constitutively open form of syntaxin 1A and found that it still promoted G-protein inhibition of the channels, but it did not affect N-type channel availability. This state dependence of the ability of syntaxin 1 to mediate N-type calcium channel availability suggests that syntaxin 1 dynamically regulates N-type channel function during various steps of exocytosis. Finally, syntaxin 1A appeared to compete with Ggamma for the Gbeta subunit both in vitro and under physiological conditions, suggesting that syntaxin 1A may contain a G-protein gamma subunit-like domain.	Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB T2N 4N1, Canada; NeuroMed Technol Inc, Vancouver, BC V6T 1Z4, Canada	University of Calgary; University of Calgary	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	Zamponi@ucalgary.ca		Zamponi, Gerald W./0000-0002-0644-9066				Aguado F, 1999, NEUROSCIENCE, V88, P437, DOI 10.1016/S0306-4522(98)00247-4; Arnot MI, 2000, J PHYSIOL-LONDON, V527, P203, DOI 10.1111/j.1469-7793.2000.00203.x; Bergsman JB, 2000, J NEUROSCI, V20, P4368, DOI 10.1523/JNEUROSCI.20-12-04368.2000; Bezprozvanny I, 2000, P NATL ACAD SCI USA, V97, P13943, DOI 10.1073/pnas.220389697; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Blackmer T, 2001, SCIENCE, V292, P293, DOI 10.1126/science.1058803; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; Coppola T, 2001, J BIOL CHEM, V276, P32756, DOI 10.1074/jbc.M100929200; Degtiar VE, 2000, J NEUROSCI, V20, P4355, DOI 10.1523/JNEUROSCI.20-12-04355.2000; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; ELFAR O, 1995, FEBS LETT, V361, P101, DOI 10.1016/0014-5793(95)00156-4; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Forsythe ID, 1998, NEURON, V20, P797, DOI 10.1016/S0896-6273(00)81017-X; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Hibino H, 2002, NEURON, V34, P411, DOI 10.1016/S0896-6273(02)00667-0; Hicks A, 1997, NEUROSCIENCE, V79, P329, DOI 10.1016/S0306-4522(96)00700-2; IKEDA SR, 1989, J PHYSIOL-LONDON, V409, P221, DOI 10.1113/jphysiol.1989.sp017494; IKEDA SR, 1992, J PHYSIOL-LONDON, V458, P339, DOI 10.1113/jphysiol.1992.sp019421; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; Jarvis SE, 2001, J NEUROSCI, V21, P2939, DOI 10.1523/JNEUROSCI.21-09-02939.2001; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; Leveque C, 1998, J BIOL CHEM, V273, P13488, DOI 10.1074/jbc.273.22.13488; Lu Q, 2001, J NEUROSCI, V21, P2949, DOI 10.1523/JNEUROSCI.21-09-02949.2001; Magga JM, 2000, NEURON, V28, P195, DOI 10.1016/S0896-6273(00)00096-9; Martin TFJ, 2002, NEURON, V34, P9, DOI 10.1016/S0896-6273(02)00651-7; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Neves G, 2001, P NATL ACAD SCI USA, V98, P15282, DOI 10.1073/pnas.261311698; Page KM, 1998, J NEUROSCI, V18, P4815; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; RuizMontasell B, 1996, EUR J NEUROSCI, V8, P2544, DOI 10.1111/j.1460-9568.1996.tb01548.x; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; STANLEY EF, 1993, NEURON, V11, P1007, DOI 10.1016/0896-6273(93)90214-C; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TURNER TJ, 1993, P NATL ACAD SCI USA, V90, P9518, DOI 10.1073/pnas.90.20.9518; TURNER TJ, 1992, SCIENCE, V258, P310, DOI 10.1126/science.1357749; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhong HJ, 1999, NAT NEUROSCI, V2, P939, DOI 10.1038/14721	56	73	78	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44399	44407		10.1074/jbc.M206902200	http://dx.doi.org/10.1074/jbc.M206902200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221094	hybrid			2022-12-25	WOS:000179272000111
J	Jin, P; Weiger, TM; Levitan, IB				Jin, P; Weiger, TM; Levitan, IB			Reciprocal modulation between the alpha and beta 4 subunits of hSlo calcium-dependent potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNEL; LARGE-CONDUCTANCE; SURFACE EXPRESSION; LINKED GLYCOSYLATION; NERVE-TERMINALS; VOLTAGE; PROTEIN; PHOSPHORYLATION; INACTIVATION; CLONING	Large conductance Ca2+-dependent potassium (K-Ca or maxi K) channels are composed of a pore-forming alpha subunit and an auxiliary beta subunit. We have shown that the brain-specific beta4 subunit modulates the voltage dependence, activation kinetics, and toxin sensitivity of the hSlo channel (Weiger, T. M., Holmqvist, M. H., Levitan, I. B., Clark, F. T., Sprague, S., Huang, W. J., Ge, P., Wang, C., Lawson, D., Jurman, M. E., Glucksmann, M. A., Silos-Santiago, L, DiStefano, P. S., and Curtis, R. (2000) J. Neurosci. 20, 3563-3570). We investigated here the N-linked glycosylation of the beta4 subunit and its effect on the modulation of the hSlo a subunit. When expressed alone in HEK293 cells, the beta4 subunit runs as a single molecular weight band on an SDS gel. However, when coexpressed with the hSlo alpha subunit, the beta4 subunit appears as two different molecular weight bands. Enzymatic deglycosylation or mutation of the N-linked glycosylation residues in beta4 converts it to a single lower molecular weight band, even in the presence of the hSlo alpha subunit, suggesting that the beta4 subunit can be present as an immature, core glycosylated form and a mature, highly glycosylated form. Blockage of protein transport from the endoplasmic reticulum to the Golgi compartment with brefeldin A abolishes the mature, highly glycosylated beta4 band. Glycosylation of the beta4 subunit is not required for its binding to the hSlo channel a subunit. It also is not necessary for cell membrane targeting of the beta4 subunit, as demonstrated by surface biotinylation experiments. However, the double glycosylation site mutant beta4 (beta4 N53A/N90A) protects the channel less against toxin blockade, as compared with the hSlo, channel coexpressed with wild type beta4 subunit. Taken together, these data show that the pore-forming a subunit of the hSlo channel promotes N-linked glycosylation of its auxiliary beta4 subunit, and this in turn influences the modulation of the channel by the beta4 subunit.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; Salzburg Univ, Inst Zool, Dept Mol Neurosci & Cell Physiol, A-5020 Salzburg, Austria	University of Pennsylvania; Salzburg University	Jin, P (corresponding author), Univ Penn, Sch Med, Dept Neurosci, 223 Stemmler Hall,3450 Hamilton Walk, Philadelphia, PA 19104 USA.		Weiger, Thomas M/D-8133-2017	Weiger, Thomas M/0000-0002-5231-930X				Behrens R, 2000, FEBS LETT, V474, P99, DOI 10.1016/S0014-5793(00)01584-2; Bennett E, 1997, J GEN PHYSIOL, V109, P327, DOI 10.1085/jgp.109.3.327; BIELEFELDT K, 1994, J PHYSIOL-LONDON, V475, P241, DOI 10.1113/jphysiol.1994.sp020065; Bravo-Zehnder M, 2000, P NATL ACAD SCI USA, V97, P13114, DOI 10.1073/pnas.240455697; Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GHO M, 1992, J EXP BIOL, V170, P93; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Holmes TC, 1997, J NEUROSCI, V17, P8964; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; Jiang Z, 1999, GENOMICS, V55, P57, DOI 10.1006/geno.1998.5627; Jin P, 2002, J BIOL CHEM, V277, P10014, DOI 10.1074/jbc.M107682200; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; Kwak YG, 1999, J BIOL CHEM, V274, P13928, DOI 10.1074/jbc.274.20.13928; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 2000, P NATL ACAD SCI USA, V97, P5562, DOI 10.1073/pnas.100118597; O'Riordan CR, 2000, GLYCOBIOLOGY, V10, P1225, DOI 10.1093/glycob/10.11.1225; Pabon A, 2000, J BIOL CHEM, V275, P30677, DOI 10.1074/jbc.M005338200; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; ROBITAILLE R, 1993, J PHYSIOLOGY-PARIS, V87, P15, DOI 10.1016/0928-4257(93)90020-T; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; Schopperle WM, 1998, NEURON, V20, P565, DOI 10.1016/S0896-6273(00)80995-2; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; STROUS GJ, 1993, J BIOL CHEM, V268, P2341; TAI T, 1975, J BIOL CHEM, V250, P8569; Tyrrell L, 2001, J NEUROSCI, V21, P9629, DOI 10.1523/JNEUROSCI.21-24-09629.2001; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; Wang J, 1999, J Neurosci, V19, pRC4; Wanner SG, 1999, BIOCHEMISTRY-US, V38, P5392, DOI 10.1021/bi983040c; Weiger TM, 2000, J NEUROSCI, V20, P3563, DOI 10.1523/JNEUROSCI.20-10-03563.2000; Weiger TM, 2002, J COMP PHYSIOL A, V188, P79, DOI 10.1007/s00359-002-0281-2; Zhou Y, 1999, NEURON, V22, P809, DOI 10.1016/S0896-6273(00)80739-4; Zhu J, 2001, J BIOL CHEM, V276, P39419, DOI 10.1074/jbc.M107399200	41	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43724	43729		10.1074/jbc.M205795200	http://dx.doi.org/10.1074/jbc.M205795200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223479	hybrid			2022-12-25	WOS:000179272000025
J	Jongbloed, JDH; Antelmann, H; Hecker, M; Nijland, R; Bron, S; Airaksinen, U; Pries, F; Quax, WJ; van Dijl, JM; Braun, PG				Jongbloed, JDH; Antelmann, H; Hecker, M; Nijland, R; Bron, S; Airaksinen, U; Pries, F; Quax, WJ; van Dijl, JM; Braun, PG			Selective contribution of the twin-arginine translocation pathway to protein secretion in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE-PROTEIN; SIGNAL PEPTIDASE-I; ESCHERICHIA-COLI; ALPHA-AMYLASE; EFFICIENT SECRETION; SEC; IDENTIFICATION; MOTIF; EXPRESSION; PREDICTION	The availability of the complete genome sequence of Bacillus subtilis has allowed the prediction of all exported proteins of this Gram-positive eubacterium. Recently, similar to180 secretory and 114 lipoprotein signal peptides were predicted to direct protein export from the cytoplasm. Whereas most exported proteins appear to use the Sec pathway, 69 of these proteins could potentially use the Tat pathway, as their signal peptides contain RR- or KR-motifs. In the present studies, proteomic techniques were applied to verify how many extracellular B. subtilis proteins follow the Tat pathway. Strikingly, the extracellular accumulation of 13 proteins with potential RR/KR-signal peptides was Tat-independent, showing that their RR/KR-motifs are not recognized by the Tat machinery. In fact, only the phosphodiesterase PhoD was shown to be secreted in a strictly Tat-dependent manner. Sodium azide-inhibition of SecA strongly affected the extracellular appearance of de novo synthesized proteins, including the lipase LipA and two other proteins with predicted RR/KR-signal peptides. The SecA-dependent export of pre-LipA is particularly remarkable, because its RR-signal peptide conforms well to stringent criteria for the prediction of Tat-dependent export in Escherichia coli. Taken together, our observations show that the Tat pathway makes a highly selective contribution to the extracellular proteome of B. subtilis.	Univ Groningen, Dept Pharmaceut Biol, NL-9713 AV Groningen, Netherlands; Groningen Biomol Sci & Biotechnol Inst, Dept Genet, NL-9751 NN Haren, Netherlands; Univ Greifswald, Inst Mikrobiol & Mol Biol, D-17487 Greifswald, Germany; Natl Publ Hlth Inst, FIN-00300 Helsinki, Finland	University of Groningen; University of Groningen; Ernst Moritz Arndt Universitat Greifswald; Finland National Institute for Health & Welfare	van Dijl, JM (corresponding author), Univ Groningen, Dept Pharmaceut Biol, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands.		van Dijl, Jan Maarten/G-1205-2013; Quax, Wim/O-2875-2019; Antelmann, Haike/I-3129-2019; Nijland, Reindert/B-8206-2008; Quax, Wim/K-2802-2012	Quax, Wim/0000-0002-5162-9947; Antelmann, Haike/0000-0002-1766-4386; Nijland, Reindert/0000-0003-0049-3768; Quax, Wim/0000-0002-5162-9947; Braun, Peter/0000-0002-9870-465X				Antelmann H, 2000, J BACTERIOL, V182, P4478, DOI 10.1128/JB.182.16.4478-4490.2000; Antelmann H, 1997, J BACTERIOL, V179, P7251, DOI 10.1128/jb.179.23.7251-7256.1997; Antelmann H, 2002, PROTEOMICS, V2, P591, DOI 10.1002/1615-9861(200205)2:5<591::AID-PROT591>3.0.CO;2-8; Antelmann H, 2001, GENOME RES, V11, P1484, DOI 10.1101/gr.182801; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Bernhardt J, 1999, ELECTROPHORESIS, V20, P2225, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2225::AID-ELPS2225>3.3.CO;2-#; Bogsch E, 1997, EMBO J, V16, P3851, DOI 10.1093/emboj/16.13.3851; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Bolhuis A, 1998, J BIOL CHEM, V273, P21217, DOI 10.1074/jbc.273.33.21217; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brink S, 1998, FEBS LETT, V434, P425, DOI 10.1016/S0014-5793(98)01028-X; BRON S, 1972, MUTAT RES, V15, P1, DOI 10.1016/0027-5107(72)90086-3; Cristobal S, 1999, EMBO J, V18, P2982, DOI 10.1093/emboj/18.11.2982; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; DARTOIS V, 1994, APPL ENVIRON MICROB, V60, P1670, DOI 10.1128/AEM.60.5.1670-1673.1994; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; GueroutFleury AM, 1995, GENE, V167, P335, DOI 10.1016/0378-1119(95)00652-4; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; Hinsley AP, 2001, FEBS LETT, V497, P45, DOI 10.1016/S0014-5793(01)02428-0; Hirose I, 2000, MICROBIOL-SGM, V146, P65, DOI 10.1099/00221287-146-1-65; Ignatova Z, 2002, BIOCHEM BIOPH RES CO, V291, P146, DOI 10.1006/bbrc.2002.6420; Jongbloed JDH, 2000, J BIOL CHEM, V275, P41350, DOI 10.1074/jbc.M004887200; KLEIN M, 1994, FEMS MICROBIOL LETT, V124, P393; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leloup L, 1999, J BACTERIOL, V181, P1820, DOI 10.1128/JB.181.6.1820-1826.1999; LESUISSE E, 1993, EUR J BIOCHEM, V216, P155, DOI 10.1111/j.1432-1033.1993.tb18127.x; Molik S, 2001, J BIOL CHEM, V276, P42761, DOI 10.1074/jbc.M106690200; Muller JP, 1999, FEMS MICROBIOL LETT, V180, P287; Muller JP, 1997, MICROBIOL-SGM, V143, P947, DOI 10.1099/00221287-143-3-947; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Otto A, 1996, ELECTROPHORESIS, V17, P1643, DOI 10.1002/elps.1150171027; PALVA I, 1982, GENE, V19, P81, DOI 10.1016/0378-1119(82)90191-3; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; Sambrook J., 2002, MOL CLONING LAB MANU; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V271, P5463; Scotti PA, 1999, J BIOL CHEM, V274, P29883, DOI 10.1074/jbc.274.42.29883; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; Tjalsma H, 2000, MICROBIOL MOL BIOL R, V64, P515, DOI 10.1128/MMBR.64.3.515-547.2000; TJALSMA H, 2001, ENZYMES, P3; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; VanDijl J. M., 2001, BACILLUS SUBTILIS IT, P337; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANDIJL JM, 1991, J GEN MICROBIOL, V137, P2073, DOI 10.1099/00221287-137-9-2073; VIEIRA J, 1991, GENE, V100, P189, DOI 10.1016/0378-1119(91)90365-I; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6	56	107	113	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44068	44078		10.1074/jbc.M203191200	http://dx.doi.org/10.1074/jbc.M203191200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12218047	hybrid, Green Published			2022-12-25	WOS:000179272000070
J	Piwien-Pilipuk, G; MacDougald, O; Schwartz, J				Piwien-Pilipuk, G; MacDougald, O; Schwartz, J			Dual regulation of phosphorylation and dephosphorylation of C/EBP beta modulate its transcriptional activation and DNA binding in response to growth hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; KIDNEY MINERALOCORTICOID RECEPTOR; TERNARY COMPLEX FACTORS; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; 3T3-L1 PREADIPOCYTES; GLUCOSE-TRANSPORT; MAMMALIAN-CELLS; FAMILY MEMBERS; FOS	The phosphorylation state of transcription factors is a critical determinant of their function. C/EBPbeta occurs in cells as the transcriptional activator liver-enriched activating protein (LAP) and in the truncated form liver-enriched inhibitory protein (LIP) that inhibits transcription. Analysis of C/EBPbeta phosphorylation by isoelectric focusing (IEF) shows that LAP is present in multiple forms, each with a different degree of phosphorylation in 3T3-F442A fibroblasts. Growth hormone (GH) treatment induces a new band near the negative pole, consistent, with GH-promoted dephosphorylation of LAP. In addition, bands near the positive pole are rapidly and transiently induced, suggesting that GH also stimulates phosphorylation at some site(s) on LAP. C/EBPbeta contains a highly conserved MAPK consensus site that corresponds to Thr(188) in murine (m) LAP and Thr(37) in mLIP. Immunoblotting with antiphosphopeptide antibodies specific for Thr(188/37) of C/EBPbeta (anti-P-C/EBPbeta) shows that GH rapidly and transiently promotes phosphorylation of mLAP and mLIP on the MAPK site. MEK inhibitors prevent this GH-promoted phosphorylation of LAP and LIP, suggesting that such phosphorylation depends on GH-activated MAPK signaling. Mutation of Thr(235) to Ala in the homologous MAPK site of human (h) LAP (hLAPT235A) inhibits transcription mediated by the c-fos promoter in response to GH, indicating that phosphorylation at the MAPK site is required for LAP to be transcriptionally active in the context of GH-stimulated activation of the c-fos promoter. Complexes bound to the c-fos C/EBP site transiently contain C/EBPbeta phosphorylated at the MAPK site. As phosphorylation subsides, the binding of less transcriptionally active forms of LAP increases, consistent with the transient nature of c-fos stimulation by GH and other growth factors. Thus, both phosphorylation and dephosphorylation of C/EBPbeta, in response to a single physiological stimulus such as GH, coordinately modulate the ability of C/EBPbeta to activate transcription by modulating its DNA binding activity and its transactivation capacity.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Schwartz, J (corresponding author), Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA.			MacDougald, Ormond/0000-0001-6907-7960	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046072] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46072] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BILLESTRUP N, 1994, P SOC EXP BIOL MED, V206, P205; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XN, 1997, BLOOD, V90, P156; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; Galigniana MD, 1998, BIOCHEM J, V333, P555, DOI 10.1042/bj3330555; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gong TWL, 1998, ENDOCRINOLOGY, V139, P1863, DOI 10.1210/en.139.4.1863; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; HARVAT BL, 1995, CELL GROWTH DIFFER, V6, P955; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Liao J, 1999, J BIOL CHEM, V274, P31597, DOI 10.1074/jbc.274.44.31597; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; Pall M, 1997, EMBO J, V16, P5273, DOI 10.1093/emboj/16.17.5273; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; Piwien-Pilipuk G, 1998, MOL CELL ENDOCRINOL, V144, P119, DOI 10.1016/S0303-7207(98)00142-7; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Ruocco MR, 1996, J BIOL CHEM, V271, P22479, DOI 10.1074/jbc.271.37.22479; SCHWARTZ J, 1988, ENDOCRINOLOGY, V122, P2247; SCOTT LM, 1992, BLOOD, V80, P1725; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WINSTON LA, 1992, J BIOL CHEM, V267, P4747	59	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44557	44565		10.1074/jbc.M206886200	http://dx.doi.org/10.1074/jbc.M206886200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12213825	hybrid, Green Submitted			2022-12-25	WOS:000179272000128
J	Sasagawa, K; Matsudo, Y; Kang, M; Fujimura, L; Iitsuka, Y; Okada, S; Ochiai, T; Tokuhisa, T; Hatano, M				Sasagawa, K; Matsudo, Y; Kang, M; Fujimura, L; Iitsuka, Y; Okada, S; Ochiai, T; Tokuhisa, T; Hatano, M			Identification of Nd1, a novel murine kelch family protein, involved in stabilization of actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTININ; BINDING PROTEIN; CELL MOTILITY; V(D)J RECOMBINATION; INTERACTION MOTIF; FINGER PROTEIN; CYTOCHALASIN-D; 3T3 CELLS; GENE; DROSOPHILA	We isolated Nd1, a novel kelch family gene that encodes two forms of proteins, Nd1-L and Nd1-S. Nd1-L contains a BTB/POZ domain in its N terminus and six kelch repeats in the C terminus. Nd1-S has the BTB/POZ domain but lacks the six kelch repeats. Nd1-L but not Nd1-S mRNA is detected ubiquitously in normal mouse tissues. Nd1-L and Nd1-S proteins can form a dimer through the BTB/POZ domain. Nd1-L colocalizes with actin filaments detected using a confocal microscope, and its kelch repeats bind to them in vitro. Overexpression of Nd1-L in NIH3T3 cells delayed cell growth by affecting the transition of cytokinesis. Furthermore, the overexpression prevented NIH3T3 cells from cell death induced by actin destabilization but not by microtubule dysfunction. These data suggest that Nd1-L functions as a stabilizer of actin filaments as an actin-binding protein and may play a role in the dynamic organization of the actin cytoskeleton.	Chiba Univ, Grad Sch Med, Dept Dev Genet H2, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Acad Surg M9, Chuo Ku, Chiba 2608670, Japan	Chiba University; Chiba University	Hatano, M (corresponding author), Chiba Univ, Grad Sch Med, Dept Dev Genet H2, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.		Okada, Seiji/F-5785-2013					Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Bomont P, 2000, NAT GENET, V26, P370, DOI 10.1038/81701; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; CHANGYEH A, 1991, NUCLEIC ACIDS RES, V19, P3667, DOI 10.1093/nar/19.13.3667; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Dalakas MC, 2000, NEW ENGL J MED, V342, P770, DOI 10.1056/NEJM200003163421104; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Frazer JK, 1997, J IMMUNOL METHODS, V207, P1, DOI 10.1016/S0022-1759(97)00091-4; GLUCK U, 1994, J CELL SCI, V107, P1773; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GODT D, 1993, DEVELOPMENT, V119, P799; Gomez CA, 2000, MOL CELL BIOL, V20, P5653, DOI 10.1128/MCB.20.15.5653-5664.2000; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; Hatano M, 1997, J CLIN INVEST, V100, P795, DOI 10.1172/JCI119593; Hernandez MC, 1998, EXP CELL RES, V242, P470, DOI 10.1006/excr.1998.4109; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Kang M, 2001, BBA-GENE STRUCT EXPR, V1519, P167, DOI 10.1016/S0167-4781(01)00231-7; KELLER H, 1995, EUR J CELL BIOL, V66, P157; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; MIKI T, 1994, BLOOD, V83, P26; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Okabe S, 1998, MOL CELL BIOL, V18, P4235, DOI 10.1128/MCB.18.7.4235; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; PETERSON MG, 1986, EUR J BIOCHEM, V160, P579, DOI 10.1111/j.1432-1033.1986.tb10077.x; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; ROBINSON DN, 1994, DEVELOPMENT, V120, P2015; SCHLIWA M, 1982, J CELL BIOL, V92, P79, DOI 10.1083/jcb.92.1.79; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Shirasawa S, 1997, NAT MED, V3, P646, DOI 10.1038/nm0697-646; SMALL JV, 1993, SYM SOC EXP BIOL, V47, P57; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Sung KLP, 1996, P NATL ACAD SCI USA, V93, P9182, DOI 10.1073/pnas.93.17.9182; VARKEY JP, 1995, GENE DEV, V9, P1074, DOI 10.1101/gad.9.9.1074; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YE BHH, 1993, CANCER RES, V53, P2732	51	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44140	44146		10.1074/jbc.M202596200	http://dx.doi.org/10.1074/jbc.M202596200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12213805	hybrid			2022-12-25	WOS:000179272000079
J	You, ZY; Ishimi, Y; Masai, H; Hanaoka, F				You, ZY; Ishimi, Y; Masai, H; Hanaoka, F			Roles of Mcm7 and Mcm4 subunits in the DNA helicase activity of the mouse Mcm4/6/7 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; LARGE T-ANTIGEN; ESCHERICHIA-COLI; BIOCHEMICAL-ANALYSIS; BINDING-ACTIVITY; ZINC-FINGER; REPLICATION; HYDROLYSIS; DOMAIN; ORIGIN	Mcm, which is composed of six structurally related subunits (Mcm2-7), is essential for eukaryotic DNA replication. A subassembly of Mcm, the Mcm4/6/7 doubletrimeric complex, possesses DNA helicase activity, and it has been proposed that Mcm may function as a replicative helicase at replication forks. We show here that conserved ATPase motifs of Mcm7 are essential for ATPase and DNA helicase activities of the Mcm4/6/7 complex. Because uncomplexed Mcm7 displayed neither ATPase nor DNA helicase activity, Mcm7 contributes to the DNA helicase activity of the Mcm complex through interaction with other subunits. In contrast, the Mcm4/ 6/7 complex containing a zinc finger mutant of Mcm4 with partially impaired DNA binding activity exhibited elevated DNA helicase activity. The Mcm4/6/7 complex containing this Mcm4 mutant tended to dissociate into trimeric complexes, suggesting that the zinc finger of Mcm4 is involved in subunit interactions of trimers. The Mcm4 mutants lacking the N-terminal 35 or 112 amino acids could form hexameric Mcm4/6/7 complexes, but displayed very little DNA helicase activity. In conjunction with the previously reported essential role of Mcm6 in ATP binding (You, Z., Komamura, Y., and Ishimi, Y. (1999) Mol Cell Biol 19, 8003-8015), our data indicate distinct roles of Mcm4, Mcm6, and Mcm7 subunits in activation of the DNA helicase activity of the Mcm.4/6/7 complex.	Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Mitsubishi Kagaku Inst Life Sci, Biomol Sci & Technol Dept, Tokyo 1948511, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Japan Sci & Technol, Core Res & Evolut Sci & Technol, Suita, Osaka 5650871, Japan	Tokyo Metropolitan Institute of Medical Science; RIKEN; Mitsubishi Kagaku Institute of Life Sciences (MITILS); Osaka University; Japan Science & Technology Agency (JST)	You, ZY (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, 18-22 Honkomagome 3-chome, Tokyo 1138613, Japan.	yzhiying@rinshoken.or.jp						Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Biswas EE, 1999, BIOCHEMISTRY-US, V38, P10929, DOI 10.1021/bi990049l; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; Cao WH, 1998, J BIOL CHEM, V273, P20629, DOI 10.1074/jbc.273.32.20629; Cox EH, 2000, CURR OPIN CHEM BIOL, V4, P162, DOI 10.1016/S1367-5931(99)00070-8; DEAN FB, 1992, J BIOL CHEM, V267, P14129; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Ishimi Y, 2001, J BIOL CHEM, V276, P34428, DOI 10.1074/jbc.M104480200; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lei M, 2001, J CELL SCI, V114, P1447; LOEBER G, 1991, J VIROL, V65, P3167, DOI 10.1128/JVI.65.6.3167-3174.1991; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Marintcheva B, 2001, J BIOL CHEM, V276, P6605, DOI 10.1074/jbc.M007743200; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; PERRIER V, 1994, BIOCHEMISTRY-US, V33, P9960, DOI 10.1021/bi00199a019; Poplawski A, 2001, J BIOL CHEM, V276, P49371, DOI 10.1074/jbc.M108519200; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROSE PE, 1995, J VIROL, V69, P2842, DOI 10.1128/JVI.69.5.2842-2849.1995; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Turnage MA, 2000, MOL CELL BIOL, V20, P8198, DOI 10.1128/MCB.20.21.8198-8208.2000; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; Weng YM, 1996, MOL CELL BIOL, V16, P5477; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; You ZY, 1999, MOL CELL BIOL, V19, P8003	42	64	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42471	42479		10.1074/jbc.M205769200	http://dx.doi.org/10.1074/jbc.M205769200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12207017	hybrid			2022-12-25	WOS:000179081200008
J	Gallo, A; Cuozzo, C; Esposito, I; Maggiolini, M; Bonofiglio, D; Vivacqua, A; Garramone, M; Weiss, C; Bohmann, D; Musti, AM				Gallo, A; Cuozzo, C; Esposito, I; Maggiolini, M; Bonofiglio, D; Vivacqua, A; Garramone, M; Weiss, C; Bohmann, D; Musti, AM			Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation	ONCOGENE			English	Article						AP-1; menin; Elk-1; MAPK; JunD	MULTIPLE ENDOCRINE NEOPLASIA; SIGNAL-REGULATED KINASE; CELL-PROLIFERATION; SOMATIC MUTATION; GROWTH-FACTORS; FOS PROMOTER; HA-RAS; PROTEIN; TRANSFORMATION; TRANSCRIPTION	Menin, a nuclear protein encoded by the tumor suppressor gene MEN1, interacts with the AP-1 transcription factor JunD and inhibits its transcriptional activity. In addition, overexpression of Menin counteracts Ras-induced tumorigenesis. We show that Menin inhibits ERK-dependent phosphorylation and activation of both JunD and the Ets-domain transcription factor Elk-1. We also show that Menin represses the inducible activity of the c-fos promoter. Furthermore, Menin expression inhibits Jun N-terminal kinase (JNK)mediated phosphorylation of both JunD and c-Jun. Kinase assays show that Menin overexpression does not interfere with activation of either ERK2 or JNK1, suggesting that Menin acts at a level downstream of MAPK activation. An N-terminal deletion mutant of Menin that cannot inhibit JunD phosphorylation by JNK, can still repress JunD phosphorylation by ERK2, suggesting that Menin interferes with ERK and JNK pathways through two distinct inhibitory mechanisms. Taken together, our data suggest that Menin uncouples ERK and JNK activation from phosphorylation of their nuclear targets Elk-1, JunD and c-Jun, hence inhibiting accumulation of active Fos/Jun heterodimers. This study provides new molecular insights into the tumor suppressor function of Menin and suggests a mechanism by which Menin may interfere with Ras-dependent cell transformation and oncogenesis.	Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Calabria, Dipartimento Farmacobiol, I-87036 Arcavacata Di Rende, CS, Italy; Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Calabria; University of Rochester	Musti, AM (corresponding author), Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy.		vivacqua, adele/I-2771-2015; Musti, Anna Maria/M-2520-2019; Maggiolini, Marcello/Z-4729-2019; Bonofiglio, Daniela/AAV-8371-2020; Weiss, Carsten/I-1811-2013	vivacqua, adele/0000-0001-5333-8396; Weiss, Carsten/0000-0002-5380-3208; BONOFIGLIO, Daniela/0000-0002-4142-0496; MUSTI, Anna Maria/0000-0003-1443-2739; Maggiolini, Marcello/0000-0002-7485-854X				Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Marx SJ, 1999, RECENT PROG HORM RES, V54, P397; Marx SJ, 1998, J INTERN MED, V243, P447; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; Sambrook J., 1989, MOL CLONING LAB MANU; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Wang HL, 1996, ONCOGENE, V13, P2639; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710	52	70	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6434	6445		10.1038/sj.onc.1205822	http://dx.doi.org/10.1038/sj.onc.1205822			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226747				2022-12-25	WOS:000177925300004
J	Matei, D; Graeber, TG; Baldwin, RL; Karlan, BY; Rao, JY; Chang, DD				Matei, D; Graeber, TG; Baldwin, RL; Karlan, BY; Rao, JY; Chang, DD			Gene expression in epithelial ovarian carcinoma	ONCOGENE			English	Article						ovarian epithelial cells; oligonucleotide arrays; RT-PCR; periostin	CELL ADHESION MOLECULE; TISSUE TRANSGLUTAMINASE; GROWTH-FACTOR; SERUM LEVEL; CANCER; PROTEIN; CLONING; PERIOSTIN; ONCOGENE; HOMOLOG	We analysed the mRNA levels corresponding to 12 600 transcripts in primary cultures of ovarian epithelial cells derived from nine normal ovaries and 21 epithelial ovarian carcinoma. The class distinction and hierarchical clustering of expression data revealed a clear distinction in gene expression between normal and carcinoma-derived ovarian epithelial cells. Comparison of expression levels revealed 111 genes with mean expression values of >2.5-fold higher in carcinoma cells. Similarly, 62 genes were expressed at >2.5-fold higher levels in normal ovarian epithelial cells. For a few selected genes, we demonstrate that the pattern of differential expression observed in cultured epithelial cells is present in the normal ovaries and epithelial ovarian carcinoma. Use of cultured epithelial cells represents a novel strategy to study gene expression in a cell-type specific manner.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Energy, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Cedars Sinai Med Ctr, Div Gynecol Oncol, Los Angeles, CA 90048 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center	Chang, DD (corresponding author), Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Factor 11-934,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	ddchang@mednet.ucla.edu		Graeber, Thomas/0000-0001-8574-9181; Matei, Daniela/0000-0003-2169-5035	NCI NIH HHS [T32CA09297] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009297] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; AUERSPERG N, 1994, LAB INVEST, V71, P510; BELL DA, 1994, CANCER, V73, P1859, DOI 10.1002/1097-0142(19940401)73:7<1859::AID-CNCR2820730714>3.0.CO;2-L; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Dubeau L, 1999, GYNECOL ONCOL, V72, P437, DOI 10.1006/gyno.1998.5275; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Foster KA, 1996, CANCER RES, V56, P3622; FRAIJ BM, 1992, J BIOL CHEM, V267, P22616; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Greenwood M, 2000, HIST TODAY, V50, P3; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; HENRIKSEN R, 1993, CANCER RES, V53, P4550; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Hough CD, 2000, CANCER RES, V60, P6281; ISHIKAWA J, 1995, GENOMICS, V26, P527, DOI 10.1016/0888-7543(95)80171-H; Ismail RS, 2000, CANCER RES, V60, P6744; JACOBS I, 1989, HUM REPROD, V4, P1; KARLAN BY, 1995, GYNECOL ONCOL, V59, P67, DOI 10.1006/gyno.1995.1269; Kozma R, 1996, MOL CELL BIOL, V16, P5069; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; Lin CJ, 1996, GYNECOL ONCOL, V60, P347, DOI 10.1006/gyno.1996.0054; Mains RE, 1997, BIOCHEM J, V321, P587, DOI 10.1042/bj3210587; MARKS JR, 1991, CANCER RES, V51, P2979; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Ono K, 2000, CANCER RES, V60, P5007; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; PRESS WH, 1992, NUMERICAL RECIPES C, P226; Sasaki H, 2001, CANCER-AM CANCER SOC, V92, P843, DOI 10.1002/1097-0142(20010815)92:4<843::AID-CNCR1391>3.0.CO;2-P; Sasaki H, 2001, CANCER LETT, V172, P37, DOI 10.1016/S0304-3835(01)00633-4; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stasko SE, 2001, DEV DYNAM, V220, P49, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1086>3.0.CO;2-5; TAKAHASHI H, 1995, CANCER RES, V55, P2998; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211; YOUNY RC, 2001, CANC PRINCIPLES PRAC, P1226	43	83	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6289	6298		10.1038/sj.onc.1205785	http://dx.doi.org/10.1038/sj.onc.1205785			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214269				2022-12-25	WOS:000177829000005
J	Vetter, R; Rehfeld, U; Reissfelder, C; Weiss, W; Wagner, KD; Gunther, J; Hammes, A; Tschope, C; Dillmann, W; Paul, M				Vetter, R; Rehfeld, U; Reissfelder, C; Weiss, W; Wagner, KD; Gunther, J; Hammes, A; Tschope, C; Dillmann, W; Paul, M			Transgenic overexpression of the sarcoplasmic reticulum Ca2+ ATPase improves reticular Ca2+ handling in normal and diabetic rat hearts	FASEB JOURNAL			English	Article						calcium regulation; relaxation; papillary muscle; streptozotocin-induced cardiomyopathy	LEFT-VENTRICULAR FUNCTION; CARDIAC CONTRACTILITY; CALCIUM-TRANSPORT; MESSENGER-RNA; GENE-TRANSFER; EXPRESSION; CA2+-ATPASE; DYSFUNCTION; FAILURE; CARDIOMYOCYTES	Slowed relaxation in diabetic cardiomyopathy (CM) is partially related to diminished expression of the sarcoplasmic reticulum (SR) Ca2+-ATPase SERCA2a. To evaluate the impact of SERCA2a overexpression on SR Ca2+ handling in diabetic CM, we 1) generated transgenic rats harboring a human cytomegalovirus enhancer/chicken beta-actin promotor-controlled rat SERCA2 transgene (SERCA2-TGR), 2) characterized their SR phenotype, and 3) examined whether transgene expression may rescue SR Ca2+ transport in streptozotocin-induced diabetes. The transgene was expressed in all heart chambers. Compared to wild-type (WT) rats, a heterozygous line exhibited increased SERCA2 mRNA (1.5-fold), SERCA2 protein (+26%) and SR Ca2+ uptake (+37%). Phospholamban expression was not altered. In SERCA2-TGR, contraction amplitude (+48%) and rates of contraction (+34%) and relaxation (+35%) of isolated papillary muscles (PM) were increased (P<0.05 vs. WT, respectively); the lusitropic and inotropic responses of PM to forskolin were stronger than in WT. In diabetic myocardium with SR dysfunction, Ca2+ uptake and SERCA2 protein of SERCA2-TGR were 1.3-fold higher (P<0.05 vs. diabetic WT). Thus, a SERCA2 overexpression in rat heart improves Ca2+ uptake, accelerates relaxation and compensates, in part, for depressed Ca2+ uptake in diabetic CM. Therefore, SERCA2 expression might constitute an important therapeutic target to rescue cardiac SR Ca2+ handling in diabetes.	Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Clin Pharmacol & Toxicol, Dept Toxicol, D-14195 Berlin, Germany; Free Univ Berlin, Benjamin Franklin Med Ctr, Dept Cardiol & Pulmol, D-14195 Berlin, Germany; Humboldt Univ, Charite, Dept Physiol, D-10117 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of California System; University of California San Diego	Vetter, R (corresponding author), Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Clin Pharmacol & Toxicol, Dept Toxicol, D-14195 Berlin, Germany.	rvetter@zedat.fu-berlin.de	Wagner, Kay-Dietrich/E-6119-2016; Paul, Martin/K-5425-2015	Wagner, Kay-Dietrich/0000-0001-5483-7760; Tschope, Carsten/0000-0001-5243-8985; Hammes-Lewin, Annette/0000-0003-1663-8378				Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; Bers DM, 1997, BASIC RES CARDIOL, V92, P1, DOI 10.1007/BF00794062; Bluhm WF, 1999, CARDIOVASC RES, V43, P382, DOI 10.1016/S0008-6363(99)00109-1; Cernohorsky J, 1998, AM J PHYSIOL-HEART C, V275, pH264, DOI 10.1152/ajpheart.1998.275.1.H264; CHUA BHL, 1983, AM J PHYSIOL, V245, P91; del Monte F, 1999, CIRCULATION, V100, P2308, DOI 10.1161/01.CIR.100.23.2308; Depre C, 2000, J MOL CELL CARDIOL, V32, P985, DOI 10.1006/jmcc.2000.1139; Dhalla NS, 1998, CARDIOVASC RES, V40, P239, DOI 10.1016/S0008-6363(98)00186-2; DILLMANN WH, 1985, AM J PHYSIOL, V248, pE602, DOI 10.1152/ajpendo.1985.248.5.E602; FEIN FS, 1980, CIRC RES, V47, P922, DOI 10.1161/01.RES.47.6.922; Frank K, 2000, ANN MED, V32, P572, DOI 10.3109/07853890008998837; GANGULY PK, 1983, AM J PHYSIOL, V244, pE528, DOI 10.1152/ajpendo.1983.244.6.E528; Greene AL, 2000, J BIOL CHEM, V275, P24722, DOI 10.1074/jbc.M001783200; Han XL, 2000, BIOCHEM J, V352, P79, DOI 10.1042/0264-6021:3520079; Hattori Y, 2000, J PHYSIOL-LONDON, V527, P85, DOI 10.1111/j.1469-7793.2000.00085.x; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; Ishikawa T, 1999, AM J PHYSIOL-HEART C, V277, pH2185, DOI 10.1152/ajpheart.1999.277.6.H2185; Ito K, 2001, CIRC RES, V89, P422, DOI 10.1161/hh1701.095522; JANE LM, 2001, CIRC RES, V89, P160; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; Kotsanas G, 2000, CARDIOVASC RES, V46, P450, DOI 10.1016/S0008-6363(00)00062-6; KOZLOWSKI RZ, 1994, BRIT J PHARMACOL, V111, P250, DOI 10.1111/j.1476-5381.1994.tb14052.x; LagadicGossmann D, 1996, AM J PHYSIOL-HEART C, V270, pH1529, DOI 10.1152/ajpheart.1996.270.5.H1529; LOPASCHUK GD, 1982, P W PHARMACOL SOC, V25, P47; MAHLER F, 1975, AM J CARDIOL, V35, P626, DOI 10.1016/0002-9149(75)90048-X; MAKINO N, 1987, AM J PHYSIOL, V253, P202; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; MULLINS JJ, 1990, J HYPERTENS, V8, pS35; Netticadan T, 2001, DIABETES, V50, P2133, DOI 10.2337/diabetes.50.9.2133; PENPARGKUL S, 1981, J MOL CELL CARDIOL, V13, P303, DOI 10.1016/0022-2828(81)90318-7; Ren J, 1997, AM J PHYSIOL-HEART C, V273, pH2876, DOI 10.1152/ajpheart.1997.273.6.H2876; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; Rothermund L, 2000, CIRCULATION, V102, P1582, DOI 10.1161/01.CIR.102.13.1582; Rupp H, 2000, BRIT J PHARMACOL, V131, P1748, DOI 10.1038/sj.bjp.0703741; RUSS M, 1991, BIOCHEM BIOPH RES CO, V178, P906, DOI 10.1016/0006-291X(91)90977-F; Sato Y, 2001, J BIOL CHEM, V276, P9392, DOI 10.1074/jbc.M006889200; Sprung J, 1998, ANESTHESIOLOGY, V88, P1202, DOI 10.1097/00000542-199805000-00010; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; Teshima Y, 2000, J MOL CELL CARDIOL, V32, P655, DOI 10.1006/jmcc.2000.1107; Tschope C, 1999, AM J PHYSIOL-HEART C, V277, pH2333, DOI 10.1152/ajpheart.1999.277.6.H2333; VADLAMUDI R, 1980, P W PHARMACOL SOC, V23, P29; Wagner KD, 1998, J MOL CELL CARDIOL, V30, P2341, DOI 10.1006/jmcc.1998.0794; WANG DW, 1995, AM J PHYSIOL-HEART C, V269, pH1288, DOI 10.1152/ajpheart.1995.269.4.H1288; XU KY, 1995, CIRC RES, V77, P88, DOI 10.1161/01.RES.77.1.88; Yao A, 1998, J MOL CELL CARDIOL, V30, P2711, DOI 10.1006/jmcc.1998.0834; ZARAINHERZBERG A, 1994, BIOCHEM BIOPH RES CO, V203, P113, DOI 10.1006/bbrc.1994.2156; Zhong Y, 2001, AM J PHYSIOL-HEART C, V281, pH1137, DOI 10.1152/ajpheart.2001.281.3.H1137	48	77	81	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10					1657	+		10.1096/fj.01-1019fje	http://dx.doi.org/10.1096/fj.01-1019fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206992				2022-12-25	WOS:000177814000012
J	Miller, SK; Good, RT; Drew, DR; Delorenzi, M; Sanders, PR; Hodder, AN; Speed, TP; Cowman, AF; de Koning-Ward, TF; Crabb, BS				Miller, SK; Good, RT; Drew, DR; Delorenzi, M; Sanders, PR; Hodder, AN; Speed, TP; Cowman, AF; de Koning-Ward, TF; Crabb, BS			A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-REPEAT ANTIGEN; BLOOD STAGE ANTIGEN; PROTECTIVE IMMUNITY; MALARIA PARASITES; AOTUS MONKEYS; PARASITOPHOROUS VACUOLE; ESCHERICHIA-COLI; TERMINAL DOMAIN; ANTIBODIES; PROTEIN	The Plasmodium falciparum serine repeat antigen (SERA) has shown considerable promise as a blood stage vaccine for the control of malaria. A related protein, SERPH, has also been described in P. falciparum. Whereas their biological role remains unknown, both proteins possess papain-like protease domains that may provide attractive targets for therapeutic intervention. Genomic sequencing has recently shown that SERA and SERPH are the fifth and sixth genes, respectively, in a cluster of eight SERA homologues present on chromosome 2. In this paper, the expression and functional relevance of these eight genes and of a ninth SERA homologue found on chromosome 9 were examined in blood stage parasites. Using reverse transcriptase-PCR and microarray approaches, we demonstrate that whereas mRNA to all nine SERA genes is synthesized late in the erythrocytic cycle, it is those genes in the central region of the chromosome 2 cluster that are substantially up-regulated at this time. Using antibodies specific to each SERA, it was apparent that SERA4 to -6, and possibly also SERA9, are synthesized in blood stage parasites. The reactivity of antibodies from malaria-immune individuals with the SERA recombinant proteins suggested that SERA2 and SERA3 are also expressed at least in some parasite populations. To examine whether SERA genes are essential to blood stage growth, each of the eight chromosome 2 SERA genes was targeted for disruption. Whereas genes at the periphery of the cluster were mostly dispensable (SERA2 and -3 and SERA7 and -8), those in the central region (SERA4 to -6) could not be disrupted. The inability to disrupt SERA4, -5, and -6 is consistent with their apparent dominant expression and implies an important role for these genes in maintenance of the erythrocytic cycle.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Crabb, BS (corresponding author), Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Melbourne, Vic 3050, Australia.		Crabb, Brendan/F-5287-2013; de Koning-Ward, Tania F/N-3572-2017; Speed, Terence P/B-8085-2009; Cowman, Alan F/C-7642-2013	de Koning-Ward, Tania F/0000-0001-5810-8063; Speed, Terence P/0000-0002-5403-7998; Cowman, Alan F/0000-0001-5145-9004				Anders RF, 2000, PARASITOL TODAY, V16, P444, DOI 10.1016/S0169-4758(00)01784-1; BARR PJ, 1991, MOL BIOCHEM PARASIT, V45, P159, DOI 10.1016/0166-6851(91)90038-8; BZIK DJ, 1988, MOL BIOCHEM PARASIT, V30, P279, DOI 10.1016/0166-6851(88)90097-7; COOPER JA, 1992, MOL BIOCHEM PARASIT, V51, P301, DOI 10.1016/0166-6851(92)90080-4; COPPEL RL, 1987, MOL BIOCHEM PARASIT, V25, P73, DOI 10.1016/0166-6851(87)90020-X; Cowman AF, 2000, FEBS LETT, V476, P84, DOI 10.1016/S0014-5793(00)01703-8; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Crabb BS, 1997, CELL, V89, P287, DOI 10.1016/S0092-8674(00)80207-X; DEBRABANT A, 1989, MOL BIOCHEM PARASIT, V33, P151, DOI 10.1016/0166-6851(89)90029-7; DEBRABANT A, 1992, MOL BIOCHEM PARASIT, V53, P89, DOI 10.1016/0166-6851(92)90010-H; DELPLACE P, 1988, BIOL CELL, V64, P215, DOI 10.1016/0248-4900(88)90080-9; DELPLACE P, 1987, MOL BIOCHEM PARASIT, V23, P193, DOI 10.1016/0166-6851(87)90026-0; EAKIN AE, 1989, NATURE, V342, P132, DOI 10.1038/342132b0; Fernandez V, 1998, INFECT IMMUN, V66, P2969, DOI 10.1128/IAI.66.6.2969-2975.1998; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; FOX BA, 1994, MOL BIOCHEM PARASIT, V68, P133, DOI 10.1016/0166-6851(94)00162-6; Fox BA, 1997, EXP PARASITOL, V85, P121, DOI 10.1006/expr.1996.4118; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gor DO, 1998, VACCINE, V16, P1193, DOI 10.1016/S0264-410X(98)80119-9; HIGGINS DG, 1989, NATURE, V340, P604, DOI 10.1038/340604a0; INSELBURG J, 1993, INFECT IMMUN, V61, P2048, DOI 10.1128/IAI.61.5.2048-2052.1993; INSELBURG J, 1993, INFECT IMMUN, V61, P2041, DOI 10.1128/IAI.61.5.2041-2047.1993; INSELBURG J, 1991, INFECT IMMUN, V59, P1247, DOI 10.1128/IAI.59.4.1247-1250.1991; Kiefer MC, 1996, MOL BIOCHEM PARASIT, V78, P55, DOI 10.1016/S0166-6851(96)02607-2; KNAPP B, 1989, MOL BIOCHEM PARASIT, V32, P73, DOI 10.1016/0166-6851(89)90131-X; KNAPP B, 1991, MOL BIOCHEM PARASIT, V44, P1, DOI 10.1016/0166-6851(91)90215-R; KNAPP B, 1991, BEHRING I MITT, V88, P147; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Li J, 2002, MOL BIOCHEM PARASIT, V120, P177, DOI 10.1016/S0166-6851(01)00452-2; LI WB, 1989, MOL BIOCHEM PARASIT, V33, P13, DOI 10.1016/0166-6851(89)90037-6; LYON JA, 1989, MOL BIOCHEM PARASIT, V36, P77, DOI 10.1016/0166-6851(89)90203-X; Marshall VM, 1998, MOL BIOCHEM PARASIT, V94, P13, DOI 10.1016/S0166-6851(98)00045-0; MOTTRAM JC, 1989, FEBS LETT, V258, P211, DOI 10.1016/0014-5793(89)81655-2; O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403; O'Donnell RA, 2000, NAT MED, V6, P91, DOI 10.1038/71595; Okech BA, 2001, AM J TROP MED HYG, V65, P912, DOI 10.4269/ajtmh.2001.65.912; Pang XL, 1999, INFECT IMMUN, V67, P1821; Pang XL, 1998, VACCINE, V16, P1299, DOI 10.1016/S0264-410X(98)00057-7; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sugiyama T, 1996, VACCINE, V14, P1069, DOI 10.1016/0264-410X(95)00238-V; Suzuki H, 1997, EXP ANIM TOKYO, V46, P17, DOI 10.1538/expanim.46.17; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	47	128	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47524	47532		10.1074/jbc.M206974200	http://dx.doi.org/10.1074/jbc.M206974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12228245	Green Published, hybrid			2022-12-25	WOS:000179663700090
J	Gallagher, ED; Xu, SC; Moomaw, C; Slaughter, CA; Cobb, MH				Gallagher, ED; Xu, SC; Moomaw, C; Slaughter, CA; Cobb, MH			Binding of JNK/SAPK to MEKK1 is regulated by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; ALPHA-PAK; PTP-SL; DOMAIN; ERK2; JNK; CASCADE; DOCKING; CDC42	We sought to characterize the role of upstream kinases in the regulation of the MAP3 kinase MEKK1 and the potential impact on signaling to MAP kinase cascades. We find that the MAP4 kinase PAK1 phosphorylates the amino terminus of MEKK1 on serine 67. We show that serine 67 lies in a D domain, which binds to the c-Jun-NH2-terminal kinase/stress-activated protein kinases (JNK/SAPK). Serine 67 is constitutively phosphorylated in resting 293 cells, but is dephosphorylated following exposure to stress stimuli such as anisomycin and UV irradiation. Phosphorylation of this site inhibits binding of JNK/SAPK to MEKK1. Thus, we propose a mechanism by which the MEKK1-dependent JNK/SAPK pathway is negatively regulated by PAK through phosphorylation of serine 67.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NIGMS NIH HHS [GM53032, GM56498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Christerson LB, 2002, J CELL PHYSIOL, V192, P200, DOI 10.1002/jcp.10125; Cobb M H, 1996, Adv Pharmacol, V36, P49, DOI 10.1016/S1054-3589(08)60576-1; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Drewett V, 2000, J BIOL CHEM, V275, P1757, DOI 10.1074/jbc.275.3.1757; Elion EA, 2000, CURR OPIN MICROBIOL, V3, P573, DOI 10.1016/S1369-5274(00)00143-0; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; FROST JA, 1998, J BIOL CHEM, V273, P28253; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Karandikar M, 1999, CELL CALCIUM, V26, P219, DOI 10.1054/ceca.1999.0074; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Roig J, 1999, J BIOL CHEM, V274, P31119, DOI 10.1074/jbc.274.44.31119; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	46	38	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45785	45792		10.1074/jbc.M207702200	http://dx.doi.org/10.1074/jbc.M207702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12228228	hybrid			2022-12-25	WOS:000179529300011
J	Wang, J; Kirby, CE; Herbst, R				Wang, J; Kirby, CE; Herbst, R			The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRENYLATION-DEPENDENT ASSOCIATION; MICROTUBULE DYNAMICS; CELL-CYCLE; K-RAS; PROTEIN; KINASE; PHOSPHORYLATION; METHYLATION; ROLES; YEAST	PRL-1 is one of three closely related protein-tyrosine phosphatases, which are characterized by C-terminal farnesylation. Recent reports suggest that they are involved in the regulation of cell proliferation and transformation. However, their biological function has not yet been determined. Here we show that PRL-1 mRNA is overexpressed in a number of human tumor cell lines, including HeLa cells. Using immunofluorescence we studied the subcellular localization of endogenous PRL-1, and our results demonstrate that PRL-1 exhibits cell cycle-dependent localization; in non-mitotic HeLa cells, PRL-1 is localized to the endoplasmic reticulum in a farnesylation-dependent manner. In mitotic cells PRL-1 relocalizes to the centrosomes and the spindle apparatus, proximal to the centrosomes, in a farnesylation-independent manner. Conditional expression of a catalytic domain mutant in HeLa cells results in a delay in the progression of cells through mitosis but has no effect on other phases of the cell cycle. Further, expression of a farnesylation site PRL-1 mutant results in mitotic defects, characterized by chromosomal bridges in anaphase and lagging chromosomes, without affecting spindle checkpoint function. Together, these results suggest that PRL-1 function is regulated in a cell cycle-dependent manner and implicate PRL-1 in regulating progression through mitosis, possibly by modulating spindle dynamics.	DNAX Res Inst Molec & Cellular Biol Inc, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Herbst, R (corresponding author), DNAX Res Inst Molec & Cellular Biol Inc, 901 Calif Ave, Palo Alto, CA 94304 USA.	ronald.herbst@dnax.org						Andersen SSL, 1999, BIOESSAYS, V21, P53, DOI 10.1002/(SICI)1521-1878(199901)21:1<53::AID-BIES7>3.0.CO;2-L; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Dixon JE, 1996, RECENT PROG HORM RES, V51, P405; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; Fujii GH, 1999, ONCOGENE, V18, P1765, DOI 10.1038/sj.onc.1202492; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Peng Y, 1999, J BIOL CHEM, V274, P4513, DOI 10.1074/jbc.274.8.4513; Peng Y, 1998, J BIOL CHEM, V273, P17286, DOI 10.1074/jbc.273.27.17286; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Sorger PK, 1997, CURR OPIN CELL BIOL, V9, P807, DOI 10.1016/S0955-0674(97)80081-6; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; van Huijsduijnen RH, 1998, GENE, V225, P1; Wang Q, 2002, CANCER LETT, V175, P63, DOI 10.1016/S0304-3835(01)00703-0; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zeng Q, 1998, BIOCHEM BIOPH RES CO, V244, P421, DOI 10.1006/bbrc.1998.8291; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	31	106	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46659	46668		10.1074/jbc.M206407200	http://dx.doi.org/10.1074/jbc.M206407200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235145	hybrid			2022-12-25	WOS:000179529300124
J	Gill, A; Gao, NG; Lehrman, MA				Gill, A; Gao, NG; Lehrman, MA			Rapid activation of glycogen phosphorylase by the endoplasmic reticulum unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED OLIGOSACCHARIDES; GLYCOSYLATION; PYROPHOSPHATE; TISSUES	Endoplasmic reticulum (ER) stress is associated with misfolding of ER proteins and triggers the unfolded protein response (UPR). The UPR, in turn, helps restore normal ER function. Since fastidious N-linked glycosylation. is critical for folding of most ER proteins, this study examined whether metabolic interconversions of precursors used for glycan assembly were controlled by the UPR. Thus, eight enzymes and factors with key roles in hexose phosphate metabolism were assayed in cytoplasmic extracts from primary dermal fibroblasts treated with UPR inducers. Stimulation of only one activity by the UPR was detected, AMP-independent glycogen phosphorylase (GP). GP activation required only 20 min of ER stress, with concurrent decreases in cellular glycogen and elevations of its metabolites Glc-1-P and Glc-6-P. Addition of phosphatase inhibitors to enzyme extracts from unstressed cells mimicked the effect of ER stress on GP activity, suggesting that phosphorylation of GP or a regulatory factor was involved. These data show that the UPR can modulate hexose metabolism in a manner beneficial for protein glycosylation. Since activation of GP appears to occur by a rapid posttranslational process, it may be part of a general strategy of ER damage control, preceding the well-known transcription-dependent processes of the UPR that are manifested hours after the occurrence of ER stress.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lehrman, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	mlehrm@mednet.swmed.edu			NIGMS NIH HHS [GM38545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038545, R01GM038545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand M, 2001, MOL BIOL CELL, V12, P487, DOI 10.1091/mbc.12.2.487; Doerrler WT, 1999, P NATL ACAD SCI USA, V96, P13050, DOI 10.1073/pnas.96.23.13050; FURUYA E, 1981, J BIOL CHEM, V256, P7109; Gao NG, 2002, GLYCOBIOLOGY, V12, P353, DOI 10.1093/glycob/12.5.353; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; KEPPLER D, 1974, METHOD ENZYMAT AN, V6, P1127; Lehrman MA, 2001, J BIOL CHEM, V276, P8623, DOI 10.1074/jbc.R100002200; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Marquardt T, 2001, BIOL CHEM, V382, P161, DOI 10.1515/BC.2001.024; MARTYS JL, 1995, J BIOL CHEM, V270, P25976, DOI 10.1074/jbc.270.43.25976; McMahon RJ, 1996, AM J PHYSIOL-ENDOC M, V270, pE640, DOI 10.1152/ajpendo.1996.270.4.E640; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; ROBSON RL, 1974, BIOCHEM J, V144, P513, DOI 10.1042/bj1440513; Shang J, 2002, GLYCOBIOLOGY, V12, P307, DOI 10.1093/glycob/12.5.307; SPIRO MJ, 1984, DIABETOLOGIA, V26, P70; UYEDA K, 1981, J BIOL CHEM, V256, P8394; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1	22	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44747	44753		10.1074/jbc.M205001200	http://dx.doi.org/10.1074/jbc.M205001200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223475	hybrid			2022-12-25	WOS:000179404800021
J	Melendez, J; Welch, S; Schaefer, E; Moravec, CS; Avraham, S; Avraham, H; Sussman, MA				Melendez, J; Welch, S; Schaefer, E; Moravec, CS; Avraham, S; Avraham, H; Sussman, MA			Activation of pyk2/related focal adhesion tyrosine kinase and focal adhesion kinase in cardiac remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR; DILATED CARDIOMYOPATHY; SUBCELLULAR TRANSLOCATION; VENTRICULAR MYOCYTES; PRESSURE-OVERLOAD; PYK2 EXPRESSION; ANGIOTENSIN-II; C BETA; PAXILLIN	Cellular remodeling during progression of dilation involves focal adhesion contact reorganization. However, the signaling mechanisms and structural consequences leading to impaired cardiomyocyte adhesion are poorly defined. These events were studied in tropomodulin-overexpressing transgenic mice that develop dilated cardiomyopathy associated with chronic elevation of intracellular calcium. Analysis of tropomodulin-overexpressing transgenic hearts by immunoblot and confocal microscopy revealed activation and redistribution of signaling molecules known to regulate adhesion. Calcium-dependent pyk2/related focal adhesion tyrosine kinase (RAFTK) showed changes in expression and phosphorylation state, similar to changes observed for a related downstream target molecule of pyk2/RAFTK termed focal adhesion kinase. Paxillin, the target substrate molecule for focal adhesion kinase phosphorylation, was redistributed in tropomodulin-overexpressing transgenic hearts with enhanced paxillin phosphorylation and cleavage. Certain aspects of the in vivo signaling phenotype including increased paxillin phosphorylation could be recapitulated in vitro using neonatal rat cardiomyocytes infected with recombinant adenovirus to overexpress tropomodulin. In addition, increasing intracellular calcium levels with ionomycin induced pyk2/ RAFTK phosphorylation, and adenovirally mediated expression of wild-type pyk2/RAFTK resulted in increased phospho-pyk2/RAFTK levels and concomitant paxillin phosphorylation. Collectively, these results delineate a cardiomyocyte signaling pathway associated with dilation that has potential relevance for cardiac remodeling, focal adhesion reorganization, and loss of contractility.	Childrens Hosp Res Fdn, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Biosource Int, Hopkinton, MA 01748 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Kaufman Ctr Heart Failure, Cleveland, OH 44195 USA; Beth Israel Hosp, Div Expt Med, Harvard Inst Med, Boston, MA 02215 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cleveland Clinic Foundation; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Sussman, MA (corresponding author), Childrens Hosp Res Fdn, Div Mol Cardiovasc Biol, Rm 3033,3333 Burnet Ave, Cincinnati, OH 45229 USA.	sussman@heart.chmce.org	; Sussman, Mark/H-2284-2014	Avraham, Hava/0000-0002-7545-3640; Sussman, Mark/0000-0002-0104-4799; Melendez Rojel, Jaime/0000-0003-4711-864X	NHLBI NIH HHS [HL66035, HL58224, HL67245] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066035, R29HL058224, R01HL058224, R01HL067245] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bayer AL, 2002, AM J PHYSIOL-HEART C, V283, pH695, DOI 10.1152/ajpheart.00021.2002; Bayer AL, 2001, J MOL CELL CARDIOL, V33, P1017, DOI 10.1006/jmcc.2001.1369; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BELTRAMI CA, 1995, J MOL CELL CARDIOL, V27, P291, DOI 10.1016/S0022-2828(08)80028-4; BEUCKELMANN DJ, 1992, CIRCULATION, V85, P1046, DOI 10.1161/01.CIR.85.3.1046; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Bowman JC, 1997, J CLIN INVEST, V100, P2189, DOI 10.1172/JCI119755; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Chay KO, 2002, J BIOL CHEM, V277, P14521, DOI 10.1074/jbc.M111639200; CLERK A, 1994, J BIOL CHEM, V269, P32848; DANOWSKI BA, 1992, J CELL BIOL, V118, P1411, DOI 10.1083/jcb.118.6.1411; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Domingos PP, 2002, AM J PHYSIOL-HEART C, V282, pH556, DOI 10.1152/ajpheart.00534.2001; Du QS, 2001, J CELL SCI, V114, P2977; Eble DM, 2000, AM J PHYSIOL-HEART C, V278, pH1695, DOI 10.1152/ajpheart.2000.278.5.H1695; Franchini KG, 2000, CIRC RES, V87, P558, DOI 10.1161/01.RES.87.7.558; Francis GS, 1998, CURR OPIN CARDIOL, V13, P156; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Koziak K, 2001, BRIT J HAEMATOL, V114, P134, DOI 10.1046/j.1365-2141.2001.02894.x; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; Laser M, 2000, J BIOL CHEM, V275, P35624, DOI 10.1074/jbc.M006124200; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Mukhopadhyay D, 1998, CANCER RES, V58, P1278; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Park SY, 2000, J BIOL CHEM, V275, P19768, DOI 10.1074/jbc.M909932199; Pham CG, 2000, AM J PHYSIOL-HEART C, V279, pH2916, DOI 10.1152/ajpheart.2000.279.6.H2916; Richard S, 1998, CARDIOVASC RES, V37, P300, DOI 10.1016/S0008-6363(97)00273-3; Rocic P, 2001, AM J PHYSIOL-CELL PH, V280, pC90, DOI 10.1152/ajpcell.2001.280.1.C90; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHAPER J, 1991, CIRCULATION, V83, P504, DOI 10.1161/01.CIR.83.2.504; Seko Y, 1999, BIOCHEM BIOPH RES CO, V262, P290, DOI 10.1006/bbrc.1999.1185; Seko Y, 1999, BIOCHEM BIOPH RES CO, V259, P8, DOI 10.1006/bbrc.1999.0720; SHARP WW, 1997, AM J PHYSIOL, V273, P546; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sussman MA, 1999, AM J PATHOL, V155, P2101, DOI 10.1016/S0002-9440(10)65528-9; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Sussman MA, 2000, J CLIN INVEST, V105, P875, DOI 10.1172/JCI8497; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Takahashi N, 1999, CIRC RES, V84, P1194, DOI 10.1161/01.RES.84.10.1194; Taylor JM, 2000, J BIOL CHEM, V275, P19250, DOI 10.1074/jbc.M909099199; TURNER CE, 1994, J CELL SCI, V107, P1583; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Welch S, 2002, CIRC RES, V90, P641, DOI 10.1161/01.RES.0000013780.77774.75; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	61	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45203	45210		10.1074/jbc.M204886200	http://dx.doi.org/10.1074/jbc.M204886200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228222	hybrid			2022-12-25	WOS:000179404800079
J	Park, SG; Kang, YS; Ahn, YH; Lee, SH; Kim, KR; Kim, KW; Koh, GY; Ko, YG; Kim, S				Park, SG; Kang, YS; Ahn, YH; Lee, SH; Kim, KR; Kim, KW; Koh, GY; Ko, YG; Kim, S			Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, in angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ACTIVATING POLYPEPTIDE-II; PROTEIN-PROTEIN INTERACTIONS; HUMAN ENDOTHELIAL-CELLS; IN-VITRO; MULTISYNTHETASE COMPLEX; INDUCED APOPTOSIS; ATP SYNTHASE; CYTOKINE; JNK	Mammalian aminoacyl tRNA synthetases form a macromolecular protein complex with three non-enzymatic cofactors. Among these factors, p43 is also secreted to work as a cytokine on endothelial as well as immune cells. Here we investigated the activity of p43 in angiogenesis and determined the related mediators. It promoted the migration of endothelial cells at low dose but induced their apoptosis at high dose. p43 at low concentration activated extracellular signal-regulating kinase, which resulted in the induction and activation of matrix metalloproteinase 9. In contrast, p43 at high concentration activated Jun N-terminal kinase, which mediated apoptosis of endothelial cells. These results suggest that p43 is a novel cytokine playing a dose-dependent biphasic role in angiogenesis.	Seoul Natl Univ, Coll Pharm, Natl Creat Res Initiat Ctr ARS Network, Seoul 151742, South Korea; Seoul Natl Univ, Coll Pharm, Angiogenesis Res Lab, Seoul 151742, South Korea; Postech, Natl Creat Res Initiat Ctr Cardiac Regenerat, Pohang 790784, South Korea	Seoul National University (SNU); Seoul National University (SNU); Pohang University of Science & Technology (POSTECH)	Kim, S (corresponding author), Seoul Natl Univ, Coll Pharm, Ctr ARS Network, Kwanak Ku, San 56-1,Shillim Dong, Seoul 151746, South Korea.	sungkim@snu.ac.kr	Koh, Gou Young/C-1615-2011; Kim, Sunghoon/AAE-8314-2020	Ahn, Young Ha/0000-0002-6843-5444				Banerjee SK, 1997, MOL CELL BIOCHEM, V177, P97, DOI 10.1023/A:1006888020596; Berger AC, 2000, MICROVASC RES, V60, P70, DOI 10.1006/mvre.2000.2249; Chang SY, 2002, J BIOL CHEM, V277, P8388, DOI 10.1074/jbc.M108792200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; Genersch E, 2000, J CELL SCI, V113, P4319; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Ho FM, 2000, CIRCULATION, V101, P2618, DOI 10.1161/01.CIR.101.22.2618; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Khan KMF, 2002, J BIOL CHEM, V277, P2353, DOI 10.1074/jbc.M108989200; Kim JY, 2002, P NATL ACAD SCI USA, V99, P7912, DOI 10.1073/pnas.122110199; Kim T, 2000, J BIOL CHEM, V275, P21768, DOI 10.1074/jbc.M002404200; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; Ko YG, 2001, J BIOL CHEM, V276, P23028, DOI 10.1074/jbc.M101544200; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Kraling BM, 1999, J CELL SCI, V112, P1599; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Norcum MT, 2000, J BIOL CHEM, V275, P17921, DOI 10.1074/jbc.C000266200; Park H, 2002, J LEUKOCYTE BIOL, V71, P223; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; Pazouki S, 1996, BIOCHEM SOC T, V24, pS368, DOI 10.1042/bst024368s; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Puyraimond A, 1999, J CELL SCI, V112, P1283; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Rho SB, 1998, J BIOL CHEM, V273, P11267, DOI 10.1074/jbc.273.18.11267; Robinson JC, 2000, J MOL BIOL, V304, P983, DOI 10.1006/jmbi.2000.4242; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; Schwarz MA, 1999, J EXP MED, V190, P341, DOI 10.1084/jem.190.3.341; Shalak V, 2001, J BIOL CHEM, V276, P23769, DOI 10.1074/jbc.M100489200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wakasugi K, 2002, P NATL ACAD SCI USA, V99, P173, DOI 10.1073/pnas.012602099; Wakasugi K, 1999, J BIOL CHEM, V274, P23155, DOI 10.1074/jbc.274.33.23155; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5	43	93	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45243	45248		10.1074/jbc.M207934200	http://dx.doi.org/10.1074/jbc.M207934200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237313	hybrid			2022-12-25	WOS:000179404800084
J	Selva, DM; Hogeveen, KN; Seguchi, K; Tekpetey, F; Hammond, GL				Selva, DM; Hogeveen, KN; Seguchi, K; Tekpetey, F; Hammond, GL			A human sex hormone-binding globulin isoform accumulates in the acrosome during spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; PROTEIN GENE; EXPRESSION; RNA; CONTAINS; HOMOLOGY; PROMOTER; SEQUENCE; SHBG	Human sex hormone-binding globulin (SHBG) binds estradiol and testosterone with high affinity. Plasma SHBG is produced by hepatocytes, but the human SHBG gene is also expressed in the testis. Little is known about SHBG gene expression in the human testis, but human SHBG transcripts accumulate in a spermatogenic stage-dependent manner in the testes of mice containing an 11-kb human SHBG transgene. We have now found that human SHBG transcripts containing an alternative exon 1 sequence are located specifically in the testicular germ cells of these transgenic mice, whereas murine SHBG transcripts are confined to Sertoli cells. In addition, we have detected immunoreactive human SHBG in the acrosome during all stages of spermiogenesis in mice containing an 11-kb human SHBG transgene. Western blots of germ cell extracts from these transgenic mice and from human sperm indicate that the immunoreactive human SHBG in the acrosome composes electrophoretic variants, which are 3-5 kDa smaller than the major electrophoretic isoforms of human SHBG in the blood. This apparent size difference is due in part to differences in glycosylation of plasma and acrosomal SHBG isoforms. The function of the human SHBG isoform in the acrosome is unknown, but it binds steroid ligands with high affinity. This is the first demonstration that human SHBG transcripts encode an SHBG isoform that remains within a cellular compartment.	Univ Western Ontario, Dept Obstet & Gynecol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 4L6, Canada; Univ Western Ontario, Canadian Inst Hlth Res Grp Fetal & Neonatal Hlth, London, ON N6A 4L6, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Hammond, GL (corresponding author), London Reg Canc Ctr, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.	ghammond@uwo.ca	Selva, David Martínez/O-6444-2016	Hammond, Geoffrey/0000-0002-4639-7336				Avvakumov GV, 2000, J BIOL CHEM, V275, P25920, DOI 10.1074/jbc.M004484200; AVVAKUMOV GV, 1988, BIOCHEMISTRY-MOSCOW+, V53, P726; BERUBE D, 1990, CYTOGENET CELL GENET, V54, P65, DOI 10.1159/000132958; BOCCHINFUSO WP, 1992, ENDOCRINOLOGY, V131, P2331, DOI 10.1210/en.131.5.2331; GERSHAGEN S, 1989, NUCLEIC ACIDS RES, V17, P9245, DOI 10.1093/nar/17.22.9245; HALL SH, 1990, MOL ENDOCRINOL, V4, P349, DOI 10.1210/mend-4-2-349; HAMMOND GL, 1983, CLIN CHIM ACTA, V132, P101, DOI 10.1016/0009-8981(83)90237-1; HAMMOND GL, 1987, FEBS LETT, V215, P100, DOI 10.1016/0014-5793(87)80121-7; HAMMOND GL, 1989, MOL ENDOCRINOL, V3, P1869, DOI 10.1210/mend-3-11-1869; HAMMOND GL, 1993, STEROID HORMONE ACTI, P1; Hogeveen KN, 2002, J CLIN INVEST, V109, P973, DOI 10.1172/JCI200214060; Hogeveen KN, 2001, J BIOL CHEM, V276, P36383, DOI 10.1074/jbc.M104681200; Janne M, 1998, J BIOL CHEM, V273, P34105, DOI 10.1074/jbc.273.51.34105; Janne M, 1998, MOL ENDOCRINOL, V12, P123; Janne M, 1999, ENDOCRINOLOGY, V140, P4166, DOI 10.1210/en.140.9.4166; JOSEPH DR, 1994, VITAM HORM, V49, P197; JOSEPH DR, 1987, P NATL ACAD SCI USA, V84, P339, DOI 10.1073/pnas.84.2.339; Joseph DR, 1996, ENDOCRINOLOGY, V137, P1138, DOI 10.1210/en.137.3.1138; MARTINEZMENARGUEZ JA, 1992, HISTOCHEMISTRY, V97, P439, DOI 10.1007/BF00270391; Misao R, 1997, CANCER RES, V57, P5579; Misao R, 1998, FERTIL STERIL, V69, P324, DOI 10.1016/S0015-0282(97)00495-0; REVENTOS J, 1993, MOL CELL ENDOCRINOL, V96, P69, DOI 10.1016/0303-7207(93)90096-3; REVENTOS J, 1988, MOL ENDOCRINOL, V2, P125, DOI 10.1210/mend-2-2-125; RUSSELL LD, 1990, HISTOLOGICAL HISTOPA, P140; SANTIEMMA V, 1992, J STEROID BIOCHEM, V43, P423, DOI 10.1016/0960-0760(92)90080-3; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Selva DM, 2000, ENDOCRINOLOGY, V141, P1168, DOI 10.1210/en.141.3.1168; SULLIVAN PM, 1993, MOL ENDOCRINOL, V7, P702, DOI 10.1210/me.7.5.702; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; WANG YM, 1989, MOL CELL ENDOCRINOL, V63, P85, DOI 10.1016/0303-7207(89)90084-1; WANG YM, 1990, ENDOCRINOLOGY, V127, P3124, DOI 10.1210/endo-127-6-3124; Weiss M, 1997, BIOL REPROD, V57, P68, DOI 10.1095/biolreprod57.1.68; WESTPHAL U, 1986, MONOGRAPHS ENDOCRINO, P276	34	26	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45291	45298		10.1074/jbc.M205903200	http://dx.doi.org/10.1074/jbc.M205903200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235141	hybrid			2022-12-25	WOS:000179404800090
J	Angus, SP; Wheeler, LJ; Ranmal, SA; Zhang, XP; Markey, MP; Mathews, CK; Knudsen, ES				Angus, SP; Wheeler, LJ; Ranmal, SA; Zhang, XP; Markey, MP; Mathews, CK; Knudsen, ES			Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; S-PHASE; RIBONUCLEOTIDE REDUCTASE; DIHYDROFOLATE-REDUCTASE; PRB PHOSPHORYLATION; G(1)/S TRANSITION; G1 ARREST; PROTEIN; INHIBITION; GENE	The retinoblastoma tumor suppressor, 1113, is a negative regulator of the cell cycle that is inactivated in the majority of human tumors. Cell cycle inhibition elicited by RB has been attributed to the attenuation of CDK2 activity. Although ectopic cyclins partially overcome RB-mediated S-phase arrest at the replication fork, DNA replication remains inhibited and cells fail to progress to G(2) phase. These data suggest that RB regulates an additional execution point in S phase. We observed that constitutively active 1113 attenuates the expression of specific dNTP synthetic enzymes: dihydrofolate reductase, ribonucleotide reductase (RNR) subunits R1/R2, and thymidylate synthase (TS). Activation of endogenous RB and related proteins by p16ink4a yielded similar effects on enzyme expression. Conversely, targeted disruption of RB resulted in increased metabolic protein levels (dihydrofolate reductase, TS, RNR-R2) and conferred resistance to the effect of TS or RNR inhibitors that diminish available dNTPs. Analysis of dNTP pools during RB-mediated cell cycle arrest revealed significant depletion, concurrent with the loss of TS and RNR protein. Importantly, the effect of active RB on cell cycle position and available dNTPs was comparable to that observed with specific antimetabolites. Together, these results show that RB-mediated transcriptional repression attenuates available dNTP pools to control S-phase progression. Thus, RB employs both canonical cyclin-dependent kinase/cyclin regulation and metabolic regulation as a means to limit proliferation, underscoring its potency in tumor suppression.	Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	University System of Ohio; University of Cincinnati; Oregon State University	Angus, SP (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA.			Angus, Steven/0000-0002-7655-657X; Markey, Michael/0000-0002-8593-2290	NCI NIH HHS [CA82525] Funding Source: Medline; NIGMS NIH HHS [GM55134] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055134] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BERTINO JR, 1992, MT SINAI J MED, V59, P391; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Chabes A, 1999, J BIOL CHEM, V274, P36679, DOI 10.1074/jbc.274.51.36679; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; COLLINS JM, 1978, J BIOL CHEM, V253, P8570; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; DOU QP, 1994, J BIOL CHEM, V269, P1306; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; Fukushima M, 2001, EUR J CANCER, V37, P1681, DOI 10.1016/S0959-8049(01)00174-5; GRIFFIG J, 1989, CANCER RES, V49, P6923; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Kaelin WG, 1997, CANCER INVEST, V15, P243, DOI 10.3109/07357909709039722; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; LEEDS JM, 1985, MOL CELL BIOL, V5, P3443, DOI 10.1128/MCB.5.12.3443; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502; MATHEWS CK, 1993, PROG NUCLEIC ACID RE, V44, P167, DOI 10.1016/S0079-6603(08)60220-2; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; PINEDO HM, 1988, J CLIN ONCOL, V6, P1653, DOI 10.1200/JCO.1988.6.10.1653; Reed SI, 1997, CANCER SURV, V29, P7; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SARGENT RG, 1987, J BIOL CHEM, V262, P5546; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4	52	74	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44376	44384		10.1074/jbc.M205911200	http://dx.doi.org/10.1074/jbc.M205911200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221087	Green Published, hybrid			2022-12-25	WOS:000179272000109
J	Deepa, SS; Umehara, Y; Higashiyama, S; Itoh, N; Sugahara, K				Deepa, SS; Umehara, Y; Higashiyama, S; Itoh, N; Sugahara, K			Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors - Implications as a physiological binding partner in the brain and other tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHATASE ZETA/RPTP-BETA; AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; NEURITE OUTGROWTH; FACTOR MIDKINE; MESSENGER-RNA; CELL-ADHESION; N-SYNDECAN; HB-EGF	We previously observed that the cortical neuronal cell adhesion mediated by midkine (AM), a heparin (Hep)-binding growth factor, is specifically inhibited by oversulfated chondroitin sulfate-E (CS-E) (Ueoka, C., Kaneda, N., Okazaki, I., Nadanaka, S., Muramatsu, T., and Sugahara, K. (2000) J. BioL ChenL 275, 37407-37413) and that CS-E exhibits neurite outgrowth promoting activities toward embryonic rat hippocampal neurons. We have also shown oversulfated CS chains in embryonic chick and rat brains and demonstrated that the CS disaccharide composition changes during brain development. In view of these findings, here we tested the possibility of CS-E interacting with Hep-binding growth factors during development, using squid cartilage CS-E. The binding ability of Hep-binding growth factors (MK, pleiotrophin (PTN), fibroblast growth factor-1 (FGF-1), FGF-2, Hep-binding epidermal growth factor-like growth factor (HB-EGF), FGF-10, FGF-16, and FGF-18) toward [H-3]CS-E was first tested by a filter binding assay, which demonstrated direct binding of all growth factors, except FGF-1, to CS-E. The bindings were characterized further in an Interaction Analysis system, where all of the growth factors, except FGF-1, gave concentration-dependent and specific bindings. The kinetic constants k(a), k(d), and K-d suggested that MK, PTN, FGF-16, FGF-18, and HB-EGF bound strongly to CS-E, in comparable degrees to the binding to Hep, whereas the intensity of binding of FGF-2 and FGF-10 toward CS-E was lower than that for Hep. These findings suggest the possibility of CS-E being a binding partner, a coreceptor, or a genuine receptor for various Hep-binding growth factors in the brain and possibly also in other tissues.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Ehime Univ, Sch Med, Dept Biochem Med, Onsen, Ehime 7910295, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Kyoto 6068501, Japan	Kobe Pharmaceutical University; Ehime University; Kyoto University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyama Kita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp		Deepa, Sathyaseelan/0000-0002-3669-4820				Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bagai S, 2002, J BIOL CHEM, V277, P23828, DOI 10.1074/jbc.M201658200; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Danilenko DM, 1999, ARCH BIOCHEM BIOPHYS, V361, P34, DOI 10.1006/abbi.1998.0967; DEEPA SS, 2002, 23 JAP CARB S YOK JA; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; Farkas LM, 2002, J NEURAL TRANSM, V109, P267, DOI 10.1007/s007020200022; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; FOXALL C, 1995, ANAL BIOCHEM, V231, P366, DOI 10.1006/abio.1995.0065; Garwood J, 1999, J NEUROSCI, V19, P3888; GREEN NM, 1965, BIOCHEM J, V94, pC23, DOI 10.1042/bj0940023C; Hajihosseini MK, 2002, MECH DEVELOP, V113, P79, DOI 10.1016/S0925-4773(01)00656-6; Harada H, 2002, DEVELOPMENT, V129, P1533; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; Hattori Y, 1997, MOL BRAIN RES, V47, P139, DOI 10.1016/S0169-328X(97)00044-2; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; Hu MCT, 1998, MOL CELL BIOL, V18, P6063, DOI 10.1128/MCB.18.10.6063; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kaneda N, 1996, J BIOCHEM-TOKYO, V119, P1150; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kinoshita A, 2001, BIOCHEMISTRY-US, V40, P12654, DOI 10.1021/bi015577n; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Konishi M, 2000, J BIOL CHEM, V275, P12119, DOI 10.1074/jbc.275.16.12119; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MARK M P, 1990, International Journal of Developmental Biology, V34, P191; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; Muramatsu T, 2001, TRENDS GLYCOSCI GLYC, V13, P563, DOI 10.4052/tigg.13.563; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Nakagawa T, 1998, DEV BRAIN RES, V108, P263, DOI 10.1016/S0165-3806(98)00057-1; Nakanishi T, 1997, J BIOCHEM-TOKYO, V121, P197; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; Ohmachi S, 2000, BIOCHEM BIOPH RES CO, V277, P355, DOI 10.1006/bbrc.2000.3675; Ohuchi H, 2000, MECH DEVELOP, V95, P55, DOI 10.1016/S0925-4773(00)00331-2; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Owada K, 1999, J NEUROCHEM, V73, P2084; Patrie KM, 1999, BIOCHEMISTRY-US, V38, P9264, DOI 10.1021/bi9903345; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; POOLE AR, 1986, BIOCHEM J, V236, P1; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RODEN L, 1980, BIOCH GLYCOPROTEINS, P491; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAIGO K, 1970, J NEUROCHEM, V17, P633, DOI 10.1111/j.1471-4159.1970.tb00543.x; Sakaue H, 2002, GENE DEV, V16, P908, DOI 10.1101/gad.983202; Salinero O, 2000, J NEUROSCI RES, V60, P87, DOI 10.1002/(SICI)1097-4547(20000401)60:1<87::AID-JNR9>3.0.CO;2-C; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; SUGAHARA K, 2002, IN PRESS IUBMB LIFE; Tsuchida K, 2001, J BIOL CHEM, V276, P37155, DOI 10.1074/jbc.M105818200; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Whitsett JA, 2002, J BIOL CHEM, V277, P22743, DOI 10.1074/jbc.M202253200; Wu AF, 1997, J NEUROSCI, V17, P4987; Xian CJ, 1999, MOL NEUROBIOL, V20, P157, DOI 10.1007/BF02742440; Xu JS, 2000, DEVELOPMENT, V127, P1833; Yamane Y, 1998, J BIOL CHEM, V273, P7375, DOI 10.1074/jbc.273.13.7375; YANG BH, 1995, ANAL BIOCHEM, V228, P299, DOI 10.1006/abio.1995.1354; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x	78	284	290	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43707	43716		10.1074/jbc.M207105200	http://dx.doi.org/10.1074/jbc.M207105200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221095	hybrid			2022-12-25	WOS:000179272000023
J	Eto, M; Elliott, E; Prickett, TD; Brautigan, DL				Eto, M; Elliott, E; Prickett, TD; Brautigan, DL			Inhibitor-2 regulates protein phosphatase-1 complexed with NimA-related kinase to induce centrosome separation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN PHOSPHATASE; MAMMALIAN INHIBITOR-2; CELLULAR-REGULATION; CATALYTIC SUBUNIT; SMOOTH-MUSCLE; PHOSPHORYLATION; IDENTIFICATION; LOCALIZATION; NEK2; ACTIVATION	Centrosome separation is regulated by balance of in situ protein kinase/phosphatase activities during the cell cycle. The mammalian NimA-related kinase Nek2 forms a complex with the catalytic subunit of protein phosphatase-1 (PP1C). This complex is located at centrosomes and has been implicated in regulation of the cycle of duplication and separation. Inhibitor-2 (Inh2) is an inhibitor protein specific for PP1C, and its expression level fluctuates during the cell cycle. Here we report cellular regulation of the Nek2(.)PP1C complex by Inh2. PP1C-binding segments of Nek2 were isolated by yeast two-hybrid screening using Inh2 bait. Inh2 indirectly associates with Nek2 via PP1C, which binds to both proteins, forming a bridged heterotrimeric complex. Double Ala mutation of the PP1C-binding site (KVHF) in Nek2 eliminated both PPIC and Inh2 interactions in both a yeast conjugation assay and an in vitro binding assay. The kinase activity of Nek2(.)PP1C was enhanced 2-fold by addition of recombinant Inh2, with EC50 = 10 am. Immunofluorescence showed concentration of endogenous Inh2 at centrosomes and in a region surrounding the centrosomes. Transient expression of wild-type Inh2 increased by 5-fold dispersed/split centrosomes in fibroblasts, mimicking the phenotype produced by overexpression of Nek2. Deletion of the Inh2 C-terminal domain yielded Inh2-(1-118), which failed to interact with or activate the Nek2(.)PP1C complex, suggesting that the C-terminal region of Inh2 is required for regulation of the Nek2(.)PP1C complex. Thus, Inh2 can enhance the kinase activity of the Nek2-PP1C complex via inhibition of phosphatase activity to initiate centrosome separation.	Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia	Eto, M (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, POB 800577,W Complex Rm 7225,1400 Jefferson Pk, Charlottesville, VA 22908 USA.	me2h@virginia.edu	Eto, Masumi/ABE-4700-2020	Eto, Masumi/0000-0002-0651-5836	NCI NIH HHS [CA40042] Funding Source: Medline; NIGMS NIH HHS [GM56362] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal-Mawal A, 2001, J BIOL CHEM, V276, P23712, DOI 10.1074/jbc.M010002200; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; Cohen PTW, 2002, J CELL SCI, V115, P241; Connor JH, 2000, J BIOL CHEM, V275, P18670, DOI 10.1074/jbc.M909312199; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; Di Agostino S, 2002, DEVELOPMENT, V129, P1715; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Eto M, 1999, BIOCHEMISTRY-US, V38, P16952, DOI 10.1021/bi992030o; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; Eto M, 2000, CELL MOTIL CYTOSKEL, V46, P222, DOI 10.1002/1097-0169(200007)46:3<222::AID-CM6>3.3.CO;2-2; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Hayashi Y, 2001, J BIOL CHEM, V276, P39858, DOI 10.1074/jbc.M107302200; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Helps NR, 1998, FEBS LETT, V438, P131, DOI 10.1016/S0014-5793(98)01286-1; HUANG FL, 1976, FEBS LETT, V62, P326, DOI 10.1016/0014-5793(76)80086-5; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; Kakinoki Y, 1997, J BIOL CHEM, V272, P32308, DOI 10.1074/jbc.272.51.32308; Leach C, 2002, J CELL SCI, V115, P3739, DOI 10.1242/jcs.00052; Liu J, 2001, P NATL ACAD SCI USA, V98, P6650, DOI 10.1073/pnas.111154698; Liu QR, 2002, J BIOL CHEM, V277, P13312, DOI 10.1074/jbc.M107558200; MacKintosh C, 1996, FEBS LETT, V397, P235, DOI 10.1016/S0014-5793(96)01175-1; Meraldi P, 2001, J CELL SCI, V114, P3749; Meraldi P, 2002, FEBS LETT, V521, P9, DOI 10.1016/S0014-5793(02)02865-X; PARK IK, 1994, J BIOL CHEM, V269, P28919; PUNTONI F, 1995, BIOCHEM BIOPH RES CO, V207, P732, DOI 10.1006/bbrc.1995.1248; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; Senba S, 1999, J BIOCHEM-TOKYO, V125, P354, DOI 10.1093/oxfordjournals.jbchem.a022294; SHERLINE P, 1982, J CELL BIOL, V93, P507, DOI 10.1083/jcb.93.2.507; SHERLINE P, 1982, J CELL BIOL, V95, P316, DOI 10.1083/jcb.95.1.316; Shirato H, 2000, BIOCHEMISTRY-US, V39, P13848, DOI 10.1021/bi001326n; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; Watanabe T, 2001, P NATL ACAD SCI USA, V98, P3080, DOI 10.1073/pnas.051003898; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200	45	81	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44013	44020		10.1074/jbc.M208035200	http://dx.doi.org/10.1074/jbc.M208035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221103	hybrid			2022-12-25	WOS:000179272000063
J	He, L; Ronis, MJJ; Badger, TM				He, L; Ronis, MJJ; Badger, TM			Ethanol induction of Class I alcohol dehydrogenase expression in the rat occurs through alterations in CCAAT/enhancer binding proteins beta and gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY HEPATOCYTE CULTURE; MESSENGER-RNA; GROWTH-HORMONE; 5'-FLANKING SEQUENCE; RESPONSE ELEMENT; C/EBP-GAMMA; ADH-1 GENE; CYCLIC-AMP; TRANSCRIPTION; FAMILY	Alcohol dehydrogenase (ADH) is the principal ethanol-metabolizing enzyme. Ethanol induces rat Class I ADH mRNA and activity by an as yet unknown mechanism. In the current study, adult male rats were fed an ethanol-containing diet by continuous intragastric infusion for 42 days. Hepatic Class I ADH mRNA, protein, and activity levels in the ethanol-infused rats increased 3.9-, 3.3-, and 1.7-fold, respectively (p <0.05). Cis-acting elements within the proximal promoter region of the ADH gene were studied by electrophoretic mobility shift assay (EMSA). Hepatic nuclear extract (HNE) binding to either the consensus or ADH-specific CCAAT/enhancer binding protein (C/EBP) sites was >2.4-fold greater in ethanol-fed rats (p <0.05) than controls. Antibody-specific EMSA assays demonstrated binding of the transcription factor C/EBPbeta to the C/EBP site. Western blot immunoblot analysis of HNEs demonstrated 3.5- and 2.3-fold increases in C/EBPbeta (LAP) and C/EBPdelta (p <0.05), respectively, in ethanol-fed rats compared with controls, whereas levels of the truncated C/EBP&delta; (LIP) and C/EBP&gamma; were lower in ethanol-fed rats (p &LT;0.05). HNE from ethanol-fed rats increased (3-fold) the in vitro transcription of rat Class I ADH (p &LT;0.05), and mutation of the C/EBP element in the proximal promoter region blocked this effect. Antisera against LIP or C/EBP&gamma; enhanced transcription efficiency (p &LT;0.05). These data provide the first evidence for the mechanism by which ethanol regulates rat hepatic Class I ADH gene expression in vivo. This mechanism involves the C/EBP site and the enhancer binding proteins &beta; and &gamma;.	Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA		Badger, TM (corresponding author), Arkansas Childrens Nutr Ctr, 1120 Marshall St, Little Rock, AR 72202 USA.				NIAAA NIH HHS [AA0845] Funding Source: Medline	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BADGER TM, 1993, J PHARMACOL EXP THER, V264, P938; Badger TM, 2000, BIOCHEM BIOPH RES CO, V274, P684, DOI 10.1006/bbrc.2000.3186; BAGCHI MK, 1990, J BIOL CHEM, V265, P5129; BOLEDA MD, 1992, BIOCHEM PHARMACOL, V43, P1555, DOI 10.1016/0006-2952(92)90214-4; BUETLER TM, 1995, TOXICOL APPL PHARM, V135, P45, DOI 10.1006/taap.1995.1207; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen B, 2000, CANCER RES, V60, P3290; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; CORTESE JF, 1994, J BIOL CHEM, V269, P21898; CRABB DW, 1989, GENOMICS, V5, P906, DOI 10.1016/0888-7543(89)90133-X; CRABB DW, 1986, GENE, V48, P287, DOI 10.1016/0378-1119(86)90087-9; CRABB DW, 1987, PHARMACOL THERAPEUT, V34, P59, DOI 10.1016/0163-7258(87)90092-1; DAVYDOV IV, 1995, GENE, V161, P271, DOI 10.1016/0378-1119(95)00271-7; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DUESTER G, 1986, J BIOL CHEM, V261, P2027; DUSTER G, 1991, MOL CELL BIOL, V11, P1638; Edenberg HJ, 2000, PROG NUCLEIC ACID RE, V64, P295, DOI 10.1016/S0079-6603(00)64008-4; ESTONIUS M, 1993, EUR J BIOCHEM, V215, P497, DOI 10.1111/j.1432-1033.1993.tb18059.x; FELDER MR, 1988, J BIOL CHEM, V263, P14531; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; McGehee RE, 1997, DNA CELL BIOL, V16, P725, DOI 10.1089/dna.1997.16.725; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MEZEY E, 1986, GASTROENTEROLOGY, V91, P1271, DOI 10.1016/S0016-5085(86)80027-0; MEZEY E, 1986, HEPATOLOGY, V6, P1386, DOI 10.1002/hep.1840060627; MEZEY E, 1990, ARCH BIOCHEM BIOPHYS, V280, P390, DOI 10.1016/0003-9861(90)90347-2; MEZEY E, 1993, ARCH BIOCHEM BIOPHYS, V225, P787; POTTER JJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P360, DOI 10.1016/0003-9861(92)90529-6; POTTER JJ, 1993, BIOCHEM BIOPH RES CO, V191, P1040, DOI 10.1006/bbrc.1993.1322; POTTER JJ, 1995, ARCH BIOCHEM BIOPHYS, V321, P329, DOI 10.1006/abbi.1995.1402; POTTER JJ, 1989, ARCH BIOCHEM BIOPHYS, V274, P548, DOI 10.1016/0003-9861(89)90469-4; QULALI M, 1991, ARCH BIOCHEM BIOPHYS, V288, P406, DOI 10.1016/0003-9861(91)90213-3; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; RONIS MJJ, 1993, J PHARMACOL EXP THER, V264, P944; TSUKAMOTO H, 1985, ALCOHOL CLIN EXP RES, V9, P31, DOI 10.1111/j.1530-0277.1985.tb05046.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WINTER LA, 1990, GENE, V91, P233, DOI 10.1016/0378-1119(90)90093-7; ZHANG K, 1987, GENE, V57, P27, DOI 10.1016/0378-1119(87)90173-9	39	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43572	43577		10.1074/jbc.M204535200	http://dx.doi.org/10.1074/jbc.M204535200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12213809	hybrid			2022-12-25	WOS:000179272000006
J	Ito, M; Tchoua, U; Okamoto, M; Tojo, H				Ito, M; Tchoua, U; Okamoto, M; Tojo, H			Purification and properties of a phospholipase A(2)/lipase preferring phosphatidic acid, bis(monoacylglycerol) phosphate, and monoacylglycerol from rat testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INDUCED LIPIDOSIS; LYSOPHOSPHATIDIC ACID; CRYSTAL-STRUCTURE; CATALYTIC TRIAD; BOVINE TESTIS; GUINEA-PIG; LIPASE; LIVER; A(2); CARBOXYLESTERASE	Phospholipase A(2) (PLA(2)) was purified to homogeneity from the supernatant fraction of rat testis homogenate. The purified 63-kDa enzyme did not require Ca2+ ions for activity and exhibited both phosphatidic acid-preferring PLA(2) and monoacylglycerol lipase activities with a modest specificity toward unsaturated acyl chains. Anionic detergents enhanced these activities. Serine-modifying irreversible inhibitors, (p-amidinophenyl) methanesulfonyl fluoride and methylarachidonyl fluorophosphonate, inhibited both activities to a similar extent, indicating a single active site is involved in PLA(2) and lipase activities. The sequence of NH2-terminal 12 amino acids of purified enzyme was identical to that of a carboxylesterase from rat liver. The optimal pH for PLA(2) activity (around 5.5) differed from that for lipase activity (around 8.0). At pH 5.5 the enzyme also hydrolyzed bis(monoacylglycerol) phosphate, or lysobisphosphatidic acid (LBPA), that has been hitherto known as a secretory PLA(2)-resistant phospholipid and a late endosome marker. LBPA-enriched fractions were prepared from liver lysosome fractions of chloroquine-treated rats, treated with excess of pancreatic PLA(2) and then used for assaying LBPA-hydrolyzing activity. LBPA and the reaction products were identified by microbore normal phase high performance liquid chromatography/electrospray ionization ion-trap mass spectrometry. These enzymatic properties suggest that the enzyme can metabolize phosphatidic and lysobisphosphatidic acids in cellular acidic compartments.	Osaka Univ, Grad Sch Med, Dept Mol Physiol Chem, Suita, Osaka 5650871, Japan	Osaka University	Tojo, H (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Physiol Chem, H-1,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Abe A, 1998, J BIOL CHEM, V273, P8467, DOI 10.1074/jbc.273.14.8467; AMIDON B, 1995, BIOCHEMISTRY-US, V34, P5554, DOI 10.1021/bi00016a029; BACHOVCHIN WW, 1978, J AM CHEM SOC, V100, P8041, DOI 10.1021/ja00494a001; Bencharit S, 2002, NAT STRUCT BIOL, V9, P337, DOI 10.1038/nsb790; Bhattacharyya D, 1999, MOL CELL BIOCHEM, V198, P179, DOI 10.1023/A:1006902031255; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; Chevallier J, 2000, ORG LETT, V2, P1859, DOI 10.1021/ol0059246; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; DAS AK, 1989, LIPIDS, V24, P329, DOI 10.1007/BF02535172; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; Ghosh S, 1995, BBA-LIPID LIPID MET, V1259, P305, DOI 10.1016/0005-2760(95)00184-0; Higgs HN, 1998, J BIOL CHEM, V273, P5468, DOI 10.1074/jbc.273.10.5468; Higgs HN, 1996, J BIOL CHEM, V271, P10874, DOI 10.1074/jbc.271.18.10874; Karlsson M, 1997, J BIOL CHEM, V272, P27218, DOI 10.1074/jbc.272.43.27218; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Luquain C, 2000, BIOCHEM J, V351, P795, DOI 10.1042/0264-6021:3510795; MASON RJ, 1972, J CLIN INVEST, V51, P2399, DOI 10.1172/JCI107052; MATSUZAWA Y, 1980, J LIPID RES, V21, P202; MAUCO G, 1978, BIOCHIMIE, V60, P653, DOI 10.1016/S0300-9084(78)80784-6; MENTLEIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P230, DOI 10.1016/0003-9861(84)90064-X; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; Roussel A, 1999, J BIOL CHEM, V274, P16995, DOI 10.1074/jbc.274.24.16995; Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257; Shinozaki K, 1999, BIOCHEMISTRY-US, V38, P1669, DOI 10.1021/bi982123q; Simons K, 2000, TRENDS CELL BIOL, V10, P459, DOI 10.1016/S0962-8924(00)01847-X; Snitko Y, 1997, BIOCHEM J, V321, P737, DOI 10.1042/bj3210737; Stennicke HR, 1996, BIOCHEMISTRY-US, V35, P7131, DOI 10.1021/bi952758e; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; THOMSON FJ, 1995, BIOCHEM J, V306, P305, DOI 10.1042/bj3060305; TOJO H, 1993, EUR J BIOCHEM, V215, P81, DOI 10.1111/j.1432-1033.1993.tb18009.x; Tojo H, 1998, J BIOL CHEM, V273, P2214, DOI 10.1074/jbc.273.4.2214; TOJO H, 1993, J LIPID RES, V34, P837; TORNQVIST H, 1976, J BIOL CHEM, V251, P813; WAITE M, 1992, BIOCHIM BIOPHYS ACTA, V1128, P281, DOI 10.1016/0005-2760(92)90319-Q; Wallace TJ, 2001, J BIOL CHEM, V276, P33165, DOI 10.1074/jbc.M105644200; WHERRETT JR, 1973, LIPIDS, V8, P531, DOI 10.1007/BF02531989; WithersMartinez C, 1996, STRUCTURE, V4, P1363, DOI 10.1016/S0969-2126(96)00143-8; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; YAMAMOTO A, 1976, LIPIDS, V11, P616, DOI 10.1007/BF02532875; YANG SF, 1967, J BIOL CHEM, V242, P477	46	32	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43674	43681		10.1074/jbc.M202817200	http://dx.doi.org/10.1074/jbc.M202817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223468	hybrid			2022-12-25	WOS:000179272000019
J	Sasaki, T; Knyazev, PG; Cheburkin, Y; Gohring, W; Tisi, D; Ullrich, A; Timpl, R; Hohenester, E				Sasaki, T; Knyazev, PG; Cheburkin, Y; Gohring, W; Tisi, D; Ullrich, A; Timpl, R; Hohenester, E			Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6 - Receptor tyrosine kinase activation by laminin G-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHBG-LIKE REGION; ALPHA-DYSTROGLYCAN; BINDING-SITES; LIGAND; AXL; PERLECAN; PRODUCT; CELLS; SKY; IDENTIFICATION	Receptor tyrosine kinases of the Axl family are activated by Gas6, the product of growth arrest-specific gene 6. Gas6-Axl signaling is implicated in cell survival, adhesion, and migration. The receptor-binding site of Gas6 is located within a C-terminal pair of laminin G-like (LG) domains that do not resemble any other receptor tyrosine kinase ligand. We report the crystal structure at 2.2-Angstrom resolution of a Gas6 fragment spanning both LG domains (Gas6-LG). The structure reveals a V-shaped arrangement of LG domains strengthened by an interdomain calcium-binding site. LG2 of Gas6-LG contains two unusual features: an a-helix cradled by one edge of the LG beta-sandwich and a conspicuous patch of surface-exposed hydrophobic residues. Mutagenesis of some residues in this patch reduces Gas6-LG binding to the extracellular domain of Axl as well as Axl activation in glioblastoma cells, identifying a component of the receptor-binding site of Gas6.	Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, Dept Biol Sci, London SW7 2BW, England; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Imperial College London; Max Planck Society	Hohenester, E (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, Dept Biol Sci, Prince Consort Rd, London SW7 2BW, England.	e.hohenester@ic.ac.uk	Cheburkin, Yuri/AAD-9521-2019	Cheburkin, Yuri/0000-0002-1896-5703	Wellcome Trust [054334] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen MP, 2002, MOL CELL BIOL, V22, P599, DOI 10.1128/MCB.22.2.599-613.2002; Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Evenas P, 2000, BIOL CHEM, V381, P199, DOI 10.1515/BC.2000.027; Evenas P, 1999, EUR J BIOCHEM, V266, P935, DOI 10.1046/j.1432-1327.1999.00928.x; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; Giri TK, 2002, J BIOL CHEM, V277, P15099, DOI 10.1074/jbc.M103036200; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; Goruppi S, 1999, ONCOGENE, V18, P4224, DOI 10.1038/sj.onc.1202788; Goruppi S, 1996, ONCOGENE, V12, P471; Grishkovskaya I, 2000, EMBO J, V19, P504, DOI 10.1093/emboj/19.4.504; He XH, 1997, BIOCHEMISTRY-US, V36, P3745, DOI 10.1021/bi962315q; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1994, MOSFLM USERS GUIDE; Li RH, 1996, J NEUROSCI, V16, P2012; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; McCloskey P, 1997, J BIOL CHEM, V272, P23285, DOI 10.1074/jbc.272.37.23285; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Nakano T, 1997, J BIOL CHEM, V272, P29411, DOI 10.1074/jbc.272.47.29411; Nyberg P, 1997, EUR J BIOCHEM, V246, P147, DOI 10.1111/j.1432-1033.1997.t01-2-00147.x; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; Rudenko G, 2001, TRENDS BIOCHEM SCI, V26, P363, DOI 10.1016/S0968-0004(01)01832-1; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Villoutreix BO, 2001, PROTEINS, V43, P203, DOI 10.1002/1097-0134(20010501)43:2<203::AID-PROT1031>3.0.CO;2-W; Wiesmann C, 2000, J MOL MED, V78, P247, DOI 10.1007/s001090000082	50	71	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44164	44170		10.1074/jbc.M207340200	http://dx.doi.org/10.1074/jbc.M207340200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12218057	hybrid			2022-12-25	WOS:000179272000082
J	Schneider, G; Oswald, F; Wahl, C; Greten, FR; Adler, G; Schmid, RM				Schneider, G; Oswald, F; Wahl, C; Greten, FR; Adler, G; Schmid, RM			Cyclosporine inhibits growth through the activating transcription factor/cAMP-responsive element-binding protein binding site in the cyclin D1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRE-DECOY OLIGONUCLEOTIDE; CELL-LINE AR42J; GENE-TRANSCRIPTION; PHOSPHATASE-ACTIVITY; ENDOTHELIAL-CELLS; CANCER CELLS; GLIOMA-CELLS; FACTOR-BETA; T-CELLS; CAMP	The immunosuppressive agent cyclosporine affects proliferation depending on the cellular system used. In an attempt to study the inhibitory effect of cyclosporine on proliferation of pancreatic acinar cells, we used AR42J cells as a model system. Here we demonstrate that cyclosporine inhibits growth of these cells by inducing G, cell cycle arrest. This effect is mediated by the 5' regulatory region of the cyclin D1 gene and leads to a reduction of cyclin D1 mRNA expression and protein abundance. We show that in AR42J cells the proximal cyclin D1 promoter contains a cis-regulated element, which is important for the maintenance of basal transcriptional activity. This element overlaps the described cAMP-responsive element (CRE) and confers cyclosporine sensitivity to the cyclin D1 promoter. Furthermore, the DNA binding activity of the CRE-binding protein (CREB) decreases through cyclosporine treatment and this is mediated by cyclosporine-induced reduction of CREB steady-state levels. These results demonstrate that cyclosporine can inhibit proliferation of acinar cells by targeting the cyclin D1 promoter at the proximal CRE via a reduction of CREB protein abundance.	Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Ulm, Dept Med Microbiol & Hyg, D-89081 Ulm, Germany	Ulm University; Ulm University	Schmid, RM (corresponding author), Univ Ulm, Dept Internal Med 1, Robert Koch Str 8, D-89081 Ulm, Germany.		Greten, Florian R/AAF-5196-2020; Oswald, Franz/AAO-9584-2020	Greten, Florian R/0000-0002-3928-6080; 				ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; ANDRES D, 2001, BIOCHEM PHARMACOL, V61, P27; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Cardenas ME, 1998, TRENDS BIOTECHNOL, V16, P427, DOI 10.1016/S0167-7799(98)01239-6; Cho-Chung YS, 2000, MOL CELL BIOCHEM, V212, P29, DOI 10.1023/A:1007144618589; CHRISTOPHE J, 1994, AM J PHYSIOL, V266, pG963, DOI 10.1152/ajpgi.1994.266.6.G963; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Esposito C, 2000, KIDNEY INT, V58, P123, DOI 10.1046/j.1523-1755.2000.00147.x; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Florio T, 1996, ENDOCRINOLOGY, V137, P4409, DOI 10.1210/en.137.10.4409; Fukami-Kobayashi J, 1998, EXP CELL RES, V241, P435, DOI 10.1006/excr.1998.4079; Guerini D, 1997, BIOCHEM BIOPH RES CO, V235, P271, DOI 10.1006/bbrc.1997.6802; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HERBER B, 1994, ONCOGENE, V9, P1295; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Karashima T, 1996, J DERMATOL SCI, V12, P246, DOI 10.1016/0923-1811(95)00480-7; Khanna AK, 1999, TRANSPLANTATION, V67, P1262, DOI 10.1097/00007890-199905150-00011; KleinHessling S, 1996, P NATL ACAD SCI USA, V93, P15311, DOI 10.1073/pnas.93.26.15311; Lally C, 1999, KIDNEY INT, V56, P1254, DOI 10.1046/j.1523-1755.1999.00696.x; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LI B, 1991, J EXP MED, V174, P1259, DOI 10.1084/jem.174.5.1259; LOGSDON CD, 1992, AM J PHYSIOL, V262, pG364, DOI 10.1152/ajpgi.1992.262.2.G364; Longoni B, 2001, FASEB J, V15, P731, DOI 10.1096/fj.00-0163com; Medina J, 2000, BIOCHEM PHARMACOL, V59, P1459, DOI 10.1016/S0006-2952(00)00262-8; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; Miracco C, 2000, BRIT J DERMATOL, V143, P950, DOI 10.1046/j.1365-2133.2000.03826.x; Mosieniak G, 1997, J NEUROCHEM, V68, P1142; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; NAIR AP, 1994, NATURE, V19, P239; NICKOLOFF BJ, 1988, AM J PATHOL, V131, P12; Park YG, 2001, BIOCHEM BIOPH RES CO, V281, P1213, DOI 10.1006/bbrc.2001.4521; Perry SS, 1999, CELL TRANSPLANT, V8, P339, DOI 10.1177/096368979900800401; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Pyrzynska B, 2000, J NEUROCHEM, V74, P42, DOI 10.1046/j.1471-4159.2000.0740042.x; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SCHWANINGER M, 1993, N-S ARCH PHARMACOL, V348, P541; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shin GT, 1997, TRANSPL P, V29, P284, DOI 10.1016/S0041-1345(96)00094-2; Siemann G, 1999, MOL PHARMACOL, V55, P1094, DOI 10.1124/mol.55.6.1094; Tavares P, 1998, J CARDIOVASC PHARM, V31, P46, DOI 10.1097/00005344-199801000-00007; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Thommesen L, 2000, J BIOL CHEM, V275, P4244, DOI 10.1074/jbc.275.6.4244; TWENTYMAN PR, 1992, BRIT J CANCER, V65, P335, DOI 10.1038/bjc.1992.68; Vaquero E, 1999, GUT, V45, P269, DOI 10.1136/gut.45.2.269; Wagner M, 2001, GENE DEV, V15, P286, DOI 10.1101/gad.184701; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Zhang LZ, 2001, AM J PHYSIOL-GASTR L, V280, pG1247, DOI 10.1152/ajpgi.2001.280.6.G1247	59	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43599	43607		10.1074/jbc.M204787200	http://dx.doi.org/10.1074/jbc.M204787200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12215435	hybrid			2022-12-25	WOS:000179272000010
J	Torres, VI; Weiss, DS				Torres, VI; Weiss, DS			Identification of a tyrosine in the agonist binding site of the homomeric rho 1 gamma-aminobutyric acid (GABA) receptor that, when mutated, produces spontaneous opening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; A-RECEPTOR; XENOPUS OOCYTES; ALPHA-SUBUNIT; NICOTINIC RECEPTORS; AMINO-ACID; M2 DOMAIN; CHANNEL; LIGAND; ACTIVATION	Mutagenesis of recombinant rho1 gamma-aminobutyric acid (GABA) receptors has previously identified five residues in the amino terminal extracellular domain that play an important role in GABA binding. Here, we present evidence that the tyrosine at position 102 of the rho1 receptor is also associated with the agonist binding site. Wildtype and mutant pl receptors were expressed in Xenopus laevis oocytes and examined using the two-electrode voltage clamp. When Tyr-102 was mutated to cysteine, serine, tryptophan, or glycine the EC50 increased 31-, 214-, 664-, and 8752-fold, respectively. An increase in the IC50 was also observed for the competitive antagonist 3-APMPA, but not for the non-competitive antagonist picrotoxin. Y102C was accessible to modification by methanethiosulfonate, and this modification was prevented by both GABA and 3-APMPA. An interesting characteristic of the Y102S mutant receptor was that, in the absence of GABA, there was an unusually high oocyte resting conductance that was blocked by both 3-APMPA and picrotoxin, indicating spontaneously opening GABA receptors. It appears that mutation of Tyr-102 perturbs the binding site and gates the pore. We conclude that Tyr-102 is a component of the GABA binding domain and speculate that Tyr-102 might be important for coupling agonist binding to channel opening.	Univ Alabama Birmingham, Sch Med, Dept Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Weiss, DS (corresponding author), Univ Alabama Birmingham, Sch Med, Dept Neurobiol, 1719 6th Ave S CIRC 410, Birmingham, AL 35294 USA.	dweiss@nrc.uab.edu	Torres, Viviana/AAC-3329-2019	Torres, Viviana/0000-0002-1220-7709	NINDS NIH HHS [NS36195, NS35291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036195, R01NS035291, R37NS035291] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; AMIN J, 1994, RECEPTOR CHANNEL, V2, P227; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Buhr A, 2001, J BIOL CHEM, V276, P7775, DOI 10.1074/jbc.M008907200; Chang YC, 2000, MOL PHARMACOL, V58, P1375, DOI 10.1124/mol.58.6.1375; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; Chang YC, 1999, NAT NEUROSCI, V2, P219, DOI 10.1038/6313; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; Enz R, 1996, J NEUROSCI, V16, P4479; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; JACKSON MB, 1995, ANNU REV PHYSIOL, V57, P447; KAMMANN M, 1989, NUCLEIC ACIDS RES, V12, P4445; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KUSAMA T, 1993, BRIT J PHARMACOL, V109, P200, DOI 10.1111/j.1476-5381.1993.tb13554.x; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; Newell JG, 2000, J BIOL CHEM, V275, P14198, DOI 10.1074/jbc.275.19.14198; OHNO K, 1995, P NATL ACAD SCI USA, V92, P758, DOI 10.1073/pnas.92.3.758; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Pan ZH, 1997, P NATL ACAD SCI USA, V94, P6490, DOI 10.1073/pnas.94.12.6490; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Thompson SA, 1999, BRIT J PHARMACOL, V127, P1349, DOI 10.1038/sj.bjp.0702687; Wegelius K, 1998, EUR J NEUROSCI, V10, P350, DOI 10.1046/j.1460-9568.1998.00023.x; WOODWARD RM, 1992, MOL PHARMACOL, V42, P165; Wotring VE, 1999, J PHYSIOL-LONDON, V521, P327, DOI 10.1111/j.1469-7793.1999.00327.x; Zhang DX, 2001, TRENDS PHARMACOL SCI, V22, P121, DOI 10.1016/S0165-6147(00)01625-4; ZHANG HG, 1994, J PHYSIOL-LONDON, V479, P65, DOI 10.1113/jphysiol.1994.sp020278; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	39	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43741	43748		10.1074/jbc.M202007200	http://dx.doi.org/10.1074/jbc.M202007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226075	hybrid			2022-12-25	WOS:000179272000028
J	Wang, XH; Krupczak-Hollis, K; Tan, YJ; Dennewitz, MB; Adami, GR; Costa, RH				Wang, XH; Krupczak-Hollis, K; Tan, YJ; Dennewitz, MB; Adami, GR; Costa, RH			Increased hepatic forkhead box M1B (FoxM1B) levels in old-aged mice stimulated liver regeneration through diminished p27(KiP1) protein levels and increased Cdc25B expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR HFH-11B; CELL-CYCLE REGULATION; HEPATOCYTE ENTRY; S-PHASE; GROWTH; HEAD; PHOSPHORYLATION; ENDODERM; LACKING; INJURY	Recent liver regeneration studies indicate that maintaining hepatic Forkhead Box M1B (FoxM1B) expression in 12-month-old (old-aged) Transthyretin-FoxM1B transgenic mice increases hepatocyte proliferation and expression of cell cycle regulatory genes. Because these transgenic CD-1 mice maintain FoxM1B levels during the aging process, we conducted the current study to determine whether adenovirus delivery of the FoxM1B gene (AdFoxM1B) is sufficient to stimulate liver regeneration in old-aged Balb/c mice. Here we show that AdFoxM1B infection of old-aged mice caused a significant increase in FoxM1B expression, hepatocyte DNA replication, and mitosis following partial hepatectomy. This stimulation in hepatocyte S-phase progression was associated with diminished protein expression and perinuclear localization of cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) (p27) protein following partial hepatectomy. In contrast, old-aged mice infected with control virus displayed high hepatocyte levels of p27 protein, which had been localized to the nucleus prior to S-phase. Furthermore, we found that restoring FoxM1B expression did not influence p27 mRNA levels, and this new finding implicates FoxM1B in regulation of p27 protein levels. Likewise, AdFoxM1B-infected regenerating livers displayed elevated S-phase levels of Cdk2 kinase activity compared with old-aged mice infected with control virus. Furthermore, restoring FoxM1B expression in old-aged mice caused elevated levels of Cyclin B1, Cyclin B2, Cdc25B, Cdk1, and p55CDC mRNA as well as stimulating Cdc25B nuclear localization during liver regeneration, all of which are required for mitosis. These studies indicated that an acute delivery of the FoxM1B gene in old-aged mice is sufficient to re-establish proliferation of regenerating hepatocytes, suggesting that FoxM1B can be used for therapeutic intervention to alleviate the reduction in cellular proliferation observed in the elderly.	Univ Illinois, Coll Med & Dent, Dept Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Coll Med & Dent, Dept Oral Med & Diagnost Sci, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Costa, RH (corresponding author), Univ Illinois, Dept Mol Genet MC699, Coll Med, 900 S Ashland Ave,Rm 2220 MBRB, Chicago, IL 60607 USA.				NIDDK NIH HHS [R01 DK 54687-04] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054687] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benihoud K, 2000, J GENE MED, V2, P194, DOI 10.1002/(SICI)1521-2254(200005/06)2:3<194::AID-JGM102>3.0.CO;2-5; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Diehl AM, 2000, IMMUNOL REV, V174, P160, DOI 10.1034/j.1600-0528.2002.017411.x; Duncan SA, 2000, DEV DYNAM, V219, P131, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1051>3.3.CO;2-E; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Kaestner KH, 2000, TRENDS ENDOCRIN MET, V11, P281, DOI 10.1016/S1043-2760(00)00271-X; Kaestner KH, 2000, GENE DEV, V14, P142; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; Rausa FM, 1998, METHODS, V16, P29, DOI 10.1006/meth.1998.0642; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tan YJ, 2002, HEPATOLOGY, V35, P30, DOI 10.1053/jhep.2002.30317; Tan YJ, 2001, GENE EXPRESSION, V9, P237, DOI 10.3727/000000001783992542; Taub R, 1999, SEMIN LIVER DIS, V19, P117, DOI 10.1055/s-2007-1007104; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Trembley JH, 1996, CELL GROWTH DIFFER, V7, P903; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Wang XH, 2001, HEPATOLOGY, V33, P1404, DOI 10.1053/jhep.2001.24666; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zaret K, 1999, DEV BIOL, V209, P1, DOI 10.1006/dbio.1999.9228	39	126	136	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44310	44316		10.1074/jbc.M207510200	http://dx.doi.org/10.1074/jbc.M207510200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221098	hybrid			2022-12-25	WOS:000179272000101
J	Whetstine, JR; Witt, TL; Matherly, LH				Whetstine, JR; Witt, TL; Matherly, LH			The human reduced folate carrier gene is regulated by the AP2 and Sp1 transcription factor families and a functional 61-base pair polymorphism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLYLPOLYGLUTAMATE SYNTHETASE GENE; ACUTE LYMPHOBLASTIC-LEUKEMIA; GAMMA-GLUTAMATE SYNTHETASE; TISSUE-SPECIFIC PROMOTERS; MESSENGER-RNA; 5'-UNTRANSLATED REGION; RESPONSE ELEMENT; RECEPTOR GENE; FOLIC-ACID; CELL LINE	Recently, our laboratory reported an intricate regulation of the human reduced folate carrier (hRFC) gene, involving multiple promoters and noncoding exons. We localized promoter activity to a 452-bp GC-rich region upstream of noncoding exon A, including a 47-bp basal promoter with a CRE/AP-1-like consensus element that bound the bZip family of DNA-binding proteins (e.g. CREB-1 and c -Jun). We now report that three nearly identical tandem repeats (49-61 bp) in the hRFC-A upstream region are involved in regulating promoter activity. By in vitro binding assays, multiple transcription factors (e.g. AP2 and Sp1/Sp3) bound this region. When AP2 was cotransfected with the hRFC-A reporter construct into HT1080 cells, promoter activity increased 3-fold. In Drosophila SL2 cells, Sp1 transactivated promoter A and showed synergism with CREB-1. However, c-Jun was antagonistic to the effects of Sp1. A sequence variant in the hRFC-A repeated region was identified, involving an exact duplication of a 61-bp sequence. This variant had an allelic frequency of 78% in 72 genomic DNAs and resulted in a 63% increase in promoter activity. These results identify important regions in the hRFC-A promoter and critical roles for AP2 and Sp1, in combination with the bZip transcription factors. Moreover, they document a functionally novel polymorphism that increases promoter activity and may contribute to interpatient variations in hRFC expression and effects on tissue folate homeostasis and antitumor response to antifolates.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Pharmacol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Matherly, LH (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, 110 E Warren Ave, Detroit, MI 48201 USA.				NCI NIH HHS [CA53535] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBLE FM, 1998, CURRENT PROTOCOLS MO; Butterworth CE, 1996, ANNU REV NUTR, V16, P73, DOI [10.1146/annurev.nutr.16.1.73, 10.1146/annurev.nu.16.070196.000445]; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; Chen SJ, 1998, GENE, V215, P101, DOI 10.1016/S0378-1119(98)00268-6; Choi SW, 2000, J NUTR, V130, P129, DOI 10.1093/jn/130.2.129; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Elwood PC, 1997, BIOCHEMISTRY-US, V36, P1467, DOI 10.1021/bi962070h; Fiaschi T, 2000, FEBS LETT, V473, P42, DOI 10.1016/S0014-5793(00)01496-4; Fournier B, 2001, J BACTERIOL, V183, P2367, DOI 10.1128/JB.183.7.2367-2371.2001; Gao B, 1997, MOL PHARMACOL, V52, P1019, DOI 10.1124/mol.52.6.1019; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; Gong MK, 1997, BLOOD, V89, P2494, DOI 10.1182/blood.V89.7.2494; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Guo W, 1999, CLIN CANCER RES, V5, P621; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; Ito T, 2002, BIOCHEM BIOPH RES CO, V290, P1048, DOI 10.1006/bbrc.2001.6325; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; Jansen G, 1999, ANTIFOLATE DRUGS CAN, P293; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kocarek TA, 2000, ARCH BIOCHEM BIOPHYS, V376, P180, DOI 10.1006/abbi.2000.1704; Matherly LH, 1996, LEUKEMIA LYMPHOMA, V21, P359, DOI 10.3109/10428199609093433; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; Pullarkat S. T., 2001, Pharmacogenomics Journal, V1, P65; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Roberts SJ, 1997, BIOCHEM J, V326, P439, DOI 10.1042/bj3260439; Roy K, 1996, J BIOL CHEM, V271, P23820, DOI 10.1074/jbc.271.39.23820; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; Serot JM, 2001, J NEURAL TRANSM, V108, P93, DOI 10.1007/s007020170100; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1985, CANCER RES, V45, P3992; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; Sumpio BE, 1997, AM J PHYSIOL-CELL PH, V273, pC1441, DOI 10.1152/ajpcell.1997.273.5.C1441; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Turner FB, 1999, CANCER RES, V59, P6074; Turner FB, 2000, J BIOL CHEM, V275, P35960, DOI 10.1074/jbc.M005228200; Ueland PM, 2001, TRENDS PHARMACOL SCI, V22, P195, DOI 10.1016/S0165-6147(00)01675-8; Whetstine Johnathan R., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P101; Whetstine JR, 2002, BIOCHEM J, V367, P629, DOI 10.1042/BJ20020512; Whetstine JR, 2001, CLIN CANCER RES, V7, P3416; Whetstine JR, 2001, J BIOL CHEM, V276, P6350, DOI 10.1074/jbc.M008074200; Williams FMR, 1998, SOMAT CELL MOLEC GEN, V24, P143, DOI 10.1023/B:SCAM.0000007117.50428.63; Wong SC, 1999, J BIOL CHEM, V274, P10388, DOI 10.1074/jbc.274.15.10388; Wong SC, 1997, BIOCHEM PHARMACOL, V53, P199, DOI 10.1016/S0006-2952(96)00710-1; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401; Zhang L, 1998, CLIN CANCER RES, V4, P2169; Zhang L, 1998, BIOCHEM J, V332, P773, DOI 10.1042/bj3320773	59	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43873	43880		10.1074/jbc.M208296200	http://dx.doi.org/10.1074/jbc.M208296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228234	hybrid			2022-12-25	WOS:000179272000046
J	Wu, ZL; O'Kane, TM; Scott, RW; Savage, MJ; Bozyczko-Coyne, D				Wu, ZL; O'Kane, TM; Scott, RW; Savage, MJ; Bozyczko-Coyne, D			Protein tyrosine phosphatases are up-regulated and participate in cell death induced by polyglutamine expansion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; DUAL-SPECIFICITY PHOSPHATASE; HUNTINGTONS-DISEASE; MOUSE MODEL; GLUTAMINE REPEATS; HEAT-SHOCK; GENE; TOXICITY; NUCLEAR; TRACT	Polyglutamine expansion is the cause of several neuro-degenerative diseases. An in vitro model of polyglutamine-induced neuronal cell death was developed using truncated mutant huntingtin (Htt) and PC12 cells. Cell death was specifically observed in cells expressing a truncated mutant huntingtin-green fluorescence protein (GFP) fusion protein with 118 glutamine repeats (Gln(118)), as demonstrated by the release of lactate dehydrogenase (LDH). To gain further insights into the mechanisms of polyglutamine expansion-induced cell death, the Affymetrix rat genome array U34A was used to investigate gene expression changes associated with polyglutamine-mediated protein aggregation and cell death. Among the up-regulated genes, the increase of four protein tyrosine phosphatases (PTPs) was further confirmed by real-time quantitative reverse transcription PCR Protein expression of mitogen activated protein (MAP) kinase phosphatase 1 (MKP1) was also increased as demonstrated by Western blot. Furthermore, phosphorylation of MAP kinase extracellular signal-regulated kinase 1/2 (ERK1/2) was substantially reduced in association with protein aggregation, and two general PTP inhibitors, sodium orthovanadate and bpV(pic), dramatically rescued the cells from polyglutamine-induced cell death. These results suggest that one or more of the PTPs are involved in the polyglutamine-induced cell death.	Cephalon Inc, W Chester, PA 19380 USA	Teva Pharmaceutical Industries; Cephalon Inc.	Wu, ZL (corresponding author), Cephalon Inc, 145 Brandywine Pkwy, W Chester, PA 19380 USA.							Bozyczko-Coyne D, 2001, J NEUROCHEM, V77, P849, DOI 10.1046/j.1471-4159.2001.00294.x; Cao LG, 1998, J BIOL CHEM, V273, P21077, DOI 10.1074/jbc.273.33.21077; Carter RJ, 1999, J NEUROSCI, V19, P3248; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Iannicola C, 2000, J NEUROCHEM, V75, P830, DOI 10.1046/j.1471-4159.2000.0750830.x; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Lunkes A, 1998, HUM MOL GENET, V7, P1355, DOI 10.1093/hmg/7.9.1355; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Moulder KL, 1999, J NEUROSCI, V19, P705; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Seta KA, 2001, J BIOL CHEM, V276, P44405, DOI 10.1074/jbc.M103346200; Song C, 2002, J BIOL CHEM, V277, P6703, DOI 10.1074/jbc.M110338200; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	29	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44208	44213		10.1074/jbc.M206890200	http://dx.doi.org/10.1074/jbc.M206890200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226089	hybrid			2022-12-25	WOS:000179272000088
J	Zhao, MJ; Tang, D; Lechpammer, S; Hoffman, A; Asea, A; Stevenson, MA; Calderwood, SK				Zhao, MJ; Tang, D; Lechpammer, S; Hoffman, A; Asea, A; Stevenson, MA; Calderwood, SK			Double-stranded RNA-dependent protein kinase (pkr) is essential for thermotolerance, accumulation of HSP70, and stabilization of ARE-containing HSP70 mRNA during stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK FACTOR; AU-RICH ELEMENTS; TRANSCRIPTIONAL ACTIVATION; BINDING-PROTEINS; C-FOS; GENE; EXPRESSION; STABILITY; FACTOR-1; DESTABILIZATION	We have investigated the role of the double-stranded RNA-dependent protein kinase gene (pkr) in the regulation of the heat shock response. We show that the pkr gene is essential for efficient activation of the heat shock response and that pkr disruption profoundly inhibits heat shock protein 70 (HSP70) synthesis and blocks the development of thermotolerance. Despite these profound effects, pkr disruption did not markedly affect the activation of heat shock factor 1 by heat and did not reduce the rate of transcription of the HSP70 gene after heat shock. However, despite the lack of effect of pkr disruption on HSP70 gene transcription, we found a significant decrease in the expression of HSP70 mRNA in pkr-/- cells after heat shock. Kinetic studies of mRNA turnover suggested a block in the thermal stabilization of HSP70 mRNA in pkr-/- cells. As the thermal stabilization of HSP70 mRNA is thought to involve cis-acting A+U rich (ARE) elements in the 3'-untranslated region (UTR), we examined a potential role for pkr in this process. We found that a reporter beta-galactosidase mRNA destabilized by introduction of a functional ARE into the 3'-UTR became stabilized by heat but only in cells containing an intact pkr gene. Our studies suggest therefore that pkr plays a significant role in the stabilization of mRNA species containing ARE destruction sequences in the 3'-UTR and through this mechanism, contributes to the regulation of the heat shock response and other processes.	Boston Univ, Sch Med, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02115 USA; CALTECH, Pasadena, CA 91125 USA	Boston University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; California Institute of Technology	Calderwood, SK (corresponding author), Boston Med Ctr, Ctr Mol Stress Response, 88 E Newton St,E645, Boston, MA 02118 USA.	stuart_calderwood@medicine.bu.edu	Asea, Alexzander/X-6432-2019; Asea, Alexzander A/I-4112-2013	Asea, Alexzander A/0000-0003-3592-3481	NATIONAL CANCER INSTITUTE [R01CA077465, R01CA047407, R01CA083890] Funding Source: NIH RePORTER; NCI NIH HHS [CA47407-11, CA83890-01, CA77465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Bruce JL, 1999, CELL STRESS CHAPERON, V4, P36, DOI 10.1054/csac.1999.0005; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; HICKEY E, 1982, HEAT SHOCK BACTERIA, P199; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; LaGrandeur TE, 1998, EMBO J, V17, P1487, DOI 10.1093/emboj/17.5.1487; Lai WS, 1999, MOL CELL BIOL, V19, P4311; LAROIA G, SCIENCE, V284, P498; Lechpammer S, 2002, INT J HYPERTHER, V18, P203, DOI 10.1080/02656730110110034; LI GC, 1982, INT J RADIAT ONCOL, V8, P63, DOI 10.1016/0360-3016(82)90386-8; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Melville MW, 1999, J BIOL CHEM, V274, P3797, DOI 10.1074/jbc.274.6.3797; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MOORE M, 1987, MOL CELL BIOL, V7, P4505, DOI 10.1128/MCB.7.12.4505; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MOSELEY PL, 1993, AM J PHYSIOL, V264, pL533, DOI 10.1152/ajplung.1993.264.6.L533; PETERSEN RB, 1989, CELL REGUL, V1, P135, DOI 10.1091/mbc.1.1.135; PRICE BD, 1992, J CELL PHYSIOL, V153, P392, DOI 10.1002/jcp.1041530219; Proud CG, 2001, ESSAYS BIOCHEM, V37, P97, DOI 10.1042/bse0370097; Quijada L, 2000, MOL BIOCHEM PARASIT, V110, P79, DOI 10.1016/S0166-6851(00)00258-9; SCHLESINGER MJ, 1994, PEDIATR RES, V36, P1; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIMCOX AA, 1985, MOL CELL BIOL, V5, P3397, DOI 10.1128/MCB.5.12.3397; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SUBJECK JR, 1982, HEAT SHOCK BACTERIA, P405; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; Wang ZR, 2000, MOL CELL BIOL, V20, P6334, DOI 10.1128/MCB.20.17.6334-6341.2000; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; Wilson GM, 2001, J BIOL CHEM, V276, P44450, DOI 10.1074/jbc.M108521200; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; YOST HJ, 1990, TRENDS GENET, V6, P223, DOI 10.1016/0168-9525(90)90183-7; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	45	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44539	44547		10.1074/jbc.M208408200	http://dx.doi.org/10.1074/jbc.M208408200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12207033	hybrid, Green Accepted			2022-12-25	WOS:000179272000126
J	Okada, Y; Yamada, S; Toyoshima, M; Dong, J; Nakajima, M; Sugahara, K				Okada, Y; Yamada, S; Toyoshima, M; Dong, J; Nakajima, M; Sugahara, K			Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis - Hierarchical sulfate groups with differential effects and the essential target disulfated trisaccharide sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE INTESTINAL HEPARIN; SUBSTRATE-SPECIFICITY; CELL-SURFACE; MACROMOLECULAR HEPARIN; MAMMALIAN HEPARANASE; MOUSE MASTOCYTOMA; GENE-EXPRESSION; PURIFICATION; TETRASACCHARIDES; PROTEOGLYCANS	Human heparanase is an endo-beta-D-glucuronidase that degrades heparan sulfate/heparin and has been implicated in a variety of biological processes, such as inflammation, tumor angiogenesis, and metastasis. Although the cloned enzyme has been demonstrated to have a critical role in tumor metastasis, the substrate specificity has been poorly understood. In the present study, the specificity of the purified recombinant human heparanase was investigated for the first time using a series of structurally defined oligosaccharides isolated from heparin/heparan sulfate. The best substrates were DeltaHexUA(+/-2S)-GlcN(NS,6S)-GIcUA-GlcN(NS,6S)-GlcUA-GlcN(NS,6S) and DeltaHexUA(2S)-GlcN(NS,6S)-GIcUA-GlcN(NS,6S) (where DeltaHexUA, GlcN, GlcUA NS, 2S, and 6S represent unsaturated hexuronic acid, D-glucosamine, D-glucuronic acid, 2-N-sulfate, 2-O-sulfate, and 6-O-disulfate, respectively). Based on the percentage conversion of the substrates to products under identical assay conditions, several aspects of the recognition structures were revealed. 1) The minimum recognition backbone is the trisaccharide GlcN-GlcUA-GlcN. 2) The target GlcUA residues are in the sulfated region. 3) The -GlcN(6S)-GlcUA-GlcN(NS)-sequence is essential but not sufficient as the cleavage site. 4) The IdoUA(2S) residue, located two saccharides away from the target GlcUA residue, claimed previously to be essential, is not indispensable. 5) The 3-O-sulfate group on the GlcN is dispensable and even has an inhibitory effect when located in a highly sulfated region. 6) Based on these and previous results, HexUA(2S)-GlcN(NS,6S)-ldoUA-GlcNAc(6S)GlcUA-GlcN(NS, 6S)-ldoUA(2S)-GlcN(NS,6S) (where HexUA represents hexuronic acid) has been proposed as a probable physioloGlcal target octasaccharide sequence. These findings will aid establishing a quantitative assay method using the above tetrasaccharide and designing heparan sulfate-based specific inhibitors of the heparanase for new therapeutic strategies.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Novartis Pharma KK, Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan	Kobe Pharmaceutical University; Novartis	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan.							Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172; Bame KJ, 2000, GLYCOBIOLOGY, V10, P715, DOI 10.1093/glycob/10.7.715; Bame KJ, 1998, BIOCHEM J, V336, P191, DOI 10.1042/bj3360191; Bame KJ, 2001, GLYCOBIOLOGY, V11, p91R, DOI 10.1093/glycob/11.6.91R; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brickman YG, 1998, GLYCOBIOLOGY, V8, P463, DOI 10.1093/glycob/8.5.463; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Chuang WL, 2000, BIOCHEMISTRY-US, V39, P3542, DOI 10.1021/bi9926025; CONRAD HE, 1998, HEPARIN BINDING PROT, P301; DAVID G, 1991, BIOCHEM SOC T, V19, P816, DOI 10.1042/bst0190816; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; Erickson AC, 2000, J HISTOCHEM CYTOCHEM, V48, P1291, DOI 10.1177/002215540004801001; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Gohji K, 2001, J UROLOGY, V166, P1286, DOI 10.1016/S0022-5347(05)65754-0; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; JACOBSSON KG, 1987, BIOCHEM J, V246, P409, DOI 10.1042/bj2460409; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Lindahl U., 1989, HEPARIN, P159; LINKER A, 1984, CARBOHYD RES, V127, P75, DOI 10.1016/0008-6215(84)85107-1; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; Mikami S, 2001, JPN J CANCER RES, V92, P1062, DOI 10.1111/j.1349-7006.2001.tb01061.x; NADER HB, 1990, J BIOL CHEM, V265, P16807; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OGREN S, 1976, BIOCHEM J, V154, P605; OGREN S, 1975, J BIOL CHEM, V250, P2690; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; OLDBERG A, 1990, BIOCHEM SOC T, V18, P789, DOI 10.1042/bst0180789; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Podyma-Inoue KA, 2002, J BIOL CHEM, V277, P32459, DOI 10.1074/jbc.M203282200; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Sanderson RD, 2001, SEMIN CELL DEV BIOL, V12, P89, DOI 10.1006/scdb.2000.0241; Stringer SE, 1997, INT J BIOCHEM CELL B, V29, P709, DOI 10.1016/S1357-2725(96)00170-7; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; THUNBERG L, 1982, J BIOL CHEM, V257, P278; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Tsuda H, 1996, J BIOL CHEM, V271, P10495, DOI 10.1074/jbc.271.18.10495; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; Uno F, 2001, CANCER RES, V61, P7855; VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Yamada S, 1998, J BIOL CHEM, V273, P1863, DOI 10.1074/jbc.273.4.1863; Yamada S, 1999, BIOCHEMISTRY-US, V38, P838, DOI 10.1021/bi981889n; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; Yamada SH, 1998, TRENDS GLYCOSCI GLYC, V10, P95, DOI 10.4052/tigg.10.95; YAMADA SH, 1993, J BIOL CHEM, V268, P4780	64	116	118	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42488	42495		10.1074/jbc.M206510200	http://dx.doi.org/10.1074/jbc.M206510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12213822	hybrid			2022-12-25	WOS:000179081200010
J	Sigurdsson, S; Van Komen, S; Petukhovan, G; Sung, P				Sigurdsson, S; Van Komen, S; Petukhovan, G; Sung, P			Homologous DNA pairing by human recombination factors Rad51 and Rad54	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; YEAST RAD51; PROTEIN; EXCHANGE; MOUSE	Human Rad51 (hRad51) and Rad54 proteins are key members of the RAD52 group required for homologous recombination. We show an ability of hRad54 to promote transient separation of the strands in duplex DNA via its ATP hydrolysis-driven DNA supercoiling function. The ATPase, DNA supercoiling, and DNA strand opening activities of hRad54 are greatly stimulated through an interaction with hRad51. Importantly, we demonstrate that hRad51 and hRad54 functionally cooperate in the homologous DNA pairing reaction that forms recombination DNA intermediates. Our results should provide a biochemical model for dissecting the role of hRad51 and hRad54 in recombination reactions in human cells.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78254 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78254 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Sung, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 7703 Floyd Curl Dr, San Antonio, TX 78254 USA.	sung@uthscsa.edu	Sigurdsson, Stefan/L-9820-2015	Sigurdsson, Stefan/0000-0002-5284-0058	NATIONAL CANCER INSTITUTE [P01CA081020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000165] Funding Source: NIH RePORTER; NCI NIH HHS [CA81020] Funding Source: Medline; NIA NIH HHS [T32AG00165] Funding Source: Medline; NIGMS NIH HHS [GM57814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BIANCO PR, 1998, FRONT BIOSCI, V3, pD580; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; Morrison C, 1999, MOL CELL BIOL, V19, P6891; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; SHIBATA T, 1982, J BIOL CHEM, V257, P3981; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Stark JM, 2002, J BIOL CHEM, V277, P20185, DOI 10.1074/jbc.M112132200; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	30	108	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42790	42794		10.1074/jbc.M208004200	http://dx.doi.org/10.1074/jbc.M208004200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12205100	hybrid			2022-12-25	WOS:000179081200049
J	Szaszi, K; Paulsen, A; Szabo, EZ; Numata, M; Grinstein, S; Orlowski, J				Szaszi, K; Paulsen, A; Szabo, EZ; Numata, M; Grinstein, S; Orlowski, J			Clathrin-mediated endocytosis and recycling of the neuron-specific Na+/H+ exchanger NHE5 isoform - Regulation by phosphatidylinositol 3 '-kinase and the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; PROTEIN-KINASE-A; CULTURED HIPPOCAMPAL-NEURONS; INTRACELLULAR PH; MAMMALIAN-CELLS; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; EXTRACELLULAR PH; HUMAN BRAIN; TRANSFERRIN RECEPTORS	Mammalian Na+/H+ exchangers (NHEs) are a family of integral membrane proteins that play central roles in sodium, acid-base, and cell volume homeostasis. The recently cloned NHE5 isoform is expressed predominantly in brain, but its functional and cellular properties are poorly understood. To facilitate its characterization, an epitope-tagged construct of NHE5 was ectopically expressed in nonneuronal and neuronal cells. In NHE-deficient Chinese hamster ovary AP-1 cells, NHE5 localized at the plasmalemma, but a significant fraction accumulated intracellularly in vesicles that concentrated in a juxtanuclear region. Similarly, in nerve growth factor-differentiated neuroendocrine PC12 cells and primary hippocampal neurons, immunolabeling of NHE5 was detected in endomembrane vesicles in the perinuclear region of the cell body but also along the processes. More detailed characterization in AP-1 cells using organelle-specific markers showed that NHE5 colocalized with internalized transferrin, a marker of recycling endosomes. Transient transfection of a dominant negative mutant of dynamin-1, which inhibits clathrin-mediated endocytosis, blocked uptake of transferrin as well as internalization of NHE5. Likewise, wortmannin inhibition of phosphatidylinositol X-kinase, a lipid kinase implicated in endosomal traffic, induced coalescence of vesicles containing NHE5 and caused a pronounced inhibition of plasmalemmal Na+/H+ exchange. By contrast, disruption of the F-actin cytoskeleton with cytochalasin D increased cell surface NHE5 activity and abundance. These observations demonstrate that NHE5 is localized to the recycling endosomal pathway and is dynamically regulated by phosphatidylinositol 3'-kinase and by the state of F-actin assembly.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; Hosp Sick Children, Res Inst, Cell Biol Programme, Toronto, ON M5G 1X8, Canada	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Orlowski, J (corresponding author), McGill Univ, Dept Physiol, McIntyre Med Sci Bldg,3655 Promenade Sri William, Montreal, PQ H3G 1Y6, Canada.		Szaszi, Katalin/J-7522-2012	Szaszi, Katalin/0000-0002-2490-8422; Orlowski, John/0000-0001-7371-175X	Canadian Institutes of Health Research [37401] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Attaphitaya S, 1999, J BIOL CHEM, V274, P4383, DOI 10.1074/jbc.274.7.4383; Attaphitaya S, 2001, AM J PHYSIOL-CELL PH, V281, pC1146, DOI 10.1152/ajpcell.2001.281.4.C1146; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; Baird NR, 1999, J BIOL CHEM, V274, P4377, DOI 10.1074/jbc.274.7.4377; Bell SM, 1999, AM J PHYSIOL-CELL PH, V276, pC788, DOI 10.1152/ajpcell.1999.276.4.C788; BIEMESDERFER D, 1997, AM J PHYSIOL, V273, P289; Bondarenko A, 2001, GLIA, V34, P134, DOI 10.1002/glia.1048; CAMERON IL, 1993, CELL BIOL INT, V17, P93, DOI 10.1006/cbir.1993.1009; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; Chavez RA, 1996, J CELL BIOL, V133, P1177, DOI 10.1083/jcb.133.6.1177; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chow CW, 1999, J BIOL CHEM, V274, P37551, DOI 10.1074/jbc.274.53.37551; Church J, 1998, J PHYSIOL-LONDON, V511, P119, DOI 10.1111/j.1469-7793.1998.119bi.x; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deitmer JW, 1996, PROG NEUROBIOL, V48, P73, DOI 10.1016/0301-0082(95)00039-9; DeVries SH, 2001, NEURON, V32, P1107, DOI 10.1016/S0896-6273(01)00535-9; Douglas RM, 2001, NEUROSCIENCE, V102, P217, DOI 10.1016/S0306-4522(00)00473-5; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Gu XQ, 2001, AM J PHYSIOL-CELL PH, V281, pC496, DOI 10.1152/ajpcell.2001.281.2.C496; HAVENGA MJE, 1994, MOL BRAIN RES, V25, P97, DOI 10.1016/0169-328X(94)90283-6; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; Horikawa N, 2001, PHARMACOLOGY, V63, P76, DOI 10.1159/000056116; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; Jess TJ, 1996, CELL SIGNAL, V8, P297, DOI 10.1016/0898-6568(96)00054-X; Kempski O, 2001, SEMIN NEPHROL, V21, P303, DOI 10.1053/snep.2001.21665; Kempski O, 1990, Adv Neurol, V52, P39; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Kiwull-Schone H, 2001, AM J RESP CRIT CARE, V164, P1303, DOI 10.1164/ajrccm.164.7.2010147; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; KOBAYASHI S, 1994, J NEUROSCI, V14, P6266; KRISHTAL OA, 1987, BRAIN RES, V436, P352, DOI 10.1016/0006-8993(87)91678-7; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Li PA, 1997, ACTA PHYSIOL SCAND, V161, P567, DOI 10.1046/j.1365-201X.1997.00264.x; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; Ma E, 1997, NEUROSCIENCE, V79, P591, DOI 10.1016/S0306-4522(96)00674-4; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Miyazaki E, 2001, J BIOL CHEM, V276, P49221, DOI 10.1074/jbc.M106267200; MORIMOTO T, 1995, NEURON, V15, P689, DOI 10.1016/0896-6273(95)90156-6; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Putnam RW, 2001, RESP PHYSIOL, V129, P37, DOI 10.1016/S0034-5687(01)00281-X; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; Ransom BR, 2000, PROG BRAIN RES, V125, P217; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Szabo EZ, 2000, J BIOL CHEM, V275, P6302, DOI 10.1074/jbc.275.9.6302; Szaszi K, 2000, J BIOL CHEM, V275, P28599, DOI 10.1074/jbc.M001193200; Szaszi K, 2001, J BIOL CHEM, V276, P40761, DOI 10.1074/jbc.M106724200; Takahashi KI, 1996, NEUROSCI RES, V24, P109, DOI 10.1016/0168-0102(95)00989-2; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Tombaugh GC, 1996, J PHYSIOL-LONDON, V493, P719, DOI 10.1113/jphysiol.1996.sp021417; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; VANDYKE RW, 1995, AM J PHYSIOL-CELL PH, V269, pC943, DOI 10.1152/ajpcell.1995.269.4.C943; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang T, 2001, AM J PHYSIOL-RENAL, V281, pF1117, DOI 10.1152/ajprenal.2001.281.6.F1117; Wheeler DG, 2001, J BIOL CHEM, V276, P31978, DOI 10.1074/jbc.M103667200; Wiemann M, 2001, RESP PHYSIOL, V129, P57, DOI 10.1016/S0034-5687(01)00282-1; Wiemann M, 1999, PFLUG ARCH EUR J PHY, V438, P255, DOI 10.1007/s004240050907; Wilson JM, 1997, J CELL BIOL, V136, P319, DOI 10.1083/jcb.136.2.319; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yip JW, 1997, J BIOL CHEM, V272, P18473, DOI 10.1074/jbc.272.29.18473; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; Zhai J, 1998, PFLUG ARCH EUR J PHY, V435, P539, DOI 10.1007/s004240050550; Zizak M, 1999, J BIOL CHEM, V274, P24753, DOI 10.1074/jbc.274.35.24753	86	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42623	42632		10.1074/jbc.M206629200	http://dx.doi.org/10.1074/jbc.M206629200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12205089	hybrid			2022-12-25	WOS:000179081200026
J	McMahon, B; Mitchell, D; Shattock, R; Martin, F; Brady, HR; Godson, C				McMahon, B; Mitchell, D; Shattock, R; Martin, F; Brady, HR; Godson, C			Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation	FASEB JOURNAL			English	Article						eicosanoids; GPCR; RTK; transactivation	ACTIVATED PROTEIN-KINASE; GROWTH; A(4); B-4; IDENTIFICATION; NEUTROPHILS; INHIBITION; ROLES; RAS	The lipoxygenase-derived leukotrienes (LTs) are important proinflammatory lipid mediators. Lipoxins (LXs), more recently described lipoxygenase products, modulate many proinflammatory actions of LTs and have impressive proresolution properties. Mesangial cell (MC) proliferation is a central event in the pathogenesis of glomerulonephritis. LTD4-induced proliferation of mesangial cells is modulated by LXA(4). Here, we demonstrate that LXA(4) inhibits PDGF- and LTD4-stimulated proliferation through modulation of platelet-derived growth factor receptor beta (PDGFRbeta) activation. Specifically, we demonstrate that LTD4 transactivates the PDGFRbeta, a process associated with c-src recruitment and ras activation. We demonstrate expression of cysLT(1) and cysLT(2) receptors in MCs. LTD4-induced c-src activation was insensitive to pertussis toxin and the cysLT(1) receptor antagonist Zafirlukast but was blocked by the nonselective antagonist Pobilukast. We show that LXA(4) inhibits LTD4-stimulated activation of the PDGFRbeta and that LXA(4) modulates PDGF-BB-stimulated tyrosine phosphorylation of the PDGFRbeta and subsequent mitogenic events. Furthermore, expression of recombinant LXA(4) receptor (ALXR) in CHOK1 cells was associated with an attenuation of serum-stimulated proliferation. These data demonstrate that LXA(4) receptor (ALXR) activation is accompanied by antimitogenic effects coupled with inactivation of growth factor receptors, highlighting the complex cross-talk between G protein-coupled receptors and receptor tyrosine kinases in an inflammatory milieu. These data elaborate on the profile of cell signaling events that underpin the anti-inflammatory and proresolution bioactions of LX.	Univ Coll Dublin, Dept Med & Therapeut, Dublin 7, Ireland; Mater Misericordiae Univ Hosp, Dept Med & Therapeut, Ctr Mol Inflammat & Vasc Res, Dublin 7, Ireland; Univ Coll Dublin, Dept Pharmacol, Dublin 7, Ireland; Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 7, Ireland; Dublin Mol Med Ctr, Dublin, Ireland	University College Dublin; Mater Misericordiae University Hospital; University College Dublin; University College Dublin; University College Dublin; Trinity College Dublin; University College Dublin	Godson, C (corresponding author), Univ Coll Dublin, Dept Med & Therapeut, 41 Eccles St, Dublin 7, Ireland.	cgodson@mater.ie		Godson, Catherine/0000-0003-0655-1041				BADR KF, 1989, P NATL ACAD SCI USA, V86, P3438, DOI 10.1073/pnas.86.9.3438; BADR KF, 1992, J AM SOC NEPHROL, V3, P907; BADR KF, 1988, J CLIN INVEST, V81, P1702, DOI 10.1172/JCI113509; BARNETT R, 1986, AM J PHYSIOL, V250, pF838, DOI 10.1152/ajprenal.1986.250.5.F838; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Bokemeyer D, 2000, KIDNEY INT, V58, P549, DOI 10.1046/j.1523-1755.2000.t01-1-00201.x; BRADY HR, 1990, AM J PHYSIOL, V259, pF809, DOI 10.1152/ajprenal.1990.259.5.F809; Chiang N, 1999, J CLIN INVEST, V104, P309, DOI 10.1172/JCI7016; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Gilbert RE, 2001, KIDNEY INT, V59, P1324, DOI 10.1046/j.1523-1755.2001.0590041324.x; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Grewal JS, 2001, J BIOL CHEM, V276, P27335, DOI 10.1074/jbc.M103578200; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Harris RC, 2000, KIDNEY INT, V58, P898, DOI 10.1046/j.1523-1755.2000.00240.x; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; KATOH T, 1993, J CLIN INVEST, V91, P1507, DOI 10.1172/JCI116356; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; LEE TH, 1991, BIOCHEM BIOPH RES CO, V180, P1416, DOI 10.1016/S0006-291X(05)81354-3; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Lynch KR, 1999, NATURE, V399, P789; McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5; McMahon B, 2000, J BIOL CHEM, V275, P27566; Mene P, 2001, J NEPHROL, V14, P198; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; Papayianni A, 1996, J IMMUNOL, V156, P2264; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; SASAKI S, 1994, EXP NEPHROL, V2, P269; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; WU SH, 1994, IMMUNOPHARMACOLOGY, V28, P125, DOI 10.1016/0162-3109(94)90028-0	38	108	116	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1817	+		10.1096/fj.02-0416fje	http://dx.doi.org/10.1096/fj.02-0416fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223454				2022-12-25	WOS:000181189100008
J	Black, EJ; Walker, M; Clark, W; MacLaren, A; Gillespie, DAF				Black, EJ; Walker, M; Clark, W; MacLaren, A; Gillespie, DAF			Cell transformation by v-Jun deactivates ERK MAP kinase signalling	ONCOGENE			English	Article						v-Jun; MAP kinase; autocrine; transformation	ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; GROWTH-FACTOR; CYCLE ARREST; RAS; EXPRESSION; PROLIFERATION; FIBROBLASTS; ENTRY; GENE	Previous studies have shown that v-Jun accelerates G1 progression and enables cells to sustain S phase entry in the absence of serum growth factors. Since growth factor-dependent ERK MAP kinase signalling plays an important role in regulating the G1/S transition, we investigated whether aberrant ERK regulation might contribute to cell cycle deregulation by v-Jun. Contrary to expectation, we find that cells transformed by v-Jun exhibit a profound reduction in the basal level of active, dual-phosphorylated ERK. In addition, ERK becomes refractory to stimulation by a subset of agonists including serum, LPA, and EGF, but remains partially responsive to the phorbol ester, TPA. Biochemical analysis indicates that these defects are attributable to a combination of inefficient signal propagation between Ras and Raf within the ERK pathway and increased tonic deactivation by MAP kinase phosphatases. Taken together, these results demonstrate that cell transformation by v-Jun induces alterations in cell physiology which antagonize ERK signalling at multiple levels. The potential significance of this phenotype for oncogenesis by v-Jun is discussed.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Canc Res UK Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	University of Glasgow; Beatson Institute	Gillespie, DAF (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.		Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Black EJ, 2000, CURR BIOL, V10, P1119, DOI 10.1016/S0960-9822(00)00699-0; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Clark W, 1997, CELL GROWTH DIFFER, V8, P371; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kilbey A, 1996, ONCOGENE, V12, P2409; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MacLaren A, 2000, ONCOGENE, V19, P5906, DOI 10.1038/sj.onc.1203954; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; SU HY, 1991, ONCOGENE, V6, P1759; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Treinies I, 1999, MOL CELL BIOL, V19, P321; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	31	15	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6540	6548		10.1038/sj.onc.1205851	http://dx.doi.org/10.1038/sj.onc.1205851			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226757				2022-12-25	WOS:000177925300014
J	Knockaert, M; Lenormand, P; Gray, N; Schultz, P; Pouyssegur, J; Meijer, L				Knockaert, M; Lenormand, P; Gray, N; Schultz, P; Pouyssegur, J; Meijer, L			p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol	ONCOGENE			English	Article						kinases; inhibitors; CDKs; MAPK; erk; purvalanol	CYCLIN-DEPENDENT KINASE; ACTIVATED PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE-3-BETA; P70 S6 KINASE; CELL-CYCLE; NUCLEAR TRANSLOCATION; CHEMICAL INHIBITORS; SELECTIVE INHIBITOR; ALZHEIMERS-DISEASE; CRYSTAL-STRUCTURE	Chemical inhibitors of cyclin-dependent kinases (CDKs) have a great therapeutic potential against various proliferative and neurodegenerative disorders. Intensive screening of a combinatorial chemistry library of 2,6,9-trisubstituted purines has led to the identification of purvalanol, one of the most potent and selective CDK inhibitors to date. In preliminary studies, this compound demonstrates definite anti-mitotic properties, consistent with its nanomolar range efficiency towards purified CDK1 and CDK2. However, the actual intracellular targets of purvalanol remain to be identified, and a method for the determination of its in vivo selectivity was developed. In this technique, cell extracts were screened for purvalanol-interacting proteins by affinity chromatography on immobilized inhibitor. In addition to CDK1, p42/p44 MAPK were found to be two major purvalanol-interacting proteins in five different mammalian cell lines (CCL39, PC12, HBL100, MCF-7 and Jurkat cells), suggesting the generality of the purvalanol/p42/p44 MAPK interaction. The Chinese hamster lung fibroblast cell line CCL39 was used as a model to investigate the anti-proliferative properties of purvalanol. The compound inhibited cell growth with a GI(50) value of 2.5 muM and induced a G2/M block when added to exponentially growing cells. It did not appear to trigger massive activation of caspase. We next tested whether CDKs and p42/p44 MAPK were actually targeted by the compound in vivo. p42/p44 MAPK activity was visuatized using an Elk-Gal4 luciferase reporter system and CDK1 activity was detected by the phosphonucleolin level. When cells were treated with purvalanol, p42/p44 MAPK and CDK1 activities were inhibited in a dose-dependent manner. Furthermore, purvalanol inhibited the nuclear accumulation of p42/p44 MAPK, an event dependent on the catalytic activity of these kinases. We conclude that the anti-proliferative properties of purvalanol are mediated by inhibition of both p42/p44 MAPK and CDKs. These observations highlight the potency of moderate selectivity compounds and encourage the search for new therapeutics which simultaneously target distinct but relevant pathways of cell proliferation.	CNRS, Stn Biol Roscoff, F-29682 Roscoff, France; Ctr Antoine Lacassagne, UNSA, CNRS, UMR 6453, F-06189 Nice, France; Novartis Inst Funct Genom, San Diego, CA 92121 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; Novartis	Meijer, L (corresponding author), CNRS, Stn Biol Roscoff, BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr	Lenormand, Philippe/N-5996-2018	, laurent/0000-0003-3511-4916				Arris CE, 2000, J MED CHEM, V43, P2797, DOI 10.1021/jm990628o; Barvian M, 2000, J MED CHEM, V43, P4606, DOI 10.1021/jm000271k; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Brooks EE, 1997, J BIOL CHEM, V272, P29207, DOI 10.1074/jbc.272.46.29207; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Carini DJ, 2001, BIOORG MED CHEM LETT, V11, P2209, DOI 10.1016/S0960-894X(01)00416-4; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Clare PM, 2001, J BIOL CHEM, V276, P48292, DOI 10.1074/jbc.M102034200; Damiens E, 2000, PATHOL BIOL, V48, P340; Davis ST, 2001, SCIENCE, V291, P134, DOI 10.1126/science.291.5501.134; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Dranovsky A, 2001, NEUROBIOL AGING, V22, P517, DOI 10.1016/S0197-4580(00)00248-7; Dreyer MK, 2001, J MED CHEM, V44, P524, DOI 10.1021/jm001043t; DUNPHY WG, 1997, METHOD ENZYMOL, V283, P1; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Fischer PM, 2000, CURR MED CHEM, V7, P1213, DOI 10.2174/0929867003374048; Fry DW, 2001, J BIOL CHEM, V276, P16617, DOI 10.1074/jbc.M008867200; Garrett MD, 1999, CURR OPIN GENET DEV, V9, P104, DOI 10.1016/S0959-437X(99)80015-X; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gray N, 1999, CURR MED CHEM, V6, P859; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Hardcastle IR, 2002, ANNU REV PHARMACOL, V42, P325, DOI 10.1146/annurev.pharmtox.42.090601.125940; Herrera R, 2002, TRENDS MOL MED, V8, pS27, DOI 10.1016/S1471-4914(02)02307-9; HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jeong HW, 2000, BIOORG MED CHEM LETT, V10, P1819, DOI 10.1016/S0960-894X(00)00357-7; Kaiser A, 2001, ARCH BIOCHEM BIOPHYS, V386, P179, DOI 10.1006/abbi.2000.2220; Kaubisch A, 2000, CANCER J, V6, P192; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; Kent LL, 1999, BIOCHEM BIOPH RES CO, V260, P768, DOI 10.1006/bbrc.1999.0891; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; Knockaert M, 2002, J BIOL CHEM, V277, P25493, DOI 10.1074/jbc.M202651200; KNOCKAERT M, 2002, IN PRESS TRENDS PHAR; Lane ME, 2001, CANCER RES, V61, P6170; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Legraverend M, 2000, J MED CHEM, V43, P1282, DOI 10.1021/jm9911130; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Leost M, 2000, EUR J BIOCHEM, V267, P5983, DOI 10.1046/j.1432-1327.2000.01673.x; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Malumbres M, 2000, BIOL CHEM, V381, P827, DOI 10.1515/BC.2000.105; Mani S, 2000, EXPERT OPIN INV DRUG, V9, P1849, DOI 10.1517/13543784.9.8.1849; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Meijer L, 2000, DRUG RESIST UPDATE, V3, P83, DOI 10.1054/drup.2000.0129; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NEANT I, 1988, EXP CELL RES, V176, P68, DOI 10.1016/0014-4827(88)90121-8; Nugiel DA, 2001, J MED CHEM, V44, P1334, DOI 10.1021/jm0100032; Oikonomakos NG, 2000, J BIOL CHEM, V275, P34566, DOI 10.1074/jbc.M004485200; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Park SG, 1996, MOL CELLS, V6, P679; PARKER CW, 1986, PHYTOCHEMISTRY, V25, P303, DOI 10.1016/S0031-9422(00)85471-0; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; RIALET V, 1991, ANTICANCER RES, V11, P1581; Rosania GR, 1999, P NATL ACAD SCI USA, V96, P4797, DOI 10.1073/pnas.96.9.4797; ROSANIA GR, 2000, EXPERT OPIN THER PAT, V10, P1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schang LM, 2002, J VIROL, V76, P7874, DOI 10.1128/JVI.76.15.7874-7882.2002; Schnier JB, 1999, FEBS LETT, V454, P100, DOI 10.1016/S0014-5793(99)00773-5; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; Shewchuk L, 2000, J MED CHEM, V43, P133, DOI 10.1021/jm990401t; Shum PW, 2001, NUCLEOS NUCLEOT NUCL, V20, P1067, DOI 10.1081/NCN-100002493; Sielecki TM, 2001, BIOORG MED CHEM LETT, V11, P1157, DOI 10.1016/S0960-894X(01)00185-8; Sielecki TM, 2000, J MED CHEM, V43, P1, DOI 10.1021/jm990256j; Soni R, 2000, BIOCHEM BIOPH RES CO, V275, P877, DOI 10.1006/bbrc.2000.3349; Soni R, 2001, JNCI-J NATL CANCER I, V93, P436, DOI 10.1093/jnci/93.6.436; Toogood PL, 2001, MED RES REV, V21, P487, DOI 10.1002/med.1021; URBANI L, 1995, EXP CELL RES, V219, P159, DOI 10.1006/excr.1995.1216; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Villerbu N, 2002, INT J CANCER, V97, P761, DOI 10.1002/ijc.10125; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143; Zaharevitz DW, 1999, CANCER RES, V59, P2566; ZIMMERMANN J, 1995, Patent No. 9509853	89	55	60	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6413	6424		10.1038/sj.onc.1205908	http://dx.doi.org/10.1038/sj.onc.1205908			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226745	Bronze			2022-12-25	WOS:000177925300002
J	Britt, KL; Kerr, J; O'Donnell, L; Jones, MEE; Drummond, AE; Davis, SR; Simpson, ER; Findlay, JK				Britt, KL; Kerr, J; O'Donnell, L; Jones, MEE; Drummond, AE; Davis, SR; Simpson, ER; Findlay, JK			Estrogen regulates development of the somatic cell phenotype in the eutherian ovary	FASEB JOURNAL			English	Article						estrogen deficiency; Sertoli cell; granulosa cell; sex steroids	SEX-DETERMINING REGION; TARGETED DISRUPTION; GERM-CELLS; AROMATASE-ACTIVITY; RECEPTORS ALPHA; MAMMALIAN GONAD; MOUSE; GENE; MICE; REVERSAL	Steroids play a critical role in gonadal differentiation in birds, reptiles, and amphibia whereas gonadal differentiation in mammals is thought to be determined by genetic mechanisms. The gonads of female mice incapable of synthesizing estrogens due to disruption of the aromatase gene (ArKO) provide a unique model to test the role of estrogen in regulating the gonadal phenotype. We have shown that in the absence of estrogen, genetically female mice develop testicular tissue within their ovaries. The ovaries develop cells that possess structural and functional characteristics of testicular interstitial cells and of seminiferous tubule-like structures lined with Sertoli cells. Moreover, the ovaries express mRNA for the testis-specific Sertoli cell transcription factor Sox 9 and espin protein, which is specific for inter-Sertoli cell junctions. The development of the testicular tissue in this model can be reverted/postponed by replacing estrogen. When ArKO female mice were fed a diet containing phytoestrogens, the appearance of Leydig and Sertoli cells was postponed and reduced. Furthermore, administration of estradiol-17beta decreased the number of Sertoli and Leydig cells in the ovaries. These findings constitute definitive evidence that estrogen plays a critical role in maintaining female somatic interstitial and granulosa cells in the eutherian ovary.	Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; Monash Univ, Dept Anat & Cell Biol, Clayton, Vic 3168, Australia; Jean Hailes Fdn, Clayton, Vic 3168, Australia	Prince Henry's Institute of Medical Research; Monash University; Monash University	Britt, KL (corresponding author), Prince Henrys Inst Med Res, POB 5152, Clayton, Vic 3168, Australia.	kara.britt@med.monash.edu.au	Britt, Kara/B-2437-2013; Davis, Susan D/GZL-2361-2022; Britt, Kara/A-5568-2009; Davis, Susan R/A-3111-2009	Britt, Kara/0000-0001-6069-7856; Davis, Susan R/0000-0002-2955-0415; Jones, Margaret/0000-0002-0678-3187; Drummond, Ann/0000-0002-2183-6013; O'Donnell, Liza/0000-0001-5848-6136	NATIONAL INSTITUTE ON AGING [R37AG008174] Funding Source: NIH RePORTER; NIA NIH HHS [R37AG08174] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; Bishop CE, 2000, NAT GENET, V26, P490, DOI 10.1038/82652; BRITT K, 2001, US END SOC M JUN 18; Britt KL, 2000, ENDOCRINOLOGY, V141, P2614, DOI 10.1210/en.141.7.2614; Burns RK, 1925, J EXP ZOOL, V42, P31, DOI 10.1002/jez.1400420104; Buyse A, 1935, J EXP ZOOL, V70, P1, DOI 10.1002/jez.1400700102; Capel B, 1996, CURR TOP DEV BIOL, V32, P1, DOI 10.1016/S0070-2153(08)60423-8; Chapin CL, 1917, J EXP ZOOL, V23, P453, DOI 10.1002/jez.1400230209; Colvin JS, 2001, CELL, V104, P875, DOI 10.1016/S0092-8674(01)00284-7; Couse JF, 1999, SCIENCE, V286, P2328, DOI 10.1126/science.286.5448.2328; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Coveney D, 2001, BIOL REPROD, V65, P613, DOI 10.1095/biolreprod65.2.613; CRUMEYROLLEARIAS M, 1976, GERONTOLOGY, V22, P185, DOI 10.1159/000212133; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; DESVAGES G, 1992, J STEROID BIOCHEM, V41, P851, DOI 10.1016/0960-0760(92)90437-N; DESVAGES G, 1993, GEN COMP ENDOCR, V92, P54, DOI 10.1006/gcen.1993.1142; Dorizzi M, 1996, DIFFERENTIATION, V60, P193, DOI 10.1046/j.1432-0436.1996.6040193.x; Dupont S, 2000, DEVELOPMENT, V127, P4277; Dym M, 1970, Biology Reprod., V3, P308; ENGLE ET, 1946, CANCER RES, V6, P578; Findlay JK, 2000, MOL CELL ENDOCRINOL, V163, P81, DOI 10.1016/S0303-7207(99)00243-9; Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965; GONDOS B, 1980, J ENDOCRINOL, V87, P265, DOI 10.1677/joe.0.0870265; GREENE R. R., 1942, Biol. Sympos., V9, P105; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HACKER A, 1995, DEVELOPMENT, V121, P1603; HASHIMOTO N, 1990, J EXP ZOOL, V253, P61, DOI 10.1002/jez.1402530109; Jones MEE, 2000, P NATL ACAD SCI USA, V97, P12735, DOI 10.1073/pnas.97.23.12735; Jost A., 1973, Recent Progress Hormone Res, V29, P1; Kent J, 1996, DEVELOPMENT, V122, P2813; Lillie FR, 1917, J EXP ZOOL, V23, P371, DOI 10.1002/jez.1400230208; MACINTYRE MN, 1956, ANAT RECORD, V124, P27, DOI 10.1002/ar.1091240103; MCLAREN A, 1991, BIOESSAYS, V13, P151, DOI 10.1002/bies.950130402; MERCHANT H, 1975, DEV BIOL, V44, P1, DOI 10.1016/0012-1606(75)90372-3; Merchant-Larios H, 1981, Prog Clin Biol Res, V59B, P383; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; O'Donnell L, 2000, BIOL REPROD, V63, P99, DOI 10.1095/biolreprod63.1.99; O'Donnell L, 2001, ENDOCR REV, V22, P289, DOI 10.1210/er.22.3.289; Pailhoux E, 2001, DEV DYNAM, V222, P328, DOI 10.1002/dvdy.1194; PIEAU C, 1994, ENV CONTROL GONADAL; RUSSELL L, 1977, TISSUE CELL, V9, P475, DOI 10.1016/0040-8166(77)90007-6; Scully RE, 1979, ATLAS TUMOR PATHOLOG; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TAKETO T, 1984, ANN NY ACAD SCI, V438, P671, DOI 10.1111/j.1749-6632.1984.tb38370.x; TAKETOHOSOTANI T, 1985, J EXP ZOOL, V236, P229, DOI 10.1002/jez.1402360213; Toda K, 2001, J ENDOCRINOL, V170, P99, DOI 10.1677/joe.0.1700099; TURNER CD, 1962, AM ZOOL, V2, P565; Vaillant S, 2001, DEV DYNAM, V222, P228, DOI 10.1002/dvdy.1190; Vaillant S, 2001, J EXP ZOOL, V290, P727, DOI 10.1002/jez.1123; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Vidal VPI, 2001, NAT GENET, V28, P216, DOI 10.1038/90046; VOGL AW, 1989, INT REV CYTOL, V119, P1; Whitworth DJ, 1998, TRENDS ENDOCRIN MET, V9, P2, DOI 10.1016/S1043-2760(98)00002-2; Wilson J D, 1981, Recent Prog Horm Res, V37, P1; WILSON JD, 1981, SCIENCE, V211, P1278, DOI 10.1126/science.7010602; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15	57	81	81	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2002	16	11					1389	1397		10.1096/fj.01-0992com	http://dx.doi.org/10.1096/fj.01-0992com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12205030				2022-12-25	WOS:000178441800013
J	Yao, ZX; Papadopoulos, V				Yao, ZX; Papadopoulos, V			Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity	FASEB JOURNAL			English	Article						cholesterol-binding protein; high-density lipoproteins; neurotoxicity; Alzheimer's Disease	APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; PEPTIDE; MEMBRANE; RECEPTOR; BINDING; PREVALENCE	Amyloid beta-peptide (Abeta), Abeta precursor protein (APP), apolipoprotein E (apoE), and elevated cholesterol levels have been linked to Alzheimer's disease (AD) pathology. High cholesterol levels increase APP and apoE expression in human NT2 neuron progenitor cells. A cholesterol-rich environment also induces processing of APP, leading to the formation of Abeta and Abeta peptide fragments. Using a novel method, we determined that 1) cholesterol binds to Abeta at alpha-secretase cleavage site; 2) Abeta(17-40) rather than Abeta(1-40) prevents cholesterol from binding to apoE; 3) Abeta(1-40) inhibits cholesterol from binding to low-density lipoprotein (LDL), leading to decrease cholesterol influx and intracellular cholesterol levels; 4) the binding of cholesterol to apoE or LDL was abolished completely in presence of Abeta(1-42). Increased extracellular free cholesterol levels are toxic to neurons; this toxicity is prevented by specific lipoproteins, such as high-density lipoproteins, which maintain their ability to bind cholesterol in the presence of Abeta. We propose that one of the physiological functions of Abeta and APP is to control cholesterol transport. AD is associated with increased Abeta production. High cholesterol levels also lead to overproduction of Abeta. Abeta blocks cholesterol trafficking and changes cholesterol homeostasis leading to neurodegeneration and the onset and/or progression of AD pathology.	Georgetown Univ, Sch Med, Dept Cell Biol, Div Hormone Res, Washington, DC 20057 USA; Georgetown Univ, Sch Med, Dept Pharmacol, Washington, DC 20057 USA; Georgetown Univ, Sch Med, Dept Neurosci, Washington, DC 20057 USA	Georgetown University; Georgetown University; Georgetown University	Papadopoulos, V (corresponding author), Georgetown Univ, Sch Med, Dept Cell Biol, Div Hormone Res, 3900 Reservoir Rd NW, Washington, DC 20057 USA.	papadopv@georgetown.edu	Papadopoulos, Vassilios/AAI-2613-2019	Papadopoulos, Vassilios/0000-0002-1183-8568				Avdulov NA, 1997, J NEUROCHEM, V69, P1746; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Futerman AH, 1996, TRENDS NEUROSCI, V19, P144, DOI 10.1016/S0166-2236(96)80025-7; Galbete JL, 2000, BIOCHEM J, V348, P307, DOI 10.1042/0264-6021:3480307; GINSBERG L, 1993, MOL CHEM NEUROPATHOL, V19, P37, DOI 10.1007/BF03160167; GINSBERG L, 1993, BRAIN RES, V615, P355, DOI 10.1016/0006-8993(93)90050-W; Havel RJ, 1995, METABOLIC MOL BASES, V7th, P1841, DOI [10.1036/ommbid.142, DOI 10.1036/OMMBID.142]; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Johnson W J, 1997, Subcell Biochem, V28, P235; LaDu MJ, 1997, J NEUROSCI RES, V49, P9, DOI 10.1002/(SICI)1097-4547(19970701)49:1<9::AID-JNR2>3.0.CO;2-H; Li H, 2001, P NATL ACAD SCI USA, V98, P1267, DOI 10.1073/pnas.031461598; Liang JS, 1996, BIOCHEM BIOPH RES CO, V219, P962, DOI 10.1006/bbrc.1996.0332; Liu YB, 1998, P NATL ACAD SCI USA, V95, P13266, DOI 10.1073/pnas.95.22.13266; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Michikawa M, 2000, J NEUROCHEM, V74, P1008, DOI 10.1046/j.1471-4159.2000.0741008.x; NASLUND J, 1995, NEURON, V15, P219, DOI 10.1016/0896-6273(95)90079-9; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SING CF, 1985, AM J HUM GENET, V37, P268; Small DH, 1999, J NEUROCHEM, V73, P443, DOI 10.1046/j.1471-4159.1999.0730443.x; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Tokuda T, 2000, BIOCHEM J, V348, P359, DOI 10.1042/0264-6021:3480359; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yao ZX, 2001, BRAIN RES, V889, P181, DOI 10.1016/S0006-8993(00)03131-0	31	93	95	1	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1677	+		10.1096/fj.02-0285fje	http://dx.doi.org/10.1096/fj.02-0285fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206998				2022-12-25	WOS:000177814000011
J	Hu, VW; Black, GE; Torres-Duarte, A; Abramson, FP				Hu, VW; Black, GE; Torres-Duarte, A; Abramson, FP			H-3-thymidine is a defective tool with which to measure rates of DNA synthesis	FASEB JOURNAL			English	Article						radiation damage; stable isotopes; mass spectrometry	CHEMICAL-REACTION INTERFACE; CELL-CYCLE PROGRESSION; MASS-SPECTROMETRY; PROLIFERATION; <H-3>THYMIDINE; RADIOTOXICITY; FRAGMENTATION; APOPTOSIS; TRITIUM; ARREST	Metabolic incorporation of H-3-thymidine into cellular DNA is a widely used protocol to monitor rates of DNA synthesis and cell proliferation. However, this radiochemical has also been reported to induce cell-cycle arrest and apoptosis in addition to DNA damage. Using stable isotope-labeled thymidine, we demonstrate that H-3-thymidine induces dose-dependent inhibition of the rate of DNA synthesis. This inhibition occurred within the first round of replication after addition of the radiolabeled tracer and demonstrates the cytotoxic effects of conventional doses of H-3-thymidine (typically greater than or equal to1 muCi/ml). These results thus show that stable isotope methods are superior to radioisotopes for determining rates of DNA synthesis and cell replication. Because H-3-thymidine perturbs the very process it was employed to study, experiments using H-3-thymidine to monitor DNA synthesis and cell proliferation should be interpreted with caution.	George Washington Univ, Dept Biochem & Mol Biol, Med Ctr, Washington, DC 20037 USA; George Washington Univ, Dept Pharmacol, Med Ctr, Washington, DC 20037 USA	George Washington University; George Washington University	Hu, VW (corresponding author), George Washington Univ, Dept Biochem & Mol Biol, Med Ctr, 2300 Eye St NW, Washington, DC 20037 USA.	bcmvwh@gwumc.edu		Hu, Valerie/0000-0002-3357-0777				ABRAMSON FP, 1994, MASS SPECTROM REV, V13, P341, DOI 10.1002/mas.1280130403; Chen P, 1998, ANAL CHEM, V70, P1664, DOI 10.1021/ac971294i; CLEAVER JE, 1972, SCIENCE, V177, P996, DOI 10.1126/science.177.4053.996; DOVER R, 1994, J CELL SCI, V107, P1181; EHMANN UK, 1975, NATURE, V258, P633, DOI 10.1038/258633a0; HOFER KG, 1971, RADIAT RES, V47, P94, DOI 10.2307/3573291; Hu VW, 2001, FASEB J, V15, P1562, DOI 10.1096/fj.01-0102com; Hu VW, 2000, FASEB J, V14, P448, DOI 10.1096/fasebj.14.3.448; KASSIS AI, 1980, RADIAT RES, V84, P407, DOI 10.2307/3575480; LEMOTTE PK, 1982, P NATL ACAD SCI-BIOL, V79, P7763, DOI 10.1073/pnas.79.24.7763; Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708; MAURER HR, 1981, CELL TISSUE KINET, V14, P111, DOI 10.1111/j.1365-2184.1981.tb00516.x; Neese RA, 2001, ANAL BIOCHEM, V298, P189, DOI 10.1006/abio.2001.5375; Nias AHW, 1998, INTRO RADIOBIOLOGY; Nissim I, 2000, ANAL BIOCHEM, V278, P198, DOI 10.1006/abio.1999.4427; Olive PL, 1999, INT J RADIAT BIOL, V75, P395, DOI 10.1080/095530099140311; SOLARY E, 1992, EXP CELL RES, V203, P495, DOI 10.1016/0014-4827(92)90027-6; Teffera Y, 1996, ANAL CHEM, V68, P1888, DOI 10.1021/ac951255b; VESTAL ML, 1990, ACS SYM SER, V420, P215; Wang B, 1999, HEALTH PHYS, V77, P16, DOI 10.1097/00004032-199907000-00005; Yanokura M, 2000, INT J RADIAT BIOL, V76, P295, DOI 10.1080/095530000138637; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	22	38	42	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1456	+		10.1096/fj.02-0142fje	http://dx.doi.org/10.1096/fj.02-0142fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205046				2022-12-25	WOS:000177813100015
J	Patel, HH; Ludwig, LM; Fryer, RM; Hsu, AK; Warltier, DC; Gross, GJ				Patel, HH; Ludwig, LM; Fryer, RM; Hsu, AK; Warltier, DC; Gross, GJ			Delta opioid agonists and volatile anesthetics facilitate cardioprotection via potentiation of K-ATP channel opening	FASEB JOURNAL			English	Article						isoflurane; infarction; ischemia; preconditioning	PROTEIN-KINASE-C; SENSITIVE POTASSIUM CHANNELS; RABBIT VENTRICULAR MYOCYTES; MYOCARDIAL PROTECTION; STUNNED MYOCARDIUM; NITRIC-OXIDE; RAT-HEART; ISOFLURANE; MITOCHONDRIAL; MECHANISM	Opioids and volatile anesthetics produce marked cardioprotective effects against myocardial infarction via the activation of ATP-sensitive potassium (K-ATP) channels, however, the effect of combined treatment with both drugs is unknown. We examined the hypothesis that opioids and volatile anesthetics potentiate cardiac K-ATP channel opening, thereby enhancing cardioprotection. Rats were treated with the delta opioid agonists, TAN-67 or BW373U86, or isoflurane, together or alone with and without diazoxide, a mitochondrial K-ATP channel opener. Glibenclamide, a non-selective K-ATP channel blocker, was used to further characterize the signaling mechanism involved. Myocardial infarct size (IS) was determined by tetrazolium staining and was expressed as a percent of the area at risk (AAR). High doses of TAN-67 (10 mg/kg), diazoxide (10 mg/kg), and isoflurane (1 MAC) produced a significant reduction in IS compared with the control group (30+/-3%, 36+/-5%, and 42+/-2 vs. 58+/-2%, respectively), whereas lower doses of the drugs had no effect except for the low dose of isoflurane (0.5 MAC). The combination of TAN-67 and diazoxide or isoflurane and diazoxide resulted in a marked reduction in IS compared with controls in the presence of high (9+/-3% and 14+/-3%) and low (17+/-7% and 31+/-7%) dose combinations, respectively. The combination of TAN-67 or BW373U86 and isoflurane also caused a striking reduction in IS/AAR (16+/-7% and 7+/-2%, respectively). To date, this is the first demonstration that opioids and volatile anesthetics work in conjunction to confer protection against myocardial infarction through potentiation of cardiac K-ATP channel opening.	Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; Harvard Univ, Inst Med, Ctr Neurol Dis, Boston, MA 02115 USA; Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Harvard University; Medical College of Wisconsin	Gross, GJ (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	ggross@mcw.edu	Patel, Hemal/C-7325-2019	Patel, Hemal/0000-0001-6722-9625				Benedict PE, 1999, CIRCULATION, V100, P357; Carroll R, 2001, CARDIOVASC RES, V51, P691, DOI 10.1016/S0008-6363(01)00330-3; Forbes RA, 2001, CIRC RES, V88, P802, DOI 10.1161/hh0801.089342; Fryer RM, 2001, AM J PHYSIOL-HEART C, V280, pH1346, DOI 10.1152/ajpheart.2001.280.3.H1346; Fryer RM, 1999, CIRC RES, V84, P846; Fryer RM, 2000, J PHARMACOL EXP THER, V294, P451; Han J, 1996, BIOCHEM BIOPH RES CO, V229, P852, DOI 10.1006/bbrc.1996.1891; Hu KL, 1996, CIRC RES, V78, P492, DOI 10.1161/01.RES.78.3.492; Kashimoto S, 1998, EUR J ANAESTH, V15, P553; Kersten JR, 1996, ANESTH ANALG, V83, P27, DOI 10.1097/00000539-199607000-00006; Kersten JR, 1997, ANESTHESIOLOGY, V86, P1128, DOI 10.1097/00000542-199705000-00017; Kersten JR, 1996, ANESTHESIOLOGY, V85, P794, DOI 10.1097/00000542-199610000-00015; Kersten JR, 1997, ANESTHESIOLOGY, V87, P361, DOI 10.1097/00000542-199708000-00024; Liu YG, 1997, AM J PHYSIOL-HEART C, V273, pH1637, DOI 10.1152/ajpheart.1997.273.4.H1637; Liu YG, 1996, CIRC RES, V78, P443, DOI 10.1161/01.RES.78.3.443; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nakayama M, 1997, ACTA ANAESTH SCAND, V41, P531, DOI 10.1111/j.1399-6576.1997.tb04737.x; Ockaili R, 1999, AM J PHYSIOL-HEART C, V277, pH2425, DOI 10.1152/ajpheart.1999.277.6.H2425; Patel HH, 2001, J MOL CELL CARDIOL, V33, P1455, DOI 10.1006/jmcc.2001.1408; Piriou V, 1997, BRIT J ANAESTH, V79, P68, DOI 10.1093/bja/79.1.68; Piriou V, 2000, ANESTHESIOLOGY, V93, P756, DOI 10.1097/00000542-200009000-00025; SAKAI K, 2000, ACTA ANAESTHESIOL SC, V44; Sasaki N, 2000, CIRCULATION, V101, P439, DOI 10.1161/01.CIR.101.4.439; Sato T, 2000, CIRCULATION, V102, P800, DOI 10.1161/01.CIR.102.7.800; Schultz JE, 1998, CIRCULATION, V97, P1282, DOI 10.1161/01.CIR.97.13.1282; Schultz JEJ, 1998, AM J PHYSIOL-HEART C, V274, pH909, DOI 10.1152/ajpheart.1998.274.3.H909; Schultz JEJ, 1996, CIRC RES, V78, P1100, DOI 10.1161/01.RES.78.6.1100; Toller WG, 1999, ANESTHESIOLOGY, V91, P713, DOI 10.1097/00000542-199909000-00024; Toller WG, 2000, ANESTHESIOLOGY, V92, P1400, DOI 10.1097/00000542-200005000-00031; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Vanden Hoek TL, 2000, CIRC RES, V86, P541, DOI 10.1161/01.RES.86.5.541	31	48	52	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1468	+		10.1096/fj.02-0170fje	http://dx.doi.org/10.1096/fj.02-0170fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205051				2022-12-25	WOS:000177813100011
J	Kim, HY; Heo, YS; Kim, JH; Park, MH; Moon, JH; Kim, E; Kwon, D; Yoon, J; Shin, D; Jeong, EJ; Park, SY; Lee, TG; Jeon, YH; Ro, S; Cho, JM; Hwang, KY				Kim, HY; Heo, YS; Kim, JH; Park, MH; Moon, JH; Kim, E; Kwon, D; Yoon, J; Shin, D; Jeong, EJ; Park, SY; Lee, TG; Jeon, YH; Ro, S; Cho, JM; Hwang, KY			Molecular basis for the local conformational rearrangement of human phosphoserine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; D-SERINE; NMDA RECEPTORS; DEHALOGENASE; GLYCINE; ASPARTATE; PROTEINS; ANALOG	Human phosphoserine phosphatase (HPSP) regulates the levels of glycine and D-serine, the putative co-agonists for the glycine site of the NMDA receptor in the brain. Here, we describe the first crystal structures of the HPSP in complexes with the competitive inhibitor 2-amino-3-phosphonopropionic acid (AP3) at 2.5 Angstrom, and the phosphate ion (Pi) and the product uncompetitive inhibitor L-serine ((HPSPL)-L-.-Ser(.)Pi) at 2.8 Angstrom. The complex structures reveal that the open-closed environmental change of the active site, generated by local rearrangement of the a-helical bundle domain, is important to substrate recognition and hydrolysis. The maximal extent of this structural rearrangement is shown to be about 13 Angstrom at the L4 loop and about 25degrees at the helix alpha3. Both the structural change and mutagenesis data suggest that Arg-65 and Glu-29 play an important role in the binding of the substrate. Interestingly, the AP3 binding mode turns out to be significantly different from that of the natural substrate, phospho-L-serine, and the (HPSPL)-L-.-Ser(.)Pi structure provides a structural basis for the feedback control mechanism of serine. These analyses allow us to provide a clear model for the mechanism of HPSP and a framework for structure-based drug development.	CrystalGenom Inc, Div Drug Discovery, Yuseong Gu, Taejon 305600, South Korea; Yokohama City Univ, Grad Sch Integrated Sci, Div Prot Design, Yokohama, Kanagawa 2300045, Japan	Yokohama City University	Hwang, KY (corresponding author), CrystalGenom Inc, Div Drug Discovery, Yuseong Gu, Taejon 305600, South Korea.	hwangky@crystalgenomics.com						Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Collet JF, 1997, FEBS LETT, V408, P281, DOI 10.1016/S0014-5793(97)00438-9; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Dunlop DS, 1997, BIOCHEM BIOPH RES CO, V235, P26, DOI 10.1006/bbrc.1997.6724; GUYNN RW, 1986, ARCH BIOCHEM BIOPHYS, V245, P204, DOI 10.1016/0003-9861(86)90206-7; Hawkinson JE, 1996, EUR J PHARMACOL, V307, P219, DOI 10.1016/0014-2999(96)00253-1; Hawkinson JE, 1997, EUR J PHARMACOL, V337, P315, DOI 10.1016/S0014-2999(97)01304-6; MATSUI T, 1995, J NEUROCHEM, V65, P454; MOROFURLANI AM, 1980, ANN HUM GENET, V43, P323, DOI 10.1111/j.1469-1809.1980.tb01566.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paudice P, 1998, EUR J NEUROSCI, V10, P2934, DOI 10.1046/j.1460-9568.1998.00302.x; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; Ridder IS, 1997, J BIOL CHEM, V272, P33015, DOI 10.1074/jbc.272.52.33015; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P721, DOI 10.1073/pnas.96.2.721; WOOD PL, 1995, LIFE SCI, V57, P301, DOI 10.1016/0024-3205(95)00288-H	24	32	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46651	46658		10.1074/jbc.M204866200	http://dx.doi.org/10.1074/jbc.M204866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12213811	hybrid			2022-12-25	WOS:000179529300123
J	Taverner, T; Hall, NE; O'Hair, RAJ; Simpson, RJ				Taverner, T; Hall, NE; O'Hair, RAJ; Simpson, RJ			Characterization of an antagonist interleukin-6 dimer by stable isotope labeling, cross-linking, and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT MURINE INTERLEUKIN-6; CRYSTAL-STRUCTURE; RECEPTOR COMPLEX; IL-6 RECEPTOR; BINDING; REAGENTS; DOMAIN; GP130; CELLS; IDENTIFICATION	The homodimeric form of a recombinant cytokine interleukin-6 (IL-6(D)) is known to antagonize IL-6 signaling. In this study, spatially proximal residues between IL-6 chains in IL-6, were identified using a method for specific recognition of intermolecular cross-linked peptides. Our strategy involved mixing 1:1 N-15-labeled and unlabeled (N-14) protein to form a mixture of isotopically labeled and unlabeled homodimers, which was chemically cross-linked. This cross-linked IL-6(D) was subjected to proteolysis by trypsin and the generated peptides were analyzed by electrospray ionization time-of-flight mass spectrometry (MS). Molecular ions from crosslinked peptides of intermolecular origin are labeled with [N-15/N-15] + [N-15/N-14] + [N-14/N-15] + [N-14/N-14] yielding readily identified triplet/quadruplet MS peaks. All other peptide species are labeled with [N-15] + [N-14] yielding doublet peaks. Intermolecular cross-linked peptides were identified by MS, and cross-linked residues were identified. This intermolecular cross-link detection method, which we have designated "mixed isotope cross-linking" MIX may have more general application to protein-protein interaction studies. The pattern of proximal residues found was consistent with IL-6(D) having a domain-swapped fold similar to IL-10 and interferon-gamma. This fold implies that IL-6(D)-mediated antagonism of IL-6 signaling is caused by obstruction of cooperative gp130 binding on IL-6(D), rather than direct blocking of gp-130-binding sites on IL-6(D).	Ludwig Inst Canc Res, Joint Proteom Lab, Parkville, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Melbourne, Sch Chem, Melbourne, Vic 3010, Australia	Ludwig Institute for Cancer Research; Walter & Eliza Hall Institute; University of Melbourne	Simpson, RJ (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Joint Proteom Lab, POB 2008, Parkville, Vic 3050, Australia.	Richard.Simpson@ludwig.edu.au		Simpson, Richard/0000-0002-9834-0796; O'Hair, Richard/0000-0002-8044-0502; Hall, Nathan/0000-0001-8942-0498				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Apuy JL, 2001, BIOCHEMISTRY-US, V40, P15153, DOI 10.1021/bi0112199; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; Bennett KL, 2000, PROTEIN SCI, V9, P1503, DOI 10.1110/ps.9.8.1503; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BIEMANN K, 1994, ACCOUNTS CHEM RES, V27, P370, DOI 10.1021/ar00047a008; Chen XH, 1999, ANAL BIOCHEM, V273, P192, DOI 10.1006/abio.1999.4243; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; Cole AR, 1999, J BIOL CHEM, V274, P7207, DOI 10.1074/jbc.274.11.7207; FONG YM, 1989, J IMMUNOL, V142, P2321; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; HANIU M, 1993, PROTEIN SCI, V2, P1441, DOI 10.1002/pro.5560020908; Henry CM, 2001, CHEM ENG NEWS, V79, P24, DOI 10.1021/cen-v079n029.p024; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; JABLONS DM, 1989, J IMMUNOL, V142, P1542; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; Jones SA, 2001, FASEB J, V15, P43, DOI 10.1096/fj.99-1003rev; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuster B, 1998, CURR OPIN STRUC BIOL, V8, P393, DOI 10.1016/S0959-440X(98)80075-4; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Matthews JM, 1998, BIOCHEMISTRY-US, V37, P10671, DOI 10.1021/bi980127p; MAY LT, 1991, J BIOL CHEM, V266, P9950; Means GE, 1990, BIOCONJUGATE CHEM, V1, P2, DOI 10.1021/bc00001a001; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moreno A, 2001, BLOOD, V97, P242, DOI 10.1182/blood.V97.1.242; Moritz RL, 1999, GROWTH FACTORS, V16, P265, DOI 10.3109/08977199909069145; MORTON CJ, 1995, BBA-PROTEIN STRUCT M, V1249, P189, DOI 10.1016/0167-4838(95)00023-N; Muller DR, 2001, ANAL CHEM, V73, P1927, DOI 10.1021/ac001379a; NAKAJIMA K, 1989, J IMMUNOL, V142, P531; Nishimoto N, 2000, ANN RHEUM DIS, V59, P21, DOI 10.1136/ard.59.suppl_1.i21; NISHIMURA C, 1992, FEBS LETT, V311, P271, DOI 10.1016/0014-5793(92)81118-6; Onishi M, 1998, Int Rev Immunol, V16, P617, DOI 10.3109/08830189809043011; Pearson KM, 2002, RAPID COMMUN MASS SP, V16, P149, DOI 10.1002/rcm.554; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Rappsilber J, 2000, ANAL CHEM, V72, P267, DOI 10.1021/ac991081o; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Sinz A, 2001, BIOCHEMISTRY-US, V40, P7903, DOI 10.1021/bi010259+; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Wallon G, 2000, EMBO J, V19, P213, DOI 10.1093/emboj/19.2.213; WARD LD, 1994, J BIOL CHEM, V269, P23286; Ward LD, 1996, J BIOL CHEM, V271, P20138, DOI 10.1074/jbc.271.33.20138; WIJDENES J, 1991, MOL IMMUNOL, V28, P1183, DOI 10.1016/0161-5890(91)90004-4; Xu GY, 1997, J MOL BIOL, V268, P468, DOI 10.1006/jmbi.1997.0933; Yamada N, 2002, RAPID COMMUN MASS SP, V16, P293, DOI 10.1002/rcm.579; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; Young MM, 2000, P NATL ACAD SCI USA, V97, P5802, DOI 10.1073/pnas.090099097; ZDANOV A, 1995, STRUCTURE, V3, P591, DOI 10.1016/S0969-2126(01)00193-9; ZHANG JG, 1992, EUR J BIOCHEM, V207, P903, DOI 10.1111/j.1432-1033.1992.tb17123.x	59	93	97	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46487	46492		10.1074/jbc.M207370200	http://dx.doi.org/10.1074/jbc.M207370200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235153	hybrid			2022-12-25	WOS:000179529300102
J	Feng, W; Tu, JC; Yang, TZ; Vernon, PS; Allen, PD; Worley, PF; Pessah, IN				Feng, W; Tu, JC; Yang, TZ; Vernon, PS; Allen, PD; Worley, PF; Pessah, IN			Homer regulates gain of ryanodine receptor type 1 channel complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CALCIUM-RELEASE UNITS; SARCOPLASMIC-RETICULUM; CA2+ RELEASE; SKELETAL; PROTEIN; ACTIVATION; FAMILY; MODULATION; PSD-ZIP45	Homer proteins form an adapter system that regulates coupling of group 1 metabotropic glutamate receptors with intracellular inositol trisphosphate receptors and is modified by neuronal activity. Here, we demonstrate that Homer proteins also physically associate with ryanodine receptors type 1 (RyR1) and regulate gating responses to Ca2+, depolarization, and caffeine. In contrast to the prevailing notion of Homer function, Homerlc (long form) and Homer1-EVH1 (short form) evoke similar changes in RyR activity. The EVH1 domain mediates these actions of Homer and is selectively blocked by a peptide that mimics the Homer ligand. 1135 dyspedic myotubes expressing RyR1 with a point mutation of a putative Homer-binding domain exhibit significantly reduced (similar to33%) amplitude in their responses to K+ depolarization compared with cells expressing wild type protein. These results reveal that in addition to its known role as an adapter protein, Homer is a direct modulator of Ca2+ release gain. Homer is the first example of an "adapter" that also modifies signaling properties of its target protein. The present work reveals a novel mechanism by which Homer directly modulates the function of its target protein RyR1 and excitation-contraction coupling in skeletal myotubes. This form of regulation may be important in other cell types that express Homer and RyR1.	Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Brigham & Womens Hosp, Dept Anesthesia Preoperat & Pain Med, Boston, MA 02115 USA	University of California System; University of California Davis; Johns Hopkins University; Harvard University; Brigham & Women's Hospital	Pessah, IN (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, 1 Shields Ave, Davis, CA 95616 USA.	inpessah@ucdavis.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	NIAMS NIH HHS [AR17605] Funding Source: Medline; NIDA NIH HHS [DA10309] Funding Source: Medline; NIEHS NIH HHS [ES10173, ES11269] Funding Source: Medline; NIMH NIH HHS [MH01153] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011269, R03ES010173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K20MH001153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA010309, R01DA010309] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alkon DL, 1998, TRENDS NEUROSCI, V21, P529, DOI 10.1016/S0166-2236(98)01277-6; Ango F, 2001, NATURE, V411, P962, DOI 10.1038/35082096; Beneken J, 2000, NEURON, V26, P143, DOI 10.1016/S0896-6273(00)81145-9; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Fajloun Z, 2000, FEBS LETT, V469, P179, DOI 10.1016/S0014-5793(00)01239-4; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; Franzini-Armstrong C, 1998, ANN NY ACAD SCI, V853, P20, DOI 10.1111/j.1749-6632.1998.tb08253.x; Futatsugi A, 1999, NEURON, V24, P701, DOI 10.1016/S0896-6273(00)81123-X; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Gonzalez A, 2000, P NATL ACAD SCI USA, V97, P4380, DOI 10.1073/pnas.070056497; IVANENKO A, 1993, J NEUROPHYSIOL, V70, P710, DOI 10.1152/jn.1993.70.2.710; KANO M, 1995, J PHYSIOL-LONDON, V487, P1; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Korkotian E, 1999, P NATL ACAD SCI USA, V96, P12068, DOI 10.1073/pnas.96.21.12068; Kurebayashi N, 2001, J PHYSIOL-LONDON, V533, P185, DOI 10.1111/j.1469-7793.2001.0185b.x; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; LLANO I, 1994, NEURON, V12, P663, DOI 10.1016/0896-6273(94)90221-6; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Murayama T, 1999, J BIOL CHEM, V274, P17297, DOI 10.1074/jbc.274.24.17297; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; O'Brien JJ, 2002, BIOPHYS J, V82, P2428, DOI 10.1016/S0006-3495(02)75586-0; Okabe S, 2001, J NEUROSCI, V21, P9561, DOI 10.1523/JNEUROSCI.21-24-09561.2001; PALADE P, 1987, J BIOL CHEM, V262, P6135; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; Protasi F, 2000, BIOPHYS J, V79, P2494, DOI 10.1016/S0006-3495(00)76491-5; Protasi F, 1998, J CELL BIOL, V140, P831, DOI 10.1083/jcb.140.4.831; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Sandona D, 2000, BIOCHEM BIOPH RES CO, V279, P348, DOI 10.1006/bbrc.2000.3948; Serge A, 2002, J NEUROSCI, V22, P3910, DOI 10.1523/JNEUROSCI.22-10-03910.2002; Soloviev MM, 2000, EUR J BIOCHEM, V267, P634, DOI 10.1046/j.1432-1327.2000.01078.x; Sun J, 1998, FEBS LETT, V437, P304, DOI 10.1016/S0014-5793(98)01256-3; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; Sun MK, 2000, P NATL ACAD SCI USA, V97, P12300, DOI 10.1073/pnas.210396697; Tadokoro S, 1999, P NATL ACAD SCI USA, V96, P13801, DOI 10.1073/pnas.96.24.13801; Thomas U, 2002, J NEUROCHEM, V81, P407, DOI 10.1046/j.1471-4159.2002.00869.x; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Usachev YM, 1997, J NEUROSCI, V17, P7404; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Wang Y, 2000, AM J PHYSIOL-CELL PH, V278, pC619, DOI 10.1152/ajpcell.2000.278.3.C619; Ward CW, 2002, BIOPHYS J, V82, p284A; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8	52	121	124	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44722	44730		10.1074/jbc.M207675200	http://dx.doi.org/10.1074/jbc.M207675200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223488	hybrid			2022-12-25	WOS:000179404800018
J	Hou, SY; Wu, SY; Chiang, CM				Hou, SY; Wu, SY; Chiang, CM			Transcriptional activity among high and low risk human papillomavirus E2 proteins correlates with E2 DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ONCOGENIC HUMAN PAPILLOMAVIRUSES; E1 REPLICATION PROTEIN; TRANSACTIVATION DOMAIN; IN-VITRO; FUNCTIONAL INTERACTION; EPISOMAL MAINTENANCE; VIRAL TRANSCRIPTION; ACTIVATION DOMAINS; COMPLEX-FORMATION	The full-length E2 protein, encoded by human papillomaviruses (HPVs), is a sequence-specific transcription factor found in all HPVs, including cancer-causing high risk HPV types 16 and 18 and wart-inducing low risk HPV types 6 and 11. To investigate whether E2 proteins encoded by high risk HPVs may function differentially from E2 proteins encoded by low risk HPVs and animal papillomaviruses, we conducted comparative DNA-binding and transcription studies using electrophoretic mobility shift assays and cell-free transcription systems reconstituted with purified general transcription factors, cofactor, RNA polymerase II, and with E2 proteins encoded by HPV-16, HPV-18, HPV-11, and bovine papillomavirus type 1 (BPV-1). We found that although different types of E2 proteins all exhibited transactivation and repression activities, depending on the sequence context of the E2-binding sites, HPV-16 E2 shows stronger transcription activity and greater DNA-binding affinity than those displayed by the other E2 proteins. Surprisingly, HPV-18 E2 behaves more similarly to BPV-1 E2 than HPV-16 E2 in its functional properties. Our studies thus categorize HPV-18 E2 and BPV-1 E2 in the same protein family, a finding consistent with the available E2 structural data that separate the closely related HPV-16 and HPV-18 E2 proteins but classify together the more divergent BPV-1 and HPV-18 E2 proteins.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Chiang, CM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave,W-409, Cleveland, OH 44106 USA.				NCI NIH HHS [CA81017] Funding Source: Medline; NIGMS NIH HHS [GM59643] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059643] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abroi A, 1996, J VIROL, V70, P6169, DOI 10.1128/JVI.70.9.6169-6179.1996; Antson AA, 2000, NATURE, V403, P805, DOI 10.1038/35001638; Bellanger S, 2001, J VIROL, V75, P7244, DOI 10.1128/JVI.75.16.7244-7251.2001; Benson JD, 1997, J VIROL, V71, P8041, DOI 10.1128/JVI.71.10.8041-8047.1997; BERNARD BA, 1989, J VIROL, V63, P4317, DOI 10.1128/JVI.63.10.4317-4324.1989; Boeckle S, 2002, VIROLOGY, V293, P103, DOI 10.1006/viro.2001.1231; Boner W, 2002, J BIOL CHEM, V277, P22297, DOI 10.1074/jbc.M202163200; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; CHIANG CM, 1991, J VIROL, V65, P3317, DOI 10.1128/JVI.65.6.3317-3329.1991; CHONG T, 1991, J VIROL, V65, P5933, DOI 10.1128/JVI.65.11.5933-5943.1991; Dell C, 2001, CELL MOL LIFE SCI, V58, P1923, DOI 10.1007/PL00000827; DEMERET C, 1994, J VIROL, V68, P7075, DOI 10.1128/JVI.68.11.7075-7082.1994; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DONG G, 1994, J VIROL, V68, P1115, DOI 10.1128/JVI.68.2.1115-1127.1994; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Enzenauer C, 1998, INTERVIROLOGY, V41, P80, DOI 10.1159/000024918; Ferran MC, 1998, J VIROL, V72, P796, DOI 10.1128/JVI.72.1.796-801.1998; Ferreiro DU, 2000, BIOCHEMISTRY-US, V39, P14692, DOI 10.1021/bi001694r; Francis DA, 2000, J VIROL, V74, P2679, DOI 10.1128/JVI.74.6.2679-2686.2000; Frattini MG, 1997, EMBO J, V16, P318, DOI 10.1093/emboj/16.2.318; FRATTINI MG, 1994, P NATL ACAD SCI USA, V91, P12398, DOI 10.1073/pnas.91.26.12398; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; Hartley KA, 2002, J VIROL, V76, P5014, DOI 10.1128/JVI.76.10.5014-5023.2002; Hegde RS, 2002, ANNU REV BIOPH BIOM, V31, P343, DOI 10.1146/annurev.biophys.31.100901.142129; Hines CS, 1998, J MOL BIOL, V276, P809, DOI 10.1006/jmbi.1997.1578; Hou SY, 2000, MOL CELL BIOL, V20, P113, DOI 10.1128/MCB.20.1.113-125.2000; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; Ilves I, 1999, J VIROL, V73, P4404, DOI 10.1128/JVI.73.5.4404-4412.1999; JACKSON ME, 1995, J VIROL, V69, P6038, DOI 10.1128/JVI.69.10.6038-6046.1995; Kim SS, 2000, J BIOL CHEM, V275, P31245, DOI 10.1074/jbc.M004541200; Kovelman R, 1996, J VIROL, V70, P7549, DOI 10.1128/JVI.70.11.7549-7560.1996; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lee D, 2002, J BIOL CHEM, V277, P6483, DOI 10.1074/jbc.M105085200; Lefebvre O, 1997, J MOL BIOL, V266, P465, DOI 10.1006/jmbi.1996.0807; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; Lewis H, 1999, J MOL BIOL, V294, P885, DOI 10.1006/jmbi.1999.3314; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munoz N, 2000, J CLIN VIROL, V19, P1, DOI 10.1016/S1386-6532(00)00125-6; Nelson DL, 2000, LEHNINGER PRINCIPLES, p[243, 203]; O'Connor M, 1995, HUMAN PAPILLOMAVIRUS, pIII21; Peng YC, 2000, J VIROL, V74, P5872, DOI 10.1128/JVI.74.13.5872-5879.2000; Pepinsky RB, 1997, J VIROL, V71, P828, DOI 10.1128/JVI.71.1.828-831.1997; Piirsoo M, 1996, EMBO J, V15, P1; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; SANDLER AB, 1993, J VIROL, V67, P5079, DOI 10.1128/JVI.67.9.5079-5087.1993; SARVER N, 1982, P NATL ACAD SCI-BIOL, V79, P7147, DOI 10.1073/pnas.79.23.7147; Skiadopoulos MH, 1998, J VIROL, V72, P2079, DOI 10.1128/JVI.72.3.2079-2088.1998; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; STENLUND A, 1990, GENE DEV, V4, P123, DOI 10.1101/gad.4.1.123; Stubenrauch F, 1996, J VIROL, V70, P119, DOI 10.1128/JVI.70.1.119-126.1996; Stubenrauch F, 2001, J VIROL, V75, P4139, DOI 10.1128/JVI.75.9.4139-4149.2001; Stubenrauch F, 2000, J VIROL, V74, P1178, DOI 10.1128/JVI.74.3.1178-1186.2000; TAN SH, 1994, J VIROL, V68, P6411, DOI 10.1128/JVI.68.10.6411-6420.1994; THIERRY F, 1991, NEW BIOL, V3, P90; USHIKAI M, 1994, J VIROL, V68, P6655, DOI 10.1128/JVI.68.10.6655-6666.1994; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; Voitenleitner C, 2002, J VIROL, V76, P3440, DOI 10.1128/JVI.76.7.3440-3451.2002; Wang JC, 1998, BBA-GENE STRUCT EXPR, V1397, P141, DOI 10.1016/S0167-4781(98)00012-8; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Wu SY, 1998, J BIOL CHEM, V273, P12492, DOI 10.1074/jbc.273.20.12492; Wu SY, 1999, J BIOL CHEM, V274, P23480, DOI 10.1074/jbc.274.33.23480; Wu SY, 2001, J BIOL CHEM, V276, P34235, DOI 10.1074/jbc.M102463200; Wu SY, 1998, EMBO J, V17, P4478, DOI 10.1093/emboj/17.15.4478; Yao JM, 1998, J VIROL, V72, P1013, DOI 10.1128/JVI.72.2.1013-1019.1998; Zou NX, 2000, J VIROL, V74, P3761, DOI 10.1128/JVI.74.8.3761-3770.2000; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	75	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45619	45629		10.1074/jbc.M206829200	http://dx.doi.org/10.1074/jbc.M206829200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239214	hybrid			2022-12-25	WOS:000179404800128
J	Zhu, T; Ling, L; Lobie, PE				Zhu, T; Ling, L; Lobie, PE			Identification of a JAK2-independent pathway regulating growth hormone (GH)-stimulated p44/42 mitogen-activated protein kinase activity - GH activation of Ral and phospholipase D is Src-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; HUMAN NEUTROPHILS; PHOSPHATIDIC-ACID; GENE-EXPRESSION; SH2 DOMAIN; RECEPTOR; JAK2; GTPASE	We have demonstrated here that growth hormone (GH) stimulates the formation of the active GTP-bound form of both RalA and RalB in NIH-3T3 cells. Full activation of RalA and RalB by GH required the combined activity of c-Src and JAK2, both kinases activated by GH independent of the other. Activation of RalA and RalB by growth hormone did not require the activity of JAK2 per se. Ras was also activated by GH and was required for the GH-stimulated formation of GTP-bound RalA and RalB. Activation of RalA by GH subsequently resulted in increased phospholipase D activity and the formation of its metabolite, phosphatidic acid. GH-stimulated RalA-phospholipase D-dependent formation of phosphatidic acid was required for activation of p44/42 MAPK and subsequent Elk-1-mediated transcription stimulated by GH. Thus we report the identification of a JAK2-independent pathway regulating GH-stimulated p44/42 MAPK activity.	Inst Mol & Cell Biol, Singapore 117609, Singapore; Natl Univ Singapore, Dept Med, Singapore 119074, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Lobie, PE (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbpel@imcb.nus.edu.sg						Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Arai A, 2001, J BIOL CHEM, V276, P33282, DOI 10.1074/jbc.M102924200; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Gaur S, 1996, AM J PHYSIOL-CELL PH, V270, pC1485, DOI 10.1152/ajpcell.1996.270.5.C1485; GAUR S, 2000, P 8I END SOC M TOR O; Goh ELK, 2000, J BIOL CHEM, V275, P17683, DOI 10.1074/jbc.M001972200; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Gomez-Cambronero J, 1998, CELL SIGNAL, V10, P387, DOI 10.1016/S0898-6568(97)00197-6; Graichen R, 2002, J BIOL CHEM, V277, P26662, DOI 10.1074/jbc.M109931200; Gu YP, 2001, MOL CELL BIOCHEM, V223, P35, DOI 10.1023/A:1017941625858; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Herrington J, 2001, TRENDS ENDOCRIN MET, V12, P252, DOI 10.1016/S1043-2760(01)00423-4; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Johnson SAS, 2000, MOL CELL BIOL, V20, P5000, DOI 10.1128/MCB.20.14.5000-5009.2000; Kariya K, 2000, J BIOL CHEM, V275, P18399, DOI 10.1074/jbc.M000521200; Kaulsay KK, 2001, ENDOCRINOLOGY, V142, P767, DOI 10.1210/en.142.2.767; Kopchick JJ, 2000, MOL GENET METAB, V71, P293, DOI 10.1006/mgme.2000.3068; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; M'Rabet L, 1999, J BIOL CHEM, V274, P21847, DOI 10.1074/jbc.274.31.21847; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; Matozaki T, 2000, CELL SIGNAL, V12, P515, DOI 10.1016/S0898-6568(00)00102-9; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Park JB, 2001, EXP MOL MED, V33, P54, DOI 10.1038/emm.2001.10; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Sayeski PP, 1999, CIRC RES, V84, P1332, DOI 10.1161/01.RES.84.11.1332; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; TOLLET P, 1995, J BIOL CHEM, V270, P12569, DOI 10.1074/jbc.270.21.12569; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; Vara JAF, 2000, BIOCHEM J, V345, P17, DOI 10.1042/0264-6021:3450017; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Xu YJ, 1996, AM J PHYSIOL-HEART C, V271, pH651, DOI 10.1152/ajpheart.1996.271.2.H651; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682	69	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45592	45603		10.1074/jbc.M201385200	http://dx.doi.org/10.1074/jbc.M201385200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12218045	hybrid			2022-12-25	WOS:000179404800125
J	Biroccio, A; Benassi, B; Filomeni, G; Amodei, S; Marchini, S; Chiorino, G; Rotilio, G; Zupi, G; Ciriolo, MR				Biroccio, A; Benassi, B; Filomeni, G; Amodei, S; Marchini, S; Chiorino, G; Rotilio, G; Zupi, G; Ciriolo, MR			Glutathione influences c-Myc-induced apoptosis in M14 human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTISENSE OLIGODEOXYNUCLEOTIDES ENHANCE; MEDIATED APOPTOSIS; DOWN-REGULATION; S-TRANSFERASE; GSH EXTRUSION; CYCLE ARREST; IN-VITRO; EXPRESSION; CISPLATIN; DEATH	The objective of this article is to dissect the mechanisms by which the down-regulation of c-Myc induces programmed cell death in melanoma cells. In stable and doxycycline-inducible M14 melanoma cells, down-regulation of c-Myc induced apoptosis subsequent to a decrease in the intracellular reduced glutathione content and a concomitant accumulation of its oxidized form. This redox alteration was associated with a decrease of the enzyme activities of gamma-glutamyl-cysteine synthetase and NADPH-dependent GSSG reductase, as well as a consequent glutathione release in the extracellular medium. Cytochrome c was released into the cytosol at very early stages of apoptosis induction, long before detectable production of reactive oxygen species and activation of caspase-9 and -3. Macroarray analysis revealed that down-regulation of c-Myc produced striking changes in gene expression in the section related to metabolism, where the expression of gamma-glutamyl-cysteine synthetase and GSSG reductase was found to be significantly reduced. The addition of N-acetyl-L-cysteine or glutathione ethyl ester inhibited the apoptotic process, thus confirming the key role of glutathione in programmed cell death induced by c-Myc.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I-00158 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; G Dannunzio Univ, Dept Biomed Sci, I-66013 Chieti, Italy; Mario Negri Inst Pharmacol Res, Dept Oncol, I-20154 Milan, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Rome Tor Vergata; G d'Annunzio University of Chieti-Pescara; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Biroccio, A (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Via Messi Doro 156, I-00158 Rome, Italy.		Biroccio, Annamaria/B-2861-2018; Marchini, sergio/J-3968-2018; Chiorino, Giovanna/K-5037-2016; Ciriolo, Maria Rosa/K-6572-2016	Biroccio, Annamaria/0000-0003-3198-3532; Marchini, sergio/0000-0003-1783-7651; Chiorino, Giovanna/0000-0002-9502-6400; Filomeni, Giuseppe/0000-0002-2719-1412; Ciriolo, Maria Rosa/0000-0002-7863-9029				ASKEW DS, 1991, ONCOGENE, V6, P1915; Backway KL, 1997, CANCER RES, V57, P2446; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Biroccio A, 2002, ONCOGENE, V21, P3011, DOI 10.1038/sj.onc.1205415; Biroccio A, 2001, MOL PHARMACOL, V60, P174, DOI 10.1124/mol.60.1.174; Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530; Citro G, 1998, CANCER RES, V58, P283; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Desbarats L, 1996, EXPERIENTIA, V52, P1123, DOI 10.1007/BF01952111; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Franklin CC, 2002, AM J PATHOL, V160, P1887, DOI 10.1016/S0002-9440(10)61135-2; FREEDMAN JH, 1989, J BIOL CHEM, V264, P5598; Fruehauf JP, 1997, PIGM CELL RES, V10, P236, DOI 10.1111/j.1600-0749.1997.tb00490.x; Fruehauf JP, 1998, CHEM-BIOL INTERACT, V112, P277, DOI 10.1016/S0009-2797(97)00167-1; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KIMURA S, 1995, CANCER RES, V55, P1379; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Macho A, 1997, J IMMUNOL, V158, P4612; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 1998, BLOOD, V92, P1003; PENA A, 1993, J BIOL CHEM, V268, P27277; Pierce RH, 2000, AM J PATHOL, V157, P221, DOI 10.1016/S0002-9440(10)64533-6; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Um HD, 1996, J IMMUNOL, V156, P3469; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; VanWardenburg RCAM, 1997, INT J CANCER, V73, P544, DOI 10.1002/(SICI)1097-0215(19971114)73:4<544::AID-IJC15>3.3.CO;2-C; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299	44	40	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43763	43770		10.1074/jbc.M207684200	http://dx.doi.org/10.1074/jbc.M207684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226097	hybrid, Green Published			2022-12-25	WOS:000179272000031
J	Cichy, J; Bals, R; Potempa, J; Mani, A; Pure, E				Cichy, J; Bals, R; Potempa, J; Mani, A; Pure, E			Proteinase-mediated release of epithelial cell-associated CD44 - Extracellular CD44 complexes with components of cellular matrices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-HOMING RECEPTOR; SOLUBLE CD44; PERICELLULAR MATRICES; CHONDROITIN SULFATE; HYALURONAN-BINDING; SPLICE VARIANTS; EXPRESSION; ISOFORMS; PATHOGENESIS; ACTIVATION	CD44 is a receptor for the matrix glycosaminoglycan hyaluronan. Proteoglycan forms of CD44 also exhibit affinity for fibronectin and collagen as well as chemokines and growth factors. CD44 plays a role in autoimmunity, inflammation, and tumor progression. Soluble CD44 (sCD44) is found in plasma, and the levels of sCD44 correlate with immune function and some malignancies. The mechanisms by which sCD44 is generated and its function are unknown. We demonstrate here that normal bronchial epithelial cells spontaneously release sCD44. Exposure to phagocyte- and bacterium-derived proteinases markedly increased the release of sCD44 from epithelial cells. The spontaneously released sCD44 was incorporated into high molecular mass complexes derived from the matrix that also contained chondroitin sulfate, fibronectin, hyaluronan, and collagens I and IV. Enzymatic digestion with proteinases liberated sCD44 from the high molecular mass complex. Consistent with the homology of CD44 to proteoglycan core and link proteins, these data suggest that CD44 spontaneously released from normal bronchial epithelial cells can accumulate as an integral component of the matrix, where it may play a role in the organization of matrices and in anchoring growth factors and chemokines to the matrix. Increases in plasma CD44 during immune activation and tumor progression therefore may be a manifestation of the matrix remodeling that occurs in the face of the enhanced proteolytic activity associated with infection, inflammation, and tumor metastasis, leading to alterations in cell-matrix interactions.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Jagiellonian Univ, Inst Mol Biol & Biotechnol, PL-31120 Krakow, Poland; Univ Munich, Med Klin & Poliklin 1, D-81377 Munich, Germany; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Ludwig Inst Canc Res, New York, NY 10158 USA	The Wistar Institute; Jagiellonian University; University of Munich; University System of Georgia; University of Georgia; Ludwig Institute for Cancer Research	Pure, E (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	pure@wistar.upenn.edu		Cichy, Joanna/0000-0002-0552-8344	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045813, R21AI045813] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26148] Funding Source: Medline; NIAID NIH HHS [AI45813] Funding Source: Medline; PHS HHS [6P05A14721] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1995, J CELL SCI, V108, P1723; Blass SL, 2001, J IMMUNOL, V166, P5726, DOI 10.4049/jimmunol.166.9.5726; Cichy J, 2000, J BIOL CHEM, V275, P18061, DOI 10.1074/jbc.M907962199; Cuff CA, 2001, J CLIN INVEST, V108, P1031, DOI 10.1172/JCI12455; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DROLL A, 1995, J BIOL CHEM, V270, P11567, DOI 10.1074/jbc.270.19.11567; Ehnis T, 1996, EXP CELL RES, V229, P388, DOI 10.1006/excr.1996.0384; Estess P, 1998, J CLIN INVEST, V102, P1173, DOI 10.1172/JCI4235; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GREEN SJ, 1988, J CELL SCI, V90, P145; Greenfield B, 1999, J BIOL CHEM, V274, P2511, DOI 10.1074/jbc.274.4.2511; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; Katoh S, 1999, ALLERGY, V54, P1286, DOI 10.1034/j.1398-9995.1999.00277.x; KATOH S, 1994, J IMMUNOL, V153, P3440; Kessler E., 1998, HDB PROTEOLYTIC ENZY, P1058; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; Knudson W, 1996, EXP CELL RES, V228, P216, DOI 10.1006/excr.1996.0320; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; Konig H, 1996, EMBO J, V15, P4030, DOI 10.1002/j.1460-2075.1996.tb00776.x; Lackie PM, 1997, AM J RESP CELL MOL, V16, P14, DOI 10.1165/ajrcmb.16.1.8998074; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; Nandi A, 2000, J BIOL CHEM, V275, P14939, DOI 10.1074/jbc.275.20.14939; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; POTEMPA J, 1998, HDB PROTEINASES, P1540; SALVESEN GS, 1998, HDB PROTEOLYTIC ENZY, P60; SCHLOSSMAN SF, 1995, WHITE CELL DIFFERENT; Schrager HM, 1998, J CLIN INVEST, V101, P1708, DOI 10.1172/JCI2121; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STOCKLEY RA, 1994, AM J RESP CRIT CARE, V150, pS109, DOI 10.1164/ajrccm/150.6_Pt_2.S109; SUTER S, 1994, AM J RESP CRIT CARE, V150, pS118, DOI 10.1164/ajrccm/150.6_Pt_2.S118; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; VANWEERING DHJ, 1993, PCR METH APPL, V3, P100; Wolff EA, 1999, J BIOL CHEM, V274, P2518, DOI 10.1074/jbc.274.4.2518; Yu Q, 1996, J BIOL CHEM, V271, P20603, DOI 10.1074/jbc.271.34.20603; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	41	33	37	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44440	44447		10.1074/jbc.M207437200	http://dx.doi.org/10.1074/jbc.M207437200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226094	hybrid			2022-12-25	WOS:000179272000115
J	Karsdal, MA; Larsen, L; Engsig, MT; Lou, H; Ferreras, M; Lochter, A; Delaisse, JM; Foged, NT				Karsdal, MA; Larsen, L; Engsig, MT; Lou, H; Ferreras, M; Lochter, A; Delaisse, JM; Foged, NT			Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATINASE-A MMP-2; TGF-BETA; BONE-FORMATION; IN-VITRO; COLLAGEN LATTICES; MC3T3-E1 CELLS; MT1-MMP MMP-14; EXPRESSION; MINERALIZATION; FIBROBLASTS	Upon termination of bone matrix synthesis, osteoblasts either undergo apoptosis or differentiate into osteocytes or bone lining cells. In this study, we investigated the role of matrix metalloproteinases (MMPs) and growth factors in the differentiation of osteoblasts into osteocytes and in osteoblast apoptosis. The mouse osteoblast cell line MC3T3-El and primary mouse calvarial osteoblasts were either grown on two-dimensional (2-D) collagen-coated surfaces, where they morphologically resemble flattened, cuboidal bone lining cells, or embedded in three-dimensional (3-D) collagen gels, where they resemble dendritic osteocytes constituting a network of cells. When MC3T3-El osteoblasts were grown in a 3-D matrix in the presence of an MMP inhibitor (GM6001), the cell number was dose-dependently reduced by approximately 50%, whereas no effect was observed on a 2-D substratum. In contrast, the murine mature osteocyte cell line, MLO-Y4, was unaffected by GM6001 under all culture conditions. According to TUNEL assay, the osteoblast apoptosis was increased 2.5-fold by 10 muM GM6001. To investigate the mechanism by which MMPs mediate the survival of osteoblasts, we examined the effect of GM6001 on MC3T3-E1 osteoblasts in the presence of extracellular matrix components and growth factors, including tenascin, fibronectin, laminin, collagenase-cleaved collagen, gelatin, parathyroid hormone, basic fibroblast growth factor, vascular epidermal growth factor, insulin-like growth factor, interleukin-1, and latent and active transforming growth factor-beta (TGF-beta). Only active TGF-beta, but not latent TGF-beta or other agents tested, restored cell number and apoptosis to control levels. Furthermore, we found that the membrane type MMP, MT1-MMP, which is produced by osteoblasts, could activate latent TGF-beta and that antibodies neutralizing endogenous TGF-beta led to a similar decrease in cell number as GM6001. Whereas inhibitors of other protease families did not induce osteoblast apoptosis, an inhibitor of the p44/42 mitogen-activated protein kinase showed the same but non-synergetic effect as GM6001. These findings suggest that MMP-activated TGF-beta maintains osteoblast survival during trans-differentiation into osteocytes by a p44/42-dependent pathway.	Nord Biosci AS, Ctr Clin & Basic Res, DK-2730 Herlev, Denmark	Center Clinical & Basic Research; Nordic Bioscience	Karsdal, MA (corresponding author), Nord Biosci AS, Ctr Clin & Basic Res, DK-2730 Herlev, Denmark.		Foged, Niels T/AHA-2122-2022	Delaisse, Jean-Marie/0000-0001-7370-1500; Karsdal, Morten/0000-0001-5026-8740				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BELLOWS CG, 1981, J CELL SCI, V50, P299; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bonewald LF, 1999, J BONE MINER METAB, V17, P61, DOI 10.1007/s007740050066; Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754; BOUVIER M, 1990, ARCH ORAL BIOL, V35, P301, DOI 10.1016/0003-9969(90)90047-E; BOUVIER M, 1990, DIFFERENTIATION, V45, P128, DOI 10.1111/j.1432-0436.1990.tb00466.x; CASSERBETTE M, 1990, CALCIFIED TISSUE INT, V46, P46, DOI 10.1007/BF02555824; Chaudhary LR, 2001, J CELL BIOCHEM, V81, P304, DOI 10.1002/1097-4644(20010501)81:2<304::AID-JCB1045>3.3.CO;2-L; Cheng BX, 2001, ENDOCRINOLOGY, V142, P3464, DOI 10.1210/en.142.8.3464; Choi JY, 1996, J CELL BIOCHEM, V61, P609, DOI 10.1002/(SICI)1097-4644(19960616)61:4<609::AID-JCB15>3.3.CO;2-Q; CLARK RAF, 1995, J CELL SCI, V108, P1251; Cooper LF, 2000, J CELL PHYSIOL, V185, P401, DOI 10.1002/1097-4652(200012)185:3<401::AID-JCP10>3.0.CO;2-C; D'Angelo M, 2001, J BONE MINER RES, V16, P2339, DOI 10.1359/jbmr.2001.16.12.2339; D'Angelo M, 2001, J BIOL CHEM, V276, P11347, DOI 10.1074/jbc.M009725200; Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879; Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Ferrera D, 2002, BONE, V30, P718, DOI 10.1016/S8756-3282(02)00691-9; Festuccia C, 2000, INT J CANCER, V85, P407, DOI 10.1002/(SICI)1097-0215(20000201)85:3<407::AID-IJC18>3.0.CO;2-8; Filanti C, 2000, J BONE MINER RES, V15, P2154, DOI 10.1359/jbmr.2000.15.11.2154; Filvaroff E, 1999, DEVELOPMENT, V126, P4267; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200; Kim MK, 2001, YONSEI MED J, V42, P338, DOI 10.3349/ymj.2001.42.3.338; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; Li S, 1999, J ORTHOP RES, V17, P891, DOI 10.1002/jor.1100170614; Lin HC, 2001, INVEST OPHTH VIS SCI, V42, P2517; Maeda S, 2002, CALCIFIED TISSUE INT, V70, P54, DOI 10.1007/s002230010032; Maeda S, 2001, J BONE MINER RES, V16, P1281, DOI 10.1359/jbmr.2001.16.7.1281; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; MAUCH C, 1988, EXP CELL RES, V178, P493, DOI 10.1016/0014-4827(88)90417-X; MCGUIRE PG, 1989, J CELL BIOCHEM, V40, P215, DOI 10.1002/jcb.240400210; Morimura N, 2001, J BIOL CHEM, V276, P42172, DOI 10.1074/jbc.M103216200; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; Sato A, 1999, ADV SPACE RES, V24, P807, DOI 10.1016/S0273-1177(99)00076-9; SPRAGUE SM, 1994, KIDNEY INT, V46, P1199, DOI 10.1038/ki.1994.385; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Takamine Y, 2002, CLIN ORTHOP RELAT R, P240; Uchida M, 2000, J CELL PHYSIOL, V185, P207, DOI 10.1002/1097-4652(200011)185:2<207::AID-JCP5>3.0.CO;2-J; Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002-9343(99)00420-9; Yu Q, 2000, GENE DEV, V14, P163; Zhao WG, 2000, J CLIN INVEST, V106, P941, DOI 10.1172/JCI10158	58	192	201	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44061	44067		10.1074/jbc.M207205200	http://dx.doi.org/10.1074/jbc.M207205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226090	hybrid			2022-12-25	WOS:000179272000069
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; PREDICTED TRANSMEMBRANE DOMAIN; CYSTEINE-SCANNING MUTAGENESIS; DRUG-BINDING; FUNCTIONAL CONSEQUENCES; CROSS-LINKING; SUBSTRATE-SPECIFICITY; MUTATIONS; MUTANTS; IDENTIFICATION	The human multidrug resistance P-glycoprotein (P-gp) pumps a wide variety of structurally diverse compounds out of the cell. It is an ATP-binding cassette transporter with two nucleotide-binding domains and twos transmembrane (TM) domains. One class of compounds transported by P-gp is the rhodamine dyes. A P-gp deletion mutant (residues 1-379 plus 681-1025) With only the TM domains retained the ability to bind rhodamine. Therefore, to identify the residues involved in rhodamine binding, 252 mutants containing a cysteine in the predicted TM segments were generated and reacted with a thiol-reactive analog of rhodamine, methanethiosulfonate (MTS)-rhodamine. The activities of 28 mutants (in TMs 2-12) were inhibited by at least 50% after reaction with MTS-rhodamine. The activities of five mutants, 1340C(TM6), A841C(TM9), L975C(TM12), V981C(TM12), and V982C(TM12), however, were significantly protected from inhibition by MTS-rhodamine by pretreatment with rhodamine B, indicating that residues in TMs 6, 9, and 12 contribute to the binding of rhodamine dyes. These results, together with those from previous labeling studies with other thiol-reactive compounds, dibromobimane, MTS-verapamil, and MTS-cross-linker substrates, indicate that common residues are involved in the binding of structurally different drug substrates and that P-gp has a common drug-binding site. The results support the "substrate-induced fit" hypothesis for drug binding.	Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Loo, TW (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NCI NIH HHS [R01 CA80900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ayesh S, 1996, BBA-MOL BASIS DIS, V1316, P8, DOI 10.1016/0925-4439(96)00008-7; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Bruice T.W., 1982, J PROTEIN CHEM, V1, P47, DOI DOI 10.1007/BF01025550; CARDO CC, 1989, P NATL ACAD SCI USA, V86, P695; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Demeule M, 1998, BIOCHEMISTRY-US, V37, P18110, DOI 10.1021/bi981992c; Demmer A, 1997, J BIOL CHEM, V272, P20913, DOI 10.1074/jbc.272.33.20913; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; Ecker GF, 2002, MOL PHARMACOL, V61, P637, DOI 10.1124/mol.61.3.637; Eytan GD, 1997, EUR J BIOCHEM, V248, P104, DOI 10.1111/j.1432-1033.1997.00104.x; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hrycyna CA, 2001, SEMIN CELL DEV BIOL, V12, P247, DOI 10.1006/scdb.2000.0250; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kenyon G L, 1977, Methods Enzymol, V47, P407; Krishna R, 2000, EUR J PHARM SCI, V11, P265, DOI 10.1016/S0928-0987(00)00114-7; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1999, BIOCHEM CELL BIOL, V77, P11, DOI 10.1139/bcb-77-1-11; Loo TW, 1999, FASEB J, V13, P1724, DOI 10.1096/fasebj.13.13.1724; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOO TW, 1994, J BIOL CHEM, V269, P28683; Loo TW, 2000, JNCI-J NATL CANCER I, V92, P898, DOI 10.1093/jnci/92.11.898; Loo TW, 1998, METHOD ENZYMOL, V292, P480; Muller M, 1996, J BIOL CHEM, V271, P1877; Pascaud C, 1998, BIOCHEM J, V333, P351, DOI 10.1042/bj3330351; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Senior AE, 1998, ARCH BIOCHEM BIOPHYS, V357, P121, DOI 10.1006/abbi.1998.0778; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Shapiro AB, 1999, EUR J BIOCHEM, V259, P841, DOI 10.1046/j.1432-1327.1999.00098.x; Song JM, 2001, MOL PHARMACOL, V60, P254, DOI 10.1124/mol.60.2.254; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735	59	169	173	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44332	44338		10.1074/jbc.M208433200	http://dx.doi.org/10.1074/jbc.M208433200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223492	hybrid			2022-12-25	WOS:000179272000104
J	Luo, SH; Scott, DA; Docampo, R				Luo, SH; Scott, DA; Docampo, R			Trypanosoma cruzi H+-ATPase 1 (TcHA1) and 2 (TcHA2) genes complement yeast mutants defective in H+ pumps and encode plasma membrane P-type H+-ATPases with different enzymatic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; LEISHMANIA-DONOVANI; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; CHAGAS-DISEASE; CALCIUM-PUMP; PROTON PUMPS; PLANT; PROTEIN	Previous studies in Trypanosoma cruzi have shown that intracellular pH homeostasis requires ATP and is affected by H+-ATPase inhibitors, indicating a major role for ATP-driven proton pumps in intracellular pH control. In the present study, we report the cloning and sequencing of a pair of genes linked in tandem (TcHA1 and TcHA2) in T. cruzi which encode proteins with homology to fungal and plant P-type proton-pumping ATPases. The genes are expressed at the mRNA level in different developmental stages of T. cruzi: TcHA1 is expressed maximally in epimastigotes, whereas TcHA2 is expressed predominantly in trypomastigotes. The proteins predicted from the nucleotide sequence of the genes have 875 and 917 amino acids and molecular masses of 96.3 and 101.2 kDa, respectively. Full-length TcHA1 and an N-terminal truncated version of TcHA2 complemented a Saccharomyces cerevisiae strain deficient in P-type H+-ATPase activity, the proteins localized to the yeast plasma membrane, and ATP-driven proton pumping could be detected in proteoliposomes reconstituted from plasma membrane purified from transfected yeast. The reconstituted proton transport activity was reduced by inhibitors of P-type H+-ATPases. C-terminal truncation did not affect complementation of mutant yeast, suggesting the lack of C-terminal autoinhibitory domains in these proteins. ATPase activity in plasma membrane from TcHA1- and (N-terminal truncated) TcHA2-transfected yeast was inhibited to different extents by vanadate, whereas the latter yeast strain was more resistant to extremes of pH, suggesting that the native proteins may serve different functions at different stages in the T. cruzi life cycle.	Univ Illinois, Coll Vet Med, Mol Parasitol Lab, Dept Pathobiol, Urbana, IL 61802 USA; Univ Illinois, Ctr Zoonoses Res, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Mol Parasitol Lab, Dept Pathobiol, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu		Scott, David/0000-0002-8668-2449	NIAID NIH HHS [AI-23259] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023259, R21AI023259] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; BENAIM G, 1995, BIOCHEM J, V306, P299, DOI 10.1042/bj3060299; Bockelmann C, 1998, J PLANT PHYSIOL, V152, P194, DOI 10.1016/S0176-1617(98)80132-6; BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CHUNG SH, 1990, NUCLEIC ACIDS RES, V18, P4561, DOI 10.1093/nar/18.15.4561; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; DEXAERDE AD, 1995, J BIOL CHEM, V270, P23828, DOI 10.1074/jbc.270.40.23828; Drose S, 1997, J EXP BIOL, V200, P1; Ferreira T, 2001, J BIOL CHEM, V276, P29613, DOI 10.1074/jbc.R100022200; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GONZALEZ A, 1985, NUCLEIC ACIDS RES, V13, P5789, DOI 10.1093/nar/13.16.5789; Hill JE, 2000, BIOCHEM J, V351, P281, DOI 10.1042/0264-6021:3510281; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; JOHANSSON F, 1993, PLANT CELL, V5, P321, DOI 10.2307/3869599; KIRCHHOFF LV, 1993, NEW ENGL J MED, V329, P639, DOI 10.1056/NEJM199308263290909; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Luo H, 1999, PLANT PHYSIOL, V119, P627, DOI 10.1104/pp.119.2.627; Maudoux O, 2000, J BIOL CHEM, V275, P17762, DOI 10.1074/jbc.M909690199; MEADE JC, 1987, MOL CELL BIOL, V7, P3937, DOI 10.1128/MCB.7.11.3937; MEADE JC, 1989, MOL BIOCHEM PARASIT, V33, P81, DOI 10.1016/0166-6851(89)90045-5; Meade JC, 2000, PARASITOL INT, V49, P309, DOI 10.1016/S1383-5769(00)00061-1; MEADE JC, 1991, MOL BIOCHEM PARASIT, V45, P29, DOI 10.1016/0166-6851(91)90024-Z; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MONK BC, 1994, CRIT REV MICROBIOL, V20, P209, DOI 10.3109/10408419409114555; Morsomme P, 2000, BBA-BIOMEMBRANES, V1465, P1, DOI 10.1016/S0005-2736(00)00128-0; PALMGREN MG, 1994, J BIOL CHEM, V269, P3027; Palmgren MG, 2001, ANNU REV PLANT PHYS, V52, P817, DOI 10.1146/annurev.arplant.52.1.817; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 1998, BIOCHEM J, V331, P583, DOI 10.1042/bj3310583; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; SKEIKY YAW, 1992, J EXP MED, V176, P201, DOI 10.1084/jem.176.1.201; Souto RP, 1996, MOL BIOCHEM PARASIT, V83, P141, DOI 10.1016/S0166-6851(96)02755-7; Stiles JK, 1999, MOL BIOCHEM PARASIT, V103, P105, DOI 10.1016/S0166-6851(99)00105-X; SUPPLY P, 1993, J BIOL CHEM, V268, P19753; Van Der Heyden N, 2000, MOL BIOCHEM PARASIT, V105, P237, DOI 10.1016/S0166-6851(99)00184-X; Vanderheyden N, 1996, BIOCHEM J, V318, P103, DOI 10.1042/bj3180103; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; 1997, 13 PROGRAM REPORT UN, P112	51	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44497	44506		10.1074/jbc.M202267200	http://dx.doi.org/10.1074/jbc.M202267200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221074	hybrid			2022-12-25	WOS:000179272000121
J	Obin, M; Lee, BY; Meinke, G; Bohm, A; Lee, RH; Gaudet, R; Hopp, JA; Arshavsky, VY; Willardson, BM; Taylor, A				Obin, M; Lee, BY; Meinke, G; Bohm, A; Lee, RH; Gaudet, R; Hopp, JA; Arshavsky, VY; Willardson, BM; Taylor, A			Ubiquitylation of the transducin beta gamma subunit complex - Regulation by phosducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; ROD OUTER SEGMENTS; HETEROTRIMERIC G-PROTEINS; DEPENDENT PROTEOLYSIS; PHOTORECEPTOR CELLS; ALPHA-SUBUNIT; 3RD FORM; IN-VIVO; IDENTIFICATION; DEGRADATION	G proteins (Galphabetagamma) are essential signaling molecules, which dissociate into Galpha and Gbetagamma upon activation by heptahelical membrane receptors. We have identified the betagamma subunit complex of the photoreceptor-specific G protein, transducin (T), as a target of the ubiquitin-proteasome pathway. Ubiquitylated species of the transducin gamma-subunit (Tgamma) but not the alpha- or beta-subunits were assembled de novo in bovine photoreceptor preparations. In addition, Tgamma was exclusively ubiquitylated when Tbetagamma was dissociated from Talpha. Ubiquitylation of Tbetagamma on Tgamma was selectively catalyzed by human ubiquitin-conjugating enzymes UbcH5 and UbcH7 and was coincident with degradation of the entire Tbetagamma subunit complex in vitro by a mechanism requiring ATP and the proteasome. We also show that Tbetagamma association with phosducin, a photoreceptor-specific protein of unknown physiological function, blocks Tbetagamma ubiquitylation and subsequent degradation. Phosphorylation of phosducin by Ca2+/calmodulin-dependent protein kinase II, which inhibits phosducin-Tbetagamma complex formation, completely restored Toy ubiquitylation and degradation. We conclude that Tbetagamma is a substrate of the ubiquitin-proteasome pathway and suggest that phosducin serves to protect Tbetagamma following the light-dependent dissociation of Talphabetagamma.	Tufts Univ, JMUSDA, HNRCA, Lab Nutr & Vis Res, Boston, MA 02111 USA; Tufts Ctr Vis Res, Boston, MA 02111 USA; Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; Boston Biomed Res Inst, Watertown, MA 02472 USA; Jules Stein Eye Inst, Sepulveda, CA 90095 USA; Greater Los Angeles Healthcare Syst, Sepulveda, CA 90095 USA; Harvard Univ, Dept Mol & Cellular Biol, Boston, MA 02138 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA	Tufts University; United States Department of Agriculture (USDA); Brigham Young University; Boston Biomedical Research Institute; Harvard University; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary	Obin, M (corresponding author), Tufts Univ, JMUSDA, HNRCA, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.	mobin@hnrc.tufts.edu	Gaudet, Rachelle/I-4133-2014; Gaudet, Rachelle/Y-3985-2019	Gaudet, Rachelle/0000-0002-9177-054X; Gaudet, Rachelle/0000-0002-9177-054X; Willardson, Barry/0000-0002-8503-2268	NEI NIH HHS [EY11704, EY12287, EY13250, EY10336, P30 EY13078] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010336, R01EY013250, R01EY012287, P30EY013078] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 2000, EXP EYE RES, V71, pS179; Barhite S, 1998, BBA-MOL CELL RES, V1402, P95, DOI 10.1016/S0167-4889(97)00141-9; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897; Chen FY, 1997, BIOCHEM BIOPH RES CO, V233, P370, DOI 10.1006/bbrc.1997.6460; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Flanary PL, 2000, J BIOL CHEM, V275, P18462, DOI 10.1074/jbc.M002163200; FUNG BKK, 1992, J BIOL CHEM, V267, P24782; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5; GIROD PA, 1993, J BIOL CHEM, V268, P955; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; Kimple Randall J, 2002, Mol Interv, V2, P88, DOI 10.1124/mi.2.2.88; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; LEE RH, 1992, J BIOL CHEM, V267, P24776; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1992, J BIOL CHEM, V267, P25104; LEE RH, 1993, METH NEUROSCI, V15, P196; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; MCGUIRE MJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P273, DOI 10.1016/0003-9861(88)90189-0; Nakano K, 2001, P NATL ACAD SCI USA, V98, P4693, DOI 10.1073/pnas.071067198; NAVON SE, 1988, J BIOL CHEM, V263, P489; Obin M, 1999, J BIOL CHEM, V274, P11789, DOI 10.1074/jbc.274.17.11789; OBIN M, 1994, BIOCHEM BIOPH RES CO, V200, P1169, DOI 10.1006/bbrc.1994.1574; Obin M, 2002, FASEB J, V16, pA196; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; Oughtred R, 1998, J BIOL CHEM, V273, P18435, DOI 10.1074/jbc.273.29.18435; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; PICKART CM, 1998, UBIQUITIN BIOL CELL, P19; Pierce EA, 2001, BIOESSAYS, V23, P605, DOI 10.1002/bies.1086; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Savage JR, 2000, J BIOL CHEM, V275, P30399, DOI 10.1074/jbc.M005120200; Schauber C, 1998, GENES CELLS, V3, P307, DOI 10.1046/j.1365-2443.1998.00192.x; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Schulz R, 2001, PHARMACOL RES, V43, P1, DOI 10.1006/phrs.2000.0757; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Taylor A, 1997, MOL ASPECTS MED, V18, P307, DOI 10.1016/S0098-2997(95)00049-6; Thulin CD, 2001, J BIOL CHEM, V276, P23805, DOI 10.1074/jbc.M101482200; Thulin CD, 1999, MOL VIS, V5, pU13; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Varshavsky A., 1998, UBIQUITIN BIOL CELL, P223; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; WING SS, 1995, BIOCHEM J, V305, P125, DOI 10.1042/bj3050125; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050; Zhu X, 1998, Mol Vis, V4, P13	61	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44566	44575		10.1074/jbc.M205308200	http://dx.doi.org/10.1074/jbc.M205308200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12215439	Green Published, hybrid			2022-12-25	WOS:000179272000129
J	Vishnivetskiy, SA; Hirsch, JA; Velez, MG; Gurevich, YV; Gurevich, VV				Vishnivetskiy, SA; Hirsch, JA; Velez, MG; Gurevich, YV; Gurevich, VV			Transition of arrestin into the active receptor-binding state requires an extended interdomain hinge	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISUAL ARRESTIN; CRYSTAL-STRUCTURE; PHOSPHORYLATION-RECOGNITION; BETA-ARRESTIN; RHODOPSIN; MECHANISM; ROD; SELECTIVITY; ANGSTROM; COMPLEX	Arrestins selectively bind to the phosphorylated activated form of G protein-coupled receptors, thereby blocking further G protein activation. Structurally, arrestins consist of two domains topologically connected by a 12-residue long loop, which we term the "hinge" region. Both domains contain receptor-binding elements. The relative size and shape of arrestin and rhodopsin suggest that dramatic changes in arrestin conformation are required to bring all of its receptor-binding elements in contact with the cytoplasmic surface of the receptor. Here we use the visual arrestin/ rhodopsin system to test the hypothesis that the transition of arrestin into its active receptor-binding state involves a movement of the two domains relative to each other that might be limited by the length of the hinge. We have introduced three insertions and 24 deletions in the hinge region and measured the binding of all of these mutants to light-activated phosphorylated (P-Rh*), dark phosphorylated (P-Rh), dark unphosphorylated (Rh), and light-activated unphosphorylated rhodopsin (Rh*). The addition of 1-3 extra residues to the hinge has no effect on arrestin function. In contrast, sequential elimination of 1-8 residues results in a progressive decrease in P-Rh* binding without changing arrestin selectivity for P-Rh*. These results suggest that there is a minimum length of the hinge region necessary for high affinity binding, consistent with the idea that the two domains move relative to each other in the process of arrestin transition into its active receptor-binding state. The same length of the hinge is also necessary for the binding of constitutively active" arrestin mutants to P-Rh*, dark P-Rh, and Rh*, suggesting that the active (receptor-bound) arrestin conformation is essentially the same in both wild type and mutant forms.	Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA; Tel Aviv Univ, Dept Biochem, George S Wise Fac Life Sci, IL-69978 Ramat Aviv, Israel	Vanderbilt University; Tel Aviv University	Gurevich, VV (corresponding author), Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA.	Vsevolod.Gurevich@mcmail.vanderbilt.edu	Hirsch, Joel/AAC-8000-2021; Gurevich, Vsevolod/A-3236-2008; Vishnivetskiy, Sergey/AAJ-8661-2020	Hirsch, Joel/0000-0001-7544-8668; Gurevich, Vsevolod/0000-0002-3950-5351; 	NEI NIH HHS [EY11500] Funding Source: Medline; NIGMS NIH HHS [GM63097] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063097] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Luttrell LM, 2002, J CELL SCI, V115, P455; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200; Pulvermuller A, 1997, BIOCHEMISTRY-US, V36, P9253, DOI 10.1021/bi970772g; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; Smith WC, 2000, INVEST OPHTH VIS SCI, V41, P2445; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451	30	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43961	43967		10.1074/jbc.M206951200	http://dx.doi.org/10.1074/jbc.M206951200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12215448	hybrid			2022-12-25	WOS:000179272000056
J	Roje, S; Janave, MT; Ziemak, MJ; Hanson, AD				Roje, S; Janave, MT; Ziemak, MJ; Hanson, AD			Cloning and characterization of mitochondrial 5-formyltetrahydrofolate cycloligase from higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; HUMAN 5,10-METHENYLTETRAHYDROFOLATE SYNTHETASE; NITROUS-OXIDE INACTIVATION; METHENYLTETRAHYDROFOLATE SYNTHETASE; SERINE HYDROXYMETHYLTRANSFERASE; RABBIT LIVER; SACCHAROMYCES-CEREVISIAE; FOLATE DERIVATIVES; PURIFICATION; POLYGLUTAMATES	5-Formyltetrahydrofolate cycloligase (5-FCL) catalyzes the conversion of 5-formyltetrahydrofolate (5CHO-H(4)PteGlu(n)) to 5,10-methenyltetrahydrofolate and is considered to be the main means whereby 5-CHOH(4)PteGlu(n) is metabolized in mammals, yeast, and bacteria. 5-CHO-H(4)PteGlu(n) is known to occur in plants and to be highly abundant in leaf mitochondria. Genomics-based approaches identified Arabidopsis and tomato cDNAs encoding proteins homologous to 5-FCLs of other organisms but containing N-terminal extensions with the features of mitochondrial targeting peptides. These homologs were shown to have 5-FCL activity by characterizing recombinant enzymes produced in Escherichia coli and by functional complementation of a yeast fau1 mutation with the Arabidopsis 5-FCL cDNA. The recombinant Arabidopsis enzyme is active as a monomer, prefers the penta- to the monoglutamyl form of 5-CHOH(4)PteGlu(n), and has kinetic properties broadly similar to those of 5-FCLs from other organisms. Enzyme assays and immunoblot analyses indicated that 5-FCL is located predominantly if not exclusively in plant mitochondria and that the mature, active enzyme lacks the putative targeting sequence. Serine hydroxymethyltransferase (SHMT) from plant mitochondria was shown to be inhibited by 5-CHO-H(4)PteGlu(n) as are SEMs from other organisms. Since mitochondrial SHMT is crucial to photorespiration, 5-FCL may help prevent 5-CHO-H(4)PteGlu(n) from reaching levels that would inhibit this process. Consistent with this possibility, 5-FCL activity was far higher in leaf mitochondria than root mitochondria.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Hanson, AD (corresponding author), Univ Florida, Dept Hort Sci, POB 110690, Gainesville, FL 32611 USA.	adha@mail.ifas.ufl.edu		Roje, Sanja/0000-0002-6302-5382				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Baggott JE, 2000, BIOCHEMISTRY-US, V39, P14647, DOI 10.1021/bi001362m; BALAGHI M, 1993, BIOCHEM J, V291, P145, DOI 10.1042/bj2910145; BERTRAND R, 1995, BBA-MOL CELL RES, V1266, P245, DOI 10.1016/0167-4889(95)00020-S; BERTRAND R, 1987, BIOCHIM BIOPHYS ACTA, V911, P154, DOI 10.1016/0167-4838(87)90004-5; BERTRAND R, 1989, J BIOL CHEM, V264, P8843; BESSON V, 1995, PLANT PHYSIOL BIOCH, V33, P665; BESSON V, 1993, BIOCHEM J, V292, P425, DOI 10.1042/bj2920425; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen LF, 1997, PLANT PHYSIOL, V115, P299, DOI 10.1104/pp.115.1.299; CLINE K, 1986, J BIOL CHEM, V261, P4804; Cossins E, 2000, CAN J BOT, V78, P691, DOI 10.1139/cjb-78-6-691; Cossins EA, 1997, PHYTOCHEMISTRY, V45, P437, DOI 10.1016/S0031-9422(96)00833-3; DAYAN A, 1995, GENE, V165, P307, DOI 10.1016/0378-1119(95)00321-V; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Gambonnet B, 2001, J SCI FOOD AGR, V81, P835, DOI 10.1002/jsfa.870; Girgis S, 1997, J BIOL CHEM, V272, P4729, DOI 10.1074/jbc.272.8.4729; GREENBERG DM, 1965, BIOCHEMISTRY-US, V4, P1872, DOI 10.1021/bi00885a026; GRIMSHAW CE, 1984, J BIOL CHEM, V259, P2728; Hanson AD, 2002, CURR OPIN PLANT BIOL, V5, P244, DOI 10.1016/S1369-5266(02)00249-2; Hanson AD, 2001, ANNU REV PLANT PHYS, V52, P119, DOI 10.1146/annurev.arplant.52.1.119; Harlow E., 1988, ANTIBODIES LAB MANUA; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Holmes WB, 2002, J BIOL CHEM, V277, P20205, DOI 10.1074/jbc.M201242200; HOPKINS S, 1984, J BIOL CHEM, V259, P5618; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; Horne DW, 1997, J NUTR, V127, P1772, DOI 10.1093/jn/127.9.1772; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HUENNEKENS FM, 1984, ADV ENZYME REGUL, V22, P3, DOI 10.1016/0065-2571(84)90005-0; Jolivet J, 1997, METHOD ENZYMOL, V281, P162; KRUSCHWITZ HL, 1994, J BIOL CHEM, V269, P28757; MARAS B, 1994, J BIOL CHEM, V269, P18429; Prabhu V, 1998, PLANT PHYSIOL, V116, P137, DOI 10.1104/pp.116.1.137; Raymond RK, 1999, ARCH BIOCHEM BIOPHYS, V372, P300, DOI 10.1006/abbi.1999.1498; Rebeille F, 1999, PR PHYT SOC, V42, P53; Schirch V, 1997, METHOD ENZYMOL, V281, P146; SHIN YS, 1975, CAN J BIOCHEM CELL B, V53, P338, DOI 10.1139/o75-047; Small I, 1998, PLANT MOL BIOL, V38, P265, DOI 10.1023/A:1006081903354; STORER AC, 1976, BIOCHEM J, V159, P1; STOVER P, 1993, TRENDS BIOCHEM SCI, V18, P102, DOI 10.1016/0968-0004(93)90162-G; STOVER P, 1990, J BIOL CHEM, V265, P14227; STOVER P, 1991, J BIOL CHEM, V266, P1543; Suh JR, 2000, J BIOL CHEM, V275, P35646, DOI 10.1074/jbc.M005864200; TAYLOR RT, 1965, ANAL BIOCHEM, V13, P80, DOI 10.1016/0003-2697(65)90120-X; Tissot G, 1997, BIOCHEM J, V323, P179, DOI 10.1042/bj3230179; Trossat C, 1996, PLANT PHYSIOL, V111, P965, DOI 10.1104/pp.111.4.965; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Yamaguchi Y, 2002, J CONTROL RELEASE, V81, P235, DOI 10.1016/S0168-3659(02)00060-3	50	37	39	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42748	42754		10.1074/jbc.M205632200	http://dx.doi.org/10.1074/jbc.M205632200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12207015	hybrid			2022-12-25	WOS:000179081200043
J	Schmitt, JM; Stork, PJS				Schmitt, JM; Stork, PJS			G alpha and G beta gamma require distinct Src-dependent pathways to activate Rap1 and ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; EPIDERMAL GROWTH-FACTOR; REGULATED KINASES ERKS; C-SRC; B-RAF; TYROSINE KINASES; MAP KINASE; BETA(2)-ADRENERGIC RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION	The Src tyrosine kinase is necessary for activation of extracellular signal-regulated kinases (ERKs) by the beta-adrenergic receptor agonist, isoproterenol. In this study, we examined the role of Src in the stimulation of two small G proteins, Ras and Rap1, that have been implicated in isoproterenol's signaling to ERKs. We demonstrate that the activation of isoproterenol of both Rap1 and Ras requires Src. In HEK293 cells, isoproterenol activates Rap1, stimulates Rap1 association with B-Raf, and activates ERKs, all via PKA. In contrast, the activation by isoproterenol of Ras requires Gbetagamma sub-units, is independent of PKA, and results in the phosphoinositol 3-kinase-dependent activation of AKT. Interestingly, beta-adrenergic stimulation of both Rap1 and ERKs, but not Ras and AKT, can be blocked by a Src mutant (SrcS17A) that is incapable of being phosphorylated and activated by PKA. Furthermore, a Src mutant (SrcS17D), which mimics PKA phosphorylation at serine 17, stimulates Rap1 activation, Rap1/B-Raf association, and ERK activation but does not stimulate Ras or AKT. These data suggest that Rap1 activation, but not that of Ras, is mediated through the direct phosphorylation of Src by PKA. We propose that the beta(2)-adrenergic receptor activates Src via two independent mechanisms to mediate distinct signaling pathways, one through Galpha(s) to Rap1 and ERKs and the other through Gbetagamma to Ras and AKT.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Stork, PJS (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474,SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NCI NIH HHS [CA07291] Funding Source: Medline; NHLBI NIH HHS [T32 HL07781] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007781] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; BIRNBAUMER L, 1992, CELL, V71, P10069; Bisotto S, 2001, BIOCHEM J, V360, P77, DOI 10.1042/0264-6021:3600077; Bommakanti RK, 2000, J BIOL CHEM, V275, P38870, DOI 10.1074/jbc.M007403200; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Fredriksson JM, 2000, J BIOL CHEM, V275, P13802, DOI 10.1074/jbc.275.18.13802; Friedman J, 2002, MOL PHARMACOL, V62, P1094, DOI 10.1124/mol.62.5.1094; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Iacovelli L, 2001, MOL PHARMACOL, V60, P924, DOI 10.1124/mol.60.5.924; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klinger M, 2002, J BIOL CHEM, V277, P32490, DOI 10.1074/jbc.M200556200; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kobierski LA, 1999, J NEUROCHEM, V73, P129, DOI 10.1046/j.1471-4159.1999.0730129.x; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Lindquist JM, 2000, J BIOL CHEM, V275, P22670, DOI 10.1074/jbc.M909093199; Lou LG, 2002, J BIOL CHEM, V277, P32799, DOI 10.1074/jbc.M201491200; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; Shah BH, 2002, MOL PHARMACOL, V61, P343, DOI 10.1124/mol.61.2.343; Shinohara M, 2001, J BIOL CHEM, V276, P18941, DOI 10.1074/jbc.M100909200; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WALKER F, 1993, J BIOL CHEM, V268, P19552; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200; Zhong HY, 1999, BIOCHEM J, V344, P889, DOI 10.1042/0264-6021:3440889	77	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43024	43032		10.1074/jbc.M204006200	http://dx.doi.org/10.1074/jbc.M204006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12221082	hybrid			2022-12-25	WOS:000179081200079
J	Wang, QB; Sharma, D; Ren, Y; Fondell, JD				Wang, QB; Sharma, D; Ren, Y; Fondell, JD			A coregulatory role for the TRAP-Mediator complex in androgen receptor-mediated gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; PROLIFERATOR-ACTIVATED RECEPTOR; AMINO-TERMINAL DOMAIN; CREB-BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTORS; ESTROGEN-RECEPTOR; COACTIVATOR COMPLEXES; RESPONSE ELEMENT; LIGAND-BINDING	The human thyroid hormone receptor-associated protein (TRAP)-Mediator complex was originally identified as a large multimeric complex that copurifies with the thyroid hormone receptor (TR) from HeLa cells and markedly enhances TR-mediated transcription in vitro. More recent studies have implicated TRAP-Mediator as a coactivator for a broad range of nuclear hormone receptors as well as other classes of transcriptional activators. Here we present evidence that TRAP-Mediator plays a functional role in androgen receptor (AR)-mediated transcription. We show that several subunits of the complex ligand-dependently coimmunoprecipitate with AR from both prostate cancer LNCaP cells and from HeLa cells stably transfected with AR. The 220-kDa subunit of the complex (TRAP220) can contact the ligand-binding domain of AR in vitro, possibly implicating TRAP220 involvement in targeting AR to the holocomplex. Consistent with a TRAP-Mediator coactivator role, transient overexpression of the TRAP220, TRAP170, and TRAP100 subunits enhanced ligand-dependent transcription by AR in cultured cells. Finally, chromatin immunoprecipitation assays show that TRAP220 is recruited to the androgen-responsive prostate-specific antigen gene promoter in vivo in ligand-stimulated LNCaP cells. Collectively, these data suggest that TRAP-Mediator may play an important coregulatory role in AR-mediated gene expression.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Fondell, JD (corresponding author), UMDNJ, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.		Wang, Qianben/E-4267-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060883] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60883] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Alen P, 1999, MOL CELL BIOL, V19, P6085; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Glass CK, 2000, GENE DEV, V14, P121; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sharma D, 2000, MOL ENDOCRINOL, V14, P2001, DOI 10.1210/me.14.12.2001; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Treuter E, 1999, J BIOL CHEM, V274, P6667, DOI 10.1074/jbc.274.10.6667; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Wang G, 2001, MOL CELL BIOL, V21, P4604, DOI 10.1128/MCB.21.14.4604-4613.2001; Wang QB, 2001, ANAL BIOCHEM, V289, P217, DOI 10.1006/abio.2000.4960; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Yoshikawa H, 1998, GENOMICS, V49, P237, DOI 10.1006/geno.1998.5246; Zhang JC, 1999, MOL ENDOCRINOL, V13, P1130, DOI 10.1210/me.13.7.1130; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	52	84	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42852	42858		10.1074/jbc.M206061200	http://dx.doi.org/10.1074/jbc.M206061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12218053	hybrid			2022-12-25	WOS:000179081200057
J	Brun, S; Rincheval, V; Gaumer, S; Mignotte, B; Guenal, I				Brun, S; Rincheval, V; Gaumer, S; Mignotte, B; Guenal, I			reaper and bax initiate two different apoptotic pathways affecting mitochondria and antagonized by bcl-2 in Drosophila	ONCOGENE			English	Article						apoptosis; Drosophila; bcl-2; reaper; bax; mitochondria	PROGRAMMED CELL-DEATH; NF-KAPPA-B; IMMUNE-DEFICIENCY IMD; CYTOCHROME-C; CASPASE; HOMOLOG; PROTEIN; FAMILY; GENES; HID	bcl-2 was the first regulator of apoptosis shown to be involved in oncogenesis. Subsequent studies in mammals, in the nematode and in Drosophila revealed wide evolutionary conservation of the regulation of apoptosis. Although dbok/debcl, a member of the bcl-2 gene family described in Drosophila, shows pro-apoptotic activities, no anti-apoptotic bcl-2 family gene has been studied in Drosophila. We have previously reported that the human anti-apoptotic gene bcl-2 is functional in Drosophila, suggesting that the fruit fly shares regulatory mechanisms with vertebrates and the nematode, involving antiapoptotic members of the bcl-2 family. We now report that bcl-2 suppresses rpr-induced apoptosis in Drosophila. Additionally, we have compared features of bax- and rpr-induced apoptosis. Flow cytometry analysis of wing disc cells demonstrate that both killers trigger mitochondrial defects. Interestingly, bcl-2 suppresses both bax- and rpr-induced mitochondrial defects while the caspase-inhibitor p35 is specific to the rpr pathway. Finally, we show that the inhibition of apoptosis by bcl-2 is associated with the down-regulation of rpr expression.	Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, UPRESA 8087, F-78035 Versailles, France; Univ Versailles, Lab Genet Mol & Physiol, EPHE, F-78035 Versailles, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite Paris Saclay	Guenal, I (corresponding author), Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, UPRESA 8087, 45 Ave Etats Unis, F-78035 Versailles, France.	guenal@genetique.uvsq.fr	Mignotte, Bernard/A-3499-2009; Guenal, Isabelle/F-3415-2019	Mignotte, Bernard/0000-0002-8512-8518; Guenal, Isabelle/0000-0003-1186-1458; Brun, Sylvain/0000-0002-6714-4012				Baehrecke EH, 2000, CELL DEATH DIFFER, V7, P1057, DOI 10.1038/sj.cdd.4400753; Brachmann CB, 2000, CURR BIOL, V10, P547, DOI 10.1016/S0960-9822(00)00474-7; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; CAMPOSORTEGA JA, 1995, EMBRYONIC DEV DROSOP; Chen P, 2000, J CELL BIOL, V148, P625, DOI 10.1083/jcb.148.4.625; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Claveria C, 1998, EMBO J, V17, P7199, DOI 10.1093/emboj/17.24.7199; Cohen SM., 1993, DEV DROSOPHILA MELAN; Colussi PA, 2000, J CELL BIOL, V148, P703, DOI 10.1083/jcb.148.4.703; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Doumanis J, 2001, CELL DEATH DIFFER, V8, P387, DOI 10.1038/sj.cdd.4400864; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Gaumer S, 2000, CELL DEATH DIFFER, V7, P804, DOI 10.1038/sj.cdd.4400714; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haining WN, 1999, P NATL ACAD SCI USA, V96, P4936, DOI 10.1073/pnas.96.9.4936; Harvey NL, 2001, J BIOL CHEM, V276, P25342, DOI 10.1074/jbc.M009444200; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hour TC, 2000, EUR J CELL BIOL, V79, P121, DOI 10.1078/S0171-9335(04)70014-X; Hu SM, 2000, J BIOL CHEM, V275, P30761, DOI 10.1074/jbc.C000341200; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thress K, 1999, EMBO J, V18, P5486, DOI 10.1093/emboj/18.20.5486; Tzou P, 2002, METHOD MICROBIOL, V31, P507, DOI 10.1016/S0580-9517(02)31028-6; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhang H, 2000, J BIOL CHEM, V275, P27303; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	54	16	16	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6458	6470		10.1038/sj.onc.1205839	http://dx.doi.org/10.1038/sj.onc.1205839			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226749	Green Submitted			2022-12-25	WOS:000177925300006
J	Aldaz, CM; Hu, YH; Daniel, R; Gaddis, S; Kittrell, F; Medina, D				Aldaz, CM; Hu, YH; Daniel, R; Gaddis, S; Kittrell, F; Medina, D			Serial analysis of gene expression in normal p53 null mammary epithelium	ONCOGENE			English	Article						SAGE; p53; mammary gland; breast cancer; gene expression; preneoplasia	TUMOR-SUPPRESSOR GENE; BREAST-CANCER; C-MYC; CELLS; GELSOLIN; MODEL; ADRENOMEDULLIN; INSTABILITY; APOPTOSIS; MECHANISM	Much evidence has accumulated implicating the p53 gene as of importance in breast carcinogenesis. However, much still remains to be uncovered on the specific downstream pathways influenced by this important activator/repressor of transcription. This study investigated the effects of a p53 null genotype on the transcriptome of 'normal' mouse mammary epithelium using a unique in vivo model of preneoplastic transformation. We used SAGE for the comparative analysis of p53 wild type (wt) and null mammary epithelium unexposed and exposed to hormonal stimulation. Analysis of the hormone exposed samples provided a comprehensive view of the dramatic changes in gene expression as consequence of the functional differentiation of the mammary epithelium in an in vivo system. We detected the dysregulation in p53(null) epithelium of <1% of the transcriptome. Changes in expression affected not only known p53 target genes, but also several unexpected genes such as Expi (Wdnm1), Cyp1b1, Gelsolin, Ramp2 and class I MHC genes. The dysregulation of specific genes and their potential use as preneoplastic markers was further validated using an independent model of premalignant mammary outgrowth lines. This is the first study to examine the transcriptome of very early stages of preneoplastic progression in an in vivo model that mimics human breast cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX 78957 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Aldaz, CM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, POB 389,PK Rd 1-C, Smithville, TX 78957 USA.		Aldaz, C. Marcelo/E-7868-2011	Aldaz, C. Marcelo/0000-0002-2453-2939	NCI NIH HHS [CA84243] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Asch HL, 1996, CANCER RES, V56, P4841; Charpentier AH, 2000, CANCER RES, V60, P5977; Cui XS, 2000, ONCOGENE, V19, P5988, DOI 10.1038/sj.onc.1203993; DEAR TN, 1988, CANCER RES, V48, P5203; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELLEDGE RM, 1994, BREAST CANCER RES TR, V32, P39, DOI 10.1007/BF00666204; Goepfert TM, 2000, FASEB J, V14, P2221, DOI 10.1096/fj.00-0165com; Griffioen M, 1998, MOL IMMUNOL, V35, P829, DOI 10.1016/S0161-5890(98)00074-1; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; KLEIN B, 1991, CANCER, V67, P2295, DOI 10.1002/1097-0142(19910501)67:9<2295::AID-CNCR2820670915>3.0.CO;2-T; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; Lal A, 1999, CANCER RES, V59, P5403; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; MORRISON BW, 1994, ONCOGENE, V9, P3417; Oehler MK, 2001, ONCOGENE, V20, P2937, DOI 10.1038/sj.onc.1204422; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Williams JA, 2000, CANCER RES, V60, P4667; Winston JS, 2001, BREAST CANCER RES TR, V65, P11, DOI 10.1023/A:1006446108411; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhao RB, 2000, GENE DEV, V14, P981; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768	28	29	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6366	6376		10.1038/sj.onc.1205816	http://dx.doi.org/10.1038/sj.onc.1205816			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214277				2022-12-25	WOS:000177829000013
J	Hoenderop, JGJ; Dardenne, O; Van Abel, M; Van der Kemp, AWCM; Van Os, CH; St-Arnaud, R; Bindels, RJM				Hoenderop, JGJ; Dardenne, O; Van Abel, M; Van der Kemp, AWCM; Van Os, CH; St-Arnaud, R; Bindels, RJM			Modulation of renal Ca2+ transport protein genes by dietary Ca2+ and 1,25-dihydroxyvitamin D-3 in 25-hydroxyvitamin D-3-1 alpha-hydroxylase knockout mice	FASEB JOURNAL			English	Article						ECaC; CaT1; vitamin D; calcium reabsorption	VITAMIN-D-RECEPTOR; EPITHELIAL CALCIUM-CHANNEL; D ENDOCRINE SYSTEM; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; TARGETED ABLATION; BINDING-PROTEIN; RABBIT KIDNEY; ANIMAL-MODEL; IDENTIFICATION; STIMULATION	Pseudovitamin D-deficiency rickets (PDDR) is an autosomal disease characterized by hyperparathyroidism, rickets, and undetectable levels of 1,25-dihydroxyvitaminD(3) (1,25(OH)(2)D-3). Mice in which the 1,25-hydroxyvitamin D-3-1alpha-hydroxylase (1alpha-OHase) gene was inactivated presented the same clinical phenotype as patients with PDDR and were used to study renal expression of the epithelial Ca2+ channel (ECaC1), the calbindins, Na+/Ca2+ exchanger (NCX1), and Ca2+-ATPase (PMCA1b). Serum Ca2+ (1.20+/-0.05 mM) and mRNA/protein expression of ECaC1 (41+/-3%), calbindin-D-28K (31+/-2%), calbindin-D-9K (58+/-7%), NCX1 (10+/-2%), PMCA1b (96+/-4%) were decreased in 1alpha-OHase(-/-) mice compared with 1alpha-OHase(+/-) littermates. Feeding these mice a Ca2+-enriched diet normalized serum Ca2+ levels and expression of Ca2+ proteins except for calbindin-D-9K expression. 1,25(OH)(2)D-3 repletion resulted in increased expression of Ca2+ transport proteins and normalization of serum Ca2+ levels. Localization of Ca2+ transport proteins was clearly polarized in which ECaC1 was localized along the apical membrane, calbindin-D-28K in the cytoplasm, and calbindin-D-9K along the apical and basolateral membranes, resulting in a comprehensive mechanism facilitating renal transcellular Ca2+ transport. This study demonstrated that high dietary Ca2+ intake is an important regulator of the renal Ca2+ transport proteins in 1,25(OH)(2)D-3-deficient status and thus contributes to the normalization of blood Ca2+ levels.	Univ Med Ctr Nijmegen, Dept Cell Physiol, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Shriners Hosp Children, Genet Unit, Montreal, PQ, Canada	Radboud University Nijmegen; McGill University	Bindels, RJM (corresponding author), Univ Med Ctr Nijmegen, Dept Cell Physiol, Nijmegen Ctr Mol Life Sci, POB 9101, NL-6500 HB Nijmegen, Netherlands.	r.bindels@ncmls.kun.nl	Bindels, René JM/B-9824-2013; Hoenderop, Joost G.J./H-8047-2014	Bindels, René JM/0000-0003-1167-1339; Hoenderop, Joost G.J./0000-0002-1816-8544				Arnold DB, 1997, P NATL ACAD SCI USA, V94, P8842, DOI 10.1073/pnas.94.16.8842; BARAN DT, 1994, J CELL BIOCHEM, V56, P510, DOI 10.1002/jcb.240560411; Baran DT, 2000, J CELL BIOCHEM, V80, P259; Chirayath MV, 1998, AM J PHYSIOL-GASTR L, V274, pG389, DOI 10.1152/ajpgi.1998.274.2.G389; Dardenne O, 2001, ENDOCRINOLOGY, V142, P3135, DOI 10.1210/en.142.7.3135; de Boland AR, 1998, J CELL BIOCHEM, V69, P470, DOI 10.1002/(SICI)1097-4644(19980615)69:4<470::AID-JCB8>3.0.CO;2-K; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HOENDEROP JG, 2002, IN PRESS ANN REV PHY, V64; Hoenderop JGJ, 2000, AM J PHYSIOL-RENAL, V278, pF352, DOI 10.1152/ajprenal.2000.278.3.F352; Hoenderop JGJ, 2000, J AM SOC NEPHROL, V11, P1171, DOI 10.1681/ASN.V1171171; Hoenderop JGJ, 1999, P NATL ACAD SCI USA, V96, P6084, DOI 10.1073/pnas.96.11.6084; Hoenderop JGJ, 2001, J AM SOC NEPHROL, V12, P1342, DOI 10.1681/ASN.V1271342; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Kato A, 1998, BIOCHEM BIOPH RES CO, V244, P724, DOI 10.1006/bbrc.1998.8318; Kim YS, 1996, ENDOCRINOLOGY, V137, P3649, DOI 10.1210/en.137.9.3649; KUMAR R, 1994, AM J PHYSIOL, V266, pF477, DOI 10.1152/ajprenal.1994.266.3.F477; LAWSON DEM, 1971, NATURE, V230, P228, DOI 10.1038/230228a0; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Li YC, 2001, AM J PHYSIOL-ENDOC M, V281, pE558, DOI 10.1152/ajpendo.2001.281.3.E558; Loffing J, 2001, AM J PHYSIOL-RENAL, V281, pF1021, DOI 10.1152/ajprenal.0085.2001; Muller D, 2000, BIOCHEM BIOPH RES CO, V275, P47, DOI 10.1006/bbrc.2000.3227; NEMERE I, 1994, J BIOL CHEM, V269, P23750; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; NING G, 1993, FEBS LETT, V336, P521, DOI 10.1016/0014-5793(93)80868-U; Norman AW, 2001, STEROIDS, V66, P147, DOI 10.1016/S0039-128X(00)00165-3; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; Panda DK, 2001, P NATL ACAD SCI USA, V98, P7498, DOI 10.1073/pnas.131029498; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; THEOFAN G, 1986, J BIOL CHEM, V261, P7311; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; VanBaal J, 1996, AM J PHYSIOL-RENAL, V271, pF985, DOI 10.1152/ajprenal.1996.271.5.F985; Vazquez G, 2000, J BIOL CHEM, V275, P16134, DOI 10.1074/jbc.C901008199; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Weber K, 2001, BIOCHEM BIOPH RES CO, V289, P1287, DOI 10.1006/bbrc.2001.6121; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zanello LP, 1997, J BIOL CHEM, V272, P22617, DOI 10.1074/jbc.272.36.22617	39	172	182	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1398	1406		10.1096/fj.02-0225com	http://dx.doi.org/10.1096/fj.02-0225com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12205031				2022-12-25	WOS:000178441800014
J	Teunis, MAT; Kavelaars, A; Voest, E; Bakker, JM; Ellenbroek, BA; Cools, AR; Heijnen, CJ				Teunis, MAT; Kavelaars, A; Voest, E; Bakker, JM; Ellenbroek, BA; Cools, AR; Heijnen, CJ			Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system	FASEB JOURNAL			English	Article						dopamine; cancer progression; MADB106; VEGF	SCHIZOPHRENIC-PATIENTS; WISTAR RATS; LUNG-CANCER; MICE; SUSCEPTIBILITY; APOMORPHINE; TUMORIGENESIS; INTERLEUKIN-4; NEUROBIOLOGY; PROGRESSION	Outgrowth of solid tumors requires blood supply to the tumor. Tumor angiogenesis is dependent on the interplay between tumor-derived angiogenic factors and stromal cells. Recently, it has been shown that the neurotransmitter dopamine is a potent inhibitor of VEGF-induced angiogenesis. Moreover, there is evidence that patients with schizophrenia have a hyperreactive dopaminergic system and are relatively protected from cancer. We hypothesized that hyperreactivity of the dopaminergic system is related to reduced angiogenesis and tumor development. Therefore, we investigated tumor growth and angiogenesis in two lines of Wistar rats with high (APO-SUS) or low (APO-UNSUS) dopaminergic reactivity. Subcutaneous implants of mammary adenocarcinoma cells (MADB106) in matrigel remained 35% smaller in APO-SUS rats than in APO-UNSUS rats (P<0.01). Moreover, APO-SUS rats developed less lung metastases after i.v. administration of MADB106 tumor cells. Furthermore, hemoglobin content (APO-SUS: 40.6+/-7.6; APO-UNSUS: 76.9+/-13 mg/dl, P<0.05) and expression of the endothelial determinant PECAM-1 in tumors from APO-SUS rats were reduced (APO-SUS: 37+/-18; APO-UNSUS 69+/-25 units, P<0.01), indicating that reduced angiogenesis is responsible for reduced tumor development in APO-SUS rats. These results suggest a novel link between dopaminergic reactivity, angiogenesis, and tumor development and may explain part of the individual differences in cancer progression.	UMC Utrecht, Lab Psychoneuroimmunol, NL-3584 EA Utrecht, Netherlands; UMC Utrecht, Dept Med Oncol, NL-3584 EA Utrecht, Netherlands; Univ Nijmegen, Dept Psychoneuropharmacol, Nijmegen Inst Neurosci, Nijmegen, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen	Heijnen, CJ (corresponding author), UMC Utrecht, Lab Psychoneuroimmunol, Room KC 03-068-0,Lundlaan 6, NL-3584 EA Utrecht, Netherlands.	c.heijnen@wkz.azu.nl	Ellenbroek, Bart/C-4570-2012	Ellenbroek, Bart/0000-0003-1996-4873				BARUCH I, 1988, J NERV MENT DIS, V176, P598, DOI 10.1097/00005053-198810000-00004; BASU S, 1995, J NEUROIMMUNOL, V60, P1, DOI 10.1016/0165-5728(95)00044-3; Basu S, 2001, NAT MED, V7, P569, DOI 10.1038/87895; Ben-Eliyahu S, 1999, INT J CANCER, V80, P880; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; BRAFF D, 1978, PSYCHOPHYSIOLOGY, V15, P339, DOI 10.1111/j.1469-8986.1978.tb01390.x; Breivik T, 2000, BEHAV GENET, V30, P123, DOI 10.1023/A:1001903221046; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Compagni A, 2000, BRIT J CANCER, V83, P1; COOLS AR, 1990, BRAIN RES BULL, V24, P49, DOI 10.1016/0361-9230(90)90288-B; COOLS AR, 2002, PHARM BIOCH BEHAV, V60, P151; DASGUPTA PS, 1987, J CANCER RES CLIN, V113, P363, DOI 10.1007/BF00397720; DeClerck YA, 2000, EUR J CANCER, V36, P1258, DOI 10.1016/S0959-8049(00)00094-0; Egan MF, 1997, CURR OPIN NEUROBIOL, V7, P701, DOI 10.1016/S0959-4388(97)80092-X; ELLENBROEK BA, 1995, J NEUROSCI, V15, P7604; Fukushi J, 2000, J IMMUNOL, V165, P2818, DOI 10.4049/jimmunol.165.5.2818; GULBINAT W, 1992, BRIT J PSYCHIAT, V161, P75, DOI 10.1192/S0007125000297080; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARRIS AE, 1988, SCHIZOPHRENIA BULL, V14, P85, DOI 10.1093/schbul/14.1.85; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; ISHIBASHI M, 1994, CANCER RES, V54, P3442; Kavelaars A, 1997, J NEUROSCI, V17, P2580; Kim SS, 2001, KOREAN J RADIOL, V2, P68, DOI 10.3348/kjr.2001.2.2.68; Lammers CH, 1995, BIOL PSYCHIAT, V38, P803, DOI 10.1016/0006-3223(95)00065-8; Laruelle M, 2000, BRAIN RES REV, V31, P371, DOI 10.1016/S0165-0173(99)00054-5; Lewis DA, 2000, NEURON, V28, P325, DOI 10.1016/S0896-6273(00)00111-2; LIEBERMAN JA, 1987, PSYCHOPHARMACOLOGY, V91, P415, DOI 10.1007/BF00216006; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Los M, 2001, SEMIN ONCOL, V28, P93, DOI 10.1016/S0093-7754(01)90047-8; Matar P, 1997, J EXP CLIN CANC RES, V16, P249; Matsuyama W, 2000, CHEST, V118, P948, DOI 10.1378/chest.118.4.948; Moon HS, 2000, INT J GYNECOL CANCER, V10, P151, DOI 10.1046/j.1525-1438.2000.00013.x; MORTENSEN PB, 1994, SCHIZOPHR RES, V12, P185, DOI 10.1016/0920-9964(94)90028-0; Muller-Spahn F, 1998, J PSYCHIATR RES, V32, P265, DOI 10.1016/S0022-3956(98)00005-3; Overmier JB, 1997, PHYSIOL BEHAV, V61, P555, DOI 10.1016/S0031-9384(96)00502-1; PASSANITI A, 1992, LAB INVEST, V67, P519; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Rots NY, 1996, ENDOCRINOLOGY, V137, P1678, DOI 10.1210/en.137.5.1678; Rots NY, 1996, BRAIN RES, V710, P189, DOI 10.1016/0006-8993(95)01379-2; Saleh M, 1999, J NATL CANCER I, V91, P438, DOI 10.1093/jnci/91.5.438; SEEMAN P, 1987, SYNAPSE, V1, P133, DOI 10.1002/syn.890010203; SWERDLOW NR, 2002, SCHIZOPHR B, V24, P285; Toru M, 1998, PSYCHIAT CLIN NEUROS, V52, pS170, DOI 10.1111/j.1440-1819.1998.tb03213.x; Volpert OV, 1998, J EXP MED, V188, P1039, DOI 10.1084/jem.188.6.1039; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497	48	56	59	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1465	+		10.1096/fj.02-0145fje	http://dx.doi.org/10.1096/fj.02-0145fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205050				2022-12-25	WOS:000177813100012
J	Courbard, JR; Fiore, F; Adelaide, J; Borg, JP; Birnbaum, D; Ollendorff, V				Courbard, JR; Fiore, F; Adelaide, J; Borg, JP; Birnbaum, D; Ollendorff, V			Interaction between two ubiquitin-protein isopeptide ligases of different classes, CBLC and AIP4/ITCH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-CBL; TYROSINE; GENE; ELEGANS; DOMAIN; REGULATOR; CLONING; SLI-1	In metazoans, CBL proteins are RING finger type ubiquitin-protein isopeptide (E3) ligases involved in the down-regulation of epidermal growth factor tyrosine kinase receptors (EGFR). Among the three CBL proteins described in humans, CBLC (CBL3) remains poorly studied. By screening in parallel a human and a Caenorhabditis elegans library using the two-hybrid procedure in yeast, we found a novel interaction between Hsa-CBLC and Hsa-AIP4 or its C. elegans counterpart Cel-WWP1. Hsa-AIP4 and Cel-WWP1 are also ubiquitin E3 ligases. They contain a HECT (homologous to E6-AP C terminus) catalytic domain and four WW domains known to bind proline-rich regions. We confirmed the interaction between Hsa-CBLC and Hsa-AIP4 by a combination of glutathione S-transferase pull-down, co-immunoprecipitation, and colocalization experiments. We show that these two E3 ligases are involved in EGFR signaling because both become phosphorylated on tyrosine following epidermal growth factor stimulation. In addition, we observed that CBLC increases the ubiquitination of EGFR, and that coexpressing the WW domains of AIP4 exerts a dominant negative effect on EGFR ubiquitination. Finally, coexpressing CBLC and AIP4 induces a down-regulation of EGFR signaling. In conclusion, our data demonstrate that two E3 ligases of different classes can interact and cooperate to down-regulate EGFR signaling.	INSERM, Dept Mol Oncol, U119, F-13009 Marseille, France; Inst J Paoli I Calmettes, Ipsogen SA, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Birnbaum, D (corresponding author), INSERM, Dept Mol Oncol, U119, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	ADELAIDE, José JA/O-4390-2017; Borg, Jean-Paul/AAX-8096-2020	ADELAIDE, José JA/0000-0003-4364-9857; Borg, Jean-Paul/0000-0001-8418-3382; Ollendorff, Vincent/0000-0001-9751-2202; Birnbaum, Daniel/0000-0001-7920-9883; FIORE, FREDERIC/0000-0001-7955-6594				Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Baumann CA, 2001, J BIOL CHEM, V276, P6065, DOI 10.1074/jbc.C000856200; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Fiore F, 2001, BIOCHEM BIOPH RES CO, V280, P182, DOI 10.1006/bbrc.2000.4116; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Huang K, 2000, GENE, V252, P137, DOI 10.1016/S0378-1119(00)00216-X; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Jehn BM, 2002, J BIOL CHEM, V277, P8033, DOI 10.1074/jbc.M108552200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONGEWARD GD, 1995, GENETICS, V139, P1553; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; LANGDON W, 1989, P NATL ACAD SCI USA, V91, P9665; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ollendorff V, 1998, INT J ONCOL, V13, P1159; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Popovici C, 2001, FEBS LETT, V491, P237, DOI 10.1016/S0014-5793(01)02187-1; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Smit L, 1996, ONCOGENE, V13, P381; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Yoon CH, 2000, MOL BIOL CELL, V11, P4019, DOI 10.1091/mbc.11.11.4019; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	50	69	73	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45267	45275		10.1074/jbc.M206460200	http://dx.doi.org/10.1074/jbc.M206460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12226085	hybrid, Green Published			2022-12-25	WOS:000179404800087
J	Pang, TX; Wakabayashi, S; Shigekawa, M				Pang, TX; Wakabayashi, S; Shigekawa, M			Expression of calcineurin B homologous protein 2 protects serum deprivation-induced cell death by serum-independent activation of Na+/H+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES NA-H; INTRACELLULAR PH; GROWTH-FACTOR; CA2+-BINDING PROTEIN; CYTOPLASMIC DOMAIN; NHE1; APOPTOSIS; KINASE; ANTIPORTER; ISOFORM-1	The calcineurin B homologous protein (designated CHP1) has been shown to be a common essential cofactor for the plasma membrane Na+/H+ exchangers (NHEs) (Pang, T., Su, YL, Wakabayashi, S., and Shigekawa, M. (2001) J. BioL Chem. 276,17367-17372). In this study, we characterized the function of another isoform of CHP (designated CHP2) that has a 61% amino acid identity with CHP1. CHP2, like CHP1, conferred the ability to NHEs 1-3 to express a high exchange activity by binding to the juxtamembrane region of the cytoplasmic domain of the exchanger, but it interacts more strongly (similar to5-fold) with NHE1 than does CHP1. Although CHP1 is expressed ubiquitously at relatively high levels, CHP2 expression was extremely low in most human tissues but was higher in tumor cells. We produced stable cell clones overexpressing either CHP1 or CHP2 in which one of them is predominantly bound to NHE1. Serum (10%) induced a significant cytoplasmic alkalinization (0.1-0.2 pH unit) in cells co-expressing CHP1 and NHE1 but not in cells co-expressing CHP2 and NHE1. In the latter, pH(i) was high (7.4-7.5) even in the absence of serum, suggesting that NHE1 was already activated. Surprisingly, most (>80%) of CHP2/NHE1 cells unlike CHP1/NHE1 cells were viable even after long serum starvation (>7 days). Thus, the expression of CHP2 appears to protect cells from serum deprivation-induced death by increasing pHi. These properties of CHP2/NHE1 cells are similar to those of malignantly transformed cells. We propose that serum-independent activation of NHE1 by bound CHP2 is one of the key mechanisms for the maintenance of high pHi and the resistance to serum deprivation-induced cell death in malignantly transformed cells.	Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Suita, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Wakabayashi, S (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Fujishiro Dai 5-7-1, Suita, Osaka 5658565, Japan.							Aharonovitz O, 2000, J CELL BIOL, V150, P213, DOI 10.1083/jcb.150.1.213; Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Bianchini L, 1997, J BIOL CHEM, V272, P271; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Ikeda T, 1997, J BIOCHEM-TOKYO, V121, P295; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; Kluza J, 2000, CANCER RES, V60, P4077; Lehoux S, 2001, J BIOL CHEM, V276, P15794, DOI 10.1074/jbc.M100410200; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; MALY K, 1989, J BIOL CHEM, V264, P11839; Marches R, 2001, P NATL ACAD SCI USA, V98, P3434, DOI 10.1073/pnas.061028998; Matsumoto M, 2001, J BIOCHEM, V130, P217, DOI 10.1093/oxfordjournals.jbchem.a002975; McLean LA, 2000, AM J PHYSIOL-CELL PH, V278, pC676, DOI 10.1152/ajpcell.2000.278.4.C676; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Pang TX, 2001, J BIOL CHEM, V276, P17367, DOI 10.1074/jbc.M100296200; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RAO GN, 1991, J BIOL CHEM, V266, P13485; Reshkin SJ, 2000, J BIOL CHEM, V275, P5361, DOI 10.1074/jbc.275.8.5361; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Rich IN, 2000, BLOOD, V95, P1427, DOI 10.1182/blood.V95.4.1427.004k48_1427_1434; Sailer BL, 1998, CANCER RES, V58, P413; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Takasu T, 1998, CANCER RES, V58, P2504; Thangaraju M, 1999, CANCER RES, V59, P1649; Thangaraju M, 1999, J BIOL CHEM, V274, P29549, DOI 10.1074/jbc.274.41.29549; Timm S, 1999, MOL BIOL CELL, V10, P3473, DOI 10.1091/mbc.10.10.3473; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1995, J BIOL CHEM, V270, P26460, DOI 10.1074/jbc.270.44.26460; Wang HY, 1997, J BIOL CHEM, V272, P26545, DOI 10.1074/jbc.272.42.26545; Yan WH, 2001, J BIOL CHEM, V276, P31349, DOI 10.1074/jbc.M102679200	42	68	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43771	43777		10.1074/jbc.M208313200	http://dx.doi.org/10.1074/jbc.M208313200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226101	hybrid			2022-12-25	WOS:000179272000032
J	Zhang, M; Xuan, SH; Bouxsein, ML; von Stechow, D; Akeno, N; Faugere, MC; Malluche, H; Zhao, GS; Rosen, CJ; Efstratiadis, A; Clemens, TL				Zhang, M; Xuan, SH; Bouxsein, ML; von Stechow, D; Akeno, N; Faugere, MC; Malluche, H; Zhao, GS; Rosen, CJ; Efstratiadis, A; Clemens, TL			Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; POSTNATAL-GROWTH; TRANSGENIC MICE; RAT BONE; EXPRESSION; MOUSE; APOPTOSIS; HORMONE; CELLS; PROLIFERATION	To examine the local actions of IGF signaling in skeletal tissue in a physiological context, we have used Cre-mediated recombination to disrupt selectively in mouse osteoblasts the gene encoding the type 1 IGF receptor (Igf1r). Mice carrying this bone-specific mutation were of normal size and weight but, in comparison with normal siblings, demonstrated a striking decrease in cancellous bone volume, connectivity, and trabecular number, and an increase in trabecular spacing. These abnormalities correlated with a striking decrease in the rate of mineralization of osteoid that occurred despite an unexpected osteoblast and osteoclast hyperactivity, detected from the significant increments in both osteoblast and erosion surfaces. Our findings indicate that IGF1 is essential for coupling matrix biosynthesis to sustained mineralization. This action is likely to be particularly important during the pubertal growth spurt when rapid bone formation and consolidation are required.	Univ Cincinnati, Dept Med, Cincinnati, OH 45267 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Beth Israel Deaconess Med Ctr, Orthopaed Biomech Lab, Boston, MA 02215 USA; Univ Kentucky, Dept Med, Lexington, KY 40536 USA; St Josephs Hosp, Maine Ctr Osteoporosis Res & Educ, Bangor, ME 04401 USA	University System of Ohio; University of Cincinnati; Columbia University; Harvard University; Beth Israel Deaconess Medical Center; University of Kentucky	Clemens, TL (corresponding author), Vontz Ctr Mol Studies, Div Endocrinol & Metab, 3125 Eden Ave, Cincinnati, OH 45267 USA.		Zhang, Mei/O-6070-2015	Zhang, Mei/0000-0002-3960-9978	NCI NIH HHS [CA75553] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA075553] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander JM, 2001, J BONE MINER RES, V16, P1665, DOI 10.1359/jbmr.2001.16.9.1665; ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Baserga R, 1997, VITAM HORM, V53, P65, DOI 10.1016/S0083-6729(08)60704-9; BIRNBAUM RS, 1995, J ENDOCRINOL, V144, P251, DOI 10.1677/joe.0.1440251; Boskey AL, 1996, CONNECT TISSUE RES, V35, P357, DOI 10.3109/03008209609029212; CANALIS E, 1993, BONE, V14, P273, DOI 10.1016/8756-3282(93)90151-Y; Caverzasio J, 1996, KIDNEY INT, V49, P975, DOI 10.1038/ki.1996.138; Clemens TL, 1997, J BONE MINER RES, V12, P1570, DOI 10.1359/jbmr.1997.12.10.1570; Conover CA, 2000, GROWTH HORM IGF RES, V10, P107, DOI 10.1016/S1096-6374(00)80020-9; D'Ercole A. J., 2001, Growth Hormone and IGF Research, V11, P261, DOI 10.1054/ghir.2001.0243; Dietrich P, 2000, MAMM GENOME, V11, P196, DOI 10.1007/s003350010037; Dragatsis I, 2000, GENESIS, V26, P133, DOI 10.1002/(SICI)1526-968X(200002)26:2<133::AID-GENE10>3.0.CO;2-V; Efstratiadis A, 1998, INT J DEV BIOL, V42, P955; GOLDNER JACQUES, 1938, AMER JOUR PATH, V14, P237; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Hill PA, 1997, ENDOCRINOLOGY, V138, P3849, DOI 10.1210/en.138.9.3849; HILL PA, 1995, ENDOCRINOLOGY, V136, P124, DOI 10.1210/en.136.1.124; Hughes DE, 1997, J CLIN PATHOL-MOL PA, V50, P132, DOI 10.1136/mp.50.3.132; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Lupu F, 2001, DEV BIOL, V229, P141, DOI 10.1006/dbio.2000.9975; MALLUCHE HH, 1982, CALCIFIED TISSUE INT, V34, P439, DOI 10.1007/BF02411282; Malluche HH, 1986, ATLAS MINERALIZED BO; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Parfitt AM, 1996, J BONE MINER RES, V11, P150; PFEILSCHIFTER J, 1995, J CLIN INVEST, V96, P767, DOI 10.1172/JCI118121; Richman C, 2001, J BONE MINER RES, V16, P386, DOI 10.1359/jbmr.2001.16.2.386; Rizzoli R, 2001, J MOL ENDOCRINOL, V26, P79, DOI 10.1677/jme.0.0260079; Ruegsegger P, 1996, CALCIFIED TISSUE INT, V58, P24, DOI 10.1007/s002239900006; SHINAR DM, 1993, ENDOCRINOLOGY, V132, P1158, DOI 10.1210/en.132.3.1158; Sims Natalie, 2000, P1; Suzuki A, 2001, BONE, V28, P589, DOI 10.1016/S8756-3282(01)00459-8; WANG EM, 1995, ENDOCRINOLOGY, V136, P2741, DOI 10.1210/en.136.6.2741; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Zhang Q, 2001, J BONE MINER RES, V16, pS356; Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674	41	543	569	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44005	44012		10.1074/jbc.M208265200	http://dx.doi.org/10.1074/jbc.M208265200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12215457	hybrid			2022-12-25	WOS:000179272000062
J	Akama, TO; Misra, AK; Hindsgaul, O; Fukuda, MN				Akama, TO; Misra, AK; Hindsgaul, O; Fukuda, MN			Enzymatic synthesis in vitro of the disulfated disaccharide unit of corneal keratan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY-N-ACETYLLACTOSAMINE; I-EXTENSION ENZYME; L-SELECTIN LIGANDS; MOLECULAR-CLONING; GENE FAMILY; UDP-GALACTOSE; O-GLYCANS; CORE 2; LUMICAN; PROTEOGLYCAN	Among the enzymes of the carbohydrate sulfotransferase family, human corneal GIcNAc 6-O-sulfotransferase (hCGn6ST, also known as human GIcNAc6ST-5/ GST4beta]) and human intestinal GlcNAc 6-O-sulfotransferase (hIGn6ST or human GlcNAc6ST-3/GST4alpha) are highly homologous. In the mouse, intestinal GlcNAc 6-O-sulfotransferase (mIGn6ST or mouse GlcNAc6ST-3/ GST4beta) is the only orthologue of hCGn6ST and hIGn6ST. In the previous study, we found that hCGn6ST and mIGn6ST, but not hIGn6ST, have sulfotransferase activity to produce keratan sulfate (Akama, T.O., Nakayama, J., Nishida, K., Hiraoka, N., Suzuki, M., McAuliffe, J., Hindsgaul, 0., Fukuda, M., and Fukuda, M. N. (2001) J. Biol Chem. 276, 16271-16278). In this study, we analyzed the substrate specificities of these sulfotransferases in vitro using synthetic carbohydrate substrates. We found that all three sulfotransferases can transfer sulfate to the nonreducing terminal GlcNAc of short carbohydrate substrates. Both hCGn6ST and mIGn6ST, but not hIGn6ST, transfer sulfate to longer carbohydrate substrates that have poly-N-acetyllactosamine structures, suggesting the involvement of hCGn6ST and mIGn6ST in production of keratan sulfate. To clarify further the involvement of hCGn6ST in biosynthe is of keratan sulfate, we reconstituted the biosynthetic pathway in vitro by sequential enzymatic treatment of a synthetic carbohydrate substrate. Using four enzymes, beta1,4-galactosyltransferase-1, beta1,3-N-acetylglucosaminyl-transferase-2, hCGn6ST, and keratan sulfate Gal 6-O-sulfotransferase, we were able to synthesize in vitro a product that conformed to the basic structural unit of keratan sulfate. Based on these results, we propose a biosynthetic pathway for N-linked keratan sulfate on corneal proteoglycans.	Burnham Inst, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Akama, TO (corresponding author), Burnham Inst, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA71932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akama TO, 2000, NAT GENET, V26, P237, DOI 10.1038/79987; Akama TO, 2001, J BIOL CHEM, V276, P16271, DOI 10.1074/jbc.M009995200; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Bowman KG, 2001, BIOCHEMISTRY-US, V40, P5382, DOI 10.1021/bi001750o; Chakravarti S, 2000, INVEST OPHTH VIS SCI, V41, P3365; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CORNUET PK, 1994, INVEST OPHTH VIS SCI, V35, P870; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DICKENSON JM, 1991, BIOCHEM J, V278, P779, DOI 10.1042/bj2780779; Dunlevy JR, 2000, EXP EYE RES, V70, P349, DOI 10.1006/exer.1999.0789; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; Funderburgh JL, 2000, GLYCOBIOLOGY, V10, P951, DOI 10.1093/glycob/10.10.951; FUNDERBURGH JL, 1986, DEV BIOL, V116, P267, DOI 10.1016/0012-1606(86)90130-2; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; Greiling H, 1994, EXS, V70, P101; Guo S, 2001, GLYCOBIOLOGY, V11, P813, DOI 10.1093/glycob/11.10.813; HART GW, 1976, J BIOL CHEM, V251, P6513; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; Hemmerich S, 2001, GLYCOBIOLOGY, V11, P75, DOI 10.1093/glycob/11.1.75; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; KELLER R, 1983, H-S Z PHYSIOL CHEM, V364, P239, DOI 10.1515/bchm2.1983.364.1.239; KELLER R, 1983, H-S Z PHYSIOL CHEM, V364, P253; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; Liu CY, 1998, J BIOL CHEM, V273, P22584, DOI 10.1074/jbc.273.35.22584; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; NAKAZAWA K, 1995, J BIOCHEM-TOKYO, V117, P707, DOI 10.1093/oxfordjournals.jbchem.a124767; NAKAZAWA K, 1975, J BIOL CHEM, V250, P912; OEBEN M, 1987, BIOCHEM J, V248, P85, DOI 10.1042/bj2480085; Plaas AHK, 2001, GLYCOBIOLOGY, V11, P779, DOI 10.1093/glycob/11.10.779; Quantock AJ, 2001, INVEST OPHTH VIS SCI, V42, P1750; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Saika S, 2000, J BIOL CHEM, V275, P2607, DOI 10.1074/jbc.275.4.2607; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; SCOTT JE, 1992, J ANAT, V180, P155; Seko A, 1998, FEBS LETT, V440, P307, DOI 10.1016/S0014-5793(98)01458-6; SHAKLEE PN, 1986, BIOCHEM J, V235, P225, DOI 10.1042/bj2350225; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Tai GH, 1997, J BIOL CHEM, V272, P28227, DOI 10.1074/jbc.272.45.28227; Tai GH, 1996, J BIOL CHEM, V271, P23535, DOI 10.1074/jbc.271.38.23535; TODA N, 1970, BIOCHIM BIOPHYS ACTA, V208, P227, DOI 10.1016/0304-4165(70)90241-2; Torii T, 2000, GLYCOBIOLOGY, V10, P203, DOI 10.1093/glycob/10.2.203; Uchimura K, 2002, J BIOL CHEM, V277, P3979, DOI 10.1074/jbc.M106587200; Ujita M, 2000, J BIOL CHEM, V275, P15868, DOI 10.1074/jbc.M001034200; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; Ujita M, 1999, J BIOL CHEM, V274, P16717, DOI 10.1074/jbc.274.24.16717; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Ying SX, 1997, J BIOL CHEM, V272, P30306, DOI 10.1074/jbc.272.48.30306	54	36	39	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42505	42513		10.1074/jbc.M207412200	http://dx.doi.org/10.1074/jbc.M207412200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12218059	hybrid			2022-12-25	WOS:000179081200012
J	Gu, JM; Crawley, JTB; Ferrell, G; Zhang, FJ; Li, WH; Esmon, NL; Esmon, CT				Gu, JM; Crawley, JTB; Ferrell, G; Zhang, FJ; Li, WH; Esmon, NL; Esmon, CT			Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR; EPCR GENE; THROMBOMODULIN; ACTIVATION; MURINE; EXPRESSION; IDENTIFICATION; INVOLVEMENT; MODEL	The endothelial cell protein C receptor (EPCR) is a type 1 transmembrane protein found primarily on endothelium that binds both protein C and activated protein C with similar affinity. EPCR augments the activation of protein C by the thrombin-thrombomodulin complex. To determine the physiological importance of EPCR, we generated EPCR-deficient mice by homologous targeting in embryonic stem cells. Genotyping of progeny obtained from EPCR+/- interbreeding indicated that EPCR-/- embryos died on or before embryonic day 10.5 (E10.5). Reverse transcriptase-PCR confirmed the absence of EPCR mRNA in EPCR-/- embryos. EPCR-/- embryos removed from extra-embryonic membranes and tissues at day E7.5 and cultured in vitro developed beyond E10.5, suggesting a role for EPCR in the normal function of the placenta and/or at the materno-embryonic interface. Immunohistochemistry revealed the lack of EPCR in trophoblast giant cells of EPCR-/- embryos. These cells, which normally express EPCR, are in direct contact with the maternal circulation and its clotting factors. In EPCR-/- embryos, greatly increased fibrin deposition was detected around these cells. To prevent this fibrin deposition, EPCR+/--crossed female mice received a daily subcutaneous injection of enoxaparin through pregnancy. Although some EPCR-/- embryos were rescued from midgestational lethality, this regimen yielded no EPCR-/- pups. We conclude that EPCR is essential for normal embryonic development. Moreover, EPCR plays a key role in preventing thrombosis at the maternal-embryonic interface.	Univ Oklahoma, Oklahoma Med Res Fdn, Howard Hughes Med Inst, Hlth Sci Ctr,Dept Pathol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Oklahoma Med Res Fdn, Hlth Sci Ctr, Dept Biochem, Oklahoma City, OK 73104 USA; Univ Oklahoma, Oklahoma Med Res Fdn, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Esmon, CT (corresponding author), Univ Oklahoma, Oklahoma Med Res Fdn, Howard Hughes Med Inst, Hlth Sci Ctr,Dept Pathol, 825 NE 13th St, Oklahoma City, OK 73104 USA.	Charles-Esmon@omrf.ouhsc.edu	Crawley, James TB/A-9290-2008	Crawley, James TB/0000-0002-6723-7841	NHLBI NIH HHS [P50 HL54502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054502] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDWIN HS, 1994, CIRC RES, V74, P244, DOI 10.1161/01.RES.74.2.244; Biguzzi E, 2001, THROMB HAEMOSTASIS, V86, P945; Crawley JTB, 2002, THROMB HAEMOSTASIS, V88, P259; Erlich J, 1999, P NATL ACAD SCI USA, V96, P8138, DOI 10.1073/pnas.96.14.8138; Esmon CT, 1999, HAEMATOLOGICA, V84, P363; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1982, J BIOL CHEM, V257, P7944; Esmon CT, 2000, THROMB HAEMOSTASIS, V83, P639; FUKUDOME K, 1995, J BIOL CHEM, V270, P5571, DOI 10.1074/jbc.270.10.5571; Gu JM, 2000, J BIOL CHEM, V275, P12481, DOI 10.1074/jbc.275.17.12481; Gu JM, 2000, BLOOD, V95, P1687, DOI 10.1182/blood.V95.5.1687.005k08_1687_1693; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; Healy AM, 1998, BLOOD, V92, P4188, DOI 10.1182/blood.V92.11.4188.423k09_4188_4197; Isermann B, 2001, DEVELOPMENT, V128, P827; Iwaki T, 2002, AM J PATHOL, V160, P1021, DOI 10.1016/S0002-9440(10)64923-1; Jalbert LR, 1998, J CLIN INVEST, V102, P1481, DOI 10.1172/JCI3011; Kurosawa S, 1997, J CLIN INVEST, V100, P411, DOI 10.1172/JCI119548; Kurosawa S, 1998, BLOOD, V91, P725, DOI 10.1182/blood.V91.2.725; Kurosawa S, 2000, J IMMUNOL, V165, P4697, DOI 10.4049/jimmunol.165.8.4697; Laszik Z, 1997, CIRCULATION, V96, P3633; Liang Z, 1999, THROMB HAEMOSTASIS, V81, P585; Oganesyan V, 2002, J BIOL CHEM, V277, P24851, DOI 10.1074/jbc.C200163200; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Shu F, 2000, FEBS LETT, V477, P208, DOI 10.1016/S0014-5793(00)01740-3; Simmonds RE, 1999, BLOOD, V94, P632, DOI 10.1182/blood.V94.2.632.414k24_632_641; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; Taylor FB, 2000, BLOOD, V95, P1680, DOI 10.1182/blood.V95.5.1680.005k33_1680_1686; Taylor FB, 2001, BLOOD, V97, P1685, DOI 10.1182/blood.V97.6.1685; Weiler H, 2001, ARTERIOSCL THROM VAS, V21, P1531, DOI 10.1161/hq0901.094496; Xu J, 1999, J BIOL CHEM, V274, P6704, DOI 10.1074/jbc.274.10.6704; Xu J, 2000, J BIOL CHEM, V275, P6038, DOI 10.1074/jbc.275.8.6038	32	111	118	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43335	43343		10.1074/jbc.M207538200	http://dx.doi.org/10.1074/jbc.M207538200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12218060	hybrid			2022-12-25	WOS:000179081200117
J	Tjernberg, L; Hosia, W; Bark, N; Thyberg, J; Johansson, J				Tjernberg, L; Hosia, W; Bark, N; Thyberg, J; Johansson, J			Charge attraction and beta propensity are necessary for amyloid fibril formation from tetrapeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; FRAGMENT; RESIDUE	Amyloid fibrils in which specific proteins have polymerized into a cross-beta-sheet structure are found in about 20 diseases. In contrast to the close structural similarity of fibrils formed in different amyloid diseases, the structures of the corresponding native proteins differ widely. We show here that peptides as short as 4 residues with the sequences KFFE or KVVE can form amyloid fibrils that are practically identical to fibrils formed in association with disease, as judged by electron microscopy and Congo red staining. In contrast, KLLE or KAAE do not form fibrils. The fibril-forming KFFE and KVVE show partial beta-strand conformation in solution, whereas the non-fibril-forming KLLE and KAAE show random structure only, suggesting that inherent propensity for beta-strand conformation promotes fibril formation. The peptides KFFK or EFFE do not form fibrils on their own but do so in an equimolar mixture. Thus, intermolecular electrostatic interactions, either between charged dipolar peptides or between complementary charges of co-fibrillating peptides favor fibril formation.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Neurotec, S-14157 Huddinge, Sweden; Karolinska Inst, Dept Clin Neurosci, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Johansson, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.			Johansson, Jan/0000-0002-8719-4703				Azriel R, 2001, J BIOL CHEM, V276, P34156, DOI 10.1074/jbc.M102883200; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Gazit E, 2002, FASEB J, V16, P77, DOI 10.1096/fj.01-0442hyp; Kallberg Y, 2001, J BIOL CHEM, V276, P12945, DOI 10.1074/jbc.M010402200; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Taddei N, 2001, J BIOL CHEM, V276, P37149, DOI 10.1074/jbc.M105720200; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tjernberg LO, 1999, J BIOL CHEM, V274, P12619, DOI 10.1074/jbc.274.18.12619; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; WOUTERS MA, 1995, PROTEINS, V22, P119, DOI 10.1002/prot.340220205; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334	13	199	201	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43243	43246		10.1074/jbc.M205570200	http://dx.doi.org/10.1074/jbc.M205570200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12215440				2022-12-25	WOS:000179081200106
J	Forbes, LV; Gale, RE; Pizzey, A; Pouwels, K; Nathwani, A; Linch, DC				Forbes, LV; Gale, RE; Pizzey, A; Pouwels, K; Nathwani, A; Linch, DC			An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia	ONCOGENE			English	Article						point mutation; constitutive activation; helix-helix interaction; asparagine	CELL-SURFACE RECEPTORS; RAS GENE-MUTATIONS; ERYTHROPOIETIN RECEPTOR; HEMATOPOIETIC-CELLS; POINT MUTATIONS; BETA-SUBUNIT; IN-VIVO; N-RAS; G-CSF; DIFFERENTIATION	To date, constitutively activating point mutations reported in hematopoietic growth factor receptors in patients with acute myeloid leukemia (AML) have been restricted to receptors with intrinsic tyrosine kinase activity such as c-kit and FLT3. We describe here a Thr617Asn mutation in the transmembrane domain of the non-tyrosine kinase receptor for granulocyte colony-stimulating factor (G-CSF) in the blast cells of two out of 555 AML patients examined. The mutant receptor conferred growth factor independence on factor-dependent Ba/F3 cells. In the absence of ligand, immunoblotting showed weak phosphorylation of JAK2, STAT3, ERKs 1 and 2 and the receptor itself, and there was approximately 70% of maximal growth in a proliferation assay. All signals were significantly enhanced in the presence of G-CSF. Retroviral transduction of mutant receptor into primary hematopoietic CD34+ cells induced G-CSF independent myeloid differentiation as assessed by the development of neutrophils and surface expression of CD11b and CD14. These results confirm the importance of the transmembrane domain for receptor function and suggest that introduction of an asparagine residue can cause sufficient stabilization of helix-helix interactions in the absence of ligand to activate downstream signaling pathways involved in directing proliferation and differentiation.	UCL, Dept Haematol, London WC1E 6HX, England	University of London; University College London	Gale, RE (corresponding author), UCL, Dept Haematol, 98 Chenies Mews, London WC1E 6HX, England.	rosemary.gale@ucl.ac.uk	Ashby, Louisa/GRN-9388-2022; SHAKOORI, ABDUL RAUF/Q-9373-2019; Pizzey, Arnold/E-6301-2015	Ashby, Louisa/0000-0001-8247-096X; Pizzey, Arnold/0000-0003-1850-1121				Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P983, DOI 10.1046/j.1365-2141.2001.02850.x; Alexander WS, 1998, LEUKEMIA RES, V22, P1097, DOI 10.1016/S0145-2126(98)00110-6; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Bernard T, 1996, BRIT J HAEMATOL, V93, P527, DOI 10.1046/j.1365-2141.1996.d01-1696.x; BERNSTEIN ID, 1991, BLOOD, V77, P2316; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Byrne JL, 1998, BRIT J HAEMATOL, V100, P256; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Dong F, 1998, J IMMUNOL, V161, P6503; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; Gonda TJ, 1997, BLOOD, V89, P355, DOI 10.1182/blood.V89.2.355; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Ihle JN, 1996, ADV CANCER RES, V68, P23, DOI 10.1016/S0065-230X(08)60351-6; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Jenkins BJ, 1998, BLOOD, V92, P1989, DOI 10.1182/blood.V92.6.1989; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; Kelly PF, 2000, BLOOD, V96, P1206, DOI 10.1182/blood.V96.4.1206.h8001206_1206_1214; Kitamura T, 1998, BLOOD, V92, P2596, DOI 10.1182/blood.V92.7.2596; Kiyoi H, 1999, BLOOD, V93, P3074; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; KOTTARIDIS PD, 2002, IN PRESS BLOOD; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; McKinstry WJ, 1997, BLOOD, V89, P65, DOI 10.1182/blood.V89.1.65.65_65_71; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; MOLINEUX G, 1991, BLOOD, V78, P961; Nakano Y, 1999, BRIT J HAEMATOL, V104, P659, DOI 10.1046/j.1365-2141.1999.01256.x; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Persons DA, 1998, BLOOD CELL MOL DIS, V24, P167, DOI 10.1006/bcmd.1998.0184; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; SHINJO K, 1995, BRIT J HAEMATOL, V91, P783, DOI 10.1111/j.1365-2141.1995.tb05390.x; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Zaliauskiene L, 2000, MOL BIOL CELL, V11, P2643, DOI 10.1091/mbc.11.8.2643; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	41	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					5981	5989		10.1038/sj.onc.1205767	http://dx.doi.org/10.1038/sj.onc.1205767			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203110				2022-12-25	WOS:000177671300001
J	Jiang, M; Milner, J				Jiang, M; Milner, J			Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference	ONCOGENE			English	Article						RNA interference; HPV 16; human cervical cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; DOUBLE-STRANDED-RNA; MESSENGER-RNA; P53; PROTEIN; E6; DEGRADATION; INHIBITION	Selective silencing of mammalian gene expression has recently been achieved using short interfering RNA (siRNA). Synthetic siRNA targets homologous mRNA for degradation and the process is highly efficient. Here we demonstrate siRNA silencing of pathogenic viral gene expression. As a well characterized model we chose cervical carcinoma cells positive for human papillomavirus type 16. Over 90% of human cervical cancers are positive for papillomavirus and abnormal cell proliferation is driven by co-operative effects of viral E6 and E7 genes. We sought to silence HPV E6 and E7 gene expression using siRNAs to target the respective viral mRNAs. Our results indicate selective degradation of E6 and E7 mRNAs. Silencing was sustained for at least 4 days following a single dose of siRNA. E6 silencing induced accumulation of cellular p53 protein, transactivation of the cell cycle control p21 gene and reduced cell growth. In contrast, E7 silencing induced apoptotic cell death. HPV-negative cells appeared unaffected by the anti-viral siRNAs. Thus we demonstrate for the first time (i) that siRNA can induce selective silencing of exogenous viral genes in mammalian cells, and (ii) that the process of siRNA interference does not interfere with the recovery of cellular regulatory systems previously inhibited by viral gene expression.	Univ York, Dept Biol, YCR P53 Res Grp, York YO10 5DD, N Yorkshire, England	University of York - UK	Milner, J (corresponding author), Univ York, Dept Biol, YCR P53 Res Grp, York YO10 5DD, N Yorkshire, England.	ajm24@york.ac.uk		Jiang, Ming/0000-0003-3361-9881				Aguilar-Lemarroy A, 2002, ONCOGENE, V21, P165, DOI 10.1038/sj.onc.1204979; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BUTZ K, 1995, ONCOGENE, V10, P927; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Carthew RW, 2001, CURR OPIN CELL BIOL, V13, P244, DOI 10.1016/S0955-0674(00)00204-0; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gu W, 2002, J CELL BIOL, V156, P41, DOI 10.1083/jcb.200105133; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Koromilas AE, 2001, CYTOKINE GROWTH F R, V12, P157, DOI 10.1016/S1359-6101(00)00023-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; McMurray HR, 2001, INT J EXP PATHOL, V82, P15, DOI 10.1046/j.1365-2613.2001.00177.x; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; STEELE C, 1993, CANCER RES, V53, P2330; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	26	302	386	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6041	6048		10.1038/sj.onc.1205878	http://dx.doi.org/10.1038/sj.onc.1205878			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203116				2022-12-25	WOS:000177671300007
J	Koliopanos, A; Kleeff, J; Xiao, Y; Safe, S; Zimmermann, A; Buchler, MW; Friess, H				Koliopanos, A; Kleeff, J; Xiao, Y; Safe, S; Zimmermann, A; Buchler, MW; Friess, H			Increased arythydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer	ONCOGENE			English	Article						pancreatic cancer; chemotherapy; arylhydrocarbon receptor; cytochrome-P450; cell cycle	ARYL-HYDROCARBON RECEPTOR; SIGNAL-TRANSDUCTION PATHWAYS; NUCLEAR TRANSLOCATOR ARNT; HUMAN AH RECEPTOR; D GENE-EXPRESSION; CELL-CYCLE; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; POLYCHLORINATED DIBENZOFURANS; ANTITUMORIGENIC ACTIVITY; GLUCOCORTICOID-RECEPTOR	The arylhydrocarbon receptor (AhR) was initially identified as a member of the adaptive metabolic and toxic response pathway to polycyclic aromatic hydrocarbons and to halogenated dibenzo-p-dioxins and dibenzofurans. In the present study, we sought to determine the functional significance of the AhR pathway in pancreatic carcinogenesis. AhR expression was analysed by Northern blotting. The exact site of AhR expression was analysed by in situ hybridization and immunohistochemistry. The effects of TCDD and four selective AhR agonists on pancreatic cancer cell lines were investigated by growth assays, apoptosis assays, and induction of the cyclin-dependent kinase inhibitor p21. There was strong AhR mRNA expression in 14 out of 15 pancreatic cancer samples, weak expression in chronic pancreatitis tissues, and faint expression in all normal pancreata. In pancreatic cancer tissues, AhR mRNA and protein expression were localized in the cytoplasm of pancreatic cancer cells. TCDD and the four AhR agonists inhibited pancreatic cancer cell growth in a dose-dependent manner, and decreased anchorage-independent cell growth. DAPI staining did not reveal nuclear fragmentation and CYP1A1 and was not induced by TCDD and AhR agonists. In contrast, TCDD and AhR agonists induced the expression of the cyclin-dependent kinase inhibitor p21. In conclusion, the relatively non-toxic AhR agonists caused growth inhibition in pancreatic cancer cells with high AhR expression levels via cell cycle arrest. In addition, almost all human pancreatic cancer tissues expressed this receptor at high levels, suggesting that these or related compounds may play a role in the therapy of pancreatic cancer in the future.	Heidelberg Univ, Dept Gen Surg, D-69120 Heidelberg, Germany; Univ Bern, Dept Visceral & Transplantat Surg, Inselspital, Bern, Switzerland; Univ Bern, Inst Pathol, Inselspital, Bern, Switzerland; Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Ruprecht Karls University Heidelberg; University of Bern; University of Bern; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Friess, H (corresponding author), Heidelberg Univ, Dept Gen Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	helmut_friess@med.uni-heidelberg.de	Kleeff, Jorg/B-2124-2009	Kleeff, Jorg/0000-0003-3432-6669				Abe M, 2000, CANCER, V88, P2000, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2000::AID-CNCR4>3.0.CO;2-B; Andren-Sandberg A, 1999, ANN ONCOL, V10, P131, DOI 10.1023/A:1008377928466; Angus WGR, 1999, CARCINOGENESIS, V20, P947, DOI 10.1093/carcin/20.6.947; ASTROFF B, 1989, TOXICOLOGY, V59, P285, DOI 10.1016/0300-483X(89)90198-4; Becher H, 1996, CANCER CAUSE CONTROL, V7, P312, DOI 10.1007/BF00052936; Bertazzi PA, 2001, AM J EPIDEMIOL, V153, P1031, DOI 10.1093/aje/153.11.1031; Bertazzi PA, 1997, EPIDEMIOLOGY, V8, P646, DOI 10.1097/00001648-199710000-00006; BUCHLER M, 1991, CANCER-AM CANCER SOC, V68, P1507, DOI 10.1002/1097-0142(19911001)68:7<1507::AID-CNCR2820680707>3.0.CO;2-0; BUCKINGHAM J, 1997, DICT ORGANIC COMPOUN; CARVER LA, 1994, NUCLEIC ACIDS RES, V22, P3038, DOI 10.1093/nar/22.15.3038; Chen I, 1998, CARCINOGENESIS, V19, P1631, DOI 10.1093/carcin/19.9.1631; Cheung YL, 1999, CANCER LETT, V139, P199, DOI 10.1016/S0304-3835(99)00045-2; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DREISBACH RH, 1987, HDB POISONING PREVEN; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; FRIESS H, 1992, PANCREAS, V7, P516, DOI 10.1097/00006676-199209000-00002; FRIESS H, 1993, CANCER RES, V53, P2704; GEIGER LE, 1981, TOXICOL APPL PHARM, V59, P125, DOI 10.1016/0041-008X(81)90459-2; Goodman LS., 2018, GOODMAN GILMANS PHAR; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HARRIS M, 1989, MOL PHARMACOL, V35, P729; HAYASHI S, 1994, CARCINOGENESIS, V15, P801, DOI 10.1093/carcin/15.5.801; Hayes, 1982, PESTICIDES STUDIED M, V247, P3140; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUFF J, 1994, ANNU REV PHARMACOL, V34, P343; *IARC WHO, 1987, IARC MON, V1; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1987, IARC MON, V1; Jana NR, 1999, BIOCHEM BIOPH RES CO, V256, P462, DOI 10.1006/bbrc.1999.0367; JOHNSON ES, 1992, CRIT REV TOXICOL, V21, P451, DOI 10.3109/10408449209089883; JONES PBC, 1986, J BIOL CHEM, V261, P6647; Kashani M, 1998, PROSTATE, V37, P98; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; KOJIMA T, 1994, CANCER RES, V54, P1446; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; Kuil CW, 1998, J BIOL CHEM, V273, P8829, DOI 10.1074/jbc.273.15.8829; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; Ledirac N, 2000, TOXICOL APPL PHARM, V164, P273, DOI 10.1006/taap.2000.8920; Li W, 1998, BIOCHEM PHARMACOL, V56, P599, DOI 10.1016/S0006-2952(98)00208-1; Ma Q, 1996, MOL CELL BIOL, V16, P2144; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; McDougal A, 1997, CANCER LETT, V120, P53, DOI 10.1016/S0304-3835(97)00299-1; McDougal A, 2001, BREAST CANCER RES TR, V66, P147, DOI 10.1023/A:1010608000074; MORSE MA, 1990, CANCER RES, V50, P2613; NORMAN J, 1994, J SURG RES, V57, P33, DOI 10.1006/jsre.1994.1105; Oikawa K, 2001, CANCER RES, V61, P5707; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1979, CANCER RES, V39, P3341; POLAND AP, 1974, J BIOL CHEM, V249, P5599; QUATTROCHI LC, 1994, J BIOL CHEM, V269, P6949; Ramamoorthy K, 1999, CARCINOGENESIS, V20, P115, DOI 10.1093/carcin/20.1.115; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Rininger JA, 1997, CHEMOSPHERE, V34, P1557, DOI 10.1016/S0045-6535(96)00451-1; ROWLANDS C, 1993, CANCER RES, V53, P1802; Roy NK, 1997, ARCH BIOCHEM BIOPHYS, V344, P373, DOI 10.1006/abbi.1997.0238; Safe S, 1998, TOXICOL LETT, V103, P343; Safe S, 2001, TOXICOL LETT, V120, P1, DOI 10.1016/S0378-4274(01)00301-0; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; Sax N. I., 1989, DANGEROUS PROPERTIES; Sittig M, 1985, HDB TOXIC HAZARDOUS; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SKENE SA, 1989, HUM TOXICOL, V8, P173, DOI 10.1177/096032718900800301; Spink BC, 1998, J CELL BIOCHEM, V70, P289, DOI 10.1002/(SICI)1097-4644(19980901)70:3<289::AID-JCB1>3.3.CO;2-H; Steenland K, 1999, J NATL CANCER I, V91, P779, DOI 10.1093/jnci/91.9.779; STOEWSAND GS, 1988, CANCER LETT, V39, P199, DOI 10.1016/0304-3835(88)90105-X; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; Sun GL, 1997, CANCER CHEMOTH PHARM, V40, P239, DOI 10.1007/s002800050653; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; Takahashi Y, 1996, EUR J BIOCHEM, V242, P512, DOI 10.1111/j.1432-1033.1996.0512r.x; TAKEUCHI Y, 1993, AM J GASTROENTEROL, V88, P1928; VANG O, 1990, CARCINOGENESIS, V11, P1259, DOI 10.1093/carcin/11.8.1259; VICKERS PJ, 1989, MOL ENDOCRINOL, V3, P157, DOI 10.1210/mend-3-1-157; Wang F, 1999, BIOCHEMISTRY-US, V38, P11490, DOI 10.1021/bi982578f; WANG XH, 1995, EUR J PHARM-ENVIRON, V293, P191, DOI 10.1016/S0922-4106(05)80044-6; WANG XH, 1992, BIOCHEM PHARMACOL, V43, P1635; WATTENBERG LW, 1978, CANCER RES, V38, P1410; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Windholz M., 1983, MERCK INDEX ENCY CHE, Vtenth; Wormke M, 2000, J STEROID BIOCHEM, V72, P197, DOI 10.1016/S0960-0760(00)00030-3; WU L, 1992, P NATL ACAD SCI USA, V89, P4811, DOI 10.1073/pnas.89.11.4811; ZACHAREWSKI TR, 1994, CANCER RES, V54, P2707	89	109	118	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6059	6070		10.1038/sj.onc.1205633	http://dx.doi.org/10.1038/sj.onc.1205633			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203118				2022-12-25	WOS:000177671300009
J	Ying, WZ; Sanders, PW				Ying, WZ; Sanders, PW			Dietary salt intake activates MAP kinases in the rat kidney	FASEB JOURNAL			English	Article						p42 MAP kinase; p44 MAP kinase; p38 MAP kinase; shear; transforming growth factor beta; nitric oxide; flavones; imidazoles	NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR-BETA; SIGNAL-REGULATED KINASE; SHEAR-STRESS; PROTEIN-KINASE; SENSITIVE HYPERTENSION; GENE-EXPRESSION; CELL; TYROSINE; SMAD	This study explored the hypothesis that dietary salt promoted changes in renal expression of TGF-beta1 and NOS3 by modulating the mitogen-activated protein kinase (MAPK) pathways. Sprague-Dawley rats were maintained for four days on formulated diets that contained 0.3, 1.0, 3.0, or 8.0% NaCl. An increase in salt intake to greater than or equal to3.0% NaCl increased kinase activities of p38 MAPK and p42/44 MAPK, but not p46/54 JNK/SAPK, in the cortex and outer and inner medulla. Associated with this increased activity was a relative increase in the phosphorylated forms of the transcription factors ATF-2 and Elk-1. Compared with rats on 0.3% NaCl diet, glomerular preparations from rats on 8.0% NaCl diet contained more NOS3 and produced greater amounts of total and active TGF-beta1 and NOx. PD-098059, a MEK1 inhibitor, and SB-203580, an inhibitor of p38 MAPKalpha-gamma, diminished NOS3 expression and production of TGF-beta1 and NOx. TEA, administered intravenously 5 min before harvesting kidneys of rats on the 8.0% NaCl diet, decreased activities of both p38 MAPK and p42/44 MAPK, compared with vehicle-treated animals. Thus, an increase in dietary salt activated through a TEA-sensitive pathway the p38 MAPK and p42/44 MAPK signaling cascades, which promoted the increase in glomerular TGF-beta1 and NOS3 expression.	Univ Alabama Birmingham, Dept Med, Div Nephrol, Cell Adhes & Matrix Res Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Nephrol Res & Training, Birmingham, AL USA; Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Dept Vet Affairs Med Ctr, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Sanders, PW (corresponding author), Univ Alabama Birmingham, Dept Med, Div Nephrol, Cell Adhes & Matrix Res Ctr, 642 Lyons Harrison Res Bldg,1530 3rd Ave S, Birmingham, AL 35294 USA.	psanders@uab.edu		Sanders, Paul/0000-0002-2915-5714				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Azuma N, 2001, AM J PHYSIOL-HEART C, V280, pH189, DOI 10.1152/ajpheart.2001.280.1.H189; Bech JN, 1998, AM J PHYSIOL-RENAL, V274, pF914, DOI 10.1152/ajprenal.1998.274.5.F914; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; CHEN PY, 1991, J CLIN INVEST, V88, P1559, DOI 10.1172/JCI115467; Chen PY, 1998, HYPERTENSION, V31, P918, DOI 10.1161/01.HYP.31.4.918; CHEN PY, 1993, HYPERTENSION, V22, P812, DOI 10.1161/01.HYP.22.6.812; CHEN PY, 1993, LAB INVEST, V68, P174; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; DENG AH, 1993, AM J PHYSIOL, V264, pF212, DOI 10.1152/ajprenal.1993.264.2.F212; DENG XL, 1994, KIDNEY INT, V46, P639, DOI 10.1038/ki.1994.316; Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Hamaguchi A, 1999, HYPERTENSION, V34, P126, DOI 10.1161/01.HYP.34.1.126; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Li YS, 1996, MOL CELL BIOL, V16, P5947; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Maulik N, 1998, AM J PHYSIOL-HEART C, V275, pH1857, DOI 10.1152/ajpheart.1998.275.5.H1857; OHNO M, 1995, J CLIN INVEST, V95, P1363, DOI 10.1172/JCI117787; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; PATEL A, 1993, HYPERTENSION, V22, P863, DOI 10.1161/01.HYP.22.6.863; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RELMAN AS, 1949, P SOC EXP BIOL MED, V70, P11; SAKAI T, 1987, ANAT EMBRYOL, V176, P373; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; SHULTZ PJ, 1993, J CLIN INVEST, V91, P642, DOI 10.1172/JCI116244; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; TOLINS JP, 1990, AM J PHYSIOL, V258, pH655, DOI 10.1152/ajpheart.1990.258.3.H655; TOLINS JP, 1994, KIDNEY INT, V46, P230, DOI 10.1038/ki.1994.264; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Ying WZ, 1999, AM J PHYSIOL-HEART C, V277, pH1293, DOI 10.1152/ajpheart.1999.277.4.H1293; Ying WZ, 1998, KIDNEY INT, V54, P1150, DOI 10.1046/j.1523-1755.1998.00117.x; Ying WZ, 1998, AM J PHYSIOL-RENAL, V275, pF18, DOI 10.1152/ajprenal.1998.275.1.F18; Ying WZ, 1998, AM J PHYSIOL-RENAL, V274, pF635, DOI 10.1152/ajprenal.1998.274.4.F635; Zhang ZJ, 1998, RNA, V4, P394	46	23	24	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1683	+		10.1096/fj.02-0982fje	http://dx.doi.org/10.1096/fj.02-0982fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206991				2022-12-25	WOS:000177814000008
J	Kampa, M; Papakonstanti, EA; Hatzoglou, A; Stathopoulos, EN; Stournaras, C; Castanas, E				Kampa, M; Papakonstanti, EA; Hatzoglou, A; Stathopoulos, EN; Stournaras, C; Castanas, E			The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors, which increase PSA secretion and modify actin cytoskeleton	FASEB JOURNAL			English	Article						testosterone receptor; membrane receptor; cancer cells (LNCaP)	HORMONE-BINDING GLOBULIN; HUMAN ENDOMETRIAL CELLS; FOCAL ADHESION KINASE; PITUITARY-TUMOR CELLS; ANDROGEN RECEPTOR; PLASMA-MEMBRANES; STEROID-HORMONES; TYROSINE PHOSPHORYLATION; CALCIUM-CONCENTRATION; CHANNEL ACTIVATION	Recent findings have shown that, in addition to the genomic action of steroids, through intracellular receptors, short-time effects could be mediated through binding to membrane sites. In the present study of prostate cancer LNCaP cells, we report that dihydrotestosterone and the non-internalizable analog testosterone-BSA increase rapidly the release of prostate-specific antigen (PSA) in the culture medium. Membrane testosterone binding sites were identified through ligand binding on membrane preparations, flow cytometry, and confocal laser microscopy of the non-internalizable fluorescent analog testosterone-BSA-FITC, on whole cells. Binding on these sites is time- and concentration-dependent and specific for testosterone, presenting a K-D of 10.9 nM and a number of 144 sites/mg protein (similar to13000 sites/cell). Membrane sites differ immunologically for intracellular androgen receptors. The secretion of PSA after membrane testosterone receptor stimulation was inhibited after pretreatment with the actin cytoskeleton disrupting agent cytochalasin B. In addition, membrane testosterone binding modifies the intracellular dynamic equilibrium of monomeric to filamentous actin and remodels profoundly the actin cytoskeleton organization. These results are discussed in the context of a possible involvement of these sites in cancer chemotherapy.	Univ Crete, Sch Med, Lab Expt Endocrinol, GR-71110 Iraklion, Greece; Univ Crete, Sch Med, Biochem Lab, GR-71110 Iraklion, Greece; Univ Crete, Sch Med, Pathol Lab, GR-71110 Iraklion, Greece	University of Crete; University of Crete; University of Crete	Castanas, E (corresponding author), Univ Crete, Sch Med, Lab Expt Endocrinol, POB 1393, GR-71110 Iraklion, Greece.	castanas@med.uoc.gr	Castanas, Elias/E-7007-2010	Castanas, Elias/0000-0002-8370-1835; Papakonstanti, Evangelia/0000-0002-7119-6026				Armen TA, 2000, J CELL BIOCHEM, V79, P620, DOI 10.1002/1097-4644(20001215)79:4<620::AID-JCB110>3.3.CO;2-8; Benten WPM, 1997, FEBS LETT, V407, P211, DOI 10.1016/S0014-5793(97)00346-3; Benten WPM, 1999, FASEB J, V13, P123, DOI 10.1096/fasebj.13.1.123; Benten WPM, 1999, MOL BIOL CELL, V10, P3113, DOI 10.1091/mbc.10.10.3113; BILHARTZ DL, 1991, UROLOGY, V38, P95, DOI 10.1016/S0090-4295(05)80066-4; Borski RJ, 2000, TRENDS ENDOCRIN MET, V11, P427, DOI 10.1016/S1043-2760(00)00325-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANN DW, 1995, J STEROID BIOCHEM, V52, P113, DOI 10.1016/0960-0760(94)00160-N; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; Dermitzaki E, 2001, ENDOCRINOLOGY, V142, P2022, DOI 10.1210/en.142.5.2022; DIEZ A, 1984, HORM METAB RES, V16, P475, DOI 10.1055/s-2007-1014823; Ding AQ, 2001, J APPL PHYSIOL, V91, P2742, DOI 10.1152/jappl.2001.91.6.2742; Ding VDH, 1998, ENDOCRINOLOGY, V139, P213, DOI 10.1210/en.139.1.213; Falkenstein E, 2001, MOL CELL BIOCHEM, V218, P71, DOI 10.1023/A:1007269507856; FELDEN F, 1992, J STEROID BIOCHEM, V42, P279, DOI 10.1016/0960-0760(92)90130-B; FORTUNATI N, 1992, J STEROID BIOCHEM, V42, P185, DOI 10.1016/0960-0760(92)90027-G; FRAIRIA R, 1991, J STEROID BIOCHEM, V40, P805, DOI 10.1016/0960-0760(91)90306-P; FULLER CM, 1994, AM J PHYSIOL, V266, pC661, DOI 10.1152/ajpcell.1994.266.3.C661; GOLENHOFEN N, 1995, KIDNEY INT, V48, P1837, DOI 10.1038/ki.1995.482; GORCZYNSKA E, 1995, ENDOCRINOLOGY, V136, P2052, DOI 10.1210/en.136.5.2052; Grazzini E, 1998, NATURE, V392, P509, DOI 10.1038/33176; GUEANT JL, 1991, J MOL ENDOCRINOL, V7, P113, DOI 10.1677/jme.0.0070113; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HRYB DJ, 1990, J BIOL CHEM, V265, P6048; JENSEN EV, 1996, ANN NY ACAD SCI, V748, P1; KILEY SC, 1992, MOL ENDOCRINOL, V6, P120, DOI 10.1210/me.6.1.120; KONOPLYA EF, 1992, INT J BIOCHEM, V24, P1979, DOI 10.1016/0020-711X(92)90294-B; Koukouritaki SB, 1997, J CELL BIOCHEM, V65, P492, DOI 10.1002/(SICI)1097-4644(19970615)65:4<492::AID-JCB5>3.0.CO;2-J; Koukouritaki SB, 1996, J CELL BIOCHEM, V62, P251, DOI 10.1002/(SICI)1097-4644(199608)62:2<251::AID-JCB13>3.0.CO;2-O; Koukouritaki SB, 1999, MOL MED, V5, P382, DOI 10.1007/BF03402127; Koukouritaki SB, 1999, MOL MED, V5, P731, DOI 10.1007/BF03402097; KRUPENKO SA, 1994, J STEROID BIOCHEM, V51, P115, DOI 10.1016/0960-0760(94)90122-8; Kumar MV, 1998, PROG NUCLEIC ACID RE, V59, P289; Leung GPH, 2001, AM J PHYSIOL-CELL PH, V280, pC1160, DOI 10.1152/ajpcell.2001.280.5.C1160; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; Lyng FM, 2000, BIOL REPROD, V63, P736, DOI 10.1095/biolreprod63.3.736; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; Mosmann T., 1973, J IMMUNOL METHODS, V65, P53; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nadal A, 1998, FASEB J, V12, P1341, DOI 10.1096/fasebj.12.13.1341; Nakhla AM, 1996, ENDOCRINOLOGY, V137, P4126, DOI 10.1210/en.137.10.4126; Nemere I, 1998, BIOCHEM BIOPH RES CO, V248, P443, DOI 10.1006/bbrc.1998.8492; OESTERLING JE, 1997, CANC PRINCIPLES PRAC, V1, P1322; Panagiotou S, 1999, J CELL BIOCHEM, V73, P204, DOI 10.1002/(SICI)1097-4644(19990501)73:2<204::AID-JCB6>3.0.CO;2-V; Papakonstanti EA, 1998, J CELL BIOCHEM, V70, P60, DOI 10.1002/(SICI)1097-4644(19980701)70:1<60::AID-JCB7>3.0.CO;2-1; Papakonstanti EA, 2000, MOL MED, V6, P303, DOI 10.1007/BF03401939; PORTO CS, 1995, J STEROID BIOCHEM, V53, P561, DOI 10.1016/0960-0760(95)00111-C; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; THEODOROPOULOS PA, 1992, FEBS LETT, V311, P241, DOI 10.1016/0014-5793(92)81111-X; Watson CS, 1999, EXP PHYSIOL, V84, P1013, DOI 10.1111/j.1469-445X.1999.01903.x; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; YOUNG CYF, 1991, CANCER RES, V51, P3748; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249	55	135	138	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1429	+		10.1096/fj.02-0131fje	http://dx.doi.org/10.1096/fj.02-0131fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205037	Bronze			2022-12-25	WOS:000177813100009
J	Sriram, K; Matheson, JM; Benkovic, SA; Miller, DB; Luster, MI; O'Callaghan, JP				Sriram, K; Matheson, JM; Benkovic, SA; Miller, DB; Luster, MI; O'Callaghan, JP			Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease	FASEB JOURNAL			English	Article						brain; neurodegeneration; neuroprotection; MPTP	TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA PRODUCTION; ALZHEIMERS-DISEASE; SUBSTANTIA-NIGRA; GLIAL-CELLS; RAT-BRAIN; COMPLEX-I; QUANTITATIVE ASPECTS; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS	The pathogenic mechanisms underlying idiopathic Parkinson's disease (PD) remain enigmatic. Recent findings suggest that inflammatory processes are associated with several neurodegenerative disorders, including PD. Enhanced expression of the proinflammatory cytokine, tumor necrosis factor (TNF)-alpha, has been found in association with glial cells in the substantia nigra of patients with PD. To determine the potential role for TNF-alpha in PD, we examined the effects of the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP), a dopaminergic neurotoxin that mimics some of the key features associated with PD, using transgenic mice lacking TNF receptors. Administration of MPTP to wild-type (+/+) mice resulted in a time-dependent expression of TNF-alpha in striatum, which preceded the loss of dopaminergic markers and reactive gliosis. In contrast, transgenic mice carrying homozygous mutant alleles for both the TNF receptors (TNFR-DKO), but not the individual receptors, were completely protected against the dopaminergic neurotoxicity of MPTP. The data indicate that the proinflammatory cytokine TNF-alpha is an obligatory component of dopaminergic neurodegeneration. Moreover, because TNF-alpha is synthesized predominantly by microglia and astrocytes, our findings implicate the participation of glial cells in MPTP-induced neurotoxicity. Similar mechanisms may underlie the etiopathogenesis of PD.	NIOSH, CDC, TMBB, HELD, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	O'Callaghan, JP (corresponding author), NIOSH, CDC, TMBB, HELD, Mailstop L-3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.	jdo5@cdc.gov	Sriram, Krishnan/F-1039-2014; O'Callaghan, James/O-2958-2013	Sriram, Krishnan/0000-0001-7005-1872				Aloe L, 1997, NEUROSCI LETT, V238, P65, DOI 10.1016/S0304-3940(97)00850-1; BALABAN CD, 1988, NEUROSCIENCE, V26, P337, DOI 10.1016/0306-4522(88)90150-9; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Cleeter MWJ, 2001, FEBS LETT, V504, P50, DOI 10.1016/S0014-5793(01)02763-6; Dabbeni-Sala F, 2001, FASEB J, V15, P1786, DOI 10.1096/fj.00-0427fje; deBock F, 1996, NEUROREPORT, V7, P1125, DOI 10.1097/00001756-199604260-00004; Declercq W, 1998, J IMMUNOL, V161, P390; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K; FRANCIS JW, 1995, NEUROTOXICOL TERATOL, V17, P7, DOI 10.1016/0892-0362(94)00048-I; Galasso JM, 2000, NEUROREPORT, V11, P231, DOI 10.1097/00001756-200002070-00002; GIASSON BI, 2000, NEURODEGENERATIVE DE, P219; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Goossens V, 1999, ANTIOXID REDOX SIGN, V1, P285, DOI 10.1089/ars.1999.1.3-285; GRAMSBERGEN JBP, 1994, BRAIN RES, V667, P216, DOI 10.1016/0006-8993(94)91499-0; HETIER E, 1991, EXP BRAIN RES, V86, P407; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; Hunot S, 1999, J NEUROSCI, V19, P3440; Hunot S, 2001, CLIN NEUROSCI RES, V1, P434, DOI 10.1016/S1566-2772(01)00022-6; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LEE SC, 1993, J IMMUNOL, V150, P2659; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; Lippa CF, 1995, NEURODEGENERATION, V4, P425, DOI 10.1006/neur.1995.0051; LITTLE AR, 2002, CEL MOL MEC TOX ACT, V3, P233; Masliah E., 2000, NEURODEGENERATIVE DE, P131; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; Miller DB, 1998, ANN NY ACAD SCI, V844, P153, DOI 10.1111/j.1749-6632.1998.tb08230.x; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; MIZUNO Y, 1987, J NEUROCHEM, V48, P1787, DOI 10.1111/j.1471-4159.1987.tb05737.x; MIZUNO Y, 1993, ADV NEUROL, V60, P282; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Mogi M, 1999, NEUROSCI LETT, V268, P101, DOI 10.1016/S0304-3940(99)00388-2; MOGI M, 1995, J NEURAL TRANSM-PARK, V9, P87, DOI 10.1007/BF02252965; Nagatsu T, 2000, ADV RES NEURODEGENER, V8, P277; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; Nishimura M, 2001, NEUROSCI LETT, V311, P1, DOI 10.1016/S0304-3940(01)02111-5; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; O'Callaghan JP, 1999, ANAL BIOCHEM, V274, P18, DOI 10.1006/abio.1999.4260; O'Callaghan JP, 1998, ANN NY ACAD SCI, V844, P40; OCALLAGHAN JP, 1990, BRAIN RES, V521, P73, DOI 10.1016/0006-8993(90)91526-M; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; OCALLAGHAN JP, 1995, NEUROCHEM INT, V26, P115, DOI 10.1016/0197-0186(94)00106-5; OCALLAGHAN JP, 1993, ANN NY ACAD SCI, V679, P195, DOI 10.1111/j.1749-6632.1993.tb18299.x; OCALLAGHAN JP, 2002, CURRENT PROTOCOLS TO; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; Pearce RKB, 1997, J NEURAL TRANSM, V104, P661, DOI 10.1007/BF01291884; Raivich Gennadij, 1996, Keio Journal of Medicine, V45, P239; Ransohoff Richard M., 1996, Cytokine and Growth Factor Reviews, V7, P35, DOI 10.1016/1359-6101(96)00003-2; Ren LQ, 1999, MOL BRAIN RES, V65, P198, DOI 10.1016/S0169-328X(99)00016-9; RODNITZKY RL, 1995, NEUROSCIENCE MED, P427; Sairanen T, 2001, STROKE, V32, P1750, DOI 10.1161/01.STR.32.8.1750; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOFIC E, 1992, NEUROSCI LETT, V142, P128, DOI 10.1016/0304-3940(92)90355-B; Sriram K, 1998, J NEUROSCI, V18, P10287; Sriram K, 1997, BRAIN RES, V749, P44, DOI 10.1016/S0006-8993(96)01271-1; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Unger JW, 1998, MICROSC RES TECHNIQ, V43, P24, DOI 10.1002/(SICI)1097-0029(19981001)43:1<24::AID-JEMT4>3.0.CO;2-P; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200	80	292	302	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1474	+		10.1096/fj.02-0216fje	http://dx.doi.org/10.1096/fj.02-0216fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205053	Green Submitted			2022-12-25	WOS:000177813100001
J	Kuettner, EB; Hilgenfeld, R; Weiss, MS				Kuettner, EB; Hilgenfeld, R; Weiss, MS			The active principle of garlic at atomic resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLIUM-SATIVUM; ALLIINASE; CRYSTALLIZATION; MOLSCRIPT; PROGRAM	Despite the fact that many cultures around the world value and utilize garlic as a fundamental component of their cuisine as well as of their medicine cabinets, relatively little is known about the plant's protein configuration that is responsible for the specific properties of garlic. Here, we report the three-dimensional structure of the garlic enzyme alliinase at 1.5 Angstrom resolution. Alliinase constitutes the major protein component in garlic bulbs, and it is able to cleave carbon-sulfur bonds. The active enzyme is a pyridoxal-5'-phosphate-dependent homodimeric glycoprotein and belongs to the class I family of pyridoxal-5'-phosphate-dependent enzymes. In addition, it contains a novel epidermal growth factor-like domain that makes it unique among all pyridoxal5'-phosphate-dependent enzymes.	Inst Mol Biotechnol, Dept Struct Biol & Crystallog, D-07745 Jena, Germany		Weiss, MS (corresponding author), DESY, European Mol Biol Lab, Hamburg Outstn, Notkestr 85, D-22603 Hamburg, Germany.	msweiss@embl-hamburg.de	Hilgenfeld, Rolf/C-9675-2011; Weiss, Manfred S/B-6857-2013	Weiss, Manfred S/0000-0002-2362-7047				Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1&lt;111::AID-MED4&gt;3.0.CO;2-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Birolo L, 1999, BIOCHEMISTRY-US, V38, P905, DOI 10.1021/bi981467d; BLOCK E, 1992, ANGEW CHEM INT EDIT, V31, P1135, DOI 10.1002/anie.199211351; Brandl M, 2001, J MOL BIOL, V307, P357, DOI 10.1006/jmbi.2000.4473; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Capitani G, 1999, J MOL BIOL, V294, P745, DOI 10.1006/jmbi.1999.3255; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Denesyuk AI, 2002, J MOL BIOL, V316, P155, DOI 10.1006/jmbi.2001.5310; ELLMORE GS, 1994, AM J BOT, V81, P89, DOI 10.2307/2445567; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krest I, 1999, PHARMAZIE, V54, P289; Kuettner EB, 2002, ARCH BIOCHEM BIOPHYS, V402, P192, DOI 10.1016/S0003-9861(02)00088-7; Louie GV, 1997, MOL CELL, V1, P67, DOI 10.1016/S1097-2765(00)80008-8; Matsui I, 2000, J BIOL CHEM, V275, P4871, DOI 10.1074/jbc.275.7.4871; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; Shimon LJW, 2002, ACTA CRYSTALLOGR D, V58, P1335, DOI 10.1107/S0907444902010466; Siegel G, 1999, Wien Med Wochenschr, V149, P217; STOLL A, 1947, EXPERIENTIA, V3, P114; Tchernychev B, 2000, IMMUNOL LETT, V71, P43, DOI 10.1016/S0165-2478(99)00162-5; TSAI Y, 1985, PLANTA MED, V51, P460, DOI 10.1055/s-2007-969553; VANDAMME EJM, 1992, EUR J BIOCHEM, V209, P751	29	54	58	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46402	46407		10.1074/jbc.M208669200	http://dx.doi.org/10.1074/jbc.M208669200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235163	hybrid			2022-12-25	WOS:000179529300091
J	Liu, F; Virshup, DM; Nairn, AC; Greengard, P				Liu, F; Virshup, DM; Nairn, AC; Greengard, P			Mechanism of regulation of casein kinase I activity by group I metabotropic glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ALZHEIMERS-DISEASE; STRIATAL NEURONS; PHOSPHORYLATION; DOPAMINE; DARPP-32; EPSILON; PHOSPHOPROTEIN; CLONING; FAMILY	Previously, we reported that (S)-3,5-dihydroxypenyl-glycine (DHPG), an agonist for group I metabotropic glutamate receptors (mGluRs), stimulates CK1 and Cdk5 kinase activities in neostriatal neurons, leading to enhanced phosphorylation, respectively, of Ser-137 and Thr-75 of DARPP-32 (dopamine and cAMP-regulated phosphoprotein, (32) under bar kDa). We have now investigated the signaling pathway that leads from mGluRs to casein kinase 1 (CK1) activation. In mouse neostriatal slices, the effect of DHPG on phosphorylation of Ser-137 or Thr-75 of DARPP-32 was blocked by the phospholipase Cbeta inhibitor U73122, the Ca2+ chelator 1,2-bis(2-amino-phenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA/AM), and the calcineurin inhibitor cyclosporin A. In neuroblastoma N2a cells, the effect of DHPG on the activity of transfected RA-tagged CK1epsilon was blocked by BAPTA/AM and cyclosporin A. In neostriatal slices, the effect of DHPG on Cdk5 activity was also abolished by BAPTA/AM and cyclosporin A, presumably through blocking activation of CK1. Metabolic labeling studies and phosphopeptide mapping revealed that a set of C-terminal sites in HA-CK1epsilon were transiently dephosphorylated in N2a cells upon treatment with DHPG, and this was blocked by cyclosporin A. A mutant CK1epsilon with a nonphosphorylatable C-terminal domain was not activated by DHPG. Together, these studies suggest that DHPG activates CK1epsilon via Ca2+-dependent stimulation of calcineurin and subsequent dephosphorylation of inhibitory C-terminal autophosphorylation sites.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Univ Utah, Dept Pediat, Div Hematol Oncol, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Yale Univ, Dept Psychiat, New Haven, CT 06520 USA	Rockefeller University; Utah System of Higher Education; University of Utah; Yale University	Nairn, AC (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.	nairn@mail.rockefeller.edu	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X; Nairn, Angus/0000-0002-7075-0195	NATIONAL CANCER INSTITUTE [P01CA073992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060387] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA073992-06A10004] Funding Source: Medline; NIGMS NIH HHS [R01 GM060387-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; Cartmell J, 1998, BRAIN RES, V791, P191, DOI 10.1016/S0006-8993(98)00094-8; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; DESDOUITS F, 1995, P NATL ACAD SCI USA, V92, P2682, DOI 10.1073/pnas.92.7.2682; DESDOUITS F, 1995, J BIOL CHEM, V270, P8772, DOI 10.1074/jbc.270.15.8772; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Eide EJ, 2001, CHRONOBIOL INT, V18, P389, DOI 10.1081/CBI-100103963; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Ghoshal N, 1999, AM J PATHOL, V155, P1163, DOI 10.1016/S0002-9440(10)65219-4; GOTO S, 1986, BRAIN RES, V397, P161, DOI 10.1016/0006-8993(86)91381-8; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kuret J, 1997, J NEUROCHEM, V69, P2506; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu F, 2001, P NATL ACAD SCI USA, V98, P11062, DOI 10.1073/pnas.191353898; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Nishi A, 1997, J NEUROSCI, V17, P8147; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Paolillo M, 1998, EUR J NEUROSCI, V10, P1937, DOI 10.1046/j.1460-9568.1998.00203.x; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Sallese M, 2000, BBA-MOL CELL RES, V1498, P112, DOI 10.1016/S0167-4889(00)00088-4; Schwab C, 2000, NEUROBIOL AGING, V21, P503, DOI 10.1016/S0197-4580(00)00110-X; Takano A, 2000, FEBS LETT, V477, P106, DOI 10.1016/S0014-5793(00)01755-5; Tobin AB, 1997, J BIOL CHEM, V272, P20844, DOI 10.1074/jbc.272.33.20844; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X	39	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45393	45399		10.1074/jbc.M204499200	http://dx.doi.org/10.1074/jbc.M204499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223474	hybrid, Green Accepted			2022-12-25	WOS:000179404800102
J	Zeng, MS; Kumar, A; Meng, GY; Gao, QS; Dimri, G; Wazer, D; Band, H; Band, V				Zeng, MS; Kumar, A; Meng, GY; Gao, QS; Dimri, G; Wazer, D; Band, H; Band, V			Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; ACUTE PROMYELOCYTIC LEUKEMIA; P53 ACTIVITY; PROTEIN; TYPE-16; COMPLEX; DIFFERENTIATION; CANCER; GENE; ACTIVATION	The expression of human papillomavirus (HPV) E6 oncoprotein is causally linked to high-risk HPV-associated human cancers. We have recently isolated hADA3, the human homologue of yeast transcriptional co-activator yADA3, as a novel E6 target. Human ADA3 binds to the high-risk (cancer-associated) but not the low-risk HPV E6 proteins and to immortalization-competent but not to immortalization-defective HPV16 E6 mutants, suggesting a role for the perturbation of hADA3 function in E6-mediated oncogenesis. We demonstrate here that hADA3 directly binds to the retinoic X receptor (RXR)alpha in vitro and in vivo. Using chromatin immuno-precipitation, we show that hADA3 is part of activator complexes bound to the native RXR response elements within the promoter of the cyclin-dependent kinase inhibitor gene p21. We show that hADA3 enhances the RYRalpha-mediated sequence-specific transactivation of retinoid target genes, cellular retinoic acid-binding protein II and p21. Significantly, we demonstrate that E6 inhibits the RYRalpha-mediated transactivation. of target genes, implying that perturbation of RXR-mediated transactivation by E6 could contribute to HPV oncogenesis.	Tufts Univ New England Med Ctr, Dept Radiat Oncol, Div Radiat & Canc Biol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	Tufts Medical Center; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Band, V (corresponding author), Tufts Univ New England Med Ctr, Dept Radiat Oncol, Div Radiat & Canc Biol, Box 824,750 Washington St, Boston, MA 02111 USA.		Dimri, Goberdhan/AAO-4210-2021	zeng, musheng/0000-0003-3509-5591	NCI NIH HHS [CA81076, CA70195, CA87986, CA75075, CA76118] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087986, R01CA081076, R01CA075075, R01CA070195, R01CA076118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; Benecke A, 2002, NUCLEIC ACIDS RES, V30, P2508, DOI 10.1093/nar/30.11.2508; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; Degenhardt YY, 2001, J VIROL, V75, P151, DOI 10.1128/JVI.75.1.151-160.2001; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Henriksson A, 1997, MOL CELL BIOL, V17, P3065, DOI 10.1128/MCB.17.6.3065; HILL DL, 1992, ANNU REV NUTR, V12, P161, DOI 10.1146/annurev.nu.12.070192.001113; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; Kung AL, 2000, GENE DEV, V14, P272; Kurie Jonathan M., 1999, Current Opinion in Oncology, V11, P497, DOI 10.1097/00001622-199911000-00011; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LOTAN R, 1994, CANCER RES, V54, pS1987; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; MUNGER K, 1989, J VIROL, V63, P4417; ODWYER PJ, 1987, J SURG RES, V43, P550, DOI 10.1016/0022-4804(87)90130-2; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Peng YC, 2001, MOL CELL BIOL, V21, P5913, DOI 10.1128/MCB.21.17.5913-5924.2001; Ratsch SB, 2001, RADIAT RES, V155, P143, DOI 10.1667/0033-7587(2001)155[0143:MGCARF]2.0.CO;2; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P43; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Yamada O, 1998, LEUKEMIA RES, V22, P711, DOI 10.1016/S0145-2126(98)00065-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zur Hausen H, 1999, EUR J CANCER, V35, P1878, DOI 10.1016/S0959-8049(99)00291-9	49	55	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45611	45618		10.1074/jbc.M208447200	http://dx.doi.org/10.1074/jbc.M208447200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235159	hybrid			2022-12-25	WOS:000179404800127
J	Kolodziejczak, M; Kolaczkowska, A; Szczesny, B; Urantowka, A; Knorpp, C; Kieleczawa, J; Janska, H				Kolodziejczak, M; Kolaczkowska, A; Szczesny, B; Urantowka, A; Knorpp, C; Kieleczawa, J; Janska, H			A higher plant mitochondrial homologue of the yeast m-AAA protease - Molecular cloning, localization, and putative function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; INNER MEMBRANE; SACCHAROMYCES-CEREVISIAE; FTSH PROTEASE; PROTEINS; CHLOROPLAST; DEGRADATION; MUTATIONS; METALLOPROTEASE; ARABIDOPSIS	Mitochondrial AAA metalloproteases play a fundamental role in mitochondrial biogenesis and function. They have been identified in yeast and animals but not yet in plants. This work describes the isolation and sequence analysis of the full-length cDNA from the pea (Pisum sativum) with significant homology to the yeast matrix AAA (m-AAA) protease. The product of this clone was imported into isolated pea mitochondria where it was processed to its mature form (PsFtsH). We have shown that the central region of PsFtsH containing the chaperone domain is exposed to the matrix space. Furthermore, we have demonstrated that the pea protease can complement respiration deficiency in the yta10 and/or yta12 null yeast mutants, indicating that the plant protein can compensate for the loss of at least some of the important m-AAA functions in yeast. Based on biochemical experiments using isolated pea mitochondria, we propose that PsFtsH-like m-AAA is involved in the accumulation of the subunit 9 of the ATP synthase in the mitochondrial membrane.	Wroclaw B Beirut Univ, Inst Biochem & Mol Biol, PL-50137 Wroclaw, Poland; Swedish Univ Agr Sci, Dept Plant Biol, S-75007 Uppsala, Sweden; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	University of Wroclaw; Swedish University of Agricultural Sciences; United States Department of Energy (DOE); Brookhaven National Laboratory	Janska, H (corresponding author), Wroclaw B Beirut Univ, Inst Biochem & Mol Biol, Tamka 2, PL-50137 Wroclaw, Poland.		Szczesny, Bartosz/D-1026-2012	Janska, Hanna/0000-0002-6542-343X; Urantowka, Adam/0000-0003-1144-0549				Adam Z, 2001, BIOCHEM SOC T, V29, P427, DOI 10.1042/BST0290427; Adam Z, 2001, PLANT PHYSIOL, V125, P1912, DOI 10.1104/pp.125.4.1912; Arlt H, 1998, EMBO J, V17, P4837, DOI 10.1093/emboj/17.16.4837; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Chen M, 2000, PLANT J, V22, P303, DOI 10.1046/j.1365-313x.2000.00738.x; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; HAKANSSON G, 1988, THEOR APPL GENET, V76, P431, DOI 10.1007/BF00265345; Juhola MK, 2000, FEBS LETT, V481, P91, DOI 10.1016/S0014-5793(00)01989-X; Kaser M, 2000, SEMIN CELL DEV BIOL, V11, P181, DOI 10.1006/scdb.2000.0166; Klanner C, 2001, MOL BIOL CELL, V12, P2858, DOI 10.1091/mbc.12.9.2858; KNORPP C, 1995, BIOCHEM J, V310, P527, DOI 10.1042/bj3100527; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Leonhard K, 1999, NATURE, V398, P348, DOI 10.1038/18704; Lindahl M, 1996, J BIOL CHEM, V271, P29329, DOI 10.1074/jbc.271.46.29329; MICHON T, 1988, EUR J BIOCHEM, V172, P621, DOI 10.1111/j.1432-1033.1988.tb13934.x; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; PAUL MF, 1995, FEBS LETT, V373, P66, DOI 10.1016/0014-5793(95)00979-J; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schumann W, 1999, FEMS MICROBIOL REV, V23, P1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Steglich G, 1999, MOL CELL BIOL, V19, P3435; SZCZEPANIAK A, 1990, J BIOL CHEM, V265, P17720; VERHEUL FEAM, 1981, EUR J BIOCHEM, V119, P401, DOI 10.1111/j.1432-1033.1981.tb05622.x; WHELAN J, 1991, PLANT MOL BIOL, V16, P283, DOI 10.1007/BF00020559; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957; Zhang LX, 1999, J BIOL CHEM, V274, P16062, DOI 10.1074/jbc.274.23.16062	31	24	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43792	43798		10.1074/jbc.M203831200	http://dx.doi.org/10.1074/jbc.M203831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228240	hybrid			2022-12-25	WOS:000179272000035
J	Roos-Mattjus, P; Vroman, BT; Burtelow, MA; Rauen, M; Eapen, AK; Karnitz, LM				Roos-Mattjus, P; Vroman, BT; Burtelow, MA; Rauen, M; Eapen, AK; Karnitz, LM			Genotoxin-induced Rad9-Hus1-Rad1 (9-1-1) chromatin association is an early checkpoint signaling event	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; PROTEIN-KINASE; RADIOSENSITIZING AGENT; SLIDING CLAMP; HUMAN RAD9; ATM; CAFFEINE; COMPLEX; REPLICATION; PHOSPHORYLATION	Rad17, Rad1, Hus1, and Rad9 are key participants in checkpoint signaling pathways that block cell cycle progression in response to genotoxins. Biochemical and molecular modeling data predict that Rad9, Hus1, and Rad1 form a heterotrimeric complex, dubbed 9-1-1, which is loaded onto chromatin by a complex of Rad17 and the four small replication factor C (RFC) subunits (Rad17-RFC) in response to DNA damage. It is unclear what checkpoint proteins or checkpoint signaling events regulate the association of the 9-1-1 complex with DNA. Here we show that genotoxin-induced chromatin binding of 9-1-1 does not require the Rad9-inducible phosphorylation site (Ser-272). Although we found that Rad9 undergoes an additional phosphatidylinositol 3-kinase-related kinase (PIKK)-dependent posttranslational modification, we also show that genotoxin-triggered 9-1-1 chromatin binding does not depend on the catalytic activity of the PIKKs ataxia telangiectasia-mutated (ATM), ataxia telangiectasia and Rad3-related (ATR), or DNA-PK. Additionally, 9-1-1 chromatin binding does not require DNA replication, suggesting that the complex can be loaded onto DNA in response to DNA structures other than stalled DNA replication forks. Collectively, these studies demonstrate that 9-1-1 chromatin binding is a proximal event in the checkpoint signaling cascade.	Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Radiat Oncol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Guggenheim 13,200 1st St SW, Rochester, MN 55905 USA.			Roos-Mattjus, Pia/0000-0002-7187-2012	NCI NIH HHS [R01-CA84321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Eapen AK, 2001, MOL CELL BIOL, V21, P6113, DOI 10.1128/MCB.21.18.6113-6121.2001; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Oakley GG, 2001, MOL BIOL CELL, V12, P1199, DOI 10.1091/mbc.12.5.1199; Rhind N, 2000, J CELL SCI, V113, P3889; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; St Onge RP, 2001, J BIOL CHEM, V276, P41898, DOI 10.1074/jbc.M105152200; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	30	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43809	43812		10.1074/jbc.M207272200	http://dx.doi.org/10.1074/jbc.M207272200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228248	hybrid			2022-12-25	WOS:000179272000037
J	Bellu, AR; Salomons, FA; Kiel, JAKW; Veenhuis, M; van der Klei, IJ				Bellu, AR; Salomons, FA; Kiel, JAKW; Veenhuis, M; van der Klei, IJ			Removal of Pex3p is an important initial stage in selective peroxisome degradation in Hansenula polymorpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; YEAST PICHIA-PASTORIS; ASSEMBLY PROTEIN; GENE ENCODES; BIOGENESIS; MEMBRANE; PROLIFERATION; AUTOPHAGY; TURNOVER; OXIDASE	Selective degradation of peroxisomes (macropexophagy) in Hansenula polymorpha involves the sequestration of individual organelles to be degraded by membranes prior to the fusion of this compartment with the vacuole and subsequent degradation of the whole organelle by vacuolar hydrolases. Here we show that Pex3p, a peroxisomal membrane protein essential for peroxisome biogenesis, escapes this autophagic process. Upon induction of macropexophagy, Pex3p is removed from the organelle tagged for degradation prior to its sequestration. Our data indicate that Pex3p degradation is essential to allow the initiation of the organellar degradation process. Also, in a specific peroxisome degradation-deficient (pdd) mutant in which sequestration still occurs but the vacuolar fusion event is disturbed, the turnover of Pex3p is still observed. Taken together, our data suggest that degradation of Pex3p is part of the initial degradation machinery of individual peroxisomes.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands	University of Groningen	van der Klei, IJ (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, POB 14, NL-9750 AA Haren, Netherlands.		van der Klei, Ida J/D-1919-2012	Van der Klei, Ida J./0000-0001-7165-9679				Abeliovich H, 2001, MICROBIOL MOL BIOL R, V65, P463, DOI 10.1128/MMBR.65.3.463-479.2001; Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Baerends RJS, 1997, YEAST, V13, P1449, DOI 10.1002/(SICI)1097-0061(199712)13:15<1449::AID-YEA191>3.0.CO;2-Q; Bellu AR, 2001, FEMS YEAST RES, V1, P23, DOI 10.1111/j.1567-1364.2001.tb00010.x; Bellu AR, 2001, J BIOL CHEM, V276, P44570, DOI 10.1074/jbc.M107599200; BELLU AR, 2002, IN PRESS MICROSC RES; Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; Haan GJ, 2002, J BIOL CHEM, V277, P26609, DOI 10.1074/jbc.M108569200; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; Kiel JAKW, 1999, YEAST, V15, P741, DOI 10.1002/(SICI)1097-0061(19990630)15:9<741::AID-YEA416>3.0.CO;2-O; Kiel JAKW, 1995, FEBS LETT, V377, P434, DOI 10.1016/0014-5793(95)01385-7; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; Komori M, 2000, CELL BIOCHEM BIOPHYS, V32, P283, DOI 10.1385/CBB:32:1-3:283; Kranz A, 2001, MOL BIOL CELL, V12, P711, DOI 10.1091/mbc.12.3.711; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Muntau AC, 2000, BIOL CHEM, V381, P337, DOI 10.1515/BC.2000.044; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Salomons FA, 2000, J BIOL CHEM, V275, P12603, DOI 10.1074/jbc.275.17.12603; Sambrook J., 2002, MOL CLONING LAB MANU; Shimozawa N, 2000, HUM MOL GENET, V9, P1995, DOI 10.1093/hmg/9.13.1995; Skach WR, 2000, KIDNEY INT, V57, P825, DOI 10.1046/j.1523-1755.2000.00921.x; Stromhaug PE, 2001, TRAFFIC, V2, P524, DOI 10.1034/j.1600-0854.2001.20802.x; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; TITORENKO VI, 1995, J BACTERIOL, V177, P357, DOI 10.1128/jb.177.2.357-363.1995; TUTTLE DL, 1995, J CELL SCI, V108, P25; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; Veenhuis M, 1996, FEBS LETT, V383, P114, DOI 10.1016/0014-5793(96)00220-7; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757; VEENHUIS M, 1978, ARCH MICROBIOL, V117, P153, DOI 10.1007/BF00402303; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973	38	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42875	42880		10.1074/jbc.M205437200	http://dx.doi.org/10.1074/jbc.M205437200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12221086	Green Published, hybrid			2022-12-25	WOS:000179081200060
J	Lee, HC; Bernstein, HD				Lee, HC; Bernstein, HD			Trigger factor retards protein export in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; INNER MEMBRANE-PROTEINS; NASCENT CHAINS; SELECTIVE BINDING; BACTERIAL PROTEIN; CHAPERONE SECB; SRP; TRANSLOCATION; DNAK; SPECIFICITY	Trigger factor (TF) is a ribosome-associated protein that interacts with a wide variety of nascent polypeptides in Escherichia coli. Previous studies have indicated that TF cooperates with DnaK to facilitate protein folding, but the basis of this cooperation is unclear. In this study we monitored protein export in E. coli that lack or overproduce TF to obtain further insights into its function. Whereas inactivation of genes encoding most molecular chaperones (including dnaK) impairs protein export, inactivation of the TF gene accelerated protein export and suppressed the need for targeting factors to maintain the translocation competence of pre-secretory proteins. Furthermore, overproduction of TF (but not DnaK) markedly retarded protein export. Manipulation of TF levels produced similar effects on the export of a cytosolic enzyme fused to a signal peptide. The data strongly suggest that TF has a unique ability to sequester nascent polypeptides for a relatively prolonged period. Based on our results, we propose that TF and DnaK promote protein folding by distinct (but complementary) mechanisms.	NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bernstein, HD (corresponding author), NIDDK, Genet & Biochem Branch, NIH, Bldg 10,Rm 9D-20, Bethesda, MD 20892 USA.							Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; BERNSTEIN HD, 1989, CELL, V58, P1017, DOI 10.1016/0092-8674(89)90497-2; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; de Gier JW, 2001, MOL MICROBIOL, V40, P314, DOI 10.1046/j.1365-2958.2001.02392.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; FREUDL R, 1986, J BIOL CHEM, V261, P1355; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; GOLDSTEIN J, 1991, J BIOL CHEM, V266, P14413; GUTHRIE B, 1990, J BACTERIOL, V172, P5555, DOI 10.1128/jb.172.10.5555-5562.1990; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; Izard JW, 1996, J BIOL CHEM, V271, P21579, DOI 10.1074/jbc.271.35.21579; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1993, J BACTERIOL, V175, P2184, DOI 10.1128/JB.175.8.2184-2188.1993; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LEE CA, 1986, J BACTERIOL, V166, P878, DOI 10.1128/jb.166.3.878-883.1986; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; Maier R, 2001, J MOL BIOL, V314, P1181, DOI 10.1006/jmbi.2000.5192; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; Newitt JA, 1998, J BIOL CHEM, V273, P12451, DOI 10.1074/jbc.273.20.12451; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; POGLIANO KJ, 1993, GENETICS, V133, P763; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; Prinz WA, 1996, EMBO J, V15, P5209, DOI 10.1002/j.1460-2075.1996.tb00906.x; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Tradler T, 1997, FEBS LETT, V407, P184, DOI 10.1016/S0014-5793(97)00345-1; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; Wild J, 1996, J BACTERIOL, V178, P3608, DOI 10.1128/jb.178.12.3608-3613.1996; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; Xu ZH, 2000, NAT STRUCT BIOL, V7, P1172, DOI 10.1038/82040	43	67	79	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43527	43535		10.1074/jbc.M205950200	http://dx.doi.org/10.1074/jbc.M205950200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12205085	hybrid			2022-12-25	WOS:000179081200138
J	Paavilainen, VO; Merckel, MC; Falck, S; Ojala, PJ; Pohl, E; Wilmanns, M; Lappalainen, P				Paavilainen, VO; Merckel, MC; Falck, S; Ojala, PJ; Pohl, E; Wilmanns, M; Lappalainen, P			Structural conservation between the actin monomer-binding sites of twinfilin and actin-depolymerizing factor (ADF)/Cofilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; ADP-ACTIN; CRYSTAL-STRUCTURE; PLASMA GELSOLIN; PROTEIN; COFILIN; YEAST; ACTOPHORIN; DYNAMICS; COMPLEX	Twinfilin is an evolutionarily conserved actin monomer-binding protein that regulates cytoskeletal dynamics in organisms from yeast to mammals. It is composed of two actin-depolymerization factor homology (ADF-H) domains that show similar to20% sequence identity to ADF/cofilin proteins. In contrast to ADF/cofilins, which bind both G-actin and F-actin and promote filament depolymerization, twinfilin interacts only with G-actin. To elucidate the molecular mechanisms of twinfilin-actin monomer interaction, we determined the crystal structure of the N-terminal ADF-H domain of twinfilin and mapped its actin-binding site by site-directed mutagenesis. This domain has similar overall structure to ADF/cofilins, and the regions important for actin monomer binding in ADF/cofilins are especially well conserved in twinfilin. Mutagenesis studies show that the N-terminal ADF-H domain of twinfilin and ADF/cofilins also interact with actin monomers through similar interfaces, although the binding surface is slightly extended in twinfilin. In contrast, the regions important for actin-filament interactions in ADF/cofilins are structurally different in twinfilin. This explains the differences in actin-interactions (monomer versus filament binding) between twinfilin and ADF/cofilins. Taken together, our data show that the ADF-H domain is a structurally conserved actin-binding motif and that relatively small structural differences at the actin interfaces of this domain are responsible for the functional variation between the different classes of ADF-H domain proteins.	Univ Helsinki, Program Cellular Biotechnol, Helsinki 00014, Finland; Univ Helsinki, Program Struct Biol & Biophys, Inst Biotechnol, Helsinki 00014, Finland; European Mol Biol Lab, EMBL Hamburg Outstn, D-22603 Hamburg, Germany	University of Helsinki; University of Helsinki; European Molecular Biology Laboratory (EMBL)	Lappalainen, P (corresponding author), Univ Helsinki, Program Cellular Biotechnol, POB 56, Helsinki 00014, Finland.	pekka.lappalainen@helsinki.fi	Pohl, Ehmke/I-2408-2012; Paavilainen, Ville/I-9131-2019	Pohl, Ehmke/0000-0002-9949-4471; Paavilainen, Ville/0000-0002-3160-7767; Lappalainen, Pekka/0000-0001-6227-0354; Wilmanns, Matthias/0000-0002-4643-5435				Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Blanchoin L, 2000, J MOL BIOL, V295, P203, DOI 10.1006/jmbi.1999.3336; Bowman GD, 2000, PROTEINS, V41, P374, DOI 10.1002/1097-0134(20001115)41:3<374::AID-PROT90>3.0.CO;2-F; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DETMERS P, 1981, J BIOL CHEM, V256, P99; Fedorov AA, 1997, NAT STRUCT BIOL, V4, P366, DOI 10.1038/nsb0597-366; Galkin VE, 2001, J CELL BIOL, V153, P75, DOI 10.1083/jcb.153.1.75; Goode BL, 1998, J CELL BIOL, V142, P723, DOI 10.1083/jcb.142.3.723; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Guan JQ, 2002, BIOCHEMISTRY-US, V41, P5765, DOI 10.1021/bi0121104; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; Hayashi K, 1999, J NEUROSCI, V19, P3918; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Jiang CJ, 1997, P NATL ACAD SCI USA, V94, P9973, DOI 10.1073/pnas.94.18.9973; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leonard SA, 1997, NAT STRUCT BIOL, V4, P369, DOI 10.1038/nsb0597-369; MACIVER SK, 1994, FEBS LETT, V347, P251, DOI 10.1016/0014-5793(94)00552-4; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ojala PJ, 2002, MOL BIOL CELL, V13, P3811, DOI 10.1091/mbc.E02-03-0157; Ojala PJ, 2001, BIOCHEMISTRY-US, V40, P15562, DOI 10.1021/bi0117697; Ono S, 1999, J CELL BIOL, V145, P491, DOI 10.1083/jcb.145.3.491; Ono S, 2001, J BIOL CHEM, V276, P5952, DOI 10.1074/jbc.M007563200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palmgren S, 2002, J CELL SCI, V115, P881; Palmgren S, 2001, J CELL BIOL, V155, P251, DOI 10.1083/jcb.200106157; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; SILFHOUT RG, 1995, REV SCI INSTRUM, V66, P1818; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Van Troys M, 2000, BIOCHEMISTRY-US, V39, P12181, DOI 10.1021/bi000816c; Vartiainen M, 2000, MOL CELL BIOL, V20, P1772, DOI 10.1128/MCB.20.5.1772-1783.2000; Wahlstrom G, 2001, J CELL BIOL, V155, P787, DOI 10.1083/jcb.200108022; WEEDS AG, 1986, EUR J BIOCHEM, V161, P77, DOI 10.1111/j.1432-1033.1986.tb10126.x; Wriggers W, 1998, J MOL BIOL, V282, P921, DOI 10.1006/jmbi.1998.2048	47	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43089	43095		10.1074/jbc.M208225200	http://dx.doi.org/10.1074/jbc.M208225200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12207032	hybrid			2022-12-25	WOS:000179081200087
J	Huang, LE; Pete, EA; Schau, M; Milligan, J; Gu, J				Huang, LE; Pete, EA; Schau, M; Milligan, J; Gu, J			Leu-574 of HIF-1 alpha is essential for the von Hippel-Lindau (VHL)-mediated degradation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; INDUCIBLE FACTOR 1-ALPHA; UBIQUITIN-PROTEASOME PATHWAY; ARNT TRANSCRIPTION FACTOR; PROLYL HYDROXYLATION; PROLINE HYDROXYLATION; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; ALPHA-SUBUNIT; HIF-ALPHA	Oxygen homeostasis is crucial for a myriad of developmental, physiological, and pathophysiological processes. Hypoxia-inducible factor 1alpha (HIF-1alpha) plays a pivotal role in response to hypoxia by transcriptionally activating target genes involving oxygen uptake, transport, delivery, and consumption. HIF-1alpha activity is regulated primarily through the ubiquitin-proteasome degradation pathway, which targets the oxygen-dependent degradation domain (ODD) of HIF-1alpha. In particular, the von Hippel-Lindau (VHL) protein complex, an E3 ubiquitin ligase, binds to the ODD upon hydroxylation of HIF-1alpha Pro-564. Here, we show that in vivo VHL interacts with the N-terminal as well as the C-terminal ODD independently, supporting the notion of functional redundancy within the ODD. Moreover, we demonstrate that Leu-574 of HIF-1alpha is essential for VHL binding to the C-terminal ODD. Despite the presence of Pro-564, deletion or mutation of Leu-574 resulted in a loss of VHL binding and a gain of protein stability. Furthermore, the identification of Leu-574 redefines the N-terminal activation domain of HIF-1alpha to be constitutively active. Taken together, this study provides new insight into the mechanisms underlying VHL-mediated HIF-1alpha degradation and transcriptional activation, and a molecular basis for drug targeting.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Huang, LE (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041234] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK41234] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Mabjeesh NJ, 2002, CANCER RES, V62, P2478; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Ravi R, 2000, GENE DEV, V14, P34; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	53	36	43	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41750	41755		10.1074/jbc.M207280200	http://dx.doi.org/10.1074/jbc.M207280200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12205091	hybrid			2022-12-25	WOS:000178985300058
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			The "LSGGQ" motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing Walker A sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; DISULFIDE CROSS-LINKING; TRANSMEMBRANE SEGMENTS; CRYSTAL-STRUCTURE; ABC TRANSPORTER; DRUG-BINDING; SITES; CYSTEINE; RESIDUES; MUTANTS	The human multidrug resistance P-glycoprotein (P-gp, ABCB1), a member of the ATP-binding cassette (ABC) family of transport proteins, actively transports many cytotoxic compounds out of the cell. ABC transporters have two nucleotide-binding domains (NBD) and two transmembrane domains. The presence of the conserved "signature" sequence (LSGGQ) in each NBD is a unique feature in these transporters. The function of the signature sequences is unknown. In this study, we tested whether the signature sequences ((531)LSGGQ(535) in NBD1; (1176)LSGGQ(1180) in NBD2) in P-gp are in close proximity to the opposing Walker A consensus nucleotide-binding sequences ((1070)GSSGCGKS(1077) in NBD2; (427)GNS- GCGKS(434) in NBD1). Pairs of cysteines were introduced into a Cys-less P-gp at the signature and "Walker A" sites and the mutant P-gps were subjected to oxidative cross-linking. At 4 degreesC, when thermal motion is low, P-gp mutants (L531C(Signature)/C1074(Walker A) and C431(Walker A)/L1176C (Signature) were cross-linked. Cross-linking inhibited the drug-stimulated ATPase activities of these two mutants. Their activities were restored, however, after addition of the reducing agent, dithiothreitol. Vanadate trapping of nucleotide at the ATP-binding sites prevented cross-linking of the mutants. These results indicate that the signature sequences are adjacent to the opposing Walker A site. They likely participate in forming the ATP-binding sites and are displaced upon ATP hydrolysis. The resulting conformational change may be the signal responsible for coupling ATP hydrolysis to drug transport by inducing conformational changes in the transmembrane segments.	Univ Toronto, Dept Med, Canadian Inst Hlth Res, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Canadian Inst Hlth Res, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada	Institute for Work & Health; University of Toronto; Institute for Work & Health; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res, Grp Membrane Biol, 100 Coll St, Toronto, ON M5S 1A8, Canada.	david.clarke@utoronto.ca	Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER; NCI NIH HHS [CA80900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; Loo TW, 2000, JNCI-J NATL CANCER I, V92, P898, DOI 10.1093/jnci/92.11.898; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	35	136	138	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41303	41306		10.1074/jbc.C200484200	http://dx.doi.org/10.1074/jbc.C200484200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12226074	hybrid			2022-12-25	WOS:000178985300003
J	Mayr, M; Hu, YH; Hainaut, P; Xu, QB				Mayr, M; Hu, YH; Hainaut, P; Xu, QB			Mechanical stress-induced DNA damage and rac-p38MAPK signal pathways mediate p53-dependent apoptosis in vascular smooth muscle cells	FASEB JOURNAL			English	Article						signaling; cyclic strain stress; cell death; oxidative stress; arteriosclerosis	ACTIVATED PROTEIN-KINASES; ATHEROSCLEROTIC PLAQUES; P53-MEDIATED APOPTOSIS; SUPEROXIDE-PRODUCTION; HUMAN CYTOMEGALOVIRUS; OXIDATIVE STRESS; NAD(P)H OXIDASE; GENE-EXPRESSION; P53 PROTEIN; VEIN GRAFTS	Recently, we demonstrated that biomechanical stress induces apoptosis of vascular smooth muscle cells (SMCs) (Mayr et al., FASEB J. 2000; 15:261-270). In this article we investigated the molecular mechanisms of mechanical stress-induced apoptosis. When SMCs were subjected to cyclic strain, tumor-suppressor p53 was activated as evidenced by gel mobility shift assays and Western blot analyses. p53 activation was largely attenuated if SMCs were pretreated with SB202190, a specific p38MAPK inhibitor, or were stably transfected with dominant negative rac, an upstream signal transducer of p38MAPK pathways. Kinase assays provided direct evidence that p38MAPKs phosphorylated p53 within 30 min of cyclic strain. Additionally, mechanical stress resulted in oxidative DNA damage as detected by the presence of 8-oxoguanine. Treatment with the antioxidant U-74389G abrogated p53 activation. p53 activation was followed by expression and mitochondrial translocation of the proapoptotic protein Bax. Likewise, mechanical stress resulted in up-regulation of anti-apoptotic Bcl-2 proteins, including Bcl-2 and Bcl-xL. However, a marked loss of mitochondrial membrane potential occurred in wild-type, but not in p53-/-, SMCs. The latter lost their ability to express Bax and showed no apoptosis in response to cyclic strain. Taken together, our data provide the first evidence that SMC apoptosis induced by mechanical stress is p53-dependent.	St George Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England; Univ Innsbruck, Inst Pathophysiol, A-6020 Innsbruck, Austria; Austrian Acad Sci, Inst Biomed Aging Res, Innsbruck, Austria; Int Agcy Res Canc, F-69372 Lyon, France	St Georges University London; University of Innsbruck; Austrian Academy of Sciences; World Health Organization; International Agency for Research on Cancer (IARC)	Xu, QB (corresponding author), St George Hosp, Sch Med, Dept Cardiol Sci, Cranmer Terrace, London SW17 0RE, England.	q.xu@sghms.ac.uk	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610; Mayr, Manuel/0000-0002-0597-829X				BENES AJ, 1985, J CELL SCI, V75, P35; Bennett MR, 1998, CIRC RES, V82, P704, DOI 10.1161/01.RES.82.6.704; Bennett MR, 1997, CIRC RES, V81, P591, DOI 10.1161/01.RES.81.4.591; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cook SA, 1999, CIRC RES, V85, P940; Frangos SG, 1999, ARCH SURG-CHICAGO, V134, P1142, DOI 10.1001/archsurg.134.10.1142; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Goldschmidt ME, 2001, CIRC RES, V88, P674, DOI 10.1161/hh0701.089749; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; HENGARTNER MO, 2000, NATURE, V407, P775; Hishikawa K, 1997, CIRC RES, V81, P797; Hu YH, 1999, CIRCULATION, V100, P861, DOI 10.1161/01.CIR.100.8.861; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Ihling C, 1997, ARTERIOSCL THROM VAS, V17, P2218, DOI 10.1161/01.ATV.17.10.2218; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; KASAI H, 1997, MUTAT RES, V87, P147; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lehoux S, 1998, HYPERTENSION, V32, P338, DOI 10.1161/01.HYP.32.2.338; Li, 2000, Arterioscler Thromb Vasc Biol, V20, pE1; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Malins DC, 2000, P NATL ACAD SCI USA, V97, P12442, DOI 10.1073/pnas.230438797; Mallat Z, 2001, CIRC RES, V88, P998, DOI 10.1161/hh1001.090571; MARINET W, 2001, CIRC RES, V88, P648; Matsushita H, 2000, CIRCULATION, V101, P1447, DOI 10.1161/01.CIR.101.12.1447; Mayr M, 2000, FASEB J, V14, P261, DOI 10.1096/fasebj.14.2.261; Mayr M, 2001, EXP GERONTOL, V36, P969, DOI 10.1016/S0531-5565(01)00090-0; Mayr U, 2002, CIRC RES, V90, P197, DOI 10.1161/hh0202.103715; Metzler B, 2000, AM J PATHOL, V156, P1875, DOI 10.1016/S0002-9440(10)65061-4; MIYASHITA T, 1995, CELL, V80, P293; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perlman H, 1997, CIRCULATION, V95, P981; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; SINGH B, 1992, DNA CELL BIOL, V11, P489, DOI 10.1089/dna.1992.11.489; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Tanaka K, 1999, CIRCULATION, V99, P1656, DOI 10.1161/01.CIR.99.13.1656; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walsh K, 2000, CIRC RES, V87, P184, DOI 10.1161/01.RES.87.3.184; West NEJ, 2001, ARTERIOSCL THROM VAS, V21, P189, DOI 10.1161/01.ATV.21.2.189; Xu QB, 2000, TRENDS CARDIOVAS MED, V10, P35, DOI 10.1016/S1050-1738(00)00042-6; Xu QB, 1997, J CLIN INVEST, V100, P1089, DOI 10.1172/JCI119619; XU QB, 1995, CIRCULATION, V92, P1223, DOI 10.1161/01.CIR.92.5.1223; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517	47	119	127	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1423	+		10.1096/fj.02-0042fje	http://dx.doi.org/10.1096/fj.02-0042fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205035	Green Submitted			2022-12-25	WOS:000177813100020
J	Ikonomov, OC; Sbrissa, D; Yoshimori, T; Cover, TL; Shisheva, A				Ikonomov, OC; Sbrissa, D; Yoshimori, T; Cover, TL; Shisheva, A			PIKfyve kinase and SKD1 AAA ATPase define distinct endocytic compartments - Only PIKfyve expression inhibits the cell-vacuolating activity of Helicobacter pylori VacA toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID KINASE; MOUSE SKD1; CYTOTOXIN; TRAFFICKING; YEAST; INSULIN; MORPHOLOGY; ENDOSOMES; CLONING; VPS4P	The mammalian phosphatidylinositol (PtdIns)-5-P/-PtdIns-3,5-P-2-producing kinase PIKfyve and AAA ATPase SKD1, as their yeast counterparts, are implicated in the formation and function of multivesicular bodies/late endosomes. Point mutations inhibiting the enzyme activities convert PIKfyve and SKD1 into dominant-negative mutants (PIKfyve(K1831E) and SKD1(E235Q)), whose expression in cells of kidney origin induces a vacuolation phenotype. This phenotype closely resembles the changes in late endosomal-lysosomal morphology that occur following cell exposure to the vacuolating cytotoxin (VacA) from Helicobacter pylori. Here we have examined the possible functional relationship between PIKfyve and SKD1 as wen as the role of these enzymes in the molecular mechanism of VacA-induced intracellular vacuolation. When co-expressed in COS cells, PIKfyve(WT) reduced SKD1(E235Q) dependent vacuole formation, whereas SKD1(WT) did not alter the vacuolation induced by PIKfyve(K1831E). In addition, SED1(E235Q) disrupted the normal distribution of PIKfyve(WT). Expression of PEKfyve(WT) in COS and HEK293 cells inhibited vacuolation induced by subsequent intoxication with VacA, and microWection of the PIKfyve lipid product PtdIns-3,5,P-2 produced a similar inhibitory effect. In contrast, in COS cells expressing SKD1(WT), VacA induced the formation of characteristic vacuoles with an efficiency similar to that in the control cells. These observations demonstrate that, although PIKfyve and SKD1 are functionally related, only PIKfyve regulates VacA action, and suggest that the inhibition of PIKfyve Ptdlns-3,5-P-2-producing activity is a key molecular event in VacA-induced cellular vacuolation.	Wayne State Univ, Sch Med, Dept Phys, Detroit, MI 48201 USA; Natl Inst Genet, Dept Cell Genet, Shizuoka, Japan; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA	Wayne State University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Shisheva, A (corresponding author), Wayne State Univ, Sch Med, Dept Phys, 540 E Canfield, Detroit, MI 48201 USA.		Cover, Timothy/I-3814-2015	Cover, Timothy/0000-0001-8503-002X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058058, R01DK053623] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58058, DK53623] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; Hotchin NA, 2000, J BIOL CHEM, V275, P14009, DOI 10.1074/jbc.C000153200; Ikonomov OC, 2002, J BIOL CHEM, V277, P9206, DOI 10.1074/jbc.M108750200; Ikonomov OC, 2001, J BIOL CHEM, V276, P26141, DOI 10.1074/jbc.M101722200; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; Papini E, 2001, TOXICON, V39, P1757, DOI 10.1016/S0041-0101(01)00162-3; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Sbrissa D, 2000, BIOCHEMISTRY-US, V39, P15980, DOI 10.1021/bi001897f; SBRISSA D, 2002, IN PRESS J BIOL CHEM, V277; Scheuring S, 1999, GENE, V234, P149, DOI 10.1016/S0378-1119(99)00163-8; Shisheva A, 2001, J BIOL CHEM, V276, P11859, DOI 10.1074/jbc.M008437200; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Shisheva A, 1999, MOL CELL BIOL, V19, P623; Suzuki J, 2001, J CLIN INVEST, V107, P363, DOI 10.1172/JCI10254; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	23	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46785	46790		10.1074/jbc.M208068200	http://dx.doi.org/10.1074/jbc.M208068200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12213828	hybrid			2022-12-25	WOS:000179529300139
J	Li, QX; Wang, J; Armant, DR; Bagchi, MK; Bagchi, IC				Li, QX; Wang, J; Armant, DR; Bagchi, MK; Bagchi, IC			Calcitonin down-regulates E-cadherin expression in rodent uterine epithelium during implantation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE EXPRESSION; CELL-ADHESION; JUNCTIONAL COMPLEX; RECEPTOR; RECEPTIVITY; BLASTOCYST; PREGNANCY; UTERUS; ESTABLISHMENT; ENDOMETRIUM	Previous studies indicated that calcitonin (CT), a peptide hormone involved in calcium homeostasis, is transiently expressed in the receptive rat and human endometrial epithelia within the window of implantation. Attenuation of uterine CT expression using antisense methods severely impaired implantation in the rat. The molecular pathway of CT in the pregnant uterus, however, remains unknown. In the present study, we investigated the cellular events following the binding of CT to its membrane receptors in human endometrial epithelial cell line Ishikawa. We observed that CT treatment triggers a transient rise in intracellular calcium in these cells. Most interestingly, CT treatment also led to the disappearance of E-cadherin, a critical cell adhesion molecule, from cell-cell contact sites. Blockade of intracellular calcium release by BAPTA-AM (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl) prevented the CT-induced disappearance of E-cadherin. Our studies further revealed that CT treatment markedly down-regulates the level of E-cadherin mRNA in Ishikawa cells. We also examined whether CT influences the expression of E-cadherin mRNA in intact rat uterine tissue during implantation. In pregnant rats, high levels of E-cadherin mRNA were expressed during the first 3 days of gestation when the CT mRNA in uterine epithelial cells is undetectable. Concomitant with a transient burst of CT expression during days 4-5 of pregnancy, the level of E-cadherin mRNA declined sharply. Furthermore, administration of exogenous CT to animals on day 2 of pregnancy led to a premature suppression of E-cadherin mRNA level on day 3, indicating a direct link between elevated levels of uterine CT and the down-regulation of E-cadherin expression in the surface epithelium. Collectively, our results are consistent with the hypothesis that CT-induced reduction in E-cadherin expression may remodel the adherens junctions between epithelial cells, and this change in epithelial cell phenotype might be a critical event during the implantation of the blastocyst.	Univ Illinois, Dept Vet Biosci, Urbana, IL 61802 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61802 USA; Wayne State Univ, Sch Med, Dept Obstet & Gynecol, CS Mott Ctr Human Growth & Dev, Detroit, MI 48201 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Wayne State University	Bagchi, IC (corresponding author), Univ Illinois, Dept Vet Biosci, 3641 VMBSB,2001 S Lincoln, Urbana, IL 61802 USA.	ibagchi@uiuc.edu		Armant, D. Randall/0000-0001-5904-9325	NICHD NIH HHS [U54-HD-13541, R01 HD-39291, R01 HD-34527] Funding Source: Medline; NIDDK NIH HHS [R01-DK-50257] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD013541, R01HD039291, R01HD034527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050257] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; Chen Y, 1998, J BIOL CHEM, V273, P19809, DOI 10.1074/jbc.273.31.19809; CHIBA T, 1989, AM J PHYSIOL, V256, pE331, DOI 10.1152/ajpendo.1989.256.2.E331; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; DENKER HW, 1993, J EXP ZOOL, V266, P541, DOI 10.1002/jez.1402660606; DING YQ, 1994, ENDOCRINOLOGY, V135, P2265, DOI 10.1210/en.135.5.2265; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Geisert R D, 1990, J Reprod Fertil Suppl, V40, P293; GEISERT RD, 1982, BIOL REPROD, V27, P925, DOI 10.1095/biolreprod27.4.925; GEISERT RD, 1982, BIOL REPROD, V27, P957, DOI 10.1095/biolreprod27.4.957; GLASSER SR, 1993, MICROSC RES TECHNIQ, V25, P106, DOI 10.1002/jemt.1070250204; GLASSER SR, 1990, TROPH RES, V4, P377; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HEERSCHE JN, 1974, ENDOCRINOLOGY, V94, P241, DOI 10.1210/endo-94-1-241; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Illingworth IM, 2000, BIOL REPROD, V63, P1764, DOI 10.1095/biolreprod63.6.1764; KOIDA M, 1982, JPN J PHARMACOL, V32, P981, DOI 10.1254/jjp.32.981; KUESTNER RE, 1994, MOL PHARMACOL, V46, P246; Kumar S, 1998, J CLIN ENDOCR METAB, V83, P4443, DOI 10.1210/jc.83.12.4443; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; Parr MB., 1989, BIOL UTERUS, P233; Psychoyos A, 1976, J Reprod Fertil Suppl, P17; PSYCHOYOS A, 1986, ANN NY ACAD SCI, V476, P36, DOI 10.1111/j.1749-6632.1986.tb20920.x; PSYCHOYOS A, 1973, HDB PHYSL, P187; RIZZO AJ, 1981, ENDOCRINOLOGY, V108, P1672, DOI 10.1210/endo-108-5-1672; SCHLAFKE S, 1975, BIOL REPROD, V12, P41, DOI 10.1095/biolreprod12.1.41; Sharkey A, 1998, REV REPROD, V3, P52, DOI 10.1530/revreprod/3.1.52; Thie M, 1996, EUR J CELL BIOL, V70, P221; THIE M, 1995, EUR J CELL BIOL, V66, P180; TWERY MJ, 1988, EUR J PHARMACOL, V155, P285, DOI 10.1016/0014-2999(88)90515-8; Wang J, 1998, DEVELOPMENT, V125, P4293; YAMAGUCHI M, 1985, ACTA ENDOCRINOL-COP, V110, P239, DOI 10.1530/acta.0.1100239; YOSHINAGA K, 1988, ANN NY ACAD SCI, V541, P424, DOI 10.1111/j.1749-6632.1988.tb22279.x; Zhu LJ, 1998, ENDOCRINOLOGY, V139, P3923, DOI 10.1210/en.139.9.3923; Zhu LJ, 1998, ENDOCRINOLOGY, V139, P330, DOI 10.1210/en.139.1.330	40	61	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46447	46455		10.1074/jbc.M203555200	http://dx.doi.org/10.1074/jbc.M203555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237291	hybrid			2022-12-25	WOS:000179529300097
J	Li, HW; Park, SM; Kilburn, B; Jelinek, MA; Henschen-Edman, A; Aswad, DW; Stallcup, MR; Laird-Offringa, IA				Li, HW; Park, SM; Kilburn, B; Jelinek, MA; Henschen-Edman, A; Aswad, DW; Stallcup, MR; Laird-Offringa, IA			Lipopolysaccharide-induced methylation of HuR, an mRNA-stabilizing protein, by CARM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEINS; ARGININE N-METHYLTRANSFERASE; FACTOR MESSENGER-RNAS; IN-VIVO; 3'-UNTRANSLATED REGION; SUBCELLULAR-LOCALIZATION; GENE-EXPRESSION; RICH ELEMENTS; ELAV PROTEIN; COACTIVATOR	The RNA-binding protein HuR stabilizes labile mRNAs carrying AU-rich instability elements. This mRNA stabilization can be induced by hypoxia, lipopolysaccharide, and UV light. The mechanism by which these stimuli activate HuR is unclear and might be related to post-translational modification of this protein. Here we show that HuR can be methylated on arginine. However, HuR is not a substrate for PRMT1, the most prominent protein-arginine methyltransferase in mammalian cells, which methylates a number of heterogeneous nuclear ribonucleoproteins. Instead, HuR is specifically methylated by coactivator-associated arginine methyltransferase I (CARM1), a protein-arginine methyltransferase previously shown to serve as a transcriptional coactivator. By analyzing methylation of specific HuR arginine-to-lysine mutants and by sequencing radioactively methylated HuR peptides, Arg(217) was identified as the major HuR methylation site. Arg(217) is located in the hinge region between the second and third of the three HuR RNA recognition motif domains. Antibodies against a methylated HuR peptide were used to demonstrate in vivo methylation of HuR. HuR methylation increased in cells that overexpressed CARM1. Importantly, lipopolysaccharide stimulation of macrophages, which leads to HuR-mediated stabilization of tumor necrosis factor a mRNA in these cells, caused increased methylation of endogenous HuR. Thus, CARM1, which plays a role in transcriptional activation through histone H3 methylation, may also play a role in post-transcriptional gene regulation by methylating HuR.	Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of Southern California; University of Southern California; University of Southern California; University of California System; University of California Irvine	Laird-Offringa, IA (corresponding author), Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90089 USA.		Offringa, Ite/R-4101-2019		NCI NIH HHS [R29CA78407] Funding Source: Medline; NIDDK NIH HHS [DK55274] Funding Source: Medline; NINDS NIH HHS [NS17269] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078407] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055274, R37DK055274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Atasoy U, 1998, J CELL SCI, V111, P3145; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Di Marco S, 2001, NUCLEIC ACIDS RES, V29, P863, DOI 10.1093/nar/29.4.863; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; LAIRDOFFRINGA IA, 1995, P NATL ACAD SCI USA, V92, P11859, DOI 10.1073/pnas.92.25.11859; Lau JS, 2000, J CELL BIOCHEM, V79, P395, DOI 10.1002/1097-4644(20001201)79:3<395::AID-JCB50>3.0.CO;2-M; Lee J, 2002, EMBO REP, V3, P268, DOI 10.1093/embo-reports/kvf052; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Ma H, 1999, MOL CELL BIOL, V19, P6164; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Moore MJ, 2001, SCIENCE, V294, P1841, DOI 10.1126/science.1067676; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Nabors LB, 2001, CANCER RES, V61, P2154; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; Okano HJ, 1997, J NEUROSCI, V17, P3024; Park SM, 2000, MOL CELL BIOL, V20, P4765, DOI 10.1128/MCB.20.13.4765-4772.2000; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; RAJPUROHIT R, 1994, BIOCHEM J, V304, P903, DOI 10.1042/bj3040903; Rho J, 2001, J VIROL, V75, P8031, DOI 10.1128/JVI.75.17.8031-8044.2001; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Valentini SR, 1999, RNA, V5, P272, DOI 10.1017/S1355838299981633; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961	67	193	199	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44623	44630		10.1074/jbc.M206187200	http://dx.doi.org/10.1074/jbc.M206187200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237300	hybrid			2022-12-25	WOS:000179404800006
J	Micheau, O; Thome, M; Schneider, P; Holler, N; Tschopp, J; Nicholson, DW; Briand, C; Grutter, MG				Micheau, O; Thome, M; Schneider, P; Holler, N; Tschopp, J; Nicholson, DW; Briand, C; Grutter, MG			The long form of FLIP is an activator of caspase-8 at the fas death-inducing signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERLEUKIN-1-BETA CONVERTING-ENZYME; DOMAIN-CONTAINING PROTEIN; PROGRAMMED CELL-DEATH; INHIBITORY PROTEIN; KINASE RIP; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; INDUCED APOPTOSIS; C-FLIP	Death receptors, such as Fas and tumor necrosis factor-related apoptosis-inducing ligand receptors, recruit Fas-associated death domain and pro-caspase-8 homodimers, which are then autoproteolytically activated. Active caspase-8 is released into the cytoplasm, where it cleaves various proteins including pro-caspase-3, resulting in apoptosis. The cellular Fas-associated death domain-like interleukin-1-beta-converting enzyme-inhibitory protein long form (FLIPL), a structural homologue of caspase-8 lacking caspase activity because of several mutations in the active site, is a potent inhibitor of death receptor-induced apoptosis. FLIPL is proposed to block caspase-8 activity by forming a proteolytically in active heterodimer with caspase-8. In contrast, we propose that FLPLL-bound caspase-8 is an active protease. Upon heterocomplex formation, a limited caspase-8 autoprocessing occurs resulting in the generation of the p43/41 and the p12 subunits. This partially processed form but also the non-cleaved FLIPL-caspase-8 heterocomplex are proteolytically active because they both bind synthetic substrates efficiently. Moreover, FLIPL expression favors receptor-interacting kinase (RIP) processing within the Fas-signaling complex. We propose that FLIPL inhibits caspase-8 release-dependent pro-apoptotic signals, whereas the single, membrane-restricted active site of the FLIPL-caspase-8 heterocomplex is proteolytically active and acts on local substrates such as RIP.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Lausanne; Merck & Company; University of Zurich	Tschopp, J (corresponding author), Univ Lausanne, Inst Biochem, 155 Chemin Boveresses, CH-1066 Epalinges, Switzerland.		micheau, olivier/C-3574-2011; Thome, Margot/F-8167-2011	micheau, olivier/0000-0001-8499-7984; Thome, Margot/0000-0002-5656-2139; Schneider, Pascal/0000-0003-0677-9409				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Blanchard H, 2000, J MOL BIOL, V302, P9, DOI 10.1006/jmbi.2000.4041; Blanchard H, 1999, STRUCTURE, V7, P1125, DOI 10.1016/S0969-2126(99)80179-8; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DIEDERICHS K, 1995, PROTEINS, V23, P187, DOI 10.1002/prot.340230208; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; EVANS SV, 1993, J MOL GRAPHICS, V11, P127; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kangas E, 1998, J CHEM PHYS, V109, P7522, DOI 10.1063/1.477375; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lee D, 2000, J BIOL CHEM, V275, P16007, DOI 10.1074/jbc.275.21.16007; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okamoto Y, 1999, CHEM PHARM BULL, V47, P11; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; THORNBERRY NA, 1995, PROTEIN SCI, V4, P3; Watt W, 1999, STRUCTURE, V7, P1135, DOI 10.1016/S0969-2126(99)80180-4; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; Willems F, 2000, BLOOD, V95, P3478, DOI 10.1182/blood.V95.11.3478.011k10_3478_3482; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	67	372	395	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45162	45171		10.1074/jbc.M206882200	http://dx.doi.org/10.1074/jbc.M206882200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12215447	Green Published, hybrid			2022-12-25	WOS:000179404800074
J	Torres-Padilla, ME; Sladek, FM; Weiss, MC				Torres-Padilla, ME; Sladek, FM; Weiss, MC			Developmentally regulated N-terminal variants of the nuclear receptor hepatocyte nuclear factor 4 alpha mediate multiple interactions through coactivator and corepressor-histone deacetylase complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; SMRT COREPRESSOR; APOLIPOPROTEIN-CIII; HORMONE-RECEPTORS; CELL-TYPE; REPRESSION; EXPRESSION; PROTEIN; GENE	To understand the mechanisms governing the regulation of nuclear receptor (NR) function, we compared the parameters of activation and repression of two isoforms of the orphan receptor hepatocyte nuclear factor (HNF) 4alpha. HNF4alpha7 and HNFalpha1 differ only in their N-terminal domains, and their expression in the liver is regulated developmentally. We show that the N-terminal activation function (AF)-1 of HNF4alpha1 possesses significant activity that can be enhanced through interaction with glucocorticoid receptor-interacting protein 1 (GRIP-1) and cAMP response element-binding protein-binding protein (CBP). In striking contrast, HNF4alpha7 possesses no measurable AF-1, implying major functional differences between the isoforms. Indeed, although HNF4alpha1 and HNF4a7 are able to interact via AF-2 with GRIP-1, p300, and silencing mediator for retinoid and thyroid receptors (SMRT), only HNF4alpha1 interacts in a synergistic fashion with GRIP-1 and p300. Although both isoforms interact physically and functionally with SMRT, the repression of HNF4alpha7 is less robust than that of HNF4alpha1, which may be caused by an increased ability of the latter to recruit histone deacetylase (HDAC) activity to target promoters. Moreover, association of SMRT with HDACs enhanced recruitment of HNF4alpha1 but not of HNF4alpha7. These observations suggest that NR isoform-specific association with SMRT could affect activity of the SMRT complex, implying that selection of HDAC partners is a novel point of regulation for NR activity. Possible physiological consequences of the multiple interactions with these coregulators are discussed.	Inst Pasteur, Dept Dev Biol, Unite Genet Differenciat, FRE 2364 CNRS, F-75724 Paris 15, France; Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of California System; University of California Riverside	Weiss, MC (corresponding author), Inst Pasteur, Dept Dev Biol, Unite Genet Differenciat, FRE 2364 CNRS, 25 Rue Dr Roux, F-75724 Paris 15, France.	mweiss@pasteur.fr			NIDDK NIH HHS [R01 DK053892, DK53892] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK053892, R01DK053892] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Green VJ, 1998, J BIOL CHEM, V273, P29950, DOI 10.1074/jbc.273.45.29950; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guenther MG, 2000, GENE DEV, V14, P1048; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kan HY, 2000, J BIOL CHEM, V275, P30423, DOI 10.1074/jbc.M005641200; Kao HY, 2000, GENE DEV, V14, P55; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; Li JX, 2000, GENE DEV, V14, P464; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; Lizcano F, 2001, MOL CELL ENDOCRINOL, V172, P13, DOI 10.1016/S0303-7207(00)00400-7; Ma H, 1999, MOL CELL BIOL, V19, P6164; MAEVA Y, 2002, MOL ENDOCRINOL, V16, P402; Manet Evelyne, 1993, Gene Expression, V3, P49; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakhei H, 1998, NUCLEIC ACIDS RES, V26, P497, DOI 10.1093/nar/26.2.497; Privalsky ML, 2001, CURR TOP MICROBIOL, V254, P117; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Ruse MD, 2002, MOL CELL BIOL, V22, P1626, DOI 10.1128/MCB.22.6.1626-1638.2002; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SCHOEPFER R, 1993, GENE, V124, P83, DOI 10.1016/0378-1119(93)90764-T; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; Sladek FM, 1998, DIABETES, V47, P985, DOI 10.2337/diabetes.47.6.985; Sladek FM, 2001, NUCL RECEPTORS GENET; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Spath GF, 1997, MOL CELL BIOL, V17, P1913; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Torres-Padilla ME, 2001, MECH DEVELOP, V109, P183, DOI 10.1016/S0925-4773(01)00521-4; Tremblay GB, 1999, MOL CELL BIOL, V19, P1919; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200; Yang ZH, 1999, J BIOL CHEM, V274, P37131, DOI 10.1074/jbc.274.52.37131; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871	69	51	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44677	44687		10.1074/jbc.M207545200	http://dx.doi.org/10.1074/jbc.M207545200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12205093	hybrid			2022-12-25	WOS:000179404800012
J	Zugaza, JL; Lopez-Lago, MA; Caloca, MJ; Dosil, M; Movilla, N; Bustelo, XR				Zugaza, JL; Lopez-Lago, MA; Caloca, MJ; Dosil, M; Movilla, N; Bustelo, XR			Structural determinants for the biological activity of Vav proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; DBL HOMOLOGY DOMAIN; T-CELL; PLECKSTRIN HOMOLOGY; SIGNAL-TRANSDUCTION; RHO-FAMILY; ACTIVATION; RECOGNITION; RESPONSES; SELECTION	We have used an extensive mutagenesis approach to study the specific role of the eight structural domains of Vav during both the activation and signaling steps of this Rac1 exchange factor. Our results indicate that several Vav domains (Dbl homology, pleckstrin homology, and zinc finger) are essential for all the biological activities tested, whereas others are required for discrete, cell type-specific biological effects. Interestingly, we have found that Vav domains have no unique functions. Thus, the calponin homology domain mediates the inhibition of Vav both in vitro and in vivo but, at the same time, exerts effector functions in lymphocytes upon receptor activation. The Vav SH2 and SH3 regions play regulatory roles in the activation of Vav in fibroblasts, mediating both its phosphorylation and translocation to the plasma membrane. In contrast, the Vav SH2 and SH3 regions act as scaffolding platforms in T-cells, ensuring the proper phosphorylation of Vav and the subsequent engagement of downstream effectors. We also provide evidence indicating that the zinc finger region exerts at least three different functional roles in Vav, aiding in the down-regulation of its basal activity, the engagement of substrates, and the induction of ancillary pathways required for cell transformation. Finally, the results obtained are consistent with a new regulatory model for Vav, in which the calponin homology region inhibits the basal activity of Vav through interactions with the zinc finger region.	Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./AAD-2081-2022; Caloca, María-José/K-9357-2014; Bustelo, Xose R./A-9526-2010; Dosil, Mercedes/A-9536-2016	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Dosil, Mercedes/0000-0001-8119-8263; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671; Caloca, Maria-Jose/0000-0002-1003-2685	NCI NIH HHS [CA7373501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; Bustelo XR, 2002, FRONT BIOSCI, V7, pD24, DOI 10.2741/bustelo; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Groysman M, 2000, FEBS LETT, V467, P75, DOI 10.1016/S0014-5793(00)01121-2; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kong YY, 1998, J EXP MED, V188, P2099, DOI 10.1084/jem.188.11.2099; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Nishida M, 2001, EMBO J, V20, P2995, DOI 10.1093/emboj/20.12.2995; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; van der Eb A J, 1980, Methods Enzymol, V65, P826; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; WU J, 1995, MOL CELL BIOL, V15, P4337; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	40	99	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45377	45392		10.1074/jbc.M208039200	http://dx.doi.org/10.1074/jbc.M208039200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228230	hybrid			2022-12-25	WOS:000179404800101
J	Efendiev, R; Yudowski, GA; Zwiller, J; Leibiger, B; Katz, AI; Berggren, PO; Pedemonte, CH; Leibiger, IB; Bertorello, AM				Efendiev, R; Yudowski, GA; Zwiller, J; Leibiger, B; Katz, AI; Berggren, PO; Pedemonte, CH; Leibiger, IB; Bertorello, AM			Relevance of dopamine signals anchoring dynamin-2 to the plasma membrane during Na+,K+-ATPase endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; ALPHA-SUBUNIT; DISTINCT FUNCTIONS; PROTEIN; PHOSPHORYLATION; RECRUITMENT; INHIBITION; BINDING; DOMAIN; BETA	Clathrin-dependent endocytosis of Na+,K+-ATPase in response to dopamine regulates its catalytic activity in intact cells. Because fission of clathrin-coated pits requires dynamin, we examined the mechanisms by which dopamine receptor signals promote dynamin-2 recruitment and assembly at the site of Na+,K+-ATPase endocytosis. Western blotting revealed that dopamine increased the association of dynamin-2 with the plasma membrane and with phosphatidylinositol 3-kinase. Dopamine inhibited Na+,K+-ATPase activity in OK cells and in those overexpressing wild type dynamin-2 but not in cells expressing a dominant-negative mutant. Dephosphorylation of dynamin is important for its assembly. Dopamine increased protein phosphatase 2A activity and dephosphorylated dynamin-2. In cells expressing a dominant-negative mutant of protein phosphatase 2A, dopamine failed to dephosphorylate dynamin-2 and to reduce Na+,K+-ATPase activity. Dynamin-2 is phosphorylated at Ser(848), and expression of the S848A mutant significantly blocked the inhibitory effect of dopamine. These results demonstrate a distinct signaling network originating from the dopamine receptor that regulates the state of dynamin-2 phosphorylation and that promotes its location (by interaction with phosphatidylinositol 3-kinase) at the site of Na+,K+-ATPase endocytosis.	Karolinska Hosp, Dept Mol Med, Rolf Luft Ctr Diabet Res, Karolinska Inst, S-17176 Stockholm, Sweden; Univ Houston, Dept Pharmacol & Pharmaceut Sci, Coll Pharm, Houston, TX 77204 USA; INSERM, Unite 338, F-67084 Strasbourg, France; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Karolinska Institutet; Karolinska University Hospital; University of Houston System; University of Houston; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Chicago	Bertorello, AM (corresponding author), Karolinska Hosp, Dept Mol Med, Rolf Luft Ctr Diabet Res, Karolinska Inst, L3, S-17176 Stockholm, Sweden.	alejandro.bertorello@molmed.ki.se		Yudowski, Guillermo/0000-0001-5989-4131; Berggren, Per-Olof/0000-0001-8991-413X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053460] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53460] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; ALEXANDER RW, 1974, J CLIN INVEST, V54, P194, DOI 10.1172/JCI107743; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; BALL SG, 1970, BR J CLIN PHARM, V4, P115; BERTORELLO A, 1988, AM J PHYSIOL, V254, pF795, DOI 10.1152/ajprenal.1988.254.6.F795; Bertorello AM, 1999, AM J PHYSIOL-LUNG C, V276, pL20, DOI 10.1152/ajplung.1999.276.1.L20; BERTORELLO AM, 1993, AM J PHYSIOL, V265, pF743, DOI 10.1152/ajprenal.1993.265.6.F743; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; Carranza ML, 1998, J PHYSIOL-LONDON, V511, P235, DOI 10.1111/j.1469-7793.1998.235bi.x; Chibalin AV, 1998, J BIOL CHEM, V273, P8814, DOI 10.1074/jbc.273.15.8814; Chibalin AV, 1997, AM J PHYSIOL-CELL PH, V273, pC1458, DOI 10.1152/ajpcell.1997.273.5.C1458; Chibalin AV, 1998, MOL BIOL CELL, V9, P1209, DOI 10.1091/mbc.9.5.1209; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Done SC, 2002, J BIOL CHEM, V277, P17108, DOI 10.1074/jbc.M201326200; Efendiev R, 1999, FEBS LETT, V456, P45, DOI 10.1016/S0014-5793(99)00925-4; Efendiev R, 2000, BIOCHEMISTRY-US, V39, P9884, DOI 10.1021/bi0007831; Evans DRH, 1999, J BIOL CHEM, V274, P24038, DOI 10.1074/jbc.274.34.24038; EWART HS, 1995, AM J PHYSIOL-CELL PH, V269, pC295, DOI 10.1152/ajpcell.1995.269.2.C295; Goldstien J, 2001, FR HIST STUD, V24, P1, DOI 10.1215/00161071-24-1-1; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai MM, 1999, J BIOL CHEM, V274, P25963, DOI 10.1074/jbc.274.37.25963; Larsson O, 1997, SCIENCE, V278, P471, DOI 10.1126/science.278.5337.471; LIU JP, 1994, J BIOL CHEM, V269, P21043; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Moede T, 1999, FEBS LETT, V461, P229, DOI 10.1016/S0014-5793(99)01446-5; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Ogimoto G, 2000, P NATL ACAD SCI USA, V97, P3242, DOI 10.1073/pnas.060025597; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Pedemonte CH, 1997, MOL PHARMACOL, V52, P88, DOI 10.1124/mol.52.1.88; Powell KA, 2000, J BIOL CHEM, V275, P11610, DOI 10.1074/jbc.275.16.11610; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; SLOBODYANSKY E, 1995, AM J PHYSIOL-RENAL, V268, pF279, DOI 10.1152/ajprenal.1995.268.2.F279; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; Yu PY, 2000, HYPERTENSION, V36, P1053, DOI 10.1161/01.HYP.36.6.1053; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297	50	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44108	44114		10.1074/jbc.M205173200	http://dx.doi.org/10.1074/jbc.M205173200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12205083	hybrid			2022-12-25	WOS:000179272000075
J	Franca-Koh, J; Yeo, M; Fraser, E; Young, N; Dale, TC				Franca-Koh, J; Yeo, M; Fraser, E; Young, N; Dale, TC			The regulation of glycogen synthase kinase-3 nuclear export by Frat/GBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-BETA; FRAT1; PHOSPHORYLATION; ONCOGENESIS; SIGNALS; GSK-3	Previous studies have shown that nuclear levels of glycogen synthase kinase-3 (GSK-3) are dynamically regulated and may affect access of GSK-3 to its substrates. In this study we show that the GSK-3-binding protein Frat/GBP regulates the nuclear export of GSK-3. We show that Frat/GBP contains a nuclear export sequence that promotes its own nuclear export and that of associated GSK-3. Treating cells with leptomycin B increased nuclear levels of endogenous GSK-3 suggesting that an endogenous process targets GSK-3 for nuclear export. To investigate this further, we used two approaches to disrupt the interaction between GSK-3 and endogenous Frat. First we isolated mutants of GSK-3 that selectively interfered with Frat binding and found that these mutants were poorly exported. Second we expressed a peptide that competes with Frat for GSK-3 binding and found that it caused endogenous GSK-3 to accumulate in the nucleus. Together these data suggest that Frat may be the endogenous factor that targets GSK-3 for nuclear export. The dynamic expression patterns of Frat mRNAs together with the role of Frat in mediating GSK-3 nuclear export have important implications for the control of the substrate access of GSK-3 in several signaling pathways.	Inst Canc Res, Chester Beatty Labs, Sect Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Dale, TC (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Cell & Mol Biol, London SW3 6JB, England.		Dale, Trevor C/D-3749-2009; Fraser, Elizabeth/M-7049-2015	Dale, Trevor C/0000-0002-4880-9963; Fraser, Elizabeth/0000-0001-8420-3208				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Ginger RS, 2000, EMBO J, V19, P5483, DOI 10.1093/emboj/19.20.5483; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Jonkers J, 1999, MECH DEVELOP, V88, P183, DOI 10.1016/S0925-4773(99)00187-2; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; WOODGETT JR, 2001, SCI STKE; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	22	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43844	43848		10.1074/jbc.M207265200	http://dx.doi.org/10.1074/jbc.M207265200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223487	hybrid			2022-12-25	WOS:000179272000042
J	Potrykus, K; Wegrzyn, G; Hernandez, VJ				Potrykus, K; Wegrzyn, G; Hernandez, VJ			Multiple mechanisms of transcription inhibition by ppGpp at the lambda rho(R) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; OPEN COMPLEX-FORMATION; ESCHERICHIA-COLI; GUANOSINE TETRAPHOSPHATE; STRINGENT CONTROL; SPOT; ELONGATION; DEGRADATION; INITIATION; REQUIRES	General stress conditions in bacterial cells cause a global cellular response called the stringent response. The first event in this control is production of large amounts of a regulatory nucleotide, guanosine-3',5'-(bis)pyrophospahte (ppGpp). It was proposed recently that ppGpp acts by decreasing stability of open complexes at promoters that make short-lived open complexes, e.g. the rRNA promoters. However, here we report that the bacteriophage lambdap(R) promoter, which forms long-lived open complexes, is inhibited by ppGpp in vitro as observed in vivo. We performed a systematic investigation of the ppGpp-specific inhibition of transcription initiation at lambdap(R) and found that ppGpp does decrease stability of open complexes at lambdap(R), but only slightly. Likewise the equilbrium binding constant and rate of open complex formation by RNA polymerase at lambdap(R) are only slightly affected by ppGpp. The major effect of ppGpp-mediated inhibition is to decrease the rate of promoter escape. We conclude that ppGpp-mediated inhibition of transcription initiation is not restricted to promoters that make short-lived open complexes. Rather we conclude that the initial catalytic step of transcript formation is affected by ppGpp, specifically formation of the first phosphodiester bond is inhibited by ppGpp at) lambdap(R).	SUNY Buffalo, Dept Microbiol, Buffalo, NY 14214 USA; Univ Gdansk, Dept Mol Biol, PL-80822 Gdansk, Poland; Polish Acad Sci, Inst Oceanol, PL-81347 Gdynia, Poland	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Fahrenheit Universities; University of Gdansk; Polish Academy of Sciences; Institute of Oceanology of the Polish Academy of Sciences	Hernandez, VJ (corresponding author), SUNY Buffalo, Dept Microbiol, Buffalo, NY 14214 USA.		Wegrzyn, Grzegorz/AAL-1179-2020; Wegrzyn, Grzegorz/ABD-6699-2020	Wegrzyn, Grzegorz/0000-0003-4042-7466; Potrykus, Katarzyna/0000-0002-4902-3348	FIC NIH HHS [TW01244] Funding Source: Medline; NIGMS NIH HHS [GM57189] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057189] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barker MM, 2001, J MOL BIOL, V305, P689, DOI 10.1006/jmbi.2000.4328; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Chatterji D, 1998, GENES CELLS, V3, P279, DOI 10.1046/j.1365-2443.1998.00190.x; Gentry DR, 1996, MOL MICROBIOL, V19, P1373, DOI 10.1111/j.1365-2958.1996.tb02480.x; GILADI H, 1992, J MOL BIOL, V227, P985, DOI 10.1016/0022-2836(92)90514-K; GOODRICH JA, 1992, J MOL BIOL, V224, P15, DOI 10.1016/0022-2836(92)90573-3; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; HERNANDEZ VJ, 1991, J BIOL CHEM, V266, P5991; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; McKane M, 2000, J MOL BIOL, V299, P337, DOI 10.1006/jmbi.2000.3757; Murray KD, 1996, J MOL BIOL, V259, P41; OHLSEN KL, 1992, MOL MICROBIOL, V6, P2243, DOI 10.1111/j.1365-2958.1992.tb01400.x; Petersen C, 2000, J BIOL CHEM, V275, P3931, DOI 10.1074/jbc.275.6.3931; REDDY PS, 1995, MOL MICROBIOL, V15, P255, DOI 10.1111/j.1365-2958.1995.tb02240.x; Slominska M, 1999, VIROLOGY, V262, P431, DOI 10.1006/viro.1999.9907; SZALEWSKAPALASZ A, 1994, EMBO J, V13, P5779, DOI 10.1002/j.1460-2075.1994.tb06916.x; TAYLOR K, 1998, MOL MICROBIOL, P81; Toulokhonov II, 2001, J BIOL CHEM, V276, P1220, DOI 10.1074/jbc.M007184200; TRAVERS AA, 1984, NUCLEIC ACIDS RES, V12, P2605, DOI 10.1093/nar/12.6.2605; VOGEL U, 1995, J BIOL CHEM, V270, P18335, DOI 10.1074/jbc.270.31.18335; VOGEL U, 1994, J BIOL CHEM, V269, P16236; WRGRZYN G, 2001, RECENT RES DEV VIROL, V3, P375; Wrobel B, 1998, MOL GEN GENET, V257, P490, DOI 10.1007/s004380050674; XIAO H, 1991, J BIOL CHEM, V266, P5980	25	23	23	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43785	43791		10.1074/jbc.M208768200	http://dx.doi.org/10.1074/jbc.M208768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226106	hybrid			2022-12-25	WOS:000179272000034
J	Scholze, P; Freissmuth, M; Sitte, HH				Scholze, P; Freissmuth, M; Sitte, HH			Mutations within an intramembrane leucine heptad repeat disrupt oligomer formation of the rat GABA transporter 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+CL COTRANSPORT FUNCTION; OOCYTE MEMBRANE PATCHES; GAMMA-AMINOBUTYRIC-ACID; PROTEIN-KINASE-C; SEROTONIN TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; TRANSMEMBRANE HELIX; POINT MUTATION; RECEPTOR; CELLS	Na+/Cl--dependent neurotransmitter transporters form constitutive oligomers, the significance of which is not known. In soluble proteins, leucine heptad repeats drive dimerization; the rat gamma-aminobutyric acid transporter GAT-1 (rGAT) contains a motif reminiscent of a leucine heptad repeat in the second transmembrane helix (TM2). We substituted leucine residues in TM2 of rGAT by alanine and tested the ability of the resulting mutants to form oligomers by three methods of Forster resonance energy transfer (FRET) microscopy. Replacement of one leucine (L97A) resulted in considerable loss of energy transfer, replacing two or more ablated it completely. Furthermore, intracellular trapping increased with the number of leucine substitutions. Only rGAT-L97A reached the cell surface to a sufficient amount such that, in intact cells, it was indistinguishable from wild type rGAT with respect to substrate transport, binding of inhibitors, and regulation by protein kinase C. However, in membrane vesicles prepared from transfected cells, all mutants were still functional. In addition, FRET was readily detected during maturation of wild type rGAT, when the bulk of the protein resided in the endoplasmic reticulum. Hence, our findings strongly argue for a role of oligomer formation during biosynthesis and subsequent delivery of the multimer from the endoplasmic reticulum to the plasma membrane.	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria	University of Vienna	Sitte, HH (corresponding author), Univ Vienna, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.		Sitte, Harald/N-2681-2013; Sitte, Harald/O-7025-2019	Sitte, Harald/0000-0002-1339-7444; Sitte, Harald/0000-0002-1339-7444; Scholze, Petra/0000-0003-4984-6034; Freissmuth, Michael/0000-0001-9398-1765				ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; ASANO T, 1992, J BIOL CHEM, V267, P19636; AXELROD J, 1961, SCIENCE, V133, P383, DOI 10.1126/science.133.3450.383; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Beckman ML, 1998, J NEUROSCI, V18, P6103; Beckman ML, 1998, J MEMBRANE BIOL, V164, P1; BECKMAN ML, 1999, J NEUROSCI RC, V9, P1; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; Cammack JN, 1996, P NATL ACAD SCI USA, V93, P723, DOI 10.1073/pnas.93.2.723; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; DeFelice LJ, 1996, BIOPHYS J, V70, P579, DOI 10.1016/S0006-3495(96)79604-2; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; Fleming KG, 2001, P NATL ACAD SCI USA, V98, P14340, DOI 10.1073/pnas.251367498; Forster T., 1948, ANN PHYS, V437, P57; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Garcia J, 1997, BIOPHYS J, V72, P2515, DOI 10.1016/S0006-3495(97)78896-9; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; Iversen L, 2000, MOL PSYCHIATR, V5, P357, DOI 10.1038/sj.mp.4000728; Jentsch TJ, 2002, NATURE, V415, P276, DOI 10.1038/415276a; Jess U, 1996, FEBS LETT, V394, P44, DOI 10.1016/0014-5793(96)00916-7; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; LEVI G, 1993, TRENDS NEUROSCI, V16, P415, DOI 10.1016/0166-2236(93)90010-J; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; Lu CC, 1999, J GEN PHYSIOL, V114, P445, DOI 10.1085/jgp.114.3.445; MABJEESH NJ, 1992, J BIOL CHEM, V267, P2563; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Perego C, 1997, J BIOL CHEM, V272, P6584, DOI 10.1074/jbc.272.10.6584; Quick MW, 2002, P NATL ACAD SCI USA, V99, P5686, DOI 10.1073/pnas.082712899; Risso S, 1996, J PHYSIOL-LONDON, V490, P691, DOI 10.1113/jphysiol.1996.sp021178; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; SATO K, 1995, FEBS LETT, V375, P99, DOI 10.1016/0014-5793(95)01191-G; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P21505, DOI 10.1074/jbc.M112265200; Sitte HH, 2002, BRIT J PHARMACOL, V135, P93, DOI 10.1038/sj.bjp.0704446; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Su HP, 2000, J BIOL CHEM, V275, P9542, DOI 10.1074/jbc.275.13.9542; Veenhoff LM, 2002, TRENDS BIOCHEM SCI, V27, P242, DOI 10.1016/S0968-0004(02)02077-7; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	50	94	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43682	43690		10.1074/jbc.M205602200	http://dx.doi.org/10.1074/jbc.M205602200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223478	hybrid			2022-12-25	WOS:000179272000020
J	Van Komen, S; Petukhova, G; Sigurdsson, S; Sung, P				Van Komen, S; Petukhova, G; Sigurdsson, S; Sung, P			Functional cross-talk among Rad51, Rad54, and replication protein A in heteroduplex DNA joint formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; YEAST RAD51; RECOMBINATION FACTORS; RECA PROTEIN; BINDING; EXCHANGE; REPAIR; MECHANISMS; CATALYSIS	Saccharomyces cerevisiae Rad51, Rad54, and replication protein A (RPA) proteins work in concert to make heteroduplex DNA joints during homologous recombination. With plasmid length DNA substrates, maximal DNA joint formation is observed with amounts of Rad51. substantially below what is needed to saturate the initiating single-stranded DNA template, and, relative to Rad51, Rad54 is needed in only catalytic quantities. RPA is still indispensable for optimal reaction efficiency, but its role in this instance is to sequester free single-stranded DNA, which otherwise inhibits Rad51 and Rad54 functions. We also demonstrate that Rad54 helps overcome various reaction constraints in DNA joint formation. These results thus shed light on the function of Rad54 in the Rad51-mediated homologous DNA pairing reaction and also reveal a novel role of RPA in the presynaptic stage of this reaction.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Sung, P (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	sung@uthscsa.edu	Sigurdsson, Stefan/L-9820-2015	Sigurdsson, Stefan/0000-0002-5284-0058	NIEHS NIH HHS [R01ES07061] Funding Source: Medline; NIGMS NIH HHS [R01GM57814] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 1998, EMBO J, V17, P1161, DOI 10.1093/emboj/17.4.1161; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nakagawa T, 2001, J BIOL CHEM, V276, P31487, DOI 10.1074/jbc.M104003200; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; Petukhova G, 1999, J BIOL CHEM, V274, P33839, DOI 10.1074/jbc.274.48.33839; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	29	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43578	43587		10.1074/jbc.M205864200	http://dx.doi.org/10.1074/jbc.M205864200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226081	hybrid			2022-12-25	WOS:000179272000007
J	DeGraff, JL; Gurevich, VV; Benovic, JL				DeGraff, JL; Gurevich, VV; Benovic, JL			The third intracellular loop of alpha(2)-adrenergic receptors determines subtype specificity of arrestin interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; BETA-ARRESTIN; ALPHA-2-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; DEPENDENT DESENSITIZATION; ADENYLATE-CYCLASE; CLATHRIN ADAPTER; PROTEIN-KINASE; BINDING	Nonvisual arrestins (arrestin-2 and -3) serve as adaptors to link agonist-activated G protein-coupled receptors to the endocytic machinery. Although many G protein-coupled receptors bind arrestins, the molecular determinants involved in binding remain largely unknown. Because arrestins selectively promote the internalization of the alpha(2b)- and alpha(2c)-adrenergic receptors (ARs) while having no effect on the alpha(2a)AR, here we used alpha(2)ARs to identify molecular determinants involved in arrestin binding. Initially, we assessed the ability of purified arrestins to bind glutathione S-transferase fusions containing the third intracellular loops of the alpha(2a)AR, alpha(2b)AR; or alpha(2c)AR. These studies revealed that arrestin-3 directly binds to the alpha(2b)AR and alpha(2c)AR but not the alpha(2a)AR, whereas arrestin-2 only binds to the alpha(2b)AR, Truncation mutagenesis of the alpha(2b)AR identified two arrestin-3 binding domains in the third intracellular loop, one at the N-terminal end (residues 194-214) and the other at the C-terminal end (residues 344-368). Site-directed mutagenesis further revealed a critical role for several basic residues in arrestin-3 binding to the alpha(2b)AR third intracellular loop. Mutation of these residues in the holo-alpha(2b)AR and subsequent expression in HEK 293 cells revealed that the mutations had no effect on the ability of the receptor to activate ERK1/2. However, agonist-promoted internalization of the mutant a2bAR was significantly attenuated as compared with wild type receptor. These results demonstrate that arrestin-3 binds to two discrete regions within the alpha(2b)AR third intracellular loop and that disruption of arrestin binding selectively abrogates agonist-promoted receptor internalization.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Jefferson University; Vanderbilt University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.		Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063097] Funding Source: NIH RePORTER; NEI NIH HHS [EY11500] Funding Source: Medline; NIAID NIH HHS [T32-AI07523] Funding Source: Medline; NIGMS NIH HHS [GM63097, GM47419] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Altman JD, 1999, MOL PHARMACOL, V56, P154, DOI 10.1124/mol.56.1.154; Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Gelber EI, 1999, J NEUROCHEM, V72, P2206, DOI 10.1046/j.1471-4159.1999.0722206.x; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; JEWELLMOTZ EA, 1995, BIOCHEMISTRY-US, V34, P11946, DOI 10.1021/bi00037a036; JONES SB, 1991, MOL PHARMACOL, V39, P239; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUROSE H, 1994, J BIOL CHEM, V269, P10093; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Mukherjee S, 1999, J BIOL CHEM, V274, P12984, DOI 10.1074/jbc.274.19.12984; MURAKAMI A, 1993, FEBS LETT, V334, P203, DOI 10.1016/0014-5793(93)81712-9; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; Prezeau L, 1999, J BIOL CHEM, V274, P13462, DOI 10.1074/jbc.274.19.13462; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; RICHMAN JG, 2001, J BIOL CHEM, V40, P19; SEUWEN K, 1990, CELL REGUL, V1, P445, DOI 10.1091/mbc.1.6.445; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; Vilardaga JP, 2002, J BIOL CHEM, V277, P8121, DOI 10.1074/jbc.M110433200; Wade SM, 1999, MOL PHARMACOL, V56, P1005, DOI 10.1124/mol.56.5.1005; Wade SM, 1996, MOL PHARMACOL, V50, P351; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; YAMAKI K, 1987, BIOCHEM BIOPH RES CO, V142, P904, DOI 10.1016/0006-291X(87)91499-9	45	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43247	43252		10.1074/jbc.M207495200	http://dx.doi.org/10.1074/jbc.M207495200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12205092	hybrid			2022-12-25	WOS:000179081200107
J	Nowak, G				Nowak, G			Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST ATP SYNTHASE; SIGNAL-REGULATED KINASE; INDUCED NEPHROTOXICITY; CASPASE ACTIVATION; EPITHELIAL-CELLS; INDUCED TOXICITY; IN-VITRO; MEMBRANE; RAT; INHIBITION	Initiation of apoptosis by many agents is preceded by mitochondrial dysfunction and depolarization of the mitochondrial inner membrane. Here we demonstrate that, in renal proximal tubular cells (RPTC), cisplatin induces mitochondrial dysfunction associated with hyperpolarization of the mitochondrial membrane and that these events are mediated by protein kinase C (PKC)-alpha and ERK1/2. Cisplatin induced sustained decreases in RPTC respiration, oxidative phosphorylation, and increases in the mitochondrial transmembrane potential (Deltapsi(m)), which were preceded by the inhibition of F0F1-ATPase and cytochrome c release from the mitochondria, accompanied by caspase-3 activation, and followed by RPTC apoptosis. Cisplatin also decreased active Na+ transport as a result, in part, of the inhibition of Na+/K+-ATPase. These changes were preceded by PKC-alpha and ERK1/2 activation. Inhibition of cisplatin-induced PKC-alpha and ERK1/2 activation using Go6976 and PD98059, respectively, abolished increases in Deltapsi(m), diminished decreases in oxidative phosphorylation, active Na+ transport, and decreased caspase-3 activation without blocking cytochrome c release. Caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-Ruoromethylketone (zVAD-fmk) did not prevent increases in Deltapsi(m). Furthermore, inhibition of PKC-alpha did not prevent cisplatin-induced ERK1/2 activation. We concluded that in RFTC: 1) cisplatin-induced mitochondrial dysfunction, decreases in active Na+ transport, and apoptosis are mediated by PKC-alpha and ERK1/2; 2) PKC-alpha and ERK1/2 mediate activation of caspase-3 by acting downstream of cytochrome c release from mitochondria; and 3) ERK1/2 activation by cisplatin occurs through a PKC-alpha-independent pathway.	Univ Arkansas Med Sci, Dept Pharmaceut Sci, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Nowak, G (corresponding author), Univ Arkansas Med Sci, Dept Pharmaceut Sci, Slot 522-3,4301 W Markham St, Little Rock, AR 72205 USA.	nowakgrazyna@uams.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059558] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK059558, R01DK59558, R01 DK059558-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Autieri MV, 1999, DNA CELL BIOL, V18, P555, DOI 10.1089/104454999315105; Basu A, 1999, BIOCHEMISTRY-US, V38, P4245, DOI 10.1021/bi982854q; BRADY HR, 1990, AM J PHYSIOL, V258, pF1181, DOI 10.1152/ajprenal.1990.258.5.F1181; Bunney TD, 2001, P NATL ACAD SCI USA, V98, P4249, DOI 10.1073/pnas.061437498; Chanda B, 1999, BBA-BIOMEMBRANES, V1416, P92, DOI 10.1016/S0005-2736(98)00217-X; CHOPRA S, 1982, KIDNEY INT, V21, P54, DOI 10.1038/ki.1982.8; Di Mari JF, 1999, AM J PHYSIOL-RENAL, V277, pF195, DOI 10.1152/ajprenal.1999.277.2.F195; DILISA F, 1995, J PHYSIOL-LONDON, V486, P1; Dong Y, 1997, BIOCHEM PHARMACOL, V53, P1673, DOI 10.1016/S0006-2952(97)00015-4; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; Dzeja PP, 2001, CIRC RES, V89, P744, DOI 10.1161/res.89.9.744; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Evans RM, 1998, EXP CELL RES, V245, P69, DOI 10.1006/excr.1998.4250; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; GOLDSTEIN RS, 1983, LIFE SCI, V32, P685, DOI 10.1016/0024-3205(83)90299-0; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; HANIGAN MH, 1994, CANCER RES, V54, P5925; Henkels KM, 1999, CANCER RES, V59, P3077; Ikeda S, 1999, INT J UROL, V6, P245, DOI 10.1046/j.1442-2042.1999.00058.x; Kanekatsu M, 1998, BIOCHEM MOL BIOL INT, V46, P99; Kazanietz MG, 2001, ARCH BIOCHEM BIOPHYS, V388, P74, DOI 10.1006/abbi.2000.2264; Khaled AR, 2001, J BIOL CHEM, V276, P6453, DOI 10.1074/jbc.M006391200; Kojima H, 1998, J BIOL CHEM, V273, P16647, DOI 10.1074/jbc.273.27.16647; KRUIDERING M, 1994, EXP NEPHROL, V2, P334; Kruidering M, 1998, CELL DEATH DIFFER, V5, P601, DOI 10.1038/sj.cdd.4400392; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASH LH, 1993, MITOCHONDRIAL DYSFUN, V2, P8; Lau AH, 1999, KIDNEY INT, V56, P1295, DOI 10.1046/j.1523-1755.1999.00687.x; Law RHP, 1995, METHOD ENZYMOL, V260, P133, DOI 10.1016/0076-6879(95)60135-X; LEIBBRANDT MEI, 1995, KIDNEY INT, V48, P761, DOI 10.1038/ki.1995.348; LEVI J, 1980, J PHARMACOL EXP THER, V213, P545; Li LW, 1999, MOL CELL BIOL, V19, P8547; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Melendez-Zajgla J, 1999, BIOCHEM MOL BIOL INT, V47, P765; MIURA K, 1987, TOXICOLOGY, V44, P147, DOI 10.1016/0300-483X(87)90145-4; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; Nowak G, 1996, AM J PHYSIOL-CELL PH, V271, pC2072, DOI 10.1152/ajpcell.1996.271.6.C2072; Nowak G, 2000, TOXICOL APPL PHARM, V167, P37, DOI 10.1006/taap.2000.8986; Okuda M, 2000, BIOCHEM PHARMACOL, V59, P195, DOI 10.1016/S0006-2952(99)00303-2; Osman AM, 2000, PHARMACOL RES, V41, P115; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Poppe M, 2001, J NEUROSCI, V21, P4551, DOI 10.1523/JNEUROSCI.21-13-04551.2001; SAFIRSTEIN R, 1987, INT J ANDROL, V10, P325, DOI 10.1111/j.1365-2605.1987.tb00200.x; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Scarlett JL, 2000, FEBS LETT, V475, P267, DOI 10.1016/S0014-5793(00)01681-1; Sener G, 2000, FUNDAM CLIN PHARM, V14, P553; Shiraishi Y, 2000, LIFE SCI, V67, P1047, DOI 10.1016/S0024-3205(00)00704-9; Somani SM, 2000, PHARMACOL TOXICOL, V86, P234, DOI 10.1034/j.1600-0773.2000.d01-41.x; Tashker JS, 2002, MOL BIOL CELL, V13, P393, DOI 10.1091/mbc.01-06-0291; TKACOVA E, 1985, NEOPLASMA, V32, P679; van de Water B, 2000, J BIOL CHEM, V275, P25805, DOI 10.1074/jbc.M001680200; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VANVERHEIDEN MG, 2001, J BIOL CHEM, V276, P19414; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; White RJ, 1996, J NEUROSCI, V16, P5688; Zhan Y, 1999, ONCOGENE, V18, P6505, DOI 10.1038/sj.onc.1203060; ZHANG JG, 1993, BIOCHEM PHARMACOL, V45, P2215; Zhang JG, 1996, TOXICOL LETT, V89, P11, DOI 10.1016/S0378-4274(96)03776-9	62	217	221	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43377	43388		10.1074/jbc.M206373200	http://dx.doi.org/10.1074/jbc.M206373200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12218054	Green Accepted, hybrid			2022-12-25	WOS:000179081200122
J	Soriano, GM; Guo, LW; de Vitry, C; Kallas, T; Cramer, WA				Soriano, GM; Guo, LW; de Vitry, C; Kallas, T; Cramer, WA			Electron transfer from the Rieske iron-sulfur protein (ISP) to cytochrome f in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL WATER CHAIN; LUMEN-SIDE DOMAIN; BC(1) COMPLEX; B(6)F COMPLEX; OXYGENIC PHOTOSYNTHESIS; REDOX REACTIONS; PH-DEPENDENCE; BOVINE HEART; BC1 COMPLEX; IN-VIVO	The time course of electron transfer in vitro between soluble domains of the Rieske iron-sulfur protein (ISP) and cytochrome f subunits of the cytochrome b(6)f complex of oxygenic photosynthesis was measured by stopped-flow mixing. The domains were derived from Chlamydomonas reinhardtii and expressed in Escherichia coli. The expressed 142-residue soluble ISP apoprotein was reconstituted with the [2Fe-2S] cluster. The second-order rate constant, k(2)((ISP-f)) = 1.5 X 10(6) m(-1) s(-1), for ISP to cytochrome f electron transfer was <10(-2) of the rate constant at low ionic strength, k(2)((f-PC))(> 200 X 10(6) M-1 s(-1)), for the reduction of plastocyanin by cytochrome f, and similar to1/30 of k(2)((f-PC)) at the ionic strength estimated mated for the thylakoid interior. In contrast to k(2)((f-PC)), k(2)((ISP-f)) was independent of pH and ionic strength, implying no significant role of electrostatic interactions. Effective pK values of 6.2 and 8.3, respectively, of oxidized and reduced ISP were derived from the pH dependence of the amplitude of cytochrome f reduction. The first-order rate constant, k(1)((ISP-f)), predicted from k(2)((ISP-f)) is similar to 10 and similar to150 times smaller than the millisecond and microsecond phases of cytochrome f reduction observed in vivo. It is proposed that in the absence of electrostatic guidance, a productive docking geometry for fast electron transfer is imposed by the guided trajectory of the ISP extrinsic domain. The requirement of a specific electrically neutral docking configuration for ISP electron transfer is consistent with structure data for the related cytochrome bc(1) complex.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Purdue Univ, Program Biochem Mol Biol, W Lafayette, IN 47907 USA; Inst Biol Physicochim, CNRS UPR 1261, F-75005 Paris, France; Univ Wisconsin, Dept Biol & Microbiol, Oshkosh, WI 54901 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Centre National de la Recherche Scientifique (CNRS); University of Wisconsin System	Soriano, GM (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038323, R56GM038323] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38323] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1976, BIOCHIM BIOPHYS ACTA, V422, P260, DOI 10.1016/0005-2744(76)90137-6; BENDALL DS, 1982, BIOCHIM BIOPHYS ACTA, V683, P119, DOI 10.1016/0304-4173(82)90008-8; Bron P, 1999, J MOL BIOL, V287, P117, DOI 10.1006/jmbi.1999.2604; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; CHENG H, 1995, ARCH BIOCHEM BIOPHYS, V316, P619, DOI 10.1006/abbi.1995.1082; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; Crofts AR, 1998, CURR OPIN STRUC BIOL, V8, P501, DOI 10.1016/S0959-440X(98)80129-2; CROFTS AR, 1999, BIOCHEMISTRY, V38; Darrouzet E, 2000, BIOCHEMISTRY-US, V39, P15475, DOI 10.1021/bi000750l; DELOSME R, 1991, PHOTOSYNTH RES, V29, P45, DOI 10.1007/BF00035205; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; GROSS R, 1999, GENE INSPECTOR SEQUE; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; HAEHNEL W, 1989, J CELL BIOL, V108, P1397, DOI 10.1083/jcb.108.4.1397; HAUSKA G, 1996, OXYGENIC PHOTOSYNTHE; Heimann S, 2000, BIOCHEMISTRY-US, V39, P2692, DOI 10.1021/bi9921992; Holton B, 1996, BIOCHEMISTRY-US, V35, P15485, DOI 10.1021/bi961367c; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; HURT E, 1981, EUR J BIOCHEM, V117, P591; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Izrailev S, 1999, BIOPHYS J, V77, P1753, DOI 10.1016/S0006-3495(99)77022-0; JONES RW, 1988, BIOCHIM BIOPHYS ACTA, V933, P258, DOI 10.1016/0005-2728(88)90033-3; KAISER WM, 1983, Z PFLANZENPHYSIOL, V113, P15, DOI 10.1016/S0044-328X(83)80015-4; Kallas T, 1994, MOL BIOL CYANOBACTER, V1, P259, DOI DOI 10.1007/978-94-011-0227-8_9; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Kramer DM, 1999, PHOTOSYNTH RES, V60, P151, DOI 10.1023/A:1006212014787; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LINK TA, 1992, EUR J BIOCHEM, V208, P685, DOI 10.1111/j.1432-1033.1992.tb17235.x; Martinez SE, 1996, PROTEIN SCI, V5, P1081; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Metzger SU, 1997, BBA-BIOENERGETICS, V1319, P233, DOI 10.1016/S0005-2728(96)00164-8; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4552, DOI 10.1021/bi00068a010; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NITSCHKE W, 1992, BIOCHIM BIOPHYS ACTA, V1102, P266, DOI 10.1016/0167-4838(92)90519-J; Ponamarev MV, 1998, BIOCHEMISTRY-US, V37, P17199, DOI 10.1021/bi981814j; QIN L, 1992, BIOCHEMISTRY-US, V31, P5145, DOI 10.1021/bi00137a008; REDINBO MR, 1993, BIOCHEMISTRY-US, V32, P10560, DOI 10.1021/bi00091a005; Roberts AG, 2002, BIOCHEMISTRY-US, V41, P4070, DOI 10.1021/bi015996k; Sadoski RC, 2000, BIOCHEMISTRY-US, V39, P4231, DOI 10.1021/bi000003o; Sainz G, 2000, BIOCHEMISTRY-US, V39, P9164, DOI 10.1021/bi0004596; Schoepp B, 1999, FEBS LETT, V450, P245, DOI 10.1016/S0014-5793(99)00511-6; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; Soriano GM, 1998, BIOCHEMISTRY-US, V37, P15120, DOI 10.1021/bi9807714; Soriano GM, 2001, BIOCHEMISTRY-US, V40, P15109, DOI 10.1021/bi011465k; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; Ugulava NB, 1998, FEBS LETT, V440, P409, DOI 10.1016/S0014-5793(98)01493-8; WHITMARSH J, 1982, BIOCHIM BIOPHYS ACTA, V682, P404, DOI 10.1016/0005-2728(82)90054-8; WHITMARSH J, 1979, BIOPHYS J, V26, P223, DOI 10.1016/S0006-3495(79)85246-7; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; Zhang JM, 1996, J BIOL CHEM, V271, P31360, DOI 10.1074/jbc.271.49.31360; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	52	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41865	41871		10.1074/jbc.M205772200	http://dx.doi.org/10.1074/jbc.M205772200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12207018	hybrid, Green Submitted			2022-12-25	WOS:000178985300073
J	Ashiuchi, M; Kuwana, E; Yamamoto, T; Komatsu, K; Soda, K; Misono, H				Ashiuchi, M; Kuwana, E; Yamamoto, T; Komatsu, K; Soda, K; Misono, H			Glutamate racemase is an endogenous DNA gyrase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TOPOISOMERASE-I; GENE; MURI; IDENTIFICATION; PURIFICATION	Almost all bacteria possess glutamate racemase to synthesize D-glutamate as an essential component of peptidoglycans in the cell walls. The enforced production of glutamate racemase, however, resulted in suppression of cell proliferation. In the Escherichia coli JM109/pGR3 clone, the overproducer of glutamate racemase, the copy number (i.e. replication efficiency) of plasmid DNA declined dramatically, whereas the E. coli WM335 mutant that is defective in the gene of glutamate racemase showed little genetic competency. The comparatively low and high activities for DNA supercoiling were contained in the E. coli JM109/pGR3 and WM335 cells, respectively. Furthermore, we found that the DNA gyrase of E. coli was modulated by the glutamate racemase of E. coli in the presence of LTDP-N-acetylmuramyl-L-alanine, which is a peptidoglycan precursor and functions as an absolute activator for the racemase. This is the first finding of the enzyme protein participating in both D-amino acid metabolism and DNA processing.	Kochi Univ, Dept Bioresources Sci, Nankoku, Kochi 7838502, Japan; Kansai Univ, Dept Biotechnol, Suita, Osaka 5648680, Japan	Kochi University; Kansai University	Ashiuchi, M (corresponding author), Kochi Univ, Dept Bioresources Sci, Nankoku, Kochi 7838502, Japan.	ashiuchi@cc.kochi-u.ac.jp						ASHIUCHI M, 1995, J BIOCHEM, V117, P495, DOI 10.1093/oxfordjournals.jbchem.a124735; Ashiuchi M, 1998, J BIOCHEM-TOKYO, V123, P1156; Ashiuchi M, 1999, BIOSCI BIOTECH BIOCH, V63, P792, DOI 10.1271/bbb.63.792; BALIKO G, 1993, J BACTERIOL, V175, P6571, DOI 10.1128/jb.175.20.6571-6577.1993; Bhaduri T, 1998, J BIOL CHEM, V273, P13925, DOI 10.1074/jbc.273.22.13925; Chandler MS, 1996, GENE, V169, P25, DOI 10.1016/0378-1119(95)00777-6; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; DOUBLET P, 1992, J BACTERIOL, V174, P5772, DOI 10.1128/jb.174.18.5772-5779.1992; Doublet P, 1996, MICROB DRUG RESIST, V2, P43, DOI 10.1089/mdr.1996.2.43; FERRO AM, 1984, J BIOL CHEM, V259, P547; INOUE N, 1991, J BACTERIOL, V173, P1208, DOI 10.1128/jb.173.3.1208-1214.1991; KATO J, 1992, J BIOL CHEM, V267, P25676; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; Nakanishi A, 1998, J BIOL CHEM, V273, P1933, DOI 10.1074/jbc.273.4.1933; PROJAN SJ, 1983, PLASMID, V9, P182, DOI 10.1016/0147-619X(83)90019-7; Reina-San-Martin B, 2000, NAT MED, V6, P890, DOI 10.1038/78651; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Snoep JL, 2002, EUR J BIOCHEM, V269, P1662, DOI 10.1046/j.1432-1327.2002.02803.x; STRAUSBERG R, 2000, HUMAN TUMOR INDEX CA; YOSHIMURA T, 1993, J BIOL CHEM, V268, P24242	21	27	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39070	39073		10.1074/jbc.C200253200	http://dx.doi.org/10.1074/jbc.C200253200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12213801	hybrid, Green Published			2022-12-25	WOS:000178662500004
J	Larmonier, N; Billerey, C; Rebe, C; Parcellier, A; Moutet, M; Fromentin, A; Kroemer, G; Garrido, C; Solary, E; Martin, F; Bonnotte, B				Larmonier, N; Billerey, C; Rebe, C; Parcellier, A; Moutet, M; Fromentin, A; Kroemer, G; Garrido, C; Solary, E; Martin, F; Bonnotte, B			An atypical caspase-independent death pathway for an immunogenic cancer cell line	ONCOGENE			English	Article						apoptosis; necrosis; caspase-independent; z-VAD; tumor immunology	DENDRITIC CELLS; NUCLEAR TRANSLOCATION; APOPTOTIC CELLS; ACTIVATED DNASE; ANTIGEN; BCL-2; INHIBITION; EXPRESSION; MATURATION; FORM	REGb cell line, a highly immunogenic tumor cell variant isolated from a rat colon cancer, yields regressive tumors when injected into syngeneic hosts. We previously demonstrated that REGb tumor immunogenicity was related to the capacity of releasing dead cells in vivo. Also, in vitro, REGb cell monolayers release dead cells, especially when cultured in serum-free medium. In the current study, we show that the release of dead cells results from an atypical death process associating features of necrosis and apoptosis. In spite of features considered as hallmarks of caspase-dependent apoptosis, including chromatin fragmentation and DNA oligonucleosomal cleavage, caspases are not activated and caspase inhibitors are ineffective to prevent REGb cell death. In contrast with a number of other types of cell death, the spontaneous death of REGb cells in culture depends on de novo protein synthesis as this death is blocked by low doses of the mRNA translation inhibitor cycloheximide. This unusual mode of cell death that associates necrotic and apoptotic features could provide optimal conditions for triggering a specific immune response.	Fac Med & Pharm Dijon, INSERM U517, IFR 100, F-21079 Dijon, France; Inst Gustave Roussy, CNRS UMR 1599, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UNICANCER; Gustave Roussy	Bonnotte, B (corresponding author), Fac Med & Pharm Dijon, INSERM U517, IFR 100, 7 Blvd Jeanne Arc, F-21079 Dijon, France.		Kroemer, Guido/AAY-9859-2020; Garrido, Carolina/GWM-5557-2022; Garrido, carmen/G-1633-2018; KROEMER, Guido/B-4263-2013; Bonnotte, Bernard/ABA-2525-2021; REBE, Cédric/AAD-4316-2019	Garrido, carmen/0000-0003-1368-1493; KROEMER, Guido/0000-0002-9334-4405; Bonnotte, Bernard/0000-0002-1098-4598; REBE, Cédric/0000-0001-8831-145X; Solary, Eric/0000-0002-8629-1341				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Belmokhtar CA, 2000, EXP CELL RES, V254, P99, DOI 10.1006/excr.1999.4737; Belmokhtar CA, 2001, ONCOGENE, V20, P3354, DOI 10.1038/sj.onc.1204436; Bonnotte B, 1998, J IMMUNOL, V161, P1433; Bonnotte B, 2000, J IMMUNOL, V164, P1995, DOI 10.4049/jimmunol.164.4.1995; CAIGNARD A, 1985, INT J CANCER, V36, P273, DOI 10.1002/ijc.2910360221; Chen DX, 2000, J BIOL CHEM, V275, P38508, DOI 10.1074/jbc.M003906200; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Dumont C, 2000, BLOOD, V96, P1030, DOI 10.1182/blood.V96.3.1030.015k21_1030_1038; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Famulski KS, 1999, CELL DEATH DIFFER, V6, P281, DOI 10.1038/sj.cdd.4400495; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Rovere P, 1998, J IMMUNOL, V161, P4467; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Shaif-Muthana M, 2000, CANCER RES, V60, P6441; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Torriglia A, 2000, ANN NY ACAD SCI, V926, P192; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956	25	13	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6091	6100		10.1038/sj.onc.1205738	http://dx.doi.org/10.1038/sj.onc.1205738			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203121				2022-12-25	WOS:000177671300012
J	Tselepis, C; Perry, I; Dawson, C; Hardy, R; Darnton, SJ; McConkey, C; Stuart, RC; Wright, N; Harrison, R; Jankowski, JAZ				Tselepis, C; Perry, I; Dawson, C; Hardy, R; Darnton, SJ; McConkey, C; Stuart, RC; Wright, N; Harrison, R; Jankowski, JAZ			Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action	ONCOGENE			English	Article						tumour necrosis factor-alpha (TNF-alpha); Barrett's oesophagus; cancer; cadherins and catenins	GROWTH-FACTOR RECEPTOR; BETA-CATENIN; CANCER; ESOPHAGUS; CELLS; INFLAMMATION; EXPRESSION; ADENOCARCINOMA; ACTIVATION; REGULATORS	Barrett's metaplasia (BM) is an early lesion in the progression from oesophageal inflammation through dysplasia to the development of Barrett's adenocarcinoma (BA). Previous work indicates that BM and BA are associated with reduced E-cadherin expression and increased cytoplasmic/nuclear pools of its associated protein beta-catenin. beta-catenin participates in Wnt signalling and activates oncogene transcription by complexing with T-cells factors (TCF). One such oncogene is c-myc. We have previously shown that TNF-alpha can down-regulate E-cadherin expression. Here, we assess TNF-alpha expression in Barrett's metaplasia and examine if TNF-alpha can promote beta-catenin mediated transcription of oncogenes in a gastrointestinal model system. Employing immunohistochemistry and Western blot analysis of oesophageal tissue, epithelial expression of TNF-alpha increases with progression along the metaplasia-dysplasia-carcinoma sequence (P<0.001). beta-catenin mediated transcription was then assessed in TNF-alpha stimulated cell lines using the TOPFLASH reporter system whilst c-myc expression was assessed by real time PCR. In a columnar intestinal cell model, TNF-alpha induces c-myc expression which is induced via beta-catenin mediated transcription (P<0.05). This beta-catenin mediated transcription is independent of NF-kappaB activation. Thus, TNF-alpha is up-regulated in the progression of Barrett's oesophagus and beta-catenin mediated transcription of c-myc is a novel pathway whereby elevated levels of TNF-alpha may lead to oncogene transcription and altered biology in gastrointestinal epithelia and metaplasia.	Univ Birmingham, Queen Elizabeth Hosp, Epithelial Lab, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Queen Elizabeth Hosp, CRVK Lab, Birmingham B15 2TH, W Midlands, England; Birmingham Heartlands Hosp, Oesophageal Res Lab, Birmingham B9 SS, W Midlands, England; Univ Glasgow, Lister Dept Surg, Histopathol Unit, Glasgow G31 2ER, Lanark, Scotland; Imperial Canc Res Fund, London WC2A 3PN, England; Univ Leicester, Dept Med, Leicester LE1 5WW, Leics, England; Univ Leicester, Dept Oncol, Leicester LE1 5WW, Leics, England	University of Birmingham; University of Birmingham; Heart of England NHS Foundation Trust; University of Glasgow; Cancer Research UK; University of Leicester; University of Leicester	Jankowski, JAZ (corresponding author), Leicester Royal Infirm, Dept Med & Oncol, Mycosal Biol Lab, Leicester LE1 5WW, Leics, England.		Jankowski, Janusz/H-2706-2012; Wright, Nicholas/HHY-7227-2022	Jankowski, Janusz/0000-0003-2130-9181; Wright, Nicholas/0000-0002-5525-3457				Bailey T, 1998, AM J PATHOL, V152, P135; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; CAMERON AJ, 1990, GASTROENTEROLOGY, V99, P918, DOI 10.1016/0016-5085(90)90607-3; COTTAM DW, 1993, INT J ONCOL, V2, P861; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Dixon MF, 2001, GUT, V49, P359, DOI 10.1136/gut.49.3.359; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; Frommel TO, 1999, MED HYPOTHESES, V52, P27, DOI 10.1054/mehy.1997.0621; Goldblum JR, 1998, GASTROENTEROLOGY, V114, P633, DOI 10.1016/S0016-5085(98)70576-1; Haller D, 2000, GUT, V47, P79, DOI 10.1136/gut.47.1.79; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Jankowski JA, 2000, LANCET, V356, P2079, DOI 10.1016/S0140-6736(00)03411-5; Jankowski JA, 2002, GASTROENTEROLOGY, V122, P588, DOI 10.1053/gast.2002.31599; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; MENKEPLUYMERS MBE, 1992, GUT, V33, P1454, DOI 10.1136/gut.33.11.1454; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Murthy S, 2000, J BIOL CHEM, V275, P9222, DOI 10.1074/jbc.275.13.9222; NATHKE I, 1999, MOL PATHOL, V52, P166; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Papadakis KA, 2000, GASTROENTEROLOGY, V119, P1148, DOI 10.1053/gast.2000.18160; Perry I, 1999, LAB INVEST, V79, P1489; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Rockett JC, 1997, BRIT J CANCER, V75, P258, DOI 10.1038/bjc.1997.42; Sampliner RE, 1998, AM J GASTROENTEROL, V93, P1028; Schmitz H, 1999, J CELL SCI, V112, P137; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOMAS P, 1997, BRIT J SURG, V84, P110; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X	34	141	148	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6071	6081		10.1038/sj.onc.1205731	http://dx.doi.org/10.1038/sj.onc.1205731			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203119				2022-12-25	WOS:000177671300010
J	Corbi, N; Di Padova, M; De Angelis, R; Bruno, T; Libri, V; Iezzi, S; Floridi, A; Fanciulli, M; Passananti, C				Corbi, N; Di Padova, M; De Angelis, R; Bruno, T; Libri, V; Iezzi, S; Floridi, A; Fanciulli, M; Passananti, C			The alpha-like RNA polymerase II core subunit 3 (RPB3) is involved in tissue-specific transcription and muscle differentiation via interaction with the myogenic factor myogenin	FASEB JOURNAL			English	Article						pol II subunits; doxorubicin; yeast two hybrid	YEAST; DOXORUBICIN; MYOD; INTERFERENCE; ADRIAMYCIN; PROTEINS; MUTATION; FAMILY	RNA polymerase II core subunit 3 (RPB3) is an alpha-like core subunit of RNA polymerase II (pol II). It is selectively down-regulated upon treatment with doxorubicin (dox). Due to the failure of skeletal muscle cells to differentiate when exposed to dox, we hypothesized that RPB3 is involved in muscle differentiation. To this end, we have isolated human muscle RPB3-interacting proteins by using yeast two-hybrid screening. It is of interest that an interaction between RPB3 and the myogenic transcription factor myogenin was identified. This interaction involves a specific region of RPB3 protein that is not homologous to the prokaryotic alpha subunit. Although RPB3 contacts the basic helix-loop-helix (HLH) region of myogenin, it does not bind other HLH myogenic factors such as MyoD, Myf5, and MRF4. Coimmunoprecipitation experiments indicate that myogenin contacts the pol II complex and that the RPB3 subunit is responsible for this interaction. We show that RPB3 expression is regulated during muscle differentiation. Exogenous expression of RPB3 slightly promotes myogenin transactivation activity and muscle differentiation, whereas the region of RPB3 that contacts myogenin, when used as a dominant negative molecule (Sud), counteracts these effects. These results indicate for the first time that the RPB3 pol II subunit is involved in the regulation of tissue-specific transcription.	CNR, Ist Tecnol Biomed, I-00137 Rome, Italy; Regina Elena Inst Canc Res, Cell Metab & Pharmacokinet Lab, I-00158 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of L'Aquila	Passananti, C (corresponding author), CNR, Ist Tecnol Biomed, Viale Marx 43, I-00137 Rome, Italy.	passananti@itbm.rm.cnr.it	Iezzi, Simona/AAA-3275-2021; Corbi, Nicoletta/AAW-8835-2020; Corbi, Nicoletta/K-2313-2014; bruno, tiziana/AAC-4913-2022; Passananti, Claudio/K-9593-2016; fanciulli, maurizio/ABH-6745-2020	Iezzi, Simona/0000-0002-7484-5861; bruno, tiziana/0000-0003-0352-4523; DI PADOVA, Monica/0000-0003-3808-7159; PASSANANTI, CLAUDIO/0000-0002-9288-5736; CORBI, NICOLETTA/0000-0002-4505-1632; Libri, Valentina/0000-0002-2080-1089	Telethon [A.160] Funding Source: Medline	Telethon(Fondazione Telethon)		AZUMA Y, 1993, NUCLEIC ACIDS RES, V21, P3749, DOI 10.1093/nar/21.16.3749; Bergstrom DA, 2001, MOL CELL BIOL, V21, P2404, DOI 10.1128/MCB.21.7.2404-2412.2001; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Biesiada E, 1999, MOL CELL BIOL, V19, P2577; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DOROSHOW JH, 1983, CANCER RES, V43, P4543; Fanciulli M, 1998, FEBS LETT, V427, P236, DOI 10.1016/S0014-5793(98)00431-1; Fanciulli M, 1996, FEBS LETT, V384, P48, DOI 10.1016/0014-5793(96)00277-3; FORNARI FA, 1994, MOL PHARMACOL, V45, P649; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Groisman R, 1996, J BIOL CHEM, V271, P5258; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Ishihama A, 1981, Adv Biophys, V14, P1; Kimura M, 1997, J BIOL CHEM, V272, P25851, DOI 10.1074/jbc.272.41.25851; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; Korobko IV, 1997, GENE, V185, P1, DOI 10.1016/S0378-1119(96)00626-9; KURABAYASHI M, 1993, J BIOL CHEM, V268, P5524; KURABAYASHI M, 1994, J BIOL CHEM, V269, P6031; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; Larkin RM, 1997, J BIOL CHEM, V272, P12824, DOI 10.1074/jbc.272.19.12824; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MAIONE R, 1997, BIOCHIM BIOPHYS ACTA, V1332, P19; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MOLTENKIN JD, 1995, CELL, V83, P1125; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON E, 1992, SYM SOC EXP BIOL, V46, P331; PATI UK, 1994, GENE, V145, P289, DOI 10.1016/0378-1119(94)90022-1; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rawls A, 1998, DEVELOPMENT, V125, P2349; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Schneider S, 1996, BIOTECHNIQUES, V20, P960; SIEGFRIED JA, 1983, J BIOL CHEM, V258, P339; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; Tan Q, 2000, GENE DEV, V14, P339; TREICH I, 1991, J BIOL CHEM, V266, P21971; Ulmasov T, 1996, J BIOL CHEM, V271, P5085, DOI 10.1074/jbc.271.9.5085; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Woychik Nancy A., 1993, Gene Expression, V3, P77; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; Yasui K, 1998, BIOCHEMISTRY-US, V37, P5542, DOI 10.1021/bi972939b; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; YU YJ, 1994, MUTAT RES LETT, V325, P91, DOI 10.1016/0165-7992(94)90007-8; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	50	21	21	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1639	+		10.1096/fj.02-0123fje	http://dx.doi.org/10.1096/fj.02-0123fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207009				2022-12-25	WOS:000177814000018
J	Harteneck, C; Kuchta, SN; Huber, A; Paulsen, R; Schultz, G				Harteneck, C; Kuchta, SN; Huber, A; Paulsen, R; Schultz, G			The PDZ-scaffold protein INAD abolishes apparent store-dependent regulation of the light-activated cation channel TRP	FASEB JOURNAL			English	Article						photoreceptors; TRP channels; PDZ proteins	DROSOPHILA TRP; SIGNALING COMPLEXES; DOMAIN PROTEIN; CA2+ CHANNEL; VISUAL TRANSDUCTION; INSP(3) RECEPTOR; KINASE-C; PHOTORECEPTORS; BINDING; GENE	In fly photoreceptor cells, light initiates a G protein-coupled phospholipase Cbeta-dependent signaling cascade that results in the depolarization of the cell membrane, which is mediated by the cation channels TRP and TRPL. Together with phospholipase Cbeta and an eye-specific protein kinase C, TRP is tethered to the scaffolding protein INAD, which forms a multimolecular signaling complex. Divergent data from expressed TRP and studies from photoreceptor cells have brought up a controversy whether or not a capacitative calcium entry (CCE) mechanism is involved in the Drosophila phototransduction pathway. Our initial characterization of TRP from photoreceptors of Calliphora vicina supported the hypothesis of a CCE mechanism, as heterologously expressed TRP was stimulated after application of thapsigargin. The situation changed when the PDZ domain protein INAD was coexpressed with TRP. In cells coexpressing TRP and INAD, no calcium entry was detectable on application of store depletion protocols. Suppression of CCE by INAD was not observed when the described interaction was disrupted by mutations in TRP and INAD. Our data show that apparent activation of TRP by CCE is abolished by INAD. Within the complex, the proteins necessary for phototransduction mutually influence their activities. The results support the hypothesis of a store-independent activation of TRP.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany; Univ Karlsruhe, Inst Zool, Abt Zellbiol & Neurobiol, D-76131 Karlsruhe, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Karlsruhe Institute of Technology	Harteneck, C (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.	hartenek@zedat.fu-berlin.de		Huber, Armin/0000-0003-3977-089X				Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; Adamski FM, 1998, J BIOL CHEM, V273, P17713, DOI 10.1074/jbc.273.28.17713; Bahner M, 2002, NEURON, V34, P83, DOI 10.1016/S0896-6273(02)00630-X; Bahner M, 2000, J BIOL CHEM, V275, P2901, DOI 10.1074/jbc.275.4.2901; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Cook B, 1999, CELL CALCIUM, V25, P161, DOI 10.1054/ceca.1998.0018; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; Gillo B, 1996, J PHOTOCH PHOTOBIO B, V35, P77, DOI 10.1016/1011-1344(96)07303-4; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; Hardie RC, 1996, CELL CALCIUM, V20, P315, DOI 10.1016/S0143-4160(96)90037-8; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Hardie RC, 2001, NATURE, V413, P186, DOI 10.1038/35093002; HARTENECK C, 1995, FEBS LETT, V358, P297, DOI 10.1016/0014-5793(94)01455-A; Huber A, 1996, J BIOL CHEM, V271, P11710, DOI 10.1074/jbc.271.20.11710; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; Huber A, 2001, EUR J NEUROSCI, V14, P769, DOI 10.1046/j.0953-816x.2001.01704.x; Kumar R, 2001, J BIOL CHEM, V276, P24971, DOI 10.1074/jbc.M103570200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li HS, 2000, J CELL BIOL, V150, P1411, DOI 10.1083/jcb.150.6.1411; Minke B, 1996, MOL NEUROBIOL, V12, P163, DOI 10.1007/BF02740652; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; Paulsen R, 2000, PFLUG ARCH EUR J PHY, V439, pR181, DOI 10.1007/s004240000138; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Raghu P, 2000, MOL CELL NEUROSCI, V15, P429, DOI 10.1006/mcne.2000.0846; RANGANATHAN R, 1994, NEURON, V13, P837, DOI 10.1016/0896-6273(94)90250-X; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Sinkins WG, 1996, J BIOL CHEM, V271, P2955, DOI 10.1074/jbc.271.6.2955; Tsunoda S, 1999, CELL CALCIUM, V26, P165, DOI 10.1054/ceca.1999.0070; Tsunoda S, 2001, J NEUROSCI, V21, P150, DOI 10.1523/JNEUROSCI.21-01-00150.2001; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Wes PD, 1999, NAT NEUROSCI, V2, P447, DOI 10.1038/8116; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	45	8	9	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1668	+		10.1096/fj.02-0192fje	http://dx.doi.org/10.1096/fj.02-0192fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206995	Bronze			2022-12-25	WOS:000177814000007
J	Romerio, F; Zella, D				Romerio, F; Zella, D			MEK and ERK inhibitors enhance the antiproliferative effect of interferon-alpha 2b	FASEB JOURNAL			English	Article						signal transduction; cancer; T lymphocytes	ACTIVATED PROTEIN-KINASE; T-CELL PROLIFERATION; DEPENDENT KINASE; GROWTH-FACTOR; PHOTODYNAMIC THERAPY; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; IN-VITRO; ALPHA; ARREST	Interferon (IFN)-alpha, initially characterized as an antiviral cytokine, affects several cellular functions. It is used in clinical practice for the treatment of several tumors, including hematopoietic malignancies, due to its antiproliferative effects. To better characterize the molecular mechanism(s) underlying this property, we conducted our studies in purified primary CD4+ T cells stimulated with anti-CD3 and interleukin (IL)-2. Upon treatment with IFN-alpha, the cells were blocked in the G0/G1 phase of the cell cycle and exhibited impaired entry into S phase and reduced proliferation. Moreover, we detected short- and long-term inhibition of extracellular signal-regulated kinase (ERK) and mitogen-activated ERK-regulating kinase (MEK) function, known to control cellular proliferation. The activity of the upstream regulators, Ras and Raf-1, was not affected. Analysis of downstream events controlled by the MEK/ERK pathway showed reduced activity of cyclin-dependent kinase (Cdk)-2 and -4, high levels of the mitotic inhibitors, p21(Waf1) and p27(Kip1), and decreased cyclin D and E expression. When IFN-alpha was used in combination with MEK and ERK inhibitors, we observed a dose-dependent additive effect in reducing cellular proliferation. Our data demonstrate that IFN-alpha may be associated with other molecules to inhibit cellular growth by targeting the MEK/ERK pathway. This may eventually lead to new clinical strategies to strengthen its anticancer effect.	Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Zella, D (corresponding author), Univ Maryland, Inst Biotechnol, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA.	zella@umbi.umd.edu	ZELLA, DAVIDE/AAC-7630-2020	ZELLA, DAVIDE/0000-0001-5576-5770				AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; Alecu M, 1998, ANTICANCER RES, V18, P4651; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arora T, 1999, J IMMUNOL, V162, P3289; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Baumgarth N, 1997, J IMMUNOL, V159, P1182; BORDEN EC, 1997, CANC MED, P1199; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; BRUNET A, 1994, ONCOGENE, V9, P3379; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; Chen B, 2000, CANCER LETT, V150, P111, DOI 10.1016/S0304-3835(99)00381-X; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DeSilva DR, 1996, J EXP MED, V183, P2017, DOI 10.1084/jem.183.5.2017; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Erickson S, 1999, CELL GROWTH DIFFER, V10, P575; Essayan DM, 1999, J ALLERGY CLIN IMMUN, V103, P451, DOI 10.1016/S0091-6749(99)70470-7; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Herberman Ronald B., 1997, Seminars in Oncology, V24, P78; Hulleman E, 1999, J CELL PHYSIOL, V180, P325, DOI 10.1002/(SICI)1097-4652(199909)180:3<325::AID-JCP3>3.0.CO;2-R; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KLIMPEL GR, 1990, CELL IMMUNOL, V128, P603, DOI 10.1016/0008-8749(90)90052-S; Krishnaswamy G, 1996, J INTERF CYTOK RES, V16, P819, DOI 10.1089/jir.1996.16.819; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; Lund TC, 1999, CELL IMMUNOL, V192, P133, DOI 10.1006/cimm.1999.1466; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; OKAZAKI K, 1995, ONCOGENE, V10, P1149; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; Pfeffer LM, 1998, CANCER RES, V58, P2489; Porras A, 1998, MOL ENDOCRINOL, V12, P825, DOI 10.1210/me.12.6.825; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; Romerio F, 2000, BRIT J CANCER, V83, P532, DOI 10.1054/bjoc.2000.1263; RUBINSTEIN S, 1981, J VIROL, V37, P755, DOI 10.1128/JVI.37.2.755-758.1981; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Subramaniam PS, 1998, ONCOGENE, V16, P1885, DOI 10.1038/sj.onc.1201712; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; Tachibana K, 1997, EMBO J, V16, P4333, DOI 10.1093/emboj/16.14.4333; TAKAHASHI I, 1989, J ANTIBIOT, V42, P153; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3851, DOI 10.1073/pnas.95.7.3851; Zella D, 1999, J IMMUNOL, V163, P3169; Zella D, 2000, J IMMUNOL, V164, P2296, DOI 10.4049/jimmunol.164.5.2296; Zhang W, 1996, NEUROSURGERY, V38, P587, DOI 10.1097/00006123-199603000-00035; ZHANG Y, 1999, CRYST ENG, V2, P1	64	53	61	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1680	+		10.1096/fj.02-0120fje	http://dx.doi.org/10.1096/fj.02-0120fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206994				2022-12-25	WOS:000177814000003
J	Warren, GL; Hulderman, T; Jensen, N; McKinstry, M; Mishra, M; Luster, MI; Simeonova, PP				Warren, GL; Hulderman, T; Jensen, N; McKinstry, M; Mishra, M; Luster, MI; Simeonova, PP			Physiological role of tumor necrosis factor alpha in traumatic muscle injury	FASEB JOURNAL			English	Article						muscle function; inflammation; inflammatory cytokines	CONTRACTION-INDUCED INJURY; MURINE SKELETAL-MUSCLE; TNF-ALPHA; KAPPA-B; ECCENTRIC CONTRACTIONS; INDUCED HEPATOTOXICITY; CONTUSION INJURY; SATELLITE CELLS; BALB/C MICE; DIFFERENTIATION	The degenerative and regenerative roles of tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory cytokine with pleiotropic functions, were investigated by using TNF receptor 1 and 2 double knockout (TNFR-DKO) and TNF-alpha antibody neutralized mice following traumatic freeze injury to the tibialis anterior muscle. In wild-type control mice, TNF-alpha mRNA transcripts and protein increased following injury and gradually returned to control (uninjured) levels by 13 days. A reduction in MyoD mRNA expression occurred in TNF-alpha-deficient mice, although there were no visible differences in MyoD immunostaining or histological characteristics in regenerating muscles. At 5 days post-injury, the reductions in isometric strength in TNFR-DKO and TNF-alpha-depleted mice did not differ from that of wild-type mice but by 13 days after injury, the TNFR-DKO and TNF-alpha depleted mice exhibited strength deficits twice that of wild-type mice (i.e., 27-31% vs 13%). Muscle injury was also accompanied by increased expression of interleukin-6 (IL-6), but IL-6-deficient mice demonstrated MyoD expression and recovery of isometric strength similar to that of wild-type mice. These data indicate that TNF-alpha is involved in the recovery of muscle function after traumatic muscle injury, and this effect might be associated with modulation of muscle regulatory genes, including MyoD.	NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA; Georgia State Univ, Dept Phys Therapy, Atlanta, GA 30303 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); University System of Georgia; Georgia State University	Simeonova, PP (corresponding author), NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA.	phs9@cdc.gov	Warren, Gordon/A-9794-2008	Warren, Gordon/0000-0002-7073-8524				AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; Alloatti G, 2000, AM J PHYSIOL-REG I, V279, pR2156, DOI 10.1152/ajpregu.2000.279.6.R2156; ANDERSON JE, 1995, EXP CELL RES, V216, P325, DOI 10.1006/excr.1995.1041; Beiner JM, 1999, AM J SPORT MED, V27, P2, DOI 10.1177/03635465990270011101; Bruccoleri A, 1997, HEPATOLOGY, V25, P133, DOI 10.1002/hep.510250125; CANTINI M, 1994, BIOCHEM BIOPH RES CO, V202, P1688, DOI 10.1006/bbrc.1994.2129; CANTINI M, 1995, J NEUROPATH EXP NEUR, V54, P121, DOI 10.1097/00005072-199501000-00014; Collins RA, 2001, J HISTOCHEM CYTOCHEM, V49, P989, DOI 10.1177/002215540104900807; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRISCO JJ, 1994, AM J SPORT MED, V22, P702, DOI 10.1177/036354659402200521; Gallucci RM, 2000, FASEB J, V14, P2525, DOI 10.1096/fj.00-0073com; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; KAYAMA F, 1995, TOXICOL APPL PHARM, V131, P224, DOI 10.1006/taap.1995.1065; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Li YP, 2001, FASEB J, V15, P1413, DOI 10.1096/fj.00-0632fje; Li YP, 2001, CURR OPIN RHEUMATOL, V13, P483, DOI 10.1097/00002281-200111000-00005; LOWE DA, 1995, J APPL PHYSIOL, V79, P1260, DOI 10.1152/jappl.1995.79.4.1260; Luster MI, 1999, CRIT REV TOXICOL, V29, P491, DOI 10.1080/10408449991349258; Massimino ML, 1997, BIOCHEM BIOPH RES CO, V235, P754, DOI 10.1006/bbrc.1997.6823; Merly F, 1999, MUSCLE NERVE, V22, P724, DOI 10.1002/(SICI)1097-4598(199906)22:6<724::AID-MUS9>3.0.CO;2-O; MITCHELL CA, 1992, CELL TISSUE RES, V269, P159, DOI 10.1007/BF00384736; Pavlath GK, 1998, DEV DYNAM, V212, P495, DOI 10.1002/(SICI)1097-0177(199808)212:4<495::AID-AJA3>3.3.CO;2-I; RALPH P, 1983, J IMMUNOL, V130, P108; ROBERTSON TA, 1992, J ANAT, V181, P265; Spencer MJ, 2000, NEUROMUSCULAR DISORD, V10, P612, DOI 10.1016/S0960-8966(00)00160-7; Szalay K, 1997, EUR J CELL BIOL, V74, P391; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Warren G L, 2001, Exerc Sport Sci Rev, V29, P82; Warren GL, 1998, J APPL PHYSIOL, V84, P2171, DOI 10.1152/jappl.1998.84.6.2171; Warren GL, 1999, SPORTS MED, V27, P43, DOI 10.2165/00007256-199927010-00004; Warren GL, 1999, J PHYSIOL-LONDON, V515, P609, DOI 10.1111/j.1469-7793.1999.609ac.x; Warren GL, 2000, MED SCI SPORT EXER, V32, P820, DOI 10.1097/00005768-200004000-00015; WILCOX PG, 1994, AM J RESP CRIT CARE, V150, P1368, DOI 10.1164/ajrccm.150.5.7952566; Zador E, 2001, MUSCLE NERVE, V24, P1058, DOI 10.1002/mus.1110; Zhang Minghuang, 1998, P517	38	175	191	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1630	+		10.1096/fj.02-0187fje	http://dx.doi.org/10.1096/fj.02-0187fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207010				2022-12-25	WOS:000177814000014
J	Cattaruzza, S; Schiappacassi, M; Ljungberg-Rose, A; Spessotto, P; Perissinotto, D; Morgelin, M; Mucignat, MT; Colombatti, A; Perris, R				Cattaruzza, S; Schiappacassi, M; Ljungberg-Rose, A; Spessotto, P; Perissinotto, D; Morgelin, M; Mucignat, MT; Colombatti, A; Perris, R			Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; SMOOTH-MUSCLE CELLS; HYALURONAN-BINDING PROTEOGLYCANS; LARGE AGGREGATING PROTEOGLYCAN; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; BOVINE AORTA; FETAL SKIN; VERSICAN; AGGRECAN	We have carried out a comprehensive molecular mapping of PG-M/versican isoforms V0-V3 in adult human tissues and have specifically investigated how the expression of these isoforms is regulated in endothelial cells in vitro. A survey of 21 representative tissues highlighted a prevalence of V1 mRNA, demonstrated that the relative frequency of expression was V1>V2>V3greater than or equal toV2; and showed that <15% of the tissues transcribed significant levels of all four isoforms. By employing novel and previously described anti-versican antibodies we verified a ubiquitous versican deposition in normal and tumor-associated vascular structures and disclosed differences in the glycanation profiles of versicans produced in different vascular beds. Resting endothelial cells isolated from different tissue sources transcribed several of the versican isoforms but consistently failed to translate these mRNAs into detectable proteoglycans. However, if stimulated with tumor necrosis factor-alpha or vascular endothelial growth factor, they altered their versican expression by de novo transcribing the V3 isoform and by exhibiting a moderate V1/V2 production. Induced versican synthesis and de novo V3 expression was also observed in endothelial cells elicited to migrate in a wound-healing model in vitro and in angiogenic endothelial cells forming tubule-like structures in Matrigel or fibrin clots. The results suggest that, independent of the degree of vascularization, human adult tissues show a limited expression of versican isoforms V0, V2, and V3 and that endothelial cells may contribute to the deposition of versican in vascular structures, but only following proper stimulation.	Univ Parma, Dept Evolutionary & Funct Biol, I-43100 Parma, Italy; Natl Canc Inst, Ctr Riferimento Oncol, Inst Ric & Cura Carattere Sci, Div Expt Oncol 2, I-33081 Aviano, Italy; Lund Univ, Dept Cell & Mol Biol, S-22100 Lund, Sweden; Univ Udine, Dept Tech & Biomed Sci, I-35100 Padua, Italy; Univ Udine, Micrograv Aging Training & Immobil Ctr Excellence, I-35100 Padua, Italy	University of Parma; IRCCS Aviano (CRO); Lund University; University of Udine; University of Udine	Perris, R (corresponding author), Univ Parma, Dept Evolutionary & Funct Biol, Viale Sci 11-A, I-43100 Parma, Italy.	rperris@cro.it	Mucignat, Maria Teresa/AAY-3908-2020; Schiappacassi, Monica/AAX-5505-2020; Spessotto, Paola/K-5005-2012	Mucignat, Maria Teresa/0000-0002-9601-054X; Schiappacassi, Monica/0000-0003-4804-4291; Spessotto, Paola/0000-0002-3033-404X; colombatti, alfonso/0000-0002-3676-2379				ASHER R, 1991, J NEUROSCI RES, V28, P410, DOI 10.1002/jnr.490280314; Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; CARRINO DA, 1994, BIOCHEM J, V298, P51, DOI 10.1042/bj2980051; DALFERES ER, 1987, EXP MOL PATHOL, V47, P363, DOI 10.1016/0014-4800(87)90019-0; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; Eriksen GV, 1999, BIOCHEM J, V340, P613, DOI 10.1042/0264-6021:3400613; Evanko SP, 1998, AM J PATHOL, V152, P533; HABUCHI H, 1986, J BIOL CHEM, V261, P1031; Henderson DJ, 1998, CIRC RES, V83, P523, DOI 10.1161/01.RES.83.5.523; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Isogai Z, 1996, CANCER RES, V56, P3902; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; KAPOOR R, 1986, BIOCHEM J, V240, P575, DOI 10.1042/bj2400575; KIMATA K, 1986, J BIOL CHEM, V261, P3517; LANDOLT RM, 1995, ANAL BIOCHEM, V155, P275; LARK MW, 1988, J HISTOCHEM CYTOCHEM, V36, P1211, DOI 10.1177/36.10.3047228; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Lee RT, 2001, J BIOL CHEM, V276, P13847, DOI 10.1074/jbc.M010556200; Lemire JM, 2002, J CELL PHYSIOL, V190, P38, DOI 10.1002/jcp.10043; Lemire JM, 1999, ARTERIOSCL THROM VAS, V19, P1630, DOI 10.1161/01.ATV.19.7.1630; Matsuura R, 1996, J PATHOL, V180, P311, DOI 10.1002/(SICI)1096-9896(199611)180:3<311::AID-PATH657>3.0.CO;2-B; MAZZUCATO M, 2002, IN PRESS FASEB J; MCMURTREY J, 1979, J BIOL CHEM, V254, P1621; Merrilees MJ, 2002, CIRC RES, V90, P481, DOI 10.1161/hh0402.105791; Milev P, 1998, BIOCHEM BIOPH RES CO, V247, P207, DOI 10.1006/bbrc.1998.8759; MORITA H, 1990, BIOCHEM J, V265, P61, DOI 10.1042/bj2650061; OEGEMA TR, 1979, J BIOL CHEM, V254, P1312; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; PERIDES G, 1992, J BIOL CHEM, V267, P23883; Perissinotto D, 2000, DEVELOPMENT, V127, P2823; RIESSEN R, 1994, AM J PATHOL, V144, P962; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Schmalfeldt M, 1998, J BIOL CHEM, V273, P15758, DOI 10.1074/jbc.273.25.15758; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; SHINOMURA T, 1995, J BIOL CHEM, V270, P10328, DOI 10.1074/jbc.270.17.10328; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; Sorrell JM, 1999, ANAT EMBRYOL, V199, P45, DOI 10.1007/s004290050208; Stigson M, 1997, J BIOL CHEM, V272, P3246, DOI 10.1074/jbc.272.6.3246; TAN EML, 1991, LAB INVEST, V64, P474; Tufvesson E, 2000, J CELL BIOCHEM, V77, P298, DOI 10.1002/(SICI)1097-4644(20000501)77:2<298::AID-JCB12>3.0.CO;2-D; Wight TN, 1997, AM J PATHOL, V151, P963; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; Zako M, 1997, J BIOL CHEM, V272, P9325, DOI 10.1074/jbc.272.14.9325; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	49	99	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47626	47635		10.1074/jbc.M206521200	http://dx.doi.org/10.1074/jbc.M206521200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12221092	hybrid			2022-12-25	WOS:000179663700103
J	Dunty, JM; Schaller, MD				Dunty, JM; Schaller, MD			The N termini of focal adhesion kinase family members regulate substrate phosphorylation, localization, and cell morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ACTIN CYTOSKELETON; GROWTH-FACTOR; STABLE ASSOCIATION; ANGIOTENSIN-II; FERM DOMAIN; PYK2; SRC; FAK; CALCIUM	The focal adhesion kinase (FAK) and cell adhesion kinase beta (CAKbeta, PYK2, CADTK, RAFTK) are highly homologous FAK family members, yet clearly have unique roles in the cell. Comparative analyses of FAK and CAKbeta have revealed intriguing differences in their activities. These differences were investigated further through the characterization of a set of FAF/CAKbeta chimeric kinases. CAKbeta exhibited greater catalytic activity than FAK in vitro, providing a molecular basis for differential substrate phosphorylation by FAK and CAKbeta in vivo. Furthermore, the N terminus may regulate catalytic activity since chimeras containing the FAK N terminus and CAKbeta catalytic domain exhibited a striking high level of catalytic activity and substrate phosphorylation. Unexpectedly, a modulatory role for the N termini in subcellular localization was also revealed. Chimeras containing the FAK N terminus and CAKbeta C terminus localized to focal adhesions, whereas chimeras containing the N and C termini of CAKbeta did not. Finally, prominent changes in cell morphology were induced upon expression of chimeras containing the CAKbeta N terminus, which were not associated with apoptotic cell death, cell cycle progression delay, or changes in Rho activity. These results demonstrate novel regulatory roles for the N terminus of FAK family kinases.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Schaller, MD (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, CB7090, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA090901] Funding Source: NIH RePORTER; NCI NIH HHS [CA90901] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreev J, 1999, MOL CELL BIOL, V19, P2338; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Du QS, 2001, J CELL SCI, V114, P2977; Duong LT, 2001, J BIOL CHEM, V276, P7484, DOI 10.1074/jbc.M008368200; Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gabarra-Niecko V, 2002, BIOCHEM J, V365, P591, DOI 10.1042/BJ20020065; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Ivankovic-Dikic I, 2000, NAT CELL BIOL, V2, P574, DOI 10.1038/35023515; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; Park SY, 2000, J BIOL CHEM, V275, P19768, DOI 10.1074/jbc.M909932199; Ren XD, 2000, J CELL SCI, V113, P3673; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1996, J ENDOCRINOL, V150, P1, DOI 10.1677/joe.0.1500001; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Watson JM, 2001, J BIOL CHEM, V276, P3536, DOI 10.1074/jbc.M006916200; Williams LM, 2000, J IMMUNOL, V164, P2028, DOI 10.4049/jimmunol.164.4.2028; Xiong WC, 1998, J CELL SCI, V111, P1981; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zhao JH, 2000, J CELL SCI, V113, P3063; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7	68	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45644	45654		10.1074/jbc.M201779200	http://dx.doi.org/10.1074/jbc.M201779200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223467	Green Published, hybrid			2022-12-25	WOS:000179404800131
J	Lantto, J; Ohlin, M				Lantto, J; Ohlin, M			Functional consequences of insertions and deletions in the complementarity-determining regions of human antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATIC HYPERMUTATION; ANTIGEN INTERACTIONS; STRUCTURAL REPERTOIRE; FRAMEWORK RESIDUE-71; HYPERVARIABLE LOOPS; RECEPTOR REVISION; IMMUNE-RESPONSE; B-LYMPHOCYTES; BINDING-SITE; HEAVY	Insertions and deletions of nucleotides in the genes encoding the variable domains of antibodies are natural components of the hypermutation process, which may expand the available repertoire of hypervariable loop lengths and conformations. Although insertion of amino acids has also been utilized in antibody engineering, little is known about the functional consequences of such modifications. To investigate this further, we have introduced single-codon insertions and deletions as well as more complex modifications in the complementarity-determining regions of human antibody fragments with different specificities. Our results demonstrate that single amino acid insertions and deletions are generally well tolerated and permit production of stably folded proteins, often with retained antigen recognition, despite the fact that the thus modified loops carry amino acids that are disallowed at key residue positions in canonical loops of the corresponding length or are of a length not associated with a known canonical structure. We have thus shown that single-codon insertions and deletions can efficiently be utilized to expand structure and sequence space of the antigen-binding site beyond what is encoded by the germline gene repertoire.	Lund Univ, Dept Immunotechnol, S-22007 Lund, Sweden	Lund University	Ohlin, M (corresponding author), Lund Univ, Dept Immunotechnol, POB 7031, S-22007 Lund, Sweden.		Ohlin, Mats/A-7307-2010	Ohlin, Mats/0000-0002-5105-1938; Lantto, Johan/0000-0002-8650-7157				AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; Brezinschek HP, 1997, J CLIN INVEST, V99, P2488, DOI 10.1172/JCI119433; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; de Wildt RMT, 1999, J MOL BIOL, V285, P895, DOI 10.1006/jmbi.1998.2396; de Wildt RMT, 1999, J MOL BIOL, V294, P701, DOI 10.1006/jmbi.1999.3289; Ellmark P, 2002, MOL IMMUNOL, V39, P349, DOI 10.1016/S0161-5890(02)00109-8; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; HELMS LR, 1995, PROTEIN SCI, V4, P2073, DOI 10.1002/pro.5560041012; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Itoh K, 2000, J EXP MED, V192, P1151, DOI 10.1084/jem.192.8.1151; Jirholt P, 2001, PROTEIN ENG, V14, P67, DOI 10.1093/protein/14.1.67; Jirholt P, 1998, GENE, V215, P471, DOI 10.1016/S0378-1119(98)00317-5; Lamminmaki U, 1999, J MOL BIOL, V291, P589, DOI 10.1006/jmbi.1999.2981; Lantto J, 2002, J GEN VIROL, V83, P2001, DOI 10.1099/0022-1317-83-8-2001; Lantto J, 2002, EUR J IMMUNOL, V32, P1659, DOI 10.1002/1521-4141(200206)32:6<1659::AID-IMMU1659>3.0.CO;2-9; Lantto J, 2002, J MOL EVOL, V54, P346, DOI 10.1007/s00239-001-0049-2; LANTTO J, 2002, IN PRESS VIROLOGY; Lantto Johan, 2002, Methods Mol Biol, V178, P303; Lefranc MP, 2001, NUCLEIC ACIDS RES, V29, P207, DOI 10.1093/nar/29.1.207; MacCallum RM, 1996, J MOL BIOL, V262, P732, DOI 10.1006/jmbi.1996.0548; Martin ACR, 1996, J MOL BIOL, V263, P800, DOI 10.1006/jmbi.1996.0617; McGrew JT, 1997, GENE, V187, P193, DOI 10.1016/S0378-1119(96)00747-0; McMahon MJ, 2000, J IMMUNOL METHODS, V241, P1, DOI 10.1016/S0022-1759(00)00196-4; Nemazee D, 2000, J EXP MED, V191, P1813, DOI 10.1084/jem.191.11.1813; Noppe SM, 1999, BRIT J HAEMATOL, V107, P625, DOI 10.1046/j.1365-2141.1999.01732.x; OHLIN M, 1993, J VIROL, V67, P703, DOI 10.1128/JVI.67.2.703-710.1993; Ohlin M, 1996, MOL IMMUNOL, V33, P47, DOI 10.1016/0161-5890(95)00123-9; Ohlin M, 1998, MOL IMMUNOL, V35, P233, DOI 10.1016/S0161-5890(98)00030-3; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Parhami-Seren B, 2002, J IMMUNOL METHODS, V259, P43, DOI 10.1016/S0022-1759(01)00488-4; Soderlind E, 2000, NAT BIOTECHNOL, V18, P852, DOI 10.1038/78458; TOMLINSON IM, 1995, EMBO J, V14, P4628, DOI 10.1002/j.1460-2075.1995.tb00142.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAMONTANO A, 1990, J MOL BIOL, V215, P175, DOI 10.1016/S0022-2836(05)80102-0; VARGASMADRAZO E, 1995, J MOL BIOL, V254, P497, DOI 10.1006/jmbi.1995.0633; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; Whitelegg NRJ, 2000, PROTEIN ENG, V13, P819, DOI 10.1093/protein/13.12.819; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; Wilson PC, 2000, J EXP MED, V191, P1881, DOI 10.1084/jem.191.11.1881; Wilson PC, 1998, J EXP MED, V187, P59, DOI 10.1084/jem.187.1.59; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; XIANG J, 1995, J MOL BIOL, V253, P385, DOI 10.1006/jmbi.1995.0560	44	16	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45108	45114		10.1074/jbc.M208401200	http://dx.doi.org/10.1074/jbc.M208401200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237318	hybrid			2022-12-25	WOS:000179404800067
J	Morris, MT; Coppin, A; Tomavo, S; Carruthers, VB				Morris, MT; Coppin, A; Tomavo, S; Carruthers, VB			Functional analysis of Toxoplasma gondii protease inhibitor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITOPHOROUS VACUOLE MEMBRANE; PROTEINASE-INHIBITORS; MOLECULAR CHARACTERIZATION; POLYACRYLAMIDE-GELS; MYXOMA VIRUS; TRYPSIN; COMPLEX; SECRETION; MECHANISM; SERPIN	We have characterized a Kazal family serine protease inhibitor, Toxoplasma gondii protease inhibitor 1 (TgPI-1), in the obligate intracellular parasite Toxoplasma gondii. TgPI-1 contains four inhibitor domains predicted to inhibit trypsin, chymotrypsin, and elastase. Antibodies against recombinant TgPI-1 detect two polypeptides, of 43 and 41 kDa, designated TgPI-1(43) and TgPI-1(41), in tachyzoites, bradyzoites, and sporozoites. TgPI-1(43) and TgPI-1(41) are secreted constitutively from dense granules into the excreted/secreted antigen fraction as well as the parasitophorous vacuole that T. gondii occupies during intracellular replication. Recombinant TgPI-1 inhibits trypsin, chymotrypsin, pancreatic elastase, and neutrophil elastase. Immunoprecipitation studies with anti-rTgPI-1 antibodies reveal that recombinant TgPI-1 forms a complex with trypsin that is dependent on interactions with the active site of the pro- tease. TgPI-1 is the first anti-trypsin/chymotrypsin inhibitor to be identified in bradyzoites and sporozoites, stages of the parasite that would be exposed to proteolytic enzymes in the digestive tract of the host.	Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Univ Sci & Technol Lille, CNRS, Chim Biol Lab, UMR 8576, F-59655 Villeneuve Dascq, France	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Carruthers, VB (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, 615 N Wolfe St, Baltimore, MD 21205 USA.	vcarruth@jhsph.edu		Carruthers, Vern/0000-0001-6859-8895	NIAID NIH HHS [AI074417-06, R01 AI046675] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI074417, R01AI046675, R56AI074417] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Black MW, 2000, MICROBIOL MOL BIOL R, V64, P607, DOI 10.1128/MMBR.64.3.607-623.2000; Bliss SK, 2001, INFECT IMMUN, V69, P4898, DOI 10.1128/IAI.69.8.4898-4905.2001; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Brydges SD, 2000, MOL BIOCHEM PARASIT, V111, P51, DOI 10.1016/S0166-6851(00)00296-6; Carruthers VB, 2000, J BIOL CHEM, V275, P14346, DOI 10.1074/jbc.275.19.14346; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; CARTER AO, 1986, CAN MED ASSOC J, V135, P618; CESBRONDELAUW MF, 1993, RES IMMUNOL, V144, P41, DOI 10.1016/S0923-2494(05)80096-3; CORNELISSEN AWCA, 1981, PARASITOLOGY, V83, P103, DOI 10.1017/S0031182000050071; Del Rio L, 2001, J IMMUNOL, V167, P6503, DOI 10.4049/jimmunol.167.11.6503; Dzierszinski F, 1999, J BIOL CHEM, V274, P24888, DOI 10.1074/jbc.274.35.24888; KAZAL LA, 1948, J AM CHEM SOC, V70, P3034, DOI 10.1021/ja01189a060; KHAN IA, 2001, AM ASSN IMMUNOLOGIST, V1, P1930; Labruyere E, 1999, MOL BIOCHEM PARASIT, V102, P311, DOI 10.1016/S0166-6851(99)00092-4; Laskowski Jr. M., 2000, PROTEIN PROTEIN RECO, P228; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LASKOWSKI M, 1968, ANN NY ACAD SCI, V146, P374, DOI 10.1111/j.1749-6632.1968.tb20295.x; LAURA R, 1980, BIOCHEMISTRY-US, V19, P4859, DOI 10.1021/bi00562a024; LECORDIER L, 1993, MOL BIOCHEM PARASIT, V59, P143, DOI 10.1016/0166-6851(93)90015-P; Lingelbach K, 1998, J CELL SCI, V111, P1467; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; LUTHY JA, 1973, J BIOL CHEM, V248, P1760; MACEN JL, 1993, VIROLOGY, V195, P348, DOI 10.1006/viro.1993.1385; Mercier C, 1998, J CELL SCI, V111, P2171; Milstone AM, 2000, J BIOL CHEM, V275, P29391, DOI 10.1074/jbc.M002715200; Nash P, 1998, J BIOL CHEM, V273, P20982, DOI 10.1074/jbc.273.33.20982; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Onnerfjord P, 1999, RAPID COMMUN MASS SP, V13, P315; OSSORIO PN, 1994, J BIOL CHEM, V269, P15350; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Pszenny V, 2000, MOL BIOCHEM PARASIT, V107, P241, DOI 10.1016/S0166-6851(00)00202-4; Roberts RM, 1995, CRIT REV EUKAR GENE, V5, P385, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.80; SHARMA SP, 1981, AM J VET RES, V42, P128; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIBLEY LD, 1995, J CELL SCI, V108, P1669; SILVERMAN JA, 1997, HOST RESPONSE INTRAC, P315; Speer CA, 1995, MOL BIOCHEM PARASIT, V75, P75, DOI 10.1016/0166-6851(95)02515-4; Stubbs MT, 1997, J BIOL CHEM, V272, P19931, DOI 10.1074/jbc.272.32.19931; Turner PC, 2001, ASM NEWS, V67, P201; VANDELOCHT A, 1995, EMBO J, V14, P5149, DOI 10.1002/j.1460-2075.1995.tb00199.x; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X	42	58	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45259	45266		10.1074/jbc.M205517200	http://dx.doi.org/10.1074/jbc.M205517200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228242	hybrid			2022-12-25	WOS:000179404800086
J	Kiakos, K; Howard, TT; Lee, M; Hartley, JA; McHugh, PJ				Kiakos, K; Howard, TT; Lee, M; Hartley, JA; McHugh, PJ			Saccharomyces cerevisiae RAD5 influences the excision repair of DNA minor groove adducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING-ENZYME; SIMPLE REPETITIVE SEQUENCES; THYMINE-THYMINE DIMER; UV-DAMAGED DNA; POSTREPLICATION REPAIR; POLYUBIQUITIN CHAINS; POLYMERASE-DELTA; ERROR-PRONE; YEAST RAD6; PROTEIN	Nucleotide excision repair (NER) is the primary pathway for the removal of DNA adducts that distort the double helix. In the yeast Saccharomyces cerevisiae the RAD6 epistasis group defines a more poorly characterized set of DNA damage response pathways, believed to be distinct from NER. Here we show that the elimination of the DNA minor groove adducts formed by an important class of anticancer antibiotic (CC-1065 family) requires NER factors in S. cerevisiae. We also demonstrate that the elimination of this class of minor groove adduct from the active MFA2 gene depends upon functional Rad18 and Rad6. This is most clear for the repair of adducts on the transcribed strand, where an absolute requirement for Rad6 and Rad18 was seen. Further experiments revealed that a specific RAD6-RAD18-controlled subpathway, the RAD5 branch, mediates these events. Cells disrupted for rad5 are highly sensitive to this minor groove binding agent, and rad5 cells exhibit an in vivo adduct elimination defect indistinguishable from that seen in rad6 and rad18 cells as well as in NER-defective cells. Our results indicate that the RAD5 subpathway may interact with NER factors during the repair of certain DNA adducts.	UCL, Royal Free & Univ Coll, Sch Med,Dept Oncol, Canc Res UK Drug DNA Interact Res Grp, London W1W 7BS, England; Furman Univ, Dept Chem, Greenville, SC 29613 USA	Cancer Research UK; University of London; University College London; UCL Medical School	McHugh, PJ (corresponding author), Univ Oxford, Canc Res UK Mol Oncol Labs, Weatherall Inst Mol Med, John Radcliffe Hosp, Oxford OX3 9DS, England.	peter.mchugh@cancer.org.uk	Hartley, John/GRY-6691-2022	McHugh, Peter/0000-0002-8679-4627				Ahne F, 1997, NUCLEIC ACIDS RES, V25, P743, DOI 10.1093/nar/25.4.743; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Balajee AS, 2000, GENE, V250, P15, DOI 10.1016/S0378-1119(00)00172-4; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; Bessho T, 1997, MOL CELL BIOL, V17, P6822, DOI 10.1128/MCB.17.12.6822; Brooks N, 2000, CHEM BIOL, V7, P659, DOI 10.1016/S1074-5521(00)00010-7; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; Cejka P, 2001, GENETICS, V159, P953; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Grimaldi K A, 1997, Methods Mol Biol, V90, P157; Gunz D, 1996, J BIOL CHEM, V271, P25089, DOI 10.1074/jbc.271.41.25089; HANAWALT PC, 1989, GENOME, V2, P605; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Howard TT, 2002, BIOORGAN MED CHEM, V10, P2941, DOI 10.1016/S0968-0896(02)00157-8; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; Huang ME, 2000, CURR GENET, V38, P178, DOI 10.1007/s002940000149; HURLEY LH, 1984, SCIENCE, V226, P843, DOI 10.1126/science.6494915; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; JOHNSON RE, 1994, J BIOL CHEM, V269, P28259; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Kuraoka I, 2000, J BIOL CHEM, V275, P26632, DOI 10.1074/jbc.C000337200; Li SS, 1999, J BIOL CHEM, V274, P12201, DOI 10.1074/jbc.274.18.12201; MCCREADY S, 1994, MUTAT RES-DNA REPAIR, V315, P261, DOI 10.1016/0921-8777(94)90037-X; McDonald JP, 1997, GENETICS, V147, P1557; McHugh PJ, 1999, NUCLEIC ACIDS RES, V27, P3259, DOI 10.1093/nar/27.16.3259; Mu D, 2000, MOL CELL BIOL, V20, P2446, DOI 10.1128/MCB.20.7.2446-2454.2000; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; PICOLOGLOU S, 1990, MOL CELL BIOL, V10, P1017, DOI 10.1128/MCB.10.3.1017; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; REYNOLDS VL, 1986, J ANTIBIOT, V39, P319, DOI 10.7164/antibiotics.39.319; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SELBY CP, 1988, BIOCHEMISTRY-US, V27, P7184, DOI 10.1021/bi00419a004; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Torres-Ramos CA, 2002, MOL CELL BIOL, V22, P2419, DOI 10.1128/MCB.22.7.2419-2426.2002; TorresRamos CA, 1997, J BIOL CHEM, V272, P25445, DOI 10.1074/jbc.272.41.25445; TorresRamos CA, 1996, P NATL ACAD SCI USA, V93, P9676, DOI 10.1073/pnas.93.18.9676; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Ulrich HD, 2001, NUCLEIC ACIDS RES, V29, P3487, DOI 10.1093/nar/29.17.3487; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Xiao W, 2000, GENETICS, V155, P1633; Xiao W, 1999, MUTAT RES-DNA REPAIR, V435, P1, DOI 10.1016/S0921-8777(99)00034-8; Xiao W, 1996, CURR GENET, V30, P461, DOI 10.1007/s002940050157	51	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44576	44581		10.1074/jbc.M208169200	http://dx.doi.org/10.1074/jbc.M208169200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226100	hybrid			2022-12-25	WOS:000179272000130
J	Takayama, K; Garcia-Cardena, G; Sukhova, GK; Comander, J; Gimbrone, MA; Libby, P				Takayama, K; Garcia-Cardena, G; Sukhova, GK; Comander, J; Gimbrone, MA; Libby, P			Prostaglandin E-2 suppresses chemokine production in human macrophages through the EP4 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	74th Annual Scientific Sessions of the American-Heart-Association	NOV 11-14, 2001	ANAHEIM, CA	Amer Heart Assoc			SMOOTH-MUSCLE CELLS; MONOCYTE CHEMOATTRACTANT PROTEIN-1; TISSUE FACTOR EXPRESSION; NF-KAPPA-B; ATHEROSCLEROTIC PLAQUES; DIFFERENTIAL EXPRESSION; ATHEROMATOUS PLAQUES; IMMUNE-RESPONSES; RABBIT ATHEROMA; DEFICIENT MICE	Pro-inflammatory pathways participate in the pathogenesis of atherosclerosis. However, the role of endogenous anti-inflammatory pathways in atheroma has received much less attention. Therefore, using cDNA microarrays, we screened for genes regulated by prostaglandin E-2 (PGE(2)), a potential endogenous anti-inflammatory mediator, in lipopolysaccharide (LPS)-treated human macrophages (MPhi). PGE(2) (50 nm) attenuated LPS-induced mRNA and protein expression of chemokines including monocyte chemoattractant protein-1, interleukin-8, macrophage inflammatory protein-1alpha and -1beta, and interferon-inducible protein-10. PGE(2) also inhibited the tumor necrosis factor-alpha-, interferon-gamma-, and interleukin-1beta-mediated expression of these chemokines. In contrast to the case of MPhi, PGE(2) did not suppress chemokine expression in human endothelial and smooth muscle cells (SMC) treated with LPS and pro-inflammatory cytokines. To assess the potential paracrine effect of endogenous PGE(2) on macrophage-derived chemokine production, we co-cultured MO with SMC in the presence of LPS. In these co-cultures, cyclooxygenase-2-dependent PGE2 production exceeded that in the mono-cultures, and MIP-1beta declined significantly compared with MPhi cultured without SMC. We further documented prominent expression of the PGE(2) receptor EP4 in MPhi in both culture and human atheroma. Moreover, a selective EP4 antagonist completely reversed PGE(2)-mediated suppression of chemokine production. Thus, endogenous PGE(2) may modulate inflammation during atherogenesis and other inflammatory diseases by suppressing macrophage-derived chemokine production via the EP4 receptor.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Leducq Ctr Cardiovasc Res, Dept Med,Cardiovasc Div,Eugene Braunwald Res Ctr, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Excellence Vasc Biol,Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Libby, P (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Leducq Ctr Cardiovasc Res, Dept Med,Cardiovasc Div,Eugene Braunwald Res Ctr, Rm 307, Boston, MA 02115 USA.	plibby@rics.bwh.harvard.edu	Libby, Peter/AAY-6404-2021; Garcia-Cardena, Guillermo/Q-6649-2019	Libby, Peter/0000-0002-1502-502X; Comander, Jason/0000-0002-4257-7145	NHLBI NIH HHS [HL-34636] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034636, R01HL034636] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abi-Younes S, 2000, CIRC RES, V86, P131, DOI 10.1161/01.RES.86.2.131; Aikawa M, 1999, CIRCULATION, V100, P1215, DOI 10.1161/01.CIR.100.11.1215; Aikawa M, 1998, CIRCULATION, V97, P2433, DOI 10.1161/01.CIR.97.24.2433; Apostolopoulos J, 1996, ARTERIOSCL THROM VAS, V16, P1007, DOI 10.1161/01.ATV.16.8.1007; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; Belton O, 2000, CIRCULATION, V102, P840; BishopBailey D, 1997, ARTERIOSCL THROM VAS, V17, P1644, DOI 10.1161/01.ATV.17.9.1644; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; BrunwaldE, 2001, HEARTDISEASE ATEXTBO, P995; Bustos C, 1998, J AM COLL CARDIOL, V32, P2057, DOI 10.1016/S0735-1097(98)00487-2; Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161/hc3401.093152; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Comander J, 2001, GENOME RES, V11, P1603, DOI 10.1101/gr.186601; De Caterina R, 2000, AM J CLIN NUTR, V71, p213S, DOI 10.1093/ajcn/71.1.213S; DE CR, 1995, J CLIN INVEST, V96, P60; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Garcia-Cardena G, 2001, P NATL ACAD SCI USA, V98, P4478, DOI 10.1073/pnas.071052598; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; Hilkens C, 1996, ANN NY ACAD SCI, V795, P349, DOI 10.1111/j.1749-6632.1996.tb52689.x; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Hwang D, 2000, ANNU REV NUTR, V20, P431, DOI 10.1146/annurev.nutr.20.1.431; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kornbluth RS, 1998, P NATL ACAD SCI USA, V95, P5205, DOI 10.1073/pnas.95.9.5205; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; Mach F, 1999, J CLIN INVEST, V104, P1041, DOI 10.1172/JCI6993; Machwate M, 2001, MOL PHARMACOL, V60, P36, DOI 10.1124/mol.60.1.36; Marx N, 2001, CIRCULATION, V103, P213; Moriuchi H, 1997, J IMMUNOL, V158, P3483; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Nataraj C, 2001, J CLIN INVEST, V108, P1229, DOI 10.1172/JCI13640; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Parry GCN, 1997, J IMMUNOL, V159, P5450; ROLLAND PH, 1984, ARTERIOSCLEROSIS, V4, P70, DOI 10.1161/01.ATV.4.1.70; Schecter AD, 2000, J BIOL CHEM, V275, P5466, DOI 10.1074/jbc.275.8.5466; Schonbeck U, 1999, AM J PATHOL, V155, P1281, DOI 10.1016/S0002-9440(10)65230-3; Soler M, 2000, CIRC RES, V87, P504; TERKELTAUB R, 1994, ARTERIOSCLER THROMB, V14, P47, DOI 10.1161/01.ATV.14.1.47; Tomura K, 1999, INT J MOL MED, V3, P477; UEDA A, 1994, J IMMUNOL, V153, P2052; WANG JM, 1991, ARTERIOSCLER THROMB, V11, P1166, DOI 10.1161/01.ATV.11.5.1166; WIDMER U, 1993, J IMMUNOL, V150, P4996; ZIEGLER SF, 1991, J IMMUNOL, V147, P2234	50	268	278	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44147	44154		10.1074/jbc.M204810200	http://dx.doi.org/10.1074/jbc.M204810200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	615XE	12215436	hybrid			2022-12-25	WOS:000179272000080
J	Bozinovski, S; Jones, JE; Vlahos, R; Hamilton, JA; Anderson, GP				Bozinovski, S; Jones, JE; Vlahos, R; Hamilton, JA; Anderson, GP			Granulocyte/macrophage-colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NF kappa B and AP-1 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; MAP KINASE; C-JUN; ENDOTOXIN; MICE; AKT; INDUCTION; INSTILLATION; INFLAMMATION; APOPTOSIS	The lung innate immune response to lipopolysaccharide (LPS) coordinates cellular inflammation, mediator, and protease release essential for host defense but deleterious in asthma, chronic obstructive pulmonary disease, and cystic fibrosis. In vitro, LPS signals to the transcription factors NFkappaB via TLR4, MyD88, and IL-1R-associated kinase (IRAK), to AP-1 by mitogen-activated protein (MAP) kinases, and via an alternate route in IRAK-deficient mice, but the in vivo lung signaling pathway(s) are not understood. We investigated the role of Akt and Erk1/2 as LPS intensely stimulates granulocyte/macrophage-colony-stimulating factor (GM-CSF) release, and neutralizing GM-CSF profoundly suppressed LPS-induced inflammation, suppressed expression and activity of lung proteases, significantly reduced GMCSF and tumor necrosis factor alpha (TNFalpha) mRNA expression, and dampened nuclear localization of both NFkappaB (p50/65) and AP-1. LPS markedly activated Akt and Erk1/2, but not p38, in a GM-CSF-dependent manner in direct temporal association with NFkappaB and AP-1 activation. Pharmacological inhibition of Akt or Erk activation in LPS-treated tracheal explants ex vivo inhibited the release of GM-CSF. These data implicate GM-CSF-dependent activation of Akt in the amplification of this response and demonstrate the role of Erks rather than p38 in lung LPS inflammatory responses. Inhibition of GM-CSF may be of therapeutic benefit in inflammatory diseases in which LPS contributes to lung damage.	Univ Melbourne, Dept Pharmacol, CRC Chron Inflammatory Dis, Lung Dis Res Labs, Parkville, Vic 3010, Australia; Univ Melbourne, Arthrit & Inflammat Res Ctr, Dept Med,Royal Melbourne Hosp, Cooperat Res Ctr Chron Inflammatory Dis, Parkville, Vic 3010, Australia	University of Melbourne; Royal Melbourne Hospital; University of Melbourne	Anderson, GP (corresponding author), Univ Melbourne, Dept Pharmacol, CRC Chron Inflammatory Dis, Lung Dis Res Labs, Parkville, Vic 3010, Australia.	gpa@unimelb.edu.au	Vlahos, Ross/AAM-3837-2020	Vlahos, Ross/0000-0001-8443-7071; Anderson, Gary/0000-0001-6580-3398; Bozinovski, Steven/0000-0001-6533-8641; Hamilton, John A/0000-0002-9493-9224				Aljada A, 2001, J CLIN ENDOCR METAB, V86, P5988, DOI 10.1210/jc.86.12.5988; Basu S, 1997, J IMMUNOL, V159, P1412; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Blyth DI, 1998, AM J RESP CELL MOL, V19, P38, DOI 10.1165/ajrcmb.19.1.2930; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Coles LS, 2000, J BIOL CHEM, V275, P14482, DOI 10.1074/jbc.275.19.14482; deMoraes VLG, 1996, BRIT J PHARMACOL, V117, P1792; Dijkers PF, 1999, ONCOGENE, V18, P3334, DOI 10.1038/sj.onc.1202678; Gabri MR, 1999, PATHOBIOLOGY, V67, P180, DOI 10.1159/000028070; Goyal A, 2002, AM J RESP CELL MOL, V26, P224, DOI 10.1165/ajrcmb.26.2.4640; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; JONGENEEL CV, 1995, IMMUNOBIOLOGY, V193, P210, DOI 10.1016/S0171-2985(11)80545-0; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kim HG, 2000, BIOCHEM BIOPH RES CO, V269, P401; Klein JB, 2001, CELL SIGNAL, V13, P335, DOI 10.1016/S0898-6568(01)00151-6; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Martin TR, 2000, AM J RESP CELL MOL, V23, P128, DOI 10.1165/ajrcmb.23.2.f189; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Meja KK, 2000, BRIT J PHARMACOL, V131, P1143, DOI 10.1038/sj.bjp.0703684; Metcalf D, 1999, BLOOD, V93, P1579, DOI 10.1182/blood.V93.5.1579.405k01_1579_1585; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Monick MM, 2001, J IMMUNOL, V166, P4713, DOI 10.4049/jimmunol.166.7.4713; Monick MM, 2001, J IMMUNOL, V167, P5977, DOI 10.4049/jimmunol.167.10.5977; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NAKATA K, 1991, J IMMUNOL, V147, P1266; O'Grady NP, 2001, AM J RESP CRIT CARE, V163, P1591, DOI 10.1164/ajrccm.163.7.2009111; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; Ozes ON, 1999, NATURE, V401, P82; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; Shibata Y, 2001, IMMUNITY, V15, P557, DOI 10.1016/S1074-7613(01)00218-7; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; STARCHER B, 1989, LAB ANIM, V23, P234, DOI 10.1258/002367789780810536; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; Thomas JA, 1999, J IMMUNOL, V163, P978; Turner H, 1997, J EXP MED, V185, P43, DOI 10.1084/jem.185.1.43; Underwood DC, 2000, AM J PHYSIOL-LUNG C, V279, pL895, DOI 10.1152/ajplung.2000.279.5.L895; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152, DOI 10.1165/ajrcmb.26.1.4652; Xing Z, 1996, J CLIN INVEST, V97, P1102, DOI 10.1172/JCI118503; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458	44	143	146	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42808	42814		10.1074/jbc.M207840200	http://dx.doi.org/10.1074/jbc.M207840200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12208854	hybrid			2022-12-25	WOS:000179081200052
J	Couplan, E; Gelly, C; Goubern, M; Fleury, C; Quesson, B; Silberberg, M; Thiaudiere, E; Mateo, P; Lonchampt, M; Levens, N; de Montrion, C; Ortmann, S; Klaus, S; Gonzalez-Barroso, MDM; Cassard-Doulcier, AM; Ricquier, D; Bigard, AX; Diolez, P; Bouillaud, F				Couplan, E; Gelly, C; Goubern, M; Fleury, C; Quesson, B; Silberberg, M; Thiaudiere, E; Mateo, P; Lonchampt, M; Levens, N; de Montrion, C; Ortmann, S; Klaus, S; Gonzalez-Barroso, MDM; Cassard-Doulcier, AM; Ricquier, D; Bigard, AX; Diolez, P; Bouillaud, F			High level of uncoupling protein 1 expression in muscle of transgenic mice selectively affects muscles at rest and decreases their IIb fiber content	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-A; SKELETAL-MUSCLE; ENERGY-METABOLISM; GENE ENCODES; BROWN-FAT; UCP1; MITOCHONDRIA; REGULATORS; MECHANISMS; HOMOLOGS	The mitochondrial uncoupling protein of brown adipose tissue (UCP1) was expressed in skeletal muscle and heart of transgenic mice at levels comparable with the amount found in brown adipose tissue mitochondria. These transgenic mice have a lower body weight, and when related to body weight, food intake and energy expenditure are increased. A specific reduction of muscle mass was observed but varied according to the contractile activity of muscles. Heart and soleus muscle are unaffected, indicating that muscles undergoing regular contractions, and therefore with a continuous mitochondrial ATP production, are protected. In contrast, the gastrocnemius and plantaris muscles showed a severely reduced mass and a fast to slow shift in fiber types promoting mainly IIa and IIx: fibers at the expense of fastest and glycolytic type IIb fibers. These observations are interpreted as a consequence of the strong potential dependence of the UCP1 protonophoric activity, which ensures a negligible proton leak at the membrane potential observed when mitochondrial ATP production is intense. Therefore UCP1 is not deleterious for an intense mitochondrial ATP production and this explains the tolerance of the heart to a high expression level of UCP1. In muscles at rest, where ATP production is low, the rise in membrane potential enhances UCP1 activity. The proton return through UCP1 mimics the effect of a sustained ATP production, permanently lowering mitochondrial membrane potential. This very likely constitutes the origin of the signal leading to the transition in fiber types at rest.	CNRS, UPR 9078, F-92190 Meudon, France; INRA, Lab Nutr & Securite Alimentaire, F-78352 Jouy En Josas, France; Univ Victor Segalen, CNRS, UMR 5536, F-33076 Bordeaux, France; Ctr Rech, Serv Sante Armees, Unite Bioenerget & Environm, F-38702 La Tronche, France; Univ Paris Sud, Fac Pharm, INSERM, U446, F-92296 Chatenay Malabry, France; Inst Rech Servier, F-92150 Suresnes, France; German Inst Human Nutr, DIfE, D-14558 Bergholz Rehbrucke, Germany	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Servier; Institut de Recherches Internationales Servier; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE)	Bouillaud, F (corresponding author), CNRS, UPR 9078, Inst Rech Necker Enfants Malades, 156 Rue Vaugirard, F-75730 Paris 15, France.		CASSARD, Anne-Marie/B-6095-2019; Ortmann, Sylvia/B-7088-2015; Silberberg, Mathieu/X-9974-2019; Klaus, Susanne/P-9299-2018; Bouillaud, Frédéric R/L-3238-2017	CASSARD, Anne-Marie/0000-0002-1813-5128; Ortmann, Sylvia/0000-0003-2520-6251; Silberberg, Mathieu/0000-0003-3345-8088; Klaus, Susanne/0000-0001-8726-185X; Bouillaud, Frédéric R/0000-0002-7518-9237; GONZALEZ BARROSO, MARIA DEL MAR/0000-0002-0278-8298; Thiaudiere, Eric/0000-0002-9993-4035; Diolez, Philippe/0000-0002-7548-2070; quesson, bruno/0000-0001-6434-3684				Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; BOOTH FW, 1991, PHYSIOL REV, V71, P541, DOI 10.1152/physrev.1991.71.2.541; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Bouillaud F, 2001, BBA-BIOENERGETICS, V1504, P107, DOI 10.1016/S0005-2728(00)00241-3; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Gordon JW, 2001, J APPL PHYSIOL, V90, P389, DOI 10.1152/jappl.2001.90.1.389; Jackman MR, 1996, AM J PHYSIOL-CELL PH, V270, pC673, DOI 10.1152/ajpcell.1996.270.2.C673; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; Klaus S, 1998, AM J PHYSIOL-REG I, V274, pR287, DOI 10.1152/ajpregu.1998.274.2.R287; Klingenberg M, 1999, INT J OBESITY, V23, pS24, DOI 10.1038/sj.ijo.0800939; Larsson NG, 1996, NAT GENET, V13, P296, DOI 10.1038/ng0796-296; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; LOCKE RM, 1982, EUR J BIOCHEM, V129, P373, DOI 10.1111/j.1432-1033.1982.tb07060.x; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NICHOLLS DG, 1973, EUR J BIOCHEM, V37, P523, DOI 10.1111/j.1432-1033.1973.tb03014.x; Pette D, 1998, ACTA PHYSIOL SCAND, V162, P367, DOI 10.1046/j.1365-201X.1998.0296e.x; REN JM, 1995, PFLUG ARCH EUR J PHY, V430, P389, DOI 10.1007/BF00373914; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; SIECK GC, 1995, J APPL PHYSIOL, V79, P1629, DOI 10.1152/jappl.1995.79.5.1629; Sjogren K, 2001, J NUTR, V131, P2963, DOI 10.1093/jn/131.11.2963; Talmadge RJ, 2000, MUSCLE NERVE, V23, P661, DOI 10.1002/(SICI)1097-4598(200005)23:5<661::AID-MUS3>3.0.CO;2-J; TALMADGE RJ, 1993, J APPL PHYSIOL, V75, P2337, DOI 10.1152/jappl.1993.75.5.2337; VEECH RL, 1979, J BIOL CHEM, V254, P6538; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363	34	51	51	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43079	43088		10.1074/jbc.M206726200	http://dx.doi.org/10.1074/jbc.M206726200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12221093	hybrid			2022-12-25	WOS:000179081200086
J	Kowaltowski, AJ; Cosso, RG; Campos, CB; Fiskum, G				Kowaltowski, AJ; Cosso, RG; Campos, CB; Fiskum, G			Effect of Bcl-2 overexpression on mitochondrial structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION; HEART-MITOCHONDRIA; CYTOCHROME-C; APOPTOSIS; MEMBRANE; PROTEIN; DEATH; CELLS; ONCOPROTEIN; DIGITONIN	Overexpression of the antiapoptotic Bcl-2 protein enhances the uptake of fluorimetric dyes sensitive to mitochondrial membrane potential, suggesting that Bcl-2 changes the mitochondrial proton gradient. In this study, we performed calibrated measurements of mitochondrial respiration, membrane potential, DeltapH, and intramitochondrial [K+] in digitonin-permeabilized PC12 and GT1-7 neural cells that either do not express human Bcl-2 (control transfectants) or that were transfected with and overexpressed the human bcl-2 gene to evaluate whether Bcl-2 alters mitochondrial inner membrane ion transport. We found that although Bcl-2-overexpressing cells exhibit higher fluorescence responses to membrane potential, pH, and K+-sensitive dyes, this increased response is due to an enhanced accumulation of these dyes and not an increased mitochondrial membrane potential, DeltapH, or [K+]. This result is supported by the presence of equal respiratory rates in Bcl-2+ and Bcl-2- cells. Possible structural alterations in Bcl-2+ mitochondria that could account for increases in fluorescent dye uptake were evaluated using flow cytometry particle sizing and light scattering determinations. These experiments established that Bcl-2-overexpressing mitochondria present both increased volume and structural complexity. We suggest that increased mitochondrial volume and structural complexity in Bcl-2+ cells may be related to many of the effects of this protein involved in the prevention of cell death.	Univ Estadual Campinas, Fac Ciencias Med, Dept Patol Clin, BR-13083970 Campinas, SP, Brazil; Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA	Universidade Estadual de Campinas; University System of Maryland; University of Maryland Baltimore	Kowaltowski, AJ (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil.		Kowaltowski, Alicia J/H-8698-2012					Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; Armstrong JS, 2002, FASEB J, V16, P1263, DOI 10.1096/fj.02-0097fje; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; Esposti MD, 1999, J BIOL CHEM, V274, P29831, DOI 10.1074/jbc.274.42.29831; Fiskum G, 2000, METHOD ENZYMOL, V322, P222; GARLID KD, 1985, J BIOL CHEM, V260, P3434; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; JUNG DW, 1995, J BIOL CHEM, V270, P672, DOI 10.1074/jbc.270.2.672; JUNG DW, 1990, BIOCHEMISTRY-US, V29, P4121, DOI 10.1021/bi00469a015; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Kowaltowski A, 2000, CELL DEATH DIFFER, V7, P903, DOI 10.1038/sj.cdd.4400722; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MOREADITH RW, 1984, ANAL BIOCHEM, V137, P360, DOI 10.1016/0003-2697(84)90098-8; MULLANEY PF, 1969, REV SCI INSTRUM, V40, P1029, DOI 10.1063/1.1684143; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Polster BM, 2001, J BIOL CHEM, V276, P37887; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	28	108	109	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42802	42807		10.1074/jbc.M207765200	http://dx.doi.org/10.1074/jbc.M207765200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12207028	hybrid			2022-12-25	WOS:000179081200051
J	Piccolo, E; Innominato, PF; Mariggio, MA; Maffucci, T; Iacobelli, S; Falasca, M				Piccolo, E; Innominato, PF; Mariggio, MA; Maffucci, T; Iacobelli, S; Falasca, M			The mechanism involved in the regulation of phospholipase C gamma 1 activity in cell migration	ONCOGENE			English	Article						cell motility; epidermal growth factor; phosphoinositide 3-kinase; phospholipase C; pleckstrin homology domain	FOCAL ADHESION KINASE; C-GAMMA; GROWTH-FACTOR; TUMOR-SUPPRESSOR; ACTIVATION; MOTILITY; DOMAIN; OVEREXPRESSION; IDENTIFICATION; INHIBITION	Activation of the enzyme phospholipase C (PLC) leads to the formation of second messengers inositol 1,4,5-trisphosphate and diacylglycerol. Tyrosine kinase receptors activate this reaction through PLCgamma isoenzymes. PLCgamma activity involves its activation with, and phosphorylation by, receptor tyrosine kinases. Recently, it has been shown that phosphoinositide 3-kinase (PI 3-K) may regulate PLCgamma activity through the interaction of the PI 3-K product phosphatidylinositol 3,4,5-trisphosphate (PtdIns-3,4,5-P-3) and the PLCgamma pleckstrin homology (PH) domain. In an effort to understand the signalling pathway that involves PI 3-K regulation of PLCgamma, we found that EGF induces a PI 3-K-dependent translocation of PLCgamma1 at the leading edge of migrating cells in a wound healing assay. Similarly, the isolated PH, but not the Src-homology (SH) domains, N-SH2 or SH3, of PLCgamma1, translocates at the leading edge. Our experiments also showed that stable PH PLCgamma1 expression blocks epidermal growth factor (EGF)- and serum-induced cell motility and increases cell adhesion in MDA-MB-231 cells. This may suggest that influence of PI 3-K on PLCgamma1 could be relevant in cell migration, where PLCgamma1 seems to play a key role by modulating a series of events involved in actin polymerization.	Univ G DAnnunzio, Dept Oncol & Neurosci, Sect Med Oncol, I-66100 Chieti, Italy; Univ G DAnnunzio, Dept Drug Sci, Lab Cellular Physiol, I-66100 Chieti, Italy; UCL, Sackler Inst, London WC1E 6JJ, England	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; University of London; University College London	Falasca, M (corresponding author), Univ G DAnnunzio, Dept Oncol & Neurosci, Sect Med Oncol, Via Vestini 1, I-66100 Chieti, Italy.	m.falasca@ucl.ac.uk	Mariggiò, Maria Addolorata/T-9047-2017; Falasca, Marco/S-4020-2016	Mariggiò, Maria Addolorata/0000-0001-5306-7143; Falasca, Marco/0000-0002-9801-7235; Mariggio, Maria Addolorata/0000-0002-3508-8706				Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Carloni V, 1997, GASTROENTEROLOGY, V112, P522, DOI 10.1053/gast.1997.v112.pm9024306; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Chang JS, 1997, CANCER RES, V57, P5465; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Khoshyomn S, 1999, NEUROSURGERY, V44, P568, DOI 10.1097/00006123-199903000-00073; LI J, 1997, SCIENCE, V275, P1876; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; Matsuda M, 2001, J CELL BIOL, V153, P599, DOI 10.1083/jcb.153.3.599; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; Nakamura I, 2001, J CELL BIOL, V152, P361, DOI 10.1083/jcb.152.2.361; NOMOTO K, 1995, MOL CARCINOGEN, V12, P146, DOI 10.1002/mc.2940120306; Polk DB, 1998, GASTROENTEROLOGY, V114, P493, DOI 10.1016/S0016-5085(98)70532-3; Price JT, 1999, CANCER RES, V59, P5475; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; SODERQUIST AM, 1992, CANCER RES, V52, P4526; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Turner T, 1997, CLIN CANCER RES, V3, P2275; Wells A, 2000, ADV CANCER RES, V78, P31; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	32	86	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6520	6529		10.1038/sj.onc.1205821	http://dx.doi.org/10.1038/sj.onc.1205821			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226755				2022-12-25	WOS:000177925300012
J	Johnson, KC; Kissil, JL; Fry, JL; Jacks, T				Johnson, KC; Kissil, JL; Fry, JL; Jacks, T			Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene	ONCOGENE			English	Article						Nf2; merlin; dominant-negative; transformation; contact inhibition	NEUROFIBROMATOSIS TYPE-2 GENE; MERLIN; PRODUCT; PROTEIN; GROWTH; ACTIN; EXPRESSION; COLOCALIZES; MEMBRANE; ADHESION	Mutations in the Nf2 tumor suppressor gene lead to tumor formation in humans and mice and cellular overproliferation phenotypes in Drosophila. The Nf2 encoded protein, merlin, shares close sequence similarity in its amino terminus to members of the band 4.1 family of membrane-cytoskeletal linkers. Similarities between merlin and this family suggest a role for merlin in regulating cytoskeletal function. However, the mechanism of the tumor suppressing activity of merlin is not yet understood. Mutational analysis of Nf2 in flies has led to the identification of a dominant-negative allele, which harbors mutations in the amino terminus of the protein. Here, we report that expression of a murine analog of this amino-terminal mutant of Nf2 leads to complete transformation of NIH3T3 fibroblasts in culture. Cells that express this Nf2 mutant allele display disruptions of the actin cytoskeleton, lack of contact inhibition of growth, and anchorage-independent growth. Finally, fibroblasts that express this mutant Nf2 allele form tumors when injected into nude mice.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Canc Res Ctr, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Jacks, T (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tjacks@mit.edu		Fry, Jessica/0000-0003-2748-0334				FERNANDEZVALLE C, 1994, J NEUROBIOL, V25, P1207, DOI 10.1002/neu.480251004; FRANCK Z, 1993, J CELL SCI, V105, P219; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Harwalkar JA, 1998, AM J OTOL, V19, P654; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Koga H, 1998, ONCOGENE, V17, P801, DOI 10.1038/sj.onc.1202010; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MCCLATCHEY AI, 2001, GENE DEV, V12, P1121; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Ruttledge MH, 1996, AM J HUM GENET, V59, P331; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Sainio M, 1997, J CELL SCI, V110, P2249; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Stokowski RP, 2000, AM J HUM GENET, V66, P873, DOI 10.1086/302812; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	34	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					5990	5997		10.1038/sj.onc.1205693	http://dx.doi.org/10.1038/sj.onc.1205693			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203111	Bronze			2022-12-25	WOS:000177671300002
J	Stroh, C; Cassens, U; Samraj, AK; Sibrowski, W; Schulze-Osthoff, K; Los, M				Stroh, C; Cassens, U; Samraj, AK; Sibrowski, W; Schulze-Osthoff, K; Los, M			The role of caspases in cryoinjury: caspase inhibition strongly improves the recovery of cryopreserved hematopoietic and other cells	FASEB JOURNAL			English	Article						apoptosis; cryopreservation; stem cells; cathepsins; calpains	INDUCED APOPTOSIS; PRESERVATION INJURY; ENDOTHELIAL-CELLS; DEATH; ACTIVATION; MECHANISMS; HEPATOCYTES; HYPOTHERMIA; RECEPTORS; SURVIVAL	Cryopreserved cells and tissues are increasingly used for stem cell transplantation and tissue engineering. However, their freezing, storage, and thawing is associated with severe damage, suggesting the need for better cryopreservation methods. Here, we show that activation of caspase-3 is induced during the freeze-thaw process. Moreover, we demonstrate that prevention of caspase activation by the caspase inhibitor zVAD-fmk strongly improves the recovery and survival of several cryopreserved cell types and hematopoietic progenitor cells. A short preincubation with the caspase inhibitor after thawing also enhances the colony-forming activity of hematopoietic progenitor cells up to threefold. Furthermore, overexpression of Bcl-2, but not the blockade of the death receptor signaling, confers protection, indicating that cryoinjury-associated cell death is mediated by a Bcl-2-controlled mitochondrial pathway. Thus, our data suggest the use of zVAD-fmk as an efficient cryoprotective agent. The addition of caspase inhibitors may be an important tool for the cryopreservation of living cells and advantageous in cell transplantation, tissue engineering, and other genetic technologies.	Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany; Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Munster, Inst Transfus Med, D-48149 Munster, Germany	University of Munster; Heinrich Heine University Dusseldorf; University of Munster	Los, M (corresponding author), Univ Munster, Inst Expt Dermatol, Rontgenstr 21, D-48149 Munster, Germany.	los@uni-muenster.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Los, Marek/0000-0001-9518-1411				Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bilzer M, 2000, J HEPATOL, V32, P508, DOI 10.1016/S0168-8278(00)80404-3; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Burek C, 2001, ONCOGENE, V20, P6493, DOI 10.1038/sj.onc.1204841; Cassens U, 2001, BONE MARROW TRANSPL, V28, P13, DOI 10.1038/sj.bmt.1703082; COUNDOURIS JA, 1993, XENOBIOTICA, V23, P1399, DOI 10.3109/00498259309059449; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; EAVES CJ, 1978, BLOOD, V52, P1196; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eroglu A, 2000, NAT BIOTECHNOL, V18, P163, DOI 10.1038/72608; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fowke KR, 2000, J IMMUNOL METHODS, V244, P139, DOI 10.1016/S0022-1759(00)00263-5; Fu T, 2001, CELL TRANSPLANT, V10, P59; Gao D, 2000, ILAR J, V41, P187; HANSEN TN, 1994, CRYOBIOLOGY, V31, P101, DOI 10.1006/cryo.1994.1013; Hollister WR, 1998, MOL UROL, V2, P13; Hubel A, 2001, TRANSFUSION, V41, P579, DOI 10.1046/j.1537-2995.2001.41050579.x; Jaeschke H, 1996, J HEPATOL, V25, P774, DOI 10.1016/S0168-8278(96)80253-4; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kato S, 2000, BONE MARROW TRANSPL, V26, P1281, DOI 10.1038/sj.bmt.1702707; KRUUV J, 1983, J CELL PHYSIOL, V115, P179, DOI 10.1002/jcp.1041150212; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Los M, 1998, J IMMUNOL, V161, P3050; Los M, 2001, TRENDS IMMUNOL, V22, P31, DOI 10.1016/S1471-4906(00)01814-7; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MAZUR P, 1984, AM J PHYSIOL, V247, pC125, DOI 10.1152/ajpcell.1984.247.3.C125; Peters SMA, 1998, TRANSPLANTATION, V65, P625, DOI 10.1097/00007890-199803150-00005; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Rauen U, 1999, FASEB J, V13, P155, DOI 10.1096/fasebj.13.1.155; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; Rowley S D, 1992, J Hematother, V1, P233, DOI 10.1089/scd.1.1992.1.233; Rudner J, 2001, J CELL SCI, V114, P4161; Sadowski-Debbing K, 2002, ARCH IMMUNOL THER EX, V50, P19; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	42	85	99	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1651	+		10.1096/fj.02-0034fje	http://dx.doi.org/10.1096/fj.02-0034fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207004	Green Submitted			2022-12-25	WOS:000177814000020
J	Hotokezaka, H; Sakai, E; Kanaoka, K; Saito, K; Matsuo, K; Kitaura, H; Yoshida, N; Nakayama, K				Hotokezaka, H; Sakai, E; Kanaoka, K; Saito, K; Matsuo, K; Kitaura, H; Yoshida, N; Nakayama, K			U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; FACTOR RECEPTOR FAMILY; NERVE GROWTH-FACTOR; CATHEPSIN-K; PC12 CELLS; CYCLIN D1; NEURONAL DIFFERENTIATION; SUSTAINED ACTIVATION; CYSTEINE PROTEINASE	Osteoclasts are multinucleated cells that differentiate from hematopoietic cells and possess characteristics responsible for bone resorption. To study the involvement of mitogen-activated protein kinases (MAPKs) in osteoclastogenesis of the murine monocytic cell line RAW264.7, which can differentiate into osteoclast-like cells in the presence of the receptor activator of nuclear factor kappa B ligand (RANKL), we treated the cells with specific inhibitors of p38 MAPK, PD169316 and SB203580, and specific inhibitors of MAPK extracellular signaling-regulated kinase (ERK) kinase (MEK), U0126 and PD98059. Each inhibitor blocked differentiation into osteoclast-like cells when the cells were plated at the standard cell density (2000-4000 cells per well (96-well)). However, the effect of MEK inhibitors on osteoclastogenesis varied according to the initial cell density during culture, because cell growth was clearly inhibited by them. When the cells were plated at more than 8000 cells per well, marked enhancement and acceleration of the differentiation were observed. In addition, immunoblot analysis revealed that phosphorylation of ERK was increased by treatment with the p38 inhibitors, whereas the MEK inhibitors increased phosphorylation of p38, which implies a seesaw-like balance between ERK and p38 phosphorylation. We suggest that osteoclastogenesis is regulated under a balance between ERK and p38 pathways and that the MEK/ERK pathway negatively regulates osteoclastogenesis while the p38 pathway does so positively. This is the first report that an inhibitor of signal transduction enhanced osteoclastogenesis.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Orthodont & Biomed Engn, Nagasaki 8528588, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Oral Mol Pharmacol, Nagasaki 8528588, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Pediat Dent, Nagasaki 8528588, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Microbial & Oral Infect, Nagasaki 8528588, Japan	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University	Hotokezaka, H (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Orthodont & Biomed Engn, Sakamoto 1-7-1, Nagasaki 8528588, Japan.	hotoke@net.nagasaki-u.ac.jp	Saito, Kan/AAG-3507-2020; Saito, Kan/AFS-5564-2022; Kitaura, Hideki/U-7277-2019	Saito, Kan/0000-0002-2151-6204; Saito, Kan/0000-0002-2151-6204; sakai, eiko/0000-0002-6776-6540				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Assoian RK, 2002, NAT CELL BIOL, V4, pE187, DOI 10.1038/ncb0802-e187; Asthagiri AR, 2001, BIOTECHNOL PROGR, V17, P227, DOI 10.1021/bp010009k; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Huang M, 2002, J BIOL CHEM, V277, P28364, DOI 10.1074/jbc.C200321200; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; Kaji H, 1997, J BONE MINER RES, V12, P734, DOI 10.1359/jbmr.1997.12.5.734; Kamiya T, 1998, J BIOCHEM-TOKYO, V123, P752; Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014-5793(98)01731-1; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788; New LG, 2001, J CELL BIOCHEM, V83, P585, DOI 10.1002/jcb.1253; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; Rohde T, 1996, EUR J APPL PHYSIOL, V74, P428; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Seghatoleslami MR, 2002, J CELL BIOCHEM, V84, P237, DOI 10.1002/jcb.10019; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	46	258	269	0	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47366	47372		10.1074/jbc.M208284200	http://dx.doi.org/10.1074/jbc.M208284200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12237315	hybrid			2022-12-25	WOS:000179663700069
J	Sfakianos, MK; Wilson, L; Sakalian, M; Falany, CN; Barnes, S				Sfakianos, MK; Wilson, L; Sakalian, M; Falany, CN; Barnes, S			Conserved residues in the putative catalytic triad of human bile acid coenzyme A : amino acid N-acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA THIOESTERASES; RAT-LIVER; PEROXISOME PROLIFERATORS; MOLECULAR-CLONING; ESCHERICHIA-COLI; CHOLYL-COA; LONG-CHAIN; PURIFICATION; CONJUGATION; EXPRESSION	Human bile acid-CoA:amino acid N-acyltransferase (hBAT), an enzyme catalyzing the conjugation of bile acids with the amino acids glycine or taurine has significant sequence homology with dienelactone hydrolases and other alpha/beta hydrolases. These enzymes have a conserved catalytic triad that maps onto the mammalian BATs at residues Cys-235, Asp-328, and His-362 of the human sequence, albeit that the hydrolases contain a serine instead of a cysteine. In the present study, the function of the putative catalytic triad of hBAT was examined by chemical modification with the cysteine alkylating reagent N-ethylmaleimide (NEM) and by site-directed mutagenesis of the triad residues followed by enzymology studies of mutant and wild-type hBATs. Treatment with NEM caused inactivation of wild-type hBAT. However, preincubation of wild-type hBAT with the substrate cholyl-CoA before NEM treatment prevented loss of N-acyltransferase activity. Substitution of His-362 or Asp-328 with alanine results in inactivation of hBAT. Although substitution of Cys-235 with serine generated an hBAT mutant with lower N-acyltransferase activity, it substantially increased the bile acid-CoA thioesterase activity compared with wild type. In summary, data from this study support the existence of an essential catalytic triad within hBAT consisting of Cys-235, His-362, and Asp-328 with Cys-235 serving as the probable nucleophile and thus the site of covalent attachment of the bile acid molecule.	Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Alabama, Comprehens Canc Ctr Mass Spectrometry Shared Faci, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Barnes, S (corresponding author), Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046390] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA13148] Funding Source: Medline; NCRR NIH HHS [S10RR06487] Funding Source: Medline; NIAID NIH HHS [AI43230, R01 AI043230-02] Funding Source: Medline; NIDDK NIH HHS [DK-46390] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CZUBA B, 1981, BIOCHEM J, V195, P263, DOI 10.1042/bj1950263; FALANY CN, 1994, J BIOL CHEM, V269, P19375; Falany CN, 1997, J LIPID RES, V38, P1139; FURUTANI M, 1995, BIOCHEM J, V311, P203, DOI 10.1042/bj3110203; Huhtinen K, 2002, J BIOL CHEM, V277, P3424, DOI 10.1074/jbc.M109040200; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; JOHNSON MR, 1991, J BIOL CHEM, V266, P10227; JOHNSON MR, 1989, ANAL BIOCHEM, V182, P360, DOI 10.1016/0003-2697(89)90608-8; KILLENBERG PG, 1978, J BIOL CHEM, V253, P1005; KIMURA M, 1983, H-S Z PHYSIOL CHEM, V364, P637, DOI 10.1515/bchm2.1983.364.1.637; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PAZIRANDEH M, 1991, J BIOL CHEM, V266, P20946; Schroeder A, 1998, AM J PHYSIOL-GASTR L, V274, pG370, DOI 10.1152/ajpgi.1998.274.2.G370; SHAH PP, 1968, STEROIDS, V12, P571, DOI 10.1016/S0039-128X(68)80034-0; Solaas K, 2000, J LIPID RES, V41, P1154; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; SWEENY DJ, 1987, P NATL ACAD SCI USA, V84, P5439, DOI 10.1073/pnas.84.15.5439; VESSEY DA, 1983, BIOCHEM J, V214, P923, DOI 10.1042/bj2140923; VESSEY DA, 1979, J BIOL CHEM, V254, P2059; WITKOWSKI A, 1994, J BIOL CHEM, V269, P379; WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514; WITKOWSKI A, 1992, J BIOL CHEM, V267, P18488; ZOUBOULISVAFIADIS I, 1982, AM J PHYSIOL, V243, pG208, DOI 10.1152/ajpgi.1982.243.3.G208	29	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47270	47275		10.1074/jbc.M207463200	http://dx.doi.org/10.1074/jbc.M207463200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12239217	hybrid			2022-12-25	WOS:000179663700056
J	Kitagawa, Y; Inoue, K; Sasaki, S; Hayashi, Y; Matsuo, Y; Lieber, MR; Mizoguchi, H; Yokota, J; Kohno, T				Kitagawa, Y; Inoue, K; Sasaki, S; Hayashi, Y; Matsuo, Y; Lieber, MR; Mizoguchi, H; Yokota, J; Kohno, T			Prevalent involvement of illegitimate V(D)J recombination in chromosome 9p21 deletions in lymphoid leukemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINES; METHYLTHIOADENOSINE PHOSPHORYLASE; GENOMIC INSTABILITY; GENE; TRANSLOCATIONS; SIGNALS; CANCER; MALIGNANCIES; BREAKPOINTS; NEOPLASIA	To understand molecular pathways underlying 9p21 deletions, which lead to inactivation of the p16/CDKN2A, p14/ARF, and/or p15/CDKN2B genes, in lymphoid leukemia, 30 breakpoints were cloned from 15 lymphoid leukemia cell lines. Seventeen (57%) breakpoints were mapped at five breakpoint cluster sites, BCS-LL1 to LL5, each of <15 bp. Two breakpoint cluster sites were located within the ARF and CDMN2B loci, respectively, whereas the remaining three were located >100 kb distal to the CDKN2A, ARF, and CDMN2B loci. The sequences of breakpoint junctions indicated that deletions in the 11 (73%) cell lines were mediated by illegitimate V(D)J recombination targeted at the five BCS-LL and six other sites, which contain sequences similar to recombination signal sequences for V(D)J recombination. An extrachromosomal V(D)J recombination assay indicated that BCS-LLS, at which the largest number of breakpoints (ie. five breakpoints) was clustered, has a V(D)J recombination potential 150-fold less than the consensus recombination signal sequence. Three other BCS-LLs tested also showed V(D)J recombination potential, although it was lower than that of BCS-LL3. These results indicated that illegitimate V(D)J recombination, which was targeted at several ectopic recombination signal sequences widely distributed in 9p21, caused a large fraction of 9p21 deletions in lymphoid leukemia.	Natl Inst Canc Res, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Tokyo Womens Med Univ, Dept Hematol, Tokyo 1628666, Japan; Univ Tokyo, Dept Pediat, Grad Sch Med, Tokyo 1038655, Japan; Fujisaki Cell Ctr, Hayashibara Biochem Labs, Okayama 7028006, Japan; Univ So Calif, Norris Comprehens Canc Ctr, Sch Med, Los Angeles, CA 90089 USA	National Cancer Center - Japan; Tokyo Women's Medical University; University of Tokyo; Hayashibara Biochemical Laboratories, Inc.; University of Southern California	Yokota, J (corresponding author), Natl Inst Canc Res, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.			Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345				AKAMATSU Y, 1994, J IMMUNOL, V153, P4520; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Cherry SR, 1999, P NATL ACAD SCI USA, V96, P10788, DOI 10.1073/pnas.96.19.10788; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; Davila M, 2001, ADV CANCER RES, V81, P61, DOI 10.1016/S0065-230X(01)81002-2; Drexler HG, 2000, LEUKEMIA RES, V24, P881, DOI 10.1016/S0145-2126(00)00070-9; Drexler HG, 1998, LEUKEMIA LYMPHOMA, V31, P305, DOI 10.3109/10428199809059223; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Furukawa Y, 2000, BRIT J HAEMATOL, V110, P663, DOI 10.1046/j.1365-2141.2000.02253.x; GAUSS GH, 1993, MOL CELL BIOL, V13, P3900, DOI 10.1128/MCB.13.7.3900; Gauss GH, 1996, MOL CELL BIOL, V16, P258; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; Gauss GH, 1998, EUR J IMMUNOL, V28, P351, DOI 10.1002/(SICI)1521-4141(199801)28:01<351::AID-IMMU351>3.0.CO;2-#; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Hamada K, 2000, GENE CHROMOSOME CANC, V27, P308, DOI 10.1002/(SICI)1098-2264(200003)27:3<308::AID-GCC12>3.3.CO;2-N; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Kirsch I R, 1997, Semin Immunol, V9, P207, DOI 10.1006/smim.1997.0071; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; Kohno T, 1996, DNA Res, V3, P421, DOI 10.1093/dnares/3.6.421; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kwon J, 2000, MOL CELL, V6, P1037, DOI 10.1016/S1097-2765(00)00102-7; Lewis SM, 1997, MOL CELL BIOL, V17, P3125, DOI 10.1128/MCB.17.6.3125; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Lieber MR, 1998, AM J PATHOL, V153, P1323, DOI 10.1016/S0002-9440(10)65716-1; Marculescu R, 2002, J EXP MED, V195, P85, DOI 10.1084/jem.20011578; Nishioka M, 2000, ONCOGENE, V19, P6251, DOI 10.1038/sj.onc.1204031; Nobori T, 1996, P NATL ACAD SCI USA, V93, P6203, DOI 10.1073/pnas.93.12.6203; OCHMAN H, 1988, GENETICS, V120, P621; OHNISHI H, 1995, BLOOD, V86, P1269, DOI 10.1182/blood.V86.4.1269.bloodjournal8641269; POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raghavan SC, 2001, J BIOL CHEM, V276, P29126, DOI 10.1074/jbc.M103797200; Sherr CJ, 2000, CANCER RES, V60, P3689; Vanasse GJ, 1999, BLOOD, V94, P3997, DOI 10.1182/blood.V94.12.3997.424k44_3997_4010; Yu J, 1997, CLIN CANCER RES, V3, P433	39	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46289	46297		10.1074/jbc.M208353200	http://dx.doi.org/10.1074/jbc.M208353200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12228235	hybrid			2022-12-25	WOS:000179529300078
J	Sakamoto, H; Mashima, T; Yamamoto, K; Tsuruo, T				Sakamoto, H; Mashima, T; Yamamoto, K; Tsuruo, T			Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCT; ALPHA-B-CRYSTALLIN; GLYOXALASE-I; CELL-DEATH; PROTECTIVE ACTIVITY; PROSTATE-CANCER; SERUM-ALBUMIN; CROSS-LINKING; CYTOCHROME-C; PHOSPHORYLATION	Methylglyoxal (MG) is one of the side-products in glycolysis, and it reacts with proteins under physiological conditions. Here, we identified heat-shock protein 27 (Hsp27) as a major MG-modified protein in cells. MG modification of Hsp27 selectively occurs at Arg-188 to form argpyrimidine, and mutation in the residue represses the formation of a large oligomer. This modification process is essential to its repressing activity for cytochrome c-mediated caspase activation. Inhibition of MG modification of Hsp27 causes sensitization of the cells to anti-tumor drug-induced apoptosis. Thus, MG is a novel modulator of cell survival by directly incorporating with the specific protein residue.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Tokyo 1130032, Japan	University of Tokyo; Japanese Foundation for Cancer Research; University of Tokyo	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Chaplen FWR, 1998, P NATL ACAD SCI USA, V95, P5533, DOI 10.1073/pnas.95.10.5533; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; Cornford PA, 2000, CANCER RES, V60, P7099; Davidson SD, 1999, J UROLOGY, V161, P690, DOI 10.1016/S0022-5347(01)61996-7; Du J, 2000, J CELL BIOCHEM, V77, P333, DOI 10.1002/(SICI)1097-4644(20000501)77:2<333::AID-JCB15>3.0.CO;2-Q; EGYUD LG, 1968, SCIENCE, V160, P1140, DOI 10.1126/science.160.3832.1140; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; Kang YB, 1996, LEUKEMIA RES, V20, P397, DOI 10.1016/0145-2126(95)00162-X; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Koschinsky T, 1997, P NATL ACAD SCI USA, V94, P6474, DOI 10.1073/pnas.94.12.6474; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LO TWC, 1994, J BIOL CHEM, V269, P32299; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Miyata T, 1998, J AM SOC NEPHROL, V9, P2349; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; Okado A, 1996, BIOCHEM BIOPH RES CO, V225, P219, DOI 10.1006/bbrc.1996.1157; Oya T, 1999, J BIOL CHEM, V274, P18492, DOI 10.1074/jbc.274.26.18492; PAPOULIS A, 1995, BIOCHEMISTRY-US, V34, P648, DOI 10.1021/bi00002a032; RANGANATHAN S, 1995, BIOCHEM J, V309, P127, DOI 10.1042/bj3090127; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sakamoto H, 2001, CLIN CANCER RES, V7, P2513; Shamsi FA, 1998, J BIOL CHEM, V273, P6928, DOI 10.1074/jbc.273.12.6928; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; Shipanova IN, 1997, ARCH BIOCHEM BIOPHYS, V344, P29, DOI 10.1006/abbi.1997.0195; THORNALLEY PJ, 1995, CRIT REV ONCOL HEMAT, V20, P99, DOI 10.1016/1040-8428(94)00149-N; Vargas-Roig LM, 1998, INT J CANCER, V79, P468, DOI 10.1002/(SICI)1097-0215(19981023)79:5<468::AID-IJC4>3.0.CO;2-Z; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293; Wilker SC, 2001, ANAL BIOCHEM, V290, P353, DOI 10.1006/abio.2001.4992; Zhao HR, 1997, J BIOL CHEM, V272, P14465, DOI 10.1074/jbc.272.22.14465	43	115	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45770	45775		10.1074/jbc.M207485200	http://dx.doi.org/10.1074/jbc.M207485200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12226095	hybrid			2022-12-25	WOS:000179529300009
J	Das, S; Lin, JH; Papamatheakis, J; Sykulev, Y; Tsichlis, PN				Das, S; Lin, JH; Papamatheakis, J; Sykulev, Y; Tsichlis, PN			Differential splicing generates Tvl-1/RFXANK isoforms with different functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARE LYMPHOCYTE SYNDROME; CLASS-II DEFICIENCY; ADAPTER PROTEIN TVL-1; REGULATORY FACTOR-X; HISTOCOMPATIBILITY COMPLEX; DNA-BINDING; GENE-EXPRESSION; COMPLEMENTATION GROUP; TRANSACTIVATOR CIITA; EPH RECEPTOR	Earlier studies have shown that Tvl-1 gives rise to at least two differentially spliced mRNAs, one of which (Tvl-S) encodes a protein that lacks amino acids 91-112. DNA binding of RFX complexes assembled in the presence of Tvl-S is impaired. As a result, Tvl-S does not support the expression of Class 11 major histocompatibility complex (MHQ genes. Here, we show that the reason Tvl-S is inactive as a transcriptional regulator of Class H MHC genes is that the RFX complexes assembled in the presence of Tvl-S are unstable. Additionally, we show that interferon-gamma, which induces Class 11 MHC gene expression in 293 cells, promotes a shift in the splicing pattern of RFXANK/Tvl-1 toward the transcriptionally active TvI-L isoform, suggesting that differential splicing of Tvl-1 is a signal-regulated process. Finally, we show that Tvl-1 regulates the expression of non-MHC genes. One such gene encodes the ephrin receptor EphA3. Since both Tvl-L and Tvl-S are identical in their ability to induce the expression of EphA3, we conclude that Tvl-1 regulates the expression of non-MHC genes by RFX-independent mechanisms.	Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Fdn Res & Technol, Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece	Tufts Medical Center; Tufts University; Jefferson University	Tsichlis, PN (corresponding author), Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, 75 Kneeland St,10th Floor,Rm 10025, Boston, MA 02111 USA.	p_tsichlis@lifespan.org			NCI NIH HHS [R01 CA/GM80219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENICHOU B, 1991, P NATL ACAD SCI USA, V88, P4285, DOI 10.1073/pnas.88.10.4285; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; Bontron S, 1997, HUM GENET, V99, P541, DOI 10.1007/s004390050403; Boss JM, 1997, CURR OPIN IMMUNOL, V9, P107, DOI 10.1016/S0952-7915(97)80166-5; Brown A, 2000, CELL, V102, P77, DOI 10.1016/S0092-8674(00)00012-X; Cattaruzza M, 2002, J BIOL CHEM, V277, P6582, DOI 10.1074/jbc.M108283200; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Chiari R, 2000, CANCER RES, V60, P4855; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; COOPER TA, 2001, SCI STKE; Cressman DE, 1999, IMMUNITY, V10, P163, DOI 10.1016/S1074-7613(00)80017-5; DeSandro AM, 2000, MOL CELL BIOL, V20, P6587, DOI 10.1128/MCB.20.17.6587-6599.2000; Dottori M, 1999, BLOOD, V94, P2477, DOI 10.1182/blood.V94.7.2477.419k13_2477_2486; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; Emery P, 1996, MOL CELL BIOL, V16, P4486; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; FLAVELL RA, 1986, SCIENCE, V233, P437, DOI 10.1126/science.3726537; FOX GM, 1995, ONCOGENE, V10, P897; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; HAMMERLING GJ, 1975, ISRAEL J MED SCI, V11, P1331; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Harton JA, 2001, J BIOL CHEM, V276, P38715, DOI 10.1074/jbc.M106652200; Huai JS, 2001, J BIOL CHEM, V276, P6689, DOI 10.1074/jbc.M008127200; KLEIN C, 1993, J PEDIATR-US, V123, P921, DOI 10.1016/S0022-3476(05)80388-9; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Lanzavecchia A, 1997, J EXP MED, V185, P1717, DOI 10.1084/jem.185.10.1717; Lennon AM, 1996, IMMUNOGENETICS, V43, P352; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; Lin JH, 1999, J BIOL CHEM, V274, P14706, DOI 10.1074/jbc.274.21.14706; MACH B, 1994, IMMUNOL REV, V138, P207, DOI 10.1111/j.1600-065X.1994.tb00853.x; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; Magner WJ, 2000, J IMMUNOL, V165, P7017, DOI 10.4049/jimmunol.165.12.7017; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; Masternak K, 2000, Rev Immunogenet, V2, P267; Moreno CS, 1997, J IMMUNOL, V158, P5841; Nagarajan UM, 1999, IMMUNITY, V10, P153, DOI 10.1016/S1074-7613(00)80016-3; Nekrep N, 2000, MOL CELL BIOL, V20, P4455, DOI 10.1128/MCB.20.12.4455-4461.2000; Nekrep N, 2001, MOL CELL BIOL, V21, P5566, DOI 10.1128/MCB.21.16.5566-5576.2001; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Patriotis C, 2001, J CELL PHYSIOL, V187, P176, DOI 10.1002/jcp.1066; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; SANCHEZ CH, 1992, MOL CELL BIOL, V12, P4076, DOI 10.1128/MCB.12.9.4076; SEIDL C, 1992, J IMMUNOL, V148, P1576; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; Villard J, 1997, NEW ENGL J MED, V337, P748, DOI 10.1056/NEJM199709113371104; Waldburger JM, 2000, IMMUNOL REV, V178, P148, DOI 10.1034/j.1600-065X.2000.17813.x; Westerheide SD, 1999, NUCLEIC ACIDS RES, V27, P1635, DOI 10.1093/nar/27.7.1635	57	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45172	45180		10.1074/jbc.M204117200	http://dx.doi.org/10.1074/jbc.M204117200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12215433	hybrid			2022-12-25	WOS:000179404800075
J	Jono, H; Shuto, T; Xu, HD; Kai, H; Lim, DJ; Gum, JR; Kim, YS; Yamaoka, S; Feng, XH; Li, JD				Jono, H; Shuto, T; Xu, HD; Kai, H; Lim, DJ; Gum, JR; Kim, YS; Yamaoka, S; Feng, XH; Li, JD			Transforming growth factor-beta-Smad signaling pathway cooperates with NF-kappa B to mediate nontypeable Haemophilus influenzae-induced MUC2 mucin transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; EPITHELIAL-CELLS; GENE-EXPRESSION; ACTIVATION; PATHOGENESIS; REQUIRES; DISEASE; ALPHA; SPECIFICITY; SEQUENCES	Transforming growth factor-beta (TGF-beta) and related factors are multifunctional cytokines that regulate diverse cellular processes, including proliferation, differentiation, apoptosis, and immune response. The involvement of TGF-beta receptor-mediated signaling in bacteria-induced up-regulation of mucin, a primary innate defensive response for mammalian airways, however, still remains unknown. Here, we report that the bacterium nontypeable Haemophilus influenzae (NTHi), an important human respiratory pathogen, utilizes the TGF-beta-Smad signaling pathway together with the TLR2-MyD88-TAK1-NIK-IKKbeta/gamma-IkappaBalpha pathway to mediate NF-kappaB-dependent MUC2 mucin transcription. The NTHi- induced TGF-beta receptor Type II phosphorylation occurred at as early as 5 min. Pretreatment of NTHi with TGF-beta neutralization antibody reduced up-regulation of MUC2 transcription. Moreover, functional cooperation of NF-kappaB p65/p50 with Smad3/4 appears to positively mediate NF-kappaB-dependent MUC2 transcription. These data are the first to demonstrate the involvement of TGF-beta receptor-mediated signaling in bacteria-induced up-regulation of mucin transcription, bring insights into the novel role of TGF-beta signaling in bacterial pathogenesis, and may lead to new therapeutic intervention of NTHi infections.	Univ So Calif, Gonda Dept Cell & Mol Biol, House Ear Inst, Los Angeles, CA 90057 USA; Kumamoto Univ, Dept Mol Med, Kumamoto 8620973, Japan; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, Gastrointestinal Res Lab, San Francisco, CA 94121 USA; Tokyo Med & Dent Univ, Dept Mol Virol, Tokyo 1138519, Japan; Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	House Research Institute; University of Southern California; Kumamoto University; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Tokyo Medical & Dental University (TMDU); Baylor College of Medicine; Baylor College of Medicine	Li, JD (corresponding author), Univ So Calif, Gonda Dept Cell & Mol Biol, House Ear Inst, 2100 W 3rd St, Los Angeles, CA 90057 USA.			Li, Jian-Dong/0000-0002-5593-050X	NATIONAL CANCER INSTITUTE [R01CA024321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004562] Funding Source: NIH RePORTER; NCI NIH HHS [CA24321] Funding Source: Medline; NIDCD NIH HHS [R01-DC04562] Funding Source: Medline; NIGMS NIH HHS [GM63773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; Beauparlant P, 1996, J VIROL, V70, P5777, DOI 10.1128/JVI.70.9.5777-5785.1996; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; CARRIE S, 1992, ACTA OTO-LARYNGOL, V112, P504, DOI 10.3109/00016489209137432; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Foxwell AR, 1998, MICROBIOL MOL BIOL R, V62, P294, DOI 10.1128/MMBR.62.2.294-308.1998; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Hill CS, 2001, CURR OPIN GENET DEV, V11, P533, DOI 10.1016/S0959-437X(00)00229-X; Horng T, 2001, P NATL ACAD SCI USA, V98, P12654, DOI 10.1073/pnas.231471798; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim WD, 1997, EUR RESPIR J, V10, P1914, DOI 10.1183/09031936.97.10081914; KIM YS, 1995, GASTROENTEROLOGY, V109, P999, DOI 10.1016/0016-5085(95)90412-3; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Lawler S, 1997, J BIOL CHEM, V272, P14850, DOI 10.1074/jbc.272.23.14850; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; Li JM, 1998, MOL CELL BIOL, V18, P110, DOI 10.1128/MCB.18.1.110; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; Murphy T F, 2000, Semin Respir Infect, V15, P41; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Rao VK, 1999, FEMS MICROBIOL REV, V23, P99, DOI 10.1016/S0168-6445(98)00039-4; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; Rose MC, 2001, AM J RESP CELL MOL, V25, P533, DOI 10.1165/ajrcmb.25.5.f218; Sethi S, 2000, NEW ENGL J MED, V343, P1969; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; 1995, AM J RSP CRIT CARE M, V152, pS78	43	87	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45547	45557		10.1074/jbc.M206883200	http://dx.doi.org/10.1074/jbc.M206883200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237307	hybrid			2022-12-25	WOS:000179404800120
J	Lammich, S; Okochi, M; Takeda, M; Kaether, C; Capell, A; Zimmer, AK; Edbauer, D; Walter, J; Steiner, H; Haass, C				Lammich, S; Okochi, M; Takeda, M; Kaether, C; Capell, A; Zimmer, AK; Edbauer, D; Walter, J; Steiner, H; Haass, C			Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an A beta-like peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; NUCLEAR TRANSLOCATION; THYMOCYTE DEVELOPMENT; SIGNAL-TRANSDUCTION; GAMMA; NOTCH; CLEAVAGE; INHIBITORS; PROTEASES	Alzheimer's disease (AD)-associated gamma-secretase is a presenilin (PS)-dependent proteolytic activity involved in the intramembraneous cleavage of the beta-amyloid precursor protein, Notch, LDL receptor-related protein, E-cadherin, and ErbB-4. This cut produces the corresponding intracellular domains (ICD), which are required for nuclear signaling of Notch and probably ErbB-4, the beta-amyloid precursor protein, E-cadherin, and the LDL receptor-related protein as well. We have now investigated CD44, a cell surface adhesion molecule, which also undergoes an intramembraneous cleavage to liberate its ICD. We demonstrate that this cleavage requires a PS-dependent gamma-secretase activity. A loss-of-function PS1 mutation, a PS1/PS2 knockout, as well as two independent and highly specific gamma-secretase inhibitors, abolish this cleavage. Surprisingly, small peptides similar to the amyloid beta-peptide (Abeta) are generated by an additional cut in the middle of the transmembrane region of CD44. Like Abeta, these CD44 beta-peptides are generated in a PS-dependent manner. These findings therefore suggest a dual intramembraneous cleavage mechanism mediated by PS proteins. The dual cleavage mechanism is required for nuclear signaling as well as removal of remaining transmembrane domains, a general function of PS in membrane protein metabolism.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany; Osaka Univ, Grad Sch Med, Dept Post Genom & Dis, Div Psychiat & Behav Preteom, Osaka 5650871, Japan	University of Munich; Osaka University	Haass, C (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.		Wang, Caihong/T-5837-2019; Walter, Jochen/B-3677-2014; Edbauer, Dieter/M-9906-2019	Wang, Caihong/0000-0002-6808-3709; Edbauer, Dieter/0000-0002-7186-4653; Okochi, Masayasu/0000-0002-2318-7651; Walter, Jochen/0000-0002-4678-2912				Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2002, J BIOL CHEM, V277, P13389, DOI 10.1074/jbc.M111571200; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; LaPointe CF, 2000, J BIOL CHEM, V275, P1502, DOI 10.1074/jbc.275.2.1502; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee JR, 2001, CELL, V107, P161, DOI 10.1016/S0092-8674(01)00526-8; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Martys-Zage JL, 2000, J MOL NEUROSCI, V15, P189, DOI 10.1385/JMN:15:3:189; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Steinhilb ML, 2001, J BIOL CHEM, V276, P4476, DOI 10.1074/jbc.M008793200; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Urban S, 2001, CELL, V107, P173, DOI 10.1016/S0092-8674(01)00525-6; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 2002, J BIOL CHEM, V277, P15069, DOI 10.1074/jbc.M105375200; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	62	241	252	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44754	44759		10.1074/jbc.M206872200	http://dx.doi.org/10.1074/jbc.M206872200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223485	hybrid			2022-12-25	WOS:000179404800022
J	Antenos, M; Casper, RF; Brown, TJ				Antenos, M; Casper, RF; Brown, TJ			Interaction with Nedd8, a ubiquitin-like protein, enhances the transcriptional activity of the aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH RECEPTOR; SUBCELLULAR-LOCALIZATION; PATHWAY; DEGRADATION; EXPRESSION; RESVERATROL; BINDING; SYSTEM; ARNT	The aryl hydrocarbon receptor (AhR) is a ligand-activated member of the basic helix-loop-helix period aryl hydrocarbon nuclear translocator single-minded (PAS) transcription factor family. This receptor has been shown to be important in various aspects of growth and development as demonstrated by AhR-null mice. A yeast two-hybrid screen of a mouse embryonic day 11 library for AhR-interacting proteins revealed Nedd8 as a candidate. The interaction was confirmed in a cell-free system and in mammalian cells by co-immunoprecipitation; however, in vitro neddylation assays showed that Nedd8 does not covalently modify AhR. Transfection of Nedd8 into a cell line stably transfected with a dioxin response element linked to a chloramphenicol acetyltransferase reporter gene demonstrated that Nedd8 amplified ligand-induced transcription. Deletion of the Gly-76 residue in the carboxyl terminus of Nedd8 abolished this effect and prevented AhR-Nedd8 interaction. Nedd8 overexpression also resulted in accumulation of AhR protein in the nucleus, independent of exogenous ligand. These studies demonstrate that the AhR interacts with Nedd8 and suggest that this interaction enhances the transcriptional activity of the receptor, perhaps involving increased nuclear accumulation or retention. Immunohistochemistry performed on embryonic day 11.5 mouse sections indicated Nedd8 and AhR localize to overlapping areas in the heart and spinal ganglia, raising the possibility that this interaction may play a role in organogenesis.	Mt Sinai Hosp, Div Reprod Sci, Samuel Lunenfeld Res Inst, Dept Obstet & Gynecol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Zool, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Obstet & Gynecol, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto	Brown, TJ (corresponding author), Mt Sinai Hosp, Div Reprod Sci, Samuel Lunenfeld Res Inst, Dept Obstet & Gynecol, 600 Univ Ave,Rm 876, Toronto, ON M5G 1X5, Canada.	brown@mshri.on.ca	Antenos, Monica/J-8985-2017; Brown, Theodore J./E-2192-2013; Casper, Robert F./E-3775-2013	Antenos, Monica/0000-0001-6350-2911; Brown, Theodore J./0000-0002-3074-4516; Casper, Robert F./0000-0002-6249-462X				ABBOTT BD, 1995, DEV DYNAM, V204, P133, DOI 10.1002/aja.1002040204; Casper RF, 1999, MOL PHARMACOL, V56, P784; Deshaies RJ, 1999, CURR OPIN CELL BIOL, V11, P705, DOI 10.1016/S0955-0674(99)00040-X; Fan MY, 2002, MOL ENDOCRINOL, V16, P315, DOI 10.1210/me.16.2.315; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Gonzalez FJ, 1998, DRUG METAB DISPOS, V26, P1194; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Holmes JL, 1997, MOL PHARMACOL, V52, P202, DOI 10.1124/mol.52.2.202; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 2001, J BIOL CHEM, V276, P46655, DOI 10.1074/jbc.M108636200; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lin TM, 2001, J TOXICOL ENV HEAL A, V64, P327, DOI 10.1080/152873901316981312; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; Ma Q, 1997, J BIOL CHEM, V272, P8878; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mitchell SH, 1999, CANCER RES, V59, P5892; NICOLAS GPD, 2001, PROMEGA ENOTES APPL; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Okino S T, 2000, Vitam Horm, V59, P241, DOI 10.1016/S0083-6729(00)59009-8; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; Petrulis JR, 2000, J BIOL CHEM, V275, P37448, DOI 10.1074/jbc.M006873200; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Sambrook J, 2001, MOL CLONING LAB MANU; Savouret JF, 2001, J BIOL CHEM, V276, P3054, DOI 10.1074/jbc.M005988200; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	36	18	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44028	44034		10.1074/jbc.M202413200	http://dx.doi.org/10.1074/jbc.M202413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12215427	hybrid			2022-12-25	WOS:000179272000065
J	Coppolino, MG; Dierckman, R; Loijens, J; Collins, RF; Pouladi, M; Jongstra-Bilen, J; Schreiber, AD; Trimble, WS; Anderson, R; Grinstein, S				Coppolino, MG; Dierckman, R; Loijens, J; Collins, RF; Pouladi, M; Jongstra-Bilen, J; Schreiber, AD; Trimble, WS; Anderson, R; Grinstein, S			Inhibition of phosphatidylinositol-4-phosphate 5-kinase I alpha impairs localized actin remodeling and suppresses phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; PHOSPHATE KINASES; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; PLASMA-MEMBRANE; BINDING; PROTEIN; REQUIREMENTS; SEQUENCE; TALIN	Actin polymerization drives the extension of pseudopods required for phagocytosis. Phosphatidylinositol 4,5-bisphosphate (PIP2) is thought to play a central role in this process, because it interacts with several actin-regulatory proteins and undergoes acute and localized changes at sites of phagocytosis. We therefore studied whether phosphatidylinositol-4-phosphate 5-kinase (PIPK), the enzyme responsible for the generation of PIP2 from phosphatidylinositol 4-phosphate, is involved in the control of phagocytosis. PIPKIalpha was found to accumulate transiently on forming phagosomes. To test the functional involvement of PIPKIalpha in particle engulfment, we generated a double mutant (D309N/R427Q) that lacks kinase activity. When ectopically expressed in cultured cells, this mutant is targeted to the plasma membrane and accumulates at the phagosomal cup during particle engulfment. Expression of PIP5KIalpha D309N/R427Q impaired phagocytosis in RAW264.7 macrophages and in engineered phagocytes generated by transfection of Fc receptors in Chinese hamster ovary cells. Inhibition of phagocytosis could not be attributed to defects in particle binding or receptor clustering, which was monitored using green fluorescent protein-tagged Fcy receptors. Instead, expression of the inactive kinase diminished the accumulation of PIP2 and of F-actin in the phagosomal cup. These data suggest that PIPKIalpha activity is involved in the actin remodeling that is a prerequisite for efficient phagocytosis. PIPKIalpha appears to contribute to the transient changes in PIP2 levels that are associated with, and likely required for, the recruitment and regulation of actin-modulating proteins.	Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Wisconsin System; University of Wisconsin Madison; University of Pennsylvania	Grinstein, S (corresponding author), Hosp Sick Children, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.ca	Pouladi, Mahmoud A/B-8743-2016	Pouladi, Mahmoud A/0000-0002-9030-0976; Anderson, Richard/0000-0001-6265-8359				Allen LAH, 1996, CURR OPIN IMMUNOL, V8, P36, DOI 10.1016/S0952-7915(96)80102-6; Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; Booth JW, 2002, EMBO J, V21, P251, DOI 10.1093/emboj/21.3.251; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; BROOKSBANK CEL, 1993, BIOCHEM J, V291, P77, DOI 10.1042/bj2910077; BROWN EJ, 1995, BIOESSAYS, V17, P109, DOI 10.1002/bies.950170206; Burden LM, 1999, BIOCHEMISTRY-US, V38, P15141, DOI 10.1021/bi991571a; Chaudhary A, 1998, CHEM BIOL, V5, P273, DOI 10.1016/S1074-5521(98)90620-2; Cox D, 1996, J BIOL CHEM, V271, P16597, DOI 10.1074/jbc.271.28.16597; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Cox D, 2001, SEMIN IMMUNOL, V13, P339, DOI 10.1006/smim.2001.0330; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GREENBERG S, 1990, J EXP MED, V172, P1853, DOI 10.1084/jem.172.6.1853; GRIFFIN FM, 1975, J EXP MED, V142, P1263, DOI 10.1084/jem.142.5.1263; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; INDIK ZK, 1995, IMMUNOL LETT, V44, P133, DOI 10.1016/0165-2478(94)00204-5; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; Kunz J, 2002, J BIOL CHEM, V277, P5611, DOI 10.1074/jbc.M110775200; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Kwiatkowska K, 1999, BIOESSAYS, V21, P422, DOI 10.1002/(SICI)1521-1878(199905)21:5<422::AID-BIES9>3.0.CO;2-#; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; May RC, 2000, NAT CELL BIOL, V2, P246, DOI 10.1038/35008673; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Sechi AS, 2000, J CELL SCI, V113, P3685; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TEMPEL M, 1995, BIOPHYS J, V69, P228, DOI 10.1016/S0006-3495(95)79894-0; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YU FX, 1992, J BIOL CHEM, V267, P14616; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	45	116	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43849	43857		10.1074/jbc.M209046200	http://dx.doi.org/10.1074/jbc.M209046200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223494	hybrid			2022-12-25	WOS:000179272000043
J	Grzesik, WJ; Frazier, CR; Shapiro, JR; Sponseller, PD; Robey, PG; Fedarko, NS				Grzesik, WJ; Frazier, CR; Shapiro, JR; Sponseller, PD; Robey, PG; Fedarko, NS			Age-related changes in human bone proteoglycan structure - Impact of osteogenesis imperfecta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; PERFORMANCE LIQUID-CHROMATOGRAPHY; COLLAGEN-MUTATION-DATABASE; TRANSFORMING GROWTH-FACTOR-BETA-1; DERMATAN SULFATE; HYALURONIC-ACID; CELLS-INVITRO; NITROUS-ACID; OSTEOBLASTS; BIOSYNTHESIS	Proteoglycans (PGs) are a family of molecules that undergo extensive post-translational modifications that include addition of glycosaminoglycan (GAG) chains as well as N- and O-linked oligosaccharides to the protein core. PG composition and structure have been reported to alter with age. To test whether the post-translational modifications to PGs can serve as in vitro surrogate end point markers for chronological age, the extent of GAG modifications was determined for PGs derived from normal human bone cells of 14 donors (age range, fetal to 60 years). Isolated cells were steady state radiolabeled with (SO42-)-S-35 and [H-3]GlcN. For biglycan and decorin, iduronate content was linearly correlated with age (increased 1.5X between fetal and age 60 years). For the syndecan-like heparan sulfate PG, the N-sulfation of post-natal cells increased over 3.5-fold until reaching a plateau during the 4th decade of life. The amount of O-linked oligosaccharides was also found to decrease as a function of increasing normal donor age, whereas the specific activity of the metabolic precursor pool remained constant regardless of donor age. These age-related changes in post-translational modifications were then used to demonstrate that osteoblasts derived from patients with osteogenesis imperfecta did not exhibit facets of a pre-mature aging, but rather were arrested in a fetal-like phenotypic state. A growth matrix rich in thrombospondin altered PG metabolism in osteoblastic cells, resulting in the production and secretion of the fetal-like (rich in O-linked oligosaccharides) forms of decorin and biglycan. This effect was qualitatively different from the effect of transforming growth factor-beta, which predominantly altered GAGs rather than O-linked oligosaccharides. No other Arg-Gly-Asp protein (fibronectin, vitronectin, type I collagen, osteopontin, and bone sialoprotein) showed any detectable effect on PG metabolism in bone cells. These results indicate that a proper matrix stoichiometry is critical for metabolism of PGs.	Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA; Univ N Carolina, Dent Res Ctr, Sch Dent, Chapel Hill, NC 27599 USA; Johns Hopkins Univ, Kennedy Krieger Inst, Osteogenesis Imperfecta Program, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Orthoped, Baltimore, MD 21205 USA; NIDCR, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill; Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Fedarko, NS (corresponding author), Rm 5A-64 JHAAC,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	ndarko@jhmi.edu	Robey, Pamela Gehron/H-1429-2011	Robey, Pamela Gehron/0000-0002-5316-5576; Fedarko, Neal/0000-0001-6055-6279	NIAMS NIH HHS [AR 42358] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042358, R55AR042358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000649] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADAMS P, 1977, RHEUMATOL REHABIL, V16, P22, DOI 10.1093/rheumatology/16.1.22; ADAMS P, 1976, ANN RHEUM DIS, V35, P289, DOI 10.1136/ard.35.4.289; ASCH AS, 1991, J BIOL CHEM, V266, P1740; BARSH GS, 1985, P NATL ACAD SCI USA, V82, P2870, DOI 10.1073/pnas.82.9.2870; BARTOLD PM, 1986, J CELL PHYSIOL, V126, P37, DOI 10.1002/jcp.1041260106; BERESFORD JN, 1987, J BIOL CHEM, V262, P17164; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BREUER B, 1990, BIOCHEM J, V269, P551, DOI 10.1042/bj2690551; Buckwalter J A, 1988, Electron Microsc Rev, V1, P87; BUCKWALTER JA, 1994, MICROSC RES TECHNIQ, V28, P398, DOI 10.1002/jemt.1070280506; BYERS PH, 1992, ANNU REV MED, V43, P269, DOI 10.1146/annurev.med.43.1.269; Carrino DA, 2000, ARCH BIOCHEM BIOPHYS, V373, P91, DOI 10.1006/abbi.1999.1545; Dalgleish R, 1998, NUCLEIC ACIDS RES, V26, P253, DOI 10.1093/nar/26.1.253; Dalgleish R, 1997, NUCLEIC ACIDS RES, V25, P181, DOI 10.1093/nar/25.1.181; DELANEY SR, 1980, ANAL BIOCHEM, V108, P25, DOI 10.1016/0003-2697(80)90689-2; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FEDARKO NS, 1990, ANAL BIOCHEM, V188, P398, DOI 10.1016/0003-2697(90)90627-L; FEDARKO NS, 1992, J BONE MINER RES, V7, P921; FEDARKO NS, 1990, J BIOL CHEM, V265, P12200; FEDARKO NS, 1995, J BONE MINER RES, V10, P1705; Fedarko NS, 1996, J BONE MINER RES, V11, P800; FEDARKO NS, 1995, J BONE MINER RES, V10, P1122; FEDARKO NS, 1992, J CELL PHYSIOL, V151, P215, DOI 10.1002/jcp.1041510202; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; Gebken J, 2000, PATHOBIOLOGY, V68, P106, DOI 10.1159/000055910; Glorieux FH, 2000, J BONE MINER RES, V15, P1650, DOI 10.1359/jbmr.2000.15.9.1650; GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408; JOHNSTONE B, 1995, SPINE, V20, P674, DOI 10.1097/00007632-199503150-00008; Jones SJ, 1999, CALCIFIED TISSUE INT, V64, P8, DOI 10.1007/s002239900571; Kauppila S, 1998, EUR J CLIN INVEST, V28, P831; KIM JJ, 1976, J BIOL CHEM, V251, P6210; KOBAYASHI K, 1990, BIOCHEM BIOPH RES CO, V172, P217, DOI 10.1016/S0006-291X(05)80196-2; LINDAHL U, 1990, HAEMOSTASIS, V20, P146; MALMSTROM A, 1975, J BIOL CHEM, V250, P3419; McCarthy EF, 1997, CLIN ORTHOP RELAT R, P254; McKusick V A, 1975, Birth Defects Orig Artic Ser, V11, P1; MINTZ KP, 1993, J BONE MINER RES, V8, P985; MORIKE M, 1993, J ORTHOPAED RES, V11, P564, DOI 10.1002/jor.1100110411; PROCKOP DJ, 1988, ARTHRITIS RHEUM, V31, P1, DOI 10.1002/art.1780310101; Rauch F, 2000, BONE, V26, P581, DOI 10.1016/S8756-3282(00)00269-6; ROBERTS CR, 1991, AM J PHYSIOL, V261, pL92, DOI 10.1152/ajplung.1991.261.2.L92; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROWE DW, 1985, J CLIN INVEST, V76, P604, DOI 10.1172/JCI112012; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; Sames K, 1994, EXS, V70, P243; SCHONHERR E, 1993, ARTERIOSCLER THROMB, V13, P1026, DOI 10.1161/01.ATV.13.7.1026; Schwartz NB, 2000, FRONT BIOSCI, V5, pD649; SCHWARTZ NB, 1985, FED PROC, V44, P369; SHIRAGA H, 1992, P NATL ACAD SCI USA, V89, P426, DOI 10.1073/pnas.89.1.426; SHIVELY JE, 1970, BIOCHEMISTRY-US, V9, P33, DOI 10.1021/bi00803a005; Sillence D O, 1988, Ann N Y Acad Sci, V543, P1, DOI 10.1111/j.1749-6632.1988.tb55311.x; SILLENCE DO, 1978, LANCET, V1, P1041; SYKES B, 1990, NATURE, V348, P18, DOI 10.1038/348018a0; TAKEUCHI Y, 1993, J BONE MINER RES, V8, P823; Ward L M, 2001, Hum Mutat, V17, P434, DOI 10.1002/humu.1124; YANAGISHITA M, 1989, METHOD ENZYMOL, V179, P435; ZEBROWER ME, 1986, ANAL BIOCHEM, V157, P93, DOI 10.1016/0003-2697(86)90201-0	58	61	63	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43638	43647		10.1074/jbc.M202124200	http://dx.doi.org/10.1074/jbc.M202124200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221073	hybrid			2022-12-25	WOS:000179272000015
J	Gual, P; Shigematsu, S; Kanzaki, M; Gremeaux, T; Gonzalez, T; Pessin, JE; Le Marchand-Brustel, Y; Tanti, JF				Gual, P; Shigematsu, S; Kanzaki, M; Gremeaux, T; Gonzalez, T; Pessin, JE; Le Marchand-Brustel, Y; Tanti, JF			A Crk-II/TC10 signaling pathway is required for osmotic shock-stimulated glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-GAMMA; BINDING PROTEIN-RHO; DIFFICILE TOXIN-B; 3T3-L1 ADIPOCYTES; INSULIN-RECEPTOR; CLOSTRIDIUM-DIFFICILE; GLUT4 TRANSLOCATION; HYPEROSMOTIC STRESS; COMPLEX-FORMATION; 3T3L1 ADIPOCYTES	Osmotic shock stimulates the translocation of the glucose transporter Glut 4 to plasma membrane by a tyrosine kinase signaling pathway involving Gab-1 (the Grb2-associated binder-1 protein). We show here that, in response to osmotic shock, Gab-1 acts as a docking protein for phospholipase Cgammal, the p85 subunit of the phosphoinositide 3-kinase and Crk-II. It has been shown that the adapter Crk-II is constitutively associated with C3G, a GDP to GTP exchange factor for several small GTP-binding proteins. We found that inhibition of the activity of phosphoinositide 3-kinase or phospholipase C did not prevent the stimulation of glucose transport by osmotic shock, whereas inactivation of Rho proteins by Clostridium difficile toxin B severely inhibited glucose uptake. Among the Rho family members, overexpression of dominant-interfering TC10/T31N mutant inhibited osmotic shock-mediated Glut 4 translocation suggesting that TC10 is required for this process. Further, disruption of cortical actin integrity by latrunculin B or jasplakinolide severely impaired osmotic shock-induced glucose transport. In contrast, osmotic shock increased the amount of cortical actin associated with caveolin-enriched plasma membrane domains. These data provide the first evidence that activation of TC10 and remodeling of cortical actin, which could occur through the TC10 signaling, are required for osmotic shock-mediated Glut 4 translocation and glucose uptake.	INSERM, U568, Fac Med, F-06107 Nice 02, France; IFR 50, Fac Med, F-06107 Nice, France; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Iowa	Tanti, JF (corresponding author), INSERM, U568, Fac Med, Ave Vallombrose, F-06107 Nice 02, France.		Gual, Philippe/M-8787-2017; Gual, Philippe/P-9833-2019; Kanzaki, Makoto/H-6680-2017	Gual, Philippe/0000-0001-7393-8356; Gual, Philippe/0000-0001-7393-8356; Kanzaki, Makoto/0000-0002-6884-2955; Gonzalez, Teresa/0000-0001-7558-6833; Tanti, Jean-Francois/0000-0003-1782-1318				Ahmed Z, 2000, FEBS LETT, V475, P31, DOI 10.1016/S0014-5793(00)01621-5; Barros LF, 2001, PFLUG ARCH EUR J PHY, V442, P614; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Holman GD, 2001, TRENDS CELL BIOL, V11, P173, DOI 10.1016/S0962-8924(01)01953-5; Janez A, 2000, J BIOL CHEM, V275, P26870; JUST I, 1995, J CLIN INVEST, V95, P1026, DOI 10.1172/JCI117747; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C200292200; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kanzaki M, 2001, J BIOL CHEM, V276, P49331, DOI 10.1074/jbc.M109657200; Kayali AG, 1998, J BIOL CHEM, V273, P13808, DOI 10.1074/jbc.273.22.13808; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kultz D, 2001, COMP BIOCHEM PHYS A, V130, P421, DOI 10.1016/S1095-6433(01)00440-8; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Thurmond DC, 2001, MOL MEMBR BIOL, V18, P237; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Ueno E, 2001, HORM METAB RES, V33, P402, DOI 10.1055/s-2001-16227; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; Watson RT, 2001, EXP CELL RES, V271, P75, DOI 10.1006/excr.2001.5375; Watson RT, 2000, J BIOL CHEM, V275, P1261, DOI 10.1074/jbc.275.2.1261; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200	37	27	27	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43980	43986		10.1074/jbc.M203042200	http://dx.doi.org/10.1074/jbc.M203042200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12215429	hybrid			2022-12-25	WOS:000179272000059
J	Slabas, AR; Kroon, JTM; Scheirer, TP; Gilroy, JS; Hayman, M; Rice, DW; Turnbull, AP; Rafferty, JB; Fawcett, T; Simon, WJ				Slabas, AR; Kroon, JTM; Scheirer, TP; Gilroy, JS; Hayman, M; Rice, DW; Turnbull, AP; Rafferty, JB; Fawcett, T; Simon, WJ			Squash glycerol-3-phosphate (1)-acyltransferase - Alteration of substrate selectivity and identification of arginine and lysine residues important in catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHILLING-SENSITIVE PLANT; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; ARABIDOPSIS-THALIANA; AMARANTHUS-LIVIDUS; ESCHERICHIA-COLI; LIPIDS; CHLOROPLASTS; SPECIFICITY; PEA; PURIFICATION	Glycerol-3-phosphate 1-acyltransferase is a soluble chloroplast enzyme involved in glycerol-lipid biosynthesis associated with chilling resistance in plants (1). Resistance is associated with higher selectivity for unsaturated acyl substrates over saturated ones. In vitro substrate selectivity assays performed under physiologically relevant conditions have been established that discriminate between selective and non-selective forms of the enzyme. A mutation, L261F, in the squash protein converts it from a non-selective enzyme into a selective one. The mutation lies within 10 Angstrom of the predicted acyl binding site and results in a higher K-m for 16:0 acyl carrier protein (ACP). Site-directed mutagenesis was used to determine the importance of four residues, Arg(235), Arg(237), Lys(193), and His(194), implicated to be in volved in binding of the phosphate group of glycerol 3-phosphate to the enzyme. All the proteins were highly homologous in structure to the wild type enzyme. Mutations in Arg(235), Arg(237), and Lys(193) resulted in inactive enzyme, while His 194 had reduced catalytic activity. The mutant proteins retained the ability to bind stoichiometric quantities of acyl-ACPs supporting the potential role of these residues in glycerol 3-phosphate binding.	Univ Durham, Sci Labs, Dept Biol & Biomed Sci, Durham DH1 3LE, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomol Res, Sheffield S10 2TN, S Yorkshire, England	Durham University; University of Sheffield	Slabas, AR (corresponding author), Univ Durham, Sci Labs, Dept Biol & Biomed Sci, Durham DH1 3LE, England.		Kroon, Johan Theodorus Maria/S-8415-2019; Fawcett, Tony/O-8033-2015	Kroon, Johan Theodorus Maria/0000-0003-2086-6074; Fawcett, Tony/0000-0001-7657-0120; Rafferty, John/0000-0003-1183-7474				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Broun P, 1998, SCIENCE, V282, P1315, DOI 10.1126/science.282.5392.1315; Brown AP, 1998, PLANT PHYSIOL BIOCH, V36, P629, DOI 10.1016/S0981-9428(98)80011-9; CRONAN JE, 1987, PLANT PHYSIOL, V83, P676, DOI 10.1104/pp.83.3.676; Ferri SR, 1997, ARCH BIOCHEM BIOPHYS, V337, P202, DOI 10.1006/abbi.1996.9769; FRENTZEN M, 1983, EUR J BIOCHEM, V129, P629; FRENTZEN M, 1987, PLANT CELL PHYSIOL, V28, P1195; GREEN PR, 1981, J BIOL CHEM, V256, P1151; Hayman MW, 2002, FEBS LETT, V514, P281, DOI 10.1016/S0014-5793(02)02381-5; Heath RJ, 1998, J BACTERIOL, V180, P1425, DOI 10.1128/JB.180.6.1425-1430.1998; ISHIZAKI O, 1988, FEBS LETT, V238, P424, DOI 10.1016/0014-5793(88)80525-8; JOHNSON BH, 1994, BIO-TECHNOL, V12, P1357, DOI 10.1038/nbt1294-1357; LEEGOOD RC, 1993, PLANT BIOCH MOL BIOL, P30; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; MURATA N, 1983, PLANT CELL PHYSIOL, V24, P81, DOI 10.1093/oxfordjournals.pcp.a076516; MURATA N, 1992, NATURE, V356, P710, DOI 10.1038/356710a0; Murata N, 1997, BBA-LIPID LIPID MET, V1348, P10, DOI 10.1016/S0005-2760(97)00115-X; NISHIDA I, 1993, PLANT MOL BIOL, V21, P267, DOI 10.1007/BF00019943; ROUGHAN G, 1990, ARCH BIOCHEM BIOPHYS, V276, P38, DOI 10.1016/0003-9861(90)90007-L; SAUER A, 1984, Z NATURFORSCH C, V39, P593; SIMON JW, 2002, MOL STRUCTURAL STUDI; Slabas AR, 2001, J PLANT PHYSIOL, V158, P505, DOI 10.1078/0176-1617-00363; SOL J, 1982, FEBS LETT, V146, P189; Turnbull AP, 2001, STRUCTURE, V9, P347, DOI 10.1016/S0969-2126(01)00595-0; WEBER S, 1991, PLANT MOL BIOL, V17, P1067, DOI 10.1007/BF00037145; WOLTER FP, 1992, EMBO J, V11, P4685, DOI 10.1002/j.1460-2075.1992.tb05573.x	26	19	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43918	43923		10.1074/jbc.M206429200	http://dx.doi.org/10.1074/jbc.M206429200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12205087	hybrid			2022-12-25	WOS:000179272000051
J	Taylor, AL; Hewett, SJ				Taylor, AL; Hewett, SJ			Potassium-evoked glutamate release liberates arachidonic acid from cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCITOTOXIC CELL-DEATH; FREE FATTY-ACIDS; PHOSPHOLIPASE A(2); PRIMARY CULTURES; D-ASPARTATE; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; BRAIN SYNAPTOSOMES; CEREBRAL-ISCHEMIA; NMDA RECEPTORS	Brain cells in situ contain low concentrations of free polyunsaturated fatty acids such as arachidonic acid (AA) that are released following pathological insults. As a large rise in extracellular [K+] accompanies cerebral ischemia, we explored whether this was a stimulus for cellular AA release employing a murine mixed cortical cell culture preparation radiolabeled with AA. Elevating the [K+], from 5 to 52 mm induced a time-dependent increase in [H-3]AA release, which reached a plateau after 15 min. Removal of [Ca2+](o) or addition of CdCl2 (100 muM) diminished the net high K+-induced AA release, as did treatment of the cultures with tetanus toxin (300 ng/ml) to block endogenous neurotransmitter release. Pharmacological antagonism of both ionotropic and metabotropic glutamate receptors completely prevented high K+-evoked AA release, indicating that glutamate was the neurotransmitter in question. Addition of exogenous glutamate mimicked precisely the characteristics of AA release that followed increases in [K+](o). Finally, glutamate and AA were released solely from neurons as tetanus toxin did not cleave astrocytic synaptobrevin-2, nor was AA released from pure astrocyte cultures using the same stimuli that were effective in mixed cultures. Taken in toto, our data are consistent with the following scenario: high [K+](o) depolarizes neurons, causing an influx of Ca2+ via voltage-gated Ca2+ channels. This Ca2+ influx stimulates the release of glutamate into the synaptic cleft, where it activates postsynaptic glutamate receptors. Events likely converge on the activation of a phospholipase A(2) family member and possibly the enzymes diacylglycerol and monoacylglycerol lipases to yield free AA.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Sch Med, Farmington, CT 06030 USA	University of Connecticut	Hewett, SJ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, Sch Med, MC-3401,263 Farmington Ave, Farmington, CT 06030 USA.	shewett@neuron.uchc.edu		Hewett, Sandra/0000-0002-2987-3791	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS036812, R01NS036812] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS036812, NS36812] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen JW, 2001, EXP NEUROL, V169, P449, DOI 10.1006/exnr.2001.7672; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BAZAN NG, 1989, ANN NY ACAD SCI, V559, P1; BAZAN NG, 1970, LIFE SCI, V9, P501, DOI 10.1016/0024-3205(70)90205-5; BRADFORD PG, 1983, J NEUROCHEM, V41, P1684, DOI 10.1111/j.1471-4159.1983.tb00881.x; Briand S I, 1998, Methods Mol Biol, V105, P161; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; CHAN PH, 1985, PROG BRAIN RES, V63, P227; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clements MP, 1996, J NEUROCHEM, V67, P1317; COLE DJ, 1993, J PHARMACOL EXP THER, V266, P1713; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Cummings BS, 2000, J PHARMACOL EXP THER, V294, P793; DORMAN RV, 1986, BRAIN RES BULL, V17, P243, DOI 10.1016/0361-9230(86)90121-8; DUGAN LL, 1994, ANN NEUROL, V35, pS17, DOI 10.1002/ana.410350707; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUMUIS A, 1993, MOL PHARMACOL, V43, P976; EATON SA, 1993, EUR J PHARM-MOLEC PH, V244, P195, DOI 10.1016/0922-4106(93)90028-8; Egan R W, 1980, Adv Prostaglandin Thromboxane Res, V6, P153; FAROOQUI AA, 1993, BRAIN RES, V604, P180, DOI 10.1016/0006-8993(93)90366-U; Gido G, 1997, STROKE, V28, P206, DOI 10.1161/01.STR.28.1.206; GORDINIER AL, 2001, SOC NEUROSCI ABS, V27; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; HILLERED L, 1988, J NEUROSCI RES, V19, P94, DOI 10.1002/jnr.490190113; JANE DE, 1993, NEUROPHARMACOLOGY, V32, P725, DOI 10.1016/0028-3908(93)90088-K; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; LAZAREWICZ JW, 1990, J NEUROCHEM, V55, P1875, DOI 10.1111/j.1471-4159.1990.tb05771.x; LAZAREWICZ JW, 1983, NEUROCHEM INT, V5, P471, DOI 10.1016/0197-0186(83)90077-3; LEFER AM, 1986, BIOCHEM PHARMACOL, V35, P123, DOI 10.1016/0006-2952(86)90502-2; Liu XH, 1998, CANCER RES, V58, P4245; MANZONI OJ, 1994, EUR J NEUROSCI, V6, P1050, DOI 10.1111/j.1460-9568.1994.tb00599.x; MATSUBARA C, 1983, ANAL BIOCHEM, V130, P128, DOI 10.1016/0003-2697(83)90659-0; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; MOORE SA, 1991, J NEUROCHEM, V56, P518, DOI 10.1111/j.1471-4159.1991.tb08180.x; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Nogawa S, 1997, J NEUROSCI, V17, P2746; Parpura V, 1995, FEBS LETT, V377, P489, DOI 10.1016/0014-5793(95)01401-2; PATEL PM, 1993, BRAIN RES, V614, P315, DOI 10.1016/0006-8993(93)91050-3; PetersGolden M, 1996, BIOCHEM J, V318, P797, DOI 10.1042/bj3180797; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; RABASSEDA X, 1987, FEBS LETT, V213, P337, DOI 10.1016/0014-5793(87)81518-1; RUBIN RP, 1970, PHARMACOL REV, V22, P389; SANFELIU C, 1990, BRAIN RES, V526, P241, DOI 10.1016/0006-8993(90)91228-9; SASAKI T, 1988, STROKE, V19, P1399, DOI 10.1161/01.STR.19.11.1399; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; STELLA N, 1995, J NEUROSCI, V15, P3307; STELLA N, 1994, J NEUROSCI, V14, P568; TAKEUCHI Y, 1991, ARCH BIOCHEM BIOPHYS, V289, P33, DOI 10.1016/0003-9861(91)90438-O; TAPIAARANCIBIA L, 1992, EUR J PHARM-MOLEC PH, V225, P253, DOI 10.1016/0922-4106(92)90027-S; Trackey JL, 2001, J NEUROCHEM, V79, P445, DOI 10.1046/j.1471-4159.2001.00584.x; Uliasz TF, 2000, J NEUROSCI METH, V100, P157, DOI 10.1016/S0165-0270(00)00248-X; VAZQUEZ E, 1994, NEUROSCI LETT, V174, P9, DOI 10.1016/0304-3940(94)90106-6; Vesce S, 1999, CELL MOL LIFE SCI, V56, P991, DOI 10.1007/s000180050488; Vidwans AS, 2001, BIOCHEMISTRY-US, V40, P11533, DOI 10.1021/bi0108960; VOLTERRA A, 1994, MOL PHARMACOL, V46, P986; WATKINS J, 1994, TRENDS PHARMACOL SCI, V15, P333, DOI 10.1016/0165-6147(94)90028-0; WIELOCH T, 1982, PATHOL BIOL, V30, P269; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; YU ACH, 1986, J NEUROCHEM, V47, P1181	63	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43881	43887		10.1074/jbc.M205872200	http://dx.doi.org/10.1074/jbc.M205872200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12235140	hybrid			2022-12-25	WOS:000179272000047
J	Braathen, R; Sorensen, V; Brandtzaeg, P; Sandlie, I; Johansen, FE				Braathen, R; Sorensen, V; Brandtzaeg, P; Sandlie, I; Johansen, FE			The carboxyl-terminal domains of IgA and IgM direct Isotype-specific polymerization and interaction with the polymeric immunoglobulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SECRETORY COMPONENT; MEDIATED EPITHELIAL TRANSPORT; J-CHAIN; DIMERIC IGA; STRUCTURAL REQUIREMENTS; EFFECTOR FUNCTIONS; C-ALPHA-3 DOMAIN; PENTAMERIC IGM; IN-VITRO; ANTIBODIES	Mucosal surfaces are protected by polymeric immunoglobulins that are transported across the epithelium by the polymeric immunoglobulin receptor (pIgR). Only polymeric IgA and IgM containing a small polypeptide called the "joining" (J) chain can bind to the pIgR. J chain-positive IgA consists of dimers, and some larger polymers, whereas only IgM pentamers incorporate the J chain. We made domain swap chimeras between human IgA1 and IgM and found that the COOH-terminal domains of the heavy chains (Calpha3 and Cmu4, respectively) dictated the size of the polymers formed and also which polymers incorporated the J chain. We also showed that chimeric IgM molecules engineered to contain Calpha3 were able to bind the rabbit pIgR. Since the rabbit pIgR normally does not bind IgM, these results suggest that the COOH-terminal domain of the polymeric immunoglobulins is primarily responsible for interaction with the pIgR. Finally, we made a novel chimeric IgA immunoglobulin, containing the terminal domain from IgM. This recombinant molecule formed J chain-containing pentamers that could, like IgA, efficiently form covalent complexes with the human pIgR ectodomain, known as secretory component.	Univ Oslo, Inst Pathol, Rikshosp, Lab Immunohistochem & Immunopathol, N-0027 Oslo, Norway; Univ Oslo, Inst Biol, Dept Mol Cell Biol, N-0316 Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo	Braathen, R (corresponding author), Univ Oslo, Inst Pathol, Rikshosp, Lab Immunohistochem & Immunopathol, N-0027 Oslo, Norway.	ranveig.braathen@labmed.uio.no						BEALE D, 1969, BIOCHEM J, V112, P187, DOI 10.1042/bj1120187; BORNEMANN KD, 1995, P NATL ACAD SCI USA, V92, P4912, DOI 10.1073/pnas.92.11.4912; BRANDTZAEG P, 1975, SCAND J IMMUNOL, V4, P837, DOI 10.1111/j.1365-3083.1975.tb03725.x; BRANDTZAEG P, 1977, IMMUNOCHEMISTRY, V14, P179, DOI 10.1016/0019-2791(77)90192-6; Brandtzaeg P, 1999, IMMUNOL REV, V171, P45, DOI 10.1111/j.1600-065X.1999.tb01342.x; BRANDTZAEG P, 1976, SCAND J IMMUNOL, V5, P411, DOI 10.1111/j.1365-3083.1976.tb00295.x; BRANDTZAEG P, 1974, SCAND J IMMUNOL, V3, P579, DOI 10.1111/j.1365-3083.1974.tb01291.x; BRANDTZAEG P, 1984, NATURE, V311, P71, DOI 10.1038/311071a0; BRANDTZAEG P, 1975, SCAND J IMMUNOL, V4, P309, DOI 10.1111/j.1365-3083.1975.tb02631.x; Brewer JW, 1997, MOL IMMUNOL, V34, P323, DOI 10.1016/S0161-5890(97)00029-1; CARAYANNOPOULOS L, 1994, P NATL ACAD SCI USA, V91, P8348, DOI 10.1073/pnas.91.18.8348; CATTANEO A, 1987, EMBO J, V6, P2753, DOI 10.1002/j.1460-2075.1987.tb02569.x; Chintalacharuvu KR, 2001, CLIN IMMUNOL, V101, P21, DOI 10.1006/clim.2001.5083; Crottet P, 1998, J IMMUNOL, V161, P5445; DAVIS AC, 1989, EMBO J, V8, P2519, DOI 10.1002/j.1460-2075.1989.tb08389.x; ESKELAND T, 1974, IMMUNOCHEMISTRY, V11, P161, DOI 10.1016/0019-2791(74)90214-6; FALLGREENGEBAUER E, 1993, BIOL CHEM H-S, V374, P1023, DOI 10.1515/bchm3.1993.374.7-12.1023; HENDRICKSON BA, 1995, J EXP MED, V182, P1905, DOI 10.1084/jem.182.6.1905; Hexham JM, 1999, J EXP MED, V189, P747, DOI 10.1084/jem.189.4.747; Johansen FE, 1999, EUR J IMMUNOL, V29, P1701, DOI 10.1002/(SICI)1521-4141(199905)29:05<1701::AID-IMMU1701>3.0.CO;2-Z; Johansen FE, 2000, SCAND J IMMUNOL, V52, P240; Johansen FE, 2001, J IMMUNOL, V167, P5185, DOI 10.4049/jimmunol.167.9.5185; KABAT EA, 1991, SEQUENCES PROTEINS I, P661; KOHLER G, 1982, EMBO J, V1, P555, DOI 10.1002/j.1460-2075.1982.tb01208.x; Krugmann S, 1997, J IMMUNOL, V159, P244; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MA JKC, 1995, SCIENCE, V268, P716, DOI 10.1126/science.7732380; MACH JP, 1970, NATURE, V228, P1278, DOI 10.1038/2281278a0; MILSTEIN CP, 1975, BIOCHEM J, V151, P615, DOI 10.1042/bj1510615; MOSTOV K, 1999, MUCOSAL IMMUNOLOGY, P181; Natvig IB, 1997, J IMMUNOL, V159, P4330; NILES MJ, 1995, P NATL ACAD SCI USA, V92, P2884, DOI 10.1073/pnas.92.7.2884; Norderhaug IN, 1999, EUR J IMMUNOL, V29, P3401, DOI 10.1002/(SICI)1521-4141(199910)29:10<3401::AID-IMMU3401>3.0.CO;2-G; Norderhaug IN, 1999, CRIT REV IMMUNOL, V19, P481; POON PH, 1995, J BIOL CHEM, V270, P8571, DOI 10.1074/jbc.270.15.8571; RANDALL TD, 1992, J BIOL CHEM, V267, P18002; Roe M, 1999, J IMMUNOL, V162, P6046; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; SMITH RIF, 1994, BIO-TECHNOL, V12, P683, DOI 10.1038/nbt0794-683; SMITH RIF, 1995, J IMMUNOL, V154, P2226; Sorensen V, 1996, J IMMUNOL, V156, P2858; Sorensen V, 1999, J IMMUNOL, V162, P3448; Sorensen V, 2000, INT IMMUNOL, V12, P19, DOI 10.1093/intimm/12.1.19; SWITZER IC, 1992, MOL IMMUNOL, V29, P31, DOI 10.1016/0161-5890(92)90153-O; Vaerman JP, 1998, IMMUNOLOGY, V95, P90; Vaerman JP, 1998, EUR J IMMUNOL, V28, P171, DOI 10.1002/(SICI)1521-4141(199801)28:01<171::AID-IMMU171>3.0.CO;2-#; VAERMAN JP, 1995, IMMUNOL INVEST, V24, P631, DOI 10.3109/08820139509066863; WARR GW, 1995, IMMUNOL TODAY, V16, P392, DOI 10.1016/0167-5699(95)80008-5; WEICKER J, 1975, J IMMUNOL, V114, P1337; WIERSMA EJ, 1995, J IMMUNOL, V154, P5265; Wiersma EJ, 1998, J IMMUNOL, V160, P5979; Yoo EM, 1999, J BIOL CHEM, V274, P33771, DOI 10.1074/jbc.274.47.33771	52	41	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42755	42762		10.1074/jbc.M205502200	http://dx.doi.org/10.1074/jbc.M205502200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12213814	Green Published, hybrid			2022-12-25	WOS:000179081200044
J	Greenhalgh, CJ; Metcalf, D; Thaus, AL; Corbin, JE; Uren, R; Morgan, PO; Fabri, LJ; Zhang, JG; Martin, HM; Willson, TA; Billestrup, N; Nicola, NA; Baca, M; Alexander, WS; Hilton, DJ				Greenhalgh, CJ; Metcalf, D; Thaus, AL; Corbin, JE; Uren, R; Morgan, PO; Fabri, LJ; Zhang, JG; Martin, HM; Willson, TA; Billestrup, N; Nicola, NA; Baca, M; Alexander, WS; Hilton, DJ			Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND DEVELOPMENT; MICE LACKING SUPPRESSOR; NEGATIVE REGULATION; TRANSGENIC MICE; CYTOKINE; RECEPTOR; EXPRESSION; INHIBITION; STAT5B; TRANSDUCTION	Suppressor of cytokine signaling (SOCS)-2 is a member of a family of intracellular proteins implicated in the negative regulation of cytokine signaling. The generation of SOCS-2-deficient mice, which grow to one and a half times the size of their wild-type littermates, suggests that SOCS-2 may attenuate growth hormone (GH) signaling. In vitro studies indicate that, while SOCS-2 can inhibit GH action at low concentrations, at higher concentrations it may potentiate signaling. To determine whether a similar enhancement of signaling is observed in vivo or alternatively whether increased SOCS-2 levels repress growth in vivo, we generated and analyzed transgenic mice that overexpress SOCS-2 from a human ubiquitin C promoter. These mice are not growth-deficient and are, in fact, significantly larger than wild-type mice. The overexpressed SOCS-2 was found to bind to endogenous GH receptors in a number of mouse organs, while phosphopeptide binding studies with recombinant SOCS-2 defined phosphorylated tyrosine 595 on the GH receptor as the site of interaction. Together, the data implicate SOCS-2 as having dual effects on GH signaling in vivo.	PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; PO Royal Melbourne Hosp, Cooperat Res Cellular Growth Factors, Melbourne, Vic 3050, Australia; AMRAD Operat Ltd, Richmond 3121, Australia; Steno Diabet Ctr, DK-2820 Gentofte, Denmark	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Steno Diabetes Center	Greenhalgh, CJ (corresponding author), PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Nicola, Nicos/D-2989-2011; Hilton, Douglas J/C-7250-2013	Nicola, Nicos/0000-0003-1054-7889; Hilton, Douglas J/0000-0002-7698-2392; fabri, louis/0000-0003-4033-3304; Uren, Rachel/0000-0001-7456-478X; Billestrup, Nils/0000-0002-4968-8067	NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA 22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Dif F, 2001, ENDOCRINOLOGY, V142, P5286, DOI 10.1210/en.142.12.5286; Favre H, 1999, FEBS LETT, V453, P63, DOI 10.1016/S0014-5793(99)00681-X; Greenhalgh CJ, 2001, J LEUKOCYTE BIOL, V70, P348; Greenhalgh CJ, 2002, MOL ENDOCRINOL, V16, P1394, DOI 10.1210/me.16.6.1394; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Horvat S, 2001, GENOMICS, V72, P209, DOI 10.1006/geno.2000.6441; Kile BT, 2001, MOL CELL BIOL, V21, P6189, DOI 10.1128/MCB.21.18.6189-6197.2001; Krebs DL, 2000, J CELL SCI, V113, P2813; Lindeman GJ, 2001, GENE DEV, V15, P1631, DOI 10.1101/gad.880801; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; Pezet A, 1999, J BIOL CHEM, V274, P24497, DOI 10.1074/jbc.274.35.24497; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PK, 2000, J BIOL CHEM, V275, P39487, DOI 10.1074/jbc.M004755200; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Schultheis B, 2002, BLOOD, V99, P1766, DOI 10.1182/blood.V99.5.1766; Stofega MR, 2000, MOL ENDOCRINOL, V14, P1338, DOI 10.1210/me.14.9.1338; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	29	136	147	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40181	40184		10.1074/jbc.C200450200	http://dx.doi.org/10.1074/jbc.C200450200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12208853	hybrid			2022-12-25	WOS:000178791400004
J	Blagosklonny, MV				Blagosklonny, MV			Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs	ONCOGENE			English	Article						p53; mitosis; G2 arrest; checkpoints; paclitaxel	G(2) ARREST; DNA-DAMAGE; P53; CANCER; UCN-01; KINASE; P21(WAF1/CIP1); APOPTOSIS; PATHWAYS; THERAPY	By inducing p53-dependent G2 arrest, the pretreatment with low concentrations of DNA damaging drugs (e.g., doxorubicin, DOX) can prevent cell death caused by microtubule-active drugs (e.g., paclitaxel, PTX), thus potentially permitting selective killing of p53-deficient cancer cells. However, DOX still protects a subset of tumor cell lines lacking wt p53 (HL60 and Jurkat leukemia cells), thus limiting the utility of protection of cells with wt p53 (e.g., normal cells). The present work overcomes this obstacle by adding an abrogator of p53-independent checkpoint (e.g., UCN-01) to the DOX-PTX sequence. By inhibiting a p53-independent pathway, UCN-01 overrode DOX-induced G2 arrest and instead induced G1 arrest in HL60 and Jurkat, thus propelling these p53-deficient cells from G2 to G1. Once they entered mitosis, cells were killed by PTX. Induction of G2 arrest with sequential abrogation of a p53-independent checkpoint allows pharmacological manipulation of Raf-1/Bcl-2 hyperphosphorylation, PARP and Rb cleavage and cell death caused by PTX in p53-deficient cells. Unlike previous approaches, this strategy is intended to increase selectivity, not the cytotoxicity of PTX. This rational sequence of agents that induces p53-dependent and abrogates p53-independent arrest represents a cancer-selective strategy for treatment of p53-deficient tumors.	New York Med Coll, Brander Canc Res Inst, Dept Med, Hawthorne, NY 10532 USA	New York Medical College	Blagosklonny, MV (corresponding author), New York Med Coll, Brander Canc Res Inst, Dept Med, 19 Bradhurst Ave, Hawthorne, NY 10532 USA.							An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; Blagosklonny MV, 1999, LEUKEMIA, V13, P2031, DOI 10.1038/sj.leu.2401623; Blagosklonny MV, 2002, CANCER BIOL THER, V1, P113, DOI 10.4161/cbt.53; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 2001, INT J ONCOL, V19, P257; Blagosklonny MV, 2001, CANCER RES, V61, P4301; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Busby EC, 2000, CANCER RES, V60, P2108; Chan TA, 2000, GENE DEV, V14, P1584; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Li W, 1999, MOL PHARMACOL, V55, P1988; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Sherr CJ, 2002, CELL CYCLE, V1, P36, DOI 10.4161/cc.1.1.106; Smith APL, 2002, CELL CYCLE, V1, P16, DOI 10.4161/cc.1.1.96; Torres K, 1998, CANCER RES, V58, P3620; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1996, NATURE, V381, P643; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455	26	51	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6249	6254		10.1038/sj.onc.1205793	http://dx.doi.org/10.1038/sj.onc.1205793			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214265				2022-12-25	WOS:000177829000001
J	Blanchard, F; Kinzie, E; Wang, YP; Duplomb, L; Godard, A; Held, WA; Asch, BB; Baumann, H				Blanchard, F; Kinzie, E; Wang, YP; Duplomb, L; Godard, A; Held, WA; Asch, BB; Baumann, H			FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins	ONCOGENE			English	Article						cytokine receptor; inflammatory mediators; signal transduction; gene regulation; cytotoxicity	BREAST-CANCER CELLS; ONCOSTATIN-M; DNA METHYLATION; BINDING-PROTEIN; UP-REGULATION; TRANSCRIPTIONAL REPRESSION; GELSOLIN EXPRESSION; TARGETED DISRUPTION; GROWTH-INHIBITION; SIGNAL TRANSDUCER	The related members of the interleukin-6 (IL-6) family of cytokines, leukemia inhibitory factor (LIF), oncostatin M (OSM) and IL-6 are inflammatory mediators that control differentiated cell functions as well as proliferation. The cellular responsiveness to these cytokines is largely determined by the expression of the appropriate receptor proteins. The receptor expression profile for each cell type is established during differentiation and is often altered during oncogenic transformation. Since inhibition of histone deacetylases (HDAC) has the potential to re-activate epigenetically silenced genes, we asked whether inhibition of HDAC enhances the expression of IL-6 cytokine receptors and, thus, increase desirable cytokine responses. We demonstrate that treatment with FR901228 (FR), an HDAC inhibitor, increases the responsiveness to LIF in different cell types, including normal fibroblasts, epithelial cells, macrophages and splenocytes, as well as various tumor cell lines. Depending on the cell type, FR treatment also enhances the responsiveness to OSM and IL-6. These effects involve a transcriptional induction of the cytokine receptor subunits LIFRalpha, OSMRbeta, gp130, or the transcription factor STAT3. FR-specific induction of LIFRalpha occurs independently of de noro protein synthesis and cell proliferation and is mediated in part by the CBP/p300 coactivator. Chromatin immunoprecipitation experiments indicate that the expression of LIFRalpha. and gp130 genes correlates with the level of acetylated histone 3 associated with the receptor promoter regions. The FR-stimulated expression of IL-6-type cytokine receptors in certain tumor cells also provided improved conditions for suppression of cell growth by taking advantage of the growth inhibitory effect of these cytokines.	INSERM, U463, Inst Biol, F-44035 Nantes 01, France; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Div Expt Pathol, Buffalo, NY 14263 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Roswell Park Cancer Institute; Roswell Park Cancer Institute	Blanchard, F (corresponding author), INSERM, U463, Inst Biol, 9 Quai Moncousu, F-44035 Nantes 01, France.		Blanchard, Frederic/K-8018-2015; Blanchard, Frederic/AAS-1930-2021	Blanchard, Frederic/0000-0003-1055-2573; Blanchard, Frederic/0000-0003-1055-2573; Duplomb, Laurence/0000-0002-5715-3759	NATIONAL CANCER INSTITUTE [P30CA016056, R01CA068612, R01CA085580] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056, CA 68612, CA 85580] Funding Source: Medline; NIDDK NIH HHS [DK 38866] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Armenante F, 1999, BIOCHEM BIOPH RES CO, V258, P644, DOI 10.1006/bbrc.1999.0566; Auernhammer CJ, 2000, ENDOCR REV, V21, P313, DOI 10.1210/er.21.3.313; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAJAJ P, 1993, CANCER LETT, V71, P143, DOI 10.1016/0304-3835(93)90109-M; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; BHUYAN BK, 1992, CANCER RES, V52, P5687; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; Blanchard F, 2001, J BIOL CHEM, V276, P47038, DOI 10.1074/jbc.M107971200; Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886; Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200; BREITMAN TR, 1990, CANCER RES, V50, P6268; Byrd JC, 1999, BLOOD, V94, P1401, DOI 10.1182/blood.V94.4.1401.416k30_1401_1408; CAMERON DJ, 1980, J IMMUNOL, V124, P708; Chen B, 2000, CANCER RES, V60, P3290; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Grenier A, 1999, BLOOD, V93, P1413, DOI 10.1182/blood.V93.4.1413.404k06_1413_1421; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Kantarjian HM, 1997, LEUKEMIA, V11, P1617, DOI 10.1038/sj.leu.2400796; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kim H, 1999, MOL CELL BIOL, V19, P5326; Klausen P, 2000, ONCOGENE, V19, P3675, DOI 10.1038/sj.onc.1203707; Klouche M, 1999, J IMMUNOL, V163, P4583; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; Lindberg RA, 1998, MOL CELL BIOL, V18, P3357, DOI 10.1128/MCB.18.6.3357; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Melki JR, 1999, CANCER RES, V59, P3730; Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461; Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; NAIR BC, 1992, SCIENCE, V255, P1432; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; OBrien CA, 1997, J BIOL CHEM, V272, P15003, DOI 10.1074/jbc.272.23.15003; Okamoto H, 1997, ARTHRITIS RHEUM, V40, P1096, DOI 10.1002/art.1780400614; RICHARDS CD, 1994, CYTOKINE, V6, P40, DOI 10.1016/1043-4666(94)90006-X; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; Shin JY, 2000, CANCER RES, V60, P262; Thibault A, 1998, TUMORI, V84, P87, DOI 10.1177/030089169808400120; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang YP, 2000, J BIOL CHEM, V275, P25273, DOI 10.1074/jbc.M002296200; Wang ZY, 1997, J BIOL CHEM, V272, P27957, DOI 10.1074/jbc.272.44.27957; WARE CB, 1995, DEVELOPMENT, V121, P1283; Weidle UH, 2000, ANTICANCER RES, V20, P1471; Wong HR, 1997, AM J PHYSIOL-LUNG C, V273, pL1, DOI 10.1152/ajplung.1997.273.1.L1; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	60	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6264	6277		10.1038/sj.onc.1205777	http://dx.doi.org/10.1038/sj.onc.1205777			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214267				2022-12-25	WOS:000177829000003
J	Karimpour, S; Lou, JY; Lin, LL; Rene, LM; Lagunas, L; Ma, XR; Karra, S; Bradbury, CM; Markovina, S; Goswami, P; Spitz, DR; Hirota, K; Kalvakolanu, DV; Yodoi, J; Gius, D				Karimpour, S; Lou, JY; Lin, LL; Rene, LM; Lagunas, L; Ma, XR; Karra, S; Bradbury, CM; Markovina, S; Goswami, P; Spitz, DR; Hirota, K; Kalvakolanu, DV; Yodoi, J; Gius, D			Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation	ONCOGENE			English	Article						thioredoxin reductase; thioredoxin; AP-1; redox; ionizing radiation	NF-KAPPA-B; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; REDOX REGULATION; GENE-EXPRESSION; RETINOID COMBINATION; OXIDATIVE STRESS; DRUG TARGET; CELL-LINES; ACTIVATION	A recently identified class of signaling factors uses critical cysteine motif(s) that act as redox-sensitive 'sulfhydryl switches' to reversibly modulate specific signal transduction cascades regulating downstream proteins with similar redox-sensitive sites. For example, signaling factors such as redox factor-1 (Ref-1) and transcription factors such as the AP-1 complex both contain redox-sensitive cysteine motifs that regulate activity in response to oxidative stress. The mammalian thioredoxin reductase-1 (TR) is an oxidoreductase selenocysteine-containing flavoprotein that also appears to regulate multiple downstream intracellular redox-sensitive proteins. Since ionizing radiation (IR) induces oxidative stress as well as increases AP-1 DNA-binding activity via the activation of Ref-1, the potential roles of TR and thioredoxin (TRX) in the regulation of AP-1 activity in response to IR were investigated. Permanently transfected cell lines that overexpress wild type TR demonstrated constitutive increases in AP-1 DNA-binding activity as well as AP-1-dependent reporter gene expression, relative to vector control cells. In contrast, permanently transfected cell lines expressing a TR gene with the active site cysteine motif deleted were unable to induce AP-1 activity or reporter gene expression in response to IR. Transient genetic overexpression of either the TR wild type or dominant-negative genes demonstrated similar results using a transient assay system. One mechanism through which TR regulates AP-1 activity appears to involve TRX sub-cellular localization, with no change in the total TRX content of the cell. These results identify a novel function of the TR enzyme as a signaling factor in the regulation of AP-1 activity via a cysteine motif located in the protein.	NCI, Radiat Oncol Branch, Radiat Oncol Sci Program, Canc Res Ctr,NIH, Bethesda, MD 20892 USA; Washington Univ, Sch Med, Sect Canc Biol, Mallinckrodt Inst Radiol, St Louis, MO USA; Univ Maryland, Sch Med, Greenbaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, Baltimore, MD 21201 USA; Univ Iowa, Free Rad & Radiat Biol Program, Dept Radiol, Iowa City, IA USA; Kyoto Univ Hosp, Dept Anesthesia, Kyoto 606, Japan; Kyoto Univ, Dept Biol Responses, Inst Virus Res, Kyoto, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Washington University (WUSTL); University System of Maryland; University of Maryland Baltimore; University of Iowa; Kyoto University; Kyoto University	Gius, D (corresponding author), NCI, Radiat Oncol Branch, Radiat Oncol Sci Program, Canc Res Ctr,NIH, 9000 Rockville Pike,Bldg 10,Room B3B69, Bethesda, MD 20892 USA.	giusd@mail.nih.gov	; Hirota, Kiichi/E-9181-2010	Goswami, Prabhat/0000-0002-5700-2096; Spitz, Douglas/0000-0002-1254-8765; Hirota, Kiichi/0000-0003-1110-0827	NATIONAL CANCER INSTITUTE [R01CA078282, R29CA069593, R01CA071401, K08CA072602] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051469] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 78282, CA69593, CA 71401, 1 K08 CA72602-01] Funding Source: Medline; NHLBI NIH HHS [R01 HL51469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1991, ONCOGENE, V6, P2179; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Beetz A, 2000, INT J RADIAT BIOL, V76, P1443, DOI 10.1080/09553000050176207; Berggren M, 1996, ANTICANCER RES, V16, P3459; Curry HA, 1999, J BIOL CHEM, V274, P23061, DOI 10.1074/jbc.274.33.23061; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; Gallegos A, 1996, CANCER RES, V56, P5765; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HALLIWELL B, 1988, HUM TOXICOL, V7, P7, DOI 10.1177/096032718800700102; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 2000, BIOCHEM BIOPH RES CO, V275, P825, DOI 10.1006/bbrc.2000.3392; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Hu JD, 2001, ONCOGENE, V20, P4235, DOI 10.1038/sj.onc.1204585; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; KERR L D, 1992, Current Opinion in Cell Biology, V4, P496, DOI 10.1016/0955-0674(92)90017-7; Kirkpatrick DL, 1997, ONCOL RES, V9, P351; Ma XR, 2001, ONCOGENE, V20, P3703, DOI 10.1038/sj.onc.1204477; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; Martin M, 1997, ONCOGENE, V15, P981, DOI 10.1038/sj.onc.1201433; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Oberley TD, 2001, FREE RADICAL BIO MED, V30, P412, DOI 10.1016/S0891-5849(00)00486-X; Poole LB, 2000, EUR J BIOCHEM, V267, P6126, DOI 10.1046/j.1432-1327.2000.01704.x; Powis G, 1998, CHEM-BIOL INTERACT, V112, P23, DOI 10.1016/S0009-2797(97)00148-8; Sasada Tetsuro, 1996, Journal of Toxicological Sciences, V21, P285; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TUTTLE SW, 1992, INT J RADIAT ONCOL, V22, P671, DOI 10.1016/0360-3016(92)90500-H; Wei SJ, 2000, CANCER RES, V60, P6688; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; Xanthoudakis S, 1996, ADV EXP MED BIOL, V387, P69; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	39	101	107	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6317	6327		10.1038/sj.onc.1205749	http://dx.doi.org/10.1038/sj.onc.1205749			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214272				2022-12-25	WOS:000177829000008
J	Muller, N; Reinacher-Schick, A; Baldus, S; van Hengel, J; Berx, G; Baar, A; van Roy, F; Schmiegel, W; Schwarte-Waldhoff, I				Muller, N; Reinacher-Schick, A; Baldus, S; van Hengel, J; Berx, G; Baar, A; van Roy, F; Schmiegel, W; Schwarte-Waldhoff, I			Smad4 induces the tumor suppressor E-cadherin and P-cadherin in colon carcinoma cells	ONCOGENE			English	Article						Smad4; tumor suppressor gene; TGF-beta; E-cadherin; invasion	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTOR SNAIL; TGF-BETA; MESENCHYMAL TRANSDIFFERENTIATION; COLORECTAL-CANCER; GENE; DPC4; MUTATIONS; EXPRESSION; PROTEINS	Smad4 is an intracellular transmitter of TGF-beta signals and its tumor suppressor function is presumed to reside in its capacity to mediate TGF-beta-induced growth inhibition. However, there is accumulating evidence that this hypothesis may be too simple. The roles of TGF-beta in carcinogenesis are complex and also comprise tumor promoting functions particularly in late stage carcinogenesis. Importantly, functional inactivation of Smad4 in colon carcinomas frequently occurs at late stages when tumors acquire invasive and metastatic capabilities. We have previously reported that stable re-expression of Smad4 in SW480 human colon carcinoma cells was adequate to suppress tumor growth in nude mice. However, it did not affect cell growth in vitro nor did it restore TGF-beta responsiveness. Here, we report that Smad4 transcriptionally induced classical cadherins including the invasion suppressor E-cadherin, presumably re-establishing epithelial morphology. Smad4-induced cadherins were able to recruit catenins to the plasma membrane and were functionally active in cell-cell adhesion. These results indicate a novel pathway of Smad4-mediated tumor suppression and suggest that Smad4 in colon cells may be involved in the maintenance of epithelial traits.	Ruhr Univ Bochum, IMBL, Dept Internal Med, D-4630 Bochum, Germany; Univ Cologne, Dept Pathol, Cologne, Germany; State Univ Ghent VIB, Dept Mol Biomed Res, Mol Cell Biol Unit, B-9000 Ghent, Belgium	Ruhr University Bochum; University of Cologne; Flanders Institute for Biotechnology (VIB); Ghent University	Schwarte-Waldhoff, I (corresponding author), Ruhr Univ Bochum, Knappschaftskrankenhaus, Schornau 23-25, D-44892 Bochum, Germany.	irmgard.schwarte-waldhoff@ruhr-uni-bochum.de	van Roy, Frans M/C-6123-2009; Reinacher-Schick, Anke C/F-2722-2012	van Roy, Frans M/0000-0003-4358-1039; Berx, Geert/0000-0001-5770-2458				Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Baldus SE, 1998, INT J CANCER, V79, P133, DOI 10.1002/(SICI)1097-0215(19980417)79:2<133::AID-IJC6>3.0.CO;2-U; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Blaker H, 2002, ONCOGENE, V21, P158, DOI 10.1038/sj.onc.1205041; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ellenrieder V, 2001, CANCER RES, V61, P4222; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Fink SP, 2001, CANCER RES, V61, P256; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Hajra KM, 2002, CANCER RES, V62, P1613; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HENNIG G, 1995, ONCOGENE, V11, P475; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Kern Scott E., 1998, Current Opinion in Oncology, V10, P74, DOI 10.1097/00001622-199801000-00012; KINGSTON P, 1994, RES SOCIAL STRATIFIC, V13, P3; Kitagawa K, 1996, INT J CANCER, V66, P91, DOI 10.1002/(SICI)1097-0215(19960328)66:1<91::AID-IJC16>3.0.CO;2-E; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Maitra A, 2000, AM J PATHOL, V157, P1105, DOI 10.1016/S0002-9440(10)64625-1; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Montgomery E, 2001, AM J PATHOL, V158, P537, DOI 10.1016/S0002-9440(10)63995-8; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Piek E, 1999, J CELL SCI, V112, P4557; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Reiss M, 1997, ONCOL RES, V9, P447; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Schutte M, 1996, CANCER RES, V56, P2527; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Verschueren K, 1999, CYTOKINE GROWTH F R, V10, P187, DOI 10.1016/S1359-6101(99)00012-X; Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x; Wilentz RE, 2000, CANCER RES, V60, P2002; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	64	57	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6049	6058		10.1038/sj.onc.1205766	http://dx.doi.org/10.1038/sj.onc.1205766			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203117				2022-12-25	WOS:000177671300008
J	Salven, P; Hattori, K; Heissig, B; Rafii, S				Salven, P; Hattori, K; Heissig, B; Rafii, S			Interleukin-1 alpha (IL-1 alpha) promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion	FASEB JOURNAL			English	Article						inflammation; leukocyte; mononuclear; endothelium	ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; VASCULAR DEVELOPMENT; FACTOR RECEPTOR-1; TYROSINE KINASE; FLT-1; EXPRESSION; ATHEROSCLEROSIS; DISEASE; CANCER	During inflammation, functional changes occur in the vasculature, including extensive endothelial cell mitotic activity and remodeling of capillaries. Interleukin-1alpha (IL-1alpha) is a prototypical proinflammatory cytokine. Vascular endothelial growth factor (VEGF) is a strong endothelial cell-specific mitogen that exerts a pivotal role in angiogenesis under physiological and pathological conditions. We show that IL-1alpha stimulates VEGF secretion by human peripheral blood mononuclear cells (PBMNCs) in a dose-dependent manner. This represents induction of de novo VEGF synthesis, as an induction of VEGF mRNA was observed. Also, the release of VEGF was blocked by cycloheximide. Reverse transcription-polymerase chain reaction (RT-PCR) detected four VEGF splice variants in unstimulated and in IL-1alpha-stimulated PBMNCs. In vivo in mice, subcutaneously administered IL-1alpha caused a strong local angiogenic response, which was accompanied by an infiltrate of VEGF-expressing inflammatory cells. The angiogenic effect of IL-1alpha was blocked when the mice were treated with VEGF receptor 2 (VEGFR-2) neutralizing antibodies. VEGFR-1 blocking antibodies had a marginal inhibitory effect on IL-1alpha-induced angiogenesis. These observations indicate that IL-1alpha induces angiogenesis by activating the VEGF-VEGFR-2 signaling pathway between inflammatory cells and blood vessel endothelial cells. This novel mechanism of IL-1alpha-action may enhance the shift to angiogenic phenotype in various conditions designated by excessive angiogenesis.	Cornell Univ, Weill Med Coll, Div Hematol Oncol, New York, NY 10021 USA	Cornell University	Salven, P (corresponding author), Cornell Univ, Weill Med Coll, Div Hematol Oncol, 1300 York Ave,Room C-606, New York, NY 10021 USA.	pjs2004@med.cornell.edu	Heissig, Beate/AAF-6771-2021	Heissig, Beate/0000-0002-0348-5934				Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; BENEZRA D, 1990, ARCH OPHTHALMOL-CHIC, V108, P573, DOI 10.1001/archopht.1990.01070060121061; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Brown LF, 1997, LAB INVEST, V76, P245; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Couper LL, 1997, CIRC RES, V81, P932; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FREEMAN MR, 1995, CANCER RES, V55, P4140; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hiratsuka S, 2001, CANCER RES, V61, P1207; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lu D, 2000, J BIOL CHEM, V275, P14321, DOI 10.1074/jbc.275.19.14321; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; MAHADEVAN V, 1989, CANCER RES, V49, P415; MCKANE WR, 1994, J BONE MINER RES, V9, P1313; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; NICOSIA RF, 1994, AM J PATHOL, V145, P1023; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Salven P, 2001, FASEB J, V15, P1318, DOI 10.1096/fj.00-0627fje; Siemeister G, 1996, BIOCHEM BIOPH RES CO, V222, P249, DOI 10.1006/bbrc.1996.0730; Sullivan GW, 2000, J LEUKOCYTE BIOL, V67, P591, DOI 10.1002/jlb.67.5.591; Suzuma K, 2000, J BIOL CHEM, V275, P40725, DOI 10.1074/jbc.M006509200; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832	39	112	117	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1471	+		10.1096/fj.02-0134fje	http://dx.doi.org/10.1096/fj.02-0134fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205052				2022-12-25	WOS:000177813100002
J	Behne, MJ; Meyer, JW; Hanson, KM; Barry, NP; Murata, S; Crumrine, D; Clegg, RW; Gratton, E; Holleran, WM; Elias, PM; Mauro, TM				Behne, MJ; Meyer, JW; Hanson, KM; Barry, NP; Murata, S; Crumrine, D; Clegg, RW; Gratton, E; Holleran, WM; Elias, PM; Mauro, TM			NHE1 regulates the stratum corneum permeability barrier homeostasis - Microenvironment acidification assessed with fluorescence lifetime imaging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCOCEREBROSIDASE ACTIVITY; PHOSPHOLIPASE A(2); KERATINOCYTE DIFFERENTIATION; MURINE EPIDERMIS; CROSSOVER TRIAL; FATTY-ACIDS; PH GRADIENT; HUMAN-SKIN; IN-VIVO; AMILORIDE	The outermost epidermal layer, the stratum corneum (SC), exhibits an acidic surface pH, whereas the pH at its base approaches neutrality. NHE1 is the only Na+/H+ antiporter isoform in keratinocytes and epidermis, and has been shown to regulate intracellular pH. We now demonstrate a novel function for NHE1, as we find that it also controls acidification of extracellular "microdomains" in the SC that are essential for activation of pH-sensitive enzymes and the formation of the epidermal permeability barrier. NHE1 expression in epidermis is most pronounced in granular cell layers, and although the surface pH of NHE1 knockout mice is only slightly more alkaline than normal using conventional pH measurements, a more sensitive method, fluorescence lifetime imaging, demonstrates that the acidic intercellular domains at the surface and of the lower SC disappear in NHE1 -/- animals. Fluorescence lifetime imaging studies also reveal that SC acidification does not occur through a uniform gradient, but through the progressive accumulation of acidic microdomains. These findings not only visualize the spatial distribution of the SC pH gradient, but also demonstrate a role for NHE1 in the generation of acidic extracellular domains of the lower SC, thus providing the acidification of deep SC interstices necessary for lipid processing and barrier homeostasis.	Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Illinois, Dept Phys, Fluorescence Dynam Lab, Urbana, IL 61801 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Ohio; University of Cincinnati; University of Illinois System; University of Illinois Urbana-Champaign	Behne, MJ (corresponding author), Univ Calif San Francisco, Dept Dermatol, 4150 Clement St, San Francisco, CA 94121 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044341, R01AR019098] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61974] Funding Source: Medline; NIAMS NIH HHS [AR19098, AR44341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALY R, 1978, J INVEST DERMATOL, V71, P378, DOI 10.1111/1523-1747.ep12556778; Bell SM, 1999, AM J PHYSIOL-CELL PH, V276, pC788, DOI 10.1152/ajpcell.1999.276.4.C788; BERG RW, 1994, PEDIATR DERMATOL, V11, P18, DOI 10.1111/j.1525-1470.1994.tb00066.x; BLANK IRVIN H., 1939, JOUR INVEST DERMAT, V2, P67; Bonnet U, 2000, EUR NEUROPSYCHOPHARM, V10, P97, DOI 10.1016/S0924-977X(99)00063-2; Bouwstra J A, 1998, J Investig Dermatol Symp Proc, V3, P69; Bouwstra JA, 2000, CELL MOL BIOL, V46, P979; Capasso G, 1997, MINER ELECTROL METAB, V23, P243; CHRISTOPHERS E, 1971, J INVEST DERMATOL, V56, P165, DOI 10.1111/1523-1747.ep12260765; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; Fluhr JW, 2001, J INVEST DERMATOL, V117, P44, DOI 10.1046/j.0022-202x.2001.01399.x; FRELIN C, 1987, KIDNEY INT, V32, P785, DOI 10.1038/ki.1987.277; Hanson KM, 2002, BIOPHYS J, V83, P1682, DOI 10.1016/S0006-3495(02)73936-2; HOLLERAN WM, 1992, J LIPID RES, V33, P1201; HOLLERAN WM, 1993, J CLIN INVEST, V91, P1656, DOI 10.1172/JCI116374; Jensen JM, 1999, J CLIN INVEST, V104, P1761, DOI 10.1172/JCI5307; Komuves LG, 2000, J INVEST DERMATOL, V115, P361, DOI 10.1046/j.1523-1747.2000.00076.x; KORTING HC, 1987, ACTA DERM-VENEREOL, V67, P41; KORTING HC, 1990, ACTA DERM-VENEREOL, V70, P429; Krien PM, 2000, J INVEST DERMATOL, V115, P414, DOI 10.1046/j.1523-1747.2000.00083.x; LEE SH, 1994, J INVEST DERMATOL, V102, P976, DOI 10.1111/1523-1747.ep12384225; LIECKFELDT R, 1995, PHARM RES-DORDR, V12, P1614, DOI 10.1023/A:1016280714593; Loh SH, 1996, BRIT J PHARMACOL, V118, P1905, DOI 10.1111/j.1476-5381.1996.tb15623.x; MACKENZI.JC, 1969, NATURE, V222, P881, DOI 10.1038/222881a0; MACKENZIE IC, 1981, J INVEST DERMATOL, V76, P459, DOI 10.1111/1523-1747.ep12521107; MAN MQ, 1993, ARCH DERMATOL, V129, P728, DOI 10.1001/archderm.129.6.728; MaoQiang M, 1996, J INVEST DERMATOL, V106, P57, DOI 10.1111/1523-1747.ep12327246; Masters BR, 1997, BIOPHYS J, V72, P2405, DOI 10.1016/S0006-3495(97)78886-6; Mauro T, 1998, ARCH DERMATOL RES, V290, P215, DOI 10.1007/s004030050293; Mauro T, 2002, J INVEST DERMATOL, V118, P589, DOI 10.1046/j.1523-1747.2002.01721.x; MAURO T, 1995, J INVEST DERMATOL, V105, P203, DOI 10.1111/1523-1747.ep12317130; MENON GK, 1992, J INVEST DERMATOL, V98, P209, DOI 10.1111/1523-1747.ep12555880; Menon GK, 1997, SKIN PHARMACOL, V10, P235; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Ogata Y, 2002, COMP BIOCHEM PHYS C, V131, P315, DOI 10.1016/S1532-0456(02)00005-4; Ohman H, 1998, J INVEST DERMATOL, V111, P674, DOI 10.1046/j.1523-1747.1998.00356.x; OHMAN H, 1994, ACTA DERM-VENEREOL, V74, P375; Pannabecker TL, 2002, PFLUG ARCH EUR J PHY, V443, P446, DOI 10.1007/s004240100705; Patterson MJ, 2000, EXP PHYSIOL, V85, P869, DOI 10.1017/S0958067000020583; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Rousselle AV, 2002, BONE, V30, P533, DOI 10.1016/S8756-3282(02)00672-5; Sarangarajan R, 2001, BBA-BIOMEMBRANES, V1511, P181, DOI 10.1016/S0005-2736(01)00273-5; Schadow A, 2001, J INVEST DERMATOL, V116, P31, DOI 10.1046/j.1523-1747.2001.00179.x; Schmuth M, 2000, J INVEST DERMATOL, V115, P459, DOI 10.1046/j.1523-1747.2000.00081.x; SIT KH, 1993, ANAT RECORD, V235, P183, DOI 10.1002/ar.1092350202; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; SZMACINSKI H, 1993, ANAL CHEM, V65, P1668, DOI 10.1021/ac00061a007; Tadrous PJ, 2000, J PATHOL, V191, P229; Takagi Y, 1999, J LIPID RES, V40, P861; THUNE P, 1988, ACTA DERM-VENEREOL, V68, P277; Tominaga T, 1998, MOL BIOL CELL, V9, P2287, DOI 10.1091/mbc.9.8.2287; Turner N G, 1998, J Investig Dermatol Symp Proc, V3, P110; Uchida Y, 2001, J INVEST DERMATOL, V117, P1307, DOI 10.1046/j.0022-202x.2001.01555.x; VIGNE P, 1984, MOL PHARMACOL, V25, P131; Wepf R, 2002, J INVEST DERMATOL, V119, P250	55	138	147	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47399	47406		10.1074/jbc.M204759200	http://dx.doi.org/10.1074/jbc.M204759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12221084	hybrid			2022-12-25	WOS:000179663700074
J	Sevcik, J; Urbanikova, L; Leland, PA; Raines, RT				Sevcik, J; Urbanikova, L; Leland, PA; Raines, RT			X-ray structure of two crystalline forms of a Streptomycete ribonuclease with cytotoxic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SEMINAL RIBONUCLEASE; ELECTRON-DENSITY MAPS; CONFORMATIONAL STABILITY; EXOCELLULAR RIBONUCLEASE; BIOLOGICAL-ACTIVITIES; CATALYTIC ACTIVITY; PROTEIN STABILITY; ALPHA-SARCIN; RNASE SA; AUREOFACIENS	Ribonuclease (RNase) Sa3 is secreted by the Gram-positive bacterium Streptomyces aureofaciens. The enzyme catalyzes the cleavage of RNA on the 3' side of guanosine residues. Here, x-ray diffraction analysis was used to determine the three-dimensional structure of two distinct crystalline forms of RNase Sa3 to a resolution of 2.0 and 1.7 Angstrom. These two structures are similar to each other as well as to that of a homolog, RNase Sa. All of the key active-site residues of RNase Sa (Asn(42), Glu(44), Glu(57), Arg(72), and His(88)) are located in the putative active site of RNase Sa3. Also herein, RNase Sa3 is shown to be toxic to human erythroleukemia cells in culture. Like onconase, which is an amphibian ribonuclease in Phase III clinical trials as a cancer chemotherapeutic, RNase Sa3 is not inhibited by the cytosolic ribonuclease inhibitor protein. Thus, a prokaryotic ribonuclease can be toxic to mammalian cells.	Slovak Acad Sci, Inst Mol Biol, Bratislava 84251, Slovakia; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	Slovak Academy of Sciences; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Sevcik, J (corresponding author), Slovak Acad Sci, Inst Mol Biol, Dubravska Cesta 21, Bratislava 84251, Slovakia.		Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719; Urbanikova, Lubica/0000-0002-5592-8346	NCI NIH HHS [CA73808] Funding Source: Medline; NIGMS NIH HHS [T32 GM07215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACOVA M, 1971, BIOCHIM BIOPHYS ACTA, V235, P335, DOI 10.1016/0005-2744(71)90212-9; Bretscher LE, 2000, J BIOL CHEM, V275, P9893, DOI 10.1074/jbc.275.14.9893; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CAFARO V, 1995, FEBS LETT, V359, P31, DOI 10.1016/0014-5793(94)01450-F; CHO SW, 1989, ANAL BIOCHEM, V176, P175, DOI 10.1016/0003-2697(89)90289-3; Cruickshank D.W.J, 1996, P CCP4 STUD WEEK, P11; EGAMI F, 1964, PROG NUCLEIC ACID RE, V3, P59, DOI 10.1016/S0079-6603(08)60739-4; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Futami J, 2001, BIOCHEMISTRY-US, V40, P7518, DOI 10.1021/bi010248g; Haigis MC, 2002, J BIOL CHEM, V277, P11576, DOI 10.1074/jbc.M112227200; HARTLEY RW, 1980, J MOL EVOL, V15, P355, DOI 10.1007/BF01733142; HARTLEY RW, 1996, PROTEIN PEPTIDE LETT, V4, P225; Hebert EJ, 1997, PROTEIN EXPRES PURIF, V11, P162, DOI 10.1006/prep.1997.0776; Hebert EJ, 1998, BIOCHEMISTRY-US, V37, P16192, DOI 10.1021/bi9815243; Hlinkova V, 2001, ACTA CRYSTALLOGR D, V57, P737, DOI 10.1107/S0907444901003456; Hofsteenge J., 1997, RIBONUCLEASES STRUCT, P621, DOI [10.1016/b978-012588945-2/50020-0, DOI 10.1016/B978-012588945-2/50020-0]; HOMEROVA D, 1992, GENE, V119, P147, DOI 10.1016/0378-1119(92)90082-Z; Ilinskaya O, 2001, TOXICOLOGY, V156, P101, DOI 10.1016/S0300-483X(00)00335-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kao R, 1999, J BIOL CHEM, V274, P12576, DOI 10.1074/jbc.274.18.12576; KIM JS, 1995, J BIOL CHEM, V270, P10525, DOI 10.1074/jbc.270.18.10525; KIM JS, 1995, BIOCHEM J, V308, P547, DOI 10.1042/bj3080547; Klink TA, 2000, J BIOL CHEM, V275, P17463, DOI 10.1074/jbc.M001132200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; Leland PA, 2001, J BIOL CHEM, V276, P43095, DOI 10.1074/jbc.M106636200; Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8; Leland PA, 2000, FEBS LETT, V477, P203, DOI 10.1016/S0014-5793(00)01804-4; Madan T, 1997, MOL CELL BIOCHEM, V175, P21, DOI 10.1023/A:1006822906343; Matousek J, 2001, COMP BIOCHEM PHYS C, V129, P175, DOI 10.1016/S1532-0456(01)90202-9; Matousek J, 1997, COMP BIOCHEM PHYS B, V118, P881, DOI 10.1016/S0305-0491(97)00278-2; Mikulski SM, 2002, J CLIN ONCOL, V20, P274, DOI 10.1200/JCO.20.1.274; Murshudov G.N., 1997, CCP4 NEWSLETTER, V33, P31; MURTHY BS, 1992, BIOCHEM J, V281, P343, DOI 10.1042/bj2810343; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NAZAROV V, 1991, THESIS I MOL BIOL; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pace CN, 2000, PROTEIN SCI, V9, P1395; Pace CN, 2001, J MOL BIOL, V312, P393, DOI 10.1006/jmbi.2001.4956; Perez-Canadillas JM, 2000, J MOL BIOL, V299, P1061, DOI 10.1006/jmbi.2000.3813; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; RAPPUOLI R, 1997, GUIDEBOOK PROTEIN TO; SCHINDLER DG, 1977, NUCLEIC ACIDS RES, V4, P1097, DOI 10.1093/nar/4.4.1097; SEVCIK J, 1993, ACTA CRYSTALLOGR D, V49, P257, DOI 10.1107/S0907444992007261; SEVCIK J, 1991, ACTA CRYSTALLOGR B, V47, P240, DOI 10.1107/S0108768190009569; Sevcik J, 1996, ACTA CRYSTALLOGR D, V52, P327, DOI 10.1107/S0907444995007669; SEVCIK J, 1993, EUR J BIOCHEM, V216, P301, DOI 10.1111/j.1432-1033.1993.tb18145.x; Sevcik J, 1998, ACTA CRYSTALLOGR D, V54, P954, DOI 10.1107/S0907444998004429; SEVCIK J, 1990, TRENDS BIOCHEM SCI, V15, P158, DOI 10.1016/0968-0004(90)90217-Y; Shapiro R, 2001, METHOD ENZYMOL, V341, P611, DOI 10.1016/S0076-6879(01)41180-3; Shaw KL, 2001, PROTEIN SCI, V10, P1206, DOI 10.1110/ps.440101; SHLYAPNIKOV SV, 1986, FEBS LETT, V209, P335; Urbanikova L, 1998, ACTA CRYSTALLOGR D, V54, P403, DOI 10.1107/S0907444997010688; Wilson AJC, 1942, NATURE, V150, P151, DOI 10.1038/150152a0; Wool I.G., 1997, RIBONUCLEASES STRUCT, P131; WU YN, 1993, J BIOL CHEM, V268, P10686; Yang XJ, 1996, STRUCTURE, V4, P837, DOI 10.1016/S0969-2126(96)00090-1; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491; ZELINKOVA E, 1971, BIOCHIM BIOPHYS ACTA, V235, P343, DOI 10.1016/0005-2744(71)90213-0	63	42	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47325	47330		10.1074/jbc.M208425200	http://dx.doi.org/10.1074/jbc.M208425200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12228255	hybrid			2022-12-25	WOS:000179663700064
J	Srimathi, T; Kumar, TKS; Chi, YH; Chiu, IM; Yu, C				Srimathi, T; Kumar, TKS; Chi, YH; Chiu, IM; Yu, C			Characterization of the structure and dynamics of a near-native equilibrium intermediate in the unfolding pathway of an all beta-barrel protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; MOLTEN GLOBULE STATE; BACKBONE DYNAMICS; SUCROSE OCTASULFATE; HYDROGEN-EXCHANGE; ALPHA-LACTALBUMIN; CRYSTAL-STRUCTURE; BINDING; N-15; DENATURATION	The structure and dynamics of equilibrium intermediate in the unfolding pathway of the human acidic fibroblast growth factor (hFGF-1) are investigated using a variety of biophysical techniques including multidimensional NMR spectroscopy. Guanidinium hydrochloride (GdnHCl)-induced unfolding of hFGF-1 proceeds with the accumulation of a stable intermediate state. The transition from the intermediate state to the unfolded state(s) is cooperative without the accumulation of additional intermediate(s). The intermediate state induced maximally in 0.96 M GdnHCl is found to be obligatory in the folding/unfolding pathway of hFGF-1. Most of the native tertiary structure interactions are preserved in the intermediate state. H-1-N-15 chemical shift perturbation data suggest that the residues in the C-terminal segment including those located in the P-strands M X, and XI undergo the most discernible structural change(s) in the intermediate state in 0.96 M GdnHCl. hFGF-1 in the intermediate state (0.96 M GdnHCl) does not bind to its ligand, sucrose octasulfate. Limited proteolytic digestion experiments and hydrogen-deuterium exchange monitored by N-15 heteronuclear single quantum coherence (HSQC) spectra show that the conformational flexibility of the protein in the intermediate state is significantly higher than in the native conformation. N-15 spin relaxation experiments show that many residues located in beta-strands IX, X, and XI exhibit conformational motions in the micro- to millisecond time scale. Analysis of N-15 relaxation data in conjunction with the amide proton exchange kinetics suggests that residues in the beta-strands II, VIII, and XII possibly constitute the stability core of the protein in the near-native intermediate state.	Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA	National Tsing Hua University; University System of Ohio; Ohio State University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan.	cyu@mx.nthu.edu.tw	Chi, Ya-Hui/B-1080-2010; KUMAR, P. SURESH/AAT-8951-2020; Kumar, Dr Suresh/HHZ-2615-2022; Chiu, Ing-Ming/B-1534-2008; Kumar, Suresh Thallapuranam/R-5606-2016; Chi, Ya-Hui/ABE-8550-2020	KUMAR, P. SURESH/0000-0003-3222-2604; Kumar, Dr Suresh/0000-0002-2539-6553; Kumar, Suresh Thallapuranam/0000-0001-7262-1373; Chi, Ya-Hui/0000-0002-9216-0938				ALEXANDRESCU AT, 1994, J MOL BIOL, V242, P527, DOI 10.1006/jmbi.1994.1598; ALEXANDRESCU AT, 1993, BIOCHEMISTRY-US, V32, P1707, DOI 10.1021/bi00058a003; Arai M, 2000, ADV PROTEIN CHEM, V53, P209; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Bilsel O, 2000, ADV PROTEIN CHEM, V53, P153; Blaber M, 1996, BIOCHEMISTRY-US, V35, P2086, DOI 10.1021/bi9521755; Blaber SI, 1999, BIOPHYS J, V77, P470, DOI 10.1016/S0006-3495(99)76904-3; Brandts J. F., 1969, STRUCTURE STABILITY, V2, P213; Burton RE, 1998, BIOCHEMISTRY-US, V37, P5337, DOI 10.1021/bi980245c; Bychkova VE, 1996, BIOCHEMISTRY-US, V35, P6058, DOI 10.1021/bi9522460; Bychkova VE, 1998, FOLD DES, V3, P285, DOI 10.1016/S1359-0278(98)00039-X; Cavagnero S, 2001, BIOCHEMISTRY-US, V40, P14459, DOI 10.1021/bi011500n; Chamberlain AK, 1998, BIOCHEMISTRY-US, V37, P1736, DOI 10.1021/bi972692i; Chi YH, 2001, BIOCHEMISTRY-US, V40, P7746, DOI 10.1021/bi002364+; Chi YH, 2000, J BIOL CHEM, V275, P39444, DOI 10.1074/jbc.M007205200; CLARKE J, 1995, CURR OPIN STRUC BIOL, V8, P112; DABORA JM, 1991, J BIOL CHEM, V266, P23637; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Dobson CM, 2001, BIOCHEM SOC SYMP, V68, P1; DOBSON CM, 1994, CURR BIOL, V4, P636, DOI 10.1016/S0960-9822(00)00141-X; Dyson HJ, 1998, NAT STRUCT BIOL, V5, P499, DOI 10.1038/739; ENGLANDER WW, 1993, Q REV BIOPHYS, V16, P521; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fersht AR, 2002, CELL, V108, P573, DOI 10.1016/S0092-8674(02)00620-7; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Li RH, 1999, PROTEIN SCI, V8, P1571, DOI 10.1110/ps.8.8.1571; LIU ZP, 1994, BIOCHEMISTRY-US, V33, P134, DOI 10.1021/bi00167a017; MACH H, 1995, BIOCHEMISTRY-US, V34, P9913, DOI 10.1021/bi00031a013; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; Mosavi LK, 2002, J MOL BIOL, V320, P165, DOI 10.1016/S0022-2836(02)00441-2; NATH U, 1995, BIOCHEMISTRY-US, V34, P1702, DOI 10.1021/bi00005a027; Ogura K, 1999, J BIOMOL NMR, V13, P11, DOI 10.1023/A:1008330622467; OREKHOV VY, 1995, J BIOMOL NMR, V6, P113, DOI 10.1007/BF00211774; PACE CN, 1979, ADV PROTEIN CHEM, V33, P167; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PALMER AG, 1999, APPL NMR STUDY STRUC, P171; PinedaLucena A, 1996, J MOL BIOL, V264, P162, DOI 10.1006/jmbi.1996.0631; Press W., 1992, NUMERICAL RECIPES FO; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Ren JH, 1999, SCIENCE, V284, P955, DOI 10.1126/science.284.5416.955; Samuel D, 2001, J BIOL CHEM, V276, P4134, DOI 10.1074/jbc.M005921200; Samuel D, 2000, J BIOL CHEM, V275, P34968, DOI 10.1074/jbc.M005147200; Sanz JM, 1997, EUR J BIOCHEM, V246, P328, DOI 10.1111/j.1432-1033.1997.00328.x; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schulman BA, 1997, NAT STRUCT BIOL, V4, P630, DOI 10.1038/nsb0897-630; Schwartz MP, 1999, J BIOL CHEM, V274, P12759, DOI 10.1074/jbc.274.18.12759; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; Soulages JL, 1998, BIOPHYS J, V75, P484, DOI 10.1016/S0006-3495(98)77537-X; Van Mierlo CPM, 2000, PROTEIN SCI, V9, P145; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VANMIERLO CPM, 1993, J MOL BIOL, V229, P1125, DOI 10.1006/jmbi.1993.1108; VOLKIN DB, 1993, BIOCHIM BIOPHYS ACTA, V1203, P18, DOI 10.1016/0167-4838(93)90031-L; WANG L, 1998, PROTEIN SCI, V7, P2360; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x; Wijesinha-Bettoni R, 2001, J MOL BIOL, V312, P261, DOI 10.1006/jmbi.2001.4927; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wong KB, 1996, J MOL BIOL, V259, P805, DOI 10.1006/jmbi.1996.0359; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	64	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47507	47516		10.1074/jbc.M203407200	http://dx.doi.org/10.1074/jbc.M203407200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12226076	hybrid			2022-12-25	WOS:000179663700088
J	Hamm, J; Alessi, DR; Biondi, RM				Hamm, J; Alessi, DR; Biondi, RM			Bi-functional, substrate mimicking RNA inhibits MSK1-mediated cAMP-response element-binding protein phosphorylation and reveals magnesium ion-dependent conformational changes of the kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO SELECTION; EXPORT SIGNAL; NUCLEIC-ACIDS; CREB; CELLS; ACTIVATION; EXPRESSION; POLYMERASE; RIBOZYMES; EVOLUTION	The design of specific inhibitors for protein kinases is an important step toward elucidation of intracellular signal transduction pathways and to guide drug discovery programs. We devised a model approach to generate specific, competitive kinase inhibitors by isolating substrate mimics containing two independent binding sites with an anti-idiotype strategy from combinatorial RNA libraries. As a general test for the ability to generate highly specific kinase inhibitors, we selected the transcription factor cAMP-response element-binding protein (CREB) that is phosphorylated on the same serine residue by the protein kinase MSK1 as well as by RSK1. The sequences and structures of these kinases are very similar, about 60% of their amino acids are identical. Nevertheless, we can demonstrate that the selected RNA inhibitors inhibit specifically CREB phosphorylation by MSK1 but do not affect CREB phosphorylation by RSK1. The inhibitors interact preferentially with the inactive form of MSK1. Furthermore, we demonstrate that RNA ligands can be conformation-specific probes, and this feature allowed us to describe magnesium ion-dependent conformational changes of MSK1 upon activation.	Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland; MSI, WTB Complex, Div Signal Transduct Therapy, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Hamm, J (corresponding author), Univ Turin, Dipartimento Genet Biol & Biochim, Sez Biol, Centro Ric Med Sperimentale, Via Santena 5bis, I-10126 Turin, Italy.	jorg.hamm@unito.it		Alessi, Dario/0000-0002-2140-9185; Biondi, Ricardo/0000-0002-8873-7167				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barcellini-Couget S, 1998, ANTISENSE NUCLEIC A, V8, P379, DOI 10.1089/oli.1.1998.8.379; Bertrand E, 1997, RNA, V3, P75; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DOUDNA JA, 1995, P NATL ACAD SCI USA, V92, P2355, DOI 10.1073/pnas.92.6.2355; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Famulok M, 2001, CHEM BIOL, V8, P931, DOI 10.1016/S1074-5521(01)00070-9; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Gwizdek C, 2001, J BIOL CHEM, V276, P25910, DOI 10.1074/jbc.M100493200; HAMM J, 1990, METHOD ENZYMOL, V181, P273; Hamm J, 1996, NUCLEIC ACIDS RES, V24, P2220, DOI 10.1093/nar/24.12.2220; Hamm J, 1997, P NATL ACAD SCI USA, V94, P12839, DOI 10.1073/pnas.94.24.12839; Hamm J, 2000, CHEM BIOL, V7, P345, DOI 10.1016/S1074-5521(00)00112-5; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Johnson DA, 2001, CHEM REV, V101, P2243, DOI 10.1021/cr000226k; JOYCE GF, 1994, CURR OPIN STRUC BIOL, V4, P331, DOI 10.1016/S0959-440X(94)90100-7; Keane JD, 1996, CHEM BIOL, V3, P505, DOI 10.1016/S1074-5521(96)90139-8; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SMITH D, 1995, CHEM BIOL, V2, P741, DOI 10.1016/1074-5521(95)90102-7; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; White RR, 2000, J CLIN INVEST, V106, P929, DOI 10.1172/JCI11325; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611	32	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45793	45802		10.1074/jbc.M205072200	http://dx.doi.org/10.1074/jbc.M205072200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235136	hybrid			2022-12-25	WOS:000179529300012
J	Todeschin, AR; Girard, MF; Wieruszeski, JM; Nunes, MP; DosReis, GA; Mendonca-Previato, L; Previato, JO				Todeschin, AR; Girard, MF; Wieruszeski, JM; Nunes, MP; DosReis, GA; Mendonca-Previato, L; Previato, JO			trans-sialidase from Trypanosoma cruzi binds host T-lymphocytes in a lectin manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER DIFFERENCE NMR; NEURAMINIDASE ACTIVITIES; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; CHAGAS-DISEASE; CD43; RECEPTOR; ADHESION; ACTIVATION	Trypanosoma cruzi, the protozoan parasite responsible for Chagas' disease, expresses on its surface an uncommon membrane-bound sialidase, known as trans-sialidase. trans-Sialidase is the product of a multigene family encoding both active and inactive proteins. We report here that an inactive mutant of trans-sialidase physically interacts with CD4(+) T cells. Using a combination of flow cytometry and immunoprecipitation techniques, we identified the sialomucin CD43 as a counter-receptor for trans-sialidase on CD4(+) T cells. Using biochemical, immunological, and spectroscopic approaches, we demonstrated that the inactive trans-sialidase is a sialic acid-binding protein displaying the same specificity required by active trans-sialidase. Taken together, these results suggest that inactive members of the trans-sialidase family can physically interact with sialic acid-containing molecules on host cells and could play a role in host cell/T. cruzi interaction.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho, Ilha Fdn, BR-21944970 Rio De Janeiro, Brazil; Univ Estado Rio De Janeiro, Inst Biol, Dept Bioquim, BR-20551013 Rio De Janeiro, Brazil; Inst Pasteur, Lab RMN Synth, F-59019 Lille, France	Universidade Federal do Rio de Janeiro; Universidade do Estado do Rio de Janeiro; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Mendonca-Previato, L (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho, Ilha Fdn, Bloco G,Cidade Univ, BR-21944970 Rio De Janeiro, Brazil.			DosReis, George/0000-0002-8924-4727; Girard, Murielle/0000-0003-1222-0329; Previato, Jose Osvaldo/0000-0002-9233-9954; Mendonca Previato, Lucia/0000-0003-3927-3244				ABRAMSON JS, 1995, BLOOD, V85, P1615, DOI 10.1182/blood.V85.6.1615.bloodjournal8561615; Baum LG, 1996, J BIOL CHEM, V271, P10793, DOI 10.1074/jbc.271.18.10793; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8625, DOI 10.1074/jbc.275.12.8625; BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135; Buschiazzo A, 2000, EMBO J, V19, P16, DOI 10.1093/emboj/19.1.16; Buschiazzo A, 1996, CELL MOL BIOL, V42, P703; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CHUENKOVA M, 1995, J EXP MED, V181, P1693, DOI 10.1084/jem.181.5.1693; Costa F, 1998, VACCINE, V16, P768, DOI 10.1016/S0264-410X(97)00277-6; CREMONA ML, 1995, GENE, V160, P123, DOI 10.1016/0378-1119(95)00175-6; Cremona ML, 1999, GLYCOBIOLOGY, V9, P581, DOI 10.1093/glycob/9.6.581; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; Diercks T, 2001, CURR OPIN CHEM BIOL, V5, P285, DOI 10.1016/S1367-5931(00)00204-0; DosReis GA, 1997, PARASITOL TODAY, V13, P335, DOI 10.1016/S0169-4758(97)01073-9; Frasch ACC, 2000, PARASITOL TODAY, V16, P282, DOI 10.1016/S0169-4758(00)01698-7; Fratazzi C, 2000, J EXP MED, V192, P183, DOI 10.1084/jem.192.2.183; GARSKELL A, 1995, STRUCTURE, V15, P1197; HARLOW E, 1988, ANTIBODIES LABORATOR, P340; Hunter CA, 1997, J IMMUNOL, V158, P3311; Iorio RM, 2001, J VIROL, V75, P1918, DOI 10.1128/JVI.75.4.1918-1927.2001; JONES AT, 1994, J IMMUNOL, V153, P3426; LOPES MF, 1995, J IMMUNOL, V154, P744; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; Maaheimo H, 2000, BIOCHEMISTRY-US, V39, P12778, DOI 10.1021/bi000780o; MANJUNATH N, 1995, NATURE, V377, P535, DOI 10.1038/377535a0; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; Moller H, 2002, EUR J BIOCHEM, V269, P1444, DOI 10.1046/j.1432-1033.2002.02787.x; Ostberg JR, 1998, IMMUNOL TODAY, V19, P546, DOI 10.1016/S0167-5699(98)01343-7; Paris G, 2001, GLYCOBIOLOGY, V11, P305, DOI 10.1093/glycob/11.4.305; PARODI AJ, 1992, EMBO J, V11, P1705, DOI 10.1002/j.1460-2075.1992.tb05221.x; POLLEVICK GD, 1991, MOL BIOCHEM PARASIT, V47, P247, DOI 10.1016/0166-6851(91)90185-9; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; REUTER G, 1994, METHOD ENZYMOL, V230, P168; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; ROTHWELL SW, 1994, J IMMUNOL, V152, P2358; Sabri S, 2000, J CELL SCI, V113, P1589; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; Stockl J, 1996, J EXP MED, V184, P1769, DOI 10.1084/jem.184.5.1769; Todeschini AR, 2002, J IMMUNOL, V168, P5192, DOI 10.4049/jimmunol.168.10.5192; Todeschini AR, 2000, GLYCOBIOLOGY, V10, P213, DOI 10.1093/glycob/10.2.213; UEMURA H, 1992, EMBO J, V11, P3837, DOI 10.1002/j.1460-2075.1992.tb05476.x; van den Berg TK, 2001, J IMMUNOL, V166, P3637, DOI 10.4049/jimmunol.166.6.3637; VANDEKERCKHOVE F, 1992, GLYCOBIOLOGY, V2, P541, DOI 10.1093/glycob/2.6.541; Vogtherr M, 2000, J AM CHEM SOC, V122, P6093, DOI 10.1021/ja0001916	49	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45962	45968		10.1074/jbc.M203185200	http://dx.doi.org/10.1074/jbc.M203185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237289	hybrid			2022-12-25	WOS:000179529300035
J	Tzagarakis-Foster, C; Geleziunas, R; Lomri, A; An, JP; Leitman, DC				Tzagarakis-Foster, C; Geleziunas, R; Lomri, A; An, JP; Leitman, DC			Estradiol represses human T-cell leukemia virus type 1 tax activation of tumor necrosis factor-a gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR-ALPHA GENE; HORMONE REPLACEMENT THERAPY; ESTROGEN-RECEPTOR; BINDING-PROTEIN; BONE-RESORPTION; INTERLEUKIN-6 PROMOTER; TRANSGENIC MICE; DNA-BINDING; I CARRIERS	Adult T-cell leukemia is caused by human T-cell leukemia virus type I (HTLV-I). The HTLV-I Tax protein is essential for clinical manifestations because it activates viral and cellular gene transcription. Tax enhances production of tumor necrosis factor-alpha (TNF-alpha), which may lead to bone and joint destruction. Because estrogens might prevent osteoporosis by repressing TNF-alpha gene transcription, we investigated whether estrogens inhibit the transcriptional effects of Tax on the TNF-alpha promoter. Tax activated the -1044, -163, and -125 TNF-a promoters by 9-25-fold but not the -82 promoter, demonstrating that Tax activation requires the -125 to -82 region, known as the TNF response element (TNF-RE). Three copies of the TNF-RE upstream of the minimal thymidine kinase promoter conferred a similar magnitude of activation by Tax. We demonstrated that c-Jun, NFkappaB, p50, and p65 interact with and activate the TNF-RE by using mutational analysis of the TNF-RE, Tax mutants that selectively activate NFkappaB or the cAMP-response element binding proteinlactivating transcription factor pathway, and gel shift assays with nuclear extracts. Estradiol markedly repressed Tax-activated transcription of the TNF-a gene with estrogen receptor (ER) alpha or beta. Nuclear extracts from U2OS cells stably transfected with ERalpha demonstrated that ERs interact with the TNF-RE. Our studies provide evidence that ERs repress Tax-activated TNF-alpha transcription by interacting with a c-Jun and NFkappaB platform on the TNF-RE. Estrogens may ameliorate bone and inflammatory joint diseases in patients infected with HTLV-1 by repressing transcription of the TNF-alpha gene.	Univ Calif San Francisco, Ctr Reprod Sci, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Merck Res Labs, W Point, PA 19486 USA	University of California System; University of California San Francisco; Merck & Company	Leitman, DC (corresponding author), Univ Calif San Francisco, Ctr Reprod Sci, Dept Obstet Gynecol & Reprod Sci, HSE 1619 POB 0556, San Francisco, CA 94143 USA.			Lomri, Abderrahim/0000-0001-9847-026X				ALBRECHT H, 1992, J VIROL, V66, P6191, DOI 10.1128/JVI.66.10.6191-6193.1992; Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333; An JP, 1999, P NATL ACAD SCI USA, V96, P15161, DOI 10.1073/pnas.96.26.15161; An JP, 2001, J BIOL CHEM, V276, P17808, DOI 10.1074/jbc.M100953200; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; CENTRELLA M, 1988, ENDOCRINOLOGY, V123, P1442, DOI 10.1210/endo-123-3-1442; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Cowan EP, 1997, J VIROL, V71, P6982, DOI 10.1128/JVI.71.9.6982-6989.1997; Dennison EM, 1998, BRIT J RHEUMATOL, V37, P1198; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Galien R, 1996, MOL ENDOCRINOL, V10, P713, DOI 10.1210/me.10.6.713; GESSAIN A, 1985, LANCET, V2, P407; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; Goldring M B, 2000, Curr Rheumatol Rep, V2, P459, DOI 10.1007/s11926-000-0021-y; Hausmann S, 1999, J IMMUNOL, V162, P5389; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; Hisada M, 2001, INT J CANCER, V91, P497, DOI 10.1002/1097-0215(20010215)91:4&lt;497::AID-IJC1044&gt;3.0.CO;2-A; Hisada M, 1998, INT J CANCER, V77, P188, DOI 10.1002/(SICI)1097-0215(19980717)77:2&lt;188::AID-IJC3&gt;3.0.CO;2-M; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; IWAKURA Y, 1995, J IMMUNOL, V155, P1588; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; JOHNSON RA, 1989, ENDOCRINOLOGY, V124, P1424, DOI 10.1210/endo-124-3-1424; Johnson SR, 1998, MED CLIN N AM, V82, P297, DOI 10.1016/S0025-7125(05)70608-8; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; Kenny AM, 2000, RHEUM DIS CLIN N AM, V26, P569, DOI 10.1016/S0889-857X(05)70157-5; Kimble RB, 1997, J BONE MINER RES, V12, P935, DOI 10.1359/jbmr.1997.12.6.935; KIYOKAWA T, 1987, CANCER, V59, P1187, DOI 10.1002/1097-0142(19870315)59:6<1187::AID-CNCR2820590626>3.0.CO;2-8; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; Lenzmeier BA, 1999, J MOL BIOL, V291, P731, DOI 10.1006/jmbi.1999.2969; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Lomri A, 1999, CALCIFIED TISSUE INT, V64, P394, DOI 10.1007/PL00005821; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MORI N, 1994, BLOOD, V84, P2904; Ozden S, 1996, J ACQ IMMUN DEF SYND, V13, pS154, DOI 10.1097/00042560-199600001-00024; Pacifici R, 1996, J BONE MINER RES, V11, P1043; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUDDLE NH, 1993, VIROLOGY, V197, P196, DOI 10.1006/viro.1993.1580; Shimamoto Y, 1996, INT J HEMATOL, V64, P111; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; STEIN B, 1995, MOL CELL BIOL, V15, P4971; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SUZUKI T, 1993, ONCOGENE, V8, P2391; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; TERADA K, 1994, LANCET, V344, P1116, DOI 10.1016/S0140-6736(94)90630-0; Teyssier C, 2001, J BIOL CHEM, V276, P36361, DOI 10.1074/jbc.M101806200; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; TSCHACHLER E, 1993, BLOOD, V81, P95; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Watanabe T, 1997, INT J HEMATOL, V66, P257; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	71	30	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44772	44777		10.1074/jbc.M205355200	http://dx.doi.org/10.1074/jbc.M205355200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237295	hybrid			2022-12-25	WOS:000179404800025
J	Kim, BE; Smith, K; Meagher, CK; Petris, MJ				Kim, BE; Smith, K; Meagher, CK; Petris, MJ			A conditional mutation affecting localization of the Menkes disease copper ATPase - Suppression by copper supplementation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; TERMINAL DI-LEUCINE; FUNCTIONAL EXPRESSION; CANDIDATE GENE; BIOCHEMICAL-CHARACTERIZATION; DEPENDENT TRAFFICKING; CYSTIC-FIBROSIS; PLASMA-MEMBRANE; BINDING SITES; PROTEIN	Copper is an essential co-factor for several key metabolic processes. This requirement in humans is underscored by Menkes disease, an X-linked copper deficiency disorder caused by mutations in the copper transporting P-type ATPase, MNK. MNK is located in the trans-Golgi network where it transports copper to secreted cuproenzymes. Increases in copper concentration stimulate the trafficking of MNK to the plasma membrane where it effluxes copper. In this study, a Menkes disease mutation, G1019D, located in the large cytoplasmic loop of MNK, was characterized in transfected cultured cells. In copper-limiting conditions the G1019D mutant protein was retained in the endoplasmic reticulum. However, this mislocalization was corrected by the addition of copper to cells via a process that was dependent upon the copper binding sites at the N-terminal region of MNK. Reduced growth temperature and the chemical chaperone, glycerol, were found to correct the mislocalization of the G1019D mutant, suggesting this mutation interferes with protein folding in the secretory pathway. These findings identify G1019D as the first conditional mutation associated with Menkes disease and demonstrate correction of the mislocalized protein by copper supplementation. Our findings provide a molecular framework for understanding how mutations that affect the proper folding of the MNK transporter in Menkes patients may be responsive to parenteral copper therapy.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Petris, MJ (corresponding author), Univ Missouri, Dept Nutr Sci, 217 Gwynn Hall, Columbia, MO 65211 USA.	PetrisM@missouri.edu	Petris, Carisa/Z-4470-2019	Petris, Carisa/0000-0001-9059-1956	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059893] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 59893] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAMAKARIS J, 1995, HUM MOL GENET, V4, P2117, DOI 10.1093/hmg/4.11.2117; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Forbes JR, 2000, HUM MOL GENET, V9, P1927, DOI 10.1093/hmg/9.13.1927; Gal CSL, 2001, CARDIOVASC DRUG REV, V19, P201; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Kaler SG, 1996, BIOCHEM MOL MED, V57, P37, DOI 10.1006/bmme.1996.0007; Kaler SG, 1998, AM J CLIN NUTR, V67, p1029S, DOI 10.1093/ajcn/67.5.1029S; La Fontaine S, 1998, J BIOL CHEM, V273, P31375; Linder MC, 1998, AM J CLIN NUTR, V67, p965S, DOI 10.1093/ajcn/67.5.965S; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; LOO TW, 1994, J BIOL CHEM, V269, P7243; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Petris MJ, 1999, HUM MOL GENET, V8, P2107, DOI 10.1093/hmg/8.11.2107; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Tumer Z, 1997, AM J HUM GENET, V60, P63; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Wang J, 1999, J BIOL CHEM, V274, P12883, DOI 10.1074/jbc.274.18.12883; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030	31	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44079	44084		10.1074/jbc.M208737200	http://dx.doi.org/10.1074/jbc.M208737200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221109	hybrid			2022-12-25	WOS:000179272000071
J	Regelsberger, G; Atzenhofer, W; Ruker, F; Peschek, GA; Jakopitsch, C; Paumann, M; Furtmuller, PG; Obinger, C				Regelsberger, G; Atzenhofer, W; Ruker, F; Peschek, GA; Jakopitsch, C; Paumann, M; Furtmuller, PG; Obinger, C			Biochemical characterization of a membrane-bound manganese-containing superoxide dismutase from the cyanobacterium Anabaena PCC 7120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE-GREEN-ALGAE; CYTOCHROME-C-OXIDASE; ANACYSTIS-NIDULANS; ESCHERICHIA-COLI; PURIFIED PLASMA; PROTEIN; LOCALIZATION; PURIFICATION; CYLINDRICA; RESOLUTION	The filamentous cyanobacterium Anabaena PCC 7120 (now renamed Nostoc PCC 7120) possesses two genes for superoxide dismutase (SOD). One is an iron-containing (FeSOD) whereas the other is a manganese-containing superoxide dismutase (MnSOD). Localization experiments and analysis of the sequence showed that the FeSOD is cytosolic, whereas the MnSOD is a membrane-bound homodimeric protein containing one transmembrane helix, a spacer region, and a soluble catalytic domain. It is localized in both cytoplasmic and thylakoid membranes at the same extent with the catalytic domains positioned either in the periplasm or the thylakoid lumen. A phylogenetic analysis revealed that generally the highly homologous MnSODs of filamentous cyanobacteria are unique in being membrane-bound. Two recombinant variants of Anabaena MnSOD lacking either the hydrophobic region (MnSOD(Delta28)) or the hydrophobic and the linker region (MnSOD(Delta60)) are shown to exhibit the characteristic manganese peak at 480 nm, an almost 100% occupancy of manganese per subunit, a specific activity using the ferricytochrome assay of (660 +/- 90) unit mg(-1) protein and a dissociation constant for the inhibitor azide of (0.84 +/- 0.05) mm. Using stopped-flow spectroscopy it is shown that the decay of superoxide in the presence of various (MnSOD(Delta28)) or (MnSOD(Delta60)) concentrations is first-order in enzyme concentration allowing the calculation of catalytic rate constants which increase with decreasing pH: 8 x 106 M-1 s(-1) (pH 10) and 6 X 10(7) M-1 S-1 (pH 7). The physiological relevance of these findings is discussed with respect to the bioenergetic peculiarities of cyanobacteria.	Univ Agr Sci, Inst Chem, A-1190 Vienna, Austria; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Univ Agr Sci, Inst Appl Microbiol, A-1190 Vienna, Austria; Univ Vienna, Inst Phys Chem, Mol Bioenerget Grp, A-1090 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; Max Planck Society; University of Natural Resources & Life Sciences, Vienna; University of Vienna	Obinger, C (corresponding author), Univ Agr Sci, Inst Chem, Muthgasse 18, A-1190 Vienna, Austria.		Furtmüller, Paul G./Y-5819-2018; Obinger, Christian/AAV-3173-2021	Furtmüller, Paul G./0000-0002-1199-2469; Rueker, Florian/0000-0001-7639-2686; Jakopitsch, Christa/0000-0002-5855-2057; Regelsberger, Gunther/0000-0002-3233-1491; Obinger, Christian/0000-0002-7133-3430				Asada K., 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P77; ASADA K, 1975, J BIOL CHEM, V250, P2801; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BULL C, 1985, J AM CHEM SOC, V107, P3295, DOI 10.1021/ja00297a040; BULL C, 1991, J AM CHEM SOC, V113, P4076; CAMPBELL WS, 1995, J BACTERIOL, V177, P964, DOI 10.1128/jb.177.4.964-972.1995; Canini A, 1998, NEW PHYTOL, V139, P247, DOI 10.1046/j.1469-8137.1998.00187.x; CANINI A, 1992, PLANTA, V187, P438, DOI 10.1007/BF00199961; Edwards RA, 1998, J BIOL INORG CHEM, V3, P161, DOI 10.1007/s007750050217; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; GREGORY EM, 1973, J BACTERIOL, V114, P543, DOI 10.1128/JB.114.2.543-548.1973; GREGORY EM, 1973, J BACTERIOL, V114, P1193, DOI 10.1128/JB.114.3.1193-1197.1973; Hennig L, 1999, BIOTECHNIQUES, V26, P1170, DOI 10.2144/99266bc02; HENRY LEA, 1978, BIOCHEM J, V174, P373, DOI 10.1042/bj1740373; Hsu JL, 1996, J BIOL CHEM, V271, P17687, DOI 10.1074/jbc.271.30.17687; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Johnson E A, 1996, Adv Biochem Eng Biotechnol, V53, P119; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDENBACH DE, 1989, MOL GEN GENET, V216, P455, DOI 10.1007/BF00334390; Liu YF, 2000, BBA-GENE STRUCT EXPR, V1491, P248, DOI 10.1016/S0167-4781(00)00022-1; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MITTLER R, 1991, FREE RADICAL RES COM, V12-3, P845, DOI 10.3109/10715769109145866; MOLITOR V, 1987, CURR MICROBIOL, V14, P263, DOI 10.1007/BF01568134; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; OKADA S, 1979, FEBS LETT, V103, P106, DOI 10.1016/0014-5793(79)81260-0; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARKER MW, 1988, J MOL BIOL, V199, P649, DOI 10.1016/0022-2836(88)90308-7; Peschek G A, 1984, Subcell Biochem, V10, P85; PESCHEK GA, 1989, BIOCHEMISTRY-US, V28, P3057, DOI 10.1021/bi00433a048; Peschek GA, 1996, BIOCHEM SOC T, V24, P729, DOI 10.1042/bst0240729; PESCHEK GA, 1994, FEMS MICROBIOL LETT, V124, P431, DOI 10.1111/j.1574-6968.1994.tb07320.x; REISS U, 1976, EUR J BIOCHEM, V63, P617, DOI 10.1111/j.1432-1033.1976.tb10266.x; RILEY DP, 1991, ANAL BIOCHEM, V196, P344, DOI 10.1016/0003-2697(91)90476-A; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shirkey B, 2000, J BACTERIOL, V182, P189, DOI 10.1128/JB.182.1.189-197.2000; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TYTLER EM, 1984, FEMS MICROBIOL LETT, V23, P239	42	34	35	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43615	43622		10.1074/jbc.M207691200	http://dx.doi.org/10.1074/jbc.M207691200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12215453	hybrid			2022-12-25	WOS:000179272000012
J	Shin, EY; Shin, KS; Lee, CS; Woo, KN; Quan, SH; Soung, NK; Kim, YG; Cha, CI; Kim, SR; Park, D; Bokoch, GM; Kim, EG				Shin, EY; Shin, KS; Lee, CS; Woo, KN; Quan, SH; Soung, NK; Kim, YG; Cha, CI; Kim, SR; Park, D; Bokoch, GM; Kim, EG			Phosphorylation of p85 beta PIX, a Rac/Cdc42-specific guanine nucleotide exchange factor, via the Ras/ERK/PAK2 pathway is required for basic fibroblast growth factor-induced neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P21-ACTIVATED KINASE PAK1; ADAPTER PROTEIN NCK; PC12 CELL-DIFFERENTIATION; THREONINE PHOSPHORYLATION; LYSOPHOSPHATIDIC ACID; REGULATORY REGION; FOCAL ADHESION; NEURONAL CELLS; RHO GTPASES; SH3 DOMAIN	Guanine nucleotide exchange factors (GEFs) have been implicated in growth factor-induced neuronal differentiation through the activation of small GTPases. Although phosphorylation of these GEFs is considered an activation mechanism, little is known about the upstream of PAK-interacting exchange factor (PIX), a member of the Dbl family of GEFs. We report here that phosphorylation of p85 betaPIX/Cool/p85SPR is mediated via the Ras/ERK/PAK2 pathway. To understand the role of p85 betaPIX in basic fibroblast growth factor (bFGF)induced neurite outgrowth, we established PC12 cell lines that overexpress the fibroblast growth factor receptor-1 in a tetracycline-inducible manner. Treatment with bFGF induces the phosphorylation of p85 PPIX, as determined by metabolic labeling and mobility shift upon gel electrophoresis. Interestingly, phosphorylation of p85 betaPIX is inhibited by PD98059, a specific MEK inhibitor, suggesting the involvement of the ERK cascade. PAK2, a major PAK isoforin in PC12 cells as well as a binding partner of p85 betaPIX, also functions upstream of p85 betaPIX phosphorylation. Surprisingly, PAK2 directly binds to ERK, and its activation is dependent on ERK. p85 betaPIX specifically localizes to the lamellipodia at neuronal growth cones in response to bFGF. A mutant form of p85 betaPIX (S525A/T526A), in which the major phosphorylation sites are replaced by alanine, shows significant defect in targeting. Moreover, expression of the mutant p85 betaPIX efficiently blocks PC 12 cell neurite outgrowth. Our study defines a novel signaling pathway for bFGF-induced neurite outgrowth that involves activation of the PAK2-p85 betaPIX complex via the ERK cascade and subsequent translocation of this complex.	Chungbuk Natl Univ, Coll Med, Dept Biochem, Med Res Inst,Heungduk Ku, Cheongju 361763, South Korea; Chungbuk Natl Univ, Coll Med, Dept Neurosurg, Cheongju 361763, South Korea; Daewoong Pharmaceut Co, R&D Ctr, Biotechnol Res Team, Yongin 449814, South Korea; Seoul Natl Univ, Coll Med, Dept Anat, Seoul 110799, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; The Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; The Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Chungbuk National University; Chungbuk National University; Samsung; Seoul National University (SNU); Seoul National University (SNU); Scripps Research Institute; Scripps Research Institute	Kim, EG (corresponding author), Chungbuk Natl Univ, Coll Med, Dept Biochem, Med Res Inst,Heungduk Ku, San 48, Cheongju 361763, South Korea.		Cha, Choong Ik/J-5680-2012		NIGMS NIH HHS [GM39434] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Albertinazzi C, 1998, J CELL BIOL, V142, P815, DOI 10.1083/jcb.142.3.815; AltunGultekin ZF, 1996, J NEUROSCI RES, V44, P308, DOI 10.1002/(SICI)1097-4547(19960515)44:4<308::AID-JNR2>3.0.CO;2-G; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; Feng QY, 2002, J BIOL CHEM, V277, P5644, DOI 10.1074/jbc.M107704200; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Goi T, 1999, MOL CELL BIOL, V19, P1731; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KIM EG, 1993, AM J PHYSIOL, V264, pF66, DOI 10.1152/ajprenal.1993.264.1.F66; Kim MD, 2002, J NEUROSCI, V22, P1794, DOI 10.1523/JNEUROSCI.22-05-01794.2002; Kim S, 2000, BIOCHEM BIOPH RES CO, V272, P721, DOI 10.1006/bbrc.2000.2845; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Kita Y, 1998, J CELL SCI, V111, P907; Koh CG, 2001, J CELL SCI, V114, P4239; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Kuhn TB, 1998, J NEUROBIOL, V37, P524, DOI 10.1002/(SICI)1097-4695(199812)37:4<524::AID-NEU3>3.0.CO;2-H; Lamoureux P, 1997, J CELL SCI, V110, P635; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matafora V, 2001, J CELL SCI, V114, P4509; Meakin SO, 1998, J NEUROCHEM, V71, P1875; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Nunn MF, 1996, J VIROL, V70, P6157, DOI 10.1128/JVI.70.9.6157-6161.1996; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Posern G, 2000, J CELL PHYSIOL, V183, P416, DOI 10.1002/(SICI)1097-4652(200006)183:3<416::AID-JCP15>3.0.CO;2-R; Renkema GH, 1999, CURR BIOL, V9, P1407, DOI 10.1016/S0960-9822(00)80086-X; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rockow S, 1996, ONCOGENE, V12, P2351; Roig J, 2000, P NATL ACAD SCI USA, V97, P14346, DOI 10.1073/pnas.97.26.14346; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Tanabe K, 2000, J NEUROSCI, V20, P4138; Tang JP, 1997, ONCOGENE, V15, P1823, DOI 10.1038/sj.onc.1201351; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	70	110	111	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44417	44430		10.1074/jbc.M203754200	http://dx.doi.org/10.1074/jbc.M203754200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226077	hybrid			2022-12-25	WOS:000179272000113
J	Tahir, TA; Berrin, JG; Flatman, R; Roussel, A; Roepstorff, P; Williamson, G; Juge, N				Tahir, TA; Berrin, JG; Flatman, R; Roussel, A; Roepstorff, P; Williamson, G; Juge, N			Specific characterization of substrate and inhibitor binding sites of a glycosyl hydrolase family 11 xylanase from Aspergillus niger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BIOSPECIFIC INTERACTION ANALYSIS; SURFACE-PLASMON RESONANCE; HIGH-LEVEL PRODUCTION; 3-DIMENSIONAL STRUCTURE; ENDOXYLANASE INHIBITOR; ENDO-1,4-XYLANASE II; DIRECTED MUTAGENESIS; ENZYME INTERMEDIATE; TRICHODERMA-REESEI	The importance of aromatic and charged residues at the surface of the active site of a family 11 xylanase from Aspergillus niger was evaluated using site-directed mutagenesis. Ten mutant proteins were heterologously produced in Pichia pastoris, and their biochemical properties and kinetic parameters were determined. The specific activity of the Y6A, Y10A, Y89A, Y164A, and W172A mutant enzymes was drastically reduced. The low specific activities of Y6A and Y89A were entirely accounted for by a change in k(cat) and K-m, respectively, whereas the lower values of Y10A, Y164A and W172A were due to a combination of increased K. and decreased k(cat), Tyr(6), Tyr(10), Tyr(89), Tyr(164), and Trp(172) are proposed as substrate-binding residues, a finding consistent with structural sequence alignments of family 11 xylanases and with the three-dimensional structure of the A niger xylanase in complex with the modeled xylobiose. All other variants, D113A, D113N, N117A, E118A, and E118Q, retained full wild-type activity. Only N117A lost its sensitivity to xylanase inhibitor protein I (XIP-1), a protein inhibitor isolated from wheat, and this mutation did not affect the fold of the xylanase as revealed by circular dichroism. The N117A variant showed kinetics, pH stability, hydrolysis products pattern, substrate specificity, and structural properties identical to that of the wild-type xylanase. The loss of inhibition, as measured in activity assays, was due to abolition of the interaction between XIP-1 and the mutant enzyme, as demonstrated by surface plasmon resonance and electrophoretic titration. A close inspection of the three-dimensional structure of A. niger xylanase suggests that the binding site of XIP-1 is located at the conserved "thumb" hairpin loop of family 11 xylanases.	IFR, Norwich NR4 7UA, Norfolk, England; Fac Sci & Tech St Jerome, Inst Mediterraneen Rech Nutr, UMR 1111, INRA, F-13397 Marseille 20, France; CNRS, AFMB, UMR 6098, F-13402 Marseille 20, France; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark	INRAE; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Southern Denmark	Juge, N (corresponding author), IFR, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.	nathalie.juge@bbsrc.ac.uk	BERRIN, Jean-Guy/AAF-3107-2021; BERRIN, Jean-Guy/E-1460-2014; Williamson, Gary/AAE-9665-2019	BERRIN, Jean-Guy/0000-0001-7570-3745; Williamson, Gary/0000-0002-5624-6267; Juge, Nathalie/0000-0001-8515-1315; Tahir, Tariq/0000-0002-3992-6877				BAILEY MJ, 1992, J BIOTECHNOL, V23, P257, DOI 10.1016/0168-1656(92)90074-J; BEDFORD MR, 1992, PROGR BIOTECHNOL, V7, P361; Berrin JG, 2000, PROTEIN EXPRES PURIF, V19, P179, DOI 10.1006/prep.2000.1229; BIELY P, 1993, PORT PR R M, V4, P29; BIELY P, 1985, TRENDS BIOTECHNOL, V3, P286, DOI 10.1016/0167-7799(85)90004-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL RL, 1993, P 2 TRICEL S TRICH R, P63; CHRISTOPHER JA, 1998, SPOCK MANUAL; Christophersen C, 1997, STARCH-STARKE, V49, P5, DOI 10.1002/star.19970490104; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Debyser W, 1997, J AM SOC BREW CHEM, V55, P153; Debyser W, 1999, J CEREAL SCI, V30, P39, DOI 10.1006/jcrs.1999.0272; DEBYSER W, 1998, Patent No. 9849278; Flatman R, 2002, BIOCHEM J, V365, P773, DOI 10.1042/BJ20020168; Fushinobu S, 1998, PROTEIN ENG, V11, P1121, DOI 10.1093/protein/11.12.1121; Gebruers K, 2001, BIOCHEM J, V353, P239, DOI 10.1042/0264-6021:3530239; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Goesaert H, 2001, CEREAL CHEM, V78, P453, DOI 10.1094/CCHEM.2001.78.4.453; GRAHAM H, 1992, PROGR BIOTECHNOL, V7, P535; GRANZOW R, 1992, BIO-TECHNOL, V10, P390, DOI 10.1038/nbt0492-390; Gruber K, 1998, BIOCHEMISTRY-US, V37, P13475, DOI 10.1021/bi980864l; Harris GW, 1997, PROTEINS, V29, P77, DOI 10.1002/(SICI)1097-0134(199709)29:1<77::AID-PROT6>3.3.CO;2-K; Havukainen R, 1996, BIOCHEMISTRY-US, V35, P9617, DOI 10.1021/bi953052n; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HESSING JGM, 1994, CURR GENET, V26, P228, DOI 10.1007/BF00309552; HESSING JGM, 1991, Patent No. 9119782; HESSING M, 2000, Patent No. 0979830; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jeffries TW, 1996, CURR OPIN BIOTECH, V7, P337, DOI 10.1016/S0958-1669(96)80041-3; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Joshi MD, 2001, BIOCHEMISTRY-US, V40, P10115, DOI 10.1021/bi0105429; Juge N, 2001, FEMS YEAST RES, V1, P127, DOI 10.1016/S1567-1356(01)00020-4; Krengel U, 1996, J MOL BIOL, V263, P70, DOI 10.1006/jmbi.1996.0556; Kumar PR, 2000, J MOL BIOL, V295, P581, DOI 10.1006/jmbi.1999.3348; Luttig M, 1997, BIOTECHNOL LETT, V19, P411, DOI 10.1023/A:1018327623422; MAAT J, 1992, PROGR BIOTECHNOL, V7, P349; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McCarthy AA, 2000, ACTA CRYSTALLOGR D, V56, P1367, DOI 10.1107/S0907444900009896; McLauchlan WR, 1999, BIOCHEM J, V338, P441, DOI 10.1042/0264-6021:3380441; McLauchlan WR, 2000, VTT SYMP, V207, P55; Muilu J, 1998, PROTEINS, V31, P434; Rouau X, 1998, J CEREAL SCI, V28, P63, DOI 10.1006/jcrs.1997.0180; Roussel A, 1991, SILICON GRAPHICS GEO, P86; Sabini E, 2001, ACTA CRYSTALLOGR D, V57, P1344, DOI 10.1107/S0907444901010873; Sabini E, 1999, CHEM BIOL, V6, P483, DOI 10.1016/S1074-5521(99)80066-0; Sapag A, 2002, J BIOTECHNOL, V95, P109, DOI 10.1016/S0168-1656(02)00002-0; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; TORRONEN A, 1994, EMBO J, V13, P2493, DOI 10.1002/j.1460-2075.1994.tb06536.x; TORRONEN A, 1995, BIOCHEMISTRY-US, V34, P847, DOI 10.1021/bi00003a019; Torronen A, 1997, J BIOTECHNOL, V57, P137, DOI 10.1016/S0168-1656(97)00095-3; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; WAKARCHUK WW, 1994, PROTEIN SCI, V3, P467; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; Withers SG, 1995, PROGR BIOTECHNOL, V10, P97, DOI 10.1016/S0921-0423(06)80097-3; Wouters J, 2001, ACTA CRYSTALLOGR D, V57, P1813, DOI 10.1107/S0907444901015153	62	62	65	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44035	44043		10.1074/jbc.M205657200	http://dx.doi.org/10.1074/jbc.M205657200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12207016	hybrid			2022-12-25	WOS:000179272000066
J	Zhang, RZ; Sabatelli, P; Pan, TC; Squarzoni, S; Mattioli, E; Bertini, E; Pepe, G; Chu, ML				Zhang, RZ; Sabatelli, P; Pan, TC; Squarzoni, S; Mattioli, E; Bertini, E; Pepe, G; Chu, ML			Effects on collagen VI mRNA stability and microfibrillar assembly of three COL6A2 mutations in two families with Ullrich congenital muscular dystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; BETHLEM MYOPATHY; VONWILLEBRAND-FACTOR; GLOBULAR DOMAINS; ALPHA-3 CHAIN; TRIPLE-HELIX; A-DOMAINS; GENE; PROCOLLAGEN; VARIANTS	We recently reported a severe deficiency in collagen type VI, resulting from recessive mutations of the COMA2 gene, in patients with Ullrich congenital muscular dystrophy. Their parents, who are all carriers of one mutant allele, are unaffected, although heterozygous mutations in collagen VI caused Bethlem myopathy. Here we investigated the consequences of three COMA2 mutations in fibroblasts from patients and their parents in two Ullrich families. All three mutations lead to nonsense-mediated mRNA decay. However, very low levels of undegraded mutant mRNA remained in patient B with compound heterozygous mutations at the distal part of the triple-helical domain, resulting in deposition of abnormal microfibrils that cannot form extensive networks. This observation suggests that the C-terminal globular domain is not essential for triple-helix formation but is critical for microfibrillar assembly. In all parents, the COMA2 mRNA levels are reduced to 57-73% of the control, but long term collagen VI matrix depositions are comparable with that of the control. The almost complete absence of abnormal protein and near-normal accumulation of microfibrils in the parents may account for their lack of myopathic symptoms.	Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; IOR, CNR, Inst Normal & Pathol Cytomorphol, I-40136 Bologna, Italy; IOR, Neuromuscular Unit, I-40136 Bologna, Italy; IRCCS, Bambino Gesu Hosp, Dept Neurosci Mol Med, I-00165 Rome, Italy; Univ Florence, Dept Med & Surg Crit Care, I-50134 Florence, Italy	Jefferson University; Jefferson University; Consiglio Nazionale delle Ricerche (CNR); IRCCS Bambino Gesu; University of Florence	Chu, ML (corresponding author), Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, 233 S 10th St, Philadelphia, PA 19107 USA.	Mon-Li.Chu@mail.tju.edu	Pepe, Guglielmina/K-8013-2016; Bertini, Enrico/A-2284-2014; Bertini, Enrico/ABG-1278-2020; Squarzoni, Stefano/AAM-9729-2020; Sabatelli, Patrizia/C-7479-2019	Pepe, Guglielmina/0000-0001-9825-6618; Bertini, Enrico/0000-0001-9276-4590; Squarzoni, Stefano/0000-0001-6538-5923; Sabatelli, Patrizia/0000-0003-2345-5094; Mattioli, Elisabetta/0000-0002-1395-1927	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038912] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38912] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; Ball SG, 2001, J BIOL CHEM, V276, P7422, DOI 10.1074/jbc.M002816200; BETHLEM J, 1976, BRAIN, V99, P91, DOI 10.1093/brain/99.1.91; BRUNS RR, 1986, J CELL BIOL, V103, P393, DOI 10.1083/jcb.103.2.393; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Chen Q, 1999, MOL BIOL CELL, V10, P2149, DOI 10.1091/mbc.10.7.2149; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; Demir E, 2002, AM J HUM GENET, V70, P1446, DOI 10.1086/340608; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Higuchi I, 2001, ANN NEUROL, V50, P261, DOI 10.1002/ana.1120; Higuchi I, 2001, ANN NEUROL, V49, P544, DOI 10.1002/ana.109; Illidge C, 1998, J BIOL CHEM, V273, P22091, DOI 10.1074/jbc.273.34.22091; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; Lamande SR, 1999, J BIOL CHEM, V274, P21817, DOI 10.1074/jbc.274.31.21817; Lamande SR, 1998, HUM MOL GENET, V7, P981, DOI 10.1093/hmg/7.6.981; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; Mendell JT, 2001, CELL, V107, P411, DOI 10.1016/S0092-8674(01)00583-9; NONAKA I, 1981, NEUROPEDIATRICS, V12, P197, DOI 10.1055/s-2008-1059651; Pan TC, 1998, HUM MOL GENET, V7, P807, DOI 10.1093/hmg/7.5.807; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; Pepe G, 1999, BIOCHEM BIOPH RES CO, V258, P802, DOI 10.1006/bbrc.1999.0680; Pepe G, 1999, NEUROMUSCULAR DISORD, V9, P264, DOI 10.1016/S0960-8966(99)00014-0; SAITTA B, 1994, EUR J BIOCHEM, V223, P675, DOI 10.1111/j.1432-1033.1994.tb19040.x; SAITTA B, 1992, J BIOL CHEM, V267, P6188; SAITTA B, 1990, J BIOL CHEM, V265, P6473; Scacheri PC, 2002, NEUROLOGY, V58, P593, DOI 10.1212/WNL.58.4.593; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; STOKES DG, 1991, J BIOL CHEM, V266, P8626; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; Ullrich O, 1930, MONATSSCHR KINDERH, V47, P502; Vanegas OC, 2002, MUSCLE NERVE, V25, P513, DOI 10.1002/mus.10100; Vanegas OC, 2001, P NATL ACAD SCI USA, V98, P7516; Voit T, 1998, BRAIN DEV-JPN, V20, P65, DOI 10.1016/S0387-7604(97)00094-6; WEIL D, 1988, AM J HUM GENET, V42, P435	39	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43557	43564		10.1074/jbc.M207696200	http://dx.doi.org/10.1074/jbc.M207696200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12218063	hybrid			2022-12-25	WOS:000179272000004
J	Fukuda, M; Kuroda, TS				Fukuda, M; Kuroda, TS			Slac2-c (synaptotagmin-like protein homologue lacking C2 domains-c), a novel linker protein that interacts with Rab27, myosin Va/VIIa, and actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOSOME TRANSPORT; BINDING DOMAIN; PC12 CELLS; FAMILY; VA; GENE; EFFECTOR; GTPASES; IDENTIFICATION; MELANOCYTES	Slac2-a (synaptotagmin-like protein (Slp) homologue lacking C2 domains-a)/melanophilin is a melanosome-associated protein that links Rab27A on melanosomes with myosin Va, an actin-based motor protein, and formation of the tripartite protein complex (Rab27A(.)Slac2a(.)myosin Va) has been suggested to regulate melanosome transport (Fukuda, M., Kuroda, T. S., and Mikoshiba, K. (2002) J. Biol. Chem. 277, 12432-12436). Here we report the structure of a novel form of Slac2, named Slac2-c, that is homologous to Slac2-a. Slac2-a and Slac2-c exhibit the same overall structure, consisting of a highly conserved N-terminal Slp homology domain (about 50% identity) and a less conserved C-terminal myosin Va-binding domain (about 20% identity). As with other Slac2 members and the Slp family, the Slp homology domain of Slac2-c was found to interact specifically with the GTP-bound form of Rab27A/B both in vitro and in intact cells, and the C-terminal domain of Slac2-c interacted with myosin Va and myosin VIIa. In addition, we discovered that the most C-terminal conserved region of Slac2-a (amino acids 400-590) and Slac2-c (amino acids 670-856), which is not essential for myosin Va binding, directly binds actin and that expression of these regions in PC12 cells and melanoma cells colocalized with actin filaments at the cell periphery, suggesting a novel role of Slac2-a/c in capture of Rab27-containing organelles in the actin-enriched cell periphery.	RIKEN Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN Inst Phys & Chem Res, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853; Kuroda, Taruho/0000-0001-6693-4496				Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Berkowitz JKM, 2001, J BIOL CHEM, V276, P18855, DOI 10.1074/jbc.M011167200; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Chen D, 1997, BIOCHEM MOL MED, V60, P27, DOI 10.1006/bmme.1996.2559; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; Fukuda M, 2002, J BIOL CHEM, V277, P40118, DOI 10.1074/jbc.M205765200; Fukuda M, 2002, J BIOL CHEM, V277, P39673, DOI 10.1074/jbc.M205349200; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, J BIOL CHEM, V276, P27670, DOI 10.1074/jbc.M100851200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; Huang JD, 1998, GENETICS, V148, P1963; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Ibata K, 2000, J NEUROCHEM, V74, P518, DOI 10.1046/j.1471-4159.2000.740518.x; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Miyata M, 2000, NEURON, V28, P233, DOI 10.1016/S0896-6273(00)00099-4; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; Pereira-Leal JB, 2000, J MOL BIOL, V301, P1077, DOI 10.1006/jmbi.2000.4010; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Ramalho JS, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-2; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Rodriguez OC, 2002, J CELL SCI, V115, P991; Schott D, 1999, J CELL BIOL, V147, P791, DOI 10.1083/jcb.147.4.791; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Tabb JS, 1998, J CELL SCI, V111, P3221; Takagishi Y, 1996, NEUROSCI LETT, V215, P169, DOI 10.1016/S0304-3940(96)12967-0; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang XD, 2002, NEURON, V34, P599, DOI 10.1016/S0896-6273(02)00671-2; Zhao LP, 1996, P NATL ACAD SCI USA, V93, P10826, DOI 10.1073/pnas.93.20.10826; Zhao SL, 2002, ENDOCRINOLOGY, V143, P1817, DOI 10.1210/en.143.5.1817	61	131	140	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43096	43103		10.1074/jbc.M203862200	http://dx.doi.org/10.1074/jbc.M203862200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12221080	hybrid			2022-12-25	WOS:000179081200088
J	Li, ZY; Wang, CC				Li, ZY; Wang, CC			Functional characterization of the 11 Non-ATPase subunit proteins in the trypanosome 19 S proteasomal regulatory Complex*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIUBIQUITIN-CHAIN-BINDING; YEAST SACCHAROMYCES-CEREVISIAE; 26S PROTEASOME; CELL-CYCLE; GENE-EXPRESSION; MITOCHONDRIAL-DNA; RNA INTERFERENCE; BRUCEI; TRANSCRIPTION; PROTEOLYSIS	The ubiquitin-proteasome pathway is responsible for selective degradation of short-lived and dysfunctional proteins in eukaryotes. The recently demonstrated presence of a functional 26 S proteasome in Trypanosoma brucei led to the identification and isolation of genes encoding all 11 non-ATPase (Rpn) subunit proteins in the trypanosome 19 S regulatory complex. Using the technique of RNA interference, expression of individual RPN genes was disrupted in the procyclic form of T. brucei, resulting, in each case, in intracellular accumulation of polyubiquitinated protein, cell arrest at the G(2)/M phase, and eventual cell death. With the exception of Rpn10, depletion of individual Rpn proteins disrupted also trypanosome 19 S complex formation, with the complex virtually depleted in the cell lysate. This functional and structural essentiality of 10 of the 11 Rpn proteins in T. brucei differs significantly from that observed in other organisms. When Rpn10 was deficient in trypanosomes, a 19 S complex without Rpn10 was still formed, whereas cell growth was arrested. This structural dispensability but functional indispensability of Rpn10 may constitute another unique aspect of the proteasomes in T. brucei.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 513 Parnassus Ave, San Francisco, CA 94143 USA.			Li, Ziyin/0000-0002-3960-9716	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021786] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI-21786, R01 AI021786] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bailly E, 1999, MOL CELL BIOL, V19, P6872; Bech-Otschir D, 2002, J CELL SCI, V115, P467; BERBEROF M, 1995, EMBO J, V14, P2925, DOI 10.1002/j.1460-2075.1995.tb07292.x; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Fujimuro M, 1998, FEBS LETT, V423, P149, DOI 10.1016/S0014-5793(98)00084-2; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Girod PA, 1999, PLANT CELL, V11, P1457; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Haracska L, 1997, FEBS LETT, V412, P331, DOI 10.1016/S0014-5793(97)00808-9; Henke W, 1999, MOL BIOL REP, V26, P29, DOI 10.1023/A:1006991419464; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Hua SB, 1996, MOL BIOCHEM PARASIT, V78, P33, DOI 10.1016/S0166-6851(96)02599-6; Huang L, 2001, J BIOL CHEM, V276, P28327, DOI 10.1074/jbc.M008342200; Kapelari B, 2000, J MOL BIOL, V300, P1169, DOI 10.1006/jmbi.2000.3912; Kawamura M, 1996, MOL GEN GENET, V251, P146; Kim TH, 2001, TRENDS PLANT SCI, V6, P379, DOI 10.1016/S1360-1385(01)02015-5; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; KOMINAMI K, 1995, EMBO J, V14, P3105, DOI 10.1002/j.1460-2075.1995.tb07313.x; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lambertson D, 1999, GENETICS, V153, P69; Li ZY, 2002, J BIOL CHEM, V277, P15486, DOI 10.1074/jbc.M109029200; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P195, DOI 10.1016/S0968-0004(97)01058-X; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; Monaco JJ, 1995, ANNU REV GENET, V29, P729, DOI 10.1146/annurev.ge.29.120195.003501; Mutomba MC, 1997, MOL BIOCHEM PARASIT, V90, P491, DOI 10.1016/S0166-6851(97)00197-7; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; Rinaldi T, 1998, MOL BIOL CELL, V9, P2917, DOI 10.1091/mbc.9.10.2917; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SHIMANUKI M, 1995, J CELL SCI, V108, P569; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Takeuchi J, 1999, MOL CELL BIOL, V19, P6575; Takeuchi J, 2001, BIOCHIMIE, V83, P333, DOI 10.1016/S0300-9084(01)01238-X; To WY, 1997, FEBS LETT, V404, P253, DOI 10.1016/S0014-5793(97)00116-6; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	54	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42686	42693		10.1074/jbc.M207183200	http://dx.doi.org/10.1074/jbc.M207183200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12213827	hybrid			2022-12-25	WOS:000179081200034
J	Qiu, W; Campbell, RL; Gangloff, A; Dupuis, P; Boivin, RP; Tremblay, MR; Poirier, D; Lin, SX				Qiu, W; Campbell, RL; Gangloff, A; Dupuis, P; Boivin, RP; Tremblay, MR; Poirier, D; Lin, SX			A concerted, rational design of type 1 17 beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity	FASEB JOURNAL			English	Article						hybrid inhibitor; inhibition kinetics; protein crystallography; molecular modeling; drug design	STEROID-BINDING-SITE; HUMAN-PLACENTA; ESTROGENIC 17-BETA-HYDROXYSTEROID-DEHYDROGENASE; 20-ALPHA-HYDROXYSTEROID DEHYDROGENASE; CHEMICAL-SYNTHESIS; METHYL-ETHER; ACTIVE-SITE; 17-BETA-DEHYDROGENASE; ESTRONE; INACTIVATION	Human estrogenic 17beta-hydroxysteroid dehydrogenase (17beta-HSD type 1) catalyzes the final step in the synthesis of active estrogens that stimulate the proliferation of breast cancer cells. Based on the initial premise to make use of the binding energies of both the substrate and cofactor sites, and molecular modeling starting from the enzyme structure, several estradiol-adenosine hybrids were designed and synthesized. Among these hybrids, EM-1745 with a linker of 8-CH2 groups is proved to be the best competitive inhibitor with a K-i of 3.0 +/- 0.8 nM. The crystal structure of the EM-1745 enzyme complex at 1.6 Angstrom provides evidence at atomic resolution of strong interactions between both the steroid and cofactor moieties and the enzyme molecule, as illustrated by a sigma(A)-weighted 2F(o)-F-c electron density map contoured at 3.0 sigma. The substrate entry loop is further stabilized in this complex compared with previous complexes of the enzyme. These results confirm our initial strategy of combining studies of structural biology and enzyme mechanism in the inhibitor design, which may be applied to other steroidogenic enzymes involved in human diseases.	Univ Laval, CHUL, Oncol & Mol Endocrinol Res Ctr, Med Ctr, Quebec City, PQ G1V 4G2, Canada	Laval University	Poirier, D (corresponding author), Univ Laval, CHUL, Oncol & Mol Endocrinol Res Ctr, Med Ctr, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	sxlin@crchul.ulaval.ca		Dupuis, Philippe/0000-0002-5970-6716; Campbell, Robert/0000-0002-5473-5876; Gangloff, Anne/0000-0002-6848-6559; Lin, Sheng-Xiang/0000-0001-9149-375X				ADAMS J, 1981, CANCER RES, V41, P4720; ADAMS JB, 1985, MOL CELL ENDOCRINOL, V41, P1, DOI 10.1016/0303-7207(85)90138-8; American Cancer Society, 2002, CANC FACTS FIG 2002; AUCHUS RJ, 1986, BIOCHEMISTRY-US, V25, P7295, DOI 10.1021/bi00371a008; Azzi A, 1996, NAT STRUCT BIOL, V3, P665, DOI 10.1038/nsb0896-665; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BHATNAGAR YM, 1978, J BIOL CHEM, V253, P811; BIELLMANN JF, 1976, EUR J BIOCHEM, V63, P477, DOI 10.1111/j.1432-1033.1976.tb10250.x; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; Bull HG, 1996, J AM CHEM SOC, V118, P2359, DOI 10.1021/ja953069t; CHIN CC, 1980, J BIOL CHEM, V255, P3660; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; GHOSH D, 1995, STRUCTURE, V3, P503, DOI 10.1016/S0969-2126(01)00183-6; INANO H, 1985, J STEROID BIOCHEM, V22, P681; INANO H, 1980, J BIOL CHEM, V255, P7694; INANO H, 1983, EUR J BIOCHEM, V129, P691; Jin YW, 1999, J VAC SCI TECHNOL B, V17, P489, DOI 10.1116/1.590582; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LABRIE C, 1992, CANCER RES, V52, P610; Labrie F, 1985, Important Adv Oncol, P193; Labrie F, 1997, STEROIDS, V62, P148, DOI 10.1016/S0039-128X(96)00174-2; Le Bail JC, 1998, CANCER LETT, V133, P101, DOI 10.1016/S0304-3835(98)00211-0; Le Bail JC, 2001, LIFE SCI, V68, P751, DOI 10.1016/S0024-3205(00)00974-7; LIN SX, 1983, BIOCHEMISTRY-US, V22, P681, DOI 10.1021/bi00272a024; LIN SX, 1984, U SCI VIE TERRE, P173; MAKELA S, 1995, P SOC EXP BIOL MED, V208, P51; McPherson A, 1982, PREPARATION ANAL PRO; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miyoshi Y, 2001, INT J CANCER, V94, P685, DOI 10.1002/ijc.1525; MURDOCK GL, 1988, BIOCHEMISTRY-US, V27, P4452, DOI 10.1021/bi00412a036; *NAT CANC I CAN, 2001, CAN CANC STAT 2001; OTWINOWSKI Z, 1996, METHODS ENZYMOLOGY, V76; Parang K, 2001, NAT STRUCT BIOL, V8, P37; Pelletier JD, 1996, BIOORGAN MED CHEM, V4, P1617, DOI 10.1016/0968-0896(96)00154-X; Peltoketo H, 1999, J MOL ENDOCRINOL, V23, P1, DOI 10.1677/jme.0.0230001; Penning TM, 1996, ENDOCR-RELAT CANCER, V3, P41, DOI 10.1677/erc.0.0030041; PHILIPPSEN A, 2001, DINO VISUALIZING STR; Poirier D, 1998, J STEROID BIOCHEM, V64, P83, DOI 10.1016/S0960-0760(97)00136-2; *POV TEAM, 1999, PERS VIS RAY TRAC V; Qiu W, 1999, J STEROID BIOCHEM, V68, P239, DOI 10.1016/S0960-0760(99)00036-9; Sam K M, 1998, Drug Des Discov, V15, P157; SANTNER SJ, 1993, J STEROID BIOCHEM, V45, P383, DOI 10.1016/0960-0760(93)90007-J; Sawicki MW, 1999, P NATL ACAD SCI USA, V96, P840, DOI 10.1073/pnas.96.3.840; Segel I. H, 1976, BIOCH CALCULATION, V2nd; SIMARD J, 1987, J STEROID BIOCHEM, V26, P539, DOI 10.1016/0022-4731(87)90005-7; SWEET F, 1991, BIOCHEM BIOPH RES CO, V180, P1057, DOI 10.1016/S0006-291X(05)81173-8; THOMAS DB, 1984, CANCER-AM CANCER SOC, V53, P595, DOI 10.1002/1097-0142(19840201)53:3+<595::AID-CNCR2820531304>3.0.CO;2-Y; THOMAS JL, 1986, J STEROID BIOCHEM, V25, P103, DOI 10.1016/0022-4731(86)90287-6; THOMAS JL, 1983, J BIOL CHEM, V258, P1500; TOBIAS B, 1982, J BIOL CHEM, V257, P2783; Tremblay MR, 2001, STEROIDS, V66, P821, DOI 10.1016/S0039-128X(01)00116-7; Tremblay MR, 1998, J STEROID BIOCHEM, V66, P179, DOI 10.1016/S0960-0760(98)00043-0; VIHKO R, 1989, CRIT REV ONCOL HEMAT, V9, P1, DOI 10.1016/S1040-8428(89)80012-5; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wolf E, 2002, J MOL BIOL, V317, P215, DOI 10.1006/jmbi.2001.5371; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222; Zhorov BS, 2000, PROTEINS, V38, P414, DOI 10.1002/(SICI)1097-0134(20000301)38:4<414::AID-PROT7>3.0.CO;2-X; ZHU DW, 1993, J MOL BIOL, V234, P242, DOI 10.1006/jmbi.1993.1578	60	83	87	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1829	+		10.1096/fj.02-0026fje	http://dx.doi.org/10.1096/fj.02-0026fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223444				2022-12-25	WOS:000181189100006
J	Xiao, BL; Masumiya, H; Jiang, DW; Wang, RW; Sei, Y; Zhang, L; Murayama, T; Ogawa, Y; Lai, FA; Wagenknecht, T; Chen, SRW				Xiao, BL; Masumiya, H; Jiang, DW; Wang, RW; Sei, Y; Zhang, L; Murayama, T; Ogawa, Y; Lai, FA; Wagenknecht, T; Chen, SRW			Isoform-dependent formation of heteromeric Ca2+ release channels (ryanodine receptors)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; VASCULAR SMOOTH-MUSCLE; SKELETAL-MUSCLE; MOLECULAR-IDENTIFICATION; TYPE-3; COMPLEX; CELLS; RYR3; PURIFICATION; MYOCYTES	Three ryanodine receptor (RyR) isoforms, RyR1, RyR2, and RyR3, are expressed in mammalian tissues. It is unclear whether RyR isoforms are capable of forming heteromeric channels. To investigate their ability to form heteromeric channels, we co-expressed different RyR isoforms in HEK293 cells and examined their interactions biochemically and functionally. Immunoprecipitation studies revealed that RyR2 is able to interact physically with RyR3 and RyR1 in HEK293 cells and that RyR1 does not interact with RyR3. Co-expression of a ryanodine binding deficient mutant of RyR2, RyR2 (14827T), with RyR3 (wt) restored [H-3]ryanodine binding to the mutant. Interactions between RyR isoforms were further assessed by complementation analysis using mutants RyR2 (14827T), RyR2 (E3987A), RyR3 (14732T), RyR3 (E3885A), and RyR1 (E4032A), all of which are deficient in caffeine response. Caffeine-induced Ca2+ release was restored in HEK293 cells co-transfected with mutants RyR2 (14827T) and RyR3 (E3885A), RyR2 (E3987A) and RyR3 (14732T), or RyR2 (14827T) and RyR1 (E4032A), but not with RyR1 (E4032A) and RyR3 (14732T), indicating that mutants of RyR2 and RyR,3, or RyR2 and RyR1, but not RyR1 and RyR3, are able to complement each other. Co-expression of RyR3 (wt) and a pore mutant of RyR2, RyR2 (G4824A), produced regulatable single channels with intermediate unitary conductances. These observations demonstrate that RyR2 is capable of forming functional heteromeric channels with RyR,3 and RyR1, whereas RyR1 is incapable of forming heteromeric channels with RyR3.	Univ Calgary, Dept Physiol & Biophys, Cardiovasc Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; Univ Wales Coll Med, Wales Heart Res Inst, Dept Cardiol, Cardiff CF14 4XN, S Glam, Wales; Juntendo Univ, Sch Med, Dept Pharmacol, Tokyo 1138421, Japan; Uniformed Serv Univ Hlth Sci, Dept Anesthesiol, Bethesda, MD 20814 USA	University of Calgary; University of Calgary; State University of New York (SUNY) System; Wadsworth Center; Cardiff University; Juntendo University; Uniformed Services University of the Health Sciences - USA	Chen, SRW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Cardiovasc Res Grp, Calgary, AB T2N 4N1, Canada.		Xiao, Bailong/B-6187-2012	Lai, Tony/0000-0003-2852-8547	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40615] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; Coussin F, 2000, J BIOL CHEM, V275, P9596, DOI 10.1074/jbc.275.13.9596; Flucher BE, 1999, J CELL BIOL, V146, P621, DOI 10.1083/jcb.146.3.621; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hosoi E, 2001, J IMMUNOL, V167, P4887, DOI 10.4049/jimmunol.167.9.4887; Jeyakumar LH, 1998, J BIOL CHEM, V273, P16011, DOI 10.1074/jbc.273.26.16011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1989, J BIOL CHEM, V264, P16776; Li P, 2001, J GEN PHYSIOL, V118, P33, DOI 10.1085/jgp.118.1.33; Liu Z, 2001, P NATL ACAD SCI USA, V98, P6104, DOI 10.1073/pnas.111382798; Lohn M, 2001, CIRC RES, V89, P1051, DOI 10.1161/hh2301.100250; Lynch PJ, 1999, P NATL ACAD SCI USA, V96, P4164, DOI 10.1073/pnas.96.7.4164; Mironneau J, 2002, J PHYSIOL-LONDON, V538, P707, DOI 10.1113/jphysiol.2001.013046; Mironneau J, 2001, J BIOL CHEM, V276, P11257, DOI 10.1074/jbc.M005994200; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; Murayama T, 1997, J BIOL CHEM, V272, P24030, DOI 10.1074/jbc.272.38.24030; Murayama T, 1996, J BIOL CHEM, V271, P5079; MURAYAMA T, 1992, J BIOCHEM, V112, P514, DOI 10.1093/oxfordjournals.jbchem.a123931; Murayama T, 2001, J BIOL CHEM, V276, P2953, DOI 10.1074/jbc.M005809200; NEYLON CB, 1995, BIOCHEM BIOPH RES CO, V215, P814, DOI 10.1006/bbrc.1995.2536; O'Brien JJ, 2002, BIOPHYS J, V82, P2428, DOI 10.1016/S0006-3495(02)75586-0; Ogawa Y, 1999, ADV BIOPHYS, V36, P27, DOI 10.1016/S0065-227X(99)80004-5; Sambrook J., 2002, MOL CLONING LAB MANU; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Tanna B, 1998, J GEN PHYSIOL, V112, P55, DOI 10.1085/jgp.112.1.55; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971	34	32	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41778	41785		10.1074/jbc.M208210200	http://dx.doi.org/10.1074/jbc.M208210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12213830	hybrid			2022-12-25	WOS:000178985300062
J	Fiorini, M; Ballaro, C; Sala, G; Falcone, G; Alema, S; Segatto, O				Fiorini, M; Ballaro, C; Sala, G; Falcone, G; Alema, S; Segatto, O			Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control	ONCOGENE			English	Article						ErbB; RALT; proteasome; cell cycle; Ras pathways	ACTIVATED PROTEIN-KINASE; UBIQUITIN-PROTEASOME PATHWAY; MAMMARY EPITHELIAL-CELLS; EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE; NEGATIVE REGULATORS; IN-VIVO; C-CBL; DEGRADATION; DIFFERENTIATION	Over-expression studies have demonstrated that RALT (receptor associated late transducer) is a feedback inhibitor of ErbB-2 mitogenic and transforming signals. In growth-arrested cells, expression of endogenous RALT is induced by mitogenic stimuli, is high throughout mid to late G1 and returns to baseline as cells move into S phase. Here, we show that physiological levels of RALT effectively suppress ErbB-2 mitogenic signals. We also investigate the regulatory mechanisms that preside to the control of RALT expression. We demonstrate that pharmacological ablation of extracellular signal-regulated kinase (ERK) activation leads to blockade of RALT expression, unlike genetic and/or pharmacological interference with the activities of PKC, Src family kinases, p38 SAPK and PI-3K. Tamoxifen-dependent activation of an inducible Raf:ER chimera was sufficient to induce RALT expression. Thus, activation of the Ras-Raf-ERK pathway is necessary and sufficient to drive RALT expression. The RALT protein is labile and was found to accumulate robustly upon pharmacological inhibition of the proteasome. We were able to detect ubiquitin-conjugated RALT species in living cells, suggesting that ubiquitinylation targets RALT for proteasome-dependent degradation. Such an integrated transcriptional and posttranslational control is likely to provide RALT with the ability to fluctuate timely in order to tune ErbB signals.	Ist Regina Elena, Immunol Lab, I-00156 Rome, Italy; CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR)	Segatto, O (corresponding author), Ist Regina Elena, Immunol Lab, I-00156 Rome, Italy.		Sala, Gianluca/C-2056-2017; Falcone, Germana/A-3735-2016	Sala, Gianluca/0000-0002-4494-915X; Segatto, Oreste/0000-0003-2561-1142; Falcone, Germana/0000-0002-3508-7623; Alema, Stefano/0000-0002-9869-6354				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Douglas DN, 1999, BBA-MOL CELL RES, V1448, P439, DOI 10.1016/S0167-4889(98)00161-X; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Flanagan A M, 1998, Curr Opin Hematol, V5, P181, DOI 10.1097/00062752-199805000-00006; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; Ghiglione C, 1999, DEV BIOL, V205, P181, DOI 10.1006/dbio.1998.9102; Greenwood S, 1997, DEVELOPMENT, V124, P4879; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690; Hughes EA, 1996, J EXP MED, V183, P1569, DOI 10.1084/jem.183.4.1569; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Jones SM, 2001, FEBS LETT, V490, P110, DOI 10.1016/S0014-5793(01)02113-5; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; LEE KL, 1989, ARCH BIOCHEM BIOPHYS, V269, P106, DOI 10.1016/0003-9861(89)90091-X; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; McMahon M, 2001, BBA-REV CANCER, V1471, pM63, DOI 10.1016/S0304-419X(00)00027-5; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009.abs; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Ozaki K, 2001, BIOCHEM BIOPH RES CO, V285, P1084, DOI 10.1006/bbrc.2001.5295; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pai LM, 2000, CELL, V103, P51, DOI 10.1016/S0092-8674(00)00104-5; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; WICK M, 1995, EXP CELL RES, V219, P527, DOI 10.1006/excr.1995.1261; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	70	67	72	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6530	6539		10.1038/sj.onc.1205823	http://dx.doi.org/10.1038/sj.onc.1205823			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226756				2022-12-25	WOS:000177925300013
J	Budanov, AV; Shoshani, T; Faerman, A; Zelin, E; Kamer, I; Kalinski, H; Gorodin, S; Fishman, A; Chajut, A; Einat, P; Skaliter, R; Gudkov, AV; Chumakov, PM; Feinstein, E				Budanov, AV; Shoshani, T; Faerman, A; Zelin, E; Kamer, I; Kalinski, H; Gorodin, S; Fishman, A; Chajut, A; Einat, P; Skaliter, R; Gudkov, AV; Chumakov, PM; Feinstein, E			Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability	ONCOGENE			English	Article						hypoxia; p53-responsive gene; cell viability; stress response	GROWTH ARREST; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; DNA-DAMAGE; HYPOXIA; P53; EXPRESSION; PROTEIN; ACTIVATION; APOPTOSIS	cDNA microarray hybridization was used in an attempt to identify novel genes participating in cellular responses to prolonged hypoxia. One of the identified novel genes, designated Hi95 shared significant homology to a p53-regulated GADD family member PA26. In addition to its induction in response to prolonged hypoxia, the increased Hi95 transcription was observed following DNA damage or oxidative stress, but not following hyperthermia or serum starvation. Whereas induction of Hi95 by prolonged hypoxia or by oxidative stress is most likely p53-independent, its induction in response to DNA damaging treatments (gamma- or UV-irradiation, or doxorubicin) occurs in a p53-dependent manner. Overexpression of Hi95 full-length cDNA was found toxic for many types of cultured cells directly leading either to their apoptotic death or to sensitization to serum starvation and DNA damaging treatments. Unexpectedly, conditional overexpression of the Hi95 cDNA in MCF7-tet-off cells resulted in their protection against cell death induced by hypoxia/glucose deprivation or H2O2. Thus, Hi95 gene seems to be involved in complex regulation of cell viability in response to different stress conditions.	Quark Biotech Inc, QBI Enterprises Ltd, IL-70400 Ness Ziona, Israel; Cleveland Clin Fdn, Dept Biol Mol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Chumakov, PM (corresponding author), Quark Biotech Inc, QBI Enterprises Ltd, Weizmann Sci Pk,POB 4071, IL-70400 Ness Ziona, Israel.	chumakp@ccf.org; elenaf@qbi.co.il	Chumakov, Peter M/E-7731-2014; Budanov, Andrei V/HGD-5487-2022	Budanov, Andrei V/0000-0002-7943-1000; Chumakov, Peter/0000-0002-8078-2908; Gudkov, Andrei/0000-0003-2548-0154				Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DINI MM, 1980, OBSTET GYNECOL, V55, P728; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; Faerman A, 1997, METHOD CELL BIOL, V52, P373, DOI 10.1016/S0091-679X(08)60388-X; Feldser D, 1999, CANCER RES, V59, P3915; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; JONES PA, 1975, CELL, V6, P245, DOI 10.1016/0092-8674(75)90015-X; Kataoka Y, 2000, INT J RADIAT BIOL, V76, P633; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; PINKERTON H, 1976, P SOC EXP BIOL MED, V151, P532; PRICE BD, 1992, CANCER RES, V52, P3814; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Sowter HM, 2001, CANCER RES, V61, P6669; Stratmann R, 1997, J NEUROPATH EXP NEUR, V56, P1242, DOI 10.1097/00005072-199711000-00009; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; WALLACH D, 1984, J IMMUNOL, V132, P2464; WESTLEY B, 1979, BIOCHEM BIOPH RES CO, V90, P410, DOI 10.1016/0006-291X(79)91250-6; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; Zhang W, 2001, INT J ONCOL, V18, P749	44	271	291	4	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6017	6031		10.1038/sj.onc.1205877	http://dx.doi.org/10.1038/sj.onc.1205877			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203114				2022-12-25	WOS:000177671300005
J	Iervolino, A; Trisciuoglio, D; Ribatti, D; Candiloro, A; Biroccio, A; Zupi, G; Del Bufalo, D				Iervolino, A; Trisciuoglio, D; Ribatti, D; Candiloro, A; Biroccio, A; Zupi, G; Del Bufalo, D			Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity	FASEB JOURNAL			English	Article						endothelial cells; cancer line; angiogenic factor; vascularization	ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1; MESSENGER-RNA STABILITY; KAPPA-B ACTIVITY; FACTOR EXPRESSION; CARCINOMA-CELLS; SYNERGISTICALLY ACT; HUMAN GLIOBLASTOMA; CANCER CELLS; FACTOR GENE	The aim of this paper was to study the molecular mechanisms by which bcl-2 increases hypoxia-induced vascular endothelial growth factor (VEGF) expression. We demonstrated that bcl-2 overexpression in M14 human melanoma cell line enhances hypoxia-induced VEGF mRNA stability and promoter activation. In particular, the half-life of the message was longer in bcl-2 transfectants (approximately 330 min) than in control cells (approximately 180 min). In addition, bcl-2 overexpression increased VEGF promoter activity through the hypoxia-inducible factor-1 (HIF-1) transcription factor. Increased HIF-1 protein expression and DNA binding activity were detected in bcl-2 overexpressing cells compared with control cells. An enhanced functional activity of secreted VEGF was found both in in vitro and in vivo angiogenic assays, and the use of VEGF specific antibodies validated the role of VEGF on bcl-2-induced angiogenesis. Taken together our results indicate that bcl-2 plays an important role in melanoma angiogenesis, and that VEGF mRNA stabilization and HIF-1-mediated transcriptional activity are two important control points in bcl-2/hypoxia-induced VEGF expression.	Regina Elena Inst Canc Res, Dept Expt Chemotherapy, I-00158 Rome, Italy; Univ Bari, Sch Med, Dept Human Anat & Histol, I-70121 Bari, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita degli Studi di Bari Aldo Moro	Del Bufalo, D (corresponding author), Regina Elena Inst Canc Res, Dept Expt Chemotherapy, Via Messi Oro 156, I-00158 Rome, Italy.	delbufalo@ifo.it	Biroccio, Annamaria/B-2861-2018; Del Bufalo, Donatella/AAC-1594-2021; Del Bufalo, Donatella/K-8673-2016; trisciuoglio, Daniela/H-2131-2016; trisciuoglio, daniela/AAL-4002-2021	Biroccio, Annamaria/0000-0003-3198-3532; Del Bufalo, Donatella/0000-0002-3148-6096; Del Bufalo, Donatella/0000-0002-3148-6096; trisciuoglio, Daniela/0000-0002-7007-7914; 				Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Biroccio A, 2000, FASEB J, V14, P652, DOI 10.1096/fasebj.14.5.652; Biroccio A, 1999, INT J CANCER, V82, P125, DOI 10.1002/(SICI)1097-0215(19990702)82:1<125::AID-IJC21>3.0.CO;2-Q; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; Desbaillets I, 1999, ONCOGENE, V18, P1447, DOI 10.1038/sj.onc.1202424; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Grover R, 1996, EUR J SURG ONCOL, V22, P342, DOI 10.1016/S0748-7983(96)90154-7; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harmey JH, 1998, ANN SURG ONCOL, V5, P271, DOI 10.1007/BF02303785; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Huang ZW, 2000, ONCOGENE, V19, P6627, DOI 10.1038/sj.onc.1204087; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; KIESER A, 1994, ONCOGENE, V9, P963; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Levy AP, 1998, TRENDS CARDIOVAS MED, V8, P246, DOI 10.1016/S1050-1738(98)00020-6; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Mazure NM, 1996, CANCER RES, V56, P3436; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nabors LB, 2001, CANCER RES, V61, P2154; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Ribatti D, 1999, J CELL SCI, V112, P4213; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Richard DE, 1999, BIOCHEM BIOPH RES CO, V266, P718, DOI 10.1006/bbrc.1999.1889; Rivard A, 2000, J BIOL CHEM, V275, P29643, DOI 10.1074/jbc.M001029200; SCOTLANDI K, 1994, INT J CANCER, V58, P95, DOI 10.1002/ijc.2910580116; Selzer E, 1998, MELANOMA RES, V8, P197, DOI 10.1097/00008390-199806000-00001; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Straume O, 2001, AM J PATHOL, V159, P223, DOI 10.1016/S0002-9440(10)61688-4; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	49	96	106	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1453	+		10.1096/fj.02-0122fje	http://dx.doi.org/10.1096/fj.02-0122fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205045				2022-12-25	WOS:000177813100016
J	Williamson, AL; Brindley, PJ; Abbenante, G; Prociv, P; Berry, C; Girdwood, K; Pritchard, DI; Fairlie, DP; Hotez, PJ; Dalton, JP; Loukas, A				Williamson, AL; Brindley, PJ; Abbenante, G; Prociv, P; Berry, C; Girdwood, K; Pritchard, DI; Fairlie, DP; Hotez, PJ; Dalton, JP; Loukas, A			Cleavage of hemoglobin by hookworm cathepsin D aspartic proteases and its potential contribution to host specificity	FASEB JOURNAL			English	Article						parasite; Ancylostoma caninum; Necator americanus; nematode	HUMAN EOSINOPHILIC ENTERITIS; ADULT HAEMONCHUS-CONTORTUS; BLOOD-FEEDING PARASITES; ANCYLOSTOMA-CANINUM; PLASMODIUM-FALCIPARUM; CAENORHABDITIS-ELEGANS; IN-VIVO; DEGRADATION; INFECTION; IDENTIFICATION	Hookworms routinely reach the gut of nonpermissive hosts but fail to successfully feed, develop, and reproduce. To investigate the effects of host-parasite coevolution on the ability of hookworms to feed in nonpermissive hosts, we cloned and expressed aspartic proteases from canine and human hookworms. We show here that a cathepsin D-like protease from the canine hookworm Ancylosotoma caninum (Ac-APR-1) and the orthologous protease from the human hookworm Necator americanus (Na-APR-1) are expressed in the gut and probably exert their proteolytic activity extracellularly. Both proteases were detected immunologically and enzymatically in somatic extracts of adult worms. The two proteases were expressed in baculovirus, and both cleaved human and dog hemoglobin (Hb) in vitro. Each protease digested Hb from its permissive host between twofold (whole molecule) and sixfold (synthetic peptides) more efficiently than Hb from the nonpermissive host, despite the two proteases' having identical residues lining their active site clefts. Furthermore, both proteases cleaved Hb at numerous distinct sites and showed different substrate preferences. The findings suggest that the paradigm of matching the molecular structure of the food source within a host to the molecular structure of the catabolic proteases of the parasite is an important contributing factor for host-parasite compatibility and host species range.	Queensland Inst Med Res, Div Infect Dis & Immunol, Brisbane, Qld 4006, Australia; Univ Queensland, Dept Microbiol & Parasitol, Brisbane, Qld, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; Tulane Univ, Dept Trop Med, New Orleans, LA 70118 USA; Cardiff Univ, Sch Biosci, Cardiff, S Glam, Wales; Univ Nottingham, Boots Sci Inst, Nottingham NG7 2RD, England; George Washington Univ, Ctr Med, Dept Microbiol & Trop Med, Washington, DC 20037 USA; Dublin City Univ, Fac Hlth & Sci, Sch Biotechnol, Dublin 9, Ireland	QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland; Tulane University; Cardiff University; University of Nottingham; George Washington University; Dublin City University	Loukas, A (corresponding author), George Washington Univ, Ctr Med, Dept Microbiol & Trop Med, Ross Hall,Room 727,2300 Eye St NW, Washington, DC 20037 USA.	mtmacl@gwumc.edu	Loukas, Alex/B-7355-2014; Fairlie, David P/F-8865-2014; Berry, Colin/A-4338-2010; Dalton, John/K-4457-2014	Loukas, Alex/0000-0002-0896-8441; Fairlie, David P/0000-0002-7856-8566; Berry, Colin/0000-0002-9943-548X; Plummer, Beverley/0000-0002-6559-7237; Hotez, Peter/0000-0001-8770-1042; Brindley, Paul J./0000-0003-1765-0002				BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY, P919; Beyer BM, 1996, J BIOL CHEM, V271, P15590, DOI 10.1074/jbc.271.26.15590; Bielefeldt-Ohmann H, 1998, VIRUS RES, V57, P63, DOI 10.1016/S0168-1702(98)00087-2; Brindley PJ, 1997, MOL BIOCHEM PARASIT, V89, P1, DOI 10.1016/S0166-6851(97)00098-4; Brindley PJ, 2001, MOL BIOCHEM PARASIT, V112, P103, DOI 10.1016/S0166-6851(00)00351-0; Brinkworth RI, 2001, J BIOL CHEM, V276, P38844, DOI 10.1074/jbc.M101934200; Brinkworth RI, 2000, INT J PARASITOL, V30, P785, DOI 10.1016/S0020-7519(00)00045-X; Chen Ming Gang, 1993, P237; Coombs GH, 2001, TRENDS PARASITOL, V17, P532, DOI 10.1016/S1471-4922(01)02037-2; CROESE J, 1994, ANN INTERN MED, V120, P369, DOI 10.7326/0003-4819-120-5-199403010-00003; Crompton DWT, 1999, J PARASITOL, V85, P397, DOI 10.2307/3285768; Daub J, 2000, PARASITOLOGY, V120, P171, DOI 10.1017/S0031182099005375; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Fruitier I, 1998, BIOCHEM BIOPH RES CO, V246, P719, DOI 10.1006/bbrc.1998.8614; Geier G, 1999, EUR J BIOCHEM, V264, P872, DOI 10.1046/j.1432-1327.1999.00679.x; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Harrop SA, 1996, BIOCHEM BIOPH RES CO, V227, P294, DOI 10.1006/bbrc.1996.1503; HOTEZ PJ, 1995, SCI AM, V272, P68, DOI 10.1038/scientificamerican0695-68; Humason G. L., 1979, ANIMAL TISSUE TECHNI; Jolodar A, 1998, BBA-PROTEIN STRUCT M, V1382, P13, DOI 10.1016/S0167-4838(97)00141-6; Jones BF, 2002, MOL BIOCHEM PARASIT, V119, P107, DOI 10.1016/S0166-6851(01)00409-1; KNOX DP, 1993, PARASITOLOGY, V106, P395, DOI 10.1017/S0031182000067147; Longbottom D, 1997, MOL BIOCHEM PARASIT, V88, P63, DOI 10.1016/S0166-6851(97)00074-1; LOUKAS A, 1992, T ROY SOC TROP MED H, V86, P650, DOI 10.1016/0035-9203(92)90175-C; Loukas A, 1998, PARASITOL TODAY, V14, P54, DOI 10.1016/S0169-4758(97)01188-5; Loukas A, 2001, CLIN MICROBIOL REV, V14, P689, DOI 10.1128/CMR.14.4.689-703.2001; Prociv P, 1997, CHEM IMMUNOL, V66, P62; Prociv P, 1998, PARASITOL TODAY, V14, P51, DOI 10.1016/S0169-4758(97)01187-3; PROCIV P, 1990, LANCET, V335, P1299, DOI 10.1016/0140-6736(90)91186-E; SAWANGJAROEN N, 1995, PARASITE IMMUNOL, V17, P29, DOI 10.1111/j.1365-3024.1995.tb00963.x; SWOFFORD DL, 1998, PAUP ASTERISQUE PHYL; Tcherepanova I, 2000, J BIOL CHEM, V275, P26359, DOI 10.1074/jbc.M000956200; Wasilewski MM, 1996, MOL BIOCHEM PARASIT, V81, P179, DOI 10.1016/0166-6851(96)02703-X; Yoshida Y., 1960, Japanese Journal of Parasitology, V9, P735	36	98	101	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1458	+		10.1096/fj.02-0181fje	http://dx.doi.org/10.1096/fj.02-0181fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205047				2022-12-25	WOS:000177813100003
J	Bocharov, EV; Korzhnev, DM; Blommers, MJJ; Arvinte, T; Orekhov, VY; Billeter, M; Arseniev, AS				Bocharov, EV; Korzhnev, DM; Blommers, MJJ; Arvinte, T; Orekhov, VY; Billeter, M; Arseniev, AS			Dynamics-modulated biological activity of transforming growth factor beta 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODEL-FREE APPROACH; GROWTH-FACTOR-BETA; MAGNETIC-RESONANCE RELAXATION; TGF-BETA; CRYSTAL-STRUCTURE; BACKBONE DYNAMICS; ORDER PARAMETERS; RECEPTOR; BINDING; MACROMOLECULES	Transforming growth factor beta3 (TGF-beta3) is an important mediator of growth, maintenance, and repair processes in human cells. Internal dynamic properties have been derived from N-15 NMR relaxation data and mapped onto the spatial structure of TGF-beta3. The pattern of internal dynamics in the structure identifies potential "hot spots" of binding free energy and reveals the importance of conformational entropy in the interaction of TGF-beta3 with the receptors. The observed internal dynamics set TGF-beta3 apart from other TGF-beta isoforms, with which it shares the same fold. These findings may explain functional differences among the various TGF-beta isoforms and thus prove essential in the search for related therapeutic agents.	Novartis Pharma AG, CH-4002 Basel, Switzerland; Russian Acad Sci, Shemyakin Ovchinnikow Inst Bioorgan Chem, Moscow, Russia; Univ Gothenburg, Swedish NMR Ctr, S-40530 Gothenburg, Sweden; Univ Gothenburg, Lundberg Lab, S-40530 Gothenburg, Sweden	Novartis; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; University of Gothenburg; University of Gothenburg	Blommers, MJJ (corresponding author), Novartis Pharma AG, CH-4002 Basel, Switzerland.	marcel_jj.blommers@pharma.novartis.com	Orekhov, Vladislav/AAD-8464-2019; Billeter, Martin/A-8293-2010	Orekhov, Vladislav/0000-0002-7892-6896; 				BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bocharov EV, 2000, J BIOMOL NMR, V16, P179, DOI 10.1023/A:1008315600134; Burmester JK, 1998, GROWTH FACTORS, V15, P231, DOI 10.3109/08977199809002119; CERLETTI N, 1995, Patent No. 9603433; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; De Crescenzo G, 2001, J BIOL CHEM, V276, P29632, DOI 10.1074/jbc.M009765200; DELATORRE JG, 1981, Q REV BIOPHYS, V14, P81, DOI 10.1017/S0033583500002080; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Gray PC, 2000, J BIOL CHEM, V275, P3206, DOI 10.1074/jbc.275.5.3206; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Hofsteenge J, 1999, J BIOL CHEM, V274, P32786, DOI 10.1074/jbc.274.46.32786; Huang SS, 1999, J BIOL CHEM, V274, P27754, DOI 10.1074/jbc.274.39.27754; Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korzhnev DM, 2000, J BIOMOL NMR, V17, P231, DOI 10.1023/A:1008348827208; Korzhnev DM, 2001, PROG NUCL MAG RES SP, V38, P197, DOI 10.1016/S0079-6565(00)00028-5; Korzhnev DM, 2001, FEBS LETT, V495, P52, DOI 10.1016/S0014-5793(01)02363-8; Krasagakis K, 1998, BRIT J CANCER, V77, P1492, DOI 10.1038/bjc.1998.245; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; Mostov K, 1997, SCIENCE, V276, P219, DOI 10.1126/science.276.5310.219; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; Orekhov VY, 1995, APPL MAGN RESON, V9, P581, DOI 10.1007/BF03162365; Palmer AG, 2001, ANNU REV BIOPH BIOM, V30, P129, DOI 10.1146/annurev.biophys.30.1.129; Pellaud J, 1999, J BIOL CHEM, V274, P7699, DOI 10.1074/jbc.274.12.7699; Phan IQH, 1996, J BIOMOL NMR, V8, P369, DOI 10.1007/BF00228140; POWERS R, 1993, J MAGN RESON SER B, V101, P325, DOI 10.1006/jmrb.1993.1051; PRESS WH, 1997, NUMERICAL RECIPES C, P689; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; WEBER G, 1993, J PHYS CHEM-US, V97, P7108, DOI 10.1021/j100129a031; WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yang DW, 1996, J MOL BIOL, V263, P369, DOI 10.1006/jmbi.1996.0581; 2002, Patent No. 6057430; 9502718	48	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46273	46279		10.1074/jbc.M206274200	http://dx.doi.org/10.1074/jbc.M206274200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12221089	hybrid			2022-12-25	WOS:000179529300076
J	Nakamura, Y; Haines, N; Chen, JH; Okajima, T; Furukawa, K; Urano, T; Stanley, P; Irvine, KD; Furukawa, K				Nakamura, Y; Haines, N; Chen, JH; Okajima, T; Furukawa, K; Urano, T; Stanley, P; Irvine, KD; Furukawa, K			Identification of a Drosophila gene encoding xylosylprotein 84-galactosyltransferase that is essential for the synthesis of glycosaminoglycans and for morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; CAENORHABDITIS-ELEGANS; HEPARAN-SULFATE; GALACTOSYLTRANSFERASE-I; UDP-GALACTOSE; MOLECULAR-CLONING; EPITHELIAL INVAGINATION; STRUCTURAL-ANALYSIS; FIBROBLAST GROWTH; TOUT-VELU	In mammals, the xylosylprotein beta4-galactosyltransferase termed beta4GalT7 (XgaIT-1, EC 2.4.1.133) participates in proteoglycan biosynthesis through the transfer of galactose to the xylose that initiates each glycosaminoglycan chain. A Drosophila cDNA homologous to mammalian beta4-galactosyltransferases was identified using a human beta4GalT7 cDNA as a probe in a BLAST analysis of expressed sequence tags. The Drosophila cDNA encodes a type 11 membrane protein with 322 amino acids and shows 49% identity to human beta4GalT7. Extracts from L cells transfected with the cDNA exhibited marked galactosyltransferase activity specific for a xylopyranoside acceptor. Moreover, transfection with the cloned cDNA restored glycosaminoglycan synthesis in beta4GalT7-deficient Chinese hamster ovary cells. In transfectant lysates the properties of Drosophila and human beta4GalT7 resembled each other, except that Drosophila beta4GalT7 showed a less restricted specificity and was active at a wider range of temperatures. Drosophila beta4GalT7 is expressed throughout development, with higher expression levels in adults. Reduction of Drosophila beta4GalT7 levels using expressed RNA interference (RNAi) in imaginal discs resulted in an abnormal wing and leg morphology similar to that of flies with defective Hedgehog and Decapentaplegic signaling, which are known to depend on intact proteoglycan biosynthesis. Immimohistochemical analysis of tissues confirmed that both heparan sulfate and chondroitin sulfate biosynthesis were impaired. Our results demonstrate that Drosophila beta4GalT7 has the in vitro and in vivo properties predicted for an ortholog of human beta4GalT7 and is essential for normal animal development through its role in proteoglycan biosynthesis.	Nagoya Univ, Dept Biochem 2, Sch Med, Showa Ku, Nagoya, Aichi 4660065, Japan; Rutgers State Univ, Howard Hughes Med Inst, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Nagoya University; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Yeshiva University; Albert Einstein College of Medicine	Furukawa, K (corresponding author), Nagoya Univ, Dept Biochem 2, Sch Med, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Okajima, Tetsuya/I-7332-2014	Okajima, Tetsuya/0000-0002-3677-648X; Urano, Takeshi/0000-0003-3383-3554; Stanley, Pamela/0000-0001-5704-3747	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054594] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM54594] Funding Source: Medline; PHS HHS [P01-13330, R01-36434] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Baeg GH, 2000, CURR OPIN CELL BIOL, V12, P575, DOI 10.1016/S0955-0674(00)00134-4; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; ESKO JD, 1987, J BIOL CHEM, V262, P12189; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Goto S, 2001, NAT CELL BIOL, V3, P816, DOI 10.1038/ncb0901-816; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; HELTING T, 1969, J BIOL CHEM, V244, P2790; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Klein T, 1997, DEV BIOL, V189, P123, DOI 10.1006/dbio.1997.8564; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kuroiwa A, 2000, CYTOGENET CELL GENET, V89, P8, DOI 10.1159/000015578; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Lugemwa FN, 1996, J BIOL CHEM, V271, P19159, DOI 10.1074/jbc.271.32.19159; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Okajima T, 1999, J BIOL CHEM, V274, P28841, DOI 10.1074/jbc.274.41.28841; POWELL JT, 1976, J BIOL CHEM, V251, P3645; QUENTIN E, 1990, P NATL ACAD SCI USA, V87, P1342, DOI 10.1073/pnas.87.4.1342; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SanchezHerrero E, 1996, MECH DEVELOP, V55, P159, DOI 10.1016/0925-4773(96)00498-4; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SCHWARTZ NB, 1975, J BIOL CHEM, V250, P5200; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Selva EM, 2001, NAT CELL BIOL, V3, P809, DOI 10.1038/ncb0901-809; Seppo A, 2000, EUR J BIOCHEM, V267, P3549, DOI 10.1046/j.1432-1327.2000.01383.x; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; Strigini M, 1997, DEVELOPMENT, V124, P4697; THAMPOE IJ, 1989, CANCER RES, V49, P6258; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; Vervoort M, 1999, CURR BIOL, V9, P632, DOI 10.1016/S0960-9822(99)80285-1; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	53	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46280	46288		10.1074/jbc.M203873200	http://dx.doi.org/10.1074/jbc.M203873200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12215432	hybrid			2022-12-25	WOS:000179529300077
J	Radcliffe, CM; Diedrich, G; Harvey, DJ; Dwek, RA; Cresswell, P; Rudd, PM				Radcliffe, CM; Diedrich, G; Harvey, DJ; Dwek, RA; Cresswell, P; Rudd, PM			Identification of specific glycoforms of major histocompatibility complex class I heavy chains suggests that class I peptide loading is an adaptation of the quality control pathway involving calreticulin and ERp57	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; N-LINKED OLIGOSACCHARIDES; MOLECULAR CHAPERONE; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; CALNEXIN; GLYCOPROTEINS; TAP; PROTEIN; TAPASIN	Glycosylation analysis was used to probe the sequence of events accompanying the binding of antigenic peptides to the major histocompatibility complex class I heavy chains. Free heavy chains were isolated from the beta(2)-microglobulin-negative cell line Daudi and from the B-lymphoblastoid cell line Raji. Heavy chains were also isolated from Raji cells in multimolecular complexes (peptide loading complexes) containing the transporter associated with antigen processing, tapasin and ERp57 with and without the lectin-like folding chaperone, calreticulin. Calreticulin is a soluble protein that recognizes primarily the terminal glucose of Glc(1)Man(7-9)GlcNAC(2) glycans. This paper shows that monoglucosylated glycoforms of heavy chain, which exist transiently in the endoplasmic reticulum in the initial stages of the glycosylation processing pathway, are present in the peptide loading complex. The data are consistent with a model in which the release of peptide-loaded major histocompatibility complex class I molecules from calreticulin, induced by deglucosylation of the heavy chain N-linked glycan, signals the dissociation of the complex. This is consistent with the hypothesis that the class I loading process is an adaptation of the quality control mechanism involving calreticulin and ERp57.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA	University of Oxford; Howard Hughes Medical Institute; Yale University	Rudd, PM (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.		Harvey, David/A-5579-2013	Harvey, David/0000-0003-0544-771X				BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; Barber LD, 1996, J IMMUNOL, V156, P3275; Bergeron JJM, 1998, ADV EXP MED BIOL, V435, P105; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Diedrich G, 2001, J IMMUNOL, V166, P1703, DOI 10.4049/jimmunol.166.3.1703; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Farmery MR, 2000, J BIOL CHEM, V275, P14933, DOI 10.1074/jbc.275.20.14933; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; Harris MR, 1998, J IMMUNOL, V160, P5404; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; KARLSSON GB, 1993, J BIOL CHEM, V268, P570; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Morrice NA, 1998, CURR BIOL, V8, P713, DOI 10.1016/S0960-9822(98)70279-9; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Patil AR, 2000, J BIOL CHEM, V275, P24348, DOI 10.1074/jbc.M003102200; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; Suh WK, 1996, J EXP MED, V184, P337, DOI 10.1084/jem.184.2.337; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697	38	54	57	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46415	46423		10.1074/jbc.M202466200	http://dx.doi.org/10.1074/jbc.M202466200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235131	hybrid			2022-12-25	WOS:000179529300093
J	Rueda, D; Navarro, B; Martinez-Serrano, A; Guzman, M; Galve-Roperh, I				Rueda, D; Navarro, B; Martinez-Serrano, A; Guzman, M; Galve-Roperh, I			The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR; CANNABINOID RECEPTOR; MAP KINASE; NEUROGENESIS; CERAMIDE; BRAIN; RAP1; IDENTIFICATION	Endocannabinoids are neuromodulators that act as retrograde synaptic messengers inhibiting the release of different neurotransmitters in cerebral areas such as hippocampus, cortex, and striatum. However, little is known about other roles of the endocannabinoid system in brain. In the present work we provide substantial evidence that the endocannabinoid anandamide (AEA) regulates neuronal differentiation both in culture and in vivo. Thus AEA, through the CB1 receptor, inhibited cortical neuron progenitor differentiation to mature neuronal phenotype. In addition, human neural stem cell differentiation and nerve growth factor-induced PC12 cell differentiation were also inhibited by cannabinoid challenge. AEA decreased PC12 neuronal-like generation via CB1-mediated inhibition of sustained extracellular signal-regulated kinase (ERK) activation, which is responsible for nerve growth factor action. AEA thus inhibited TrkA-induced Rap1/B-Raf/ERK activation. Finally, immunohistochemical analyses by confocal microscopy revealed that adult neurogenesis in dentate gyrus was significantly decreased by the AEA analogue methanandamide and increased by the CB, antagonist SR141716. These data indicate that endocannabinoids inhibit neuronal progenitor cell differentiation through attenuation of the ERK pathway and suggest that they constitute a new physiological system involved in the regulation of neurogenesis.	Univ Complutense Madrid, Dept Biochem & Mol Biol 1, Sch Biol, E-28040 Madrid, Spain; Univ Autonoma Madrid, Mol Biol Ctr Severo Ochoa, Madrid 28049, Spain	Complutense University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Galve-Roperh, I (corresponding author), Univ Complutense Madrid, Dept Biochem & Mol Biol 1, Sch Biol, E-28040 Madrid, Spain.	igr@bbml.ucm.es	Galve-Roperh, Ismael/AAG-2369-2020; Navarro-Galve, Beatriz/A-4880-2009; Martínez-Serrano, Alberto/J-8146-2014; Navarro Galve, Beatriz/K-8755-2014; Rueda, Daniel/I-1176-2015	Navarro Galve, Beatriz/0000-0002-2021-9937; Rueda, Daniel/0000-0002-5377-8890; Guzman, Manuel/0000-0001-7475-118X; Martinez Serrano, Alberto/0000-0003-3927-6699				Blazquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00-0122com; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DELPULGAR MTG, 2001, BIOCHEM J, V347, P369; Derkinderen P, 1999, NEUROREPORT, V10, pR24; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Duman RS, 2001, J PHARMACOL EXP THER, V299, P401; Fernandez-Ruiz J, 2000, TRENDS NEUROSCI, V23, P14, DOI 10.1016/S0166-2236(99)01491-5; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268; Gould E, 2002, J NEUROSCI, V22, P619, DOI 10.1523/JNEUROSCI.22-03-00619.2002; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Guzman M, 2001, TRENDS PHARMACOL SCI, V22, P19, DOI 10.1016/S0165-6147(00)01586-8; Hampson RE, 2000, J NEUROSCI, V20, P8932; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Katona I, 1999, J NEUROSCI, V19, P4544; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; LANGGUT W, 1995, FEBS LETT, V372, P173, DOI 10.1016/0014-5793(95)00971-B; MartinezSerrano A, 1996, J NEUROSCI, V16, P4604; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Porter AC, 2001, PHARMACOL THERAPEUT, V90, P45, DOI 10.1016/S0163-7258(01)00130-9; Rubio FJ, 2000, MOL CELL NEUROSCI, V16, P1, DOI 10.1006/mcne.2000.0854; Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814; Sachinidis A, 2002, FASEB J, V16, P893, DOI 10.1096/fj.01-0799fje; Schlicker E, 2001, TRENDS PHARMACOL SCI, V22, P565, DOI 10.1016/S0165-6147(00)01805-8; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Villa A, 2000, EXP NEUROL, V161, P67, DOI 10.1006/exnr.1999.7237; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	41	178	190	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46645	46650		10.1074/jbc.M206590200	http://dx.doi.org/10.1074/jbc.M206590200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237305	hybrid			2022-12-25	WOS:000179529300122
J	Sugishima, M; Sakamoto, H; Higashimoto, Y; Omata, Y; Hayashi, S; Noguchi, M; Fukuyama, K				Sugishima, M; Sakamoto, H; Higashimoto, Y; Omata, Y; Hayashi, S; Noguchi, M; Fukuyama, K			Crystal structure of rat heme oxygenase-1 in complex with heme bound to azide - Implication for regiospecific hydroxylation of heme at the alpha-meso carbon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; REDUCING EQUIVALENT; RESONANCE RAMAN; PORPHYRIN RING; CATALYTIC SITE; SOLUBLE FORM; HYDROXYHEME; VERDOHEME; DIFFRACTION; ACTIVATION	Heme oxygenase (HO) catalyzes physiological heme degradation consisting of three sequential oxidation steps that use dioxygen molecules and reducing equivalents. We determined the crystal structure of rat HO-1 in complex with heme and azide (HO-heme-N-3(-)) at 1.9-Angstrom resolution. The azide, whose terminal nitrogen atom is coordinated to the ferric heme iron, is situated nearly parallel to the heme plane, and its other end is directed toward the a-meso position of the heme. Based on resonance Raman spectroscopic analysis of HO-heme bound to dioxygen, this parallel coordination mode suggests that the azide is an analog of dioxygen. The azide is surrounded by residues of the distal F-helix with only the direction to the alpha-meso carbon being open. This indicates that regiospecific oxygenation of the heme is primarily caused by the steric constraint between the dioxygen bound to heme and the F-helix. The azide interacts with Asp-140, Arg-136, and Thr-135 through a hydrogen bond network involving five water molecules on the distal side of the heme. This network, also present in HO-heme, may function in dioxygen activation in the first hydroxylation step. From the orientation of azide in HO-heme-N-3(-), the dioxygen or hydroperoxide bound to HO-heme, the active oxygen species of the first reaction, is inferred to have a similar orientation suitable for a direct attack on the alpha-meso carbon.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; Kurume Univ, Sch Med, Dept Med Biochem, Kurume, Fukuoka 8300011, Japan	Osaka University; Kurume University	Fukuyama, K (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan.		Sugishima, Masakazu/M-2773-2019; Sakamoto, Hiroshi/A-3181-2011; Sugishima, Masakazu/B-1049-2010	Sugishima, Masakazu/0000-0002-0840-4929; Sugishima, Masakazu/0000-0002-0840-4929; Higashimoto, Yuichiro/0000-0003-1382-8598				BEALE SI, 1994, CIBA F SYMP, V180, P156; BLUMBERG WE, 1971, ADV CHEM, V100, P271; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cary SPL, 2001, J CLIN INVEST, V107, P1071, DOI 10.1172/JCI12823; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; Davydov RM, 1999, J AM CHEM SOC, V121, P10656, DOI 10.1021/ja992425v; Fujii H, 2001, J AM CHEM SOC, V123, P6475, DOI 10.1021/ja010490a; Hawkins BK, 1996, BBA-PROTEIN STRUCT M, V1295, P165, DOI 10.1016/0167-4838(96)00031-3; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; Hidaka Toshihiro, 1996, Kurume Medical Journal, V43, P313; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Liu Y, 1997, J BIOL CHEM, V272, P6909, DOI 10.1074/jbc.272.11.6909; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; Maurus R, 1998, BIOCHEM J, V332, P67, DOI 10.1042/bj3320067; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Migita CT, 1999, BBA-PROTEIN STRUCT M, V1432, P203; Omata Y, 1998, ACTA CRYSTALLOGR D, V54, P1017, DOI 10.1107/S0907444998003448; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pond AE, 1999, BIOCHEMISTRY-US, V38, P7601, DOI 10.1021/bi9825448; Prabhakar NR, 1999, RESP PHYSIOL, V115, P161, DOI 10.1016/S0034-5687(99)00019-5; Prabhakar NR, 1998, RESP PHYSIOL, V114, P57, DOI 10.1016/S0034-5687(98)00072-3; Sakamoto H, 1999, J BIOL CHEM, V274, P18196, DOI 10.1074/jbc.274.26.18196; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; WILKS A, 1994, J BIOL CHEM, V269, P29553; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1982, J BIOL CHEM, V257, P9345; YOSHINAGA T, 1990, BIOCHEM J, V270, P659, DOI 10.1042/bj2700659	43	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45086	45090		10.1074/jbc.M207267200	http://dx.doi.org/10.1074/jbc.M207267200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235152	hybrid			2022-12-25	WOS:000179404800064
J	Tupling, AR; Asahi, M; MacLennan, DH				Tupling, AR; Asahi, M; MacLennan, DH			Sarcolipin overexpression in rat slow twitch muscle inhibits sarcoplasmic reticulum Ca2+ uptake and impairs contractile function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; SKELETAL-MUSCLE; MYOCARDIAL-CONTRACTILITY; PHOSPHOLAMBAN GENE; BRODY-DISEASE; CA2+-ATPASE; PHOSPHORYLATION; SERCA1; SITE; STIMULATION	Sarcolipin (SLN) is an inhibitor of sarco(endo)plasmic reticulum Ca2+-ATPases (SERCAs) in vitro, but its function in vivo has not been defined. NF-SLN cDNA (SLN tagged N-terminally with a FLAG epitope) was introduced into rat soleus muscle in one hindlimb by plasmid injection and electrotransfer. Western blotting showed expression and co-immunoprecipitation showed physical interaction between NF-SLN and SERCA2a. Contractile properties and SERCA2a function were assessed and compared with vector-injected contralateral soleus muscles. NF-SLN reduced both peak twitch force (P-t) (123.9 +/- 12.5 versus 69.8 +/- 8.9 millinewtons) and tetanic force (P-o) (562.3 +/- 51.0 versus 300.7 +/- 56.9 millinewtons) and reduced both twitch and tetanic rates of contraction (+dF/dt) and relaxation (-dF/dt) significantly. Repetitive stimulation (750-ms trains at 50 Hz once every 2 s for 3 min) showed that NF-SLN increased susceptibility to fatigue. These changes in contractile function were observed in the absence of endogenous phospholamban, and NF-SLN had no effect on either SERCA2a or SERCA1a expression levels. NF-SLN also decreased maximal Ca2+ transport activity at pCa 5 by 31% with no significant change in apparent Ca2+ affinity (6.36 +/- 0.07 versus 6.39 +/- 0.08 pCa units). These results show that NF-SLN expression impairs muscle contractile function by inhibiting SERCA function and diminishing sarcoplasmic reticulum Ca2+ stores.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Res, Toronto, ON M5G 1L6, Canada	University of Toronto	MacLennan, DH (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.			Tupling, A. Russell/0000-0002-3895-6767				ALLEN DG, 1995, EXP PHYSIOL, V80, P497, DOI 10.1113/expphysiol.1995.sp003864; Asahi M, 1999, J BIOL CHEM, V274, P32855, DOI 10.1074/jbc.274.46.32855; Asahi M, 2002, J BIOL CHEM, V277, P26725, DOI 10.1074/jbc.C200269200; BRODY IA, 1969, NEW ENGL J MED, V281, P187, DOI 10.1056/NEJM196907242810403; Carvalho AJ, 1997, PLAST RECONSTR SURG, V99, P163, DOI 10.1097/00006534-199701000-00025; CHIN ER, 1995, CAN J PHYSIOL PHARM, V73, P1154, DOI 10.1139/y95-165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; DAMIANI E, 2000, BIOCHIM BIOPHYS ACTA, V1464, P1; Davia K, 1999, PHYSIOL GENOMICS, V1, P41, DOI 10.1152/physiolgenomics.1999.1.2.41; de Groof AJC, 2002, J BIOL CHEM, V277, P5275, DOI 10.1074/jbc.M108157200; Dux L, 1993, Rev Physiol Biochem Pharmacol, V122, P69, DOI 10.1007/BFb0035274; FUJII J, 1988, FEBS LETT, V227, P51, DOI 10.1016/0014-5793(88)81412-1; Gayan-Ramirez G, 2000, J PHYSIOL-LONDON, V524, P387, DOI 10.1111/j.1469-7793.2000.t01-2-00387.x; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Li S, 2001, GENE THER, V8, P400, DOI 10.1038/sj.gt.3301418; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MACLENNAN DH, 1972, COLD SPRING HARB SYM, V37, P469; Maruyama H, 2001, GENE THER, V8, P461, DOI 10.1038/sj.gt.3301412; Mayer EJ, 2000, BIOCHEM BIOPH RES CO, V267, P40, DOI 10.1006/bbrc.1999.1920; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; Odermatt A, 1997, GENOMICS, V45, P541, DOI 10.1006/geno.1997.4967; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; Slack JP, 1997, J BIOL CHEM, V272, P18862, DOI 10.1074/jbc.272.30.18862; Vilquin JT, 2001, GENE THER, V8, P1097, DOI 10.1038/sj.gt.3301484; WAWRZYNOW A, 1992, ARCH BIOCHEM BIOPHYS, V298, P620, DOI 10.1016/0003-9861(92)90457-8; WESTERBLAD H, 1993, J PHYSIOL-LONDON, V468, P729, DOI 10.1113/jphysiol.1993.sp019797; WU KD, 1993, AM J PHYSIOL, V264, P333; Zador E, 1996, BIOCHEM J, V320, P107, DOI 10.1042/bj3200107; Zubrzycka-Gaarn E, 1984, Prog Clin Biol Res, V168, P19; Zvaritch E, 2000, J BIOL CHEM, V275, P14985, DOI 10.1074/jbc.275.20.14985	40	77	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44740	44746		10.1074/jbc.M206171200	http://dx.doi.org/10.1074/jbc.M206171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237298	hybrid			2022-12-25	WOS:000179404800020
J	Komissarov, AA; Declerck, PJ; Shore, JD				Komissarov, AA; Declerck, PJ; Shore, JD			Mechanisms of conversion of plasminogen activator inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; SERPIN-PROTEASE COMPLEXES; INTERACTION SITES; TISSUE-TYPE; NEUTRALIZING ANTIBODIES; FLUORESCENT-PROBE; ENDOTHELIAL-CELLS; UROKINASE-TYPE; IDENTIFICATION; EPITOPE	We have delineated two different reaction mechanisms of monoclonal antibodies (mAbs), MA-8H9D4 and either MA-55F4C12 or MA-33H1F7, that convert plasminogen activator inhibitor 1 (PAI-1) to a substrate for tissue (tPA)- and urokinase plasminogen activators. MA-8H9D4 almost completely (98-99%) shifts the reaction to the substrate pathway by preventing disordering of the proteinase active site. MA-8H9D4 does not affect the rate-limiting constants (k(lim)) for the insertion of the reactive center loop cleaved by tPA (3.5 s(-1)) but decreases klim for urokinase plasminogen activator from 25 to 4.0 s(-1). MA-8H9D4 does not cause deacylation of preformed PAI-1/proteinase complexes and probably acts prior to the formation of the final inhibitory complex, interfering with displacement of the acylated serine from the proteinase active site. MA-55F4Cl2 and MA-33H1F7 (50-80% substrate reaction) do not interfere with initial PAI-1/proteinase complex formation but retard the inhibitory pathway by decreasing k(lim) (>10-fold for tPA). Interaction of two mAbs with the same molecule of PAI-1 has been directly demonstrated for pairs MA-8H9D4/MA-55F4C12 and MA-8H9D4/MA-33H1F7 but not for MA-55F4C12/MA-33H1F7. The strong functional additivity observed for MA-8H9D4 and MA-55F4C12 demonstrates that these mAbs interact independently and affect different steps of the PAI-1 reaction mechanism.	Henry Ford Hlth Syst, Div Biochem Res, Detroit, MI 48202 USA; Katholieke Univ Leuven, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium	Henry Ford Health System; Henry Ford Hospital; KU Leuven	Shore, JD (corresponding author), Henry Ford Hlth Syst, Div Biochem Res, Detroit, MI 48202 USA.		Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105	NHLBI NIH HHS [HL 54930] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AERTGEERTS K, 1995, PROTEINS, V23, P118, DOI 10.1002/prot.340230114; Bijnens AP, 2000, J BIOL CHEM, V275, P6375, DOI 10.1074/jbc.275.9.6375; Bijnens AP, 2001, THROMB HAEMOSTASIS, V85, P866; Bijnens AP, 2001, J BIOL CHEM, V276, P44912, DOI 10.1074/jbc.M103077200; Bjorquist P, 1997, BBA-PROTEIN STRUCT M, V1341, P87, DOI 10.1016/S0167-4838(97)00065-4; Bjorquist P, 1998, BIOCHEMISTRY-US, V37, P1227, DOI 10.1021/bi971554q; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; ChaillanHuntington CE, 1997, BIOCHEMISTRY-US, V36, P9562, DOI 10.1021/bi970651g; Charlton PA, 1996, THROMB HAEMOSTASIS, V75, P808; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; Debrock S, 1998, THROMB HAEMOSTASIS, V79, P597; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; EVANS SA, 1982, J BIOL CHEM, V257, P3014; Folkes A, 2002, BIOORG MED CHEM LETT, V12, P1063, DOI 10.1016/S0960-894X(02)00078-1; Folkes A, 2001, BIOORG MED CHEM LETT, V11, P2589, DOI 10.1016/S0960-894X(01)00508-X; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; KEIJER J, 1991, BLOOD, V78, P401; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; Ngo TH, 1997, FEBS LETT, V416, P373, DOI 10.1016/S0014-5793(97)01242-8; OLSON ST, 1982, J BIOL CHEM, V257, P4891; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; Petersen HH, 2001, EUR J BIOCHEM, V268, P4430, DOI 10.1046/j.1432-1327.2001.02365.x; Rajpal A, 1998, PROTEIN SCI, V7, P1868, DOI 10.1002/pro.5560070903; RANDO RR, 1974, SCIENCE, V185, P320, DOI 10.1126/science.185.4148.320; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stout TJ, 2000, BIOCHEMISTRY-US, V39, P8460, DOI 10.1021/bi000290w; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; vanMeijer M, 1996, J BIOL CHEM, V271, P7423, DOI 10.1074/jbc.271.13.7423; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; vanZonneveld AJ, 1995, GENE, V167, P49, DOI 10.1016/0378-1119(95)00614-1; VAUGHAN DE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P221, DOI 10.1016/0167-4838(93)90008-F; Verhamme I, 1999, J BIOL CHEM, V274, P17511, DOI 10.1074/jbc.274.25.17511; Walsh C, 1978, Methods Enzymol, V53, P437; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WIMAN B, 1995, THROMB HAEMOSTASIS, V74, P71; Wind T, 2001, EUR J BIOCHEM, V268, P1095, DOI 10.1046/j.1432-1327.2001.2680041095.x	52	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43858	43865		10.1074/jbc.M204110200	http://dx.doi.org/10.1074/jbc.M204110200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223472	hybrid			2022-12-25	WOS:000179272000044
J	Korichneva, I; Hoyos, B; Chua, R; Levi, E; Hammerling, U				Korichneva, I; Hoyos, B; Chua, R; Levi, E; Hammerling, U			Zinc release from protein kinase C as the common event during activation by lipid second messenger or reactive oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; CYSTEINE-RICH DOMAIN; REDOX SWITCH; CHAPERONE; RAS	Zinc is a structural component of many regulatory molecules including transcription factors and signaling molecules. We report that two alternate signaling pathways of protein kinase C (PKC) activation involving either the lipid second messengers (diacylglycerol and its mimetics, the phorbol esters) or reactive oxygen converge at the zinc finger of the regulatory domain. They all trigger the release of zinc ions. An increase in intracellular free Zn2+ was observed by confocal microscopy in intact cells treated with phorbol ester or by mild oxidation. The source of liberated Zn2+ was traced to PKC and particularly the zinc finger domains. The activated form of native PKCalpha contained significantly less Zn2+ than the resting form. Furthermore, purified recombinant PKC protein fragments shed stoichiometric amounts of Zn2+ upon reaction with diacylglycerol, phorbol ester, or reactive oxygen in vitro. Our results offer new insight into the regulation of PKC. Far from cementing rigid structures, zinc actually is the linchpin that orchestrates dynamic changes in response to specific signals, allowing kinase activity to be turned on or off.	Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Korichneva, I (corresponding author), Mem Sloan Kettering Canc Ctr, Program Immunol, 1275 York Ave,Box 382, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA049933, R01CA089362] Funding Source: NIH RePORTER; NCI NIH HHS [CA 49933, CA 89362] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; Barbirz S, 2000, J BIOL CHEM, V275, P18759, DOI 10.1074/jbc.M001089200; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; Hoyos B, 2000, J EXP MED, V192, P835, DOI 10.1084/jem.192.6.835; HUNT JB, 1984, J BIOL CHEM, V259, P4793; Hurley JH, 1997, CURR OPIN STRUC BIOL, V7, P557, DOI 10.1016/S0959-440X(97)80122-4; Hurley JH, 1997, PROTEIN SCI, V6, P477; Imam A, 2001, FASEB J, V15, P28; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Jakob U, 2000, J BIOL CHEM, V275, P38302, DOI 10.1074/jbc.M005957200; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Mochly-Rosen D, 1998, FASEB J, V12, P35; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; Velazquez RA, 1999, J NEUROSCI, V19, P2288; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	24	138	141	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44327	44331		10.1074/jbc.M205634200	http://dx.doi.org/10.1074/jbc.M205634200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12213816	hybrid			2022-12-25	WOS:000179272000103
J	Romano, M; Marcucci, R; Buratti, E; Ayala, YM; Sebastio, G; Baralle, FE				Romano, M; Marcucci, R; Buratti, E; Ayala, YM; Sebastio, G; Baralle, FE			Regulation of 3 ' splice site selection in the 844ins68 polymorphism of the cystathionine beta-synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HNRNP-H; INTRON; ENHANCER; BINDING; EXON; HYPERHOMOCYSTEINEMIA; THROMBOSIS; MUTATIONS; VARIANT	844ins68 is a frequent polymorphism of the cystathionine beta-synthase gene (CBS) that consists of a 68-bp insertion duplicating the 3' splice site of intron 7 and the 5'-end of exon 8. The presence of two identical 3' splice sites spaced by 68 bp should lead to either a selection of the proximal site or to at least two alternatively spliced CBS mRNA variants. Instead, an accurate selection of the distal 3' splice site is observed in the 844ins68 carriers. The duplication has generated a gene re-arrangement at the 3' splice site where two GGGG runs have been brought close to each other. Using a minigene system, we have investigated the effect this peculiar configuration might have on the selection of the 3' splice site of intron 7 in the CBS gene. Minimal disruption of the G runs resulted in a dramatic shift toward the proximal 3' splice site selection with inclusion of the 68-bp insertion and a consequent change of the reading frame. The insertional event created this peculiar configuration of two G repeats close to each other that subsequently acquired the ability to strongly bind heterogeneous nuclear ribonucleoprotein (hnRNP) H1, a specific trans-acting factor. The interaction of hnRNP H1 with G runs within the 844ins68 context might interfere with the recruitment of splicing factors to the proximal 3' splice site thus favoring the selection of the distal 3' splice site. Our results therefore suggest the possibility that the insertion was an evolutionary event that allowed the rescue of the wild-type sequence, so preserving protein function.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Trieste, Dept Physiol & Pathol, I-34127 Trieste, Italy; Univ Naples Federico II, Dept Pediat, I-80131 Naples, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Trieste; University of Naples Federico II	Baralle, FE (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.		Romano, Maurizio/G-9431-2012; Buratti, Emanuele/K-4691-2016	Romano, Maurizio/0000-0002-4820-2897; Buratti, Emanuele/0000-0002-1356-9074	Telethon [E.1038] Funding Source: Medline	Telethon(Fondazione Telethon)		Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; Caputi M, 2001, J BIOL CHEM, V276, P43850, DOI 10.1074/jbc.M102861200; Carlo T, 1996, RNA, V2, P342; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; de Franchis R, 2000, THROMB HAEMOSTASIS, V84, P576, DOI 10.1055/s-0037-1614070; Franco R, 1998, HAEMATOLOGICA, V83, P1006; Franco RF, 1998, HUM HERED, V48, P338, DOI 10.1159/000022826; Gaustadnes M, 2000, THROMB HAEMOSTASIS, V83, P554, DOI 10.1055/s-0037-1613862; Haut DD, 1998, J VIROL, V72, P1834, DOI 10.1128/JVI.72.3.1834-1843.1998; Kluijtmans LAJ, 1997, BIOCHEM MOL MED, V62, P23, DOI 10.1006/bmme.1997.2623; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; Mazzarella R, 1998, GENOME RES, V8, P1007, DOI 10.1101/gr.8.10.1007; McCarthy EMS, 1998, HUM MOL GENET, V7, P1491, DOI 10.1093/hmg/7.9.1491; McCullough AJ, 1997, MOL CELL BIOL, V17, P4562, DOI 10.1128/MCB.17.8.4562; McCullough AJ, 2000, MOL CELL BIOL, V20, P9225, DOI 10.1128/MCB.20.24.9225-9235.2000; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; NUSSINOV R, 1989, J BIOMOL STRUCT DYN, V6, P985, DOI 10.1080/07391102.1989.10506526; Orendac M, 1999, J INHERIT METAB DIS, V22, P674, DOI 10.1023/A:1005554702861; SEBASTIO G, 1995, AM J HUM GENET, V56, P1324; SIRANDPUGNET P, 1995, NUCLEIC ACIDS RES, V23, P3501, DOI 10.1093/nar/23.17.3501; Sperandeo MP, 1996, AM J HUM GENET, V59, P1391; Tsai MY, 2000, ATHEROSCLEROSIS, V149, P131, DOI 10.1016/S0021-9150(99)00297-X; Tsai MY, 1996, AM J HUM GENET, V59, P1262	24	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43821	43829		10.1074/jbc.M208107200	http://dx.doi.org/10.1074/jbc.M208107200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228232	hybrid			2022-12-25	WOS:000179272000039
J	Wang, XK; Xu, L; Wang, H; Young, PR; Gaestel, M; Feuerstein, GZ				Wang, XK; Xu, L; Wang, H; Young, PR; Gaestel, M; Feuerstein, GZ			Mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 deficiency protects brain from ischemic injury in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; EXPRESSION; RAT; BIOSYNTHESIS; INHIBITOR; CASCADE; DAMAGE; STROKE; STRESS; MRI	Mitogen-activated protein (MAP) kinase-activated protein kinase 2 (MK2) is one of several kinases directly regulated by p38 MAP kinase. A role of p38 MAP kinase in ischemic brain injury has been previously suggested by pharmacological means. In the present study, we provide evidence for a role of MK2 in cerebral ischemic injury using MM-deficient (MK2(-/-)) mice. MM2(-/-) mice subjected to focal ischemia markedly reduced infarct size by 64 and 76% after transient and permanent ischemia, respectively, compared with wild-type mice. Furthermore, MK2(-/-) mice had significant reduction in neurological deficits. Real-time PCR analysis identified a significantly lower expression in interleukin-1beta mRNA (53% reduction) but not in tumor necrosis factor-a mRNA in MK2(-/-) mice over wild-type animals after ischemic injury. The significant reduction in interleukin-1beta was also confirmed in MK2(-/-) mice by enzyme-linked immunosorbent assay. The marked neuroprotection from ischemic brain injury in MK2(-/-) mice was not associated with the alteration of hemodynamic or systemic variables, activation of caspase-3, or apoptosis. Our data provide new evidence for the involvement of MAP kinase pathway in focal ischemic brain injury and suggest that this effect might be associated with the expression of interleukin-1beta in the ischemic brain tissue.	Bristol Myers Squibb Co, Dept Cardiovasc Sci, Expt Stn, Wilmington, DE 19880 USA; Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany	Bristol-Myers Squibb; DuPont; Hannover Medical School	Wang, XK (corresponding author), Bristol Myers Squibb Co, Dept Cardiovasc Sci, Expt Stn, E400-3418, Wilmington, DE 19880 USA.		Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652				Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; BARONE FC, 1991, BRAIN RES BULL, V26, P285, DOI 10.1016/0361-9230(91)90240-K; Barone FC, 2001, J PHARMACOL EXP THER, V296, P312; Basu A, 2002, J NEUROSCI, V22, P6071; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; *DHHS DHEW NIH, 1996, PUBL NIH DHHS DHEW, V8523; Floyd RA, 1992, ANN NEUROL, V32, P22; Graham SH, 2001, J CEREBR BLOOD F MET, V21, P99, DOI 10.1097/00004647-200102000-00001; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; Irving EA, 2000, MOL BRAIN RES, V77, P65, DOI 10.1016/S0169-328X(00)00043-7; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lin SP, 2001, STROKE, V32, P925, DOI 10.1161/01.STR.32.4.925; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; MINEMATSU K, 1992, NEUROLOGY, V42, P235, DOI 10.1212/WNL.42.1.235; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Thomas G, 1997, EUR J BIOCHEM, V247, P1180, DOI 10.1111/j.1432-1033.1997.01180.x; Wang H, 2001, BIOCHEM BIOPH RES CO, V286, P869, DOI 10.1006/bbrc.2001.5482; Wang H, 2001, STROKE, V32, P1020, DOI 10.1161/01.STR.32.4.1020; Wang XK, 2000, J NEUROSCI RES, V59, P238, DOI 10.1002/(SICI)1097-4547(20000115)59:2<238::AID-JNR10>3.0.CO;2-G; Wang XK, 2000, DRUG NEWS PERSPECT, V13, P133, DOI 10.1358/dnp.2000.13.3.657283; Werz O, 2002, J BIOL CHEM, V277, P14793, DOI 10.1074/jbc.M111945200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhang RL, 1997, BRAIN RES, V766, P83, DOI 10.1016/S0006-8993(97)00580-5	29	47	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43968	43972		10.1074/jbc.M206837200	http://dx.doi.org/10.1074/jbc.M206837200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12215446	hybrid			2022-12-25	WOS:000179272000057
J	Brickley, DR; Mikosz, CA; Hagan, CR; Conzen, SD				Brickley, DR; Mikosz, CA; Hagan, CR; Conzen, SD			Ubiquitin modification of serum and glucocorticoid-induced protein kinase-1 (SGK-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-PHOSPHATE; SIGNALING PATHWAY; CELLS; ACTIVATION; DOMAIN; GENE	The serum and glucocorticoid-induced protein kinase gene (sgk-1) encodes a multifunctional kinase that can be phosphorylated and activated through a phosphatidylinositol 3-kinase-dependent signaling pathway. In many cell types, endogenous SGK-1 steady-state protein levels are very low but can be acutely up-regulated after glucocorticoid receptor-mediated transcriptional activation; in breast epithelial and cancer cell lines, this up-regulation is associated with promotion of cell survival. We and others have noted that ectopically introduced full-length SGK-1 is poorly expressed, although SGK-1 lacking the first 60 amino acids (Delta60SGK-1) is expressed at much higher-fold protein levels than wildtype SGK-1 in both human embryonic kidney 293T and MCF10A mammary epithelial cells. In this report, we demonstrate for the first time that the low steady-state expression level of SGK-1 is due to polyubiquitination and subsequent degradation by the 26S proteasome. Deletion of the amino-terminal 60 amino acids of SGK-1 results in a mutant SGK-1 protein that is neither efficiently polyubiquitinated nor degraded by the 26S proteasome, accounting for the higher steady-state levels of the truncated protein. We also demonstrate that a subset of SGK-1 localizes to the plasma membrane and that the polyubiquitin-modified SGK-1 localizes to a membrane-associated fraction of the cell. Taken together, these data suggest that a significant fraction of SGK-1 is membrane-associated and ubiquitinated. These findings are consistent with the recently described role of SGK-1 in phosphorylating the membrane-associated protein Nedd4-2 and the integral membrane Na+/H+ exchanger isoform 3 (NHE3) and suggest a novel mechanism of regulation of SGK-1.	Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA	University of Chicago	Conzen, SD (corresponding author), Univ Chicago, Dept Med, Hematol Oncol Sect, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	sconzen@medicine.bsd.uchicago.edu			NCI NIH HHS [K08 CA90459, CA14599-25] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014599, K08CA090459] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; Evans-Storms RB, 2000, ENDOCRINOLOGY, V141, P1854, DOI 10.1210/en.141.5.1854; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Lang F, 2001, SCI STKE, V2001; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200; Moran TJ, 2000, CANCER RES, V60, P867; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Shelly C, 2002, J CELL SCI, V115, P1985; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Yun CC, 2002, J BIOL CHEM, V277, P7676, DOI 10.1074/jbc.M107768200	25	76	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43064	43070		10.1074/jbc.M207604200	http://dx.doi.org/10.1074/jbc.M207604200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12218062	hybrid			2022-12-25	WOS:000179081200084
J	Grosfeld, A; Andre, J; Hauguel-de-Mouzon, S; Berra, E; Pouyssegur, J; Guerre-Millo, M				Grosfeld, A; Andre, J; Hauguel-de-Mouzon, S; Berra, E; Pouyssegur, J; Guerre-Millo, M			Hypoxia-inducible factor 1 transactivates the human leptin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; ANGIOGENIC FACTOR; FACTOR 1-ALPHA; SKIN REPAIR; HIF-ALPHA; OB GENE; HYDROXYLATION; TRANSCRIPTION; PREECLAMPSIA; EXPRESSION	Increased placental leptin has been demonstrated in preeclampsia, a pregnancy disorder associated with placental hypoxia. This suggests that leptin gene expression is enhanced in response to oxygen deficiency in this organ. In support of this hypothesis, we have previously shown that hypoxia activates the leptin promoter in trophoblast-derived BeWo cells. Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric HIF-1alpha/HIF-1beta complex that regulates the transcription of hypoxia-responsive genes. To test whether this factor is involved in hypoxia-induced leptin promoter activation, BeWo cells were transiently transfected with a HIF-1alpha expression vector. Exogenous HIF-1alpha markedly increased luciferase reporter activity driven by the leptin promoter when HIF-1beta was co-expressed in the same cells. This effect was similar to that elicited by CoCl2, an agent known to stabilize endogenous HIF-1alpha. These data suggest that HIF-1alpha/HIF-1beta dimers are involved in the effect of CoCl2 to activate the leptin promoter. To confirm the implication of HIF-1, the cells were transfected with a dominant negative form of HIF-1alpha producing transcriptionally inactive HIF-1beta/HIF-1alpha dimers. This mutant HIF-1alpha protein abolished CoCl2 activation of the leptin promoter, providing direct evidence that the effect of CoCl2 is mediated by endogenous HIF-1alpha. Deletion analysis and site-specific mutagenesis demonstrated that a HIF-1 consensus binding site (HRE) spanning -120 to -116 bp relative to the start site was required for CoCl2 and exogenous HIF-1a induction of leptin promoter activity. Electrophoretic mobility shift assays performed with in vitro-translated HIF-1alpha and HIF-1beta proteins demonstrated binding to this HRE and not to mutated sequences only when both subunits were used together. These data demonstrate that leptin is a new hypoxia-inducible gene, which is stimulated in a placental cell line through HIF-1 interaction with a consensus HRE site located at -116 in the proximal promoter.	Univ Paris 06, Ctr Rech Cordeliers, U465, INSERM, F-75006 Paris, France; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; CNRS, UMR 6543, F-06189 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Case Western Reserve University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Guerre-Millo, M (corresponding author), Univ Paris 06, Ctr Rech Cordeliers, U465, INSERM, 15 Rue Ecole Med, F-75006 Paris, France.		Guerre-Millo, Michele/G-7253-2017; Grosfeld, Alexandra/R-1404-2017; Grosfeld, Alexandra/AAH-3510-2020; Berra, Edurne/F-9692-2011	Grosfeld, Alexandra/0000-0002-9508-036X; Berra, Edurne/0000-0002-3820-5744				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Benyo DF, 1997, J CLIN ENDOCR METAB, V82, P1582, DOI 10.1210/jc.82.5.1582; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; Brahimi-Horn C, 2001, TRENDS CELL BIOL, V11, pS32, DOI 10.1016/S0962-8924(01)02126-2; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; DEMOUZON SH, 2001, DIABETES S2, V50, pA4; Frank S, 2000, J CLIN INVEST, V106, P501, DOI 10.1172/JCI9148; Grosfeld A, 2002, DIABETOLOGIA, V45, P527, DOI 10.1007/s00125-002-0804-y; Grosfeld A, 2001, FEBS LETT, V502, P122, DOI 10.1016/S0014-5793(01)02673-4; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Konturek PC, 2001, EUR J PHARMACOL, V414, P87, DOI 10.1016/S0014-2999(01)00748-8; Konturek PC, 1999, J PHYSIOL PHARMACOL, V50, P587; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Miller SG, 1996, P NATL ACAD SCI USA, V93, P5507, DOI 10.1073/pnas.93.11.5507; Mise H, 1998, J CLIN ENDOCR METAB, V83, P3225, DOI 10.1210/jc.83.9.3225; REDMAN CWG, 1991, PLACENTA, V12, P301, DOI 10.1016/0143-4004(91)90339-H; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; SILVERMAN KJ, 1988, BIOCHEM BIOPH RES CO, V153, P347, DOI 10.1016/S0006-291X(88)81229-4; Spinella F, 2002, J BIOL CHEM, V277, P27850, DOI 10.1074/jbc.M202421200; Stallmeyer B, 2001, J INVEST DERMATOL, V117, P98, DOI 10.1046/j.0022-202x.2001.01387.x; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Wilczynski JR, 2002, MEDIAT INFLAMM, V11, P105, DOI 10.1080/09629350220131962; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang QX, 1997, J SURG RES, V67, P147, DOI 10.1006/jsre.1996.4983	30	210	233	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42953	42957		10.1074/jbc.M206775200	http://dx.doi.org/10.1074/jbc.M206775200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12215445	hybrid			2022-12-25	WOS:000179081200069
J	Hansen, SB; Radic, Z; Talley, TT; Molles, BE; Deerinck, T; Tsigelny, I; Taylor, P				Hansen, SB; Radic, Z; Talley, TT; Molles, BE; Deerinck, T; Tsigelny, I; Taylor, P			Tryptophan fluorescence reveals conformational changes in the acetylcholine binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC RECEPTOR; CHOLINERGIC RECEPTOR; TORPEDO-CALIFORNICA; KINETICS; MUSCLE; AGONIST; DOMAIN; SITE; DISSOCIATION; CHANNELS	The recent characterization of an acetylcholine binding protein (AChBP) from the fresh water snail, Lymnaea stagnalis, shows it to be a structural homolog of the extracellular domain of the nicotinic acetylcholine receptor (nAChR). To ascertain whether the AChBP exhibits the recognition properties and functional states of the nAChR, we have expressed the protein in milligram quantities from a synthetic cDNA transfected into human embryonic kidney (HEK) cells. The protein secreted into the medium shows a pentameric rosette structure with ligand stoichiometry approximating five sites per pentamer. Surprisingly, binding of acetylcholine, selective agonists, and antagonists ranging from small alkaloids to larger peptides results in substantial quenching of the intrinsic tryptophan fluorescence. Using stopped-flow techniques, we demonstrate rapid rates of association and dissociation of agonists and slow rates for the alpha-neurotoxins. Since agonist binding occurs in millisecond time frames, and the a-neurotoxins may induce a distinct conformational. state for the AChBP-toxin complex, the snail protein shows many of the properties expected for receptor recognition of interacting ligands. Thus, the marked tryptophan quenching not only documents the importance of aromatic residues in ligand recognition, but establishes that the AChBP will be a useful functional as well as structural surrogate of the nicotinic receptor.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr,BSB 3027, La Jolla, CA 92093 USA.	pwtaylor@ucsd.edu	Talley, Todd/B-3630-2010	Talley, Todd/0000-0002-1077-1947	NIGMS NIH HHS [R37-GM 18360, T32-GM 07752, T32 GM007752, R37 GM018360] Funding Source: Medline; NINDS NIH HHS [F32 NS043063] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752, R37GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS043063] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beene DL, 2002, BIOCHEMISTRY-US, V41, P10262, DOI 10.1021/bi020266d; Bouzat C, 2000, J GEN PHYSIOL, V115, P663, DOI 10.1085/jgp.115.5.663; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; BROCKES JP, 1975, BIOCHEMISTRY-US, V14, P2092, DOI 10.1021/bi00681a008; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Figl A, 1996, J GEN PHYSIOL, V107, P369, DOI 10.1085/jgp.107.3.369; FLANAGAN SD, 1976, J BIOL CHEM, V251, P858; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; Grosman C, 2001, P NATL ACAD SCI USA, V98, P14102, DOI 10.1073/pnas.251402498; ITAKURA K, 1977, SCIENCE, V198, P1056, DOI 10.1126/science.412251; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; LACKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P185; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Mandell JG, 2001, PROTEIN ENG, V14, P105, DOI 10.1093/protein/14.2.105; Prince RJ, 1998, BIOPHYS J, V75, P1817, DOI 10.1016/S0006-3495(98)77623-4; Radic Z, 2001, J BIOL CHEM, V276, P4622, DOI 10.1074/jbc.M006855200; Salamone FN, 1999, J PHYSIOL-LONDON, V516, P315, DOI 10.1111/j.1469-7793.1999.0315v.x; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 2000, HANDB EXP PHARM, V144, P79; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; WANG GK, 1980, J BIOL CHEM, V255, P1156; Wang HL, 1997, J GEN PHYSIOL, V109, P757, DOI 10.1085/jgp.109.6.757; WEILAND G, 1977, J BIOL CHEM, V252, P7648; Wenningmann I, 2001, MOL PHARMACOL, V60, P790; Xie Y, 2001, J BIOL CHEM, V276, P2417, DOI 10.1074/jbc.M009085200; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	28	87	92	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41299	41302		10.1074/jbc.C200462200	http://dx.doi.org/10.1074/jbc.C200462200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12235129	Green Accepted, hybrid			2022-12-25	WOS:000178985300002
J	Kun, E; Kirsten, E; Ordahl, CP				Kun, E; Kirsten, E; Ordahl, CP			Coenzymatic activity of randomly broken or intact double-stranded DNAs in auto and histone H-1 trans-poly(ADP-ribosylation), catalyzed by poly(ADP-ribose) polymerase (PARP I)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC TRANSCRIPTION; CAT BINDING-FACTOR; MOLECULAR-INTERACTIONS; SECONDARY STRUCTURE; TOPOISOMERASE-I; TEF-1; IDENTIFICATION; ELEMENTS; ASSOCIATION; TRANSFERASE	The enzymatic transfer of ADP-ribose from NAD to histone H, (defined as trans-poly(ADP-ribosylation)) or to PARP I (defined as auto-poly(ADP-ribosylation)) was studied with respect to the nature of the DNA required as a coenzyme. Linear double-stranded DNA (dsDNA) containing the MCAT core motif was compared with DNA containing random nicks (discontinuous or dcDNA). The dsDNAs activated trans-poly(ADP-ribosylation) about 5 times more effectively than dcDNA as measured by V-max. Activation of auto-poly(ADP-ribosylation) by dcDNA was 10 times greater than by dsDNA. The affinity of PARP I toward dcDNA or dsDNA in the auto-poly(ADP-ribosylation) was at least 100-fold lower than in trans-poly(ADP-ribosylation) (K-alpha = 1400 versus 3-15, respectively). Mg2+ inhibited trans-poly(ADP-ribosylation) and so did dcDNA at concentrations required to maximally activate auto-poly(ADP-ribosylation). Mg2+ activated auto-poly(ADP-ribosylation) of PARP I. These results for the first time demonstrate that physiologically occurring dsDNAs can serve as coenzymes for PARP I and catalyze preferentially trans-poly(ADP-ribosylation), thereby opening the possibility to study the physiologic function of PARP I.	Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Cellular Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ordahl, CP (corresponding author), Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA.				NHLBI NIH HHS [HL-59693, HL-35561] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035561, R01HL059693] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; Azakie A, 1996, J BIOL CHEM, V271, P8260, DOI 10.1074/jbc.271.14.8260; Bauer PI, 2000, INT J MOL MED, V5, P533; BAUER PI, 1990, BIOCHEM J, V270, P17, DOI 10.1042/bj2700017; Bauer PI, 1996, INT J ONCOL, V8, P239; Bauer PI, 2001, INT J MOL MED, V8, P691; Bauer PI, 2001, FEBS LETT, V506, P239, DOI 10.1016/S0014-5793(01)02919-2; BAUER PI, 1990, FEBS LETT, V273, P6, DOI 10.1016/0014-5793(90)81038-P; BUKI KG, 1995, J BIOL CHEM, V270, P3370, DOI 10.1074/jbc.270.7.3370; Butler AJ, 1999, MOL CELL BIOL, V19, P296; DeMurcia G., 2000, DNA DAMAGE STRESS SI; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FARZANEH F, 1979, DEV BIOL, V72, P254, DOI 10.1016/0012-1606(79)90116-7; HAKAM A, 1987, FEBS LETT, V212, P73, DOI 10.1016/0014-5793(87)81559-4; Kun E, 1998, INT J MOL MED, V2, P131; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MENDOZAALVAREZ H, 1993, J BIOL CHEM, V268, P22575; MINAGA T, 1983, J BIOL CHEM, V258, P725; MINAGA T, 1979, J BIOL CHEM, V254, P9663; PANZETER PL, 1994, BIOCHEMISTRY-US, V33, P9600, DOI 10.1021/bi00198a028; SASTRY SS, 1989, BIOCHEMISTRY-US, V28, P5670, DOI 10.1021/bi00439a050; SASTRY SS, 1988, J BIOL CHEM, V263, P1505; SASTRY SS, 1990, BIOCHEM BIOPH RES CO, V167, P842, DOI 10.1016/0006-291X(90)92102-6; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; Yao N, 2000, J BIOL CHEM, V275, P1421, DOI 10.1074/jbc.275.2.1421	28	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39066	39069		10.1074/jbc.C200410200	http://dx.doi.org/10.1074/jbc.C200410200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12205080	hybrid			2022-12-25	WOS:000178662500003
J	Chen, YQ; Zhou, YQ; Fisher, JH; Wang, MH				Chen, YQ; Zhou, YQ; Fisher, JH; Wang, MH			Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo	ONCOGENE			English	Article						receptor tyrosine kinase; transgenic mice; lung tumors; type II cells	MACROPHAGE-STIMULATING PROTEIN; HEPATOCYTE GROWTH-FACTOR; TRANSGENIC MICE; PULMONARY ADENOCARCINOMAS; C GENE; MOUSE; ACTIVATION; OVEREXPRESSION; IDENTIFICATION; CARCINOMA	RON, a member of the MET proto-oncogene family, has been implicated in the progression of certain epithelial cancers. The purpose of this study was to determine the oncogenic potential of RON in vivo in lung epithelial cells. Transgenic mice were established using surfactant protein C promoter to express human RON in the distal lung epithelial cells. These mice were born normal but developed multiple lung tumors with distinct morphology and growth patterns. Tumors appeared as a single mass in the lung around 2 months of age and gradually developed into multiple nodules located mostly in the peripheral portions of the lung. A transition from early adenomas to later adenocarcinomas was observed. Morphologically, tumors were characterized as cuboidal epithelial cells with a type 11 cell phenotype, grew along the alveolar walls, and projected into the alveolar septa. RON was highly expressed and constitutively activated in tumors. These results indicate that overexpression of human wild-type RON causes the formation of lung tumors with unique biological characteristics in vivo. This model provides opportunities to study the role of RON in the pathogenesis of lung tumors and to elucidate the mechanisms underlying this distinct lung tumor.	UCHSC, Dept Med, Denver Hlth Med Ctr, Denver, CO 80204 USA; Univ Colorado, Sch Med, Dept Med, Div Pulm Sci & Crit Care,CU Canc Ctr, Denver, CO 80204 USA; Zhejiang Univ, Sch Med, Div Neurosurg, Affiliated Hosp 1, Hangzhou 310003, Peoples R China	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Zhejiang University	Wang, MH (corresponding author), UCHSC, Dept Med, Denver Hlth Med Ctr, 777 Bannock St,Mail Box 4000, Denver, CO 80204 USA.				NATIONAL CANCER INSTITUTE [R01CA091980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043516] Funding Source: NIH RePORTER; NCI NIH HHS [CA91980] Funding Source: Medline; NIAID NIH HHS [R01 AI43516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Clark JC, 2001, AM J PHYSIOL-LUNG C, V280, pL705, DOI 10.1152/ajplung.2001.280.4.L705; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959; HOGAN B, 1996, MANIPULATING MOUSE E; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Kerkhoff E, 2000, CELL GROWTH DIFFER, V11, P185; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEBEL M, 1995, CELL GROWTH DIFFER, V6, P1591; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Malkinson AM, 1998, EXP LUNG RES, V24, P541, DOI 10.3109/01902149809087385; Mason RJ, 2000, AM J PATHOL, V156, P175, DOI 10.1016/S0002-9440(10)64717-7; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; RONSIN C, 1993, ONCOGENE, V8, P1195; Sakamoto O, 1997, J CLIN INVEST, V99, P701, DOI 10.1172/JCI119214; SANDMOLLER A, 1995, CELL GROWTH DIFFER, V6, P97; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Singh G, 1997, AM J RESP CELL MOL, V17, P141, DOI 10.1165/ajrcmb.17.2.f138; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Wang MH, 1996, ONCOGENE, V13, P2167; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Willett CG, 1997, J CLIN INVEST, V99, P2979, DOI 10.1172/JCI119493	30	46	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6382	6386		10.1038/sj.onc.1205783	http://dx.doi.org/10.1038/sj.onc.1205783			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214279				2022-12-25	WOS:000177829000015
J	Georget, M; Mateo, P; Vandecasteele, G; Jurevicius, J; Lipskaia, L; Defer, N; Hanoune, J; Hoerter, J; Fischmeister, R				Georget, M; Mateo, P; Vandecasteele, G; Jurevicius, J; Lipskaia, L; Defer, N; Hanoune, J; Hoerter, J; Fischmeister, R			Augmentation of cardiac contractility with no change in L-type Ca2+ current in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8)	FASEB JOURNAL			English	Article						cAMP; isolated heart; calcium transient; cell shortening; compartmentation	BETA(2)-ADRENERGIC RECEPTOR OVEREXPRESSION; GENETICALLY-ENGINEERED MICE; LEFT-VENTRICULAR FUNCTION; HEART-FAILURE; MYOCARDIAL-CONTRACTILITY; RYANODINE RECEPTORS; TROPONIN-I; PHOSPHORYLATION; PHOSPHOLAMBAN; MOUSE	The beta-adrenergic cascade is severely impaired in heart failure(HF), in part because of a reduction in the activity of the two dominant cardiac adenylyl cyclase (AC) isoforms, AC5 and AC6. Hence, cardiac-directed AC overexpression is a conceivable therapeutic strategy in HF. In this study, we explored the consequences at the cellular and organ level of a cardiac-directed expression of the human AC8 in the transgenic mouse line AC8TG. Unlike AC5 and AC6, which are inhibited by intracellular Ca2+, AC8 is stimulated by Ca2+-calmodulin. Langendorff perfused hearts from AC8TG mice had a twofold higher left ventricular systolic pressure, a 40% faster heart rate, a 37% faster relaxation, and a 30% higher sensitivity to external Ca2+ than nontransgenic control mice (NTG). Cell shortening measured in isolated ventricular myocytes developed 22% faster and relaxed 43% faster in AC8TG than in NTG mice. Likewise, Ca2+ transients measured in fluo-3 AM-loaded myocytes were 30% higher and relaxed 24% faster in AC8TG compared with NTG mice. In spite of the large increase in Ca2+ transients and contraction, expression of AC8 had no effect on the whole-cell L-type Ca2+ current (I-Ca,I-L) amplitude. Moreover, I-Ca,I-L was unchanged even when AC8 was activated by raising intracellular Ca2+. Thus, cardiac expression of AC8 leads to an increase in cAMP that activates specifically Ca2+ uptake into the sarcoplasmic reticulum but not Ca2+ influx at the sarcolemma, suggesting a strong compartmentation of the cAMP signal.	Univ Paris Sud, Fac Pharm, INSERM, U446,Lab Cardiol Cellulaire & Mol, F-92296 Chatenay Malabry, France; Hop Henri Mondor, INSERM, U99, Lab Regulat Genes & Signalisat Cellulaire, F-94010 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Fischmeister, R (corresponding author), Univ Paris Sud, Fac Pharm, INSERM, U446,Lab Cardiol Cellulaire & Mol, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	Fisch@vjf.inserm.fr	Lipskaia, Larissa/AAK-9322-2020; Fischmeister, Rodolphe/L-6061-2018; Vandecasteele, Gregoire/M-2922-2018	Fischmeister, Rodolphe/0000-0003-2086-9865; Vandecasteele, Gregoire/0000-0002-4046-4171				Bittner HB, 1997, J MOL CELL CARDIOL, V29, P961, DOI 10.1006/jmcc.1996.0339; CALI JJ, 1994, J BIOL CHEM, V269, P12190; Cross HR, 1999, CIRC RES, V85, P1077; DEFER N, 1994, FEBS LETT, V351, P109, DOI 10.1016/0014-5793(94)00836-1; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; Du XJ, 2000, CARDIOVASC RES, V48, P448, DOI 10.1016/S0008-6363(00)00187-5; Du XJ, 2000, CIRCULATION, V101, P71, DOI 10.1161/01.CIR.101.1.71; Du XJ, 2001, CARDIOVASC RES, V50, P443, DOI 10.1016/S0008-6363(01)00244-9; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; Espinasse I, 1999, CARDIOVASC RES, V42, P87, DOI 10.1016/S0008-6363(98)00283-1; Gao MH, 1999, CIRCULATION, V99, P1618, DOI 10.1161/01.CIR.99.12.1618; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; ISHIKAWA Y, 1994, J CLIN INVEST, V93, P2224, DOI 10.1172/JCI117219; Iwase M, 1997, AM J PHYSIOL-HEART C, V272, pH585, DOI 10.1152/ajpheart.1997.272.1.H585; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Lai NC, 2000, CIRCULATION, V102, P2396, DOI 10.1161/01.CIR.102.19.2396; Li L, 2000, AM J PHYSIOL-HEART C, V278, pH769, DOI 10.1152/ajpheart.2000.278.3.H769; Li L, 1998, AM J PHYSIOL-HEART C, V274, pH1335, DOI 10.1152/ajpheart.1998.274.4.H1335; Liggett SB, 2000, CIRCULATION, V101, P1707; Lipskaia L, 2000, CIRC RES, V86, P795, DOI 10.1161/01.RES.86.7.795; LORENZ JN, 1997, AM J PHYSIOL-HEART C, V273, pH2826; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Rapundalo ST, 1998, CARDIOVASC RES, V38, P559, DOI 10.1016/S0008-6363(98)00063-7; Reithmann C, 1997, EUR J PHARMACOL, V330, P79, DOI 10.1016/S0014-2999(97)10131-5; Rockman HA, 1997, AM J PHYSIOL-HEART C, V272, pH1553, DOI 10.1152/ajpheart.1997.272.4.H1553; Rockman HA, 1996, J CLIN INVEST, V97, P1618, DOI 10.1172/JCI118587; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Tepe NM, 1999, BIOCHEMISTRY-US, V38, P16706, DOI 10.1021/bi991619k; Tepe NM, 1999, FEBS LETT, V458, P236, DOI 10.1016/S0014-5793(99)01147-3; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Wang X, 2000, MOL CELL BIOCHEM, V214, P131, DOI 10.1023/A:1007131925048; Wolska BM, 1996, AM J PHYSIOL-HEART C, V271, pH1250, DOI 10.1152/ajpheart.1996.271.3.H1250; YOSHIDA A, 1992, J BIOCHEM-TOKYO, V111, P186, DOI 10.1093/oxfordjournals.jbchem.a123735; ZHANG R, 1995, CIRC RES, V76, P1028, DOI 10.1161/01.RES.76.6.1028; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773; Zhou YY, 1999, MOL PHARMACOL, V56, P485, DOI 10.1124/mol.56.3.485; Zhou YY, 1999, J PHYSIOL-LONDON, V521, P351, DOI 10.1111/j.1469-7793.1999.00351.x; Zhou YY, 1997, AM J PHYSIOL-HEART C, V273, pH1611, DOI 10.1152/ajpheart.1997.273.3.H1611	43	30	30	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1636	+		10.1096/fj.02-0292fje	http://dx.doi.org/10.1096/fj.02-0292fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206999				2022-12-25	WOS:000177814000009
J	Govindarajan, R; Zhao, S; Song, XH; Guo, RJ; Wheelock, M; Johnson, KR; Mehta, PP				Govindarajan, R; Zhao, S; Song, XH; Guo, RJ; Wheelock, M; Johnson, KR; Mehta, PP			Impaired trafficking of connexins in androgen-independent human prostate cancer cell lines and its mitigation by alpha-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTIONAL COMMUNICATION; C6 GLIOMA-CELLS; E-CADHERIN; TRANSFORMED-CELLS; INTERCELLULAR COMMUNICATION; INTRACELLULAR-TRANSPORT; PROTEIN INTERACTIONS; CHANNEL PROTEIN; MOLECULAR-BASIS; P-CADHERIN	Gap junctions, composed of connexins, provide a pathway of direct intercellular communication for the diffusion of small molecules between cells. Evidence suggests that connexins act as tumor suppressors. We showed previously that expression of connexin-43 and connexin-32 in an indolent prostate cancer cell line, LNCaP, resulted in gap junction formation and growth inhibition. To elucidate the role of connexins in the progression of prostate cancer from a hormone-dependent to -independent state, we introduced connexin-43 and connexin-32 into an invasive, androgen-independent cell line, PC-3. Expression of these proteins in PC-3 cells resulted in intracellular accumulation. Western blot analysis revealed a lack of Triton-insoluble, plaque-assembled connexins. In contrast to LNCaP cells, connexins could not be cell surface-biotinylated and did not reside in the cell surface derived endocytic vesicles, in PC-3 cells, suggesting impaired trafficking to the cell surface. Intracellular accumulation of connexins was observed in several androgen-independent prostate cancer cell lines. Transient expression of a-catenin facilitated the trafficking of both connexins to the cell surface and induced gap junction assembly. Our results suggest that impaired trafficking, and not the inability to form gap junctions, is the major cause of communication deficiency in human prostate cancer cell lines.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Dept Oral Biol, Omaha, NE 68182 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68182 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Mehta, PP (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Dept Oral Biol, Omaha, NE 68182 USA.	pmehta@unmc.edu			NATIONAL CANCER INSTITUTE [R01CA073769] Funding Source: NIH RePORTER; NCI NIH HHS [CA 73769] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BERTHOUD VM, 2001, METHODS COMPANION ME, V20, P180; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CHEN SC, 1995, CELL GROWTH DIFFER, V6, P681; Chen TS, 1999, CANCER RES, V59, P213; Deschenes SM, 1997, J NEUROSCI, V17, P9077; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; EWING CM, 1995, CANCER RES, V55, P4813; Frenzel EM, 1996, DEV BIOL, V179, P1, DOI 10.1006/dbio.1996.0237; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Habermann H, 2002, J UROLOGY, V167, P655, DOI 10.1016/S0022-5347(01)69118-3; Habermann H, 2001, ENDOCRINOLOGY, V142, P359, DOI 10.1210/en.142.1.359; Hegarty NJ, 1999, PROSTATE, V40, P261, DOI 10.1002/(SICI)1097-0045(19990901)40:4<261::AID-PROS8>3.0.CO;2-H; Hernandez-Blazquez FJ, 2001, EXP CELL RES, V270, P235, DOI 10.1006/excr.2001.5342; HSIEH JT, 1995, CANCER RES, V55, P190; Isaacs JT, 1997, AM J PATHOL, V150, P1511; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; ISAACS WB, 1994, SEMIN ONCOL, V21, P514; Jarrard DF, 1997, CLIN CANCER RES, V3, P2121; JOHNSON KR, 1993, EXP CELL RES, V207, P252, DOI 10.1006/excr.1993.1191; JONGEN WMF, 1991, J CELL BIOL, V114, P545, DOI 10.1083/jcb.114.3.545; Kelsell DP, 2001, TRENDS CELL BIOL, V11, P2, DOI 10.1016/S0962-8924(00)01866-3; Kelsell DP, 2001, AM J HUM GENET, V68, P559, DOI 10.1086/318803; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; KLIEN KA, 1997, NAT GENET, V3, P402; Krutovskikh V, 2000, MUTAT RES-REV MUTAT, V462, P197, DOI 10.1016/S1383-5742(00)00037-5; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUMAR NM, 1995, J CELL SCI, V108, P3725; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; LAMPE PD, 1994, J CELL BIOL, V127, P1895, DOI 10.1083/jcb.127.6.1895; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Loewenstein W R, 1992, Semin Cell Biol, V3, P59; Martin PEM, 2001, J CELL SCI, V114, P3845; Mehta P, 1999, DEV GENET, V24, P91, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<91::AID-DVG10>3.0.CO;2-#; Mehta PP, 1996, MOL CARCINOGEN, V15, P18, DOI 10.1002/(SICI)1098-2744(199601)15:1<18::AID-MC4>3.0.CO;2-O; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; MEHTA PP, 1992, MOL BIOL CELL, V3, P839, DOI 10.1091/mbc.3.8.839; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MESNIL M, 1995, CANCER RES, V55, P629; MEYER RA, 1992, J CELL BIOL, V119, P179, DOI 10.1083/jcb.119.1.179; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORTON RA, 1993, CANCER RES, V53, P3585; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; NAUS CCG, 1993, EXP CELL RES, V206, P72, DOI 10.1006/excr.1993.1122; Paulson AF, 2000, J CELL SCI, V113, P3037; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Statuto M, 1997, J BIOL CHEM, V272, P24710, DOI 10.1074/jbc.272.39.24710; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; Tomita K, 2000, BIOCHEM BIOPH RES CO, V267, P870, DOI 10.1006/bbrc.1999.2040; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; Trosko James E., 1998, Frontiers in Bioscience, V3, pD208; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Umbas R, 1997, INT J CANCER, V74, P374, DOI 10.1002/(SICI)1097-0215(19970822)74:4<374::AID-IJC2>3.0.CO;2-S; VanSlyke JK, 2000, METHODS, V20, P156, DOI 10.1006/meth.1999.0933; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Wang YJ, 1997, J CELL SCI, V110, P301; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	76	68	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50087	50097		10.1074/jbc.M202652200	http://dx.doi.org/10.1074/jbc.M202652200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12205082	hybrid			2022-12-25	WOS:000180028900128
J	Zerbe, K; Pylypenko, O; Vitali, F; Zhang, WW; Rouse, S; Heck, M; Vrijbloed, JW; Bischoff, D; Bister, B; Sussmuth, RD; Pelzer, S; Wohlleben, W; Robinson, JA; Schlichting, I				Zerbe, K; Pylypenko, O; Vitali, F; Zhang, WW; Rouse, S; Heck, M; Vrijbloed, JW; Bischoff, D; Bister, B; Sussmuth, RD; Pelzer, S; Wohlleben, W; Robinson, JA; Schlichting, I			Crystal structure of OxyB, a cytochrome P450 implicated in an oxidative phenol coupling reaction during vancomycin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPEPTIDE ANTIBIOTICS; AMINO-ACID; HETEROLOGOUS EXPRESSION; PEPTIDE SYNTHETASE; MOLECULAR-CLONING; CRYSTALLOGRAPHY; CHLOROEREMOMYCIN; MOLSCRIPT; SYNTHASE; PROGRAM	Gene-inactivation studies point to the involvement of OxyB in catalyzing the first oxidative phenol coupling reaction during glycopeptide antibiotic biosynthesis. The oxyB gene has been cloned and sequenced from the vancomycin producer Amycolatopsis orientalis, and the hemoprotein has been produced in Escherichia coli, crystallized, and its structure determined to 1.7-Angstrom resolution. OxyB gave UV-visible spectra characteristic of a P450-like hemoprotein in the low spin ferric state. After reduction to the ferrous state by dithionite or by spinach ferredoxin and ferredoxin reductase, the CO-ligated form gave a 450-nm peak in a UV-difference spectrum. Addition of putative heptapeptide substrates to resting OxyB produced type I changes to the UV spectrum, but no turnover was observed in the presence of ferredoxin and ferredoxin reductase, showing that either the peptides or the reduction system, or both, are insufficient to support a full catalytic cycle. OxyB exhibits the typical P450-fold, with helix L containing the signature sequence FGHGXHXCLG and Cys(347) being the proximal axial thiolate ligand of the heme iron. The structural similarity of OxyB is highest to P450nor, P450terp, CYP119, and P450eryF. In OxyB, the F and G helices are rotated out of the active site compared with P450nor, resulting in a much more open active site, consistent with the larger size of the presumed heptapeptide substrate.	Univ Zurich, Inst Organ Chem, CH-8057 Zurich, Switzerland; Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Heidelberg, Germany; Max Planck Inst Med Res, Dept Biomol Mech, D-69120 Heidelberg, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; Univ Tubingen, Lehrstuhl Mikrobiol Biotechnol, D-72076 Tubingen, Germany	University of Zurich; Max Planck Society; Max Planck Society; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Robinson, JA (corresponding author), Univ Zurich, Inst Organ Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	robinson@oci.unizh.ch	Schlichting, Ilme/I-1339-2013	Pylypenko, Olena/0000-0001-7073-5238; Sussmuth, Roderich/0000-0001-7027-2069; Heck, Markus/0000-0003-1954-1635				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bischoff D, 2001, ANGEW CHEM INT EDIT, V40, P4688, DOI 10.1002/1521-3773(20011217)40:24<4688::AID-ANIE4688>3.0.CO;2-M; Bischoff D, 2001, ANGEW CHEM INT EDIT, V40, P1693, DOI 10.1002/1521-3773(20010504)40:9<1693::AID-ANIE16930>3.0.CO;2-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen H, 2002, CHEM BIOL, V9, P103, DOI 10.1016/S1074-5521(02)00090-X; Chen HW, 2000, P NATL ACAD SCI USA, V97, P11942, DOI 10.1073/pnas.210395097; Chen HW, 2001, CHEM BIOL, V8, P301, DOI 10.1016/S1074-5521(01)00009-6; Chiu HT, 2001, P NATL ACAD SCI USA, V98, P8548, DOI 10.1073/pnas.151246498; Choroba OW, 2000, J AM CHEM SOC, V122, P5389, DOI 10.1021/ja000076v; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GOTOH O, 1992, J BIOL CHEM, V267, P83; Haines DC, 2001, BIOCHEMISTRY-US, V40, P13456, DOI 10.1021/bi011197q; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; Hubbard BK, 2000, CHEM BIOL, V7, P931, DOI 10.1016/S1074-5521(00)00043-0; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; KIMATA Y, 1995, BIOCHEM BIOPH RES CO, V208, P96, DOI 10.1006/bbrc.1995.1310; Kirkpatrick PN, 2000, CHEM COMMUN, P1565, DOI 10.1039/b004463f; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUS PFX, 1995, P NATL ACAD SCI USA, V92, P2071, DOI 10.1073/pnas.92.6.2071; Losey HC, 2001, BIOCHEMISTRY-US, V40, P4745, DOI 10.1021/bi010050w; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; O'Brien DP, 2000, CHEM COMMUN, P103, DOI 10.1039/a907953j; OMURA T, 1964, J BIOL CHEM, V239, P2370; Park SY, 1997, NAT STRUCT BIOL, V4, P827, DOI 10.1038/nsb1097-827; Pelzer S, 1999, ANTIMICROB AGENTS CH, V43, P1565, DOI 10.1128/AAC.43.7.1565; Peterson Julian A., 1995, P151; Pfeifer V, 2001, J BIOL CHEM, V276, P38370, DOI 10.1074/jbc.M106580200; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; POULOS TL, 1985, J BIOL CHEM, V260, P6122; Puk O, 2002, CHEM BIOL, V9, P225, DOI 10.1016/S1074-5521(02)00101-1; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Recktenwald J, 2002, MICROBIOL-SGM, V148, P1105, DOI 10.1099/00221287-148-4-1105; Sandercock AM, 2001, CHEM COMMUN, P1252, DOI 10.1039/b103668h; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Solenberg PJ, 1997, CHEM BIOL, V4, P195, DOI 10.1016/S1074-5521(97)90288-X; Sosio M, 2000, ANTON LEEUW INT J G, V78, P379, DOI 10.1023/A:1010239717396; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sussmuth RD, 1999, ANGEW CHEM INT EDIT, V38, P1976, DOI 10.1002/(SICI)1521-3773(19990712)38:13/14<1976::AID-ANIE1976>3.0.CO;2-3; Trauger JW, 2000, P NATL ACAD SCI USA, V97, P3112, DOI 10.1073/pnas.040560597; van Wageningen AMA, 1998, CHEM BIOL, V5, P155, DOI 10.1016/S1074-5521(98)90060-6; Vidakovic M, 1998, BIOCHEMISTRY-US, V37, P9211, DOI 10.1021/bi980189f; Williams DH, 1999, ANGEW CHEM INT EDIT, V38, P1173, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1172::AID-ANIE1172>3.0.CO;2-C; Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200	52	108	111	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47476	47485		10.1074/jbc.M206342200	http://dx.doi.org/10.1074/jbc.M206342200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12207020	hybrid			2022-12-25	WOS:000179663700084
J	Shimamura, T; Ibuka, A; Fushinobu, S; Wakagi, T; Ishiguro, M; Ishii, Y; Matsuzawa, H				Shimamura, T; Ibuka, A; Fushinobu, S; Wakagi, T; Ishiguro, M; Ishii, Y; Matsuzawa, H			Acyl-intermediate structures of the extended-spectrum class A beta-lactamase, Toho-1, in complex with cefotaxime, cephalothin, and benzylpenicillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEIN; SITE-DIRECTED MUTAGENESIS; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ENZYME INTERMEDIATE; ANGSTROM RESOLUTION; E166A MUTANT; ACTIVE-SITE; RESISTANCE	Bacterial resistance to beta-lactam antibiotics is a serious problem limiting current clinical therapy. The most common form of resistance is the production of beta-lactamases that inactivate beta-lactam antibiotics. Toho-1 is an extended-spectrum beta-lactamase that has acquired efficient activity not only to penicillins but also to cephalosporins including the expanded-spectrum cephalosporins that were developed to be stable in former beta-lactamases. We present the acyl-intermediate structures of Toho-1 in complex with cefotaxime (expanded-spectrum cephalosporin), cephalothin (non-expanded-spectrum cephalosporin), and benzylpenicillin at 1.8-, 2.0-, and 2.1-Angstrom resolutions, respectively. These structures reveal distinct features that can explain the ability of Toho-1 to hydrolyze expanded-spectrum cephalosporins. First, the Omega-loop of Toho-1 is displaced to avoid the steric contacts with the bulky side chain of cefotaxime. Second, the conserved residues Asn(104) and Asp(240) form unique interactions with the bulky side chain of cefotaxime to fix it tightly. Finally, the unique interaction between the conserved Ser(237) and cephalosporins probably helps to bring the beta-lactam carbonyl group to the suitable position in the oxyanion hole, thus increasing the cephalosporinase activity.	Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, London SW7 2AY, England; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Shizuoka, Dept Food Sci & Nutr, Shizuoka 4228526, Japan; Suntory Inst Bioorgan Res, Osaka 6188503, Japan; Toho Univ, Sch Med, Dept Microbiol, Ota Ku, Tokyo 1438540, Japan	Imperial College London; University of Tokyo; University of Shizuoka; Suntory Holdings Ltd	Shimamura, T (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, London SW7 2AY, England.		Fushinobu, Shinya/E-4987-2011; Wakagi, Takayoshi/AAJ-4145-2021	Fushinobu, Shinya/0000-0003-1346-6435; SHIMIZU-IBUKA, Akiko/0000-0002-5310-9216				ADACHI H, 1991, J BIOL CHEM, V266, P3186; Banerjee S, 1998, BIOCHEMISTRY-US, V37, P3286, DOI 10.1021/bi972127f; Beadle BM, 2002, STRUCTURE, V10, P413, DOI 10.1016/S0969-2126(02)00725-6; Blazquez J, 1998, ANTIMICROB AGENTS CH, V42, P1042, DOI 10.1128/AAC.42.5.1042; Bouthors AT, 1999, PROTEIN ENG, V12, P313, DOI 10.1093/protein/12.4.313; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantu C, 1997, J BIOL CHEM, V272, P29144, DOI 10.1074/jbc.272.46.29144; Chen CCH, 2001, BIOCHEMISTRY-US, V40, P2351, DOI 10.1021/bi002277h; Crichlow GV, 1999, BIOCHEMISTRY-US, V38, P10256, DOI 10.1021/bi9908787; DELAIRE M, 1992, J BIOL CHEM, V267, P20600; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fonze E, 2002, BIOCHEMISTRY-US, V41, P1877, DOI 10.1021/bi015789k; Gazouli M, 1998, ANTIMICROB AGENTS CH, V42, P1259, DOI 10.1128/AAC.42.5.1259; Giakkoupi P, 2001, FEMS MICROBIOL LETT, V201, P37, DOI 10.1111/j.1574-6968.2001.tb10729.x; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; Herzberg O, 1991, CURR OPIN STRUC BIOL, V1, P946, DOI 10.1016/0959-440X(91)90090-G; Ibuka A, 1999, J MOL BIOL, V285, P2079, DOI 10.1006/jmbi.1998.2432; ISHII Y, 1995, ANTIMICROB AGENTS CH, V39, P2269, DOI 10.1128/AAC.39.10.2269; JACOB F, 1990, PROTEIN ENG, V4, P79, DOI 10.1093/protein/4.1.79; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; KNOX JR, 1991, J MOL BIOL, V220, P435, DOI 10.1016/0022-2836(91)90023-Y; KNOX JR, 1993, PROTEIN ENG, V6, P11, DOI 10.1093/protein/6.1.11; Knox JR, 1996, CHEM BIOL, V3, P937, DOI 10.1016/S1074-5521(96)90182-9; KUZIN AP, 1995, BIOCHEMISTRY-US, V34, P9532, DOI 10.1021/bi00029a030; Kuzin AP, 1999, BIOCHEMISTRY-US, V38, P5720, DOI 10.1021/bi990136d; Matagne A, 1998, BIOCHEM J, V330, P581, DOI 10.1042/bj3300581; Mouz N, 1999, J BIOL CHEM, V274, P19175, DOI 10.1074/jbc.274.27.19175; Orencia MC, 2001, NAT STRUCT BIOL, V8, P238, DOI 10.1038/84981; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PETIT A, 1995, BIOCHEM J, V305, P33, DOI 10.1042/bj3050033; Powers RA, 2001, BIOCHEMISTRY-US, V40, P9207, DOI 10.1021/bi0109358; RAQUET X, 1994, J MOL BIOL, V244, P625, DOI 10.1006/jmbi.1994.1756; SEOANE A, 1991, J GEN MICROBIOL, V137, P141, DOI 10.1099/00221287-137-1-141; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Swaren P, 1998, J BIOL CHEM, V273, P26714, DOI 10.1074/jbc.273.41.26714; TaibiTronche P, 1996, J AM CHEM SOC, V118, P7441, DOI 10.1021/ja9529753; TAMAKI M, 1994, BIOCHEMISTRY-US, V33, P10200, DOI 10.1021/bi00199a049; Tranier S, 2000, J BIOL CHEM, V275, P28075; Tzouvelekis LS, 2000, INT J ANTIMICROB AG, V14, P137, DOI 10.1016/S0924-8579(99)00165-X; Vakulenko SB, 1999, J BIOL CHEM, V274, P23052, DOI 10.1074/jbc.274.33.23052; Wang XJ, 2002, J MOL BIOL, V320, P85, DOI 10.1016/S0022-2836(02)00400-X; ZAFARALLA G, 1992, BIOCHEMISTRY-US, V31, P3847, DOI 10.1021/bi00130a016	44	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46601	46608		10.1074/jbc.M207884200	http://dx.doi.org/10.1074/jbc.M207884200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12221102	hybrid			2022-12-25	WOS:000179529300116
J	Babenko, AP; Bryan, J				Babenko, AP; Bryan, J			SUR-dependent modulation of K-ATP channels by an N-terminal K(IR)6.2 peptide - Defining intersubunit gating interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CHANNEL; CASSETTE ABC TRANSPORTERS; PORE-FORMING SUBUNIT; SULFONYLUREA RECEPTOR; NUCLEOTIDE SENSITIVITY; INTRACELLULAR DOMAINS; MEMBRANE TOPOLOGY; TOLBUTAMIDE SITE; MOLECULAR-BASIS; BETA-SUBUNIT	Ntp and Ctp, synthetic peptides based on the N- and C-terminal sequences of K(IR)6.0, respectively, were used to probe gating of K(IR)6.0/SUR K-ATP channels. Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P-O(max)) and attenuated the ATP inhibition of K(IR)6.2/SUR1, but had no effect on homomeric K(IR)6.2 channels. Ntp (up to similar to10(-4) M) did not affect significantly the mean open or "fast," K+ driving force-dependent, intraburst closed times, verifying that Ntp selectively modulates the ratio of mean burst to interburst times. Ctp and Rnp, a randomized Ntp, had no effect, indicating that the effects of Ntp are structure specific. Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg- nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with KATp pore closure. These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to DeltaNK(ATP) channels decreased their P-O(max) and apparent IC50 for ATP in the absence of Mg2+. The results are consistent with a competition between Ntp and the endogenous N terminus for a site of interaction on the cytoplasmic face of the channel or with partial replacement of the deleted N terminus by Ntp, respectively. The K-IR N terminus and the TMD0-L0 segment of SUR1 are known to control the P-O(max). The L0 linker has been reported to be required for glibenclamide binding, and DeltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of KIR with I-125-azidoglibenclamide, implying that the KIR N terminus and L0 of SUR1 are in proximity. We hypothesize that L0 interacts with the KIR N terminus in ligand-inhibited K-ATP channels and put forward a model, based on the architecture of BtuCD, MsbA, and the KcsA channel, in which TMD0-L0 links the MDR-like core of SUR with the K-IR pore.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Babenko, AP (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,112C, Houston, TX 77030 USA.	ababenko@bcm.tme.edu			PHS HHS [44311] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashfield R, 1999, DIABETES, V48, P1341, DOI 10.2337/diabetes.48.6.1341; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; Babenko AP, 1999, FEBS LETT, V445, P131, DOI 10.1016/S0014-5793(99)00102-7; Babenko AP, 2001, J BIOL CHEM, V276, P49083, DOI 10.1074/jbc.M108763200; Babenko AP, 1999, BIOCHEM BIOPH RES CO, V255, P231, DOI 10.1006/bbrc.1999.0172; Babenko AP, 2001, BIOPHYS J, V80, p625A; Babenko AP, 2000, J BIOL CHEM, V275, P717, DOI 10.1074/jbc.275.2.717; Babenko AP, 1999, FEBS LETT, V459, P367, DOI 10.1016/S0014-5793(99)01215-6; BABENKO AP, 2002, PHARMACOLOGIST, V44, pA189; Bakos E, 2000, J CELL SCI, V113, P4451; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Conti LR, 2001, J BIOL CHEM, V276, P41270, DOI 10.1074/jbc.M106555200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Giblin JP, 1999, J BIOL CHEM, V274, P22652, DOI 10.1074/jbc.274.32.22652; GILLIS KD, 1989, AM J PHYSIOL, V257, pC1119, DOI 10.1152/ajpcell.1989.257.6.C1119; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Jones PA, 2001, FEBS LETT, V508, P85, DOI 10.1016/S0014-5793(01)03023-X; Karplus K, 1999, PROTEINS, P121; Kondo C, 1998, RECEPTOR CHANNEL, V6, P129; Koster JC, 1999, J PHYSIOL-LONDON, V515, P19, DOI 10.1111/j.1469-7793.1999.019ad.x; Li LH, 2000, BIOPHYS J, V79, P841, DOI 10.1016/S0006-3495(00)76340-5; Li LH, 2002, J GEN PHYSIOL, V119, P105, DOI 10.1085/jgp.119.1.105; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Mikhailov MV, 2001, FEBS LETT, V499, P154, DOI 10.1016/S0014-5793(01)02538-8; Proks P, 1999, J PHYSIOL-LONDON, V514, P19, DOI 10.1111/j.1469-7793.1999.019af.x; Raab-Graham KF, 1999, J BIOL CHEM, V274, P29122, DOI 10.1074/jbc.274.41.29122; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Sakura H, 1999, J PHYSIOL-LONDON, V521, P337, DOI 10.1111/j.1469-7793.1999.00337.x; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Takano M, 1998, J PHYSIOL-LONDON, V512, P395, DOI 10.1111/j.1469-7793.1998.395be.x; TRUBE G, 1984, PFLUG ARCH EUR J PHY, V401, P178, DOI 10.1007/BF00583879; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Tucker SJ, 1999, J BIOL CHEM, V274, P33393, DOI 10.1074/jbc.274.47.33393; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Uhde I, 1999, J BIOL CHEM, V274, P28079, DOI 10.1074/jbc.274.40.28079; Wissmann R, 1999, J BIOL CHEM, V274, P35521, DOI 10.1074/jbc.274.50.35521; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; ZILBERTER Y, 1988, PFLUG ARCH EUR J PHY, V411, P584, DOI 10.1007/BF00582382	49	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43997	44004		10.1074/jbc.M208085200	http://dx.doi.org/10.1074/jbc.M208085200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12213829	hybrid			2022-12-25	WOS:000179272000061
J	Barylko, B; Wlodarski, P; Binns, DD; Gerber, SH; Earnest, S; Sudhof, TC; Grichine, N; Albanesi, JP				Barylko, B; Wlodarski, P; Binns, DD; Gerber, SH; Earnest, S; Sudhof, TC; Grichine, N; Albanesi, JP			Analysis of the catalytic domain of phosphatidylinositol 4-kinase type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; LIPID KINASE; SACCHAROMYCES-CEREVISIAE; INOSITOL LIPIDS; CLONING; PURIFICATION; MEMBRANE; YEAST; PHOSPHOINOSITIDES; FAMILY	Phosphatidylinositol (PtdIns) 4-kinases catalyze the conversion of PtdIns to PtdIns 4-phosphate, the major precursor of phosphoinositides that regulates a vast array of cellular processes. Based on enzymatic differences, two classes of PtdIns 4-kinase have been distinguished termed Types 11 and Ill. Type III kinases, which belong to the phosphatidylinositol (PI) 3/4-kinase family, have been extensively characterized. In contrast, little is known about the Type 11 enzymes (PI4KIIs), which have been cloned and sequenced very recently. PI4KIIs bear essentially no sequence similarity to other protein or lipid kinases; hence, they represent a novel and distinct branch of the kinase superfamily. Here we define the minimal catalytic domain of a rat PI4KII isoform, PI4KIIalpha, and identify conserved amino acid residues required for catalysis. We further show that the catalytic domain by itself determines targeting of the kinase to membrane rafts. To verify that the PI4KII family extends beyond mammalian sources, we expressed and characterized Drosophila PI4KII and its catalytic domain. Depletion of PI4KII from Drosophila cells resulted in a severe reduction of PtdIns 4-kinase activity, suggesting the in vivo importance of this enzyme.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA; Med Univ Warsaw, Dept Histol & Embryol, Ctr Biostruct Res, PL-02004 Warsaw, Poland	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Medical University of Warsaw	Albanesi, JP (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jalban@mednet.swmed.edu		Wlodarski, Pawel/0000-0002-0683-1791	NIGMS NIH HHS [GM55562] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055562] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Balla A, 2002, J BIOL CHEM, V277, P20041, DOI 10.1074/jbc.M111807200; Balla T, 1998, BBA-MOL CELL BIOL L, V1436, P69, DOI 10.1016/S0005-2760(98)00134-9; Balla T, 1997, J BIOL CHEM, V272, P18358, DOI 10.1074/jbc.272.29.18358; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Brill JA, 2000, DEVELOPMENT, V127, P3855; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Cockcroft S, 2001, J MEMBRANE BIOL, V180, P187, DOI 10.1007/s002320010069; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Gehrmann T, 1996, BBA-MOL CELL RES, V1311, P53, DOI 10.1016/0167-4889(95)00180-8; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; HUSEBYE ES, 1990, BIOCHIM BIOPHYS ACTA, V1042, P330, DOI 10.1016/0005-2760(90)90161-P; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; Nakagawa T, 1996, BIOCHEM J, V320, P643, DOI 10.1042/bj3200643; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P124; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; PORTER FD, 1988, J BIOL CHEM, V263, P8989; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STACK JH, 1994, J BIOL CHEM, V269, P31552; Steinbacher S, 1999, EMBO J, V18, P2923, DOI 10.1093/emboj/18.11.2923; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; Taylor SS, 1999, PHARMACOL THERAPEUT, V82, P133, DOI 10.1016/S0163-7258(99)00007-8; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Waugh MG, 1998, J BIOL CHEM, V273, P17115, DOI 10.1074/jbc.273.27.17115; WETZKER R, 1991, EUR J BIOCHEM, V200, P179, DOI 10.1111/j.1432-1033.1991.tb21065.x; WONG K, 1994, J BIOL CHEM, V269, P28878; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; Zajchowski LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/j.0014-2956.2001.02715.x	55	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44366	44375		10.1074/jbc.M203241200	http://dx.doi.org/10.1074/jbc.M203241200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12215430	hybrid			2022-12-25	WOS:000179272000108
J	Crean, JKG; Finlay, D; Murphy, M; Moss, C; Godson, C; Martin, F; Brady, HR				Crean, JKG; Finlay, D; Murphy, M; Moss, C; Godson, C; Martin, F; Brady, HR			The role of p42/44 MAPK and protein kinase B in connective tissue growth factor induced extracellular matrix protein production, cell migration, and actin cytoskeletal rearrangement in human mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING-PROTEIN; FACTOR-BETA; GENE-EXPRESSION; RHO FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; IN-VITRO; IIB-IIIA; INTEGRIN; ADHESION	Connective tissue growth factor (CTGF) is a member of an emerging family of immediate-early gene products that coordinate complex biological processes during differentiation and tissue repair. Here we describe the role of CTGF in integrin-mediated adhesive signaling and the production of extracellular matrix components in human mesangial cells. The addition of CTGF to primary mesangial cells induced fibronectin production, cell migration, and cytoskeletal rearrangement. These functional responses were associated with recruitment of Src and phosphorylation of p42/44 MAPK and protein kinase B. The inhibition of CTGF-induced p42/44 MAPK or phosphatidylinositol 3-kinase (PI3K)/protein kinase B pathway activities abrogated the induction of fibronectin expression. In addition, anti-beta(3) integrin antibodies attenuated the activation of both the p42/44 MAPK and protein kinase B and the increase in fibronectin levels. CTGF also induced mesangial cell migration via a beta(3) integrin-dependent mechanism that was similarly sensitive to the inhibition of the p42/44 MAPK and PI3K pathways, and it promoted the adhesion of the mesangial cells to type I collagen via up-regulation of a, integrin. Transient actin cytoskeletal disassembly was observed following treatment with the ligand over the course of a 24-h period. CTGF induced the loss of focal adhesions from the mesangial cell as evidenced by the loss of punctate vinculin. However, these processes are p42/44 MAPK and PI3K pathway-independent. Our data support the hypothesis that CTGF mediates a number of its biological effects by the induction of signaling processes via beta(3) integrin. However, others such as actin cytoskeleton disassembly are modulated in a beta(3), integrin/MALPK/PI3K-independent manner, indicating that CTGF is a complex pleiotropic factor with the potential to amplify primary pathophysiological responses.	Natl Univ Ireland Univ Coll Dublin, Mater Misericordiae Hosp, Dept Med & Therapeut, Conway Inst Biomol & Biomed Res, Dublin 7, Ireland; Natl Univ Ireland Univ Coll Dublin, Mater Misericordiae Hosp, Dept Pharmacol, Conway Inst Biomol & Biomed Res, Dublin 7, Ireland; Dublin Mol Med Ctr, Dublin 4, Ireland	Mater Misericordiae University Hospital; University College Dublin; Mater Misericordiae University Hospital; University College Dublin; Trinity College Dublin; University College Dublin	Crean, JKG (corresponding author), Natl Univ Ireland Univ Coll Dublin, Mater Misericordiae Hosp, Dept Med & Therapeut, Conway Inst Biomol & Biomed Res, 41 Eccles St, Dublin 7, Ireland.	john.crean@ucd.ie		/0000-0002-4337-6177; Godson, Catherine/0000-0003-0655-1041				Akiyama S K, 1996, Hum Cell, V9, P181; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Babic AM, 1999, MOL CELL BIOL, V19, P2958; BOCKHOLT SM, 1995, CELL ADHES COMMUN, V3, P91, DOI 10.3109/15419069509081279; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BRADY HR, 1992, KIDNEY INT, V42, P480, DOI 10.1038/ki.1992.312; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brill S, 1996, MOL CELL BIOL, V16, P4869; CARVER W, 1995, J CELL PHYSIOL, V165, P425, DOI 10.1002/jcp.1041650224; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Cortes P, 2000, KIDNEY INT, V58, P2452, DOI 10.1046/j.1523-1755.2000.00428.x; Crean John KG, 2001, Expert Opin Ther Targets, V5, P519; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Delehedde M, 2001, EUR J BIOCHEM, V268, P4423, DOI 10.1046/j.1432-1327.2001.02363.x; Dogic D, 1998, J CELL SCI, V111, P793; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; Finlay D, 2000, CELL DEATH DIFFER, V7, P302, DOI 10.1038/sj.cdd.4400652; FOX JEB, 1993, J BIOL CHEM, V268, P25973; Gilmore AP, 1996, STRUCTURE, V4, P647, DOI 10.1016/S0969-2126(96)00069-X; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Gupta S, 2000, KIDNEY INT, V58, P1389, DOI 10.1046/j.1523-1755.2000.00301.x; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hapke S, 2001, J BIOL CHEM, V276, P26340, DOI 10.1074/jbc.M100181200; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Honore S, 2000, HISTOCHEM CELL BIOL, V114, P323; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Ito Y, 2001, J AM SOC NEPHROL, V12, P472, DOI 10.1681/ASN.V123472; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Johnson JL, 1996, J BIOL CHEM, V271, P21574, DOI 10.1074/jbc.271.35.20981; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kagami S, 2001, EXP CELL RES, V268, P274, DOI 10.1006/excr.2001.5279; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Liu WL, 2001, ENDOCRINOLOGY, V142, P1710, DOI 10.1210/en.142.5.1710; Loeser RF, 1997, ARTHRITIS RHEUM, V40, P270, DOI 10.1002/art.1780400211; Miller LA, 1999, EUR J IMMUNOL, V29, P1426, DOI 10.1002/(SICI)1521-4141(199905)29:05<1426::AID-IMMU1426>3.0.CO;2-J; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; Nishida T, 1998, BIOCHEM BIOPH RES CO, V247, P905, DOI 10.1006/bbrc.1998.8895; PELLETIER AJ, 1995, J BIOL CHEM, V270, P18133, DOI 10.1074/jbc.270.30.18133; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Riser BL, 2001, RENAL FAILURE, V23, P459, DOI 10.1081/JDI-100104729; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sondermann H, 1999, CELL ADHES COMMUN, V7, P43, DOI 10.3109/15419069909034391; STUDER RK, 1993, DIABETES, V42, P118, DOI 10.2337/diabetes.42.1.118; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wahab NA, 2001, BIOCHEM J, V359, P77, DOI 10.1042/0264-6021:3590077; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Xu WM, 1998, J CELL SCI, V111, P1535; Yokoi H, 2001, AM J KIDNEY DIS, V38, pS134, DOI 10.1053/ajkd.2001.27422; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; ZHOU XP, 1995, LAB INVEST, V73, P372; Zhou XP, 1997, KIDNEY INT, V51, P1797, DOI 10.1038/ki.1997.247	77	131	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44187	44194		10.1074/jbc.M203715200	http://dx.doi.org/10.1074/jbc.M203715200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12218048	hybrid			2022-12-25	WOS:000179272000085
J	Hu, Y; Ippolito, JE; Garabedian, EM; Humphrey, PA; Gordon, JI				Hu, Y; Ippolito, JE; Garabedian, EM; Humphrey, PA; Gordon, JI			Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRADER-WILLI-SYNDROME; BHLH TRANSCRIPTION FACTORS; CHROMOGRANIN-A; DETERMINATION GENES; BINDING PROTEIN; NECDIN GENE; DIFFERENTIATION; GROWTH; EXPRESSION; DECARBOXYLASE	The features and functions of prostatic neuroendocrine (NE) cells remain ill-defined. Neuroendocrine differentiation (NED) in adenocarcinoma of the human prostate (Cap) is associated with more aggressive disease, but the underlying mediators are poorly understood. We examined these issues in transgenic mice that utilize regulatory elements from the cryptdin-2 gene (Defcr2) to express simian virus 40 large T antigen (TAg) in prostatic NE cells. CR2-TAg mice develop prostatic intraepithelial neoplasia at 8 weeks of age, I week after the onset of TAg expression. An invasive phase follows 2-4 weeks later, with lymph node, liver, lung, brain, and bone metastases appearing within 16 weeks. DNA microarray studies revealed 122 mRNAs that were increased greater than or equal to2-fold in duplicate assays of 16-week-old CR2-TAg versus normal prostates. Thirty two transcripts encode proteins associated with neurons and endocrine cells (e.g. basic helix loop helix, SRY-related high mobility group box and sine-oculis homeobox transcription factors, Hu RNA-binding proteins, neuronatin, Racgap1, collapsin response mediator protein-1, synaptotagmin-1, proprotein convertase, and secretogranins). Follow-up studies of candidate mediators and biomarkers of differentiation/growth in the microarray data set involved real time quantitative reverse transcriptase-PCR assays of laser capture microdissected NE cells from CR2-TAg prostates plus liver metastases, and immunohistochemical comparisons of transgenic mouse prostates and 35 human Cap samples. Our findings include (a) expression of the bHLH mouse achaete-scute homolog (mASH1) in normal and CR2-TAg NE cells and foci of NED in human CaP, (b) glutamic, acid decarboxylase and its product (gamma-aminobutyric acid) in neoplastic NE cells juxtaposed next to cohorts of normal gamma-aminobutyric acid receptor expressing secretory cells (a potential route for paracrine interactions between these two epithelial lineages), and (c) aromatic L-amino-acid decarboxylase, but not its dopamine/serotonin products, in CR2-TAg NE cells and NED. These results underscore the value of CR2-TAg mice for characterizing normal NE cell biology and tumorigenesis.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA.	jgordon@molecool.wustl.edu		Hu, Yan Helen/0000-0003-3269-4505	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059129] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59129] Funding Source: Medline; NIGMS NIH HHS [GM08492] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alaiya AA, 1997, INT J CANCER, V73, P678, DOI 10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Bae SK, 2000, DEVELOPMENT, V127, P2933; BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; BOHRER MH, 1993, VERH DEUT G, V77, P107; BONKHOFF H, 1994, HUM PATHOL, V25, P42, DOI 10.1016/0046-8177(94)90169-4; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; BOSTWICK DG, 1993, HUM PATHOL, V24, P298, DOI 10.1016/0046-8177(93)90041-E; Cardoso C, 1998, HUM MOL GENET, V7, P679, DOI 10.1093/hmg/7.4.679; Casarosa S, 1999, DEVELOPMENT, V126, P525; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1; Cho SH, 1999, SYNAPSE, V34, P135, DOI 10.1002/(SICI)1098-2396(199911)34:2<135::AID-SYN6>3.0.CO;2-H; COHEN RJ, 1990, BRIT J UROL, V66, P405, DOI 10.1111/j.1464-410X.1990.tb14963.x; Collignon J, 1996, DEVELOPMENT, V122, P509; CUELLO AC, 1982, LANCET, V1, P771; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; Darlington DN, 1997, J ENDOCRINOL, V155, P329, DOI 10.1677/joe.0.1550329; delaPompa J, 1997, DEVELOPMENT, V124, P1139; Dema A, 1996, Rom J Morphol Embryol, V42, P83; DISANTAGNESE PA, 1992, HUM PATHOL, V23, P287; DISANTAGNESE PA, 1984, HUM PATHOL, V15, P1034; DOPAZO A, 1993, J MOL NEUROSCI, V4, P225, DOI 10.1007/BF02821554; El Gedaily A, 2001, PROSTATE, V46, P184; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fode C, 2000, GENE DEV, V14, P67; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; FRIEDRICH B, 1995, PROSTATE, V27, P102, DOI 10.1002/pros.2990270207; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; Gilbert JA, 2000, CLIN CANCER RES, V6, P4365; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Gotter AL, 2000, NAT NEUROSCI, V3, P755, DOI 10.1038/77653; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; Hooper LV, 2002, METHOD MICROBIOL, V31, P559, DOI 10.1016/S0580-9517(02)31030-4; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; Ito T, 2000, DEVELOPMENT, V127, P3913; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; Jongsma J, 2002, PROSTATE, V50, P203, DOI 10.1002/pros.10049; Kageyama R, 1997, INT J BIOCHEM CELL B, V29, P1389, DOI 10.1016/S1357-2725(97)89968-2; Kikyo N, 1997, DEV BIOL, V190, P66, DOI 10.1006/dbio.1997.8681; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; LAMPRECHT F, 1972, BRAIN RES, V41, P503, DOI 10.1016/0006-8993(72)90525-2; Lanigan TM, 1998, J NEUROBIOL, V34, P126, DOI 10.1002/(SICI)1097-4695(19980205)34:2<126::AID-NEU3>3.0.CO;2-4; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Maillard M, 2001, J CLIN PATHOL-MOL PA, V54, P275, DOI 10.1136/mp.54.4.275; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; Masumori N, 2001, CANCER RES, V61, P2239; Millevoi S, 2001, EUR J BIOCHEM, V268, P781, DOI 10.1046/j.1432-1327.2001.01934.x; NAGATSU T, 1985, BIOCHEM MED METAB B, V34, P52, DOI 10.1016/0006-2944(85)90061-4; Nakada Y, 1998, GENE, V213, P65, DOI 10.1016/S0378-1119(98)00206-6; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Newey SE, 2001, MOL CELL NEUROSCI, V17, P127, DOI 10.1006/mcne.2000.0918; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; OCONNOR DT, 1986, NEW ENGL J MED, V314, P1145, DOI 10.1056/NEJM198605013141803; Ohto H, 1998, INT J DEV BIOL, V42, P141; OMALLEY KL, 1995, J NEUROCHEM, V65, P2409; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Raynal JF, 1998, MOL BRAIN RES, V56, P227, DOI 10.1016/S0169-328X(98)00048-5; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Seidah NG, 1999, ANN NY ACAD SCI, V885, P57; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; Speights VO, 1997, BRIT J UROL, V80, P281, DOI 10.1046/j.1464-410X.1997.00359.x; Stappenbeck TS, 2002, METHOD ENZYMOL, V356, P167; Thambisetty MR, 2001, J NEURO-OPHTHALMOL, V21, P164, DOI 10.1097/00041327-200109000-00002; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; TILLAKARATNE NJK, 1995, COMP BIOCHEM PHYS A, V112, P247, DOI 10.1016/0300-9629(95)00099-2; Tomita K, 1996, GENES CELLS, V1, P765, DOI 10.1111/j.1365-2443.1996.tb00016.x; Toure A, 1998, J BIOL CHEM, V273, P6019, DOI 10.1074/jbc.273.11.6019; VANDENBERG C, 1995, CLIN CANCER RES, V1, P11; Vos MD, 1996, J CELL BIOCHEM, P257; Wang HY, 2002, J BIOL CHEM, V277, P17564, DOI 10.1074/jbc.M111037200; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200	89	81	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44462	44474		10.1074/jbc.M205784200	http://dx.doi.org/10.1074/jbc.M205784200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228243	hybrid			2022-12-25	WOS:000179272000118
J	Marvaud, JC; Stiles, BG; Chenal, A; Gillet, D; Gibert, M; Smith, LA; Popoff, MR				Marvaud, JC; Stiles, BG; Chenal, A; Gillet, D; Gibert, M; Smith, LA; Popoff, MR			Clostridium perfringens iota toxin - Mapping of the Ia domain involved in docking with Ib and cellular internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM C2 TOXIN; RIBOSYLATING C3 EXOENZYME; LIPID BILAYER-MEMBRANES; ADP-RIBOSYLTRANSFERASE; LETHAL FACTOR; CRYSTAL-STRUCTURE; BINARY TOXIN; CHANNEL FUNCTION; COMPONENT C2II; BINDING	Clostridium perfringens iota toxin consists of two unlinked proteins. The binding component (Ib) is required to internalize into cells an enzymatic component (Ia) that ADP-ribosylates G-actin. To characterize the Ia domain that interacts with Ib, fusion proteins were constructed between the C. botulinum C3 enzyme, which ADP-ribosylates Rho, and various truncated versions of Ia. These chimeric molecules retained the wild type ADP-ribosyltransferase activity specific for Rho and were recognized by antibodies against C3 enzyme and Ia. Internalization of each chimera into Vero cells was assessed by measuring the disorganization of the actin cytoskeleton and intracellular ADP-ribosylation of Rho. Fusion proteins containing C3 linked to the C terminus of Ia were transported most efficiently into cells like wild type Ia in an Ib-dependent manner that was blocked by bafilomycin A1. The minimal Ia fragment that promoted translocation of Ia-C3 chimeras into cells consisted of 128 central residues (129-257). These findings revealed that iota toxin is a suitable system for mediating the entry of heterologous proteins such as C3 into cells.	Inst Pasteur, CNR Anaerobies, F-75724 Paris 15, France; USA, Med Res Inst Infect Dis, Toxinol Div, Ft Detrick, MD 21702 USA; CEA Saclay, Dept Ingenierie & Etud Prot, F-91191 Gif Sur Yvette, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CEA; UDICE-French Research Universities; Universite Paris Saclay	Popoff, MR (corresponding author), Inst Pasteur, CNR Anaerobies, 28 Rue Dr Roux, F-75724 Paris 15, France.	mpopoff@pasteur.fr	Gillet, Daniel/C-5592-2008; Chenal, Alexandre/C-2240-2009	Gillet, Daniel/0000-0003-0477-3599; Chenal, Alexandre/0000-0002-4959-1003				Adler A J, 1973, Methods Enzymol, V27, P675; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; ARORA N, 1993, J BIOL CHEM, V268, P3334; ARORA N, 1994, J BIOL CHEM, V269, P26165; AULLO P, 1993, EMBO J, V12, P921, DOI 10.1002/j.1460-2075.1993.tb05733.x; Bachmeyer C, 2001, FASEB J, V15, P1658, DOI 10.1096/fj.00-0671fje; Barth H, 2000, J BIOL CHEM, V275, P18704, DOI 10.1074/jbc.M000596200; Barth H, 2002, J BIOL CHEM, V277, P5074, DOI 10.1074/jbc.M109167200; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; Blocker D, 2000, INFECT IMMUN, V68, P4566, DOI 10.1128/IAI.68.8.4566-4573.2000; Blocker D, 2001, INFECT IMMUN, V69, P2980, DOI 10.1128/IAI.69.5.2980-2987.2001; BRAGG TS, 1989, GENE, V81, P45, DOI 10.1016/0378-1119(89)90335-1; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chenal A, 2002, PROTEIN ENG, V15, P383, DOI 10.1093/protein/15.5.383; Coligan JE, 1995, CURRENT PROTOCOLS PR; CONSIDINE RV, 1991, TOXICON, V29, P913, DOI 10.1016/0041-0101(91)90076-4; Gibert M, 2000, INFECT IMMUN, V68, P3848, DOI 10.1128/IAI.68.7.3848-3853.2000; Gill D., 1978, BACTERIAL TOXINS CEL, P291; Han S, 1999, NAT STRUCT BIOL, V6, P932, DOI 10.1038/13300; Han SI, 2001, J MOL BIOL, V305, P95, DOI 10.1006/jmbi.2000.4292; Lacy DB, 2002, J BIOL CHEM, V277, P3006, DOI 10.1074/jbc.M109997200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; LEPPLA SH, 1999, COMPREHENSIVE SOURCE, P243; Marvaud JC, 2001, INFECT IMMUN, V69, P2435, DOI 10.1128/IAI.69.4.2435-2441.2001; MAUSS S, 1990, EUR J BIOCHEM, V194, P237, DOI 10.1111/j.1432-1033.1990.tb19448.x; Menetrey J, 2002, J BIOL CHEM, V277, P30950, DOI 10.1074/jbc.M201844200; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; Miyaoka T, 1996, J BIOCHEM-TOKYO, V119, P200; OLSNES S, 1999, COMPREHENSIVE SOURCE, P73; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; Perelle S, 1997, INFECT IMMUN, V65, P1402, DOI 10.1128/IAI.65.4.1402-1407.1997; PERELLE S, 1995, INFECT IMMUN, V63, P4967, DOI 10.1128/IAI.63.12.4967-4967.1995; Perelle S, 1996, FEBS LETT, V395, P191, DOI 10.1016/0014-5793(96)01035-6; PERELLE S, 1993, INFECT IMMUN, V61, P5147, DOI 10.1128/IAI.61.12.5147-5156.1993; PERELLE S, 1997, FEMS MICROBIOL LETT, V146, P117; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Popoff MR, 2000, HANDB EXP PHARM, V145, P275; POPOFF MR, 1988, INFECT IMMUN, V56, P2299, DOI 10.1128/IAI.56.9.2299-2306.1988; POPOFF MR, 1991, INFECT IMMUN, V59, P3673, DOI 10.1128/IAI.59.10.3673-3679.1991; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; POPOFF MR, 1989, INFECT IMMUN, V57, P2462, DOI 10.1128/IAI.57.8.2462-2469.1989; Richard JF, 2002, MOL MICROBIOL, V43, P907, DOI 10.1046/j.1365-2958.2002.02806.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMID A, 1994, J BIOL CHEM, V269, P16706; SIMPSON LI, 1989, J PHARMACOL EXP THER, V251, P1223; Stiles BG, 2000, INFECT IMMUN, V68, P3475, DOI 10.1128/IAI.68.6.3475-3484.2000; VANDEKERCKHOVE J, 1987, FEBS LETT, V225, P48, DOI 10.1016/0014-5793(87)81129-8; VANDERSPECK JC, 1999, COMPREHENSIVE SOURCE, P682; Warren G.W., 1996, Patent Coop. Treaty, Patent No. [WO96/ 10083, 9610083, WO 96/10083 A1]; Wilde C, 2001, TOXICON, V39, P1647, DOI 10.1016/S0041-0101(01)00152-0	52	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43659	43666		10.1074/jbc.M207828200	http://dx.doi.org/10.1074/jbc.M207828200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221101	hybrid			2022-12-25	WOS:000179272000017
J	Zang, XX; Taylor, P; Wang, JM; Meyer, DJ; Scott, AL; Walkinshaw, MD; Maizels, RM				Zang, XX; Taylor, P; Wang, JM; Meyer, DJ; Scott, AL; Walkinshaw, MD; Maizels, RM			Homologues of human macrophage migration inhibitory factor from a parasitic nematode - Gene cloning, protein activity, and crystal structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYMPHATIC FILARIASIS; BRUGIA-MALAYI; FACTOR MIF; IMMUNE EVASION; PHENYLPYRUVATE TAUTOMERASE; CYTOKINE MIF; MODULATION; RESPONSES; MICROFILARIAE; PURIFICATION	Cytokines are the molecular messengers of the vertebrate immune system, coordinating the local and systemic immune responses to infective organisms. We report here functional and structural data on cytokine-like proteins from a eukaryotic pathogen. Two homologues of the human cytokine macrophage migration inhibitory factor (MIF) have been isolated from the parasitic nematode Brugia malayi. Both molecules (Bm-MIF-1 and Bm-MIF-2) show parallel functions to human MIF. They are chemotactic for human monocytes and activate them to produce IL-8, TNF-alpha, and endogenous MIF. The human and nematode MIF homologues share a tautomerase enzyme activity, which is in each case abolished by the mutation of the N-terminal proline residue. The crystal structure of Bm-MIF-2 at 1.8-Angstrom resolution has been determined, revealing a trimeric assembly with an inner pore created by beta-stranded sheets from each subunit. Both biological activity and crystal structure reveal remarkable conservation between a human cytokine and its parasite counterpart despite the considerable phylogenetic divide among these organisms. The strength of the similarity implies that MIF-mediated pathways play an important role in nematode immune evasion strategies.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JT, Midlothian, Scotland; NCI, Frederick Canc Res & Dev Ctr, Mol Immunoregulat Lab, Frederick, MD 21702 USA; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA	University of Edinburgh; University of Edinburgh; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of London; London School of Hygiene & Tropical Medicine; Johns Hopkins University	Zang, XX (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.		walkinshaw, malcolm/AAB-7497-2019	walkinshaw, malcolm/0000-0001-5955-9325; Zang, Xingxing/0000-0001-5380-1942				Alcami A, 2000, IMMUNOL TODAY, V21, P447, DOI 10.1016/S0167-5699(00)01699-6; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Blaxter M, 1999, PARASITOLOGY, V118, pS39, DOI 10.1017/S0031182099004060; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Bucala R, 2000, NATURE, V408, P146, DOI 10.1038/35041654; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; Falcone FH, 2001, J IMMUNOL, V167, P5348, DOI 10.4049/jimmunol.167.9.5348; GALAT A, 1993, FEBS LETT, V319, P233, DOI 10.1016/0014-5793(93)80553-7; Goerdt S, 1999, IMMUNITY, V10, P137, DOI 10.1016/S1074-7613(00)80014-X; Gomez-Escobar N, 2000, INFECT IMMUN, V68, P6402, DOI 10.1128/IAI.68.11.6402-6410.2000; Gregory WF, 1997, MOL BIOCHEM PARASIT, V87, P85, DOI 10.1016/S0166-6851(97)00050-9; KING CL, 1993, J CLIN INVEST, V92, P1667, DOI 10.1172/JCI116752; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Lawrence RA, 1996, PARASITOL TODAY, V12, P267, DOI 10.1016/0169-4758(96)10025-9; Liu SG, 1997, CLIN BIOCHEM, V30, P455, DOI 10.1016/S0009-9120(97)00049-0; Loke P, 2000, EUR J IMMUNOL, V30, P2669, DOI 10.1002/1521-4141(200009)30:9&lt;2669::AID-IMMU2669&gt;3.0.CO;2-1; LoVerde PT, 1998, PARASITOL TODAY, V14, P284, DOI 10.1016/S0169-4758(98)01261-7; Lubetsky JB, 1999, BIOCHEMISTRY-US, V38, P7346, DOI 10.1021/bi990306m; MacDonald AS, 1998, J IMMUNOL, V160, P4124; MAIZELS RM, 1991, PARASITOL TODAY, V7, P271, DOI 10.1016/0169-4758(91)90093-4; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; MAIZELS RM, 1995, PARASITOL TODAY, V11, P50, DOI 10.1016/0169-4758(95)80116-2; Maizels RM, 2001, INT J PARASITOL, V31, P889, DOI 10.1016/S0020-7519(01)00213-2; Manoury B, 2001, CURR BIOL, V11, P447, DOI 10.1016/S0960-9822(01)00118-X; Marson AL, 2001, GENE, V278, P53, DOI 10.1016/S0378-1119(01)00706-5; Matsunaga J, 1999, J BIOL CHEM, V274, P3268, DOI 10.1074/jbc.274.6.3268; Metz CN, 1997, ADV IMMUNOL, V66, P197, DOI 10.1016/S0065-2776(08)60598-2; Michael E, 1996, PARASITOLOGY, V112, P409, DOI 10.1017/S0031182000066646; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; MozeticFrancky B, 1997, PROTEIN EXPRES PURIF, V9, P115, DOI 10.1006/prep.1996.0641; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pastrana DV, 1998, INFECT IMMUN, V66, P5955, DOI 10.1128/IAI.66.12.5955-5963.1998; Pennock JL, 1998, BIOCHEM J, V331, P905, DOI 10.1042/bj3310905; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Rosengren E, 1997, FEBS LETT, V417, P85, DOI 10.1016/S0014-5793(97)01261-1; Schonemeyer A, 2001, J IMMUNOL, V167, P3207, DOI 10.4049/jimmunol.167.6.3207; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Suzuki M, 1996, NAT STRUCT BIOL, V3, P259, DOI 10.1038/nsb0396-259; Swope M, 1998, EMBO J, V17, P3534, DOI 10.1093/emboj/17.13.3534; Tan THP, 2001, BIOCHEM J, V357, P373, DOI 10.1042/0264-6021:3570373; Tang L, 1996, EXP PARASITOL, V82, P329, DOI 10.1006/expr.1996.0041; Taylor AB, 1999, BIOCHEMISTRY-US, V38, P7444, DOI 10.1021/bi9904048; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; Williams SA, 2000, INT J PARASITOL, V30, P411, DOI 10.1016/S0020-7519(00)00014-X; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568; Zang XX, 2000, J IMMUNOL, V165, P5161, DOI 10.4049/jimmunol.165.9.5161; Zang XX, 1999, BLOOD, V94, P1418, DOI 10.1182/blood.V94.4.1418.416k03_1418_1428; Zang XX, 2001, TRENDS BIOCHEM SCI, V26, P191, DOI 10.1016/S0968-0004(00)01761-8	56	93	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44261	44267		10.1074/jbc.M204655200	http://dx.doi.org/10.1074/jbc.M204655200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221083	hybrid			2022-12-25	WOS:000179272000095
J	Cheetham, GMT; Knegtel, RMA; Coll, JT; Renwick, SB; Swenson, L; Weber, P; Lippke, JA; Austen, DA				Cheetham, GMT; Knegtel, RMA; Coll, JT; Renwick, SB; Swenson, L; Weber, P; Lippke, JA; Austen, DA			Crystal structure of aurora-2, an oncogenic serine/threonine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROTEIN-KINASE; CHROMOSOME SEGREGATION; CATALYTIC SUBUNIT; COMPLEX; FAMILY; PHOSPHORYLATION; SPINDLE; DOMAIN; EXPRESSION; INHIBITORS	Aurora-2 is a key member of a closely related subgroup of serine/threonine kinases that plays important roles in the completion of essential mitotic events. Aurora-2 is oncogenic and amplified in various human cancers and could be an important therapeutic target for inhibitory molecules that would disrupt the cell cycle and block proliferation. We report the first crystal structure of Aurora-2 kinase in complex with adenosine. Analysis of residues in the active site suggests differences with structurally and biologically related protein kinases. The activation loop, which contains residues specific to the Aurora family of kinases, has a unique conformation. These results provide valuable insight into the design of selective and highly potent ATP-competitive inhibitors of the Aurora kinases.	Vertex Pharmaceut Europe Ltd, Abingdon OX14 4RY, Oxon, England; Vertex Pharmaceut Inc, Cambridge, MA 02139 USA	Vertex Pharmaceuticals; Vertex Pharmaceuticals	Cheetham, GMT (corresponding author), Vertex Pharmaceut Europe Ltd, 88 Milton Pk, Abingdon OX14 4RY, Oxon, England.	cheetham@vpharm.com						Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bicher A, 1997, GYNECOL ONCOL, V66, P36, DOI 10.1006/gyno.1997.4709; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; BRUNGER AT, 1991, ACTA CRYSTALLOGR A, V47, P195, DOI 10.1107/S0108767390011795; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, CURR OPIN STRUC BIOL, V8, P606, DOI 10.1016/S0959-440X(98)80152-8; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Fox T, 1998, PROTEIN SCI, V7, P2249, DOI 10.1002/pro.5560071102; Garcia-Echeverria C, 2000, MED RES REV, V20, P28, DOI 10.1002/(SICI)1098-1128(200001)20:1<28::AID-MED2>3.3.CO;2-U; Giet R, 1999, J CELL SCI, V112, P3591; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goepfert TM, 2000, CURR TOP DEV BIOL, V49, P331; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hoglund M, 1998, GENE CHROMOSOME CANC, V21, P8; Kaitna S, 2000, CURR BIOL, V10, P1172, DOI 10.1016/S0960-9822(00)00721-1; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Narayana N, 1997, BIOCHEMISTRY-US, V36, P4438, DOI 10.1021/bi961947+; Nigg EA, 1996, EXP CELL RES, V229, P174, DOI 10.1006/excr.1996.0356; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sondhi D, 1999, BIOCHEMISTRY-US, V38, P11147, DOI 10.1021/bi990827+; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tereshko V, 2001, NAT STRUCT BIOL, V8, P899, DOI 10.1038/nsb1001-899; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	39	146	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42419	42422		10.1074/jbc.C200426200	http://dx.doi.org/10.1074/jbc.C200426200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12237287	hybrid			2022-12-25	WOS:000179081200001
J	Krempler, A; Henry, MD; Triplett, AA; Wagner, KU				Krempler, A; Henry, MD; Triplett, AA; Wagner, KU			Targeted deletion of the Tsg101 gene results in cell cycle arrest at G(1)/S and p53-independent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; EMBRYONIC LETHALITY; TUMOR-SUPPRESSOR; A GENE; PROTEIN; P53; CHROMOSOME-11; ABNORMALITIES; EXPRESSION	The tumor susceptibility gene 101 (Tsg101) was originally discovered in a screen for potential tumor suppressors using insertional mutagenesis in immortalized fibroblasts. To investigate essential functions of this gene in cell growth and neoplastic transformation, we derived primary mouse embryonic fibroblasts from Tsg101 conditional knockout mice. Expression of Cre recombinase from a retroviral vector efficiently down-regulated Tsg101. The deletion of Tsg101 caused growth arrest and cell death but did not result in increased proliferation and cellular transformation. Inactivation of p53 had no influence on the deleterious phenotype, but Tsg101(-/-) cells were rescued through expression of exogenous Tsg101. Fluorescence-activated cell sorting, proliferation assays, and Western blot analysis of crucial regulators of the cell cycle revealed that Tsg101 deficiency resulted in growth arrest at the G(1)/S transition through inactivation of cyclin-dependent kinase 2. As a consequence, DNA replication was not initiated in Tsg101-deficient cells. Our results clearly demonstrate that Tsg101 is not a primary tumor suppressor in mouse embryonic fibroblasts. However, the protein is crucial for cell proliferation and cell survival.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Wagner, KU (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr,Rm 8009, Omaha, NE 68198 USA.		Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	NATIONAL CANCER INSTITUTE [R01CA093797] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA93797, R01 CA093797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; DEOCALUNA R, 1995, NATURE, V0378; EL DW, 1993, CELL, V75, P817; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feng GH, 2000, CANCER RES, V60, P1736; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Oh H, 2002, P NATL ACAD SCI USA, V99, P5430, DOI 10.1073/pnas.082123999; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; Ponting CP, 1997, J MOL MED-JMM, V75, P467; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; VANDELOOSDRECHT AA, 1994, J IMMUNOL METHODS, V174, P311, DOI 10.1016/0022-1759(94)90034-5; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wagner KU, 1998, ONCOGENE, V17, P2761, DOI 10.1038/sj.onc.1202529; Wang Q, 1998, ONCOGENE, V16, P677, DOI 10.1038/sj.onc.1201563; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; Wu CL, 2001, CANCER RES, V61, P7325; XIANG Y, 1993, NATURE, V366, P701; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhong Q, 1998, CANCER RES, V58, P2699	43	74	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43216	43223		10.1074/jbc.M207662200	http://dx.doi.org/10.1074/jbc.M207662200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12205095	hybrid, Green Accepted			2022-12-25	WOS:000179081200103
J	Mahnke-Zizelman, DK; Sabina, RL				Mahnke-Zizelman, DK; Sabina, RL			N-terminal sequence and distal histidine residues are responsible for pH-regulated cytoplasmic membrane binding of human AMP deaminase isoform E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; PHOSPHATIDATE BILAYERS; RAT; CLONING; EXPRESSION; NEOMYCIN; HEART; GENE; CDNA; PURIFICATION	Mammalian AMP deaminase 3 (AMPD3) enzymes reportedly bind to intracellular membranes, plasma lipid vesicles, and artificial lipid bilayers with associated alterations in enzyme conformation and function. However, proteolytic sensitivity of AMPD polypeptides makes it likely that prior studies were performed with N-truncated enzymes. This study uses erythrocyte ghosts to characterize the reversible cytoplasmic membrane association of human full-sized recombinant isoform E (AMPD3). Membrane-bound isoform E exhibits diminished catalytic activity whereas low micromolar concentrations of the cationic antibiotic, neomycin, disrupt this protein-lipid interaction and relieve catalytic inhibition. The cytoplasmic membrane association of isoform E also displays an inverse correlation with pH in the physiological range. Diethyl pyrocarbonate (DEPC) modification of isoform E nearly abolishes its cytoplasmic membrane binding capacity, and this effect can be reversed by hydroxylamine. Difference spectra reveal that 18 of 29 histidine residues in each isoform E subunit are N-carbethoxylated by DEPC. These combined data demonstrate that protonated imidazole rings of histidine residues mediate a pH-responsive association of isoform E with anionic charges on the surface of the cytoplasmic membrane, possibly phosphatidylinositol 4,5-bisphosphate, a pure noncompetitive inhibitor of the enzyme. Finally, AMPD1 and a series of N-truncated AMPD3 enzymes are used to show that these behaviors are specific to isoform. E and require up to 48 N-terminal amino acids, even though this stretch of sequence contains no histidine residues. The pH-responsive cytosol-membrane partitioning of isoform E may be an important mechanism for branch point regulation of adenylate catabolism.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Sabina, RL (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050902] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-50902] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arbuzova A, 2000, BBA-BIOMEMBRANES, V1464, P35, DOI 10.1016/S0005-2736(99)00243-6; ASHBY B, 1981, J BIOL CHEM, V256, P519; ASKARI A, 1963, SCIENCE, V141, P44, DOI 10.1126/science.141.3575.44; BAUSCHJURKEN MT, 1992, J BIOL CHEM, V267, P22407; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; Chilson OP, 1997, COMP BIOCHEM PHYS B, V116, P371, DOI 10.1016/S0305-0491(96)00270-2; DUDLEY GA, 1985, AM J PHYSIOL, V248, pC43, DOI 10.1152/ajpcell.1985.248.1.C43; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; Hohl AM, 1999, MOL CELL BIOCHEM, V201, P151, DOI 10.1023/A:1007083000564; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; Knecht K, 2001, J NEUROSCI RES, V66, P941, DOI 10.1002/jnr.10059; KOCHAN Z, 1994, J MOL CELL CARDIOL, V26, P1497, DOI 10.1006/jmcc.1994.1168; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Mahnke-Zizelman DK, 2001, BIOCHEM BIOPH RES CO, V285, P489, DOI 10.1006/bbrc.2001.5180; Mahnke-Zizelman DK, 1998, J BIOL CHEM, V273, P35118, DOI 10.1074/jbc.273.52.35118; MahnkeZizelman DK, 1996, BBA-GENE STRUCT EXPR, V1306, P75, DOI 10.1016/0167-4781(95)00231-6; MahnkeZizelman DK, 1996, BBA-GENE STRUCT EXPR, V1308, P122, DOI 10.1016/0167-4781(96)00089-9; MahnkeZizelman DK, 1997, BIOCHEM J, V326, P521, DOI 10.1042/bj3260521; MAHNKEZIZELMAN DK, 1992, J BIOL CHEM, V267, P20866; MARQUETANT R, 1989, BIOCHEMISTRY-US, V28, P8744, DOI 10.1021/bi00448a010; MEGHJI P, 1988, BIOCHEM J, V249, P695, DOI 10.1042/bj2490695; MINEO I, 1990, MOL CELL BIOL, V10, P5271, DOI 10.1128/MCB.10.10.5271; MORISAKI T, 1990, J BIOL CHEM, V265, P11482; Norman B, 2001, J APPL PHYSIOL, V91, P258, DOI 10.1152/jappl.2001.91.1.258; OGASAWARA N, 1982, BIOCHIM BIOPHYS ACTA, V714, P298; OVADI J, 1967, Acta Biochimica et Biophysica Academiae Scientiarum Hungaricae, V2, P455; PIPOLY GM, 1979, J CLIN INVEST, V63, P1066, DOI 10.1172/JCI109376; PRENTKI M, 1986, FEBS LETT, V197, P285, DOI 10.1016/0014-5793(86)80343-X; RANIERIRAGGI M, 1980, BIOCHEM J, V189, P367, DOI 10.1042/bj1890367; RUNDELL KW, 1992, AM J PHYSIOL, V263, pC287, DOI 10.1152/ajpcell.1992.263.2.C287; RUNDELL KW, 1992, AM J PHYSIOL, V263, pC294, DOI 10.1152/ajpcell.1992.263.2.C294; SABINA RL, 1984, J CLIN INVEST, V73, P720, DOI 10.1172/JCI111265; SABINA RL, 1992, NEUROLOGY, V42, P170, DOI 10.1212/WNL.42.1.170; SABINA RL, 1990, J BIOL CHEM, V265, P9423; SABINA RL, 1987, J BIOL CHEM, V262, P12397; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHACHT J, 1976, J NEUROCHEM, V27, P1119, DOI 10.1111/j.1471-4159.1976.tb00318.x; SCHACHT J, 1978, J LIPID RES, V19, P1063; Sermsuvitayawong K, 1997, MAMM GENOME, V8, P767, DOI 10.1007/s003359900562; Sims B, 1999, J BIOL CHEM, V274, P25701, DOI 10.1074/jbc.274.36.25701; SINKELER SPT, 1987, CLIN SCI, V72, P475, DOI 10.1042/cs0720475; STANKIEWICZ A, 1981, INT J BIOCHEM, V13, P1177, DOI 10.1016/0020-711X(81)90211-1; Steck T L, 1974, Methods Enzymol, V31, P172; SWAIN JL, 1982, AM J PHYSIOL, V242, P818; Tanfani F, 1998, MOL GENET METAB, V65, P51, DOI 10.1006/mgme.1998.2740; TANFANI F, 1993, BIOCHEM J, V291, P921, DOI 10.1042/bj2910921; TAVENIER M, 1995, BBA-GEN SUBJECTS, V1244, P351, DOI 10.1016/0304-4165(95)98595-C; VANDENBERGH F, 1995, BIOCHEM J, V312, P401, DOI 10.1042/bj3120401; VONKUPPEVELT TH, 1994, J HISTOCHEM CYTOCHEM, V42, P861; WOZNIAK M, 1988, BIOCHEM J, V255, P977; YAMADA Y, 1992, BIOCHIM BIOPHYS ACTA, V1171, P125, DOI 10.1016/0167-4781(92)90153-Q; YUN SL, 1978, J BIOL CHEM, V253, P404	54	8	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42654	42662		10.1074/jbc.M203473200	http://dx.doi.org/10.1074/jbc.M203473200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12213808	hybrid			2022-12-25	WOS:000179081200030
J	Seo, JH; Rah, JC; Choi, SH; Shin, JK; Min, K; Kim, HS; Park, CH; Kim, S; Kim, EM; Lee, SH; Lee, S; Suh, SW; Suh, YH				Seo, JH; Rah, JC; Choi, SH; Shin, JK; Min, K; Kim, HS; Park, CH; Kim, S; Kim, EM; Lee, SH; Lee, S; Suh, SW; Suh, YH			alpha-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway	FASEB JOURNAL			English	Article						cytotoxicity; protection	NERVE-CELL INCLUSIONS; PHOSPHATIDYLINOSITOL 3-KINASE; NACP/ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; PROTEIN-KINASE; CYTOCHROME-C; MICE; COMPONENT; RELEASE; DISPLAY	alpha-Synuclein (alpha-SN) is a ubiquitous protein that is especially abundant in the brain and has been postulated to play a central role in the pathogenesis of Parkinson's disease, Alzheimer's disease, and other neurodegenerative disorders. However, little is known about the neuronal functions of alpha-SN and the molecular and cellular mechanisms underlying neuronal loss. Here, we show that alpha-SN plays dual roles of neuroprotection and neurotoxicity depending on its concentration or level of expression. At nanomolar concentrations, alpha-SN protected neurons against serum deprivation, oxidative stress, and excitotoxicity through the PI3/Akt signaling pathway, and its protective effect was increased by Bcl-2 overexpression. Conversely, at both low micromolar and overexpressed levels in the cell, alpha-SN resulted in cytotoxicity. This might be related to decreased Bcl-xL expression and increased bax expression, which is subsequently followed by cytochrome c release and caspase activation and also by microglia-mediated inflammatory responses via the NFkappaB and mitogen-activated protein kinase pathways.	Seoul Natl Univ, Coll Med, Natl Creat Res Initiat Ctr Alzheimers Dementia, Dept Pharmacol, Seoul 110799, South Korea; Seoul Natl Univ, MRC, Neurosci Res Inst, Seoul 110799, South Korea; Seoul Natl Univ, Boramae Hosp, Coll Med, Dept Neurosurg, Seoul 156707, South Korea; Seoul Natl Univ, Sch Chem & Mol Engn, Lab Struct Proteom, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU)	Suh, YH (corresponding author), Seoul Natl Univ, Coll Med, Natl Creat Res Initiat Ctr Alzheimers Dementia, Dept Pharmacol, Seoul 110799, South Korea.	yhsuh@plaza.snu.ac.kr	Suh, Yoo-Hun/J-2761-2012; Kim, Hye Sun/J-2752-2012; Suh, Won/H-8306-2013	Suh, Won/0000-0002-1768-4635; Rah, Jong-Cheol/0000-0003-3780-0522				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Borghi R, 2000, NEUROSCI LETT, V287, P65, DOI 10.1016/S0304-3940(00)01153-8; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Goedert M, 1998, MOL PSYCHIATR, V3, P462, DOI 10.1038/sj.mp.4000458; Goedert M, 1999, PHILOS T ROY SOC B, V354, P1101, DOI 10.1098/rstb.1999.0466; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Goedert M, 1998, BIOCHEM SOC T, V26, P463, DOI 10.1042/bst0260463; Golbe LI, 1999, MOVEMENT DISORD, V14, P6, DOI 10.1002/1531-8257(199901)14:1<6::AID-MDS1004>3.0.CO;2-L; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Iwai A, 2000, BBA-MOL BASIS DIS, V1502, P95, DOI 10.1016/S0925-4439(00)00036-3; Kakimura J, 2001, EUR J PHARMACOL, V417, P59, DOI 10.1016/S0014-2999(01)00902-5; Kholodilov NG, 1999, J NEUROCHEM, V73, P2586, DOI 10.1046/j.1471-4159.1999.0732586.x; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; Mizuno Y, 1998, ANN NEUROL, V44, pS99, DOI 10.1002/ana.410440715; Nunez G, 1998, CURR OPIN NEUROBIOL, V8, P613, DOI 10.1016/S0959-4388(98)80089-5; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Przedborski S, 2001, J NEUROCHEM, V76, P637, DOI 10.1046/j.1471-4159.2001.00174.x; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Stefanis L, 2001, J NEUROCHEM, V76, P1165, DOI 10.1046/j.1471-4159.2001.00114.x; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Takeda A, 1998, LAB INVEST, V78, P1169; Takeda A, 1998, AM J PATHOL, V152, P367; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Yang FS, 2000, BRAIN RES, V853, P381, DOI 10.1016/S0006-8993(99)02207-6; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0	40	183	194	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1826	+		10.1096/fj.02-0041fje	http://dx.doi.org/10.1096/fj.02-0041fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223445				2022-12-25	WOS:000181189100007
J	Hicks, AER; Leppanen, A; Cummings, RD; McEver, RP; Hellewell, PG; Norman, KE				Hicks, AER; Leppanen, A; Cummings, RD; McEver, RP; Hellewell, PG; Norman, KE			Glycosulfopeptides modeled on P-selectin glycoprotein ligand-1 inhibit P-selectin-dependent leukocyte rolling in vivo	FASEB JOURNAL			English	Article						intravital microscopy; inflammation; adhesion molecules; microcirculation; venules	IN-VIVO; SIALYL LEWIS(X); ADHESION MOLECULE-1; CARBOHYDRATE LIGAND; CELL-ADHESION; BINDING; PSGL-1; OLIGOSACCHARIDE; VENULES; ELAM-1	Leukocytic inflammation can be limited by inhibiting selectin-dependent leukocyte rolling. In spite of intensive efforts to develop small molecule selectin inhibitors with defined structure-activity profiles, inhibition of P-selectin-dependent leukocyte rolling in vivo by such a compound has yet to be described. We recently reported that glycosulfopeptides (GSP), modeled on the high affinity selectin ligand PSGL-1, inhibit leukocyte binding to P-selectin in vitro. Here, we have used intravital microscopy to investigate whether GSP can inhibit P-selectin-dependent leukocyte rolling in vivo. Surgical preparation of the mouse cremaster muscle for intravital microscopy induced P-selectin-dependent leukocyte rolling. Baseline rolling was recorded for 1 min followed by i.v. injection of GSP. 2-GSP-6 and 4-GSP-6 substantially reversed P-selectin-dependent leukocyte rolling, whereas control GSP, which are not fully glycosylated, did not. Inhibition of leukocyte rolling by 2- and 4-GSP-6 lasted 2-4 min. Clearance studies with I-125-labeled 4-GSP-6 demonstrated rapid reduction in its circulating levels concurrent with accumulation in urine. These data represent the first demonstration that a precisely defined structure based on a natural P-selectin ligand can inhibit P-selectin-dependent leukocyte rolling in vivo.	Univ Sheffield, Div Clin Sci N, Cardiovasc Res Grp, Sheffield, S Yorkshire, England; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	University of Sheffield; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation	Norman, KE (corresponding author), No Gen Hosp, Ctr Clin Sci, Cardiovasc Res Grp, Sheffield S5 7AU, S Yorkshire, England.	k.norman@shef.ac.uk						Baran KW, 2001, CIRCULATION, V104, P2778, DOI 10.1161/hc4801.100236; BERG EL, 1991, J BIOL CHEM, V266, P14869; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; CUMMINGS RD, 1999, ESSENTIALS GLYCOBIOL, P391; Eguchi H, 1999, CIRC RES, V84, P525, DOI 10.1161/01.RES.84.5.525; Eriksson EE, 2001, FASEB J, V15, P1149, DOI 10.1096/fj.00-0537com; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Goetz DJ, 1997, J CELL BIOL, V137, P509, DOI 10.1083/jcb.137.2.509; GRANERT C, 1994, J CLIN INVEST, V93, P929, DOI 10.1172/JCI117098; Hartwell DM, 1998, J CELL BIOL, V143, P1129, DOI 10.1083/jcb.143.4.1129; Hicks AE, 2001, FASEB J, V15, pA1183; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; Johnson RC, 1997, J CLIN INVEST, V99, P1037, DOI 10.1172/JCI119231; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KANWAR S, 1995, CIRC RES, V77, P879, DOI 10.1161/01.RES.77.5.879; Khor SP, 2000, J PHARMACOL EXP THER, V293, P618; Kim MK, 1998, AM J RESP CELL MOL, V19, P836, DOI 10.1165/ajrcmb.19.5.3032; Kunkel EJ, 1996, J EXP MED, V183, P57, DOI 10.1084/jem.183.1.57; Lefer DJ, 2000, ANNU REV PHARMACOL, V40, P283, DOI 10.1146/annurev.pharmtox.40.1.283; LEFER DJ, 1994, CIRCULATION, V90, P2390, DOI 10.1161/01.CIR.90.5.2390; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; LEY K, 1993, BLOOD, V81, P177; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; LEY K, 1991, J PHYSL, V260, pH1667; LINDBOM L, 1992, ACTA PHYSIOL SCAND, V146, P415, DOI 10.1111/j.1748-1716.1992.tb09442.x; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; Murohara T, 1995, CARDIOVASC RES, V30, P965, DOI 10.1016/S0008-6363(95)00157-3; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; Norman KE, 1998, BLOOD, V91, P475, DOI 10.1182/blood.V91.2.475.475_475_483; Norman KE, 2000, BLOOD, V96, P3585; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Salmela K, 1999, TRANSPLANTATION, V67, P729, DOI 10.1097/00007890-199903150-00015; Sherman DG, 2001, NEUROLOGY, V57, P1428, DOI 10.1212/wnl.57.8.1428; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Sperandio M, 2001, BLOOD, V97, P3812, DOI 10.1182/blood.V97.12.3812; Yang J, 1999, THROMB HAEMOSTASIS, V81, P1; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557; Zimmerman GA, 2001, P NATL ACAD SCI USA, V98, P10023, DOI 10.1073/pnas.191367898	47	18	22	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1461	+		10.1096/fj.02-0075fje	http://dx.doi.org/10.1096/fj.02-0075fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205048				2022-12-25	WOS:000177813100014
J	Capitani, G; McCarthy, DL; Gut, H; Grutter, MG; Kirsch, JF				Capitani, G; McCarthy, DL; Gut, H; Grutter, MG; Kirsch, JF			Apple 1-aminocyclopropane-1-carboxylate synthase in complex with the inhibitor L-aminoethoxyvinylglycine - Evidence for a ketimine intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MUTANT FORMS; WILD-TYPE; ENZYME; BIOSYNTHESIS; ETHYLENE	The 1.6-Angstrom crystal structure of the covalent ketimine complex of apple 1-aminocyclopropane-1-carboxylate (ACC) synthase with the potent inhibitor L-aminoethoxyvinylglycine (AVG) is described. ACC synthase catalyzes the committed step in the biosynthesis of ethylene, a plant hormone that is responsible for the initiation of fruit ripening and for regulating many other developmental processes. AVG is widely used in plant physiology studies to inhibit the activity of ACC synthase. The structural assignment is supported by the fact that the complex absorbs maximally at 341 nm. These results are not in accord with the recently reported crystal structure of the tomato ACC synthase AVG complex, which claims that the inhibitor only associates noncovalently. The rate constant for the association of AVG with apple ACC synthase was determined by stopped-flow spectrophotometry (2.1 X 10(5) M-1 s(-1)) and by the rate of loss of enzyme activity (1.1 X 10(5) M-1 s(-1)). The dissociation rate constant determined by activity recovery is 2.4 x 10(-6) s(-1). Thus, the calculated K-d value is 10-20 pM.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Zurich; University of California System; University of California Berkeley	Capitani, G (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035393] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35393] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Capitani G, 1999, J MOL BIOL, V294, P745, DOI 10.1006/jmbi.1999.3255; Clausen T, 1997, BIOCHEMISTRY-US, V36, P12633, DOI 10.1021/bi970630m; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Feng L, 2000, BIOCHEMISTRY-US, V39, P2436, DOI 10.1021/bi9922704; Goldberg JM, 1996, BIOCHEMISTRY-US, V35, P5280, DOI 10.1021/bi952138d; Hayward S, 1997, PROTEINS, V27, P425, DOI 10.1002/(SICI)1097-0134(199703)27:3<425::AID-PROT10>3.0.CO;2-N; HOOFT RW, 1997, NATURE, V381, P272; Huai Q, 2001, J BIOL CHEM, V276, P38210; ICEKSON I, 1983, BIOCHEM BIOPH RES CO, V113, P586, DOI 10.1016/0006-291X(83)91766-7; JONES SA, 1995, J AM SOC NEPHROL, V5, P1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Krupka HI, 2000, EMBO J, V19, P3168, DOI 10.1093/emboj/19.13.3168; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li YS, 1997, BIOCHEMISTRY-US, V36, P15477, DOI 10.1021/bi971625l; McCarthy DL, 2001, BIOCHEMISTRY-US, V40, P12276, DOI 10.1021/bi011050z; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WHITE MF, 1994, P NATL ACAD SCI USA, V91, P12428, DOI 10.1073/pnas.91.26.12428; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103	22	43	47	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49735	49742		10.1074/jbc.M208427200	http://dx.doi.org/10.1074/jbc.M208427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12228256	hybrid			2022-12-25	WOS:000180028900084
J	Kasparkova, J; Zehnulova, J; Farrell, N; Brabec, V				Kasparkova, J; Zehnulova, J; Farrell, N; Brabec, V			DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464 - Conformation, recognition by high mobility group domain proteins, and nucleotide excision	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CISPLATIN-DAMAGED DNA; DIETHYL PYROCARBONATE; CHEMICAL-REACTIVITY; BBR 3464; PHASE-I; REPAIR; BINDING; HMG1; TRANS-DIAMMINEDICHLOROPLATINUM(II); CIS-DIAMMINEDICHLOROPLATINUM(II)	The novel phase II antitumor polynuclear platinum drug BBR3464 ([(trans-PtCl(NH3)(2))(2)(mu-trans-Pt(NH3)(2)(NH2(CH2)(6)NH2)(2))](NO3)(4)) forms intra- and interstrand cross-links (CLs) on DNA (which is the pharmacological target of platinum drugs). We examined first in our recent work how various intrastrand CLs of BBR3464 affect the conformation of DNA and its recognition by cellular components (Zehnulova, J., Kasparkova, J., Farrell, N., and Brabec, V. (2001) J. Biol. Chem. 276, 22191-22199). In the present work, we have extended the studies on the DNA interstrand CLs of this drug. The results have revealed that the interstrand CLs are preferentially formed between guanine residues separated by 2 base pairs in both the 3' --> 3' and 5' --> 5' directions. The major 1,4-interstrand CLs distort DNA, inducing a directional bending of the helix axis and local unwinding of the duplex. Although such distortions represent a potential structural motif for recognition by high mobility group proteins, these proteins do not recognize 1,4-interstrand CLs of BBR3464. On the other hand, in contrast to intrastrand adducts of BBR3464, 1,4-interstrand CLs are not removed from DNA by nucleotide excision repair. It has been suggested that interstrand CLs of BBR3464 could persist considerably longer in cells compared with intrastrand adducts, which would potentiate the toxicity of the interstrand lesions to tumors sensitive to this polynuclear drug.	Virginia Commonwealth Univ, Dept Chem, Richmond, VA 23284 USA; Acad Sci Czech Republ, Inst Biophys, CZ-61265 Brno, Czech Republic	Virginia Commonwealth University; Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences	Farrell, N (corresponding author), Virginia Commonwealth Univ, Dept Chem, Box 2006, Richmond, VA 23284 USA.	nafrrell@mail1.vcu.edu	Brabec, Viktor/H-1946-2014	Brabec, Viktor/0000-0002-8233-1393				BAILLY C, 1994, BIOCHEM J, V300, P165, DOI 10.1042/bj3000165; BAILLY C, 1997, DRUG DNA INTERACTION, P51; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BRABEC V, 1993, P NATL ACAD SCI USA, V90, P5345, DOI 10.1073/pnas.90.11.5345; BRABEC V, 1993, BIOCHEMISTRY-US, V32, P11676, DOI 10.1021/bi00094a025; Brabec V, 2000, CANC DRUG DISC DEV, V7, P37; Brabec V, 2000, J BIOL INORG CHEM, V5, P364, DOI 10.1007/PL00010665; Brabec V, 1999, BIOCHEMISTRY-US, V38, P6781, DOI 10.1021/bi990124s; BRABEC V, 1992, BIOCHEMISTRY-US, V31, P12397, DOI 10.1021/bi00164a014; Brabec V, 2002, PROG NUCLEIC ACID RE, V71, P1, DOI 10.1016/S0079-6603(02)71040-4; Buschta-Hedayat N, 1999, P NATL ACAD SCI USA, V96, P6090, DOI 10.1073/pnas.96.11.6090; CALVERT AH, 2001, EUR C CLIN ONC OCT 2; Calvert PM, 1999, CLIN CANCER RES, V5, p3796S; Cohen SM, 2000, BIOCHEMISTRY-US, V39, P11771, DOI 10.1021/bi001352l; COMESS KM, 1990, BIOCHEMISTRY-US, V29, P2102, DOI 10.1021/bi00460a020; Coste F, 1999, NUCLEIC ACIDS RES, V27, P1837, DOI 10.1093/nar/27.8.1837; DALBIES R, 1994, P NATL ACAD SCI USA, V91, P8147, DOI 10.1073/pnas.91.17.8147; Farrell N, 2000, CANC DRUG DISC DEV, V7, P321; FARRELL N, 1999, CISPLATIN CHEM BIOCH, P479; He Q, 2000, P NATL ACAD SCI USA, V97, P5768, DOI 10.1073/pnas.100108697; He Q, 2000, BIOCHEMISTRY-US, V39, P14426, DOI 10.1021/bi001700j; Hermanson-Miller IL, 2002, BIOCHEMISTRY-US, V41, P2402, DOI 10.1021/bi0112863; HERR W, 1985, P NATL ACAD SCI USA, V82, P8009, DOI 10.1073/pnas.82.23.8009; HUANG HF, 1995, SCIENCE, V270, P1842, DOI 10.1126/science.270.5243.1842; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; JONES SL, 1994, INT J CANCER, V59, P388, DOI 10.1002/ijc.2910590317; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7; KASPARKOVA J, 1995, BIOCHEMISTRY-US, V34, P12379, DOI 10.1021/bi00038a035; Kasparkova J, 1996, BIOCHEMISTRY-US, V35, P16705, DOI 10.1021/bi961160j; Kasparkova J, 1999, BIOCHEMISTRY-US, V38, P10997, DOI 10.1021/bi990245s; Kasparkova J, 2000, J BIOL CHEM, V275, P15789, DOI 10.1074/jbc.M000777200; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; LEMAIRE MA, 1991, P NATL ACAD SCI USA, V88, P1982, DOI 10.1073/pnas.88.5.1982; LENG M, 1990, BIOPHYS CHEM, V35, P155, DOI 10.1016/0301-4622(90)80005-R; Li MJ, 1999, INT J ONCOL, V15, P1177; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MALINGE JM, 1994, NUCLEIC ACIDS RES, V22, P3834, DOI 10.1093/nar/22.19.3834; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Manzotti C, 2000, CLIN CANCER RES, V6, P2626; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MCCARTHY JG, 1991, NUCLEIC ACIDS RES, V19, P3421, DOI 10.1093/nar/19.12.3421; MCCARTHY JG, 1990, BIOCHEMISTRY-US, V29, P6071, DOI 10.1021/bi00477a027; Missura M, 2001, EMBO J, V20, P3554, DOI 10.1093/emboj/20.13.3554; Moggs JG, 1997, NUCLEIC ACIDS RES, V25, P480, DOI 10.1093/nar/25.3.480; Naegeli H., 1997, MECH DNA DAMAGE RECO; Nielsen P E, 1990, J Mol Recognit, V3, P1, DOI 10.1002/jmr.300030102; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Patrick SM, 1999, J BIOL CHEM, V274, P14972, DOI 10.1074/jbc.274.21.14972; Perego P, 1999, J INORG BIOCHEM, V77, P59, DOI 10.1016/S0162-0134(99)00142-7; QU Y, 2002, IN PRESS J BIOL INOR; Reardon JT, 1999, CANCER RES, V59, P3968; REARDON JT, 1998, ADV DNA DAMAGE REPAI, P377; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; Roberts JD, 1999, J INORG BIOCHEM, V77, P51, DOI 10.1016/S0162-0134(99)00147-6; Ross SA, 1996, NUCLEIC ACIDS RES, V24, P5062, DOI 10.1093/nar/24.24.5062; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCAGLIOTTI G, 2001, EUR C CLIN ONC OCT 2; Sessa C, 2000, ANN ONCOL, V11, P977, DOI 10.1023/A:1008302309734; Stros M, 1998, J BIOL CHEM, V273, P10355; Stros M, 2001, BIOCHEMISTRY-US, V40, P4769, DOI 10.1021/bi002741i; Vrana O, 1996, NUCLEIC ACIDS RES, V24, P3918, DOI 10.1093/nar/24.20.3918; Wakasugi M, 1999, J BIOL CHEM, V274, P18759, DOI 10.1074/jbc.274.26.18759; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; WEMER MH, 1995, CELL, V81, P705; Wood RD, 2000, COLD SPRING HARB SYM, V65, P173, DOI 10.1101/sqb.2000.65.173; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; ZAMBLE DB, 1999, CISPLATIN CHEM BIOCH, P73; Zehnulova J, 2001, J BIOL CHEM, V276, P22191, DOI 10.1074/jbc.M103118200; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791	76	153	153	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48076	48086		10.1074/jbc.M208016200	http://dx.doi.org/10.1074/jbc.M208016200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12226099	hybrid			2022-12-25	WOS:000179789600015
J	Kim, JS; Krasieva, TB; LaMorte, V; Taylor, AMR; Yokomori, K				Kim, JS; Krasieva, TB; LaMorte, V; Taylor, AMR; Yokomori, K			Specific recruitment of human cohesin to laser-induced DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; SISTER-CHROMATID COHESION; HUMAN CONDENSIN COMPLEX; CHROMOSOME CONDENSATION; ATAXIA-TELANGIECTASIA; MRE11 COMPLEX; REPAIR; PROTEIN; CELL; DISRUPTION	Cohesin is a conserved multiprotein complex that plays an essential role in sister chromatid cohesion. During interphase, cohesin is required for the establishment of cohesion following DNA replication. Because cohesin mutants resulted in increased sensitivity to DNA damage, a role for cohesin in DNA repair was also suggested. However, it was unclear whether this was due to general perturbation of cohesion or whether cohesin has a specialized role at the damage site. We therefore used a laser microbeam to create DNA damage at discrete sites in the cell nucleus and observed specific in vivo assembly of proteins at these sites by immunofluorescent detection. We observed that human cohesin is recruited to the damage site immediately after damage induction. Analysis of mutant cells revealed that cohesin recruitment to the damage site is dependent on the DNA double-strand break repair factor Mre11/Rad50 but not ATM or Nbs1. Consistently, Mre11/Rad50 and cohesin interact with each other in an interphase-specific manner. This interaction peaks in S/G(2) phase, during which cohesin is recruited to the DNA damage. Our results demonstrate the S/G(2)-specific and Mre11/Rad50-dependent recruitment of human cohesin to DNA damage, suggesting a specialized subfunction for cohesin in cell cycle-specific DNA double strand break repair.	Univ Calif Irvine, Dept Biol Chem, Coll Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Surg, Laser Microbeam & Med Program, Beckman Laser Inst, Irvine, CA 92612 USA; Univ Birmingham, Canc Res Campaign, Inst Canc Studies, Sch Med, Birmingham B15 2TT, W Midlands, England	University of California System; University of California Irvine; University of California System; University of California Irvine; University of Birmingham	Yokomori, K (corresponding author), Univ Calif Irvine, Dept Biol Chem, Coll Med, 240D Med Sci 1, Irvine, CA 92697 USA.				NCI NIH HHS [CA-62203] Funding Source: Medline; NCRR NIH HHS [RR01192] Funding Source: Medline; NIGMS NIH HHS [GM59150] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA062203] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001192] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059150] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aono N, 2002, NATURE, V417, P197, DOI 10.1038/417197a; Berns MW, 1998, METHOD CELL BIOL, V55, P71; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Gregson HC, 2001, J BIOL CHEM, V276, P47575, DOI 10.1074/jbc.M103364200; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Krasieva TB, 1998, P SOC PHOTO-OPT INS, V3260, P38, DOI 10.1117/12.307113; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Losada A, 2001, CURR BIOL, V11, P268, DOI 10.1016/S0960-9822(01)00066-5; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Schmiesing JA, 2000, MOL CELL BIOL, V20, P6996, DOI 10.1128/MCB.20.18.6996-7006.2000; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Venugopalan V, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.078103; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	37	195	198	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45149	45153		10.1074/jbc.M209123200	http://dx.doi.org/10.1074/jbc.M209123200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228239	hybrid			2022-12-25	WOS:000179404800072
J	Lerch-Gaggl, A; Haque, J; Li, JX; Ning, G; Traktman, P; Duncan, SA				Lerch-Gaggl, A; Haque, J; Li, JX; Ning, G; Traktman, P; Duncan, SA			Pescadillo is essential for nucleolar assembly, ribosome biogenesis, and mammalian cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN B23; CHROMOSOME PERIPHERY; LIVER-REGENERATION; HEPATOCYTE ENTRY; MOUSE EMBRYOS; RNA; MITOSIS; LOCALIZATION; ASSOCIATION; IDENTIFICATION	Mutation of the zebrafish pescadillo gene blocks expansion of a number of tissues in the developing embryo, suggesting roles for its gene product in controlling cell proliferation. We report that levels of the pescadillo protein increase in rodent hepatocytes as they enter the cell cycle. Pescadillo protein localizes to distinct substructures of the interphase nucleus including nucleoli, the site of ribosome biogenesis. During mitosis pescadillo closely associates with the periphery of metaphase chromosomes and by late anaphase is associated with nucleolus-derived foci and prenucleolar bodies. Blastomeres in mouse embryos lacking pescadillo arrest at morula stages of development, the nucleoli fail to differentiate and accumulation of ribosomes is inhibited. We propose that in mammalian cells pescadillo is essential for ribosome biogenesis and nucleologenesis and that disruption to its function results in cell cycle arrest.	Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Duncan, SA (corresponding author), Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA.	duncans@mcw.edu		Traktman, Paula/0000-0002-6517-0225; Duncan, Stephen/0000-0002-2507-7827	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055743, R01DK060064] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55743, DK60064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CC, 2002, RNA, V8, P150, DOI 10.1017/S1355838202010026; Allende ML, 1996, GENE DEV, V10, P3141, DOI 10.1101/gad.10.24.3141; Anderson MT, 2001, CALC VAR PARTIAL DIF, V12, P1, DOI 10.1007/s005260000043; BARAN V, 1995, MOL REPROD DEV, V40, P305, DOI 10.1002/mrd.1080400306; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; BOND VC, 1993, MOL CELL BIOL, V13, P3221, DOI 10.1128/MCB.13.6.3221; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; DELATORRE C, 1975, NATURE, V256, P503, DOI 10.1038/256503a0; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Dundr M, 2000, J CELL BIOL, V150, P433, DOI 10.1083/jcb.150.3.433; Dundr M, 1998, MOL BIOL CELL, V9, P2407, DOI 10.1091/mbc.9.9.2407; Dundr M, 1997, CHROMOSOMA, V105, P407, DOI 10.1007/BF02510477; FANG GW, 1995, J CELL BIOL, V130, P243, DOI 10.1083/jcb.130.2.243; Gaiano N, 1996, P NATL ACAD SCI USA, V93, P7777, DOI 10.1073/pnas.93.15.7777; Ganot P, 1999, MOL CELL BIOL, V19, P6906; GAUTIER T, 1992, EXP CELL RES, V200, P5, DOI 10.1016/S0014-4827(05)80065-5; GAUTIER T, 1994, BIOL CELL, V82, P81, DOI 10.1016/S0248-4900(94)80010-3; GEUSKENS M, 1984, CELL DIFFER DEV, V14, P125, DOI 10.1016/0045-6039(84)90037-X; Haque J, 2000, GENOMICS, V70, P201, DOI 10.1006/geno.2000.6375; HERNANDEZVERDUN D, 1994, BIOESSAYS, V16, P179, DOI 10.1002/bies.950160308; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Higgins GM, 1931, ARCH PATHOL, V12, P186; HILLMAN N, 1969, AM J ANAT, V126, P151, DOI 10.1002/aja.1001260203; Hyttel P, 2000, BIOL REPROD, V63, P1848, DOI 10.1095/biolreprod63.6.1848; Jacobson MR, 1998, P NATL ACAD SCI USA, V95, P7981, DOI 10.1073/pnas.95.14.7981; KINOSHITA Y, 2000, J BIOL CHEM; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KOPECNY V, 1989, Molecular Reproduction and Development, V1, P79; Laurincik J, 2000, BIOL REPROD, V62, P1024, DOI 10.1095/biolreprod62.4.1024; Leary DJ, 2001, FEBS LETT, V509, P145, DOI 10.1016/S0014-5793(01)03143-X; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Oeffinger M, 2002, RNA, V8, P626, DOI 10.1017/S1355838202020022; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pestov DG, 1998, ONCOGENE, V17, P3187, DOI 10.1038/sj.onc.1202260; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; PIKO L, 1982, DEV BIOL, V89, P362, DOI 10.1016/0012-1606(82)90325-6; Pinol-Roma S, 1999, MOL BIOL CELL, V10, P77, DOI 10.1091/mbc.10.1.77; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Sund NJ, 2000, MOL CELL BIOL, V20, P5175, DOI 10.1128/MCB.20.14.5175-5183.2000; Szebeni A, 1999, PROTEIN SCI, V8, P905; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Weglarz TC, 2000, P NATL ACAD SCI USA, V97, P12595, DOI 10.1073/pnas.220430497; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Ye HG, 1999, MOL CELL BIOL, V19, P8570	52	90	101	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45347	45355		10.1074/jbc.M208338200	http://dx.doi.org/10.1074/jbc.M208338200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237316	hybrid			2022-12-25	WOS:000179404800097
J	Arnt, CR; Chiorean, MV; Heldebrant, MV; Gores, GJ; Kaufmann, SH				Arnt, CR; Chiorean, MV; Heldebrant, MV; Gores, GJ; Kaufmann, SH			Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS INHIBITORY PROTEIN; CELL-DEATH; STRUCTURAL BASIS; BACULOVIRAL-INHIBITOR; ACTIVE CASPASES; CYTOCHROME-C; LINKED IAP; FAMILY; GENE; DROSOPHILA	Inhibitor of apoptosis proteins (IAPs) interact with and inhibit caspases-3, -7, and -9. This interaction can be inhibited by Smac/DIABLO, a polypeptide released from mitochondria upon initiation of the apoptotic signaling process. Here we demonstrate that the first 4-8 N-terminal amino acids of Smac/DIABLO fused to the Drosophila antennapaedia penetratin sequence, a carrier peptide, enhance the induction of apoptosis and long term antiproliferative effects of diverse antineoplastic agents including paclitaxel, etoposide, 7-ethyl-10-hydroxycamptothecin (SN-38), and doxorubicin in MCF-7 breast cancer cells. Similar effects were observed in additional breast cancer and immortalized cholangiocyte cell lines. Further analysis demonstrated that the Smac-penetratin fusion peptide crossed the cellular membrane, bound XIAP and cIAP1, displaced caspase-3 from cytoplasmic aggregates, and enhanced drug-induced caspase action in situ. These studies demonstrate that inhibition of LAP proteins can modulate the efficacy of antineoplastic agents.	Mayo Clin & Mayo Fdn, Div Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, GI Basic Res Ctr, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55901 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Kaufmann, SH (corresponding author), Mayo Clin & Mayo Fdn, Div Oncol Res, 200 1st St SW,Guggenheim 1342C,200 1st St SW, Rochester, MN 55905 USA.	Kaufmann.scott@mayo.edu	Chiorean, Michael/AAZ-5305-2021	Kaufmann, Scott/0000-0002-4900-7145	NCI NIH HHS [CA73709, R01 CA069008, R01 CA69008] Funding Source: Medline; NIDDK NIH HHS [DK41876] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Asselin E, 2001, CANCER RES, V61, P1862; Bangs P, 2000, CELL DEATH DIFFER, V7, P1027, DOI 10.1038/sj.cdd.4400754; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Christich A, 2002, CURR BIOL, V12, P137, DOI 10.1016/S0960-9822(01)00658-3; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Huang HK, 2000, J BIOL CHEM, V275, P26661; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; KAUFMANN SH, 1991, CANCER RES, V51, P3534; Kaufmann SH, 2001, ANAL BIOCHEM, V296, P283, DOI 10.1006/abio.2001.5313; KAUFMANN SH, 1989, J BIOL CHEM, V264, P13946; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; Mano Y, 1998, LAB INVEST, V78, P1467; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Nicholson DW, 2001, NATURE, V410, P33, DOI 10.1038/35065201; Notarbartolo M, 2002, CANCER LETT, V180, P91, DOI 10.1016/S0304-3835(01)00834-5; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Silke J, 2002, J CELL BIOL, V157, P115, DOI 10.1083/jcb.200108085; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Song ZW, 2000, MOL CELL BIOL, V20, P2907, DOI 10.1128/MCB.20.8.2907-2914.2000; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 2002, CURR BIOL, V12, P125, DOI 10.1016/S0960-9822(01)00657-1; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; van den Hoff M J, 1995, Methods Mol Biol, V48, P185; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Wing JP, 2002, CURR BIOL, V12, P131, DOI 10.1016/S0960-9822(01)00664-9; Wright CW, 2002, J BIOL CHEM, V277, P2454, DOI 10.1074/jbc.M110500200; Wyllie A H, 1980, Int Rev Cytol, V68, P251	74	231	268	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44236	44243		10.1074/jbc.M207578200	http://dx.doi.org/10.1074/jbc.M207578200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12218061	hybrid			2022-12-25	WOS:000179272000092
J	Berthold, DA; Voevodskaya, N; Stenmark, P; Graslund, A; Nordlund, P				Berthold, DA; Voevodskaya, N; Stenmark, P; Graslund, A; Nordlund, P			EPR studies of the mitochondrial alternative oxidase - Evidence for a diiron carboxylate center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOSINUS-TRICHOSPORIUM OB3B; CYANIDE-RESISTANT RESPIRATION; SITE-DIRECTED MUTAGENESIS; HIGHER PLANT-MITOCHONDRIA; HERPES-SIMPLEX-VIRUS; NONHEME IRON PROTEIN; METHANE MONOOXYGENASE; PARTIAL-PURIFICATION; ACTIVE-SITE; RIBONUCLEOTIDE REDUCTASE	The alternative oxidase (AOX) is a ubiquinol oxidase found in the mitochondrial respiratory chain of plants as well as some fungi and protists. It has been predicted to contain a coupled diiron center on the basis of a conserved sequence motif consisting of the proposed iron ligands, four glutamate and two histidine residues. However, this prediction has not been experimentally verified. Here we report the high level expression of the Arabidopsis thaliana alternative oxidase AOX1a as a maltose-binding protein fusion in Escherichia coli. Reduction and reoxidation of a sample of isolated E. coli membranes containing the alternative oxidase generated an EPR signal characteristic of a mixed-valent Fe(II)/Fe(III) binuclear iron center. The high anisotropy of the signal, the low value of the g-average tensor, and a small exchange coupling (-J) suggest that the iron center is hydroxo-bridged. A reduced membrane preparation yielded a parallel mode EPR signal with a g-value of about 15. In AOX containing a mutation of a putative glutamate ligand of the diiron center (E222A or E273A) the EPR signals are absent. These data provide evidence for an antiferromagnetic-coupled binuclear iron center, and together with the conserved sequence motif, identify the alternative oxidase as belonging to the growing family of diiron carboxylate proteins. The alternative oxidase is the first integral membrane protein in this family, and adds a new catalytic activity (ubiquinol oxidation) to this group of enzymatically diverse proteins.	Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden	Stockholm University	Berthold, DA (corresponding author), Stockholm Univ, Dept Biochem & Biophys, Svante Arrhenius Vag 12, S-10691 Stockholm, Sweden.	berthold@dbb.su.se		Stenmark, Pal/0000-0003-4777-3417				Ajayi WU, 2002, J BIOL CHEM, V277, P8187, DOI 10.1074/jbc.M111477200; ANDERSSON KK, 1990, ADV INORG CHEM, V43, P359; Andersson ME, 1999, FEBS LETT, V449, P17, DOI 10.1016/S0014-5793(99)00376-2; Atta M, 1996, J BIOL INORG CHEM, V1, P210, DOI 10.1007/s007750050045; ATTA M, 1994, J AM CHEM SOC, V116, P6429, DOI 10.1021/ja00093a051; Berthold DA, 2000, BBA-BIOENERGETICS, V1460, P241, DOI 10.1016/S0005-2728(00)00149-3; BERTHOLD DA, 1993, PLANT PHYSIOL, V101, P113, DOI 10.1104/pp.101.1.113; Berthold DA, 1998, BBA-BIOENERGETICS, V1364, P73, DOI 10.1016/S0005-2728(98)00015-2; BERTHOLD DA, 2002, IN PRESS PROTEIN SCI; BONNER WD, 1986, PLANT PHYSIOL, V80, P838, DOI 10.1104/pp.80.4.838; Carol P, 1999, PLANT CELL, V11, P57, DOI 10.1105/tpc.11.1.57; CHAUDHURI M, 1995, J EUKARYOT MICROBIOL, V42, P467, DOI 10.1111/j.1550-7408.1995.tb05892.x; Davydov RM, 1997, BIOCHEMISTRY-US, V36, P9093, DOI 10.1021/bi9700375; Davydov RM, 1999, J BIOL INORG CHEM, V4, P292, DOI 10.1007/s007750050315; DAY EP, 1988, J BIOL CHEM, V263, P15561; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; Dinant M, 2001, CURR GENET, V39, P101, DOI 10.1007/s002940000183; Djajanegara I, 1999, FEBS LETT, V454, P220, DOI 10.1016/S0014-5793(99)00808-X; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; ELTHON TE, 1989, PLANT PHYSIOL, V89, P1311, DOI 10.1104/pp.89.4.1311; ELTHON TE, 1987, P NATL ACAD SCI USA, V84, P8399, DOI 10.1073/pnas.84.23.8399; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1991, J BIOL CHEM, V266, P540; HENDRICH MP, 1990, J AM CHEM SOC, V112, P5861, DOI 10.1021/ja00171a029; HENRY MF, 1975, SUB-CELL BIOCHEM, V4, P1; Hoefnagel MHN, 1998, ARCH BIOCHEM BIOPHYS, V355, P262, DOI 10.1006/abbi.1998.0737; HUQ S, 1978, FEBS LETT, V95, P217, DOI 10.1016/0014-5793(78)80997-1; KUMAR AM, 1992, P NATL ACAD SCI USA, V89, P10842, DOI 10.1073/pnas.89.22.10842; Maxwell DP, 1999, P NATL ACAD SCI USA, V96, P8271, DOI 10.1073/pnas.96.14.8271; MCCORMICK JM, 1991, J AM CHEM SOC, V113, P9066, DOI 10.1021/ja00024a007; MEEUSE BJD, 1975, ANNU REV PLANT PHYS, V26, P117, DOI 10.1146/annurev.pp.26.060175.001001; MINAGAWA N, 1990, FEBS LETT, V267, P114, DOI 10.1016/0014-5793(90)80302-Y; Moller IM, 2001, ANNU REV PLANT PHYS, V52, P561, DOI 10.1146/annurev.arplant.52.1.561; OHNISHI T, 1976, J BIOL CHEM, V251, P2105; OHNISHI T, 1975, BIOCHIM BIOPHYS ACTA, V387, P475, DOI 10.1016/0005-2728(75)90087-0; OHNISHI T, 1976, J BIOL CHEM, V251, P2094; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RAVI N, 1993, BIOCHEMISTRY-US, V32, P8487, DOI 10.1021/bi00084a013; RHOADS DM, 1991, P NATL ACAD SCI USA, V88, P2122, DOI 10.1073/pnas.88.6.2122; RICH PR, 1978, FEBS LETT, V96, P252, DOI 10.1016/0014-5793(78)80412-8; RICH PR, 1978, BIOCHIM BIOPHYS ACTA, V501, P381, DOI 10.1016/0005-2728(78)90106-8; RICH PR, 1977, BIOCHIM BIOPHYS ACTA, V462, P501, DOI 10.1016/0005-2728(77)90097-4; RICH PR, 1978, BIOCHIM BIOPHYS ACTA, V504, P345, DOI 10.1016/0005-2728(78)90059-2; SCHONBAUM GR, 1971, PLANT PHYSIOL, V47, P124, DOI 10.1104/pp.47.1.124; SIEDOW JN, 1995, FEBS LETT, V362, P10, DOI 10.1016/0014-5793(95)00196-G; Siedow JN, 2000, BBA-BIOENERGETICS, V1459, P432, DOI 10.1016/S0005-2728(00)00181-X; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; Veiga A, 2000, FEMS MICROBIOL LETT, V190, P93, DOI 10.1111/j.1574-6968.2000.tb09268.x; WOODLAND MP, 1986, BIOCHIM BIOPHYS ACTA, V873, P237, DOI 10.1016/0167-4838(86)90050-6; Yang YS, 1997, J AM CHEM SOC, V119, P11832, DOI 10.1021/ja971896j; Yao Z, 1992, PCR Methods Appl, V1, P205; YIM MB, 1982, J MAGN RESON, V46, P247, DOI 10.1016/0022-2364(82)90140-8; Zhang QS, 1996, PHYSIOL PLANTARUM, V96, P551, DOI 10.1111/j.1399-3054.1996.tb00226.x	55	63	70	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43608	43614		10.1074/jbc.M206724200	http://dx.doi.org/10.1074/jbc.M206724200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12215444	hybrid			2022-12-25	WOS:000179272000011
J	Eyles, JL; Metcalf, D; Grusby, MJ; Hilton, DJ; Starr, R				Eyles, JL; Metcalf, D; Grusby, MJ; Hilton, DJ; Starr, R			Negative regulation of interleukin-12 signaling by suppressor of cytokine signaling-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL STIMULATORY FACTOR; INTERFERON-GAMMA-PRODUCTION; MOUSE IL-12 RECEPTOR; NATURAL-KILLER; T-CELLS; IMMUNE-RESPONSES; IFN-GAMMA; NK CELLS; IN-VIVO; TYROSINE PHOSPHORYLATION	Suppressor of cytokine signaling-1 (SOCS-1) is an inhibitory protein that regulates responses to cytokines. Previously, we have shown SOCS-1 to be a key inhibitor of interferon gamma (IFNgamma). Recent data suggest that SOCS-1 may regulate other cytokines in vivo, in addition to IFNgamma. Uncontrolled responses to interleukin-12 (IL-12), an inflammatory cytokine, could contribute to increased IFNgamma production and the development of inflammatory disease in SOCS-1(-/-) mice. Here, we assess responses of SOCS-1-deficient cells to IL-12. Both IL-12-induced T cell proliferation and NK cytotoxic activity are enhanced in SOCS-1-deficient cells, relative to controls. To examine the contribution of continued IL-12 signaling to the SOCS-1(-/-) disease, we generated mice lacking both SOCS-1 and signal transducer and activator of transcription 4 (STAT4), an essential component of the IL-12 signaling pathway. SOCS-1(-/-) STAT4(-/-)mice have improved survival relative to SOCS-1(-/-) mice, but die between 1 and 2 months of age. We conclude that, in addition to IFNgamma, SOCS-1 regulates responses to IL-12.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic 3050, Australia; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Walter & Eliza Hall Institute; Harvard University; Harvard T.H. Chan School of Public Health	Starr, R (corresponding author), Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Melbourne, Vic 3050, Australia.		Hilton, Douglas J/C-7250-2013	Hilton, Douglas J/0000-0002-7698-2392	NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040171, R21AI040171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062135] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22556] Funding Source: Medline; NIAID NIH HHS [AI40171] Funding Source: Medline; NIGMS NIH HHS [GM62135] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; Bullen DVR, 2001, IMMUNOLOGY, V104, P92, DOI 10.1046/j.1365-2567.2001.01294.x; Chakir H, 2000, J IMMUNOL, V165, P4985, DOI 10.4049/jimmunol.165.9.4985; CHAN SH, 1992, J IMMUNOL, V148, P92; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; Chang JT, 1999, J EXP MED, V189, P969, DOI 10.1084/jem.189.6.969; CHUA AO, 1995, J IMMUNOL, V155, P4286; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; Davidson NJ, 1998, J IMMUNOL, V161, P3143; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Ertel W, 1997, BLOOD, V89, P1612, DOI 10.1182/blood.V89.5.1612.1612_1612_1620; GATELY MK, 1991, J IMMUNOL, V147, P874; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Howard M, 1994, GUIDEBOOK CYTOKINES; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Losman JA, 1999, J IMMUNOL, V162, P3770; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; MCKNIGHT AJ, 1994, J IMMUNOL, V152, P2172; MEHROTRA PT, 1993, J IMMUNOL, V151, P2444; Metcalf D, 2000, P NATL ACAD SCI USA, V97, P9174, DOI 10.1073/pnas.160255197; Metcalf D, 2002, P NATL ACAD SCI USA, V99, P943, DOI 10.1073/pnas.022628499; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Parrello T, 2000, J IMMUNOL, V165, P7234, DOI 10.4049/jimmunol.165.12.7234; PERUSSIA B, 1992, J IMMUNOL, V149, P3495; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; ROBERTSON MJ, 1992, J EXP MED, V175, P779, DOI 10.1084/jem.175.3.779; Romani L, 1997, J IMMUNOL, V158, P5349; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; Simpson SJ, 1998, J EXP MED, V187, P1225, DOI 10.1084/jem.187.8.1225; Sporri B, 2001, BLOOD, V97, P221, DOI 10.1182/blood.V97.1.221; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; Takenaka H, 1997, J LEUKOCYTE BIOL, V61, P80, DOI 10.1002/jlb.61.1.80; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Wu CY, 1997, J IMMUNOL, V159, P1658; Zhang JG, 2001, P NATL ACAD SCI USA, V98, P13261, DOI 10.1073/pnas.231486498	50	83	88	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43735	43740		10.1074/jbc.M208586200	http://dx.doi.org/10.1074/jbc.M208586200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221108	hybrid			2022-12-25	WOS:000179272000027
J	Cornet, PB; Picquet, C; Lemoine, P; Osteen, KG; Bruner-Tran, KL; Tabibzadeh, S; Courtoy, PJ; Eeckhout, Y; Marbaix, E; Henriet, P				Cornet, PB; Picquet, C; Lemoine, P; Osteen, KG; Bruner-Tran, KL; Tabibzadeh, S; Courtoy, PJ; Eeckhout, Y; Marbaix, E; Henriet, P			Regulation and function of LEFTY-A/EBAF in the human endometrium mRNA - Expression during the menstrual cycle, control by progesterone, and effect on matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACIDS; FACTOR-BETA SUPERFAMILY; GROWTH-FACTORS; GELATINASE-B; IN-VITRO; COLLAGENASE; BREAKDOWN; RECEPTOR; LEVONORGESTREL; QUANTITATION	The human endometrium is a unique tissue that is periodically shed during menstruation. Although overall triggered by ovarian steroids withdrawal, menstrual induction of matrix metalloproteinases (MMPs) and resulting tissue breakdown are focal responses, pointing to additional local modulators. LEFTY-A, a novel member of the transforming growth factor-beta family identified originally as an endometrial bleeding-associated factor (EBAF), is a candidate for this local control. We measured LEFTY-A and beta-ACTIN mRNA concentration during the menstrual cycle in vivo and found that their ratio was dramatically (similar to100-fold) increased at the perimenstrual phase. A similar increase was seen when proliferative explants were cultured for 24 h in the absence of ovarian steroids; this was followed by spontaneous production of proMMP-1, -3, and -9. Both responses were inhibited by progesterone. Moreover, addition of recombinant LEFTY-A to proliferative explants was sufficient to stimulate the expression of proMMP-3 and -7; this response was also blocked by ovarian steroids. Collectively, these data indicate that LEFTY-A may provide a crucial signal for endometrial breakdown and bleeding by triggering expression of several MMPs. Progesterone appears to exert a dual block, upstream by inhibiting LEFTY-A expression and downstream by suppressing its stimulatory effect on MMPs.	Univ Catholique Louvain, Christian De Duve Inst Cellular Pathol, Cell Biol Unit, B-1200 Brussels, Belgium; Vanderbilt Univ, Sch Med, Dept Obstet Gynecol, Nashville, TN 37232 USA; SUNY Stony Brook, Dept Obstet & Gynecol & Reprod Med, Stony Brook, NY 11794 USA	Universite Catholique Louvain; Vanderbilt University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Marbaix, E (corresponding author), Clin Univ St Luc, Dept Pathol, Ave Hippocrate 10, B-1200 Brussels, Belgium.			Henriet, Patrick/0000-0003-4602-8888	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD037321] Funding Source: NIH RePORTER; NCI NIH HHS [CA8466] Funding Source: Medline; NICHD NIH HHS [U54-HD-37321] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMMALA M, 1995, FERTIL STERIL, V63, P773; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNER KL, 1995, P NATL ACAD SCI USA, V92, P7362, DOI 10.1073/pnas.92.16.7362; Casslen B, 1998, BIOL REPROD, V58, P1343, DOI 10.1095/biolreprod58.6.1343; Chegini N, 1999, AM J REPROD IMMUNOL, V42, P297; Galant C, 2000, J CLIN ENDOCR METAB, V85, P4827, DOI 10.1210/jc.85.12.4827; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GIUDICE LC, 1993, J CLIN ENDOCR METAB, V76, P1115, DOI 10.1210/jc.76.5.1115; HAMPTON AL, 1994, J ENDOCRINOL, V141, pR1, DOI 10.1677/joe.0.141R001; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Henriet P, 2002, ANN NY ACAD SCI, V955, P119, DOI 10.1111/j.1749-6632.2002.tb02773.x; Inoue T, 1996, J CLIN ENDOCR METAB, V81, P1502, DOI 10.1210/jc.81.4.1502; Jeziorska M, 1996, J REPROD FERTIL, V107, P43; KOJIMA K, 1994, BIOL REPROD, V50, P882, DOI 10.1095/biolreprod50.4.882; Kokorine I, 1996, J CELL SCI, V109, P2151; Kosaki K, 1999, AM J HUM GENET, V64, P712, DOI 10.1086/302289; Kothapalli R, 1997, J CLIN INVEST, V99, P2342, DOI 10.1172/JCI119415; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; MARBAIX E, 1992, P NATL ACAD SCI USA, V89, P11789, DOI 10.1073/pnas.89.24.11789; Marbaix E, 1996, P NATL ACAD SCI USA, V93, P9120, DOI 10.1073/pnas.93.17.9120; Marbaix E, 2000, HUM REPROD, V15, P120, DOI 10.1093/humrep/15.suppl_3.120; Mason JM, 2002, J BIOL CHEM, V277, P407, DOI 10.1074/jbc.M108103200; NOYES RW, 1950, FERTIL STERIL, V1, P3, DOI 10.1016/s0015-0282(16)30062-0; Osteen KG, 1999, GYNECOL OBSTET INVES, V48, P2, DOI 10.1159/000052863; OSTEEN KG, 1994, P NATL ACAD SCI USA, V91, P10129, DOI 10.1073/pnas.91.21.10129; Oulad-Abdelghani M, 1998, INT J DEV BIOL, V42, P23; Rigot V, 2001, BIOCHEM J, V358, P275, DOI 10.1042/0264-6021:3580275; RODGERS WH, 1993, AM J OBSTET GYNECOL, V168, P253, DOI 10.1016/S0002-9378(12)90922-9; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; Roy RN, 1999, MOL CELL ENDOCRINOL, V153, P19, DOI 10.1016/S0303-7207(99)00092-1; Rudolph-Owen LA, 1998, BIOL REPROD, V59, P1349, DOI 10.1095/biolreprod59.6.1349; Salamonsen LA, 1999, CLIN EXP PHARMACOL P, V26, P154, DOI 10.1046/j.1440-1681.1999.03012.x; Singer CF, 1997, P NATL ACAD SCI USA, V94, P10341, DOI 10.1073/pnas.94.19.10341; Skinner JL, 1999, HUM REPROD, V14, P793, DOI 10.1093/humrep/14.3.793; Tabibzadeh S, 1998, MOL HUM REPROD, V4, P595, DOI 10.1093/molehr/4.6.595; Tabibzadeh S, 2000, J CLIN ENDOCR METAB, V85, P2526, DOI 10.1210/jc.85.7.2526; Tabibzadeh Siamak, 1997, Frontiers in Bioscience (online), V2, pA18; Ulloa L, 2001, J BIOL CHEM, V276, P21397, DOI 10.1074/jbc.M010783200; Ulloa L, 2001, J BIOL CHEM, V276, P21387, DOI 10.1074/jbc.M006933200; von Wolff M, 2000, MOL HUM REPROD, V6, P627; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678	41	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42496	42504		10.1074/jbc.M201793200	http://dx.doi.org/10.1074/jbc.M201793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12215426	hybrid			2022-12-25	WOS:000179081200011
J	Medvedev, AV; Robidoux, J; Bai, X; Cao, WH; Floering, LM; Daniel, KW; Collins, S				Medvedev, AV; Robidoux, J; Bai, X; Cao, WH; Floering, LM; Daniel, KW; Collins, S			Regulation of the uncoupling protein-2 gene in INS-1 13-cells by oleic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; ELEMENT-BINDING PROTEINS; TRANSCRIPTION FACTOR; GLUCOSE REGULATION; SYNTHASE PROMOTER; ADIPOSE-TISSUE; RECEPTOR-GAMMA; FATTY-ACIDS; IN-VIVO; E-BOX	Current evidence suggests that uncoupling protein-2 (UCP2) is a regulator of insulin secretion. It is also known that chronic exposure of pancreatic islets to free fatty acids (FFAs) blunts glucose-stimulated insulin secretion and is accompanied by elevated levels of UCP2. However, the mechanisms regulating expression of UCP2 in beta-cells are unknown. Here, we show that UCP2 mRNA and protein levels were increased after a 48-h exposure of INS-1(832/13) beta-cells to oleic acid (0.5 mm) by activation of the UCP2 promoter. Furthermore, progressive deletions of the mouse UCP2 promoter (from -7.3 kb to +12 bp) indicated that an enhancer region (-86/-44) was responsible for both basal and FFA-stimulated UCP2 gene transcription. This enhancer contains tightly clustered Sp1, sterol regulatory element (SRE), and double E-Box elements. While all three sequence motifs were required for basal activity of the UCP2 promoter, the mutations in either the SRE or the E-Box elements eliminated the response to FFAs. The SRE and sterol regulatory element binding protein-1 (SREBP1) appear to be crucial for the response of the UCP2 gene to FFAs, since overexpression of the nuclear forms of the SREBPs increased UCP2 promoter activity by 7-10-fold and restored the ability of E-Box mutants to respond to oleic acid. These data support a model in which SREBP is the major modulator of UCP2 gene transcription by FFA, while E-Box binding factors play a supportive role.	Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Duke University	Collins, S (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Box 3557, Durham, NC 27710 USA.			Medvedev, Alexander/0000-0001-6983-1687; Robidoux, JAcques/0000-0002-4809-4734	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054024] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK54024] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boss O, 1997, FEBS LETT, V412, P111, DOI 10.1016/S0014-5793(97)00755-2; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dulloo AG, 2001, BRIT J NUTR, V86, P123, DOI 10.1079/BJN2001412; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Jackson SM, 1998, J LIPID RES, V39, P767; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Kakuma T, 2000, P NATL ACAD SCI USA, V97, P8536, DOI 10.1073/pnas.97.15.8536; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Li LX, 2002, ENDOCRINOLOGY, V143, P1371, DOI 10.1210/en.143.4.1371; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Rufo C, 2001, J BIOL CHEM, V276, P21969, DOI 10.1074/jbc.M100461200; Saleh MC, 2002, DIABETOLOGIA, V45, P174, DOI 10.1007/s00125-001-0737-x; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Tordjman K, 2002, J LIPID RES, V43, P936; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	40	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42639	42644		10.1074/jbc.M208645200	http://dx.doi.org/10.1074/jbc.M208645200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12205102	hybrid			2022-12-25	WOS:000179081200028
J	He, Q; Luo, XQ; Huang, Y; Sheikh, MS				He, Q; Luo, XQ; Huang, Y; Sheikh, MS			Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells	ONCOGENE			English	Article						NSAIDs; TRAIL/Apo2L; death receptor 5; Bax; caspases; colon cancer	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYTOCHROME-C; COLORECTAL-CANCER; DEATH RECEPTORS; GENE-EXPRESSION; IN-VIVO; LIGAND; COLON; MECHANISMS; RELEASE	The nonsteroidal anti-inflammatory drugs (NSAIDs) are believed to mediate their anticancer effects by inducing apoptosis but the molecular mechanisms of their apoptotic effects remain largely unknown. Here we report that two different NSAIDs, sulindac sulfide and SC-'236 engage the death receptor 5 (DR5) and mitochondrial pathways to mediate apoptosis in human colon cancer cells. We show that sulindac sulfide and SC-'236-induced apoptosis is coupled with upregulation of DR5, caspase 8 activation and Bid cleavage. Thus, a cross talk appears to exist between the DR5 and mitochondrial pathways during apoptosis induced by these NSAIDs. We further show that sulindac sulfide and SC-'236-induced DR5 upregulation occurs independent of the COX inhibitory effects of these NSAIDs. Using Bax-proficient (Bax+/-) and Bax-deficient (Bax-/-) HCT116 human colon cancer cells, we further demonstrate that Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac sulfide and SC-'236. For example, sulindac sulfide upregulates DR5 in both Bax-deficient and proficient cells, but Apo2L/TRAIL efficiently potentiates sulindac sulfide-induced apoptosis as well as activation of caspase-8, -9 and -3 only in Bax-proficient cells. SC-'236 also upregulates DR5 in both Bax-proficient and Bax-deficient cells but Apo2L/TRAIL potentiates SC-'236- mediated apoptosis and caspases-8 and -3 activation in both Bax-proficient and Bax-deficient cells. Further, in Bax-deficient cells, neither sulindac sulfide nor SC-'236 in combination with Apo2L/TRAIL effectively promotes the release of cytochrome c from mitochondria into cytosol and caspase-9 activation. Collectively, our results suggest that unlike sulindac sulfide, SC-'236 in combination with Apo2L/TRAIL can overcome Bax deficiency to induce apoptosis. These results have important clinical implications in that the tumors harboring Bax mutations are likely to develop resistance to sulindac but not to SC-'236-like NSAIDs. In conclusion, the data presented herein form the basis of future in-depth studies to further explore the utility of Apo2L/TRAIL and NSAIDs, in combination, as a novel cancer preventive/therapeutic strategy.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	sheikhm@mail.upstate.edu			NCI NIH HHS [CA89043] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA089043] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahnen DJ, 1998, EUR J SURG, V164, P111, DOI 10.1080/11024159850191544; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Burns TF, 2001, J BIOL CHEM, V276, P37879; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han ZY, 2001, J BIOL CHEM, V276, P38748, DOI 10.1074/jbc.M106214200; Huang Y, 2001, CANCER RES, V61, P6918; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; LANCASTER T, 1994, DIGEST DIS, V12, P170, DOI 10.1159/000171450; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lynch HT, 1999, J MED GENET, V36, P801; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ravi R, 2002, CANCER RES, V62, P1583; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sheikh MS, 1998, CANCER RES, V58, P1593; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Song XQ, 2002, J NATL CANCER I, V94, P585; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wei MC, 2000, GENE DEV, V14, P2060; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	34	46	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6032	6040		10.1038/sj.onc.1205897	http://dx.doi.org/10.1038/sj.onc.1205897			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203115				2022-12-25	WOS:000177671300006
J	Hecquet, C; Lefevre, G; Valtink, M; Engelmann, K; Mascarelli, F				Hecquet, C; Lefevre, G; Valtink, M; Engelmann, K; Mascarelli, F			CAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1/2 in a PKA-independent manner	ONCOGENE			English	Article						retinal pigment epithelium; signal transduction	MAP KINASE ERK; SIGNALING PATHWAYS; ACTIVE-TRANSPORT; PROTEIN; PHOSPHORYLATION; ACTIVATION; RAF-1; COMPLEXITY; SECRETION; REQUIRES	Retinal pigmented epithelial (RPE) cell integrity is critical to the maintenance of retina functions and RPE cells do not proliferate in adults. The activation of RPE results in cell proliferation which may be associated with proliferative retinopathy and choroidal melanoma. Mitogen-activated protein kinase (MAPK) is believed to be a key participant in the response to mitogenic stimuli. We therefore investigated the involvement of the extracellular signal-regulated protein kinase (ERK) I and 2 during the induction of RPE cell proliferation. After foetal calf serum (FCS) stimulation activation of the Ras/Raf/ERK signalling pathway was detected by Western blotting and immunochemistry, with specific anti-phosphosignalling protein antibodies. Pharmacological and antisense (AS) oligonucleotide (ODN) strategies were used to analyse the signalling involved in FCS-induced RPE cell proliferation. Activation of the small G protein Ras and, to a lesser extent of Raf-1, the kinase directly downstream from Ras, was necessary to FCS-induced cell proliferation. MEK1/2 and ERK1/2 were activated during cell proliferation. Inhibition of MEK1/2 with UO 126 completely abolished ERK1/2 activation and reduced cell proliferation by 33-43%. ERK1/2 depletion by an AS ODN approach reduced cell proliferation by 27-33%, confirming the role of ERK1/2 in the FCS stimulation of RPE cells. We also investigated the role of PKA/cAMP, one of the major inhibitory pathways of ERK1/2. PKA blockade did not modify ERK1/2 activation or cell proliferation. In contrast, agents that increased cAMP concentration, abolished RPE proliferation, and MEK/ERK activation. Moreover, inhibition of the cAMP-activated small G protein Rap1, partially reversed the inhibitory effects of cAMP on cell proliferation and MEK/ERK activation. The requirement for Ras and ERK1/2, the lack of ERK1/2 regulation by PKA and the cAMP/Rap1 counter-regulatory pathway for ERK-mediated cell proliferation suggest complex regulation of signalling in RPE cells. These data may have important implications for the development of more selective models for retinal anti-proliferative therapies.	CNRS, Ctr Biomed Cordeliers, INSERM U450, F-75006 Paris, France; Univ Klinikum Hamburg Eppendorf, Dept Ophthalmol, Cornea Bank Transplantat Lab, D-20246 Hamburg, Germany	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; University of Hamburg; University Medical Center Hamburg-Eppendorf	Mascarelli, F (corresponding author), CNRS, Ctr Biomed Cordeliers, INSERM U450, 15 Rue Ecole Med, F-75006 Paris, France.	fmascar@infobiogen.fr	Mascarelli, Frederic/L-8916-2018; Valtink, Monika/I-1507-2013	Valtink, Monika/0000-0003-3205-1876				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Bornfeldt KE, 1999, CELL SIGNAL, V11, P465, DOI 10.1016/S0898-6568(99)00020-0; Bryckaert M, 2000, ONCOGENE, V19, P4917, DOI 10.1038/sj.onc.1203872; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Enzmann V, 1998, OPHTHALMIC RES, V30, P189, DOI 10.1159/000055473; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; Monia BP, 1996, P NATL ACAD SCI USA, V93, P15481, DOI 10.1073/pnas.93.26.15481; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Valtink H, 1999, GRAEF ARCH CLIN EXP, V237, P1001, DOI 10.1007/s004170050336; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231; Zubilewicz A, 2001, INVEST OPHTH VIS SCI, V42, P488	27	53	55	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6101	6112		10.1038/sj.onc.1205765	http://dx.doi.org/10.1038/sj.onc.1205765			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203122	Bronze			2022-12-25	WOS:000177671300013
J	Sugano, M; Koyanagi, M; Tsuchida, K; Hata, T; Makino, N				Sugano, M; Koyanagi, M; Tsuchida, K; Hata, T; Makino, N			In vivo gene transfer of soluble TNF-alpha receptor 1 alleviates myocardial infarction	FASEB JOURNAL			English	Article						acute myocardial infarction; soluble TNF-alpha receptor 1; apoptosis; gene therapy	TUMOR-NECROSIS-FACTOR; FACTOR-BINDING PROTEIN; ISCHEMIA/REPERFUSION INJURY; APOPTOSIS; EXPRESSION; REPERFUSION; CARDIOMYOCYTES; ISCHEMIA; RATS; ATTENUATION	Apoptosis is the major independent form of cardiomyocyte cell death in acute myocardial infarction (AMI). TNF-alpha release early in the course of AMI contributes to myocardial injury, and TNF-alpha induces apoptosis in cardiomyocytes. Soluble TNF-alpha receptor 1 (sTNFR1) is an antagonist to TNF-alpha. However, the effect of sTNFR1 on AMI remains unclear. Here we report that direct injection of an sTNFR1 expression plasmid DNA to the myocardium reduces infarct size in experimental rat AMI. Treatment with sTNFR1 expression plasmid DNA reduced the TNF-alpha bioactivity in the myocardium and the apoptosis of cardiomyocytes. These findings suggest that the anti-TNF-alpha therapy by sTNFR1 can be a new strategy for treatment of AMI.	Kyushu Univ, Dept Mol & Cellular Biol, Div Mol & Clin Gerontol, Med Inst Bioregulat, Beppu, Oita 8740838, Japan	Kyushu University	Sugano, M (corresponding author), Kyushu Univ, Dept Mol & Cellular Biol, Div Mol & Clin Gerontol, Med Inst Bioregulat, 4546 Tsurumihara, Beppu, Oita 8740838, Japan.	massy@tsurumi.beppu.kyushu-u.ac.jp						Belosjorow S, 1999, AM J PHYSIOL-HEART C, V277, pH2470, DOI 10.1152/ajpheart.1999.277.6.H2470; Bryant D, 1998, CIRCULATION, V97, P1375, DOI 10.1161/01.CIR.97.14.1375; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; ENTMAN ML, 1994, CARDIOVASC RES, V28, P1301, DOI 10.1093/cvr/28.9.1301; Gaines GC, 1999, J VASC SURG, V29, P370, DOI 10.1016/S0741-5214(99)70390-3; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Gurevitch J, 1997, J AM COLL CARDIOL, V30, P1554, DOI 10.1016/S0735-1097(97)00328-8; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; Irwin MW, 1999, CIRCULATION, V99, P1492, DOI 10.1161/01.CIR.99.11.1492; Kajstura J, 1996, LAB INVEST, V74, P86; Li DY, 1999, AM HEART J, V137, P1145, DOI 10.1016/S0002-8703(99)70375-3; Makino N, 1996, J MOL CELL CARDIOL, V28, P507, DOI 10.1006/jmcc.1996.0047; Oskarsson HJ, 2000, CARDIOVASC RES, V45, P679, DOI 10.1016/S0008-6363(99)00400-9; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; Selinsky CL, 1998, IMMUNOLOGY, V94, P88; Song W, 2000, CARDIOVASC RES, V45, P595, DOI 10.1016/S0008-6363(99)00395-8; Su X, 1998, ARTHRITIS RHEUM-US, V41, P139, DOI 10.1002/1529-0131(199801)41:1<139::AID-ART17>3.3.CO;2-K; Sugano M, 2000, BIOCHEM BIOPH RES CO, V272, P872, DOI 10.1006/bbrc.2000.2877; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; YAMAZAKI T, 1993, AM J PATHOL, V143, P410; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yoshida H, 2000, HYPERTENSION, V35, P25, DOI 10.1161/01.HYP.35.1.25	22	24	26	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1421	+		10.1096/fj.01-0894fje	http://dx.doi.org/10.1096/fj.01-0894fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205034				2022-12-25	WOS:000177813100021
J	Ceulemans, H; Vulsteke, V; De Maeyer, M; Tatchell, K; Stalmans, W; Bollen, M				Ceulemans, H; Vulsteke, V; De Maeyer, M; Tatchell, K; Stalmans, W; Bollen, M			Binding of the concave surface of the Sds22 superhelix to the alpha 4/alpha 5/alpha 6-triangle of protein phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; 3-DIMENSIONAL STRUCTURE; STRUCTURAL BASIS; YEAST; TYPE-1; REGULATOR; RECOGNITION; COMPLEX	Functional studies of the protein phosphatase-1 (PP1) regulator Sds22 suggest that it is indirectly and/or directly involved in one of the most ancient functions of PP1, i.e. reversing phosphorylation by the Aurora-related protein kinases. We predict that the conserved portion of Sds22 folds into a curved superhelix and demonstrate that mutation to alanine of any of eight residues (Asp(148), Phe(170), Glu(192), Phe(214), Asp(280), Glu(300), Trp(302), or Tyr(327)) at the concave surface of this superhelix thwarts the interaction with PP1. Furthermore we show that all mammalian isoforms of PP1 have the potential to bind Sds22. Interaction studies with truncated versions of PP1 and with chimeric proteins comprising fragments of PP1 and the yeast PP1-like protein phosphatase Ppz1 suggest that the site(s) required for the binding of Sds22 reside between residues 43 and 173 of PP1gamma(1). Within this region, a major interaction site was mapped to a triangular region delineated by the alpha4-, alpha5-, and alpha6-helices. Our data also show that well known regulatory binding sites of PP1, such as the RVXF-binding channel, the beta12/beta13-loop, and the acidic groove, are not essential for the interaction with Sds22.	Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochim, B-3000 Louvain, Belgium; Catholic Univ Louvain, Fac WEtenschappen, Biomolec Modelling Lab, B-3000 Louvain, Belgium; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	KU Leuven; Universite Catholique Louvain; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Ceulemans, H (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochim, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Hugo.Ceulemans@med.kuleuven.ac.be	Tatchell, Kelly/A-9643-2009	Ceulemans, Hugo/0000-0002-7059-4399				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ansai T, 1996, J BIOL CHEM, V271, P24401, DOI 10.1074/jbc.271.40.24401; Baker SH, 1997, GENETICS, V145, P615; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; Ceulemans H, 1999, FEBS LETT, V456, P349, DOI 10.1016/S0014-5793(99)00965-5; Chun YS, 2000, BIOCHEM BIOPH RES CO, V273, P972, DOI 10.1006/bbrc.2000.3045; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; De Maeyer M, 2000, METH MOL B, V143, P265; Dinischiotu A, 1997, FEBS LETT, V402, P141, DOI 10.1016/S0014-5793(96)01514-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Evdokimov AG, 2001, J MOL BIOL, V312, P807, DOI 10.1006/jmbi.2001.4973; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; HARPER JW, 1993, CELL, V75, P805; HISAMOTO N, 1995, MOL CELL BIOL, V15, P3767; Ho DN, 2002, P NATL ACAD SCI USA, V99, P1888, DOI 10.1073/pnas.042698599; Hong G, 2000, ARCH BIOCHEM BIOPHYS, V376, P288, DOI 10.1006/abbi.2000.1715; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Kajava AV, 2002, PROTEIN SCI, V11, P1082, DOI 10.1110/ps.4010102; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Li L, 1998, J PHYSIOL-LONDON, V508, P871, DOI 10.1111/j.1469-7793.1998.871bp.x; Lin Q, 1999, MOL PHYLOGENET EVOL, V12, P57, DOI 10.1006/mpev.1998.0560; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; Moorhead G, 1998, FEBS LETT, V438, P141, DOI 10.1016/S0014-5793(98)01276-9; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; Peggie MW, 2002, J CELL SCI, V115, P195; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; RENOUF S, 1995, FEBS LETT, V375, P75, DOI 10.1016/0014-5793(95)01180-M; Schubert WD, 2001, J MOL BIOL, V312, P783, DOI 10.1006/jmbi.2001.4989; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Venturi GM, 2000, GENETICS, V155, P69; Wu XL, 2001, BIOCHEMISTRY-US, V40, P7410, DOI 10.1021/bi002796k; Zhang H, 2000, STRUCTURE, V8, P241, DOI 10.1016/S0969-2126(00)00102-7	43	63	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47331	47337		10.1074/jbc.M206838200	http://dx.doi.org/10.1074/jbc.M206838200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12226088	hybrid			2022-12-25	WOS:000179663700065
J	Guo, FS; Maurizi, MR; Esser, L; Xia, D				Guo, FS; Maurizi, MR; Esser, L; Xia, D			Crystal structure of ClpA, an Hsp100 chaperone and regulator of ClpAP protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; AAA-ATPASE; COMPLEX; PROTEOLYSIS; DOMAIN; UBIQUITIN; HOMOLOGY; RUVB; NSF	Escherichia coli ClpA, an Hsp100/Clp chaperone and an integral component of the ATP-dependent ClpAP protease, participates in regulatory protein degradation and the dissolution and degradation of protein aggregates. The crystal structure of the ClpA subunit reveals an N-terminal domain with pseudo-twofold symmetry and two AAA(+) modules (D1 and D2) each consisting of a large and a small sub-domain with ADP bound in the sub-domain junction. The N-terminal domain interacts with the D1 domain in a manner similar to adaptor-binding domains of other AAA(+) proteins. D1 and D2 are connected head-to-tail consistent with a cooperative and vectorial translocation of protein substrates. In a planar hexamer model of ClpA, built by assembling ClpA D1 and D2 into homohexameric rings of known structures of AAA(+) modules, the differences in D1-D1 and D2-D2 interfaces correlate with their respective contributions to hexamer stability and ATPase activity.	NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Xia, D (corresponding author), 37 Convent Dr,Bldg 37,Rm 1B22, Bethesda, MD 20892 USA.	dixia@helix.hih.gov						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karata K, 1999, J BIOL CHEM, V274, P26225, DOI 10.1074/jbc.274.37.26225; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim YI, 2001, NAT STRUCT BIOL, V8, P230, DOI 10.1038/84967; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Neuwald AF, 1999, GENOME RES, V9, P27; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; SEOL JH, 1995, BIOCHEM BIOPH RES CO, V217, P41, DOI 10.1006/bbrc.1995.2743; SINGH SK, 1994, J BIOL CHEM, V269, P29537; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Wilson AJC, 1942, NATURE, V150, P151, DOI 10.1038/150152a0; Yamada K, 2001, P NATL ACAD SCI USA, V98, P1442, DOI 10.1073/pnas.031470598; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	52	168	171	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46743	46752		10.1074/jbc.M207796200	http://dx.doi.org/10.1074/jbc.M207796200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12205096	hybrid			2022-12-25	WOS:000179529300134
J	Guo, FS; Esser, L; Singh, SK; Maurizi, MR; Xia, D				Guo, FS; Esser, L; Singh, SK; Maurizi, MR; Xia, D			Crystal structure of the heterodimeric complex of the adaptor, ClpS, with the N-domain of the AAA(+) chaperone, ClpA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUBSTRATE-RECOGNITION; RIBOSOMAL-PROTEIN; HSP100 CHAPERONE; DEGRADATION; PROTEOLYSIS; REGULATOR; PROTEASES; IDENTIFICATION; TRANSLOCATION	Substrate selectivity and proteolytic activity for the E. coli ATP-dependent protease, ClpAP, is modulated by an adaptor protein, ClpS. ClpS binds to ClpA, the regulatory component of the ClpAP complex. We report the crystal structure of ClpS in complex with the isolated N-terminal domain of CIpA in two different crystal forms at 2.3- and 3.3-Angstrom resolution. The ClpS structure forms an alpha/beta-sandwich and is topologically analogous to the C-terminal domain of the ribosomal protein L7/L12. ClpS contacts two surfaces on the N-terminal domain in both crystal forms; the more extensive interface was shown to be favored in solution by protease protection experiments. The N-terminal 20 residues of ClpS are not visible in the crystal structures; the removal of the first 17 residues produces ClpSDeltaN, which binds to the CIpA N-domain but no longer inhibits CIpA activity. A zinc binding site involving two His and one Glu residue was identified crystallographically in the N-terminal domain of ClpA. In a model of ClpS bound to hexameric ClpA, ClpS is oriented with its N terminus directed toward the distal surface of ClpA, suggesting that the N-terminal region of ClpS may affect productive substrate interactions at the apical surface or substrate entry into the CIpA translocation channel.	NCI, Ctr Canc Res, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Xia, D (corresponding author), NCI, Ctr Canc Res, Cell Biol Lab, NIH, 37 Convent Dr,MSC 4255,Bldg 37,Rm 1B22, Bethesda, MD 20892 USA.	dixia@helix.nih.gov						Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAN AWE, 1993, PROTEIN SCI, V2, P1574, DOI 10.1002/pro.5560021004; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLMES MA, 1981, BIOCHEMISTRY-US, V20, P6912, DOI 10.1021/bi00527a026; Hoskins JR, 2000, J BIOL CHEM, V275, P35361, DOI 10.1074/jbc.M006288200; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISCHA K, 1971, NATURE-NEW BIOL, V233, P62, DOI 10.1038/newbio233062a0; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEIJONMARCK M, 1987, J MOL BIOL, V195, P555, DOI 10.1016/0022-2836(87)90183-5; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; Littlefield O, 2001, PROTEINS, V45, P219, DOI 10.1002/prot.1142; Lo JH, 2001, PROTEIN SCI, V10, P551, DOI 10.1110/ps.41401; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; MOLLER W, 1983, J MOL BIOL, V163, P553, DOI 10.1016/0022-2836(83)90112-2; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Ortega J, 2002, EMBO J, V21, P4938, DOI 10.1093/emboj/cdf483; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Pratt LA, 1996, P NATL ACAD SCI USA, V93, P2488, DOI 10.1073/pnas.93.6.2488; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Sheldrick GM, 1998, DIRECT METHODS SOLVI; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; Turgay K, 1998, EMBO J, V17, P6730; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wahl MC, 2000, EMBO J, V19, P174, DOI 10.1093/emboj/19.2.174; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401	49	88	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46753	46762		10.1074/jbc.M208104200	http://dx.doi.org/10.1074/jbc.M208104200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235156	hybrid			2022-12-25	WOS:000179529300135
J	Jenne, N; Frey, K; Brugger, B; Wieland, FT				Jenne, N; Frey, K; Brugger, B; Wieland, FT			Oligomeric state and stoichiometry of p24 proteins in the early secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPI-COATED VESICLES; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; GOLGI-APPARATUS; FAMILY MEMBERS; CYTOPLASMIC DOMAIN; CARGO RECEPTORS; TRANSPORT; COMPLEX; LOCALIZATION	The p24 proteins belong to a highly conserved family of membrane proteins that cycle in the early secretory pathway. They bind to the coat proteins of COPI and COPII vesicles, and are proposed to be involved in vesicle biogenesis, cargo uptake, and quality control, but their precise function is still under debate. Most p24 proteins form hetero-oligomers, essential for their correct localization and stability. Functional insights regarding the mechanisms of their steady state localization and the role of interaction with coat proteins has been hampered by a lack of data on their concentration and state of oligomerization within the endoplasmic reticulum, the intermediate compartment, and Golgi complex. We have determined for all mammalian p24 family members the size of the oligomers formed and their stoichiometric relation in each of these individual organelles. In contrast to earlier reports, we show that individual members exist as dimers and monomers and that the ratio between these two forms depends on both the organelle investigated and the p24 protein. We find unequal quantities, with p23 and p27 building up concentration gradients, ruling out a simple 1:1 stoichiometry. In addition, we show differential cycling of individual p24 members. These data point to a complex and dynamic system of altering dimerizations of the family members.	Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Wieland, FT (corresponding author), Univ Heidelberg, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.							Barr FA, 2001, J CELL BIOL, V155, P885, DOI 10.1083/jcb.200108102; Belden WJ, 2001, J BIOL CHEM, V276, P43040, DOI 10.1074/jbc.M108113200; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Blum R, 1999, J CELL SCI, V112, P537; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; BREW K, 1975, J BIOL CHEM, V250, P1434; Brugger B, 2000, J CELL BIOL, V151, P507, DOI 10.1083/jcb.151.3.507; Denzel A, 2000, CURR BIOL, V10, P55, DOI 10.1016/S0960-9822(99)00266-3; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; Emery G, 1999, PROTOPLASMA, V207, P24, DOI 10.1007/BF01294710; Emery G, 2000, J CELL SCI, V113, P2507; Fullekrug J, 1999, MOL BIOL CELL, V10, P1939, DOI 10.1091/mbc.10.6.1939; Gommel D, 1999, FEBS LETT, V447, P179, DOI 10.1016/S0014-5793(99)00246-X; Gommel DU, 2001, EMBO J, V20, P6751, DOI 10.1093/emboj/20.23.6751; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; HARLOWE E, 1988, ANTIBODIES LAB MANUA; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Majoul I, 2001, DEV CELL, V1, P139, DOI 10.1016/S1534-5807(01)00004-1; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Nickel W, 1997, P NATL ACAD SCI USA, V94, P11393, DOI 10.1073/pnas.94.21.11393; Nickel W, 1998, J CELL SCI, V111, P3081; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Orci L, 2000, P NATL ACAD SCI USA, V97, P10400, DOI 10.1073/pnas.190292497; Reinhard C, 1999, P NATL ACAD SCI USA, V96, P1224, DOI 10.1073/pnas.96.4.1224; Rojo M, 2000, J CELL SCI, V113, P1043; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; TABAS I, 1979, J BIOL CHEM, V254, P1655; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; WARNOCK DE, 1993, J BIOL CHEM, V268, P10145; Weidler M, 2000, BIOCHEM BIOPH RES CO, V271, P401, DOI 10.1006/bbrc.2000.2511; Wen CH, 1999, J CELL BIOL, V145, P1165, DOI 10.1083/jcb.145.6.1165	39	95	101	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46504	46511		10.1074/jbc.M206989200	http://dx.doi.org/10.1074/jbc.M206989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237308	hybrid			2022-12-25	WOS:000179529300104
J	Ullan, RV; Casqueiro, J; Banuelos, O; Fernandez, FJ; Gutierrez, S; Martin, JF				Ullan, RV; Casqueiro, J; Banuelos, O; Fernandez, FJ; Gutierrez, S; Martin, JF			A novel epimerization system in fungal secondary metabolism involved in the conversion of isopenicillin N into penicillin N in Acremonium chrysogenum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEACETYLCEPHALOSPORIN-C ACETYLTRANSFERASE; CEPHALOSPORIN BIOSYNTHETIC GENES; METHYLACYL-COA RACEMASE; CELL-FREE CONVERSION; DEACETOXYCEPHALOSPORIN-C; CEFG GENE; EPIMERASE ACTIVITY; MOLECULAR-CLONING; CHIRAL INVERSION; BETA-OXIDATION	The epimerization step that converts isopenicillin N into penicillin N during cephalosporin biosynthesis has remained uncharacterized despite its industrial relevance. A transcriptional analysis of a 9-kb region located downstream of the pcbC gene revealed the presence of two transcripts that correspond to the genes named cefD1 and cefD2 encoding proteins with high similarity to long chain acyl-CoA synthetases and acyl-CoA racemases from Mus musculus, Homo sapiens, and Rattus norvegicus. Both genes are expressed in opposite orientations from a bidirectional promoter region. Targeted inactivation of cefD1 and cefD2 was achieved by the two-marker gene replacement procedure. Disrupted strains lacked isopenicillin N epimerase activity, were blocked in cephalosporin C production, and accumulated isopenicillin N. Complementation in trans of the disrupted nonproducer mutant with both genes restored epimerase activity and cephalosporin biosynthesis. However, when cefD1 or cefD2 were introduced separately into the double-disrupted mutant, no epimerase activity was detected, indicating that the concerted action of both proteins encoded by cetD1 and cetD2 is required for epimerization of isopenicillin N into penicillin N. This epimerization system occurs in eukaryotic cells and is entirely different from the known epimerization systems involved in the biosynthesis of bacterial beta-lactam antibiotics.	Univ Leon, Area Microbiol, Fac Ciencias Biol & Ambientales, E-24071 Leon, Spain; Inst Biotecnol Leon, Leon 24006, Spain	Universidad de Leon	Martin, JF (corresponding author), Univ Leon, Area Microbiol, Fac Ciencias Biol & Ambientales, E-24071 Leon, Spain.	degjmm@unileon.es	Gutiérrez, Santiago/H-6456-2015; Fernandez, Francisco/L-3320-2015	Gutiérrez, Santiago/0000-0001-6659-1390; Fernandez, Francisco/0000-0003-4676-1828; Casqueiro, Javier/0000-0001-9046-2708; Banuelos, Oscar/0000-0002-7418-5955				ACKMAN RG, 1967, LIPIDS, V2, P357, DOI 10.1007/BF02531848; AHARONOWITZ Y, 1992, ANNU REV MICROBIOL, V46, P461, DOI 10.1146/annurev.mi.46.100192.002333; BALDWIN JE, 1981, BIOCHEM J, V194, P649, DOI 10.1042/bj1940649; CALDWELL J, 1988, BIOCHEM PHARMACOL, V37, P105, DOI 10.1016/0006-2952(88)90762-9; Cheng YQ, 2000, J BIOL CHEM, V275, P4906, DOI 10.1074/jbc.275.7.4906; COQUE JJR, 1993, MOL GEN GENET, V236, P453, DOI 10.1007/BF00277148; Demain AL, 1983, ANTIBIOTICS CONTAINI, P189; FINGERHUT R, 1993, J INHERIT METAB DIS, V16, P591, DOI 10.1007/BF00711690; Gutierrez S, 1999, MICROBIOL-SGM, V145, P317, DOI 10.1099/13500872-145-2-317; Gutierrez S, 1999, ANTON LEEUW INT J G, V75, P81, DOI 10.1023/A:1001861025070; GUTIERREZ S, 1992, J BACTERIOL, V174, P3056; GUTIERREZ S, 1991, J BACTERIOL, V173, P2354; Gutierrez S, 1997, APPL MICROBIOL BIOT, V48, P606, DOI 10.1007/s002530051103; GUTIERREZ S, 1991, MOL GEN GENET, V225, P56; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JAYATILAKE GS, 1981, BIOCHEM J, V194, P645, DOI 10.1042/bj1940645; JENSEN SE, 1983, CAN J MICROBIOL, V29, P1526, DOI 10.1139/m83-234; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; KNIHINICKI RD, 1991, BIOCHEM PHARMACOL, V42, P1905, DOI 10.1016/0006-2952(91)90588-V; KONOMI T, 1979, BIOCHEM J, V184, P427, DOI 10.1042/bj1840427; Kosalkova K, 2001, J IND MICROBIOL BIOT, V27, P252, DOI 10.1038/sj.jim.7000192; KOVACEVIC S, 1990, J BACTERIOL, V172, P3952, DOI 10.1128/jb.172.7.3952-3958.1990; LAIZ L, 1990, J GEN MICROBIOL, V136, P663, DOI 10.1099/00221287-136-4-663; Liras P, 1999, ANTON LEEUW INT J G, V75, P109, DOI 10.1023/A:1001804925843; Liu YY, 2000, CLIN CANCER RES, V6, p4502S; LUBBE C, 1986, APPL MICROBIOL BIOT, V23, P367; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Martin J F, 1989, Adv Biochem Eng Biotechnol, V39, P153; Martin JF, 2000, J ANTIBIOT, V53, P1008, DOI 10.7164/antibiotics.53.1008; Martin JF, 1998, APPL MICROBIOL BIOT, V50, P1, DOI 10.1007/s002530051249; Martin JF, 2000, J BACTERIOL, V182, P2355, DOI 10.1128/JB.182.9.2355-2362.2000; Martin JF, 1990, MOL IND MYCOLOGY, P149; MARTIN JF, 1997, FUNGAL BIOTECHNOLOGY, P91; MARTIN JF, 2000, ENCY MICROBIOLOGY, P213; NEUSS N, 1982, J ANTIBIOT, V35, P580, DOI 10.7164/antibiotics.35.580; PUNT PJ, 1990, GENE, V93, P101, DOI 10.1016/0378-1119(90)90142-E; Reichel C, 1997, MOL PHARMACOL, V51, P576, DOI 10.1124/mol.51.4.576; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAMSON SM, 1985, NATURE, V318, P191, DOI 10.1038/318191a0; SAMSON SM, 1987, P NATL ACAD SCI USA, V84, P5705, DOI 10.1073/pnas.84.16.5705; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADA Y, 1980, ANTIMICROB AGENTS CH, V27, P380; SCHMITZ W, 1994, EUR J BIOCHEM, V222, P313, DOI 10.1111/j.1432-1033.1994.tb18870.x; Schmitz W, 1997, EUR J BIOCHEM, V244, P434, DOI 10.1111/j.1432-1033.1997.00434.x; Schmitz W, 1997, BIOCHEM J, V326, P883, DOI 10.1042/bj3260883; SCHMITZ W, 1995, EUR J BIOCHEM, V231, P815, DOI 10.1111/j.1432-1033.1995.0815d.x; SHEN YQ, 1986, BIO-TECHNOL, V4, P61, DOI 10.1038/nbt0186-61; SHIEH WR, 1993, J BIOL CHEM, V268, P3487; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1016/0378-1097(94)00459-5; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; Ullan RV, 2002, MOL GENET GENOMICS, V267, P673, DOI 10.1007/s00438-002-0702-5; USUI S, 1989, BIOCHIM BIOPHYS ACTA, V999, P78, DOI 10.1016/0167-4838(89)90033-2; VanVeldhoven PP, 1996, FEBS LETT, V388, P80, DOI 10.1016/0014-5793(96)00508-X; Velasco J, 1999, BIOCHEM J, V337, P379, DOI 10.1042/0264-6021:3370379; VELASCO J, 1994, J BACTERIOL, V176, P985, DOI 10.1128/JB.176.4.985-991.1994; Velasco J, 2001, APPL MICROBIOL BIOT, V57, P350	57	52	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46216	46225		10.1074/jbc.M207482200	http://dx.doi.org/10.1074/jbc.M207482200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12228250	hybrid			2022-12-25	WOS:000179529300069
J	Allen, DL; Leinwand, LA				Allen, DL; Leinwand, LA			Intracellular calcium and myosin isoform transitions - Calcineurin and calcium-calmodulin kinase pathways regulate preferential activation of the iia myosin heavy chain promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; SKELETAL-MUSCLE FIBERS; GENE-EXPRESSION; SLOW MYOSIN; DEPENDENT PATHWAY; SARCOPLASMIC-RETICULUM; ELECTRICAL-ACTIVITY; ADULT FAST; C-JUN; TRANSCRIPTION	Intracellular calcium levels can have profound effects on muscle biology via alterations in gene expression. In particular, intracellular calcium levels increase during muscle activation and are thought to underlie fast-to-slow shifts in muscle gene expression. In the present work, we determined that increased intracellular calcium has a significant effect on the activity of the adult fast myosin heavy chain (MyHC) promoters in the order of MyHC IIa much greater than IId/x > IIb. We have identified the pathways by which the calcium signal mediates increased activation of the MyHC IIa promoter. Inhibition of calcineurin or calcium-calmodulin kinase greatly attenuates ionophore-induced activation of the MyHC IIa promoter, whereas protein kinase C inhibitors have no effect. Inhibition and overexpression studies with members of the mitogen-activated protein kinase family reveal roles for MEK1/MEK2 and MEKK1, but not p38 or phosphatidylinositol 3-kinase. Downstream mediators of these effects are the activities of the MEF-2 and NFAT transcription factors, whose binding sites in the MyHC IIa promoter are required for calcium-induced activation of the MyHC IIa promoter.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Allen, DL (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Campus Box 347, Boulder, CO 80309 USA.			LEINWAND, LESLIE/0000-0003-1470-4810	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029090] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM29090] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen DL, 2001, J BIOL CHEM, V276, P43524, DOI 10.1074/jbc.M108017200; Altiok N, 2001, FEBS LETT, V487, P333, DOI 10.1016/S0014-5793(00)02311-5; Bernal-Mizrachi E, 2000, J BIOL CHEM, V275, P25681, DOI 10.1074/jbc.M003424200; Bigard X, 2000, J BIOL CHEM, V275, P19653, DOI 10.1074/jbc.M000430200; Boppart MD, 2000, J PHYSIOL-LONDON, V526, P663, DOI 10.1111/j.1469-7793.2000.00663.x; Buonanno A, 1999, CURR OPIN NEUROBIOL, V9, P110, DOI 10.1016/S0959-4388(99)80014-2; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DiMario JX, 1999, DEV DYNAM, V216, P177; Dunn SE, 2001, J BIOL CHEM, V276, P45243, DOI 10.1074/jbc.M105445200; Fluck M, 2000, BIOCHEM BIOPH RES CO, V270, P488, DOI 10.1006/bbrc.2000.2457; Fluck M, 1999, J APPL PHYSIOL, V86, P1793, DOI 10.1152/jappl.1999.86.6.1793; Freyssenet D, 1999, J BIOL CHEM, V274, P9305, DOI 10.1074/jbc.274.14.9305; Friday BB, 2001, J CELL SCI, V114, P303; Gordon SE, 2001, J APPL PHYSIOL, V90, P1174, DOI 10.1152/jappl.2001.90.3.1174; Halseth AE, 2000, J APPL PHYSIOL, V88, P669, DOI 10.1152/jappl.2000.88.2.669; Johnson CM, 1997, J NEUROSCI, V17, P6189; Kubis HP, 1997, P NATL ACAD SCI USA, V94, P4205, DOI 10.1073/pnas.94.8.4205; Lakich MM, 1998, J BIOL CHEM, V273, P15217, DOI 10.1074/jbc.273.24.15217; Marshall P, 2001, J BIOL CHEM, V276, P20719, DOI 10.1074/jbc.M102100200; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Meissner JD, 2001, J PHYSIOL-LONDON, V533, P215, DOI 10.1111/j.1469-7793.2001.0215b.x; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; NEUFER PD, 1993, AM J PHYSIOL, V265, pC1597; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; PETTE D, 1984, MED SCI SPORT EXER, V16, P517; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; Shin KS, 1997, J BIOL CHEM, V272, P21227, DOI 10.1074/jbc.272.34.21227; Swoap SJ, 2000, AM J PHYSIOL-CELL PH, V279, pC915, DOI 10.1152/ajpcell.2000.279.4.C915; Thelen MHM, 1997, BIOCHEM J, V321, P845, DOI 10.1042/bj3210845; Torgan CE, 2001, MOL BIOL CELL, V12, P1499, DOI 10.1091/mbc.12.5.1499; Vali S, 2000, J CELL PHYSIOL, V185, P184, DOI 10.1002/1097-4652(200011)185:2<184::AID-JCP3>3.0.CO;2-T; Wei L, 2000, AM J PHYSIOL-HEART C, V278, pH1736, DOI 10.1152/ajpheart.2000.278.6.H1736; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yu M, 2001, J PHYSIOL-LONDON, V536, P273, DOI 10.1111/j.1469-7793.2001.00273.x; Zhao M, 1999, MOL CELL BIOL, V19, P21	46	81	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45323	45330		10.1074/jbc.M208302200	http://dx.doi.org/10.1074/jbc.M208302200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235157	hybrid			2022-12-25	WOS:000179404800094
J	Saito, S; Frank, GD; Mifune, M; Ohba, M; Utsunomiya, H; Motley, ED; Inagami, T; Eguchi, S				Saito, S; Frank, GD; Mifune, M; Ohba, M; Utsunomiya, H; Motley, ED; Inagami, T; Eguchi, S			Ligand-independent trans-activation of the platelet-derived growth factor receptor by reactive oxygen species requires protein kinase C-delta and C-Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SIGNAL-REGULATED KINASE; FACTOR-BETA-RECEPTOR; ANGIOTENSIN-II; TYROSINE KINASE; COUPLED RECEPTORS; PHOSPHORYLATION; TRANSACTIVATION; EGF; ATHEROSCLEROSIS	Reactive oxygen species are involved in the mitogenic signal transduction cascades initiated by several growth factors and play a critical role in mediating cardiovascular diseases. Interestingly, H2O2 induces tyrosine phosphorylation and trans-activation of the platelet-derived growth factor receptor and the epidermal growth factor receptor in many cell lines including vascular smooth muscle cells. To investigate the molecular mechanism by which reactive oxygen species contribute to vascular diseases, we have examined a signal transduction cascade involved in H2O2-induced platelet-derived growth factor receptor activation in vascular smooth muscle cells. We found that H2O2 induced a ligand-independent phosphorylation of the platelet-derived growth factor-beta receptor at Tyr(1012), a phospholipase C-gamma binding site, involving the requirement of protein kinase C-delta and c-Src that is distinct from a ligand-dependent autophosphorylation. Also, H2O2 induced the association of protein kinase C-delta with the platelet-derived growth factor-beta receptor and c-Src in vascular smooth muscle cells. These findings will provide new mechanistic insights by which enhanced reactive oxygen species production in vascular smooth muscle cells induces unique alleys of signal transduction distinct from those induced by endogenous ligands leading to an abnormal vascular remodeling process.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Showa Univ, Inst Mol Oncol, Tokyo 1428555, Japan; Wakayama Med Univ, Dept Pathol, Wakayama 6410012, Japan; Meharry Med Coll, Dept Anat & Physiol, Nashville, TN 37208 USA	Vanderbilt University; Showa University; Wakayama Medical University; Meharry Medical College	Eguchi, S (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007323, R01HL058205, R37HL058205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NHLBI NIH HHS [HL-07323, HL58205] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Benes C, 2001, AM J PHYSIOL-CELL PH, V280, pC1498, DOI 10.1152/ajpcell.2001.280.6.C1498; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dowler S, 2000, BIOCHEM J, V349, P605, DOI 10.1042/0264-6021:3490605; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Escargueil-Blanc I, 2001, CIRCULATION, V104, P1814, DOI 10.1161/hc4001.097179; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Frank GD, 2000, ENDOCRINOLOGY, V141, P3120, DOI 10.1210/en.141.9.3120; Frank GD, 2002, MOL ENDOCRINOL, V16, P367, DOI 10.1210/me.16.2.367; Frank GD, 2001, BIOCHEM BIOPH RES CO, V280, P1116, DOI 10.1006/bbrc.2001.4251; Frank GD, 2000, BIOCHEM BIOPH RES CO, V270, P761, DOI 10.1006/bbrc.2000.2505; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Heldin CH, 1997, FEBS LETT, V410, P17, DOI 10.1016/S0014-5793(97)00318-9; Heldin CH, 2002, ARCH BIOCHEM BIOPHYS, V398, P284, DOI 10.1006/abbi.2001.2707; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; Motley ED, 2002, HYPERTENSION, V39, P508, DOI 10.1161/hy02t2.102907; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Pawson T, 1997, NATURE, V385, P582, DOI 10.1038/385582b0; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rao GN, 1996, ONCOGENE, V13, P713; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sanna PP, 2000, P NATL ACAD SCI USA, V97, P8653, DOI 10.1073/pnas.140219097; Schwartz SM, 1997, J CLIN INVEST, V100, pS87; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699	41	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44695	44700		10.1074/jbc.M208332200	http://dx.doi.org/10.1074/jbc.M208332200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12226102	hybrid			2022-12-25	WOS:000179404800014
J	Szeltner, Z; Rea, D; Juhasz, T; Renner, V; Mucsi, Z; Orosz, G; Fulop, V; Polgar, L				Szeltner, Z; Rea, D; Juhasz, T; Renner, V; Mucsi, Z; Orosz, G; Fulop, V; Polgar, L			Substrate-dependent competency of the catalytic triad of prolyl oligopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEPTIDASE INHIBITORS; SERINE PROTEASES; ENZYME; SITE; MECHANISM; HISTIDINE; ACID; IDENTIFICATION; INACTIVATION; CONSTANT	Prolyl oligopeptidase, a serine peptidase unrelated to trypsin and subtilisin, is implicated in memory disorders and is an important target of drug design. The catalytic competence of the Asp 641 residue of the catalytic triad (Ser(554), Asp(641), His(680)) was studied using the D641N and D641A variants of the enzyme. Both variants displayed 3 orders of magnitude reduction in k(cat)/K-m for benzyloxycarbonyl-Gly-Pro-2-naphthylamide. Using an octapeptide substrate, the decrease was 6 orders of magnitude, whereas with Z-Gly-Pro-4-nitrophenyl ester there was virtually no change in k(cat)/K-m. This indicates that the contribution of Asp641 is very much dependent on the substrate-leaving group, which was not the case for the classic serine peptidase, trypsin. The rate constant for benzyloxycarbonyl-Gly-Pro-thiobenzylester conformed to this series as demonstrated by a method designed for monitoring the hydrolysis of thiolesters in the presence of thiol groups. Alkylation of His(680) with Z-Gly-Pro-CH2Cl was concluded with similar rate constants for wild-type and D641A variant. However, kinetic measurements with Z-Gly-Pro-OH, a product-like inhibitor, indicated that the His(680) is not accessible in the enzyme variants. Crystal structure determination of these mutants revealed subtle perturbations related to the catalytic activity. Many of these observations show differences in the catalysis between trypsin and prolyl oligopeptidase.	Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, H-1518 Budapest 112, Hungary; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Eotvos Lorand Univ, Dept Organ Chem, H-1117 Budapest 112, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; University of Warwick; Eotvos Lorand University	Polgar, L (corresponding author), Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, POB 7, H-1518 Budapest 112, Hungary.	polgar@enzim.hu	Fulop, Vilmos/AAZ-7720-2021; Mucsi, Zoltan/J-9404-2019					ATACK JR, 1991, EUR J PHARMACOL, V205, P157, DOI 10.1016/0014-2999(91)90814-7; BACHOVCHIN WW, 1981, P NATL ACAD SCI-BIOL, V78, P7323, DOI 10.1073/pnas.78.12.7323; BACHOVCHIN WW, 1978, J AM CHEM SOC, V100, P8041, DOI 10.1021/ja00494a001; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; Cornish-Bowden A, 1995, FUNDAMENTALS ENZYME, p[44, 108, 139]; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; Cunningham DF, 1997, BBA-PROTEIN STRUCT M, V1343, P160, DOI 10.1016/S0167-4838(97)00134-9; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERSHT AR, 1973, J MOL BIOL, V74, P137, DOI 10.1016/0022-2836(73)90103-4; Fulop V, 2000, EMBO REP, V1, P277, DOI 10.1093/embo-reports/kvd048; Fulop V, 2001, J BIOL CHEM, V276, P1262, DOI 10.1074/jbc.M007003200; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDAN F, 1981, BIOCHEMISTRY-US, V20, P6366, DOI 10.1021/bi00525a013; KETTNER C, 1981, METHOD ENZYMOL, V80, P826; Kirschke H, 1999, PROTEOLYTIC ENZYMES, P11; KOSSIAKOFF AA, 1981, BIOCHEMISTRY-US, V20, P6462, DOI 10.1021/bi00525a027; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leatherbarrow R.J., 2001, GRAFIT VERSION 5; MAES M, 1994, BIOL PSYCHIAT, V35, P545, DOI 10.1016/0006-3223(94)90101-5; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; MIURA N, 1995, NEUROSCI LETT, V196, P128, DOI 10.1016/0304-3940(95)11821-D; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Polg?r L., 1987, NEW COMPREHENSIVE BI, V16, P159; POLGAR L, 1969, P NATL ACAD SCI USA, V64, P1335, DOI 10.1073/pnas.64.4.1335; POLGAR L, 1993, FEBS LETT, V322, P227, DOI 10.1016/0014-5793(93)81575-K; POLGAR L, 1995, BIOCHEM J, V312, P267, DOI 10.1042/bj3120267; POLGAR L, 1992, BIOCHEM J, V283, P647, DOI 10.1042/bj2830647; Polgar L, 2002, CELL MOL LIFE SCI, V59, P349, DOI 10.1007/s00018-002-8427-5; POLGAR L, 1994, METHOD ENZYMOL, V244, P188; POLGAR L, 1972, ACTA BIOCHIMICA B A, V7, P29; POLGAR L, 1989, MECHANISMS PROTEASE, P87; Portevin B, 1996, J MED CHEM, V39, P2379, DOI 10.1021/jm950858c; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; SEGEL IH, 1975, ENZYME KINETICS, P72; SHAW E, 1981, METHOD ENZYMOL, V80, P820; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; St?cker, 1999, PROTEOLYTIC ENZYMES, P148, DOI 10.1007/978-3-642-59816-6; STONE SR, 1991, BIOCHEM J, V276, P837, DOI 10.1042/bj2760837; Szeltner Z, 2000, J BIOL CHEM, V275, P15000, DOI 10.1074/jbc.M000942200; Szeltner Z, 2000, PROTEIN SCI, V9, P353; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TSOU CL, 1988, ADV ENZYMOL RAMB, V61, P381; WARSHEL A, 1978, P NATL ACAD SCI USA, V75, P5250, DOI 10.1073/pnas.75.11.5250; WELCHES WR, 1993, LIFE SCI, V52, P1461, DOI 10.1016/0024-3205(93)90108-F; WILK S, 1983, LIFE SCI, V33, P2149, DOI 10.1016/0024-3205(83)90285-0; Williams RSB, 1999, EMBO J, V18, P2734, DOI 10.1093/emboj/18.10.2734; YOSHIMOTO T, 1977, BIOCHEMISTRY-US, V16, P660	53	28	29	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44597	44605		10.1074/jbc.M207386200	http://dx.doi.org/10.1074/jbc.M207386200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228249	hybrid			2022-12-25	WOS:000179404800003
J	Hashiguchi, M; Saito, T; Hisanaga, S; Hashiguchi, T				Hashiguchi, M; Saito, T; Hisanaga, S; Hashiguchi, T			Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser(202)/Thr(205) of human tau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; CDC2-LIKE PROTEIN-KINASE; RECOMBINANT-TAU; P25; CALPAIN; CLEAVAGE; BINDING; EPITOPE; BRAIN; SITE	Hyperphosphorylated tau is a major component of neurofibrillary tangles, one of the hallmarks of Alzheimer's disease. CDK5 is a kinase that phosphorylates the tau protein, and its endogenous activator, p35, regulates its activity. Recently, calpain was found to digest p35 to its truncated product, p25. Several lines of evidence suggest that p25-CDK5 has much more powerful kinase activity and that it may cause abnormal hyperphosphorylation of tau. In this study, we have examined the kinetic characteristics of in vitro phosphorylation of the longest isoform of human tau by CDK5 and its activators using recombinant proteins. Although the kinase activity of CDK5 in phosphorylating tau was significantly higher in the presence of p25, the affinity of CDK5 for tau was not different. Phosphopeptide mapping revealed enhanced phosphorylation of Ser(202)/Thr(205) residues by p25-CDK5 (amino acid residues of tau are numbered according to the longest isoform of human tau). These results suggest that cleavage of p35 to p25 greatly enhances the kinase activity of CDK5 and increases the phosphorylation of Ser(202)/Thr(205). Considering the fact that phosphorylation of Ser(202)/Thr(205) antagonizes the tau-mediated nucleation of tubulin, p25-CDK5 may play a pivotal role in neuronal cell death in Alzheimer's disease.	Tokyo Med Univ, Dept Physiol, Shinjuku Ku, Tokyo 1608402, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Sci Biol, Hachioji, Tokyo 1920397, Japan	Tokyo Medical University; Tokyo Metropolitan University	Hashiguchi, M (corresponding author), Tokyo Med Univ, Dept Physiol, Shinjuku Ku, 6-1-1 Shinjuku, Tokyo 1608402, Japan.	Mhashigu@aol.com						Alvarez A, 1999, FEBS LETT, V459, P421, DOI 10.1016/S0014-5793(99)01279-X; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Jicha GA, 1999, J NEUROCHEM, V72, P214, DOI 10.1046/j.1471-4159.1999.0720214.x; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; LUC B, 2000, BRAIN RES REV, V33, P95; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; Paudel HK, 1997, J BIOL CHEM, V272, P1777; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; PREUSS U, 1995, MOL BIOL CELL, V6, P1397, DOI 10.1091/mbc.6.10.1397; Sengupta A, 1997, MOL CELL BIOCHEM, V167, P99, DOI 10.1023/A:1006883924775; Sharma P, 1999, J BIOL CHEM, V274, P9600, DOI 10.1074/jbc.274.14.9600; Sironi JJ, 1998, FEBS LETT, V436, P471, DOI 10.1016/S0014-5793(98)01185-5; Smith DS, 2001, CELL GROWTH DIFFER, V12, P277; Sobue K, 2000, J BIOL CHEM, V275, P16673, DOI 10.1074/jbc.M000784200; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; Taniguchi S, 2001, FEBS LETT, V489, P46, DOI 10.1016/S0014-5793(00)02431-5; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x	24	119	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44525	44530		10.1074/jbc.M207426200	http://dx.doi.org/10.1074/jbc.M207426200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226093	hybrid			2022-12-25	WOS:000179272000124
J	Franek, WR; Chowdary, YC; Lin, XC; Hu, MW; Miller, EJ; Kazzaz, JA; Razzano, P; Romashko, J; Davis, JM; Narula, P; Horowitz, S; Scott, W; Mantell, LL				Franek, WR; Chowdary, YC; Lin, XC; Hu, MW; Miller, EJ; Kazzaz, JA; Razzano, P; Romashko, J; Davis, JM; Narula, P; Horowitz, S; Scott, W; Mantell, LL			Suppression of nuclear Factor-kappa B activity by nitric oxide and hyperoxia in oxygen-resistant cells*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; DNA-BINDING; OXIDATIVE STRESS; INHIBITION; ACTIVATION; INDUCTION; ALPHA; TRANSLOCATION; INFLAMMATION; EXPRESSION	Inhaled nitric oxide (iNO) is used clinically to treat pulmonary hypertension in newborns, often in conjunction with hyperoxia (NO/O-2). Prolonged exposure to NO/O-2, causes synergistic lung injury and death of lung epithelial cells. To explore the mechanisms involved, oxygen-resistant HeLa-80 cells were exposed to NO +/- O-2. Exposure to NO and O-2 induced a synergistic cytotoxicity, accompanied with apoptotic characteristics, including elevated caspase-3-like activity, Annexin V incorporation, and nuclear condensation. This apoptosis was associated with a synergistic suppression of NF-kappaB activity. Cells lacking functional NF-kappaB p65 subunit were more sensitive to NO/O-2, than their wild type counterparts. This injury was partially rescued by transfection with a p65 expression construct, suggesting an inverse relationship between NF-kappaB and susceptibility to the cytotoxicity of NO/O-2. Despite the reduced NF-kappaB activity in cells exposed to NO +/- O-2, IkappaBalpha was degraded, suggesting that pathways regulating the steady-state levels of IkappaB were not involved. However, exposure to NO/O-2 caused a marked reduction in nuclear localization and an increase in protein carbonyl formation of NF-kappaB p65 subunit. These results suggest that NO/O-2-induced apoptosis occurs by suppressing NF-kappaB activity.	NYU, Sch Med, N Shore Long Isl Jewish Hlth Syst, Dept Surg,Cardiac Res Lab, Manhasset, NY 11030 USA; SUNY Stony Brook, Winthrop Univ Hosp, Sch Med, Dept Cardiovasc Thorac Surg, Mineola, NY 11501 USA; SUNY Stony Brook, Winthrop Univ Hosp, Sch Med, Dept Pediat, Mineola, NY 11501 USA; SUNY Stony Brook, Winthrop Univ Hosp, Sch Med, Dept Med, Mineola, NY 11501 USA; Univ Louisville, Jewish Hosp Hearth & Lung Inst, Dept Med, Louisville, KY 40202 USA; Univ Louisville, Jewish Hosp Hearth & Lung Inst, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA	New York University; Northwell Health; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; University of Louisville; University of Louisville	Mantell, LL (corresponding author), NYU, Sch Med, N Shore Long Isl Jewish Hlth Syst, Dept Surg,Cardiac Res Lab, 350 Community Dr, Manhasset, NY 11030 USA.		Mordwinkin, Nicholas M/A-4347-2010					Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; CARMICHAEL J, 1987, CANCER RES, V47, P943; Connelly L, 2001, J IMMUNOL, V166, P3873, DOI 10.4049/jimmunol.166.6.3873; D'Acquisto F, 2001, CELL DEATH DIFFER, V8, P144, DOI 10.1038/sj.cdd.4400784; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ekekezie II, 2000, BIOL NEONATE, V77, P37, DOI 10.1159/000014193; Fortenberry JD, 1998, AM J RESP CELL MOL, V18, P421, DOI 10.1165/ajrcmb.18.3.2875; Franek WR, 2001, J BIOL CHEM, V276, P569, DOI 10.1074/jbc.M004716200; Ibe W, 2001, CELL PHYSIOL BIOCHEM, V11, P231, DOI 10.1159/000047808; JOENJE H, 1985, LAB INVEST, V52, P420; JOENJE H, 1997, OXYGEN EXPRESSION CE, P67; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Marshall HE, 1999, AM J RESP CELL MOL, V21, P296, DOI 10.1165/ajrcmb.21.3.f164; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Michelakis E, 2002, CIRCULATION, V105, P2398, DOI 10.1161/01.CIR.0000016641.12984.DC; Nader ND, 1999, ANESTHESIOLOGY, V91, P741, DOI 10.1097/00000542-199909000-00027; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Narula P, 1998, AM J PHYSIOL-LUNG C, V274, pL411, DOI 10.1152/ajplung.1998.274.3.L411; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; Popov S, 1996, P NATL ACAD SCI USA, V93, P11859, DOI 10.1073/pnas.93.21.11859; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; ROBBINS CG, 1995, AM J PHYSIOL, V269, P545; Roman J, 2000, J BIOL CHEM, V275, P14684, DOI 10.1074/jbc.275.19.14684; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Spiecker M, 1997, J BIOL CHEM, V272, P30969, DOI 10.1074/jbc.272.49.30969; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stork E, 1997, NEW ENGL J MED, V336, P597; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Umansky V, 1998, EUR J IMMUNOL, V28, P2276, DOI 10.1002/(SICI)1521-4141(199808)28:08<2276::AID-IMMU2276>3.0.CO;2-H; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914	39	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42694	42700		10.1074/jbc.M202623200	http://dx.doi.org/10.1074/jbc.M202623200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12215428	hybrid			2022-12-25	WOS:000179081200035
J	Rui, LY; Yuan, MS; Frantz, D; Shoelson, S; White, MF				Rui, LY; Yuan, MS; Frantz, D; Shoelson, S; White, MF			SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; BOX MOTIF; IFN-GAMMA; RESISTANCE; SUPPRESSORS; MICE; PROTEINS; LIVER; GENE	Inflammation associates with peripheral insulin resistance, which dysregulates nutrient homeostasis and leads to diabetes. Inflammation induces the expression of SOCS proteins. We show that SOCS1 or SOCS3 targeted IRS1 and IRS2, two critical signaling molecules for insulin action, for ubiquitin-mediated degradation. SOCS1 or SOCS3 bound both recombinant and endogenous IRS1 and IRS2 and promoted their ubiquitination and subsequent degradation in multiple cell types. Mutations in the conserved SOCS box of SOCS1 abrogated its interaction with the elongin BC ubiquitin-ligase complex without affecting its binding to IRS1 or IRS2. The SOCS1 mutants also failed to promote the ubiquitination and degradation of either IRS1 or IRS2. Adenoviral-mediated expression of SOCS1 in mouse liver dramatically reduced hepatic IRS1 and IRS2 protein levels and caused glucose intolerance; by contrast, expression of the SOCS1 mutants had no effect. Thus, SOCS-mediated degradation of IRS proteins, presumably via the elongin BC ubiquitin-ligase, might be a general mechanism of inflammation-induced insulin resistance, providing a target for therapy.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Howard Hughes Med Inst, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute	White, MF (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Howard Hughes Med Inst, 1 Joslin Pl, Boston, MA 02215 USA.	whitemor@joslab.harvard.edu						Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Campbell JS, 2001, J CLIN INVEST, V107, P1285, DOI 10.1172/JCI11867; Chan JCN, 2002, INT J OBESITY, V26, P994, DOI 10.1038/sj.ijo.0802017; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Colson A, 2000, ENDOCRINOLOGY, V141, P3687, DOI 10.1210/en.141.10.3687; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hostamisligil GS, 1999, EXP CLIN ENDOCR DIAB, V107, P119, DOI 10.1055/s-0029-1212086; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Konstantopoulos N, 2000, DIABETES, V49, pA14; Krebs DL, 2000, J CELL SCI, V113, P2813; Krebs DL, 2002, MOL CELL BIOL, V22, P4567, DOI 10.1128/MCB.22.13.4567-4578.2002; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Naka T, 2001, IMMUNITY, V14, P535, DOI 10.1016/S1074-7613(01)00132-7; Ogle CK, 2000, SHOCK, V14, P392, DOI 10.1097/00024382-200014030-00026; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Waite KJ, 2001, J BIOL CHEM, V276, P7062, DOI 10.1074/jbc.M007894200; WHITE MF, 2001, ENDOCRINOLOGY; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Withers DJ, 2000, ENDOCRINOLOGY, V141, P1917, DOI 10.1210/en.141.6.1917; Withers DJ, 1999, CURR OPIN ENDOCRINOL, V6, P141; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	45	666	701	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42394	42398		10.1074/jbc.C200444200	http://dx.doi.org/10.1074/jbc.C200444200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12228220	hybrid			2022-12-25	WOS:000178985300137
J	Gallagher, RCJ; Hay, T; Meniel, V; Naughton, C; Anderson, TJ; Shibata, H; Ito, M; Clevers, H; Noda, T; Sansom, OJ; Mason, JO; Clarke, AR				Gallagher, RCJ; Hay, T; Meniel, V; Naughton, C; Anderson, TJ; Shibata, H; Ito, M; Clevers, H; Noda, T; Sansom, OJ; Mason, JO; Clarke, AR			Inactivation of Apc perturbs mammary development, but only directly results in acanthoma in the context of Tcf-1 deficiency	ONCOGENE			English	Article						Apc; Tcf-1; mammary; acanthoma; cre	BETA-CATENIN; CYCLIN D1; BREAST-CANCER; GENE; EXPRESSION; GLAND; PROTEIN; TARGET; TUMORIGENESIS; HYPERPLASIA	Apc (adenomatous polyposis colt) encodes a tumour suppressor gene that is mutated in the majority of colorectal cancers. Recent evidence has also implicated Apc mutations in the aetiology of breast tumours. Ape is a component of the canonical Wnt signal transduction pathway, of which one target is Tcf-1. In the mouse, mutations of both Ape and Tcf-1 have been implicated in mammary tumorigenesis. We have conditionally inactivated Apc in both the presence and absence of Tcf-1 to examine the function of these genes in both normal and neoplastic development. Mice harbouring mammary-specific mutations in Apc show markedly delayed development of the mammary ductal network. During lactation, the mice develop multiple metaplastic growths which, surprisingly, do not spontaneously progress to neoplasia up to a year following their induction. However, additional deficiency of Tcf-1 completely blocks normal mammary development and results in acanthoma.	Cardiff Univ, Dept Biol Sci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Sch Med, Dept Biomed Sci, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Inst Canc Res, Dept Cell Biol, Toshima Ku, Tokyo 170, Japan; Univ Med Ctr, Ctr Biomed Genet, Utrecht, Netherlands; Univ Med Ctr, Dept Immunol, Utrecht, Netherlands	Cardiff University; University of Edinburgh; University of Edinburgh; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Clarke, AR (corresponding author), Cardiff Univ, Dept Biol Sci, Cardiff CF10 3US, S Glam, Wales.	ClarkeAR@cf.ac.uk	Noda, Tetsuo/B-1667-2016; Mason, John O/A-1926-2010; Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Mason, John O/0000-0002-0489-2400; Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X; Naughton, Catherine/0000-0002-9576-5983	Biotechnology and Biological Sciences Research Council [G06054] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Brisken C, 2000, GENE DEV, V14, P650; Bukholm IK, 2000, J PATHOL, V190, P15; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Guger KA, 2000, DEV BIOL, V223, P441, DOI 10.1006/dbio.2000.9770; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Ho KYK, 1999, HISTOPATHOLOGY, V35, P249; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853; KASHIWABA M, 1994, J CANCER RES CLIN, V120, P727, DOI 10.1007/BF01194271; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Midgley CA, 1997, J PATHOL, V181, P426; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Moser AR, 2001, CANCER RES, V61, P3480; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Polakis P, 2000, GENE DEV, V14, P1837; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Schlosshauer PW, 2000, CARCINOGENESIS, V21, P1453, DOI 10.1093/carcin/21.7.1453; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Woodage T, 1998, NAT GENET, V20, P62, DOI 10.1038/1722; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	51	32	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6446	6457		10.1038/sj.onc.1205892	http://dx.doi.org/10.1038/sj.onc.1205892			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226748				2022-12-25	WOS:000177925300005
J	Ratcliffe, KE; Tao, Q; Yavuz, B; Stoletov, KV; Spring, SC; Terman, BI				Ratcliffe, KE; Tao, Q; Yavuz, B; Stoletov, KV; Spring, SC; Terman, BI			Sck is expressed in endothelial cells and participates in vascular endothelial growth factor-induced signaling	ONCOGENE			English	Article						VEGF; KDR; Shc; Sck; angiogenesis	FACTOR RECEPTOR KDR; PHOSPHOTYROSINE INTERACTION DOMAIN; TYROSINE KINASE; PERMEABILITY FACTOR; ADAPTER PROTEIN; SH2 DOMAINS; FOCAL ADHESIONS; DNA-SYNTHESIS; TUMOR-GROWTH; IN-VIVO	Sek, a member of the She family of cell signaling proteins, has only been studied in neuronal cells, though previous studies have demonstrated its expression in tissues other than brain. Using RT-PCR and RNase protection assays, we detected Sek mRNA expression in endothelial cells, and Sek protein was detected by Western blotting using polyclonal and monoclonal antibodies targeting the Sek CH1 domain. Immunohistochemistry protocols demonstrate that Sck is expressed in KDR and PECAM positive cells found in the mouse retina, mouse heart and human umbilical chord. Treatment of human umbilical vein endothelial (HUVE) cells with vascular endothelial growth factor (VEGF) leads to the recruitment of Sck to the KDR VEGF receptor and an enhanced Sek tyrosine phosphorylation. Sek is recruited to KDR tyrosine 1175, as coimmunoprecipitation of KDR and Sek is not observed in VEGF-treated porcine aortic endothelial cells expressing a receptor mutated at this autophosphorylation site. The Sek and She SH2 domains, and not the PTB domain, mediates its interactions with KDR, as recombinant Sek SH2 domain binds to a tyrosine phosphorylated KDR 1175-derived synthetic peptide, but not to a peptide synthesized without tyrosine phosphate. Recombinant PLCgamma, SH2 domain also interacts with the phosphotyrosine 1175 containing peptide. VEGF-induced MAPK activation is dependent upon PLCgamma activity, and chimeric proteins consisting of the She or Sek SH2 domains fused with a cellular internalization sequence attenuated this activation. Taken together, these results demonstrate that Sck is expressed in vascular endothelial cells, and participates in VEGF-induced signal transduction.	Albert Einstein Coll Med, Div Cardiol, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Terman, BI (corresponding author), Albert Einstein Coll Med, Div Cardiol, Dept Med, Forchheimer 715,1300 Morris Pk Ave, Bronx, NY 10461 USA.	Terman@aecom.yu.edu		Stoletov, Konstantin/0000-0002-7384-2917	NCI NIH HHS [R01 CA86289-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fournier E, 1996, J BIOL CHEM, V271, P12956, DOI 10.1074/jbc.271.22.12956; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kendall RL, 1999, J BIOL CHEM, V274, P6453, DOI 10.1074/jbc.274.10.6453; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Kojima T, 2001, BIOCHEM BIOPH RES CO, V284, P1039, DOI 10.1006/bbrc.2001.5080; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Lai KMV, 2000, GENE DEV, V14, P1132; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PEER J, 1995, LAB INVEST, V72, P638; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tao Q, 2001, J BIOL CHEM, V276, P21916, DOI 10.1074/jbc.M100763200; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Warner AJ, 2000, BIOCHEM J, V347, P501, DOI 10.1042/0264-6021:3470501; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yoshiji H, 1996, CANCER RES, V56, P2013; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6307	6316		10.1038/sj.onc.1205781	http://dx.doi.org/10.1038/sj.onc.1205781			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214271				2022-12-25	WOS:000177829000007
J	Vorburger, SA; Pataer, A; Yoshida, K; Barber, GN; Xia, WY; Chiao, P; Ellis, LM; Hung, MC; Swisher, SG; Hunt, KK				Vorburger, SA; Pataer, A; Yoshida, K; Barber, GN; Xia, WY; Chiao, P; Ellis, LM; Hung, MC; Swisher, SG; Hunt, KK			Role for the double-stranded RNA activated protein kinase PKR in E2F-1-induced apoptosis	ONCOGENE			English	Article						E2F-1; PKR; apoptosis; gene therapy; adenovirus	NF-KAPPA-B; TRANSCRIPTION FACTOR E2F-1; TUMOR-SUPPRESSOR P53; DNA-BINDING; CELLULAR ACTIVATOR; C-MYC; GENE; EXPRESSION; INDUCTION; INITIATION	The transcription factor E2F-1 induces cell cycle progression at the G1/S checkpoint, and deregulation of E2F-1 provokes apoptosis in a wide variety of malignant cells. To date only p14(ARF) and p73, a p53 homologue, have been identified as E2F-1-inducible genes capable of mediating an apoptotic response. Here we show that adenovirus-mediated E2F-1 overexpression in cancer cells induces expression and autophosphorylation of the double-stranded RNA-dependent protein kinase PKR leading to phosphorylation of its downstream target, the alpha-subunit of the eukaryotic translation initiation factor 2 (eIF-2alpha) and to apoptotic cell death. This PKR-dependent apoptosis occurs in cell lines with mutated p53 and in cell lines with mutated p53 and p73, and is significantly reduced by the chemical inhibition of PKR activation. Further, PKR-/- mouse embryo fibroblasts, but not PKR+/+ mouse embryo fibroblasits, demonstrate significant resistance to E2F-1-induced apoptosis. We conclude that an important pathway of E2F-1-mediated apoptosis is dependent on PKR activation and does not require p53 or p73.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Jikei Univ, Dept Surg, Sch Med, Tokyo 105, Japan; Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Jikei University; University of Miami	Hunt, KK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,Box 444, Houston, TX 77030 USA.	khunt@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Aktas H, 1998, P NATL ACAD SCI USA, V95, P8280, DOI 10.1073/pnas.95.14.8280; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blair LA, 2001, DIABETES, V50, P283, DOI 10.2337/diabetes.50.2.283; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; Gil J, 2001, ONCOGENE, V20, P385, DOI 10.1038/sj.onc.1204109; GUSELLA GL, 1995, J IMMUNOL, V154, P345; HAINES GK, 1993, ARCH OTOLARYNGOL, V119, P1142; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; KATZE MG, 1992, J INTERFERON RES, V12, P241, DOI 10.1089/jir.1992.12.241; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lieber A, 1996, J VIROL, V70, P8944, DOI 10.1128/JVI.70.12.8944-8960.1996; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Patel RC, 1998, MOL CELL BIOL, V18, P7009, DOI 10.1128/MCB.18.12.7009; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; RICE AP, 1985, J VIROL, V54, P894, DOI 10.1128/JVI.54.3.894-898.1985; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SAMUEL CE, 1992, PHARMACOL THERAPEUT, V54, P307, DOI 10.1016/0163-7258(92)90005-K; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Tanaka H, 2000, GENE, V246, P373, DOI 10.1016/S0378-1119(00)00080-9; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; Wong AHT, 2001, J BIOL CHEM, V276, P13727, DOI 10.1074/jbc.M011240200; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Yoshikawa H, 1999, ONCOGENE, V18, P3415, DOI 10.1038/sj.onc.1202677; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	58	34	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6278	6288		10.1038/sj.onc.1205761	http://dx.doi.org/10.1038/sj.onc.1205761			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214268				2022-12-25	WOS:000177829000004
J	Barker-Carlson, K; Lawrence, DA; Schwartz, BS				Barker-Carlson, K; Lawrence, DA; Schwartz, BS			Acyl-enzyme complexes between tissue-type plasminogen activator and neuroserpin are short-lived in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERPIN-PROTEASE COMPLEX; REACTIVE-CENTER LOOP; HUMAN-PLASMA; INHIBITOR; RECEPTOR; NEURONS; DEGENERATION; PURIFICATION; LIPOPROTEIN; UROKINASE	The serine protease tissue-type plasminogen activator (t-PA) initiates the fibrinolytic protease cascade and plays a significant role in motor learning, memory, and neuronal cell death induced by excitotoxin and ischemia. In the fibrinolytic system, the serpin PAI-1 negatively regulates the enzymatic activity of both single-chain and two-chain t-PA (sct-PA and tct-PA). In the central nervous system, neuroserpin (NSP) is a serpin thought to regulate t-PA enzymatic activity. We report that although both set-PA and tct-PA rapidly form acyl-enzyme complexes with NSP in vitro, the interactions are short-lived, rapidly progressing to complete cleavage of NSP and regeneration of fully active enzyme. All NSP molecules appear to transit through the detectable acyl-enzyme intermediate and progress to completion of cleavage; no subpopulation that functions as a pure substrate was detected. Likewise, all molecules were reactive, with no evidence of a latent subpopulation. The interactions between NSP and t-PA were distinct from those between plasmin and NSP, wherein the same peptide bond was cleaved but there was no evidence of a detectable plasmin-NSP acyl-enzyme complex. The interactions between t-PA and NSP contrast with the formation of long-lived, physiologically irreversible acylenzyme complexes between t-PA and PAI-1, suggesting that the physiologic effect of t-PA-NSP interactions may be more complex than previously thought.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Med Scientist Training Program, Madison, WI 53706 USA; Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Med, Urbana, IL 61801 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; American Red Cross; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Schwartz, BS (corresponding author), 190 Med Sci Bldg,MC-714,506 S Mathews, Urbana, IL 61801 USA.			Carlson, Karen-Sue/0000-0003-0418-652X; Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055374, R01HL043506, R01HL055747] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43506, HL55374, HL55747] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akassoglou K, 2000, J CELL BIOL, V149, P1157, DOI 10.1083/jcb.149.5.1157; BOOSE JA, 1987, J BIOCH, V28, P635; Calabresi P, 2000, EUR J NEUROSCI, V12, P1002, DOI 10.1046/j.1460-9568.2000.00991.x; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Cinelli P, 2001, MOL CELL NEUROSCI, V18, P443, DOI 10.1006/mcne.2001.1028; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; GALLAGHER S, 1997, CURRENT PROTOCOLS MO, V2; GAUSSEM P, 1993, J BIOL CHEM, V268, P12150; Gils A, 1998, THROMB HAEMOSTASIS, V80, P286, DOI 10.1055/s-0037-1615189; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Kjoller L, 1996, EUR J BIOCHEM, V241, P38, DOI 10.1111/j.1432-1033.1996.0038t.x; Krueger SR, 1997, J NEUROSCI, V17, P8984; KRUITHOF EKO, 1984, BLOOD, V64, P907; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; MUSSONI L, 1984, THROMB RES, V34, P241, DOI 10.1016/0049-3848(84)90008-2; Osterwalder T, 1998, J BIOL CHEM, V273, P2312, DOI 10.1074/jbc.273.4.2312; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; PITTMAN RN, 1989, J NEUROSCI, V9, P4269; Plotnick MI, 2002, BIOCHEMISTRY-US, V41, P334, DOI 10.1021/bi015650+; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RANBY M, 1982, THROMB RES, V27, P175, DOI 10.1016/0049-3848(82)90197-9; SCHAGGER H, 1988, ANAL BIOCHEM, V173, P201, DOI 10.1016/0003-2697(88)90179-0; Schwartz BS, 1999, J BIOL CHEM, V274, P15278, DOI 10.1074/jbc.274.21.15278; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; Tachias K, 1997, J BIOL CHEM, V272, P28; Takao M, 2000, J NEUROPATH EXP NEUR, V59, P1070, DOI 10.1093/jnen/59.12.1070; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979; Yepes M, 2002, J CLIN INVEST, V109, P1571, DOI 10.1172/JCI200214308; Yepes M, 2000, BLOOD, V96, P569; Zhang JC, 1998, J BIOL CHEM, V273, P32273, DOI 10.1074/jbc.273.48.32273; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	37	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46852	46857		10.1074/jbc.M207740200	http://dx.doi.org/10.1074/jbc.M207740200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12228252	hybrid			2022-12-25	WOS:000179663700004
J	Arunkumar, AI; Srisailam, S; Krishnaswamy, T; Kumar, S; Kathir, KM; Chi, YH; Wang, HM; Chang, GG; Chiu, IM; Yu, C				Arunkumar, AI; Srisailam, S; Krishnaswamy, T; Kumar, S; Kathir, KM; Chi, YH; Wang, HM; Chang, GG; Chiu, IM; Yu, C			Structure and stability of an acidic fibroblast growth factor from Notophthalmus viridescens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-STRUCTURE DETERMINATION; FGF RECEPTOR DIMERIZATION; CRYSTAL-STRUCTURE; SUCROSE OCTASULFATE; DIRECT REFINEMENT; CHEMICAL-SHIFTS; RIBONUCLEASE-S; HEPARIN; BINDING; OLIGOMERIZATION	The three-dimensional solution structure of an acidic fibroblast growth factor (nFGF-1) from the newt (Notophthalmus viridescens) is determined using multidimensional NMR techniques. Complete assignment of all the atoms (H-1, N-15, and C-13) has been achieved using a variety of triple resonance experiments. 50 structures were calculated using hybrid distance geometry-dynamical simulated annealing technique with a total of 1359 constraints. The atomic root mean square distribution for the backbone atoms in the structured region is 0.60 Angstrom. The secondary structural elements include 12 beta-strands arranged antiparallely into a beta-barrel structure. The protein (nFGF-1) exists in a monomeric state upon binding to the ligand, sucrose octa sulfate (SOS), in a stoichiometric ratio of 1:1. The SOS binding site consists of a dense cluster of positively charged residues located at the C-terminal end of the molecule. The conformational stabilities of nFGF-1 and its structural and functional homologue from the human source (hFGF-1) are drastically different. The differential stabilities of nFGF-1 and hFGF-1 are attributed to the differences in the number of hydrogen bonds and the presence of solvent inaccessible cavities in the two proteins.	Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Natl Tsing Hua Univ, Dept Chem, Hsinchu 30013, Taiwan; Natl Def Med Ctr, Dept Biochem, Taipei 10764, Taiwan	University System of Ohio; Ohio State University; National Tsing Hua University; National Defense Medical Center	Chiu, IM (corresponding author), Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA.	chiu.1@osu.edu; cyu@mx.nthu.edu.tw	Kumar, Suresh Thallapuranam/R-5606-2016; Chi, Ya-Hui/B-1080-2010; Chi, Ya-Hui/ABE-8550-2020; Kumar, Dr Suresh/HHZ-2615-2022; KUMAR, P. SURESH/AAT-8951-2020; Chiu, Ing-Ming/B-1534-2008	Kumar, Suresh Thallapuranam/0000-0001-7262-1373; Chi, Ya-Hui/0000-0002-9216-0938; Kumar, Dr Suresh/0000-0002-2539-6553; KUMAR, P. SURESH/0000-0003-3222-2604; Alphonse Ignatius, Arun/0000-0002-7342-044X				Arrington CB, 2000, METHOD ENZYMOL, V323, P104; Arunkumar AI, 2000, J BIOMOL NMR, V17, P279, DOI 10.1023/A:1008339701691; Arunkumar AI, 2002, PROTEIN SCI, V11, P1050, DOI 10.1110/ps.2270102; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Bai YW, 1996, PROTEINS, V24, P145, DOI 10.1002/(SICI)1097-0134(199602)24:2<145::AID-PROT1>3.0.CO;2-I; Bai YW, 1995, METHOD ENZYMOL, V259, P344; BAIRD A, 1990, PEPTIDE GROWTH FACTO; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; Blaber M, 1996, BIOCHEMISTRY-US, V35, P2086, DOI 10.1021/bi9521755; BRUNGER AT, 1992, XPLOR SOFTWARE MANUA; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Chi YH, 2002, J BIOL CHEM, V277, P34941, DOI 10.1074/jbc.M205446200; Chi YH, 2000, J BIOL CHEM, V275, P39444, DOI 10.1074/jbc.M007205200; CLORE GM, 1991, PROTEIN SCI, V3, P379; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DABORA JM, 1991, J BIOL CHEM, V266, P23637; DAVIES J, 1999, BIOCHEM J, V341, P611; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; FOLKMAN J, 1990, SCIENCE, V238, P442; Gardner KH, 1998, ANNU REV BIOPH BIOM, V27, P357, DOI 10.1146/annurev.biophys.27.1.357; GILSON MK, 1988, PROTEINS, V3, P32, DOI 10.1002/prot.340030104; KIM EE, 1992, BIOCHEMISTRY-US, V31, P12304, DOI 10.1021/bi00164a004; KUSZEWSKI J, 1995, J MAGN RESON SER B, V107, P293, DOI 10.1006/jmrb.1995.1093; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LEE B, 1991, BIOPOLYMERS, V31, P993, DOI 10.1002/bip.360310809; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; Markley JL, 1998, EUR J BIOCHEM, V256, P1, DOI 10.1046/j.1432-1327.1998.2560001.x; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Ogura K, 1999, J BIOMOL NMR, V13, P11, DOI 10.1023/A:1008330622467; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Patrie KM, 1997, GROWTH FACTORS, V14, P39, DOI 10.3109/08977199709021509; Patrie KM, 1999, BIOCHEMISTRY-US, V38, P9264, DOI 10.1021/bi9903345; PinedaLucena A, 1996, J MOL BIOL, V264, P162, DOI 10.1006/jmbi.1996.0631; PINEDALUCENA A, 1994, J MOL BIOL, V242, P81, DOI 10.1006/jmbi.1994.1558; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; POULIN ML, 1994, BBA-MOL CELL RES, V1220, P209, DOI 10.1016/0167-4889(94)90137-6; Ratnaparkhi GS, 2000, BIOCHEMISTRY-US, V39, P12365, DOI 10.1021/bi000775k; Ricciardi A, 2000, J BIOL CHEM, V275, P18302, DOI 10.1074/jbc.275.24.18302; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; Romero A, 1996, EUR J BIOCHEM, V241, P453, DOI 10.1111/j.1432-1033.1996.00453.x; Samuel D, 2000, J BIOL CHEM, V275, P34968, DOI 10.1074/jbc.M005147200; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Sivaraman T, 2000, BIOCHEMISTRY-US, V39, P8705, DOI 10.1021/bi992867j; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P1421, DOI 10.1021/bi00120a019; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P1892, DOI 10.1073/pnas.96.5.1892; VOLKIN DB, 1993, BIOCHIM BIOPHYS ACTA, V1203, P18, DOI 10.1016/0167-4838(93)90031-L; WUTHRICH K, 1982, J MOL BIOL, V155, P311, DOI 10.1016/0022-2836(82)90007-9; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	63	23	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46424	46432		10.1074/jbc.M207814200	http://dx.doi.org/10.1074/jbc.M207814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12205097	hybrid			2022-12-25	WOS:000179529300094
J	Joyce, JG; Hurni, WM; Bogusky, MJ; Garsky, VM; Liang, XP; Citron, MP; Danzeisen, RC; Miller, MD; Shiver, JW; Keller, PM				Joyce, JG; Hurni, WM; Bogusky, MJ; Garsky, VM; Liang, XP; Citron, MP; Danzeisen, RC; Miller, MD; Shiver, JW; Keller, PM			Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro - Implications for vaccine design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL FUSION MECHANISM; ENVELOPE GLYCOPROTEIN; MEMBRANE-FUSION; COILED-COIL; GP41 CORE; ATOMIC-STRUCTURE; ROTATING-FRAME; EPITOPE; ENTRY	The synthetic peptide DP178, derived from the carboxyl-terminal heptad repeat region of human immunodeficiency virus type 1 GP41 protein is a potent inhibitor of viral-mediated fusion and contains the sequence ELDKWA, which constitutes the recognition epitope for the broadly neutralizing human monoclonal antibody 2F5. Efforts at eliciting a 2F5-like immune response by immunization with peptides or fusion proteins containing this sequence have not met with success, possibly because of incorrect structural presentation of the epitope. Although the structure of the carboxyl-terminal heptad repeat on the virion is not known, several recent reports have suggested a propensity for a-helical conformation. We have examined DP178 in the context of a model for optimized a-helices and show that the native sequence conforms poorly to the model. Solution conformation of DP178 was studied by circular dichroism and NMR spectroscopy and found to be predominantly random, consistent with previous reports. NMR mapping was used to show that the low percentage of a-helix present was localized to residues Glu(662) through Asn(671), a region encompassing the 2F5 epitope. Using NH2-terminal extensions derived from either GP41 or the yeast GCN4 leucine zipper dimerization domain, we designed peptide analogs in which the average helicity is significantly increased compared with DP178 and show that these peptides exhibit both a modest increase in affinity for 2F5 using a novel competitive solution-based binding assay and an increased ability to inhibit viral entry in a single-cycle infectivity model. Selected peptides were conjugated to carrier protein and used for guinea pig immunizations. High peptide-specific titers were achieved using these immunogens, but the resulting sera were incapable of viral neutralization. We discuss these findings in terms of structural and immunological considerations as to the utility of a 2F5-like response.	Merck Res Labs, Dept Virus & Cell Biol, W Point, PA 19486 USA; Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA; Merck Res Labs, Dept Biol Chem, W Point, PA 19486 USA	Merck & Company; Merck & Company; Merck & Company	Joyce, JG (corresponding author), Merck Res Labs, Dept Virus & Cell Biol, W Point, PA 19486 USA.							Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Coeffier E, 2000, VACCINE, V19, P684, DOI 10.1016/S0264-410X(00)00267-X; CONLEY AJ, 1994, P NATL ACAD SCI USA, V91, P3348, DOI 10.1073/pnas.91.8.3348; Contreras LM, 2001, BIOCHEMISTRY-US, V40, P3196, DOI 10.1021/bi002613u; Dong XN, 2001, IMMUNOL LETT, V75, P215, DOI 10.1016/S0165-2478(00)00302-3; Earl PL, 2001, J VIROL, V75, P645, DOI 10.1128/JVI.75.2.645-653.2001; Eckhart L, 1996, J GEN VIROL, V77, P2001, DOI 10.1099/0022-1317-77-9-2001; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Follis KE, 2002, J VIROL, V76, P7356, DOI 10.1128/JVI.76.14.7356-7362.2002; Gorny MK, 2000, J VIROL, V74, P6186, DOI 10.1128/JVI.74.13.6186-6192.2000; GRIESINGER C, 1987, J MAGN RESON, V75, P261, DOI 10.1016/0022-2364(87)90035-7; Houston ME, 1996, J MOL BIOL, V262, P270, DOI 10.1006/jmbi.1996.0512; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kliger Y, 2000, J MOL BIOL, V301, P905, DOI 10.1006/jmbi.2000.4004; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; LEVITT MH, 1982, J MAGN RESON, V47, P328, DOI 10.1016/0022-2364(82)90124-X; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Mant CT, 1997, J CHROMATOGR A, V791, P85, DOI 10.1016/S0021-9673(97)00767-X; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; Moulard M, 2000, BBA-REV BIOMEMBRANES, V1469, P121, DOI 10.1016/S0304-4157(00)00014-9; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; PAI E, 2000, Patent No. 0061618; Phelan JC, 1997, J AM CHEM SOC, V119, P455, DOI 10.1021/ja9611654; Purtscher M, 1996, AIDS, V10, P587, DOI 10.1097/00002030-199606000-00003; Rabenstein MD, 1996, BIOCHEMISTRY-US, V35, P13922, DOI 10.1021/bi961743t; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; Sattentau QJ, 1996, CURR OPIN IMMUNOL, V8, P540, DOI 10.1016/S0952-7915(96)80044-6; SATTENTAU QJ, 1995, VIROLOGY, V206, P713, DOI 10.1016/S0042-6822(95)80094-8; Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u; Shu W, 2000, BIOCHEMISTRY-US, V39, P1634, DOI 10.1021/bi9921687; Shu W, 2000, J BIOL CHEM, V275, P1839, DOI 10.1074/jbc.275.3.1839; Shu W, 1999, BIOCHEMISTRY-US, V38, P5378, DOI 10.1021/bi990199w; SHULER KR, 1992, J IMMUNOL METHODS, V156, P137, DOI 10.1016/0022-1759(92)90020-T; Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796; Sodroski JG, 1999, CELL, V99, P243, DOI 10.1016/S0092-8674(00)81655-4; SOLTYSIK S, 1995, VACCINE, V13, P1403, DOI 10.1016/0264-410X(95)00077-E; Suarez T, 2000, J VIROL, V74, P8038, DOI 10.1128/JVI.74.17.8038-8047.2000; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; URRY DW, 1971, BIOCHIM BIOPHYS ACTA, V241, P600, DOI 10.1016/0005-2736(71)90058-7; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002	60	108	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45811	45820		10.1074/jbc.M205862200	http://dx.doi.org/10.1074/jbc.M205862200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237296	hybrid			2022-12-25	WOS:000179529300014
J	Takashima, S; Tsuji, S; Tsujimoto, M				Takashima, S; Tsuji, S; Tsujimoto, M			Characterization of the second type of human beta-galactoside alpha 2,6-sialyltransferase (ST6Gal II), which sialylates Gal beta 1,4GlcNAc structures on oligosaccharides preferentially	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; MOUSE SIALYLTRANSFERASE GENES; N-LINKED OLIGOSACCHARIDES; B-CELL ACTIVATION; MOLECULAR-CLONING; GALNAC ALPHA-2,6-SIALYLTRANSFERASE; TRANSCRIPTIONAL REGULATION; GENOMIC ORGANIZATION; EXPRESSION; FAMILY	A novel member of the human beta-galactoside alpha2,6-sialyltransferase (ST6Gal) family, designated ST6Gal II, was identified by BLAST analysis of expressed sequence tags and genomic sequences. The sequence of ST6Gal II encoded a protein of 529 amino acids, and it showed 48.9% amino acid sequence identity with human ST6Gal I. Recombinant ST6Gal II exhibited a2,6-sialyltransferase activity toward oligosaccharides that have the Galbeta1,4GlcNAc sequence at the nonreducing end of their carbohydrate groups, but it exhibited relatively low and no activities toward some glycoproteins and glycolipids, respectively. It is concluded that ST6Gal H is an oligosaccharide-specific enzyme compared with ST6Gal I, which exhibits broad substrate specificities, and is mainly involved in the synthesis of sialyloligosaccharides. The expression of the ST6Gal II gene was significantly detected by reverse transcription PCR in small intestine, colon, and fetal brain, whereas the ST6Gal I gene was ubiquitously expressed, and its expression levels were much higher than those of the ST6GaI II gene. The ST6GaI I gene was also expressed in all tumors examined, but no expression was observed for the ST6Gal II gene in these tumors. The ST6Gal II gene is located on chromosome 2 (2q11.2-q12.1), and it spans over 85 kb of human genomic DNA consisting of at least eight exons and shares a similar genomic structure with the ST6GaI I gene. In this paper, we have shown that ST6Gal 1, which has been known as the sole member of the ST6Gal family, also has the counterpart enzyme (ST6GaI II) like other sialyltransferases.	RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; Ochanomizu Univ, Fac Sci, Dept Chem, Bunkyo Ku, Tokyo 1128610, Japan	RIKEN; Ochanomizu University	Tsujimoto, M (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.							Dall'Olio Fabio, 2000, Glycoconjugate Journal, V17, P669, DOI 10.1023/A:1011077000164; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; HAMAMOTO T, 2001, HDB GLYCOSYLTRANSFER, P295; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; HARDUINLEPERS A, 2001, RRD CANCER 1, V3, P111; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Ikehara Y, 1999, GLYCOBIOLOGY, V9, P1213, DOI 10.1093/glycob/9.11.1213; Ikehara Y, 1999, FEBS LETT, V463, P92, DOI 10.1016/S0014-5793(99)01605-1; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; Kim KW, 2001, GENE, V273, P163, DOI 10.1016/S0378-1119(01)00595-9; Kitagawa H, 1996, J BIOL CHEM, V271, P931, DOI 10.1074/jbc.271.2.931; Kitazume-Kawaguchi S, 2001, J BIOL CHEM, V276, P15696, DOI 10.1074/jbc.M010371200; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kono M, 1996, J BIOL CHEM, V271, P29366, DOI 10.1074/jbc.271.46.29366; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; Kurosawa N, 2000, J BIOCHEM-TOKYO, V127, P845, DOI 10.1093/oxfordjournals.jbchem.a022678; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee YC, 1999, J BIOL CHEM, V274, P11958, DOI 10.1074/jbc.274.17.11958; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; Nakano Taku, 2001, Acta Paediatrica Taiwanica, V42, P11; Okajima T, 2000, J BIOL CHEM, V275, P6717, DOI 10.1074/jbc.275.10.6717; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; Okajima T, 1999, J BIOL CHEM, V274, P30557, DOI 10.1074/jbc.274.43.30557; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1994, J BIOL CHEM, V269, P10628; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; Takashima S, 2002, J BIOL CHEM, V277, P24030, DOI 10.1074/jbc.M112367200; Takashima S, 1999, BIOCHEM BIOPH RES CO, V260, P23, DOI 10.1006/bbrc.1999.0794; Takashima S, 2000, J BIOCHEM-TOKYO, V128, P1033, DOI 10.1093/oxfordjournals.jbchem.a022831; Taniguchi A, 2001, BIOCHEM BIOPH RES CO, V287, P1148, DOI 10.1006/bbrc.2001.5709; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; Tsuji S., 1999, SIALOBIOLOGY OTHER N, P145; WANG XC, 1993, J BIOL CHEM, V268, P4355; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628	47	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45719	45728		10.1074/jbc.M206808200	http://dx.doi.org/10.1074/jbc.M206808200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235148	hybrid			2022-12-25	WOS:000179529300002
J	Battaini, G; Monzani, E; Casella, L; Lonardi, E; Tepper, AWJW; Canters, GW; Bubacco, L				Battaini, G; Monzani, E; Casella, L; Lonardi, E; Tepper, AWJW; Canters, GW; Bubacco, L			Tyrosinase-catalyzed oxidation of fluorophenols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-ANTIBIOTICUS TYROSINASE; CRYSTAL-STRUCTURE; KOJIC ACID; MUSHROOM TYROSINASE; ACTIVE-SITE; INHIBITION; HEMOCYANIN; MECHANISM; BINDING; NMR	The activity of the type 3 copper enzyme tyrosinase toward 2-, 3-, and 4-fluorophenol was studied by kinetic methods and H-1 and F-19 NMR spectroscopy. Whereas 3- and 4-fluorophenol react with tyrosinase to give products that undergo a rapid polymerization process, 2-fluorophenol is not reactive and actually acts as a competitive inhibitor in the enzymatic oxidation of 3,4-dihydroxyphenylalanine (L-dopa). The tyrosinase-mediated polymerization of 3- and 4-fluorophenols has been studied in detail. It proceeds through a phenolic coupling pathway in which the common reactive fluoro-quinone, produced stereospecifically by tyrosinase, eliminates an inorganic fluorine ion. The enzymatic reaction studied as a function of substrate concentration shows a prominent lag that is completely depleted in the presence Of L-dopa. The kinetic parameters of the reactions can be correlated to the electronic and steric effects of the fluorine substituent position. Whereas the fluorine electron withdrawing effect appears to control the binding of the substrates (K-m for 3- and 4-fluorophenols and K-1 for 2-fluorophenol), the k(cat) parameters do not follow the expected trend, indicating that in the transition state some additional steric effect rules the reactivity.	Univ Pavia, Dipartimento Chim Gen, I-27100 Pavia, Italy; Leiden Univ, Gorlaeus Labs, Leiden Inst Chem, NL-2333 CC Leiden, Netherlands; Univ Padua, Dipartimento Biol, I-3012 Padua, Italy	University of Pavia; Leiden University; Leiden University - Excl LUMC; University of Padua	Casella, L (corresponding author), Univ Pavia, Dipartimento Chim Gen, Via Taramelli 12, I-27100 Pavia, Italy.		Bubacco, Luigi/B-5602-2012; Hu, Ruogu/B-2203-2008	Bubacco, Luigi/0000-0001-7927-9208; MONZANI, ENRICO/0000-0002-8791-6446				Boersma MG, 2001, J IND MICROBIOL BIOT, V26, P22, DOI 10.1038/sj.jim.7000027; Bubacco L, 1999, FEBS LETT, V442, P215, DOI 10.1016/S0014-5793(98)01662-7; Bubacco L, 2000, J MOL CATAL B-ENZYM, V8, P27, DOI 10.1016/S1381-1177(99)00064-8; CABANES J, 1994, J PHARM PHARMACOL, V46, P982, DOI 10.1111/j.2042-7158.1994.tb03253.x; CHEN JS, 1991, J AGR FOOD CHEM, V39, P1897, DOI 10.1021/jf00011a001; CHEN JS, 1991, J AGR FOOD CHEM, V39, P1396, DOI 10.1021/jf00008a008; Clementi V, 1998, ACCOUNTS CHEM RES, V31, P351, DOI 10.1021/ar960159+; Cooksey CJ, 1997, J BIOL CHEM, V272, P26226, DOI 10.1074/jbc.272.42.26226; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; Decker H, 2000, ANGEW CHEM INT EDIT, V39, P1591, DOI 10.1002/(SICI)1521-3773(20000502)39:9<1591::AID-ANIE1591>3.0.CO;2-H; Decker H, 2000, TRENDS BIOCHEM SCI, V25, P392, DOI 10.1016/S0968-0004(00)01602-9; DUCKWORTH HW, 1970, J BIOL CHEM, V245, P1613; Espin JC, 1998, BIOCHEM J, V331, P547, DOI 10.1042/bj3310547; HAZES B, 1993, PROTEIN SCI, V2, P597; JACKMAN MP, 1991, BIOCHEM J, V274, P707, DOI 10.1042/bj2740707; KABALPURWALA K, 1966, J AM CHEM SOC, V88, P3224; Key BD, 1997, ENVIRON SCI TECHNOL, V31, P2445, DOI 10.1021/es961007c; Leffler J. E., 1963, RATES EQUILIBRIA ORG; MENON S, 1990, ARCH BIOCHEM BIOPHYS, V280, P27, DOI 10.1016/0003-9861(90)90513-X; Olivares C, 2002, BIOCHEMISTRY-US, V41, P679, DOI 10.1021/bi011535n; Park JW, 1999, ENVIRON SCI TECHNOL, V33, P2028, DOI 10.1021/es9810787; Park JW, 2000, ARCH ENVIRON CON TOX, V38, P405, DOI 10.1007/s002449910054; PETER MG, 1989, ANGEW CHEM INT EDIT, V28, P555, DOI 10.1002/anie.198905551; Rodriguez-Lopez JN, 2001, BBA-PROTEIN STRUCT M, V1548, P238, DOI 10.1016/S0167-4838(01)00237-0; SANCHEZFERRER A, 1995, BBA-PROTEIN STRUCT M, V1247, P1; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; Tepper AWJW, 2002, J BIOL CHEM, V277, P30436, DOI 10.1074/jbc.M202461200; VanGelder CWG, 1997, PHYTOCHEMISTRY, V45, P1309, DOI 10.1016/S0031-9422(97)00186-6; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; WILCOX DE, 1985, J AM CHEM SOC, V107, P4015, DOI 10.1021/ja00299a043; [No title captured]	32	65	66	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44606	44612		10.1074/jbc.M207829200	http://dx.doi.org/10.1074/jbc.M207829200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235154	hybrid			2022-12-25	WOS:000179404800004
J	Han, DC; Shen, TL; Miao, H; Wang, BC; Guan, JL				Han, DC; Shen, TL; Miao, H; Wang, BC; Guan, JL			EphB1 associates with Grb7 and regulates cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL-ADHESION-KINASE; R-RAS; TRANSMEMBRANE LIGANDS; INTEGRIN ACTIVATION; NEURAL DEVELOPMENT; TYROSINE KINASES; BINDING PROTEINS; EPHRIN LIGANDS; RECEPTOR; FAMILY	EphB1 is a member of the Eph family of receptor tyrosine kinases that play important roles in diverse biological processes including nervous system development, angiogenesis, and neural synapsis formation and maturation. Grb7 is an adaptor molecule implicated in the regulation of cell migration. Here we report identification of an interaction between Grb7 and the cytoplasmic domain of EphB1 by using Grb7 as a "bait" in a yeast two-hybrid screening. Co-immunoprecipitation was used to confirm the interaction of Grb7 with the cytoplasmic domain of EphB1 as well as the full-length receptor in intact cells. This interaction is mediated by the SH2 domain of Grb7 and requires tyrosine autophosphorylation of EphB1. Furthermore, Tyr-928 of EphB1 was identified as the primary binding site for Grb7. Stimulation of endogenous EphB1 in embryonal carcinoma P19 cells with its ligand ephrinB1 increased its association with Grb7, which is consistent with a role for the autophosphorylation of EphB1. We also found that EphB1 could phosphorylate Grb7 and mutation of either Tyr-928 or Tyr-594 to Phe decreased this activity. Finally, we show that EphB1 could stimulate fibroblast motility on extracellular matrix in a kinase-dependent manner, which also correlated with its association with Grb7. Consistent with this, co-expression of Grb7 with EphB1 further enhanced cell motility, whereas co-expression of the Grb7 SH2 domain abolished EphB1-stimulated cell migration. Together, our results identified a novel interaction between EphB1 with the adaptor molecule Grb7 and suggested that this interaction may play a role in the regulation of cell migration by EphB1.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Korea Res Inst Biosci & Biotechnol, Taejon 305600, South Korea; Case Western Reserve Univ, Sch Med, Rammelkamp Ctr Res, Cleveland, OH 44109 USA	Cornell University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Case Western Reserve University; MetroHealth System	Guan, JL (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.		Shen, Tang-Long/C-7460-2011	Shen, Tang-Long/0000-0001-6264-3608	NATIONAL CANCER INSTITUTE [R01CA096533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK057933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052890] Funding Source: NIH RePORTER; NCI NIH HHS [CA96533] Funding Source: Medline; NIDDK NIH HHS [DK57933] Funding Source: Medline; NIGMS NIH HHS [GM52890, GM48050] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams RH, 2000, TRENDS CARDIOVAS MED, V10, P183, DOI 10.1016/S1050-1738(00)00046-3; Binns KL, 2000, MOL CELL BIOL, V20, P4791, DOI 10.1128/MCB.20.13.4791-4805.2000; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BOYD AW, 2001, SCI STKE, pRE20; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Cary LA, 1996, J CELL SCI, V109, P1787; CARY LA, 1999, FRONT BIOSCI, V4, P102; Choi S, 1999, ONCOGENE, V18, P5413, DOI 10.1038/sj.onc.1202917; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gale NW, 1997, CELL TISSUE RES, V290, P227, DOI 10.1007/s004410050927; Gu C, 2001, MOL CELL BIOL, V21, P4579, DOI 10.1128/MCB.21.14.4579-4597.2001; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Holland SJ, 1998, CURR OPIN NEUROBIOL, V8, P117, DOI 10.1016/S0959-4388(98)80015-9; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Knoll B, 2002, TRENDS NEUROSCI, V25, P145, DOI 10.1016/S0166-2236(00)02093-2; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Murai KK, 2002, NEURON, V33, P159, DOI 10.1016/S0896-6273(02)00565-2; OOI J, 1995, ONCOGENE, V10, P1621; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Shen TL, 2002, J BIOL CHEM, V277, P29069, DOI 10.1074/jbc.M203085200; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Tanaka S, 2000, J CELL PHYSIOL, V183, P411, DOI 10.1002/(SICI)1097-4652(200006)183:3<411::AID-JCP14>3.0.CO;2-Z; Wang BC, 2000, J BIOL CHEM, V275, P5222, DOI 10.1074/jbc.275.7.5222; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Yue Y, 1999, J NEUROSCI, V19, P2090; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHOU S, 1995, J BIOL CHEM, V270, P14863; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	51	67	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45655	45661		10.1074/jbc.M203165200	http://dx.doi.org/10.1074/jbc.M203165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223469	hybrid			2022-12-25	WOS:000179404800132
J	Han, SJ; Ko, HM; Choi, JH; Seo, KH; Lee, HS; Choi, EK; Choi, IW; Lee, HK; Im, SY				Han, SJ; Ko, HM; Choi, JH; Seo, KH; Lee, HS; Choi, EK; Choi, IW; Lee, HK; Im, SY			Molecular mechanisms for lipopolysaccharide-induced biphasic activation of nuclear factor-kappa B (NF-kappa B)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR ANTAGONIST; PHOSPHOLIPASE A(2); FACTOR-ALPHA; INNATE IMMUNITY; REL PROTEINS; CELL LINE; INTERLEUKIN-1; EXPRESSION; TNF	The nuclear factor-kappaB (NF-kappaB) is an important transcription factor necessary for initiating and sustaining inflammatory and immune reactions. The inducers of NF-kappaB are well characterized, but the molecular mechanisms underlying multiple in vivo NF-kappaB activation processes are poorly understood. The injection of lipopolysaccharide resulted in a biphasic activation of NF-kappaB during the 18-h observation period in various organs of mice. The early and late phases of NF-kappaB activation occurred at 0.5-2 h and 8-12 h, respectively. Platelet-activating factor, which is released in response to lipopolysaccharide injection, was responsible for the activation of the early phase of NF-kappaB The early NF-kappaB activity led to the induction of proinflammatory cytokines, tumor necrosis factor (TNF), and interleukin (IL)-1beta, which are known to be efficient inducers of NF-kappaB. Using the TNF knockout and IL-1 receptor knockout mice, we found that TNF and IL-1beta had a role in the second phase activation of NF-kappaB. These cytokines did promote the synthesis of platelet-activating factor, which in turn induced the secondary activation of NF-kappaB. These observations describe a novel autoregulatory molecular mechanism for the biphasic activation of NF-kappaB.	Chonnam Natl Univ, Dept Sci Biol, Coll Nat Sci, Inst Basic Sci, Kwangju 500757, South Korea; Chonnam Natl Univ, Sch Med, Dept Immunol, Chonju 561182, South Korea; Chonnam Natl Univ, Sch Med, Inst Med Sci, Chonju 561182, South Korea	Chonnam National University; Chonnam National University; Chonnam National University	Im, SY (corresponding author), Chonnam Natl Univ, Dept Sci Biol, Coll Nat Sci, Inst Basic Sci, Kwangju 500757, South Korea.							Aggarwal BB, 2000, ANN RHEUM DIS, V59, P6; BAUERLE PA, 1988, CELL, V53, P211; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Choi JH, 2001, J IMMUNOL, V166, P5139, DOI 10.4049/jimmunol.166.8.5139; Choi JH, 2000, INFLAMMATION, V24, P385, DOI 10.1023/A:1007068010645; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GODFREY RW, 1988, PROSTAGLANDINS, V35, P107, DOI 10.1016/0090-6980(88)90278-X; GOMEZCAMBRONERO J, 1985, BIOCHIM BIOPHYS ACTA, V845, P511, DOI 10.1016/0167-4889(85)90218-6; Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402; Han SJ, 1999, EUR J IMMUNOL, V29, P1334, DOI 10.1002/(SICI)1521-4141(199904)29:04<1334::AID-IMMU1334>3.0.CO;2-0; Hauf N, 1997, P NATL ACAD SCI USA, V94, P9394, DOI 10.1073/pnas.94.17.9394; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; Im SY, 1997, EUR J IMMUNOL, V27, P2800, DOI 10.1002/eji.1830271109; Im SY, 1996, CANCER RES, V56, P2662; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kimbrell DA, 2001, NAT REV GENET, V2, P256, DOI 10.1038/35066006; KONIECZKOWSKI M, 1993, J CLIN INVEST, V92, P2524, DOI 10.1172/JCI116861; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Liu SJ, 1998, AM J PHYSIOL-HEART C, V275, pH1462, DOI 10.1152/ajpheart.1998.275.4.H1462; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NOURSHARGH S, 1995, BLOOD, V85, P2553, DOI 10.1182/blood.V85.9.2553.bloodjournal8592553; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; POUBELLE PE, 1991, IMMUNOLOGY, V72, P181; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SMITH CS, 1994, CELL IMMUNOL, V155, P292, DOI 10.1006/cimm.1994.1123; Sporn LA, 1997, INFECT IMMUN, V65, P2786, DOI 10.1128/IAI.65.7.2786-2791.1997; Suputtamongkol Y, 2000, ANTIMICROB AGENTS CH, V44, P693, DOI 10.1128/AAC.44.3.693-696.2000; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Thommesen L, 1998, J IMMUNOL, V161, P3421; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TOUQUI L, 1985, BIOCHIM BIOPHYS ACTA, V833, P111, DOI 10.1016/0005-2760(85)90258-9; van Puijenbroek AAFL, 1999, CYTOKINE, V11, P104, DOI 10.1006/cyto.1998.0404; Vincent JL, 2000, CRIT CARE MED, V28, P638, DOI 10.1097/00003246-200003000-00006; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; YUROCHKO AD, 1995, J VIROL, V69, P5391, DOI 10.1128/JVI.69.9.5391-5400.1995	50	74	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44715	44721		10.1074/jbc.M202524200	http://dx.doi.org/10.1074/jbc.M202524200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235132	hybrid			2022-12-25	WOS:000179404800017
J	Momose, F; Naito, T; Yano, K; Sugimoto, S; Morikawa, Y; Nagata, K				Momose, F; Naito, T; Yano, K; Sugimoto, S; Morikawa, Y; Nagata, K			Identification of Hsp90 as a stimulatory host factor involved in influenza virus RNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; HEAT-SHOCK-PROTEIN; MESSENGER-RNA; SENDAI VIRUS; MOLECULAR CHAPERONES; POLYMERASE ACTIVITY; PHOSPHOPROTEIN P; IN-VITRO; TRANSCRIPTION; REPLICATION	Efficient transcription and replication of the influenza virus genome are dependent upon host-derived factors. Using an in vitro RNA synthesis system, we have purified and identified Hsp90 as one of the host factors that stimulate viral RNA polymerase activity. Hsp90 interacted with the PB2 subunit of the viral RNA polymerase through the amino-terminal chaperone domain and the middle region containing a highly acidic domain. The acidic middle region was also responsible for its stimulatory activity. We found that a portion of Hsp90 is re-localized to the cell nucleus after viral infection. A PB2 fragment containing a Hsp90 binding domain inhibited viral gene expression in a dominant-negative manner. These results suggest that Hsp90 is a host factor for the influenza virus RNA polymerase.	Univ Tsukuba, Inst Basic Med Sci, Dept Infect Biol, Tsukuba, Ibaraki 3058575, Japan; Kitasato Univ, Kitasato Inst Life Sci, Minato Ku, Tokyo 1088641, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 1948533, Japan; Tokyo Inst Technol, Yokohama, Kanagawa 2268501, Japan	University of Tsukuba; Kitasato University; Kyowa Kirin Ltd; Tokyo Institute of Technology	Nagata, K (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Infect Biol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.		Naito, Toshio/AAR-5071-2021					BRAAM J, 1983, CELL, V34, P609; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CHATTOPADHYAY D, 1987, P NATL ACAD SCI USA, V84, P8932, DOI 10.1073/pnas.84.24.8932; CHATTOPADHYAY D, 1988, P NATL ACAD SCI USA, V85, P7977, DOI 10.1073/pnas.85.21.7977; CURRAN J, 1994, VIROLOGY, V202, P875, DOI 10.1006/viro.1994.1409; DAS T, 1993, CELL MOL BIOL RES, V39, P93; DE BP, 1991, J VIROL, V65, P3268, DOI 10.1128/JVI.65.6.3268-3275.1991; Galarza JM, 1996, J VIROL, V70, P2360, DOI 10.1128/JVI.70.4.2360-2368.1996; HARTY RN, 1995, J GEN VIROL, V76, P2863, DOI 10.1099/0022-1317-76-11-2863; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; HUANG YT, 1993, VIROLOGY, V193, P862, DOI 10.1006/viro.1993.1195; Hung JJ, 2002, J VIROL, V76, P1379, DOI 10.1128/JVI.76.3.1379-1390.2002; ISHIHAMA A, 1988, CRC CR REV BIOCH MOL, V23, P27, DOI 10.3109/10409238809103119; KIMURA N, 1992, J GEN VIROL, V73, P1321, DOI 10.1099/0022-1317-73-6-1321; KRUG RM, 1975, J VIROL, V16, P790, DOI 10.1128/JVI.16.4.790-796.1975; Lai MMC, 1998, VIROLOGY, V244, P1, DOI 10.1006/viro.1998.9098; Li ML, 2001, EMBO J, V20, P2078, DOI 10.1093/emboj/20.8.2078; LUO GX, 1991, J VIROL, V65, P2861, DOI 10.1128/JVI.65.6.2861-2867.1991; Meng X, 1996, J CELL SCI, V109, P1677; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; Momose F, 2001, J VIROL, V75, P1899, DOI 10.1128/JVI.75.4.1899-1908.2001; Momose F, 1996, BIOCHIMIE, V78, P1103, DOI 10.1016/S0300-9084(97)86736-3; MOYER SA, 1986, P NATL ACAD SCI USA, V83, P5405, DOI 10.1073/pnas.83.15.5405; MOYER SA, 1990, J GEN VIROL, V71, P775, DOI 10.1099/0022-1317-71-4-775; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; NAGATA K, 1999, RRD VIROLOGY III, V1, P559; NAKAGAWA Y, 1995, J VIROL, V69, P728, DOI 10.1128/JVI.69.2.728-733.1995; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Nemoto T, 1998, BIOCHEM J, V330, P989, DOI 10.1042/bj3300989; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohtsu Y, 2002, MICROBIOL IMMUNOL, V46, P167, DOI 10.1111/j.1348-0421.2002.tb02682.x; OHTSU Y, MICROBIOL IMMUNOL, V46, P16702; Okuwaki M, 2001, J MOL BIOL, V311, P41, DOI 10.1006/jmbi.2001.4812; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; Poon LLM, 1999, J VIROL, V73, P3473, DOI 10.1128/JVI.73.4.3473-3476.1999; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SHIMIZU K, 1994, NUCLEIC ACIDS RES, V22, P5047, DOI 10.1093/nar/22.23.5047; SPRIGGS MK, 1986, J GEN VIROL, V67, P2705, DOI 10.1099/0022-1317-67-12-2705; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Takagi T, 1996, ARCH VIROL, V141, P1623, DOI 10.1007/BF01718287; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; YAMANAKA K, 1990, J BIOL CHEM, V265, P11151	48	185	194	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45306	45314		10.1074/jbc.M206822200	http://dx.doi.org/10.1074/jbc.M206822200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12226087	hybrid			2022-12-25	WOS:000179404800092
J	Thoden, JB; Kim, J; Raushel, FM; Holden, HM				Thoden, JB; Kim, J; Raushel, FM; Holden, HM			Structural and kinetic studies of sugar binding to galactose mutarotase from Lactococcus lactis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; PROTEIN STRUCTURES; CLONING; PROGRAM; GENES	Galactose mutarotase catalyzes the conversion of beta-D-galactose to a-D-galactose in the Leloir pathway for galactose metabolism. The high resolution x-ray structure of the dimeric enzyme from Lactococcus lactis was recently solved and shown to be topologically similar to the 18-stranded, anti-parallel beta-motif observed for domain 5 of beta-galactosidase. In addition to determining the overall molecular fold of galactose mutarotase, this initial investigation also provided a detailed description of the electrostatic interactions between the enzyme and its physiologically relevant substrate, galactose. Specifically, the side chains of His-96 and His-170 were shown to be located within hydrogen bonding distance to the C-5 oxygen of the substrate, while the carboxylate of Glu-304 was positioned near the C-1 hydroxyl group of the sugar. On the basis of this initial study, a possible role for Glu-304 as the general acid/base group in catalysis was put forth. Here we describe the combined x-ray crystallographic and kinetic analyses of L. lactis galactose mutarotase complexed with D-glucose, D-fucose, D-quinovose, L-arabinose, or D-xylose. These investigations have revealed that there are several distinct binding modes for these sugars, which are dependent upon the spatial orientation of the C-4 hydroxyl group. In those sugars with the same C-4 hydroxyl group orientation as galactose, their C-1 hydroxyl groups are invariably located near Glu-304. For those sugars, which have the same C-4 hydroxyl group configuration as glucose, the C-1 hydroxyls are typically located near Asp-243. These different binding modes correlate with both the observed kinetic parameters and the presence or absence of a hydrogen bond between the guanidinium group of Arg-71 and the C-4 hydroxyl group of the sugar ligand.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77842 USA	University of Wisconsin System; University of Wisconsin Madison; Texas A&M University System; Texas A&M University College Station	Thoden, JB (corresponding author), Univ Wisconsin, Dept Biochem, 443 Babcock Dr, Madison, WI 53706 USA.		Kim, Jungwook/AAP-1322-2020; Raushel, Frank/B-7125-2015	Kim, Jungwook/0000-0001-5213-9299; Raushel, Frank/0000-0002-5918-3089	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047814, R01DK030343, R56DK030343, R56DK047814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47814, DK30343] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY JM, 1969, J BIOL CHEM, V244, P781; BAILEY JM, 1967, J BIOL CHEM, V242, P4263; BENTLEY R, 1960, J BIOL CHEM, V235, P1219; BENTLEY R, 1960, J BIOL CHEM, V235, P1225; BOUFFARD GG, 1994, J MOL BIOL, V244, P269, DOI 10.1006/jmbi.1994.1728; Egloff MP, 2001, STRUCTURE, V9, P689, DOI 10.1016/S0969-2126(01)00626-8; Erlandson KA, 2001, APPL ENVIRON MICROB, V67, P1445, DOI 10.1128/AEM.67.4.1445-1452.2001; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; GATZ C, 1986, J BACTERIOL, V168, P31, DOI 10.1128/jb.168.1.31-39.1986; HUCHO F, 1971, EUR J BIOCHEM, V23, P489, DOI 10.1111/j.1432-1033.1971.tb01645.x; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; KESTON AS, 1954, SCIENCE, V120, P355, DOI 10.1126/science.120.3113.355-a; KESTON AS, 1963, ARCH BIOCHEM BIOPHYS, V102, P306, DOI 10.1016/0003-9861(63)90184-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAPEDES SL, 1968, BIOCHEM BIOPH RES CO, V31, P967, DOI 10.1016/0006-291X(68)90547-0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LI LK, 1965, ARCH BIOCHEM BIOPHYS, V110, P156, DOI 10.1016/0003-9861(65)90167-0; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; MASKELL DJ, 1992, MOL MICROBIOL, V6, P3051, DOI 10.1111/j.1365-2958.1992.tb01763.x; MOLLET B, 1991, J BACTERIOL, V173, P4464, DOI 10.1128/JB.173.14.4464-4473.1991; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; POOLMAN B, 1990, J BACTERIOL, V172, P4037, DOI 10.1128/jb.172.7.4037-4047.1990; Roussel A, 1990, ACTA CRYSTALLOGR A, V46, pC66; Thoden JB, 2002, J BIOL CHEM, V277, P20854, DOI 10.1074/jbc.M201415200; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALLENFELS K, 1965, BIOCHEM Z, V343, P294	26	32	32	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45458	45465		10.1074/jbc.M208395200	http://dx.doi.org/10.1074/jbc.M208395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12218067	hybrid			2022-12-25	WOS:000179404800110
J	Werten, S; Mitschler, A; Romier, C; Gangloff, YG; Thuault, S; Davidson, I; Moras, D				Werten, S; Mitschler, A; Romier, C; Gangloff, YG; Thuault, S; Davidson, I; Moras, D			Crystal structure of a subcomplex of human transcription factor TFIID formed by TATA binding protein-associated factors hTAF4 (hTAF(II)135) and hTAF12 (hTAF(II)20)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-FOLD; DNA-BINDING; CORE; COMPLEX; TAFS; DROSOPHILA; REQUIREMENT; TAF(II)250; SIMILARITY; PROGRAM	The crystal structure is presented of a complex formed by the interacting domains from two subunits of the general transcription factor TFIID, the human TATA binding protein-associated factors hTAF4 (hTAF(II)135) and hTAF12 (hTAF(II)20). In agreement with predictions, hTAF12 forms a histone fold that is very similar to that of histone H2B, yet unexpected differences are observed between the structures of the hTAF12 interaction domain of hTAF4 and histone H2A. Most importantly, the hTAF4 fragment forms only the first two helices of a classical histone fold, which are followed by a 26-residue disordered region. This indicates that either full-length TAF4 contains an unusually long connecting loop between its second and third helix, and this helix is not required for stable interaction with TAF12, or that TAF4 represents a novel class of partial histone fold motifs. Structural models and structure-based sequence alignments support a role for TAF4b and hSTAF42/yADA1 as alternative partners for TAF12 and are consistent with the formation of nucleosome-like histone-fold octamers through interaction of TAF12 with a TAF6-TAF9 tetramer, yet argue against involvement of TAF12-containing histone-fold pairs in DNA binding.	Univ Louis Pasteur Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), Univ Louis Pasteur Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, BP 163, F-67404 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr	Werten, Sebastiaan/AAU-9011-2021; GANGLOFF, Yann-Gaël/I-2161-2014	Werten, Sebastiaan/0000-0003-2244-9688; GANGLOFF, Yann-Gaël/0000-0001-9031-1184; Davidson, Irwin/0000-0001-5533-1171; Romier, Christophe/0000-0002-3680-935X; THUAULT, Sylvie/0000-0003-0133-3803				Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; FLOCCO MW, 1995, J MOL BIOL, V254, P96, DOI 10.1006/jmbi.1995.0602; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Fribourg S, 2001, J MOL BIOL, V306, P363, DOI 10.1006/jmbi.2000.4376; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2; Gangloff YG, 2001, MOL CELL BIOL, V21, P1841, DOI 10.1128/MCB.21.5.1841-1853.2001; Hiller MA, 2001, GENE DEV, V15, P1021, DOI 10.1101/gad.869101; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Otwinowski Z, 1993, P CCP4 STUD WEEK DAT, P55; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; Selleck W, 2001, NAT STRUCT BIOL, V8, P695, DOI 10.1038/90408; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thuault S, 2002, J BIOL CHEM, V277, P45510, DOI 10.1074/jbc.M206556200; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Wassarman DA, 2001, J CELL SCI, V114, P2895; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0	45	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45502	45509		10.1074/jbc.M206587200	http://dx.doi.org/10.1074/jbc.M206587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237304	Green Published, hybrid			2022-12-25	WOS:000179404800115
J	He, GC; Gupta, S; Yi, M; Michaely, P; Hobbs, HH; Cohen, JC				He, GC; Gupta, S; Yi, M; Michaely, P; Hobbs, HH; Cohen, JC			ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin, and AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA; BETA-ARRESTIN; INTERNALIZATION; RECOGNITION; BINDING; DOMAIN; MOTIF; IDENTIFICATION; ENDOCYTOSIS; MUTATIONS	Mutations in the phosphotyrosine binding domain protein ARH cause autosomal recessive hypercholesterolemia, a disorder caused by defective internalization of low density lipoprotein receptors (LDLR) in the liver. To examine the function of ARH, we used pull-down experiments to test for interactions between ARH, the LDLR, and proteins involved in clathrin-mediated endocytosis. The phosphotyrosine binding domain of ARH interacted with the internalization sequence (NPVY) in the cytoplasmic tail of LDLR in a sequence-specific manner. Mutations in the NPVY sequence that were previously shown to decrease LDLR internalization abolished in vitro binding to ARH. Recombinant ARH bound purified bovine clathrin with high affinity (K-D, similar to44 nm). The interaction between ARH and clathrin was mapped to a canonical clathrin box sequence (LLDLE) in ARH and to the N-terminal domain of the clathrin heavy chain. A highly conserved 20-amino acid sequence in the C-terminal region of ARH bound the beta(2)-adaptin subunit of AP-2. Mutation of a glutamic acid residue in the appendage domain of beta(2)-adaptin that is required for interaction with the adapter protein beta-arrestin markedly reduced binding to ARH. These data are consistent with the hypothesis that ARH functions as an adaptor protein that couples LDLR to the endocytic machinery.	Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cohen, JC (corresponding author), Univ Texas, SW Med Ctr, Ctr Human Nutr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jonathan.cohen@utsouthwestern.edu			NHLBI NIH HHS [HL20948, HL53917] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL053917] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arca M, 2002, LANCET, V359, P841, DOI 10.1016/S0140-6736(02)07955-2; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Boll W, 2002, TRAFFIC, V3, P590, DOI 10.1034/j.1600-0854.2002.30808.x; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; Dell'Angelica EC, 2001, TRENDS CELL BIOL, V11, P315, DOI 10.1016/S0962-8924(01)02043-8; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guy GR, 2002, CELL SIGNAL, V14, P11, DOI 10.1016/S0898-6568(01)00227-3; HAVEL RJ, 1988, HEPATOLOGY, V8, P1689, DOI 10.1002/hep.1840080637; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; INNERARITY TL, 1990, J LIPID RES, V31, P1337; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; Kim Y. B., 2002, J BIOL CHEM; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 2002, J BIOL CHEM, V277, P9247, DOI 10.1074/jbc.M108490200; Michaely P, 1999, J BIOL CHEM, V274, P35908, DOI 10.1074/jbc.274.50.35908; Norman D, 1999, J CLIN INVEST, V104, P619, DOI 10.1172/JCI6677; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141; Zuliani G, 1999, ARTERIOSCL THROM VAS, V19, P802, DOI 10.1161/01.ATV.19.3.802	33	174	180	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44044	44049		10.1074/jbc.M208539200	http://dx.doi.org/10.1074/jbc.M208539200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221107	hybrid			2022-12-25	WOS:000179272000067
J	Eto, K; Kimura, H				Eto, K; Kimura, H			A novel enhancing mechanism for hydrogen sulfide-producing activity of cystathionine beta-synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; SODIUM-NITROPRUSSIDE; S-ADENOSYLMETHIONINE; SMOOTH-MUSCLE; BRAIN-TISSUE; MUTATIONS; CYSTEINE; DOMAIN	H2S is produced from cysteine by cystathionine beta-synthase (CBS) in the brain and functions as a neuromodulator. Although the production of H2S is regulated by Ca2+ and calmodulin in response to neuronal excitation, little is known about the molecular mechanism for the regulation in CBS activity. Here we show that four cysteine residues of CBS are involved in the regulation of its activity in the presence of Ca2+ and calmodulin. Sodium nitroprusside (SNP), a modifying agent for cysteine residues, enhances CBS activity, whereas N-ethylmaleimide, an alkylating agent for cysteine residues, completely abolished the effect of SNP. Site-directed mutagenesis of the 13 cysteine residues of CBS identified four cysteine residues that are involved in the regulation of CBS activity by SNP, and two of the four residues are involved in the regulation of the basal CBS activity. The enhancement of CBS activity by SNP is independent of nitric oxide production. In the presence of Staphylococcus aureus alpha-hemolysin, which permeabilizes the cell membrane, exogenously applied SNP enhances the activity of CBS in intact cells. The present study demonstrates a novel mechanism for the regulation of CBS activity and provides a possible therapeutic application of SNP for the diseases in which CBS activity is deficient.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo 1878551, Japan	National Center for Neurology & Psychiatry - Japan	Kimura, H (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, 4-1-1 Ogawahigashi, Tokyo 1878551, Japan.	kimura@ncnp.go.jp	Kimura, Hideo/J-6811-2016					Abe K, 1996, J NEUROSCI, V16, P1066; BOTTIGLIERI T, 1994, DRUGS, V48, P137, DOI 10.2165/00003495-199448020-00002; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; Dello Russo C, 2000, J NEUROENDOCRINOL, V12, P225; Eto K, 2002, BIOCHEM BIOPH RES CO, V293, P1485, DOI 10.1016/S0006-291X(02)00422-9; Eto K, 2002, J NEUROSCI, V22, P3386; FINK D, 1989, CELL SIGNAL, V1, P387, DOI 10.1016/0898-6568(89)90057-0; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; GARRY MG, 1994, J NEUROSCI, V14, P4329; GEORGES RJ, 1970, CLIN CHIM ACTA, V30, P737, DOI 10.1016/0009-8981(70)90268-8; GOODWIN LR, 1989, J ANAL TOXICOL, V13, P105, DOI 10.1093/jat/13.2.105; GRIFFITH OW, 1987, METHOD ENZYMOL, V143, P366; GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; HU FL, 1993, HUM MOL GENET, V2, P1857, DOI 10.1093/hmg/2.11.1857; KNOWLES RG, 1990, BIOCHEM J, V269, P207, DOI 10.1042/bj2690207; Kraus JP, 1999, HUM MUTAT, V13, P362; LEEUWENKAMP OR, 1984, PHARM WEEKBLAD, V6, P195, DOI 10.1007/BF01999942; Morrison LD, 1996, J NEUROCHEM, V67, P1328; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; Ogita K, 1998, NEUROCHEM INT, V33, P1, DOI 10.1016/S0197-0186(05)80002-6; Ojha S, 2002, BIOCHEMISTRY-US, V41, P4649, DOI 10.1021/bi011827o; SAVAGE JC, 1990, J CHROMATOGR-BIOMED, V526, P540, DOI 10.1016/S0378-4347(00)82537-2; Shan XY, 2001, HUM MOL GENET, V10, P635, DOI 10.1093/hmg/10.6.635; SHIH VE, 1995, AM J HUM GENET, V57, P34; STIPANUK MH, 1982, BIOCHEM J, V206, P267, DOI 10.1042/bj2060267; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; VANRHEENEN DL, 1968, J CHROMATOGR, V37, P341, DOI 10.1016/S0021-9673(01)99120-4; WARENYCIA MW, 1989, BIOCHEM PHARMACOL, V38, P973, DOI 10.1016/0006-2952(89)90288-8; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	30	68	76	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42680	42685		10.1074/jbc.M205835200	http://dx.doi.org/10.1074/jbc.M205835200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12213817	hybrid			2022-12-25	WOS:000179081200033
J	Suzuki, H; Kumagai, H				Suzuki, H; Kumagai, H			Autocatalytic processing of gamma-glutamyltranspeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMYL-TRANSFERASE TRANSPEPTIDASE; ESCHERICHIA-COLI K-12; MOLECULAR-CLONING; BACILLUS-SUBTILIS; PRECURSOR FORM; INTRAMOLECULAR AUTOPROTEOLYSIS; NUCLEOTIDE-SEQUENCE; DNA-SEQUENCE; GENE; SUBUNIT	g-Glutamyltranspeptidase is the key enzyme in glutathione metabolism, and we previously presented evidence suggesting that it belongs to the N-terminal nucleophile hydrolase superfamily. Enzymatically active gamma-glutamyltranspeptidase, which consists of one large subunit and one small subunit, is generated from an inactive common precursor through post-translational proteolytic processing. The processing mechanism for gamma-glutamyltranspeptidase of Escherichia coli K-12 has been analyzed by means of in vitro studies using purified precursors. Here we show that the processing of a precursor of gamma-glutamyltranspeptidase is an intramolecular autocatalytic event and that the catalytic nucleophile for the processing reaction is the oxygen atom of the side chain of Thr-391 (N-terminal residue of the small (beta) subunit), which is also the nucleophile for the enzymatic reaction.	Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Suzuki, H (corresponding author), Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Sakyo Ku, Kyoto 6068502, Japan.	hideyuki@lif.kyoto-u.ac.jp						BAROUKI R, 1984, J BIOL CHEM, V259, P7970; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Bruice TC, 1966, BIOORGANIC MECH, V1, P259; CAPRARO MA, 1983, FEBS LETT, V157, P139, DOI 10.1016/0014-5793(83)81132-6; Carter BZ, 1998, J BIOL CHEM, V273, P28277, DOI 10.1074/jbc.273.43.28277; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; CLAUDIO JO, 1991, J FERMENT BIOENG, V72, P125, DOI 10.1016/0922-338X(91)90322-8; COLOMA J, 1986, NUCLEIC ACIDS RES, V14, P1393, DOI 10.1093/nar/14.3.1393; Ditzel L, 1998, J MOL BIOL, V279, P1187, DOI 10.1006/jmbi.1998.1818; FINIDORI J, 1984, J BIOL CHEM, V259, P4687; GOODSPEED DC, 1989, GENE, V76, P1, DOI 10.1016/0378-1119(89)90002-4; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; HAHIMOTO W, 1995, J BIOCH, V118, P1216; HASHIMOTO W, 1995, J BIOCHEM-TOKYO, V118, P75, DOI 10.1093/oxfordjournals.jbchem.a124894; HASHIMOTO W, 1992, BIOCHEM BIOPH RES CO, V189, P173, DOI 10.1016/0006-291X(92)91540-7; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; HEISTERKAMP N, 1991, P NATL ACAD SCI USA, V88, P6303, DOI 10.1073/pnas.88.14.6303; Hewitt L, 2000, J MOL BIOL, V302, P887, DOI 10.1006/jmbi.2000.4105; HUGHEY RP, 1976, J BIOL CHEM, V251, P7863; Ikeda Y, 1996, J BIOCHEM-TOKYO, V119, P1166; Inoue M, 2000, BIOCHEMISTRY-US, V39, P7764, DOI 10.1021/bi000220p; ISHIYE M, 1993, BIOTECHNOL PROGR, V9, P323, DOI 10.1021/bp00021a012; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; Kasche V, 1999, BBA-PROTEIN STRUCT M, V1433, P76, DOI 10.1016/S0167-4838(99)00155-7; Katayama T, 2000, APPL ENVIRON MICROB, V66, P4764, DOI 10.1128/AEM.66.11.4764-4771.2000; Kim S, 2001, J BIOL CHEM, V276, P48376, DOI 10.1074/jbc.M109603200; Kim Y, 2002, J BIOL CHEM, V277, P2823, DOI 10.1074/jbc.M108888200; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNO T, 1983, BIOCHEM BIOPH RES CO, V114, P889, DOI 10.1016/0006-291X(83)90864-1; KUNO T, 1984, BIOCHEM INT, V8, P581; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; Lee YS, 1998, J BACTERIOL, V180, P4576, DOI 10.1128/JB.180.17.4576-4582.1998; Li ST, 1999, J BACTERIOL, V181, P1403, DOI 10.1128/JB.181.5.1403-1408.1999; Li Y, 1999, EUR J BIOCHEM, V262, P713, DOI 10.1046/j.1432-1327.1999.00417.x; MATSUDA Y, 1983, J BIOCHEM-TOKYO, V94, P755, DOI 10.1093/oxfordjournals.jbchem.a134416; MATSUDA Y, 1980, J BIOCHEM, V87, P1243; MATSUDA Y, 1983, J BIOCHEM-TOKYO, V93, P1427, DOI 10.1093/oxfordjournals.jbchem.a134278; NASH B, 1984, J BIOL CHEM, V259, P678; NASH B, 1982, J BIOL CHEM, V257, P585; Ogawa Y, 1997, BIOSCI BIOTECH BIOCH, V61, P1596, DOI 10.1271/bbb.61.1596; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; PAPANDRIKOPOULOU A, 1989, EUR J BIOCHEM, V183, P693, DOI 10.1111/j.1432-1033.1989.tb21100.x; Potdar PD, 1997, AM J PHYSIOL-LUNG C, V273, pL1082, DOI 10.1152/ajplung.1997.273.5.L1082; RAJPERTDEMEYTS E, 1988, P NATL ACAD SCI USA, V85, P8840, DOI 10.1073/pnas.85.23.8840; Sakai H, 1996, J BIOCHEM, V120, P26, DOI 10.1093/oxfordjournals.jbchem.a021388; SAKAMURO D, 1988, GENE, V73, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 1995, FEBS LETT, V359, P173, DOI 10.1016/0014-5793(95)00036-9; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; SUZUKI H, 1988, BIOCHEM BIOPH RES CO, V150, P33, DOI 10.1016/0006-291X(88)90482-2; Suzuki H, 1999, J MOL CATAL B-ENZYM, V6, P175, DOI 10.1016/S1381-1177(98)00116-7; SUZUKI H, 1989, J BACTERIOL, V171, P5169, DOI 10.1128/jb.171.9.5169-5172.1989; SUZUKI H, 1986, J BACTERIOL, V168, P1332, DOI 10.1128/jb.168.3.1332-1335.1986; SUZUKI H, 1986, J BACTERIOL, V168, P1325, DOI 10.1128/jb.168.3.1325-1331.1986; SUZUKI H, 1987, J BACTERIOL, V169, P3926, DOI 10.1128/jb.169.9.3926-3931.1987; SUZUKI H, 1993, J BACTERIOL, V175, P6038, DOI 10.1128/JB.175.18.6038-6040.1993; Taniguchi N, 1998, ADV ENZYMOL RAMB, V72, P239; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TATE SS, 1976, P NATL ACAD SCI USA, V73, P2599, DOI 10.1073/pnas.73.8.2599; UCHIDA I, 1993, MOL MICROBIOL, V9, P487, DOI 10.1111/j.1365-2958.1993.tb01710.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Xu K, 1996, J BACTERIOL, V178, P4319, DOI 10.1128/jb.178.14.4319-4322.1996; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5; YOKOSAWA N, 1983, ONCODEV BIOL MED, V4, pC71	67	115	117	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43536	43543		10.1074/jbc.M207680200	http://dx.doi.org/10.1074/jbc.M207680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12207027	hybrid			2022-12-25	WOS:000179081200139
J	Pall, ML				Pall, ML			NMDA sensitization and stimulation by peroxynitrite, nitric oxide, and organic solvents as the mechanism of chemical sensitivity in multiple chemical sensitivity	FASEB JOURNAL			English	Review						neural sensitization; vicious cycle; reactive nitrogen species; chemical intolerance	LONG-TERM POTENTIATION; CHRONIC-FATIGUE-SYNDROME; BLOOD-BRAIN-BARRIER; POSTTRAUMATIC-STRESS-DISORDER; CENTRAL-NERVOUS-SYSTEM; EMISSION COMPUTED-TOMOGRAPHY; NEUROLOGIC SYMPTOM COMPLEXES; INFLAMMATORY CELL INVASION; CALCIUM-CHANNEL BLOCKERS; D-ASPARTATE RECEPTOR	Multiple chemical sensitivity (MCS) is a condition where previous exposure to hydrophobic organic solvents or pesticides appears to render people hypersensitive to a wide range of chemicals, including organic solvents. The hypersensitivity is often exquisite, with MCS individuals showing sensitivity that appears to be at least two orders of magnitude greater than that of normal individuals. This paper presents a plausible set of interacting mechanisms to explain such heightened sensitivity. It is based on two earlier theories of MCS: the elevated nitric oxide/peroxynitrite theory and the neural sensitization theory. It is also based on evidence implicating excessive NMDA activity in MCS. Four sensitization mechanisms are proposed to act synergistically, each based on known physiological mechanisms: Nitric oxide-mediated stimulation of neurotransmitter (glutamate) release; peroxynitrite-mediated ATP depletion and consequent hypersensitivity of NMDA receptors; peroxynitrite-mediated increased permeability of the blood-brain barrier, producing increased accessibility of organic chemicals to the central nervous system; and nitric oxide inhibition of cytochrome P450 metabolism. Evidence for each of these mechanisms, which may also be involved in Parkinson's disease, is reviewed. These interacting mechanisms provide explanations for diverse aspects of MCS and a framework for hypothesis-driven MCS research.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Pall, ML (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	martin_pall@wsu.edu						Abou-Donia MB, 2001, J TOXICOL ENV HEAL A, V62, P523, DOI 10.1080/152873901300007824; ADAMEC R, 1994, TOXICOL IND HEALTH, V10, P391; Adamec R, 1997, NEUROSCI BIOBEHAV R, V21, P755, DOI 10.1016/S0149-7634(96)00055-3; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; ANTELMAN SM, 1994, TOXICOL IND HEALTH, V10, P335; Arnetz BB, 1999, SCAND J WORK ENV HEA, V25, P569, DOI 10.5271/sjweh.482; Ashford N., 1998, CHEM EXPOSURES LOW L; Baker DG, 1997, ARCH INTERN MED, V157, P2076, DOI 10.1001/archinte.157.18.2076; Baranano DE, 2001, TRENDS NEUROSCI, V24, P99, DOI 10.1016/S0166-2236(00)01716-1; Bascom R, 1997, ENVIRON HEALTH PERSP, V105, P531, DOI 10.2307/3433365; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Bell I, 1998, AM J MED, V105, p74S 82S; Bell IR, 1999, TOXICOL IND HEALTH, V15, P295, DOI 10.1191/074823399678846826; BELL IR, 1992, BIOL PSYCHIAT, V32, P218, DOI 10.1016/0006-3223(92)90105-9; Bell IR, 2001, INT J NEUROSCI, V108, P31, DOI 10.3109/00207450108986503; Bell IR, 1998, J WOMENS HEALTH, V7, P1135, DOI 10.1089/jwh.1998.7.1135; Bell IR, 1999, INT J NEUROSCI, V97, P41, DOI 10.3109/00207459908994302; Bennett MR, 2000, PROG NEUROBIOL, V60, P109, DOI 10.1016/S0301-0082(99)00006-4; Bested AC, 2001, MED HYPOTHESES, V57, P231, DOI 10.1054/mehy.2001.1306; Binkley K, 2001, J ALLERGY CLIN IMMUN, V107, P887, DOI 10.1067/mai.2001.114798; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blobner M, 1999, ANESTHESIOLOGY, V91, P999, DOI 10.1097/00000542-199910000-00020; BONUCCELLI U, 1992, LANCET, V340, P53, DOI 10.1016/0140-6736(92)92466-S; Broberger C, 1998, AMINO ACIDS, V14, P25, DOI 10.1007/BF01345238; BRONSTEIN AC, 1995, J TOXICOL-CLIN TOXIC, V33, P93, DOI 10.3109/15563659509000455; BUCHWALD D, 1994, ARCH INTERN MED, V154, P2049, DOI 10.1001/archinte.154.18.2049; Calingasan NY, 1998, AM J PATHOL, V153, P599, DOI 10.1016/S0002-9440(10)65602-7; CARESS SM, 2002, IN PRESS AM J PUB HL; Chase TN, 2000, J NEUROL, V247, P36, DOI 10.1007/PL00007759; Clauw DJ, 1997, NEUROIMMUNOMODULAT, V4, P134, DOI 10.1159/000097332; CODERRE TJ, 1992, J NEUROSCI, V12, P3671; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CULLEN MR, 1987, OCCUP MED, V2, P655; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; Dekundy A, 2001, ARCH TOXICOL, V74, P702, DOI 10.1007/s002040000189; Del Dotto P, 2001, MOVEMENT DISORD, V16, P515, DOI 10.1002/mds.1112; Diaz A, 1997, PAIN, V69, P93, DOI 10.1016/S0304-3959(96)03271-X; Dineley KT, 2001, J NEUROCHEM, V77, P961, DOI 10.1046/j.1471-4159.2001.00321.x; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Donnay A., 1999, J CHRONIC FATIGUE SY, V5, P71, DOI [10.1300/J092v05n03_06, DOI 10.1300/J092V05N03_06]; DONNAY A, 2000, CARBON MONOXIDE TOXI, P31; Donnay AH, 1999, INT J TOXICOL, V18, P383, DOI 10.1080/109158199225099; Dudley DL, 1998, DEFINING MULTIPLE CHEMICAL SENSITIVITY, P9; ELLIOTT KJ, 1995, PAIN, V61, P401, DOI 10.1016/0304-3959(94)00214-Y; Fan JS, 1998, J BIOL CHEM, V273, P33472, DOI 10.1074/jbc.273.50.33472; Fernandez M, 1999, TOXICOL IND HEALTH, V15, P305, DOI 10.1191/074823399678846835; Fiedler N, 2001, ANN NY ACAD SCI, V933, P24; Fiedler N, 1996, PSYCHOSOM MED, V58, P38, DOI 10.1097/00006842-199601000-00007; FRIEDMAN MJ, 1994, TOXICOL IND HEALTH, V10, P449; Furlong CE, 2000, GENOME RES, V10, P153, DOI 10.1101/gr.10.2.153; Garbe TR, 2001, Z NATURFORSCH C, V56, P483; Gilbert ME, 2001, ANN NY ACAD SCI, V933, P68; Gots RE, 1996, REGUL TOXICOL PHARM, V24, pS8, DOI 10.1006/rtph.1996.0071; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; GURDAL H, 1992, PHARMACOLOGY, V44, P290, DOI 10.1159/000138932; Hageman G, 1999, J NEUROL, V246, P198, DOI 10.1007/s004150050334; HALEY JE, 1990, BRAIN RES, V518, P218, DOI 10.1016/0006-8993(90)90975-H; Haley RW, 1999, TOXICOL APPL PHARM, V157, P227, DOI 10.1006/taap.1999.8703; Hawkins RD, 1998, PROG BRAIN RES, V118, P155; Heresco-Levy U, 1998, EUR NEUROPSYCHOPHARM, V8, P141, DOI 10.1016/S0924-977X(97)00050-3; Heuser G, 2001, ANN NY ACAD SCI, V933, P319; HEUSER G, 1994, TOXICOL IND HEALTH, V10, P561; Hodgson MJ, 1999, J OCCUP ENVIRON MED, V41, P443, DOI 10.1097/00043764-199906000-00010; Hooper DC, 2000, FASEB J, V14, P691, DOI 10.1096/fasebj.14.5.691; Hooper DC, 2001, J IMMUNOL, V167, P3470, DOI 10.4049/jimmunol.167.6.3470; *IA PERS GULF STUD, 1997, JAMA-J AM MED ASSOC, V227, P238; Ikeda K, 1997, ACT NEUR S, V70, P4; Imaizumi S, 1996, NEUROCHEM INT, V29, P205, DOI 10.1016/0197-0186(95)00120-4; Itzhak Y, 1996, NEUROPHARMACOLOGY, V35, P1065, DOI 10.1016/S0028-3908(96)00037-8; Itzhak Y, 2000, NEUROPHARMACOLOGY, V39, P32, DOI 10.1016/S0028-3908(99)00073-8; ITZHAK Y, 1995, MOL NEUROBIOL, V11, P217, DOI 10.1007/BF02740696; IZHAK Y, 1998, PSYCHOPHARMACOLOGY B, V140, P378; JOHNSON A, 2000, CASUALTIES PROGR; Kastenbauer S, 1999, J INFECT DIS, V180, P1164, DOI 10.1086/315048; Kean RB, 2000, J IMMUNOL, V165, P6511, DOI 10.4049/jimmunol.165.11.6511; Kennedy M, 1998, GASTROENTEROLOGY, V114, P510, DOI 10.1016/S0016-5085(98)70534-7; KHATSENKO OG, 1993, P NATL ACAD SCI USA, V90, P11147, DOI 10.1073/pnas.90.23.11147; Kipen HM, 1999, ARCH ENVIRON HEALTH, V54, P313, DOI 10.1080/00039899909602493; Kissin I, 2000, ANESTH ANALG, V91, P110, DOI 10.1097/00000539-200007000-00021; Kreutzer R, 1999, AM J EPIDEMIOL, V150, P1; KURIYAMA K, 1995, JPN J PHARMACOL, V34, P347; LAFONCAZAL M, 1993, NEUROPHARMACOLOGY, V32, P1259, DOI 10.1016/0028-3908(93)90020-4; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Lallement G, 1999, NEUROTOXICOLOGY, V20, P675; Lallement G, 1998, J PHYSIOLOGY-PARIS, V92, P369, DOI 10.1016/S0928-4257(99)80007-2; Lam HHD, 1996, NEUROSCI LETT, V210, P201, DOI 10.1016/0304-3940(96)12702-6; Li L, 2001, TOXICOL APPL PHARM, V177, P17, DOI 10.1006/taap.2001.9283; Liang J, 1999, NAT STRUCT BIOL, V6, P735; LIPTON SA, 1994, MOL NEUROBIOL, V8, P181, DOI 10.1007/BF02780669; Liu JSH, 2001, AM J PATHOL, V158, P2057, DOI 10.1016/S0002-9440(10)64677-9; Loopuijt LD, 1998, AMINO ACIDS, V14, P17, DOI 10.1007/BF01345237; Mao JR, 2001, ANN NY ACAD SCI, V933, P175; MATTIA CJ, 1993, MOL CHEM NEUROPATHOL, V18, P313, DOI 10.1007/BF03160122; Mayhan WG, 2000, BRAIN RES, V866, P101, DOI 10.1016/S0006-8993(00)02254-X; McMahon S B, 1993, Curr Opin Neurobiol, V3, P602, DOI 10.1016/0959-4388(93)90062-4; Meggs WJ, 1997, ENVIRON HEALTH PERSP, V105, P473, DOI 10.2307/3433355; MICKIEWICZ W, 1988, BIOCHEM PHARMACOL, V37, P4439, DOI 10.1016/0006-2952(88)90658-2; MILLER CS, 1995, ARCH ENVIRON HEALTH, V50, P119, DOI 10.1080/00039896.1995.9940889; Miller CS, 1999, TOXICOL IND HEALTH, V15, P284, DOI 10.1191/074823399678846871; Montastruc JL, 1997, NEUROSCI BIOBEHAV R, V21, P477, DOI 10.1016/S0149-7634(96)00035-8; Muller CM, 1996, ANESTHESIOLOGY, V84, P1435, DOI 10.1097/00000542-199606000-00020; MURRAY CW, 1991, PAIN, V44, P179, DOI 10.1016/0304-3959(91)90135-K; Muttray A, 1995, Int J Occup Med Environ Health, V8, P131; Nag S, 2001, LAB INVEST, V81, P41, DOI 10.1038/labinvest.3780210; Nash JE, 2000, J NEUROSCI, V20, P7782; Nicolson G L, 1998, Med Confl Surviv, V14, P156, DOI 10.1080/13623699808409384; Nohl H, 1996, FREE RADICAL BIO MED, V20, P207, DOI 10.1016/0891-5849(95)02038-1; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OHLSON CG, 1981, SCAND J WORK ENV HEA, V7, P252, DOI 10.5271/sjweh.2549; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Pall ML, 2001, ANN NY ACAD SCI, V933, P323; Pall ML, 2001, MED HYPOTHESES, V57, P139, DOI 10.1054/mehy.2001.1325; Pall ML, 2000, MED HYPOTHESES, V54, P115, DOI 10.1054/mehy.1998.0825; Pall ML, 2001, J CHRONIC FATIGUE SY, V8, P39; Pall ML, 2000, J CHRONIC FATIGUE SY, V7, P45, DOI [10.1300/J092v07n04_05, DOI 10.1300/J092V07N04_05]; PALL ML, 2002, IN PRESS J CHRONIC F; Palmer GC, 2000, AMINO ACIDS, V19, P151, DOI 10.1007/s007260070043; Parales RE, 2000, APPL ENVIRON MICROB, V66, P4098, DOI 10.1128/AEM.66.9.4098-4104.2000; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Pezzoli G, 2000, NEUROLOGY, V55, P667, DOI 10.1212/WNL.55.5.667; PIETROBON D, 1987, BIOCHEMISTRY-US, V26, P7339, DOI 10.1021/bi00397a022; Platenik J, 2000, LIFE SCI, V67, P335, DOI 10.1016/S0024-3205(00)00632-9; Prast H, 2001, PROG NEUROBIOL, V64, P51, DOI 10.1016/S0301-0082(00)00044-7; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; REA WJ, 1992, CHEM SENSITIVITY, V1; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Riederer P, 2000, J NEUROL, V247, P8; ROMERO G, 1994, LIFE SCI, V55, P981, DOI 10.1016/0024-3205(94)00632-6; Ross GH, 1999, TOXICOL IND HEALTH, V15, P415, DOI 10.1191/074823399678846853; Rossi J, 1996, TOXICOLOGY, V111, P87, DOI 10.1016/0300-483X(96)03394-X; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; Schultz JB, 1997, MOL CELL BIOCHEM, V174, P171; Sharom FJ, 2001, SEMIN CELL DEV BIOL, V12, P257, DOI 10.1006/scdb.2000.0251; SIMON TR, 1994, TOXICOL IND HEALTH, V10, P573; Singh J., 1995, Indian Journal of Physiology and Pharmacology, V39, P275; Smargiassi A, 1998, NEUROTOXICOLOGY, V19, P709; Snyder S H, 1992, Curr Opin Neurobiol, V2, P323, DOI 10.1016/0959-4388(92)90123-3; Sorg BA, 1997, ENVIRON HEALTH PERSP, V105, P467, DOI 10.2307/3433354; Sorg BA, 2001, ANN NY ACAD SCI, V933, P57; Sorg BA, 1999, CRIT REV NEUROBIOL, V13, P283, DOI 10.1615/CritRevNeurobiol.v13.i3.30; Spitsin SV, 2000, NEUROSCI LETT, V292, P137, DOI 10.1016/S0304-3940(00)01446-4; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Takemura S, 1999, J HEPATOL, V30, P1035, DOI 10.1016/S0168-8278(99)80257-8; TANNER CM, 1992, OCCUP MED, V7, P503; Tochio H, 1998, NAT STRUCT BIOL, V5, P965, DOI 10.1038/2940; TURSKI L, 1993, EXPERIENTIA, V49, P1064, DOI 10.1007/BF01929915; UITTI RJ, 1994, ANN NEUROL, V35, P616, DOI 10.1002/ana.410350516; Wang H, 1999, J NEUROSCI RES, V57, P824, DOI 10.1002/(SICI)1097-4547(19990915)57:6<824::AID-JNR7>3.0.CO;2-V; WIERTELAK EP, 1994, BRAIN RES, V649, P19, DOI 10.1016/0006-8993(94)91044-8; Williams JH, 1996, J LIPID MEDIAT CELL, V14, P331, DOI 10.1016/0929-7855(96)00542-1; Willis WD, 2001, ANN NY ACAD SCI, V933, P142; Winkler F, 2001, J INFECT DIS, V183, P1749, DOI 10.1086/320730; Yunus MB, 2000, J INDIAN RHEUM ASS, V8, P27; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213; ZIEM G, 1995, ARCH INTERN MED, V155, P1913, DOI 10.1001/archinte.155.17.1913; Ziem G, 1997, ENVIRON HEALTH PERSP, V105, P417, DOI 10.2307/3433348	162	47	48	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2002	16	11					1407	1417		10.1096/fj.01-0861hyp	http://dx.doi.org/10.1096/fj.01-0861hyp			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12205032				2022-12-25	WOS:000178441800015
J	Holmes, WF; Soprano, DR; Soprano, KJ				Holmes, WF; Soprano, DR; Soprano, KJ			Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MITOCHONDRIAL CYTOCHROME-C; CARBOXYLIC-ACID CD437; CANCER-CELLS; SELECTIVE RETINOIDS; POSSIBLE MECHANISM; GROWTH-INHIBITION; ORPHAN RECEPTOR; LEUKEMIA-CELLS; RAR-GAMMA	Retinoids have great promise in the area of cancer therapy and chemoprevention. Although some tumor cells are sensitive to the growth inhibitory effect of all-trans-retinoic acid (ATRA), many ovarian tumor cells are not. 6-((1-Admantyl)-4-hydroxyphenyl)-2-naphthalenecarboxylic acid (CD437) is a conformationally restricted synthetic retinoid that induces growth arrest and apoptosis in both ATRA-sensitive and ATRA-resistant ovarian tumor cell lines. To better understand the mechanism by which CD437 induces apoptosis in ovarian tumor cell lines, we prepared a cell line, CA-CD437R, from the ATRA-sensitive ovarian cell line, CA-OV-3, which was resistant to CD437. We found that the CD437-resistant cell line was also resistant to the induction of apoptosis by tumor necrosis factor-a but not resistant to the induction of apoptosis by another synthetic retinoid, fenretinide N-(4-hydroxyphenyl)retinamide. We also show that this cell line remains ATRA-sensitive and exhibits no deficiencies in RAR function. Analysis of this CD437-resistant cell line suggests that the pathway for induction of apoptosis by CD437 is similar to the pathway utilized by tumor necrosis factor-a and different from the pathway induced by the synthetic retinoid, fenretinide N-(4-hydroxyphenyl)retinamide. The CA-CD437R cell line is a valuable tool, permitting us to further elucidate the molecular events that mediate apoptosis induced by CD437 and other synthetic retinoids. Results of experiments utilizing this cell line suggest that the alteration responsible for resistance of CA-CD437R cells to CD437 induced event maps after the activation of p38 and TR3 expression, prior to mitochondrial depolarization, subsequent release of cytochrome c and activation of caspase-9 and caspase-3.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	sopranok@astro.temple.edu			NATIONAL CANCER INSTITUTE [R01CA064945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013139] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64945] Funding Source: Medline; NIAID NIH HHS [AI 07101] Funding Source: Medline; NIDCR NIH HHS [DE 13139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adachi H, 1998, CELL DEATH DIFFER, V5, P973, DOI 10.1038/sj.cdd.4400445; Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; AVDI NJ, 2000, J BIOL CHEM, V25, P25; Chao WR, 1997, CANCER LETT, V115, P1, DOI 10.1016/S0304-3835(97)04598-9; Chen XL, 1998, J VIROL, V72, P6902, DOI 10.1128/JVI.72.8.6902-6906.1998; Chun HS, 2001, NEUROSCI LETT, V316, P5, DOI 10.1016/S0304-3940(01)02341-2; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Dawson MI, 2001, CANCER RES, V61, P4723; DE LUCA LM, 1991, FASEB J, V5, P2924; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Gudas Lorraine J., 1994, P443; Hail N, 2001, CANCER RES, V61, P6698; Hail N, 2000, CANCER EPIDEM BIOMAR, V9, P1293; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; He JL, 2000, J PHARMACOL EXP THER, V295, P896; Holmes WF, 2000, J CELL PHYSIOL, V185, P61, DOI 10.1002/1097-4652(200010)185:1<61::AID-JCP5>3.0.CO;2-0; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Kang HJ, 2000, EXP CELL RES, V256, P545, DOI 10.1006/excr.2000.4832; Kang HJ, 2000, BIOL PHARM BULL, V23, P815; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kitareewan S, 1999, ONCOGENE, V18, P5747, DOI 10.1038/sj.onc.1202981; Kumar A, 2001, CANCER RES, V61, P7552; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liu GZ, 1998, INT J CANCER, V78, P248, DOI 10.1002/(SICI)1097-0215(19981005)78:2&lt;248::AID-IJC20&gt;3.0.CO;2-5; Liu RY, 2000, J BIOL CHEM, V275, P21086, DOI 10.1074/jbc.M001281200; Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; Marchetti P, 1999, CANCER RES, V59, P6257; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; Moon Richard C., 1994, P573; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Newman SJ, 2000, BRAIN RES, V857, P131, DOI 10.1016/S0006-8993(99)02417-8; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Pergolizzi R, 1999, INT J CANCER, V81, P829; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Ponzanelli I, 2000, BLOOD, V95, P2672; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; Salgame P, 1997, NUCLEIC ACIDS RES, V25, P680, DOI 10.1093/nar/25.3.680; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAO ZM, 1995, ONCOGENE, V11, P493; Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990; Sun SY, 1999, CANCER RES, V59, P2829; Sun SY, 1999, CANCER RES, V59, P2493; Sun SY, 1997, CANCER RES, V57, P4931; Sun SY, 2000, CANCER RES, V60, P7149; Supino R, 1996, INT J CANCER, V65, P491, DOI 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Szondy Z, 1997, MOL PHARMACOL, V51, P972, DOI 10.1124/mol.51.6.972; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Wei YH, 1996, ANN NY ACAD SCI, V786, P24, DOI 10.1111/j.1749-6632.1996.tb39049.x; Widschwendter M, 1997, INT J CANCER, V71, P497; Wu SJ, 1998, J CELL BIOCHEM, V68, P378, DOI 10.1002/(SICI)1097-4644(19980301)68:3<378::AID-JCB8>3.0.CO;2-R; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; Zhang XK, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090087; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350; Zhao M, 2000, ACTA BIOCH BIOPH SIN, V32, P258; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	70	50	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45408	45419		10.1074/jbc.M204600200	http://dx.doi.org/10.1074/jbc.M204600200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237293	hybrid			2022-12-25	WOS:000179404800104
J	Maur, AAD; Zahnd, C; Fischer, F; Spinelli, S; Honegger, A; Cambillau, C; Escher, D; Pluckthun, A; Barberis, A				Maur, AAD; Zahnd, C; Fischer, F; Spinelli, S; Honegger, A; Cambillau, C; Escher, D; Pluckthun, A; Barberis, A			Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II HOLOENZYME; IN-VITRO; ANTIBODY FRAGMENT; VARIABLE DOMAINS; FV-FRAGMENTS; INTRACELLULAR EXPRESSION; BINDING PROTEINS; ESCHERICHIA-COLI; GENE ACTIVATION; LEUCINE ZIPPER	Single-chain Fv antibody fragments (scFv) represent a convenient antibody format for intracellular expression in eukaryotic or prokaryotic cells. These so-called intrabodies have great potential in functional genomics as a tool to study the function of newly identified proteins in vivo, for example by binding-induced modulation of their activity or by blocking interactions with other proteins. However, the intracellular expression and activity of many single-chain Fvs are limited by their instability and folding efficiency in the reducing intracellular environment, where the highly conserved intrachain disulfide bonds do not form. In the present work, we used an in vivo selection system to isolate novel antigen-binding intrabodies. We screened two intrabody libraries carrying a randomized third hypervariable loop onto the heavy chain of a stable framework, which had been further optimized by random mutagenesis for better behavior in the selection system, and we biophysically characterized the selected variants to interpret the outcome of the selection. Our results show that single-framework intrabody libraries can be directly screened in vivo to rapidly select antigen-specific intrabodies.	ESBATech AG, CH-8952 Zurich, Switzerland; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; CNRS, F-13402 Marseille, France	University of Zurich; Centre National de la Recherche Scientifique (CNRS)	Barberis, A (corresponding author), ESBATech AG, Wagistr 21, CH-8952 Zurich, Switzerland.		Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306; Honegger, Annemarie/0000-0002-3378-3967				Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Barstead R, 2001, CURR OPIN CHEM BIOL, V5, P63, DOI 10.1016/S1367-5931(00)00173-3; BENVENUTO E, 1995, TRENDS MICROBIOL, V3, P272, DOI 10.1016/S0966-842X(00)88943-X; BIOCCA S, 1993, BIOCHEM BIOPH RES CO, V197, P422, DOI 10.1006/bbrc.1993.2496; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CATTANEO A, 1997, INTRACELLULAR ANTIBO; Chattopadhyaya R, 2000, J BIOMOL STRUCT DYN, V18, P181, DOI 10.1080/07391102.2000.10506657; CHEN HZ, 1983, METHOD ENZYMOL, V101, P674; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; Cochet O, 1998, CANCER RES, V58, P1170; der Maur AA, 2001, FEBS LETT, V508, P407, DOI 10.1016/S0014-5793(01)03101-5; Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602; Escher D, 2000, MOL CELL BIOL, V20, P2774, DOI 10.1128/MCB.20.8.2774-2782.2000; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Ge L, 1995, ANTIBODY ENG, P229; Giles RV, 2000, CURR OPIN MOL THER, V2, P238; GLOCKSHUBER R, 1992, BIOCHEMISTRY-US, V31, P1270, DOI 10.1021/bi00120a002; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; Hanes J, 1998, P NATL ACAD SCI USA, V95, P14130, DOI 10.1073/pnas.95.24.14130; Harris S, 2000, Pharmacogenomics, V1, P433, DOI 10.1517/14622416.1.4.433; Hassanzadeh G, 1998, FEBS LETT, V437, P75, DOI 10.1016/S0014-5793(98)01204-6; Honegger A, 2001, J MOL BIOL, V309, P657, DOI 10.1006/jmbi.2001.4662; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Jermutus L, 2001, P NATL ACAD SCI USA, V98, P75, DOI 10.1073/pnas.011311398; Jung S, 1997, PROTEIN ENG, V10, P959, DOI 10.1093/protein/10.8.959; Kaiser C, 1994, METHODS YEAST GENETI, P169; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lener M, 2000, EUR J BIOCHEM, V267, P1196, DOI 10.1046/j.1432-1327.2000.01125.x; Martineau P, 1998, J MOL BIOL, V280, P117, DOI 10.1006/jmbi.1998.1840; Maynard J, 2000, ANNU REV BIOMED ENG, V2, P339, DOI 10.1146/annurev.bioeng.2.1.339; Mossner E, 2001, J MOL BIOL, V308, P115, DOI 10.1006/jmbi.2001.4575; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Pluckthun A, 1996, ANTIBODY ENG PRACTIC, P203; POKROVSKAYA ID, 1994, ANAL BIOCHEM, V220, P420, DOI 10.1006/abio.1994.1360; Portner-Taliana A, 2000, J IMMUNOL METHODS, V238, P161, DOI 10.1016/S0022-1759(00)00145-9; Rondon IJ, 1997, ANNU REV MICROBIOL, V51, P257, DOI 10.1146/annurev.micro.51.1.257; Sambrook J., 1989, MOL CLONING; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; TAVLADORAKI P, 1993, NATURE, V366, P469, DOI 10.1038/366469a0; Tse E, 2002, J MOL BIOL, V317, P85, DOI 10.1006/jmbi.2002.5403; Verma R, 1998, J IMMUNOL METHODS, V216, P165, DOI 10.1016/S0022-1759(98)00077-5; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; Visintin M, 2002, J MOL BIOL, V317, P73, DOI 10.1006/jmbi.2002.5392; Worn A, 2000, J BIOL CHEM, V275, P2795, DOI 10.1074/jbc.275.4.2795; Worn A, 1998, BIOCHEMISTRY-US, V37, P13120, DOI 10.1021/bi980712q	53	58	81	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45075	45085		10.1074/jbc.M205264200	http://dx.doi.org/10.1074/jbc.M205264200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12215438	hybrid			2022-12-25	WOS:000179404800063
J	Okuda, T; Okamura, M; Kaitsuka, C; Haga, T; Gurwitz, D				Okuda, T; Okamura, M; Kaitsuka, C; Haga, T; Gurwitz, D			Single nucleotide polymorphism of the human high affinity choline transporter alters transport rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR ACETYLCHOLINE TRANSPORTER; ALZHEIMERS-DISEASE; MOLECULAR-CLONING; BRAIN SYNAPTOSOMES; COTRANSPORTER; EXPRESSION; SYSTEMS; RELEASE	High affinity choline uptake plays a critical role in the regulation of acetylcholine synthesis in cholinergic neurons. Recently, we succeeded in molecular cloning of the high affinity choline transporter (CHT1), which is specifically expressed in cholinergic neurons. Here we demonstrate the presence of functionally relevant, nonsynonymous single nucleotide polymorphism in the human CHT1 gene by comprehensive sequence analysis of the exons and the intron/exon boundaries including the transcription start site. The deduced amino acid change for the polymorphism is isoleucine to valine at amino acid 89 (I89V) located within the third transmembrane domain of the protein. The allele frequency of I89V was 6% for Ashkenazi Jews. Functional assessment of the I89V transporter in mammalian cell lines revealed a 40-50% decrease in V-max for choline uptake rate compared with the wild type, whereas there was no alteration in the apparent affinities for choline, sodium, chloride, and the specific inhibitor hemicholinum-3. There also was no change in the specific hemicholinum-3 binding activity. The decreased choline uptake was not associated with the surface expression level of the protein as assessed by biotinylation assay. These results suggest an impaired substrate translocation in the I89V transporter. The Caenorhabditis elegans ortholog of CHT1 has a valine residue at the corresponding position and a single replacement from valine to isoleucine caused a decrease in the choline uptake rate by 40%, suggesting that this hydrophobic residue is generally critical in the choline transport rate in CHT1. This polymorphism in the allelic CHT1 gene may represent a predisposing factor for cholinergic dysfunction.	Gakushuin Univ, Fac Sci, Inst Biomol Sci, Toshima Ku, Tokyo 1718588, Japan; Japan Sci & Technol Corp, CREST, Toshima Ku, Tokyo 1718588, Japan; Univ Tokyo, Fac Med, Dept Neurochem, Bunkyo Ku, Tokyo 1130033, Japan; Tel Aviv Univ, Sackler Fac Med, Natl Lab Genet Israeli Populat, IL-69978 Tel Aviv, Israel	Gakushuin University; Japan Science & Technology Agency (JST); University of Tokyo; Tel Aviv University; Sackler Faculty of Medicine	Haga, T (corresponding author), Gakushuin Univ, Fac Sci, Inst Biomol Sci, Toshima Ku, 1-5-1 Mejiro, Tokyo 1718588, Japan.		Gurwitz, David/E-7642-2013	Gurwitz, David/0000-0002-9363-1869				Apparsundaram S, 2000, BIOCHEM BIOPH RES CO, V276, P862, DOI 10.1006/bbrc.2000.3561; Apparsundaram S, 2001, BIOCHEM SOC T, V29, P711, DOI 10.1042/0300-5127:0290711; Bissette G, 1996, ANN NY ACAD SCI, V777, P197, DOI 10.1111/j.1749-6632.1996.tb34419.x; Calabresi P, 2000, TRENDS NEUROSCI, V23, P120, DOI 10.1016/S0166-2236(99)01501-5; Collins A, 1999, P NATL ACAD SCI USA, V96, P15173, DOI 10.1073/pnas.96.26.15173; Eiden LE, 1998, J NEUROCHEM, V70, P2227; Francis PT, 1999, J NEUROL NEUROSUR PS, V66, P137, DOI 10.1136/jnnp.66.2.137; Fujiwara H, 1997, NAT GENET, V16, P124, DOI 10.1038/ng0697-124; Guermonprez L, 2002, J NEUROCHEM, V82, P874, DOI 10.1046/j.1471-4159.2002.01044.x; HAGA T, 1971, J NEUROCHEM, V18, P781, DOI 10.1111/j.1471-4159.1971.tb12008.x; HAGA T, 1973, BIOCHIM BIOPHYS ACTA, V291, P564, DOI 10.1016/0005-2736(73)90508-7; HAPPE HK, 1993, J NEUROCHEM, V60, P1191, DOI 10.1111/j.1471-4159.1993.tb03277.x; Hyde TM, 2001, J CHEM NEUROANAT, V22, P53, DOI 10.1016/S0891-0618(01)00101-6; Isacson O, 2002, TRENDS NEUROSCI, V25, P79, DOI 10.1016/S0166-2236(02)02037-4; Kobayashi Y, 2002, NEUROSCI LETT, V317, P25, DOI 10.1016/S0304-3940(01)02413-2; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; KUHAR MJ, 1978, J NEUROCHEM, V30, P15, DOI 10.1111/j.1471-4159.1978.tb07029.x; Lips KS, 2002, CELL TISSUE RES, V307, P275, DOI 10.1007/s00441-002-0520-4; MARUYAMA K, 1994, GENE, V138, P171; Misawa H, 2001, NEUROSCIENCE, V105, P87, DOI 10.1016/S0306-4522(01)00147-6; Ohno K, 2001, P NATL ACAD SCI USA, V98, P2017, DOI 10.1073/pnas.98.4.2017; Okuda T, 2000, FEBS LETT, V484, P92, DOI 10.1016/S0014-5793(00)02134-7; Okuda T, 2000, NAT NEUROSCI, V3, P120, DOI 10.1038/72059; PARSONS SM, 1993, INT REV NEUROBIOL, V35, P279, DOI 10.1016/S0074-7742(08)60572-3; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; SIMON JR, 1975, NATURE, V255, P162, DOI 10.1038/255162a0; SLOTKIN TA, 1994, J CLIN INVEST, V94, P696, DOI 10.1172/JCI117387; Song HJ, 1997, NEURON, V18, P815, DOI 10.1016/S0896-6273(00)80320-7; TUCEK S, 1985, J NEUROCHEM, V44, P11, DOI 10.1111/j.1471-4159.1985.tb07106.x; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; Varoqui H, 1996, J BIOL CHEM, V271, P27229, DOI 10.1074/jbc.271.44.27229; Wang HP, 1999, J BIOL CHEM, V274, P14875, DOI 10.1074/jbc.274.21.14875; Wang YL, 2001, GENE, V268, P123, DOI 10.1016/S0378-1119(01)00421-8; Wright EM, 1998, AM J PHYSIOL-GASTR L, V275, pG879, DOI 10.1152/ajpgi.1998.275.5.G879; YAMAMURA HI, 1972, SCIENCE, V178, P626, DOI 10.1126/science.178.4061.626	36	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45315	45322		10.1074/jbc.M207742200	http://dx.doi.org/10.1074/jbc.M207742200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237312	hybrid			2022-12-25	WOS:000179404800093
J	Sato, C; Matsuda, T; Katajima, K				Sato, C; Matsuda, T; Katajima, K			Neuronal differentiation-dependent expression of the disialic acid epitope on CD166 and its involvement in neurite formation in neuro2A cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE; OLIGOSIALIC ACIDS; POLYSIALIC ACID; DM-GRASP; CLONING; GENE; ALPHA-2,8-SIALYLTRANSFERASE; GLYCOPROTEINS; MEMBRANE; RESIDUES	We previously demonstrated that alpha2,8-linked disialic acid (diSia) residues occur in several glycoproteins of mammalian brains (Sato, C., Fukuoka, H., Ohta, K., Matsuda, T., Koshino, R., Kobayashi, K., Troy, F. A., II, and Kitajima, K. (2000) J. Biol. Chem. 275,15422-15431). The role of the diSia epitope on these glycoproteins is not known, whereas the importance of the diSia epitope on glycolipids is well documented in neurite formation. In this study, we demonstrated that the diSia epitope (Neu5Acalpha2 --> 8Neu5Acalpha2 --> 3Gal) on glycoproteins, but not on glycolipids, is involved in neurite formation in a mouse neuroblastoma cell line, Neuro2A, based on the following lines of evidence. First, the amount of diSia epitope on glycoproteins increased during retinoic acid-induced neurite formation. Second, retinoic acid treatment primarily increased the diSia epitope on a 100-kDa glycoprotein. We identified this protein as CD166 (SC1) , an immunoglobulin superfamily cell adhesion molecule involved in neurite extension. Third, a monoclonal antibody against the diSia epitope specifically inhibited neurite formation. We also demonstrated that alpha2,8-sialyltransferase III mRNA expression increased 1.7-fold after the induction of neurite formation, suggesting that alpha2,8-sialyltransferase III is responsible for formation of the diSia epitope on CD166.	Nagoya Univ, Biosci Ctr, Dept Anim Sci, Div Organogenesis, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Grad Sch Bioagr SCi, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Katajima, K (corresponding author), Nagoya Univ, Biosci Ctr, Dept Anim Sci, Div Organogenesis, Nagoya, Aichi 4648601, Japan.		Naganawa, Shinji/I-1572-2012; SATO, Chihiro/B-7396-2014	Naganawa, Shinji/0000-0002-0214-613X; 				Angata T, 2002, J BIOL CHEM, V277, P24466, DOI 10.1074/jbc.M202833200; BOWEN MA, 2002, LEUKOCYTE TYPING, V7, P894; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUES JL, 2000, MOL CELLULAR GLYCOBI, P116; BURRNS FR, 1991, NEURON, V7, P209; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; DEBERNARDO AP, 1995, DEV BIOL, V169, P65, DOI 10.1006/dbio.1995.1127; DeBernardo AP, 1996, J CELL BIOL, V133, P657, DOI 10.1083/jcb.133.3.657; DOCTOR BP, 1987, ANAL BIOCHEM, V166, P399, DOI 10.1016/0003-2697(87)90590-2; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; ECKHART M, 1995, NATURE, V373, P213; FOLCH J, 1951, J BIOL CHEM, V191, P819; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; Hasegawa T, 2000, J BIOL CHEM, V275, P8007, DOI 10.1074/jbc.275.11.8007; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; INOUE Y, 1992, POLYSIALIC ACIDS, P171; Kawai H, 2001, J BIOL CHEM, V276, P6885, DOI 10.1074/jbc.C000847200; KOHNO M, 1996, J BIOL CHEM, V271, P29366; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; LEEDEN RW, 1984, J NEUROSCI RES, V12, P147; Liu H, 1997, GLYCOBIOLOGY, V7, P1067, DOI 10.1093/glycob/7.8.1067; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; Nadanaka S, 2001, J BIOL CHEM, V276, P33657, DOI 10.1074/jbc.M011100200; NAKAMURA M, 1987, CHEM PHARM BULL, V35, P687; Nohara K, 1998, J BIOCHEM, V124, P194, DOI 10.1093/oxfordjournals.jbchem.a022079; Ohta K, 2000, GLYCOCONJUGATE J, V17, P205, DOI 10.1023/A:1026589223811; POURQUIE O, 1992, J NEUROSCI, V12, P1548; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; Rosenberg A, 1996, BIOL SIALIC ACIDS, P197; Sato C, 1999, TRENDS GLYCOSCI GLYC, V11, P371, DOI 10.4052/tigg.11.371; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; SATO C, 1995, J BIOL CHEM, V270, P18923, DOI 10.1074/jbc.270.32.18923; Sato C, 1998, ANAL BIOCHEM, V261, P191, DOI 10.1006/abio.1998.2718; Sato C, 1998, J BIOL CHEM, V273, P2575, DOI 10.1074/jbc.273.5.2575; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Sato C, 1999, ANAL BIOCHEM, V266, P102, DOI 10.1006/abio.1998.2921; Seki T, 1998, J NEUROSCI, V18, P3757; Sekine-Aizawa Y, 1998, EUR J NEUROSCI, V10, P2810, DOI 10.1111/j.1460-9568.1998.00288.x; Sharon N., 1997, GLYCOSCIENCES STATUS, P133; Takashima S, 1999, BIOCHEM BIOPH RES CO, V260, P23, DOI 10.1006/bbrc.1999.0794; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; TROY FA, 1996, BIOL SIALIC ACIDS, P95; TSUJI S, 1988, J NEUROCHEM, V50, P414, DOI 10.1111/j.1471-4159.1988.tb02928.x; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; Yoshida Y, 1996, GLYCOBIOLOGY, V6, P573, DOI 10.1093/glycob/6.6.573; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	50	51	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45299	45305		10.1074/jbc.M206046200	http://dx.doi.org/10.1074/jbc.M206046200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235144	hybrid			2022-12-25	WOS:000179404800091
J	Shimomura, Y; Aoki, N; Schweizer, J; Langbein, L; Rogers, MA; Winter, H; Ito, M				Shimomura, Y; Aoki, N; Schweizer, J; Langbein, L; Rogers, MA; Winter, H; Ito, M			Polymorphisms in the human high sulfur hair keratin-associated protein 1, KAP1, gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH PROTEINS; INVOLUCRIN GENE; CODING REGION; EXPRESSION; FOLLICLE; LORICRIN; WOOL; ORGANIZATION; SEQUENCE; MUTATIONS	Hair fiber differentiation and maturation involves the close interaction between hair keratins and their associated proteins, KAPs. Recently, a cluster of seven human KAP multigen families has been identified on chromosome 17q12-21 among which were four hKAP1 genes (hKAP1.1B, hKAP1.3, hKAP1.4, and hYAP1.5). In addition, there were previous as well as recent reports on four additional hKAP1 genes (hKAP1.1A, hKAP1.2, hKAP1. 6, and hKAP1. 7) with unknown chromosomal location. In this study, we have analyzed these eight hKAP1 genes in unrelated Japanese and Caucasian individuals and discovered that hKAP1.1A, hKAP1.6, and hKAP1. 7 represent size polymorphisms of the hKAP1.1B gene. In addition, we show that hKAP1.2 as well as three hitherto unknown genes (hKAP1.8A, hKAP1.8B, and hKAP1.9) are size polymorphisms of the hKAP1.3 gene. In contrast, no polymorphic alleles were found for the hKAP1.4 and hKAP1.5 genes. We provide evidence that the polymorphic hKAP1.1B and hKAP1.3 alleles arose mainly by intragenic deletion and/or duplication events of distinct pentapeptide repeats typical for hKAP1 genes. We also demonstrate the occurrence of both frequent and rare population-specific hKAP1.1B and hKAP1.3 alleles, which were obviously generated after the divergence of the Caucasian and Japanese lineage. In addition, by means of a pan-hKAP1 antibody, we confirm the previous hKAP1 family mRNA localization data in the middle to upper cortex of the human anagen hair follicle.	Niigata Univ, Sch Med, Dept Dermatol, Niigata 9518510, Japan; German Canc Res Ctr, Div Cell Biol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Tumor Cell Regulat, D-69120 Heidelberg, Germany	Niigata University; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Shimomura, Y (corresponding author), Niigata Univ, Sch Med, Dept Dermatol, Asahimachi Dori, Niigata 9518510, Japan.	yshimo@med.niigata-u.ac.jp	Rogers, Michael A./J-9803-2012	Rogers, Michael A./0000-0002-3728-2107				Aoki N, 1997, J BIOL CHEM, V272, P30512, DOI 10.1074/jbc.272.48.30512; Aoki N, 1998, J INVEST DERMATOL, V111, P804, DOI 10.1046/j.1523-1747.1998.00387.x; Armstrong DKB, 1998, J INVEST DERMATOL, V111, P702, DOI 10.1046/j.1523-1747.1998.00343.x; Cole SE, 1998, GENOMICS, V54, P437, DOI 10.1006/geno.1998.5590; DJIAN P, 1995, AM J HUM GENET, V56, P1367; ELLEMAN TC, 1972, J BIOL CHEM, V247, P3900; FRATINI A, 1993, J BIOL CHEM, V268, P4511; FRATINI A, 1994, J INVEST DERMATOL, V102, P178, DOI 10.1111/1523-1747.ep12371759; FRENKEL MJ, 1989, GENOMICS, V4, P182, DOI 10.1016/0888-7543(89)90298-X; HUH N, 1994, J INVEST DERMATOL, V102, P716, DOI 10.1111/1523-1747.ep12375385; JENKINS BJ, 1994, J INVEST DERMATOL, V103, P310, DOI 10.1111/1523-1747.ep12394770; Korge BP, 1999, J INVEST DERMATOL, V113, P607, DOI 10.1046/j.1523-1747.1999.00722.x; Korge BP, 1997, J INVEST DERMATOL, V109, P604, DOI 10.1111/1523-1747.ep12337534; KUCZEK ES, 1987, EUR J BIOCHEM, V166, P79, DOI 10.1111/j.1432-1033.1987.tb13486.x; Kuhn F, 1999, MECH DEVELOP, V86, P193, DOI 10.1016/S0925-4773(99)00115-X; Langbein L, 1999, J BIOL CHEM, V274, P19874, DOI 10.1074/jbc.274.28.19874; Langbein L, 2001, J BIOL CHEM, V276, P35123, DOI 10.1074/jbc.M103305200; Li VW, 1996, DERMATOL CLIN, V14, P745, DOI 10.1016/S0733-8635(05)70401-0; MACKINNON PJ, 1990, J CELL BIOL, V111, P2587, DOI 10.1083/jcb.111.6.2587; Maestrini E, 1996, NAT GENET, V13, P70, DOI 10.1038/ng0596-70; MCNAB AR, 1989, J INVEST DERMATOL, V92, P263, DOI 10.1111/1523-1747.ep12276832; Mercier M, 1998, J INVEST DERMATOL, V111, P169, DOI 10.1046/j.1523-1747.1998.00234.x; Mitsui S, 1998, GENE, V208, P123, DOI 10.1016/S0378-1119(97)00607-0; Perez C, 1999, GENE, V227, P137, DOI 10.1016/S0378-1119(98)00616-7; Powell B C, 1997, EXS, V78, P59; POWELL BC, 1991, ANN NY ACAD SCI, V642, P1; POWELL BC, 1983, NUCLEIC ACIDS RES, V11, P5327, DOI 10.1093/nar/11.16.5327; POWELL BC, 1995, DIFFERENTIATION, V58, P227, DOI 10.1046/j.1432-0436.1995.5830227.x; ROGERS GE, 1993, J INVEST DERMATOL, V101, pS50, DOI 10.1111/1523-1747.ep12362626; ROGERS GR, 1994, ANIM GENET, V25, P407, DOI 10.1111/j.1365-2052.1994.tb00531.x; Rogers MA, 2001, J BIOL CHEM, V276, P19440, DOI 10.1074/jbc.M100657200; Shimomura Y, 2002, J INVEST DERMATOL, V118, P226, DOI 10.1046/j.0022-202x.2001.01653.x; SHIMOMURA Y, 2002, IN PRESS J INVEST DE; SIMON M, 1991, GENOMICS, V9, P576, DOI 10.1016/0888-7543(91)90349-J; SIMON M, 1989, AM J HUM GENET, V45, P910; SWART LS, 1973, BIOCHEM J, V133, P641, DOI 10.1042/bj1330641; SWART LS, 1976, P 5 INT WOOL TEXT RE, P254; Takaishi M, 1998, J INVEST DERMATOL, V111, P128, DOI 10.1046/j.1523-1747.1998.00241.x; URQUHART A, 1993, AM J HUM GENET, V53, P279; Winter H, 1997, NAT GENET, V16, P372, DOI 10.1038/ng0897-372; YONEDA K, 1992, J BIOL CHEM, V267, P18060; ZHUMABAEVA BD, 1992, MOL BIOL+, V26, P550; Zimmermann R, 1983, Dermatol Monatsschr, V169, P638	43	39	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45493	45501		10.1074/jbc.M206398200	http://dx.doi.org/10.1074/jbc.M206398200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228244	hybrid			2022-12-25	WOS:000179404800114
J	St-Pierre, J; Buckingham, JA; Roebuck, SJ; Brand, MD				St-Pierre, J; Buckingham, JA; Roebuck, SJ; Brand, MD			Topology of superoxide production from different sites in the mitochondrial electron transport chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL PRODUCTION; HEART-MITOCHONDRIA; HYDROGEN-PEROXIDE; COMPLEX-I; UBIQUINONE OXIDOREDUCTASE; TRANSFER FLAVOPROTEIN; RESPIRATORY-CHAIN; GENERATION; OXYGEN; RAT	We measured production of reactive oxygen species by intact mitochondria from rat skeletal muscle, heart, and liver under various experimental conditions. By using different substrates and inhibitors, we determined the sites of production (which complexes in the electron transport chain produced superoxide). By measuring hydrogen peroxide production in the absence and presence of exogenous superoxide dismutase, we established the topology of superoxide production (on which side of the mitochondrial inner membrane superoxide was produced). Mitochondria did not release measurable amounts of superoxide or hydrogen peroxide when respiring on complex I or complex II substrates. Mitochondria from skeletal muscle or heart generated significant amounts of superoxide from complex I when respiring on palmitoyl carnitine. They produced superoxide at considerable rates in the presence of various inhibitors of the electron transport chain. Complex I (and perhaps the fatty acid oxidation electron transfer flavoprotein and its oxidoreductase) released superoxide on the matrix side of the inner membrane, whereas center o of complex III released superoxide on the cytoplasmic side. These results do not support the idea that mitochondria produce considerable amounts of reactive oxygen species under physiological conditions. Our upper estimate of the proportion of electron flow giving rise to hydrogen peroxide with palmitoyl carnitine as substrate (0.15%) is more than an order of magnitude lower than commonly cited values. We observed no difference in the rate of hydrogen peroxide production between rat and pigeon heart mitochondria respiring on complex I substrates. However, when complex I was fully reduced using rotenone, rat mitochondria released significantly more hydrogen peroxide than pigeon mitochondria. This difference was solely due to an elevated concentration of complex I in rat compared with pigeon heart mitochondria.	MRC Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	St-Pierre, J (corresponding author), Dana Farber Canc Inst, SM 958, Boston, MA 02115 USA.	julie_stpierre@dfci.harvard.edu	St-Pierre, Julie/AGB-3651-2022; Brand, Martin D/A-9423-2012	St-Pierre, Julie/0000-0002-2815-7099; Brand, Martin D/0000-0003-4418-6153				Barja G, 1998, J BIOENERG BIOMEMBR, V30, P235, DOI 10.1023/A:1020592719405; Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188; BARJA G, 1994, FREE RADICAL RES, V21, P317, DOI 10.3109/10715769409056584; Barja G, 1999, METHODS AGING RES, P533; BECKMANN JD, 1985, BIOCHEMISTRY-US, V24, P3913, DOI 10.1021/bi00336a016; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1972, BIOCHEM J, P617; BURCH HB, 1957, METHOD ENZYMOL, V3, P960, DOI 10.1016/S0076-6879(57)03485-0; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Forman HJ, 1997, FASEB J, V11, P374, DOI 10.1096/fasebj.11.5.9141504; Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Herrero A, 1997, J BIOENERG BIOMEMBR, V29, P241, DOI 10.1023/A:1022458010266; Herrero A, 1998, MECH AGEING DEV, V103, P133, DOI 10.1016/S0047-6374(98)00035-9; Herrero A, 1997, MECH AGEING DEV, V98, P95, DOI 10.1016/S0047-6374(97)00076-6; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KU HH, 1993, MECH AGEING DEV, V72, P67, DOI 10.1016/0047-6374(93)90132-B; Kwong LK, 2000, ARCH BIOCHEM BIOPHYS, V373, P16, DOI 10.1006/abbi.1999.1495; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; RAMSAY RR, 1987, BIOCHEM J, V241, P883, DOI 10.1042/bj2410883; ROLFE DFS, 1994, BBA-BIOENERGETICS, V1188, P405, DOI 10.1016/0005-2728(94)90062-0; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; SOHAL RS, 1990, MECH AGEING DEV, V53, P209, DOI 10.1016/0047-6374(90)90039-I; SOHAL RS, 1989, MECH AGEING DEV, V49, P129, DOI 10.1016/0047-6374(89)90096-1; Staniek K, 1999, BBA-BIOENERGETICS, V1413, P70, DOI 10.1016/S0005-2728(99)00083-3; Staniek K, 2000, BBA-BIOENERGETICS, V1460, P268, DOI 10.1016/S0005-2728(00)00152-3; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	37	1156	1210	5	87	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44784	44790		10.1074/jbc.M207217200	http://dx.doi.org/10.1074/jbc.M207217200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237311	hybrid			2022-12-25	WOS:000179404800027
J	Verma, A; Mohindru, M; Deb, DK; Sassano, A; Kambhampati, S; Ravandi, F; Minucci, S; Kalvakolanu, DV; Platanias, LC				Verma, A; Mohindru, M; Deb, DK; Sassano, A; Kambhampati, S; Ravandi, F; Minucci, S; Kalvakolanu, DV; Platanias, LC			Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; MAP KINASE; INTERFERON-ALPHA; BCR-ABL; SIGNAL-TRANSDUCTION; GROWTH-INHIBITION; CELL-LINES; TRANSCRIPTIONAL ACTIVATION; SERINE PHOSPHORYLATION	Arsenic trioxide induces differentiation and apoptosis of malignant cells in vitro and in vivo, but the mechanisms by which such effects occur have not been elucidated. In the present study we provide evidence that arsenic trioxide induces activation of the small G-protein Rac1 and the alpha and beta isoforms of the p38 mitogen-activated protein (MAP) kinase in several leukemia cell lines. Such activation of Rac1 and p38-isoforms results in downstream engagement of the MAP kinase-activated protein kinase-2 and is enhanced by pre-treatment of cells with ascorbic acid. Interestingly, pharmacological inhibition of p38 potentiates arsenic-dependent apoptosis and suppression of growth of leukemia cell lines, suggesting that this signaling cascade negatively regulates induction of antileukemic responses by arsenic trioxide. Consistent with this, overexpression of a dominant-negative p38 mutant (p38betaAGF) enhances the antiproliferative effects of arsenic trioxide on target cells. To further define the relevance of activation of the Rac1/p38 MAP kinase pathway in the induction of arsenic-dependent antileukemic effects, studies were performed using bone marrows from patients with chronic myelogenous leukemia. Arsenic trioxide suppressed the growth of leukemic myeloid (CFU-GM) progenitors from such patients, whereas concomitant pharmacological inhibition of the p38 pathway enhanced its growth-suppressive effects. Altogether, these data provide evidence for a novel function of the p38 MAP kinase pathway, acting as a negative regulator of arsenic trioxide-induced apoptosis and inhibition of malignant cell growth.	Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Hematol Oncol Sect, Chicago, IL 60611 USA; Univ Illinois, Dept Med, Hematol Oncol Sect, Chicago, IL 60607 USA; W Side Vet Affairs Hosp, Chicago, IL 60607 USA; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; IRCCS European Institute of Oncology (IEO); University System of Maryland; University of Maryland Baltimore	Platanias, LC (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, 303 E Chicago Ave,Olson Pavil 8250, Chicago, IL 60611 USA.	l-platanias@northwestern.edu	Minucci, Saverio/J-9669-2012		NATIONAL CANCER INSTITUTE [R01CA094079, R01CA077816, R01CA078282, R01CA071401] Funding Source: NIH RePORTER; NCI NIH HHS [CA78282, CA94079, CA77816, CA71401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Akao Y, 1999, FEBS LETT, V455, P59, DOI 10.1016/S0014-5793(99)00841-8; Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Chen Z, 2002, SEMIN HEMATOL, V39, P22, DOI 10.1053/shem.2002.33611; Chen Z, 2001, SEMIN HEMATOL, V38, P26, DOI 10.1053/shem.2001.20863; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Davison K, 2002, SEMIN HEMATOL, V39, P3, DOI 10.1053/shem.2002.33610; Du YH, 2001, CANCER CHEMOTH PHARM, V47, P481, DOI 10.1007/s002800100278; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Gartenhaus RB, 2002, CLIN CANCER RES, V8, P566; GOEBERT M, 1997, EMBO J, V16, P3563; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Grad JM, 2001, BLOOD, V98, P805, DOI 10.1182/blood.V98.3.805; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; KRUMER JL, 1997, J BIOL CHEM, V272, P20490; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Maeda H, 2001, CANCER RES, V61, P5432; Mahieux R, 2001, BLOOD, V98, P3762, DOI 10.1182/blood.V98.13.3762; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; O'Dwyer M, 2002, ONCOLOGIST, V7, P30, DOI 10.1634/theoncologist.7-suppl_1-30; O'Dwyer ME, 2002, SEMIN HEMATOL, V39, P18, DOI 10.1053/shem.2002.33612; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Park WH, 2000, CANCER RES, V60, P3065; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Platanias LC, 1999, EXP HEMATOL, V27, P1315, DOI 10.1016/S0301-472X(99)00060-0; Puccetti E, 2000, CANCER RES, V60, P3409; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salojin KV, 1999, J IMMUNOL, V163, P844; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759; Tallman MS, 2001, BLOOD REV, V15, P133, DOI 10.1054/blre.2001.0160; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; Verma A, 2002, J IMMUNOL, V168, P5984, DOI 10.4049/jimmunol.168.12.5984; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; Wang ZY, 2001, CANCER CHEMOTH PHARM, V48, pS72, DOI 10.1007/s002800100309; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	67	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44988	44995		10.1074/jbc.M207176200	http://dx.doi.org/10.1074/jbc.M207176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239215	hybrid			2022-12-25	WOS:000179404800052
J	Yang, PK; Rotondo, G; Porras, T; Legrain, P; Chanfreau, G				Yang, PK; Rotondo, G; Porras, T; Legrain, P; Chanfreau, G			The Shq1p center dot Naf1p complex is required for box H/ACA small nucleolar ribonucleoprotein particle biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; RIBOSE METHYLATION; PRERIBOSOMAL RNA; YEAST; PSEUDOURIDINE; NHP2P; CBF5P; RNPS; ELEMENTS; SNORNPS	Small nucleolar ribonucleoprotein particles (snoRNPs) are essential cofactors in ribosomal RNA metabolism. Although snoRNP composition has been thoroughly characterized, the biogenesis process of these particles is poorly understood. We have identified two proteins from the yeast Saccharomyces cerevisiae, Yil104c/Shq1p and Ynl124w/Naf1p, which are essential and required for the stability of box H/ACA snoRNPs. Depletion of either Shq1p or Naf1p leads to a dramatic and specific decrease in box H/ACA snoRNA levels in vivo. A severe concomitant defect in ribosomal RNA processing is observed, consistent with the depletion of this family of snoRNAs. Shq1p and Naf1p show nuclear localization and interact with Nhp2p and Cbf5p, two core proteins of mature box H/ACA snoRNPs. Shq1p and Naf1p form a complex, but they are not strongly associated with box H/ACA snoRNPs. We propose that Shq1p and Naf1p are involved in the early biogenesis steps of box H/ACA snoRNP assembly.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Inst Pasteur, GIM Biotechnol, F-75724 Paris 15, France	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Chanfreau, G (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Box 951569, Los Angeles, CA 90095 USA.	guillom@chem.ucla.edu	Chanfreau, Guillaume/S-7421-2019	Rotondo, Giuseppe/0000-0001-7811-1753	NIGMS NIH HHS [GM61518] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061518] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; Billy E, 2000, EMBO J, V19, P2115, DOI 10.1093/emboj/19.9.2115; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; Chanfreau G, 1997, GENE DEV, V11, P2741, DOI 10.1101/gad.11.20.2741; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; Dez C, 2002, MOL CELL BIOL, V22, P7053, DOI 10.1128/MCB.22.20.7053-7065.2002; Dez C, 2001, NUCLEIC ACIDS RES, V29, P598, DOI 10.1093/nar/29.3.598; Dragon F, 2000, MOL CELL BIOL, V20, P3037, DOI 10.1128/MCB.20.9.3037-3048.2000; FATICA A, 2002, IN PRESS RNA; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Ganot P, 1997, GENE DEV, V11, P941, DOI 10.1101/gad.11.7.941; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Goldsmith M, 1998, AM J PHYS ANTHROPOL, V106, P103, DOI 10.1002/(SICI)1096-8644(199805)106:1<103::AID-AJPA8>3.0.CO;2-T; Henras A, 1998, EMBO J, V17, P7078, DOI 10.1093/emboj/17.23.7078; Henras A, 2001, NUCLEIC ACIDS RES, V29, P2733, DOI 10.1093/nar/29.13.2733; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; King TH, 2001, MOL CELL BIOL, V21, P7731, DOI 10.1128/MCB.21.22.7731-7746.2001; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Lafontaine DLJ, 2000, MOL CELL BIOL, V20, P2650, DOI 10.1128/MCB.20.8.2650-2659.2000; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Pogacic V, 2000, MOL CELL BIOL, V20, P9028, DOI 10.1128/MCB.20.23.9028-9040.2000; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Steinmetz EJ, 2001, NATURE, V413, P327, DOI 10.1038/35095090; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; Tremblay A, 2002, MOL CELL BIOL, V22, P4792, DOI 10.1128/MCB.22.13.4792-4802.2002; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761	37	54	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45235	45242		10.1074/jbc.M207669200	http://dx.doi.org/10.1074/jbc.M207669200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228251	hybrid			2022-12-25	WOS:000179404800083
J	Krippner-Heidenreich, A; Tubing, F; Bryde, S; Willi, S; Zimmermann, G; Scheurich, P				Krippner-Heidenreich, A; Tubing, F; Bryde, S; Willi, S; Zimmermann, G; Scheurich, P			Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-AFFECTING AGENTS; TNF-RECEPTOR; LIGAND; DEATH; CD95; INTERNALIZATION; APOPTOSIS; PATHWAYS; DOMAIN	Tumor necrosis factor (TNF) exists both as a membrane-integrated type 11 precursor protein and a soluble cytokine that have different bioactivities on TNFR2 (CD120b) but not on TNFR1 (CD120a). To identify the molecular basis of this disparity, we have investigated receptor chimeras comprising the cytoplasmic part of Fas (CD95) and the extracellular domains of the two TNF receptors. The membrane form of TNF, but not its soluble form, was capable of inducing apoptosis as well as activation of c-Jun N-terminal kinase and NF-kappaB via the TNFR2-derived chimera. In contrast, the TNFR1-Fas chimera displayed strong responsiveness to both TNF forms. This pattern of responsiveness is identical to that of wild type TNF receptors, demonstrating that the underlying mechanisms are independent of the particular type of the intracellular signaling machinery and rather are controlled upstream of the intracellular domain. We further demonstrate that the signaling strength induced by a given ligand/receptor interaction is regulated at the level of adaptor protein recruitment, as shown for FADD, caspase-8, and TRAF2. Since both incidents, strong signaling and robust adapter protein recruitment, are paralleled by a high stability of individual ligand-receptor complexes, we propose that half-lives of individual ligand-receptor complexes control signaling at the level of adaptor protein recruitment.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Scheurich, P (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.							Ahn JH, 2001, J BIOL CHEM, V276, P47100, DOI 10.1074/jbc.M107385200; Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; DECLERCQ W, 1995, CYTOKINE, V7, P701, DOI 10.1006/cyto.1995.0082; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165; EVANS TJ, 1994, J EXP MED, V180, P2173, DOI 10.1084/jem.180.6.2173; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; GRELL M, 1997, GROWTH FACTORS CYTOK, P669; HIGUCHI M, 1994, J IMMUNOL, V152, P3550; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303; PARCE JW, 1990, ANN BIOL CLIN-PARIS, V48, P639; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; PENNICA D, 1992, J BIOL CHEM, V267, P21172; Pound JD, 1999, INT IMMUNOL, V11, P11, DOI 10.1093/intimm/11.1.11; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schutze S, 1999, J BIOL CHEM, V274, P10203, DOI 10.1074/jbc.274.15.10203; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; Wajant H, 2001, ONCOGENE, V20, P4101, DOI 10.1038/sj.onc.1204558; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Weiss T, 1998, J IMMUNOL, V161, P3136; Weiss T, 1997, J IMMUNOL, V158, P2398; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2	41	61	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44155	44163		10.1074/jbc.M207399200	http://dx.doi.org/10.1074/jbc.M207399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12215450	hybrid			2022-12-25	WOS:000179272000081
J	Pedram, A; Razandi, M; Levin, ER				Pedram, A; Razandi, M; Levin, ER			Deciphering vascular endothelial cell growth factor/vascular permeability factor signaling to vascular permeability - Inhibition by atrial natriuretic peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-OH KINASE; NITRIC-OXIDE PRODUCTION; PROTEIN-KINASE; TIGHT JUNCTION; PHOSPHATIDYLINOSITOL 3-KINASE; MICROVASCULAR PERMEABILITY; TRANSDUCTION PATHWAYS; ACTIN REORGANIZATION; DIABETIC-RETINOPATHY; INDUCED ANGIOGENESIS	Vascular endothelial cell growth factor (VEGF) was originally described as a potent vascular permeability factor (VPF) that importantly contributes to Vascular pathobiology. The signaling pathways that underlie VEGF/VPF-induced permeability are not well defined. Furthermore, endogenous vascular peptides that regulate this important VPF function are currently unknown. We report here that VPF significantly enhances permeability in aortic endothelial cells via a linked signaling pathway, sequentially involving Src, ERK, JNK, and phosphatidylinositol 3-kinase/AKT. This leads to the serine/threonine phosphorylation and redistribution of actin and the tight junction (TJ) proteins, zona occludens-1 and occludin, and the loss of the endothelial cell barrier architecture. Atrial natriuretic peptide (ANP) inhibited VPF signaling, TJ protein phosphorylation and localization, and VPF-induced permeability. This involved both guanylate cyclase and natriuretic peptide clearance receptors. In vivo, transgenic mice that overexpress ANP showed significantly less VPF-induced kinase activation and vascular permeability compared with non-transgenic littermates. Thus, ANP acts as an anti-permeability factor by inhibiting the signaling functions of VPF that we define here and by preserving the endothelial cell TJ functional morphology.	Vet Affairs Med Ctr, Med Serv, Div Endocrinol, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine	Levin, ER (corresponding author), Vet Affairs Med Ctr, Med Serv, Div Endocrinol, 11-111-I,5901 E 7th St, Long Beach, CA 90822 USA.	ellis.levin@med.va.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059890] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-59890] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Andreeva AY, 2001, J BIOL CHEM, V276, P38480, DOI 10.1074/jbc.M104923200; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; BACALLAO R, 1994, J CELL SCI, V107, P3301; Basu S, 2001, NAT MED, V7, P569, DOI 10.1038/87895; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Blum MS, 1997, AM J PHYSIOL-HEART C, V273, pH286, DOI 10.1152/ajpheart.1997.273.1.H286; CAO L, 1995, HYPERTENSION, V25, P227, DOI 10.1161/01.HYP.25.2.227; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; Clancy RM, 1997, J CLIN INVEST, V100, P1789, DOI 10.1172/JCI119706; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Feng D, 1997, J PHYSIOL-LONDON, V504, P747, DOI 10.1111/j.1469-7793.1997.747bd.x; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FIELD LJ, 1991, AM J PHYSIOL, V260, pR1, DOI 10.1152/ajpregu.1991.260.1.R1; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GELFAND RA, 1991, AM J PHYSIOL, V261, pE183, DOI 10.1152/ajpendo.1991.261.2.E183; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gossmann A, 2000, AM J OBSTET GYNECOL, V183, P956, DOI 10.1067/mob.2000.107092; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Hirase T, 2001, J BIOL CHEM, V276, P10423, DOI 10.1074/jbc.M007136200; Isono M, 1998, KIDNEY INT, V53, P1133, DOI 10.1046/j.1523-1755.1998.00869.x; ITOH H, 1992, HYPERTENSION, V19, P758, DOI 10.1161/01.HYP.19.6.758; Kevil CG, 2000, AM J PHYSIOL-CELL PH, V279, pC21, DOI 10.1152/ajpcell.2000.279.1.C21; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; Kong M, 2000, J BIOL CHEM, V275, P36035, DOI 10.1074/jbc.M005621200; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Larson DM, 1988, ENDOTHELIAL CELLS, VIII, P75; Levin ER, 1998, NEW ENGL J MED, V339, P321; Levin ER, 1998, J CLIN INVEST, V102, P1978, DOI 10.1172/JCI4814; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILTON SG, 1990, J CELL PHYSIOL, V144, P498, DOI 10.1002/jcp.1041440318; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; MORISHITA Y, 1992, EUR J PHARM-MOLEC PH, V225, P203, DOI 10.1016/0922-4106(92)90021-M; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; Pedram A, 1997, J BIOL CHEM, V272, P17097, DOI 10.1074/jbc.272.27.17097; Pedram A, 2001, ENDOCRINOLOGY, V142, P1578, DOI 10.1210/en.142.4.1578; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Razandi M, 2000, J BIOL CHEM, V275, P38540, DOI 10.1074/jbc.M007555200; ROBERTS WG, 1995, J CELL SCI, V108, P2369; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SALZMAN AL, 1995, AM J PHYSIOL-GASTR L, V268, pG361, DOI 10.1152/ajpgi.1995.268.2.G361; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Shono T, 2001, EXP CELL RES, V264, P275, DOI 10.1006/excr.2001.5154; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; STEINHELPER ME, 1990, HYPERTENSION, V16, P301, DOI 10.1161/01.HYP.16.3.301; Tanno S, 2001, CANCER RES, V61, P589; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang W, 2001, AM J PHYSIOL-HEART C, V280, pH434, DOI 10.1152/ajpheart.2001.280.1.H434; WEI CM, 1993, CIRCULATION, V88, P1004, DOI 10.1161/01.CIR.88.3.1004; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wu HM, 1999, AM J PHYSIOL-HEART C, V276, pH535, DOI 10.1152/ajpheart.1999.276.2.H535	86	104	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44385	44398		10.1074/jbc.M202391200	http://dx.doi.org/10.1074/jbc.M202391200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12213803	hybrid			2022-12-25	WOS:000179272000110
J	Quentien, MH; Manfroid, I; Moncet, D; Gunz, G; Muller, M; Grino, M; Enjalbert, A; Pellegrini, I				Quentien, MH; Manfroid, I; Moncet, D; Gunz, G; Muller, M; Grino, M; Enjalbert, A; Pellegrini, I			Pitx factors are involved in basal and hormone-regulated activity of the human prolactin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; PROOPIOMELANOCORTIN GENE; PITUITARY DEVELOPMENT; HOMEODOMAIN FACTOR; RIEGER-SYNDROME; TRANSCRIPTION; PTX1; BINDING; DOMAIN; EXPRESSION	The pituitary-specific POU homeodomain factor Pit-1 likely interacts with other factors for cell-specific expression of prolactin. Here we identify the paired-like homeobox transcription factors Pitx1 and Pitx2 as factors functionally activating the proximal human prolactin promoter (hPRL-164luc). Using in vitro binding assays and a series of site-specific mutations of the proximal hPRL promoter, we mapped the 131 and B2 bicoid sites involved in Pitx-mediated transactivation of the hPRL-164luc construct. In somatolactotroph GH4C1 cells, basal proximal hPRL promoter activity was inhibited by a Pitx2 dominant-negative form in a dose-dependent manner, whereas binding disruptive mutations in the Pitx sites significantly reduced basal activity of the promoter. We also show that synergistic activation of hPRL-164luc by Pitx2 and Pit-1 requires the integrity of the B2 Pitx binding site, and at least one of the P1 and P2 Pit-1 response elements. In addition, mutation in the B2 Pitx site results in attenuation of the promoter's responsiveness to forskolin, thyrotropin-releasing hormone, and epidermal growth factor. Conversely, Pitx1 or Pitx2 overexpression in GH4C1 cells leads to an enhancement of the drugs stimulatory effects. Altogether, these results suggest that full responsiveness to several signaling pathways regulating the hPRL promoter requires the B2 Pitx binding site and that Pitx factors may be part of the proteic complex involved in these regulations. Finally, in situ hybridization analysis showing coexpression of the PRL and Pitx2 genes in rat and human lactotroph cells corroborates the physiological relevance of these results.	Univ Mediterranee, CNRS, UMR 6544, Lab ICNE,Inst Fed Jean Roche,Fac Med N, F-13916 Marseille 20, France; Univ Liege, Inst Chim, Lab Biol Mol & Genie Genet, B-4000 Sart Tilman Par Liege, Belgium; INSERM, U501, Lab IFNE, F-13258 Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Liege; Institut National de la Sante et de la Recherche Medicale (Inserm)	Pellegrini, I (corresponding author), Univ Mediterranee, CNRS, UMR 6544, Lab ICNE,Inst Fed Jean Roche,Fac Med N, Bd P Dramard, F-13916 Marseille 20, France.		Grino, Michel/O-5361-2017; Grino, Michel/M-7548-2017; Grino, Michel/GYD-8559-2022					Amendt BA, 1999, MOL CELL BIOL, V19, P7001; Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BERWAER M, 1993, MOL CELL ENDOCRINOL, V92, P1, DOI 10.1016/0303-7207(93)90068-U; Bradford AP, 2000, J BIOL CHEM, V275, P3100, DOI 10.1074/jbc.275.5.3100; Caccavelli L, 1998, MOL ENDOCRINOL, V12, P1215, DOI 10.1210/me.12.8.1215; CARRILLO AJ, 1985, ENDOCRINOLOGY, V116, P202, DOI 10.1210/endo-116-1-202; Dasen JS, 1999, CELL, V97, P587, DOI 10.1016/S0092-8674(00)80770-9; Gage PJ, 1999, MAMM GENOME, V10, P197, DOI 10.1007/s003359900970; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; Grino M, 1998, J HISTOCHEM CYTOCHEM, V46, P753, DOI 10.1177/002215549804600608; Kitamura K, 1999, DEVELOPMENT, V126, P5749; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lanctot C, 1999, ENDOCRINOLOGY, V140, P1416, DOI 10.1210/en.140.3.1416; LANTOT C, 1999, DEVELOPMENT, V126, P1805; LEMAIGRE FP, 1989, DNA-J MOLEC CELL BIO, V8, P149, DOI 10.1089/dna.1.1989.8.149; LI S, 1990, NATURE, V347, P529; Lin CR, 1999, NATURE, V401, P279, DOI 10.1038/45803; Logan M, 1999, SCIENCE, V283, P1736, DOI 10.1126/science.283.5408.1736; Lu MF, 1999, NATURE, V401, P276, DOI 10.1038/45797; Manfroid I, 2001, MOL ENDOCRINOL, V15, P625, DOI 10.1210/me.15.4.625; MAURER RA, 1980, J BIOL CHEM, V255, P8092; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; PEERS B, 1990, MOL CELL BIOL, V10, P4690, DOI 10.1128/MCB.10.9.4690; PEERS B, 1991, J BIOL CHEM, V266, P18127; PEERS B, 1992, EUR J BIOCHEM, V210, P53, DOI 10.1111/j.1432-1033.1992.tb17389.x; Pellegrini-Bouiller I, 1999, J CLIN ENDOCR METAB, V84, P2212, DOI 10.1210/jc.84.6.2212; Pernasetti F, 1997, MOL ENDOCRINOL, V11, P986, DOI 10.1210/me.11.7.986; Poulin G, 1997, MOL CELL BIOL, V17, P6673, DOI 10.1128/MCB.17.11.6673; Quentien MH, 2002, ENDOCRINOLOGY, V143, P2839, DOI 10.1210/en.143.8.2839; Quirk CC, 2001, MOL ENDOCRINOL, V15, P734, DOI 10.1210/me.15.5.734; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Suh H, 2002, DEVELOPMENT, V129, P329; Szeto DP, 1999, GENE DEV, V13, P484, DOI 10.1101/gad.13.4.484; Tremblay JJ, 2000, NEUROENDOCRINOLOGY, V71, P277, DOI 10.1159/000054547; Tremblay JJ, 1999, EMBO J, V18, P3431, DOI 10.1093/emboj/18.12.3431; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; Tremblay JJ, 1998, MOL ENDOCRINOL, V12, P428, DOI 10.1210/me.12.3.428; Van de Weerdt C, 2000, NEUROENDOCRINOLOGY, V71, P124, DOI 10.1159/000054528; Wilson DS, 1996, P NATL ACAD SCI USA, V93, P6886, DOI 10.1073/pnas.93.14.6886; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yost HJ, 1999, CURR OPIN GENET DEV, V9, P422	46	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44408	44416		10.1074/jbc.M207824200	http://dx.doi.org/10.1074/jbc.M207824200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223489	Green Submitted, hybrid			2022-12-25	WOS:000179272000112
J	Steinle, JJ; Meininger, CJ; Forough, R; Wu, G; Wu, MH; Granger, HJ				Steinle, JJ; Meininger, CJ; Forough, R; Wu, G; Wu, MH; Granger, HJ			Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIOVASCULAR DEVELOPMENT; LIGANDS; ACTIVATION; EPHRIN-B2; INVASION; GROWTH; VEINS	The goals of this study were 2-fold: 1) to determine whether stimulation of Eph B4 receptors promotes microvascular endothelial cell migration and/or proliferation, and 2) to elucidate signaling pathways involved in these responses. The human endothelial cells used possessed abundant Eph B4 receptors with no endogenous ephrin B2 expression. Stimulation of these receptors with ephrin B2/Fc chimera resulted in dose- and time-dependent phosphorylation of Akt. These responses were inhibited by LY294002 and MIL-9, blockers of phosphatidylinositol 3-kinase (PI3K) and Akt, respectively. Eph B4 receptor activation increased proliferation by 38%, which was prevented by prior blockade with LY294002, ML-9, and inhibitors of protein kinase G (KT5823) and MIEK (PD98059). Nitrite levels increased over 170% after Eph B4 stimulation, indicating increased nitric oxide production. Signaling of endothelial cell proliferation appears to be mediated by a PI3K/Akt/endothelial nitric-oxide synthase/protein kinase G/mitogen-activated protein kinase cascade. Stimulation with ephrin B2 also increased migration by 63% versus controls. This effect was inhibited by blockade with PP2 (Src inhibitor), LY294002 or ML-9 but was unaffected by the PKG and MEK blockers. Eph B4 receptor stimulation increased activation of both matrix metalloproteinase-2 and -9. The results from these studies indicate that Eph B4 stimulates migration and proliferation and may play a role in angiogenesis.	Texas A&M Univ Syst, Hlth Sci Ctr, Cardiovasc Res Inst, Temple, TX 76504 USA; Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Physiol, Coll Med, Temple, TX 76504 USA; Texas A&M Univ, Dept Anim Sci, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station	Steinle, JJ (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Cardiovasc Res Inst, 702 SW HK Dodgen Loop,Med Res Bldg,Rm 202A, Temple, TX 76504 USA.		Wu, Mack/I-6536-2012; Meininger, Cynthia/D-2846-2014	Steinle, Jena/0000-0002-7539-2892; Meininger, Cynthia/0000-0002-1314-5044	PHS HHS [446221] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams RH, 2000, TRENDS CARDIOVAS MED, V10, P183, DOI 10.1016/S1050-1738(00)00046-3; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; DANIEL TO, 1996, KIDNEY INT S, V57, P73; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Helbling PM, 2000, DEVELOPMENT, V127, P269; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Kalo MS, 1999, CELL TISSUE RES, V298, P1, DOI 10.1007/PL00008807; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Li H, 2000, J CHROMATOGR B, V746, P199, DOI 10.1016/S0378-4347(00)00328-5; Park BK, 2001, CANCER RES, V61, P7647; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Zisch AH, 1997, CELL TISSUE RES, V290, P217, DOI 10.1007/s004410050926	16	144	160	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43830	43835		10.1074/jbc.M207221200	http://dx.doi.org/10.1074/jbc.M207221200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12235151	hybrid			2022-12-25	WOS:000179272000040
J	Wilson, HL; McFie, PJ; Roesler, WJ				Wilson, HL; McFie, PJ; Roesler, WJ			Different transcription factor binding arrays modulate the cAMP responsivity of the phosphoenolpyruvate carboxykinase gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-GAMMA; DEPENDENT PROTEIN-KINASE; GTP GENE; C/EBP-ALPHA; HEPATOMA-CELLS; HORMONAL-REGULATION; THYROID-HORMONE; ELEMENT; LIVER; EXPRESSION	The cAMP responsiveness of the phosphoenolpyruvate carboxykinase (PEPCK) gene promoter is mediated by a cAMP response unit, which includes three CCAAT/enhancer-binding protein (C/EBPs) sites, and a cAMP response element (CRE). Because both the CRE-binding protein and several C/EBP isoforms can to bind to the CRE with similar affinity, a variety of transcription factor bindings arrays in the cAMP response unit are possible that may affect the protein kinase A (PKA) responsivity of the promoter. To explore this issue, we have designed PEPCK promoter variants that have the native cis-elements within the cAMP response unit replaced with one or more LexA- and/or GAL4-binding sites. We also engineered the corresponding C/EBP and CRE-binding protein chimeras, which have their basic region leucine zipper domains replaced with LexA or GAL4 DNA-binding domains. Using this approach, we have reconstituted the PKA responsiveness of permissive PEPCK promoters in hepatoma cells and have characterized the PKA responsivity of the promoter under defined transcription factor occupancy patterns. Furthermore, analysis of deletion mutants of C/EBPalpha indicated that the domains that mediate its constitutive and PKA-inducible activities vary depending on which cis-element it occupies on the PEPCK promoter. These results suggest that promoter context may influence which domains within a transcription factor are employed to mediate transactivation.	Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan	Roesler, WJ (corresponding author), Univ Saskatchewan, Dept Biochem, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.		Wilson, Heather/B-4575-2011	Wilson, Heather/0000-0002-1261-0901				CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Crosson SM, 2000, J BIOL CHEM, V275, P5804, DOI 10.1074/jbc.275.8.5804; DAVIES GF, 1995, ARCH BIOCHEM BIOPHYS, V323, P477, DOI 10.1006/abbi.1995.0070; Davies GF, 2001, BIOCHEM PHARMACOL, V62, P1071, DOI 10.1016/S0006-2952(01)00764-X; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Jacob KK, 2001, J BIOL CHEM, V276, P24931, DOI 10.1074/jbc.M102826200; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LIU JS, 1991, J BIOL CHEM, V266, P19095; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; PARK EA, 1995, BIOCHEM J, V309, P913, DOI 10.1042/bj3090913; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PATEL YM, 1994, J BIOL CHEM, V269, P5619; QUINN PG, 1993, J BIOL CHEM, V268, P16999; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; Roesler WJ, 1998, MOL CELL BIOCHEM, V178, P1, DOI 10.1023/A:1006886421795; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; Waite KJ, 2001, J BIOL CHEM, V276, P7062, DOI 10.1074/jbc.M007894200; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wilson HL, 2002, MOL CELL ENDOCRINOL, V188, P15, DOI 10.1016/S0303-7207(01)00754-7; Wilson HL, 2001, MOL CELL ENDOCRINOL, V181, P27, DOI 10.1016/S0303-7207(01)00540-8; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880	36	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43895	43902		10.1074/jbc.M203169200	http://dx.doi.org/10.1074/jbc.M203169200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12237288	hybrid			2022-12-25	WOS:000179272000049
J	Zhang, H; Shi, XQ; Zhang, QJ; Hampong, M; Paddon, H; Wahyuningsih, D; Pelech, S				Zhang, H; Shi, XQ; Zhang, QJ; Hampong, M; Paddon, H; Wahyuningsih, D; Pelech, S			Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED ACTIVATION; HUMAN CANCER-CELLS; PROTEIN-KINASE; MICROTUBULE DISRUPTION; ULTRAVIOLET-RADIATION; SIGNAL-TRANSDUCTION; P53; TUMOR; PHOSPHORYLATION; GROWTH	Microtubule-interfering agents are widely used in cancer chemotherapy, and prognostic results vary significantly from tumor to tumor, depending on the p53 status. In preliminary experiments, we compared the expression and phosphorylation profiles of more than 100 protein kinases and protein phosphatases in human colorectal carcinoma cell line HCT116 between p53+/+ and p53-/- cells in response to short term nocodazole treatment through application of Kinetworks(TM) immunoblotting screens. Among the proteins tracked, the regulation of the phosphorylation of c-Jun N-terminal kinase (JN-K)1/2 at Thr-183tryr-185 was the major difference between p53+/+ and p53-/- cells. With the loss of the p,53 gene, the levels of phosphorylation of Ser-63 of c-Jun and Thr-183/Tyr-185 of JNK1/2 in p53-/- cells did not increase as markedly as in p53+/+ cells in response to a 1-h treatment with nocodazole or other microtubule-disrupting drugs such as vinblastine and colchicine. Similar observations were also made in MCF-7 and A549 tumor cells, which were rendered p53-deficient by E6 oncoprotein expression. However, arsenate-induced JNK activation in p53-/- cells was preserved. Inhibition of p53 expression by its antisense oligonucleotide also attenuated nocodazole-induced JNK activation in p53+/+ cells. Surprisingly, cotransfection of p53+/+ cells with dominant negative mutants of JNK isoforms and treatment of p53+/+ cells with the JNK inhibitor SP600125 actually further enhanced apoptosis in p53+/+ cells by up to 2-fold in response to nocodazole. These findings indicate that inhibition of p53-mediated JNK1/2 activity in certain tumor cells could serve to enhance the apoptosis-inducing actions of cancer chemotherapeutic agents that disrupt mitotic spindle function.	Univ British Columbia, Dept Med, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; Kinexus Bioinformat Corp, Vancouver, BC V6T 1Z4, Canada	University of British Columbia; University of British Columbia	Pelech, S (corresponding author), Univ British Columbia, Dept Med, Brain Res Ctr, 1st Floor,Koerner Pavil,2211 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.							Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Hirota Y, 1996, JPN J CANCER RES, V87, P735, DOI 10.1111/j.1349-7006.1996.tb00286.x; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kyriakis JM, 1995, ANN NY ACAD SCI, V766, P303, DOI 10.1111/j.1749-6632.1995.tb26683.x; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MIYASHITA T, 1995, CELL, V80, P293; OConnor PM, 1997, CANCER RES, V57, P4285; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; Sayed M, 2001, ONCOGENE, V20, P6994, DOI 10.1038/sj.onc.1204894; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200	36	55	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43648	43658		10.1074/jbc.M203214200	http://dx.doi.org/10.1074/jbc.M203214200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221076	hybrid			2022-12-25	WOS:000179272000016
J	Bowden, MG; Visai, L; Longshaw, CM; Holland, KT; Speziale, P; Hook, M				Bowden, MG; Visai, L; Longshaw, CM; Holland, KT; Speziale, P; Hook, M			Is the GehD lipase from Staphylococcus epidermidis a collagen binding adhesin?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULASE-NEGATIVE STAPHYLOCOCCI; CAPSULAR POLYSACCHARIDE ADHESIN; AUREUS STRAINS; STREPTOCOCCUS-PNEUMONIAE; LIPOLYTIC-ACTIVITY; MATRIX MOLECULES; ALPHA-ENOLASE; PROTEIN; IDENTIFICATION; FIBRONECTIN	The opportunistic human pathogen Staphylococcus epidermidis is the major cause of nosocomial biomaterial infections. S. epidermidis has the ability to attach to indwelling materials coated with extracellular matrix proteins such as fibrinogen, fibronectin, vitronectin, and collagen. To identify the proteins necessary for S. epidermidis attachment to collagen, we screened an expression library using digoxigenin-labeled collagen as well as two monoclonal antibodies generated against the Staphylococcus aureus collagen-adhesin, Cna, as probes. These monoclonal antibodies recognize collagen binding epitopes on the surface of S. aureus and S. epidermidis cells. Using this approach, we identified GehD, the extracellular lipase originally found in S. epidermidis 9, as a collagen-binding protein. Despite the monoclonal antibody cross-reactivity, the GehD amino acid sequence and predicted structure are radically different from those of Cna. The mature GehD circular dichroism spectra differs from that of Cna but strongly resembles that of a mammalian cell-surface collagen binding receptor, known as the a, integrin I domain, suggesting that they have similar secondary structures. The GehD protein is translated as a preproenzyme, secreted, and post-translationally processed into mature lipase. GehD does not have the conserved LPXTG C-terminal motif present in cell wall-anchored proteins, but it can be detected in lysostaphin cell wall extracts. A recombinant version of mature GehD binds to collagens type 1, II, and IV adsorbed onto microtiter plates in a dose-dependent saturable manner. Recombinant, mature GehD protein and anti-GehD antibodies can inhibit the attachment of S. epidermidis to immobilized collagen. These results provide evidence that GehD may be a bi-functional molecule, acting not only as a lipase but also as a cell surface-associated collagen adhesin.	Texas A&M Univ, Inst Biosci & Technol, Syst Hlth Sci Ctr, Houston, TX 77030 USA; Univ Pavia, Dept Biochem, I-27100 Pavia, Italy; Univ Leeds, Div Microbiol, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Pavia; University of Leeds	Hook, M (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Syst Hlth Sci Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mhook@ibt.tamu.edu	Visai, Livia/R-7397-2017; Longshaw, Christopher/H-2871-2013	Visai, Livia/0000-0003-1181-3632; Longshaw, Christopher/0000-0002-5586-7256	NIAID NIH HHS [AI 10629] Funding Source: Medline; NIAMS NIH HHS [AR44415] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044415] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bergmann S, 2001, MOL MICROBIOL, V40, P1273, DOI 10.1046/j.1365-2958.2001.02448.x; Courtney HS, 1996, INFECT IMMUN, V64, P2415, DOI 10.1128/IAI.64.7.2415-2419.1996; Davis SL, 2001, J BIOL CHEM, V276, P27799, DOI 10.1074/jbc.M103873200; de Silva GDI, 2001, CLIN INFECT DIS, V33, P1520, DOI 10.1086/323338; Fagan PK, 2001, INFECT IMMUN, V69, P4851, DOI 10.1128/IAI.69.8.4851-4857.2001; Fontan PA, 2000, J INFECT DIS, V182, P1712, DOI 10.1086/317604; Garrett DO, 1999, INFECT CONT HOSP EP, V20, P167, DOI 10.1086/501605; Gotz F, 1998, CHEM PHYS LIPIDS, V93, P15, DOI 10.1016/S0009-3084(98)00025-5; GRIBBON EM, 1993, J GEN MICROBIOL, V139, P1745, DOI 10.1099/00221287-139-8-1745; HEDSTROM SA, 1983, ACTA PATH MICRO IM B, V91, P169; HEDSTROM SA, 1975, ACTA PATH MICRO IM B, V83, P285; Heilmann C, 1997, MOL MICROBIOL, V24, P1013, DOI 10.1046/j.1365-2958.1997.4101774.x; HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693; HOGT AH, 1986, J BIOMED MATER RES, V20, P533, DOI 10.1002/jbm.820200409; Holmes AR, 2001, MOL MICROBIOL, V41, P1395, DOI 10.1046/j.1365-2958.2001.02610.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBL W, 1986, MOL GEN GENET, V204, P166, DOI 10.1007/BF00330205; Longshaw CM, 2000, MICROBIOL-UK, V146, P1419, DOI 10.1099/00221287-146-6-1419; Lowe AM, 1998, MOL MICROBIOL, V27, P967, DOI 10.1046/j.1365-2958.1998.00741.x; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; MULLER E, 1993, INFECT IMMUN, V61, P551, DOI 10.1128/IAI.61.2.551-558.1993; Nilsson M, 1998, INFECT IMMUN, V66, P2666, DOI 10.1128/IAI.66.6.2666-2673.1998; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pancholi V, 1997, J EXP MED, V186, P1633, DOI 10.1084/jem.186.10.1633; PASCUAL A, 1986, EUR J CLIN MICROBIOL, V5, P518, DOI 10.1007/BF02017694; Reinscheid DJ, 2001, J BACTERIOL, V183, P1175, DOI 10.1128/JB.183.4.1175-1183.2001; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; ROLLOF J, 1987, ACTA PATH MICRO IM B, V95, P109; Rosenstein R, 2000, BIOCHIMIE, V82, P1005, DOI 10.1016/S0300-9084(00)01180-9; Simons JWFA, 1998, CHEM PHYS LIPIDS, V93, P27, DOI 10.1016/S0009-3084(98)00026-7; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; TOJO M, 1988, J INFECT DIS, V157, P713, DOI 10.1093/infdis/157.4.713; Visai L, 2000, J BIOL CHEM, V275, P39837, DOI 10.1074/jbc.M005297200; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; YU J, 1994, BIOMATERIALS, V15, P805, DOI 10.1016/0142-9612(94)90035-3	35	80	86	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43017	43023		10.1074/jbc.M207921200	http://dx.doi.org/10.1074/jbc.M207921200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12218064	hybrid			2022-12-25	WOS:000179081200078
J	Glantschnig, H; Rodan, GA; Reszka, AA				Glantschnig, H; Rodan, GA; Reszka, AA			Mapping of MST1 kinase sites of phosphorylation - Activation and autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STE20-LIKE PROTEIN-KINASE; CASPASE-MEDIATED ACTIVATION; GAMMA-PAK; INDUCED APOPTOSIS; CLEAVAGE; CLONING; CELLS; LOOP; ABSENCE; MST/KRS	MST1 is a member of the Sterile-20 family of cytoskeletal, stress, and apoptotic kinases. MST1 is activated by phosphorylation at previously unidentified sites. This study examines the role of phosphorylation at several sites and effects on kinase activation. We define Thr(183) in subdomain VIII as a primary site of phosphoactivation. Thr(187) is also critical for kinase activity. Phosphorylation of MST1 in subdomain VIII was catalyzed by active MST1 via intermolecular autophosphorylation, enhanced by homodimerization. Active MST1 (wild-type or T183E), but not inactive Thr(183)/Thr(187) mutants, was also highly autophosphorylated at the newly identified Thr(177) and Thr(387) residues. Cells expressing active MST1 were mostly detached, whereas with inactive MST1, adhesion was normal. Active MKK4, JNK, caspase-3, and caspase-9 were detected in the detached cells. These cells also contained all autophosphorylated and essentially all caspase-cleaved MST1. Similar phenotypes were elicited by a caspase-insensitive D326N mutant, suggesting that kinase activity, but not cleavage of MST1, is required. Interestingly, an S327E mutant mimicking Ser(327) autophosphorylation was also caspase-insensitive, but only when expressed in caspase-3-deficient cells. Together, these data suggest a model whereby MST1 activation is induced by existing, active MST kinase, which phosphorylates Thr(183) and possibly Thr(187). Dimerization promotes greater phosphorylation. This leads to induction of the JNK signaling pathway, caspase activation, and apoptosis. Further activation of MST1 by caspase cleavage is best promoted by caspase-3, although this appears to be unnecessary for signaling and morphological responses.	Merck Res Labs, Dept Bone Biol & Osteoporosis, W Point, PA 19486 USA	Merck & Company	Reszka, AA (corresponding author), Merck Res Labs, Dept Bone Biol & Osteoporosis, WP26A-1000 Sumneytown Pike, W Point, PA 19486 USA.							Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Graves JD, 2001, J BIOL CHEM, V276, P14909, DOI 10.1074/jbc.M010905200; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Jakobi R, 2000, EUR J BIOCHEM, V267, P4414, DOI 10.1046/j.1432-1327.2000.01488.x; Kakeya H, 1999, ANN NY ACAD SCI, V886, P273, DOI 10.1111/j.1749-6632.1999.tb09434.x; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lian JP, 2001, J IMMUNOL, V166, P6349, DOI 10.4049/jimmunol.166.10.6349; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; Messmer UK, 2001, BRIT J PHARMACOL, V133, P467, DOI 10.1038/sj.bjp.0704093; Qian ZJ, 2001, J BIOL CHEM, V276, P22439, DOI 10.1074/jbc.M009323200; Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967; Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Ura S, 2001, GENES CELLS, V6, P519, DOI 10.1046/j.1365-2443.2001.00439.x; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	31	140	145	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42987	42996		10.1074/jbc.M208538200	http://dx.doi.org/10.1074/jbc.M208538200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12223493	hybrid			2022-12-25	WOS:000179081200074
J	Wu, JM; Janknecht, R				Wu, JM; Janknecht, R			Regulation of the ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1 and protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; MAP KINASE; COACTIVATOR CBP; GENE-REGULATION; PEA3 SUBFAMILY; PHOSPHORYLATION; ACTIVATION; GROWTH; CAMP; CREB	The ETS transcription factor ER81 is activated in response to many signals via mitogen-activated protein kinases (MAPKs). However, ER81 is not only phosphorylated on MAPK sites but also at other sites that impact on its transactivation potential. Here we describe that the 90-kDa ribosomal S6 kinase 1 (RSK1), a protein kinase downstream of the extracellular signal-regulated kinase (ERK) subclass of MAPKs, binds to ER81, phosphorylates it, and enhances ER81-dependent transcription. Two in vivo RSK1 phosphorylation sites within ER81, Ser(191) and Ser(216), were identified, whose mutation to alanine reduces ER81 activity upon ERK-MAPK stimulation. Furthermore, RSK1 activates the ER81 cofactor CREB-binding protein and may thereby augment ER81-dependent transcription. Similar to RSK1, the cAMP-dependent protein kinase A (PKA) phosphorylates ER81 on Ser(191)/Ser(216). Additionally, PKA targets ER81 on Ser(334) in vivo. Surprisingly, phosphorylation of Ser(334) severely reduces the DNA-binding ability of ER81 but also enhances the transactivation potential of ER81. These counteractive effects of PKA phosphorylation on ER81-dependent transcription may cause the selective up-regulation of promoters with high but not low affinity for ER81. Collectively, we have identified mechanisms for how two distinct signaling pathways with different effector protein kinases, RSK1 and PKA, converge on ER81, which may regulate ER81 function during development and tumorigenesis.	Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 First St SW, Rochester, MN 55905 USA.			Janknecht, Ralf/0000-0003-1741-1562	NCI NIH HHS [R01 CA085257] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Baert JL, 2002, J BIOL CHEM, V277, P1002, DOI 10.1074/jbc.M107139200; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; Bosc DG, 2002, J CELL BIOCHEM, V86, P174, DOI 10.1002/jcb.10205; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Cassoni P, 1997, INT J CANCER, V72, P340, DOI 10.1002/(SICI)1097-0215(19970717)72:2<340::AID-IJC23>3.0.CO;2-I; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; ChoChung YS, 1995, CRIT REV ONCOL HEMAT, V21, P33, DOI 10.1016/1040-8428(94)00166-9; Chotteau-Lelievre A, 2001, MECH DEVELOP, V108, P191, DOI 10.1016/S0925-4773(01)00480-4; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Coutte L, 1999, ONCOGENE, V18, P6278, DOI 10.1038/sj.onc.1203020; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; FAURE M, 1994, J BIOL CHEM, V269, P7851; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Goodman RH, 2000, GENE DEV, V14, P1553; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Hung MC, 1999, SEMIN ONCOL, V26, P51; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 2001, J BIOL CHEM, V276, P41856, DOI 10.1074/jbc.M106630200; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; MONTE D, 1995, ONCOGENE, V11, P771; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; RAO VN, 1992, ONCOGENE, V7, P65; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	65	79	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42669	42679		10.1074/jbc.M205501200	http://dx.doi.org/10.1074/jbc.M205501200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12213813	hybrid			2022-12-25	WOS:000179081200032
J	Mizuta, B; Mizuta, M; Araki, S; Kitamura, D				Mizuta, B; Mizuta, M; Araki, S; Kitamura, D			RAG2 is down-regulated by cytoplasmic sequestration and ubiquitin-dependent degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V(D)J RECOMBINATION; CELL-CYCLE; P27(KIP1); REPAIR; PATHWAYS; KINASE; GENE	Periodic accumulation and degradation of RAG2 (recombination-activating gene 2) protein controls the cell-cycle-dependent V(D)J recombination of lymphocyte antigen receptor genes. Here we show the molecular mechanism of RAG2 degradation. The RAG2 protein is translocated from the nucleus to the cytoplasm and degraded through the ubiquitin/proteasome system. RAG2 translocation is mediated by the Thr-490 phosphorylation of RAG2. Inhibition of this phosphorylation by p27Kip1 stabilizes the RAG2 protein in the nucleus. These results suggest that RAG2 sequestration in the cytoplasm and its subsequent degradation by the ubiquitin/proteasome system upon entering the S phase is an integral part of G0/G1-specific V(D)J recombination.	Sci Univ Tokyo, Res Inst Biol Sci, Noda, Chiba 2780022, Japan	Tokyo University of Science	Mizuta, B (corresponding author), Sci Univ Tokyo, Res Inst Biol Sci, 2669 Yamazaki, Noda, Chiba 2780022, Japan.		Araki, Shinsuke/M-3983-2018	Araki, Shinsuke/0000-0002-9936-1417				Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Desiderio S, 1996, CURR TOP MICROBIOL, V217, P45; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hesslein DGT, 2001, ADV IMMUNOL, V78, P169, DOI 10.1016/S0065-2776(01)78004-2; Kirch SA, 1998, EMBO J, V17, P4881, DOI 10.1093/emboj/17.16.4881; Lee J, 1999, IMMUNITY, V11, P771, DOI 10.1016/S1074-7613(00)80151-X; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Mizuta R, 1997, INT IMMUNOL, V9, P1607, DOI 10.1093/intimm/9.10.1607; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5	23	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41423	41427		10.1074/jbc.M206605200	http://dx.doi.org/10.1074/jbc.M206605200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12205088	hybrid			2022-12-25	WOS:000178985300018
J	Raghuraman, G; Lapinski, PE; Raghavan, M				Raghuraman, G; Lapinski, PE; Raghavan, M			Tapasin interacts with the membrane-spanning domains of both TAP subunits and enhances the structural stability of TAP1 center dot TAP2 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; ANTIGEN-PROCESSING TAP; PEPTIDE-BINDING; TRANSPORT COMPLEX; LOADING COMPLEX; INSECT CELLS; MOLECULES; TRANSLOCATION; EXPRESSION; SUBSTRATE	The transporter associated with antigen processing (TAP) proteins are involved in transport of peptides from the cytosol into the endoplasmic reticulum. Two subunits, TAP1 and TAP2, are necessary and sufficient for peptide binding and peptide translocation across the endoplasmic reticulum. membrane. TAP1. and TAP2 contain an N-terminal hydrophobic membrane-spanning region and a C-terminal nucleotide binding domain. Tapasin is an endoplasmic reticulum resident protein that has been found associated with the TAP subunits and shown to increase expression levels of TAP. Here we investigated TAP-tapasin interactions and their effects on TAP function in insect cells. We show tapasin binding to both TAP1 and TAP2 and to the corresponding nucleotide binding domain-exchanged chimeras as well as to a truncated TAP1.TAP2 complex containing just the membrane-spanning regions of TAP1 and TAP2. However, tapasin interactions with either the truncated TAP construct containing just the nucleotide binding domain are not observed. Tapasin is not required for high affinity peptide binding to TAP1.TAP2 complexes, and in fact, the presence of tapasin slightly reduces the affinity of TAP complexes for peptides. However, at near physiological temperatures, both tapasin and nucleotides stabilize the peptide binding site of TAP1-TAP2 complexes against inactivation, and enhanced thermostability of both TAP subunits is observed in the presence of tapasin. The enhanced structural stability of TAP1.TAP2 complexes in the presence of tapasin might explain the observations that tapasin increases TAP protein expression levels in mammalian cells.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Raghavan, M (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, 5641 Med Sci Bldg 2, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI044115, R01AI044115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048310] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44115-03, R01 AI044115] Funding Source: Medline; NIAMS NIH HHS [AR48310-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abele R, 1999, BBA-BIOMEMBRANES, V1461, P405, DOI 10.1016/S0005-2736(99)00171-6; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; Antoniou AN, 2002, IMMUNOLOGY, V106, P182, DOI 10.1046/j.1365-2567.2002.01415.x; Arora S, 2001, P NATL ACAD SCI USA, V98, P7241, DOI 10.1073/pnas.131132198; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; Grandea AG, 2001, TRENDS IMMUNOL, V22, P194, DOI 10.1016/S1471-4906(01)01861-0; Grandea AG, 2000, IMMUNITY, V13, P213, DOI 10.1016/S1074-7613(00)00021-2; Lapinski PE, 2000, J BIOL CHEM, V275, P6831, DOI 10.1074/jbc.275.10.6831; Lapinski PE, 2001, J BIOL CHEM, V276, P7526, DOI 10.1074/jbc.M009448200; Lauvau G, 1999, J BIOL CHEM, V274, P31349, DOI 10.1074/jbc.274.44.31349; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Li SL, 1997, P NATL ACAD SCI USA, V94, P8708, DOI 10.1073/pnas.94.16.8708; Li SL, 2000, J BIOL CHEM, V275, P1581, DOI 10.1074/jbc.275.3.1581; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Momburg F, 2002, MOL IMMUNOL, V39, P217, DOI 10.1016/S0161-5890(02)00103-7; Momburg F, 1998, ADV IMMUNOL, V68, P191, DOI 10.1016/S0065-2776(08)60560-X; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Neumann L, 1999, J MOL BIOL, V294, P1203, DOI 10.1006/jmbi.1999.3329; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Powis SJ, 1997, EUR J IMMUNOL, V27, P2744, DOI 10.1002/eji.1830271040; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Saveanu L, 2001, J BIOL CHEM, V276, P22107, DOI 10.1074/jbc.M011221200; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; van Endert PM, 1999, J BIOL CHEM, V274, P14632, DOI 10.1074/jbc.274.21.14632; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; Vos JC, 1999, J IMMUNOL, V163, P6679	30	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41786	41794		10.1074/jbc.M207128200	http://dx.doi.org/10.1074/jbc.M207128200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12213826	hybrid			2022-12-25	WOS:000178985300063
J	Zhou, XY; Wang, X; Wang, HY; Chen, DJ; Li, GC; Iliakis, G; Wang, Y				Zhou, XY; Wang, X; Wang, HY; Chen, DJ; Li, GC; Iliakis, G; Wang, Y			Ku affects the ATM-dependent S phase checkpoint following ionizing radiation	ONCOGENE			English	Article						ku; ATM; S phase checkpoint; ionizing radiation	DOUBLE-STRAND BREAKS; DNA END BINDING; PROTEIN-KINASE; V(D)J RECOMBINATION; ATAXIA-TELANGIECTASIA; REPAIR; DAMAGE; CELLS; INVOLVEMENT; SENSITIVITY	Following exposure to genotoxic stress, proliferating cells actively slow down DNA replication through an S phase checkpoint to provide time for repair. The ATM-dependent pathway plays an important role in the S phase checkpoint response following ionizing irradiation. We report that there is a stronger S phase checkpoint response in irradiated Ku80(-/-) cells as compared with their wild-type counterparts, which has no relationship to DNA-dependent protein kinase (DNA-PK) activity but correlates with a higher ATM activity and with more ATM bound to chromatin DNA in such cells. Wortmannin, a nonspecific inhibitor of ATM, not only reduces the higher activity of ATM kinase, but also abolishes the stronger S phase checkpoint response in Ku80(-/-) cells. Furthermore, a specific ATM antisense oligonucleotide abolishes the stronger S checkpoint response in Ku80(-/-) cells and renders these cells practically indistinguishable from Ku80(+/+) cells for this endpoint. These results in aggregate indicate that the stronger S checkpoint in irradiated Ku80(-/-) cells is due to the higher ATM kinase activity.	Thomas Jefferson Univ, Dept Radiat Oncol, Kimmel Canc Ctr, Jefferson Med Coll, Philadelphia, PA 19107 USA; Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA; Univ Essen Gesamthsch, Sch Med, Inst Med Radiat Biol, D-45122 Essen, Germany	Jefferson University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Duisburg Essen	Wang, Y (corresponding author), Thomas Jefferson Univ, Dept Radiat Oncol, Kimmel Canc Ctr, Jefferson Med Coll, Thompson Bldg,B1,1020 Sansom St, Philadelphia, PA 19107 USA.				NCI NIH HHS [CA 56909, CA 50519, CA76203, T32-CA09137, P30-CA56036] Funding Source: Medline; NIA NIH HHS [AG18949] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050519, T32CA009137, R37CA050519, R29CA076203, R01CA056909, P30CA056036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Dibiase SJ, 2000, CANCER RES, V60, P1245; DYCK EV, 1999, NATURE, V401, P728; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; GETTS RC, 1994, J BIOL CHEM, V269, P15981; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; JEGGO PA, 1985, MUTAT RES, V145, P171, DOI 10.1016/0167-8817(85)90024-0; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; Sarkaria JN, 1998, CANCER RES, V58, P4375; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Wachsberger PR, 1999, RADIAT RES, V151, P398, DOI 10.2307/3579826; Wang HC, 2001, NUCLEIC ACIDS RES, V29, P1653, DOI 10.1093/nar/29.8.1653; WANG Y, 1992, CANCER RES, V52, P508; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou XY, 2002, CANCER RES, V62, P1598; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	32	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6377	6381		10.1038/sj.onc.1205782	http://dx.doi.org/10.1038/sj.onc.1205782			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214278				2022-12-25	WOS:000177829000014
J	Hopkins-Donaldson, S; Yan, P; Bourloud, KB; Muhlethaler, A; Bodmer, JL; Gross, N				Hopkins-Donaldson, S; Yan, P; Bourloud, KB; Muhlethaler, A; Bodmer, JL; Gross, N			Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells	ONCOGENE			English	Article						apoptosis; caspases; doxorubicin; caspase-8; neuroblastoma	DRUG-INDUCED APOPTOSIS; WILD-TYPE P53; CHEMOTHERAPEUTIC DRUGS; CANCER-THERAPY; PATHWAYS; FAS; MITOCHONDRIA; EXPRESSION; RESISTANCE; TRIGGERS	Death induced by doxorubicin (dox) in neuroblastoma (NB) cells was originally thought to occur via the Fas pathway, however since studies suggest that caspase-8 expression is silenced in most high stage NB tumors, it is more probable that dox-induced death occurs via a different mechanism. Caspase-8 silenced N-type invasive NB cell tines LAN-1 and IMR-32 were investigated for their sensitivity to dox, and compared to S-type noninvasive SH-EP NB cells expressing caspase-8. All cell lines had similar sensitivities to dox, independently of caspase-8 expression. Dox induced caspase-3, -7, -8 and -9 and Bid cleavage in S-type cells and death was blocked by caspase inhibitors but not by oxygen radical scavenger BHA. In contrast, dox-induced death in N-type cells was caspase-independent and was inhibited by BHA. Dox induced a drop in mitochondrial membrane permeability in all cell lines. Dox-induced death in S-type cells gave rise to apoptotic nuclei, whereas in N-type cells nuclei were non-apoptotic in morphology. Transfection of SH-EP cells with a dominant negative FADD mutant inhibited TRAIL-induced death, but had no effect on dox-induced apoptosis. These results suggest that S-type cells undergo apoptosis after dox treatment independently of death receptors, whereas N-type cells are killed by a caspase-independent mechanism.	CHU Vaudois, Dept Pediat Oncohematol, CH-1011 Lausanne, Switzerland; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne	Gross, N (corresponding author), CHU Vaudois, Dept Pediat Oncohematol, CH-1011 Lausanne, Switzerland.		Mühlethaler-Mottet, Annick/H-2848-2019	Mühlethaler-Mottet, Annick/0000-0001-8274-0907				Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Ferreira CG, 2000, CANCER RES, V60, P7133; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Goldman SC, 1996, AM J PATHOL, V148, P1381; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Kataoka T, 1998, J IMMUNOL, V161, P3936; LaQuaglia MP, 1996, J PEDIATR SURG, V31, P315, DOI 10.1016/S0022-3468(96)90025-1; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; McKenzie PP, 1999, CLIN CANCER RES, V5, P4199; Miyazaki K, 2001, J BIOCHEM-TOKYO, V129, P963, DOI 10.1093/oxfordjournals.jbchem.a002944; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Oue T, 1996, J PEDIATR SURG, V31, P251, DOI 10.1016/S0022-3468(96)90009-3; Sartorius UA, 2002, INT J CANCER, V97, P584, DOI 10.1002/ijc.10096; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Spix C, 2001, EUR J CANCER, V37, P722, DOI 10.1016/S0959-8049(01)00003-X; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108	28	40	42	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6132	6137		10.1038/sj.onc.1205879	http://dx.doi.org/10.1038/sj.onc.1205879			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203125				2022-12-25	WOS:000177671300016
J	Fiorucci, S; Mencarelli, A; Mannucci, R; Distrutti, E; Morelli, A; del Soldato, P; Moncada, S				Fiorucci, S; Mencarelli, A; Mannucci, R; Distrutti, E; Morelli, A; del Soldato, P; Moncada, S			NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function	FASEB JOURNAL			English	Article						caspase-8; caspase-9; cytochrome c; cell respiration	CYTOCHROME-C RELEASE; CONVERTING-ENZYME; S-NITROSYLATION; INHIBITION; RESPIRATION; NO; MECHANISM; DEATH; SUPPRESSION; ACTIVATION	We investigated the effect of a nitric oxide (NO)-releasing derivative of aspirin (NCX-4016) on a mitochondria-dependent model of apoptosis in human umbilical endothelial cells (HUVEC). Exposure of HUVEC to staurosporine caused a progressive fall in mitochondrial membrane potential (Deltapsi(m)) and apoptosis. Exposure to an NO donor, (z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NO), caused an early (1-3h) hyperpolarization of Deltapsi(m) and reduction of apoptosis that was followed (at 4-8 h) by an accelerated collapse of Deltapsi(m) and cell death. In contrast, treatment with NCX-4016, but not with aspirin or a non-NO-releasing analogue of NCX-4016, protected HUVEC against the apoptotic actions of staurosporine for up to 8 h. Confocal microscopy demonstrated that although NCX-4016 released NO in subcellular compartments, DETA-NO caused a generalized increase in cytosolic fluorescence. Exposure to DETA-NO resulted in a rapid and profound inhibition of cell respiration (78.3 +/- 6.4%), whereas NCX-4016 caused a less pronounced reduction in oxygen consumption (43.5 +/- 5.3%). Staurosporine caused a time-dependent activation of proapoptotic caspases. NCX-4016 prevented this activation, whereas DETA-NO failed to inhibit caspase activity. In contrast to DETA-NO, NCX-4016 did not increase mitochondrial oxidative stress. These data demonstrated that NCX-4016 conveys NO directly inside endothelial cells and modulates mitochondrial function.	Monteluce Policlin, Clin Gastroenterol & Epatol, Dipartimento Med Clin & Sperimentale, I-06122 Perugia, Italy; NicOx SA, F-06906 Sophia Antipolis, France; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; University College London	Fiorucci, S (corresponding author), Monteluce Policlin, Clin Gastroenterol & Epatol, Dipartimento Med Clin & Sperimentale, Via E dal Pozzo, I-06122 Perugia, Italy.	fiorucci@unipg.it	Fiorucci, Stefano/I-1251-2012					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Cines DB, 1998, BLOOD, V91, P3527; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; ELLIOTT SN, 1995, GASTROENTEROLOGY, V109, P524, DOI 10.1016/0016-5085(95)90341-0; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; Fiorucci S, 2000, J IMMUNOL, V165, P5245, DOI 10.4049/jimmunol.165.9.5245; Fiorucci S, 2000, GASTROENTEROLOGY, V118, P404, DOI 10.1016/S0016-5085(00)70223-X; Fiorucci S, 2001, AM J PHYSIOL-GASTR L, V281, pG654, DOI 10.1152/ajpgi.2001.281.3.G654; Fiorucci S, 2001, TRENDS IMMUNOL, V22, P232, DOI 10.1016/S1471-4906(01)01904-4; Fiorucci S, 1999, GASTROENTEROLOGY, V116, P1089, DOI 10.1016/S0016-5085(99)70012-0; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; *GRAPHP SOFTW, 2000, PRISM 3; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 2000, J BIOL CHEM, V275, P10954, DOI 10.1074/jbc.275.15.10954; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Messmer UK, 1998, EUR J PHARMACOL, V349, P333, DOI 10.1016/S0014-2999(98)00189-7; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Paxinou E, 2001, P NATL ACAD SCI USA, V98, P11575, DOI 10.1073/pnas.201293198; Poderoso JJ, 1999, J BIOL CHEM, V274, P37709, DOI 10.1074/jbc.274.53.37709; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; Vanin AF, 1997, NITRIC OXIDE-BIOL CH, V1, P191, DOI 10.1006/niox.1997.0122; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Zimmermann KC, 2000, NEOPLASIA, V2, P505, DOI 10.1038/sj.neo.7900120	35	38	41	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10					1645	+		10.1096/fj.02-0297fje	http://dx.doi.org/10.1096/fj.02-0297fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207011				2022-12-25	WOS:000177814000017
J	Majumder, B; Wahle, KWJ; Moir, S; Schofield, A; Choe, SN; Farquharson, A; Grant, I; Heys, SD				Majumder, B; Wahle, KWJ; Moir, S; Schofield, A; Choe, SN; Farquharson, A; Grant, I; Heys, SD			Conjugated linoleic acids (CLAs) regulate the expression of key apoptotic genes in human breast cancer cells	FASEB JOURNAL			English	Article						mammary cancer; apoptotic gene expression; antiapoptotic gene expression	MAMMARY EPITHELIAL-CELLS; EICOSAPENTAENOIC ACID; POOR RESPONSE; BCL-2; RISK; CHEMOTHERAPY; PROTEIN; DIET; CONSUMPTION; PREVENTION	Conjugated linoleic acid (CLA) reduces mammary tumorigenesis in rodent models, induces apoptosis in rodent mammary tumor cell lines, and decreases expression of antiapoptotic bcl-2 in rat mammary tissue. This investigation focused on the cell mechanisms underlying the antitumor effects of CLA. Changes (mRNA, protein) in expression of major proapoptotic p53, p21WAF1/CIP1, bax, bcl-Xs genes, and the antiapoptotic bcl-2 gene were observed in malignant MCF-7 and MDA-MB-231 cells and in benign MCF-10a human mammary tumor cells in culture. CLA, but not linoleic acid (LA), inhibited proliferation in all cells; CLA mix was most effective. CLA increased DNA damage (apoptosis). CLA increased mRNA expression of p53 and p21WAF1/CIP1 (three- to fivefold and twofold, respectively) but either decreased bcl-2 by 20-30% or had no effect in MCF-7 and MCF-10a cells, respectively; protein expression reflected mRNA values. In MDA-MBA-231 (mutant p53) cells, mRNA for p53 was not changed, but p21WAF1/CIP1 and bcl-2 mRNA was increased. Protein expression largely reflected mRNA changes but, surprisingly, CLA completely suppressed mutant p53 protein in MDA-MB-231 cells. Apparent antiapoptotic effects of increased bcl-2 expression in MDA-MBA-231 cells were countered by increased proapoptotic p21WAF1/CIP1, Bax, and Bcl-Xs proteins. Findings indicate that CLA elicits mainly proapoptotic effects in human breast tumor cells through both p53-dependent and p53-independent pathways, according to cell type.	Rowett Res Inst, Lipid & Cell Biol Unit, Cell Integr Grp, Bucksburn AB21 9SB, Aberdeen, Scotland; Univ Aberdeen, Sch Med, Unit Surg Oncol, Aberdeen AB25 9ZD, Scotland; Kunsan Natl Univ, Kunsan, South Korea	University of Aberdeen; University of Aberdeen; Kunsan National University	Wahle, KWJ (corresponding author), Rowett Res Inst, Lipid & Cell Biol Unit, Cell Integr Grp, Greenburn Rd, Bucksburn AB21 9SB, Aberdeen, Scotland.	kwjw@rri.sari.ac.uk						BANG HO, 1976, ACTA MED SCAND, V200, P69; Banni S, 1999, CARCINOGENESIS, V20, P1019, DOI 10.1093/carcin/20.6.1019; BOYD NF, 1993, BRIT J CANCER, V68, P627, DOI 10.1038/bjc.1993.398; CAMPOS L, 1993, BLOOD, V81, P3091; CARROLL KK, 1991, AM J CLIN NUTR, V53, pS1064, DOI 10.1093/ajcn/53.4.1064S; Choucroun P, 2001, MUTAT RES-FUND MOL M, V478, P89, DOI 10.1016/S0027-5107(01)00123-3; Connolly JM, 1996, NUTR CANCER, V25, P231, DOI 10.1080/01635589609514447; Durgam VR, 1997, CANCER LETT, V116, P121, DOI 10.1016/S0304-3835(97)00192-4; FITE A, 2001, EUR J SURG ONCOL, V27, P798; FITE A, 2002, IN PRESS CANC RES; Griinari JM, 2000, J NUTR, V130, P2285, DOI 10.1093/jn/130.9.2285; HA YL, 1987, CARCINOGENESIS, V8, P1881, DOI 10.1093/carcin/8.12.1881; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; Ip C, 2000, CANCER EPIDEM BIOMAR, V9, P689; IP C, 1995, NUTR CANCER, V24, P241, DOI 10.1080/01635589509514413; Ip C, 1996, CARCINOGENESIS, V17, P1045, DOI 10.1093/carcin/17.5.1045; IP C, 1991, CANCER RES, V51, P6118; Ip MM, 1999, EXP CELL RES, V250, P22, DOI 10.1006/excr.1999.4499; KAIZER L, 1989, NUTR CANCER, V12, P61, DOI 10.1080/01635588909514002; Kang KH, 1999, EXP CELL RES, V253, P403, DOI 10.1006/excr.1999.4644; KARMILOFFSMITH A, 1984, ADV DEV PSYCHOL, V3, P33; Kikuyama S, 2001, ANTICANCER RES, V21, P2149; Kohlmeier L, 1997, P NUTR SOC, V56, P369, DOI 10.1079/PNS19970039; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; NOBMANN ED, 1992, AM J CLIN NUTR, V55, P1024, DOI 10.1093/ajcn/55.5.1024; Noguchi M, 1997, BRIT J CANCER, V75, P348, DOI 10.1038/bjc.1997.57; OCHOA JJH, 2002, INT SOC STUD FATT AC; OCHOA JJH, 2002, IN PRESS BIOCH BIOPH; PARIZA MW, 1983, CANCER RES, V43, P2444; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rose DP, 1999, PHARMACOL THERAPEUT, V83, P217, DOI 10.1016/S0163-7258(99)00026-1; SCHULTZ T, 1992, ANTICANCER RES, V12, P21; Simonsen N, 1998, AM J EPIDEMIOL, V147, P342; Tannenbaum A, 1942, CANCER RES, V12, P468; TRICHOPOULOU A, 1995, JNCI-J NATL CANCER I, V87, P110, DOI 10.1093/jnci/87.2.110; Whitehouse AS, 2001, CANCER RES, V61, P3604; Wigmore SJ, 2000, NUTR CANCER, V36, P177, DOI 10.1207/S15327914NC3602_6; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC	42	80	92	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1447	+		10.1096/fj.01-0720fje	http://dx.doi.org/10.1096/fj.01-0720fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205043				2022-12-25	WOS:000177813100005
J	Mostyn, A; Bispham, J; Pearce, S; Evens, Y; Raver, N; Keisler, DH; Webb, R; Stephenson, T; Symonds, ME				Mostyn, A; Bispham, J; Pearce, S; Evens, Y; Raver, N; Keisler, DH; Webb, R; Stephenson, T; Symonds, ME			Differential effects of leptin on thermoregulation and uncoupling protein abundance in the neonatal lamb	FASEB JOURNAL			English	Article						adipose tissue; development; mitochondria	BROWN ADIPOSE-TISSUE; BODY-WEIGHT; MESSENGER-RNA; CORD-BLOOD; OBESE GENE; TEMPERATURE; EXPRESSION; HUMANS; SERUM; FETAL	As the role of leptin in energy balance in neonate is unknown, we investigated the effect of acute (2 h) and chronic (7 days) administration of leptin (100 mug/day) on thermoregulation and mitochondrial protein abundance in adipose tissue. The concentration of uncoupling protein (UCP)1 and voltage-dependent anion channel (VDAC) located on the inner and outer mitochondrial membranes, respectively, were measured. Administration of leptin prevented the normal decline in colonic temperature over the first few hours and days after birth. It subsequently accelerated the loss of both mRNA and protein for UCP1 but had no effect on VDAC abundance. At seven days of age, colonic temperature was correlated strongly with both mRNA abundance and thermogenic potential of UCP1 in leptin-treated but not control lambs, indicating more effective use of UCP1 for heat production following leptin administration. Leptin had no effect on weight gain or adipose tissue deposition; at one day of age only, leptin mRNA was correlated positively with adipose tissue weight. In conclusion, leptin administration to neonatal lambs improves thermoregulation and promotes the loss of UCP1 in brown adipose tissue.	Univ Hosp, Queens Med Ctr, Sch Human Dev, Acad Div Child Hlth, Nottingham NG7 2UH, England; Univ Nottingham, Sch Biosci, Div Agr Sci, Loughborough, Leics, England; Univ Missouri, Dept Anim Sci, Columbia, MO USA; Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel	Nottingham University Hospital NHS Trust; University of Nottingham; University of Nottingham; University of Missouri System; University of Missouri Columbia; Hebrew University of Jerusalem	Symonds, ME (corresponding author), Univ Hosp, Queens Med Ctr, Sch Human Dev, Acad Div Child Hlth, Nottingham NG7 2UH, England.	michael.symonds@nottingham.ac.uk	Keisler, Duane H/C-2746-2011; Mostyn, Alison/B-9126-2008; Mostyn, Alison/H-1018-2011	Keisler, Duane H/0000-0002-8792-7030; Stephenson, Terence/0000-0001-8871-7847; Symonds, Michael/0000-0001-9649-8963				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; BALL KT, 1992, ENDOCRINOLOGY, V131, P337, DOI 10.1210/en.131.1.337; BISPHAM J, 2002, IN PRESS PEDIAT RES; Cancello R, 1998, ENDOCRINOLOGY, V139, P4747, DOI 10.1210/en.139.11.4747; CASTEILLA L, 1994, BIOCHEM J, V297, P93, DOI 10.1042/bj2970093; CASTEILLA L, 1989, BIOCHEM J, V257, P665, DOI 10.1042/bj2570665; Clarke L, 1997, AM J PHYSIOL-REG I, V272, pR1931, DOI 10.1152/ajpregu.1997.272.6.R1931; Clarke L, 1997, EXP PHYSIOL, V82, P1015, DOI 10.1017/S095806709701645X; Clarke L, 1997, BRIT J NUTR, V77, P871, DOI 10.1079/BJN19970086; Clarke L, 1996, PEDIATR RES, V40, P330, DOI 10.1203/00006450-199608000-00023; CLRKE L, 1994, J APPL PHYSIOL, P1481; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Delavaud C, 2000, J ENDOCRINOL, V165, P519, DOI 10.1677/joe.0.1650519; ELIOT RJ, 1981, ENDOCRINOLOGY, V108, P1678, DOI 10.1210/endo-108-5-1678; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gertler A, 1998, FEBS LETT, V422, P137, DOI 10.1016/S0014-5793(97)01613-X; Hytinantti T, 1999, PEDIATR RES, V45, P197, DOI 10.1203/00006450-199902000-00007; Koistinen HA, 1997, J CLIN ENDOCR METAB, V82, P3328, DOI 10.1210/jc.82.10.3328; LEAN MEJ, 1989, P NUTR SOC, V48, P243, DOI 10.1079/PNS19890036; Li H, 1997, AM J PHYSIOL-ENDOC M, V272, pE1031, DOI 10.1152/ajpendo.1997.272.6.E1031; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luheshi GN, 1999, P NATL ACAD SCI USA, V96, P7047, DOI 10.1073/pnas.96.12.7047; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; Matsuda J, 1999, PEDIATR RES, V45, P71, DOI 10.1203/00006450-199901000-00012; Mistry AM, 1999, AM J PHYSIOL-REG I, V277, pR742, DOI 10.1152/ajpregu.1999.277.3.R742; Mostyn A, 2001, P NUTR SOC, V60, P187, DOI 10.1079/PNS200086; Nedergaard J, 2001, BBA-BIOENERGETICS, V1504, P82, DOI 10.1016/S0005-2728(00)00247-4; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Qian H, 1998, ENDOCRINOLOGY, V139, P791, DOI 10.1210/en.139.2.791; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Schermer SJ, 1996, REPROD FERT DEVELOP, V8, P995, DOI 10.1071/RD9960995; Schubring C, 1997, J CLIN ENDOCR METAB, V82, P1480, DOI 10.1210/jc.82.5.1480; Shek EW, 1998, HYPERTENSION, V31, P409, DOI 10.1161/01.HYP.31.1.409; Sivitz WI, 1999, ENDOCRINOLOGY, V140, P1511, DOI 10.1210/en.140.4.1511; SYMONDS ME, 1995, EXP PHYSIOL, V80, P907, DOI 10.1113/expphysiol.1995.sp003905; Symonds ME, 1996, P NUTR SOC, V55, P561, DOI 10.1079/PNS19960048; SYMONDS ME, 1992, J PHYSIOL-LONDON, V455, P487, DOI 10.1113/jphysiol.1992.sp019313; SYMONDS ME, 1989, J DEV PHYSIOL, V11, P289; TRAYHURN P, 1993, AM J PHYSIOL, V265, pR676, DOI 10.1152/ajpregu.1993.265.3.R676; Yuan CS, 2000, PEDIATR RES, V48, P380, DOI 10.1203/00006450-200009000-00021; Yuen BSJ, 1999, J ENDOCRINOL, V163, pR1, DOI 10.1677/joe.0.163R001; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	45	40	42	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1438	+		10.1096/fj.02-0077fje	http://dx.doi.org/10.1096/fj.02-0077fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205040				2022-12-25	WOS:000177813100006
J	Gallina, A; Hanley, TM; Mandel, R; Trahey, M; Broder, CC; Viglianti, GA; Ryser, HJP				Gallina, A; Hanley, TM; Mandel, R; Trahey, M; Broder, CC; Viglianti, GA; Ryser, HJP			Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 ENVELOPE; GLYCOSYLATION SITES; SECRETORY PROTEINS; ESCHERICHIA-COLI; CELL-LINE; SURFACE; BINDING; GP120; FUSION; MEMBRANE	We previously reported that monoclonal antibodies to protein-disulfide isomerase (PDI) and other membrane-impermeant PDI inhibitors prevented HIV-1 infection. PDI is present at the surface of HIV-1 target cells and reduces disulfide bonds in a model peptide attached to the cell membrane. Here we show that soluble PDI cleaves disulfide bonds in recombinant envelope glycoprotein gp120 and that gp120 bound to the surface receptor CD4 undergoes a disulfide reduction that is prevented by PDI inhibitors. Concentrations of inhibitors that prevent this reduction and inhibit the cleavage of surface-bound disulfide conjugate prevent infection at the level of HIV-1 entry. The entry of HIV-1 strains differing in their coreceptor specificities is similarly inhibited, and so is the reduction of gp120 bound to CD4 of coreceptor-negative cells. PDI inhibitors also prevent HIV envelope-mediated cell-cell fusion but have no effect on the entry of HIV-1 pseudo-typed with murine leukemia virus envelope. Importantly, PDI coprecipitates with both soluble and cellular CD4. We propose that a PDI-CD4 association at the cell surface enables PDI to reach CD4-bound virus and to reduce disulfide bonds present in the domain of gp120 that binds to CD4. Conformational changes resulting from the opening of gp120-disulfide loops may drive the processes of virus-cell and cell-cell fusion. The biochemical events described identify new potential targets for anti-HIV agents.	Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Univ Montana, Montana Biotechnol Ctr, Missoula, MT 59812 USA; Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Boston University; University of Montana System; University of Montana; Uniformed Services University of the Health Sciences - USA	Ryser, HJP (corresponding author), Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA.		Hanley, Timothy/AAG-7547-2020; Broder, Christopher/E-1169-2013	Viglianti, Gregory/0000-0002-0244-8293; Hanley, Timothy/0000-0002-6253-6850	NATIONAL CANCER INSTITUTE [R01CA014551] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043885, R21AI043885, R21AI044312, R01AI041758, R01AI044669] Funding Source: NIH RePORTER; NCI NIH HHS [CA14551] Funding Source: Medline; NHLBI NIH HHS [HLB57882] Funding Source: Medline; NIAID NIH HHS [AI44669, AI41758, AI44312, AI43885] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barbeau B, 1998, J VIROL, V72, P7125, DOI 10.1128/JVI.72.9.7125-7136.1998; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHENG SY, 1986, P NATL ACAD SCI USA, V83, P947, DOI 10.1073/pnas.83.4.947; CIMINALE V, 1990, AIDS RES HUM RETROV, V6, P1281, DOI 10.1089/aid.1990.6.1281; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; Couet J, 1996, BIOCHEMISTRY-US, V35, P14800, DOI 10.1021/bi961359w; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Donoghue N, 2000, PROTEIN SCI, V9, P2436, DOI 10.1110/ps.9.12.2436; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Dumonceaux J, 1998, J VIROL, V72, P512, DOI 10.1128/JVI.72.1.512-519.1998; EARL PL, 1994, J VIROL, V68, P3015, DOI 10.1128/JVI.68.5.3015-3026.1994; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FEENER EP, 1990, J BIOL CHEM, V265, P18780; Fenouillet E, 2001, J INFECT DIS, V183, P744, DOI 10.1086/318823; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; FREEDMAN RB, 1988, BIOCHEM SOC T, V16, P96, DOI 10.1042/bst0160096; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; Guthapfel R, 1996, EUR J BIOCHEM, V242, P315, DOI 10.1111/j.1432-1033.1996.0315r.x; HARRIS RJ, 1990, EUR J BIOCHEM, V188, P291, DOI 10.1111/j.1432-1033.1990.tb15402.x; HAWLEY RG, 1994, GENE THER, V1, P136; Hoffman TL, 1999, P NATL ACAD SCI USA, V96, P6359, DOI 10.1073/pnas.96.11.6359; Hotchkiss KA, 1998, BBA-PROTEIN STRUCT M, V1388, P478, DOI 10.1016/S0167-4838(98)00211-8; JENG MF, 1995, BIOCHEMISTRY-US, V34, P10101, DOI 10.1021/bi00032a001; Jiang XM, 1999, J BIOL CHEM, V274, P2416, DOI 10.1074/jbc.274.4.2416; KAETZEL CS, 1987, BIOCHEM J, V241, P39, DOI 10.1042/bj2410039; KALEF E, 1994, METHOD ENZYMOL, V233, P395; KIM JS, 1993, PROTEIN SCI, V2, P348; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; Maerz AL, 2001, J VIROL, V75, P6635, DOI 10.1128/JVI.75.14.6635-6644.2001; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; Matthias LJ, 2002, NAT IMMUNOL, V3, P727, DOI 10.1038/ni815; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; Ramachandran N, 2001, P NATL ACAD SCI USA, V98, P9539, DOI 10.1073/pnas.171180998; RIVERA A, 1997, THESIS BOSTON U BOST; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559; RYSER HJP, 1999, PLASMA MEMBRANE REDA, P229; RYSER HJP, 1997, PROLYL HYDROXYLASE P, P425; Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; STEVENSON KJ, 1978, BIOCHEMISTRY-US, V17, P2189, DOI 10.1021/bi00604a026; Tager M, 1997, EXP HEMATOL, V25, P601; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; TSCHACHLER E, 1990, J VIROL, V64, P2250, DOI 10.1128/JVI.64.5.2250-2259.1990; Ugolini S, 1997, J EXP MED, V186, P1287, DOI 10.1084/jem.186.8.1287; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890	55	162	170	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50579	50588		10.1074/jbc.M204547200	http://dx.doi.org/10.1074/jbc.M204547200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12218051	hybrid			2022-12-25	WOS:000180177700052
J	Gao, N; Jiang, BH; Leonard, SS; Corum, L; Zhang, Z; Roberts, JR; Antonini, J; Zheng, JZ; Flynn, DC; Castranova, V; Shi, XL				Gao, N; Jiang, BH; Leonard, SS; Corum, L; Zhang, Z; Roberts, JR; Antonini, J; Zheng, JZ; Flynn, DC; Castranova, V; Shi, XL			p38 signaling-mediated hypoxia-inducible factor 1 alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CR(VI)-INDUCED P53 ACTIVATION; UBIQUITIN-PROTEASOME PATHWAY; HYDROXYL RADICAL FORMATION; FACTOR GENE-EXPRESSION; FACTOR-KAPPA-B; TUMOR ANGIOGENESIS; NUCLEAR FACTOR; SOLID TUMORS; TRANSCRIPTION; INHIBITION	Chromium(VI) (Cr(VI)) is widely used in industry and is a potent inducer of tumors in animals. The present study demonstrates that Cr(VI) induces hypoxia-inducible factor 1 (HIF-1) activity through the specific expression of HIF-1alpha but not HIF-1beta subunit and increases the level of vascular endothelial growth factor (VEGF) expression in DU145 human prostate carcinoma cells. To dissect the signaling pathways involved in Cr(VI)-induced HIF-1 expression, we found that p38 mitogen-activated protein kinase signaling was required for HIF-1alpha expression induced by Cr(VI). Neither phosphatidylinositol 3-kinase nor extracellular signal-regulated kinase activity was required for Cr(VI)-induced HIF-1 expression. Cr(VI) induced expression of HIF-1 and VEGF through the production of reactive oxygen species in DU145 cells. The major species of reactive oxygen species responsible for the induction of HIF-1 and VEGF expression is H2O2. These results suggest that the expression of HIF-1 and VEGF induced by Cr(VI) may be an important signaling pathway in the Cr(VI)induced carcinogenesis.	W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Dept Microbiol, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA	West Virginia University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Shi, XL (corresponding author), W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Dept Microbiol, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA.		Shi, Xianglin/B-8588-2012; Zhang, Zhuo/B-8601-2012	Jiang, Bing-Hua/0000-0003-4526-2031	NATIONAL CANCER INSTITUTE [R29CA060731, R01CA060731] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016440] Funding Source: NIH RePORTER; NCI NIH HHS [CA60731] Funding Source: Medline; NCRR NIH HHS [RR16440] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Angelov L, 1999, CANCER RES, V59, P5536; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Blagosklonny MV, 2001, ONCOGENE, V20, P395, DOI 10.1038/sj.onc.1204055; Borgstrom P, 1996, CANCER RES, V56, P4032; BRITIGAN BE, 1986, J BIOL CHEM, V261, P7026; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chen RF, 2000, RARE METALS, V19, P231; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Ding M, 2001, J BIOL CHEM, V276, P9108, DOI 10.1074/jbc.M007666200; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gao N, 2002, J BIOL CHEM, V277, P31963, DOI 10.1074/jbc.M200082200; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang CS, 2001, J BIOL CHEM, V276, P22397, DOI 10.1074/jbc.M010828200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Konishi T, 2000, INT J ONCOL, V16, P501; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Pavco PA, 2000, CLIN CANCER RES, V6, P2094; Presta LG, 1997, CANCER RES, V57, P4593; Ravi R, 2000, GENE DEV, V14, P34; Rojas E, 1999, MUTAT RES-GEN TOX EN, V443, P157, DOI 10.1016/S1383-5742(99)00018-6; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Saleh M, 1996, CANCER RES, V56, P393; Salnikow K, 2000, CANCER RES, V60, P3375; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; SHI XL, 1994, ENVIRON HEALTH PERSP, V102, P231, DOI 10.2307/3431792; Shi XL, 1999, MOL CELL BIOCHEM, V194, P63, DOI 10.1023/A:1006904904514; SHI XL, 1989, BIOCHEM BIOPH RES CO, V163, P627, DOI 10.1016/0006-291X(89)92183-9; SHI XL, 1990, ARCH BIOCHEM BIOPHYS, V281, P90, DOI 10.1016/0003-9861(90)90417-W; SHI XL, 1992, ARCH BIOCHEM BIOPHYS, V292, P323, DOI 10.1016/0003-9861(92)90085-B; Shi XL, 1999, J INORG BIOCHEM, V75, P37, DOI 10.1016/S0162-0134(99)00030-6; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Vallyathan Val, 1997, Environmental Health Perspectives, V105, P165, DOI 10.2307/3433405; Volpert OV, 1997, ONCOGENE, V14, P1495, DOI 10.1038/sj.onc.1200977; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang SW, 2001, CARCINOGENESIS, V22, P757, DOI 10.1093/carcin/22.5.757; Wang SW, 2000, AM J PHYSIOL-CELL PH, V279, pC868, DOI 10.1152/ajpcell.2000.279.3.C868; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974; YE JP, 1995, CARCINOGENESIS, V16, P2401, DOI 10.1093/carcin/16.10.2401; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541	60	102	112	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45041	45048		10.1074/jbc.M202775200	http://dx.doi.org/10.1074/jbc.M202775200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12213806	hybrid			2022-12-25	WOS:000179404800059
J	Marrakchi, H; Choi, KH; Rock, CO				Marrakchi, H; Choi, KH; Rock, CO			A new mechanism for anaerobic unsaturated fatty acid formation in Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; HYDROXYDECANOYL THIOESTER DEHYDRASE; PHENYLACETYL-COA CATABOLON; SYNTHASE III FABH; ESCHERICHIA-COLI; ENZYMATIC SYNTHESIS; THERMAL REGULATION; LIPID-COMPOSITION; ACTIVE-SITE; BIOSYNTHESIS	The anaerobic pathway for unsaturated fatty acid synthesis was established in the 1960s in Escherichia coli. The double bond is introduced into the growing acyl chain by FabA, an enzyme capable of both the dehydration of beta-hydroxydecanoyl-acyl carrier protein (ACP) to trans-2-decenoyl-ACP, and the isomerization of trans-2 to cis-3-decenoyl-ACP. However, there are a number of anaerobic bacteria whose genomes do not contain a fabA homolog, although these organisms nonetheless produce unsaturated fatty acids. We cloned and biochemically characterized a new enzyme in type II fatty acid synthesis from Streptococcus pneumoniae that carries out the isomerization of trans-2-decenoyl-ACP to cis-3-decenoyl-ACP, but is not capable of catalyzing the dehydration of beta-hydroxy intermediates. This tetrameric enzyme, designated FabM, has no similarity to FabA, but rather is a member of the hydratase/isomerase superfamily. Thus, the branch point in the biosynthesis of unsaturated fatty acids in S. pneumoniae occurs following the formation of trans-2-decenoyl-ACP, in contrast to E. coli where the branch point takes place after the formation of beta-hydroxydecanoyl-ACP.	St Jude Childrens Res Hosp, Prot Sci Div, Dept Infect Dis, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Biosci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Prot Sci Div, Dept Infect Dis, 332 N Lauderdale, Memphis, TN 38105 USA.	charles.rock@stjude.org	Marrakchi, Hedia/AAF-2657-2020		NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; Alekshun MN, 2000, MOL MICROBIOL, V35, P1394, DOI 10.1046/j.1365-2958.2000.01802.x; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BLOCH K, 1969, ACCOUNTS CHEM RES, V2, P193, DOI 10.1021/ar50019a001; BLOCH K, 1987, ANNU REV BIOCHEM, V56, P1; BLOOMFIELD DK, 1960, J BIOL CHEM, V235, P337; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCK DJH, 1967, J BIOL CHEM, V242, P4432; Campbell JW, 2001, J BACTERIOL, V183, P5982, DOI 10.1128/JB.183.20.5982-5990.2001; Choi KH, 2000, J BIOL CHEM, V275, P28201; Choi KH, 2000, J BACTERIOL, V182, P365, DOI 10.1128/JB.182.2.365-370.2000; Clark D P, 1981, Methods Enzymol, V72, P693; CLARK DP, 1983, BIOCHEMISTRY-US, V22, P5897, DOI 10.1021/bi00294a032; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; DAGNOLO G, 1975, J BIOL CHEM, V250, P5289; DEMENDOZA D, 1983, TRENDS BIOCHEM SCI, V8, P49, DOI 10.1016/0968-0004(83)90388-2; DEMENDOZA D, 1983, J BIOL CHEM, V258, P2098; ENDO K, 1970, J BIOL CHEM, V245, P4293; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; GARWIN JL, 1980, J BACTERIOL, V141, P1457, DOI 10.1128/JB.141.3.1457-1459.1980; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; GELMANN EP, 1972, J BACTERIOL, V112, P381, DOI 10.1128/JB.112.1.381-387.1972; Heath RJ, 2000, NATURE, V406, P145, DOI 10.1038/35018162; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110; HELMKAMP GM, 1969, J BIOL CHEM, V244, P6014; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; KASS LR, 1967, P NATL ACAD SCI USA, V58, P1168, DOI 10.1073/pnas.58.3.1168; Luengo JM, 2001, MOL MICROBIOL, V39, P1434, DOI 10.1046/j.1365-2958.2001.02344.x; MOHAN S, 1994, J BIOL CHEM, V269, P32896; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; Patton SM, 2000, BIOCHEMISTRY-US, V39, P7595, DOI 10.1021/bi0005714; Price AC, 2001, BIOCHEMISTRY-US, V40, P12772, DOI 10.1021/bi010737g; RANDO RR, 1968, J BIOL CHEM, V243, P5627; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Rock CO, 1996, J BACTERIOL, V178, P5382, DOI 10.1128/jb.178.18.5382-5387.1996; Schujman GE, 2001, J BACTERIOL, V183, P3032, DOI 10.1128/JB.183.10.3032-3040.2001; SCHWAB JM, 1985, ANAL BIOCHEM, V150, P121, DOI 10.1016/0003-2697(85)90449-X; SEUBERT W, 1953, J AM CHEM SOC, V75, P2787, DOI 10.1021/ja01107a529; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; TROMBE MC, 1979, BIOCHIM BIOPHYS ACTA, V574, P290, DOI 10.1016/0005-2760(79)90010-9; ULRICH AK, 1983, J BACTERIOL, V154, P221, DOI 10.1128/JB.154.1.221-230.1983; Xiang H, 1999, BIOCHEMISTRY-US, V38, P7638, DOI 10.1021/bi9901432; YANG SY, 1988, J BACTERIOL, V170, P2543, DOI 10.1128/jb.170.6.2543-2548.1988; Zhang YM, 2002, J BIOL CHEM, V277, P15558, DOI 10.1074/jbc.M201399200	49	90	108	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44809	44816		10.1074/jbc.M208920200	http://dx.doi.org/10.1074/jbc.M208920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237320	hybrid			2022-12-25	WOS:000179404800030
J	Meyer, C; Notari, L; Becerra, SP				Meyer, C; Notari, L; Becerra, SP			Mapping the type I collagen-binding site on pigment epithelium-derived factor - Implications for its antiangiogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; FACTOR PEDF; NEUROTROPHIC ACTIVITY; NONINHIBITORY SERPIN; INDUCED RETINOPATHY; SELECTIN BINDING; KINETIC-ANALYSIS; CELL-ADHESION; BOVINE EYES; INHIBITOR	Pigment epithelium-derived factor (PEDF), a neurotrophic and antiangiogenic serpin, is identified in tissues rich in collagen, e.g. cornea, vitreous, bone, and cartilage. We show that recombinant human PEDF formed complexes with collagens from the bovine cornea and vitreous. We have examined the direct binding of PEDF to collagen I and found that interactions were ionic in nature and occurred when PEDF and collagen I were both in solution, when either one was immobilized, or even when collagen I was denatured under reducing conditions. 125 I-PEDF bound to immobilized collagen I in a saturable fashion (K-D = 123 nm). Compared with neurotrophic PEDF-derived peptides, ovalbumin and angiogenic inhibitors, only full-length PEDF competed efficiently with I-125-PEDF for the binding to immobilized collagen I (EC50 = 3 mug/ml). The collagen-binding region was analyzed using controlled proteolysis and chemically modified PEDF. Cleavage of the serpin exposed loop did not prevent binding to collagen 1. Conjugation of lysines with fluorescein increased the collagen binding affinity. However, treatment of PEDF with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide abolished it, implicating the PEDF aspartic and/or glutamic acid residues in its interaction with collagen 1. A negatively charged region on the surface of the PEDF molecule is rich in acidic residues (Glu(41), Glu(42), Glu(43) Asp(44) Asp(64), Asp(256), Asp(258), Glu(290), Glu(291), Glu(296) Asp(300), Glu(304)) available to interact directly with positively charged areas of collagen. This represents the first collagen-binding site described for a serpin, which in PEDF, is distinct from its heparin-binding region, neurotrophic active site, and its serpin exposed loop. The collagen-binding property of PEDF may play a role in surface localization and modulation of its antiangiogenic effects in the eye and bone.	NEI, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Becerra, SP (corresponding author), NEI, Retinal Cell & Mol Biol Lab, NIH, Bldg 6,Rm 308,6 Ctr Dr,MSC 2740, Bethesda, MD 20892 USA.			Meyer, Christina/0000-0002-0380-195X	NATIONAL EYE INSTITUTE [Z01EY000306, ZIAEY000306] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alberdi E, 1999, J BIOL CHEM, V274, P31605, DOI 10.1074/jbc.274.44.31605; Alberdi E, 1998, BIOCHEMISTRY-US, V37, P10643, DOI 10.1021/bi9802317; Aymerich MS, 2001, INVEST OPHTH VIS SCI, V42, P3287; Ball EH, 1997, ADV EXP MED BIOL, V425, P239; Becerra SP, 1997, ADV EXP MED BIOL, V425, P223; BECERRA SP, 1993, J BIOL CHEM, V268, P23148; BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992; Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6; Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200; Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6; Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646; Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263; Crawford SE, 2001, J CELL SCI, V114, P4421; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; Hadley JC, 1998, GLYCOCONJUGATE J, V15, P835, DOI 10.1023/A:1006928403140; Holmes JM, 1999, INVEST OPHTH VIS SCI, V40, P804; Houenou LJ, 1999, J COMP NEUROL, V412, P506; Karakousis PC, 2001, MOL VIS, V7, P154; KERN P, 1986, CLIN PHYSIOL BIOCH, V4, P113; Kozaki K, 1998, J BIOL CHEM, V273, P15125, DOI 10.1074/jbc.273.24.15125; LABATROBERT J, 1992, ANN NY ACAD SCI, V673, P16, DOI 10.1111/j.1749-6632.1992.tb27431.x; Lu DW, 2001, J OCUL PHARMACOL TH, V17, P343, DOI 10.1089/108076801753162753; Macdonald JR, 2001, J BIOL CHEM, V276, P25399, DOI 10.1074/jbc.M102471200; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; Ngamkitidechakul C, 2001, INVEST OPHTH VIS SCI, V42, P3135; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; Nishikawa T, 2000, CURR EYE RES, V21, P581, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT581; Ortego J, 1996, INVEST OPHTH VIS SCI, V37, P2759; Perez-Mediavilla LA, 1998, BBA-GENE STRUCT EXPR, V1398, P203, DOI 10.1016/S0167-4781(98)00055-4; REISER KM, 1992, J BIOL CHEM, V267, P24207; Robert L, 2001, PATHOL BIOL, V49, P353, DOI 10.1016/S0369-8114(01)00144-4; Simonovic M, 2001, P NATL ACAD SCI USA, V98, P11131, DOI 10.1073/pnas.211268598; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; Stratikos E, 1996, PROTEIN SCI, V5, P2575, DOI 10.1002/pro.5560051220; Sweeney SM, 1998, P NATL ACAD SCI USA, V95, P7275, DOI 10.1073/pnas.95.13.7275; Wild MK, 2001, J BIOL CHEM, V276, P31602, DOI 10.1074/jbc.M104844200; Wu YQ, 1996, INVEST OPHTH VIS SCI, V37, P1984; WU YQ, 1995, PROTEIN EXPRES PURIF, V6, P447, DOI 10.1006/prep.1995.1060; Yabe T, 2001, J BIOL CHEM, V276, P43313, DOI 10.1074/jbc.M107831200; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303	42	119	122	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45400	45407		10.1074/jbc.M208339200	http://dx.doi.org/10.1074/jbc.M208339200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237317	hybrid			2022-12-25	WOS:000179404800103
J	Zheng, YF; Schlondorff, J; Blobel, CP				Zheng, YF; Schlondorff, J; Blobel, CP			Evidence for regulation of the tumor necrosis factor alpha-convertase (TACE) by protein-tyrosine phosphatase PTPH1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEASE-DISINTEGRIN MDC9; CYTOSKELETAL-ASSOCIATED PROTEINS; AMYLOID PRECURSOR PROTEIN; GROWTH-FACTOR; INTRACELLULAR MATURATION; TRANSMEMBRANE PROTEINS; SECRETASE CLEAVAGE; DOMAIN-STRUCTURE; CELL-SURFACE; MEMBRANE	Tumor necrosis factor a-convertase (TACE) is a metalloprotease-disintegrin involved in the ectodomain shedding of several proteins and is critical for proper murine development. TACE-mediated ectodomain shedding is regulated, and the cytoplasmic domain of TACE contains several potential signaling motifs, suggesting that this domain may play a role in regulating the metalloprotease activity. Here we report that the protein-tyrosine phosphatase PTPH1, which contains both a band 4.1 domain and a single PDZ domain, can interact with the cytoplasmic domain of TACE. The interaction was initially observed in a yeast two-hybrid screen and was confirmed using an in vitro binding assay and coimmunoprecipitations from eukaryotic cell extracts. The interaction is mediated via binding of the PDZ domain of PTPH1 to the COOH terminus of TACE. The latter represents a novel group I PDZ binding sequence characterized by a terminal cysteine residue. In co-expression experiments, significantly lower levels of TACE were observed in the presence of catalytically active forms of PTPH1 compared with catalytically inactive forms of PTPH1. Furthermore, phorbol ester-stimulated shedding of the TACE substrate tumor necrosis factor-alpha was decreased in cells expressing catalytically active PTPH1 compared with inactive PTPH1. Taken together, these results suggest that PTPH1 may be a negative regulator of TACE levels and function, and thus provide the first evidence for the regulation of TACE through a cytoplasmic protein.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Grad Program Physiol Biophys & Mol Med, New York, NY 10021 USA; Cornell Univ, Rockefeller Univ, Mem Sloan Kettering Canc Ctr, Tri Inst,Training Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center; Rockefeller University	Blobel, CP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, Box 368,1275 York Ave, New York, NY 10021 USA.		Zheng, Yufang/F-1091-2011	Zheng, Yufang/0000-0002-0488-2624; Schlondorff, Johannes/0000-0002-9973-9731	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058668, T32GM007739] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NIGMS NIH HHS [R01 GM58668, 5T32GM07739-17] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; ARIMURA Y, 1992, TUMOR BIOL, V13, P180, DOI 10.1159/000217763; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; ITOH F, 1993, INT J CANCER, V55, P947, DOI 10.1002/ijc.2910550612; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nelson KK, 1999, BIOCHEM J, V343, P673, DOI 10.1042/0264-6021:3430673; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Schlondorff J, 1999, J CELL SCI, V112, P3603; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; Solomon KA, 1999, J IMMUNOL, V163, P4105; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; Zhang SH, 1999, J BIOL CHEM, V274, P17806, DOI 10.1074/jbc.274.25.17806; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281	53	98	101	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42463	42470		10.1074/jbc.M207459200	http://dx.doi.org/10.1074/jbc.M207459200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12207026	hybrid			2022-12-25	WOS:000179081200007
J	Usui, M; Egashira, K; Ohtani, K; Kataoka, C; Ishibashi, M; Hiasa, K; Katoh, M; Zhao, QW; Kitamoto, S; Takeshita, A				Usui, M; Egashira, K; Ohtani, K; Kataoka, C; Ishibashi, M; Hiasa, K; Katoh, M; Zhao, QW; Kitamoto, S; Takeshita, A			Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys	FASEB JOURNAL			English	Article						MCP-1; inflammation; monocyte; restenosis; neointimal hyperplasia	NITRIC-OXIDE SYNTHESIS; CHRONIC BLOCKADE; ATHEROSCLEROTIC LESIONS; CAROTID ARTERIES; CHEMOKINES; MICE; PATHOGENESIS; RECEPTOR; DISEASE	Prevention of restenosis after coronary intervention is a major clinical challenge, which highlights the need of new therapeutic options. Vascular injury may involve inflammatory responses that accelerate the recruitment and activation of monocytes through the activation of chemotactic factors, including monocyte chemoattractant protein-1 (MCP-1). However, there is no definitive evidence supporting the role of MCP-1 in restenosis. We recently devised a new strategy for anti-MCP-1 gene therapy by transfecting an N-terminal deletion mutant of the MCP-1 gene into skeletal muscles. We demonstrate here that this strategy suppressed monocyte infiltration/activation in the injured site and markedly inhibited restenotic changes (neointimal hyperplasia) after balloon injury of the carotid artery in rats and monkeys. This strategy also suppressed the local production of MCP-1 and inflammatory cytokines. Therefore, monocyte infiltration and activation mediated by MCP-1 are essential in the development of restenotic changes after balloon injury. This strategy may be a useful form of gene therapy against human restenosis.	Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, Fukuoka 8128582, Japan; Discovery Res Labs, Tokyo, Japan	Kyushu University	Egashira, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	egashira@cardiol.med.kyushu-u.ac.jp		Katoh, Makoto/0000-0002-5216-0271				Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Cipollone F, 2001, ARTERIOSCL THROM VAS, V21, P327, DOI 10.1161/01.ATV.21.3.327; Egashira K, 2000, FASEB J, V14, P1974, DOI 10.1096/fj.00-0141com; Furukawa Y, 1999, CIRC RES, V84, P306, DOI 10.1161/01.RES.84.3.306; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Hayashi S, 2000, CIRCULATION, V102, P1710, DOI 10.1161/01.CIR.102.14.1710; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Horvath C, 2002, CIRC RES, V90, P488, DOI 10.1161/hh0402.105956; Kitamoto S, 2000, CIRCULATION, V102, P806, DOI 10.1161/01.CIR.102.7.806; Koyanagi M, 2000, CIRCULATION, V102, P2243; Libby P, 1997, NEW ENGL J MED, V337, P418, DOI 10.1056/NEJM199708073370608; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mukaida N, 1998, CYTOKINE GROWTH F R, V9, P9, DOI 10.1016/S1359-6101(97)00022-1; Ni WH, 2001, CIRCULATION, V103, P2096; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Takemoto M, 1997, J CLIN INVEST, V99, P278, DOI 10.1172/JCI119156; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; TAUBMAN MB, 1992, CIRC RES, V70, P314, DOI 10.1161/01.RES.70.2.314; Topol EJ, 1998, CIRCULATION, V98, P1802, DOI 10.1161/01.CIR.98.17.1802; Usui M, 2000, CIRCULATION, V101, P305, DOI 10.1161/01.CIR.101.3.305; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252	24	80	85	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2002	16	13	1				1838	+		10.1096/fj.02-0094fje	http://dx.doi.org/10.1096/fj.02-0094fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223446				2022-12-25	WOS:000181189100004
J	Kostyniuk, CL; Dehm, SM; Batten, D; Bonham, K				Kostyniuk, CL; Dehm, SM; Batten, D; Bonham, K			The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases	ONCOGENE			English	Article						Src; transcription; historic deacetylase; butyrate; Trichostatin A	LARGE-BOWEL CANCER; CHAIN FATTY-ACIDS; ADENOCARCINOMA CELL-LINE; COLON-CANCER; SODIUM-BUTYRATE; C-SRC; TRICHOSTATIN-A; TRANSCRIPTIONAL ACTIVATION; DIETARY FIBER; BREAST-CANCER	Histone deacetylase inhibitors have generated keen interest as potential chemopreventive and chemotherapeutic agents due to their ability to induce cell cycle arrest, differentiation, and apoptosis in a diverse group of cancer derived cell lines. Activation of the 60 kDa nonreceptor tyrosine kinase, c-Src, has been a consistent finding in many tumors and tumor derived cell lines, and has been implicated in these same cellular processes. We have shown that the histone deacetylase inhibitors, sodium butyrate and Trichostatin A, repressed c-Src mRNA and protein expression in a dose-dependent manner in cell lines derived from cancers of the colon, breast;and liver. Our group has previously identified two distinct promoters that are responsible for SRC transcription, separated by a distance of approximately 1 kb. Sodium butyrate and Trichostatin A strongly inhibited activity of each of these highly disparate SRC promoters, demonstrating histone deacetylase inhibitors directly repress SRC transcription. This repression did not require protein neosynthesis and was not associated with a decrease in binding of protein factors essential for either promoter's activity. Our finding that sodium butyrate and Trichostatin A inhibit both SRC promoters suggest this oncogene may be a major target of these agents, and may explain in part their anti-cancer activity.	Saskatchewan Canc Agcy, Canc Res Unit, Hlth Res Div, Saskatoon, SK S7N 4H4, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan	Bonham, K (corresponding author), Saskatchewan Canc Agcy, Canc Res Unit, Hlth Res Div, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bonham K, 2000, J BIOL CHEM, V275, P37604, DOI 10.1074/jbc.M004882200; BONHAM K, 1993, ONCOGENE, V8, P1973; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cuisset L, 1997, J BIOL CHEM, V272, P24148, DOI 10.1074/jbc.272.39.24148; DArgenio G, 1996, GASTROENTEROLOGY, V110, P1727, DOI 10.1053/gast.1996.v110.pm8964397; Dehm S, 2001, FEBS LETT, V487, P367, DOI 10.1016/S0014-5793(00)02354-1; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Espinos E, 1999, MOL CELL BIOL, V19, P3474; FOSS FM, 1989, ONCOGENE RES, V5, P13; GAMET L, 1992, INT J CANCER, V52, P286, DOI 10.1002/ijc.2910520222; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Hass R, 1997, GASTROENTEROLOGY, V112, P875, DOI 10.1053/gast.1997.v112.pm9041249; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Iacomino G, 2001, BIOCHEM BIOPH RES CO, V285, P1280, DOI 10.1006/bbrc.2001.5323; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Luciano L, 1996, CELL TISSUE RES, V286, P81, DOI 10.1007/s004410050677; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; Mariadason JM, 2000, CANCER RES, V60, P4561; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Marks PA, 2001, CLIN CANCER RES, V7, P759; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MARUTA H, 1986, J CELL BIOL, V103, P571, DOI 10.1083/jcb.103.2.571; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Rajala RVS, 2000, BIOCHEM BIOPH RES CO, V273, P1116, DOI 10.1006/bbrc.2000.3066; REDDY BS, 1995, CRIT REV FOOD SCI, V35, P175, DOI 10.1080/10408399509527698; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Singh B, 1997, CARCINOGENESIS, V18, P1265, DOI 10.1093/carcin/18.6.1265; SOULEIMANI A, 1993, FEBS LETT, V326, P45, DOI 10.1016/0014-5793(93)81758-R; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Sowa Y, 1999, CANCER RES, V59, P4266; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Suzuki T, 2000, INT J CANCER, V88, P992, DOI 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9; Topping DL, 2001, PHYSIOL REV, V81, P1031, DOI 10.1152/physrev.2001.81.3.1031; TOSCANI A, 1988, ONCOGENE RES, V3, P223; TROCK B, 1990, JNCI-J NATL CANCER I, V82, P650, DOI 10.1093/jnci/82.8.650; VanLint C, 1996, GENE EXPRESSION, V5, P245; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	55	33	34	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6340	6347		10.1038/sj.onc.1205787	http://dx.doi.org/10.1038/sj.onc.1205787			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214274				2022-12-25	WOS:000177829000010
J	Toft, NJ; Curtis, LJ; Sansom, OJ; Leitch, AL; Wyllie, AH; Riele, HT; Arends, MJ; Clarke, AR				Toft, NJ; Curtis, LJ; Sansom, OJ; Leitch, AL; Wyllie, AH; Riele, HT; Arends, MJ; Clarke, AR			Heterozygosity for p53 promotes microsatellite instability and tumorigenesis on a Msh2 deficient background	ONCOGENE			English	Article						mismatch repair; p53; tumorigenesis; microsatellite instability; apoptosis	FEMALE EMBRYONIC LETHALITY; MURINE SMALL-INTESTINE; CELL-CYCLE CHECKPOINT; WILD-TYPE P53; MISMATCH REPAIR; P53-DEFICIENT MICE; COLORECTAL-CANCER; DNA-DAMAGE; IONIZING-RADIATION; MUTATION FREQUENCY	In colorectal tumorigenesis, loss of function of the mismatch repair genes is closely associated with genomic instability at the nucleotide level whereas p53 deficiency has been linked with gross chromosomal instability. We have addressed the contribution of these two forms of genetic instability to tumorigenesis using mice mutant for Msh2 and p53. As previously reported, deficiency of both genes leads to rapid lymphomagenesis Here we show that heterozygosity for p53 also markedly reduces survival on an Msh2 null background. We characterized the patterns of genomic instability in a small set of tumours and showed that, as predicted p53 deficiency predisposes to aneuploidy and Msh2 deficiency leads to microsatellite instability (MSI). However, heterozygosity for p53 in the absence of Msh2 resulted in increased MSI and not aneuploidy. This implied role for p53 in modulating MSI was confirmed using a large cohort of primary fibroblast clones. The differences observed were highly significant (P < 0.01) in both the fibroblast clones (which all retained p53 functionality) and the tumours, a proportion of which retained p53 functionality. Our results therefore demonstrate a dose sensitive role for p53 in the maintenance of genomic integrity at the nucleotide level.	Cardiff Univ, Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	Cardiff University; University of Edinburgh; Netherlands Cancer Institute; University of Cambridge	Clarke, AR (corresponding author), Cardiff Univ, Sch Biosci, POB 911, Cardiff CF10 3US, S Glam, Wales.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010				ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Bubb VJ, 1996, ONCOGENE, V12, P2641; CARDER P, 1993, ONCOGENE, V8, P1397; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cottu PH, 1996, ONCOGENE, V13, P2727; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Cranston A, 1999, MAMM GENOME, V10, P1020, DOI 10.1007/s003359901151; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DONCHOWER LA, 1992, NATURE, V356, P215; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Gong JG, 1999, NATURE, V399, P806; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY M, 1993, ONCOGENE, V8, P2457; HAWN MT, 1995, CANCER RES, V55, P3721; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; KALLIONIEMI OP, 1993, SEMIN CANCER BIOL, V4, P41; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; OZBUN MA, 1993, CANCER RES, V53, P1646; PURDIE CA, 1994, ONCOGENE, V9, P603; Rafferty JA, 1996, ONCOGENE, V12, P693; REICHMANN A, 1981, INT J CANCER, V28, P431, DOI 10.1002/ijc.2910280407; Reitmair AH, 1996, CANCER RES, V56, P3842; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2001, ONCOGENE, V20, P3580, DOI 10.1038/sj.onc.1204449; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; Toft NJ, 1998, NAT GENET, V18, P17, DOI 10.1038/ng0198-17; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; VINDELOV LL, 1983, CYTOMETRY, V3, P321; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	45	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6299	6306		10.1038/sj.onc.1205727	http://dx.doi.org/10.1038/sj.onc.1205727			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214270				2022-12-25	WOS:000177829000006
J	Xia, WL; Mullin, RJ; Keith, BR; Liu, LH; Ma, H; Rusnak, DW; Owens, G; Alligood, KJ; Spector, NL				Xia, WL; Mullin, RJ; Keith, BR; Liu, LH; Ma, H; Rusnak, DW; Owens, G; Alligood, KJ; Spector, NL			Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways	ONCOGENE			English	Article						tyrosine kinase; EGFR; erbB2; Erk1/2; AKT; tumor xenograft	GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; INTERMOLECULAR ASSOCIATION; MONOCLONAL-ANTIBODY; TGF-ALPHA; PROTEIN; ERBB-2; CELLS	Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR heterodimerization triggers potent proliferative and survival signals. Here we show that a small molecule, GW572016, potently inhibits both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR and erbB2-dependent tumor cell lines. GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival, respectively. Complete inhibition of activated AKT in erbB2 overexpressing cells correlated with a 23-fold increase in apoptosis compared with vehicle controls. EGF, often elevated in cancer patients, did not reverse the inhibitory effects of GW572016. These observations were reproduced in vivo, where GW572016 treatment inhibited activation of EGFR, erbB2, Erk1/2 and AKT in human tumor xenografts. Erk1/2 and AKT represent potential biomarkers to assess the clinical activity of GW572016. Inhibition of activated AKT in EGFR or erbB2-dependent tumors by GW572016 may lead to tumor regressions when used as a monotherapy, or may enhance the anti-tumor activity of chemotherapeutics, since constitutive activation of AKT has been linked to chemo-resistance.	GlaxoSmithKline, Dept Discovery Med, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Spector, NL (corresponding author), GlaxoSmithKline, Dept Discovery Med, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.	ns85812@gsk.com						Albanell J, 2001, CANCER RES, V61, P6500; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; Brognard J, 2001, CANCER RES, V61, P3986; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cockerill S, 2001, BIOORG MED CHEM LETT, V11, P1401, DOI 10.1016/S0960-894X(01)00219-0; Daly RJ, 1999, GROWTH FACTORS, V16, P255, DOI 10.3109/08977199909069144; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIMARCO E, 1989, ONCOGENE, V4, P831; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Howell GM, 1998, J BIOL CHEM, V273, P9214, DOI 10.1074/jbc.273.15.9214; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JANES PW, 1994, ONCOGENE, V9, P3601; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Klapper LN, 2000, ADV CANCER RES, V77, P25; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levkowitz G, 1996, ONCOGENE, V12, P1117; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Pulverer BJ, 1991, NATURE, V363, P83; QIAN XL, 1995, ONCOGENE, V10, P211; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Rusnak DW, 2001, CANCER RES, V61, P7196; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; Tari AM, 2000, INT J CANCER, V86, P295, DOI 10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K; Tenzer A, 2001, CANCER RES, V61, P8203; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Ye DW, 1999, ONCOGENE, V18, P731, DOI 10.1038/sj.onc.1202319	48	541	565	7	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6255	6263		10.1038/sj.onc.1205794	http://dx.doi.org/10.1038/sj.onc.1205794			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214266				2022-12-25	WOS:000177829000002
J	Kato, K; Ogura, T; Kishimoto, A; Minegishi, Y; Nakajima, N; Miyazaki, M; Esumi, H				Kato, K; Ogura, T; Kishimoto, A; Minegishi, Y; Nakajima, N; Miyazaki, M; Esumi, H			Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation	ONCOGENE			English	Article						cancer; tolerance; glucose deprivation; AMP-activated protein kinase (AMPK)	SOLID TUMORS; ANGIOGENESIS; GLUCOSE; METABOLISM; EXPRESSION; GROWTH; GENE; INHIBITION; METASTASIS; THERAPY	As tumors grow and invade beyond their homeostatic limits, the tumor cells are subjected to insufficient nutrient and oxygen supplies because of excessive demand for nutrition and oxygen, and insufficient vascularization. We therefore hypothesized that tolerance to nutrient deprivation as well as angiogenesis may be critical in some malignancies, including pancreatic cancers, which are seen to be a hypovascular tumor. In this study, we assessed the effect of AMP-activated protein kinase (AMPK), which plays a major role in protecting cells from metabolic stresses, on tumor biology under nutrient-deprived condition. Whereas hepatic cancer cells had mostly died within 48 h during glucose deprivation, most pancreatic cancer cells survived more than 48 h. The tolerance to glucose deprivation tended to correlate with the cells level of expression of AMPK alpha1 and alpha2. The introduction of AMPK antisense RNA expression vectors into pancreas cancer cell lines, PANC-1 and AsPC-1, significantly diminished their tolerance to glucose deprivation, and the stable transfection of AMPK antisense into PANC-1 cells inhibited tumor growth in nude mice. These findings indicate that AMPK expression contributes to tolerance to nutrient starvation in cancer cells. We propose AMPK as a new target for therapeutic strategies to suppress tumor growth and invasion.	Natl Inst Canc Res, Invest Treatment Div, Chiba 2778577, Japan; Chiba Univ, Sch Med, Dept Surg 1, Chiba 2608677, Japan	National Cancer Center - Japan; Chiba University	Esumi, H (corresponding author), Natl Inst Canc Res, Invest Treatment Div, Chiba 2778577, Japan.	hesumi@east.nec.go.jp						AGUAN K, 1994, GENE, V149, P345, DOI 10.1016/0378-1119(94)90174-0; Barinaga M, 1997, SCIENCE, V275, P482, DOI 10.1126/science.275.5299.482; Brown JM, 1998, CANCER RES, V58, P1408; CARLING D, 1994, J BIOL CHEM, V269, P11442; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hashimoto K, 2002, BIOCHEM BIOPH RES CO, V290, P263, DOI 10.1006/bbrc.2001.6193; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Heyer BS, 1997, MOL REPROD DEV, V47, P148, DOI 10.1002/(SICI)1098-2795(199706)47:2&lt;148::AID-MRD4&gt;3.0.CO;2-M; Hockel M, 1999, CANCER RES, V59, P4525; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Izuishi K, 2000, CANCER RES, V60, P6201; Koito K, 1997, AM J ROENTGENOL, V169, P1263, DOI 10.2214/ajr.169.5.9353439; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Lefebvre DL, 2001, BIOCHEM J, V355, P297, DOI 10.1042/0264-6021:3550297; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; Rofstad EK, 1999, BRIT J CANCER, V80, P1697, DOI 10.1038/sj.bjc.6690586; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Tomida A, 1996, ONCOGENE, V13, P2699; Wartenberg M, 2001, FASEB J, V15, P995, DOI 10.1096/fj.00-0350com; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Yu X, 2000, BIOCHEM BIOPH RES CO, V276, P564, DOI 10.1006/bbrc.2000.3508	33	174	180	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6082	6090		10.1038/sj.onc.1205737	http://dx.doi.org/10.1038/sj.onc.1205737			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203120				2022-12-25	WOS:000177671300011
J	Krasnova, IN; Mccoy, MT; Ladenheim, B; Cadet, JL				Krasnova, IN; Mccoy, MT; Ladenheim, B; Cadet, JL			CDNA array analysis of gene expression profiles in the striata of wild-type and Cu/Zn superoxide dismutase transgenic mice treated with neurotoxic doses of amphetamine	FASEB JOURNAL			English	Article						amphetamine; neurotoxicity; Cu/Zn SOD; striatum; gene expression analysis	STRESS-INDUCED APOPTOSIS; METHAMPHETAMINE-INDUCED NEUROTOXICITY; PROGRAMMED CELL-DEATH; C-FOS; TRANSCRIPTION FACTORS; RAT STRIATUM; RECEPTOR ACTIVATION; OXIDATIVE STRESS; NERVOUS-SYSTEM; DNA-BINDING	Amphetamine (AMPH) is a drug of abuse that causes the degeneration of striatal dopamine terminals in mammals. Superoxide radicals seem to participate in AMPH-induced damage because its toxicity is attenuated in Cu/Zn superoxide dismutase transgenic (SOD-tg) mice. To provide a detailed analysis of molecular changes associated with AMPH toxicity, we used cDNA arrays consisting of 1176 genes to detect differential changes in gene expression in the striata of wild-type and SOD-tg mice treated with neurotoxic doses of the drug. We found 42 genes that showed >1.8-fold changes in at least two consecutive time points during the course of the study and were differentially affected by AMPH in the two genotypes. Specifically, more transcription factors and genes involved in responses to injury/inflammation were affected in wild-type mice after AMPH administration. Some of these stimulant-induced superoxide-dependent alterations in gene expression might affect neuronal functions and promote neuronal damage. Other changes might help to provide some degree of protection against AMPH toxicity. These results support the view that the use of global array analysis of gene expression will help to identify novel molecular mediators of AMPH-induced neurodegeneration.	NIDA, Mol Neuropsychiat Sect, Intramural Res Program, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Cadet, JL (corresponding author), NIDA, Mol Neuropsychiat Sect, Intramural Res Program, NIH, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.	JCADET@intra.nida.nih.gov			NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000174, Z01DA000388, Z01DA000174] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Asanuma M, 2000, MOL BRAIN RES, V80, P237, DOI 10.1016/S0169-328X(00)00128-5; Barouki R, 2001, BIOCHEM PHARMACOL, V61, P511, DOI 10.1016/S0006-2952(00)00543-8; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BEREZOVSKAYA O, 1995, INT J DEV NEUROSCI, V13, P285, DOI 10.1016/0736-5748(95)00013-7; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; Cajetan Luna G, 2001, Rev Panam Salud Publica, V9, P114, DOI 10.1590/S1020-49892001000200012; Christians ES, 2002, CRIT CARE MED, V30, pS43, DOI 10.1097/00003246-200201001-00006; COLE AJ, 1992, J NEUROCHEM, V58, P1420, DOI 10.1111/j.1471-4159.1992.tb11358.x; Czerwinski W P, 1998, J La State Med Soc, V150, P491; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; Deng XL, 1999, J NEUROSCI, V19, P10107; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELLISON G, 1978, SCIENCE, V201, P276, DOI 10.1126/science.26975; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Genova LM, 1998, SYNAPSE, V30, P71, DOI 10.1002/(SICI)1098-2396(199809)30:1<71::AID-SYN9>3.0.CO;2-H; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hatayama T, 2001, BIOCHEM BIOPH RES CO, V288, P528, DOI 10.1006/bbrc.2001.5802; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Hirata H, 1998, MOL BRAIN RES, V58, P209, DOI 10.1016/S0169-328X(98)00055-2; Huang NK, 1997, LIFE SCI, V61, P2219, DOI 10.1016/S0024-3205(97)00924-7; Hughes PE, 1999, NEUROSCIENCE, V92, P197, DOI 10.1016/S0306-4522(98)00724-6; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; Ito C, 2002, CURR PHARM DESIGN, V8, P147, DOI 10.2174/1381612023396528; Jones SR, 1998, J NEUROSCI, V18, P1979; Kaina B, 1997, CANCER RES, V57, P2721; Krasnova IN, 2001, NEUROSCIENCE, V107, P265, DOI 10.1016/S0306-4522(01)00351-7; KRIEGLSTEIN K, 1995, EMBO J, V14, P736, DOI 10.1002/j.1460-2075.1995.tb07052.x; Lackinger D, 2001, MUTAGENESIS, V16, P233, DOI 10.1093/mutage/16.3.233; Lin HC, 1999, NEUROSCI LETT, V276, P141, DOI 10.1016/S0304-3940(99)00805-8; Luo YQ, 1999, MOL PHARMACOL, V56, P254, DOI 10.1124/mol.56.2.254; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Munz B, 1999, J ENDOCRINOL, V161, P187, DOI 10.1677/joe.0.1610187; Murray JB, 1998, J PSYCHOL, V132, P227, DOI 10.1080/00223989809599162; Nau ME, 2000, J CLIN MICROBIOL, V38, P1901, DOI 10.1128/JCM.38.5.1901-1908.2000; NGUYEN TV, 1992, P NATL ACAD SCI USA, V89, P4270, DOI 10.1073/pnas.89.10.4270; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; PERSICO AM, 1993, MOL BRAIN RES, V20, P91, DOI 10.1016/0169-328X(93)90113-4; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Scheffel U, 1996, SYNAPSE, V23, P61; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; Sheng P, 1996, MOL BRAIN RES, V42, P171, DOI 10.1016/S0169-328X(96)00192-1; SIMPSON JN, 1995, NEUROSCIENCE, V69, P441, DOI 10.1016/0306-4522(95)00274-M; Stumm G, 1999, FASEB J, V13, P1065, DOI 10.1096/fasebj.13.9.1065; Suzuki K, 1999, Nihon Arukoru Yakubutsu Igakkai Zasshi, V34, P465; Takeuchi A, 2001, J NEUROSCI RES, V65, P38, DOI 10.1002/jnr.1125; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; WAGNER GC, 1980, NEUROLOGY, V30, P547; Wang NP, 1999, CIRC RES, V85, P387, DOI 10.1161/01.RES.85.5.387; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5; Woiciechowsky C, 1999, J MOL MED-JMM, V77, P769, DOI 10.1007/s001099900051; Wright JD, 2000, ADDICTION, V95, P1225, DOI 10.1046/j.1360-0443.2000.95812259.x; Yamagishi N, 2000, BIOCHEM BIOPH RES CO, V272, P850, DOI 10.1006/bbrc.2000.2864; Zaman K, 1999, J NEUROSCI, V19, P9821	58	18	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1379	1388		10.1096/fj.01-0796com	http://dx.doi.org/10.1096/fj.01-0796com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12205029				2022-12-25	WOS:000178441800012
J	Guerrero, S; Figueras, A; Casanova, I; Farre, L; Lloveras, B; Capella, G; Trias, M; Mangues, R				Guerrero, S; Figueras, A; Casanova, I; Farre, L; Lloveras, B; Capella, G; Trias, M; Mangues, R			Codon 12 and codon 13 mutations at the K-ras gene induce different soft tissue sarcoma types in nude mice	FASEB JOURNAL			English	Article						tumorogenicity; apoptosis; sarcomas; K-ras	FOCAL ADHESION KINASE; ENCODED P21 PROTEIN; 3-DIMENSIONAL STRUCTURES; PROGNOSTIC IMPLICATIONS; COLORECTAL-CANCER; HUMAN TUMORS; CELL-LINE; H-RAS; APOPTOSIS; OVEREXPRESSION	K-ras codon 12 mutation is more oncogenic in in vitro and in vivo experimental systems than K-ras codon 13 mutation. Moreover, human colorectal tumors bearing a codon 12 mutation are more aggressive, invasive, and metastatic than the same tumor types carrying a codon 13 mutation. However, despite the association between specific sarcoma types and codon 12 or codon 13 mutations, the relationship between the position of the mutated codon at ras genes and tumor aggressiveness has not been studied in this tumor type. Here, we used a nude mice model to evaluate the tumorogenic capacity of stable transfectants of NIH3T3 fibroblasts, expressing K-ras mutated at codon 12 (K12) or 13 (K13), and morphologically, functionally, and molecularly compared these tumors. We found histopathological differences between them, K12-derived tumors showing fibrosarcoma-like features, whereas K13-derived tumors resembled malignant fibrous histiocytomas. Moreover, K12 tumors showed shorter latency of appearance, lower apoptotic and mitotic rates, and higher expression of markers for sarcoma aggressiveness (Ki67, p53 and c-myc) than K13 tumors. They also showed differences in the expression or activation of Ras, Ras downstream pathways [c-Jun N-terminal kinase (JNK), MAPK and AKT], and apoptotic [AKT, Bcl-2, Focal adhesion kinase (FAK)] and mitotic (cyclin B1) regulators, which could explain their functional differences. Most remarkably, the significantly diminished apoptotic rate observed in K12-derived tumors was associated with enhanced antiapoptotic signaling through the AKT pathway. These morphological, functional, and molecular differences demonstrate that codon 12 and codon 13 mutations in the K-ras oncogene can induce two different soft tissue sarcoma types in our in vivo model.	Hosp Santa Creu & Sant Pau, Inst Recerca, Lab Invest Gastrointestinal, Barcelona, Spain; Inst Catala Oncol, Lab Recerca Traslac, Barcelona, Spain; Hosp Santa Creu & Sant Pau, Serv Cirurgia, Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital of Santa Creu i Sant Pau; Catalan Institute of Oncology; Hospital of Santa Creu i Sant Pau	Mangues, R (corresponding author), Hosp Santa Creu & Sant Pau, Inst Recerca, Lab Invest Gastrointestinal, Avda St Antoni M Claret 167, Barcelona, Spain.	rmangues@santpau.es	Mangues, Ramon/J-6396-2014; CASANOVA RIGAT, ISOLDA/I-5393-2014; Capella, Gabriel/I-1879-2015	Mangues, Ramon/0000-0003-2661-9525; CASANOVA RIGAT, ISOLDA/0000-0002-1196-4724; Capella, Gabriel/0000-0002-4669-7320; Farre, Lourdes/0000-0002-3168-1940				BEDI A, 1995, CANCER RES, V55, P1811; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BRANDTRAUF PW, 1988, J PROTEIN CHEM, V7, P349, DOI 10.1007/BF01024884; CAPELLA G, 1991, ENVIRON HEALTH PERSP, V93, P125, DOI 10.2307/3431180; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Coindre JM, 1998, VERHANDLUNGEN DER DEUTSCHEN GESELLSCHAFT FUR PATHOLOGIE 82. TAGUNG, P59; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DEVIVO I, 1994, CANCER CAUSE CONTROL, V5, P273, DOI 10.1007/BF01830248; DROBNJAK M, 1994, J NATL CANCER I, V86, P549, DOI 10.1093/jnci/86.7.549; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FINKELSTEIN SD, 1993, ARCH SURG-CHICAGO, V128, P526; FINKELSTEIN SD, 1993, CANCER, V71, P3827, DOI 10.1002/1097-0142(19930615)71:12<3827::AID-CNCR2820711207>3.0.CO;2-N; FLETCHER CDM, 1992, AM J SURG PATHOL, V16, P213, DOI 10.1097/00000478-199203000-00001; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GILL S, 1991, ONCOGENE, V6, P1651; Guerrero S, 2000, CANCER RES, V60, P6750; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Heslin MJ, 1998, CANCER-AM CANCER SOC, V83, P490, DOI 10.1002/(SICI)1097-0142(19980801)83:3<490::AID-CNCR18>3.0.CO;2-R; Hill MA, 1997, CANCER EPIDEM BIOMAR, V6, P1095; Hong HHL, 2000, TOXICOL PATHOL, V28, P529, DOI 10.1177/019262330002800404; Hoos A, 2001, CANCER, V92, P869, DOI 10.1002/1097-0142(20010815)92:4<869::AID-CNCR1395>3.0.CO;2-U; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; KANTAK SS, 1992, J BIOL CHEM, V73, P16953; Kikuchi Y, 1997, VIRCHOWS ARCH, V431, P111, DOI 10.1007/s004280050076; KLIMPFINGER M, 1990, VIRCHOWS ARCH B, V59, P165, DOI 10.1007/BF02899401; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; MONACO R, 1995, J PROTEIN CHEM, V14, P457, DOI 10.1007/BF01888140; OWENS LV, 1995, CANCER RES, V55, P2752; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Peluso JJ, 2001, BIOL REPROD, V64, P1183, DOI 10.1095/biolreprod64.4.1183; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; PINCUS MR, 1985, P NATL ACAD SCI USA, V82, P3596, DOI 10.1073/pnas.82.11.3596; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; SLOAN SR, 1990, MOL CELL BIOL, V10, P405, DOI 10.1128/MCB.10.1.405; Sollinger HW, 1999, TRANSPLANTATION, V67, pS543, DOI 10.1097/00007890-199905150-00028; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Szadowska Anna, 1999, Polish Journal of Pathology, V50, P9; TOFFOLI G, 1994, ANN ONCOL, V5, P167, DOI 10.1093/oxfordjournals.annonc.a058771; van Roggen JFG, 1999, J CLIN PATHOL, V52, P481, DOI 10.1136/jcp.52.7.481; Ward RL, 1997, CANCER, V79, P1106, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1106::AID-CNCR8>3.0.CO;2-D; Wilkinson EJ, 1995, J CELL BIOCHEM, P10; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Yoo JY, 1999, MODERN PATHOL, V12, P775	48	31	34	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1642	+		10.1096/fj.02-0050fje	http://dx.doi.org/10.1096/fj.02-0050fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207005				2022-12-25	WOS:000177814000016
J	Pei, M; Solchaga, LA; Seidel, J; Zeng, L; Vunjak-Novakovic, G; Caplan, AI; Freed, LE				Pei, M; Solchaga, LA; Seidel, J; Zeng, L; Vunjak-Novakovic, G; Caplan, AI; Freed, LE			Bioreactors mediate the effectiveness of tissue engineering scaffolds	FASEB JOURNAL			English	Article						chondrocyte; Hyaff-11((R)); polyglycolic acid; cartilage	BIODEGRADABLE POLYMER SCAFFOLDS; ARTICULAR-CARTILAGE; IN-VITRO; REPAIR; COLLAGEN; CHONDROCYTES; ACID; DIFFERENTIATION; DEFECTS; SYSTEM	We hypothesized that the mechanically active environment present in rotating bioreactors mediates the effectiveness of three-dimensional (3D) scaffolds for cartilage tissue engineering. Cartilaginous constructs were engineered by using bovine calf chondrocytes in conjunction with two scaffold materials (SM) (benzylated hyaluronan and polyglycolic acid); three scaffold structures (SS) (sponge, non-woven mesh, and composite woven/non-woven mesh); and two culture systems (CS) (a bioreactor system and petri dishes). Construct size, composition [cells, glycosaminoglycans (GAG), total collagen, and type-specific collagen mRNA expression and protein levels], and mechanical function (compressive modulus) were assessed, and individual and interactive effects of model system parameters (SM, SS, CS, SM*CS and SS*CS) were demonstrated. The CS affected cell seeding (higher yields of more spatially uniform cells were obtained in bioreactor-grown than dish-grown 3-day constructs) and subsequently affected chondrogenesis (higher cell numbers, wet weights, wet weight GAG fractions, and collagen type II levels were obtained in bioreactor-grown than dish-grown 1-month constructs). In bioreactors, mesh-based scaffolds yielded 1-month constructs with lower type I collagen levels and four-fold higher compressive moduli than corresponding sponge-based scaffolds. The data imply that interactions between bioreactors and 3D tissue engineering scaffolds can be utilized to improve the structure, function, and molecular properties of in vitro-generated cartilage.	MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Case Western Reserve Univ, Dept Biol, Skeletal Res Ctr, Cleveland, OH 44106 USA	Massachusetts Institute of Technology (MIT); Case Western Reserve University	Freed, LE (corresponding author), MIT, Div Hlth Sci & Technol, E25-330,77 Massachusetts Ave, Cambridge, MA 02139 USA.	Lfreed@mit.edu	Pei, Ming/N-8175-2017	Freed, Lisa/0000-0002-0720-8432; Vunjak-Novakovic, Gordana/0000-0002-9382-1574; Caplan, Arnold/0000-0002-8677-6621				Aigner J, 1998, J BIOMED MATER RES, V42, P172, DOI 10.1002/(SICI)1097-4636(199811)42:2<172::AID-JBM2>3.3.CO;2-W; AIGNER T, 1993, J CLIN INVEST, V91, P829, DOI 10.1172/JCI116303; Altman GH, 2001, FASEB J, V15, P270, DOI 10.1096/fj.01-0656fje; BALAZS E A, 1973, International Ophthalmology Clinics, V13, P169, DOI 10.1097/00004397-197301330-00014; Bonassar LJ, 2000, ARCH BIOCHEM BIOPHYS, V379, P57, DOI 10.1006/abbi.2000.1820; Brun P, 1999, J BIOMED MATER RES, V46, P337, DOI 10.1002/(SICI)1097-4636(19990905)46:3<337::AID-JBM5>3.0.CO;2-Q; Buckwalter JA, 1997, J BONE JOINT SURG AM, V79A, P612, DOI 10.2106/00004623-199704000-00022; Campoccia D, 1998, BIOMATERIALS, V19, P2101, DOI 10.1016/S0142-9612(98)00042-8; Chen AC, 2001, J BIOMECH, V34, P1, DOI 10.1016/S0021-9290(00)00170-6; Chu CR, 1997, CLIN ORTHOP RELAT R, P220; DUNKELMAN NS, 1995, BIOTECHNOL BIOENG, V46, P299, DOI 10.1002/bit.260460402; Evans CH, 1999, CLIN ORTHOP RELAT R, pS410; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FRANK EH, 1987, J BIOMECH, V20, P615, DOI 10.1016/0021-9290(87)90282-X; FRAZZA E J, 1971, Journal of Biomedical Materials Research Biomedical Materials Symposium, V1, P43; Freed L. E., 2000, PRINCIPLES TISSUE EN, P143; FREED LE, 1994, BIOTECHNOL BIOENG, V43, P605, DOI 10.1002/bit.260430710; FREED LE, 1994, BIOTECHNOL BIOENG, V43, P597, DOI 10.1002/bit.260430709; FREED LE, 1993, J BIOMED MATER RES, V27, P11, DOI 10.1002/jbm.820270104; FREED LE, 1994, BIO-TECHNOL, V12, P689, DOI 10.1038/nbt0794-689; FREED LE, 1994, J BIOMED MATER RES, V28, P891, DOI 10.1002/jbm.820280808; Freed LE, 1998, EXP CELL RES, V240, P58, DOI 10.1006/excr.1998.4010; Freed LE, 1997, P NATL ACAD SCI USA, V94, P13885, DOI 10.1073/pnas.94.25.13885; Freed LE, 1999, CLIN ORTHOP RELAT R, pS46; FREED LE, 1995, BIOTECHNOL BIOENG, V46, P306, DOI 10.1002/bit.260460403; FREED LE, 2000, BIOMEDICAL ENG HDB, V2, P124; Fukuta S, 1998, MATRIX BIOL, V17, P65, DOI 10.1016/S0945-053X(98)90074-9; Gooch KJ, 2001, BIOCHEM BIOPH RES CO, V286, P909, DOI 10.1006/bbrc.2001.5486; Gooch KJ, 2001, BIOTECHNOL BIOENG, V72, P402, DOI 10.1002/1097-0290(20000220)72:4<402::AID-BIT1002>3.0.CO;2-Q; Grande DA, 1997, J BIOMED MATER RES, V34, P211, DOI 10.1002/(SICI)1097-4636(199702)34:2<211::AID-JBM10>3.0.CO;2-L; HALE JE, 1993, J BIOMECH, V26, P1319, DOI 10.1016/0021-9290(93)90355-I; HOLLANDER AP, 1994, J CLIN INVEST, V93, P1722, DOI 10.1172/JCI117156; HOMMINGA GN, 1993, ACTA ORTHOP SCAND, V64, P441, DOI 10.3109/17453679308993663; KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5; KNUDSON CB, 1987, DEV BIOL, V124, P82, DOI 10.1016/0012-1606(87)90462-3; KRAVIS D, 1985, DEV BIOL, V108, P164, DOI 10.1016/0012-1606(85)90018-1; MADRY H, 2001, T ORTHOP RES SOC, V26, P289; Mauck RL, 2000, J BIOMECH ENG-T ASME, V122, P252, DOI 10.1115/1.429656; Milella E, 2000, J BIOMED MATER RES, V52, P695, DOI 10.1002/1097-4636(20001215)52:4<695::AID-JBM14>3.3.CO;2-7; MILLER EJ, 1976, BIOCHEMISTRY-US, V15, P787, DOI 10.1021/bi00649a009; Pazzano D, 2000, BIOTECHNOL PROGR, V16, P893, DOI 10.1021/bp000082v; Pei M, 2002, BIOCHEM BIOPH RES CO, V294, P149, DOI 10.1016/S0006-291X(02)00439-4; Riesle J, 1998, J CELL BIOCHEM, V71, P313, DOI 10.1002/(SICI)1097-4644(19981201)71:3<313::AID-JCB1>3.0.CO;2-C; SAH RLY, 1989, J ORTHOPAED RES, V7, P619, DOI 10.1002/jor.1100070502; SANDBERG M, 1987, J CELL BIOL, V104, P1077, DOI 10.1083/jcb.104.4.1077; Schaefer D, 2002, ARTHRITIS RHEUM-US, V46, P2524, DOI 10.1002/art.10493; Shea LD, 1999, NAT BIOTECHNOL, V17, P551, DOI 10.1038/9853; Smith RL, 1995, J ORTHOPAED RES, V13, P824, DOI 10.1002/jor.1100130604; Solchaga LA, 1999, J ORTHOP RES, V17, P205, DOI 10.1002/jor.1100170209; Vunjak-Novakovic G, 1999, J ORTHOP RES, V17, P130, DOI 10.1002/jor.1100170119; VunjakNovakovic G, 1996, AICHE J, V42, P850, DOI 10.1002/aic.690420323; Wakitani S, 1998, TISSUE ENG, V4, P429, DOI 10.1089/ten.1998.4.429; WAKITANI S, 1994, J BONE JOINT SURG AM, V76A, P579, DOI 10.2106/00004623-199404000-00013; WATT FM, 1988, J CELL SCI, V89, P373; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5	56	170	196	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10					1691	+		10.1096/fj.02-0083fje	http://dx.doi.org/10.1096/fj.02-0083fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207008				2022-12-25	WOS:000177814000021
J	Rose, F; Grimminger, F; Appel, J; Heller, M; Pies, V; Weissmann, N; Fink, L; Schmidt, S; Krick, S; Camenisch, G; Gassmann, M; Seeger, W; Hanze, J				Rose, F; Grimminger, F; Appel, J; Heller, M; Pies, V; Weissmann, N; Fink, L; Schmidt, S; Krick, S; Camenisch, G; Gassmann, M; Seeger, W; Hanze, J			Hypoxic pulmonary artery fibroblasts trigger proliferation of vascular smooth muscle cells - role of hypoxia-inducible transcription factors	FASEB JOURNAL			English	Article						pulmonary artery smooth muscle cells; pulmonary artery adventitial fibroblasts; hypoxia-inducible factors	FACTOR 1-ALPHA; ADVENTITIAL FIBROBLASTS; CELLULAR PROLIFERATION; MOLECULAR MECHANISMS; NITRIC-OXIDE; FACTOR-I; HYPERTENSION; FACTOR-1-ALPHA; EXPRESSION; ENDOTHELIN-1	Chronic lung hypoxia causes vascular remodeling with pulmonary artery smooth muscle cell (SMCPA) hyperplasia, resulting in pulmonary hypertension and cor pulmonale. We investigated SMCPA and pulmonary artery adventitial fibroblasts (FBPA) for their proliferative response to hypoxia. Strong SMCPA growth occurred under hypoxic conditions in SMCPA/FBPA co-cultures, but not in SMCPA monocultures. SMCPA growth was fully reproduced by transferring serum-free supernatant from hypoxic cultured FBPA to normoxic SMCPA. Hypoxia-inducible-transcriptionfactor subtypes (HIF-1alpha, HIF-2alpha, HIF-3alpha) and its dependent target genes, carrying the hypoxia-responsive-element as regulatory component, were strongly activated in both hypoxic FBPA and SMCPA. HIF-transcription-factor decoy technique, employed to FBPA during hypoxic culturing, blocked the mitogenic activity of FBPA conditioned medium on SMCPA. The data suggest that hypoxia-driven gene regulation in pulmonary artery fibroblasts results in a mitogenic stimulus on adjacent pulmonary artery smooth muscle cells, and HIF-transcription-decoy may offer a new therapeutic approach to suppress these events.	Univ Giessen, Dept Internal Med Pulm & Crit Care Med, D-35385 Giessen, Germany; Univ Zurich, Inst Vet Physiol, CH-8057 Zurich, Switzerland	Justus Liebig University Giessen; University of Zurich	Hanze, J (corresponding author), Dept Internal Med 2, Klin Str 36, D-35392 Giessen, Germany.	Joerg.Haenze@innere.med.uni-giessen.de		Weissmann, Norbert/0000-0003-2675-3871; Gassmann, Max/0000-0003-2750-8878; Seeger, Werner/0000-0003-1946-0894; Grimminger, Friedrich/0000-0001-8725-6276				Berg JT, 1998, AM J RESP CRIT CARE, V158, P1920, DOI 10.1164/ajrccm.158.6.9804076; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Das M, 2000, AM J RESP CELL MOL, V22, P15, DOI 10.1165/ajrcmb.22.1.3536; Dumas JP, 1999, GEN PHARMACOL, V33, P289, DOI 10.1016/S0306-3623(99)00026-9; Durmowicz A G, 1999, Pediatr Rev, V20, pe91; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Giaid A, 1998, CHEST, V114, p208S, DOI 10.1378/chest.114.3_Supplement.208S; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Gu YZ, 1998, GENE EXPRESSION, V7, P205; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Maeshima Y, 1998, J CLIN INVEST, V101, P2589, DOI 10.1172/JCI429; MICHIELS C, 1994, EXP CELL RES, V213, P43, DOI 10.1006/excr.1994.1171; Minet E, 2000, INT J MOL MED, V5, P253; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; PERKETT EA, 1992, AM J RESP CELL MOL, V6, P82, DOI 10.1165/ajrcmb/6.1.82; Strauss BH, 2000, AM J RESP CELL MOL, V22, P1; Voelkel NF, 1995, EUR RESPIR J, V8, P2129, DOI 10.1183/09031936.95.08122129; Welsh DJ, 1998, AM J RESP CRIT CARE, V158, P1757, DOI 10.1164/ajrccm.158.6.9706054; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wort SJ, 2001, AM J RESP CELL MOL, V25, P104, DOI 10.1165/ajrcmb.25.1.4331; Yu AY, 1999, J CLIN INVEST, V103, P691, DOI 10.1172/JCI5912	25	84	86	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1660	+		10.1096/fj.02-0420fje	http://dx.doi.org/10.1096/fj.02-0420fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207001				2022-12-25	WOS:000177814000005
J	Glosli, H; Tronstad, KJ; Wergedal, H; Muller, F; Svardal, A; Aukrust, P; Berge, RK; Prydz, H				Glosli, H; Tronstad, KJ; Wergedal, H; Muller, F; Svardal, A; Aukrust, P; Berge, RK; Prydz, H			Human TNF-alpha in transgenic mice induces differential changes in redox status and glutathione-regulating enzymes	FASEB JOURNAL			English	Article						redox-balance; oxidative stress; T cells; glutathione reductase; glutathione peroxidase; glutathione transferase	TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; CD4(+) LYMPHOCYTES; ANTIVIRAL ACTIVITY; OXIDATIVE STRESS; GENE-EXPRESSION; CELL-DEATH; RECEPTORS; ACTIVATION; IMMUNODEFICIENCY	Tumor necrosis factor alpha (TNF-alpha) is a pleiotropic cytokine involved in several diseases. Various effects of TNF-alpha are mediated by the induction of a cellular state consistent with oxidative stress. Glutathione (GSH) is a major redox-buffer of eukaryotic cells and is important in the defense against oxidative stress. We hypothesized that persistent TNF-alpha secretion could induce oxidative stress through modulation of GSH metabolism. This hypothesis was examined in a transgenic mouse model with low, persistent expression of human TNF-alpha in the T cell compartment. Major findings were i) marked tissue-specific changes in GSH redox status and GSH regulating enzymes, with the most pronounced changes in liver; ii) moderate changes in GSH metabolism and up-regulation of GSH-regulating enzymes were observed in lung and kidney from transgenic mice; and iii) liver, lung and kidney from transgenic mice had decreased levels of total glutathione, whereas splenic CD4(+) and CD8(+) T cells had a marked increase in oxidized glutathione as the major change. Oxidative stress induced by persistent low-grade exposure to TNF-alpha in transgenic mice appears to involve marked organ-specific alterations in glutathione redox status and glutathione-regulating enzymes with the most pronounced changes in the liver. These mice constitute a useful model for immunodeficiency syndromes and chronic inflammatory diseases involving pathogenic interaction between TNF-alpha and oxidative stress.	Univ Oslo, Biotechnol Ctr Oslo, N-0317 Oslo, Norway; Univ Bergen, Haukeland Hosp, Dept Clin Biochem, N-5021 Bergen, Norway; Natl Hosp Norway, Internal Med Res Inst, Oslo, Norway; Natl Hosp Norway, Dept Med, Sect Clin Immunol & Infect Dis, Oslo, Norway; Univ Bergen, Dept Pharmacol & Toxicol, Bergen, Norway	University of Oslo; University of Bergen; Haukeland University Hospital; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Bergen	Prydz, H (corresponding author), Univ Oslo, Biotechnol Ctr Oslo, PB1125, N-0317 Oslo, Norway.	hans.prydz@biotek.uio.no		Tronstad, Karl Johan/0000-0003-3496-3123; Wergedahl, Hege/0000-0003-4614-1960				AEBI H, 1984, METHOD ENZYMOL, V105, P121; Aukrust P, 1996, BLOOD, V88, P2626, DOI 10.1182/blood.V88.7.2626.bloodjournal8872626; AUKRUST P, 1995, BLOOD, V86, P1383, DOI 10.1182/blood.V86.4.1383.bloodjournal8641383; AUKRUST P, 1995, BLOOD, V86, P258, DOI 10.1182/blood.V86.1.258.bloodjournal861258; Avdi NJ, 2001, J BIOL CHEM, V276, P2189, DOI 10.1074/jbc.M007527200; Benveniste EN, 1995, FASEB J, V9, P1577, DOI 10.1096/fasebj.9.15.8529837; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cope AP, 1997, J EXP MED, V185, P1573, DOI 10.1084/jem.185.9.1573; Driscoll KE, 2000, TOXICOL LETT, V112, P177, DOI 10.1016/S0378-4274(99)00282-9; EKLOW L, 1984, EUR J BIOCHEM, V138, P459, DOI 10.1111/j.1432-1033.1984.tb07938.x; ENGELBERTS I, 1991, LANCET, V338, P515, DOI 10.1016/0140-6736(91)90591-C; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Fernandez-Checa JC, 1998, SEMIN LIVER DIS, V18, P389, DOI 10.1055/s-2007-1007172; Feuerstein GZ, 2000, CARDIOVASC RES, V45, P560, DOI 10.1016/S0008-6363(99)00372-7; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Glosli H, 1999, EUR J HAEMATOL, V63, P50; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HELD W, 1990, P NATL ACAD SCI USA, V87, P2239, DOI 10.1073/pnas.87.6.2239; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; Herbein G, 2000, P SOC EXP BIOL MED, V223, P241, DOI 10.1046/j.1525-1373.2000.22335.x; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Jain NC, 1986, SCHALMS VET HEMATOLO; JENKINSON SG, 1994, AM J PHYSIOL, V266, pL125, DOI 10.1152/ajplung.1994.266.2.L125; Kokura S, 2000, CIRC RES, V86, P205, DOI 10.1161/01.RES.86.2.205; Kono H, 2000, J CLIN INVEST, V106, P867, DOI 10.1172/JCI9020; Kumar S, 2001, J CELL PHYSIOL, V187, P294, DOI 10.1002/jcp.1082; LEEDLE RA, 1990, LIPIDS, V25, P241, DOI 10.1007/BF02544382; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Li X, 2000, CIRCULATION, V102, P1690, DOI 10.1161/01.CIR.102.14.1690; LI XY, 1994, LIPIDS, V29, P73, DOI 10.1007/BF02537094; Liu RY, 1999, J BIOL CHEM, V274, P13877, DOI 10.1074/jbc.274.20.13877; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com; MEISTER A, 1988, J BIOL CHEM, V263, P17205; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; Obrador E, 1998, BIOFACTORS, V8, P23, DOI 10.1002/biof.5520080105; Pierce RH, 2000, AM J PATHOL, V157, P221, DOI 10.1016/S0002-9440(10)64533-6; PROBERT L, 1993, J IMMUNOL, V151, P1894; Rahman I, 1999, J BIOL CHEM, V274, P5088, DOI 10.1074/jbc.274.8.5088; ROTH S, 1987, CELL IMMUNOL, V108, P417, DOI 10.1016/0008-8749(87)90224-3; Ruby J, 1997, J EXP MED, V186, P1591, DOI 10.1084/jem.186.9.1591; SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; SVARDAL AM, 1990, ANAL BIOCHEM, V184, P338, DOI 10.1016/0003-2697(90)90691-2; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TAVERNE J, 1994, IMMUNOLOGY, V82, P397; TOBOREK M, 1995, ATHEROSCLEROSIS, V117, P179, DOI 10.1016/0021-9150(95)05568-H; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WAAGE A, 1987, LANCET, V1, P355; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1992, J IMMUNOL, V149, P3350; YANG XD, 1994, J EXP MED, V180, P995, DOI 10.1084/jem.180.3.995; Zinman B, 1999, J CLIN ENDOCR METAB, V84, P272, DOI 10.1210/jc.84.1.272	66	44	47	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1450	+		10.1096/fj.01-0948fje	http://dx.doi.org/10.1096/fj.01-0948fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205044				2022-12-25	WOS:000177813100004
J	Rottgers, K; Zufall, N; Guiard, B; Voos, W				Rottgers, K; Zufall, N; Guiard, B; Voos, W			The ClpB homolog Hsp78 is required for the efficient degradation of proteins in the mitochondrial matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; INACTIVATED PROTEINS; REGULATORY SUBUNITS; CHAPERONE SYSTEM; PIM1 PROTEASE; AAA PROTEASE; PROTEOLYSIS	Molecular chaperones perform vital functions in mitochondrial protein import and folding. In yeast mitochondria, two members of the Clp/Hsp100 chaperone family, Hsp78 and Mcx1, have been identified as homologs of the bacterial proteins ClpB and ClpX, respectively. In this report we employed a novel quantitative assay system to assess the role of Hsp78 and Mcx1 in protein degradation within the matrix. Mitochondria were preloaded with large amounts of two purified recombinant reporter proteins exhibiting different folding stabilities. Proteolysis of the imported substrate proteins depended on the mitochondrial level of ATP and was mediated by the matrix protease Pim1/LON. Degradation rates were found to be independent of the folding stability of the reporter proteins. Mitochondria from hsp78Delta cells exhibited a significant defect in the degradation efficiency of both substrates even at low temperature whereas mcx1Delta mitochondria showed wild-type activity. The proteolysis defect in hsp78Delta mitochondria was independent from the aggregation behavior of the substrate proteins. We conclude that Hsp78 is a genuine component of the mitochondrial proteolysis system required for the efficient degradation of substrate proteins in the matrix.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany; Univ Paris 06, CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France	University of Freiburg; University of Freiburg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Voos, W (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str, D-79104 Freiburg, Germany.	wolfgang.voos@biochemie.uni-freiburg.de						Adams A, 1997, METHODS YEAST GENETI; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; BLACKSCHAEFER CL, 1991, BIOCHEM J, V274, P199, DOI 10.1042/bj2740199; Bomer U, 1997, EMBO J, V16, P2205, DOI 10.1093/emboj/16.9.2205; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Halperin T, 2001, PLANT MOL BIOL, V45, P461, DOI 10.1023/A:1010677220323; Kang SG, 2002, J BIOL CHEM, V277, P21095, DOI 10.1074/jbc.M201642200; Konieczny I, 2002, J BIOL CHEM, V277, P18483, DOI 10.1074/jbc.M107580200; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; LEONHARDT SA, 1993, MOL CELL BIOL, V13, P6304, DOI 10.1128/MCB.13.10.6304; Lim JH, 2001, EMBO J, V20, P941, DOI 10.1093/emboj/20.5.941; MOCZKO M, 1995, J MOL BIOL, V254, P538, DOI 10.1006/jmbi.1995.0636; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Rep M, 1996, CURR GENET, V30, P367, DOI 10.1007/s002940050145; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Savel'ev AS, 1998, J BIOL CHEM, V273, P20596, DOI 10.1074/jbc.273.32.20596; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schmid B, 1996, FEBS LETT, V381, P111, DOI 10.1016/0014-5793(96)00080-4; Schmitt M, 1996, J CELL BIOL, V134, P1375, DOI 10.1083/jcb.134.6.1375; SCHMITT M, 1995, EMBO J, V14, P3434, DOI 10.1002/j.1460-2075.1995.tb07349.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; van Dijl JM, 1998, P NATL ACAD SCI USA, V95, P10584, DOI 10.1073/pnas.95.18.10584; van Dyck L, 1998, FEBS LETT, V438, P250, DOI 10.1016/S0014-5793(98)01310-6; van Melderen L, 1999, P NATL ACAD SCI USA, V96, P6064, DOI 10.1073/pnas.96.11.6064; VANDYCK L, 1994, J BIOL CHEM, V269, P238; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; von Ahsen O, 2000, J MOL BIOL, V297, P809, DOI 10.1006/jmbi.2000.3574; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; Watanabe YH, 2000, J BIOL CHEM, V275, P12388, DOI 10.1074/jbc.275.17.12388; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	49	52	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45829	45837		10.1074/jbc.M207152200	http://dx.doi.org/10.1074/jbc.M207152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237310	hybrid			2022-12-25	WOS:000179529300016
J	Garvie, CW; Pufall, MA; Graves, BJ; Wolberger, C				Garvie, CW; Pufall, MA; Graves, BJ; Wolberger, C			Structural analysis of the autoinhibition of Ets-1 and its role in protein partnerships	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; DNA-BINDING; AUTO-INHIBITION; DOMAIN; FAMILY; PHOSPHORYLATION; PEA3	The DNA-binding activity of the eukaryotic transcription factor Ets-1 (E26 avian erythroblastosis virus oncogene-E twenty-six) is negatively regulated by inhibitory regions that flank the ETS domain. Based on the results of solution studies, these N- and C-terminal inhibitory regions have been proposed to pack against the ETS domain and form an autoinhibitory module whose N terminus partially unfolds upon binding of Ets-1 to DNA. Mutations that disrupt autoinhibition of DNA binding also cause a structural change in the inhibitory region. We report here a crystallographic study of fragments of Ets-1 that provide structural details of the inhibitory module and the structural transition that accompanies DNA binding. The structures of free and DNA-bound Ets-1 fragments containing the ETS domain and the inhibitory regions confirm that the N-terminal inhibitory region contains two a-helices one of which unfolds upon Ets-1 binding to DNA. The observations from the crystal structure, coupled with mutagenesis experiments, allow us to propose a model for the inhibited form of Ets-1 and lend insight into the flexible interaction between Ets-1 and the acute myeloid leukemia 1 protein, AML1 (RUNX1).	Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Univ Utah, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Wolberger, C (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	ewolberg@jhmi.edu		Pufall, Miles/0000-0002-7022-6916; Wolberger, Cynthia/0000-0001-8578-2969	NATIONAL CANCER INSTITUTE [T32CA093247, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008537, R01GM038663] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA93247] Funding Source: Medline; NIGMS NIH HHS [T32-GM08537, R01 GM38663] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Bravo J, 2001, NAT STRUCT BIOL, V8, P371, DOI 10.1038/86264; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cowley DO, 2000, GENE DEV, V14, P366; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Graves BJ, 1998, COLD SPRING HARB SYM, V63, P621, DOI 10.1101/sqb.1998.63.621; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Pufall MA, 2002, ANNU REV CELL DEV BI, V18, P421, DOI 10.1146/annurev.cellbio.18.031502.133614; Schymkowitz JWH, 2001, NAT STRUCT BIOL, V8, P888, DOI 10.1038/nsb1001-888; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Sieweke Michael H., 1997, Leukemia (Basingstoke), V11, P486; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Vielhaber EL, 2001, J BIOL CHEM, V276, P45921, DOI 10.1074/jbc.M107726200; Wang H, 2002, J BIOL CHEM, V277, P2225, DOI 10.1074/jbc.M109430200	35	72	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45529	45536		10.1074/jbc.M206327200	http://dx.doi.org/10.1074/jbc.M206327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12221090	hybrid			2022-12-25	WOS:000179404800118
J	McPherson, LA; Loktev, AV; Weigel, RJ				McPherson, LA; Loktev, AV; Weigel, RJ			Tumor suppressor activity of AP2 alpha mediated through a direct interaction with p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; HUMAN BREAST-CANCER; ESTROGEN-RECEPTOR-ALPHA; DNA-DAMAGE; PROTEIN EXPRESSION; PROGNOSTIC FACTORS; MAMMARY-CARCINOMA; FACTOR FAMILY; CELL-GROWTH; IN-VIVO	The AP2 transcription factor family is a set of developmentally regulated, retinoic acid inducible genes composed of four related factors, AP2alpha, AP2beta, AP2gamma, and AP2delta. AP2 factors orchestrate a variety of cell processes including apoptosis, cell growth, and tissue differentiation during embryogenesis. In studies of primary malignancies, AP2alpha has been shown to function as a tumor suppressor in breast cancer, colon cancer, and malignant melanoma. In cell culture models, overexpression of AP2alpha inhibits cell division and stable colony formation, whereas, a dominant-negative AP2alpha mutant increases invasiveness and tumorigenicity. Here we show that AP2alpha targets the p53 tumor suppressor protein. Studies with chromatin immunoprecipitation demonstrate that AP2alpha is brought to p53 binding sites in p53-regulated promoters. The interaction between AP2alpha and p53 augments p53-mediated transcriptional activation, which results in up-regulation of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). AP2alpha is able to induce G(1) and G(2) cell cycle arrest only in the presence of wild-type p53. Thus, we conclude that the tumor suppressor activity of AP2alpha is mediated through a direct interaction with p53. These results also provide a mechanism to explain patterns of gene expression in cancers where AP2alpha is known to function as a tumor suppressor.	Stanford Univ, Dept Surg, Stanford, CA 94305 USA; Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA	Stanford University; Jefferson University	Weigel, RJ (corresponding author), 1025 Walnut St,Suite 605, Philadelphia, PA 19107 USA.			Weigel, Ronald/0000-0002-9249-0793	NCI NIH HHS [R01 CA77350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARBARESCHI M, 1992, AM J CLIN PATHOL, V98, P408, DOI 10.1093/ajcp/98.4.408; BHARGAVA V, 1994, MODERN PATHOL, V7, P361; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; CHARPIN C, 1995, HUM PATHOL, V26, P159, DOI 10.1016/0046-8177(95)90032-2; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; IWAYA K, 1991, JPN J CANCER RES, V82, P835, DOI 10.1111/j.1349-7006.1991.tb02710.x; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LiCalsi C, 2000, NUCLEIC ACIDS RES, V28, P1036, DOI 10.1093/nar/28.4.1036; MACGROGAN G, 1995, BREAST CANCER RES TR, V36, P71, DOI 10.1007/BF00690187; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTINAZZI M, 1993, AM J CLIN PATHOL, V100, P213, DOI 10.1093/ajcp/100.3.213; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; MOSER M, 1995, DEVELOPMENT, V121, P2779; Newman SP, 2000, ONCOGENE, V19, P490, DOI 10.1038/sj.onc.1203416; Nottoli T, 1998, P NATL ACAD SCI USA, V95, P13714, DOI 10.1073/pnas.95.23.13714; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSTROWSKI JL, 1991, J PATHOL, V164, P75, DOI 10.1002/path.1711640113; Perissi V, 2000, ONCOGENE, V19, P280, DOI 10.1038/sj.onc.1203303; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; POLLER DN, 1992, BRIT J CANCER, V66, P583, DOI 10.1038/bjc.1992.318; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Schuur ER, 2001, J BIOL CHEM, V276, P15519, DOI 10.1074/jbc.M009001200; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; STENMARKASKMALM M, 1994, EUR J CANCER, V30A, P175, DOI 10.1016/0959-8049(94)90082-5; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; Turner BC, 1998, CANCER RES, V58, P5466; WALDMAN T, 1995, CANCER RES, V55, P5187; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; West-Mays JA, 1999, DEV BIOL, V206, P46, DOI 10.1006/dbio.1998.9132; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	59	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45028	45033		10.1074/jbc.M208924200	http://dx.doi.org/10.1074/jbc.M208924200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12226108	hybrid			2022-12-25	WOS:000179404800057
J	Melzner, I; Scott, V; Dorsch, K; Fischer, P; Wabitsch, M; Bruderlein, S; Hasel, C; Moller, P				Melzner, I; Scott, V; Dorsch, K; Fischer, P; Wabitsch, M; Bruderlein, S; Hasel, C; Moller, P			Leptin gene expression in human preadipocytes is switched on by maturation-induced demethylation of distinct CpGs in its proximal promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; DNA METHYLATION; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTION FACTOR; CYTOSINE METHYLATION; 3T3-L1 CELLS; OB GENE; ALPHA; ACTIVATION; MECP2	The peptide hormone leptin plays a major role in the regulation of energy intake and expenditure and is predominantly expressed in mature adipocytes but not in preadipocytes. Using bisulfite genomic sequencing, we found that 32 CpGs, distributed within a 317-bp sequence of the proximal leptin promoter, were highly methylated in human preadipocytes (73.4% +/- 9.0%). During maturation toward terminally differentiated adipocytes, this promoter region was extremely demethylated (9.4% +/- 4.4%). CpG methylation-dependent transcriptional activity of the promoter fragment was determined in transfection experiments using a set of 5'-truneated mock-, HhaI-, and SssI-methylated promoter-reporter constructs. Whereas the methylated CpG within the CCAAT/enhancer-binding protein a recognition site down-regulated reporter expression, methylated CpGs proximal to the TATA motif and/or in a further upstream region abrogated promoter activity completely. These distinct promoter CpG sequences were found unmethylated in leptin-expressing mature adipocytes. As evidenced by electrophoretic mobility shift assays, nuclear protein complexes were specifically formed on methylated oligonucleotide probes corresponding to the dedicated promoter sequences, indicating that methyl-CpG binding proteins participate in transcriptional repression and regulation of the human leptin gene.	Univ Ulm, Dept Pathol, D-89081 Ulm, Germany; Univ Ulm, Dept Pediat, D-89081 Ulm, Germany	Ulm University; Ulm University	Moller, P (corresponding author), Univ Ulm, Dept Pathol, Albert Einstein Allee 11, D-89081 Ulm, Germany.	peter.moeller@medizin.uni-ulm.de						Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Campfield LA, 2000, FRONT HORM RES, V26, P12; Cao YX, 2000, BIOCHEM J, V350, P883, DOI 10.1042/0264-6021:3500883; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; Chehab FF, 2000, TRENDS PHARMACOL SCI, V21, P309, DOI 10.1016/S0165-6147(00)01514-5; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; De Smet C, 1999, MOL CELL BIOL, V19, P7327; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Feng Q, 2001, GENE DEV, V15, P827; Free A, 2001, J BIOL CHEM, V276, P3353, DOI 10.1074/jbc.M007224200; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Gong DW, 1996, J BIOL CHEM, V271, P3971; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; Huntriss J, 1997, BIOCHEM BIOPH RES CO, V235, P730, DOI 10.1006/bbrc.1997.6876; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Lu S, 1997, P NATL ACAD SCI USA, V94, P4692, DOI 10.1073/pnas.94.9.4692; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; Mason MM, 1998, ENDOCRINOLOGY, V139, P1013, DOI 10.1210/en.139.3.1013; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Miller SG, 1996, P NATL ACAD SCI USA, V93, P5507, DOI 10.1073/pnas.93.11.5507; Nan XS, 1996, MOL CELL BIOL, V16, P414; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NAVEHMANY T, 1981, P NATL ACAD SCI-BIOL, V78, P4246, DOI 10.1073/pnas.78.7.4246; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SCOTT RE, 1982, J CELL BIOL, V94, P400, DOI 10.1083/jcb.94.2.400; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; TAYLOR SM, 1985, INT J OBESITY, V9, P15; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wabitsch M, 2000, INT J CANCER, V88, P889, DOI 10.1002/1097-0215(20001215)88:6<889::AID-IJC8>3.0.CO;2-N; Yokomori N, 1999, DIABETES, V48, P685, DOI 10.2337/diabetes.48.4.685; Yokomori N, 2002, DIABETOLOGIA, V45, P140, DOI 10.1007/s125-002-8255-4; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	61	145	153	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45420	45427		10.1074/jbc.M208511200	http://dx.doi.org/10.1074/jbc.M208511200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12213831	hybrid			2022-12-25	WOS:000179404800105
J	Zhang, XH; Gan, LX; Pan, HY; Guo, SD; He, XW; Olson, ST; Mesecar, A; Adam, S; Unterman, TG				Zhang, XH; Gan, LX; Pan, HY; Guo, SD; He, XW; Olson, ST; Mesecar, A; Adam, S; Unterman, TG			Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms - Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; PROTEIN-KINASE-B; INSULIN-RESPONSE SEQUENCE; GENE-EXPRESSION; FAMILY MEMBER; PHOSPHOENOLPYRUVATE CARBOXYKINASE; CAENORHABDITIS-ELEGANS; PROMOTER ACTIVITY; FACTOR AFX; DAF-16	FKHR is a member of the FOXO subfamily of Forkhead transcription factors, which are important targets for insulin and growth factor signaling. FKHR contains three predicted protein kinase B phosphorylation sites (Thr-24, Ser-256, and Ser-319) that are conserved in other FOXO proteins. We have reported that phosphorylation of Ser-256 is critical for the ability of insulin and insulin-like growth factors to suppress transactivation by FKHR (Guo, S., Rena, G., Cichy, S., He, X., Cohen, P., and Unterman, T. (1999) J. Biol. Chem. 274, 17184-17192) and for its exclusion from the nucleus (Rena, G., Prescott, A. R., Guo, S., Cohen, P., and Unterman, T. G. (2001) Biochem. J. 354, 605-612). Ser-256 is located in a basic region of the FKHR DNA binding domain where phosphorylation may have direct effects on DNA binding and/or nuclear targeting. Phosphorylation of Ser-256 may also be required for the phosphorylation of Thr-24 and Ser-319. Here, we provide the first direct evidence that basic residues in the FKHR DNA binding domain are critical for DNA binding and that Ser-256 phosphorylation alters binding activity. Ser-256 phosphorylation also is critical for regulating nuclear/cytoplasmic trafficking; however, this effect requires Thr-24/Ser-319 phosphorylation. Transient transfection studies with reporter gene constructs in 293 cells reveal that the phosphorylation of Ser-256 can inhibit the function of FKHR independent of Thr-24/Ser-319 phosphorylation. Studies with GFP(1) fusion proteins indicate that Ser-256 phosphorylation is critical for nuclear exclusion of FKHR. However, this effect is disrupted when Thr-24 and Ser-319 are replaced by alanine, indicating that nuclear exclusion of FKHR also requires Thr-24/Ser-319 phosphorylation. Gel shift and fluorescence anisotropy studies reveal that basic residues at the C-terminal end of the FKHR DBD are important for DNA binding, and the introduction of a negative charge at the site of Ser-256 limits binding activity. Binding is rapid and reversible, providing an opportunity for the phosphorylation of Ser-256 and subsequent phosphorylation of Thr-24 and Ser-319 and nuclear exclusion of FKHR.	VA Chicago Hlth Care Syst, W Side Div, Med Res Unit, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Physiol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Biophys, Chicago, IL 60612 USA; Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Ctr Pharmaceut Biotechnol, Chicago, IL 60612 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University	Unterman, TG (corresponding author), VA Chicago Hlth Care Syst, W Side Div, Med Res Unit, Rm 6229,MP 151,820 S Damien Ave, Chicago, IL 60612 USA.			Mesecar, Andrew/0000-0002-1241-2577; Adam, Stephen/0000-0003-3444-7655	NCI NIH HHS [CA92744-01] Funding Source: Medline; NHLBI NIH HHS [HL-39888] Funding Source: Medline; NIDDK NIH HHS [DK-41430] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA092744] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039888, R37HL039888, R29HL039888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041430, R29DK041430] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam SA, 1999, CURR OPIN CELL BIOL, V11, P402, DOI 10.1016/S0955-0674(99)80056-8; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Deleage G, 2001, COMPUT BIOL MED, V31, P259, DOI 10.1016/S0010-4825(01)00008-7; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P2531; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Nakae J, 2001, BIOCHEMISTRY-US, V40, P11768, DOI 10.1021/bi015532m; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Yang ZY, 2002, J BIOL CHEM, V277, P8068, DOI 10.1074/jbc.M106091200; Yeagley D, 2001, J BIOL CHEM, V276, P33705, DOI 10.1074/jbc.M101215200	43	248	258	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45276	45284		10.1074/jbc.M208063200	http://dx.doi.org/10.1074/jbc.M208063200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228231	hybrid			2022-12-25	WOS:000179404800088
J	Pender, C; Goldfine, ID; Manchem, VP; Evans, JL; Spevak, WR; Shi, SY; Rao, S; Bajjalieh, S; Maddux, BA; Youngren, JF				Pender, C; Goldfine, ID; Manchem, VP; Evans, JL; Spevak, WR; Shi, SY; Rao, S; Bajjalieh, S; Maddux, BA; Youngren, JF			Regulation of insulin receptor function by a small molecule insulin receptor activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISCOVERY; RESISTANCE; MECHANISMS; PROTEIN	In type 2 diabetes mellitus, impaired insulin signaling leads to hyperglycemia and other metabolic abnormalities. TLK19780, a non-peptide small molecule, is a new member of a novel class of anti-diabetic agents that function as activators of the insulin receptor (IR) beta-subunit tyrosine kinase. In HTC-IR cells, 20 muM TLK19780 enhanced maximal insulin-stimulated IR autophosphorylation 2-fold and increased insulin sensitivity 2-3-fold. In contrast, TLK19780 did not potentiate the action of insulin-like growth factor-1, indicating the selectivity of TLK19780 toward the IR. The predominant effect of TLK19780 was to increase the number of IR that underwent autophosphorylation. Kinetic studies indicated that TLK19780 acted very rapidly, with a maximal effect observed 2 min after addition to insulin-stimulated cells. In 3T3-L1 adipocytes, 5 mum TLK19780 enhanced insulin-stimulated glucose transport, increasing both the sensitivity and maximal responsiveness to insulin. These studies indicate that at low micromolar levels small IR activator molecules can enhance insulin action in various cultured cells and suggest that this effect is mediated by increasing the number of IR that are tyrosine-phosphorylated in response to insulin. These studies suggest that these types of molecules could be developed to treat type 2 diabetes and other clinical conditions associated with insulin resistance.	Univ Calif San Francisco, Mt Zion Med Ctr, San Francisco, CA 94143 USA; Telik Inc, San Francisco, CA 94080 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	Youngren, JF (corresponding author), Univ Calif San Francisco, Mt Zion Med Ctr, Box 1616, San Francisco, CA 94143 USA.	drjack@itsa.ucsf.edu	Evans, Joseph L./N-4501-2013	Evans, Joseph L./0000-0002-9334-1650				FORSAYETH JR, 1987, P NATL ACAD SCI USA, V84, P3448, DOI 10.1073/pnas.84.10.3448; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; Goldfine ID, 1999, J LAB CLIN MED, V134, P100, DOI 10.1016/S0022-2143(99)90112-9; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; Li M, 2001, DIABETES, V50, P2323, DOI 10.2337/diabetes.50.10.2323; Liu K, 2000, J MED CHEM, V43, P3487, DOI 10.1021/jm000285q; Luo RZT, 1999, SCIENCE, V285, P1077, DOI 10.1126/science.285.5430.1077; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; Manchem VP, 2001, DIABETES, V50, pA125; Manchem VP, 2001, DIABETES, V50, P824, DOI 10.2337/diabetes.50.4.824; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; Salituro GM, 2001, RECENT PROG HORM RES, V56, P107, DOI 10.1210/rp.56.1.107; SBRACCIA P, 1990, J BIOL CHEM, V265, P4902; SUNG CK, 1994, MOL ENDOCRINOL, V8, P315, DOI 10.1210/me.8.3.315; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; White MF, 1998, RECENT PROG HORM RES, V53, P119; Youngren JF, 1999, AM J PHYSIOL-ENDOC M, V276, pE990, DOI 10.1152/ajpendo.1999.276.5.E990; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974; Zhang BB, 2000, CURR OPIN CHEM BIOL, V4, P461, DOI 10.1016/S1367-5931(00)00103-4; ZhangSun G, 1996, ENDOCRINOLOGY, V137, P2649, DOI 10.1210/en.137.7.2649	22	30	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43565	43571		10.1074/jbc.M202426200	http://dx.doi.org/10.1074/jbc.M202426200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12213804	hybrid			2022-12-25	WOS:000179272000005
J	Gerbod-Giannone, MC; del Castillo-Olivares, A; Janciauskiene, S; Gil, G; Hylemon, PB				Gerbod-Giannone, MC; del Castillo-Olivares, A; Janciauskiene, S; Gil, G; Hylemon, PB			Suppression of cholesterol 7 alpha-hydroxylase transcription and bile acid synthesis by an alpha(1)-antitrypsin peptide via interaction with alpha(1)-fetoprotein transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME COMPLEX RECEPTOR; ADULT-RAT-HEPATOCYTES; AMYLOID-BETA PEPTIDE; ACUTE-PHASE RESPONSE; HUMAN HEPATOMA-CELLS; STEROL 12-ALPHA-HYDROXYLASE; NUCLEAR RECEPTORS; POTENTIAL ROLE; MESSENGER-RNA; ALPHA-1-ANTITRYPSIN	alpha(1)-Antitrypsin (alpha(1)-AT) is a serum protease inhibitor that is synthesized mainly in the liver, and its rate of synthesis markedly increases in response to inflammation. This increase in alpha(1)-AT synthesis results in an increase in peptides, like its carboxyl-terminal C-36 peptide (C-36), resulting from alpha(1)-AT cleavage by proteases. Atherosclerosis is a form of chronic inflammation, and one of the risk factors is elevated plasma cholesterol levels. Because of the correlation between atherosclerosis, plasma cholesterol content, inflammation, and alpha(1)-AT rate of synthesis, we investigated the effect of the C-36 serpin peptide on hepatic bile acid biosynthesis. We discovered that C-36 is a powerful and specific transcriptional down-regulator of bile acid synthesis in primary rat hepatocytes, through inhibition of the cholesterol 7alpha-hydroxylase/CYP7A1 (7alpha-hydroxylase) promoter. Mice injected with the C-36 peptide also showed a decrease in 7alpha-hydroxylase mRNA. A mutated but very similar peptide did not have any effect on 7alpha-hydroxylase mRNA or its promoter. The sterol 12alpha-hydroxylase/ CYP8B1 (12alpha-hydroxylase) promoter is also down-regulated by the C-36 peptide in HepG2 cells but not by the mutated peptide. The DNA element involved in the C-36-mediated regulation of 7alpha- and 12a-hydroxylase promoters mapped to the alpha(1)-fetoprotein transcription factor (FTF) site in both promoters. The C-36 peptide prevented binding of FTF to its target DNA recognition site by direct interaction with FTF. We hypothesize that the C-36 peptide specifically interacts with FTF and induces a conformational change that results in loss of its DNA binding ability, which results in suppression of 7alpha- and 12alpha-hydroxylase transcription. These results suggest that peptides derived from specific serum proteins may alter hepatic gene expression in a highly specific manner.	Virginia Commonwealth Univ, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Univ Hosp, Dept Med, S-20502 Malmo, Sweden	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Lund University; Skane University Hospital	Gil, G (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biophys, Med Coll Virginia Campus, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038030, R01DK057543] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38030, DK-57543] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CABANA VG, 1989, J LIPID RES, V30, P39; COMMITTEE NRN, 1999, CELL, V97, P161; Crestani M, 1998, J LIPID RES, V39, P2192; del Castill-Olivares A, 2002, J BIOL CHEM, V277, P6750, DOI 10.1074/jbc.M106785200; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; del Castillo-Olivares A, 2001, NUCLEIC ACIDS RES, V29, P4035, DOI 10.1093/nar/29.19.4035; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINGOLD KR, 1993, J LIPID RES, V34, P2147; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; GALLOWAY MJ, 1985, THROMB RES, V38, P311, DOI 10.1016/0049-3848(85)90131-8; Glass CK, 2000, GENE DEV, V14, P121; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; HEUMAN DM, 1989, J LIPID RES, V30, P1161; HOLLANDER W, 1979, ATHEROSCLEROSIS, V34, P391, DOI 10.1016/0021-9150(79)90064-9; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; HYLEMON PB, 1985, J BIOL CHEM, V260, P1015; JAVITT NB, 1994, FASEB J, V8, P1308, DOI 10.1096/fasebj.8.15.8001744; JOHANSSON J, 1992, FEBS LETT, V299, P146, DOI 10.1016/0014-5793(92)80234-8; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; JOSLIN G, 1992, J CLIN INVEST, V90, P1150, DOI 10.1172/JCI115934; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MACKIEWICZ A, 1993, ACUTE PHASE PROTEINS, P3; Memon RA, 2001, J BIOL CHEM, V276, P30118, DOI 10.1074/jbc.M102516200; Miyake JH, 2000, J BIOL CHEM, V275, P21805, DOI 10.1074/jbc.C000275200; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PERLMUTTER DH, 1989, J CLIN INVEST, V84, P138, DOI 10.1172/JCI114133; POLLER W, 1995, J BIOL CHEM, V270, P2841, DOI 10.1074/jbc.270.6.2841; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Rubin H, 1996, NAT MED, V2, P632, DOI 10.1038/nm0696-632; SHAW R, 1979, J BIOL CHEM, V254, P7177; STRAVITZ RT, 1996, AM J PHYSIOL, V271, P293; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Vlahcevic ZR, 2000, GASTROENTEROLOGY, V118, P599, DOI 10.1016/S0016-5085(00)70267-8; Whisstock JC, 2000, J MOL BIOL, V295, P651, DOI 10.1006/jmbi.1999.3375; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	44	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42973	42980		10.1074/jbc.M205089200	http://dx.doi.org/10.1074/jbc.M205089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12223476	hybrid			2022-12-25	WOS:000179081200072
J	Gouaze, V; Andrieu-Abadie, N; Cuvillier, O; Malagarie-Cazenave, S; Frisach, MF; Mirault, ME; Levade, T				Gouaze, V; Andrieu-Abadie, N; Cuvillier, O; Malagarie-Cazenave, S; Frisach, MF; Mirault, ME; Levade, T			Glutathione peroxidase-1 protects from CD95-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; FAS-INDUCED APOPTOSIS; DOXORUBICIN-INDUCED APOPTOSIS; APO-1/FAS LIGAND EXPRESSION; OXIDATIVE STRESS; NECROSIS-FACTOR; CYTOCHROME-C; T-CELLS; CD95(FAS/APO-1)-MEDIATED APOPTOSIS; MEDIATED APOPTOSIS	Through the induction of apoptosis, CD95 plays a crucial role in the immune response and the elimination of cancer cells. Ligation of CD95 receptor activates a complex signaling network that appears to implicate the generation of reactive oxygen species (ROS). This study investigated the place of ROS production in CD95-mediated apoptosis and the role of the antioxidant enzyme glutathione peroxidase-1 (GPx1). Anti-CD95 antibodies triggered an early generation of ROS in human breast cancer T47D cells that was blocked by overexpression of GPx1 and inhibition of initiator caspase activation. Enforced expression of GPxl also resulted in inhibition of CD95-induced effector caspase activation, DNA fragmentation, and apoptotic cell death. Resistance to CD95-mediated apoptosis was not due to an increased expression of anti-apoptotic molecules and could be reversed by glutathione-depleting agents. In addition, whereas the anti-apoptotic protein Bcl-xL prevented CD95-induced apoptosis in MCF-7 cells, it did not inhibit the early ROS production. Moreover, Bcl-xL but not GPx1 overexpression could suppress the staurosporine-induced late generation of ROS and subsequent cell death. Altogether, these findings suggest that GPx1 functions upstream of the mitochondrial events to inhibit the early ROS production and apoptosis induced by CD95 ligation. Finally, transgenic mice overexpressing GPx1 were partially protected from the lethal effect of antiCD95, underlying the importance of peroxide formation (and GPx1) in CD95-triggered apoptosis.	CHU Rangueil, INSERM, U466, Lab Biochim Med, F-31059 Toulouse 9, France; CHU Laval, Res Ctr, Unit Hlth & Environm, Ste Foy, PQ G1V 4G2, Canada	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Laval University	Levade, T (corresponding author), CHU Rangueil, INSERM, U466, Lab Biochim Med, 1 Ave Jean Pulhes,TSA 50032, F-31059 Toulouse 9, France.	levade@toulouse.inserm.fr	CUVILLIER, Olivier/B-2567-2009; Andrieu-Abadie, Nathalie/N-6793-2013; Gouaze-Andersson, Valerie/O-9180-2014; CUVILLIER, Olivier/S-1631-2019; Levade, Thierry/O-8948-2014	CUVILLIER, Olivier/0000-0003-3346-375X; Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Gouaze-Andersson, Valerie/0000-0002-1797-515X; CUVILLIER, Olivier/0000-0003-3346-375X; malagarie-cazenave, sophie/0000-0001-8380-5223				Andrieu-Abadie N, 1999, FASEB J, V13, P1501, DOI 10.1096/fasebj.13.12.1501; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Banki K, 1996, J BIOL CHEM, V271, P32994, DOI 10.1074/jbc.271.51.32994; Banki K, 1999, J IMMUNOL, V162, P1466; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; Deas O, 1997, INT IMMUNOL, V9, P117, DOI 10.1093/intimm/9.1.117; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gouaze V, 2001, MOL PHARMACOL, V60, P488; Gulbins E, 1996, IMMUNOLOGY, V89, P205, DOI 10.1046/j.1365-2567.1996.d01-743.x; Haouzi D, 2001, HEPATOLOGY, V33, P1181, DOI 10.1053/jhep.2001.24235; Hentze H, 2002, J BIOL CHEM, V277, P5588, DOI 10.1074/jbc.M110766200; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; JAATTELA M, 1995, ONCOGENE, V10, P2297; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jayanthi S, 1999, MOL BRAIN RES, V72, P158, DOI 10.1016/S0169-328X(99)00216-8; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kasahara Y, 1997, BLOOD, V89, P1748, DOI 10.1182/blood.V89.5.1748.1748_1748_1753; Keane MM, 1996, CANCER RES, V56, P4791; Kiningham KK, 1999, FASEB J, V13, P1601, DOI 10.1096/fasebj.13.12.1601; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kohno T, 1996, J IMMUNOL, V156, P4722; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Kwon D, 2001, J NEUROIMMUNOL, V113, P1, DOI 10.1016/S0165-5728(00)00321-0; Laouar A, 1999, J BIOL CHEM, V274, P23526, DOI 10.1074/jbc.274.33.23526; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Malassagne B, 2001, GASTROENTEROLOGY, V121, P1451, DOI 10.1053/gast.2001.29590; MATSUDA M, 1991, J IMMUNOL, V147, P3837; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; MIRAULT ME, 1991, J BIOL CHEM, V266, P20752; MIRAULT ME, 1994, ANN NY ACAD SCI, V738, P104; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Suzuki Y, 1998, FEBS LETT, V425, P209, DOI 10.1016/S0014-5793(98)00228-2; Um HD, 1996, J IMMUNOL, V156, P3469; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Wedi B, 1999, BLOOD, V94, P2365, DOI 10.1182/blood.V94.7.2365.419k08_2365_2373; William R, 1997, BLOOD, V89, P4175, DOI 10.1182/blood.V89.11.4175; Williams MS, 1996, J IMMUNOL, V157, P2395; Wilson DJ, 1999, CELL IMMUNOL, V194, P67, DOI 10.1006/cimm.1999.1486; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	58	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42867	42874		10.1074/jbc.M203067200	http://dx.doi.org/10.1074/jbc.M203067200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12221075	hybrid			2022-12-25	WOS:000179081200059
J	Dong, QG; Sclabas, GM; Fujioka, S; Schmidt, C; Peng, BL; Wu, TA; Tsao, MS; Evans, DB; Abbruzzese, JL; McDonnell, TJ; Chiao, PJ				Dong, QG; Sclabas, GM; Fujioka, S; Schmidt, C; Peng, BL; Wu, TA; Tsao, MS; Evans, DB; Abbruzzese, JL; McDonnell, TJ; Chiao, PJ			The function of multiple I kappa B : NF-kappa B complexes in the resistance of cancer cells to Taxol-induced apoptosis	ONCOGENE			English	Article						apoptosis; gene expression; NF-kappa B; I kappa B; bcl-xl	PRECURSOR NF-KAPPA-B1; KINASE COMPLEX; MICE LACKING; ACTIVATION; ALPHA; PHOSPHORYLATION; INHIBITION; EXPRESSION; PROTEINS; PATHWAY	The Rel/NF-kappaB transcription factors play a key role in the regulation of apoptosis and in tumorigenesis by controlling the expressions of specific genes. To determine the role of the constitutive activity of RelA in tumorigenesis, we generated pancreatic tumor cell lines that express a dominant negative mutant Of IkappaBalpha (IkappaBalphaM). In this report, we show that the inhibition of constitutive NF-kappaB activity, either by ectopic expression Of IkappaBalphaM or by treating the cells with a proteasome inhibitor PS-341 which blocks intracellular degradation Of IBalpha proteins, downregulates the expression of bcl-xl. We identified two putative NF-kappaB binding sites (kappaB/A and B) in the bcl-xl promoter and found that these two sites interact with different NF-kappaB proteins. p65/p50 heterodimer interacts with kappaB/A site whereas p50/p50 homodimer interacts with kappaB/B. The bcl-xl promoter reporter gene assays reveal that NF-kappaB dependent transcriptional activation is mainly mediated by kappaB/A site, indicating that bcl-xl is one of the downstream target genes regulated by RelA/ p50. Both IkappaBalphaM and PS-341 completely abolish NF-kappaB DNA binding activity; however, PS-341, but not ectopic expression Of IkappaBalphaM, sensitized cells to apoptosis induced by Taxol. This is due to the Taxol-mediated reactivation of RelA through phosphorylation and degradation Of IkappaBbeta and the re-expression of NF-kappaB regulated bcl-xl gene in these cancer cells as ectopic expression of the bcl-xl gene confers resistance to Taxol-induced apoptosis in PS-341 sensitized cells. These results demonstrate the important function of various NF-kappaB/IkappaB complexes in regulating anti-apoptotic genes in response to apoptotic stimuli, and they raise the possibility that NF-kappaB:IkappaBalpha and NF-kappaB:IkappaBbeta complexes are regulated by different upstream activators, and that NF-kappaB plays a key role in pancreatic tumorigenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Bern, Inselspital, Dept Visceral & Transplantat Surg, CH-3010 Bern, Switzerland; Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Bern; University Hospital of Bern; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022	Tsao, Ming Sound/0000-0002-9160-5405; Schmidt, Christian/0000-0002-1260-9732	NCI NIH HHS [CA73675, CA75517, CA78778] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075517, P01CA078778, R29CA073675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGIUSEPPE JA, 1996, ADV ANAT PATHOL, V3, P139; Gilmore TD, 1996, ONCOGENE, V13, P1367; Glasgow JN, 2000, J NEUROCHEM, V75, P1377, DOI 10.1046/j.1471-4159.2000.0751377.x; Heilker R, 1999, EUR J BIOCHEM, V259, P253, DOI 10.1046/j.1432-1327.1999.00028.x; Heilker R, 1999, BIOCHEMISTRY-US, V38, P6231, DOI 10.1021/bi990220t; Herrmann JL, 1997, EXP CELL RES, V234, P442, DOI 10.1006/excr.1997.3653; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Ishikawa H, 1996, ONCOGENE, V13, P255; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Jordan MA, 1996, CANCER RES, V56, P816; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Sambrook J., 1989, MOL CLONING; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Stroka DM, 1999, BLOOD, V93, P3803, DOI 10.1182/blood.V93.11.3803.411a27_3803_3810; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; VAN AD, 1996, SCIENCE, V274, P787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	41	142	151	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6510	6519		10.1038/sj.onc.1205848	http://dx.doi.org/10.1038/sj.onc.1205848			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226754				2022-12-25	WOS:000177925300011
J	Risk, JM; Evans, KE; Jones, J; Langan, JE; Rowbottom, L; McRonald, FE; Mills, HS; Ellis, A; Shaw, JM; Leigh, IM; Kelsell, DP; Field, JK				Risk, JM; Evans, KE; Jones, J; Langan, JE; Rowbottom, L; McRonald, FE; Mills, HS; Ellis, A; Shaw, JM; Leigh, IM; Kelsell, DP; Field, JK			Characterization of a 500 kb region on 17q25 and the exclusion of candidate genes as the familial Tylosis Oesophageal Cancer (TOC) locus	ONCOGENE			English	Article						oesophageal cancer; transcript map; tylosis	PALMOPLANTAR KERATODERMA; CHROMOSOME 17Q; N-ACETYLTRANSFERASE; HUMAN GENOME; ALLELIC LOSS; EXPRESSION; CARCINOMA; TUMORS; MAP; IDENTIFICATION	The locus for a syndrome of focal palmoplantar keratoderma (Tylosis) associated with squamous cell oesophageal cancer (TOC) has been mapped to chromosome 17q25, a region frequently deleted in sporadic squamous cell oesophageal tumours. Further haplotype analysis described here, based on revised maps of marker order, has reduced the TOC minimal region to a genetic interval of 2 cM limited by the microsatellite markers D17S785 and D17S751. Partial sequence data and complete physical maps estimate the actual size of this region to be only 0.5 Mb. This analysis allowed the exclusion of proposed candidate tumour suppressor genes including MLL septin-like fusion (MSF), survivin, and deleted in multiple human cancer (DMC1). Computer analysis of sequence data from the minimal region identified 13 candidate genes and the presence of 50-70 other 'gene fragments' as ESTs and/or predicted exons and genes. Ten of the characterized genes were assayed for mutations but no disease-specific alterations were identified in the coding and promoter sequences. This region of chromosome 17q25 is, therefore, relatively gene-rich, containing 13 known and possibly as many as 50 predicted genes. Further mutation analysis of these predicted genes, and others possibly residing in the region, is required in order to identify the elusive TOC locus.	Univ Liverpool, Mol Genet & Oncol Grp, Dept Clin Dent Sci, Liverpool L69 3GN, Merseyside, England; Royal Liverpool Univ Hosp, Dept Gastroenterol, Liverpool L7 8XP, Merseyside, England; Univ London, Ctr Cutaneous Res, Barts & London Sch Med & Dent, London E1 2AT, England; Roy Castle Int Ctr Lung Canc Res, Liverpool L3 9TA, Merseyside, England	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of London; Queen Mary University London	Risk, JM (corresponding author), Univ Liverpool, Mol Genet & Oncol Grp, Dept Clin Dent Sci, Edwards Bldg,Daulby St, Liverpool L69 3GN, Merseyside, England.	j.m.risk@liverpoool.ac.uk	Field, John K./AAD-5674-2020; McRonald, Fiona/B-4005-2009; Kelsell, David P/F-8767-2011	Field, John K./0000-0003-3951-6365; Kelsell, David/0000-0002-9910-7144; McRonald, Fiona/0000-0001-7226-9461				Blank V, 1997, GENOMICS, V44, P147, DOI 10.1006/geno.1997.4847; Brown LM, 2001, AM J EPIDEMIOL, V153, P114, DOI 10.1093/aje/153.2.114; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; Dunn J, 1999, ONCOGENE, V18, P987, DOI 10.1038/sj.onc.1202371; Ellis A, 1994, Eur J Cancer B Oral Oncol, V30B, P102, DOI 10.1016/0964-1955(94)90061-2; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; Franceschi S, 2000, INT J CANCER, V86, P626, DOI 10.1002/(SICI)1097-0215(20000601)86:5&lt;626::AID-IJC4&gt;3.0.CO;2-Y; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; Fukino K, 1999, GENE CHROMOSOME CANC, V24, P345, DOI 10.1002/(SICI)1098-2264(199904)24:4<345::AID-GCC8>3.0.CO;2-Q; Geylan YS, 2001, NEOPLASMA, V48, P108; GOTTLIEB M, 1987, ANAL BIOCHEM, V165, P33, DOI 10.1016/0003-2697(87)90197-7; Harada H, 2001, J HUM GENET, V46, P90, DOI 10.1007/s100380170115; HENNIES HC, 1995, GENOMICS, V29, P537, DOI 10.1006/geno.1995.9971; HOWELEVANS W, 1958, Q J MED, V27, P413; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Iwaya T, 1998, GASTROENTEROLOGY, V114, P1206, DOI 10.1016/S0016-5085(98)70426-3; Jones J, 2002, INT J ONCOL, V20, P697; Kalikin LM, 1999, GENOMICS, V57, P36, DOI 10.1006/geno.1998.5740; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; Kelsell DP, 1996, HUM MOL GENET, V5, P857, DOI 10.1093/hmg/5.6.857; Kuhlenbaumer G, 1999, GENOMICS, V62, P242, DOI 10.1006/geno.1999.5991; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li FZ, 1999, CANCER RES, V59, P3143; Marty L, 1997, GENOMICS, V41, P453, DOI 10.1006/geno.1997.4691; MUNOZ N, 1994, EUR J GASTROEN HEPAT, V6, P649, DOI 10.1097/00042737-199408000-00002; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; Protopopov A, 2000, CYTOGENET CELL GENET, V88, P312, DOI 10.1159/000015516; RISK JM, 1994, NAT GENET, V8, P319, DOI 10.1038/ng1294-319; Risk JM, 1999, GENOMICS, V59, P234, DOI 10.1006/geno.1999.5857; RISK JM, 2002, IN PRESS BIOTECHNIQU; Robbins MJ, 2000, GENOMICS, V67, P8, DOI 10.1006/geno.2000.6226; Russell SEH, 2000, CANCER RES, V60, P4729; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; Shibuta K, 2001, AM J GASTROENTEROL, V96, P3419; Stevens HP, 1996, ARCH DERMATOL, V132, P640, DOI 10.1001/archderm.132.6.640; Sureau A, 1997, NUCLEIC ACIDS RES, V25, P4513, DOI 10.1093/nar/25.22.4513; Taniguchi A, 1998, BIOCHEM BIOPH RES CO, V243, P177, DOI 10.1006/bbrc.1998.8078; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; von Brevern M, 1998, ONCOGENE, V17, P2101, DOI 10.1038/sj.onc.1202139; WABINGA HR, 1993, INT J CANCER, V54, P26, DOI 10.1002/ijc.2910540106; Yokota T, 2001, GENE, V267, P95, DOI 10.1016/S0378-1119(01)00407-3; Zheng WP, 2001, CHEM BIOL, V8, P379, DOI 10.1016/S1074-5521(01)00020-5	45	33	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6395	6402		10.1038/sj.onc.1205768	http://dx.doi.org/10.1038/sj.onc.1205768			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214281				2022-12-25	WOS:000177829000017
J	Quesada, I; Fuentes, E; Viso-Leon, MC; Soria, B; Ripoll, C; Nadal, A				Quesada, I; Fuentes, E; Viso-Leon, MC; Soria, B; Ripoll, C; Nadal, A			Low doses of the endocrine disruptor Bisphenol-A and the native hormone 17 beta-estradiol rapidly activate the transcription factor CREB	FASEB JOURNAL			English	Article						xenoestrogens; estrogen receptors; islets of Langerhans; non-genomic	ELEMENT-BINDING PROTEIN; ESTROGEN-RECEPTOR; MEMBRANE; PHOSPHORYLATION; XENOESTROGENS; CAMP; IDENTIFICATION; NUCLEAR; GROWTH; CELLS	Endocrine-disrupting chemicals (EDCs) are hormone-like agents present in the environment that alter the endocrine system of wildlife and humans. Most EDCs have potencies far below those of the natural hormone 17beta-E2 when acting through the classic estrogen receptors (ERs). Here, we show that the environmental estrogen Bisphenol-A and the native hormone 17beta-E2 activate the transcription factor, cAMP-responsive element binding protein (CREB) with the same potency. Phosphorylated CREB (P-CREB) was increased after only a 5-minute application of either BPA or 17beta-E2 in a calcium-dependent manner. The effect was reproduced by the membrane-impermeable molecule E2 conjugated to horseradish peroxidase (E-HRP). The increase in P-CREB was not modified by the anti-estrogen ICI 182,780. Therefore, low-dose of BPA activates the transcription factor CREB via an alternative mechanism, involving a non-classical membrane estrogen receptor. Because these effects are elicited at concentrations as low as 10(-9) M, this observation is of environmental and public health relevance.	Miguel Hernandez Univ, Inst Bioengn, Alicante 03550, Spain	Universidad Miguel Hernandez de Elche	Nadal, A (corresponding author), Miguel Hernandez Univ, Inst Bioengn, San Juan Campus,Carretera Alicante Valencia Km 87, Alicante 03550, Spain.	nadal@umh.es	Fuentes, Esther/C-7545-2015; , Bernat/AAL-6470-2021; Ivan, Quesada/P-6541-2014; Nadal, Angel/G-6721-2014; Ripoll, Cristina/F-3324-2016	Ivan, Quesada/0000-0002-9808-514X; Nadal, Angel/0000-0003-4178-2152; Ripoll, Cristina/0000-0003-0935-8722; Soria, Bernat/0000-0002-2356-0380; Fuentes, Esther/0000-0002-9113-739X				ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Beyer C, 2000, J NEUROSCI RES, V59, P107, DOI 10.1002/(SICI)1097-4547(20000101)59:1<107::AID-JNR13>3.0.CO;2-W; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Cagen SZ, 1999, TOXICOL SCI, V50, P36, DOI 10.1093/toxsci/50.1.36; CARLIN L, 2000, CIRC RES, V86, P760; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Dodds EC, 1938, NATURE, V141, P247, DOI 10.1038/141247b0; Dos Santos EG, 2002, ENDOCRINOLOGY, V143, P930; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Fernandez MF, 2001, ENVIR SCI TECH LIB, V18, P149; Guillette LJ, 1999, GEN COMP ENDOCR, V116, P356, DOI 10.1006/gcen.1999.7375; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Kaiser J, 2000, SCIENCE, V290, P695, DOI 10.1126/science.290.5492.695; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Loomis AK, 2000, BIOL REPROD, V62, P995, DOI 10.1095/biolreprod62.4.995; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MCLACHLAN JA, 1993, ENVIRON HEALTH PERSP, V101, P386, DOI 10.2307/3431891; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; Nadal A, 2001, NEWS PHYSIOL SCI, V16, P251; Nadal A, 2001, TRENDS PHARMACOL SCI, V22, P597, DOI 10.1016/S0165-6147(00)01846-0; NADAL A, 1994, AM J PHYSIOL-ENDOC M, V267, pE769, DOI 10.1152/ajpendo.1994.267.5.E769; Nadal A, 1998, FASEB J, V12, P1341, DOI 10.1096/fasebj.12.13.1341; Nadal A, 2000, P NATL ACAD SCI USA, V97, P11603, DOI 10.1073/pnas.97.21.11603; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.1289/ehp.9710570; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Petersen DN, 1998, ENDOCRINOLOGY, V139, P1082, DOI 10.1210/en.139.3.1082; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Ropero AB, 2002, MOL ENDOCRINOL, V16, P497, DOI 10.1210/me.16.3.497; Ropero AB, 1999, J PHYSIOL-LONDON, V521, P397, DOI 10.1111/j.1469-7793.1999.00397.x; Ruehlmann DO, 1998, FASEB J, V12, P613, DOI 10.1096/fasebj.12.7.613; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; Steinmetz R, 1998, ENDOCRINOLOGY, V139, P2741, DOI 10.1210/en.139.6.2741; Triendl R, 2001, NATURE, V409, P274, DOI 10.1038/35053303; VALDEOLMILLOS M, 1992, J PHYSIOL-LONDON, V455, P173, DOI 10.1113/jphysiol.1992.sp019295; Watson CS, 1999, EXP PHYSIOL, V84, P1013, DOI 10.1111/j.1469-445X.1999.01903.x; Zhou Y, 1996, ENDOCRINOLOGY, V137, P2163, DOI 10.1210/en.137.5.2163	40	179	187	1	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1671	+		10.1096/fj.02-0313fje	http://dx.doi.org/10.1096/fj.02-0313fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207000	Bronze			2022-12-25	WOS:000177814000002
J	Pang, LH; Nie, M; Corbett, L; Donnelly, R; Gray, S; Knox, AJ				Pang, LH; Nie, M; Corbett, L; Donnelly, R; Gray, S; Knox, AJ			Protein kinase C-epsilon mediates bradykinin-induced cyclooxygenase-2 expression in human airway smooth muscle cells	FASEB JOURNAL			English	Article						prostanoids; inflammation; asthma	PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; CYTOSOLIC PHOSPHOLIPASE A(2); VASCULAR ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; SIGNAL-TRANSDUCTION; PHORBOL ESTER; TRANSCRIPTIONAL REGULATION; EPITHELIAL-CELLS; RESPONSE ELEMENT; NUCLEAR FACTOR	We previously reported that proinflammatory mediator bradykinin (BK) induces cyclooxygenase (COX)-2 expression in human airway smooth muscle (HASM), but the mechanism is unknown in any biological system. Here, we studied the role of specific protein kinase C (PKC) isozyme(s) in COX-2 expression. Among the eight PKC isozymes present in HASM cells, the Ca2+-independent PKC- and - and the Ca2+-dependent PKC-alpha and -betaI were translocated to the nucleus upon BK stimulation. BK-induced COX-2 expression and prostaglandin E-2 (PGE(2)) accumulation were mimicked by the direct PKC activator phorbol 12-myristate 13-acetate (PMA) and inhibited by the broad spectrum PKC inhibitor bisindolylmaleimide I. However, the selective Ca2+-dependent PKC isozyme inhibitor Go 6976 had no effect. Furthermore, the membrane-permeable calcium chelator BAPTA-AM had no effect on BK-induced COX-2 expression and COX activity despite its inhibition of PGE2 accumulation, suggesting the involvement of Ca2+-independent PKC isozymes. Rottlerin, a PKC-delta inhibitor, also had no effect, likely implicating PKC-epsilon. BK-stimulated transcriptional activation of a COX-2 promoter reporter construct was enhanced by overexpression of wildtype PKC-epsilon and abolished by a dominant negative PKC-epsilon, but it was not affected by wild-type or dominant negative PKC-alpha or -delta. Collectively, our results demonstrate that PKC-epsilon mediates BK-induced COX-2 expression in HASM cells.	Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG5 1PB, England; Univ Nottingham, Derbyshire Royal Infirm, Div Vasc Med, Derby DE1 2QY, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; University of Nottingham	Pang, LH (corresponding author), Univ Nottingham, City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall rd, Nottingham NG5 1PB, England.	linhua.pang@nottingham.ac.uk		Knox, Alan/0000-0002-5906-4143				BARNES PJ, 1992, THORAX, V47, P979, DOI 10.1136/thx.47.11.979; Carlin S, 2000, AM J RESP CELL MOL, V23, P555, DOI 10.1165/ajrcmb.23.4.4197; Carlin S, 1999, AM J PHYSIOL-LUNG C, V276, pL506, DOI 10.1152/ajplung.1999.276.3.L506; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CLARK KJ, 1995, J BIOL CHEM, V270, P7097, DOI 10.1074/jbc.270.13.7097; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Deszo EL, 2001, J BIOL CHEM, V276, P10212, DOI 10.1074/jbc.M010589200; Giroux M, 2000, J IMMUNOL, V165, P3985, DOI 10.4049/jimmunol.165.7.3985; Graness A, 1997, BIOCHEM J, V327, P147, DOI 10.1042/bj3270147; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Higaki T, 1999, MICROVASC RES, V58, P144, DOI 10.1006/mvre.1999.2163; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; Kennedy CRJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1605, DOI 10.1152/ajpcell.1997.273.5.C1605; Knox AJ, 2001, FASEB J, V15, P2480, DOI 10.1096/fj.01-0256com; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Lal MA, 1997, AM J PHYSIOL-RENAL, V273, pF907, DOI 10.1152/ajprenal.1997.273.6.F907; Lal MA, 1998, AM J PHYSIOL-RENAL, V274, pF728, DOI 10.1152/ajprenal.1998.274.4.F728; Lin CH, 2000, MOL PHARMACOL, V57, P36; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOMBOULI JV, 1995, ANNU REV PHARMACOL, V35, P679, DOI 10.1146/annurev.pa.35.040195.003335; Nagaki M, 1996, AM J PHYSIOL-LUNG C, V270, pL907, DOI 10.1152/ajplung.1996.270.6.L907; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; Pang LH, 1996, EUR J PHARMACOL, V317, P151, DOI 10.1016/S0014-2999(96)00703-0; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; Pang LH, 1997, AM J PHYSIOL-LUNG C, V273, pL1132, DOI 10.1152/ajplung.1997.273.6.L1132; POLOSA R, 1990, AM REV RESPIR DIS, V142, P1367, DOI 10.1164/ajrccm/142.6_Pt_1.1367; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; ROSSETTI M, 1995, AM J PHYSIOL-LUNG C, V268, pL966, DOI 10.1152/ajplung.1995.268.6.L966; SIROIS J, 1993, J BIOL CHEM, V268, P21931; TIPPMER S, 1994, EUR J BIOCHEM, V225, P297, DOI 10.1111/j.1432-1033.1994.00297.x; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wang HQ, 2001, MOL PHARMACOL, V59, P860, DOI 10.1124/mol.59.4.860; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; Webb BLJ, 1997, BIOCHEM PHARMACOL, V54, P199, DOI 10.1016/S0006-2952(97)00165-2; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	50	27	29	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1435	+		10.1096/fj.02-0169fje	http://dx.doi.org/10.1096/fj.02-0169fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205039				2022-12-25	WOS:000177813100007
J	Prosise, GL; Wu, JZ; Luecke, H				Prosise, GL; Wu, JZ; Luecke, H			Crystal structure of Tritrichomonas foetus inosine monophosphate dehydrogenase in complex with the inhibitor ribavirin monophosphate reveals a catalysis-dependent ion-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; FETUS INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE; 5'-MONOPHOSPHATE DEHYDROGENASE; ESCHERICHIA-COLI; KINETIC MECHANISM; MYCOPHENOLIC-ACID; PROTEIN; EXPRESSION; PURIFICATION; RESOLUTION	Inosine monophosphate dehydrogenase (IMPDH) catalyzes the rate-limiting step in GMP biosynthesis. The resulting intracellular pool of guanine nucleotides is of great importance to all cells for use in DNA and RNA synthesis, metabolism, and signal transduction. The enzyme binds IMP and the cofactor NAD(+) in random order, IMP is converted to XMP, NAD(+) is reduced to NADH, and finally, NADH and then XMP are released sequentially. XMP is subsequently converted into GMP by GMP synthetase. Drugs that decrease GMP synthesis by inhibiting IMPDH have been shown to have antiproliferative as well as antiviral activity. Several drugs are in use that target the substrate- or cofactor-binding site; however, due to differences between the mammalian and microbial isoforms, most drugs are far less effective against the microbial form of the enzyme than the mammalian form. The high resolution crystal structures of the protozoan parasite Tritrichomonas foetus IMPDH complexed with the inhibitor ribavirin monophosphate as well as monophosphate together with a second inhibitor, mycophenolic acid, are presented here. These structures reveal an active site cation identified previously only in the Chinese hamster IMPDH structure with covalently bound IMP. This cation was not found previously in apo IMPDH, IMPDH in complex with XMP, or covalently bound inhibitor,indicating that the cation-binding site may be catalysis-dependent. A comparison of T. foetus IMPDH with the Chinese hamster and Streptococcus pyogenes structures reveals differences in the active site loop architecture, which contributes to differences in cation binding during the catalytic sequence and the kinetic rates between bacterial, protozoan, and mammalian enzymes. Exploitation of these differences may lead to novel inhibitors, which favor the microbial form of the enzyme.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Ribapharm, Costa Mesa, CA 92626 USA	University of California System; University of California Irvine	Luecke, H (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	hudel@uci.edu	Luecke, Hartmut/F-4712-2012	Luecke, Hartmut/0000-0002-4938-0775	NIGMS NIH HHS [R01-GM56445] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056445] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; BECK JT, 1994, EXP PARASITOL, V78, P101, DOI 10.1006/expr.1994.1010; Bowne SJ, 2002, HUM MOL GENET, V11, P559, DOI 10.1093/hmg/11.5.559; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHIN MS, 1994, MOL BIOCHEM PARASIT, V63, P221, DOI 10.1016/0166-6851(94)90058-2; Colby TD, 1999, P NATL ACAD SCI USA, V96, P3531, DOI 10.1073/pnas.96.7.3531; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; Digits JA, 2000, BIOCHEMISTRY-US, V39, P1771, DOI 10.1021/bi992288e; Digits JA, 1999, BIOCHEMISTRY-US, V38, P2295, DOI 10.1021/bi982305k; Felleisen RSJ, 1999, MICROBES INFECT, V1, P807, DOI 10.1016/S1286-4579(99)80083-5; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAGER PW, 1995, BIOCHEM PHARMACOL, V49, P1323, DOI 10.1016/0006-2952(95)00026-V; HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001; Hubbard S. J., 1993, NACCESS; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kerr KM, 2000, ARCH BIOCHEM BIOPHYS, V375, P131, DOI 10.1006/abbi.1999.1644; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVINE ND, 1973, PROTOZOAN PARASITES, P89; Markham GD, 1999, BIOCHEMISTRY-US, V38, P4433, DOI 10.1021/bi9829579; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McMillan FM, 2000, BIOCHEMISTRY-US, V39, P4533, DOI 10.1021/bi992645l; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Nimmesgern E, 1999, PROTEIN EXPRES PURIF, V17, P282, DOI 10.1006/prep.1999.1136; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Sintchak M. D., 1999, ANTIVIR RES, V41, pA56; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; Speer C. A., 1991, Large Animal Veterinarian, V46, P18; STEHLE T, 1991, J MOL BIOL, V221, P1325, DOI 10.1016/0022-2836(91)90936-Z; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; VERHAM R, 1987, MOL BIOCHEM PARASIT, V24, P1, DOI 10.1016/0166-6851(87)90110-1; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang W, 1997, BIOCHEMISTRY-US, V36, P8479, DOI 10.1021/bi970226n; Whitby FG, 1997, BIOCHEMISTRY-US, V36, P10666, DOI 10.1021/bi9708850; Whitby FG, 1995, PROTEINS, V23, P598, DOI 10.1002/prot.340230417; YUAN L, 1990, J BIOL CHEM, V265, P13528; YULE A, 1989, PARASITOL TODAY, V5, P373, DOI 10.1016/0169-4758(89)90298-6; Zhang RG, 1999, BIOCHEMISTRY-US, V38, P4691, DOI 10.1021/bi982858v	38	33	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50654	50659		10.1074/jbc.M208330200	http://dx.doi.org/10.1074/jbc.M208330200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12235158	hybrid			2022-12-25	WOS:000180177700061
J	Lloyd, JA; Forget, AL; Knight, KL				Lloyd, JA; Forget, AL; Knight, KL			Correlation of biochemical properties with the oligomeric state of human Rad52 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS RECOMBINATION; DNA; REPAIR; VISUALIZATION; MEDIATOR; BINDING; COMPLEX; RPA	The human Rad52 protein self-associates to form ring-shaped oligonters, as well as higher order complexes of these rings. We have shown previously that there are two experimentally separable self-association domains in HsRad52, one in the N terminus (residues 1-192) responsible for assembly of individual subunits into rings, and one in the C terminus (residues 218-418) responsible for higher order oligomerization of rings. Earlier studies suggest that the higher order complexes promote DNA end-joining, and others suggest that these complexes are relevant to in vivo Rad52 function. In this study we demonstrate that although inherent binding to single-stranded DNA depends on neither higher order complexes of Rad52 rings nor the ring-shaped oligomers themselves, higher order complexes are important for activities involving simultaneous interaction with more than one DNA molecule. This provides biochemical support for what may be an important in vivo function of Rad52.	Univ Massachusetts, Sch Med, Depb Biochem & Mol Pharmacol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Knight, KL (corresponding author), Univ Massachusetts, Sch Med, Depb Biochem & Mol Pharmacol, Aaron Lazare Med Res Bldg,364 Plantat St, Worcester, MA 01655 USA.	kendall.knight@umassmed.edu			NIGMS NIH HHS [GM44772] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; Kagawa W, 2002, MOL CELL, V10, P359, DOI 10.1016/S1097-2765(02)00587-7; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Kito K, 1999, BBA-GENE STRUCT EXPR, V1489, P303, DOI 10.1016/S0167-4781(99)00214-6; Lisby M, 2001, P NATL ACAD SCI USA, V98, P8276, DOI 10.1073/pnas.121006298; Liu YL, 2000, EMBO REP, V1, P85, DOI 10.1093/embo-reports/kvd002; Liu YL, 1999, CURR BIOL, V9, P975, DOI 10.1016/S0960-9822(99)80427-8; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Ranatunga W, 2001, J BIOL CHEM, V276, P15876, DOI 10.1074/jbc.M011747200; Reddy G, 1997, MUTAT RES-FUND MOL M, V377, P53, DOI 10.1016/S0027-5107(97)00057-2; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; Sonoda E, 2001, P NATL ACAD SCI USA, V98, P8388, DOI 10.1073/pnas.111006398; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Van Dyck E, 1998, J MOL BIOL, V284, P1027, DOI 10.1006/jmbi.1998.2203; Van Dyck E, 2001, EMBO REP, V2, P905, DOI 10.1093/embo-reports/kve201; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049	32	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46172	46178		10.1074/jbc.M207262200	http://dx.doi.org/10.1074/jbc.M207262200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12226092	hybrid			2022-12-25	WOS:000179529300063
J	Sandowski, Y; Raver, N; Gussakovsky, EE; Shochat, S; Dym, O; Livnah, O; Rubinstein, M; Krishna, R; Gertler, A				Sandowski, Y; Raver, N; Gussakovsky, EE; Shochat, S; Dym, O; Livnah, O; Rubinstein, M; Krishna, R; Gertler, A			Subcloning, expression, purification, and characterization of recombinant human leptin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR EXTRACELLULAR DOMAIN; PROTEIN SECONDARY STRUCTURE; HUMAN GROWTH-HORMONE; PROLACTIN RECEPTOR; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MAMMARY-GLAND; OBESE GENE; CHICKEN; BOVINE	A subdomain of the human leptin receptor encoding part of the extracellular domain (amino acids 428 to 635) was subcloned, expressed in a prokaryotic host, and purified to homogeneity, as evidenced by SDS-PAGE, with over 95% monomeric protein. The purified leptin-binding domain (LBD) exhibited the predicted beta structure, was capable of binding human, ovine, and chicken leptins, and formed a stable 1:1 complex with all mammalian leptins. The binding kinetics, assayed by surface plasmon resonance methodology, showed respective k(on) and k(off) values (mean +/- S.E.) of 1.20 +/- 0.23 X 10(-5) mol(-1) ks(-1) and 1.85 +/- 0.30 x 10(-3) s(-1) and a K-d value of 1.54 X 10(-8) m. Similar results were achieved with conventional binding experiments. LBD blocked leptin-induced, but not interieukin-3-induced, proliferation of BAF/3 cells stably transfected with the long form of human leptin receptor. The modeled LBD structure and the known three-dimensional structure of human leptin were used to construct a model of 1:1 LBD-human leptin complex. Two main residues, Phe-500, located in loop L3, and Tyr-441, located in L1, are suggested to contribute to leptin binding.	Hebrew Univ Jerusalem, Inst Biochem Food Sci & Nutr, Fac Agr Food & Environm Qual Sci, IL-76100 Rehovot, Israel; Bar Ilan Univ, Dept Life Sci, IL-52900 Ramat Gan, Israel; Agr Res Org, Volcani Ctr, Inst Hort, IL-50250 Bet Dagan, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Fac Life Sci, IL-91904 Jerusalem, Israel; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Diagnost Syst Labs, Webster, TX 77598 USA	Hebrew University of Jerusalem; Bar Ilan University; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Hebrew University of Jerusalem; Weizmann Institute of Science	Gertler, A (corresponding author), Hebrew Univ Jerusalem, Inst Biochem Food Sci & Nutr, Fac Agr Food & Environm Qual Sci, IL-76100 Rehovot, Israel.	gertler@agri-huji.ac.il	Gussakovsky, Eugene/W-2706-2019					Almog B, 2001, MOL CELL ENDOCRINOL, V183, P179, DOI 10.1016/S0303-7207(01)00543-3; [Anonymous], 1996, CIRCULAR DICHROISM C; AUTHOR A, 1994, GRAPHPAD PRISM VERSI; Barkan D, 1999, ENDOCRINOLOGY, V140, P1731, DOI 10.1210/en.140.4.1731; Barnes PJ, 2002, ANNU REV PHARMACOL, V42, P81, DOI 10.1146/annurev.pharmtox.42.111901.111143; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; BIGNON C, 1994, J BIOL CHEM, V269, P3318; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campfield LA, 1998, P NUTR SOC, V57, P429, DOI 10.1079/PNS19980062; Campfield LA, 2000, FRONT HORM RES, V26, P12; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; Chehab FF, 2000, TRENDS PHARMACOL SCI, V21, P309, DOI 10.1016/S0165-6147(00)01514-5; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Cohen B, 2001, J BIOL CHEM, V276, P7697, DOI 10.1074/jbc.C000634200; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; DRIDI S, 2002, AM J PHYSIOL-ENDOC M, V279, pE116; Elkins PA, 2000, NAT STRUCT BIOL, V7, P808, DOI 10.1038/79047; Fong TM, 1998, MOL PHARMACOL, V53, P234, DOI 10.1124/mol.53.2.234; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; GERTLER A, 1984, MOL CELL ENDOCRINOL, V34, P51, DOI 10.1016/0303-7207(84)90158-8; Gertler A, 1998, FEBS LETT, V422, P137, DOI 10.1016/S0014-5793(97)01613-X; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; Haniu M, 1998, J BIOL CHEM, V273, P28691, DOI 10.1074/jbc.273.44.28691; Houseknecht KL, 1996, DIABETES, V45, P1638, DOI 10.2337/diabetes.45.11.1638; Houseknecht KL, 1998, J ANIM SCI, V76, P1405; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leupen SM, 1997, ENDOCRINOLOGY, V138, P2735, DOI 10.1210/en.138.7.2735; Liu CL, 1997, ENDOCRINOLOGY, V138, P3548, DOI 10.1210/en.138.8.3548; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526; Luoh SM, 1997, J MOL ENDOCRINOL, V18, P77, DOI 10.1677/jme.0.0180077; Maamra M, 2001, ENDOCRINOLOGY, V142, P4389, DOI 10.1210/en.142.10.4389; Morrison CD, 2001, J ENDOCRINOL, V168, P317, DOI 10.1677/joe.0.1680317; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Raver N, 1998, PROTEIN EXPRES PURIF, V14, P403, DOI 10.1006/prep.1998.0975; Raver N, 2002, GEN COMP ENDOCR, V126, P52, DOI 10.1006/gcen.2001.7766; Raver N, 2000, PROTEIN EXPRES PURIF, V19, P30, DOI 10.1006/prep.2000.1202; Rock FL, 1996, HORM METAB RES, V28, P748, DOI 10.1055/s-2007-979892; Roh SG, 2001, ENDOCRINOLOGY, V142, P5167, DOI 10.1210/en.142.12.5167; SANDOWSKI Y, 1995, MOL CELL ENDOCRINOL, V115, P1, DOI 10.1016/0303-7207(95)03664-S; Sandowski Y, 2000, GEN COMP ENDOCR, V118, P302, DOI 10.1006/gcen.2000.7465; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Sinha MK, 1996, J CLIN INVEST, V98, P1277, DOI 10.1172/JCI118913; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Spicer LJ, 1998, BIOL REPROD, V58, P207, DOI 10.1095/biolreprod58.1.207; Sporri B, 2001, CYTOKINE GROWTH F R, V12, P27, DOI 10.1016/S1359-6101(00)00020-4; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Taouis M, 2001, DOMEST ANIM ENDOCRIN, V21, P319, DOI 10.1016/S0739-7240(01)00122-9; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TCHELET A, 1995, J ENDOCRINOL, V144, P393, DOI 10.1677/joe.0.1440393; Verploegen SABW, 1997, FEBS LETT, V405, P237, DOI 10.1016/S0014-5793(97)00192-0; Wu ZD, 2002, J CLIN ENDOCR METAB, V87, P2931, DOI 10.1210/jc.87.6.2931; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	59	50	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46304	46309		10.1074/jbc.M207556200	http://dx.doi.org/10.1074/jbc.M207556200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12226096	hybrid			2022-12-25	WOS:000179529300080
J	Sastry, MSR; Korotkov, K; Brodsky, Y; Baneyx, F				Sastry, MSR; Korotkov, K; Brodsky, Y; Baneyx, F			Hsp31, the Escherichia coli yedU gene product, is a molecular chaperone whose activity is inhibited by ATP at high temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ALPHA-B-CRYSTALLIN; EXPRESSION; SEQUENCE; CLPB; AGGREGATION; NETWORK; K-12; DNAK; IBPB	The Escherichia coli chromosome contains several uncharacterized heat-inducible loci that may encode novel molecular chaperones or proteases. Here we show that the 31-kDa product of the yedU gene is an efficient homodimeric molecular chaperone that is conserved in a number of pathogenic eubacteria and fungi. Heat shock protein (Hsp) 31 relies on temperature-driven conformational changes to expose structured hydrophobic domains that are likely responsible for substrate binding. Complementing the function of refolding, remodeling, and holding chaperones, Hsp 31 preferentially interacts with early unfolding intermediates and rapidly releases them in an active form after transfer to low temperatures. Although Hsp 31 does not appear to exhibit intrinsic ATPase activity, binding of ATP at high temperatures restricts the size or availability of the substrate binding site, thereby modulating chaperone activity. The possible role of ATP in coordinating the function of the cellular complement of molecular chaperones is discussed.	Univ Washington, Dept Chem Engn, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Baneyx, F (corresponding author), Univ Washington, Dept Chem Engn, Box 351750, Seattle, WA 98195 USA.			Korotkov, Konstantin/0000-0002-2182-6843				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CANNON DJ, 1969, BIOCHEM BIOPH RES CO, V35, P403, DOI 10.1016/0006-291X(69)90513-0; Chevalier M, 1998, METHOD ENZYMOL, V290, P384, DOI 10.1016/S0076-6879(98)90033-7; Du XL, 2000, P NATL ACAD SCI USA, V97, P14079, DOI 10.1073/pnas.260503597; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FINDLY RC, 1983, SCIENCE, V219, P1223, DOI 10.1126/science.6828852; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Gross CA, 1996, ESCHERICHIA COLI SAL, P1382; Halio SB, 1996, J BACTERIOL, V178, P2605, DOI 10.1128/jb.178.9.2605-2612.1996; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Korber P, 2000, EMBO J, V19, P741, DOI 10.1093/emboj/19.4.741; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Lund PA, 2001, ADV MICROB PHYSIOL, V44, P93, DOI 10.1016/S0065-2911(01)44012-4; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Muchowski PJ, 1999, J BIOL CHEM, V274, P30190, DOI 10.1074/jbc.274.42.30190; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; NABERHAUS F, 2002, MICROBIOL MOL BIOL R, V66, P64; Richmond CS, 1999, NUCLEIC ACIDS RES, V27, P3821, DOI 10.1093/nar/27.19.3821; Shearstone JR, 1999, J BIOL CHEM, V274, P9937, DOI 10.1074/jbc.274.15.9937; SINGH M, 1970, J BIOL CHEM, V245, P4636; Smykal P, 2000, PLANT J, V23, P703, DOI 10.1046/j.1365-313x.2000.00837.x; SRERE PA, 1966, J BIOL CHEM, V241, P2157; Thirumalai D, 2001, ANNU REV BIOPH BIOM, V30, P245, DOI 10.1146/annurev.biophys.30.1.245; Thomas JG, 2000, MOL MICROBIOL, V36, P1360, DOI 10.1046/j.1365-2958.2000.01951.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VALLEE BL, 1955, P NATL ACAD SCI USA, V41, P327, DOI 10.1073/pnas.41.6.327; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; YOSHIDA T, 1993, MOL GEN GENET, V237, P113, DOI 10.1007/BF00282791; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	33	69	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46026	46034		10.1074/jbc.M205800200	http://dx.doi.org/10.1074/jbc.M205800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235139	hybrid			2022-12-25	WOS:000179529300043
J	Li, X; Massa, PE; Hanidu, A; Peet, GW; Aro, P; Savitt, A; Mische, S; Li, J; Marcu, KB				Li, X; Massa, PE; Hanidu, A; Peet, GW; Aro, P; Savitt, A; Mische, S; Li, J; Marcu, KB			IKK alpha, IKK beta, and NEMO/IKK gamma are each required for the NF-kappa B-mediated inflammatory response program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NECROSIS-FACTOR-ALPHA; PROTOONCOGENE BCL-3 ENCODES; SEVERE LIVER DEGENERATION; EPIDERMAL-GROWTH-FACTOR; GENE-EXPRESSION; KINASE-ALPHA; MICE LACKING; DEPENDENT TRANSCRIPTION; MOLECULAR-CLONING; DNA-BINDING	The IKKbeta and NEMO/IKKgamma subunits of the NF-kappaB-activating signalsome complex are known to be essential for activating NF-kappaB by inflammatory and other stress-like stimuli. However, the IKKalpha subunit is believed to be dispensable for the latter responses and instead functions as an in vivo mediator of other novel NF-kappaB-dependent and -independent functions. In contrast to this generally accepted view of IKKalpha's physiological functions, we demonstrate in mouse embryonic fibroblasts (NMFs) that, akin to IKKbeta and NEMO/IKKgamma, IKKalpha is also a global regulator of tumor necrosis factor alpha- and IL-1-responsive IKK signalsome-dependent target genes including many known NF-kappaB targets such as serum amyloid A3, C3, interleukin (IL)-6, IL-11, IL-1 receptor antagonist, vascular endothelial growth factor, Ptx3, beta(2)-microglobulin, IL-1alpha, Mcp-1 and -3, RANTES (regulated on activation normal T cell expressed and secreted), Fas antigen, Jun-B, c-Fos, macrophage colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor. Only a small number of NF-kappaB-dependent target genes were preferentially dependent on IKKa or IKKbeta. Constitutive expression of a trans-dominant IkappaBalpha superrepressor (IkappaBalphaSR) in wild type MEFs confirmed that these signalsome-dependent target genes were also dependent on NF-kappaB. A subset of NF-kappaB target genes were IKK-dependent in the absence of exogenous stimuli, suggesting that the signalsome was also required to regulate basal levels of activated NF-kappaB in established MEFs. Overall, a sizable number of novel NF-kappaP/IKK-dependent genes were identified including Secreted Frizzled, cadherin 13, protocadherin 7, CCAAT/enhancer-binding protein-beta and -6, osteoprotegerin, FOXC2 and FOXF2, BMP-2, p75 neurotrophin receptor, caspase-11, guanylate-binding proteins 1 and 2, ApoJ/clusterin, interferon (a and 13) receptor 2, decorin, osteoglycin, epiregulin, proliferins 2 and 3, stromal cell-derived factor, and cathepsins B, F, and Z. SOCS-3, a negative effector of STAT3 signaling, was found to be an NF-kappaB/IKK-induced gene, suggesting that IKK-mediated NF-kappaB activation can coordinately illicit negative effects on STAT signaling.	Boehringer Ingelheim Pharmaceut, Dept Biol, Ridgefield, CT 06877 USA; SUNY Stony Brook, Genet Grad Program, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Microbiol, Stony Brook, NY 11794 USA; S Orsola Univ Hosp, Ctr Appl Biomed Res, I-40138 Bologna, Italy	Boehringer Ingelheim; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; IRCCS Azienda Ospedaliero-Universitaria di Bologna	Li, J (corresponding author), Boehringer Ingelheim Pharmaceut, Dept Biol, Ridgefield, CT 06877 USA.	jli@rdg.boehringer-ingelheim.com; kmarcu@ms.ce.sunysb.edu		Mische, Sheenah/0000-0002-6055-5564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026939] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI057555] Funding Source: Medline; NIGMS NIH HHS [GM26939] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDRED AR, 1987, J BIOL CHEM, V262, P2875; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Beadling C, 1999, J IMMUNOL, V162, P2677; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Berlato C, 2002, J IMMUNOL, V168, P6404, DOI 10.4049/jimmunol.168.12.6404; Bettuzzi S, 2002, ONCOGENE, V21, P4328, DOI 10.1038/sj.onc.1205594; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Boehm U, 1998, J IMMUNOL, V161, P6715; Bono F, 1999, FEBS LETT, V457, P93, DOI 10.1016/S0014-5793(99)01006-6; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROWN AM, 1994, MOL CELL BIOL, V14, P2926, DOI 10.1128/MCB.14.5.2926; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fang JM, 2000, AM J HUM GENET, V67, P1382, DOI 10.1086/316915; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; Hay E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Krappmann D, 2000, J BIOL CHEM, V275, P29779, DOI 10.1074/jbc.M003902200; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; Li J, 2001, J BIOL CHEM, V276, P18579, DOI 10.1074/jbc.M100846200; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li X, 2000, BRAIN RES PROTOC, V5, P211, DOI 10.1016/S1385-299X(00)00015-5; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liu YJ, 1997, P NATL ACAD SCI USA, V94, P8138, DOI 10.1073/pnas.94.15.8138; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Matsushima N, 2000, PROTEINS, V38, P210, DOI 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; McKenzie FR, 2000, MOL CELL BIOL, V20, P2635, DOI 10.1128/MCB.20.8.2635-2649.2000; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miura N, 1998, GENOMICS, V50, P346, DOI 10.1006/geno.1998.5288; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; Panetta R, 1999, BIOCHEM BIOPH RES CO, V259, P550, DOI 10.1006/bbrc.1999.0817; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; Perini G, 2002, J EXP MED, V195, P907, DOI 10.1084/jem.20011797; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; Qian W, 1999, J INF STOR PROC SYST, V1, P159; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Rosenberg ME, 2002, MOL CELL BIOL, V22, P1893, DOI 10.1128/MCB.22.6.1893-1902.2002; ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rudolph D, 2000, GENE DEV, V14, P854; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Santamaria I, 1999, J BIOL CHEM, V274, P13800, DOI 10.1074/jbc.274.20.13800; Santamaria I, 1998, J BIOL CHEM, V273, P16816, DOI 10.1074/jbc.273.27.16816; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Schwarz DA, 1998, IMMUNITY, V9, P657, DOI 10.1016/S1074-7613(00)80663-9; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shimizu N, 2000, J VIROL, V74, P619, DOI 10.1128/JVI.74.2.619-626.2000; Shirakata Y, 2000, J BIOL CHEM, V275, P5748, DOI 10.1074/jbc.275.8.5748; SILKENSEN JR, 1994, BIOCHEM CELL BIOL, V72, P483, DOI 10.1139/o94-065; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Takeuchi T, 2000, J NEUROCHEM, V74, P1489, DOI 10.1046/j.1471-4159.2000.0741489.x; Tanaka M, 1999, BLOOD, V93, P804, DOI 10.1182/blood.V93.3.804.403a16_804_815; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tessitore A, 2000, HUM GENET, V107, P568, DOI 10.1007/s004390000429; Toft DJ, 2001, P NATL ACAD SCI USA, V98, P13055, DOI 10.1073/pnas.231364798; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wang Y, 2001, BMC Dev Biol, V1, P9, DOI 10.1186/1471-213X-1-9; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; WYNN TA, 1991, J IMMUNOL, V147, P4384; Yagi T, 2000, GENE DEV, V14, P1169; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yoshida K, 1998, GENOMICS, V49, P458, DOI 10.1006/geno.1998.5271; Zanocco-Marani T, 1999, CANCER RES, V59, P5331; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	125	191	205	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45129	45140		10.1074/jbc.M205165200	http://dx.doi.org/10.1074/jbc.M205165200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12221085	Green Accepted, hybrid			2022-12-25	WOS:000179404800070
J	Park, GT; Lim, SE; Jang, SI; Morasso, MI				Park, GT; Lim, SE; Jang, SI; Morasso, MI			Suprabasin, a novel epidermal differentiation marker and potential cornified envelope precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSION SUBTRACTIVE HYBRIDIZATION; PROTEIN-KINASE-C; GENE-EXPRESSION; CELL-ENVELOPE; CDNA CLONING; CALCIUM; INVOLUCRIN; COMPLEX; KERATINOCYTES; ENVOPLAKIN	The suprabasin gene is a novel gene expressed in mouse and human differentiating keratinocytes. We identified a partial cDNA encoding suprabasin using a suppression subtractive hybridization method between the proliferative basal and differentiating suprabasal populations of the mouse epidermis. A 3' gene-specific probe hybridized to transcripts of 0.7- and 2.2-kb pairs on Northern blots with specific detection in differentiated keratinocytes of stratified epithelia. The mouse gene was mapped to chromosome 7 by fluorescence in situ hybridization. This region is syntenic to human chromosome band 19q13.1, which contained the only region in the data bases with homology to the mouse suprabasin sequence. During embryonic mouse development, suprabasin mRNA was detected at day 15.5, coinciding with epidermal stratification. Suprabasin was detected in the suprabasal layers of the epithelia in the tongue, stomach, and epidermis. Differentiation of cultured primary epidermal keratinocytes with 0.12 mm Ca2+ or 12-O-tetradecanoylphorbol-13-acetate treatment resulted in the induction of suprabasin. The 2.2-kb cDNA transcript encodes a protein of 72 kDa with a predicted isoelectric point of 6.85. The translated sequence has an amino-terminal domain, a central domain composed of repeats rich in glycine and alanine, and a carboxyl-terminal domain. The alternatively spliced 0.7-kb transcript encodes a smaller protein that shares the NH2- and COOH-terminal regions but lacks the repeat domain region. Cross-linking experiments indicate that suprabasin is a substrate for transglutaminase 2 and 3 activity. Altogether, these results indicate that the suprabasin protein potentially plays a role in the process of epidermal differentiation.	NIAMS, Dev Skin Biol Unit, NIH, Bethesda, MD 20892 USA; NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Morasso, MI (corresponding author), NIAMS, Dev Skin Biol Unit, NIH, Bldg 50,Rm 1525, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041124] Funding Source: NIH RePORTER; NIAMS NIH HHS [Z01 AR041124-06] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aho S, 1998, GENOMICS, V48, P242, DOI 10.1006/geno.1997.5188; Champliaud MF, 1998, J BIOL CHEM, V273, P31547, DOI 10.1074/jbc.273.47.31547; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Diatchenko L, 1999, METHOD ENZYMOL, V303, P349; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Djian P, 2000, J CELL BIOL, V151, P381, DOI 10.1083/jcb.151.2.381; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Jarnik M, 2002, J INVEST DERMATOL, V118, P102, DOI 10.1046/j.0022-202x.2001.01661.x; Kalinin A, 2001, J CELL SCI, V114, P3069; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LICHTI U, 1988, CANCER RES, V48, P74; Maatta A, 2000, J BIOL CHEM, V275, P19857, DOI 10.1074/jbc.M001028200; Maatta A, 2001, MOL CELL BIOL, V21, P7047, DOI 10.1128/MCB.21.20.7047-7053.2001; MACKEM S, 1991, DEVELOPMENT, V112, P791; Makino T, 2001, J BIOL CHEM, V276, P47445, DOI 10.1074/jbc.M107512200; Marenholz I, 2001, GENOME RES, V11, P341, DOI 10.1101/gr.114801; Marshall D, 2001, P NATL ACAD SCI USA, V98, P13031, DOI 10.1073/pnas.231489198; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; MORASSO MI, 1994, DEV BIOL, V162, P267, DOI 10.1006/dbio.1994.1084; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; Steinert PM, 1999, J BIOL CHEM, V274, P1657, DOI 10.1074/jbc.274.3.1657; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; VOLZ A, 1993, GENOMICS, V18, P92, DOI 10.1006/geno.1993.1430; Wang A, 2001, GENOMICS, V73, P284, DOI 10.1006/geno.2001.6518; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zhao XP, 1997, GENOMICS, V45, P250, DOI 10.1006/geno.1997.4952	34	62	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45195	45202		10.1074/jbc.M205380200	http://dx.doi.org/10.1074/jbc.M205380200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228223	hybrid, Green Accepted			2022-12-25	WOS:000179404800078
J	Richter, K; Reinstein, J; Buchner, J				Richter, K; Reinstein, J; Buchner, J			N-terminal residues regulate the catalytic efficiency of the Hsp90 ATPase cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BINDING; HYDROLYSIS; CHAPERONE; DIMERIZATION; RECEPTOR; MUTL	Hsp90 is an abundant molecular chaperone involved in a variety of cellular processes ranging from signal transduction to viral replication. The function of Hsp90 has been shown to be dependent on its ability to hydrolyze ATP, and in vitro studies suggest that the dimeric nature of Hsp90 is critical for this activity. ATP binding occurs at the N-terminal domains of the Hsp90 dimer, whereas the main dimerization site resides in the very C-terminal domain. ATP hydrolysis is performed in a series of conformational changes. These include the association of the two N-terminal domains, which has been shown to stimulate the hydrolysis reaction. In this study, we set out to identify regions in the N-terminal domain that are important for this interaction. We show that N-terminal deletion variants of Hsp90 are severely impaired in their ability to hydrolyze ATP. However, nucleotide binding of these constructs is similar to that of the wild type protein. Heterodimers of the Hsp90 deletion mutants with wild type protein showed that the first 24 amino acids play a crucial role during the ATPase reaction, because their deletion abolishes the trans-activation between the two N-terminal domains. We propose that the turnover rate of Hsp90 is decisively controlled by intermolecular interactions between the N-terminal domains.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Technical University of Munich; Max Planck Society	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	johannes.buchner@ch.tum.de	Buchner, Johannes/A-2651-2010; Richter, Klaus/A-2673-2010	Richter, Klaus/0000-0002-8952-9642; Buchner, Johannes/0000-0003-1282-7737				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Brino L, 2000, J BIOL CHEM, V275, P9468, DOI 10.1074/jbc.275.13.9468; Maruya M, 1999, J MOL BIOL, V285, P903, DOI 10.1006/jmbi.1998.2349; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Morishima Y, 2001, BIOCHEMISTRY-US, V40, P1109, DOI 10.1021/bi002399+; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; SMITH DF, 1992, J BIOL CHEM, V267, P1350; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157	19	60	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44905	44910		10.1074/jbc.M208457200	http://dx.doi.org/10.1074/jbc.M208457200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235160	hybrid			2022-12-25	WOS:000179404800041
J	Thion, L; Laurine, E; Erard, M; Burlet-Schiltz, O; Monsarrat, B; Masson, JM; Saves, I				Thion, L; Laurine, E; Erard, M; Burlet-Schiltz, O; Monsarrat, B; Masson, JM; Saves, I			The two-step cleavage activity of PI-TfuI intein endonuclease demonstrated by matrix-assisted laser desorption ionization time-of-flight mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORV RESTRICTION-ENDONUCLEASE; CODED HOMING ENDONUCLEASES; ARCHAEA DNA-POLYMERASE; GROUP-I INTRON; INTERVENING SEQUENCES; PYROCOCCUS-FURIOSUS; SCEI ENDONUCLEASE; IDENTIFICATION; BINDING; GENE	PI-TfuI, an intein spliced from the DNA polymerase of Thermococcus fumicolans, is a highly specific endonuclease, whose cleavage efficiency and specificity depend on both the substrate topology and the divalent cation used as cofactor. An open circular intermediate was observed during the cleavage of supercoiled DNA by PI-TfuI, suggesting a two-step cleavage of the DNA. We characterized this nicked intermediate and, through the development of a method of analysis of the cleavage reaction based on matrix-assisted laser desorption ionization time-of-flight mass spectrometry, we demonstrated that the cleavage of DNA by PI-TfuI indeed results from two cleavage events. One step results in the cleavage of the bottom strand, which is independent of the DNA conformation or choice of the metal ion cofactor. A second step, which is slower, leads to the cleavage of the top strand and governs the specific requirements of PI-TfuI concerning the essential cofactor and the DNA topology. These two steps were shown to be independent in optimal conditions of cleavage. These data give support to the existence of two distinct and independent active sites in the endonuclease domain of the archaeal intein.	CNRS, Inst Pharmacol & Biol Struct, IPBS, F-31077 Toulouse, France; Inst Natl Sci Appl, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite de Toulouse; Institut National des Sciences Appliquees de Toulouse	Saves, I (corresponding author), CNRS, Inst Pharmacol & Biol Struct, IPBS, 205 Route de Narbonne, F-31077 Toulouse, France.			Schiltz, Odile/0000-0002-3606-2356				Chiu NHL, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e31; Christ F, 1999, EMBO J, V18, P6908, DOI 10.1093/emboj/18.24.6908; Dalgaard JZ, 1997, NUCLEIC ACIDS RES, V25, P4626, DOI 10.1093/nar/25.22.4626; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Gimble FS, 1996, J MOL BIOL, V263, P163, DOI 10.1006/jmbi.1996.0567; Gimble FS, 1998, J BIOL CHEM, V273, P30524, DOI 10.1074/jbc.273.46.30524; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; Gross J, 2001, J AM SOC MASS SPECTR, V12, P180, DOI 10.1016/S1044-0305(00)00209-9; Guhan N, 2002, J BIOL CHEM, V277, P16257, DOI 10.1074/jbc.M112365200; He ZN, 1998, J BIOL CHEM, V273, P4607, DOI 10.1074/jbc.273.8.4607; Heath PJ, 1997, NAT STRUCT BIOL, V4, P468, DOI 10.1038/nsb0697-468; HODGES RA, 1992, NUCLEIC ACIDS RES, V20, P6153, DOI 10.1093/nar/20.23.6153; Jurica NS, 1998, MOL CELL, V2, P469, DOI 10.1016/S1097-2765(00)80146-X; Jurinke C, 1998, GENET ANAL-BIOMOL E, V14, P97, DOI 10.1016/S1050-3862(97)10006-7; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4175, DOI 10.1093/nar/27.21.4175; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4167, DOI 10.1093/nar/27.21.4167; Langley GJ, 1999, RAPID COMMUN MASS SP, V13, P1717, DOI 10.1002/(SICI)1097-0231(19990915)13:17<1717::AID-RCM704>3.0.CO;2-R; MUELLER JE, 1993, NUCLEASES, V2, P111; Nishioka M, 1998, NUCLEIC ACIDS RES, V26, P4409, DOI 10.1093/nar/26.19.4409; Nordhoff E, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.20.e86; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; Saves I, 2000, NUCLEIC ACIDS RES, V28, P4391, DOI 10.1093/nar/28.21.4391; Saves I, 2000, J BIOL CHEM, V275, P2335, DOI 10.1074/jbc.275.4.2335; Saves I, 2002, J CLIN MICROBIOL, V40, P943, DOI 10.1128/JCM.40.3.943-950.2002; Saves I, 2001, NUCLEIC ACIDS RES, V29, P4310, DOI 10.1093/nar/29.21.4310; Schottler S, 2000, BIOCHEMISTRY-US, V39, P15895, DOI 10.1021/bi001775n; Stoerker J, 2000, NAT BIOTECHNOL, V18, P1213, DOI 10.1038/81226; Tolson DA, 1998, NUCLEIC ACIDS RES, V26, P446, DOI 10.1093/nar/26.2.446; TURMEL M, 1995, NUCLEIC ACIDS RES, V23, P2519, DOI 10.1093/nar/23.13.2519; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1701, DOI 10.1021/bi952391d; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1712, DOI 10.1021/bi9523926; Wada Y, 1998, J MASS SPECTROM, V33, P187, DOI 10.1002/(SICI)1096-9888(199802)33:2<187::AID-JMS625>3.0.CO;2-A; Wende W, 1996, NUCLEIC ACIDS RES, V24, P4123, DOI 10.1093/nar/24.21.4123	35	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45442	45450		10.1074/jbc.M203507200	http://dx.doi.org/10.1074/jbc.M203507200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239210	hybrid			2022-12-25	WOS:000179404800108
J	Horton, MR; Boodoo, S; Powell, JD				Horton, MR; Boodoo, S; Powell, JD			NF-kappa B activation mediates the cross-talk between extracellular matrix and interferon-gamma (IFN-gamma) leading to enhanced monokine induced by IFN-gamma (MIG) expression in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE GENE-EXPRESSION; HYALURONAN FRAGMENTS; MOUSE MACROPHAGES; MURINE MACROPHAGES; INDUCIBLE PROTEIN-10; ALVEOLAR MACROPHAGES; DEPENDENT MECHANISM; T-LYMPHOCYTES; TRANSCRIPTION; BINDING	In intact tissue, the extracellular matrix (ECM) provides support and helps maintain homeostasis but is considered biologically inert. In the setting of inflammation, not only is the ECM the target of inflammation, but its breakdown products modulate the magnitude and quality of an immune response. Fragments of the ECM component hyaluronan (HA) induce macrophage expression of chemokines, cytokines, and growth factors as well greatly enhance IFN-gamma-induced MIG expression. In this report, we demonstrate that the synergistic induction of MIG by HA and IFN-gamma occurs at the level of transcription via NF-kappaB. Using electrophoretic mobility shift assays and reporter assays, we have identified two NF-kappaB sites proximal to the IFN-gamma-responsive element-1 (gammaRE-1) that mediate this effect. Interestingly, our experiments also revealed a critical role for NF-kappaB in mediating IFN-gamma-induced MIG expression independent of HA. These data emphasize the ability of "degraded self" to activate/modify immune responses through the NF-kappaB pathway.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University	Horton, MR (corresponding author), 600 N Wolfe St,Jefferson Bldg B1-170, Baltimore, MD 21287 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003993] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL03993] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amichay D, 1996, J IMMUNOL, V157, P4511; An HZ, 2002, IMMUNOLOGY, V106, P38, DOI 10.1046/j.1365-2567.2002.01401.x; Asensio VC, 1997, J VIROL, V71, P7832, DOI 10.1128/JVI.71.10.7832-7840.1997; BALAZS EA, 1967, ARTHRITIS RHEUM, V10, P357, DOI 10.1002/art.1780100407; BJERMER L, 1989, THORAX, V44, P126, DOI 10.1136/thx.44.2.126; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; Deb A, 2001, J IMMUNOL, V166, P6170, DOI 10.4049/jimmunol.166.10.6170; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GAZZINIELLI RT, 1992, J IMMUNOL, V148, P1752; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; GUYER NB, 1995, J IMMUNOL, V155, P3472; HANCE AJ, 1975, AM REV RESPIR DIS, V112, P657; HIDENORI K, 1996, CELL, V87, P1069; HodgeDufour J, 1997, J IMMUNOL, V159, P2492; Horton MR, 2000, AM J PHYSIOL-LUNG C, V279, pL707, DOI 10.1152/ajplung.2000.279.4.L707; Horton MR, 1999, J IMMUNOL, V162, P4171; Horton MR, 1998, J BIOL CHEM, V273, P35088, DOI 10.1074/jbc.273.52.35088; Horton MR, 1998, J IMMUNOL, V160, P3023; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; LASKIN DL, 1994, AM J RESP CELL MOL, V10, P58, DOI 10.1165/ajrcmb.10.1.8292381; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1995, ANN RHEUM DIS, V54, P429, DOI 10.1136/ard.54.5.429; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; LIAO F, 1995, J EXP MED, V182, P1301, DOI 10.1084/jem.182.5.1301; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Luo GY, 2000, MOL ENDOCRINOL, V14, P114, DOI 10.1210/me.14.1.114; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MBAWUIKE IN, 1989, J LEUKOCYTE BIOL, V46, P119, DOI 10.1002/jlb.46.2.119; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Michalopoulos I, 1999, NUCLEIC ACIDS RES, V27, P503, DOI 10.1093/nar/27.2.503; Narumi S, 1997, J IMMUNOL, V158, P5536; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Nguyen VT, 2002, J BIOL CHEM, V277, P13796, DOI 10.1074/jbc.M111906200; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; Oertli B, 1998, J IMMUNOL, V161, P3431; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; PICARD V, 1999, PCR CLONING PROTOCOL, V67, P183; Powell JD, 1999, J IMMUNOL, V163, P6631; RENNARD SI, 1981, P NATL ACAD SCI-BIOL, V78, P7147, DOI 10.1073/pnas.78.11.7147; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Shenkar R, 2001, AM J PHYSIOL-LUNG C, V281, pL418, DOI 10.1152/ajplung.2001.281.2.L418; STRIETER RM, 1995, SHOCK, V4, P155, DOI 10.1097/00024382-199509000-00001; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; VANGURI P, 1990, J BIOL CHEM, V265, P15049; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914	54	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43757	43762		10.1074/jbc.M206007200	http://dx.doi.org/10.1074/jbc.M206007200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226082	hybrid			2022-12-25	WOS:000179272000030
J	Piiper, A; Dikic, I; Lutz, MP; Leser, J; Kronenberger, B; Elez, R; Cramer, H; Muller-Esterl, W; Zeuzem, S				Piiper, A; Dikic, I; Lutz, MP; Leser, J; Kronenberger, B; Elez, R; Cramer, H; Muller-Esterl, W; Zeuzem, S			Cyclic AMP induces transactivation of the receptors for epidermal growth factor and nerve growth factor, thereby modulating activation of MAP kinase, Akt, and neurite outgrowth in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; NUCLEOTIDE-EXCHANGE FACTOR; EGF RECEPTOR; B-RAF; NEURONAL DIFFERENTIATION; DEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; TRK RECEPTORS; PHOSPHATIDYLINOSITOL 3-KINASE; NEUROTROPHIN RECEPTORS	In PC12 cells, a well studied model for neuronal differentiation, an elevation in the intracellular cAMP level increases cell survival, stimulates neurite outgrowth, and causes activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2). Here we show that an increase in the intracellular cAMP concentration induces tyrosine phosphorylation of two receptor tyrosine kinases, i.e. the epidermal growth factor (EGF) receptor and the high affinity receptor for nerve growth factor (NGF), also termed TrkA. cAMP-induced tyrosine phosphorylation of the EGF receptor is rapid and correlates with ERK1/2 activation. It occurs also in Panc-1, but not in human mesangial cells. cAMP-induced tyrosine phosphorylation of the NGF receptor is slower and correlates with Akt activation. Inhibition of EGF receptor tyrosine phosphorylation, but not of the NGF receptor, reduces cAMP-induced neurite outgrowth. Expression of dominant-negative Akt does not abolish cAMP-induced survival in serum-free media, but. increases cAMP-induced ERK1/2 activation and neurite outgrowth. Together, our results demonstrate that cAMP induces dual signaling in PC12 cells: transactivation of the EGF receptor triggering the ERK1/2 pathway and neurite outgrowth; and transactivation of the NGF receptor promoting Akt activation and thereby modulating ERK1/2 activation and neurite outgrowth.	Univ Frankfurt, Dept Internal Med, D-60590 Frankfurt, Germany; Univ Frankfurt, Inst Biochem 2, D-60590 Frankfurt, Germany; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Univ Ulm, Dept Internal Med 1, D-89070 Ulm, Germany; Aventis Pharma Deutschland GmbH, D-65812 Bad Soden, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Ludwig Institute for Cancer Research; Ulm University; Sanofi-Aventis	Piiper, A (corresponding author), Univ Frankfurt, Dept Med 2, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Zeuzem, Stefan/AAE-7435-2019; Dikic, Ivan/O-4650-2015	Dikic, Ivan/0000-0001-8156-9511				ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bang OS, 2001, J CELL SCI, V114, P81; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Crowder RJ, 1999, J NEUROCHEM, V73, P466, DOI 10.1046/j.1471-4159.1999.0730466.x; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Filippa N, 1999, MOL CELL BIOL, V19, P4989; FRODIN M, 1994, J BIOL CHEM, V269, P6207; Fujita T, 2002, J BIOL CHEM, V277, P22191, DOI 10.1074/jbc.M110364200; Guan KL, 2000, J BIOL CHEM, V275, P27354; Gutkind J. S., 2000, SCI STKE, pre1, DOI DOI 10.1126/STKE.2000.40.RE1; Hanson MG, 1998, J NEUROSCI, V18, P7361; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HATA Y, 1991, J BIOL CHEM, V266, P6571; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; Huang NK, 2001, J BIOL CHEM, V276, P13838, DOI 10.1074/jbc.M008589200; Iida N, 2001, J NEUROSCI, V21, P6459, DOI 10.1523/JNEUROSCI.21-17-06459.2001; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; Ivankovic-Dikic I, 2000, NAT CELL BIOL, V2, P574, DOI 10.1038/35023515; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Klinger M, 2002, J BIOL CHEM, V277, P32490, DOI 10.1074/jbc.M200556200; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Lee FS, 2002, J BIOL CHEM, V277, P9096, DOI 10.1074/jbc.M107421200; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Leserer M, 2000, IUBMB LIFE, V49, P405; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MacInnis BL, 2002, SCIENCE, V295, P1536, DOI 10.1126/science.1064913; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Mondorf UF, 2000, FEBS LETT, V472, P129, DOI 10.1016/S0014-5793(00)01433-2; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; NAKAFUKU M, 1993, FEBS LETT, V315, P227, DOI 10.1016/0014-5793(93)81169-Z; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Okada T, 1999, MOL CELL BIOL, V19, P6057; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Patterson SL, 2001, NEURON, V32, P123, DOI 10.1016/S0896-6273(01)00443-3; Piiper A, 2000, MOL PHARMACOL, V58, P608, DOI 10.1124/mol.58.3.608; Piiper A, 1997, AM J PHYSIOL-GASTR L, V272, pG1276, DOI 10.1152/ajpgi.1997.272.5.G1276; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Wei J, 1998, NEURON, V21, P495, DOI 10.1016/S0896-6273(00)80561-9; WU J, 1993, SCIENCE, V262, P1066; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	78	79	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43623	43630		10.1074/jbc.M203926200	http://dx.doi.org/10.1074/jbc.M203926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12218049	hybrid			2022-12-25	WOS:000179272000013
J	Sanchez-Elsner, T; Botella, LM; Velasco, B; Langa, C; Bernabeu, C				Sanchez-Elsner, T; Botella, LM; Velasco, B; Langa, C; Bernabeu, C			Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY HEMORRHAGIC TELANGIECTASIA; LACTATE-DEHYDROGENASE-A; VASCULAR ENDOTHELIAL-CELLS; BINDING-PROTEIN ENDOGLIN; SMOOTH-MUSCLE CELLS; HUMAN SOLID TUMORS; TGF-BETA; INDUCIBLE FACTOR-1; MONOCLONAL-ANTIBODIES; CELLULAR-RESPONSES	Endoglin is a transforming growth factor-beta (TGF-beta) co-receptor expressed mainly on endothelial cells and involved in cardiovascular development, angiogenesis, and vascular remodeling. This is illustrated by the fact that mutations in the endoglin gene give rise to hereditary hemorrhagic telangiectasia type 1, a dominant vascular disease with clinical manifestations that originate by a mechanism of haploinsufficiency. Thus, studies on the regulated expression of endoglin are crucial to devising therapeutic strategies for hereditary hemorrhagic telangiectasia type 1. Endoglin is highly expressed in the neovasculature associated with hypoxia such as ischemic tissues and tumors, but the molecular mechanism of this up-regulation is unknown. Here, we have investigated the possible regulation of endoglin expression by hypoxia. Surface protein, transcript, and promoter activity levels of endoglin were found to be up-regulated by hypoxia, indicating that the regulation takes place at the transcriptional level. A hypoxia-responsive element downstream of the main transcription start site of the endoglin gene was functionally characterized. Whereas hypoxia alone moderately stimulated endoglin transcription, addition of TGF-beta under bypoxic conditions resulted in transcriptional cooperation between both signaling pathways, leading to marked stimulation of endoglin expression. Because basal endoglin transcription is sustained by Sp1, and TGF-beta and hypoxia signaling pathways are mediated by Smad proteins and hypoxia-inducible factor-1 (HIF-1), respectively, the involvement of these transcription factors was analyzed. Functional and co-immunoprecipitation experiments demonstrated the existence of a multiprotein complex (Sp1.Smad3.HIF-1) on the endoglin promoter, mediating the cooperation between the hypoxia and TGF-beta pathways. Within this multiprotein complex, Smad3 appears to function not only as a coactivator factor, but also as an adaptor between HIF-1 and Sp1. We propose that basal endoglin transcription (highly dependent on Sp1) may switch from a constitutive to an inducible state through Sp1 interaction with HIF-1 and Smad transcription factors, induced by hypoxia and TGF-beta, respectively.	CSIC, Ctr Invest Biol, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Bernabeu, C (corresponding author), CSIC, Ctr Invest Biol, Ramiro de Maeztu 9, E-28040 Madrid, Spain.	bernabeu.c@cib.csic.es	Botella, Luisa M/L-1392-2014; Bernabeu, Carmelo/P-4662-2019; Bernabeu, Carmelo/L-3226-2014	Bernabeu, Carmelo/0000-0002-1563-6162; Bernabeu, Carmelo/0000-0002-1563-6162; Sanchez-Elsner, Tilman/0000-0003-1915-2410				Adam PJ, 1998, BIOCHEM BIOPH RES CO, V247, P33, DOI 10.1006/bbrc.1998.8734; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Attisano L, 2001, GENOME BIOL, V2; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bodey B, 1998, ANTICANCER RES, V18, P3621; Botella LM, 2001, J BIOL CHEM, V276, P34486, DOI 10.1074/jbc.M011611200; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; Caniggia I, 2000, J CLIN INVEST, V105, P577, DOI 10.1172/JCI8316; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Conley BA, 2000, ATHEROSCLEROSIS, V153, P323, DOI 10.1016/S0021-9150(00)00422-6; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Das P, 1999, GENES CELLS, V4, P123, DOI 10.1046/j.1365-2443.1999.00244.x; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; FALANGA V, 1991, J INVEST DERMATOL, V97, P634, DOI 10.1111/1523-1747.ep12483126; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; FERNANDEZRUIZ E, 1993, CYTOGENET CELL GENET, V64, P204, DOI 10.1159/000133576; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gallione CJ, 1998, HUM MUTAT, V11, P286, DOI 10.1002/(SICI)1098-1004(1998)11:4<286::AID-HUMU6>3.0.CO;2-B; Gleadle JM, 1998, MOL MED TODAY, V4, P122, DOI 10.1016/S1357-4310(97)01198-2; GOUGOS A, 1988, J IMMUNOL, V141, P1925; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Kumar S, 1999, CANCER RES, V59, P856; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; LETARTE M, 1997, LEUKOCYTE TYPING, V6, P703; Li CG, 2000, ATHEROSCLEROSIS, V152, P249, DOI 10.1016/S0021-9150(99)00476-1; Li CG, 2001, MICROSC RES TECHNIQ, V52, P437, DOI 10.1002/1097-0029(20010215)52:4<437::AID-JEMT1029>3.0.CO;2-G; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; MA X, 2000, ARTERIOSCLER THROMB, P2546; MARCHUK DA, 2001, METABOLIC MOL BASES, V4, P5419; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuno F, 1999, CLIN CANCER RES, V5, P371; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Miller DW, 1999, INT J CANCER, V81, P568, DOI 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.3.CO;2-O; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Paquet ME, 2001, HUM MOL GENET, V10, P1347, DOI 10.1093/hmg/10.13.1347; Pece-Barbara N, 1999, HUM MOL GENET, V8, P2171, DOI 10.1093/hmg/8.12.2171; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Pichuantes S, 1997, TISSUE ANTIGENS, V50, P265, DOI 10.1111/j.1399-0039.1997.tb02870.x; Qu R, 1998, CELL TISSUE RES, V292, P333, DOI 10.1007/s004410051064; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Rius C, 1998, BLOOD, V92, P4677; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Semenza GL, 2000, GENE DEV, V14, P1983; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shovlin CL, 1997, AM J HUM GENET, V61, P68, DOI 10.1086/513906; Shovlin CL, 1999, THORAX, V54, P714, DOI 10.1136/thx.54.8.714; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Tabata M, 1999, INT J CANCER, V82, P737, DOI 10.1002/(SICI)1097-0215(19990827)82:5<737::AID-IJC18>3.3.CO;2-#; Takahashi N, 2001, CANCER RES, V61, P7846; Vincent EB, 1998, DEV DYNAM, V213, P237, DOI 10.1002/(SICI)1097-0177(199811)213:3<237::AID-AJA1>3.0.CO;2-M; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	79	257	270	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43799	43808		10.1074/jbc.M207160200	http://dx.doi.org/10.1074/jbc.M207160200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228247	Green Published, hybrid			2022-12-25	WOS:000179272000036
J	Arthur, WT; Ellerbroek, SM; Der, CJ; Burridge, K; Wennerberg, K				Arthur, WT; Ellerbroek, SM; Der, CJ; Burridge, K; Wennerberg, K			XPLN, a guanine nucleotide exchange factor for RhoA and RhoB, but not RhoC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; BINDING PROTEIN-RHO; MEMBRANE PROTRUSION; RAS TRANSFORMATION; GTPASES; FAMILY; ACTIVATION; GROWTH; CDC42; CELLS	Rho proteins cycle between an inactive, GDP-bound state and an active, GTP-bound state. Activation of these GTPases is mediated by guanine nucleotide exchange factors (GEFs), which promote GDP to GTP exchange. In this study we have characterized XPLN, a Rho family GEF. Like other Rho GEFs, XPLN contains a tandem Dbl homology and pleckstrin homology domain topography, but lacks homology with other known functional domains or motifs. XPLN protein is expressed in the brain, skeletal muscle, heart, kidney, platelets, and macrophage and neuronal cell lines. In vitro, XPLN stimulates guanine nucleotide exchange on RhoA and RhoB, but not RhoC, RhoG, Rac1, or Cdc42. Consistent with these data, XPLN preferentially associates with RhoA and RhoB. The specificity of XPLN for RhoA and RhoB, but not RhoC, is surprising given that they share over 85% sequence identity. We determined that the inability of XPLN to exchange RhoC is mediated by isoleucine 43 in RhoC, a position occupied by valine in RhoA and RhoB. When expressed in cells, XPLN activates RhoA and RhoB, but not RhoC, and stimulates the assembly of stress fibers and focal adhesions in a Rho kinase-dependent manner. We also found that XPLN possesses transforming activity, as determined by focus formation assays. In conclusion, here we describe a Rho family GEF that can discriminate between the closely related RhoA, Rholl, and RhoC, possibly giving insight to the divergent functions of these three proteins.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Arthur, WT (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, CB 7295, Chapel Hill, NC 27599 USA.		Wennerberg, Krister/AFM-0539-2022; Wennerberg, Krister/AAH-2919-2022	Wennerberg, Krister/0000-0002-1352-4220; Wennerberg, Krister/0000-0002-1352-4220; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA092240, R01CA063071] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER; NCI NIH HHS [CA63071, CA92240] Funding Source: Medline; NHLBI NIH HHS [HL45100] Funding Source: Medline; NIGMS NIH HHS [GM29860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blomquist A, 2000, BIOCHEM J, V352, P319, DOI 10.1042/0264-6021:3520319; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Chan AML, 1996, ONCOGENE, V12, P1259; CHEN SY, 1994, ONCOGENE, V9, P2691; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Gamblin SJ, 1998, CURR OPIN STRUC BIOL, V8, P195, DOI 10.1016/S0959-440X(98)80038-9; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kleer CG, 2002, AM J PATHOL, V160, P579, DOI 10.1016/S0002-9440(10)64877-8; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rumenapp U, 1999, FEBS LETT, V459, P313, DOI 10.1016/S0014-5793(99)01270-3; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schmidt A, 2002, J BIOL CHEM, V277, P14581, DOI 10.1074/jbc.M111108200; Schoenwaelder SM, 2002, J BIOL CHEM, V277, P14738, DOI 10.1074/jbc.M200661200; Shen X, 2001, J BIOL CHEM, V276, P15362, DOI 10.1074/jbc.M009534200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Thiesen S, 2000, BIOCHEM BIOPH RES CO, V273, P364, DOI 10.1006/bbrc.2000.2925; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van Golen KL, 2000, CANCER RES, V60, P5832; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056	46	99	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42964	42972		10.1074/jbc.M207401200	http://dx.doi.org/10.1074/jbc.M207401200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12221096	hybrid			2022-12-25	WOS:000179081200071
J	Martin, D; Salinas, M; Fujita, N; Tsuruo, T; Cuadrado, A				Martin, D; Salinas, M; Fujita, N; Tsuruo, T; Cuadrado, A			Ceramide and reactive oxygen species generated by H2O2 induce caspase-3-independent degradation of Akt/protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNESIUM-DEPENDENT SPHINGOMYELINASE; BREAST-CARCINOMA CELLS; NEUTRAL SPHINGOMYELINASE; PROTEIN-KINASE; PC12 CELLS; IONIZING-RADIATION; INDUCED APOPTOSIS; HEAT-SHOCK; AKT KINASE; DEATH	This study was designed to elucidate the mechanisms leading to down-regulation of the Akt/protein kinase B (PKB) survival pathway during H2O2-induced cell death. H2O2 produced early activation of Akt/PKB and also DNA damage that was followed by stabilization of p53 levels, formation of reactive oxygen species (ROS), and generation of ceramide through activation of a glutathione-sensitive neutral sphingomyelinase. These events correlated with long term dephosphorylation and subsequent degradation of Akt. A membrane-targeted active Akt version attenuated apoptosis but not necrosis induced by H2O2 and was more resistant to dephosphorylation and proteolysis induced by apoptotic concentrations of H2O2. Proteolysis of Akt was prevented by exogenous addition of glutathione, indicating a role of ROS and ceramide in Akt degradation. However, Akt was degraded similarly in cells transfected with wild type and dominant negative p53 mutant, indicating that degradation of Akt under oxidative injury may be p53-independent. Specific inhibitors of caspase groups I and III prevented proteolysis of Akt/PKB and poly(ADP-ribose) polymerase in cells submitted to apoptotic but not necrotic H2O2 concentrations. Surprisingly, in caspase-3-deficient MCF-7 cells Akt was more sensitive to H2O2-induced degradation than the caspase-3 substrate poly(ADP-ribose) polymerase. Moreover, the Akt/PKB double mutant Akt(D108A,D119A), which is not cleaved by caspase-3, and a triple mutant (D453A,D455A,D456A), which lacks the consensus sequence for caspase-3 cleavage, were also degraded in H2O2-treated cells. Our results suggest that strong oxidants generate intracellular ROS and ceramide which in term lead to down-regulation of Akt by dephosphorylation and caspase-3-independent proteolysis.	Univ Autonoma Madrid, Dept Bioquim, Fac Med, Madrid 28029, Spain; Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Fac Med, Madrid 28029, Spain; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1138654, Japan	Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Tokyo	Cuadrado, A (corresponding author), Univ Autonoma Madrid, Dept Bioquim, Fac Med, Arzobispo Morcillo 4, Madrid 28029, Spain.	antonio.cuadrado@uam.es	Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264; Cuadrado, Antonio/0000-0002-3444-9012; Cuadrado, Antonio/0000-0002-4039-7140				Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1; Andrieu-Abadie N, 2001, FREE RADICAL BIO MED, V31, P717, DOI 10.1016/S0891-5849(01)00655-4; Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bezombes C, 2001, FASEB J, V15, P1583, DOI 10.1096/fj.00-0787fje; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Collins AR, 1997, MUTAT RES-FUND MOL M, V375, P183, DOI 10.1016/S0027-5107(97)00013-4; Dbaibo GS, 2001, FEBS LETT, V503, P7, DOI 10.1016/S0014-5793(01)02625-4; Dobrowsky RT, 2001, METHOD CELL BIOL, V66, P135; Fensome AC, 2000, J BIOL CHEM, V275, P1128, DOI 10.1074/jbc.275.2.1128; FRIDOVICH I, 1997, ANN NY ACAD SCI, V893, P13; Goldkorn T, 1998, J CELL SCI, V111, P3209; Goldshmit Y, 2001, J BIOL CHEM, V276, P46379, DOI 10.1074/jbc.M105637200; Gouaze V, 2001, MOL PHARMACOL, V60, P488; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hasper HJ, 2000, CYTOMETRY, V40, P167, DOI 10.1002/(SICI)1097-0320(20000601)40:2<167::AID-CYTO11>3.3.CO;2-T; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 2001, ONCOGENE, V20, P5043, DOI 10.1038/sj.onc.1204659; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Martin D, 2001, J NEUROCHEM, V78, P1000, DOI 10.1046/j.1471-4159.2001.00472.x; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Poot M, 1999, CYTOMETRY, V36, P359, DOI 10.1002/(SICI)1097-0320(19990801)36:4<359::AID-CYTO12>3.0.CO;2-V; Rimpler MM, 1999, BIOCHEM J, V340, P291, DOI 10.1042/0264-6021:3400291; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; Salinas M, 2001, MOL CELL NEUROSCI, V17, P67, DOI 10.1006/mcne.2000.0921; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sawada M, 2001, ONCOGENE, V20, P1368, DOI 10.1038/sj.onc.1204207; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yoshimura S, 1999, J NEUROCHEM, V73, P675, DOI 10.1046/j.1471-4159.1999.0730675.x; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	53	159	164	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42943	42952		10.1074/jbc.M201070200	http://dx.doi.org/10.1074/jbc.M201070200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12213802	hybrid			2022-12-25	WOS:000179081200068
J	Ranganathan, G; Phan, D; Pokrovskaya, ID; McEwen, JE; Li, CL; Kern, PA				Ranganathan, G; Phan, D; Pokrovskaya, ID; McEwen, JE; Li, CL; Kern, PA			The translational regulation of lipoprotein lipase by epinephrine involves an RNA binding complex including the catalytic subunit of protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; ISOLATED RAT ADIPOCYTES; HUMAN ADIPOSE-TISSUE; MESSENGER-RNA; 3'-UNTRANSLATED REGION; CYCLIC-AMP; ANCHOR PROTEIN; GENE-EXPRESSION; RICH DOMAIN; GERM-CELLS	The balance of lipid flux in adipocytes is controlled by the opposing actions of lipolysis and lipogenesis, which are controlled primarily by hormone-sensitive lipase and lipoprotein lipase (LPL), respectively. Catecholamines stimulate adipocyte lipolysis through reversible phosphorylation of hormone-sensitive lipase, and simultaneously inhibit LPL activity. However, LPL regulation is complex and previous studies have described translational regulation of LPL in response to catecholamines because of an RNA-binding protein that interacts with the W-untranslated region of LPL mRNA. In this study, we identified several protein components of an LPL RNA binding complex. Using an LPL RNA affinity column, we identified two of the RNA-binding proteins as the catalytic (C) subunit of cAMP-dependent protein kinase (PKA), and A kinase anchoring protein (AKAP) 121/149, one of the PKA anchoring proteins, which has known RNA binding activity. To determine whether the C subunit was involved in LPL translation inhibition, the C subunit was depleted from the cytoplasmic extract of epinephrine-stimulated adipocytes by immunoprecipitation. This resulted in the loss of LPL translation inhibition activity of the extract, along with decreased RNA binding activity in a gel shift assay. To demonstrate the importance of the AKAPs, inhibition of PKA-AKAP binding with a peptide competitor (HT31) prevented epinephrine-mediated inhibition of LPL translation. C subunit kinase activity was necessary for LPL RNA binding and translation inhibition, suggesting that the phosphorylation of AKAP121/149 or other proteins was an important part of RNA binding complex formation. The hormonal activation of PKA results in the reversible phosphorylation of hormone-sensitive lipase, which is the primary mediator of adipocyte lipolysis. These studies demonstrate a dual role for PKA to simultaneously inhibit LPL-mediated lipogenesis through inhibition of LPL translation.	Univ Arkansas Med Sci, Cent Arkansas vet Healthcare Syst, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Med, Div Endocrinol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Kern, PA (corresponding author), Univ Arkansas Med Sci, Cent Arkansas vet Healthcare Syst, 4300 W 7th St, Little Rock, AR 72205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK039176, R37DK039176, R01DK039176] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39176] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHLEY CT, 1996, SCIENCE, V262, P563; BILEZIKIAN JP, 1983, ENDOCR REV, V4, P378, DOI 10.1210/edrv-4-4-378; CARR DW, 1992, J BIOL CHEM, V267, P13376; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIST B, 1991, BIOCHEM BIOPH RES CO, V177, P1273, DOI 10.1016/0006-291X(91)90679-2; Diviani D, 2001, J CELL SCI, V114, P1431; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; Feliciello A, 1998, J BIOL CHEM, V273, P23361, DOI 10.1074/jbc.273.36.23361; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Furusawa M, 2001, J BIOL CHEM, V276, P36647, DOI 10.1074/jbc.M103885200; GOERS JWF, 1987, ANAL BIOCHEM, V166, P27, DOI 10.1016/0003-2697(87)90541-0; Goldberg IJ, 1996, J LIPID RES, V37, P693; HAUSKEN ZE, 1997, PROTEIN TARGETING PR, P47; HOD Y, 1988, J BIOL CHEM, V263, P7747; Holm C, 1997, METHOD ENZYMOL, V286, P45; KELLEY DE, 1994, J CLIN INVEST, V94, P2349, DOI 10.1172/JCI117600; Kern PA, 1996, J LIPID RES, V37, P2332; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; McKnight GS, 1998, RECENT PROG HORM RES, V53, P139; ONG JM, 1989, J CLIN INVEST, V84, P305, DOI 10.1172/JCI114155; ONG JM, 1988, J BIOL CHEM, V263, P12933; ONG JM, 1989, J BIOL CHEM, V264, P3177; ONG JM, 1992, ENDOCRINOLOGY, V130, P2310, DOI 10.1210/en.130.4.2310; ONG JM, 1992, MOL ENDOCRINOL, V6, P61, DOI 10.1210/me.6.1.61; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; PENG H, 1995, J BIOL CHEM, V270, P23996, DOI 10.1074/jbc.270.41.23996; Ramsay TG, 1996, ENDOCRIN METAB CLIN, V25, P847, DOI 10.1016/S0889-8529(05)70358-3; Ranganathan G, 1997, J BIOL CHEM, V272, P2515; Ranganathan G, 1999, J BIOL CHEM, V274, P9122, DOI 10.1074/jbc.274.13.9122; Ranganathan G, 2000, J BIOL CHEM, V275, P40986, DOI 10.1074/jbc.M008775200; SIMSOLO RB, 1992, J LIPID RES, V33, P89; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; TAVANGAR K, 1992, J CLIN INVEST, V90, P1672, DOI 10.1172/JCI116039; Tian D, 1998, J BIOL CHEM, V273, P28454, DOI 10.1074/jbc.273.43.28454; Trendelenburg G, 1996, BIOCHEM BIOPH RES CO, V225, P313, DOI 10.1006/bbrc.1996.1172; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; Xie GF, 2001, AM J PHYSIOL-GASTR L, V281, pG1051, DOI 10.1152/ajpgi.2001.281.4.G1051; YUKHT A, 1995, J CLIN INVEST, V96, P2438, DOI 10.1172/JCI118301	47	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43281	43287		10.1074/jbc.M202560200	http://dx.doi.org/10.1074/jbc.M202560200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12218046	hybrid			2022-12-25	WOS:000179081200111
J	Rodriguez-Cuenca, S; Pujol, E; Justo, R; Frontera, M; Oliver, J; Gianotti, M; Roca, P				Rodriguez-Cuenca, S; Pujol, E; Justo, R; Frontera, M; Oliver, J; Gianotti, M; Roca, P			Sex-dependent thermogenesis, differences in mitochondrial morphology and function, and adrenergic response in brown adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN THERMOGENIN; FAT-CELLS; BETA-ADRENOCEPTOR; BINDING-SITES; MESSENGER-RNA; RATS; EXPRESSION; LIPOLYSIS; RECEPTOR; TESTOSTERONE	Gender-related differences in brown adipose tissue (BAT) thermogenesis of 110-day-old rats were studied by determining the morphological and functional features of BAT. The adrenergic control was assessed by studying the levels of beta(3)- and alpha(2A)-adrenergic receptors (AR) and by determining the lipolytic response to norepinephrine (beta(1)-,beta(2)-beta(3)-, and alpha(2)-AR agonist), isoprenaline (beta(1)-, beta(2)-, and beta(3)-AR agonist), and CGP12177A (selective partial beta(3)-AR agonist but beta(1)- and beta(2)-AR antagonist) together with post-receptor agents, forskolin and dibutyryl cyclic AMP. The female rats that had greater oxygen consumption showed higher UCP1 content, a higher multilocular arrangement, and both longer cristae and higher cristae dense mitochondria in BAT indicating heightened thermogenic capacity and activity; this picture is accompanied by a more sensitive beta(3)-AR to norepinephrine signal (EC50 10-fold lower for CGP12177A) and a lower expression of alpha(2A)-AR than male rats. Taken together, our results support the idea that the BAT hormonal environment could be involved in the control of different elements of lipolytic and thermogenic adrenergic pathways. Gender dimorphism is both at receptor (changing a2A-AR density and beta(3)-AR affinity) and post-receptor (modulating the links involved in the adrenergic signal transduction) levels. These changes in adrenergic control could be responsible, at least in part, both for the important mitochondrial recruitment differences and functional and morphological features of BAT in female rats under usual rodent housing temperatures.	Univ Illes Balears, Dept Biol Fonamental & Ciencias Salut, E-07071 Palma de Mallorca, Spain	Universitat de les Illes Balears	Roca, P (corresponding author), Univ Illes Balears, Dept Biol Fonamental & Ciencias Salut, Cra Valldemossa Km 7-5, E-07071 Palma de Mallorca, Spain.	pilar.roca@uib.es	Rodriguez-Cuenca, Sergio/C-5901-2011; Gianotti, Magdalena/H-7725-2015; Roca, Pilar/L-7578-2014; Oliver, Jordi/H-8073-2013	Gianotti, Magdalena/0000-0002-5225-9079; Roca, Pilar/0000-0003-3878-5424; Oliver, Jordi/0000-0002-5702-7306; Frontera Borrueco, Marga/0000-0001-8670-9106				Abelenda M, 1999, EUR J ENDOCRINOL, V141, P630, DOI 10.1530/eje.0.1410630; Atgie C, 1997, AM J PHYSIOL-CELL PH, V273, pC1136, DOI 10.1152/ajpcell.1997.273.4.C1136; Bengtsson T, 2000, BIOCHEM J, V347, P643, DOI 10.1042/0264-6021:3470643; BOULOUMIE A, 1994, EUR J PHARM-MOLEC PH, V269, P95, DOI 10.1016/0922-4106(94)90031-0; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; CERVANTESOLIVIER P, 1985, BIOCHEMISTRY-US, V24, P3765, DOI 10.1021/bi00335a052; Chaudhry A, 1999, AM J PHYSIOL-REG I, V277, pR147, DOI 10.1152/ajpregu.1999.277.1.R147; Cinti S, 2001, P NUTR SOC, V60, P319, DOI 10.1079/PNS200192; DEPERGOLA G, 1990, ACTA ENDOCRINOL-COP, V123, P61, DOI 10.1530/acta.0.1230061; FOLCH J, 1957, J BIOL CHEM, V226, P497; Germack R, 1997, BRIT J PHARMACOL, V120, P201, DOI 10.1038/sj.bjp.0700885; GHADIALLY F.N., 1988, ULTRASTRUCT PATHOL, P194; GIUDICELLI Y, 1993, PROSTAG LEUKOTR ESS, V48, P91, DOI 10.1016/0952-3278(93)90015-O; Gomez-Ambrosi J, 2001, INT J MOL MED, V8, P103; HERRON D, 1990, FEBS LETT, V268, P296, DOI 10.1016/0014-5793(90)81031-I; HIMMSHAGEN J, 1991, FRONT NEUROENDOCRIN, V12, P38; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; LACASA D, 1991, ENDOCRINOLOGY, V128, P747, DOI 10.1210/endo-128-2-747; LACASA D, 1994, BBA-MOL CELL RES, V1224, P527, DOI 10.1016/0167-4889(94)90290-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafontan M., 1997, Human Reproduction (Oxford), V12, P6; LAFONTAN M, 1995, ENDOCR REV, V16, P716, DOI 10.1210/er.16.6.716; Lanni A, 1996, INT J BIOCHEM CELL B, V28, P337, DOI 10.1016/1357-2725(95)00137-9; Llado I, 2002, OBES RES, V10, P296, DOI 10.1038/oby.2002.41; LONCAR D, 1988, J ULTRA MOL STRUCT R, V101, P199, DOI 10.1016/0889-1605(88)90010-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malo A, 2001, EUR J ENDOCRINOL, V145, P87, DOI 10.1530/eje.0.1450087; Matthias A, 2000, J BIOL CHEM, V275, P25073, DOI 10.1074/jbc.M000547200; MAURIEGE P, 1987, EUR J CLIN INVEST, V17, P156, DOI 10.1111/j.1365-2362.1987.tb02395.x; MCBENNET SM, 1993, OBESITY EUROPE, P399; McDonald RB, 1999, J BIOENERG BIOMEMBR, V31, P507, DOI 10.1023/A:1005404708710; MCDONALD RB, 1993, P SOC EXP BIOL MED, V204, P117; MORRONI M, 1995, INT J OBESITY, V19, P126; NAVA MP, 1994, PFLUG ARCH EUR J PHY, V426, P40, DOI 10.1007/BF00374668; NECHAD M, 1987, AM J PHYSIOL, V253, pC889, DOI 10.1152/ajpcell.1987.253.6.C889; Nedergaard J, 2001, BBA-BIOENERGETICS, V1504, P82, DOI 10.1016/S0005-2728(00)00247-4; ODONNELL ME, 1982, AM J PHYSIOL, V242, pC46, DOI 10.1152/ajpcell.1982.242.1.C46; PECQUERY R, 1995, BIOCHEM BIOPH RES CO, V206, P112, DOI 10.1006/bbrc.1995.1016; PECQUERY R, 1990, ENDOCRINOLOGY, V126, P241, DOI 10.1210/endo-126-1-241; Pedersen SB, 2001, BIOCHEM BIOPH RES CO, V288, P191, DOI 10.1006/bbrc.2001.5763; PUERTA M, 1993, CAN J PHYSIOL PHARM, V71, P858, DOI 10.1139/y93-129; PUIGSERVER P, 1991, BIOCHEM J, V279, P575, DOI 10.1042/bj2790575; Quevedo S, 1998, PFLUG ARCH EUR J PHY, V436, P689, DOI 10.1007/s004240050690; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; Ricquier D, 2000, J PHYSIOL-LONDON, V529, P3, DOI 10.1111/j.1469-7793.2000.00003.x; Roca P, 1999, PFLUG ARCH EUR J PHY, V438, P628, DOI 10.1007/s004240051086; Rodriguez E, 2001, PFLUG ARCH EUR J PHY, V442, P396, DOI 10.1007/s004240100556; THOMAS PS, 1978, ANAL BIOCHEM, V89, P35, DOI 10.1016/0003-2697(78)90724-8; Valet P, 2000, J BIOL CHEM, V275, P34797, DOI 10.1074/jbc.M005210200; Valladares A, 2000, J CELL PHYSIOL, V185, P324, DOI 10.1002/1097-4652(200012)185:3<324::AID-JCP2>3.0.CO;2-Q; Wharton DC., 1967, METHOD ENZYMOL, P245; XU XF, 1993, ENDOCRINOLOGY, V132, P1651, DOI 10.1210/en.132.4.1651; XU XF, 1991, ENDOCRINOLOGY, V128, P379, DOI 10.1210/endo-128-1-379; YOSHIDA T, 1987, METABOLISM, V36, P1, DOI 10.1016/0026-0495(87)90054-0; Zhao J, 1998, AM J PHYSIOL-REG I, V275, pR2002, DOI 10.1152/ajpregu.1998.275.6.R2002	55	152	155	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42958	42963		10.1074/jbc.M207229200	http://dx.doi.org/10.1074/jbc.M207229200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12215449	hybrid			2022-12-25	WOS:000179081200070
J	Shum, JKS; Melendez, JA; Jeffrey, JJ				Shum, JKS; Melendez, JA; Jeffrey, JJ			Serotonin-induced MMP-13 production is mediated via phospholipase C, protein kinase C, and ERK1/2 in rat uterine smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGENASE GENE-EXPRESSION; 5-HT2 BINDING CHARACTERISTICS; RECEPTOR SIGNAL-TRANSDUCTION; N-TERMINAL KINASE; FACTOR-KAPPA-B; MATRIX-METALLOPROTEINASE; PHORBOL ESTER; PHOSPHOINOSITIDE TURNOVER; EPITHELIAL-CELLS; DIFFERENTIAL REGULATION	Serotonin (5-hydroxytryptamine; 5-HT), acting via the 5-HT2A receptor, up-regulates the transcription and production of interstitial collagenase (matrix metalloproteinase-13; MMP-13), a critical enzyme responsible for maintaining the integrity of the uterus, after parturition. Serotonin treatment of rat uterine myometrial smooth muscle cells induced inositol phosphate (IP) turnover, which was abolished by the 5-HT2A receptor-specific antagonists ketanserin and spiperone. The phospholipase C (PLC) inhibitors U73122 and D609 attenuated serotonin-mediated-IP turnover with a corresponding inhibition of MMP-13 protein production. Subsequent recovery of both MMP-13 protein expression and IP generation was seen following the removal of D609. Protein kinase C (PKC) activators, the diacylglycerol analogue 1,2-dioctanoyl-sn-glycerol and phorbol myristate acetate (PMA), mimicked the effect of serotonin on MMP-13 protein expression; prolonged PMA treatment (which down-regulates PKC) lowered MMP-13 protein levels. The PKC-specific inhibitors bisindolylmaleimide I, calphostin C, CGP 41251, and the PKCdelta-selective inhibitor rottlerin were able to suppress serotonin up-regulation of MMP-13. Furthermore, the mitogen-activated protein kinase kinase (MEK) inhibitor PD98059 blocked serotonin-dependent activation of p44/42 MAPK (pERK1/2), a downstream effector of PKC and also down-regulated MMP-13 protein expression. Similarly, calphostin C and rottlerin depressed activation of p44/42 MAPK. From these studies, serotonin, binding through the 5-HT2A receptor, initiates a signaling cascade whereby stimulation of PLC leads to the activation of PKC and subsequently the ERK1/2 pathway, which ultimately results in MMP-13 production.	Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College; Albany Medical College	Melendez, JA (corresponding author), Albany Med Coll, Ctr Immunol & Microbial Dis, MC-151, Albany, NY 12208 USA.	melenda@mail.amc.edu		Melendez, Juan/0000-0001-8021-3097				Amtmann E, 1996, DRUG EXP CLIN RES, V22, P287; APUD JA, 1991, PHARMACOL RES, V23, P217, DOI 10.1016/S1043-6618(05)80081-7; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BLAIR HC, 1986, J CELL PHYSIOL, V129, P111, DOI 10.1002/jcp.1041290116; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRINCKERHOFF CE, 1979, ARTHRITIS RHEUM, V22, P1109, DOI 10.1002/art.1780221010; BURGESON RE, 1988, ANNU REV CELL BIOL, V4, P551, DOI 10.1146/annurev.cb.04.110188.003003; COHEN ML, 1987, J CARDIOVASC PHARM, V10, P176, DOI 10.1097/00005344-198708000-00007; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CONN PJ, 1985, J PHARMACOL EXP THER, V234, P195; CONN PJ, 1984, NEUROPHARMACOLOGY, V23, P993, DOI 10.1016/0028-3908(84)90017-0; Eude I, 2000, BIOL REPROD, V63, P1567, DOI 10.1095/biolreprod63.5.1567; Florian JA, 1998, J PHARMACOL EXP THER, V284, P346; Frey MR, 2001, BIOCHEM PHARMACOL, V61, P1093, DOI 10.1016/S0006-2952(01)00596-2; GLENNON RA, 1986, J MED CHEM, V29, P2375, DOI 10.1021/jm00161a038; GLENNON RA, 1986, J MED CHEM, V29, P194, DOI 10.1021/jm00152a005; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; Greene EL, 2000, AM J PHYSIOL-RENAL, V278, pF650, DOI 10.1152/ajprenal.2000.278.4.F650; HALME J, 1980, ARCH BIOCHEM BIOPHYS, V199, P51, DOI 10.1016/0003-9861(80)90255-6; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; HARKNESS MLR, 1954, J PHYSIOL-LONDON, V123, P492, DOI 10.1113/jphysiol.1954.sp005066; HARKNESS RD, 1956, J PHYSIOL-LONDON, V132, P502, DOI 10.1113/jphysiol.1956.sp005543; Hsu HY, 2002, J BIOL CHEM, V277, P22131, DOI 10.1074/jbc.M111883200; Huang CC, 1998, MOL CELL ENDOCRINOL, V139, P79, DOI 10.1016/S0303-7207(98)00071-9; JEFFREY JJ, 1991, J CELL PHYSIOL, V146, P399, DOI 10.1002/jcp.1041460310; JEFFREY JJ, 1970, BIOCHEMISTRY-US, V9, P268, DOI 10.1021/bi00804a012; Jiang TR, 1996, CIRC RES, V78, P553, DOI 10.1161/01.RES.78.4.553; Jiang Y, 2002, CANCER RES, V62, P1910; Johansson N, 2000, J CELL SCI, V113, P227; JOHNSON JA, 1995, LIFE SCI, V57, P1027, DOI 10.1016/0024-3205(95)02048-N; KISS Z, 1995, BBA-LIPID LIPID MET, V1259, P105, DOI 10.1016/0005-2760(95)00148-6; LEYSEN JE, 1982, MOL PHARMACOL, V21, P301; Li WQ, 2001, J IMMUNOL, V166, P3491, DOI 10.4049/jimmunol.166.5.3491; Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945-053X(02)00007-0; Liedtke CM, 2002, BBA-MOL CELL RES, V1589, P77, DOI 10.1016/S0167-4889(01)00189-6; Liu EB, 2000, CANCER RES, V60, P2361; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; MORT JS, 1993, MATRIX, V13, P95, DOI 10.1016/S0934-8832(11)80068-5; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; NAKAKI T, 1985, J PHARMACOL EXP THER, V234, P442; Naze S, 1997, J PHARMACOL EXP THER, V281, P15; Onodera S, 2002, J BIOL CHEM, V277, P7865, DOI 10.1074/jbc.M106020200; Passaretti TV, 1996, MOL CELL ENDOCRINOL, V120, P125, DOI 10.1016/0303-7207(96)03827-0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEROUTKA SJ, 1979, MOL PHARMACOL, V16, P687; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; ROSS R, 1971, J CELL BIOL, V50, P159, DOI 10.1083/jcb.50.1.159; ROSWIT WT, 1988, ARCH BIOCHEM BIOPHYS, V262, P67, DOI 10.1016/0003-9861(88)90169-5; ROTH BL, 1986, J PHARMACOL EXP THER, V238, P480; RYDELEKFITZGERALD L, 1993, MOL CELL ENDOCRINOL, V91, P67, DOI 10.1016/0303-7207(93)90256-J; SAKO T, 1988, TOHOKU J EXP MED, V156, P229, DOI 10.1620/tjem.156.229; SCHATZ F, 1983, ENDOCRINOLOGY, V113, P1274, DOI 10.1210/endo-113-4-1274; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Undie AS, 1999, BRAIN RES, V816, P286, DOI 10.1016/S0006-8993(98)01076-2; vanDijk MCM, 1997, J BIOL CHEM, V272, P11011; VINCENTI MP, 1994, NUCLEIC ACIDS RES, V22, P4818, DOI 10.1093/nar/22.22.4818; WATTS SW, 1994, J PHARMACOL EXP THER, V271, P832; Watts SW, 1998, ANN NY ACAD SCI, V861, P162; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILCOX BD, 1994, MOL CELL ENDOCRINOL, V101, P67, DOI 10.1016/0303-7207(94)90220-8; WILCOX BD, 1994, J BIOL CHEM, V269, P29658; WILCOX BD, 1992, J BIOL CHEM, V267, P20752; Wilcox CB, 2000, MOL CELL ENDOCRINOL, V170, P41, DOI 10.1016/S0303-7207(00)00327-0	71	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42830	42840		10.1074/jbc.M205094200	http://dx.doi.org/10.1074/jbc.M205094200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12213812	hybrid			2022-12-25	WOS:000179081200055
J	Tang, NY; Lin, TM; Ostap, EM				Tang, NY; Lin, TM; Ostap, EM			Dynamics of Myo1c (Myosin-I beta) lipid binding and dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BRUSH-BORDER; LOCALIZATION; ASSOCIATION; DOMAIN; SH3; SITES; TAIL	Myosin-I is the single-headed member of the myosin superfamily that associates with lipid membranes. Biochemical experiments have shown that myosin-I membrane binding is the result of electrostatic interactions between the basic tail domain and acidic phospholipids. To better understand the dynamics of myosin-I membrane association, we measured the rates of association and dissociation of a recombinant myo1c tail domain (which includes three IQ domains and bound calmodulins) to and from large unilamellar vesicles using fluorescence resonance energy transfer. The apparent second-order rate constant for lipid-tail association in the absence of calcium is fast with nearly every lipid-tail collision resulting in binding. The rate of binding is decreased in the presence of calcium. Time courses of myo1c-tail dissociation are best fit by two exponential rates: a fast component that has a rate that depends on the ratio of acidic phospholipid to myo1c-tail (phosphatidylserine (PS)/tail) and a slow component that predominates at high PS/tail ratios. The dissociation rate of the slow component is slower than the myo1c ATPase rate, suggesting that myo1c is able to stay associated with the lipid membrane during multiple catalytic cycles of the motor. Calcium significantly increases the lifetimes of the membrane-bound state, resulting in dissociation rates much less than 0.001 s(-1).	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Muscle Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Ostap, EM (corresponding author), Univ Penn, Sch Med, Dept Physiol, B400 Richards Bldg, Philadelphia, PA 19104 USA.	ostap@mail.med.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057247] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57247] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson BL, 1998, J CELL BIOL, V141, P1357, DOI 10.1083/jcb.141.6.1357; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Balish MF, 1999, ARCH BIOCHEM BIOPHYS, V370, P285, DOI 10.1006/abbi.1999.1409; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7970, DOI 10.1021/bi00246a014; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; Cyr JL, 2002, J NEUROSCI, V22, P2487, DOI 10.1523/JNEUROSCI.22-07-02487.2002; Diakonova M, 2002, MOL BIOL CELL, V13, P402, DOI 10.1091/mbc.01-05-0273; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; FANNING AS, 1994, CELL MOTIL CYTOSKEL, V29, P29, DOI 10.1002/cm.970290104; Gillespie PG, 1999, J BIOL CHEM, V274, P31373, DOI 10.1074/jbc.274.44.31373; HAYDEN SM, 1990, J CELL BIOL, V111, P443, DOI 10.1083/jcb.111.2.443; Holt JR, 2002, CELL, V108, P371, DOI 10.1016/S0092-8674(02)00629-3; Jung G, 2001, J CELL BIOL, V153, P1479, DOI 10.1083/jcb.153.7.1479; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Nelsestuen GL, 1999, CURR OPIN STRUC BIOL, V9, P433, DOI 10.1016/S0959-440X(99)80060-8; RUPPERT C, 1995, J CELL SCI, V108, P3775; Sokac AM, 2000, INT REV CYTOL, V200, P197, DOI 10.1016/S0074-7696(00)00005-X; SWANLJUNGCOLLINS H, 1992, J BIOL CHEM, V267, P3445; Tang NY, 2001, CURR BIOL, V11, P1131, DOI 10.1016/S0960-9822(01)00320-7; Tyska MJ, 2002, BIOPHYS J, V82, P1869, DOI 10.1016/S0006-3495(02)75537-9; Wang FS, 1996, SCIENCE, V273, P660, DOI 10.1126/science.273.5275.660; XU CJ, 1992, BIOCHIM BIOPHYS ACTA, V1120, P49, DOI 10.1016/0167-4838(92)90423-B; Xu P, 1997, P NATL ACAD SCI USA, V94, P3685, DOI 10.1073/pnas.94.8.3685; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	27	54	54	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42763	42768		10.1074/jbc.M206388200	http://dx.doi.org/10.1074/jbc.M206388200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12221091	hybrid			2022-12-25	WOS:000179081200045
J	Welch, JS; Escoubet-Lozach, L; Sykes, DB; Liddiard, K; Greaves, DR; Glass, CK				Welch, JS; Escoubet-Lozach, L; Sykes, DB; Liddiard, K; Greaves, DR; Glass, CK			T(H)2 cytokines and allergic challenge induce YM1 expression in macrophages by a STAT6-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; AIRWAY HYPERRESPONSIVENESS; EOSINOPHIL INFILTRATION; SIGNAL-TRANSDUCTION; PERITONEAL-CAVITY; GENE-EXPRESSION; HUMAN MONOCYTES; GROWTH-FACTOR; CELL-LINES; MICE	The diverse functions of macrophages as participants in innate and acquired immune responses are regulated by the specific milieu of environmental factors, cytokines, and other signaling molecules that are encountered at sites of inflammation. Microarray analysis of the transcriptional response of mouse peritoneal macrophages to the T(H)2 cytokine interleukin-4 (IL-4) identified Ym1 and arginase as the most highly up-regulated genes, exhibiting more than 68- and 88-fold induction, respectively. Molecular characterization of the Ym1 promoter in transfected epithelial and macrophage cell lines revealed the presence of multiple signal transducers and activators of transcription 6 (STAT6) response elements that function in a combinatorial manner to mediate transcriptional responses to IL-4. The participation of STAT6 as an obligate component of protein complexes binding to these sites was established by analysis of nuclear extracts derived from STAT6-deficient macrophages. Macrophage expression of Ym1 was highly induced in vivo by an IL-4- and STAT6-dependent mechanism during the evolution of allergic peritonitis, supporting the biological relevance of the IL-4-dependent pathway characterized ex vivo in peritoneal macrophages. These studies establish Ym1 as a highly inducible STAT6-dependent transcript in T(H)2-biased inflammation and define Cis-active elements in the Ym1 promoter that are required for this transcriptional response.	Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Dept Med, La Jolla, CA 92093 USA; Med Sci Training Program, La Jolla, CA 92093 USA; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Glass, CK (corresponding author), Dept Cellular & Mol Med, La Jolla, CA 92093 USA.		Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592; Greaves, David/0000-0003-2856-9410	NHLBI NIH HHS [HL59694] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059694] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; AUSUBEL FM, 2001, CURRENT PROTOCOLS MO; BOGDAN C, 1993, ANN NY ACAD SCI, V685, P713, DOI 10.1111/j.1749-6632.1993.tb35934.x; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; Chang NCA, 2001, J BIOL CHEM, V276, P17497, DOI 10.1074/jbc.M010417200; CHOMARAT P, 1998, CYTOKINE HDB, P149; Conrad DJ, 2000, AM J RESP CELL MOL, V22, P226, DOI 10.1165/ajrcmb.22.2.3786; Das AM, 1999, CLIN EXP IMMUNOL, V117, P223, DOI 10.1046/j.1365-2249.1999.00978.x; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Dickensheets HL, 1999, J LEUKOCYTE BIOL, V65, P307, DOI 10.1002/jlb.65.3.307; Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123; Falcone FH, 2001, J IMMUNOL, V167, P5348, DOI 10.4049/jimmunol.167.9.5348; Finkelman FD, 2001, J ALLERGY CLIN IMMUN, V107, P772, DOI 10.1067/mai.2001.114989; Goerdt S, 1999, PATHOBIOLOGY, V67, P222, DOI 10.1159/000028096; Goerdt S, 1999, IMMUNITY, V10, P137, DOI 10.1016/S1074-7613(00)80014-X; Gordon S, 1998, RES IMMUNOL, V149, P685, DOI 10.1016/S0923-2494(99)80039-X; Guidez F, 1998, MOL CELL BIOL, V18, P3851, DOI 10.1128/MCB.18.7.3851; Guo L, 2000, J BIOL CHEM, V275, P8032, DOI 10.1074/jbc.275.11.8032; Harbord M, 2002, J BIOL CHEM, V277, P5468, DOI 10.1074/jbc.M110635200; Hart PH, 1999, J LEUKOCYTE BIOL, V66, P575, DOI 10.1002/jlb.66.4.575; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; Ihn H, 2002, J IMMUNOL, V168, P1895, DOI 10.4049/jimmunol.168.4.1895; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; Jin HM, 1998, GENOMICS, V54, P316, DOI 10.1006/geno.1998.5593; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; MAEYER ED, 1998, CYTOKINE HDB, P491; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Munder M, 1999, J IMMUNOL, V163, P3771; Nau GJ, 2002, P NATL ACAD SCI USA, V99, P1503, DOI 10.1073/pnas.022649799; Newman SL, 1999, TRENDS MICROBIOL, V7, P67, DOI 10.1016/S0966-842X(98)01431-0; Owhashi M, 2000, J BIOL CHEM, V275, P1279, DOI 10.1074/jbc.275.2.1279; Paludan SR, 1998, SCAND J IMMUNOL, V48, P459; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Patel BKR, 1998, P NATL ACAD SCI USA, V95, P172, DOI 10.1073/pnas.95.1.172; Raes G, 2002, J LEUKOCYTE BIOL, V71, P597; Raveh D, 1998, J LEUKOCYTE BIOL, V64, P108, DOI 10.1002/jlb.64.1.108; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rutschman R, 2001, J IMMUNOL, V166, P2173, DOI 10.4049/jimmunol.166.4.2173; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; Sherman MA, 2001, IMMUNOL REV, V179, P48, DOI 10.1034/j.1600-065X.2001.790105.x; Sykes DB, 2001, BLOOD, V98, P2308, DOI 10.1182/blood.V98.8.2308; Tomkinson A, 2001, J IMMUNOL, V166, P5792, DOI 10.4049/jimmunol.166.9.5792; Walker C, 1998, J IMMUNOL, V161, P1962; Ward JM, 2001, AM J PATHOL, V158, P323, DOI 10.1016/S0002-9440(10)63972-7; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; Webb DC, 2001, J BIOL CHEM, V276, P41969, DOI 10.1074/jbc.M106223200; ZuanyAmorim C, 1996, J IMMUNOL, V157, P377; ZUANYAMORIM C, 1993, BRIT J PHARMACOL, V110, P917, DOI 10.1111/j.1476-5381.1993.tb13900.x; ZUANYAMORIM C, 1994, ANN NY ACAD SCI, V725, P34, DOI 10.1111/j.1749-6632.1994.tb39787.x	50	184	193	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42821	42829		10.1074/jbc.M205873200	http://dx.doi.org/10.1074/jbc.M205873200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12215441	hybrid, Green Published			2022-12-25	WOS:000179081200054
J	Chou, AH; Howard, BD				Chou, AH; Howard, BD			Inhibition by Wnt-1 or Wnt-3a of nerve growth factor-induced differentiation of PC12 cells is reversed by bisindolylmaleimide-I but not by several other PKC inhibitors	ONCOGENE			English	Article						bisindolylmaleimide-I; protein kinase C; signaling	PROTEIN-KINASE-C; GLYCOGEN-SYNTHASE KINASE-3; SIGNALING PATHWAY; PHEOCHROMOCYTOMA CELLS; INT-1 PROTOONCOGENE; COLON-CARCINOMA; ACTIVATION; MOUSE; EXPRESSION; POTENT	Wnt-1 and Wnt-3a exhibit redundancy in neural crest development. We have found that they do not produce the same effects on PC12 cells, which were obtained from the adrenal medulla, a neural crest derivative. However, both Wnt-1 or Wnt-3a inhibit nerve growth factor (NGF)-induced neurite outgrowth. The inhibition is reversed by the protein kinase C (PKC) inhibitor, bisindolylmaleimide-I, but it did not reverse Wnt-l-induced activation of the canonical Writ pathway. The Wnt-1 inhibitory effect was not reversed by several other PKC inhibitors, by phorbol ester-induced down-regulation of PKC, or by pertussis toxin, which is known to inhibit another Writ signaling pathway, the Wnt/Ca2+ pathway. We suggest that bisindolylmaleimide-I acts by affecting either a pathway downstream from Lef-1/Tcf in the canonical pathway or a Writ signaling pathway other than the canonical pathway. In either case, the bisindolylmaleimide-I sensitivity of this pathway should aid in its identification.	Univ Calif Los Angeles, Dept Biol Chem, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Howard, BD (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, Sch Med, Los Angeles, CA 90095 USA.							ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; BITLER CM, 1986, J NEUROCHEM, V47, P1286; Borgatti P, 1996, EXP CELL RES, V224, P72, DOI 10.1006/excr.1996.0112; BURSTEIN DE, 1982, BRAIN RES, V247, P115, DOI 10.1016/0006-8993(82)91033-2; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chou AH, 2000, MOL BRAIN RES, V77, P232, DOI 10.1016/S0169-328X(00)00058-9; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; EDREICHEPSTEIN A, 1998, GROWTH FACTORS, V15, P149; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Ito Y, 1997, J NEUROCHEM, V69, P729; Ivins KJ, 1999, J BIOL CHEM, V274, P2107, DOI 10.1074/jbc.274.4.2107; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Liu T, 1999, J BIOL CHEM, V274, P33539, DOI 10.1074/jbc.274.47.33539; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; RAMACHANDRAN B, 1993, J BIOL CHEM, V268, P23891; Sambrook J., 2002, MOL CLONING LAB MANU; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRACHTE GJ, 1995, AM J PHYSIOL-CELL PH, V268, pC978, DOI 10.1152/ajpcell.1995.268.4.C978; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; XIE RP, 1995, DEV BRAIN RES, V87, P77, DOI 10.1016/0165-3806(95)00061-H; Yoshikawa Y, 1997, DEV BIOL, V183, P234, DOI 10.1006/dbio.1997.8502; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377	35	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6348	6355		10.1038/sj.onc.1205791	http://dx.doi.org/10.1038/sj.onc.1205791			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214275				2022-12-25	WOS:000177829000011
J	Ishiguro, H; Shimokawa, T; Tsunoda, T; Tanaka, T; Fujii, Y; Nakamura, Y; Furukawa, Y				Ishiguro, H; Shimokawa, T; Tsunoda, T; Tanaka, T; Fujii, Y; Nakamura, Y; Furukawa, Y			Isolation of HELAD1, a novel human helicase gene up-regulated in colorectal carcinomas	ONCOGENE			English	Article						helicase; APC; HELAD1; colon cancer	DEAD BOX PROTEIN; BETA-CATENIN; DNA HELICASE; HEPATOCELLULAR CARCINOMAS; XERODERMA-PIGMENTOSUM; CYCLIN D1; CELL; MUTATIONS; TARGET; APC	To investigate the mechanisms of colorectal carcinogenesis, we searched for genes regulated by adenomatous polyposis coli gene product (APC) and identified a novel gene, termed HELAD1 (helicase, APC down-regulated 1). A recombinant polypeptide representing the ATPases associated with cellular activities (AAA) domain of the HELAD1 product showed 3' to 5' helicase activity and exonuclease activity in vitro. HELAD1 was abundantly expressed in 16 of 20 colon cancers examined but hardly detectable in corresponding non-cancerous mucosae. Treatment of colon-cancer cells with antisense oligonucleotides suppressed its expression and induced apoptosis. These data revealed an importance of HELAD1 in colorectal carcinogenesis and suggest that suppression of HELAD1 may be a promising therapeutic strategy.	Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; Nagoya City Univ, Dept Surg 2, Sch Med, Mizuho Ku, Nagoya, Aichi 4678601, Japan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Nagoya City University; RIKEN	Nakamura, Y (corresponding author), Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Shimokawa, Takashi/AAA-5870-2020; Tsunoda, Tatsuhiko/K-2061-2014; Tanaka, Toshihiro/J-9310-2014	Shimokawa, Takashi/0000-0001-6549-9277; Tsunoda, Tatsuhiko/0000-0002-5439-7918; Tanaka, Toshihiro/0000-0001-6201-9784				Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; BROUGHTON BC, 1994, NAT GENET, V7, P189, DOI 10.1038/ng0694-189; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; CHAUVEAU J, 1956, EXP CELL RES, V11, P317, DOI 10.1016/0014-4827(56)90107-0; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Eisen A, 1998, BIOESSAYS, V20, P634, DOI 10.1002/(SICI)1521-1878(199808)20:8<634::AID-BIES6>3.0.CO;2-I; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Freeman A, 1999, CLIN CANCER RES, V5, P2121; Fujita M, 2001, CANCER RES, V61, P7722; Godbout R, 1998, J BIOL CHEM, V273, P21161, DOI 10.1074/jbc.273.33.21161; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEKIMI S, 1993, J NEUROSCI, V13, P4254; Ishiguro H, 2000, JPN J CANCER RES, V91, P597, DOI 10.1111/j.1349-7006.2000.tb00987.x; Kanemaki M, 1999, J BIOL CHEM, V274, P22437, DOI 10.1074/jbc.274.32.22437; Kawasoe T, 2000, CANCER RES, V60, P3354; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Lin YM, 2001, CANCER RES, V61, P6345; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakagawa Y, 1999, BRIT J CANCER, V80, P914, DOI 10.1038/sj.bjc.6690441; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Neuwald AF, 1999, GENOME RES, V9, P27; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Ono K, 2000, CANCER RES, V60, P5007; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seto M, 1995, GENE, V166, P293, DOI 10.1016/0378-1119(95)00559-5; Shiratori M, 1999, J CELL BIOL, V144, P1, DOI 10.1083/jcb.144.1.1; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stradal T, 1998, FEBS LETT, V431, P134, DOI 10.1016/S0014-5793(98)00751-0; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; Xu LF, 2000, GENE DEV, V14, P585; Yamada T, 2000, CANCER RES, V60, P4761; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	50	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6387	6394		10.1038/sj.onc.1205751	http://dx.doi.org/10.1038/sj.onc.1205751			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214280				2022-12-25	WOS:000177829000016
J	Jiang, XH; Lam, SK; Lin, MC; Jiang, SH; Kung, HF; Slosberg, ED; Soh, JW; Weinstein, B; Wong, BCY				Jiang, XH; Lam, SK; Lin, MC; Jiang, SH; Kung, HF; Slosberg, ED; Soh, JW; Weinstein, B; Wong, BCY			Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway	ONCOGENE			English	Article						gastric cancer; apoptosis; protein kinase C; cyclo-oxygenase-2; cancer prevention	COLON-CANCER CELLS; NONSTEROIDAL ANTIINFLAMMATORY DRUG; KAPPA-B ACTIVITY; CYCLOOXYGENASE-2 INHIBITOR; EPITHELIAL-CELLS; COLORECTAL-CANCER; PROSTAGLANDIN E-2; SULINDAC SULFIDE; CARCINOMA CELLS; PHORBOL ESTER	Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of gastrointestinal cancers. Recently, a similar protective effect has been demonstrated by the specific cyclo-oxygenase-2 (COX-2) inhibitors. However, the exact mechanism that accounts for the anti-proliferative effect of specific COX-2 inhibitors is still not fully understood, and it is still controversial whether these protective effects are predominantly mediated through the inhibition of COX-2 activity and prostaglandin synthesis. Identification of molecular targets regulated by COX-2 inhibitors could lead to a better understanding of their pro-apoptotic and anti-neoplastic activities. In the present study, we investigated the effect and the possible molecular target of a COX-2-specific inhibitor SC-236 on gastric cancer. We showed that SC-236 induced apoptosis in gastric cancer cells. However, this effect was not dependent on COX-2 inhibition. SC-236 down-regulated the protein expression and kinase activity of PKC-beta(1), increased the expression of PKCdelta and PKCeta, but did not alter the expression of other PKC isoforms in AGS cells. Moreover, exogenous prostaglandins or PGE(2) receptor antagonists could not reverse the inhibition effect on PKCbeta(1) by SC-236, which suggested that this effect occurred through a mechanism independent of cyclo-oxygenase activity and prostaglandin synthesis. Overexpression of PKCbeta(1) attenuated the apoptotic response of AGS cells to SC-236 and was associated with overexpression of p21(wafl/cip1). Inhibition of PKQ1-mediated overexpression of p21(wafl/cip1) partially reduced the anti-apoptotic effect of PKCbeta(1). The down-regulation of PKCbeta(1) provides an explanation for COX-independent apoptotic effects of specific COX-2 inhibitor in cultured gastric cancer cells. We also suggest that PKCbeta(1) act as survival mediator in gastric cancer, and its down-regulation by COX-2 inhibitor SC-236 may provide new target for future treatment of gastric cancer.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Rui Jin Hosp, Dept Gastroenterol, Shanghai, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	University of Hong Kong; University of Hong Kong; Columbia University	Wong, BCY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.		Wong, Benjamin Chun Yu/C-4436-2009; Wong, Benjamin Chun Yu/ABB-1962-2020; jiang, cynthia xiaohua/F-7580-2017	jiang, cynthia xiaohua/0000-0002-7372-4961				Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Barnes CJ, 1998, BRIT J CANCER, V77, P573, DOI 10.1038/bjc.1998.93; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Cesaro P, 2001, INT J CANCER, V93, P179, DOI 10.1002/ijc.1314; Das D, 2000, FEBS LETT, V472, P50, DOI 10.1016/S0014-5793(00)01416-2; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Frey MR, 1997, J BIOL CHEM, V272, P9424; Goldberg Y, 1996, ONCOGENE, V12, P893; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Gupta RA, 1998, GASTROENTEROLOGY, V114, P1095, DOI 10.1016/S0016-5085(98)70330-0; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JONES DA, 1993, J BIOL CHEM, V268, P9049; Jones MK, 1999, NAT MED, V5, P1418; JUN C, 1997, J IMMUNOL, V162, P3395; KARGMAN SL, 1995, CANCER RES, V55, P3785; Kawamori T, 1998, CANCER RES, V58, P409; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kunikata T, 2001, J PHYSIOLOGY-PARIS, V95, P157, DOI 10.1016/S0928-4257(01)00021-3; Li M, 2001, CLIN CANCER RES, V7, P1010; LI Y, 1999, J BIOL CHEM, V271, P27025; Livneh E, 1996, ONCOGENE, V12, P1545; Mitchell JA, 1999, BRIT J PHARMACOL, V128, P1121, DOI 10.1038/sj.bjp.0702897; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Reddy BS, 1996, CANCER RES, V56, P4566; Richter M, 2001, CARCINOGENESIS, V22, P17, DOI 10.1093/carcin/22.1.17; Ristimaki A, 1997, CANCER RES, V57, P1276; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; SCHWARTZ GK, 1995, J NATL CANCER I, V87, P1394, DOI 10.1093/jnci/87.18.1394; SCHWARTZ GK, 1993, J NATL CANCER I, V85, P402, DOI 10.1093/jnci/85.5.402; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Sheng HM, 1998, CANCER RES, V58, P362; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Sugibayashi R, 2001, ONCOGENE, V20, P1220, DOI 10.1038/sj.onc.1204206; Teicher BA, 2001, ANTICANCER RES, V21, P3175; Teicher BA, 2001, CANCER CHEMOTH PHARM, V48, P473, DOI 10.1007/s002800100372; Teicher BA, 2001, IN VIVO, V15, P185; Thun MJ, 1996, GASTROENTEROL CLIN N, V25, P333, DOI 10.1016/S0889-8553(05)70250-8; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Tucker ON, 1999, CANCER RES, V59, P987; Weber CK, 2000, GASTROENTEROLOGY, V119, P1209, DOI 10.1053/gast.2000.19458; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wilson KT, 1998, CANCER RES, V58, P2929; Won JS, 1998, MOL BRAIN RES, V60, P203, DOI 10.1016/S0169-328X(98)00182-X; YASUI W, 1985, JPN J CANCER RES, V76, P1168; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451; Zhu GH, 2000, GASTROENTEROLOGY, V118, P507, DOI 10.1016/S0016-5085(00)70256-3; Zhu GH, 1999, BRIT J CANCER, V79, P393, DOI 10.1038/sj.bjc.6690062; Zhu GH, 1999, DIGEST DIS SCI, V44, P2020, DOI 10.1023/A:1026670301787	66	65	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6113	6122		10.1038/sj.onc.1205778	http://dx.doi.org/10.1038/sj.onc.1205778			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203123				2022-12-25	WOS:000177671300014
J	Bernassola, F; Federici, M; Corazzari, M; Terrinoni, A; Hribal, ML; De Laurenzi, V; Ranalli, M; Massa, O; Sesti, G; Mclean, WHI; Citro, G; Barbetti, F; Melino, G				Bernassola, F; Federici, M; Corazzari, M; Terrinoni, A; Hribal, ML; De Laurenzi, V; Ranalli, M; Massa, O; Sesti, G; Mclean, WHI; Citro, G; Barbetti, F; Melino, G			Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient	FASEB JOURNAL			English	Article						insulin; diabetes; mature; onset diabetes of the young	TYPE-2 DIABETES-MELLITUS; HUMAN PANCREATIC-ISLETS; TISSUE TRANSGLUTAMINASE; INSULIN-SECRETION; BINDING-PROTEINS; BETA-CELLS; APOPTOSIS; RELEASE; YOUNG; GENE	Transglutaminase 2 (TGase 2) is a Ca+2-dependent enzyme that catalyzes both intracellular and extracellular cross-linking reactions by transamidation of specific glutamine residues. TGase 2 is known to be involved in the membrane-mediated events required for glucose-stimulated insulin release from the pancreatic beta cells. Here we show that targeted disruption of TGase 2 impairs glucose-stimulated insulin secretion. TGase 2(-/-) mice show glucose intolerance after intraperitoneal glucose loading. TGase 2(-/-) mice manifest a tendency to develop hypoglycemia after administration of exogenous insulin as a consequence of enhanced insulin receptor substrate 2 (IRS-2) phosphorylation. We suggest that the increased peripheral sensitivity to insulin partially compensates for the defective secretion in this animal model. TGase 2(-/-) mouse phenotype resembles that of the maturity-onset diabetes of young (MODY) patients. In the course of screening for human TGase 2 gene in Italian subjects with the clinical features of MODY, we detected a missense mutation (N333S) in the active site of the enzyme. Collectively, these results identify TGase 2 as a potential candidate gene in type 2 diabetes.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Biochem Lab, IDI IRCCS, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Internal Med, I-00133 Rome, Italy; IBCIT, I-00144 Rome, Italy; Univ Catanzaro Magna Grecia, Dept Clin & Expt Med, I-88100 Catanzaro, Italy; Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Human Genet Unit,Epithelial Genet Grp, Dundee DD1 9SY, Scotland; IFO, Ist Regina Elena Inst, SSD SAFU, Rome, Italy; IRCCS Bambino Gesu Childrens Hosp, I-00165 Rome, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Rome Tor Vergata; Magna Graecia University of Catanzaro; University of Dundee; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Bambino Gesu	Melino, G (corresponding author), Univ Roma Tor Vergata, Dept Expt Med, Biochem Lab, IDI IRCCS, D26-F153,Via Tor Vergata 135, I-00133 Rome, Italy.	gerry.melino@uniroma2.it	Sesti, Giorgio/B-1509-2012; TERRINONI, Alessandro/J-1533-2012; Barbetti, Fabrizio/AAK-9106-2021; McLean, William HI/C-6352-2009; Corazzari, Marco/B-4631-2019; Corazzari, Marco/K-6422-2016; Corazzari, Marco/J-5825-2019; Barbetti, Fabrizio/I-7351-2018; Federici, Massimo/G-9940-2012; De Laurenzi, Vincenzo/K-7471-2016	TERRINONI, Alessandro/0000-0002-7442-2252; Barbetti, Fabrizio/0000-0003-4687-980X; Corazzari, Marco/0000-0002-6246-5968; Corazzari, Marco/0000-0002-6246-5968; Corazzari, Marco/0000-0002-6246-5968; Barbetti, Fabrizio/0000-0003-4687-980X; Federici, Massimo/0000-0003-4989-5194; McLean, William Henry Irwin/0000-0001-5539-5757; De Laurenzi, Vincenzo/0000-0002-7506-1743; Sesti, Giorgio/0000-0002-1618-7688	Telethon [E.0946, E.1224, E.0872, E.1257] Funding Source: Medline	Telethon(Fondazione Telethon)		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; Almind K, 2001, NAT MED, V7, P277, DOI 10.1038/85405; BALDWIN D, 1980, P NATL ACAD SCI-BIOL, V77, P5975, DOI 10.1073/pnas.77.10.5975; BERNTORP E, 1987, DIABETES RES CLIN EX, V5, P29; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; BUNGAY PJ, 1986, BIOCHEM J, V235, P269, DOI 10.1042/bj2350269; CHRISTESEN HBT, 2002, IN PRESS DIABETES; Clement S, 1998, J BIOL CHEM, V273, P7604, DOI 10.1074/jbc.273.13.7604; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Driscoll HK, 1997, PANCREAS, V15, P69, DOI 10.1097/00006676-199707000-00010; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Federici M, 2001, FASEB J, V15, P22; Gerich JE, 1998, ENDOCR REV, V19, P491, DOI 10.1210/er.19.4.491; GOMIS R, 1983, BIOCHIM BIOPHYS ACTA, V760, P384, DOI 10.1016/0304-4165(83)90378-1; Gomis R, 1986, Adv Exp Med Biol, V211, P443; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; Hansen L, 2000, J CLIN ENDOCR METAB, V85, P1323, DOI 10.1210/jc.85.3.1323; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Kahn CR, 1996, ANNU REV MED, V47, P509; Kowluru A, 1996, J CLIN INVEST, V98, P540, DOI 10.1172/JCI118822; Kulkarni RN, 1997, J CLIN INVEST, V100, P2729, DOI 10.1172/JCI119818; Lauro D, 1998, NAT GENET, V20, P294, DOI 10.1038/3112; Massa O, 2001, DIABETOLOGIA, V44, P898; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Melino G, 2000, METHOD ENZYMOL, V322, P433; Nagy L, 1997, CELL DEATH DIFFER, V4, P534, DOI 10.1038/sj.cdd.4400290; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Njolstad PR, 2001, NEW ENGL J MED, V344, P1588, DOI 10.1056/NEJM200105243442104; Piredda L, 1999, FASEB J, V13, P355, DOI 10.1096/fasebj.13.2.355; Porzio O, 1999, J CLIN INVEST, V104, P357, DOI 10.1172/JCI5870; Prisco F, 2000, DIABETOLOGIA, V43, P1331; SENER A, 1985, ENDOCRINOLOGY, V117, P237, DOI 10.1210/endo-117-1-237; TREJOSKALLI AV, 1995, P NATL ACAD SCI USA, V92, P8940, DOI 10.1073/pnas.92.19.8940; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	39	93	97	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1371	1378		10.1096/fj.01-0689com	http://dx.doi.org/10.1096/fj.01-0689com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12205028				2022-12-25	WOS:000178441800011
J	Kasahara, H; Hanada, A; Kuzuyama, T; Takagi, M; Kamiya, Y; Yamaguchi, S				Kasahara, H; Hanada, A; Kuzuyama, T; Takagi, M; Kamiya, Y; Yamaguchi, S			Contribution of the mevalonate and methylerythritol phosphate pathways to the biosynthesis of gibberellins in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; ENT-KAURENE BIOSYNTHESIS; ISOPRENOID BIOSYNTHESIS; TERPENOID BIOSYNTHESIS; HIGHER-PLANTS; SYNTHASE-B; ACID; ENZYME; 1-DEOXY-D-XYLULOSE; 4-PHOSPHATE	Gibberellins (GAs) are diterpene plant hormones essential for many developmental processes. Although the GA biosynthesis pathway has been well studied, our knowledge on its early stage is still limited. There are two possible routes for the biosynthesis of isoprenoids leading to GAs, the mevalonate (MVA) pathway in the cytosol and the methylerythritol phosphate (MEP) pathway in plastids. To distinguish these possibilities, metabolites from each isoprenoid pathway were selectively labeled with C-13 in Arabidopsis seedlings. Efficient C-13-labeling was achieved by blocking the endogenous pathway chemically or genetically during the feed of a C-13-labeled precursor specific to the MVA or MEP pathways. Gas chromatography-mass spectrometry analyses demonstrated that both MVA and MEP pathways can contribute to the biosyntheses of GAs and campesterol, a cytosolic sterol, in Arabidopsis seedlings. While GAs are predominantly synthesized through the MEP pathway, the MVA pathway plays a major role in the biosynthesis of campesterol. Consistent with some crossover between the two pathways, phenotypic defects caused by the block of the MVA and MEP pathways were partially rescued by exogenous application of the MEP and MVA precursors, respectively. We also provide evidence to suggest that the MVA pathway still contributes to GA biosynthesis when this pathway is limiting.	RIKEN, Inst Phys & Chem Res, Plant Sci Ctr,Growth Physiol Res Grp, Lab Cellular Growth & Dev, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	RIKEN; University of Tokyo	Yamaguchi, S (corresponding author), RIKEN, Inst Phys & Chem Res, Plant Sci Ctr,Growth Physiol Res Grp, Lab Cellular Growth & Dev, Hirosawa 2-1, Wako, Saitama 3510198, Japan.	shinjiro@postman.riken.go.jp	Takagi, Motoki/C-9052-2009; Kasahara, Hiroyuki/F-6445-2012; Takagi, Motoki/Q-7390-2019; Yamaguchi, Shinjiro/F-9684-2010; Kamiya, Yuji/F-9420-2010	Kasahara, Hiroyuki/0000-0002-4858-0978; Kamiya, Yuji/0000-0003-4415-520X; Kuzuyama, Tomohisa/0000-0002-7221-5858				AACH H, 1995, PLANTA, V197, P333, DOI 10.1007/BF00202655; Adam KP, 1998, PHYTOCHEMISTRY, V48, P953, DOI 10.1016/S0031-9422(97)00992-8; Arigoni D, 1997, P NATL ACAD SCI USA, V94, P10600, DOI 10.1073/pnas.94.20.10600; BAUERLE R, 1990, PLANTA, V181, P229, DOI 10.1007/BF02411543; BLECHSCHMIDT S, 1984, PHYTOCHEMISTRY, V23, P553, DOI 10.1016/S0031-9422(00)80379-9; Choe SW, 1999, PLANT CELL, V11, P207, DOI 10.1105/tpc.11.2.207; Crozier A, 2000, BIOCH MOL BIOL PLANT, P851; Eisenreich W, 1998, CHEM BIOL, V5, pR221, DOI 10.1016/S1074-5521(98)90002-3; Estevez JM, 2000, PLANT PHYSIOL, V124, P95, DOI 10.1104/pp.124.1.95; Estevez JM, 2001, J BIOL CHEM, V276, P22901, DOI 10.1074/jbc.M100854200; Fujioka S, 1997, PLANT CELL, V9, P1951, DOI 10.1105/tpc.9.11.1951; GASKIN P, 1971, PHYTOCHEMISTRY, V10, P1155, DOI 10.1016/S0031-9422(00)89955-0; GASKIN P, 1991, GC MS GIBBERELLINS R, P69; GOAD JL, 1997, ANAL STEROLS, P158; GRAEBE JE, 1972, PLANTA, V102, P261, DOI 10.1007/BF00386896; GRAEBE JE, 1987, ANNU REV PLANT PHYS, V38, P419, DOI 10.1146/annurev.pp.38.060187.002223; GRAY JC, 1987, ADV BOT RES, V14, P25; HANSON JR, 1969, J CHEM SOC C, P981, DOI 10.1039/j39690000981; HEDDEN P, 1981, PHYTOCHEMISTRY, V20, P1011, DOI 10.1016/0031-9422(81)83019-1; Hedden P, 2001, J PLANT GROWTH REGUL, V20, P319, DOI 10.1007/s003440010037; Hirai N, 2000, BIOSCI BIOTECH BIOCH, V64, P1448, DOI 10.1271/bbb.64.1448; KREUZ K, 1984, EUR J BIOCHEM, V141, P531, DOI 10.1111/j.1432-1033.1984.tb08225.x; Kuzuyama T, 2002, BIOSCI BIOTECH BIOCH, V66, P1619, DOI 10.1271/bbb.66.1619; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P4509, DOI 10.1016/S0040-4039(98)00802-8; Lange BM, 1998, P NATL ACAD SCI USA, V95, P2100, DOI 10.1073/pnas.95.5.2100; Lichtenthaler HK, 1999, ANNU REV PLANT PHYS, V50, P47, DOI 10.1146/annurev.arplant.50.1.47; Mandel MA, 1996, PLANT J, V9, P649, DOI 10.1046/j.1365-313X.1996.9050649.x; Okada K, 2002, PLANTA, V215, P339, DOI 10.1007/s00425-002-0762-0; Piel J, 1998, ANGEW CHEM INT EDIT, V37, P2478, DOI 10.1002/(SICI)1521-3773(19981002)37:18<2478::AID-ANIE2478>3.0.CO;2-Q; RAILTON ID, 1984, PHYTOCHEMISTRY, V23, P1261, DOI 10.1016/S0031-9422(00)80438-0; RAUSCHENBACH P, 1974, MESSUNG RADIOAKTIVEN, P360; Rohdich F, 2002, P NATL ACAD SCI USA, V99, P1158, DOI 10.1073/pnas.032658999; Rohmer M, 1999, NAT PROD REP, V16, P565, DOI 10.1039/a709175c; Rohmer M, 1996, J AM CHEM SOC, V118, P2564, DOI 10.1021/ja9538344; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; SAITO T, 1995, PLANT PHYSIOL, V109, P1239, DOI 10.1104/pp.109.4.1239; Schwender J, 2001, PLANTA, V212, P416, DOI 10.1007/s004250000409; SOLER E, 1993, PLANTA, V191, P324, DOI 10.1007/BF00195689; Sponsel VM, 2001, J PLANT GROWTH REGUL, V20, P332, DOI 10.1007/s003440010032; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; Totte N, 2000, TETRAHEDRON LETT, V41, P6407, DOI 10.1016/S0040-4039(00)01094-7; TREHARNE KJ, 1966, BIOCHEM J, V99, P239, DOI 10.1042/bj0990239; Yamaguchi S, 2000, PLANT CELL PHYSIOL, V41, P251, DOI 10.1093/pcp/41.3.251; Yamaguchi S, 1996, PLANT J, V10, P203, DOI 10.1046/j.1365-313X.1996.10020203.x	45	183	197	5	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45188	45194		10.1074/jbc.M208659200	http://dx.doi.org/10.1074/jbc.M208659200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228237	hybrid			2022-12-25	WOS:000179404800077
J	Koutzamani, E; Loborg, H; Sarg, B; Lindner, HH; Rundquist, I				Koutzamani, E; Loborg, H; Sarg, B; Lindner, HH; Rundquist, I			Linker histone subtype composition and affinity for chromatin in situ in nucleated mature erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE CAPILLARY-ELECTROPHORESIS; VARIANT OVEREXPRESSION; CHICKEN ERYTHROCYTE; H1 DEGREES; XENOPUS; H1-DEGREES; BINDING; PROTEIN; PHOSPHORYLATION; H-1	The replacement linker histones H1(0) and H5 are present in frog and chicken erythrocytes, respectively, and their accumulation coincides with cessation of proliferation and compaction of chromatin. These cells have been analyzed for the affinity of linker histones for chromatin with cytochemical and biochemical methods. Our results show a stronger association between linker histones and chromatin in chicken erythrocyte nuclei than in frog erythrocyte nuclei. Analyses of linker histones from chicken erythrocytes using capillary electrophoresis showed H5 to be the subtype strongest associated with chromatin. The corresponding analyses of frog erythrocyte linker histones using reverse-phase high performance liquid chromatography showed that H1(0) dissociated from chromatin at somewhat higher ionic strength than the three additional subtypes present in frog blood but at lower ionic strength than chicken H5. Which of the two H1(0) variants in frog is expressed in erythrocytes has thus far been unknown. Amino acid sequencing showed that H1(0)-2 is the only H1(0) subtype present in frog erythrocytes and that it is 100% acetylated at its N termini. In conclusion, our results show differences between frog and chicken linker histone affinity for chromatin probably caused by the specific subtype composition present in each cell type. Our data also indicate a lack of correlation between linker histone affinity and chromatin condensation.	Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden; Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria	Linkoping University; University of Innsbruck	Rundquist, I (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden.	ingru@mcb.liu.se	Koutzamani, Elisavet/N-4112-2015	Koutzamani, Elisavet/0000-0003-3059-5191				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BOLUND LA, 1973, EUR J BIOCHEM, V35, P546, DOI 10.1111/j.1432-1033.1973.tb02871.x; Brocard MP, 1997, GENE, V189, P127, DOI 10.1016/S0378-1119(96)00845-1; Brown DT, 1996, NUCLEIC ACIDS RES, V24, P486, DOI 10.1093/nar/24.3.486; CARY PD, 1981, EUR J BIOCHEM, V120, P371, DOI 10.1111/j.1432-1033.1981.tb05714.x; CASSIDY DM, 1978, DEV BIOL, V63, P224, DOI 10.1016/0012-1606(78)90127-6; COLE RD, 1987, INT J PEPT PROT RES, V30, P433; DESTREE OHJ, 1975, BIOCHIM BIOPHYS ACTA, V378, P450, DOI 10.1016/0005-2787(75)90189-6; Dimitrov S, 1996, EMBO J, V15, P5897, DOI 10.1002/j.1460-2075.1996.tb00976.x; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; Eufemi M, 2000, MOL BIOL REP, V27, P181, DOI 10.1023/A:1007203513462; Fan YH, 2001, MOL CELL BIOL, V21, P7933, DOI 10.1128/MCB.21.23.7933-7943.2001; GRIGORYEV SA, 1992, EXP CELL RES, V198, P268, DOI 10.1016/0014-4827(92)90379-M; Grigoryev SA, 1999, J BIOL CHEM, V274, P5626, DOI 10.1074/jbc.274.9.5626; Gunjan A, 1999, J BIOL CHEM, V274, P37950, DOI 10.1074/jbc.274.53.37950; HELLIGER W, 1988, BIOCHEM J, V255, P23, DOI 10.1042/bj2550023; HILL CS, 1991, EMBO J, V10, P1939, DOI 10.1002/j.1460-2075.1991.tb07720.x; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Khochbin S, 2001, GENE, V271, P1, DOI 10.1016/S0378-1119(01)00495-4; KUMAR NM, 1980, NUCLEIC ACIDS RES, V8, P3535, DOI 10.1093/nar/8.16.3535; LINDNER H, 1992, BIOCHEM J, V283, P467, DOI 10.1042/bj2830467; LINDNER H, 1988, J CHROMATOGR, V450, P309, DOI 10.1016/S0021-9673(01)83585-8; LINDNER H, 1992, J CHROMATOGR, V608, P211, DOI 10.1016/0021-9673(92)87126-S; LINDNER H, 1989, J CHROMATOGR, V472, P243, DOI 10.1016/S0021-9673(00)94110-4; LINDNER H, 1993, ELECTROPHORESIS, V14, P480, DOI 10.1002/elps.1150140174; LINDNER H, 1995, ELECTROPHORESIS, V16, P604, DOI 10.1002/elps.1150160197; Loborg H, 1997, CYTOMETRY, V28, P212, DOI 10.1002/(SICI)1097-0320(19970701)28:3<212::AID-CYTO5>3.0.CO;2-F; Loborg H, 2000, CYTOMETRY, V40, P1; MARION C, 1985, BIOCHEMISTRY-US, V24, P6328, DOI 10.1021/bi00344a002; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; NAGARAJA S, 1995, BBA-GENE STRUCT EXPR, V1260, P207, DOI 10.1016/0167-4781(94)00201-D; Parseghian MH, 2001, BIOCHEM CELL BIOL, V79, P289; RISLEY MS, 1981, DEV BIOL, V84, P79, DOI 10.1016/0012-1606(81)90372-9; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; RUTLEDGE RG, 1984, EUR J BIOCHEM, V144, P191, DOI 10.1111/j.1432-1033.1984.tb08448.x; RUTLEDGE RG, 1988, GENE, V70, P117, DOI 10.1016/0378-1119(88)90110-2; Sarg B, 1999, ARCH BIOCHEM BIOPHYS, V372, P333, DOI 10.1006/abbi.1999.1503; SHIMIDZU M, 1987, J BIOCHEM-TOKYO, V102, P351, DOI 10.1093/oxfordjournals.jbchem.a122061; SUN JM, 1990, EMBO J, V9, P1651, DOI 10.1002/j.1460-2075.1990.tb08285.x; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; SUNG MT, 1977, BIOCHEMISTRY-US, V16, P279, DOI 10.1021/bi00621a019; Wagner T E, 1977, Biochemistry, V16, P286; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; Wolffe A., 1998, CHROMATIN STRUCTURE; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; WRIGHT JM, 1987, EUR J BIOCHEM, V168, P281, DOI 10.1111/j.1432-1033.1987.tb13418.x; Zlatanova J, 2000, FASEB J, V14, P1697, DOI 10.1096/fj.99-0869rev; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X; ZLATANOVA J, 1994, FASEB J, V8, P1260, DOI 10.1096/fasebj.8.15.8001738; ZLATANOVA J, 1992, J CELL SCI, V103, P889	50	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44688	44694		10.1074/jbc.M203533200	http://dx.doi.org/10.1074/jbc.M203533200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223471	hybrid			2022-12-25	WOS:000179404800013
J	Yang, TB; Poovaiah, BW				Yang, TB; Poovaiah, BW			A calmodulin-binding/CGCG box DNA-binding protein family involved in multiple signaling pathways in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TRANSCRIPTION FACTOR; AUXIN ACTION; CALCIUM; ETHYLENE; ARABIDOPSIS; TRANSDUCTION; CALCIUM/CALMODULIN; PERCEPTION; DEFENSE	We reported earlier that the tobacco early ethylene-responsive gene NtER1 encodes a calmodulin-binding protein (Yang, T., and Poovaiah, B. W. (2000) J. Biol. Chem. 275, 38467-38473). Here we demonstrate that there is one NtER1 homolog as well as five related genes in Arabidopsis. These six genes are rapidly and differentially induced by environmental signals such as temperature extremes, UVB, salt, and wounding;, hormones such as ethylene and abscisic acid; and signal molecules such as methyl jasmonate, H2O2, and salicylic acid. Hence, they were designated as AtSR1-6 ((A) under bar rabidopsts (t) under bar haliana (s) under bar ignal-(r) under bar esponsive genes). Ca2+/calmodulin binds to all AtSRs, and their calmodulin-binding regions are located on a conserved basic amphiphilic a-helical motif in the C terminus. AtSR1 targets the nucleus and specifically recognizes a novel 6-bp CGCG box (A/C/G)CGCG(G/T/C). The multiple CGCG cis-elements are found in promoters of genes such as those involved in ethylene signaling, abscisic acid signaling, and light signal perception. The DNA-binding domain in AtSR1 is located on the N-terminal 146 bp where all AtSR1-related proteins share high similarity but have no similarity to other known DNA-binding proteins. The calmodulin-binding nuclear proteins isolated from wounded leaves exhibit specific CGCG box DNA binding activities. These results suggest that the AtSR gene family encodes a family of calmodulin-binding/DNA-binding proteins involved in multiple signal transduction pathways in plants.	Washington State Univ, Dept Hort, Lab Plant Mol Biol & Physiol, Pullman, WA 99164 USA	Washington State University	Poovaiah, BW (corresponding author), Washington State Univ, Dept Hort, Lab Plant Mol Biol & Physiol, Pullman, WA 99164 USA.							Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Bergey DR, 1999, PLANT MOL BIOL, V40, P815, DOI 10.1023/A:1006247624823; Bleecker AB, 2000, ANNU REV CELL DEV BI, V16, P1, DOI 10.1146/annurev.cellbio.16.1.1; Bouche N, 2002, J BIOL CHEM, V277, P21851, DOI 10.1074/jbc.M200268200; Bowler C, 2000, TRENDS PLANT SCI, V5, P241, DOI 10.1016/S1360-1385(00)01628-9; BRAAM J, 1990, CELL, V60, P357, DOI 10.1016/0092-8674(90)90587-5; BRUCE WB, 1991, EMBO J, V10, P3015, DOI 10.1002/j.1460-2075.1991.tb07852.x; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; Chao QM, 1997, CELL, V89, P1133, DOI 10.1016/S0092-8674(00)80300-1; Christou P, 1995, METHOD CELL BIOL, V50, P375, DOI 10.1016/S0091-679X(08)61044-4; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; Davis SJ, 1998, PLANT MOL BIOL, V36, P521, DOI 10.1023/A:1005991617182; Evans NH, 2001, CURR OPIN PLANT BIOL, V4, P415, DOI 10.1016/S1369-5266(00)00194-1; Fujimoto SY, 2000, PLANT CELL, V12, P393, DOI 10.1105/tpc.12.3.393; GIRAUDAT J, 1995, CURR OPIN CELL BIOL, V7, P232, DOI 10.1016/0955-0674(95)80033-6; GREEN PJ, 1987, EMBO J, V18, P4689; GREEN R, 1995, PLANT CELL, V7, P203, DOI 10.1105/tpc.7.2.203; JENA PK, 1989, P NATL ACAD SCI USA, V86, P3644, DOI 10.1073/pnas.86.10.3644; Klessig DF, 2000, P NATL ACAD SCI USA, V97, P8849, DOI 10.1073/pnas.97.16.8849; Larkindale J, 2002, PLANT PHYSIOL, V128, P682, DOI 10.1104/pp.010320; Leon J, 2001, J EXP BOT, V52, P1, DOI 10.1093/jexbot/52.354.1; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; NATALIE C, 1989, ANNU REV BIOCHEM, V58, P951; ODonnell PJ, 1996, SCIENCE, V274, P1914, DOI 10.1126/science.274.5294.1914; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Pauly N, 2000, NATURE, V405, P754, DOI 10.1038/35015671; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; POOVAIAH BW, 1987, CRC CR REV PLANT SCI, V6, P47, DOI 10.1080/07352688709382247; POOVAIAH BW, 2002, PLANT ROOTS HIDDEN H, P505; QUAIL PH, 1994, CURR OPIN GENET DEV, V4, P652, DOI 10.1016/0959-437X(94)90131-L; Reddy ASN, 2000, BIOCHEM BIOPH RES CO, V279, P762, DOI 10.1006/bbrc.2000.4032; Reddy ASN, 2001, PLANT SCI, V160, P381, DOI 10.1016/S0168-9452(00)00386-1; REINBOTHE S, 1994, PLANT CELL, V6, P1197, DOI 10.1105/tpc.6.9.1197; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Schwechheimer C, 1998, ANNU REV PLANT PHYS, V49, P127, DOI 10.1146/annurev.arplant.49.1.127; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SILVA ODE, 1994, PLANT MOL BIOL, V25, P921, DOI 10.1007/BF00028887; Snedden WA, 2001, NEW PHYTOL, V151, P35, DOI 10.1046/j.1469-8137.2001.00154.x; Stepanova AN, 2000, CURR OPIN PLANT BIOL, V3, P353, DOI 10.1016/S1369-5266(00)00096-0; Szymanski DB, 1996, PLANT CELL, V8, P1069, DOI 10.1105/tpc.8.6.1069; Tabata S, 2000, NATURE, V408, P823, DOI 10.1038/35048507; TERZAGHI WB, 1995, ANNU REV PLANT PHYS, V46, P61445; Trewavas AJ, 1997, PLANT CELL, V9, P1181, DOI 10.1105/tpc.9.7.1181; van der Luit AH, 1999, PLANT PHYSIOL, V121, P705, DOI 10.1104/pp.121.3.705; Wang ZP, 1998, PLANT J, V16, P515, DOI 10.1046/j.1365-313x.1998.00311.x; Yang T, 2002, P NATL ACAD SCI USA, V99, P4097, DOI 10.1073/pnas.052564899; Yang TB, 2000, J BIOL CHEM, V275, P3137, DOI 10.1074/jbc.275.5.3137; Yang TB, 2000, J BIOL CHEM, V275, P38467, DOI 10.1074/jbc.M003566200; Zegzouti H, 1999, PLANT J, V18, P589, DOI 10.1046/j.1365-313x.1999.00483.x; Zhu JK, 2001, CURR OPIN PLANT BIOL, V4, P401, DOI 10.1016/S1369-5266(00)00192-8; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	54	257	301	2	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45049	45058		10.1074/jbc.M207941200	http://dx.doi.org/10.1074/jbc.M207941200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12218065	hybrid			2022-12-25	WOS:000179404800060
J	Berridge, G; Dickinson, G; Parrington, J; Galione, A; Patel, S				Berridge, G; Dickinson, G; Parrington, J; Galione, A; Patel, S			Solubilization of receptors for the novel Ca2+-mobilizing messenger, nicotinic acid adenine dinucleotide phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; INOSITOL TRISPHOSPHATE RECEPTORS; CALCIUM-RELEASE CHANNEL; INDUCED CA2+ RELEASE; NAADP RECEPTORS; BINDING; COORDINATION; PURIFICATION; INHIBITION; CALMODULIN	Nicotinic acid adenine dinucleotide phosphate (NAADP) is a potent Ca2+ mobilizing agent in a variety of broken and intact cell preparations. In sea urchin egg homogenates, NAADP releases Ca2+ independently of inositol trisphosphate or ryanodine receptor activation. Little, however, is known concerning the molecular target for NAADP. Here we report for the first time solubilization of NAADP receptors from sea urchin egg homogenates. Supernatant fractions, prepared following Triton X-100 treatment, bound [P-32]NAADP with similar affinity and selectivity as membrane preparations. Furthermore, the unusual non-dissociating nature of NAADP binding to its receptor was preserved upon solubilization. NAADP receptors could also be released into supernatant fractions upon detergent treatment of membranes prelabeled with [P-32]NAADP. Tagged receptors prepared in this way, were readily resolved by native gel electrophoresis as a single protein target. Gel filtration and sucrose density gradient centrifugation analysis indicates that NAADP receptors are substantially smaller than inositol trisphosphate or ryanodine receptors, providing further biochemical evidence that NAADP activates a novel intracellular Ca2+ release channel.	UCL, Dept Physiol, London WC1E 6BT, England; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of London; University College London; University of Oxford	Patel, S (corresponding author), UCL, Dept Physiol, Gower St, London WC1E 6BT, England.	patel.s@ucl.ac.uk	Dickinson, George/H-6609-2016; Galione, Antony/E-5884-2011; Dickinson, George/D-1461-2009; Patel, Sandip/O-9591-2015	Dickinson, George/0000-0001-7711-0388; Dickinson, George/0000-0001-7711-0388; Galione, Antony/0000-0002-4132-7646; Patel, Sandip/0000-0001-7247-2013				Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; Bak J, 2001, CURR BIOL, V11, P987, DOI 10.1016/S0960-9822(01)00269-X; Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; Berridge G, 2002, BIOCHEM J, V365, P295, DOI 10.1042/BJ20020180; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Billington RA, 2000, BIOCHEM BIOPH RES CO, V276, P112, DOI 10.1006/bbrc.2000.3444; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Chini EN, 1996, BIOCHEM J, V316, P709, DOI 10.1042/bj3160709; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; Churchill GC, 2000, J BIOL CHEM, V275, P38687, DOI 10.1074/jbc.M005827200; Churchill GC, 2001, EMBO J, V20, P2666, DOI 10.1093/emboj/20.11.2666; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GALIONE A, 1994, MOL CELL ENDOCRINOL, V98, P125, DOI 10.1016/0303-7207(94)90130-9; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Iino M, 1999, MOL CELL BIOCHEM, V190, P185, DOI 10.1023/A:1006951317052; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 1997, J BIOL CHEM, V272, P20378, DOI 10.1074/jbc.272.33.20378; Lee HC, 2000, J CELL SCI, V113, P4413; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; Patel S, 2000, J BIOL CHEM, V275, P36495, DOI 10.1074/jbc.C000458200; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; Patel S, 2000, BIOCHEM J, V352, P725, DOI 10.1042/0264-6021:3520725; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; Shi Q., 1998, GEL ELECTROPHORESIS; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0	43	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43717	43723		10.1074/jbc.M203224200	http://dx.doi.org/10.1074/jbc.M203224200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223470	hybrid			2022-12-25	WOS:000179272000024
J	Shackleton, S; Hamer, I; Foti, M; Zumwald, N; Maeder, C; Carpentier, JL				Shackleton, S; Hamer, I; Foti, M; Zumwald, N; Maeder, C; Carpentier, JL			Role of two dileucine-like motifs in insulin receptor anchoring to microvilli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIN GLYCOPROTEIN LIGAND-1; GROWTH-FACTOR RECEPTOR; AP-1 CLATHRIN ADAPTER; SURFACE REDISTRIBUTION; TYROSINE KINASE; HIV-1 NEF; BETA(2)-ADRENERGIC RECEPTOR; INTERNALIZATION SIGNALS; DIFFERENTIAL REGULATION; JUXTAMEMBRANE REGION	In the absence of ligand, the insulin receptor is maintained on microvilli on the cell surface. A dileucine-like motif (LL986-987) is necessary but not sufficient for this anchoring, which also required the presence of additional sequence(s) downstream of position 1000. The aim of the present study was to identify this (these) additional sequence(s). First, exons 16 or 17 were fused to the extracellular and transmembrane domains of complement receptor 1 and stably expressed in Chinese hamster ovary cells. Results obtained indicate that exon 17 is sufficient for anchoring to microvilli. Second, analysis of insulin receptor mutants truncated within exon 17 demonstrated that whereas receptors truncated at position 1000 showed no preferential association with microvilli, receptors truncated at position 1012 displayed a level of association identical to that of the full-length insulin receptor. Third, mutation of a diisoleucine motif (II1006-1007) present within this 12-amino acid stretch abrogated the preferential association of the receptor with microvilli. These results indicate that the domain required for association of insulin receptor with microvilli is contained within the region encoded by exon 17 and that, within this sequence, two dileucine-like motifs (LL986-987 and II1006-1007) play a crucial role.	Univ Geneva, Fac Med, Dept Morphol, CH-1211 Geneva 4, Switzerland	University of Geneva	Carpentier, JL (corresponding author), CMU, Fac Med, Dept Morphol, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland.			Foti, Michelangelo/0000-0001-7199-4135				Abitorabi MA, 1997, J CELL BIOL, V139, P563, DOI 10.1083/jcb.139.2.563; Accola MA, 1999, J VIROL, V73, P9992, DOI 10.1128/JVI.73.12.9992-9999.1999; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Bresnahan PA, 1998, CURR BIOL, V8, P1235, DOI 10.1016/S0960-9822(07)00517-9; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; Bruehl RE, 1997, J LEUKOCYTE BIOL, V61, P489, DOI 10.1002/jlb.61.4.489; CARPENTIER JL, 1993, HISTOCHEMISTRY, V100, P169, DOI 10.1007/BF00269090; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; CARPENTIER JL, 1994, DIABETOLOGIA, V37, pS117, DOI 10.1007/BF00400835; CARPENTIER JL, 1981, J CELL BIOL, V91, P17, DOI 10.1083/jcb.91.1.17; CARPENTIER JL, 1995, J BIOL CHEM, V270, P5001, DOI 10.1074/jbc.270.10.5001; CARPENTIER JL, 1985, DIABETES, V34, P1002, DOI 10.2337/diabetes.34.10.1002; CARPENTIER JL, 1978, J CLIN INVEST, V61, P1056; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; Craig HM, 2000, VIROLOGY, V271, P9, DOI 10.1006/viro.2000.0277; DEDIEGO JG, 1991, ENDOCRINOLOGY, V128, P2136, DOI 10.1210/endo-128-4-2136; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; ERLANDSEN SL, 1993, J HISTOCHEM CYTOCHEM, V41, P327, DOI 10.1177/41.3.7679125; FAN JY, 1982, P NATL ACAD SCI-BIOL, V79, P7788, DOI 10.1073/pnas.79.24.7788; Foti M, 2002, P NATL ACAD SCI USA, V99, P2008, DOI 10.1073/pnas.042689099; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HAFT CR, 1994, J BIOL CHEM, V269, P26286; Hamer I, 1997, J BIOL CHEM, V272, P21685, DOI 10.1074/jbc.272.35.21685; Hamer I, 2002, DIABETOLOGIA, V45, P657, DOI 10.1007/s00125-002-0798-5; Hamer I, 1998, BIOCHEM J, V329, P183, DOI 10.1042/bj3290183; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Kawakami K, 2001, J BIOL CHEM, V276, P25114, DOI 10.1074/jbc.M100936200; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Kil SJ, 2000, J CELL PHYSIOL, V185, P47, DOI 10.1002/1097-4652(200010)185:1<47::AID-JCP4>3.3.CO;2-F; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Louvard D, 1989, CURR OPIN CELL BIOL, V1, P51, DOI 10.1016/S0955-0674(89)80036-5; LUTON F, 1994, J IMMUNOL, V153, P63; MADI N, 1991, CLIN EXP IMMUNOL, V84, P9; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; PACCAUD JP, 1993, J BIOL CHEM, V268, P23191; PACCAUD JP, 1992, J BIOL CHEM, V267, P13101; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; Signoret N, 1998, J CELL SCI, V111, P2819; Subtil A, 1998, J BIOL CHEM, V273, P29424, DOI 10.1074/jbc.273.45.29424; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; Tikkanen R, 2000, TRAFFIC, V1, P631, DOI 10.1034/j.1600-0854.2000.010807.x; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Wu Z, 2001, J BIOL CHEM, V276, P5240, DOI 10.1074/jbc.M006684200; Wyss S, 2001, J VIROL, V75, P2982, DOI 10.1128/JVI.75.6.2982-2992.2001; YAMADA K, 1995, BIOCHEMISTRY-US, V34, P946, DOI 10.1021/bi00003a029; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	64	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43631	43637		10.1074/jbc.M204036200	http://dx.doi.org/10.1074/jbc.M204036200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12218050	hybrid			2022-12-25	WOS:000179272000014
J	Ceccarelli, C; Grodsky, NB; Ariyaratne, N; Colman, RF; Bahnson, BJ				Ceccarelli, C; Grodsky, NB; Ariyaratne, N; Colman, RF; Bahnson, BJ			Crystal structure of porcine mitochondrial NADP(+)-dependent isocitrate dehydrogenase complexed with Mn2+ and isocitrate - Insights into the enzyme mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-HEART; BINDING-SITE; SUBSTRATE-SPECIFICITY; MAGNETIC-RESONANCE; SEQUENCE ALIGNMENT; MANGANOUS ION; ACTIVE-SITE; METAL-IONS; PROTEIN; PHOSPHORYLATION	The crystal structure of porcine heart mitochondrial NADP(+)-dependent isocitrate dehydrogenase (IDH) complexed with Mn2+ and isocitrate was solved to a resolution of 1.85 Angstrom. The enzyme was expressed in Escherichia coli, purified as a fusion protein with maltose binding protein, and cleaved with thrombin to yield homogeneous enzyme. The structure was determined by multi-wavelength anomalous diffraction phasing using selenium substitution in the form of selenomethionine as the anomalous scatterer. The porcine NADP(+)-IDH enzyme is structurally compared with the previously solved structures of IDH from E. coli and Bacillus subtilis that share 16 and 17% identity, respectively, with the mammalian enzyme. The porcine enzyme has a protein fold similar to the bacterial IDH structures with each monomer folding into two domains. However, considerable differences exist between the bacterial and mammalian forms of IDH in regions connecting core secondary structure. Based on the alignment of sequence and structure among the porcine, E. coli, and R subtilis IDH, a putative phosphorylation site has been identified for the mammalian enzyme. The active site, including the bound Mn2+-isocitrate complex, is highly ordered and, therefore, mechanistically informative. The consensus IDH mechanism predicts that the Mn2+-bound hydroxyl of isocitrate is deprotonated prior to its NADP(+)-dependent oxidation. The present crystal structure has an active site water that is well positioned to accept the proton and ultimately transfer the proton to solvent through an additional bound water.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Delaware	Bahnson, BJ (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.	bahnson@udel.edu			NHLBI NIH HHS [HL67774] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067774] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen F.H., 1993, CHEM DESIGN AUTOMATI, V8, P31; ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; BAILEY JM, 1987, BIOCHEMISTRY-US, V26, P4893, DOI 10.1021/bi00389a042; BAILEY JM, 1985, BIOCHEMISTRY-US, V24, P5367, DOI 10.1021/bi00341a015; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cherbavaz DB, 2000, J MOL BIOL, V295, P377, DOI 10.1006/jmbi.1999.3195; COLMAN RF, 1973, J BIOL CHEM, V248, P8137; COLMAN RF, 1972, J BIOL CHEM, V247, P215; COLMAN RF, 1983, PEPTIDE PROTEIN REV, V1, P41; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Doyle SA, 2001, BIOCHEMISTRY-US, V40, P4234, DOI 10.1021/bi002533q; EHRLICH RS, 1990, BIOCHEMISTRY-US, V29, P5179, DOI 10.1021/bi00473a026; EHRLICH RS, 1983, J BIOL CHEM, V258, P7079; EHRLICH RS, 1981, J BIOL CHEM, V256, P1276; EHRLICH RS, 1982, J BIOL CHEM, V257, P4769; EHRLICH RS, 1989, BIOCHEMISTRY-US, V28, P2058, DOI 10.1021/bi00431a014; FinerMoore J, 1997, BIOCHEMISTRY-US, V36, P13890, DOI 10.1021/bi9711691; Grodsky NB, 2000, BIOCHEMISTRY-US, V39, P2193, DOI 10.1021/bi9919753; HASELBECK RJ, 1992, BIOCHEMISTRY-US, V31, P6219, DOI 10.1021/bi00142a007; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang YC, 2002, BIOCHEMISTRY-US, V41, P5637, DOI 10.1021/bi0200716; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; JOHANSON RA, 1981, ARCH BIOCHEM BIOPHYS, V207, P9, DOI 10.1016/0003-9861(81)90002-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, CCP4 STUDY WEEKEND 1, P91; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; KELLY JH, 1981, J BIOL CHEM, V256, P330; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KLEYWEGT GJ, 1994, CCP4 P, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; MAS MT, 1984, BIOCHEMISTRY-US, V23, P1675, DOI 10.1021/bi00303a015; NORTHROP DB, 1974, J BIOL CHEM, V249, P2928; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RUSSELL RB, 1992, PROTEINS, V14, P309, DOI 10.1002/prot.340140216; Singh SK, 2002, J BIOL CHEM, V277, P7567, DOI 10.1074/jbc.M107908200; Singh SK, 2001, J BIOL CHEM, V276, P26154, DOI 10.1074/jbc.M101191200; Soundar S, 2000, J BIOL CHEM, V275, P5606, DOI 10.1074/jbc.275.8.5606; Soundar S, 1996, PROTEIN EXPRES PURIF, V8, P305, DOI 10.1006/prep.1996.0105; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9310, DOI 10.1021/bi00087a008; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9317, DOI 10.1021/bi00087a009; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1872, DOI 10.1107/S090744499901029X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; VANDERHELM D, 1968, ACTA CRYSTALL B-STRU, VB 24, P578, DOI 10.1107/S0567740868002864; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; VILLAFRANCA JJ, 1972, J BIOL CHEM, V247, P209	58	93	95	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43454	43462		10.1074/jbc.M207306200	http://dx.doi.org/10.1074/jbc.M207306200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12207025	hybrid			2022-12-25	WOS:000179081200130
J	Takei, Y; Assenberg, M; Tsujimoto, G; Laskey, R				Takei, Y; Assenberg, M; Tsujimoto, G; Laskey, R			The MCM3 acetylase MCM3AP inhibits initiation, but not elongation, of DNA replication via interaction with MCM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME MAINTENANCE PROTEIN; SACCHAROMYCES-CEREVISIAE; GERMINAL CENTER; NUCLEAR-LOCALIZATION; HELICASE ACTIVITY; BIND CHROMATIN; CELL-CYCLE; S-PHASE; COMPLEX; GANP	Minichromosome maintenance (MCM) proteins are essential components of pre-replication complexes, which limit DNA replication to once per cell cycle. MCM3 acetylating protein, MCM3AP, binds and acetylates MCM3 and inhibits cell cycle progression. In the present study, we examined inhibition of the cell cycle by MCM3AP in a cell-free system. We show here that wild type MCM3AP, but not the acetylase-deficient mutant, inhibits initiation of DNA replication, but not elongation. Both wild type and acetylase-deficient mutant MCM3AP, however, can bind to chromatin through interaction with MCM3. These results indicate that MCM3 acetylase activity of MCM3AP is required to inhibit initiation of DNA replication and that association of MCM3AP to chromatin alone is not sufficient for the inhibition. We also show that interaction between MCM3 and MCM3AP is essential for nuclear localization and chromatin binding of MCM3AP. Furthermore, the chromatin binding of MCM3AP is temporally correlated with that of endogenous MCM3 when cells were released from mitosis. Hence, MCM3AP is a potent natural inhibitor of the initiation of DNA replication whose action is mediated by interaction with MCM3.	Hutchinson MRC Res Ctr, Canc Cell Unit, Med Res Council MRC, Canc Cell Unit, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Zool, Cambridge, England; Childrens Natl Med Ctr, Div Mol Cell Pharmacol, Setagaya Ku, Tokyo 1548509, Japan	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Cambridge	Takei, Y (corresponding author), Hutchinson MRC Res Ctr, Canc Cell Unit, Med Res Council MRC, Canc Cell Unit, Hills Rd, Cambridge CB2 2XZ, England.							Abe E, 2000, GENE, V255, P219, DOI 10.1016/S0378-1119(00)00336-X; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; Krude T, 2000, J BIOL CHEM, V275, P13699, DOI 10.1074/jbc.275.18.13699; Krude T, 1996, J CELL SCI, V109, P309; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; Kuwahara K, 2000, BLOOD, V95, P2321, DOI 10.1182/blood.V95.7.2321.007k33_2321_2328; Kuwahara K, 2001, P NATL ACAD SCI USA, V98, P10279, DOI 10.1073/pnas.181335698; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takei Y, 1998, J BIOL CHEM, V273, P22177, DOI 10.1074/jbc.273.35.22177; Takei Y, 2001, EMBO REP, V2, P119, DOI 10.1093/embo-reports/kve026; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587; Young MR, 1997, GENES CELLS, V2, P631, DOI 10.1046/j.1365-2443.1997.1510349.x	21	32	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43121	43125		10.1074/jbc.C200442200	http://dx.doi.org/10.1074/jbc.C200442200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12226073	hybrid			2022-12-25	WOS:000179081200092
J	La Ferla, K; Reimann, C; Jelkmann, W; Hellwig-Burgel, T				La Ferla, K; Reimann, C; Jelkmann, W; Hellwig-Burgel, T			Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappa B	FASEB JOURNAL			English	Article						cytokines; anemia; interleukin 1; tumor necrosis factor alpha; promoter	NECROSIS-FACTOR-ALPHA; NEGATIVE REGULATION; BINDING-PROTEINS; DNA-BINDING; HIF-ALPHA; INTERLEUKIN-1-BETA; SUPPRESSION; HYDROXYLATION; PATHOGENESIS; STIMULATION	The anemia of chronic inflammatory and malignant diseases is partly due to impaired synthesis of the hormone erythropoietin (Epo). The proinflammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-alpha) suppress in vitro Epo gene expression and Epo protein secretion. However, the molecular mechanisms of this inhibition are poorly understood. The human Epo promoter and the 5' flanking region contain several recognition sequences for transcription factors acting either positively or negatively. Herein, we investigated the roles of the transcription factors GATA-2 and NF-kappaB in the modulation of Epo gene expression by IL-1beta and TNF-alpha in the human hepatoma cell line HepG2. Electrophoretic mobility shift assays revealed increased GATA-2 and NF-kappaB DNA binding in cells treated with IL-1beta or TNF-alpha. Reporter gene assays with a sequence from the Epo promoter in front of the firefly luciferase gene showed that the cytokines reduced Epo reporter gene activity. Functional inactivation of GATA-2 and NF-kappaB by oligo-decoy techniques prevented the inhibition of Epo production by IL-1beta and TNF-alpha. In HepG2 cells stably transfected with a dominant-negative form of IkappaBalpha, the activation of NF-kappaB was inhibited, while Epo mRNA levels and Epo secretion increased. Thus, both GATA-2 and NF-kappaB seem to be involved in the suppression of Epo gene expression by IL-1beta and TNF-alpha in vitro and may be responsible for impaired Epo synthesis in inflammatory diseases in vivo.	Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany	University of Lubeck	Jelkmann, W (corresponding author), Univ Lubeck, Inst Physiol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	jelkmann@physio.uni-luebeck.de	Hellwig-Bürgel, Thomas/K-6696-2013; Jelkmann, Wolfgang/AAF-8897-2019					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ebert BL, 1999, BLOOD, V94, P1864; FANDREY J, 1994, EUR J BIOCHEM, V226, P335, DOI 10.1111/j.1432-1033.1994.tb20057.x; FAQUIN WC, 1992, BLOOD, V79, P1987; Frede S, 1997, AM J PHYSIOL-REG I, V273, pR1067, DOI 10.1152/ajpregu.1997.273.3.R1067; Gires O, 2001, CANCER, V92, P620, DOI 10.1002/1097-0142(20010801)92:3<620::AID-CNCR1362>3.0.CO;2-F; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; Han YQ, 1999, J BIOL CHEM, V274, P939, DOI 10.1074/jbc.274.2.939; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; IMAGAWA S, 1994, J BIOL CHEM, V269, P9038; Imagawa S, 1997, BLOOD, V89, P1430, DOI 10.1182/blood.V89.4.1430; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwase R, 1997, Nucleic Acids Symp Ser, P203; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JELKMANN W, 1992, LIFE SCI, V50, P301, DOI 10.1016/0024-3205(92)90338-P; Jelkmann W, 1998, J INTERF CYTOK RES, V18, P555, DOI 10.1089/jir.1998.18.555; Jelkmann W, 1999, EXP HEMATOL, V27, P224, DOI 10.1016/S0301-472X(98)00054-X; JOHNSON CS, 1989, BLOOD, V73, P678; Ke S, 2001, J BIOL CHEM, V276, P39638, DOI 10.1074/jbc.M106286200; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LEEHUANG S, 1993, GENE, V128, P227, DOI 10.1016/0378-1119(93)90567-M; MEANS RT, 1992, BLOOD, V80, P1639; SCHOOLEY JC, 1987, BRIT J HAEMATOL, V67, P11, DOI 10.1111/j.1365-2141.1987.tb02289.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; Tabata M, 2001, J CELL PHYSIOL, V186, P260, DOI 10.1002/1097-4652(200002)186:2<260::AID-JCP1025>3.0.CO;2-K; Tarumoto T, 2000, BLOOD, V96, P1716, DOI 10.1182/blood.V96.5.1716.h8001716_1716_1722; Tsuchiya T, 1997, J BIOCHEM, V121, P193; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	33	117	127	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1811	+		10.1096/fj.02-0168fje	http://dx.doi.org/10.1096/fj.02-0168fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223449				2022-12-25	WOS:000181189100010
J	Budram-Mahadeo, V; Morris, PJ; Latchman, DS				Budram-Mahadeo, V; Morris, PJ; Latchman, DS			The Brn-3a transcription factor inhibits the pro-apoptotic effect of p53 and enhances cell cycle arrest by differentially regulating the activity of the p53 target genes encoding Bax and p21(CIP1/Waf1)	ONCOGENE			English	Article						Brn-3a; p53; neuronal cells; apoptosis; cell-cycle arrest	NEURONAL DEATH; SYMPATHETIC NEURONS; GROWTH-FACTOR; EXPRESSION; BCL-2; ACTIVATION; PROMOTER; SURVIVAL; OUTGROWTH; DISTINCT	We have previously shown that the anti-apoptotic transcription factor, Brn-3a and the pro-apoptotic p53 factor have antagonistic effects on the promoter of the gene encoding the anti-apoptotic Bcl-2 protein, with p53 abolishing activation by Brn-3a. Here we demonstrate that this antagonism is also observed on the gene encoding the pro-apoptotic Bax protein with Brn-3a abolishing the ability of p53 to activate the Bax promoter and induce Bax protein expression. In contrast, Brn-3a and p53 cooperative to induce maximal activation of another p53 target gene encoding the cyclin dependent kinase inhibitor, p21(CIP1/Waf1). These differential effects of Brn-3a on p53-inducible genes involved in apoptosis or growth arrest are paralleled by its effects on these processes themselves. Thus, we show that Brn-3a antagonises the anti-apoptotic effect of p53 but co-operates with p53 to induce cell cycle arrest. The potential role of Brn-3a in determining the outcome of enhanced p53 levels is discussed.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England	University of London; University College London	Budram-Mahadeo, V (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guildord St, London WC1N 1EH, England.	v.mahadeo@ich.ucl.ac.uk			Medical Research Council [G9901318] Funding Source: Medline; MRC [G9901318] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; D'Mello SR, 1998, CURR TOP DEV BIOL, V39, P187, DOI 10.1016/S0070-2153(08)60456-1; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; EL DW, 1993, CELL, V75, P817; Eng SR, 2001, J NEUROSCI, V21, P541, DOI 10.1523/JNEUROSCI.21-02-00541.2001; Ensor E, 2001, J BIOL CHEM, V276, P5204, DOI 10.1074/jbc.M007068200; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; Johnson MD, 1999, J NEUROSCI, V19, P2996; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Railson JE, 2001, J MOL CELL CARDIOL, V33, P1209, DOI 10.1006/jmcc.2001.1384; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Savitz SI, 1998, NEUROSURGERY, V42, P555, DOI 10.1097/00006123-199803000-00026; Sieber-Blum M, 1998, BIOCHEM CELL BIOL, V76, P1039, DOI 10.1139/bcb-76-6-1039; Smith MD, 1997, J BIOL CHEM, V272, P21325, DOI 10.1074/jbc.272.34.21325; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Smith MD, 2001, MOL CELL NEUROSCI, V17, P460, DOI 10.1006/mcne.2000.0927; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950	33	44	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6123	6131		10.1038/sj.onc.1205842	http://dx.doi.org/10.1038/sj.onc.1205842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203124	Bronze			2022-12-25	WOS:000177671300015
J	Hu, AH; Wang, F; Sellers, JR				Hu, AH; Wang, F; Sellers, JR			Mutations in human nonmuscle myosin IIA found in patients with May-Hegglin anomaly and Fechtner syndrome result in impaired enzymatic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; HEAVY-CHAINS; LIGHT-CHAIN; IN-VITRO; STATE; ACTIN; EXPRESSION; FRAGMENTS; PLATELET; COMPLEX	A family of autosomal-dominant diseases including May-Hegglin anomaly, Fechtner syndrome, Sebastian syndrome, Alport syndrome, and Epstein syndrome are commonly characterized by giant platelets and thrombocytopenia. In addition, there may be leukocyte inclusions, deafness, cataracts, and nephritis, depending on the syndrome. Mutations in the human nonmuscle myosin IIA heavy chain gene (WYH9) have been linked to these diseases. Two of the recently described mutations, N93K and R702C, are conserved in smooth and nonmuscle myosins from vertebrates and lie in the head domain of myosin. Interestingly, the two mutations lie within close proximity in the three-dimensional structure of myosin. These two mutations were engineered into a heavy meromyosin-like recombinant fragment of nonmuscle myosin IIA which was expressed in baculovirus along with the appropriate light chains. The R702C mutant displays 25% of the maximal MgATPase activity of wild type heavy meromyosin and moves actin filaments at half the wild type rate. The effects of the N93K mutation are more dramatic. This heavy meromyosin has only 4% of the maximal MgATPase activity of wild type and does not translocate actin filaments in an in vitro motility assay. Biochemical characterization of the mutant is consistent with this mutant being unable to fully adopt the "on" conformation.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sellers, JR (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001786, ZIAHL001786] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Bobkov AA, 2000, BIOPHYS J, V79, P460, DOI 10.1016/S0006-3495(00)76307-7; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; Cuda G, 1997, BIOPHYS J, V72, P1767, DOI 10.1016/S0006-3495(97)78823-4; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Friedman AL, 1998, BIOCHEMISTRY-US, V37, P9679, DOI 10.1021/bi973143f; HARRIS DE, 1994, J MUSCLE RES CELL M, V15, P11, DOI 10.1007/BF00123828; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; Heath KE, 2001, AM J HUM GENET, V69, P1033, DOI 10.1086/324267; Houdusse A, 2000, P NATL ACAD SCI USA, V97, P11238, DOI 10.1073/pnas.200376897; Italiano JE, 1999, J CELL BIOL, V147, P1299, DOI 10.1083/jcb.147.6.1299; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley MJ, 2000, NAT GENET, V26, P106, DOI 10.1038/79069; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; Kunishima S, 2001, J HUM GENET, V46, P722, DOI 10.1007/s100380170007; Kunishima S, 2001, BLOOD, V97, P1147, DOI 10.1182/blood.V97.4.1147; Lalwani AK, 2000, AM J HUM GENET, V67, P1121, DOI 10.1016/S0002-9297(07)62942-5; Mhawech P, 2000, AM J CLIN PATHOL, V113, P176, DOI 10.1309/FC4H-LM5V-VCW8-DNJU; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; Sellers J. R., 1999, MYOSINS; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SELLERS JR, 1983, J BIOL CHEM, V258, P4181; SELLERS JR, 1993, MOTILITY ASSAYS MOTO; Seri M, 2000, NAT GENET, V26, P103; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; Wang F, 2000, BIOCHEMISTRY-US, V39, P5555, DOI 10.1021/bi000133x	30	73	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46512	46517		10.1074/jbc.M208506200	http://dx.doi.org/10.1074/jbc.M208506200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12237319	hybrid			2022-12-25	WOS:000179529300105
J	Baumann, B; Bohnenstengel, F; Siegmund, D; Wajant, H; Weber, C; Herr, I; Debatin, KM; Proksch, P; Wirth, T				Baumann, B; Bohnenstengel, F; Siegmund, D; Wajant, H; Weber, C; Herr, I; Debatin, KM; Proksch, P; Wirth, T			Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIINFLAMMATORY SESQUITERPENE LACTONE; PROINFLAMMATORY GENE-EXPRESSION; REL TRANSCRIPTION FACTORS; CANCER-THERAPY; SIGNALING PATHWAY; INDUCED APOPTOSIS; KINASE COMPLEX; TNF; PROTEASOME; CURCUMIN	Crude extracts from different Aglaia species are used as anti-inflammatory remedies in the traditional medicine of several countries from Southeast Asia. Because NF-kappaB transcription factors represent key regulators of genes involved in immune and inflammatory responses, we supposed that the anti-inflammatory effects of Aglaia extracts are mediated by the inhibition of NF-kappaB activity. Purified compounds of Aglaia species, namely 1H-cyclopenta[b]benzofuran lignans of the rocaglamide type as well as one aglain congener were tested for their ability to inhibit NF-kappaB activity. We show that a group of rocaglamides represent highly potent and specific inhibitors of tumor necrosis factor-alpha (TNFalpha) and phorbol 12-myristate 13-acetate (PMA)-induced NF-kappaB-dependent reporter gene activity in Jurkat T cells with IC50 values in the nanomolar range. Some derivatives are less effective, and others are completely inactive. Rocaglamides are able to suppress the PMA-induced expression of NF-kappaB target genes and sensitize leukemic T cells to apoptosis induced by TNFalpha, cisplatin, and gamma-irradiation. The suppression of NF-kappaB activation correlated with the inhibition of induced IkappaBalpha degradation and IkappaBalpha kinase activation. The level of interference was determined and found to be localized upstream of the IkappaB kinase complex but downstream of the TNF receptor-associated protein 2. Our data suggest that rocaglamide derivatives could serve as lead structures in the development of anti-inflammatory and tumoricidal drugs.	Univ Ulm, Dept Chem Phys, D-89081 Ulm, Germany; Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Childrens Hosp, D-89075 Ulm, Germany; Univ Dusseldorf, Inst Pharmaceut Biol, D-40225 Dusseldorf, Germany; Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany	Ulm University; Ulm University; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Heine University Dusseldorf; University of Stuttgart; Helmholtz Association; German Cancer Research Center (DKFZ)	Wirth, T (corresponding author), Univ Ulm, Dept Chem Phys, D-89081 Ulm, Germany.	thomas.wirth@medizin.uni-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Proksch, Peter/AAR-4593-2020; Wajant, Harald/A-3020-2017; Wirth, Thomas/X-7172-2019	Debatin, Klaus-Michael/0000-0002-8397-1886; Wajant, Harald/0000-0002-2005-3949; 				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Baumann B, 1998, J BIOL CHEM, V273, P11448, DOI 10.1074/jbc.273.19.11448; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Bohnenstengel FI, 1999, Z NATURFORSCH C, V54, P55; Bohnenstengel FI, 1999, Z NATURFORSCH C, V54, P1075; Bork PM, 1997, FEBS LETT, V402, P85, DOI 10.1016/S0014-5793(96)01502-5; Brader G, 1998, J NAT PROD, V61, P1482, DOI 10.1021/np9801965; Brennan P, 1998, BIOCHEM PHARMACOL, V55, P965, DOI 10.1016/S0006-2952(97)00535-2; Chaidir, 1999, PHYTOCHEMISTRY, V52, P837, DOI 10.1016/S0031-9422(99)00327-1; Chen F, 1997, BIOCHEM BIOPH RES CO, V231, P99, DOI 10.1006/bbrc.1997.6057; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Cui BL, 1997, TETRAHEDRON, V53, P17625, DOI 10.1016/S0040-4020(97)10231-9; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Han SS, 1999, CLIN IMMUNOL, V93, P152, DOI 10.1006/clim.1999.4769; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hiort J, 1999, J NAT PROD, V62, P1632, DOI 10.1021/np990242g; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Jobin C, 1999, J IMMUNOL, V163, P3474; Kaltschmidt B, 1999, ONCOGENE, V18, P3213, DOI 10.1038/sj.onc.1202657; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kuprash DV, 1996, J IMMUNOL, V156, P2465; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee JH, 2002, J BIOL CHEM, V277, P18411, DOI 10.1074/jbc.M201368200; Lee SK, 1998, CHEM-BIOL INTERACT, V115, P215, DOI 10.1016/S0009-2797(98)00073-8; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Lyss G, 1997, BIOL CHEM, V378, P951, DOI 10.1515/bchm.1997.378.9.951; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nugroho BW, 1999, PHYTOCHEMISTRY, V51, P367, DOI 10.1016/S0031-9422(98)00751-1; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palombella VJ, 1998, P NATL ACAD SCI USA, V95, P15671, DOI 10.1073/pnas.95.26.15671; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Siegmund D, 2001, J BIOL CHEM, V276, P43708, DOI 10.1074/jbc.M106421200; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JM, 1999, MOL CELL BIOL, V19, P6195; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; Wu TS, 1997, J NAT PROD, V60, P606, DOI 10.1021/np970163+; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zwilling S, 1997, SCIENCE, V277, P221, DOI 10.1126/science.277.5323.221	78	78	83	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44791	44800		10.1074/jbc.M208003200	http://dx.doi.org/10.1074/jbc.M208003200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237314	hybrid			2022-12-25	WOS:000179404800028
J	Cory, GOC; Garg, R; Cramer, R; Ridley, AJ				Cory, GOC; Garg, R; Cramer, R; Ridley, AJ			Phosphorylation of tyrosine enhances the ability of WASp to stimulate actin polymerization and filopodium formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH-SYNDROME; SYNDROME PROTEIN WASP; SRC-FAMILY KINASES; FC-GAMMA-RI; ARP2/3 COMPLEX; N-WASP; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; FUNCTIONAL ASSOCIATION; MEDIATED PHAGOCYTOSIS; RHO GTPASES	Wiskott-Aldrich Syndrome protein (WASp) is a key regulator of the Arp2/3 complex and the actin cytoskeleton in hematopoietic cells. WASp is capable of forming an auto-inhibited conformation, which can be disrupted by binding of Cdc42 and phosphatidylinositol 4,5-bisphosphate, leading to its activation. Stimulation of the collagen receptor on platelets and crosslinking the B-cell receptor induce tyrosine phosphorylation of WASp. Here we show that the Src family kinase Hck induces phosphorylation of WASp-Tyr(291) independently of Cdc42 and that this causes a shift in the mobility of WASp upon SDS-PAGE. A phospho-mimicking mutant, WASp-Y291E, exhibited an enhanced ability to stimulate actin polymerization in a cell-free system and when microinjected into primary macrophages induced extensive filopodium formation with greater efficiency than wild-type WASp or a Y291F mutant. We propose that phosphorylation of Tyr(291) directly regulates WASp function.	Royal Free & Univ Coll Med Sch Branch, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Ridley, AJ (corresponding author), Royal Free & Univ Coll Med Sch Branch, Ludwig Inst Canc Res, Courtauld Bldg,91 Riding House St, London W1W 7BS, England.	anne@ludwig.ucl.ac.uk		Cramer, Rainer/0000-0002-8037-2511; Ridley, Anne/0000-0001-8186-5708				Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Allen WE, 1997, J CELL SCI, V110, P707; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Banin S, 1999, MOL BIOL REP, V26, P173, DOI 10.1023/A:1006954206151; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Binks M, 1998, EUR J IMMUNOL, V28, P3259; Burns S, 2001, BLOOD, V98, P1142, DOI 10.1182/blood.V98.4.1142; Cannon JL, 2001, IMMUNITY, V15, P249, DOI 10.1016/S1074-7613(01)00178-9; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; Chiaradonna F, 1999, EMBO J, V18, P3013, DOI 10.1093/emboj/18.11.3013; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; Cory GOC, 1996, J IMMUNOL, V157, P3791; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DURDEN DL, 1995, J IMMUNOL, V154, P4039; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Fradelizi J, 2001, NAT CELL BIOL, V3, P699, DOI 10.1038/35087009; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Gallego MD, 1997, BLOOD, V90, P3089, DOI 10.1182/blood.V90.8.3089; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; Gross BS, 1999, BLOOD, V94, P4166, DOI 10.1182/blood.V94.12.4166.424k36_4166_4176; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; Guinamard R, 1998, FEBS LETT, V434, P431, DOI 10.1016/S0014-5793(98)01016-3; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Le Clainche C, 2001, J BIOL CHEM, V276, P46689, DOI 10.1074/jbc.C100476200; Leverrier Y, 2001, J IMMUNOL, V166, P4831, DOI 10.4049/jimmunol.166.8.4831; Leverrier Y, 2001, CURR BIOL, V11, P195, DOI 10.1016/S0960-9822(01)00047-1; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Lorenzi R, 2000, BLOOD, V95, P2943, DOI 10.1182/blood.V95.9.2943.009k17_2943_2946; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; McGavin MKH, 2001, J EXP MED, V194, P1777, DOI 10.1084/jem.194.12.1777; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mizutani K, 2002, CANCER RES, V62, P669; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Scholz G, 2000, J BIOL CHEM, V275, P14615, DOI 10.1074/jbc.275.19.14615; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Suen PW, 1999, J CELL SCI, V112, P4067; Suzuki T, 2000, J IMMUNOL, V165, P473, DOI 10.4049/jimmunol.165.1.473; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7; Zalevsky J, 2001, J BIOL CHEM, V276, P3468, DOI 10.1074/jbc.M006407200; Zicha D, 1998, BRIT J HAEMATOL, V101, P659, DOI 10.1046/j.1365-2141.1998.00767.x	53	165	171	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45115	45121		10.1074/jbc.M203346200	http://dx.doi.org/10.1074/jbc.M203346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235133	hybrid			2022-12-25	WOS:000179404800068
J	Kim, SY; Sharma, S; Hoskins, JR; Wickner, S				Kim, SY; Sharma, S; Hoskins, JR; Wickner, S			Interaction of the DnaK and DnaJ chaperone system with a native substrate, p1 RepA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE; ESCHERICHIA-COLI; ATP HYDROLYSIS; BINDING-SPECIFICITY; NUCLEOTIDE EXCHANGE; REPLICATION ORIGIN; INITIATOR PROTEIN; PEPTIDE-BINDING; CLPA CHAPERONE	DnaK, the Hsp70 chaperone of Escherichia coli interacts with protein substrates in an ATP-dependent manner, in conjunction with DnaJ and GrpE co-chaperones, to carry out protein folding, protein remodeling, and assembly and disassembly of multisubunit protein complexes. To understand how DnaJ targets specific proteins for recognition by the DnaK chaperone system, we investigated the interaction of DnaJ and DnaK with a known natural substrate, bacteriophage PI RepA protein. By characterizing RepA deletion derivatives, we found that DnaJ interacts with a region of RepA located between amino acids 180 and 200 of the 286-amino acid protein. A peptide corresponding to amino acids 180195 inhibited the interaction of RepA and DnaJ. Two site-directed RepA mutants with alanine substitutions in this region were about 4-fold less efficiently activated for oriP1 DNA binding by DnaJ and DnaK than wild type RepA. We also identified by deletion analysis a site in RepA, in the region of amino acids 35-49, which interacts with DnaK. An alanine substitution mutant in amino acids 36-39 was constructed and found defective in activation by DnaJ and DnaK. Taken together the results suggest that DnaJ and DnaK interact with separate sites on RepA.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wickner, S (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37,Rm 5144,37 Convent Dr,MSC37-4264, Bethesda, MD 20892 USA.							ALFANO C, 1989, J BIOL CHEM, V264, P10699; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Hoskins JR, 2000, J BIOL CHEM, V275, P35361, DOI 10.1074/jbc.M006288200; ISHIAI M, 1994, P NATL ACAD SCI USA, V91, P3839, DOI 10.1073/pnas.91.9.3839; Konieczny I, 2002, J BIOL CHEM, V277, P18483, DOI 10.1074/jbc.M107580200; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Mayer MP, 2000, BIOL CHEM, V381, P877, DOI 10.1515/BC.2000.109; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SKOWYRA D, 1993, J BIOL CHEM, V268, P25296; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	40	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44778	44783		10.1074/jbc.M206176200	http://dx.doi.org/10.1074/jbc.M206176200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237299	hybrid			2022-12-25	WOS:000179404800026
J	Almoguera, C; Rojas, A; Diaz-Martin, J; Prieto-Dapena, P; Carranco, R; Jordano, J				Almoguera, C; Rojas, A; Diaz-Martin, J; Prieto-Dapena, P; Carranco, R; Jordano, J			A seed-specific heat-shock transcription factor involved in developmental regulation during embryogenesis in sunflower	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; ACTIVATION; EXPRESSION; PROMOTER; COMPLEX; THERMOTOLERANCE; ARABIDOPSIS; FAMILY	We report the cloning and functional characterization of the first heat-shock transcription factor that is specifically expressed during embryogenesis in the absence of environmental stress. In sunflower embryos this factor, HaHSFA9, trans-activated promoters with poor consensus heat-shock cis-elements, including that of the seed-specific Hahsp17.6G1 gene. Mutations that improved the heat-shock cis-element consensus at the Hahsp17.7G4 promoter impaired transient activation by HaHSFA9 in sunflower embryos. The same mutations did not affect heat-shock-induced gene expression of this promoter in transgenic tobacco plants but reduced the developmental activation by endogenous heat-shock transcription factors (HSFs) in seeds. Sunflower, and perhaps other plants such as tobacco, differs from the vertebrate animal systems in having at least one specialized HSF with expression and (or) activation patterns strictly restricted to embryos. Our results strongly indicate that HaHSFA9 is a transcription factor critically involved in the developmental activation of Hahsp17.6G1 and in that of similar target genes as Hahsp17.7G4.	CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS)	Jordano, J (corresponding author), CSIC, Inst Recursos Nat & Agrobiol, Apartado 1052, E-41080 Seville, Spain.	fraga@cica.es	Diaz-Martin, Juan/AAU-1685-2021; Diaz-Martin, Juan/GSI-9230-2022; Rojas, Anabel/E-8768-2014; Almoguera, Concepción/J-7026-2014; Jordano, Juan/J-5829-2012; Prieto-Dapena, Pilar/K-2090-2014; Diaz-Martin, Juan/F-4765-2015; Carranco, Raúl/GXG-1194-2022	Diaz-Martin, Juan/0000-0002-3985-6434; Rojas, Anabel/0000-0003-0733-8277; Almoguera, Concepción/0000-0002-7961-6507; Jordano, Juan/0000-0002-2583-4453; Prieto-Dapena, Pilar/0000-0002-2826-8688; Diaz-Martin, Juan/0000-0002-3985-6434; Carranco, Raúl/0000-0001-9359-9793; DIAZ MARTIN, JUAN JOSE/0000-0003-0962-8403				Almoguera C, 1998, PLANT J, V13, P437, DOI 10.1046/j.1365-313X.1998.00044.x; ALMOGUERA C, 1993, PLANT J, V4, P947, DOI 10.1046/j.1365-313X.1993.04060947.x; Bharti K, 2000, PLANT J, V22, P355, DOI 10.1046/j.1365-313x.2000.00746.x; Boscheinen O, 1997, MOL GEN GENET, V255, P322, DOI 10.1007/s004380050503; Carranco R, 1997, J BIOL CHEM, V272, P27470, DOI 10.1074/jbc.272.43.27470; Carranco R, 1999, PLANT PHYSIOL, V121, P723, DOI 10.1104/pp.121.3.723; Coca MA, 1996, PLANT MOL BIOL, V31, P863, DOI 10.1007/BF00019473; FIORENZA MT, 1995, NUCLEIC ACIDS RES, V23, P467, DOI 10.1093/nar/23.3.467; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Meijer AH, 2000, PLANT MOL BIOL MANUA, P1; Meisinger C, 1996, MOL BIOTECHNOL, V5, P289, DOI 10.1007/BF02900368; Mishra SK, 2002, GENE DEV, V16, P1555, DOI 10.1101/gad.228802; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Never L, 1996, CELL STRESS CHAPERON, V1, P215, DOI 10.1379/1466-1268(1996)001<0215:THWCAP>2.3.CO;2; Nover L, 2001, CELL STRESS CHAPERON, V6, P177, DOI 10.1379/1466-1268(2001)006<0177:AATHST>2.0.CO;2; Prandl R, 1998, MOL GEN GENET, V258, P269, DOI 10.1007/s004380050731; Rallu M, 1997, P NATL ACAD SCI USA, V94, P2392, DOI 10.1073/pnas.94.6.2392; Rojas A, 2002, PLANT PHYSIOL, V129, P1207, DOI 10.1104/pp.010927; Rojas A, 1999, PLANT J, V20, P601, DOI 10.1046/j.1365-313X.1999.00635.x; Schoffl F, 1998, PLANT PHYSIOL, V117, P1135, DOI 10.1104/pp.117.4.1135; Tanabe M, 1999, J BIOL CHEM, V274, P27845, DOI 10.1074/jbc.274.39.27845; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Yamanouchi U, 2002, P NATL ACAD SCI USA, V99, P7530, DOI 10.1073/pnas.112209199	26	70	84	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43866	43872		10.1074/jbc.M207330200	http://dx.doi.org/10.1074/jbc.M207330200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228226	hybrid, Green Published			2022-12-25	WOS:000179272000045
J	Haddad, LA; Smith, N; Bowser, M; Niida, Y; Murthy, V; Gonzalez-Agosti, C; Ramesh, V				Haddad, LA; Smith, N; Bowser, M; Niida, Y; Murthy, V; Gonzalez-Agosti, C; Ramesh, V			The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONE MORPHOLOGY; TUBEROUS SCLEROSIS; CELL-GROWTH; EMBRYONIC LETHALITY; GENE-PRODUCTS; COMPLEX; EXPRESSION; MOTILITY; MUTATION; RADIXIN	Tuberous sclerosis complex, an autosomal dominant disease caused by mutations in either TSC1 or TSC2, is characterized by the development of hamartomas in a variety of organs. The proteins encoded by TSC1 and TSC2, hamartin and tuberin, respectively, associate with each other forming a tight complex. Here we show that hamartin binds the neurofilament light chain and it is possible to recover the hamartin-tuberin complex over the neurofilament light chain rod domain spanning amino acids 93-156 by affinity precipitation. Homologous rod domains in other intermediate filaments such as neurofilament medium chain, a-inter-nexin, vimentin, and desmin are not able to bind hamartin. In cultured cortical neurons, hamartin and tuberin co-localize with neurofilament light chain preferentially in the proximal to central growth cone region. Interestingly, in the distal part of the growth cone hamartin overlaps with the ezrin-radixin-moesin family of actin binding proteins, and we have validated the interaction of hamartin with moesin. These results demonstrate that hamartin may anchor neuronal intermediate filaments to the actin cytoskeleton, which may be critical for some of the CNS functions of the hamartin-tuberin complex, and abolishing this through mutations in TSC1 or TSC2 may lead to certain neurological manifestations associated with the disease.	Massachusetts Gen Hosp, Ctr Canc, Mol Neurogenet Unit, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Ramesh, V (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Mol Neurogenet Unit, Bldg 149,13th St,Rm 6222, Charlestown, MA 02129 USA.	ramesh@helix.mgh.harvard.edu	Haddad, Luciana A/D-8002-2012	Haddad, Luciana A/0000-0003-1043-8981	NINDS NIH HHS [NS41917, NS24279] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279, R01NS041917] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Au KS, 1999, AM J HUM GENET, V65, P1790, DOI 10.1086/302648; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; BIRGBAUER E, 1991, J NEUROSCI RES, V30, P232; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Castelo L, 1999, MOL BIOL CELL, V10, P1511, DOI 10.1091/mbc.10.5.1511; Catania MG, 2001, J NEUROSCI RES, V63, P276, DOI 10.1002/1097-4547(20010201)63:3<276::AID-JNR1021>3.0.CO;2-A; CAVINESS VS, 1991, ANN NY ACAD SCI, V615, P187; EKER R, 1981, DIAGN HISTOPATHOL, V4, P99; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; GonzalezAgosti C, 1996, CELL MOTIL CYTOSKEL, V34, P122, DOI 10.1002/(SICI)1097-0169(1996)34:2<122::AID-CM4>3.0.CO;2-D; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; Gutmann DH, 2000, ACTA NEUROPATHOL, V99, P223, DOI 10.1007/PL00007431; Henske EP, 1996, AM J HUM GENET, V59, P400; HIROSE T, 1995, ACTA NEUROPATHOL, V90, P387; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; HUTTENLOCHER PR, 1991, ANN NY ACAD SCI, V615, P140; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; KOBAYASHI T, 1995, NAT GENET, V9, P218, DOI 10.1038/ng0295-218a; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Leung CL, 2001, J CELL SCI, V114, P3409; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Murthy V, 2001, ACTA NEUROPATHOL, V101, P202; Murthy V, 2000, AM J PHYSIOL-RENAL, V278, pF737; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Paglini G, 1998, J CELL BIOL, V143, P443, DOI 10.1083/jcb.143.2.443; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413	42	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44180	44186		10.1074/jbc.M207211200	http://dx.doi.org/10.1074/jbc.M207211200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226091	hybrid			2022-12-25	WOS:000179272000084
J	Husted, LB; Sorensen, EB; Armstrong, PB; Quigley, JP; Kristensen, L; Sottrup-Jensen, L				Husted, LB; Sorensen, EB; Armstrong, PB; Quigley, JP; Kristensen, L; Sottrup-Jensen, L			Localization of carbohydrate attachment sites and disulfide bridges in Limulus alpha(2)-macroglobulin - Evidence for two forms differing primarily in their bait region sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING DOMAIN; ALPHA-1-INHIBITOR-III MESSENGER-RNA; NATIVE HUMAN ALPHA(2)-MACROGLOBULIN; N-LINKED OLIGOSACCHARIDES; AMERICAN HORSESHOE-CRAB; AMINO-ACID-SEQUENCE; HUMAN ALPHA-2-MACROGLOBULIN; ALPHA-MACROGLOBULIN; 3-DIMENSIONAL STRUCTURE; HEMOLYTIC SYSTEM	The primary structure determination of the dimeric invertebrate alpha(2)-macroglobulin (a,M) from Limulus polyphemus has been completed by determining its sites of glycosylation and disulfide bridge pattern. Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine. Nine disulfide bridges, which are homologues with bridges in human alpha(2)M, have been identified (Cys(228)-Cys(269), cys(456)-cys(580), cys(612)-cys(799) ,cys(657)-cys(707), cys(849)-Cys(176), Cys(874)-Cys(910), Cys(946)-Cys(1328), Cys(1104)-Cys(1155), and Cys(1362)-Cys(1475)). In addition to these bridges, Limulus a2M contains three unique bridges that connect Cys(361) and Cys(382), Cys(1370) and Cys(1374), respectively, and Cys(719) in one subunit with the same residue in the other subunit of the dimer. The latter bridge forms the only interchain disulfide bridge in Limulus alpha(2)M. The location of this bridge within the bait region is discussed and compared with other alpha-macroglobulins. Several peptides identified in the course of determining the disulfide bridge pattern provided evidence for the existence of two forms of Limulus alpha(2)M. The two forms have a high degree of sequence identity, but they differ extensively in large parts of their bait regions suggesting that they have different inhibitory spectra. The two forms (Limulus alpha(2)M-1 and -2) are most likely present in an similar to2:1 ratio in the hemolymph of each animal, and they can be partially separated on a Mono Q column at pH 7.4 by applying a shallow gradient of NaCl.	Aarhus Univ, Dept Mol Biol, Sci Pk Div, DK-8000 Aarhus C, Denmark; Marine Biol Lab, Woods Hole, MA 02543 USA; Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Aarhus University; Marine Biological Laboratory - Woods Hole; University of California System; University of California Davis; Scripps Research Institute	Sottrup-Jensen, L (corresponding author), Aarhus Univ, Dept Mol Biol, Sci Pk Div, Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.	lsj@mb.au.dk		Armstrong, Peter/0000-0001-5197-1999; Sorensen, Esben Skipper/0000-0002-7050-3354				AIELLO LP, 1988, J BIOL CHEM, V263, P4013; ARMSTRONG PB, 1994, ANN NY ACAD SCI, V737, P188, DOI 10.1111/j.1749-6632.1994.tb44312.x; ARMSTRONG PB, 1991, J BIOL CHEM, V266, P2526; ARMSTRONG PB, 1987, BIOCHEM J, V248, P703, DOI 10.1042/bj2480703; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BENDIXEN E, 1992, BIOCHEMISTRY-US, V31, P3611, DOI 10.1021/bi00129a009; Bowen ME, 1998, J BIOL CHEM, V273, P1825, DOI 10.1074/jbc.273.3.1825; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; CRIMMINS DL, 1989, ANAL BIOCHEM, V176, P255, DOI 10.1016/0003-2697(89)90305-9; DOLMER K, 1993, FEBS LETT, V315, P85, DOI 10.1016/0014-5793(93)81139-Q; Dolmer K, 1996, FEBS LETT, V393, P37, DOI 10.1016/0014-5793(96)00852-6; ENGHILD JJ, 1990, BIOCHEMISTRY-US, V29, P10070, DOI 10.1021/bi00495a009; GETTINS PGW, 1995, J BIOL CHEM, V270, P14160, DOI 10.1074/jbc.270.23.14160; HARPEL PC, 1973, J EXP MED, V138, P508, DOI 10.1084/jem.138.3.508; Iwaki D, 1996, EUR J BIOCHEM, V242, P822, DOI 10.1111/j.1432-1033.1996.0822r.x; Jenner L, 1998, STRUCTURE, V6, P595, DOI 10.1016/S0969-2126(98)00061-6; JENSEN PEH, 1986, J BIOL CHEM, V261, P5863; Kolodziej SJ, 1996, J STRUCT BIOL, V116, P366, DOI 10.1006/jsbi.1996.0054; Kopacek P, 2000, EUR J BIOCHEM, V267, P465, DOI 10.1046/j.1432-1327.2000.01020.x; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Mutsuro J, 2000, IMMUNOGENETICS, V51, P847, DOI 10.1007/s002510000216; Qazi U, 1998, J BIOL CHEM, V273, P8987, DOI 10.1074/jbc.273.15.8987; QUIGLEY JP, 1983, J BIOL CHEM, V258, P7903; QUIGLEY JP, 1985, J BIOL CHEM, V260, P2715; QUIGLEY JP, 1991, J BIOL CHEM, V266, P19426; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SORENSEN ES, 1993, J DAIRY RES, V60, P535, DOI 10.1017/S0022029900027886; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1993, BIOCHEM MOL BIOL INT, V30, P789; SOTTRUPJENSEN L, 1995, ANAL BIOCHEM, V225, P187, DOI 10.1006/abio.1995.1137; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1990, J BIOL CHEM, V265, P17727; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8293; SOTTRUPJENSEN L, 1994, ANN NY ACAD SCI, V737, P172, DOI 10.1111/j.1749-6632.1994.tb44311.x; SOTTRUPJENSEN L, 1990, COMP BIOCHEM PHYS B, V96, P621, DOI 10.1016/0305-0491(90)90066-3; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; Swarnakar S, 2000, BIOCHEM J, V347, P679, DOI 10.1042/0264-6021:3470679; TANAKA N, 1992, J BIOCHEM-TOKYO, V112, P68, DOI 10.1093/oxfordjournals.jbchem.a123867; TOMIYA N, 1993, J BIOL CHEM, V268, P113; VANKUIK JA, 1987, EUR J BIOCHEM, V169, P399; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369	43	14	14	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43698	43706		10.1074/jbc.M208236200	http://dx.doi.org/10.1074/jbc.M208236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12218066	Green Submitted, hybrid			2022-12-25	WOS:000179272000022
J	Jang, YJ; Ma, S; Terada, Y; Erikson, RL				Jang, YJ; Ma, S; Terada, Y; Erikson, RL			Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; PROTEIN-KINASE; 1 PLK1; SPINDLE; PLX1; PURIFICATION; PHOSPHATASE; ACTIVATION; CLONING; MUTANT	The mammalian polo-like kinase (Plk) plays a critical role in M-phase progression. Plk is phosphorylated and activated by an upstream kinase(s), which has not yet been identified in mammalian cells. Phosphopeptide mapping and phosphoamino acid analyses of Plk labeled in vivo and phosphorylated in vitro by Xenopus polo-like kinase kinase-1 (xPlkk1) or by lymphocyte-oriented kinase, its most closely related mammalian enzyme, indicate that Thr-210 is a major phosphorylation site in activated Plk from mitotic HeLa cells. Although the amino acid sequence surrounding Ser-137 is similar to that at Thr-210 and is conserved in Plk family members, Ser-137 is not detectably phosphorylated in mitotic mammalian cells or by xPlkk1 in vitro. Nevertheless, the substitution of either Thr-210 or Ser-137 with Asp (T210D or S137D) elevates the kinase activity of Plk. The kinase activity of the double mutant S137D/T210D is not significantly different from that of T210D or S137D, demonstrating that substitution of both residues does not have an additive effect on Plk activity. Expression of the S137D mutant construct arrested HeLa cells in early S-phase with slightly separated centrosomes, whereas cells expressing wild type and T210D were arrested or delayed in M-phase. These data indicate that the Ser-137 may have an unexpected and novel role in the function of Plk.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Erikson, RL (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	erikson@biosun.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059172] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59172] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Jiang W, 1998, BIOTECHNIQUES, V24, P349; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Kelm O, 2002, J BIOL CHEM, V277, P25247, DOI 10.1074/jbc.M202855200; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Pestov DG, 1999, BIOTECHNIQUES, V26, P102, DOI 10.2144/99261st04; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SUNKEL CE, 1988, J CELL SCI, V89, P25; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x	34	171	178	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44115	44120		10.1074/jbc.M202172200	http://dx.doi.org/10.1074/jbc.M202172200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12207013	hybrid, Green Published			2022-12-25	WOS:000179272000076
J	Peck, JW; Oberst, M; Bouker, KB; Bowden, E; Burbelo, PD				Peck, JW; Oberst, M; Bouker, KB; Bowden, E; Burbelo, PD			The RhoA-binding protein, Rhophilin-2, regulates actin cytoskeleton organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; SMALL GTPASE RHO; STRESS FIBERS; TYROSINE PHOSPHORYLATION; PUTATIVE TARGET; SERINE/THREONINE KINASE; MAMMALIAN HOMOLOG; FOCAL ADHESIONS; CELL-ADHESION; IDENTIFICATION	The Rho GTPases regulate the actin cytoskeleton through interactions with various downstream effector molecules. Here we have identified a ubiquitously expressed human RhoA-binding protein, designated Rhophilin-2. Rhophilin-2 shows 40% amino acid similarity to human Rhophilin-1 and contains an N-terminal Rho-binding, a central Bro1-like, and a C-terminal PDZ domain. Glutathione S-transferase-capture experiments revealed that Rhophilin-1 and Rhophilin-2 interacted with both GDP- and GTP-bound RhoA in vitro. Despite the ability of Rhophilin-1 and Rhophilin-2 to interact with RhoA in a nucleotide-independent fashion, Rho-induced serum response element transcriptional activity was not altered by expression of either of these molecules. Although Rhophilin-2-expressing HeLa cells showed a loss of actin stress fibers, Rhophilin-1 expression had no noticeable effect on the actin cytoskeleton. Coexpression of Rhophilin-2 with a constitutively active Rho mutant reversed the disassembly phenotype, in which the coexpressing cells were more spread and less contracted than Rho alone-expressing cells. Expression of various Rhophilin-2 deletion and point mutants containing the N-terminal RhoA-binding domain but lacking other regions suggested that the disassembly of F-actin stress fibers was not simply caused by Rho sequestration. In addition, the Bro1 and PDZ domains of Rhophilin-2 were required for disassembly. RhoA activity assays also revealed that Rhophilin-2-expressing cells showed increased levels of RhoA-GTP suggesting that the Rhophilin-2-induced disassembly of stress fibers was not mediated by decreased RhoA activity. Based on the biochemical and biological activity, Rhophilin-2 may function normally in a Rho pathway to limit stress fiber formation and/or increase the turnover of F-actin structures in the absence of high levels of RhoA activity.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA	Georgetown University	Burbelo, PD (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Rm W210,New Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	burbelpd@georgetown.edu			NCI NIH HHS [R29 CA422142] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Borinstein SC, 2000, CELL SIGNAL, V12, P769, DOI 10.1016/S0898-6568(00)00129-7; Bourbon HM, 2002, MECH DEVELOP, V110, P71, DOI 10.1016/S0925-4773(01)00566-4; Brill S, 1996, MOL CELL BIOL, V16, P4869; Burbelo PD, 1999, P NATL ACAD SCI USA, V96, P9083, DOI 10.1073/pnas.96.16.9083; Cao LG, 1998, J BIOL CHEM, V273, P21077, DOI 10.1074/jbc.273.33.21077; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Che SL, 1999, J BIOL CHEM, V274, P5522, DOI 10.1074/jbc.274.9.5522; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Fujita A, 2000, J CELL SCI, V113, P103; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; Kato T, 2001, J CELL SCI, V114, P775; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Morissette MR, 2000, AM J PHYSIOL-HEART C, V278, pH1769, DOI 10.1152/ajpheart.2000.278.6.H1769; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; NegreteUrtasun S, 1997, J BACTERIOL, V179, P1832, DOI 10.1128/jb.179.5.1832-1835.1997; Nickas ME, 1996, MOL CELL BIOL, V16, P2585; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Patrie KM, 2002, J BIOL CHEM, V277, P30183, DOI 10.1074/jbc.M203072200; Pirone DM, 2000, J BIOL CHEM, V275, P22650, DOI 10.1074/jbc.M002832200; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1999, NAT CELL BIOL, V1, pE64, DOI 10.1038/11034; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; SATOH S, 2001, J BIOL CHEM, V16, P16; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Springael JY, 2002, FEBS LETT, V517, P103, DOI 10.1016/S0014-5793(02)02586-3; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tian DH, 2002, MOL CELL BIOL, V22, P2650, DOI 10.1128/MCB.22.8.2650-2662.2002; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Xu WJ, 2001, J BACTERIOL, V183, P6917, DOI 10.1128/JB.183.23.6917-6923.2001	62	60	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43924	43932		10.1074/jbc.M203569200	http://dx.doi.org/10.1074/jbc.M203569200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221077	hybrid			2022-12-25	WOS:000179272000052
J	Tauchi-Sato, K; Ozeki, S; Houjou, T; Taguchi, R; Fujimoto, T				Tauchi-Sato, K; Ozeki, S; Houjou, T; Taguchi, R; Fujimoto, T			The surface of lipid droplets is a phospholipid monolayer with a unique fatty acid composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN-LAYER-CHROMATOGRAPHY; GPI-ANCHORED PROTEINS; ELECTRON-MICROSCOPY; CHOLESTEROL; CAVEOLIN; CELLS; LIPOSOMES; BODIES	We found that caveolin-2 is targeted to the surface of lipid droplets (Fujimoto, T., Kogo, H., Ishiguro, K., Tauchi, K., and Nomura, R. (2001) J. Cell Biol. 152,1079-1085) and hypothesized that the lipid droplet surface is a kind of membrane. To elucidate the characteristics of the lipid droplet surface, we isolated lipid droplets from HepG2 cells and analyzed them by cryoelectron microscopy and by mass spectrometry. By use of cryoelectron microscopy at the stage temperature of 4.2 K, the lipid droplet surface was observed as a single line without any fixation or staining, indicating the presence of a single layer of phospholipids. This result appeared consistent with the hypothesis that the lipid droplet surface is derived from the cytoplasmic leaflet of the endoplasmic reticulum membrane and may be continuous to it. However, mass spectrometry revealed that the fatty acid composition of phosphatidylcholine and lysophosphatidylcholine in lipid droplets is different from that of the rough endoplasmic reticulum. The ample presence of free cholesterol in lipid droplets also suggests that their surface is differentiated from the bulk endoplasmic reticulum. membrane. On the other hand, although caveolin-2beta and adipose differentiation-related protein, both localizing in lipid droplets, were enriched in the low density floating fraction, the fatty acid composition of the fraction was distinct from lipid droplets. Collectively, the result indicates that the lipid droplet surface is a hemi-membrane or a phospholipid monolayer containing cholesterol but is compositionally different from the endoplasmic reticulum membrane or the sphingolipid/cholesterol-rich microdomain.	Nagoya Univ, Grad Sch Med, Dept Anat & Mol Cell Biol, Nagoya, Aichi 4668550, Japan; Nagoya City Univ, Dept Biol Mol, Grad Sch Pharmaceut Sci, Nagoya, Aichi 4678603, Japan	Nagoya University; Nagoya City University	Fujimoto, T (corresponding author), Nagoya Univ, Grad Sch Med, Dept Anat & Mol Cell Biol, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.	tfujimot@med.nagoya-u.ac.jp	Fujimoto, Toyoshi/ABH-9058-2020	Fujimoto, Toyoshi/0000-0002-3601-7977				ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Fiske CH, 1925, J BIOL CHEM, V66, P375; FUJIMOTO K, 1995, J CELL SCI, V108, P3443; Fujimoto T, 1997, J HISTOCHEM CYTOCHEM, V45, P595, DOI 10.1177/002215549704500411; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; FUJIYOSHI Y, 1980, ULTRAMICROSCOPY, V5, P459, DOI 10.1016/S0304-3991(80)80004-0; FUJIYOSHI Y, 1991, ULTRAMICROSCOPY, V38, P241, DOI 10.1016/0304-3991(91)90159-4; FUJIYOSHI Y, 1994, EMBO J, V13, P318, DOI 10.1002/j.1460-2075.1994.tb06264.x; GAMBLE W, 1978, J LIPID RES, V19, P1068; Kellner-Weibel G, 2001, J LIPID RES, V42, P768; LANGE Y, 1989, J BIOL CHEM, V264, P3786; Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4; MACALA LJ, 1983, J LIPID RES, V24, P1243; MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156; MORIMOTO T, 1998, CELLS LAB MANUAL, P1; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PEIXOTODEMENEZES A, 1979, LAB INVEST, V40, P545; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Prattes S, 2000, J CELL SCI, V113, P2977; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Sato C, 2001, NATURE, V409, P1047, DOI 10.1038/35059098; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Shi ST, 2002, VIROLOGY, V292, P198, DOI 10.1006/viro.2001.1225; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stone SJ, 2000, J BIOL CHEM, V275, P34534, DOI 10.1074/jbc.M002865200; Taguchi R, 2000, J MASS SPECTROM, V35, P953, DOI 10.1002/1096-9888(200008)35:8<953::AID-JMS23>3.0.CO;2-4; TAHARA Y, 1994, MICRON, V25, P141, DOI 10.1016/0968-4328(94)90039-6; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29; Yu WG, 1998, AM J PATHOL, V152, P759; Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	40	488	511	2	59	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44507	44512		10.1074/jbc.M207712200	http://dx.doi.org/10.1074/jbc.M207712200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221100	hybrid			2022-12-25	WOS:000179272000122
J	Tsuboi, S; Kotani, Y; Ogawa, K; Hatanaka, T; Yatsushiro, S; Otsuka, M; Moriyama, Y				Tsuboi, S; Kotani, Y; Ogawa, K; Hatanaka, T; Yatsushiro, S; Otsuka, M; Moriyama, Y			An intramolecular disulfide bridge as a catalytic switch for serotonin N-acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PINEAL-GLAND; MELATONIN SYNTHESIS; PROTEASOMAL PROTEOLYSIS; ANGSTROM RESOLUTION; HYDROGEN-PEROXIDE; MECHANISM; PROTEIN; ENZYME; TRANSCRIPTION	Serotonin N-acetyltransferase (EC. 2.3.1.87) (AA-NAT) is a melatonin rhythm-generating enzyme in pineal glands. To establish a melatonin rhythm, AA-NAT activity is precisely regulated through several signaling pathways. Here we show novel regulation of AA-NAT activity, in which an intramolecular disulfide bond may function as a switch for the catalysis. Recombinant AANAT activity was irreversibly inhibited by N-ethylmaleimide (NEM) in an acetyl-CoA-protected manner. Oxidized glutathione or dissolved oxygen reversibly inhibited AA-NAT in an acetyl-CoA-protected manner. To identify the cysteine residues responsible for the inhibition, AA-NAT was first oxidized with dissolved oxygen, treated with NEM, reduced with dithiothreitol, and then labeled with [C-14]NEM. CyS61 and Cys(177) were specifically labeled in an acetyl-CoA-protected manner. The AA-NAT with the Cys(61) to Ala and Cys(177) to Ala double substitutions (C61A/C177A-AA-NAT) was fully active but did not exhibit sensitivity to either oxidation or NEM, whereas the AA-NATs with only the single substitutions retained about 40% of these sensitivities. An intramolecular disulfide bond between Cys(61) and Cys(177) formed upon oxidation and cleaved upon reduction was identified. Furthermore, Cl61A/C177A-AA-NAT expressed in COS7 cells wag relatively insensitive to H2O2-evoked oxidative stress, whereas wild-type AA-NAT was strongly inhibited under the same conditions. These results indicate that the formation and cleavage of the disulfide bond between Cys(61) and Cys(177) produce the active and inactive states of AA-NAT. It is possible that intracellular redox conditions regulate AA-NAT activity through switching via an intramolecular disulfide bridge.	Okayama Univ, Fac Pharmaceut Sci, Dept Biochem, Okayama 7008530, Japan; Res Inst Biol Sci Okayama, Okayama 7161241, Japan	Okayama University	Moriyama, Y (corresponding author), Okayama Univ, Fac Pharmaceut Sci, Dept Biochem, Tsushima 1-1-1, Okayama 7008530, Japan.							ANGELIS JD, 1998, J BIOL CHEM, V273, P3045; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; BORJIGIN J, 1995, NATURE, V378, P783, DOI 10.1038/378783a0; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; Coon SL, 2001, J BIOL CHEM, V276, P24097, DOI 10.1074/jbc.M011298200; Craft CM, 2000, MOL BRAIN RES, V75, P198, DOI 10.1016/S0169-328X(99)00278-8; De Wit R, 2001, FASEB J, V15, P306; Ferry G, 2000, J BIOL CHEM, V275, P8794, DOI 10.1074/jbc.275.12.8794; Foulkes NS, 1997, TRENDS NEUROSCI, V20, P487, DOI 10.1016/S0166-2236(97)01109-0; Ganguly S, 2001, P NATL ACAD SCI USA, V98, P8083, DOI 10.1073/pnas.141118798; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Khalil EM, 1998, J BIOL CHEM, V273, P30321, DOI 10.1074/jbc.273.46.30321; Khalil EM, 1998, J AM CHEM SOC, V120, P6195, DOI 10.1021/ja981365a; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KOSOWER NS, 1983, FUNCTIONS GLUTATHION, P307; Maronde E, 1999, J PINEAL RES, V27, P170, DOI 10.1111/j.1600-079X.1999.tb00613.x; Maronde E, 1999, J NEUROSCI, V19, P3326; Moriyama Y, 2000, J EXP BIOL, V203, P117; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; NAMBOODIRI MAA, 1981, SCIENCE, V213, P571, DOI 10.1126/science.7017937; NAMBOODIRI MAA, 1980, J BIOL CHEM, V255, P6032; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; ROSEBOOM PH, 1995, MOL PHARMACOL, V47, P439; Scheibner KA, 2002, J BIOL CHEM, V277, P18118, DOI 10.1074/jbc.M200595200; Schomerus C, 2000, J NEUROCHEM, V75, P2123, DOI 10.1046/j.1471-4159.2000.0752123.x; THOMAS KB, 1990, ANAL BIOCHEM, V184, P228, DOI 10.1016/0003-2697(90)90673-W; TOYOOKA T, 1983, J CHROMATOGR, V282, P495, DOI 10.1016/S0021-9673(00)91626-1; Toyooka T., 1988, ANAL CHIM ACTA, V205, P29; Zatz M, 2000, J NEUROCHEM, V74, P2315, DOI 10.1046/j.1471-4159.2000.0742315.x; Zhan-Poe XY, 1999, J PINEAL RES, V27, P49, DOI 10.1111/j.1600-079X.1999.tb00596.x	35	12	12	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44229	44235		10.1074/jbc.M203305200	http://dx.doi.org/10.1074/jbc.M203305200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12215431	hybrid			2022-12-25	WOS:000179272000091
J	Garrigue-Antar, L; Hartigan, N; Kadler, KE				Garrigue-Antar, L; Hartigan, N; Kadler, KE			Post-translational modification of bone morphogenetic protein-1 is required for secretion and stability of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN C-PROTEINASE; N-LINKED OLIGOSACCHARIDES; QUALITY-CONTROL; MOLECULAR CHAPERONE; ANGSTROM RESOLUTION; SPERMADHESIN FAMILY; CRYSTAL-STRUCTURE; ENZYME-ACTIVITY; CUB DOMAIN; IN-VITRO	Bone morphogenetic protein (BMP)-1 is a glycosylated metalloproteinase that is fundamental to the synthesis of a normal extracellular matrix because it cleaves type I procollagen, as well as other precursor proteins. Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain. In this study we showed that all these sites are N-glycosylated with complex-type oligosaccharides containing sialic acid, except Asn(726) presumably because proline occurs immediately C-terminal of threonine in the consensus sequence. Recombinant BMP-1 molecules lacking all glycosylation sites or the three CUB-specific sites were not secreted. BMP-1 lacking CUB glycosylation was translocated to the proteasome for degradation. BMP-1 molecules lacking individual glycosylation sites were efficiently secreted and exhibited full procollagen C-proteinase activity, but N332Q and N599Q exhibited a slower rate of cleavage. BMP-1 molecules lacking any one of the CUB-specific glycosylation sites were sensitive to thermal denaturation. The study showed that the glycosylation sites in the CUB domains of BMP-1 are important for secretion and stability of the molecule.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Garrigue-Antar, L (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Stopford Bldg 2-205,Oxford Rd, Manchester M13 9PT, Lancs, England.	laure.garrigue-antar@man.ac.uk	KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Garrigue-Antar, Laure/0000-0001-6331-8882				Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Charlwood J, 2001, J BIOL CHEM, V276, P16739, DOI 10.1074/jbc.M009361200; Christensen LL, 2000, GLYCOBIOLOGY, V10, P931, DOI 10.1093/glycob/10.9.931; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINELLI L, 1995, GENETICS, V141, P271; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; Garrigue-Antar L, 2001, J BIOL CHEM, V276, P26237, DOI 10.1074/jbc.M010814200; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; HWANG SPL, 1994, DEVELOPMENT, V120, P559; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Imperiali B, 1999, CURR OPIN CHEM BIOL, V3, P643, DOI 10.1016/S1367-5931(99)00021-6; KADLER KE, 1987, J BIOL CHEM, V262, P15696; Kadowaki T, 2000, J BIOL CHEM, V275, P25577, DOI 10.1074/jbc.M003521200; Kessler E, 2001, J BIOL CHEM, V276, P27051, DOI 10.1074/jbc.M102921200; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lehrman MA, 2001, J BIOL CHEM, V276, P8623, DOI 10.1074/jbc.R100002200; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; MAENO M, 1993, GENE, V134, P257, DOI 10.1016/0378-1119(93)90103-A; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; Martina JA, 1998, J BIOL CHEM, V273, P3725, DOI 10.1074/jbc.273.6.3725; MATSUI C, 1995, J BIOL CHEM, V270, P23496, DOI 10.1074/jbc.270.40.23496; Mimura Y, 2001, J BIOL CHEM, V276, P45539, DOI 10.1074/jbc.M107478200; Mullins MC, 1998, TRENDS GENET, V14, P127, DOI 10.1016/S0168-9525(98)01431-0; Nagai K, 1997, GLYCOBIOLOGY, V7, P769, DOI 10.1093/glycob/7.6.769; NGUYEN T, 1994, DEV BIOL, V166, P569, DOI 10.1006/dbio.1994.1338; Oka T, 2002, J BIOL CHEM, V277, P14724, DOI 10.1074/jbc.M110725200; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Romao MJ, 1997, J MOL BIOL, V274, P650, DOI 10.1006/jmbi.1997.1423; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; SARENEVA T, 1995, BIOCHEM J, V308, P9, DOI 10.1042/bj3080009; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; Spiro RG, 2000, J BIOL CHEM, V275, P35657, DOI 10.1074/jbc.R000022200; STOCKER W, 1995, PROTEIN SCI, V4, P823; Suzuki N, 1996, DEVELOPMENT, V122, P3587; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; Ujvari A, 2001, J BIOL CHEM, V276, P5924, DOI 10.1074/jbc.M009203200; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; Varela PF, 1997, J MOL BIOL, V274, P635, DOI 10.1006/jmbi.1997.1424; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wang CQ, 1996, BIOCHEMISTRY-US, V35, P7299, DOI 10.1021/bi9517704; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; Yasuda Y, 1999, EUR J BIOCHEM, V266, P383, DOI 10.1046/j.1432-1327.1999.00863.x	59	40	43	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43327	43334		10.1074/jbc.M207342200	http://dx.doi.org/10.1074/jbc.M207342200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12218058	hybrid			2022-12-25	WOS:000179081200116
J	Ader, I; Muller, C; Bonnet, J; Favre, G; Cohen-Jonathan, E; Salles, B; Toulas, C				Ader, I; Muller, C; Bonnet, J; Favre, G; Cohen-Jonathan, E; Salles, B; Toulas, C			The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit	ONCOGENE			English	Article						high molecular form of FGF-2; DNA repair; NHEJ; DNA-PK; radioresistance	FIBROBLAST-GROWTH-FACTOR; DOUBLE-STRAND BREAKS; PHOSPHATIDYLINOSITOL 3-KINASE; V(D)J RECOMBINATION; GENE-EXPRESSION; MESSENGER-RNA; KU-PROTEIN; IN-VITRO; REPAIR; WORTMANNIN	We previously reported that overexpression of the 24 kDa basic fibroblast factor (or FGF-2) isoform provides protection from the cytotoxic effect of ionizing radiation (IR). DNA double-strand breaks (DSB), the IR-induced lethal lesions, are mainly repaired in human cells by non-homologous end joining system (NHEJ). NHEJ reaction is dependent on the DNA-PK holoenzyme (composed of a regulatory sub-unit, Ku, and a catalytic sub-unit, DNA-PKcs) that assembles at sites of DNA damage. We demonstrated here that the activity of DNA-PK was increased by twofold in two independent radioresistant cell lines, HeLa 3A and CAPAN A3, overexpressing the 24 kDa FGF-2. This increase was associated with an overexpression of the DNA-PKcs without modification of Ku expression or activity. This overexpression was due to an up-regulation of the DNA-PKcs gene transcription by the 24 kDa FGF-2 isoform. Finally, HeLa 3A cells exhibited the hallmarks of phenotypic changes associated with the overexpression of an active DNA-PKcs. Indeed, a faster repair rate of DSB and sensitization to IR by wortmannin was observed in these cells. Our results represent the characterization of a new mechanism of control of DNA repair and radioresistance in human tumor cells dependent on the overproduction of the 24 kDa FGF-2 isoform.	Ctr Lutte Contre Canc Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, F-31052 Toulouse, France; Ctr Lutte Contre Canc Claudius Regaud, Dept Radiotherapie, F-31052 Toulouse, France; CNRS, UMR 5089, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Toulas, C (corresponding author), Ctr Lutte Contre Canc Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.		Toulas, Christine/P-3838-2014; salles, bernard/B-8531-2008; Ader-Perarnau, Isabelle/F-7160-2017; MULLER, Catherine/M-2185-2018; Moyal, Elizabeth/A-9802-2015; FAVRE, Gilles/K-9189-2014; MULLER, Catherine/E-2060-2011	Toulas, Christine/0000-0003-1261-1725; Moyal, Elizabeth/0000-0002-6593-9276; FAVRE, Gilles/0000-0002-2344-1883; ADER, isabelle/0000-0001-5103-8509				Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; Boulton S, 1996, CARCINOGENESIS, V17, P2285, DOI 10.1093/carcin/17.11.2285; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CohenJonathan E, 1997, CANCER RES, V57, P1364; Connelly MA, 1998, GENOMICS, V47, P71, DOI 10.1006/geno.1997.5076; Estival A., 2001, International Journal of Molecular Medicine, V8, pS88; FERTIL B, 1984, RADIAT RES, V99, P73, DOI 10.2307/3576448; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Fujimoto M, 1997, DNA Res, V4, P151, DOI 10.1093/dnares/4.2.151; FUKS Z, 1994, CANCER RES, V54, P2582; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GODWIN AR, 1994, P NATL ACAD SCI USA, V91, P12554, DOI 10.1073/pnas.91.26.12554; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grein S, 1999, MOL CELL BIOCHEM, V191, P121, DOI 10.1023/A:1006806226764; Guo CH, 1999, MOL CELL BIOCHEM, V191, P135, DOI 10.1023/A:1006881405383; Han ZY, 1996, J BIOL CHEM, V271, P14098, DOI 10.1074/jbc.271.24.14098; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; MIMORI T, 1986, J BIOL CHEM, V261, P375; Muller C, 1998, ONCOGENE, V16, P1553, DOI 10.1038/sj.onc.1201676; Muller C, 1998, NUCLEIC ACIDS RES, V26, P1382, DOI 10.1093/nar/26.6.1382; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; OKADA T, 1994, J BIOL CHEM, V269, P3563; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Price BD, 1996, CANCER RES, V56, P246; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Santiago FS, 2001, J BIOL CHEM, V276, P41143, DOI 10.1074/jbc.M104913200; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shen B, 1998, BIOCHEM BIOPH RES CO, V252, P524, DOI 10.1006/bbrc.1998.9677; Shen HX, 1998, BBA-GEN SUBJECTS, V1381, P131, DOI 10.1016/S0304-4165(98)00020-8; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; Stachowiak EK, 1997, ONCOGENE, V14, P2201, DOI 10.1038/sj.onc.1201057; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; Van den Berghe L, 2000, MOL ENDOCRINOL, V14, P1709, DOI 10.1210/me.14.11.1709; Xu WM, 2000, NAT CELL BIOL, V2, P339, DOI 10.1038/35014028; ZAGZAG D, 1990, CANCER RES, V50, P7393; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; Zhou YY, 2001, MOL CELL BIOCHEM, V220, P1, DOI 10.1023/A:1011087910699; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	49	46	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6471	6479		10.1038/sj.onc.1205838	http://dx.doi.org/10.1038/sj.onc.1205838			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226750				2022-12-25	WOS:000177925300007
J	Versteege, I; Medjkane, S; Rouillard, D; Delattre, O				Versteege, I; Medjkane, S; Rouillard, D; Delattre, O			A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle	ONCOGENE			English	Article						hSNF5; INI1; SWI/SNF; malignant rhabdoid tumour; cell cycle; chromatin	SWI-SNF COMPLEX; RETINOBLASTOMA PROTEIN; RHABDOID TUMORS; SWI/SNF FAMILY; HUMAN CANCER; S-PHASE; C-MYC; MUTATIONS; GENE; RB	The hSNF5/INI1 gene encodes a member of the SWI/ SNF chromatin remodelling complexes. It was recently identified as a tumour suppressor gene mutated in sporadic and hereditary Malignant Rhabdoid Tumours (MRT). However, the role of hSNF5/INI1 loss-of-function in tumour development is still unknown. Here, we show that the ectopic expression of wild-type hSNF5/ INI1, but not that of truncated versions, leads to a cell cycle arrest by inhibiting the entry into S phase of MRT cells. This G1 arrest is associated with down-regulation of a subset of E2F targets including cyclin A, E2F1 and CDC6. This arrest can be reverted by coexpression of cyclin D1, cyclin E or viral E1A, whereas it cannot be counteracted by pRB-binding deficient E1A mutants. Moreover, hSNF5/INI1 is not able to arrest cells lacking a functional pRB. These observations suggest that the hSNF5/INI1-induced G1 arrest is dependent upon the presence of a functional pRB. However, the observation that a constitutively active pRB can efficiently arrest MRT cells indicates that hSNF5/INI1, at the difference of the ATPase subunits of the SWI/SNF complex, is dispensable for pRB function. Altogether, these data show that hSNF5/INI1 is a potent regulator of the entry into S phase, an effect that may account for its tumour suppressor role.	Inst Curie, Lab Pathol Mol Canc, INSERM, U509, F-75248 Paris 05, France; Inst Curie, UMR 147, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Delattre, O (corresponding author), Inst Curie, Lab Pathol Mol Canc, INSERM, U509, 26 Rue Ulm, F-75248 Paris 05, France.	olivier.delattre@curie.fr		Medjkane, Souhila/0000-0001-7973-7707; delattre, olivier/0000-0002-8730-2276				Biegel JA, 2000, CLIN CANCER RES, V6, P2759; Biegel JA, 1999, CANCER RES, V59, P74; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HERRERA VLM, 1988, SCIENCE, V241, P221, DOI 10.1126/science.2838907; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; REMVIKOS Y, 1991, BRIT J CANCER, V64, P501, DOI 10.1038/bjc.1991.338; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Savla J, 2000, JNCI-J NATL CANCER I, V92, P648, DOI 10.1093/jnci/92.8.648; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Staehling-Hampton K, 1999, GENETICS, V153, P275; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Taylor MD, 2000, AM J HUM GENET, V66, P1403, DOI 10.1086/302833; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wong AKC, 2000, CANCER RES, V60, P6171; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	43	132	138	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6403	6412		10.1038/sj.onc.1205841	http://dx.doi.org/10.1038/sj.onc.1205841			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226744				2022-12-25	WOS:000177925300001
J	Koti, RS; Seifalian, AM; McBride, AG; Yang, WX; Davidson, BR				Koti, RS; Seifalian, AM; McBride, AG; Yang, WX; Davidson, BR			The relationship of hepatic tissue oxygenation with nitric oxide metabolism in ischemic preconditioning of the liver	FASEB JOURNAL			English	Article						ischemia reperfusion injury; near-infrared spectroscopy; cytochrome oxidase; hepatoprotection	NEAR-INFRARED SPECTROSCOPY; REPERFUSION INJURY; CYTOCHROME-OXIDASE; ENERGY-METABOLISM; GRAFT FUNCTION; RAT-LIVER; HYPOXIA; TRANSPLANTATION; INHIBITION; SATURATION	Ischemic preconditioning (IPC) may increase the hepatic tolerance of ischemic injury during liver surgery and transplantation via nitric oxide (NO) formation. This study investigates the effect of IPC on hepatic tissue oxygenation and the role of NO stimulation and inhibition on the preconditioning effect in the rat liver. Study groups had 1) sham laparotomy; 2) 45-min lobar liver ischemia and 2-h reperfusion (IR); 3) IPC with 5-min ischemia and 10-min reperfusion before IR; 4) L-arginine before IR; and 5) Nomega-Nitro-L-arginine methyl ester (L-NAME) + IPC before IR. Hepatic tissue oxygenation was monitored by near-infrared spectroscopy. Plasma alanine aminotransferase and plasma nitrite/nitrate were measured. Following IR there was significant decrease in oxyhemoglobin and cytochrome oxidase and an increase in deoxyhemoglobin (P<0.05 vs. Sham). IPC produced a significant increase in intracellular oxygenation at the end of the reperfusion period (cytochrome oxidase Cu(A) redox state, P<0.05 vs IR). NO stimulation with L-arginine did not attenuate the impairment in hepatic tissue oxygenation after IR (P>0.05 vs IR). In contrast, inhibition of NO synthesis blocked the effect of IPC and further impaired tissue oxygenation (decreased cytochrome oxidase CuA redox state and increased deoxyhemoglobin, both P<0.05 vs IR), suggesting an aggravation of ischemia reperfusion injury. Hepatocellular injury was reduced by IPC and L-arginine and increased by NO blockade with L-NAME (Plasma ALT, all P< 0.05 vs IR). Hepatic tissue oxygenation correlated significantly with ALT and plasma nitrite/nitrate. Ischemic preconditioning significantly improved hepatic intra cellular oxygenation and reduced hepatocellular injury. NO stimulation reduced hepatocellular injury, whereas inhibition of nitric oxide synthesis blocked the effect of IPC and reduced tissue oxygenation and increased hepatocellular injury.	Univ London UCL Royal Free Hosp, Royal Free & Univ Coll Med Sch, Dept Surg, London NW3 2QG, England; UCL Royal Free Hosp, Univ Coll London, Royal Free & Univ Coll Med Sch, Liver Transplantat Unit, London NW3 2QG, England	University of London; University College London; University of London; University College London	Davidson, BR (corresponding author), Univ London UCL Royal Free Hosp, Royal Free & Univ Coll Med Sch, Dept Surg, Pond St, London NW3 2QG, England.	b.davidson@rfc.ucl.ac.uk	Seifalian, Alexander M/I-6028-2013	Seifalian, Alexander M/0000-0002-1180-3322				BAUEREISEN B, 1975, GASTROENTEROLOGY, V13, P70; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CHEN SS, 1993, AM J PHYSIOL, V264, pG375, DOI 10.1152/ajpgi.1993.264.2.G375; CHEONG WF, 1990, IEEE J QUANTUM ELECT, V26, P2166, DOI 10.1109/3.64354; Clavien PA, 2000, ANN SURG, V232, P155, DOI 10.1097/00000658-200008000-00001; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P33, DOI 10.1016/S0968-0004(01)02035-7; COOPER CE, 1994, BIOCHEM SOC T, V22, P974, DOI 10.1042/bst0220974; COPE M, 1991, THESIS U LONDON; DEGROOT H, 1985, ANESTHESIOLOGY, V62, P44, DOI 10.1097/00000542-198501000-00009; EDWARDS AD, 1991, J APPL PHYSIOL, V71, P1907, DOI 10.1152/jappl.1991.71.5.1907; El-Desoky AE, 2001, LIVER, V21, P37; El-Desoky AEH, 1999, LIVER TRANSPLANT SUR, V5, P219, DOI 10.1002/lt.500050316; El-Desoky AEH, 2000, EUR SURG RES, V32, P207, DOI 10.1159/000008766; Giulivi C, 1998, BIOCHEM J, V332, P673, DOI 10.1042/bj3320673; GOTO M, 1992, HEPATOLOGY, V15, P432, DOI 10.1002/hep.1840150313; GROENLAND THN, 1992, ADV EXP MED BIOL, V317, P835; HARBRECHT BG, 1992, J LEUKOCYTE BIOL, V52, P390, DOI 10.1002/jlb.52.4.390; Harbrecht BG, 1997, SHOCK, V8, P415, DOI 10.1097/00024382-199712000-00004; Hardy KJ, 1996, AUST NZ J SURG, V66, P707, DOI 10.1111/j.1445-2197.1996.tb00722.x; Jaeschke H, 1996, TOXICOL APPL PHARM, V139, P213, DOI 10.1006/taap.1996.0160; JAESCHKE H, 1990, FASEB J, V4, P3355, DOI 10.1096/fasebj.4.15.2253850; Jobsis FF, 1992, QUANTITATIVE SPECTRO, P47; Katsuramaki T, 1997, TRANSPLANTATION, V64, P360, DOI 10.1097/00007890-199707270-00031; Kawachi S, 2000, BIOCHEM BIOPH RES CO, V276, P851, DOI 10.1006/bbrc.2000.3559; KITAI T, 1995, TRANSPLANT INT, V8, P111, DOI 10.1007/BF00344420; Kiuchi T, 1996, TRANSPLANT INT, V9, P90, DOI 10.1111/j.1432-2277.1996.tb00861.x; KOO A, 1992, HEPATOLOGY, V15, P507, DOI 10.1002/hep.1840150325; LEMASTERS JJ, 1983, J CELL BIOL, V97, P778, DOI 10.1083/jcb.97.3.778; LLORISCARSI JM, 1993, TRANSPLANT P, V25, P3303; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; MURRY CE, 1990, CIRC RES, V66, P913, DOI 10.1161/01.RES.66.4.913; Peralta C, 1996, BIOCHEM BIOPH RES CO, V229, P264, DOI 10.1006/bbrc.1996.1790; RIEDER HU, 1994, SURG LIVER BILIARY T, P487; ROCKEY DC, 1995, J CLIN INVEST, V95, P1199, DOI 10.1172/JCI117769; Sankary HN, 1999, TRANSPLANTATION, V68, P958, DOI 10.1097/00007890-199910150-00010; Seifalian AM, 2001, FASEB J, V15, P2642, DOI 10.1096/fj.01-0308com; SHIBAYAMA Y, 1992, LIVER, V12, P84; SUMIMOTO K, 1987, TRANSPL P, V19, P1098; TAKASHIMA S, 1995, BRAIN DEV-JPN, V17, P312, DOI 10.1016/0387-7604(95)00072-J; Taylor D E, 1996, New Horiz, V4, P420; VOLLMAR B, 1994, AM J PATHOL, V145, P1421; WANG Y, 1995, SHOCK, V4, P282, DOI 10.1097/00024382-199510000-00009; Yin DP, 1998, TRANSPLANTATION, V66, P152, DOI 10.1097/00007890-199807270-00002; Yoshizumi T, 1998, BRIT J SURG, V85, P1636; ZEBALLOS GA, 1995, CIRCULATION, V91, P2982, DOI 10.1161/01.CIR.91.12.2982	45	55	55	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10					1654	+		10.1096/fj.01-1034fje	http://dx.doi.org/10.1096/fj.01-1034fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207003				2022-12-25	WOS:000177814000013
J	Doucey, MA; Laurence, G; Naeher, D; Michielin, O; Baumgartner, P; Guillaume, P; Palmer, E; Luescher, IF				Doucey, MA; Laurence, G; Naeher, D; Michielin, O; Baumgartner, P; Guillaume, P; Palmer, E; Luescher, IF			CD3 delta establishes a functional link between the T cell receptor and CD8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BETA; POSITIVE SELECTION; CORECEPTOR FUNCTION; LIGAND INTERACTIONS; NEGATIVE SELECTION; CTL CLONES; ACTIVATION; CHAIN; TCR; LYMPHOCYTES	T cells expressing T cell receptor (TCR) complexes that lack CD3delta, either due to deletion of the CD3delta gene, or by replacement of the connecting peptide of the TCRalpha chain, exhibit severely impaired positive selection and TCR-mediated activation of CD8 single-positive T cells. Because the same defects have been observed in mice expressing no CD8beta or tailless CD8beta, we examined whether CD3delta serves to couple TCR-CD3 with CD8. To this end we used T cell hybridomas and transgenic mice expressing the T1 TCR, which recognizes a photoreactive derivative of the PbCS 252-260 peptide in the context of H-2K(d). We report that, in thymocytes and hybridomas expressing the T1 TCR-CD3 complex, CD8alphabeta associates with the TCR. This association was not observed on T1 hybridomas expressing only CD8alphaalpha or a CD3delta(-) variant of the T1 TCR. CD3delta was selectively coimmunoprecipitated with anti-CD8 antibodies, indicating an avid association of CD8 with CD3delta. Because CD8alphabeta is a raft constituent, due to this association a fraction of TCR-CD3 is raft-associated. Cross-linking of these TCR-CD8 adducts results in extensive TCR aggregate formation and intracellular calcium mobilization. Thus, CD3delta couples TCR-CD3 with raft-associated CD8, which is required for effective activation and positive selection of CD8(+) T cells.	Univ Lausanne, Lausanne Branch, Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Univ Basel Hosp, Lab Transplantat Immunol & Nephrol, CH-4031 Basel, Switzerland	Ludwig Institute for Cancer Research; University of Lausanne; University of Lausanne; University of Basel	Luescher, IF (corresponding author), Univ Lausanne, Lausanne Branch, Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland.		Michielin, Olivier/ABE-7924-2020					Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Anel A, 1997, J IMMUNOL, V158, P19; Arcaro A, 2000, J IMMUNOL, V165, P2068, DOI 10.4049/jimmunol.165.4.2068; Arcaro A, 2001, J EXP MED, V194, P1485, DOI 10.1084/jem.194.10.1485; Backstrom BT, 1998, SCIENCE, V281, P835, DOI 10.1126/science.281.5378.835; Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; Basson MA, 2000, IMMUNOL TODAY, V21, P509, DOI 10.1016/S0167-5699(00)01711-4; Berger MA, 1997, J EXP MED, V186, P1461, DOI 10.1084/jem.186.9.1461; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; Block MS, 2001, J IMMUNOL, V167, P821, DOI 10.4049/jimmunol.167.2.821; Borroto A, 1998, J BIOL CHEM, V273, P12807, DOI 10.1074/jbc.273.21.12807; Bosselut R, 1999, J EXP MED, V190, P1517, DOI 10.1084/jem.190.10.1517; Bosselut R, 2001, IMMUNITY, V14, P483, DOI 10.1016/S1074-7613(01)00128-5; CROOKS MEC, 1994, IMMUNITY, V1, P277; Daniels MA, 2000, J EXP MED, V191, P335, DOI 10.1084/jem.191.2.335; Dave VP, 1998, INT IMMUNOL, V10, P1481, DOI 10.1093/intimm/10.10.1481; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; DeJarnette JB, 1998, P NATL ACAD SCI USA, V95, P14909, DOI 10.1073/pnas.95.25.14909; Delgado P, 2000, NATURE, V406, P426, DOI 10.1038/35019102; Doucey MA, 2001, EUR J IMMUNOL, V31, P1561, DOI 10.1002/1521-4141(200105)31:5&lt;1561::AID-IMMU1561&gt;3.0.CO;2-W; Drake DR, 2001, J IMMUNOL, V166, P7009, DOI 10.4049/jimmunol.166.12.7009; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; Fernandez-Miguel G, 1999, P NATL ACAD SCI USA, V96, P1547, DOI 10.1073/pnas.96.4.1547; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Haks MC, 1998, EMBO J, V17, P1871, DOI 10.1093/emboj/17.7.1871; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hudrisier D, 1998, J IMMUNOL, V161, P553; Irie HY, 1998, J IMMUNOL, V161, P183; ITANO A, 1994, IMMUNITY, V1, P287, DOI 10.1016/1074-7613(94)90080-9; KEARSE KP, 1995, IMMUNITY, V2, P391; Kessler B, 1998, J IMMUNOL, V161, P6939; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; LUESCHER IF, 1995, IMMUNITY, V3, P51, DOI 10.1016/1074-7613(95)90158-2; LUESCHER IF, 1994, J BIOL CHEM, V269, P5574; Naeher D, 2002, J IMMUNOL, V169, P2964, DOI 10.4049/jimmunol.169.6.2964; NAKAYAMA K, 1994, SCIENCE, V263, P1131, DOI 10.1126/science.8108731; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SHORES EW, 1994, SCIENCE, V266, P1047, DOI 10.1126/science.7526464; Stotz SH, 1999, J EXP MED, V189, P253, DOI 10.1084/jem.189.2.253; Sun ZYJ, 2001, CELL, V105, P913, DOI 10.1016/S0092-8674(01)00395-6; SUZUKI S, 1992, EUR J IMMUNOL, V22, P2475, DOI 10.1002/eji.1830221002; Trobridge PA, 2001, J IMMUNOL, V166, P809, DOI 10.4049/jimmunol.166.2.809; Ulivieri C, 2001, J BIOL CHEM, V276, P3574, DOI 10.1074/jbc.M008588200; Vignali DAA, 1996, J EXP MED, V183, P2097, DOI 10.1084/jem.183.5.2097; Wang BP, 1998, J EXP MED, V188, P1375, DOI 10.1084/jem.188.7.1375; Wang BP, 1999, J IMMUNOL, V162, P88; Werlen G, 2000, NATURE, V406, P422, DOI 10.1038/35019094; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Xu XN, 2001, IMMUNITY, V14, P591, DOI 10.1016/S1074-7613(01)00133-9; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	50	72	74	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 31	2003	278	5					3257	3264		10.1074/jbc.M208119200	http://dx.doi.org/10.1074/jbc.M208119200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644JW	12215456	hybrid			2022-12-25	WOS:000180915000063
J	Jackson, CJ; Lamb, DC; Marezylo, TH; Warrilow, AGS; Manning, NJ; Lowe, DJ; Kelly, DE; Kelly, SL				Jackson, CJ; Lamb, DC; Marezylo, TH; Warrilow, AGS; Manning, NJ; Lowe, DJ; Kelly, DE; Kelly, SL			A novel sterol 14 alpha-demethylase/ferredoxin fusion protein (MCCYP51FX) from Methylococcus capsulatus represents a new class of the cytochrome P450 superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; NADPH-P450 REDUCTASE; MONOOXYGENASE; EXPRESSION; CYP51; PURIFICATION; CONSTRUCTION; METHANE; ENZYME	Sterol 14alpha-demethylase encoded by CYP51 is a member of the cytochrome P450 (CYP) superfamily of enzymes and has been shown to have an essential role in sterol biosynthesis in eukaryotes, with orthologues recently being described in some bacteria. Examination of the genome sequence data for the proteobacterium Methylococcus capsulatus, a bacterial species known to produce sterol, revealed the presence of a single CYP with strong homology to CYP51, particularly to a form in Mycobacterium tuberculosis. This M. capsulatus CYP51 protein represents a new class of CYP consisting of the CYP domain naturally fused to a ferredoxin domain at the C terminus via an alanine-rich linker. Expression of the M. capsulatus MCCYP51FX fusion in Escherichia coli yielded a P450, which, when purified to homogeneity, had the predicted molecular mass similar to62 kDa on SDS/PAGE and bound lanosterol as a putative substrate. Sterol 14alpha-demethylase activity was shown (0.24 nmol of lanosterol metabolized per minute per nanomole of MCCYP51FX fusion) by gas chromatography/mass spectrometry with the activity dependent upon the presence of ferredoxin reductase and NADPH. Our unique findings describe a new class of naturally existing cytochrome P450, which will provide pivotal information for CYP structure/function in general.	Univ Wales Aberystwyth, Inst Biol Sci, Wolfson Lab Biodivers P450, Aberystwyth SY23 3DA, Dyfed, Wales; Sheffield Childrens Hosp, Western Bank, Dept Chem Pathol, Sheffield S10 2UH, S Yorkshire, England; John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	Aberystwyth University; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Kelly, SL (corresponding author), Univ Wales Aberystwyth, Inst Biol Sci, Wolfson Lab Biodivers P450, Aberystwyth SY23 3DA, Dyfed, Wales.			Warrilow, Andrew/0000-0003-0183-8334				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aoyama Y, 1998, J BIOCHEM-TOKYO, V124, P694; Bak S, 1997, PLANT J, V11, P191, DOI 10.1046/j.1365-313X.1997.11020191.x; Bellamine A, 1999, P NATL ACAD SCI USA, V96, P8937, DOI 10.1073/pnas.96.16.8937; BIRD CW, 1971, NATURE, V230, P473, DOI 10.1038/230473a0; BOUVIER P, 1976, BIOCHEM J, V159, P267, DOI 10.1042/bj1590267; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DALTON H, 1976, ARCH MICROBIOL, V109, P147, DOI 10.1007/BF00425127; Deeni YY, 2001, ARCH BIOCHEM BIOPHYS, V396, P16, DOI 10.1006/abbi.2001.2585; DEGTYARENKO KN, 1993, FEBS LETT, V332, P1, DOI 10.1016/0014-5793(93)80470-F; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FISHER CW, 1992, P NATL ACAD SCI USA, V89, P10817, DOI 10.1073/pnas.89.22.10817; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; Gustafsson MCU, 2001, ARCH MICROBIOL, V176, P459, DOI 10.1007/s002030100350; Jefcoate C R, 1978, Methods Enzymol, V52, P258; Lamb DC, 1998, FEBS LETT, V425, P263, DOI 10.1016/S0014-5793(98)00247-6; Lamb DC, 1997, J BIOL CHEM, V272, P5682, DOI 10.1074/jbc.272.9.5682; LEWIS DFV, 2002, GUIDE CYTOCHROMES P4, P51; MURAKAMI H, 1987, DNA-J MOLEC CELL BIO, V6, P189, DOI 10.1089/dna.1987.6.189; Nakayama N, 1996, J BIOCHEM-TOKYO, V119, P435; NARHI LO, 1986, J BIOL CHEM, V261, P7160; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OMURA T, 1964, J BIOL CHEM, V239, P2379; PETERSON JA, 1976, J BIOL CHEM, V251, P4010; PORTER TD, 1991, J BIOL CHEM, V266, P13469; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SHET MS, 1993, P NATL ACAD SCI USA, V90, P11748, DOI 10.1073/pnas.90.24.11748; Sibbesen O, 1996, J BIOL CHEM, V271, P22462, DOI 10.1074/jbc.271.37.22462; TURNER SL, 1993, PROTEIN ENG, V6, P101, DOI 10.1093/protein/6.1.101; Venkateswarlu K, 1997, ANTIMICROB AGENTS CH, V41, P776, DOI 10.1128/AAC.41.4.776; YOSHIDA Y, 1984, J BIOL CHEM, V259, P1655; Zhang Y, 1997, J BACTERIOL, V179, P3030, DOI 10.1128/jb.179.9.3030-3035.1997	32	56	59	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46959	46965		10.1074/jbc.M203523200	http://dx.doi.org/10.1074/jbc.M203523200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12235134	hybrid			2022-12-25	WOS:000179663700017
J	Melton, JV; Ewart, GD; Weir, RC; Board, PG; Lee, E; Gage, PW				Melton, JV; Ewart, GD; Weir, RC; Board, PG; Lee, E; Gage, PW			Alphavirus 6K proteins form ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI-FOREST-VIRUS; SITE-DIRECTED MUTATIONS; ESCHERICHIA-COLI-CELLS; MODIFIES MEMBRANE-PERMEABILITY; SINDBIS-VIRUS; VPU PROTEIN; INDUCIBLE EXPRESSION; M2 PROTEIN; GENE; RELEASE	Ross River virus and Barmah Forest virus are Australian arboviruses of the Alphavirus genus. Features of alphavirus infection include an increased permeability of cells to monovalent cations followed by virion budding. Virally encoded ion channels are thought to have a role in these processes. In this paper, the 6K proteins of Ross River virus and Barmah Forest virus are shown to form cation-selective ion channels in planar lipid bilayers. Using a novel purification method, bacterially expressed 6K proteins were inserted into bilayers with a defined orientation (i.e. N-terminal cis, C-terminal trans). Channel activity was reversibly inhibited by antibodies to the N and C termini of 6K protein added to the cis and trans baths, respectively. Channel conductances varied from 40-800 picosiemens, suggesting that the protein is able to form channels with a range of possible oligomerization states.	Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 2601, Australia; Australian Natl Univ, Biotron Ltd, Canberra, ACT 2601, Australia; Australian Natl Univ, Sch Biochem & Mol Biol, Canberra, ACT 2601, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; Australian National University; Australian National University; John Curtin School of Medical Research	Gage, PW (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, GPO Box 334, Canberra, ACT 2601, Australia.							ALTMANN KH, 1990, BIOPOLYMERS, V30, P107, DOI 10.1002/bip.360300112; BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; BOARD PG, 1983, BRIT J HAEMATOL, V54, P245, DOI 10.1111/j.1365-2141.1983.tb02092.x; CARRASCO L, 1995, ADV VIRUS RES, V45, P61, DOI 10.1016/S0065-3527(08)60058-5; Cordes FS, 2001, BBA-BIOMEMBRANES, V1512, P291, DOI 10.1016/S0005-2736(01)00332-7; Dick M, 1996, VIROLOGY, V220, P204, DOI 10.1006/viro.1996.0301; Ewart GD, 1996, J VIROL, V70, P7108, DOI 10.1128/JVI.70.10.7108-7115.1996; Fischer WB, 2000, BIOPOLYMERS, V53, P529, DOI 10.1002/(SICI)1097-0282(200006)53:7<529::AID-BIP1>3.0.CO;2-6; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P274, DOI 10.1016/0042-6822(90)90209-A; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P282, DOI 10.1016/0042-6822(90)90210-I; GAEDIGKNITSCHKO K, 1991, VIROLOGY, V183, P206, DOI 10.1016/0042-6822(91)90133-V; GAROFF H, 1990, J CELL BIOL, V111, P867, DOI 10.1083/jcb.111.3.867; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; Gonzalez ME, 1998, BIOCHEMISTRY-US, V37, P13710, DOI 10.1021/bi981527f; Gonzalez ME, 2001, VIROLOGY, V279, P201, DOI 10.1006/viro.2000.0708; GUINEA R, 1994, FEBS LETT, V343, P242, DOI 10.1016/0014-5793(94)80564-4; HANKE W, 1998, ION CHANNEL RECONSTI, P141; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; Hille B., 1992, IONIC CHANNELS EXCIT, P236; Ivanova L, 1995, VIRUS RES, V39, P165, DOI 10.1016/0168-1702(95)00083-6; IVANOVA L, 1995, VIROLOGY, V206, P1027, DOI 10.1006/viro.1995.1025; IVANOVA L, 1993, J VIROL, V67, P2546, DOI 10.1128/JVI.67.5.2546-2551.1993; KUHN RJ, 1991, VIROLOGY, V182, P430, DOI 10.1016/0042-6822(91)90584-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMA J, 1992, J BIOL CHEM, V267, P15932; LAMA J, 1992, BIOCHEM BIOPH RES CO, V188, P972, DOI 10.1016/0006-291X(92)91327-M; Lee E, 1997, VIROLOGY, V227, P509, DOI 10.1006/viro.1996.8343; LILJESTROM P, 1991, J VIROL, V65, P4107; LILJESTROM P, 1991, J VIROL, V65, P147; LOEWY A, 1995, J VIROL, V69, P469, DOI 10.1128/JVI.69.1.469-475.1995; LU YA, 1991, MOL IMMUNOL, V28, P623; LUSA S, 1991, VIROLOGY, V185, P843, DOI 10.1016/0042-6822(91)90556-Q; MARGOLIS MJ, 1966, CHEM PRINCIPLES CALC, P270; MUNOZ A, 1985, VIROLOGY, V146, P203, DOI 10.1016/0042-6822(85)90004-2; Piller SC, 1996, P NATL ACAD SCI USA, V93, P111, DOI 10.1073/pnas.93.1.111; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; R. New, 1990, LIPOSOMES A PRACTICA, P33; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; Sambrook J., 2002, MOL CLONING LAB MANU; SANZ MA, 1994, J BIOL CHEM, V269, P12106; Sanz MA, 2001, J VIROL, V75, P7778, DOI 10.1128/JVI.75.16.7778-7784.2001; SCHLESINGER MJ, 1993, VIROLOGY, V193, P424, DOI 10.1006/viro.1993.1139; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; STAPLES BR, 1977, J PHYS CHEM REF DATA, V6, P385, DOI 10.1063/1.555551; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Sunstrom NA, 1996, J MEMBRANE BIOL, V150, P127, DOI 10.1007/s002329900037; ULUG ET, 1984, VIROLOGY, V132, P118, DOI 10.1016/0042-6822(84)90096-5; vanKuppeveld FJM, 1997, EMBO J, V16, P3519, DOI 10.1093/emboj/16.12.3519; WELCH WJ, 1980, J VIROL, V33, P230, DOI 10.1128/JVI.33.1.230-237.1980; Yao JS, 1996, J VIROL, V70, P7910, DOI 10.1128/JVI.70.11.7910-7920.1996	50	84	85	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46923	46931		10.1074/jbc.M207847200	http://dx.doi.org/10.1074/jbc.M207847200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12228229	hybrid			2022-12-25	WOS:000179663700013
J	de Keyzer, J; van der Does, C; Driessen, AJM				de Keyzer, J; van der Does, C; Driessen, AJM			Kinetic analysis of the translocation of fluorescent precursor proteins into Escherichia coli membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; PLASMA-MEMBRANE; SIGNAL SEQUENCE; SECA PROTEIN; PREPROTEIN TRANSLOCATION; SECRETORY PROTEIN; CATALYTIC CYCLE; BINDING; DOMAIN; PROOMPA	Protein secretion in Escherichia coli is mediated by translocase, a multi-subunit membrane protein complex with SecA as ATP-driven motor protein and the SecYEG complex as translocation pore. A fluorescent assay was developed to facilitate kinetic studies of protein translocation. Single cysteine mutants of proOmpA were site-specific labeled with fluorescent dyes, and the SecA and ATP-dependent translocation into inner membrane vesicles and SecYEG proteoliposomes was monitored by means of protease accessibility and in gel fluorescent imaging. The translocation of fluorescently labeled proOmpA was largely independent on the position and the size of the fluorescent label (up to a size of 13-16 Angstrom). A fluorophore at the +4 position blocked translocation, but inhibition was completely relieved in the PrlA4 mutant. The kinetics of translocation of the fluorescently labeled proOmpA could be directly monitored by means of fluorescence quenching. Inner Membrane vesicles containing wild-type SecYEG were found to translocate proOmpA with a turnover of 4.5 molecules proOmpA/ SecYEG complex/min and an apparent K-m of 180 nm, whereas the PrlA4 mutant showed an almost 10-fold increase in turnover rate and a 3-fold increase of the apparent K-m for proOmpA translocation.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@biol.rug.nl	Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BASSILANA M, 1992, J BIOL CHEM, V267, P25246; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DRIESSEN AJM, 1992, EMBO J, V11, P847, DOI 10.1002/j.1460-2075.1992.tb05122.x; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; GOODSELL DS, 1991, TRENDS BIOCHEM SCI, V16, P203, DOI 10.1016/0968-0004(91)90083-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; Nouwen N, 1996, P NATL ACAD SCI USA, V93, P5953, DOI 10.1073/pnas.93.12.5953; Nouwen N, 2001, FEBS LETT, V508, P103, DOI 10.1016/S0014-5793(01)03033-2; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; Veenendaal AKJ, 2001, J BIOL CHEM, V276, P32559, DOI 10.1074/jbc.M103912200	29	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46059	46065		10.1074/jbc.M208449200	http://dx.doi.org/10.1074/jbc.M208449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12226104	Green Published, hybrid			2022-12-25	WOS:000179529300047
J	Kumar, A; Chaudhry, I; Reid, MB; Boriek, AM				Kumar, A; Chaudhry, I; Reid, MB; Boriek, AM			Distinct signaling pathways are activated in response to mechanical stress applied axially and transversely to skeletal muscle fibers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NH2-TERMINAL KINASE-ACTIVITY; MAP-KINASE; PROTEIN-KINASES; PHOSPHOINOSITIDE 3-KINASE; ENDOTHELIAL-CELLS; REDOX REGULATION; SHEAR-STRESS; IN-VITRO; STRETCH; TRANSDUCTION	In the diaphragm muscle we tested the hypothesis that MAP kinase signaling pathways are activated by mechanical stress and such signaling pathways are dependent on the direction in which mechanical stress is applied. Although equal magnitudes of mechanical stress were applied axially and transversely a greater level of activation of ERK1/2, p38, Raf-1, p90 RSK, Elk-1, and the DNA binding activity of AP-1 transcription factor was produced when the muscle was stretched transversely than when stretched axially. A significant up-regulation in protein tyrosine phosphorylation was observed in axially or transversely loaded diaphragm muscles and the activation of ERK1/2 was completely inhibited by gemstein (protein-tyrosine kinase inhibitor). Pretreatment of muscles with wortmannin (phosphoinositide 3-kinase inhibitor), TMB-8 (antagonist of intracellular calcium release), GF109203X (PKC inhibitor), or PD98059 (NMK1/2 inhibitor) blocked the activation of ERK1/2 kinases in response to axial but not to transverse loading. On the other hand, pretreatment of muscles with protein kinase A inhibitors H-7 and KT5720 completely suppressed the activation of ERK1/2 in response to transverse loading only. Taken together with the alterations of MAP kinases and the findings of elevations of downstream transcription targets, our data are consistent with two distinct MAP kinase signal transduction pathways in response to mechanical stress.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine	Boriek, AM (corresponding author), Baylor Coll Med, Dept Med, Suite 520B,1 Baylor Plaza, Houston, TX 77030 USA.	boriek@bcm.tmc.edu		Kumar, Ashok/0000-0001-8571-2848	NHLBI NIH HHS [HL45721] Funding Source: Medline; PHS HHS [R01-46230, R01-63134] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045721] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Berk BC, 1995, J BIOMECH, V28, P1439, DOI 10.1016/0021-9290(95)00092-5; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Bokemeyer D, 1996, KIDNEY INT, V49, P1187, DOI 10.1038/ki.1996.172; Boppart MD, 1999, J APPL PHYSIOL, V87, P1668, DOI 10.1152/jappl.1999.87.5.1668; Boppart MD, 2001, AM J PHYSIOL-CELL PH, V280, pC352, DOI 10.1152/ajpcell.2001.280.2.C352; BORIEK AM, 1994, J APPL PHYSIOL, V76, P223, DOI 10.1152/jappl.1994.76.1.223; BORIEK AM, 1994, J APPL PHYSIOL, V77, P2065, DOI 10.1152/jappl.1994.77.5.2065; Boriek AM, 1998, LUNG BIOL HEALTH DIS, V121, P181; Boriek AM, 2002, J APPL PHYSIOL, V92, P725, DOI 10.1152/jappl.2002.92.2.725; Boriek AM, 2001, AM J PHYSIOL-REG I, V280, pR156, DOI 10.1152/ajpregu.2001.280.1.R156; Boriek AM, 2001, AM J PHYSIOL-CELL PH, V280, pC46, DOI 10.1152/ajpcell.2001.280.1.C46; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; GOLDSPINK DF, 1995, AM J PHYSIOL-ENDOC M, V268, pE288, DOI 10.1152/ajpendo.1995.268.2.E288; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Ikeda M, 1999, BIOCHEM BIOPH RES CO, V257, P668, DOI 10.1006/bbrc.1999.0532; Ingber DE, 1998, BIOL BULL-US, V194, P323, DOI 10.2307/1543102; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kawano Y, 2001, AM J PHYSIOL-ENDOC M, V281, pE1255, DOI 10.1152/ajpendo.2001.281.6.E1255; Kemp TJ, 2001, GENOMICS, V72, P260, DOI 10.1006/geno.2000.6461; Kippenberger S, 2000, J INVEST DERMATOL, V114, P408, DOI 10.1046/j.1523-1747.2000.00915.x; Kleinert H, 1996, MOL PHARMACOL, V49, P15; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Kubota A, 1997, BIOCHEM BIOPH RES CO, V235, P171, DOI 10.1006/bbrc.1997.6743; Kumar A, 1999, METHOD ENZYMOL, V300, P339; Kumar A, 1998, J IMMUNOL, V161, P776; Kyriakis JM, 1999, BIOCHEM SOC SYMP, P29; Lowe DA, 1999, CELL TISSUE RES, V296, P531, DOI 10.1007/s004410051314; MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026; Martineau LC, 2001, J APPL PHYSIOL, V91, P693, DOI 10.1152/jappl.2001.91.2.693; McKoy G, 1999, J PHYSIOL-LONDON, V516, P583, DOI 10.1111/j.1469-7793.1999.0583v.x; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mitchell P, 1999, J APPL PHYSIOL, V86, P313, DOI 10.1152/jappl.1999.86.1.313; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nishioka N, 1995, FEBS LETT, V377, P393, DOI 10.1016/0014-5793(95)01382-2; Osman AA, 2001, J APPL PHYSIOL, V90, P454, DOI 10.1152/jappl.2001.90.2.454; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Ruwhof C, 2000, CARDIOVASC RES, V47, P23, DOI 10.1016/S0008-6363(00)00076-6; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Stull JT, 2001, J BIOL CHEM, V276, P2311, DOI 10.1074/jbc.R000030200; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Suzuma I, 2002, J BIOL CHEM, V277, P1047, DOI 10.1074/jbc.M105336200; Tidball JG, 1998, AM J PHYSIOL-CELL PH, V275, pC260, DOI 10.1152/ajpcell.1998.275.1.C260; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Turner C H, 1998, J Orthop Sci, V3, P346, DOI 10.1007/s007760050064; VANDENBURGH H, 1979, SCIENCE, V203, P265, DOI 10.1126/science.569901; VANDENBURGH HH, 1995, J CELL PHYSIOL, V163, P285, DOI 10.1002/jcp.1041630209; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Wojtaszewski JFP, 1999, AM J PHYSIOL-ENDOC M, V277, pE724, DOI 10.1152/ajpendo.1999.277.4.E724; Wretman C, 2000, ACTA PHYSIOL SCAND, V170, P45; Wretman C, 2001, J PHYSIOL-LONDON, V535, P155, DOI 10.1111/j.1469-7793.2001.00155.x; Yang XH, 1997, BBA-GENE STRUCT EXPR, V1350, P287, DOI 10.1016/S0167-4781(96)00225-4; Zhi G, 1998, J BIOL CHEM, V273, P8951, DOI 10.1074/jbc.273.15.8951	73	75	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46493	46503		10.1074/jbc.M203654200	http://dx.doi.org/10.1074/jbc.M203654200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12221078	hybrid			2022-12-25	WOS:000179529300103
J	Li, MH; Kwok, F; Chang, WR; Lau, CK; Zhang, JP; Lo, SCL; Jiang, T; Liang, DC				Li, MH; Kwok, F; Chang, WR; Lau, CK; Zhang, JP; Lo, SCL; Jiang, T; Liang, DC			Crystal structure of brain pyridoxal kinase, a novel member of the ribokinase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1.5 ANGSTROM RESOLUTION; ESCHERICHIA-COLI K-12; CATALYTIC ACTIVITY; ADENOSINE KINASE; BINDING-SITE; PROGRAM; IDENTIFICATION; PURIFICATION; MECHANISM; MOBILITY	The three-dimensional structures of brain pyridoxal kinase and its complex with the nucleotide ATP have been elucidated in the dimeric form at 2.1 and 2.6 Angstrom, respectively. Results have shown that pyridoxal kinase, as an enzyme obeying random sequential kinetics in catalysis, does not possess a lid shape structure common to all kinases in the ribokinase superfamily. This finding has been shown to be in line with the condition that pyridoxal kinase binds substrates with variable sizes of chemical groups at position 4 of vitamin B-6 and its derivatives. In addition, the enzyme contains a 12-residue peptide loop in the active site for the prevention of premature hydrolysis of ATP. Conserved amino acid residues Asp(118) and Tyr(127) in the peptide loop could be moved to a position covering the nucleotide after its binding so that its chance to hydrolyze in the aqueous environment of the active site was reduced. With respect to the evolutionary trend of kinase enzymes, the existence of this loop in pyridoxal kinase could be classified as an independent category in the ribokinase superfamily according to the structural feature found and mechanism followed in catalysis.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Hong Kong Polytechnic University	Jiang, T (corresponding author), 15 Datun Rd,Chaoyang Dist, Beijing 100101, Peoples R China.	x-ray@sun5.ibp.ac.cn; dcliang@sun5.ibp.ac.cn	Lau, Terrence/ABB-7900-2021	Lau, Terrence/0000-0002-7505-7306; Lo, Samuel Chun-lap/0000-0003-1134-7299				ARNONE A, 1989, J BIOL CHEM, V264, P4322; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campobasso N, 2000, BIOCHEMISTRY-US, V39, P7868, DOI 10.1021/bi0000061; Cheng G, 2002, STRUCTURE, V10, P225, DOI 10.1016/S0969-2126(02)00708-6; CHURCHICH JE, 1982, J BIOL CHEM, V257, P2136; CHURCHICH JE, 1981, J BIOL CHEM, V256, P780; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; DAKSHINAMURTI K, 1990, ANN NY ACAD SCI, V585, P128, DOI 10.1111/j.1749-6632.1990.tb28049.x; DOMINICI P, 1988, J BIOL CHEM, V263, P14712; Hanna MC, 1997, J BIOL CHEM, V272, P10756; Ito S, 2001, STRUCTURE, V9, P205, DOI 10.1016/S0969-2126(01)00577-9; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERRY JA, 1986, EUR J BIOCHEM, V158, P581, DOI 10.1111/j.1432-1033.1986.tb09794.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWOK F, 1979, J BIOL CHEM, V254, P6489; KWOK F, 1987, EUR J BIOCHEM, V168, P577, DOI 10.1111/j.1432-1033.1987.tb13456.x; KWOK F, 1979, EUR J BIOCHEM, V93, P229, DOI 10.1111/j.1432-1033.1979.tb12815.x; KWOK F, 1991, EUR J BIOCHEM, V199, P157, DOI 10.1111/j.1432-1033.1991.tb16104.x; LaineCessac P, 1996, ENZYME PROTEIN, V49, P291, DOI 10.1159/000468639; LaineCessac P, 1997, BIOCHEM PHARMACOL, V54, P863, DOI 10.1016/S0006-2952(97)00252-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li MH, 2002, ACTA CRYSTALLOGR D, V58, P1479, DOI 10.1107/S0907444902011034; Lu GG, 1999, J APPL CRYSTALLOGR, V32, P365, DOI 10.1107/S0021889898015052; Mathews II, 1998, BIOCHEMISTRY-US, V37, P15607, DOI 10.1021/bi9815445; MCCORMICK D, 1961, J BIOL CHEM, V236, P2085; MCCORMICK DB, 1959, P NATL ACAD SCI USA, V45, P1371, DOI 10.1073/pnas.45.9.1371; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; SCHOLZ G, 1989, J BIOL CHEM, V264, P4318; Schumacher MA, 2000, J MOL BIOL, V298, P875, DOI 10.1006/jmbi.2000.3753; SHETTY KT, 1980, EXP NEUROL, V70, P146, DOI 10.1016/0014-4886(80)90012-6; Sigrell JA, 1998, STRUCTURE, V6, P183, DOI 10.1016/S0969-2126(98)00020-3; Sigrell JA, 1999, J MOL BIOL, V290, P1009, DOI 10.1006/jmbi.1999.2938; UBBINK JB, 1990, ANN NY ACAD SCI, V585, P285, DOI 10.1111/j.1749-6632.1990.tb28061.x; WOLKERS WF, 1991, J BIOL CHEM, V266, P20761; Yang Y, 1996, FEMS MICROBIOL LETT, V141, P89, DOI 10.1016/0378-1097(96)00203-0; Yang Y, 1998, J BACTERIOL, V180, P1814, DOI 10.1128/JB.180.7.1814-1821.1998; ZHANG Z, 1991, P NATL ACAD SCI USA, V88, P10407, DOI 10.1073/pnas.88.23.10407	41	68	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46385	46390		10.1074/jbc.M208600200	http://dx.doi.org/10.1074/jbc.M208600200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235162	hybrid			2022-12-25	WOS:000179529300089
J	Pedarzani, P; D'hoedt, D; Doorty, KB; Wadsworth, JDF; Joseph, JS; Jeyaseelan, K; Kini, RM; Gadre, SV; Sapatnekar, SM; Stocker, M; Strong, PN				Pedarzani, P; D'hoedt, D; Doorty, KB; Wadsworth, JDF; Joseph, JS; Jeyaseelan, K; Kini, RM; Gadre, SV; Sapatnekar, SM; Stocker, M; Strong, PN			Tamapin, a venom peptide from the Indian red scorpion (Mesobuthus tamulus) that targets small conductance Ca(2+)-activated K(+) channels and afterhyperpolarization currents in central neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNEL; CHEMICAL-SYNTHESIS; LEIUROTOXIN-I; APAMIN-BINDING; BEE VENOM; PHARMACOLOGICAL CHARACTERIZATION; NEUROTOXIN APAMIN; TITYUS-SERRULATUS; TOXIN; LIGAND	The biophysical properties of small conductance Ca(2+)-activated K(+) (SK) channels are well suited to underlie afterhyperpolarizations (AHPs) shaping the firing patterns of a conspicuous number of central and peripheral neurons. We have identified a. new scorpion toxin (tamapin) that binds to SK channels with high affinity and inhibits SK channel-mediated currents in pyramidal neurons of the hippocampus as well as in cell lines expressing distinct SK channel Subunits. This toxin distinguished between the SK channels underlying the apamin-sensitive I(AHP) and the Ca(2+)-activated K(+) channels mediating the slow I(AHP) (sI(AHP)) in hippocampal neurons. Compared with related scorpion toxins, tamapin displayed a unique, remarkable selectivity for SK2 versus SK1 (similar to1750-fold) and SK3 (similar to70-fold) channels and is the most potent SK2 channel blocker characterized so far (IC(50) for SK2 channels = 24 pm). Tamapin will facilitate the characterization of the subunit composition of native SK channels and help determine their involvement in electrical and biochemical signaling.	Univ London Imperial Coll Sci & Technol, Sch Med, Dept Pediat & Neonatal Med, London W12 0NN, England; UCL, Dept Physiol, London WC1E 6BT, England; UCL, Wellcome Lab Mol Pharmacol, London WC1E 6BT, England; Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Natl Univ Singapore, Singapore 119260, Singapore; Haffkine Inst, Bombay 400012, Maharashtra, India; Sheffield Hallam Univ, Div Biomed Sci, Sheffield S1 1WB, S Yorkshire, England	Imperial College London; University of London; University College London; University of London; University College London; Max Planck Society; National University of Singapore; Sheffield Hallam University	Strong, PN (corresponding author), Univ London Imperial Coll Sci & Technol, Sch Med, Dept Pediat & Neonatal Med, London W12 0NN, England.	p.strong@shu.ac.uk	Kini, Manjunatha/H-8029-2012; Stocker, Martin/C-1844-2008	Wadsworth, Jonathan/0000-0002-4797-2259; Kini, Manjunatha/0000-0002-6100-3251	MRC [MC_U123160655] Funding Source: UKRI; Medical Research Council [MC_U123160655] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AUGUSTE P, 1992, BIOCHEMISTRY-US, V31, P648, DOI 10.1021/bi00118a003; AUGUSTE P, 1990, J BIOL CHEM, V265, P4753; Blanc E, 1997, PROTEINS, V29, P359, DOI 10.1002/(SICI)1097-0134(199711)29:3&lt;359::AID-PROT9&gt;3.0.CO;2-5; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; CASTLE NA, 1986, FEBS LETT, V209, P117, DOI 10.1016/0014-5793(86)81095-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHICCHI GG, 1988, J BIOL CHEM, V263, P10192; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Empson RM, 2001, NEUROSCIENCE, V102, P297, DOI 10.1016/S0306-4522(00)00494-2; Fajloun Z, 2000, EUR J BIOCHEM, V267, P5149, DOI 10.1046/j.1432-1327.2000.01577.x; Fournier C, 2001, BEHAV BRAIN RES, V121, P81, DOI 10.1016/S0166-4328(00)00387-9; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; Garcia ML, 2001, TOXICON, V39, P739, DOI 10.1016/S0041-0101(00)00214-2; Grunnet M, 2001, NEUROPHARMACOLOGY, V40, P879, DOI 10.1016/S0028-3908(01)00028-4; HABERMANN E, 1979, EUR J BIOCHEM, V94, P355, DOI 10.1111/j.1432-1033.1979.tb12901.x; Hille B., 2001, IONIC CHANNELS EXCIT, P814; Hosseini R, 2001, J PHYSIOL-LONDON, V535, P323, DOI 10.1111/j.1469-7793.2001.00323.x; HUGUES M, 1982, J BIOL CHEM, V257, P2762; Ikonen S, 1999, EUR J PHARMACOL, V382, P151, DOI 10.1016/S0014-2999(99)00616-0; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Kharrat R, 1997, FEBS LETT, V406, P284, DOI 10.1016/S0014-5793(97)00285-8; Kharrat R, 1996, EUR J BIOCHEM, V242, P491, DOI 10.1111/j.1432-1033.1996.0491r.x; Khawaled R, 1999, PFLUG ARCH EUR J PHY, V438, P314, DOI 10.1007/s004240050915; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LATORRE R, 1997, ION CHANNELS CELL TO; Lecomte C, 1999, J PEPT RES, V54, P369, DOI 10.1034/j.1399-3011.1999.00107.x; Legros C, 1996, FEBS LETT, V390, P81, DOI 10.1016/0014-5793(96)00616-3; McIntosh J M, 1999, Methods Enzymol, V294, P605; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; MESSIER C, 1991, BRAIN RES, V551, P322, DOI 10.1016/0006-8993(91)90950-Z; Pedarzani P, 2000, J PHYSIOL-LONDON, V527, P283, DOI 10.1111/j.1469-7793.2000.t01-1-00283.x; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; RomiLebrun R, 1997, EUR J BIOCHEM, V245, P457, DOI 10.1111/j.1432-1033.1997.00457.x; SABATIER JM, 1994, INT J PEPT PROT RES, V43, P486; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; Sah P, 2002, PROG NEUROBIOL, V66, P345, DOI 10.1016/S0301-0082(02)00004-7; SANTHANAKRISHNAN BR, 1974, J TROP MED HYG, V77, P133; Seutin V, 1999, TRENDS PHARMACOL SCI, V20, P268, DOI 10.1016/S0165-6147(99)01334-6; Shah M, 2000, BRIT J PHARMACOL, V129, P627, DOI 10.1038/sj.bjp.0703111; Shakkottai VG, 2001, J BIOL CHEM, V276, P43145, DOI 10.1074/jbc.M106981200; Stocker M, 1999, P NATL ACAD SCI USA, V96, P4662, DOI 10.1073/pnas.96.8.4662; Stocker M, 2000, MOL CELL NEUROSCI, V15, P476, DOI 10.1006/mcne.2000.0842; Strobaek D, 2000, BRIT J PHARMACOL, V129, P991, DOI 10.1038/sj.bjp.0703120; Strong PN, 2000, METH TOOLS BIOSCI ME, P127; Strong PN, 2001, ARCH BIOCHEM BIOPHYS, V385, P138, DOI 10.1006/abbi.2000.2135; Terstappen GC, 2001, NEUROPHARMACOLOGY, V40, P772, DOI 10.1016/S0028-3908(01)00007-7; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; Uchitel OD, 1997, TOXICON, V35, P1161, DOI 10.1016/S0041-0101(96)00210-3; WADSWORTH JDF, 1994, J BIOL CHEM, V269, P18053; Wolfart J, 2001, J NEUROSCI, V21, P3443, DOI 10.1523/JNEUROSCI.21-10-03443.2001; ZERROUK H, 1993, FEBS LETT, V320, P189, DOI 10.1016/0014-5793(93)80583-G; Zerrouk H, 1996, INT J PEPT PROT RES, V48, P514	55	72	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46101	46109		10.1074/JBC.m206465200	http://dx.doi.org/10.1074/JBC.m206465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12239213	hybrid			2022-12-25	WOS:000179529300053
J	Thuault, S; Gangloff, YG; Kirchner, J; Sanders, S; Werten, S; Romier, C; Weil, PA; Davidson, I				Thuault, S; Gangloff, YG; Kirchner, J; Sanders, S; Werten, S; Romier, C; Weil, PA; Davidson, I			Functional analysis of the TFIID-specific yeast TAF4 (yTAF(II)48) reveals an unexpected organization of its histone-fold domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; TAF(II)-CONTAINING COMPLEX; NUCLEOSOME ACETYLATION; TRANSCRIPTION; GENE; COMPONENTS; IDENTIFICATION; ACTIVATION; MULTIPLE; SUBUNITS	Yeast TFIID comprises the TATA binding protein and 14 TBP-associated factors (TAF(II)s), nine of which contain histone-fold domains (HFDs). The C-terminal region of the TFIID-specific yTAF4 (yTAF(II)48) containing the HFD shares strong sequence similarity with Drosophila (d)TAF4 (dTAF(II)110) and human TAF4 (hTAF(II)135). A structure/function analysis of yTAF4 demonstrates that the HFD, a short conserved C-terminal domain (CCTD), and the region separating them are all required for yTAF4 function. Temperature-sensitive mutations in the yTAF4 HFD alpha2 helix or the CCTD can be suppressed upon overexpression of yTAF12 (yTAF(II)68). Moreover, coexpression in Escherichia coli indicates direct yTAF4-yTAF12 heterodimerization optimally requires both the yTAF4 HFD and CCTD. The x-ray crystal structure of the orthologous hTAF4-hTAF12 histone-like heterodimer indicates that the alpha3 region within the predicted TAF4 HFD is unstructured and does not correspond to the bona fide alpha3 helix. Our functional and biochemical analysis of yTAF4, rather provides strong evidence that the HFD alpha3 helix of the TAF4 family lies within the CCTD. These results reveal an unexpected and novel HFD organization in which the alpha3 helix is separated from the alpha2 helix by an extended loop containing a conserved functional domain.	Univ Louis Pasteur Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Vanderbilt University	Davidson, I (corresponding author), Univ Louis Pasteur Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, Boite Postale 163, F-67404 Illkirch Graffenstaden, France.	irwin@titus.u-strasbg.fr	Werten, Sebastiaan/AAU-9011-2021; GANGLOFF, Yann-Gaël/I-2161-2014	Werten, Sebastiaan/0000-0003-2244-9688; GANGLOFF, Yann-Gaël/0000-0001-9031-1184; Romier, Christophe/0000-0002-3680-935X; Davidson, Irwin/0000-0001-5533-1171; THUAULT, Sylvie/0000-0003-0133-3803	NIGMS NIH HHS [GM52461] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM052461, R01GM052461] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Asahara H, 2001, MOL CELL BIOL, V21, P7892, DOI 10.1128/MCB.21.23.7892-7900.2001; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Chen Z, 2000, MOL CELL BIOL, V20, P5064, DOI 10.1128/MCB.20.14.5064-5076.2000; Durso RJ, 2001, MOL CELL BIOL, V21, P7331, DOI 10.1128/MCB.21.21.7331-7344.2001; Fribourg S, 2001, J MOL BIOL, V306, P363, DOI 10.1006/jmbi.2000.4376; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2; Gangloff YG, 2001, MOL CELL BIOL, V21, P1841, DOI 10.1128/MCB.21.5.1841-1853.2001; Gangloff YG, 2001, MOL CELL BIOL, V21, P5109, DOI 10.1128/MCB.21.15.5109-5121.2001; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Guermah M, 2001, MOL CELL BIOL, V21, P6882, DOI 10.1128/MCB.21.20.6882-6894.2001; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hernandez-Hernandez A, 2001, MOL CELL BIOL, V21, P614, DOI 10.1128/MCB.21.2.614-623.2001; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Kirchner J, 2001, MOL CELL BIOL, V21, P6668, DOI 10.1128/MCB.21.19.6668-6680.2001; Kirschner DB, 2002, MOL CELL BIOL, V22, P3178, DOI 10.1128/MCB.22.9.3178-3193.2002; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Mazzarelli JM, 1997, J VIROL, V71, P7978, DOI 10.1128/JVI.71.10.7978-7983.1997; Metzger D, 1999, EMBO J, V18, P4823, DOI 10.1093/emboj/18.17.4823; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; PERLETTI L, 2001, BMC MOL BIOL, V2; Reese JC, 2000, J BIOL CHEM, V275, P17391, DOI 10.1074/jbc.M001635200; Sanders SL, 2000, J BIOL CHEM, V275, P13895, DOI 10.1074/jbc.275.18.13895; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; Schroeder SC, 1998, NUCLEIC ACIDS RES, V26, P4186, DOI 10.1093/nar/26.18.4186; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; Selleck W, 2002, NAT STRUCT BIOL, V9, P231; Selleck W, 2001, NAT STRUCT BIOL, V8, P695, DOI 10.1038/90408; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Soldatov A, 1999, MOL CELL BIOL, V19, P3769; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wassarman DA, 2000, P NATL ACAD SCI USA, V97, P1154, DOI 10.1073/pnas.97.3.1154; Werten S, 2002, J BIOL CHEM, V277, P45502, DOI 10.1074/jbc.M206587200; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483	48	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45510	45517		10.1074/jbc.M206556200	http://dx.doi.org/10.1074/jbc.M206556200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237303	Green Published, hybrid			2022-12-25	WOS:000179404800116
J	Weir, AP; Burton, EA; Harrod, G; Davies, KE				Weir, AP; Burton, EA; Harrod, G; Davies, KE			A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-RELATED PROTEIN; DUCHENNE MUSCULAR-DYSTROPHY; ENDOTHELIAL-CELLS; SKELETAL-MUSCLE; ACTIN-BINDING; MONOCLONAL-ANTIBODIES; BETA-DYSTROBREVIN; DEFICIENT MICE; MOUSE; COMPLEXES	Duchenne muscular dystrophy (DMD) is a fatal childhood disease caused by mutations that abolish the expression of dystrophin in muscle. Utrophin is a paralogue of dystrophin and can functionally replace it in skeletal muscle. A method to induce utrophin up-regulation in muscle should therefore be therapeutically useful in DMD. We have previously shown that there are two full-length utrophin mRNA species: A and B. Here we describe the generation and characterization of antibodies specific to A- and B-utrophin. We show that both mRNA isoforms are translated into full-length proteins, which have very different expression patterns. B-utrophin is expressed in vascular endothelial cells; A-utrophin is expressed at the neuromuscular junction, choroid plexus, pia mater, and renal glomerulus. We have analyzed the expression of A- and B-utrophin protein and RNA in dystrophin-deficient tissues. We conclude that (i) the previously described expression patterns of utrophin represent a composite of A- and B-utrophin, (ii) A- but not B-utrophin is up-regulated in dystrophin-deficient striated muscle, and (iii) this up-regulation occurs post-transcriptionally with an additional transcriptional component in skeletal muscle. These results have important implications for understanding the biology of utrophin and are crucial for future studies aiming to effect its therapeutic up-regulation in DMD patients.	Univ Oxford, MRC, Funct Genet Unit, Dept Human Anat & Genet, Oxford OX1 3QX, England	University of Oxford	Davies, KE (corresponding author), Univ Oxford, MRC, Funct Genet Unit, Dept Human Anat & Genet, S Parks Rd, Oxford OX1 3QX, England.		Burton, Edward/AAO-9677-2021; Burton, Edward/ABB-1324-2021	Burton, Edward/0000-0002-8072-4636				Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; Blake DJ, 1999, J CELL BIOL, V147, P645, DOI 10.1083/jcb.147.3.645; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Burton EA, 1999, P NATL ACAD SCI USA, V96, P14025, DOI 10.1073/pnas.96.24.14025; Deconinck AE, 1997, J CELL BIOL, V136, P883, DOI 10.1083/jcb.136.4.883; Ferrari G, 2001, NATURE, V411, P1014, DOI 10.1038/35082631; Grady RM, 1997, J CELL BIOL, V136, P871, DOI 10.1083/jcb.136.4.871; Gramolini AO, 1999, J NEUROPATH EXP NEUR, V58, P235, DOI 10.1097/00005072-199903000-00003; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; KHURANA TS, 1992, J CELL BIOL, V119, P357, DOI 10.1083/jcb.119.2.357; Knuesel I, 2000, J COMP NEUROL, V422, P594, DOI 10.1002/1096-9861(20000710)422:4<594::AID-CNE8>3.0.CO;2-Q; KUNKEL LM, 1985, P NATL ACAD SCI USA, V82, P4778, DOI 10.1073/pnas.82.14.4778; Loh NY, 2001, MOL CELL BIOL, V21, P7442, DOI 10.1128/MCB.21.21.7442-7448.2001; Loh NY, 2000, J CELL SCI, V113, P2715; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; Lumeng C, 1999, NAT NEUROSCI, V2, P611, DOI 10.1038/10165; MATSUMURA K, 1993, FEBS LETT, V326, P289, DOI 10.1016/0014-5793(93)81810-M; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; Moores CA, 2000, CELL MOTIL CYTOSKEL, V46, P116, DOI 10.1002/1097-0169(200006)46:2<116::AID-CM4>3.0.CO;2-L; Morris GE, 1999, BIOCHEM J, V337, P119, DOI 10.1042/0264-6021:3370119; Nguyen T M, 1991, J Cell Biol, V115, P1695, DOI 10.1083/jcb.115.6.1695; Partridge T, 2000, NEUROL SCI, V21, pS939; Perkins KJ, 2001, NUCLEIC ACIDS RES, V29, P4843, DOI 10.1093/nar/29.23.4843; PONS F, 1994, CIRCULATION, V90, P369, DOI 10.1161/01.CIR.90.1.369; Raats CJI, 2000, AM J PATHOL, V156, P1749, DOI 10.1016/S0002-9440(10)65046-8; Roberts RG, 1998, HUM MOL GENET, V7, P589, DOI 10.1093/hmg/7.4.589; Sewry CA, 2001, HISTOCHEM J, V33, P9, DOI 10.1023/A:1017531627935; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; TINSLEY JM, 1993, NEUROMUSCULAR DISORD, V3, P537, DOI 10.1016/0960-8966(93)90111-V; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; Ueda H, 2000, NEUROSCI LETT, V283, P121, DOI 10.1016/S0304-3940(00)00925-3; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Wang B, 2000, P NATL ACAD SCI USA, V97, P13714, DOI 10.1073/pnas.240335297; WINDER SJ, 1995, J CELL SCI, V108, P63; Zaccaria ML, 2001, NEUROSCIENCE, V104, P311, DOI 10.1016/S0306-4522(01)00092-6	42	96	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45285	45290		10.1074/jbc.M205177200	http://dx.doi.org/10.1074/jbc.M205177200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235137	hybrid			2022-12-25	WOS:000179404800089
J	Yukitake, H; Furusawa, M; Taira, T; Iguchi-Ariga, SMM; Ariga, H				Yukitake, H; Furusawa, M; Taira, T; Iguchi-Ariga, SMM; Ariga, H			AAT-1, a novel testis-specific AMY-1-binding protein, forms a quaternary complex with AMY-1, a-kinase anchor protein 84, and a regulatory subunit of cAMP-dependent protein kinase and is phosphorylated by its kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SPERM CAPACITATION; TYROSINE PHOSPHORYLATION; MOUSE SPERMATOZOA; BINDING-PROTEIN; ASSOCIATION; EXPRESSION; S-AKAP84; AKAP149	AMY-1 has been identified by us as a c-Myc-binding protein and was found to stimulate c-Myc transcription activity. AMY-1 was also found to be associated with protein kinase A anchor protein 84/149 (S-AKAP84/AKAP149) in the mitochondria in somatic cells and sperm, suggesting that it plays a role in spermatogenesis. To determine the molecular function of AMY-1, a two-hybrid screening of cDNAs encoding AMY-1-binding proteins was carried out with AMY-1 as a bait using a human testis cDNA library, and a clone encoding a novel protein, AAT-1, was obtained. Three isoforms of AAT-1, AAT-1alpha, -beta, and -gamma, were found to be derived from an alternative splicing of the transcripts of the aat-1 gene, which was mapped at human chromosome 3q13-3q21. AAT-1 was found to be specifically expressed in the testis during the course of spermatogenesis and also to be present in the spermatid and mature sperm, as was AMY-1. AAT-1alpha was found to bind to and be colocalized in mitochondria with AMY-1 in human HeLa and mouse GC-1 cells. Furthermore, AAT-1alpha was found to bind to the N-terminal half of S-AKAP84/AKAP149 in a quaternary complex with AMY-1 and a regulatory subunit (RII) of cAMP-dependent kinase (PKA), in which AAT-1alpha was associated with RII via S-AKAP84/AKAP149, in rat testis and HeLa cells. It was then found that AAT-1alpha weakly stimulated a phosphorylation activity of PKA and also that AAT-1 itself was phosphorylated by PKA in vivo and in vitro. These results suggest that both AAT-1 and AMY-1 play roles in spermatogenesis.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Hokkaido University; Japan Science & Technology Agency (JST)	Ariga, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	hiro@pharm.hokudai.ac.jp	Ariga, Hiroyoshi/B-5895-2013; Ariga, Sanae/H-9647-2013	Ariga, Hiroyoshi/0000-0001-7384-2143; 				AITKEN RJ, 1995, J CELL SCI, V108, P2017; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P456; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; FLORKE S, 1983, DIFFERENTIATION, V24, P250, DOI 10.1111/j.1432-0436.1983.tb01328.x; Fujimoto M, 2001, GENES CELLS, V6, P1067, DOI 10.1046/j.1365-2443.2001.00488.x; Furusawa M, 2000, INT J ONCOL, V16, P339; Furusawa M, 2001, J BIOL CHEM, V276, P36647, DOI 10.1074/jbc.M103885200; Gadella BM, 2000, DEVELOPMENT, V127, P2407; GalantinoHomer HL, 1997, BIOL REPROD, V56, P707, DOI 10.1095/biolreprod56.3.707; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Haigermoser C, 1996, NUCLEIC ACIDS RES, V24, P3846, DOI 10.1093/nar/24.19.3846; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Leclerc P, 1997, FREE RADICAL BIO MED, V22, P643, DOI 10.1016/S0891-5849(96)00379-6; Leclerc P, 1996, BIOL REPROD, V55, P684, DOI 10.1095/biolreprod55.3.684; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; MALI P, 1989, REPROD FERT DEVELOP, V1, P369, DOI 10.1071/RD9890369; NAZ RK, 1991, J CELL SCI, V99, P157; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; Reinton N, 2000, DEV BIOL, V223, P194, DOI 10.1006/dbio.2000.9725; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Schillace RV, 1999, CURR BIOL, V9, P321, DOI 10.1016/S0960-9822(99)80141-9; SORRENTINO V, 1991, ONCOGENE, V6, P149; Steen RL, 2000, J CELL BIOL, V150, P1251, DOI 10.1083/jcb.150.6.1251; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Trendelenburg G, 1996, BIOCHEM BIOPH RES CO, V225, P313, DOI 10.1006/bbrc.1996.1172; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; Yukitake H, 2002, BBA-GENE STRUCT EXPR, V1577, P126, DOI 10.1016/S0167-4781(02)00411-6	30	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45480	45492		10.1074/jbc.M206201200	http://dx.doi.org/10.1074/jbc.M206201200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223483	hybrid			2022-12-25	WOS:000179404800113
J	Gentile, F; Amodeo, P; Febbraio, F; Picaro, F; Motta, A; Formisano, S; Nucci, R				Gentile, F; Amodeo, P; Febbraio, F; Picaro, F; Motta, A; Formisano, S; Nucci, R			SDS-resistant active and thermostable dimers are obtained from the dissociation of homotetrameric beta-glycosidase from hyperthermophilic Sulfolobus solfataricus in SDS - Stabilizing role of the A-C intermonomeric interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; DEPENDENT DIABETES-MELLITUS; CRYSTAL-STRUCTURE; NUCLEIC-ACIDS; SALT BRIDGES; FORCE-FIELD; MOLECULAR-DYNAMICS; ALZHEIMERS-DISEASE; THERMAL-STABILITY; APOLIPOPROTEIN-E	beta-Glycosidases are fundamental, widely conserved enzymes. Those from hyperthermophiles exhibit unusual stabilities toward various perturbants. Previous work with homotetrameric beta-glycosidase from hyperthermophilic Sulfolobus solfataricus (M-r 226,760) has shown that addition of 0.05-0.1% SDS was associated with minimal secondary structure perturbations and increased activity. This work addresses the effects of SDS on beta-glycosidase quaternary structure. In 0.1-1% SDS, the enzyme was dimeric, as determined by Ferguson analysis of transverse-gradient polyacrylamide gels. The catalytic activity of the beta-glycosidase dimer in SDS was determined by in-gel assay. A minor decrease of thermal stability in SDS was observed after exposure to temperatures up to 80 degreesC for 1 h. An analysis of beta-glycosidase crystal structure showed different changes in solvent-accessible surface area on going from the tetramer to the two possible dimers (A-C and A-D). Energy minimization and molecular dynamics calculations showed that the A-C dimer, exhibiting the lowest exposed surface area, was more stabilized by a network of polar interactions. The charge distribution around the A-C interface was characterized by a local short range anisotropy, resulting in an unfavorable interaction with SDS. This paper provides a detailed description of an SDS-resistant inter-monomeric interface, which may help understand similar interfaces involved in important biological processes.	CNR, Ist Biochim Prot, I-80125 Naples, Italy; Univ Federico II, Ist Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy; Univ Federico II, Dipartimento Biol & Patol Cellular & Mol, I-80131 Naples, Italy; CNR, Ist Chim Biomol, I-80078 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR)	Febbraio, F (corresponding author), CNR, Ist Biochim Prot, Via Marconi 10, I-80125 Naples, Italy.	febbraio@dafne.ibpe.na.cnr.it	Gentile, Fabrizio/K-2475-2012; Febbraio, Ferdinando/AAX-8255-2020; Amodeo, Pietro/P-1800-2015	Gentile, Fabrizio/0000-0002-6704-3115; Febbraio, Ferdinando/0000-0002-3653-9847; Amodeo, Pietro/0000-0002-6439-7575; Motta, Andrea/0000-0002-8643-658X				Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; Bentley NM, 2002, BIOCHEM J, V366, P273, DOI 10.1042/BJ20020207; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; CarrascoMarin E, 1996, J IMMUNOL, V156, P450; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; COZENS B, 1984, J BIOL CHEM, V259, P6248; DAuria S, 1997, BIOCHEM J, V323, P833, DOI 10.1042/bj3230833; Decker H, 2001, J BIOL CHEM, V276, P17796, DOI 10.1074/jbc.M010436200; DEHAEN C, 1987, ANAL BIOCHEM, V166, P235, DOI 10.1016/0003-2697(87)90570-7; Elcock AH, 1998, J MOL BIOL, V284, P489, DOI 10.1006/jmbi.1998.2159; Ettinger RA, 1998, J IMMUNOL, V161, P6439; Ettinger RA, 2000, J IMMUNOL, V165, P3232, DOI 10.4049/jimmunol.165.6.3232; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; Gentile F, 1997, ANAL BIOCHEM, V244, P228, DOI 10.1006/abio.1996.9863; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Henrissat B, 1998, BIOCHEM SOC T, V26, P153, DOI 10.1042/bst0260153; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; KELLY CA, 1993, BIOCHEMISTRY-US, V32, P3913, DOI 10.1021/bi00066a010; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORNDORFER I, 1995, J MOL BIOL, V246, P511, DOI 10.1006/jmbi.1994.0103; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; Lopez-Serrano D, 2002, PIGM CELL RES, V15, P104; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Munson GW, 2000, BIOCHEMISTRY-US, V39, P16119, DOI 10.1021/bi0017475; MUSAFIA B, 1995, J MOL BIOL, V254, P761, DOI 10.1006/jmbi.1995.0653; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NUCCI R, 1993, BIOTECHNOL APPL BIOC, V17, P239; NUCCI R, 1995, BIOTECHNOL APPL BIOC, V21, P265; RODBARD D, 1970, P NATL ACAD SCI USA, V65, P970, DOI 10.1073/pnas.65.4.970; RODBARD D, 1971, ANAL BIOCHEM, V40, P95, DOI 10.1016/0003-2697(71)90086-8; Russo C, 1998, P NATL ACAD SCI USA, V95, P15598, DOI 10.1073/pnas.95.26.15598; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SANJEEVI CB, 1995, TISSUE ANTIGENS, V45, P148, DOI 10.1111/j.1399-0039.1995.tb02434.x; Sanjeevi CB, 1997, TISSUE ANTIGENS, V50, P61, DOI 10.1111/j.1399-0039.1997.tb02836.x; Schiffmann R, 2002, DRUGS, V62, P733, DOI 10.2165/00003495-200262050-00002; SPASSOV VZ, 1995, PROTEIN SCI, V4, P1516, DOI 10.1002/pro.5560040809; TOMSCHY A, 1994, PROTEIN ENG, V7, P1471, DOI 10.1093/protein/7.12.1471; VANLITH HA, 1992, ANAL BIOCHEM, V201, P288, DOI 10.1016/0003-2697(92)90341-4; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; WALKER JE, 1980, EUR J BIOCHEM, V108, P581, DOI 10.1111/j.1432-1033.1980.tb04753.x; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEINER PK, 1981, J COMPUT CHEM, V2, P287, DOI 10.1002/jcc.540020311; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	48	41	45	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44050	44060		10.1074/jbc.M206761200	http://dx.doi.org/10.1074/jbc.M206761200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12213823	hybrid			2022-12-25	WOS:000179272000068
J	Hirota, T; Okano, T; Kokame, K; Shirotani-Ikejima, H; Miyata, T; Fukada, Y				Hirota, T; Okano, T; Kokame, K; Shirotani-Ikejima, H; Miyata, T; Fukada, Y			Glucose down-regulates Per1 and Per2 mRNA levels and induces circadian gene expression in cultured rat-1 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; MOLECULAR-MECHANISMS; PERIPHERAL-TISSUES; BRCA1 EXPRESSION; PHASE-SHIFTS; CLOCK; BINDING; LIGHT; MPER1; OSCILLATORS	In mammals, peripheral circadian clocks are present in most tissues, but little is known about how these clocks are synchronized with the ambient 24-h cycles. By using rat-1 fibroblasts, a model cell system of the peripheral clock, we found that an exchange of the culture medium triggered circadian gene expression that was preceded by slow down-regulation of Per1 and Per2 mRNA levels. This profile contrasts to the immediate up-regulation of these genes often observed for clock resetting. The screening of factor(s) responsible for the down-regulation revealed glucose as a key component triggering the circadian rhythm. The requirement of both glucose metabolism and RNA/protein synthesis for the down-regulation suggests the involvement of gene(s) immediately up-regulated by glucose metabolism. An analysis with high density oligonucleotide microarrays identified >100 glucose-regulated genes. We found among others immediately up-regulated genes encoding transcriptional regulators TIEG1, VDUP1, and HES1, in addition to cooperatively regulated genes that are associated with cholesterol biosynthesis and cell cycle. The immediate up-regulation of Tieg1 and Vdup1 expression was dependent on glucose metabolism but not on protein synthesis, suggesting that the transcriptional regulators mediate the glucose-induced down-regulation of Per1 and Per2 expression. These results illustrate a novel mode of peripheral clock resetting by external glucose, a major food metabolite.	Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 1130033, Japan; Natl Cardiovasc Ctr, Res Inst, Suita, Osaka 5658565, Japan	University of Tokyo; National Cerebral & Cardiovascular Center - Japan	Fukada, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	sfukada@mail.ecc.u-tokyo.ac.jp	Hirota, Tsuyoshi/D-8158-2015; 吉孝, 深田/G-5090-2014	Hirota, Tsuyoshi/0000-0003-4876-3608; Okano, Toshiyuki/0000-0001-6740-6265; Kokame, Koichi/0000-0002-9654-6299				Akashi M, 2000, GENE DEV, V14, P645; Akiyama M, 1999, J NEUROSCI, V19, P1115; Balsalobre A, 2000, CURR BIOL, V10, P1291, DOI 10.1016/S0960-9822(00)00758-2; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Brown SA, 1999, CURR OPIN GENET DEV, V9, P588, DOI 10.1016/S0959-437X(99)00009-X; Cermakian N, 2000, NAT REV MOL CELL BIO, V1, P59, DOI 10.1038/35036078; Cook T, 2000, AM J PHYSIOL-GASTR L, V278, pG513, DOI 10.1152/ajpgi.2000.278.4.G513; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; FUKUDA H, 1991, BIOCHIM BIOPHYS ACTA, V1086, P261, DOI 10.1016/0005-2760(91)90168-H; Grundschober C, 2001, J BIOL CHEM, V276, P46751, DOI 10.1074/jbc.M107499200; Hara R, 2001, GENES CELLS, V6, P269, DOI 10.1046/j.1365-2443.2001.00419.x; Hida A, 2000, GENOMICS, V65, P224, DOI 10.1006/geno.2000.6166; Hirota T, 2001, J BIOCHEM, V129, P51, DOI 10.1093/oxfordjournals.jbchem.a002836; Horikawa K, 2000, J NEUROSCI, V20, P5867, DOI 10.1523/JNEUROSCI.20-15-05867.2000; Ishida N, 1999, P NATL ACAD SCI USA, V96, P8819, DOI 10.1073/pnas.96.16.8819; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; KINLAW WB, 1987, ENDOCRINOLOGY, V120, P1563, DOI 10.1210/endo-120-4-1563; Maywood ES, 1999, P NATL ACAD SCI USA, V96, P15211, DOI 10.1073/pnas.96.26.15211; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; Morris ME, 1998, SCIENCE, V279, P1544, DOI 10.1126/science.279.5356.1544; Nishiyama A, 2001, IUBMB LIFE, V52, P29, DOI 10.1080/15216540252774739; Nonaka H, 2001, CIRCULATION, V104, P1746, DOI 10.1161/hc4001.098048; Ohtani Kiyoshi, 1999, Frontiers in Bioscience, V4, pd793, DOI 10.2741/Ohtani; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Sakakura Y, 2001, BIOCHEM BIOPH RES CO, V286, P176, DOI 10.1006/bbrc.2001.5375; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Stephan FK, 1998, PHYSIOL BEHAV, V65, P277, DOI 10.1016/S0031-9384(98)00166-8; Stephan FK, 1997, PHYSIOL BEHAV, V62, P995, DOI 10.1016/S0031-9384(97)00204-7; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Takahata S, 2000, GENES CELLS, V5, P739, DOI 10.1046/j.1365-2443.2000.00363.x; Towle HC, 2001, P NATL ACAD SCI USA, V98, P13476, DOI 10.1073/pnas.251530798; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wakamatsu H, 2001, NEUROREPORT, V12, P127, DOI 10.1097/00001756-200101220-00033; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Yagita K, 2000, FEBS LETT, V465, P79, DOI 10.1016/S0014-5793(99)01724-X; Yagita K, 2001, SCIENCE, V292, P278, DOI 10.1126/science.1059542; YAMAMOTO H, 1987, CHRONOBIOL INT, V4, P483, DOI 10.3109/07420528709078539; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Yu R, 2000, MOL ENDOCRINOL, V14, P1137, DOI 10.1210/me.14.8.1137; Yu WJ, 2002, BIOCHEM BIOPH RES CO, V290, P933, DOI 10.1006/bbrc.2001.6300; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	50	247	252	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44244	44251		10.1074/jbc.M206233200	http://dx.doi.org/10.1074/jbc.M206233200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12213820	hybrid			2022-12-25	WOS:000179272000093
J	Kang, HY; Huang, KE; Chang, SY; Ma, WL; Lin, WJ; Chang, C				Kang, HY; Huang, KE; Chang, SY; Ma, WL; Lin, WJ; Chang, C			Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; PROSTATE-CANCER CELLS; TGF-BETA RECEPTOR; TRANSCRIPTIONAL ACTIVATION; DU145 CELLS; DPC4 SMAD4; CROSS-TALK; COACTIVATOR; PROTEIN; INHIBITION	Smad proteins have been demonstrated to be key components in the transforming growth factor 13 signaling cascade. Here we demonstrate that Smad4, together with Smad3, can interact with the androgen receptor (AR) in the DNA-binding and ligand-binding domains, which may result in the modulation of 5alpha-dihydrotestosterone-induced AR transactivation. Interestingly, in the prostate PC3 and LNCaP cells, addition of Smad3 can enhance AR transactivation, and co-transfection of Smad3 and Smad4 can then repress AR transactivation in various androgen response element-promoter reporter assays as well as Northern blot and reverse transcription-PCR quantitation assays with prostate-specific antigen mRNA expression. In contrast, in the SW480-C7 cell, lacking endogenous functional Smad4, the influence of Smad3 on AR transactivation is dependent on the various androgen response element-promoters. The influence of Smad3/Smad4 on the AR transactivation may involve the acetylation since the treatment of trichostatin A or sodium butyrate can reverse Smad3/Smad4-repressed AR transactivation and Smad3/Smad4 complex can also decrease the acetylation level of AR. Together, these results suggest that the interactions between AR, Smad3, and Smad4 may result in the differential regulation of the AR transactivation, which further strengthens their roles in the prostate cancer progression.	Chang Gung Univ, Mem Hosp, Ctr Menopause & Reprod Med Res, Kaohsiung 833, Taiwan; Univ Rochester, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, George Whipple Lab Canc Res, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA	Chang Gung University; University of Rochester; University of Rochester; University of Rochester; University of Rochester	Huang, KE (corresponding author), Chang Gung Univ, Mem Hosp, Ctr Menopause & Reprod Med Res, Kaohsiung 833, Taiwan.		Kang, Hong-Yo/W-9031-2019; Lin, Wen-Jye/D-1028-2016	Kang, Hong-Yo/0000-0003-0626-5037; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060905] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60905] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brodin G, 1999, CANCER RES, V59, P2731; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Dai JL, 1999, P NATL ACAD SCI USA, V96, P1427, DOI 10.1073/pnas.96.4.1427; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hayes SA, 2001, CANCER RES, V61, P2112; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Leong GM, 2001, J BIOL CHEM, V276, P18243, DOI 10.1074/jbc.M010815200; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; List HJ, 1999, EXP CELL RES, V252, P471, DOI 10.1006/excr.1999.4638; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Schutte M, 1996, CANCER RES, V56, P2527; Sharma M, 2001, MOL ENDOCRINOL, V15, P1918, DOI 10.1210/me.15.11.1918; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Subramaniam N, 2001, J BIOL CHEM, V276, P15741, DOI 10.1074/jbc.M011033200; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wotton D, 2001, CELL GROWTH DIFFER, V12, P457; Wotton D, 2001, CURR TOP MICROBIOL, V254, P145; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	45	86	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43749	43756		10.1074/jbc.M205603200	http://dx.doi.org/10.1074/jbc.M205603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226080	hybrid			2022-12-25	WOS:000179272000029
J	Nishi, T; Shimizu, N; Hiramoto, M; Sato, L; Yamaguchi, Y; Hasegawa, M; Aizawa, S; Tanaka, H; Kataoka, K; Watanabe, H; Handa, H				Nishi, T; Shimizu, N; Hiramoto, M; Sato, L; Yamaguchi, Y; Hasegawa, M; Aizawa, S; Tanaka, H; Kataoka, K; Watanabe, H; Handa, H			Spatial redox regulation of a critical cysteine residue of NF-kappa B in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; S-NITROSYLATION; NITRIC-OXIDE; P50 SUBUNIT; IN-VIVO; THIOREDOXIN; PROTEIN; REF-1	Reduction-oxidation (redox) regulation has been implicated in the activation of the transcription factor NF-kappaB. However, the significance and mechanism of the redox regulation remain elusive, mainly due to the technical limitations caused by rapid proton transfer in redox reactions and by the presence of many redox molecules within cells. Here we establish versatile methods for measuring redox states of proteins and their individual cysteine residues in vitro and in vivo, involving thiol-modifying reagents and LC-MS analysis. Using these methods, we demonstrate that the redox state of NF-kappaB is spatially regulated by its subcellular localization. While the p65 subunit and most cysteine residues of the p50 subunit are reduced similarly in the cytoplasm and in the nucleus, Cys-62 of p50 is highly oxidized in the cytoplasm and strongly reduced in the nucleus. The reduced form of Cys-62 is essential for the DNA binding activity of NF-kappaB Several lines of evidence suggest that the redox factor Ref-1 is involved in Cys-62 reduction in the nucleus. We propose that the Ref-1-dependent reduction of p50 in the nucleus is a necessary step for NF-kappaB activation. This study also provides the first example of a drug that inhibits the redox reaction between two specific proteins.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Nihon Univ, Sch Med, Dept Anat, Itabashi Ku, Tokyo 173, Japan; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; Okazaki Natl Res Inst, Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan	Tokyo Institute of Technology; Tokyo Institute of Technology; Nihon University; University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Okazaki Institute for Integrative Bioscience (OIIB)	Handa, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.		Watanabe, Hajime/S-8957-2019; WATANABE, Hajime/AAJ-8904-2021; Yamaguchi, Yuki/B-9390-2015	Yamaguchi, Yuki/0000-0002-0197-614X; Watanabe, Hajime/0000-0001-9657-6554				ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; delaTorre A, 1999, J IMMUNOL, V162, P4101; Demple B, 1997, METHODS, V11, P267, DOI 10.1006/meth.1996.0421; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Ding HG, 1997, P NATL ACAD SCI USA, V94, P8445, DOI 10.1073/pnas.94.16.8445; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hidalgo E, 1997, CELL, V88, P121, DOI 10.1016/S0092-8674(00)81864-4; Hiramoto M, 1998, J IMMUNOL, V160, P810; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P1727, DOI 10.1093/nar/21.8.1727; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MITOMO K, 1994, GENE, V145, P197; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Park SK, 1997, BIOCHEM J, V322, P609, DOI 10.1042/bj3220609; RICHARD PH, 1998, HDB FLUORESCENT PROB, P47; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Shimizu N, 2000, NAT BIOTECHNOL, V18, P877, DOI 10.1038/78496; Takeuchi J, 2000, ANTIOXID REDOX SIGN, V2, P83, DOI 10.1089/ars.2000.2.1-83; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Wei SJ, 2000, CANCER RES, V60, P6688; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	43	190	200	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44548	44556		10.1074/jbc.M202970200	http://dx.doi.org/10.1074/jbc.M202970200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12213807	hybrid			2022-12-25	WOS:000179272000127
J	Pai, TG; Ohkimoto, K; Sakakibara, Y; Suiko, M; Sugahara, T; Liu, MC				Pai, TG; Ohkimoto, K; Sakakibara, Y; Suiko, M; Sugahara, T; Liu, MC			Manganese stimulation and stereospecificity of the dopa (3,4-dihydroxyphenylalanine)/tyrosine-sulfating activity of human monoamine-form phenol sulfotransferase - Kinetic studies of the mechanism using wild-type and mutant enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEREOSELECTIVE SULFATE CONJUGATION; HUMAN HEPATOMA-CELLS; AMINO-ACID OXIDASE; SUBSTRATE-SPECIFICITY; D-ASPARTATE; MOLECULAR-BIOLOGY; D-ALANINE; BRAIN; PROTEINS; TYROSINE	Kinetic studies were performed to dissect the mechanism underlying the remarkable Mn2+ stimulation of the Dopa/tyrosine-sulfating activity of the human monoamine (M)-form phenol sulfotransferase (PST). The activities and the stimulation by Mn2+ are highly stereospecific for the D-form enantiomers of tyrosine and Dopa. Analysis of the kinetic results strongly suggests that tyrosine-Mn2+ and tyrosine-Mn2+-tyrosine complexes are obligatory substrates, whereas Dopa-Mn2+ complexes may be better substrates than Dopa alone. This activation of the Dopa/tyrosine-sulfating activity of M-form PST by Mn2+ via complex formation between Mn2+ and the substrate is the first reported case of a regulatory mechanism in this important class of enzymes. Our previous studies using point-mutated M-form PSTs established that the Mn2+ (in the substrate-Mn2+ complex) exerts its stimulatory effect by binding predominantly to the Asp-86 residue at the active site. We present here further studies using dopamine as substrate to bolster this conclusion. The possible physiological implications of this rather unusual specificity for the D-amino acid and its derivatives and the stimulation by Mn2+ are discussed in the context of protective and detoxification mechanisms that may operate in neurodegenerative processes in the brain. The, Mn2+ stimulation of the activity of M-form PST toward D-enantiomers of Dopa/tyrosine may have implications for other substrates (including chiral drugs) and for the other cytosolic sulfotransferases that are involved in the regulation of endogenous metabolites as well as in detoxification.	Univ Texas Hlth Ctr, Biomed Res Ctr, Tyler, TX 75708 USA		Liu, MC (corresponding author), Univ Texas Hlth Ctr, Biomed Res Ctr, 11937 US Highway 271, Tyler, TX 75708 USA.			Sugahara, Takuya/0000-0002-0335-8273				BARBEAU A, 1984, NEUROTOXICOLOGY, V5, P13; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER PR, 1983, J NEUROCHEM, V41, P630, DOI 10.1111/j.1471-4159.1983.tb04788.x; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; CORELL J, 1999, NEUROEPIDEMIOLOGY, V18, P303; COTZIAS GC, 1976, MED CLIN N AM, V60, P729, DOI 10.1016/S0025-7125(16)31856-9; Coughtrie MWH, 1998, CHEM-BIOL INTERACT, V109, P3, DOI 10.1016/S0009-2797(97)00117-8; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; DANIELLO A, 1993, J BIOL CHEM, V268, P26941; Duffel MW, 1997, COMPREHENSIVE TOXICO, V3, P365; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; FERNANDO PHP, 1993, BIOSCI BIOTECH BIOCH, V5, P1974; FISHER GH, 1991, BRAIN RES BULL, V26, P983, DOI 10.1016/0361-9230(91)90266-M; GAVIN CE, 1992, TOXICOL APPL PHARM, V115, P1, DOI 10.1016/0041-008X(92)90360-5; GERGELY A, 1971, ACTA CHIM HUNG, V68, P285; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; HEROUX JA, 1988, MOL PHARMACOL, V34, P194; Keller JN, 1998, J NEUROSCI, V18, P687; Klaassen CD., 1996, CASARETT DOULLS TOXI; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin ES, 2000, BIOCHEM BIOPH RES CO, V271, P818, DOI 10.1006/bbrc.2000.2722; LIPMANN F, 1958, SCIENCE, V128, P575, DOI 10.1126/science.128.3324.575; LIU MC, 1984, P NATL ACAD SCI-BIOL, V81, P3695, DOI 10.1073/pnas.81.12.3695; Liu MC, 2000, J BIOL CHEM, V275, P13460, DOI 10.1074/jbc.275.18.13460; LONDON WP, 1969, BIOCHEMISTRY-US, V8, P1767, DOI 10.1021/bi00832a061; LUTHRA M, 1994, J BIOL CHEM, V269, P22678; MAN EH, 1987, J NEUROCHEM, V48, P510, DOI 10.1111/j.1471-4159.1987.tb04122.x; MARTELL AE, 1974, CRITICAL STABILTIY C, V1; MATSUI M, 1994, INT J BIOCHEM, V26, P1237; Mulder G.J., 1990, CONJUGATION REACTION, P107; PERSOLA GR, 1993, CHIRALITY, V5, P602; Rubin GL, 1996, XENOBIOTICA, V26, P1113, DOI 10.3109/00498259609050256; Sakakibara Y, 1998, J BIOL CHEM, V273, P6242, DOI 10.1074/jbc.273.11.6242; Sakakibara Y, 1997, BBA-MOL CELL RES, V1355, P102, DOI 10.1016/S0167-4889(96)00166-8; Segel I.H., 1975, ENZYME KINETICS; SEKURA RD, 1979, ANAL BIOCHEM, V95, P82, DOI 10.1016/0003-2697(79)90188-X; SINGH R, 1991, J ORG CHEM, V56, P2332, DOI 10.1021/jo00007a018; Stegman LD, 1998, HUM GENE THER, V9, P185, DOI 10.1089/hum.1998.9.2-185; Suiko M, 1998, J BIOCHEM-TOKYO, V124, P707, DOI 10.1093/oxfordjournals.jbchem.a022170; Suiko M, 1996, BIOCHEM J, V314, P151, DOI 10.1042/bj3140151; ULTER MF, 1976, MED CLIN N AM, V60, P713; WALLE T, 1992, DRUG METAB DISPOS, V20, P333; WALLE UK, 1993, BRIT J CLIN PHARMACO, V35, P413, DOI 10.1111/j.1365-2125.1993.tb04159.x; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Wilson AA, 1997, XENOBIOTICA, V27, P1147, DOI 10.1080/004982597239903; Yanagisawa K, 1998, BIOSCI BIOTECH BIOCH, V62, P1037, DOI 10.1271/bbb.62.1037	46	8	9	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43813	43820		10.1074/jbc.M200785200	http://dx.doi.org/10.1074/jbc.M200785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228221	hybrid			2022-12-25	WOS:000179272000038
J	Richter, S; Lamppa, GK				Richter, S; Lamppa, GK			Determinants for removal and degradation of transit peptides of chloroplast precursor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL PROCESSING PEPTIDASE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE; TUMOR NECROSIS FACTOR; SUBCELLULAR-LOCALIZATION; PEA-CHLOROPLASTS; STRUCTURAL BASIS; GENE-EXPRESSION; THYLAKOID LUMEN; IMPORT; SEQUENCE	The stromal processing peptidase (SPP) cleaves a large diversity of chloroplast precursor proteins, removing an N-terminal transit peptide. We predicted previously that this key step of the import pathway is mediated by features of the transit peptide that determine precursor binding and cleavage followed by transit peptide conversion to a degradable substrate. Here we performed competition experiments using synthesized oligopeptides of the transit peptide of ferredoxin precursor to investigate the mechanism of these processes. We found that binding and processing of ferredoxin precursor depend on specific interactions of SPP with the region consisting of the C-terminal 12 residues of the transit peptide. Analysis of four other precursors suggests that processing depends on the same region, although their transit peptides are highly divergent in primary sequence and length. Upon processing, SPP terminates its interaction with the transit peptide by a second cleavage, converting it to a subfragment form. From the competition experiments we deduce that SPP releases a subfragment consisting of the transit peptide without its original C terminus. Interestingly, examination of the ATP-dependent metallopeptidase activity responsible for degradation of transit peptide subfragments suggests that it may recognize other unrelated peptides and, hence, act separately from SPP as a novel stromal oligopeptidase.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Lamppa, GK (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58Th St, Chicago, IL 60637 USA.							ABAD MS, 1989, PLANT PHYSIOL, V90, P117, DOI 10.1104/pp.90.1.117; Adam Z, 2000, BIOCHIMIE, V82, P647, DOI 10.1016/S0300-9084(00)00612-X; Adam Z, 2001, PLANT PHYSIOL, V125, P1912, DOI 10.1104/pp.125.4.1912; ARCHER EK, 1993, PLANT MOL BIOL, V23, P1105, DOI 10.1007/BF00042345; ARSDELL JN, 1985, SCIENCE, V228, P149; BASSHAM DC, 1994, J BIOL CHEM, V269, P16062; Bauer J, 2001, CELL MOL LIFE SCI, V58, P420, DOI 10.1007/PL00000867; BEERS EP, 1992, J BIOL CHEM, V267, P15432; Bruce BD, 2001, BBA-MOL CELL RES, V1541, P2, DOI 10.1016/S0167-4889(01)00149-5; BUSHNELL TP, 1993, PLANT PHYSIOL, V103, P585, DOI 10.1104/pp.103.2.585; Chen K, 2000, BIOCHEM SOC T, V28, P485, DOI 10.1042/0300-5127:0280485; CLARK SE, 1991, J CELL BIOL, V114, P681, DOI 10.1083/jcb.114.4.681; Claros MG, 1997, CURR OPIN STRUC BIOL, V7, P394, DOI 10.1016/S0959-440X(97)80057-7; Desimone M, 1998, PLANTA, V205, P459, DOI 10.1007/s004250050344; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Halperin T, 1996, PLANT MOL BIOL, V30, P925, DOI 10.1007/BF00020804; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KUEHN MJ, 1993, SCIENCE, V262, P1234, DOI 10.1126/science.7901913; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1985, MOL CELL BIOL, V5, P1370, DOI 10.1128/MCB.5.6.1370; LEVY M, 1995, PLANT MOL BIOL, V29, P53, DOI 10.1007/BF00019118; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; OBLONG JE, 1992, EMBO J, V11, P4401, DOI 10.1002/j.1460-2075.1992.tb05540.x; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PILON M, 1992, J BIOL CHEM, V267, P19907; PILON M, 1995, J BIOL CHEM, V270, P3882, DOI 10.1074/jbc.270.8.3882; Rensink WA, 2000, J BIOL CHEM, V275, P10265, DOI 10.1074/jbc.275.14.10265; Richter S, 1999, J CELL BIOL, V147, P33, DOI 10.1083/jcb.147.1.33; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; Sarath G., 1989, PROTEOLYTIC ENZYMES, P25; SCHIGGER H, 1987, ANAL BIOCHEM, V166, P368; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; SMEEKENS S, 1985, NUCLEIC ACIDS RES, V13, P3179, DOI 10.1093/nar/13.9.3179; Sokolenko A, 1997, PLANT PHYSIOL, V115, P827, DOI 10.1104/pp.115.2.827; Soto GE, 1998, EMBO J, V17, P6155, DOI 10.1093/emboj/17.21.6155; TAME JRH, 1994, SCIENCE, V264, P1578, DOI 10.1126/science.8202710; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; The Arabidopsis Genome Initiative, 2000, NATURE, V408, P796; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; VANTHOF R, 1995, J BIOL CHEM, V270, P22368, DOI 10.1074/jbc.270.38.22368; VANTHOF R, 1993, J BIOL CHEM, V268, P4037; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; Vothknecht UC, 2000, BIOL CHEM, V381, P887, DOI 10.1515/BC.2000.110; Wan JX, 1998, PLANT J, V15, P459, DOI 10.1046/j.1365-313X.1998.00224.x; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WERNEKE JM, 1988, P NATL ACAD SCI USA, V85, P787, DOI 10.1073/pnas.85.3.787; Wienk HLJ, 1999, FEBS LETT, V453, P318, DOI 10.1016/S0014-5793(99)00653-5	51	50	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43888	43894		10.1074/jbc.M206020200	http://dx.doi.org/10.1074/jbc.M206020200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12235143	hybrid			2022-12-25	WOS:000179272000048
J	Shallom, D; Belakhov, V; Solomon, D; Shoham, G; Baasov, T; Shoham, Y				Shallom, D; Belakhov, V; Solomon, D; Shoham, G; Baasov, T; Shoham, Y			Detailed kinetic analysis and identification of the nucleophile in alpha-L-arabinofuranosidase from Geobacillus stearothermophilus T-6, a family 51 glycoside hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BASED CLASSIFICATION; ACTIVE-SITE NUCLEOPHILE; MECHANISTIC CONSEQUENCES; PURIFICATION; RESIDUES; MUTAGENESIS; ARABINOFURANOHYDROLASE; GLUCOAMYLASE; HYDROLYSIS; MUTATION	alpha-L-Arabinofuranosidases cleave the L-arabinofuranoside side chains of different hemicelluloses and are key enzymes in the complete degradation of the plant cell wall. The alpha-L-arabinofuranosidase from Geobacillus stearothermophilus T-6, a family 51 glycoside hydrolase, was subjected to a detailed mechanistic study. Aryl-alpha-Larabinofuranosides with various leaving groups were synthesized and used to verify the catalytic mechanism and catalytic residues of the enzyme. The steady-state constants and the resulting Bronsted plots for the E175A mutant are consistent with the role of Glu-175 as the acid-base catalytic residue. The proposed nucleophile residue, Glu-294, was replaced to Ala by a double-base pairs substitution. The resulting E294A mutant, with 4-nitrophenyl alpha-L-arabinofuranoside as the substrate, exhibited eight orders of magnitude lower activity and a 10-fold higher K-m value compared with the wild type enzyme. Sodium azide accelerated by more than 40-fold the rate of the hydrolysis of 2',4',6'-trichlorophenyl alpha-L-arabinofuranoside by the E294A mutant. The glycosylazide product formed during this reaction was isolated and characterized as P-L-arabinofuranosyl-azide by H-1 NMR, C-13 NMR, mass spectrometry, and Fourier transform infrared analysis. The anomeric configuration of this product supports the assignment of Glu-294 as the catalytic nucleophile residue of the alpha-L-arabinofuranosidase T-6 and allows for the first time the unequivocal identification of this residue in glycoside hydrolases family 51.	Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel; Hebrew Univ Jerusalem, Dept Inorgan Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Lab Struct Chem & Biol, IL-91904 Jerusalem, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Shoham, Y (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel.	yshoham@tx.technion.ac.il	Shoham, Yuval/M-4409-2013; Baasov, Timor/L-5173-2019	Baasov, Timor/0000-0002-1427-2619; Belakhov, Valery/0000-0003-1918-974X				Beylot MH, 2001, BIOCHEM J, V358, P607, DOI 10.1042/0264-6021:3580607; Biely P, 1997, J BIOTECHNOL, V57, P151, DOI 10.1016/S0168-1656(97)00096-5; BIELY P, 1985, TRENDS BIOTECHNOL, V3, P286, DOI 10.1016/0167-7799(85)90004-6; Davies G. J., 1998, INCOMPREHENSIVE BIOL, P119; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; de Vries RP, 2000, CARBOHYD RES, V327, P401, DOI 10.1016/S0008-6215(00)00066-5; Debeche T, 2002, PROTEIN ENG, V15, P21, DOI 10.1093/protein/15.1.21; Ferre H, 2000, EUR J BIOCHEM, V267, P6633, DOI 10.1046/j.1432-1327.2000.01758.x; Fort S, 2000, J AM CHEM SOC, V122, P5429, DOI 10.1021/ja9936520; GILEAD S, 1995, APPL ENVIRON MICROB, V61, P170, DOI 10.1128/AEM.61.1.170-174.1995; HARRIS EMS, 1993, BIOCHEMISTRY-US, V32, P1618, DOI 10.1021/bi00057a028; Hazlewood GP, 1998, PROG NUCLEIC ACID RE, V61, P211, DOI 10.1016/S0079-6603(08)60828-4; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Kaneko S, 1998, APPL ENVIRON MICROB, V64, P4021; KELLY MA, 1988, CARBOHYD RES, V181, P262, DOI 10.1016/0008-6215(88)84045-X; KELLY MA, 1987, BIOCHEM J, V245, P843, DOI 10.1042/bj2450843; Lawson SL, 1996, BIOCHEMISTRY-US, V35, P10110, DOI 10.1021/bi960586v; Leatherbarrow R. J, 2001, GRAFIT 5; Lee RC, 2001, BIOCHEM J, V356, P181, DOI 10.1042/0264-6021:3560181; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Mackenzie LF, 1998, J AM CHEM SOC, V120, P5583, DOI 10.1021/ja980833d; MacLeod AM, 1996, BIOCHEMISTRY-US, V35, P13165, DOI 10.1021/bi9610616; Malet C, 1998, FEBS LETT, V440, P208, DOI 10.1016/S0014-5793(98)01448-3; Matsuo N, 2000, BIOCHEM J, V346, P9, DOI 10.1042/0264-6021:3460009; McIntosh LP, 1996, BIOCHEMISTRY-US, V35, P9958, DOI 10.1021/bi9613234; MIKAMI B, 1994, BIOCHEMISTRY-US, V33, P7779, DOI 10.1021/bi00191a005; Moracci M, 1998, BIOCHEMISTRY-US, V37, P17262, DOI 10.1021/bi981855f; Notenboom V, 1998, NAT STRUCT BIOL, V5, P812, DOI 10.1038/1852; Palcic MM, 1999, CURR OPIN BIOTECH, V10, P616, DOI 10.1016/S0958-1669(99)00044-0; Pitson SM, 1996, FEBS LETT, V398, P7, DOI 10.1016/S0014-5793(96)01153-2; PLANAS P, 1998, CARBOHYDRASES TRICHO, P21; Saha Badal C., 2000, Biotechnology Advances, V18, P403, DOI 10.1016/S0734-9750(00)00044-6; SCHIMMEL P, 1989, ACCOUNTS CHEM RES, V22, P232, DOI 10.1021/ar00163a001; Shallom D, 2002, FEBS LETT, V514, P163, DOI 10.1016/S0014-5793(02)02343-8; SIERKS MR, 1990, PROTEIN ENG, V3, P193, DOI 10.1093/protein/3.3.193; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Sunna A, 1997, CRIT REV BIOTECHNOL, V17, P39, DOI 10.3109/07388559709146606; Suurnakki A, 1997, Adv Biochem Eng Biotechnol, V57, P261; TOTSUKA A, 1994, EUR J BIOCHEM, V221, P649, DOI 10.1111/j.1432-1033.1994.tb18777.x; Trincone A, 2000, BIOORG MED CHEM LETT, V10, P365, DOI 10.1016/S0960-894X(99)00700-3; VanLaere KMJ, 1997, APPL MICROBIOL BIOT, V47, P231; Viladot JL, 1998, BIOCHEMISTRY-US, V37, P11332, DOI 10.1021/bi980586q; WANG QP, 1994, J AM CHEM SOC, V116, P11594, DOI 10.1021/ja00104a060; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; Wolfenden R, 1998, J AM CHEM SOC, V120, P6814, DOI 10.1021/ja9813055; WONG KKY, 1993, PORT PR R M, V4, P127; Zechel D. L., 1999, COMPREHENSIVE NATURA, V5, P279; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zverlov VV, 1998, FEMS MICROBIOL LETT, V164, P337, DOI 10.1016/S0378-1097(98)00236-5	50	80	86	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43667	43673		10.1074/jbc.M208285200	http://dx.doi.org/10.1074/jbc.M208285200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221104	hybrid			2022-12-25	WOS:000179272000018
J	Bottger, P; Pedersen, L				Bottger, P; Pedersen, L			Two highly conserved glutamate residues critical for type III sodium-dependent phosphate transport revealed by uncoupling transport function from retroviral receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; CELL-SURFACE RECEPTOR; MOLECULAR-BASIS; GENE ENCODES; FELINE; CATION; ENTRY; IDENTIFICATION; COTRANSPORTER; CLONING	Type III sodium-dependent phosphate (NaPi) cotransporters, Pit1 and Pit2, have been assigned housekeeping Pi transport functions and suggested involved in chondroblastic and osteoblastic mineralization and ectopic calcification. Both proteins exhibit dual function, thus, besides being transporters, they also serve as receptors for several gammaretroviruses. We here show that it is possible to uncouple transport and receptor functions of a type III NaPi cotransporter and thus exploit the retroviral receptor function as a control for proper processing and folding of mutant proteins. Thus exchanging two putative transmembranic glutamate residues in human Pit2, Glu(55) and Glu(575), with glutamine or with lysine severely impaired or knocked out, respectively, P-i transport function, but left viral receptor function undisturbed. Both glutamates are conserved in type III NaPi cotransporters, in fungal NaPi cotransporters PHO-4 and Pho89, and in other known or putative phosphate permeases from a number of species and are the first residues shown to be critical for type III NaPi cotransport. Their putative transmembranic positions together with the presented data are consistent with Glu(55) and Glu(575) being parts of a cation liganding site or playing roles in conformational changes associated with substrate transport. Finally, the results also show that Pit2 retroviral receptor function per se is not dependent on Pit2 P-i transport function.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Aarhus Univ, Inst Expt Clin Res, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Pedersen, L (corresponding author), Aarhus Univ, Dept Mol Biol, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.	LP@mb.au.dk	Pedersen, Lene/A-3673-2014	Pedersen, Lene/0000-0002-3396-1292				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Beck GR, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997; Boyer CJC, 1998, BBA-BIOMEMBRANES, V1368, P73, DOI 10.1016/S0005-2736(97)00159-4; Chien ML, 1998, VIROLOGY, V240, P109, DOI 10.1006/viro.1997.8933; Chien ML, 1997, J VIROL, V71, P4564, DOI 10.1128/JVI.71.6.4564-4570.1997; Dibrov P, 1998, FEBS LETT, V424, P1, DOI 10.1016/S0014-5793(98)00119-7; Dreyer K, 2000, J VIROL, V74, P2926, DOI 10.1128/JVI.74.6.2926-2929.2000; Eiden MV, 1996, J VIROL, V70, P1080, DOI 10.1128/JVI.70.2.1080-1085.1996; Giachelli CM, 1999, AM J PATHOL, V154, P671, DOI 10.1016/S0002-9440(10)65313-8; Griffith DA, 1999, BIOCHEMISTRY-US, V38, P7524, DOI 10.1021/bi990076b; JOHANN SV, 1992, J VIROL, V66, P1635, DOI 10.1128/JVI.66.3.1635-1640.1992; Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10; Kaim G, 1997, BIOCHEMISTRY-US, V36, P9185, DOI 10.1021/bi970831q; Kavanaugh MP, 1996, KIDNEY INT, V49, P959, DOI 10.1038/ki.1996.135; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; Leverett BD, 1998, J VIROL, V72, P4956, DOI 10.1128/JVI.72.6.4956-4961.1998; Lundorf MD, 1999, J VIROL, V73, P3169, DOI 10.1128/JVI.73.4.3169-3175.1999; Lundorf MD, 1998, J VIROL, V72, P4524, DOI 10.1128/JVI.72.5.4524-4527.1998; Martinez P, 1998, MOL GEN GENET, V258, P628, DOI 10.1007/s004380050776; MCLACHLIN JR, 1993, VIROLOGY, V195, P1, DOI 10.1006/viro.1993.1340; Miller AD, 1996, J VIROL, V70, P5564, DOI 10.1128/JVI.70.8.5564-5571.1996; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER DG, 1994, J VIROL, V68, P8270, DOI 10.1128/JVI.68.12.8270-8276.1994; MILLER DG, 1994, P NATL ACAD SCI USA, V91, P78, DOI 10.1073/pnas.91.1.78; Nielsen LB, 2001, BONE, V28, P160, DOI 10.1016/S8756-3282(00)00418-X; OHARA B, 1990, CELL GROWTH DIFFER, V1, P119; OLAH Z, 1994, J BIOL CHEM, V269, P25426; Overbaugh J, 2001, MICROBIOL MOL BIOL R, V65, P371, DOI 10.1128/MMBR.65.3.371-389.2001; Palmer G, 1999, BONE, V24, P1, DOI 10.1016/S8756-3282(98)00151-3; PEDERSEN L, 1995, J VIROL, V69, P2401, DOI 10.1128/JVI.69.4.2401-2405.1995; Pedersen L, 1997, J VIROL, V71, P7619, DOI 10.1128/JVI.71.10.7619-7622.1997; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; Poolman B, 1996, MOL MICROBIOL, V19, P911, DOI 10.1046/j.1365-2958.1996.397949.x; Rasko JEJ, 1999, P NATL ACAD SCI USA, V96, P2129, DOI 10.1073/pnas.96.5.2129; Rodrigues P, 1999, J VIROL, V73, P3789, DOI 10.1128/JVI.73.5.3789-3799.1999; Salaun C, 2002, J VIROL, V76, P4304, DOI 10.1128/JVI.76.9.4304-4311.2002; Sommerfelt MA, 1999, J GEN VIROL, V80, P3049, DOI 10.1099/0022-1317-80-12-3049; Tailor CS, 1999, J VIROL, V73, P6500, DOI 10.1128/JVI.73.8.6500-6505.1999; Tailor CS, 2000, J VIROL, V74, P237, DOI 10.1128/JVI.74.1.237-244.2000; Tailor CS, 1999, J VIROL, V73, P4470, DOI 10.1128/JVI.73.5.4470-4474.1999; TAKEUCHI Y, 1992, J VIROL, V66, P1219, DOI 10.1128/JVI.66.2.1219-1222.1992; Tatsumi S, 1998, ENDOCRINOLOGY, V139, P1692, DOI 10.1210/en.139.4.1692; Timmer RT, 2000, J GEN PHYSIOL, V116, P363, DOI 10.1085/jgp.116.3.363; Uckert W, 1998, HUM GENE THER, V9, P2619, DOI 10.1089/10430349850019454; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; VERSAW WK, 1995, P NATL ACAD SCI USA, V92, P3884, DOI 10.1073/pnas.92.9.3884; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; WANG H, 1994, VIROLOGY, V202, P1058, DOI 10.1006/viro.1994.1439; WILSON CA, 1995, J VIROL, V69, P534, DOI 10.1128/JVI.69.1.534-537.1995; WILSON CA, 1994, J VIROL, V68, P7697, DOI 10.1128/JVI.68.12.7697-7703.1994	50	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42741	42747		10.1074/jbc.M207096200	http://dx.doi.org/10.1074/jbc.M207096200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12205090	hybrid			2022-12-25	WOS:000179081200042
J	Fontemaggi, G; Kela, I; Amariglio, N; Rechavi, G; Krishnamurthy, J; Strano, S; Sacchi, A; Givol, D; Blandino, G				Fontemaggi, G; Kela, I; Amariglio, N; Rechavi, G; Krishnamurthy, J; Strano, S; Sacchi, A; Givol, D; Blandino, G			Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-LINE; KINASE C-ABL; TRANSCRIPTIONAL ACTIVITY; APOPTOTIC RESPONSE; SPONTANEOUS TUMORS; INDUCE APOPTOSIS; REGULATES P73; P53 MUTANTS; EXPRESSION; P63	The newly discovered p53 family member, p73, has a striking homology to p53 in both sequence and modular structure. Ectopic expression of p73 promotes transcription of p53 target genes and recapitulates the most characterized p53 biological effects such as growth arrest, apoptosis, and differentiation. Unlike p53-deficient mice that develop normally but are subject to spontaneous tumor formation, p73-deficient mice exhibit severe defects in the development of central nervous system and suffer from inflammation but are not prone to tumor development. These phenotypes suggest different biological activities mediated by p53 and p73 that might reflect activation of specific sets of target genes. Here, we have analyzed the gene expression profile of H1299 cells after p73alpha or p53 activation using oligonucleotide microarrays capable of detecting similar to11,000 mRNA species. Our results indicate that p73alpha and p53 activate both common and distinct groups of genes. We found 141 and 320 genes whose expression is modulated by p73alpha and p53, respectively. p73alpha up-regulates 85 genes, whereas p53 induces 153 genes, of which 27 are in common with p73alpha. Functional classification of these genes reveals that they are involved in many aspects of cell function ranging from cell cycle and apoptosis to DNA repair. Furthermore, we report that some of the up-regulated genes are directly activated by p73alpha or p53.	Regina Elena Inst Canc Res, Dept Expt Oncol, I-00158 Rome, Italy; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; Tel Aviv Univ, Dept Pediat Hemato Oncol, Chaim Sheba Med Ctr, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Via Messi Oro 156, I-00158 Rome, Italy.		strano, sabrina/B-6743-2013; Strano, Sabrina/K-9654-2016; Fontemaggi, Giulia/K-9702-2016; Blandino, Giovanni/B-1137-2013	strano, sabrina/0000-0002-6341-4230; Fontemaggi, Giulia/0000-0001-8332-8842; Blandino, Giovanni/0000-0002-6970-2241				Agami R, 1999, NATURE, V399, P809; ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; Bingle L, 1996, THORAX, V51, P1273, DOI 10.1136/thx.51.12.1273; Blatt M, 1996, PHYS REV LETT, V76, P3251, DOI 10.1103/PhysRevLett.76.3251; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Feng G, 2001, CANCER RES, V61, P7999; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gong JG, 1999, NATURE, V399, P806; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Janciauskiene S, 2001, BBA-MOL BASIS DIS, V1535, P221, DOI 10.1016/S0925-4439(01)00025-4; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Morena A, 2002, BLOOD, V100, P96, DOI 10.1182/blood.V100.1.96; Morgan K, 1997, INT J BIOCHEM CELL B, V29, P1501, DOI 10.1016/S1357-2725(97)00118-0; Moustakas A, 2001, J CELL SCI, V114, P4359; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; URIST M, 2000, CANC CELLS, V1, P311; Valsecchi V, 1997, MECH DEVELOP, V69, P203, DOI 10.1016/S0925-4773(97)00146-9; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9; Vikhanskaya F, 2001, CANCER RES, V61, P935; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Xia LQ, 1997, CANCER RES, V57, P3055; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zhao RB, 2000, GENE DEV, V14, P981; Zhu Hong-Jian, 2001, Molecular Cell Biology Research Communications, V4, P321, DOI 10.1006/mcbr.2001.0301	61	118	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43359	43368		10.1074/jbc.M205573200	http://dx.doi.org/10.1074/jbc.M205573200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12213815	hybrid			2022-12-25	WOS:000179081200120
J	Ji, JF; Chen, X; Leung, SY; Chi, JTA; Chu, KM; Yuen, ST; Li, R; Chan, ASY; Li, JY; Dunphy, N; So, S				Ji, JF; Chen, X; Leung, SY; Chi, JTA; Chu, KM; Yuen, ST; Li, R; Chan, ASY; Li, JY; Dunphy, N; So, S			Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines	ONCOGENE			English	Article						gene expression profile; microarray; gastric cancer	PREDICTION; METAPLASIA; PATTERNS; DATABASE	Gastric adenocarcinoma is one of the major malignancies worldwide. Gastric cell lines have been widely used as the model to study the genetics, pharmacology and biochemistry of gastric cancers. Here we describe a comprehensive survey of the gene expression profiles of 12 gastric carcinoma cell lines, using cDNA microarray with 43000 clones. For comparison, we also explored the gene expression patterns of 15 cell lines derived from lymphoid, endothelial, stromal and other epithelial cancers. Expression levels of specific genes were validated through comparison to protein expression by immunohistochemistry using cell block arrays. We found sets of genes whose expression corresponds to the molecular signature of each cell type. In the gastric cancer cell lines, apart from genes that are highly expressed corresponding to their common epithelial origin from the gastrointestinal tract, we found marked heterogeneity among the gene expression patterns of these cell lines. Some of the heterogeneity may reflect their underlying molecular characteristics or specific differentiation program. Two putative gastric carcinoma cell lines were found to be B-cell lymphoma, and another one had no epithelial specific gene expression and hence was of doubtful epithelial origin. These cell lines should no longer be used in gastric carcinoma research. In conclusion, our gene expression database can serve as a powerful resource for the study of gastric cancer using these cell lines.	Stanford Univ, Med Ctr, Dept Surg, Stanford, CA 94305 USA; Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Surg, Beijing 100871, Peoples R China; Stanford Univ, Asian Liver Ctr, Stanford, CA 94305 USA; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Pathol, Beijing 100871, Peoples R China; Stanford Univ, Dept Genet, Stanford, CA 94305 USA	Stanford University; Peking University; Stanford University; University of Hong Kong; Stanford University; University of Hong Kong; Peking University; Stanford University	So, S (corresponding author), Stanford Univ, Med Ctr, Dept Surg, 300 Pasteur Dr,Room H3680, Stanford, CA 94305 USA.		Chu, Kent/C-4251-2009; Yuen, Siu/K-6311-2014; Leung, Suet Yi/C-4340-2009; Chi, Jen-Tsan/AAI-4125-2020; Leung, Suet Yi/T-9620-2019	Chi, Jen-Tsan/0000-0003-3433-903X; Leung, Suet Yi/0000-0001-8614-4619; JI, JIAFU/0000-0001-6878-5543				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Debruyne P, 1999, ACTA GASTRO-ENT BELG, V62, P393; Ebert MPA, 2000, EUR J GASTROEN HEPAT, V12, P795, DOI 10.1097/00042737-200012070-00013; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grotzinger C, 2001, GUT, V49, P73, DOI 10.1136/gut.49.1.73; Monks A, 1997, ANTI-CANCER DRUG DES, V12, P533; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; OSBORN M, 1988, VIRCHOWS ARCH A, V413, P303, DOI 10.1007/BF00783022; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Peddanna N, 1995, ANTICANCER RES, V15, P2055; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Sherlock G, 2001, NUCLEIC ACIDS RES, V29, P152, DOI 10.1093/nar/29.1.152; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; TOKUNAGA A, 1995, CANCER, V75, P1418, DOI 10.1002/1097-0142(19950315)75:6+<1418::AID-CNCR2820751505>3.0.CO;2-Y; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x	22	60	71	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6549	6556		10.1038/sj.onc.1205829	http://dx.doi.org/10.1038/sj.onc.1205829			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226758				2022-12-25	WOS:000177925300015
J	Holnthoner, W; Pillinger, M; Groger, M; Wolff, K; Ashton, AW; Albanese, C; Neumeister, P; Pestell, RG; Petzelbauer, P				Holnthoner, W; Pillinger, M; Groger, M; Wolff, K; Ashton, AW; Albanese, C; Neumeister, P; Pestell, RG; Petzelbauer, P			Fibroblast growth factor-2 induces Lef/Tcf-dependent transcription in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; ADENOMATOUS POLYPOSIS-COLI; CYCLIN D1 GENE; BETA-CATENIN; SIGNALING PATHWAY; NEGATIVE REGULATOR; KINASE 3; PROTEIN; WNT; TARGET	Lef/Tcf proteins belong to a family of architectural transcription factors that control developmental processes and play an important role in oncogenesis. Classical activators of Lef/Tcf-dependent transcription comprise the Wnt family of proteins, which translocate beta-catenin into the nucleus and allow the formation of transactivation-competent Lef/Tcf-beta-catenin complexes. Here we show that in human endothelial cells fibroblast growth factor-2 (FGF-2) reduces GSK-3 activity and augments nuclear levels of beta-catenin. FGF-2 induced Lef/Tcf-dependent transcription of a cyclin D1-luciferase construct. Gel shift assays revealed binding of Tcf-4 as the only Lef/Tcf family member and of P-catenin to the Lef/Tcf site in the cyclin D1 promoter. Cotransfection with a dominant negative Tcf-4 construct inhibited the FGF-2-induced cyclin D1 promoter activity. Overexpression of an uninhibitable GSK-3beta mutant resulted in partial inhibition of FGF-2-mediated cyclin D1 induction. The importance for cyclin D1 in FGF-2-induced angiogenesis in vivo is shown in cyclin D1(-/-) mice, where FGF-2-induced new vessel formation was significantly reduced compared with FGF-2-induced angiogenesis in cyclin D1(+/+) mice. In conclusion, FGF-2 is a novel modulator of Lef/Tcf-beta-catenin signaling in endothelial cells, suggesting that angiogenic properties of FGF-2 are at least in part mediated by Lef/Tcf-beta-catenin activation.	Univ Vienna, Sch Med, Dept Dermatol, Div Gen Dermatol, A-1090 Vienna, Austria; Albert Einstein Comprehens Canc Ctr, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	University of Vienna; Yeshiva University; Yeshiva University; Albert Einstein College of Medicine	Petzelbauer, P (corresponding author), Univ Vienna, Sch Med, Dept Dermatol, Div Gen Dermatol, Waehringer Guertel 18-2, A-1090 Vienna, Austria.	Peter.Petzelbauer@AKH-Wien.ac.at	petzelbauer, peter/GLU-3941-2022	Holnthoner, Wolfgang/0000-0001-6425-9028; Petzelbauer, Peter/0000-0001-7080-5259	NATIONAL CANCER INSTITUTE [R01CA075503, R01CA070896, R01CA086072] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA75503, R01CA86072, R01CA70896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Christian SL, 2002, J IMMUNOL, V169, P758, DOI 10.4049/jimmunol.169.2.758; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; El-Hariry I, 2001, BRIT J CANCER, V84, P1656, DOI 10.1054/bjoc.2001.1813; El-Hariry I, 2001, INT J CANCER, V94, P652, DOI 10.1002/ijc.1515; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Grimson MJ, 2000, NATURE, V408, P727, DOI 10.1038/35047099; Halama T, 2001, J INVEST DERMATOL, V116, P110, DOI 10.1046/j.1523-1747.2001.00176.x; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hobmayer B, 2000, NATURE, V407, P186, DOI 10.1038/35025063; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korswagen HC, 2000, NATURE, V406, P527, DOI 10.1038/35020099; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; Malinda KM, 2001, METH MOLEC MED, V46, P47, DOI 10.1385/1-59259-143-4:047; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Mayo LD, 2001, J BIOL CHEM, V276, P25184, DOI 10.1074/jbc.M102932200; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Murakami T, 2001, BIOCHEM BIOPH RES CO, V288, P8, DOI 10.1006/bbrc.2001.5719; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; PETZELBAUER P, 1993, J IMMUNOL, V151, P5062; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ryves WJ, 1998, ANAL BIOCHEM, V264, P124, DOI 10.1006/abio.1998.2832; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; Shih IM, 2000, CANCER RES, V60, P1671; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thorpe CJ, 2000, TRENDS CELL BIOL, V10, P10, DOI 10.1016/S0962-8924(99)01672-4; Torres MA, 1999, MOL CELL BIOL, V19, P1427; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; Venkiteswaran K, 2002, AM J PHYSIOL-CELL PH, V283, pC811, DOI 10.1152/ajpcell.00417.2001; Wang XH, 2002, CIRC RES, V90, P340, DOI 10.1161/hh0302.104466; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; Wright M, 1999, BIOCHEM BIOPH RES CO, V263, P384, DOI 10.1006/bbrc.1999.1344; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681	56	111	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45847	45853		10.1074/jbc.M209354200	http://dx.doi.org/10.1074/jbc.M209354200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12235165	hybrid			2022-12-25	WOS:000179529300018
J	Shan, Q; Haddrill, JL; Lynch, JW				Shan, Q; Haddrill, JL; Lynch, JW			Comparative surface accessibility of a pore-lining threonine residue (T6 ') in the glycine and GABA(A) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; M2 SEGMENT; ALPHA-SUBUNIT; ION CHANNELS; OPEN STATE; PROTEIN; IDENTIFICATION; MUTATIONS; LOCATION; REGION	The substituted cysteine accessibility method was used to probe the surface exposure of a pore-lining threonine residue (T6') common to both the glycine receptor (GlyR) and gamma-aminobutyric acid, type A receptor (GABAAR) chloride channels. This residue lies close to the channel activation gate, the ionic selectivity filter, and the main pore blocker binding site. Despite their high amino acid sequence homologies and common role in conducting chloride ions, recent studies have suggested that the GlyRs and GABA(A)Rs have divergent open state pore structures at the 6' position. When both the human alpha1(T6'C) homomeric GlyR and the rat alpha1(T6'C)beta1(T6'C) heteromeric GABA(A)R were expressed in human embryonic kidney 293 cells, their 6' residue surface accessibilities differed significantly in the closed state. However, when a soluble cysteine-modifying compound was applied in the presence of saturating agonist concentrations, both receptors were locked into the open state. This action was not induced by oxidizing agents in either receptor. These results provide evidence for a conserved pore opening mechanism in anion-selective members of the ligand-gated ion channel family. The results also indicate that the GABA(A)R pore structure at the 6' level may vary between different expression systems.	Univ Queensland, Sch Biomed Sci, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia	University of Queensland	Lynch, JW (corresponding author), Univ Queensland, Sch Biomed Sci, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia.		Lynch, Joseph/C-8636-2009					AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; Arias HR, 1998, BBA-REV BIOMEMBRANES, V1376, P173, DOI 10.1016/S0304-4157(98)00004-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN BN, 1992, J GEN PHYSIOL, V99, P545, DOI 10.1085/jgp.99.4.545; Gisselmann G, 2002, NAT NEUROSCI, V5, P11, DOI 10.1038/nn787; Harvey RJ, 1999, J PHYSIOL-LONDON, V520, P53, DOI 10.1111/j.1469-7793.1999.00053.x; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lynch JW, 2001, J NEUROSCI, V21, P2589, DOI 10.1523/JNEUROSCI.21-08-02589.2001; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Shan Q, 2001, J NEUROCHEM, V76, P1109, DOI 10.1046/j.1471-4159.2001.00124.x; SWEET RM, 1983, J MOL BIOL, V171, P479, DOI 10.1016/0022-2836(83)90041-4; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; VILLARROEL A, 1992, P ROY SOC B-BIOL SCI, V249, P317, DOI 10.1098/rspb.1992.0121; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; Wilson GG, 2001, P NATL ACAD SCI USA, V98, P1241, DOI 10.1073/pnas.031567798; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m	30	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44845	44853		10.1074/jbc.M208647200	http://dx.doi.org/10.1074/jbc.M208647200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12239220	hybrid			2022-12-25	WOS:000179404800034
J	Yasuda, K; Hirayoshi, K; Hirata, H; Kubota, H; Hosokawa, N; Nagata, K				Yasuda, K; Hirayoshi, K; Hirata, H; Kubota, H; Hosokawa, N; Nagata, K			The Kruppel-like factor Zf9 and proteins in the Sp1 family regulate the expression of HSP47, a collagen-specific molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; BINDING STRESS PROTEIN; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTORS; II COLLAGEN; GENE-TRANSCRIPTION; 3 FINGERS; PROMOTER; MOUSE; PROCOLLAGEN	In several cells and tissues the synthesis of HSP47, a collagen-specific molecular chaperone in the endoplasmic reticulum, is closely correlated with the synthesis of collagen. We previously reported that the Sp1 binding site at -210 bp in the promoter region and the first and second introns are required for the tissue-specific expression of HSP47 in transgenic mice (Hirata, H., Yamamura, I., Yasuda, K., Kobayashi, A., Tada, N., Suzuki, M., Hirayoshi, K., Hosokawa, N., and Nagata, K. (1999) J. Biol Chem. 274, 35703-35710). Here, we analyze how these introns influence the transcriptional regulation of the hsp47 gene in BALB/c 3T3 cells, which produce high levels of HSP47. In vitro promoter analysis using a luciferase reporter and gel mobility shift analysis revealed that two cis-acting elements in the first and second introns, BS5-B and EP7-D, respectively, are required for the activation of hsp47 in BALB/c 3T3 cells. Several members of the Kruppel-like factor (KLF) family of proteins were identified as BS5-B-binding proteins by yeast one-hybrid analysis using these elements as baits. One of these proteins, KLF-6/Zf9, binds to the BS5-B element and activates expression of the reporter construct when transfected into cells. Chromatin immunoprecipitation assay analysis revealed that the endogenous KLF-6/Zf9 binds the BS5-B elements that contain the CACCC motif, which is a consensus recognition sequence for other proteins in the KLF family. We also showed that BS5-B and EP7-D are bound by two members of the Sp1 family, Sp2 and Sp3. These results suggest that at least three sequences are required for the constitutive expression of hsp47 in BALB/c 3T3 cells: the -210 bp Sp1 binding site, the BS5-B element in the first intron, and the EP7-D element in the second intron. We suggest that KLF proteins regulate the transcription of hsp47 by binding the BS5-B element in cooperation with Sp2 and/or Sp3.	Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Sakyo Ku, Kyoto 6068397, Japan; Kyoto Univ, Dept Ultrastruct Res, Inst Frontier Med Sci, Kyoto 6068397, Japan; Kyoto Univ, Inst Virus Res, Kyoto 6065807, Japan	Kyoto University; Kyoto University; Kyoto University	Nagata, K (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Sakyo Ku, Kyoto 6068397, Japan.			Hirata, Hiromi/0000-0002-3769-7441				Asada S, 1999, CELL STRUCT FUNCT, V24, P187, DOI 10.1247/csf.24.187; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bishop CE, 2000, NAT GENET, V26, P490, DOI 10.1038/82652; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203; Higaki Y, 2002, NUCLEIC ACIDS RES, V30, P2270, DOI 10.1093/nar/30.11.2270; Hirata H, 1999, J BIOL CHEM, V274, P35703, DOI 10.1074/jbc.274.50.35703; HIRAYOSHI K, 1991, MOL CELL BIOL, V11, P4036, DOI 10.1128/MCB.11.8.4036; HOSOKAWA N, 1993, GENE, V126, P187, DOI 10.1016/0378-1119(93)90366-B; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Koide T, 2002, J BIOL CHEM, V277, P6178, DOI 10.1074/jbc.M106497200; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; Kubota H, 2000, J BIOL CHEM, V275, P28641, DOI 10.1074/jbc.M005009200; Kuroda K, 1998, J INVEST DERMATOL, V111, P1023, DOI 10.1046/j.1523-1747.1998.00437.x; MASUDA H, 1994, J CLIN INVEST, V94, P2481, DOI 10.1172/JCI117617; Masuda H, 1998, CELL STRESS CHAPERON, V3, P256, DOI 10.1379/1466-1268(1998)003<0256:EALOCB>2.3.CO;2; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Murakami S, 2001, ATHEROSCLEROSIS, V157, P361, DOI 10.1016/S0021-9150(00)00743-7; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; NAGATA K, 1988, J BIOL CHEM, V263, P8344; Naitoh M, 2001, BIOCHEM BIOPH RES CO, V280, P1316, DOI 10.1006/bbrc.2001.4257; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; Okano J, 2000, FEBS LETT, V473, P95, DOI 10.1016/S0014-5793(00)01468-X; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Sunamoto M, 1998, INT J EXP PATHOL, V79, P133, DOI 10.1046/j.1365-2613.1998.00061.x; Sunamoto M, 1998, LAB INVEST, V78, P967; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Vergeer WP, 2000, ARCH BIOCHEM BIOPHYS, V377, P69, DOI 10.1006/abbi.2000.1760; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhao JL, 2000, J BIOL CHEM, V275, P8903, DOI 10.1074/jbc.275.12.8903	45	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44613	44622		10.1074/jbc.M208558200	http://dx.doi.org/10.1074/jbc.M208558200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12235161	hybrid			2022-12-25	WOS:000179404800005
J	Chang, SC; Miller, AL; Feng, YC; Wente, SR; Majerus, PW				Chang, SC; Miller, AL; Feng, YC; Wente, SR; Majerus, PW			The human homolog of the rat inositol phosphate multikinase is an inositol 1,3,4,6-tetrakisphosphate 5-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE 3-KINASE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; MOLECULAR-CLONING; YEAST; CELLS; 1,3,4,5,6-PENTAKISPHOSPHATE; 1,3,4-TRISPHOSPHATE; TRISPHOSPHATE; EXPRESSION; KINASE	We have demonstrated that the human homolog of the rat inositol phosphate multikinase is an inositol 1,3,4,6-tetrakisphosphate 5-kinase (InSP4 5-kinase). The cDNA of the human gene contained a putative open reading frame of 1251 bp encoding 416 amino acids with 83.6% identity compared with the rat protein. The substrate specificity of the recombinant human protein demonstrated preference for Ins(1,3,4,6)P-4 with a catalytic efficiency (V-max/K-m) 43-fold greater than that of Ins(1,3,4,5)P-4 and 2-fold greater than that of Ins(1,4,5)P-3. The apparent V-max was 114 nmol of Ins(1,3,4,5,6)P-5 formed/min/mg of protein, and the apparent K-m was 0.3 mum Ins(1,3,4,6)P-4. The functional homolog in yeast is Ipk2p, and ipk2-null yeast strains do not synthesize Ins(1,3,4,5,6)P-5 or InSP6. Synthesis of these compounds was restored by transformation with wild-type yeast IPK2 but not with human InSP4 5-kinase. Thus the human gene does not complement for the loss of the yeast gene because yeast cells do not contain the substrate Ins(1,3,4,6)P-4, and the reaction of the human protein with Ins(1,3,4,5)P-4 is insufficient to effect rescue or synthesis of InSP5 and InsP,. Therefore the major activity of human InSP4 5-kinase is phosphorylation at the D-5 position, and the pathways for synthesis of Ins(1,3,4,5,6)P-5 in yeast versus humans are different.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Majerus, PW (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.	phil@im.wustl.edu			NHLBI NIH HHS [R01-HL55672, R01-HL16634] Funding Source: Medline; PHS HHS [H107088] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, R01HL055672] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bertsch U, 2000, J BIOL CHEM, V275, P1557, DOI 10.1074/jbc.275.3.1557; CHANDA VB, 1997, CURRENT PROTOCOLS MO; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; COMMUNI D, 1995, CELL SIGNAL, V7, P643, DOI 10.1016/0898-6568(95)00035-N; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; DUBOIS E, 1987, MOL GEN GENET, V207, P142, DOI 10.1007/BF00331501; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Ives EB, 2000, J BIOL CHEM, V275, P36575, DOI 10.1074/jbc.M007586200; LIN A, 1993, ARCH BIOCHEM BIOPHYS, V303, P412, DOI 10.1006/abbi.1993.1303; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; OLIVER KG, 1992, J BIOL CHEM, V267, P21528; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2001, J BIOL CHEM, V276, P39179, DOI 10.1074/jbc.M106842200; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; Sherman F, 1986, LAB COURSE MANUAL ME; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Spencer J.F.T., 1989, YEAST GENETICS MANUA; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; TAKAZAWA K, 1990, BIOCHEM J, V268, P213, DOI 10.1042/bj2680213; TAKAZAWA K, 1991, BIOCHEM J, V278, P883, DOI 10.1042/bj2780883; THOMAS S, 1994, BBA-MOL CELL RES, V1220, P219, DOI 10.1016/0167-4889(94)90139-2; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X; Zhang XL, 1998, J BIOL CHEM, V273, P1574, DOI 10.1074/jbc.273.3.1574; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	39	60	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43836	43843		10.1074/jbc.M206134200	http://dx.doi.org/10.1074/jbc.M206134200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12223481	hybrid			2022-12-25	WOS:000179272000041
J	Hanfrey, C; Franceschetti, M; Mayer, MJ; Illingworth, C; Michael, AJ				Hanfrey, C; Franceschetti, M; Mayer, MJ; Illingworth, C; Michael, AJ			Abrogation of upstream open reading frame-mediated translational control of a plant S-adenosylmethionine decarboxylase results in polyamine disruption and growth perturbations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; MESSENGER-RNA; ORNITHINE-DECARBOXYLASE; ARGININE DECARBOXYLASE; GENE; OVEREXPRESSION; IDENTIFICATION; BIOSYNTHESIS; METHYLATION; INHIBITION	S-Adenosylmethionine decarboxylase (AdoMetDC) is a key enzyme in polyamine biosynthesis. We show that the plant AdoMetDC activity is subject to post-transcriptional control by polyamines. A highly conserved small upstream open reading frame (uORF) in the AdoMetDC mRNA 5' leader is responsible for translational repression of a downstream p-glucuronidase reporter cistron in transgenic tobacco plants. Elimination of the small uORF from an AdoMetDC cDNA led to increased relative translational efficiency of the AdoMetDC proenzyme in transgenic plants. The resulting increased activity of AdoMetDC caused disruption to polyamine levels with depletion of putrescine, reduction of spermine levels, and a more than 400-fold increase in the level of decarboxylated S-adenosyhnethionine. These changes were associated with severe growth and developmental defects. The high level of decarboxylated S-adenosylmethionine was not associated with any change in 5'-methylcytosine content in genomic DNA and S-adenosylinethionine levels were more or less normal, indicating a highly efficient system for maintenance of S-adenosylmethionine levels in plants. This work demonstrates that uORF-mediated translational control of AdoMetDC is essential for polyamine homeostasis and for normal growth and development.	Inst Food Res, Div Food Safety Sci, Norwich NR4 7UA, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Michael, AJ (corresponding author), Inst Food Res, Div Food Safety Sci, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.	tony.michael@bbsrc.ac.uk						Balasundaram D, 1996, J BACTERIOL, V178, P2721, DOI 10.1128/jb.178.9.2721-2724.1996; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burtin D, 1997, BIOCHEM J, V325, P331, DOI 10.1042/bj3250331; BURTIN D, 1991, PLANT PHYSIOL, V95, P461, DOI 10.1104/pp.95.2.461; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; Cohen S A, 1998, Guttmacher Rep Public Policy, V1, P1; Franceschetti M, 2001, BIOCHEM J, V353, P403, DOI 10.1042/0264-6021:3530403; Frostesjo L, 1997, J BIOL CHEM, V272, P4359, DOI 10.1074/jbc.272.7.4359; Geballe AP, 2000, COLD SPRING HARBOR M, V39, P595; Hanzawa Y, 2000, EMBO J, V19, P4248, DOI 10.1093/emboj/19.16.4248; Heby O, 1995, INT J DEV BIOL, V39, P737; HEBY O, 1988, PROGR POLYAMINE RES, P291; HIATT AC, 1986, J BIOL CHEM, V261, P1293; HILL JR, 1992, J BIOL CHEM, V267, P21886; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KAKUTANI T, 1995, NUCLEIC ACIDS RES, V23, P130, DOI 10.1093/nar/23.1.130; Kakutani T, 1996, P NATL ACAD SCI USA, V93, P12406, DOI 10.1073/pnas.93.22.12406; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; Law GL, 2001, J BIOL CHEM, V276, P38036; Malmberg RL, 1998, CRIT REV PLANT SCI, V17, P199, DOI 10.1016/S0735-2689(98)00358-X; MAMONT PS, 1982, EUR J BIOCHEM, V123, P499; Manni A, 2001, INT J ONCOL, V19, P317; Michael AJ, 1996, BIOCHEM J, V314, P241, DOI 10.1042/bj3140241; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nishimura K, 2002, GENES CELLS, V7, P41, DOI 10.1046/j.1356-9597.2001.00494.x; PEGG AE, 1982, BIOCHEM J, V202, P519, DOI 10.1042/bj2020519; PEGG AE, 1987, INHIBITION POLYAMINE, P33; Raney A, 2000, J BIOL CHEM, V275, P24444, DOI 10.1074/jbc.M003364200; Ravanel S, 1998, P NATL ACAD SCI USA, V95, P7805, DOI 10.1073/pnas.95.13.7805; Roberts SC, 2002, J BIOL CHEM, V277, P5902, DOI 10.1074/jbc.M110118200; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; RUAN HJ, 1994, J BIOL CHEM, V269, P17905; Ryabova LA, 2000, GENE DEV, V14, P817; SHANTZ LM, 1994, BIOCHEM J, V302, P765, DOI 10.1042/bj3020765; Wang LJ, 2001, PLANT PHYSIOL, V125, P1380, DOI 10.1104/pp.125.3.1380; WHITE MW, 1990, BIOCHEM J, V268, P657, DOI 10.1042/bj2680657; Xiong HS, 1997, J BIOL CHEM, V272, P28342, DOI 10.1074/jbc.272.45.28342	42	100	115	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44131	44139		10.1074/jbc.M206161200	http://dx.doi.org/10.1074/jbc.M206161200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12205086	hybrid			2022-12-25	WOS:000179272000078
J	Sandmark, J; Mann, S; Marquet, A; Schneider, G				Sandmark, J; Mann, S; Marquet, A; Schneider, G			Structural basis for the inhibition of the biosynthesis of biotin by the antibiotic amiclenomycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DETHIOBIOTIN SYNTHETASE; 7,8-DIAMINOPELARGONIC ACID; CRYSTAL-STRUCTURE; 8-AMINO-7-OXOPELARGONATE SYNTHASE; 7-KETO-8-AMINOPELARGONIC ACID; ASPARTATE-AMINOTRANSFERASE; ENZYME; MECHANISM; SUBSTRATE; INTERMEDIATE	The antibiotic amiclenomycin blocks the biosynthesis of biotin by inhibiting the pyridoxal-phosphate-dependent enzyme diaminopelargonic acid synthase. Inactivation of the enzyme is stereoselective, i.e. the cis isomer of amiclenomycin is a potent inhibitor, whereas the trans isomer is much less reactive. The crystal structure of the complex of the holoenzyme and amiclenomycin at 1.8 Angstrom resolution reveals that the internal aldimine linkage between the cofactor and the side chain of the catalytic residue Lys-274 is broken. Instead, a covalent bond is formed between the 4-amino nitrogen of amiclenomycin and the C4' carbon atom of pyridoxal-phosphate. The electron density for the bound inhibitor suggests that aromatization of the cyclohexadiene ring has occurred upon formation of the covalent adduct. This process could be initiated by proton abstraction at the C4' carbon atom of the cyclohexadiene ring, possibly by the proximal side chain of Lys-274, leading to the tautomer Schiff base followed by the removal of the second allylic hydrogen. The carboxyl tail of the amiclenomycin moiety forms a salt link to the conserved residue Arg-391 in the substrate-binding site. Modeling suggests steric hindrance at the active site as the determinant of the weak inhibiting potency of the trans isomer.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Paris 06, Lab Chim Organ Biol, CNRS, UMR 7613, F-75252 Paris 05, France	Karolinska Institutet; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Schneider, G (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Scheeles Vag 2, S-17177 Stockholm, Sweden.	gunter@alfa.mbb.ki.se		Schneider, Gunter/0000-0003-0622-5713				ALEXEEV D, 1995, STRUCTURE, V3, P1207, DOI 10.1016/S0969-2126(01)00256-8; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAXTER RL, 1994, J CHEM SOC CHEM COMM, P759, DOI 10.1039/c39940000759; Eads JC, 1999, BIOCHEMISTRY-US, V38, P9840, DOI 10.1021/bi990018q; EISENBERG MA, 1973, ADV ENZYMOL RAMB, V38, P317; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fu MM, 1999, BIOORGAN MED CHEM, V7, P1581, DOI 10.1016/S0968-0896(99)00081-4; GEHRING H, 1984, BIOCHEMISTRY-US, V23, P6335, DOI 10.1021/bi00321a007; GIBSON KJ, 1995, BIOCHEMISTRY-US, V34, P10976, DOI 10.1021/bi00035a003; HAYASHI H, 1995, J BIOCHEM-TOKYO, V118, P463, DOI 10.1093/oxfordjournals.jbchem.a124931; Hennig M, 1997, P NATL ACAD SCI USA, V94, P4866, DOI 10.1073/pnas.94.10.4866; HOTTA K, 1975, J ANTIBIOT, V28, P222, DOI 10.7164/antibiotics.28.222; HUANG WJ, 1995, BIOCHEMISTRY-US, V34, P10985, DOI 10.1021/bi00035a004; IZUMI Y, 1973, AGR BIOL CHEM TOKYO, V37, P2683, DOI 10.1080/00021369.1973.10861063; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JULIN DA, 1989, BIOCHEMISTRY-US, V28, P3815, DOI 10.1021/bi00435a029; Kack H, 1998, P NATL ACAD SCI USA, V95, P5495, DOI 10.1073/pnas.95.10.5495; Kack H, 1999, J MOL BIOL, V291, P857, DOI 10.1006/jmbi.1999.2997; Kack H, 1998, ACTA CRYSTALLOGR D, V54, P1397, DOI 10.1107/S0907444998001954; KERN A, 1985, LIEBIGS ANN CHEM, P877; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE A, 1992, JOINT CCP4 ESF EACBM, V28; Mann S, 2002, CHEM-EUR J, V8, P439, DOI 10.1002/1521-3765(20020118)8:2<439::AID-CHEM439>3.0.CO;2-5; Marquet A, 2001, VITAM HORM, V61, P51; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; METZLER CM, 1991, J BIOL CHEM, V266, P9374; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OKAMI Y, 1974, J ANTIBIOT, V27, P656, DOI 10.7164/antibiotics.27.656; OTSUKA AJ, 1988, J BIOL CHEM, V263, P19577; Ploux O, 1996, EUR J BIOCHEM, V236, P301, DOI 10.1111/j.1432-1033.1996.00301.x; Ploux O, 1999, EUR J BIOCHEM, V259, P63, DOI 10.1046/j.1432-1327.1999.00006.x; POETSCH M, 1985, J ANTIBIOT, V38, P312, DOI 10.7164/antibiotics.38.312; RANDO RR, 1977, BIOCHEMISTRY-US, V16, P4604, DOI 10.1021/bi00640a012; Rendina AR, 1999, PESTIC SCI, V55, P236, DOI 10.1002/(SICI)1096-9063(199903)55:3&lt;236::AID-PS888&gt;3.0.CO;2-0; Schneider G, 2001, FEBS LETT, V495, P7, DOI 10.1016/S0014-5793(01)02325-0; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; Shah SA, 1997, STRUCTURE, V5, P1067, DOI 10.1016/S0969-2126(97)00258-X; STONER GL, 1975, J BIOL CHEM, V250, P4037; STONER GL, 1975, J BIOL CHEM, V250, P4019; Webster SP, 2000, BIOCHEMISTRY-US, V39, P516, DOI 10.1021/bi991620j	43	35	42	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43352	43358		10.1074/jbc.M207239200	http://dx.doi.org/10.1074/jbc.M207239200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12218056	hybrid			2022-12-25	WOS:000179081200119
J	Trowbridge, JM; Rudisill, JA; Ron, D; Gallo, RL				Trowbridge, JM; Rudisill, JA; Ron, D; Gallo, RL			Dermatan sulfate binds and potentiates activity of keratinocyte growth factor (FGF-7)*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; FIBROBLAST-GROWTH; HIGH-AFFINITY; CRYSTAL-STRUCTURE; FACTOR RECEPTORS; KGF RECEPTOR; DOMAIN; PROTEOGLYCANS; EXPRESSION; DIFFERENTIATION	FGF-7 is induced after injury and induces the proliferation of keratinocytes. Like most members of the FGF family, the activity of FGF-7 is strongly influenced by binding to heparin, but this glycosaminoglycan is absent on keratinocyte cell surfaces and minimally present in the wound environment. In this investigation we compared the relative activity of heparan sulfate and chondroitin sulfate B (dermatan sulfate), glycosaminoglycans that are present in wounds. A lymphoid cell line (BaF/KGFR) containing the FGF-7 receptor (FGFR2 IIIb) was treated with FGF-7 and with various glycosaminoglycans. FGF-7 did not support cell proliferation in the absence of glycosaminoglycan or with addition of heparan sulfate or chondroitin sulfate A/C but did stimulate BaF/KGFR division in the presence of dermatan sulfate or highly sulfated low molecular weight fractions of dermatan. Dermatan sulfate also enabled FGF7-dependent phosphorylation of mitogen-activated protein kinase and promoted binding of radiolabeled FGF-7 to FGFR2 IIIb. In addition, dermatan sulfate and FGF-7 stimulated growth of normal keratinocytes in culture. Thus, dermatan sulfate, the predominant glycosaminoglycan in skin, is the principle cofactor for FGF-7.	Univ Calif San Diego, Div Dermatol, Dept Med, San Diego, CA 92161 USA; Vet Affairs Med Ctr, La Jolla, CA 92161 USA; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Technion Israel Institute of Technology	Gallo, RL (corresponding author), Univ Calif San Diego, Div Dermatol, Dept Med, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.		Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861	NCI NIH HHS [5T32CA81211] Funding Source: Medline; NIAMS NIH HHS [AR45676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA081211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BROWN CT, 1995, J CELL BIOCHEM, V59, P57, DOI 10.1002/jcb.240590108; CAMEJO EH, 1995, ARTERIOSCL THROM VAS, V15, P1456, DOI 10.1161/01.ATV.15.9.1456; CELLA G, 1992, ANGIOLOGY, V43, P59, DOI 10.1177/000331979204300107; DELEHEDDE M, 2002, J BIOL CHEM, V17, P17; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Fernandez JA, 1999, THROMB HAEMOSTASIS, V82, P1462; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FRESHNEY IR, 2000, CULTURE ANIMAL CELLS, P345; Friedl A, 1997, AM J PATHOL, V150, P1443; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hsu YR, 1999, BIOCHEMISTRY-US, V38, P2523, DOI 10.1021/bi9821317; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KAWASHIMA H, 2002, J BIOL CHEM, V30, P30; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KREUGER J, 2001, J BIOL CHEM, V13, P13; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; LaRochelle WJ, 1999, BIOCHEMISTRY-US, V38, P1765, DOI 10.1021/bi982092z; Liaw PCY, 2001, J BIOL CHEM, V276, P20959, DOI 10.1074/jbc.M010584200; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; Marchese C, 2001, J INVEST DERMATOL, V116, P623, DOI 10.1046/j.0022-202x.2001.01280.x; MASCELLANI G, 1993, BIOCHEM J, V296, P639, DOI 10.1042/bj2960639; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; OKSALA O, 1995, J HISTOCHEM CYTOCHEM, V43, P125, DOI 10.1177/43.2.7529785; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; PIERCE GF, 1994, J EXP MED, V179, P831, DOI 10.1084/jem.179.3.831; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; RON D, 1993, J BIOL CHEM, V268, P2984; RON D, 1993, J BIOL CHEM, V268, P5388; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SHAOUL E, 1995, ONCOGENE, V10, P1553; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896	54	82	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42815	42820		10.1074/jbc.M204959200	http://dx.doi.org/10.1074/jbc.M204959200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12215437	hybrid			2022-12-25	WOS:000179081200053
J	Buechler, C; Bared, SM; Aslanidis, C; Ritter, M; Drobnik, W; Schmitz, G				Buechler, C; Bared, SM; Aslanidis, C; Ritter, M; Drobnik, W; Schmitz, G			Molecular and functional interaction of the ATP-binding cassette transporter A1 with Fas-associated death domain protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANGIER-DISEASE; TRANSBILAYER REDISTRIBUTION; CHOLESTEROL EFFLUX; T-CELLS; FIBROBLASTS; ABCA1; PHOSPHATIDYLSERINE; MUTATIONS; GROWTH; MUTANT	ATP-binding cassette transporter A1 (ABCA1) is a major regulator of cellular cholesterol and phospholipid homeostasis. Its function has not been fully characterized and may depend on the association with additional proteins. To identify ABCA1-interacting proteins a human liver yeast two-hybrid library was screened with the 144 C-terminal amino acids of ABCA1. Fas-associated death domain protein (FADD) was identified to bind to ABCA1, and this interaction was confirmed by pull-down assays and co-immunoprecipitations. Recombinant expression of a dominant negative form of FADD or the C terminus of ABCA1 in the human hepatoma cell line HepG2 markedly reduced the transfer of phospholipids to apoA-I. This indicates that the binding of additional proteins, one of them being full-length FADD, is required for ABCA1 function. The association of FADD with ABCA1 provides an unexpected link between high density lipoprotein metabolism and an adaptor molecule mainly described in death receptor signal transduction.	Univ Regensburg, Inst Clin Chem & Lab Med, D-93053 Regensburg, Germany	University of Regensburg	Schmitz, G (corresponding author), Univ Regensburg, Inst Clin Chem & Lab Med, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	gerd.schmitz@klinik.uni-regensburg.de	Buechler, Christa/AAH-3004-2020	Schmitz, Gerd/0000-0002-1325-1007				Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Buechler C, 2002, BIOCHEM BIOPH RES CO, V293, P759, DOI 10.1016/S0006-291X(02)00303-0; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Diederich W, 2001, ATHEROSCLEROSIS, V159, P313, DOI 10.1016/S0021-9150(01)00518-4; Drobnik W, 1999, ARTERIOSCL THROM VAS, V19, P28, DOI 10.1161/01.ATV.19.1.28; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hirano K, 2000, FEBS LETT, V484, P275, DOI 10.1016/S0014-5793(00)02171-2; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Hueber AO, 2000, J BIOL CHEM, V275, P10453, DOI 10.1074/jbc.275.14.10453; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kunzelmann-Marche C, 2001, J BIOL CHEM, V276, P5134, DOI 10.1074/jbc.M007924200; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; Oram JF, 1999, J LIPID RES, V40, P1769; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schmitz G, 1999, PATHOBIOLOGY, V67, P236, DOI 10.1159/000028100; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Szakacs G, 2001, BIOCHEM BIOPH RES CO, V288, P1258, DOI 10.1006/bbrc.2001.5905; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tsukamoto K, 2001, BIOCHEM BIOPH RES CO, V287, P757, DOI 10.1006/bbrc.2001.5575; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Zha XH, 2001, J BIOL CHEM, V276, P39476, DOI 10.1074/jbc.M105067200	23	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41307	41310		10.1074/jbc.C200436200	http://dx.doi.org/10.1074/jbc.C200436200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12235128	hybrid			2022-12-25	WOS:000178985300004
J	Santy, LC				Santy, LC			Characterization of a fast cycling ADP-ribosylation factor 6 mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; COP-COATED VESICLES; ACTIN CYTOSKELETON; EXCHANGE FACTOR; NUCLEOTIDE EXCHANGE; BINDING PROTEIN; PLASMA-MEMBRANE; ARF6 GTPASE; DOMAIN; ARNO	Studies of GTPase function often employ expression of dominant negative or constitutively active mutants. Dominant negative mutants cannot bind GTP and thus cannot be activated. Constitutively active mutants cannot hydrolyze GTP and therefore accumulate a large pool of GTP-bound GTPase. These mutations block the normal cycle of GTP binding, hydrolysis, and release. Therefore, although the GTPase-deficient mutants are in the active conformation, they do not fully imitate all the actions of the GTPase. This is particularly true for the ADP-ribosylation factors (ARFs), GTPases that regulate vesicular trafficking events. In Ras and Rho GTPases replacement of phenylalanine 28 with a leucine residue produces a "fast cycling" mutant that can undergo spontaneous GTP-GDP exchange and retains the ability to hydrolyze GTP. Unfortunately this phenylalanine residue is not conserved in the ARF family of GTPases. Here we report the design and characterization of a novel activated mutant of ARF6, ARF6 T157A. In vitro studies show that ARF6 T157A can spontaneously bind and release GTP more quickly than the wildtype protein suggesting that it is a fast cycling mutant. This mutant has enhanced activity in vivo and induces cortical actin rearrangements in HeLa cells and enhanced motility in Madin-Darby canine kidney cells.	Univ Virginia, Dept Cell Biol, Hlth Sci Ctr, Charlottesville, VA 22908 USA	University of Virginia	Santy, LC (corresponding author), Univ Virginia, Dept Cell Biol, Hlth Sci Ctr, POB 800732, Charlottesville, VA 22908 USA.			Santy, Lorraine/0000-0002-4795-0738	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066251] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 32991] Funding Source: Medline; NIDDK NIH HHS [F32 DK 09924] Funding Source: Medline; NIGMS NIH HHS [R01 GM 66251] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; Jackson TR, 2000, J CELL BIOL, V151, P627, DOI 10.1083/jcb.151.3.627; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1999, J CELL SCI, V112, P855; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Randazzo PA, 2001, METHOD ENZYMOL, V329, P343; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Santy LC, 1999, CURR BIOL, V9, P1173, DOI 10.1016/S0960-9822(00)80019-6; SCHLICHTING I, 1990, BIOCHEMISTRY-US, V29, P504, DOI 10.1021/bi00454a026; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; Zhang Q, 1999, MOL CELL BIOL, V19, P8158	33	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40185	40188		10.1074/jbc.C200481200	http://dx.doi.org/10.1074/jbc.C200481200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12218044	hybrid			2022-12-25	WOS:000178791400005
J	Olsen, CL; Gardie, GB; Yaswen, P; Stampfer, MR				Olsen, CL; Gardie, GB; Yaswen, P; Stampfer, MR			Raf-1-induced growth arrest in human mammary epithelial cells is p16-independent and is overcome in immortal cells during conversion	ONCOGENE			English	Article						conversion; senescence; immortalizatiom; Raf-1; p16(INK4a); human mammary epithelial cells	RAF-1 PROTEIN-KINASE; CYCLE ARREST; ONCOGENIC RAS; CANCER CELLS; SENESCENCE; TRANSFORMATION; FIBROBLASTS; EXPRESSION; ACTIVATION; INDUCTION	Using an estrogen-inducible retroviral system, we demonstrate that oncogenie Raf-1 induces growth arrest and morphological changes in finite lifespan human mammary epithelia] cells (HMEC). This arrest does not rely on expression of the cyclin-dependent kinase inhibitor (CKI) p16(INK4a), nor on changes in expression of the CKIs p21(Cip1), p14(ARF), p27(Kip1) or p57(Kip2). The Raf-induced arrest is independent of viral oncogene mediated inactivation of p53 and pRB, or e-myc overexpression. Flow cytometric analysis demonstrates that cells arrest in both G1 and G2. The Raf-induced arrest is mitigated or eliminated in some immortally transformed HMEC. Immortal HMEC that have both overcome replicative senescence and undergone the recently described conversion process maintain growth in the presence of transduced oncogenic Raf-1; they also gain EGF-independent growth and a low frequency of anchorage-independent growth. However, HMEC that have overcome replicative senescence but have not undergone conversion and HMEC immortalized by transduction with the catalytic subunit of telomerase, hTERT, remain severely growth arrested. These results indicate that the molecular mechanisms responsible for the Raf-1-induced growth arrest may Nary among different finite lifespan cell types, and that in HMEC, this mechanism is altered during the conversion process, rather than as a direct consequence of overcoming senescence or expressing hTERT.	Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Stampfer, MR (corresponding author), Lawrence Berkeley Natl Lab, Div Life Sci, 1 Cyclotron Rd,Bldg 70A-1118, Berkeley, CA 94720 USA.				NCI NIH HHS [CA-24822] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; Fanton CP, 2001, J BIOL CHEM, V276, P18871, DOI 10.1074/jbc.M011514200; FINER MH, 1994, BLOOD, V83, P43; Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Krtolica A, 1996, CANCER RES, V56, P1168; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; MCMAHON M, 2000, BIOCHIM BIOPHYS ACTA, P1; Nijjar T, 1999, CANCER RES, V59, P5112; Ravi RK, 1999, J CELL BIOCHEM, V72, P458, DOI 10.1002/(SICI)1097-4644(19990315)72:4<458::AID-JCB2>3.0.CO;2-C; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Tlsty TD, 2001, J MAMMARY GLAND BIOL, V6, P235, DOI 10.1023/A:1011369026168; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	35	70	72	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6328	6339		10.1038/sj.onc.1205780	http://dx.doi.org/10.1038/sj.onc.1205780			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214273	Green Submitted			2022-12-25	WOS:000177829000009
J	Tithof, PK; Elgayyar, M; Cho, Y; Guan, W; Fisher, AB; Peters-Golden, M				Tithof, PK; Elgayyar, M; Cho, Y; Guan, W; Fisher, AB; Peters-Golden, M			Polycyclic aromatic hydrocarbons present in cigarette smoke cause endothelial cell apoptosis by a phospholipase A(2)-dependent mechanism	FASEB JOURNAL			English	Article						phospholipase A(2); arachidonic acid; methylanthracene; benzo(a)pyrene; phenanthrene	TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE CELLS; ARACHIDONIC-ACID; CYTOSOLIC PHOSPHOLIPASE-A(2); A(2); ACTIVATION; RISK; ATHEROSCLEROSIS; MACROPHAGES; INVOLVEMENT	Smoking is a major risk factor for endothelial cell injury and subsequent coronary artery disease. Epidemiological studies implicate the phospholipase A(2)/arachidonic acid cascade in the mechanism by which smoking causes heart disease. However, specific components of cigarette smoke that activate this pathway have not been identified. The purpose of this study was to investigate the effects of polycyclic aromatic hydrocarbons contained in cigarette smoke on phospholipase A(2) (PLA(2)) activity and apoptosis of human coronary artery endothelial cells. 1-methylanthracene (1-MA), phenanthrene (PA), and benzo(a)pyrene (B(a)P) caused significant release of H-3-arachidonate from endothelial cells. 1-MA and PA, but not B(a)P, also caused significant release of H-3-linoleic acid. Release of fatty acids from membrane phospholipids preceded the onset of apoptosis. 3 H-arachidonate release and apoptosis induced by 1-MA, B(a)P, and PA were inhibited by methylarachidonoyl-fluorophosphonate, an inhibitor of Groups IV and VI PLA(2)s. Bromoenol lactone, an inhibitor of Group VI enzymes, inhibited both H-3-arachidonate release and apoptosis induced by 1-MA and PA, but not B(a)P. MJ33, an inhibitor of the acidic calcium-independent PLA(2), attenuated H-3-arachidonate release and apoptosis by PA, but not 1-MA or B(a)P. The presence of Groups IV and VI and the acidic iPLA(2) in endothelial cells was demonstrated by reverse transcriptase-polymerase chain reaction and Western analysis. These data suggest that 1-MA, B(a)P and PA induce apoptosis of endothelial cells by a mechanism that involves activation of these three distinct isoforms of PLA(2).	Univ Tennessee, Dept Comparat Med, Coll Vet Med, Knoxville, TN 37996 USA; Univ Tennessee, Ctr Environm Biotechnol, Knoxville, TN 37996 USA; Univ Penn, Med Ctr, Inst Environm Med, Philadelphia, PA 19104 USA; Univ Michigan, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Tennessee System; University of Tennessee Knoxville; University of Pennsylvania; University of Michigan System; University of Michigan	Tithof, PK (corresponding author), Univ Tennessee, Dept Comparat Med, Coll Vet Med, A205,2407 River Dr, Knoxville, TN 37996 USA.	ptithof@utk.edu		/0000-0002-6224-6685				ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Ahn SG, 1998, BBA-MOL CELL RES, V1448, P115, DOI 10.1016/S0167-4889(98)00113-X; ALMEHDI AB, 1993, BIOCHIM BIOPHYS ACTA, V1167, P56, DOI 10.1016/0005-2760(93)90217-W; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Burchiel SW, 2001, CLIN IMMUNOL, V98, P2, DOI 10.1006/clim.2000.4934; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Capper EA, 2001, PROG LIPID RES, V40, P167, DOI 10.1016/S0163-7827(01)00002-9; CHALOUPKA K, 1995, CHEM-BIOL INTERACT, V96, P207, DOI 10.1016/0009-2797(94)03586-W; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Dimmeler S, 1998, EUR CYTOKINE NETW, V9, P697; Duan L, 2001, J IMMUNOL, V166, P7469, DOI 10.4049/jimmunol.166.12.7469; Fisher AB, 1997, AM J PHYSIOL-LUNG C, V272, pL238, DOI 10.1152/ajplung.1997.272.2.L238; GOODNIGHT SH, 1989, J INVEST DERMATOL, V93, pS102, DOI 10.1111/1523-1747.ep12581218; Harada K, 1997, ATHEROSCLEROSIS, V135, P235, DOI 10.1016/S0021-9150(97)00167-6; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; Howard G, 1998, JAMA-J AM MED ASSOC, V279, P119, DOI 10.1001/jama.279.2.119; Kerzee JK, 2000, MOL PHARMACOL, V58, P152, DOI 10.1124/mol.58.1.152; Kim TS, 1998, AM J PHYSIOL-LUNG C, V274, pL750, DOI 10.1152/ajplung.1998.274.5.L750; Kockx MM, 2000, CARDIOVASC RES, V45, P736, DOI 10.1016/S0008-6363(99)00235-7; Kuwata H, 1999, ADV EXP MED BIOL, V469, P183; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Madamanchi NR, 1998, ONCOGENE, V16, P417, DOI 10.1038/sj.onc.1201551; MAOQIANG M, 1995, J LIPID RES, V36, P1925; McCarty MF, 1996, MED HYPOTHESES, V46, P337, DOI 10.1016/S0306-9877(96)90183-8; PENN A, 1988, CARCINOGENESIS, V9, P2185, DOI 10.1093/carcin/9.12.2185; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Revel A, 2001, REPROD TOXICOL, V15, P479, DOI 10.1016/S0890-6238(01)00149-6; Rice SQJ, 1998, BIOCHEM J, V330, P1309; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Rodriguez BL, 1996, CIRCULATION, V94, P952, DOI 10.1161/01.CIR.94.5.952; SBARBATI R, 1991, BLOOD, V77, P764; SEVERSON RF, 1976, CARCINOGENESIS, V1, P269; Shinozaki K, 1999, BIOCHEMISTRY-US, V38, P1669, DOI 10.1021/bi982123q; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; TAI HH, 1990, ADV EXP MED BIOL, V273, P211; Tew DG, 1996, ARTERIOSCL THROM VAS, V16, P591, DOI 10.1161/01.ATV.16.4.591; Tithof PK, 1998, J IMMUNOL, V160, P953; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628	46	60	60	2	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1463	+		10.1096/fj.02-0092fje	http://dx.doi.org/10.1096/fj.02-0092fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205049	Bronze, Green Submitted			2022-12-25	WOS:000177813100013
J	Ramanathan, MP; Curley, E; Su, M; Chambers, JA; Weiner, DB				Ramanathan, MP; Curley, E; Su, M; Chambers, JA; Weiner, DB			Carboxyl terminus of hVIP/mov34 is critical for HIV-1-Vpr interaction and glucocorticoid-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-CYCLE ARREST; VPR PROTEIN; LIVING CELLS; DNA-REPAIR; IN-VITRO; RECEPTOR; TRANSCRIPTION; REPLICATION; EXPRESSION	Human immunodeficiency virus, type 1 (HIV-1) vpr is a highly conserved gene among lentiviruses. The diverse functions of Vpr support interactions of this HIV accessory protein with host cell partners of important pathways. hVIP/mov34 (human Vpr Interacting Protein) is one of these identified Vpr ligands. hVIP is a 34-kDa member of the eIF3 family that is vital for early embryonic development in transgenic mice and important in cell cycle regulation. Its interaction with Vpr, however, is not yet clearly defined. Therefore, we constructed a panel of deletion mutants of this cytoplasmic cellular ligand to map the protein domain that mediates its interaction with Vpr. We observed that the carboxyl-terminal region of hVIP is critical for its interaction with Vpr. In the absence of Vpr or HIV infection, full-length hVIP is expressed in the cytoplasm. The cytoplasmic localization pattern of full-length hVIP protein, however, is shifted to a clear nuclear localization pattern in cells expressing both hVIP and Vpr. In contrast, Vpr did not alter the localization pattern of hVIP mutants, which have their carboxyl-terminal domain deleted. The movement of hVIP supported prior work that suggested that Vpr triggers activation of the GR receptor complex. In fact, we also observed that dexamethasone moves hVIP into the nucleus and that glucocorticoid antagonists inhibit this effect. Interestingly, the expression of an hVIP carboxyl-terminal mutant, which is not responsive to Vpr, is also not responsive to dexamethasone. These data illustrate that the carboxyl-terminal domain of hVIP is critical for mediating hVIP-Vpr interaction as well as for its glucocorticoid response. These results support the view that hVIP is a member of the complex array of nucleocytoplasmic shuttling proteins that are regulated by HIV infection and glucocorticoids.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Weiner, DB (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 422 Curie Blvd,505 Stellar Chance Labs, Philadelphia, PA 19104 USA.		Weiner, David B/H-8579-2014					Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Ayyavoo V, 2002, INT IMMUNOL, V14, P13, DOI 10.1093/intimm/14.1.13; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; DODERA D, 1989, J VIROL, V63, P3205; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Gragerov A, 1998, VIROLOGY, V245, P323, DOI 10.1006/viro.1998.9138; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; LAVALLEE C, 1994, J VIROL, V68, P1926; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LU YL, 1995, J VIROL, V69, P6873, DOI 10.1128/JVI.69.11.6873-6879.1995; Mahalingam S, 1998, P NATL ACAD SCI USA, V95, P3419, DOI 10.1073/pnas.95.7.3419; Mahalingam S, 1997, DNA CELL BIOL, V16, P137, DOI 10.1089/dna.1997.16.137; Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Planelles V, 1996, J VIROL, V70, P2516, DOI 10.1128/JVI.70.4.2516-2524.1996; Rafaeli Y, 1995, P NATL ACAD SCI USA, V92, P3621; Ramanathan MP, 2001, DNA CELL BIOL, V20, P101, DOI 10.1089/104454901750070300; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; Sawaya BE, 2000, J BIOL CHEM, V275, P35209, DOI 10.1074/jbc.M005197200; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Sherman MP, 2000, J VIROL, V74, P8159, DOI 10.1128/JVI.74.17.8159-8165.2000; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Stark LA, 1998, J VIROL, V72, P3037, DOI 10.1128/JVI.72.4.3037-3044.1998; Stewart SA, 1999, P NATL ACAD SCI USA, V96, P12039, DOI 10.1073/pnas.96.21.12039; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Stivahtis GL, 1997, J VIROL, V71, P4331, DOI 10.1128/JVI.71.6.4331-4338.1997; Vanitharani R, 2001, VIROLOGY, V289, P334, DOI 10.1006/viro.2001.1153; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; WithersWard ES, 1997, J VIROL, V71, P9732, DOI 10.1128/JVI.71.12.9732-9742.1997; YUAN XF, 1990, J VIROL, V64, P5688	46	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47854	47860		10.1074/jbc.M203905200	http://dx.doi.org/10.1074/jbc.M203905200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12237292	hybrid			2022-12-25	WOS:000179663700131
J	Petris, MJ; Voskoboinik, I; Cater, M; Smith, K; Kim, BE; Llanos, RM; Strausak, D; Camakaris, J; Mercer, JFB				Petris, MJ; Voskoboinik, I; Cater, M; Smith, K; Kim, BE; Llanos, RM; Strausak, D; Camakaris, J; Mercer, JFB			Copper-regulated trafficking of the Menkes disease copper ATPase is associated with formation of a phosphorylated catalytic intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; INTRACELLULAR-LOCALIZATION; DEPENDENT TRAFFICKING; FUNCTIONAL EXPRESSION; PLASMA-MEMBRANE; BIOCHEMICAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; MURINE HOMOLOG; BINDING SITES; PROTEIN	The Menkes protein (MNK; ATP7A) is a copper-transporting P-type ATPase that is defective in the copper deficiency disorder, Menkes disease. MINK is localized in the trans-Golgi network and transports copper to enzymes synthesized within secretory compartments. However, in cells exposed to excessive copper, MNK traffics to the plasma membrane where it functions in copper efflux. A conserved feature of all P-type ATPases is the formation of an acyl-phosphate intermediate, which occurs as part of the catalytic cycle during cation transport. In this study we investigated the effect of mutations within conserved catalytic regions of MNK on intracellular localization and trafficking from the trans-Golgi network (TGN). Our findings suggest that mutations that block formation of the phosphorylated catalytic intermediate also prevent copper-induced relocalization of MNK from the TGN. Furthermore, mutations in the phosphatase domain, which resulted in hyperphosphorylation. of MNK, caused constitutive trafficking from the TGN to the plasma membrane. A similar effect on trafficking was observed with a phosphatase mutation in the closely related copper ATPase, ATP7B, affected in Wilson disease. These findings suggest that the copper-induced trafficking of the Menkes and Wilson disease copper ATPases is associated with the phosphorylated intermediate that is formed during the catalysis of these pumps. Our findings describe a novel mechanism for regulating the subcellular location of a transport protein involving the recognition of intermediate conformations during catalysis.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Melbourne, Dept Genet, Melbourne, Vic 3010, Australia; Deakin Univ, Ctr Cellular & Mol Biol, Melbourne, Vic 3125, Australia	University of Missouri System; University of Missouri Columbia; University of Melbourne; Deakin University	Petris, MJ (corresponding author), Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA.		Mercer, Julian/R-8583-2019	Voskoboinik, Ilia/0000-0002-6410-009X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059893] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59893] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ambrosini L, 1999, HUM MOL GENET, V8, P1547, DOI 10.1093/hmg/8.8.1547; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bissig KD, 2001, BIOCHEM J, V357, P217, DOI 10.1042/0264-6021:3570217; CAMAKARIS J, 1995, HUM MOL GENET, V4, P2117, DOI 10.1093/hmg/4.11.2117; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Danks D. M, 1995, METABOLIC BASIS INHE, VI, P2211; Forbes JR, 1998, AM J HUM GENET, V63, P1663, DOI 10.1086/302163; Forbes JR, 2000, HUM MOL GENET, V9, P1927, DOI 10.1093/hmg/9.13.1927; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Kaler SG, 1996, NAT GENET, V13, P21, DOI 10.1038/ng0596-21; La Fontaine S, 1998, J BIOL CHEM, V273, P31375; La Fontaine S, 2001, HUM MOL GENET, V10, P361, DOI 10.1093/hmg/10.4.361; La Fontaine S, 1999, HUM MOL GENET, V8, P1069, DOI 10.1093/hmg/8.6.1069; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ogawa A, 1999, J HUM GENET, V44, P206, DOI 10.1007/s100380050144; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; PAYNTER JA, 1994, FEBS LETT, V351, P186, DOI 10.1016/0014-5793(94)00868-X; Petris MJ, 1999, HUM MOL GENET, V8, P2107, DOI 10.1093/hmg/8.11.2107; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Terada K, 1998, J BIOL CHEM, V273, P1815, DOI 10.1074/jbc.273.3.1815; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; Tumer Z, 1999, ADV EXP MED BIOL, V448, P83; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Yoshimizu T, 1998, BIOSCI BIOTECH BIOCH, V62, P1258, DOI 10.1271/bbb.62.1258	37	100	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46736	46742		10.1074/jbc.M208864200	http://dx.doi.org/10.1074/jbc.M208864200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12228238	hybrid, Green Submitted			2022-12-25	WOS:000179529300133
J	Ito, J; Nagayasu, Y; Ueno, S; Yokoyama, S				Ito, J; Nagayasu, Y; Ueno, S; Yokoyama, S			Apolipoprotein-mediated cellular lipid release requires replenishment of sphingomyelin in a phosphatidylcholine-specific phospholipase C-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HIGH-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; BINDING CASSETTE TRANSPORTER-1; TANGIER-DISEASE; CHOLESTEROL EFFLUX; MEMBRANE; INHIBITION; MUTATIONS; BREAKDOWN	When sphingomyelin is digested by sphingomyelinase in the plasma membrane of rat astrocytes, productions of sphingomyelin, diacylglycerol, and phosphatidylcholine are stimulated. D609, an inhibitor of phosphatidylcholine-specific phospholipase C, suppressed these effects. Similarly, when apolipoprotein A-I removed cellular cholesterol, phosphatidylcholine, and sphingomyelin to generate high density lipoprotein, cholesterol synthesis from acetate subsequently increased, and sphingomyelin synthesis from acetate and serine also increased. D609 inhibited these effects again. D609 also inhibited the cholesterol removal by apoA-I not only from the astrocytes but also from BALB/3T3 and RAW264 cells. D609 decreased cholesterol synthesis, although D609 did not directly inhibit hydroxymethylglutaryl-CoA reductase. ApoA-I-stimulated translocation of newly synthesized cholesterol to cytosol was also decreased by D609. A diacylglycerol analog increased the apoA-I-mediated cholesterol release, whereas ceramide did not influence it. We concluded that removal of cellular sphingomyelin by apolipoproteins is replenished by transfer of phosphorylcholine from phosphatidylcholine to ceramide, and this reaction may limit the removal of cholesterol by apoA-I. This reaction also produces diacylglycerol that potentially triggers subsequent cellular signal cascades and regulates intracellular cholesterol trafficking.	Nagoya City Univ, Grad Sch Med Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Yokoyama, S (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Mizuho Ku, Kawasumi 1,Mizuho Cho, Nagoya, Aichi 4678601, Japan.							Amtmann E, 1996, DRUG EXP CLIN RES, V22, P287; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arakawa R, 2000, J LIPID RES, V41, P1952; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHEN H, 1993, J LIPID RES, V34, P2159; DUSSERRE E, 1994, BIOCHEM MED METAB B, V52, P45, DOI 10.1006/bmmb.1994.1032; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Francis GA, 1996, BIOCHEMISTRY-US, V35, P15188, DOI 10.1021/bi9618169; GUPTA AK, 1991, J LIPID RES, V32, P125; Ito J, 1999, J NEUROCHEM, V72, P2362, DOI 10.1046/j.1471-4159.1999.0722362.x; Ito J, 2000, J LIPID RES, V41, P894; Ito J, 2002, J BIOL CHEM, V277, P7929, DOI 10.1074/jbc.M103878200; KANEKO I, 1978, EUR J BIOCHEM, V87, P313; KATO T, 1984, BRAIN RES, V301, P83, DOI 10.1016/0006-8993(84)90405-0; LI QQ, 1993, BIOCHEMISTRY-US, V32, P4597, DOI 10.1021/bi00068a016; Li QQ, 1997, BIOCHEMISTRY-US, V36, P12045, DOI 10.1021/bi970079t; LI QQ, 1995, J BIOL CHEM, V270, P26216, DOI 10.1074/jbc.270.44.26216; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; NAZIH H, 1994, ARTERIOSCLER THROMB, V14, P1321, DOI 10.1161/01.ATV.14.8.1321; NISHIKAWA O, 1986, J BIOCHEM, V99, P295, DOI 10.1093/oxfordjournals.jbchem.a135473; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SAUER G, 1984, P NATL ACAD SCI-BIOL, V81, P3263, DOI 10.1073/pnas.81.11.3263; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; Tomimoto S, 2001, ARTERIOSCL THROM VAS, V21, P394, DOI 10.1161/01.ATV.21.3.394; Ueno S, 2002, BBA-MOL CELL RES, V1589, P261, DOI 10.1016/S0167-4889(02)00181-7; VANBLITTERSWIJK WJ, 1987, BIOCHEMISTRY-US, V26, P1746, DOI 10.1021/bi00380a038; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; WU YQ, 1992, ENDOCRINOLOGY, V131, P2935, DOI 10.1210/en.131.6.2935; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	36	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44709	44714		10.1074/jbc.M208379200	http://dx.doi.org/10.1074/jbc.M208379200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228236	hybrid			2022-12-25	WOS:000179404800016
J	Latif, R; Graves, P; Davies, TF				Latif, R; Graves, P; Davies, TF			Ligand-dependent inhibition of oligomerization at the human thyrotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; DELTA-OPIOID RECEPTOR; PROTEIN-COUPLED RECEPTORS; LUTEINIZING-HORMONE RECEPTORS; TSH RECEPTOR; TRANSFER MICROSCOPY; LIVING CELLS; EXTRACELLULAR DOMAIN; FLUORESCENT PROTEIN; PLASMA-MEMBRANE	Recently, several studies have reported oligomerization of G protein-coupled receptors, although the functional implications of this phenomenon are still unclear. Using fluorescence resonance energy transfer (FRET) and coimmunoprecipitation (COIP), we previously reported that the human thyrotropin (TSH) receptor tagged with green fluorescent protein (TSHRGFP) and expressed in a heterologous system was present as oligomeric complexes on the cell surface. Here, we have extended this biophysical and biochemical approach to study the regulation of such oligomeric complexes. Co-expression of TSHRGFP and TSHRMyc constructs in Chinese hamster ovary cells resulted in FRET-positive cells. The specificity of the FRET signal was verified by the absence of energy transfer in individually transfected TSHRGFP and TSHRMyc:Cy3 cells cultured together and also by acceptor photobleaching. Occupation of the receptor molecule by the ligand (TSH) resulted in a dose-dependent decrease in the FRET index from 20% in the absence of TSH to <1% with 10(3) microunits/ml of TSH. Such reduction in oligomeric forms was also confirmed by coimmunoprecipitation. Exposure of TSHRGFP/Myc cells to forskolin or cytochalasin D caused no change in the FRET index, confirming that the decrease in the oligomeric complexes was a receptor-dependent phenomenon and free of energy or microtuble requirements. The TSH-induced decrease in TSHR oligomers was found to be secondary to dissociation of the TSHR complexes as evidenced by an increase in fluorescent intensity of photobleached spots of GFP fluorescence with 10(3) microunits/ml of TSH. These data indicated that the less active conformation of the TSHR was comprised of receptor complexes and that such complexes were dissociated on the binding of ligand. Such observations support the concept of a constitutively active TSHR dimer or monomer that is naturally inhibited by the formation of higher order complexes. Inhibition of these oligomeric forms by ligand binding returns the TSHR to an activated state.	Mt Sinai Sch Med, Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Latif, R (corresponding author), Mt Sinai Sch Med, Dept Med, Div Endocrinol Diabet & Bone Dis, Box 1055,1 Gustave L Levy Pl, New York, NY 10029 USA.	rauf.latif@mssm.edu	Latif, Rauf/ABH-4394-2020; latif, rauf/AAR-1634-2020	Latif, Rauf/0000-0002-4226-3728; 	NCRR NIH HHS [1S10RR9145-01] Funding Source: Medline; NIDDK NIH HHS [DK52464, DK35764, DK45011] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052464, R01DK045011, R01DK035764] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Chan FKM, 2001, CYTOMETRY, V44, P361, DOI 10.1002/1097-0320(20010801)44:4<361::AID-CYTO1128>3.0.CO;2-3; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Clegg Robert M, 2002, J Biotechnol, V82, P177; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Davies T, 2002, J CLIN INVEST, V110, P161, DOI 10.1172/JCI200216234; Day RN, 2001, METHODS, V25, P4, DOI 10.1006/meth.2001.1211; Devi LA, 2000, TRENDS PHARMACOL SCI, V21, P324, DOI 10.1016/S0165-6147(00)01519-4; Devi LA, 2000, NEUROPSYCHOPHARMACOL, V23, pS3, DOI 10.1016/S0893-133X(00)00154-8; Duprez L, 1997, FEBS LETT, V409, P469, DOI 10.1016/S0014-5793(97)00532-2; Elmhurst JL, 2000, MOL BRAIN RES, V80, P63, DOI 10.1016/S0169-328X(00)00120-0; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Graves PN, 1996, ENDOCRINOLOGY, V137, P3915, DOI 10.1210/en.137.9.3915; GRAVES PN, 1995, ENDOCRINOLOGY, V136, P521, DOI 10.1210/en.136.2.521; Graves PN, 2000, ENDOCRIN METAB CLIN, V29, P267, DOI 10.1016/S0889-8529(05)70131-6; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Guo J, 2000, MOL PHARMACOL, V58, P1050, DOI 10.1124/mol.58.5.1050; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Horvat RD, 2001, MOL ENDOCRINOL, V15, P534, DOI 10.1210/me.15.4.534; Horvat RD, 2001, MOL ENDOCRINOL, V15, P695, DOI 10.1210/me.15.5.695; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Latif R, 2001, J BIOL CHEM, V276, P45217, DOI 10.1074/jbc.M103727200; Latif R, 2000, THYROID, V10, P407, DOI 10.1089/thy.2000.10.407; Lee SP, 2000, NEUROPSYCHOPHARMACOL, V23, pS32, DOI 10.1016/S0893-133X(00)00155-X; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Periasamy A, 2001, J BIOMED OPT, V6, P287, DOI 10.1117/1.1383063; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Roess DA, 2000, ENDOCRINOLOGY, V141, P4518, DOI 10.1210/en.141.12.4518; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Sanders J, 1997, BAILLIERE CLIN ENDOC, V11, P451, DOI 10.1016/S0950-351X(97)80693-3; SMITH BR, 1988, ENDOCR REV, V9, P106, DOI 10.1210/edrv-9-1-106; Szkudlinski MW, 2002, PHYSIOL REV, V82, P473, DOI 10.1152/physrev.00031.2001; Trapaidze N, 2000, DNA CELL BIOL, V19, P195, DOI 10.1089/104454900314465; Trapaidze N, 2000, DNA CELL BIOL, V19, P93, DOI 10.1089/104454900314609; Trapaidze N, 2000, MOL BRAIN RES, V76, P220, DOI 10.1016/S0169-328X(00)00002-4; Truong K, 2001, CURR OPIN STRUC BIOL, V11, P573, DOI 10.1016/S0959-440X(00)00249-9; Vassart G, 1996, ANN ENDOCRINOL-PARIS, V57, P50; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Vlaeminck-Guillem V, 2002, MOL ENDOCRINOL, V16, P736, DOI 10.1210/me.16.4.736; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wurch T, 2001, FEBS LETT, V507, P109, DOI 10.1016/S0014-5793(01)02969-6; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	56	91	93	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45059	45067		10.1074/jbc.M206693200	http://dx.doi.org/10.1074/jbc.M206693200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223484	hybrid			2022-12-25	WOS:000179404800061
J	Le Rouzic, E; Mousnier, A; Rustum, C; Stutz, F; Hallberg, E; Dargemont, C; Benichou, S				Le Rouzic, E; Mousnier, A; Rustum, C; Stutz, F; Hallberg, E; Dargemont, C; Benichou, S			Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REGULATORY PROTEIN VPR; CELL-CYCLE ARREST; MESSENGER-RNA EXPORT; PORE COMPLEX; PREINTEGRATION COMPLEXES; MACROPHAGE INFECTION; MAMMALIAN-CELLS; TERMINAL DOMAIN; GAG PRECURSOR	The HIV-1 genome contains several genes coding for auxiliary proteins, including the small Vpr protein. Vpr affects the integrity of the nuclear envelope and participates in the nuclear translocation of the preintegration complex containing the viral DNA. Here, we show by photobleaching experiments performed on living cells expressing a Vpr-green fluorescent protein fusion that the protein shuttles between the nucleus and the cytoplasm, but a significant fraction is concentrated at the nuclear envelope, supporting the hypothesis that Vpr interacts with components of the nuclear pore complex. An interaction between HIV-1 Vpr and the human nucleoporin CG1 (hCG1) was revealed in the yeast two-hybrid system, and then confirmed both in vitro and in transfected cells. This interaction does not involve the FG repeat domain of hCG1 but rather the N-terminal region of the protein. Using a nuclear import assay based on digitonin-permeabilized cells, we demonstrate that hCG1 participates in the docking of Vpr at the nuclear envelope. This association of Vpr with a component of the nuclear pore complex may contribute to the disruption of the nuclear envelope and to the nuclear import of the viral DNA.	Univ Paris 05, U567, Inst Cochin, Dept Infect Dis,INSERM, F-75014 Paris, France; Univ Paris 06, CNRS, UMR 7592, Inst Jacques Monod, Paris, France; Univ Paris 07, Paris, France; Sodertorns Hogskola, S-14189 Huddinge, Sweden; Inst Microbiol, Lausanne, Switzerland; Stockholm Univ, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Sodertorn University; Stockholm University	Benichou, S (corresponding author), Univ Paris 05, U567, Inst Cochin, Dept Infect Dis,INSERM, Batiment Gustave Roussy,27 Rue Faubourg St Jacque, F-75014 Paris, France.		Stutz, Françoise C/N-4329-2017	Mousnier, Aurelie/0000-0002-7317-1009; Benichou, Serge/0000-0003-3602-3530; Hallberg, Einar/0000-0003-2092-457X				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Allen TD, 2000, J CELL SCI, V113, P1651; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Bachand F, 1999, J BIOL CHEM, V274, P9083, DOI 10.1074/jbc.274.13.9083; Belgareh N, 1999, PROTOPLASMA, V209, P133, DOI 10.1007/BF01453442; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; BUKRINSKY MI, 1999, FRONT BIOSCI, V4, P772; BUSS F, 1994, J CELL SCI, V107, P631; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; CRONSHAW JM, 2002, J CELL BIOL, V26, P315; Cullen BR, 2001, NAT MED, V7, P20, DOI 10.1038/83295; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; de Rocquigny H, 1997, J BIOL CHEM, V272, P30753, DOI 10.1074/jbc.272.49.30753; Depienne C, 2000, EXP CELL RES, V260, P387, DOI 10.1006/excr.2000.5016; Depienne C, 2001, J BIOL CHEM, V276, P18102, DOI 10.1074/jbc.M009029200; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Farjot G, 1999, J BIOL CHEM, V274, P17309, DOI 10.1074/jbc.274.24.17309; Fouchier RAM, 1999, ADV VIRUS RES, V52, P275, DOI 10.1016/S0065-3527(08)60302-4; Fouchier RAM, 1998, J VIROL, V72, P6004, DOI 10.1128/JVI.72.7.6004-6013.1998; FREED EO, 1995, J VIROL, V69, P3949, DOI 10.1128/JVI.69.6.3949-3954.1995; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gruenbaum Y, 2000, J STRUCT BIOL, V129, P313, DOI 10.1006/jsbi.2000.4216; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Kamata M, 2000, J VIROL, V74, P7179, DOI 10.1128/JVI.74.15.7179-7186.2000; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; MAHALINGAM S, 1995, VIROLOGY, V212, P331, DOI 10.1006/viro.1995.1490; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Ossareh-Nazari B, 2001, TRAFFIC, V2, P684, DOI 10.1034/j.1600-0854.2001.21002.x; Popov S, 1998, J BIOL CHEM, V273, P13347, DOI 10.1074/jbc.273.21.13347; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381; Segura-Totten M, 2001, SCIENCE, V294, P1016, DOI 10.1126/science.1066729; Selig L, 1999, J VIROL, V73, P592, DOI 10.1128/JVI.73.1.592-600.1999; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Stutz F, 1996, MOL CELL BIOL, V16, P7144; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Vigouroux C, 2001, J CELL SCI, V114, P4459; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Wecker K, 1999, EUR J BIOCHEM, V266, P359, DOI 10.1046/j.1432-1327.1999.00858.x; Wiegand HL, 2002, MOL CELL BIOL, V22, P245, DOI 10.1128/MCB.22.1.245-256.2002; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhou Y, 1998, VIROLOGY, V242, P414, DOI 10.1006/viro.1998.9028	59	94	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45091	45098		10.1074/jbc.M207439200	http://dx.doi.org/10.1074/jbc.M207439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228227	hybrid			2022-12-25	WOS:000179404800065
J	Sarkar, SN; Pal, S; Sen, GC				Sarkar, SN; Pal, S; Sen, GC			Crisscross enzymatic reaction between the two molecules in the active dimeric P69 form of the 2 '-5 ' oligodenylate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; 2'-5'-OLIGOADENYLATE SYNTHETASE; 100-KDA FORMS; HUMAN-CELLS; INTERFERON; ISOZYME; MUTANTS; FAMILY; SITES; BINDING	2'-5' oligoadenylate (2-5 (A)) synthetases are major components of the antiviral pathways induced by interferons. In the presence of double-stranded RNA, they polymerize ATP to form 2-5 (A) oligomers that, in turn, activate the latent ribonuclease RNase L, causing mRNA degradation. These enzymes, unlike other nucleotidyl transferases, catalyze 2'-5', not 3'-5', phosphodiester bond formation between substrates bound to the acceptor and donor sites. Moreover, unlike other members of this extended family, the P69 isozyme of 2-5 (A) synthetase functions as a homodimer. Here, we report that the need for P69 dimerization is because of a crisscross enzyme reaction joining two substrate molecules bound to two opposite subunits. Consequently, although homodimers of mutants in the previously identified acceptor site, the donor site, or the catalytic site were inactive, selective heterodimers of the mutants were active because of subunit complementation. The catalytic site had to be present in the same subunit that contained the acceptor site, whereas the donor site had to be provided by the other subunit. These results allowed us to design a mutant protein that acted as a dominant-negative inhibitor of wt P69 but not of another isozyme of 2-5 (A) synthetase.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol NC20, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Sen, GC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol NC20, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Sarkar, Saumendra N/B-5038-2011	Sarkar, Saumendra N/0000-0002-2850-6121	NATIONAL CANCER INSTITUTE [R01CA068782, P01CA062220] Funding Source: NIH RePORTER; NCI NIH HHS [CA68782, CA62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; Ghosh A, 2000, VIROLOGY, V266, P319, DOI 10.1006/viro.1999.0085; Ghosh A, 2001, J BIOL CHEM, V276, P25447, DOI 10.1074/jbc.M100496200; GRIBAUDO G, 1991, J VIROL, V65, P1748, DOI 10.1128/JVI.65.4.1748-1757.1991; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; HOVANESSIAN AG, 1988, J BIOL CHEM, V263, P4945; Justesen J, 2000, CELL MOL LIFE SCI, V57, P1593, DOI 10.1007/PL00000644; Lau FW, 1999, BIOCHEMISTRY-US, V38, P5521, DOI 10.1021/bi982763t; MARIE I, 1990, J BIOL CHEM, V265, P18601; Rebouillat D, 1999, J BIOL CHEM, V274, P1557, DOI 10.1074/jbc.274.3.1557; Rebouillat D, 1999, J INTERF CYTOK RES, V19, P295, DOI 10.1089/107999099313992; Sarkar SN, 2002, J BIOL CHEM, V277, P24321, DOI 10.1074/jbc.M110202200; Sarkar SN, 1999, J BIOL CHEM, V274, P25535, DOI 10.1074/jbc.274.36.25535; Sarkar SN, 1999, J BIOL CHEM, V274, P1848, DOI 10.1074/jbc.274.3.1848; Sarkar SN, 1998, METHODS, V15, P233, DOI 10.1006/meth.1998.0627; Saxl RL, 2001, BIOCHEMISTRY-US, V40, P5275, DOI 10.1021/bi002925x; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TOBIAS KE, 1993, BIOCHEMISTRY-US, V32, P5842, DOI 10.1021/bi00073a017; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31	21	8	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44760	44764		10.1074/jbc.M207126200	http://dx.doi.org/10.1074/jbc.M207126200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223486	hybrid			2022-12-25	WOS:000179404800023
J	Yang, YY; Chen, Q; Zhang, JT				Yang, YY; Chen, Q; Zhang, JT			Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; DRUG-BINDING DOMAIN; ABC TRANSPORTER SUPERFAMILY; MEMBRANE TOPOLOGY; LEUKOTRIENE C-4; CONFORMATIONAL-CHANGES; SUBSTRATE-SPECIFICITY; SCANNING MUTAGENESIS; NUCLEOTIDE-BINDING; CROSS-LINKING	Multidrug resistance-associated protein 1 (MRP1) is a member of the ATP-binding cassette membrane transport superfamily and is responsible for multidrug resistance in cancer cells. Currently, there are nine known human MRPs. Distinct from many other members of the ATP-binding cassette superfamily, human MRP1 and four other MRPs have an additional membrane-spanning domain (MSD) with a putative extracellular amino terminus. The functional significance of this additional MSD (MSD1) is currently unknown. To understand the role of MSD1 in human MRP1 structure and function, we studied the amino-terminal 33 amino acids. We found that the amino terminus of human MRP1 has two cysteine residues (Cys(7) and Cys(32)) that are conserved among the five human MRPs that have MSD1. Mutation analyses of the two cysteines in human MRP1 revealed that the Cys(7) residue is critical for the MRP1-mediated drug resistance and leukotriene C-4 transport activity. On the other hand, mutation of Cys(32) reduced only moderately the MRP1 function. The effect of Cys(7) mutation on MRP1 activity appears to be due to the 5-7-fold decrease in the maximal transport rate V-max. We also found that mutation of Cys(7) changed the amino-terminal conformation of MRP1. This conformational change is likely responsible for the decrease in V-max of LTC4 transport mediated by the mutant MRP1. Based on these studies, we conclude that the amino terminus of human MRP1 is important and that the Cys(7) residue plays a critical role in maintaining the proper structure and function of human MRP1.	Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Ctr Canc, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr Walther Canc Inst, Ctr Canc, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Zhang, JT (corresponding author), Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Ctr Canc, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.		Zhang, Jian-Ting/L-8334-2015		NCI NIH HHS [CA64539] Funding Source: Medline; NIGMS NIH HHS [GM59475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064539, R29CA064539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 2000, J CELL SCI, V113, P4451; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Belinsky MG, 1998, J NATL CANCER I, V90, P1735, DOI 10.1093/jnci/90.22.1735; Bera TK, 2001, MOL MED, V7, P509, DOI 10.1007/BF03401856; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; Buchler M, 1996, J BIOL CHEM, V271, P15091; Chen Q, 2002, BIOCHEMISTRY-US, V41, P9052, DOI 10.1021/bi025634s; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Daoud R, 2000, BIOCHEMISTRY-US, V39, P6094, DOI 10.1021/bi9922188; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1996, CANCER RES, V56, P3307; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hopper E, 2001, CANCER LETT, V162, P181, DOI 10.1016/S0304-3835(00)00646-7; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Lee K, 1998, CANCER RES, V58, P2741; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Longhurst TJ, 1996, BRIT J CANCER, V74, P1331, DOI 10.1038/bjc.1996.545; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; Manciu L, 2001, FEBS LETT, V493, P31, DOI 10.1016/S0014-5793(01)02270-0; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; Prechtl S, 2000, J IMMUNOL, V164, P754, DOI 10.4049/jimmunol.164.2.754; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; Stride BD, 1997, MOL PHARMACOL, V52, P344, DOI 10.1124/mol.52.3.344; Theodoulou FL, 2000, BBA-BIOMEMBRANES, V1465, P79, DOI [10.1016/S0005-2736(00)00132-2, 10.1199/tab.0153]; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200; Zhang JT, 2000, BIOCHEM J, V348, P597, DOI 10.1042/0264-6021:3480597; Zhang M, 1996, BIOCHEMISTRY-US, V35, P9728, DOI 10.1021/bi960400s; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	44	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44268	44277		10.1074/jbc.M207003200	http://dx.doi.org/10.1074/jbc.M207003200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12235150	hybrid			2022-12-25	WOS:000179272000096
J	Barazi, HO; Li, ZQ; Cashel, JA; Krutzsch, HC; Annis, DS; Mosher, DF; Roberts, DD				Barazi, HO; Li, ZQ; Cashel, JA; Krutzsch, HC; Annis, DS; Mosher, DF; Roberts, DD			Regulation of integrin function by CD47 ligands - Differential effects on alpha(v)beta(3) and alpha(4)beta(1) integrin-mediated adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-BINDING DOMAIN; PROTEIN CD47; T-CELLS; ALPHA(3)BETA(1) INTEGRIN; SIGNALING PATHWAY; PLASMA-MEMBRANE; RECEPTOR; THROMBOSPONDIN-1; ACTIVATION; IDENTIFICATION	We examined the regulation of alpha(4)beta(1) integrin function in melanoma cells and T cells by ligands of CD47. A CD47 antibody (B6H12) that inhibited alpha(v)beta(3)-mediated adhesion of melanoma cells induced by CD47-binding peptides from thrombospondin-1 directly stimulated alpha(4)beta(1)-mediated adhesion of the same cells to vascular cell adhesion molecule-1 and N-terminal regions of thrombospondin-1 or thrombospondin-2. B6H12 also stimulated alpha(4)beta(1)- as well as alpha(2)beta(1)- and alpha(5)beta(1)-mediated adhesion of CD47-expressing T cells but not of CD47-deficient T cells. alpha(4)beta(1) and CD47 co-purified as a detergent-stable complex on a CD47 antibody affinity column. CD47-binding peptides based on C-terminal sequences of thrombospondin-1 also, specifically enhanced adhesion of melanoma cells and T cells to alpha(4)beta(1) ligands. Unexpectedly, activation of alpha(4)beta(1) function by the thrombospondin-1 CD47-hinding peptides also occurred in CD47-deficient T cells. CD47-independent activation of alpha(4)beta(1), required the Val-Val-Met (VVM) motif of the peptides and was sensitive to inhibition by pertussis toxin. These results indicate that activation of alpha(4)beta(1), by the CD47 antibody B6H12 and by VVM peptides occurs by different mechanisms. The antibody directly activates a CD47-alpha(4)beta(1) complex, whereas VVM peptides may target an unidentified G(i)-linked receptor that regulates alpha(4)beta(1).	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; Univ Wisconsin, Dept Med, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wisconsin System; University of Wisconsin Madison	Roberts, DD (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Rm 2A33,10 Ctr Dr,MSC 1500, Bethesda, MD 20892 USA.		Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981				Abitorabi MA, 1997, J CELL BIOL, V139, P563, DOI 10.1083/jcb.139.2.563; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; Avice MN, 2000, J IMMUNOL, V165, P4624, DOI 10.4049/jimmunol.165.8.4624; Babic I, 2000, J IMMUNOL, V164, P3652, DOI 10.4049/jimmunol.164.7.3652; BEDNARCZYK JL, 1992, J BIOL CHEM, V267, P25274; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; GAO AG, 1994, J BIOL CHEM, V269, P29650; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Green JM, 1997, J CELL BIOL, V139, P1209, DOI 10.1083/jcb.139.5.1209; Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200; Imhof BA, 1997, EUR J IMMUNOL, V27, P3242, DOI 10.1002/eji.1830271223; Keenan RM, 1997, J MED CHEM, V40, P2289, DOI 10.1021/jm970205r; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; Krutzsch HC, 1999, J BIOL CHEM, V274, P24080, DOI 10.1074/jbc.274.34.24080; Leitinger B, 2002, J CELL SCI, V115, P963; Li ZQ, 2002, J CELL BIOL, V157, P509, DOI 10.1083/jcb.200109098; Li ZQ, 2001, J IMMUNOL, V166, P2427, DOI 10.4049/jimmunol.166.4.2427; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; Liu Y, 2001, J BIOL CHEM, V276, P40156, DOI 10.1074/jbc.M104138200; Maile LA, 2002, J BIOL CHEM, V277, P1800, DOI 10.1074/jbc.M108380200; Misenheimer TM, 2000, J BIOL CHEM, V275, P40938, DOI 10.1074/jbc.M007022200; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Palecek SP, 1998, J CELL SCI, V111, P929; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pettersen RD, 1999, J IMMUNOL, V162, P7031; Rebres RA, 2001, J BIOL CHEM, V276, P7672, DOI 10.1074/jbc.M008858200; Reinhold MI, 1997, J EXP MED, V185, P1, DOI 10.1084/jem.185.1.1; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; Rubinstein E, 1997, EUR J IMMUNOL, V27, P1919, DOI 10.1002/eji.1830270815; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; Sipes JM, 1999, J BIOL CHEM, V274, P22755, DOI 10.1074/jbc.274.32.22755; Ticchioni M, 1997, J IMMUNOL, V158, P677; Ticchioni M, 2001, FASEB J, V15, P341, DOI 10.1096/fj.99-0833com; Tulasne D, 2001, BLOOD, V98, P3346, DOI 10.1182/blood.V98.12.3346; VOGEL T, 1993, ARCH BIOCHEM BIOPHYS, V300, P501, DOI 10.1006/abbi.1993.1068; Waclavicek M, 1997, J IMMUNOL, V159, P5345; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865; Wilson KE, 1999, J IMMUNOL, V163, P3621; Wu AL, 1999, MOL CELL, V4, P619, DOI 10.1016/S1097-2765(00)80212-9; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230	52	65	69	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42859	42866		10.1074/jbc.M206849200	http://dx.doi.org/10.1074/jbc.M206849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12218055	hybrid			2022-12-25	WOS:000179081200058
J	Dupre, A; Suziedelis, K; Valuckaite, R; de Gunzburg, J; Ozon, R; Jessus, C; Haccard, O				Dupre, A; Suziedelis, K; Valuckaite, R; de Gunzburg, J; Ozon, R; Jessus, C; Haccard, O			Xenopus H-RasV12 promotes entry into meiotic M phase and cdc2 activation independently of Mos and p42(MAPK)	ONCOGENE			English	Article						Ras; Xenopus oocyte; cdc2; p42(MAPK); Mos	MAP KINASE PATHWAY; SIGNAL-TRANSDUCTION; MPF ACTIVATION; ONCOGENIC RAS; IN-VITRO; OOCYTES; MATURATION; PROTEINS; INDUCTION; PHOSPHORYLATION	In the Xenopus oocyte, progesterone triggers M phase Promoting Factor (MPF) activation in a protein synthesis dependent manner. Although the synthesis of the p42(MAPK) activator Mos appears to be required for MPF activation, p42(MAPK) activity has been shown to be dispensable. To clarify this paradox, we attempted to activate the p42(MAPK) pathway independently of Mos synthesis by cloning and using Xenopus H-Ras in the oocyte. We demonstrate that the injection of the constitutively active Xe H-RasV12 mutant induces p42(MAPK) and MPF activation through two independent pathways. Xe H-RasV12 induces only a partial activation of p42(MAPK) when protein synthesis and MPF activation are prevented. A full level of p42(MAPK) activation is reached when MPF is activated and Mos is present. In contrast, MPF activation induced by Xe H-RasV12 is achieved independently of Mos synthesis and p42(MAPK) activation but still depends on protein synthesis. Therefore, the amphibian oocyte represents a new model system to analyse an original H-Ras pathway ending to MPF activation and distinct from the p42(MAPK) pathway. The identification of the proteins synthesized in response to Xe H-RasV12 and required for MPF activation, represents an important clue in understanding the mechanism of progesterone action.	Univ Paris 06, INRA, Dev Biol Lab, CNRS,UMR 7622, F-75252 Paris 05, France; Vilnius State Univ, Dept Biochem & Biophys, LT-2009 Vilnius, Lithuania; Inst Curie, INSERM, U528, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Sorbonne Universite; Vilnius University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Jessus, C (corresponding author), Univ Paris 06, INRA, Dev Biol Lab, CNRS,UMR 7622, Boite 24,4 Pl Jussieu, F-75252 Paris 05, France.	jessus@ccr.jussieu.fr		Haccard, Olivier/0000-0002-4305-2746				ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CARNERO A, 1994, J CELL BIOCHEM, V55, P465, DOI 10.1002/jcb.240550406; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DESMEDT V, 1995, FEBS LETT, V375, P249, DOI 10.1016/0014-5793(95)01183-F; Fisher DL, 1999, DEVELOPMENT, V126, P4537; Frank-Vaillant M, 1999, MOL BIOL CELL, V10, P3279, DOI 10.1091/mbc.10.10.3279; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Gelb MH, 1997, SCIENCE, V275, P1750, DOI 10.1126/science.275.5307.1750; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; Hochegger H, 2001, DEVELOPMENT, V128, P3795; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; JESSUS C, 1987, J CELL SCI, V87, P705; Jessus C, 1998, BIOL CELL, V90, P573, DOI 10.1016/S0248-4900(99)80015-X; JESSUS C, 1991, DEVELOPMENT, V111, P813; Karaiskou A, 2001, BIOL CELL, V93, P35, DOI 10.1016/S0248-4900(01)01126-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez-Hernandez E, 1999, FEBS LETT, V451, P284, DOI 10.1016/S0014-5793(99)00595-5; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; MULNERLORILLON O, 1995, DEV BIOL, V170, P223, DOI 10.1006/dbio.1995.1209; NEBREDA AR, 1993, ONCOGENE, V8, P467; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; Pomerance M, 1996, MOL CELL BIOL, V16, P3179; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Rime H, 1998, DEV BIOL, V204, P592, DOI 10.1006/dbio.1998.9069; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Taieb F, 1997, MOL REPROD DEV, V48, P397, DOI 10.1002/(SICI)1098-2795(199711)48:3&lt;397::AID-MRD14&gt;3.0.CO;2-T; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1	39	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6425	6433		10.1038/sj.onc.1205827	http://dx.doi.org/10.1038/sj.onc.1205827			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226746				2022-12-25	WOS:000177925300003
J	Li, SL; Finley, J; Liu, ZJ; Qiu, SH; Chen, HL; Luan, CH; Carson, M; Tsao, J; Johnson, D; Lin, GD; Zhao, J; Thomas, W; Nagy, LA; Sha, BD; DeLucas, LJ; Wang, BC; Luo, M				Li, SL; Finley, J; Liu, ZJ; Qiu, SH; Chen, HL; Luan, CH; Carson, M; Tsao, J; Johnson, D; Lin, GD; Zhao, J; Thomas, W; Nagy, LA; Sha, BD; DeLucas, LJ; Wang, BC; Luo, M			Crystal structure of the cytoskeleton-associated protein glycine-rich (CAP-Gly) domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFRACTION DATA; MICROTUBULE; CLIP-170; RESOLUTION; CLONING; SYSTEM; MAPS	Cytoskeleton-associated proteins (CAPs) are involved in the organization of microtubules and transportation of vesicles and organelles along the cytoskeletal network. A conserved motif, CAP-Gly, has been identified in a number of CAPs, including CLIP-170 and dynactins. The crystal structure of the CAP-Gly domain of Caenorhabditis elegans F53F4.3 protein, solved by single wavelength sulfur-anomalous phasing, revealed a novel protein fold containing three beta-sheets. The most conserved sequence, GKNDG, is located in two consecutive sharp turns on the surface, forming the entrance to a groove. Residues in the groove are highly conserved as measured from the information content of the aligned sequences. The C-terminal tail of another molecule in the crystal is bound in this groove.	Univ Alabama Birmingham, SE Collab Struct Genom, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA; Univ Alabama Birmingham, SE Collab Struct Genom, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, SE Collab Struct Genom, Dept Microbiol, Birmingham, AL 35294 USA; Univ Georgia, SE Collab Struct Genom, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Luo, M (corresponding author), Univ Alabama Birmingham, SE Collab Struct Genom, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA.	mingluo@uab.edu	ID, IMCACAT/D-5867-2014; Liu, Zhi-Jie/A-3946-2012	Liu, Zhi-Jie/0000-0001-7279-2893	NIGMS NIH HHS [1P50-GM62407] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062407] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; BILBE G, 1992, EMBO J, V11, P2103, DOI 10.1002/j.1460-2075.1992.tb05269.x; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Collin GB, 1998, GENOMICS, V53, P359, DOI 10.1006/geno.1998.5542; Fuchs E, 1999, CELL, V98, P547, DOI 10.1016/S0092-8674(00)80041-0; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Houseweart MK, 1999, CURR BIOL, V9, pR864, DOI 10.1016/S0960-9822(00)80048-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lamzin VS, 2000, NAT STRUCT BIOL, V7, P978, DOI 10.1038/80763; Lantz VA, 1998, J CELL BIOL, V140, P897, DOI 10.1083/jcb.140.4.897; Li HP, 1997, P NATL ACAD SCI USA, V94, P1086, DOI 10.1073/pnas.94.4.1086; Liu ZJ, 2000, PROTEIN SCI, V9, P2085, DOI 10.1110/ps.9.11.2085; Norvell JC, 2000, NAT STRUCT BIOL, V7, P931, DOI 10.1038/80694; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RIEHEMANN K, 1993, TRENDS BIOCHEM SCI, V18, P82, DOI 10.1016/0968-0004(93)90159-K; Scheel J, 1999, J BIOL CHEM, V274, P25883, DOI 10.1074/jbc.274.36.25883; Schuyler SC, 2001, CELL, V105, P421, DOI 10.1016/S0092-8674(01)00364-6; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Terwilliger TC, 1997, METHOD ENZYMOL, V276, P530; Vaughan KT, 1999, J CELL SCI, V112, P1437; Walhout AJM, 2000, METHOD ENZYMOL, V328, P575, DOI 10.1016/S0076-6879(00)28419-X; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Watanabe TK, 1996, CYTOGENET CELL GENET, V72, P208, DOI 10.1159/000134191	34	79	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48596	48601		10.1074/jbc.M208512200	http://dx.doi.org/10.1074/jbc.M208512200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12221106	hybrid			2022-12-25	WOS:000179789600082
J	Avvakumov, GV; Grishkovskaya, I; Muller, YA; Hammond, GL				Avvakumov, GV; Grishkovskaya, I; Muller, YA; Hammond, GL			Crystal structure of human sex hormone-binding globulin in complex with 2-methoxyestradiol reveals the molecular basis for high affinity interactions with C-2 derivatives of estradiol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEM; CRYSTALLOGRAPHY; TRANSPORT; PROGRAM; CANCER; PLASMA; DOMAIN; SITE	In a crystal structure of the amino-terminal laminin G-like domain of human sex hormone-binding globulin (SHBG), the biologically active estrogen metabolite, 2-methoxyestradiol (2-MeOE2), binds in the same orientation as estradiol. The high affinity of SHBG for 2-MeOE2 relies primarily on hydrogen bonding between the hydroxyl at C-3 of 2-MeOE2 and Asp(65) and an interaction between the methoxy group at C-2 and the amido group of Asn(82). Accommodation of the 2-MeOE2 methoxy group causes an outward displacement of residues Ser(128)-Pro(130), which appears to disorder and displace the loop region (Leu(131)-His(136)) that covers the steroid-binding site. This could influence the binding kinetics of 2-MeOE2 and/or facilitate ligand-dependent interactions between SHBG and other proteins. Occupancy of a zinc-binding site reduces the affinity of SHBG for 2-MeOE2 and estradiol in the same way. The higher affinity of SHBG for estradiol derivatives with a halogen atom at C-2 is due to either enhanced hydrogen bonding between the hydroxyl at C-3 and Asp(65) (2-fluoroestradiol) or accommodation of the functional group at C-2 (2-bromoestradiol), rather than an interaction with Asn(82). By contrast, the low affinity of SHBG for 2-hydroxyestradiol can be attributed to intra-molecular hydrogen bonding between the hydroxyls in the aromatic steroid ring A, which generates a steric clash with the amido group of Asn(82). Understanding how C-2 derivatives of estradiol interact with SHBG could facilitate the design of biologically active synthetic estrogens.	Univ Western Ontario, Dept Obstet & Gynecol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 4L6, Canada; Univ Western Ontario, Canadian Inst Hlth, Res Grp Fetal & Neonatal Hlth & Dev, London, ON N6A 4L6, Canada; Max Delbruck Ctr Mol Med, Forsch Grp Kristallog, D-13092 Berlin, Germany; Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Sussex	Hammond, GL (corresponding author), London Reg Canc Ctr, Canc Res Labs, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.		Muller, Yves A/R-5397-2016	Muller, Yves A/0000-0003-0519-8928; Hammond, Geoffrey/0000-0002-4639-7336				Avvakumov GV, 2000, J BIOL CHEM, V275, P25920, DOI 10.1074/jbc.M004484200; AVVAKUMOV GV, 1986, BIOCHIM BIOPHYS ACTA, V881, P489, DOI 10.1016/0304-4165(86)90043-7; Avvakumov GV, 2001, J BIOL CHEM, V276, P34453, DOI 10.1074/jbc.M106274200; BOCCHINFUSO WP, 1991, MOL ENDOCRINOL, V5, P1723, DOI 10.1210/mend-5-11-1723; Brueggemeier RW, 2001, J STEROID BIOCHEM, V78, P145, DOI 10.1016/S0960-0760(01)00090-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P3964, DOI 10.1073/pnas.91.9.3964; Dawling S, 2001, CANCER RES, V61, P6716; DUNN JF, 1981, J CLIN ENDOCR METAB, V53, P58, DOI 10.1210/jcem-53-1-58; FERNLUND P, 1990, J STEROID BIOCHEM, V36, P75, DOI 10.1016/0022-4731(90)90115-9; Fletcher DA, 1996, J CHEM INF COMP SCI, V36, P746, DOI 10.1021/ci960015+; Grishkovskaya I, 2000, EMBO J, V19, P504, DOI 10.1093/emboj/19.4.504; Grishkovskaya I, 2002, J BIOL CHEM, V277, P32086, DOI 10.1074/jbc.M203999200; Grishkovskaya I, 2002, J MOL BIOL, V318, P621, DOI 10.1016/S0022-2836(02)00169-9; Grishkovskaya I, 1999, ACTA CRYSTALLOGR D, V55, P2053, DOI 10.1107/S0907444999012883; HAMMOND GL, 1983, CLIN CHIM ACTA, V132, P101, DOI 10.1016/0009-8981(83)90237-1; Hammond GL, 1995, TRENDS ENDOCRIN MET, V6, P298, DOI 10.1016/1043-2760(95)00162-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAULING L, 1960, NATURE CHEM BOND, P494; PORTO CS, 1991, ENDOCRINOLOGY, V129, P436, DOI 10.1210/endo-129-1-436; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; ROSNER W, 1991, J STEROID BIOCHEM, V40, P813, DOI 10.1016/0960-0760(91)90307-Q; Rudenko G, 2001, TRENDS BIOCHEM SCI, V26, P363, DOI 10.1016/S0968-0004(01)01832-1; Seimbille Y, 2002, STEROIDS, V67, P765, DOI 10.1016/S0039-128X(02)00025-9; VERBIST JJ, 1972, ACTA CRYSTALL B-STRU, VB 28, P3006, DOI 10.1107/S0567740872007368; WESTPHAL U, 1986, STEROID PROTEIN INTE, V2, P198; WUNDERLICH H, 1971, ACTA CRYSTALL B-STRU, VB 27, P1684, DOI 10.1107/S0567740871004618	32	28	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45219	45225		10.1074/jbc.M207762200	http://dx.doi.org/10.1074/jbc.M207762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228253	hybrid			2022-12-25	WOS:000179404800081
J	Sakurada, K; Kato, H; Nagumo, H; Hiraoka, H; Furuya, K; Ikuhara, T; Yamakita, Y; Fukunaga, K; Miyamoto, E; Matsumura, F; Matsuo, YI; Naito, Y; Sasaki, Y				Sakurada, K; Kato, H; Nagumo, H; Hiraoka, H; Furuya, K; Ikuhara, T; Yamakita, Y; Fukunaga, K; Miyamoto, E; Matsumura, F; Matsuo, YI; Naito, Y; Sasaki, Y			Synapsin I is phosphorylated at Ser(603) by p21-activated kinases (PAKs) in vitro and in PC12 cells stimulated with bradykinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LONG-TERM POTENTIATION; GTP-BINDING-PROTEIN; NEUROTRANSMITTER RELEASE; SYNAPTIC VESICLES; FOCAL COMPLEXES; F-ACTIN; RHO; CALCIUM; GTPASES	The function of synapsin I is regulated by phosphorylation of the molecule at multiple sites; among them, the Ser(603) residue (site 3) is considered to be a pivotal site targeted by Ca2+/calmodulin-dependent kinase II (CaMKII). Although phosphorylation of the Ser(603) residue responds to several kinds of stimuli, it is unlikely that many or all of the stimuli activate the CaMKII-involved pathway. Among the several stimulants tested in PC12 cells, bradykinin evoked the phosphorylation of Ser(603) without inducing the autophosphorylation of CaMKII, which was determined using phosphorylation site-specific antibodies against phospho-Ser(603)-synapsin I (pS(603)-Syn I-Ab) and phospho-Thr(286/287)-CaMKII. The bradykinin-evoked phosphorylation of Ser(603) was not suppressed by the CaAMI inhibitor KN62, whereas high KCl-evoked phosphorylation was accompanied by CaMKII autophosphorylation and inhibited by KN62. Thus, we attempted to identify Ser(603) kinase(s) besides CaMKII. We consequently detected four and three fractions with Ca2+/calmodulin-independent Ser(603) kinase activity on the DEAE column chromatography of bovine brain homogenate and PC12 cell lysate, respectively, two of which were purified and identified by amino acid sequence of proteolytic fragments as p21-activated kinase (PAK) 1 and PAK3. The immunoprecipitants from bovine brain homogenate with anti-PAK1 and PAK3 antibodies incorporated P-32 into synapsin I in a Cdc42/GTPgammaS-dependent manner, and its phosphorylation site was confirmed as Ser(603) using pS(603)-Syn I-Ab. Additionally, recombinant GST-PAK2 could phosphorylate the Ser(603) residue in the presence of Cdc42/GTPgammaS. Finally, we confirmed by immunocytochemical analysis that the transfection of constitutively active rat alphaPAK (PAK1) in PC12 cells evokes the phosphorylation of Ser(603) even in the resting mutant cells and enhances it in the bradykinin-stimulated cells, whereas that of dominant-negative aPAK quenches the phosphorylation. These results raise the possibility that Ser(603) on synapsin I is alternatively phosphorylated by PAKs, not only by CaMKII, in neuronal cells in response to some stimulants.	Asahi Chem Ind Co Ltd, Frontier 21 Project, Life Sci Res Inst, Fuji, Shizuoka 4168501, Japan; Kitasato Univ, Sch Pharmaceut Sci, Dept Pharmacol, Minato Ku, Tokyo 1088641, Japan; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; Kumamoto Univ, Sch Med, Dept Pharmacol, Kumamoto 8608501, Japan	Kitasato University; Rutgers State University New Brunswick; Kumamoto University	Sasaki, Y (corresponding author), Asahi Chem Ind Co Ltd, Frontier 21 Project, Life Sci Res Inst, 2-1 Samejima, Fuji, Shizuoka 4168501, Japan.		Yamakita, Yoshihiko/A-3003-2016; Fukunaga, Kohji/AAI-8811-2021	Ikeda-Matsuo, Yuri/0000-0001-9269-9119; Matsumura, Fumio/0000-0002-8204-153X; Fukunaga, Kohji/0000-0001-8526-2824				APPELL KC, 1989, BIOCHEM J, V263, P11, DOI 10.1042/bj2630011; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BENFENATI F, 1992, NEURON, V8, P377, DOI 10.1016/0896-6273(92)90303-U; BROWNING MD, 1992, SYNAPSE, V10, P62, DOI 10.1002/syn.890100109; CECCALDI PE, 1995, J CELL BIOL, V128, P905, DOI 10.1083/jcb.128.5.905; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Foster DB, 2000, J BIOL CHEM, V275, P1959, DOI 10.1074/jbc.275.3.1959; FUKUNAGA K, 1982, J NEUROCHEM, V39, P1607, DOI 10.1111/j.1471-4159.1982.tb07994.x; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; Gasman S, 1997, J BIOL CHEM, V272, P20564, DOI 10.1074/jbc.272.33.20564; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; Iwata SI, 1996, J PHARMACOL EXP THER, V278, P1428; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; King AJ, 2001, FEBS LETT, V497, P6, DOI 10.1016/S0014-5793(01)02425-5; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Liu J, 1999, J NEUROSCI, V19, P8292; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; Meriane M, 2000, J BIOL CHEM, V275, P33046, DOI 10.1074/jbc.M001566200; Nagumo H, 2000, AM J PHYSIOL-CELL PH, V278, pC57, DOI 10.1152/ajpcell.2000.278.1.C57; Nakamura K, 1998, J NEUROCHEM, V71, P646; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ohtakara K, 2000, BIOCHEM BIOPH RES CO, V272, P712, DOI 10.1006/bbrc.2000.2854; PARFITT KD, 1991, P NATL ACAD SCI USA, V88, P2361, DOI 10.1073/pnas.88.6.2361; Sakurada K, 1998, AM J PHYSIOL-CELL PH, V274, pC1563, DOI 10.1152/ajpcell.1998.274.6.C1563; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SHIONO S, 1993, BIOCHEM BIOPH RES CO, V193, P667, DOI 10.1006/bbrc.1993.1676; Tabuchi H, 2000, ENDOCRINOLOGY, V141, P2350, DOI 10.1210/en.141.7.2350; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; WilkBlaszczak MA, 1997, J NEUROSCI, V17, P4094; YAMAGATA Y, 1995, NEUROSCIENCE, V64, P1, DOI 10.1016/0306-4522(94)00492-N; Yokota S, 2001, J NEUROCHEM, V77, P618, DOI 10.1046/j.1471-4159.2001.00270.x; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	46	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45473	45479		10.1074/jbc.M206673200	http://dx.doi.org/10.1074/jbc.M206673200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12237306	hybrid			2022-12-25	WOS:000179404800112
J	Rajala, RVS; McClellan, ME; Ash, JD; Anderson, RE				Rajala, RVS; McClellan, ME; Ash, JD; Anderson, RE			In Vivo regulation of phosphoinositide 3-kinase in retina through ligbt-induced tyrosine phosphorylation of the insulin receptor beta-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; SH2 DOMAINS; INDUCED APOPTOSIS; LIGHT; KINASE; ACTIVATION; BINDING; PROTEINS	Recently, we have shown that phosphoinositide 3-kinase (PI3K) in bovine rod outer segment (ROS) is activated in vitro by tyrosine phosphorylation of the C-terminal tail of the insulin receptor (Rajala, R. V. S., and Anderson, R. E. (2001) Invest. Ophthal. Vis. Sci. 42,31103117). In this study, we have investigated the in vivo mechanism of PI3K activation in the rodent retina and report the novel finding that light stimulates tyrosine phosphorylation of the beta-subunit of the insulin receptor (IRbeta) in ROS membranes, which leads to the association of PI3K enzyme activity with IRbeta. Retinas from light- or dark-adapted mice and rats were homogenized and immunoprecipitated with antibodies against phosphotyrosine, IRbeta, or the p85 regulatory subunit of PI3K, and PI3K activity was measured using PI-4,5-P-2 as substrate. We observed a light-dependent increase in tyrosine phosphorylation of IRbeta and an increase in PI3K enzyme activity in isolated ROS and in anti-phosphotyrosine and anti-IRbeta immunoprecipitates of retinal homogenates. The light effect was localized to photoreceptor neurons and is independent of insulin secretion. Our results suggest that light induces tyrosine phosphorylation of IRbeta in outer segment membranes, which leads to the binding of p85 through its N-terminal Src homology 2 domain and the generation of PI-3,4,5-P-3. We suggest that the physiological role of this process may be to provide neuroprotection of the retina against light damage by activating proteins that protect against stress-induced apoptosis.	Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Dean A McGee Eye Inst, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Rajala, RVS (corresponding author), 608 Stanton L Young Blvd,Rm 409, Oklahoma City, OK 73104 USA.	raju-rajala@ouhsc.edu		Ash, John/0000-0002-8330-7301	NEI NIH HHS [EY12190, EY04149, EY00871] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004149, P30EY012190, R01EY000871] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; BASINGER S, 1976, SCIENCE, V194, P1074, DOI 10.1126/science.1086510; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; D'Mello SR, 1997, J NEUROSCI, V17, P1548; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Donovan M, 2001, J BIOL CHEM, V276, P23000, DOI 10.1074/jbc.M005359200; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; Ghalayini AJ, 1998, EXP EYE RES, V66, P817, DOI 10.1006/exer.1998.0498; GHALAYINI AJ, 1995, CURR EYE RES, V14, P1025, DOI 10.3109/02713689508998525; Ghalayini AJ, 2002, J BIOL CHEM, V277, P1469, DOI 10.1074/jbc.M011432200; Guo XX, 1997, INVEST OPHTH VIS SCI, V38, P1873; Guo XX, 2000, MOL VIS, V6, P216; Hafezi F, 1997, EXP EYE RES, V64, P963, DOI 10.1006/exer.1997.0288; Hao WS, 1999, J BIOL CHEM, V274, P6085, DOI 10.1074/jbc.274.10.6085; HOLLYFIELD JG, 1979, INVEST OPHTH VIS SCI, V18, P117; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Huang Z, 2000, J NEUROCHEM, V75, P355, DOI 10.1046/j.1471-4159.2000.0750355.x; IUVONE PM, 1984, FED PROC, V43, P2709; JAMES CRH, 1983, BRIT J OPHTHALMOL, V67, P80, DOI 10.1136/bjo.67.2.80; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kramer RH, 2001, J EXP BIOL, V204, P2921; LEM J, 1992, P NATL ACAD SCI USA, V89, P4422, DOI 10.1073/pnas.89.10.4422; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; McGinnis JF, 2002, J NEUROSCI RES, V67, P290, DOI 10.1002/jnr.10120; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; MURESAN V, 1993, J CELL SCI, V104, P1229; Nagy F, 2001, J CELL SCI, V114, P475; Nakahata Y, 2000, J NEUROCHEM, V74, P2436, DOI 10.1046/j.1471-4159.2000.0742436.x; NOELL WK, 1971, SCIENCE, V172, P76, DOI 10.1126/science.172.3978.76; NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; ORGANISCIAK DT, 1991, EXP EYE RES, V53, P773, DOI 10.1016/0014-4835(91)90113-S; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Pawson T, 2000, GENE DEV, V14, P1027; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; Rajala RVS, 2001, INVEST OPHTH VIS SCI, V42, P3110; ROOF D, 2000, PRINCIPLES PRACTICE; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAARI JC, 1977, INVEST OPHTH VIS SCI, V16, P797; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SIDMAN RL, 1965, J HERED, V56, P23, DOI 10.1093/oxfordjournals.jhered.a107364; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Spear N, 1997, J NEUROCHEM, V69, P53; Tabatabaie T, 2000, BIOCHEM BIOPH RES CO, V273, P699, DOI 10.1006/bbrc.2000.2959; WALDBILLIG RJ, 1987, EXP EYE RES, V45, P823, DOI 10.1016/S0014-4835(87)80099-4; WALDBILLIG RJ, 1987, EXP EYE RES, V45, P837, DOI 10.1016/S0014-4835(87)80100-8; Wetzel RK, 1999, J NEUROSCI, V19, P9878; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; YU KT, 1985, J BIOL CHEM, V260, P5838	61	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43319	43326		10.1074/jbc.M206355200	http://dx.doi.org/10.1074/jbc.M206355200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12213821	hybrid			2022-12-25	WOS:000179081200115
J	Taylor, NL; Day, DA; Millar, AH				Taylor, NL; Day, DA; Millar, AH			Environmental stress causes oxidative damage to plant mitochondria leading to inhibition of glycine decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE COMPLEX; LIPID-PEROXIDATION; ALTERNATIVE OXIDASE; LIPOIC ACID; CARDIAC REPERFUSION; MAIZE SEEDLINGS; FATTY-ACID; RESPIRATION; ACETYLTRANSFERASE; INACTIVATION	A cytotoxic product of lipid peroxidation, 4-hydroxy-2-nonenal (HNE), rapidly inhibited glycine, malate/pyruvate, and 2-oxoglutarate-dependent O-2 consumption by pea leaf mitochondria. Dose- and time-dependence of inhibition showed that glycine oxidation was the most severely affected with a K-0.5 of 30 mum. Several mitochondrial proteins containing lipoic acid moieties differentially lost their reactivity to a lipoic acid antibody following HNE treatment. The most dramatic loss of antigenicity was seen with the 17-kDa glycine decarboxylase complex (GDC) H-protein, which was correlated with the loss of glycine-dependent O-2 consumption. Paraquat treatment of pea seedlings induced lipid peroxidation, which resulted in the rapid loss of glycine-dependent respiration and loss of H-protein reactivity with lipoic acid antibodies. Pea plants exposed to chilling and water deficit responded similarly. In contrast, the damage to other lipoic acid-containing mitochondrial enzymes was minor under these conditions. The implication of the acute sensitivity of glycine decarboxylase complex H-protein to lipid peroxidation products is discussed in the context of photorespiration and potential repair mechanisms in plant mitochondria.	Univ Western Australia, Fac Life & Phys Sci, Plant Mol Biol Grp, Sch Biomed & Chem Sci, Crawley, WA, Australia	University of Western Australia	Millar, AH (corresponding author), Univ Western Australia, Fac Life & Phys Sci, Plant Mol Biol Grp, Sch Biomed & Chem Sci, Crawley, WA, Australia.	hmillar@cyllene.uwa.edu.au	Millar, A. Harvey/A-5452-2008; Taylor, Nicolas L/A-5731-2008; Day, David/F-6325-2011	Millar, A. Harvey/0000-0001-9679-1473; Taylor, Nicolas L/0000-0003-2004-5217; Day, David/0000-0001-7967-2173				ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; BUDDE RJA, 1990, P NATL ACAD SCI USA, V87, P673, DOI 10.1073/pnas.87.2.673; DAY DA, 1985, AUST J PLANT PHYSIOL, V12, P219, DOI 10.1071/PP9850219; De Santis A, 1999, PLANT PHYSIOL, V119, P743, DOI 10.1104/pp.119.2.743; DODGE AD, 1971, ENDEAVOUR, V30, P130, DOI 10.1016/0160-9327(71)90039-1; Douce R, 2001, TRENDS PLANT SCI, V6, P167, DOI 10.1016/S1360-1385(01)01892-1; ELTHON TE, 1989, PLANT PHYSIOL, V89, P1311, DOI 10.1104/pp.89.4.1311; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Gomez JM, 1999, FREE RADICAL RES, V31, pS11, DOI 10.1080/10715769900301261; Gronwald JW, 1998, PLANT PHYSIOL, V117, P877, DOI 10.1104/pp.117.3.877; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; Halliwell B., 1999, FREE RADICAL BIO MED, Vthird, P246; Halliwell B., 1999, FREE RADICAL BIO MED, V3, P36; HERNANDEZ JA, 1993, PHYSIOL PLANTARUM, V89, P103, DOI 10.1111/j.1399-3054.1993.tb01792.x; Hodges DM, 1999, PLANTA, V207, P604, DOI 10.1007/s004250050524; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P552, DOI 10.1021/bi971958i; Iturbe-Ormaetxe I, 1998, PLANT PHYSIOL, V116, P173, DOI 10.1104/pp.116.1.173; Jordan SW, 1997, J BIOL CHEM, V272, P17903, DOI 10.1074/jbc.272.29.17903; KRAUS TE, 1995, J PLANT PHYSIOL, V145, P570, DOI 10.1016/S0176-1617(11)81790-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu F, 2001, PLANT CELL, V13, P1063, DOI 10.1105/tpc.13.5.1063; Lucas DT, 1998, P NATL ACAD SCI USA, V95, P510, DOI 10.1073/pnas.95.2.510; Lucas DT, 1999, P NATL ACAD SCI USA, V96, P6689, DOI 10.1073/pnas.96.12.6689; Mano J, 2001, BBA-BIOENERGETICS, V1504, P275, DOI 10.1016/S0005-2728(00)00256-5; Maxwell DP, 1999, P NATL ACAD SCI USA, V96, P8271, DOI 10.1073/pnas.96.14.8271; Millar AH, 1999, EUR J BIOCHEM, V264, P973, DOI 10.1046/j.1432-1327.1999.00707.x; Millar AH, 2001, PLANT PHYSIOL, V127, P1711, DOI 10.1104/pp.010387; Millar AH, 2000, FEBS LETT, V481, P117, DOI 10.1016/S0014-5793(00)01976-1; Moller IM, 2001, TRENDS PLANT SCI, V6, P560, DOI 10.1016/S1360-1385(01)02100-8; Oberschall A, 2000, PLANT J, V24, P437, DOI 10.1046/j.1365-313x.2000.00885.x; PALMEIRA CM, 1995, BBA-BIOENERGETICS, V1229, P187, DOI 10.1016/0005-2728(94)00202-G; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRASAD TK, 1994, PLANT CELL, V6, P65, DOI 10.1105/tpc.6.1.65; Purvis AC, 1997, PHYSIOL PLANTARUM, V100, P165, DOI 10.1034/j.1399-3054.1997.1000119.x; Takamura H, 1996, BBA-LIPID LIPID MET, V1303, P83, DOI 10.1016/0005-2760(96)00076-8; Thelen JJ, 1999, J BIOL CHEM, V274, P21769, DOI 10.1074/jbc.274.31.21769; Van Camp W, 1998, TRENDS PLANT SCI, V3, P330, DOI 10.1016/S1360-1385(98)01297-7; Vauclare P, 1996, PLANT PHYSIOL, V112, P1523, DOI 10.1104/pp.112.4.1523; VIANELLO A, 1986, J PLANT PHYSIOL, V125, P217, DOI 10.1016/S0176-1617(86)80144-4; VIANELLO A, 1987, PLANT CELL PHYSIOL, V28, P1263; WAGNER AM, 1995, PHYSIOL PLANTARUM, V95, P318, DOI 10.1111/j.1399-3054.1995.tb00844.x; Wingler A, 2000, PHILOS T R SOC B, V355, P1517, DOI 10.1098/rstb.2000.0712; ZHANG QS, 1995, ARCH BIOCHEM BIOPHYS, V320, P250, DOI 10.1016/0003-9861(95)90007-1	45	144	151	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42663	42668		10.1074/jbc.M204761200	http://dx.doi.org/10.1074/jbc.M204761200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12213810	hybrid			2022-12-25	WOS:000179081200031
J	Wang, XJ; Xu, SQ; Rivolta, C; Li, LY; Peng, GH; Swain, PK; Sung, CH; Swaroop, A; Berson, EL; Dryja, TP; Chen, SM				Wang, XJ; Xu, SQ; Rivolta, C; Li, LY; Peng, GH; Swain, PK; Sung, CH; Swaroop, A; Berson, EL; Dryja, TP; Chen, SM			Barrier to autointegration factor interacts with the cone-rod homeobox and represses its Transactivation function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARDET-BIEDL-SYNDROME; DOMINANT RETINITIS-PIGMENTOSA; LEBER CONGENITAL AMAUROSIS; CRX TRANSCRIPTION FACTOR; GENE-EXPRESSION; RETROVIRAL DNA; LEUCINE-ZIPPER; HOMEODOMAIN PROTEIN; CRYSTAL-STRUCTURE; CELLULAR FACTOR	Crx (cone-rod homeobox) is a homeodomain transcription factor implicated in regulating the expression of photoreceptor and pineal genes. To identify proteins that interact with Crx in the retina, we carried out a yeast two-hybrid screen of a retinal cDNA library. One of the identified clones encodes Baf (barrier to autointegration factor), which was previously shown to have a role in mitosis and retroviral integration. Additional biochemical assays provided supporting evidence for a Baf-Crx interaction. The Baf protein is detectable in all nuclear layers of the mouse retina, including the photo-receptors and the bipolar cells where Crx is expressed. Transient transfection assays with a rhodopsin-luciferase reporter in HEK293 cells demonstrate that overexpression of Baf represses Crx-mediated transactivation, suggesting that Baf acts as a negative regulator of Crx. Consistent with this role for Baf, an E80A mutation of CRX associated with cone-rod dystrophy has a higher than normal transactivation potency but a reduced interaction with Baf. Although our studies did not identify a causative Baf mutation in retinopathies, we suggest that Baf may contribute to the phenotype of a photoreceptor degenerative disease by modifying the activity of Crx. In view of the ubiquitous expression of Baf, we hypothesize that it may play a role in regulating tissue- or cell type-specific gene expression by interacting with homeodomain transcription factors.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Mol Genet Inst, Boston, MA 02114 USA; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA; Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48105 USA; Cornell Univ, Weill Med Coll, Margaret M Dyson Vis Res Inst, Dept Cell Biol & Anat, New York, NY 10021 USA	Washington University (WUSTL); Washington University (WUSTL); Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Cornell University	Chen, SM (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.	chen@vision.wustl.edu	Huang, Yifei/ABE-7566-2020	Swaroop, Anand/0000-0002-1975-1141; Rivolta, Carlo/0000-0002-0733-9950	NEI NIH HHS [EY12543, EY00169, R01 EY012543, EY02687, EY08683, R01 EY011307, EY11115] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011115, R37EY000169, R01EY011307, P30EY002687, R01EY012543, R01EY008683, R01EY000169] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baas D, 2000, MOL BRAIN RES, V78, P26, DOI 10.1016/S0169-328X(00)00060-7; Beales PL, 1997, J MED GENET, V34, P92, DOI 10.1136/jmg.34.2.92; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; Bibb LC, 2001, HUM MOL GENET, V10, P1571, DOI 10.1093/hmg/10.15.1571; Blackshaw S, 2001, CELL, V107, P579, DOI 10.1016/S0092-8674(01)00574-8; Bobola N, 1999, MECH DEVELOP, V82, P165, DOI 10.1016/S0925-4773(98)00162-2; Bruford EA, 1997, GENOMICS, V41, P93, DOI 10.1006/geno.1997.4613; Cai M, 1998, NAT STRUCT BIOL, V5, P903, DOI 10.1038/2345; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; Chau KY, 2000, J BIOL CHEM, V275, P37264, DOI 10.1074/jbc.M002763200; Chau KY, 2000, J NEUROSCI, V20, P7317; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; Chen SM, 2002, HUM MOL GENET, V11, P873, DOI 10.1093/hmg/11.8.873; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Cohen M, 2001, TRENDS BIOCHEM SCI, V26, P41, DOI 10.1016/S0968-0004(00)01727-8; Fei YJ, 2000, INVEST OPHTH VIS SCI, V41, P2849; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fong SL, 1999, CURR EYE RES, V18, P283, DOI 10.1076/ceyr.18.4.283.5360; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa K, 1999, J CELL SCI, V112, P2485; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Hagstrom SA, 1998, NAT GENET, V18, P174, DOI 10.1038/ng0298-174; HANSON IM, 1993, HUM MOL GENET, V2, P915; Haraguchi T, 2001, J CELL SCI, V114, P4575; Hegele RA, 2001, TRENDS MOL MED, V7, P121, DOI 10.1016/S1471-4914(01)01930-X; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; Jacobson SG, 1998, INVEST OPHTH VIS SCI, V39, P2417; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; Katsanis N, 1999, AM J HUM GENET, V65, P1672, DOI 10.1086/302684; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; La Spada AR, 2001, NEURON, V31, P913, DOI 10.1016/S0896-6273(01)00422-6; Lee KK, 2001, J CELL SCI, V114, P4567; LEE MS, 1994, P NATL ACAD SCI USA, V91, P9823, DOI 10.1073/pnas.91.21.9823; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; Li XD, 1998, P NATL ACAD SCI USA, V95, P1876, DOI 10.1073/pnas.95.4.1876; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; Morris GE, 2001, TRENDS MOL MED, V7, P572, DOI 10.1016/S1471-4914(01)02128-1; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; Percin EF, 2000, NAT GENET, V25, P397, DOI 10.1038/78071; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Rivolta C, 2001, HUM MUTAT, V18, P488, DOI 10.1002/humu.1226; Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X; Segura-Totten M, 2002, J CELL BIOL, V158, P475, DOI 10.1083/jcb.200202019; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; Sohocki MM, 1998, AM J HUM GENET, V63, P1307, DOI 10.1086/302101; Swain PK, 2001, J BIOL CHEM, V276, P36824, DOI 10.1074/jbc.M105855200; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Swaroop A, 1999, HUM MOL GENET, V8, P299, DOI 10.1093/hmg/8.2.299; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; Umland TC, 2000, BIOCHEMISTRY-US, V39, P9130, DOI 10.1021/bi000572w; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Yanagi Y, 2000, BIOCHEM BIOPH RES CO, V269, P410, DOI 10.1006/bbrc.2000.2304; Young TL, 1999, AM J HUM GENET, V65, P1680, DOI 10.1086/302686; Zheng RL, 2000, P NATL ACAD SCI USA, V97, P8997, DOI 10.1073/pnas.150240197; Zhu XM, 2000, MOL CELL BIOL, V20, P5216, DOI 10.1128/MCB.20.14.5216-5226.2000	71	105	106	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43288	43300		10.1074/jbc.M207952200	http://dx.doi.org/10.1074/jbc.M207952200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12215455	hybrid, Green Accepted			2022-12-25	WOS:000179081200112
J	Zalensky, AO; Siino, JS; Gineitis, AA; Zalenskaya, IA; Tomilin, NV; Yau, P; Bradbury, EM				Zalensky, AO; Siino, JS; Gineitis, AA; Zalenskaya, IA; Tomilin, NV; Yau, P; Bradbury, EM			Human testis/sperm-specific histone H2B (hTSH2B) - Molecular cloning and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR BASIC-PROTEINS; HUMAN-SPERM CHROMATIN; N-TERMINUS; CENP-A; GENE; EXPRESSION; TH2B; SPERMATOGENESIS; RAT; SPERMIOGENESIS	Human sperm, unlike the sperm of other mammals, contain replacement histones with unknown biological functions. Here, we report the identification of the novel human gene coding for a testis/sperm-specific histone H2B (hTSH2B). This variant histone is 85% homologous to somatic H2B and has over 93% homology with the testis H2B of rodents. Using genomic PCR, two genetic alleles of hTSH2B were found in the human population. The hTSH2B gene is transcribed exclusively in testis, and the corresponding protein is also present in mature sperm. We expressed recombinant hTSH2B and identified this protein with a particular H2B subtype expressed in vivo. The subnuclear distribution of H2B variants in sperm was determined using biochemical fractionation and immunoblotting. The H2B variant associated with telomere-binding activity (15) was solubilized by Triton X-100 or micrococcal nuclease extraction, whereas hTSH2B was relatively tightly bound in nuclei. Immunofluorescence showed that hTSH2B was concentrated in spots located at the basal nuclear area of a subpopulation (20% of cells) of mature sperm. This fact may be of particular importance, because the hTSH2B "positive" and "negative" sperm cells may undergo significantly different decondensation processes following fertilization.	Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA; Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia; Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA	University of California System; University of California Davis; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; United States Department of Energy (DOE); Los Alamos National Laboratory	Zalensky, AO (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA.	aozalensky@ucdavis.edu		Yau, Peter/0000-0002-1984-185X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039830] Funding Source: NIH RePORTER; NICHD NIH HHS [HD39830] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Albig W, 1999, BIOL CHEM, V380, P7, DOI 10.1515/BC.1999.002; Aul RB, 2002, DEV BIOL, V242, P268, DOI 10.1006/dbio.2002.0575; AUSUBEL F, 1989, CURRENT PROTOCOLES M; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Choi YC, 1996, DNA CELL BIOL, V15, P495, DOI 10.1089/dna.1996.15.495; CHOI YC, 1991, J BIOL CHEM, V266, P20504; de la Barre AE, 2001, EMBO J, V20, P6383, DOI 10.1093/emboj/20.22.6383; Doenecke D, 1997, HISTOCHEM CELL BIOL, V107, P1, DOI 10.1007/s004180050083; Drabent B, 2000, HISTOCHEM CELL BIOL, V113, P433; Fantz DA, 2001, BIOL REPROD, V64, P425, DOI 10.1095/biolreprod64.2.425; GATEWOOD JM, 1987, SCIENCE, V236, P962, DOI 10.1126/science.3576213; GATEWOOD JM, 1990, J BIOL CHEM, V265, P20662; Gineitis AA, 2000, J CELL BIOL, V151, P1591, DOI 10.1083/jcb.151.7.1591; GUSSE M, 1986, BIOCHIM BIOPHYS ACTA, V884, P124, DOI 10.1016/0304-4165(86)90235-7; HUH NE, 1991, NUCLEIC ACIDS RES, V19, P93, DOI 10.1093/nar/19.1.93; HURLEY CK, 1977, ANAL BIOCHEM, V80, P624, DOI 10.1016/0003-2697(77)90687-X; HWANG IH, 1989, MOL CELL BIOL, V9, P1005, DOI 10.1128/MCB.9.3.1005; Jedrusik MA, 2002, J CELL SCI, V115, P2881; KIM YJ, 1987, DEV BIOL, V124, P23, DOI 10.1016/0012-1606(87)90455-6; Kozik A, 1998, MOL REPROD DEV, V51, P98, DOI 10.1002/(SICI)1098-2795(199809)51:1&lt;98::AID-MRD12&gt;3.0.CO;2-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM K, 1992, J BIOL CHEM, V267, P15271; Lin QC, 2000, MOL CELL BIOL, V20, P2122, DOI 10.1128/MCB.20.6.2122-2128.2000; Luger K, 1999, METHOD ENZYMOL, V304, P3; Marret C, 1998, MOL REPROD DEV, V51, P22, DOI 10.1002/(SICI)1098-2795(199809)51:1&lt;22::AID-MRD3&gt;3.0.CO;2-Y; MAYERHOFER A, 1990, J CELL BIOL, V110, pB81; Meistrich M., 1989, HISTONES OTHER BASIC, P165; MEISTRICH ML, 1985, DEV BIOL, V112, P230, DOI 10.1016/0012-1606(85)90137-X; MOSS SB, 1989, DEV BIOL, V133, P83, DOI 10.1016/0012-1606(89)90299-6; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; Rogakou EP, 2000, BIOTECHNIQUES, V28, P38, DOI 10.2144/00281bm06; Roux K H, 1997, Methods Mol Biol, V67, P39; TANPHAICHITR N, 1978, EXP CELL RES, V117, P347, DOI 10.1016/0014-4827(78)90148-9; Tseng TC, 1998, DNA CELL BIOL, V17, P823, DOI 10.1089/dna.1998.17.823; UNNI E, 1995, BIOL REPROD, V53, P820, DOI 10.1095/biolreprod53.4.820; UNNI E, 1995, MOL REPROD DEV, V42, P210, DOI 10.1002/mrd.1080420210; van Roijen JH, 1998, HUM REPROD, V13, P1559, DOI 10.1093/humrep/13.6.1559; WATTANASEREE J, 1983, ARCH BIOCHEM BIOPHYS, V225, P892, DOI 10.1016/0003-9861(83)90103-0; Wouters-Tyrou D, 1998, BIOCHIMIE, V80, P117, DOI 10.1016/S0300-9084(98)80018-7; Yoda K, 2000, P NATL ACAD SCI USA, V97, P7266, DOI 10.1073/pnas.130189697; Zalenskaya IA, 2000, BIOCHEM BIOPH RES CO, V279, P213, DOI 10.1006/bbrc.2000.3917; Zalensky AO, 1997, EXP CELL RES, V232, P29, DOI 10.1006/excr.1997.3482; ZALENSKY AO, 1995, CHROMOSOMA, V103, P577; ZALENSKY AO, 1993, CHROMOSOMA, V102, P509, DOI 10.1007/BF00368344; ZALENSKY AO, 1993, MOL REPROD DEV, V36, P164, DOI 10.1002/mrd.1080360207; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	47	108	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43474	43480		10.1074/jbc.M206065200	http://dx.doi.org/10.1074/jbc.M206065200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12213818	hybrid			2022-12-25	WOS:000179081200132
J	Bodennec, J; Pelled, D; Riebeling, C; Trajkovic, S; Futerman, AH				Bodennec, J; Pelled, D; Riebeling, C; Trajkovic, S; Futerman, AH			Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP : phosphocholine cytidylyltransferase by glucosylceramide	FASEB JOURNAL			English	Article						sphingolipid; phospholipid; conduritol-B-epoxide; glucocerebrosidase; lysosomal storage disease	FIBROBLAST-GROWTH-FACTOR; RAT SYMPATHETIC NEURONS; BILAYER-FORMING LIPIDS; AXONAL GROWTH; ENDOPLASMIC-RETICULUM; PHOSPHOLIPID BIOSYNTHESIS; HIPPOCAMPAL-NEURONS; LIVER; MEMBRANE; METABOLISM	Glucosylceramide (GlcCer) accumulates in the inherited metabolic disorder, Gaucher disease, because of the defective activity of lysosomal glucocerebrosidase. We previously demonstrated that upon GlcCer accumulation, cultured hippocampal neurons exhibit modified growth patterns, altered endoplasmic reticulum density, and altered calcium release from intracellular stores. We here examined the relationship between GlcCer accumulation and phospholipid synthesis. After treatment of neurons with an active site-directed inhibitor of glucocerebrosidase, or in neurons obtained from a mouse model of Gaucher disease, [C-14]methyl choline incorporation into [C-14]phosphatidylcholine ([C-14]PC) and [C-14]sphingomyelin was elevated, as were [C-14]CDPcholine levels, suggesting that CTP:phosphocholine cytidylyltransferase (CCT) is activated. Indeed, CCT activity was elevated in neurons that had accumulated GlcCer. GlcCer, but not galactosylceramide (GalCer), stimulated CCT activity in rat brain homogenates, and significantly higher levels of CCT were membrane associated in cortical homogenates from a mouse model of Gaucher disease compared with wild-type mice. Because CCT mRNA and protein levels were unaltered in either neurons or brain tissue that had accumulated GlcCer, it appeared likely that GlcCer activates CCT by a post-translational mechanism. This was verified by examination of the effect of GlcCer on CCT purified about 1200-fold from rat brain. GlcCer stimulated CCT activity, with stimulation observed at levels as low as 2.5 mol% and with maximal activation reached at 10 mol%. In contrast, GalCer had no effect. Together, these data demonstrate that GlcCer directly activates CCT, which results in elevated PC synthesis, which may account for some of the changes in growth rates observed upon neuronal GlcCer accumulation.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tony.futerman@weizmann.ac.il		Futerman, Anthony/0000-0003-0013-0115; Riebeling, Christian/0000-0003-1991-0170				ADACHI M, 1967, ARCH PATHOL, V83, P513; ADACHI M, 1977, ARCH PATHOL LAB MED, V101, P255; Araki W, 1998, J NEUROSCI RES, V51, P667, DOI 10.1002/(SICI)1097-4547(19980315)51:6<667::AID-JNR1>3.3.CO;2-L; Ardail D, 2001, FEBS LETT, V488, P160, DOI 10.1016/S0014-5793(00)02332-2; Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; BEUTLER E, 2001, METABOLIC MOL BASES, P3635; Bodennec J, 2000, J LIPID RES, V41, P1524; Boldin S, 1997, J NEUROCHEM, V68, P882; Boldin SA, 2000, J BIOL CHEM, V275, P9905, DOI 10.1074/jbc.275.14.9905; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Campbell HA, 2001, BBA-MOL CELL BIOL L, V1534, P85, DOI 10.1016/S1388-1981(01)00174-3; CORNELL R, 1989, J BIOL CHEM, V264, P9077; Cornell RB, 1996, CHEM PHYS LIPIDS, V81, P215, DOI 10.1016/0009-3084(96)02584-4; Cornell RB, 1998, BIOCHEM SOC T, V26, P539, DOI 10.1042/bst0260539; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Cox TM, 2001, J INHERIT METAB DIS, V24, P106; DATTA SC, 1986, LIPIDS, V21, P702, DOI 10.1007/BF02537244; DATTA SC, 1988, LIPIDS, V23, P508, DOI 10.1007/BF02535529; DECHAVES EP, 1995, J CELL BIOL, V128, P913, DOI 10.1083/jcb.128.5.913; DITTMER JC, 1964, J LIPID RES, V5, P126; Erikson A, 1997, BAILLIERE CLIN HAEM, V10, P711, DOI 10.1016/S0950-3536(97)80035-2; FOLCH J, 1957, J BIOL CHEM, V226, P497; Futerman AH, 1998, ANN NY ACAD SCI, V845, P176, DOI 10.1111/j.1749-6632.1998.tb09670.x; Futerman AH, 1996, TRENDS NEUROSCI, V19, P144, DOI 10.1016/S0166-2236(96)80025-7; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; Goslin K., 1998, CULTURING NERVE CELL, P339; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; HARA A, 1979, BIOCHIM BIOPHYS ACTA, V582, P423, DOI 10.1016/0304-4165(79)90134-X; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; JAMIL H, 1993, BIOCHEM J, V291, P419, DOI 10.1042/bj2910419; JENSEN JW, 1988, BIOCHEMISTRY-US, V27, P6315, DOI 10.1021/bi00417a017; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; Korkotian E, 1999, J BIOL CHEM, V274, P21673, DOI 10.1074/jbc.274.31.21673; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGLER G, 1988, ARCH BIOCHEM BIOPHYS, V260, P437, DOI 10.1016/0003-9861(88)90467-5; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; MACDONALD JIS, 1993, PROTEIN EXPRES PURIF, V4, P1, DOI 10.1006/prep.1993.1001; Marchell NL, 1998, J INVEST DERMATOL, V110, P383, DOI 10.1046/j.1523-1747.1998.00145.x; NAVARRO JC, 1990, CLIN NEUROPATHOL, V9, P310; NILSSON O, 1982, J NEUROCHEM, V39, P709, DOI 10.1111/j.1471-4159.1982.tb07950.x; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; Orvisky E, 2000, PEDIATR RES, V48, P233, DOI 10.1203/00006450-200008000-00018; Pelled D, 2000, J INHERIT METAB DIS, V23, P175, DOI 10.1023/A:1005622001239; Pelled D, 2002, J BIOL CHEM, V277, P1957, DOI 10.1074/jbc.M104677200; Radin NS, 1999, BIOCHEM PHARMACOL, V57, P589; Radin NS, 2001, EUR J BIOCHEM, V268, P193, DOI 10.1046/j.1432-1033.2001.01845.x; RENKONEN O, 1966, LIPIDS, V1, P160, DOI 10.1007/BF02533012; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; Schwarz A, 1997, J NEUROSCI, V17, P2929; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; Shayman JA, 2000, METHOD ENZYMOL, V311, P373; Suzuki K, 1998, NEUROCHEM RES, V23, P251, DOI 10.1023/A:1022436928925; TYBULEWICZ VLJ, 1992, NATURE, V357, P407, DOI 10.1038/357407a0; van Meer G, 2000, BBA-MOL CELL BIOL L, V1486, P145, DOI 10.1016/S1388-1981(00)00054-8; VANCE DE, 1980, J BIOL CHEM, V255, P1064; VANCE JE, 1994, J NEUROCHEM, V62, P329; Vance JE, 2000, BBA-MOL CELL BIOL L, V1486, P84, DOI 10.1016/S1388-1981(00)00050-0; Vielhaber G, 2001, J INVEST DERMATOL, V117, P1126, DOI 10.1046/j.0022-202x.2001.01527.x; WARREN KR, 1976, J LIPID RES, V17, P132; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; Xiong Y, 2000, NEUROSCI LETT, V283, P129, DOI 10.1016/S0304-3940(00)00929-0	70	67	68	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1814	+		10.1096/fj.02-0149fje	http://dx.doi.org/10.1096/fj.02-0149fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223447				2022-12-25	WOS:000181189100009
J	Tomita, M; Reinhold, MI; Molkentin, JD; Naski, MC				Tomita, M; Reinhold, MI; Molkentin, JD; Naski, MC			Calcineurin and NFAT4 induce chondrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA-SUPERFAMILY; TRANSCRIPTION FACTOR; NF-ATC; CUBITUS-INTERRUPTUS; LIMB CHONDROGENESIS; NUCLEAR FACTOR; CHICK LIMB; PROTEIN; MOUSE; DIFFERENTIATION	Nuclear factor of activated T-cells (NFAT) and calcineurin are essential regulators of immune cell and mesenchymal cell differentiation. Here we show that elevated intracellular calcium induces chondrogenesis through a calcineurin/NFAT signaling axis that activates bone morphogenetic protein (BMP) expression. The calcium ionophore, ionomycin, induced chondrogenesis through activation of calcineurin. The calcineurin substrate, NFAT4, also induced chondrogenesis and chondrocyte gene expression. Significantly, the BMP antagonist, noggin, or dominant negative BMP receptors blocked the effects of elevated intracellular calcium on chondrogenesis. This suggested that calcineurin/NFAT4 activates BMP expression. Consistent with this, BMP2 gene expression was increased by ionomycin and suppressed by the calcineurin inhibitor, cyclosporine A. Furthermore, activated NFAT4 induced BMP2 gene expression. These results have important implications for the effects of NFATs during development and adaptive responses.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA; Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	University of Texas System; University of Texas Health San Antonio; Cincinnati Children's Hospital Medical Center	Naski, MC (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.			Molkentin, Jeffery/0000-0002-3558-6529	NIAMS NIH HHS [AR47070] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047070] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Aza-Blanc P, 2000, DEVELOPMENT, V127, P4293; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; EdwallArvidsson C, 1996, ANAT EMBRYOL, V193, P453; FENG JQ, 1995, J BIOL CHEM, V270, P28364, DOI 10.1074/jbc.270.47.28364; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Ghosh-Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Helvering LM, 2000, GENE, V256, P123, DOI 10.1016/S0378-1119(00)00364-4; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756-3282(01)00470-7; Kawakami Y, 1996, DEVELOPMENT, V122, P3557; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Pizette S, 2000, DEV BIOL, V219, P237, DOI 10.1006/dbio.2000.9610; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; WIDELITZ RB, 1993, J CELL PHYSIOL, V156, P399, DOI 10.1002/jcp.1041560224; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	42	83	86	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42214	42218		10.1074/jbc.C200504200	http://dx.doi.org/10.1074/jbc.C200504200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12239209	hybrid			2022-12-25	WOS:000178985300115
J	Pineda, AO; Savvides, SN; Waksman, G; Di Cera, E				Pineda, AO; Savvides, SN; Waksman, G; Di Cera, E			Crystal structure of the anticoagulant slow form of thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; POTENT ANTICOAGULANT; SPECIFICITY; BINDING; MUTANT; SITE	Using the thrombin mutant R77aA devoid of the site of autoproteolytic degradation at exosite 1, we have solved for the first time the structure of thrombin free of any inhibitors and effector molecules and stabilized in the Na+-free slow form. The slow form shows subtle differences compared with the currently available structures of the Na+-bound fast form that carry inhibitors at the active site or exosite 1. The most notable differences are the displacement of Asp-189 in the S1 specificity pocket, a downward shift of the 190-193 strand, a rearrangement of the side chain of Glu-192, and a significant shift in the position of the catalytic Ser-195 that is no longer within H-bonding distance from His-57. The structure of the slow form explains the reduced specificity toward synthetic and natural substrates and suggests a molecular basis for its anticoagulant properties.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.	enrico@biochem.wustl.edu	Savvides, Savvas/E-1938-2011	Savvides, Savvas/0000-0003-3420-5947	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL049413, R01HL058141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49413, HL 58141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; BODE W, 1992, PROTEIN SCI, V1, P426; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantwell AM, 2000, J BIOL CHEM, V275, P39827, DOI 10.1074/jbc.C000751200; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; Di Cera E, 1998, TRENDS CARDIOVAS MED, V8, P340, DOI 10.1016/S1050-1738(98)00030-9; Di Cera E, 2001, ANN NY ACAD SCI, V936, P133; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; Gruber A, 2002, J BIOL CHEM, V277, P27581, DOI 10.1074/jbc.C200237200; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Krem MM, 2002, J BIOL CHEM, V277, P40260, DOI 10.1074/jbc.M206173200; Krishnan R, 2000, ACTA CRYSTALLOGR D, V56, P406, DOI 10.1107/S0907444900001487; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008	24	43	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40177	40180		10.1074/jbc.C200465200	http://dx.doi.org/10.1074/jbc.C200465200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12205081	hybrid			2022-12-25	WOS:000178791400003
J	Peng, K; Shu, Q; Liu, ZH; Liang, SP				Peng, K; Shu, Q; Liu, ZH; Liang, SP			Function and solution structure of huwentoxin-IV, a potent neuronal tetrodotoxin (TTX)-sensitive sodium channel antagonist from Chinese bird spider Selenocosmia huwena	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-CONOTOXIN GIIIA; DISULFIDE BRIDGES; NA+-CHANNELS; CYSTINE KNOT; ASSIGNMENT; BINDING; PEPTIDE; TOXINS; LOOP; DETERMINANTS	We have isolated a highly potent neurotoxin from the venom of the Chinese bird spider, Selenocosmia huwena. This 4.1-kDa toxin, which has been named huwentoxin-IV, contains 35 residues with three disulfide bridges: Cys-2-Cys-17, Cys-9-Cys-24, and Cys-16-Cys-31, assigned by a chemical strategy including partial reduction of the toxin and sequence analysis of the modified intermediates. It specifically inhibits the neuronal tetrodotoxin-sensitive (TTX-S) voltage-gated sodium channel with the IC50 value of 30 nM in adult rat dorsal root ganglion neurons, while having no significant effect on the tetrodotoxin-resistant (TTX-R) voltage-gated sodium channel. This toxin seems to be a site I toxin affecting the sodium channel through a mechanism quite similar to that of TTX: it suppresses the peak sodium current without altering the activation or inactivation kinetics. The three-dimensional structure of huwentoxin-IV has been determined by two-dimensional H-1 NMR combined with distant geometry and simulated annealing calculation by using 527 nuclear Overhauser effect constraints and 14 dihedral constraints. The resulting structure is composed of a double-stranded antiparallel beta-sheet (Leu-22-Ser-25 and Trp-30-Tyr-33) and four turns (Glu-4-Lys-7, Pro-11-Asp-14, Lys-18-Lys-21 and Arg-26-Arg-29) and belongs to the inhibitor cystine knot structural family. After comparison with other toxins purified from the same species, we are convinced that the positively charged residues of loop IV (residues 25-29), especially residue Arg-26, must be crucial to its binding to the neuronal tetrodotoxin-sensitive voltage-gated sodium channel.	Hunan Normal Univ, Coll Life Sci, Changsha 410081, Peoples R China	Hunan Normal University	Liang, SP (corresponding author), Hunan Normal Univ, Coll Life Sci, Changsha 410081, Peoples R China.	liangsp@public.cs.hn.cn						Boccaccio A, 1999, BIOPHYS J, V77, P229, DOI 10.1016/S0006-3495(99)76884-0; BRUNGER AT, 1992, XPLOR MANUAL VERSION; Chahine M, 1998, BIOPHYS J, V75, P236, DOI 10.1016/S0006-3495(98)77510-1; Cummins TR, 1997, J NEUROSCI, V17, P3503; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GRAY WR, 1993, PROTEIN SCI, V2, P1749, DOI 10.1002/pro.5560021018; Hilber K, 2001, J BIOL CHEM, V276, P27831, DOI 10.1074/jbc.M101933200; Hill JM, 1997, STRUCTURE, V5, P571, DOI 10.1016/S0969-2126(97)00212-8; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; Hu ZH, 1997, J PHYSIOL-LONDON, V501, P67, DOI 10.1111/j.1469-7793.1997.067bo.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li RA, 2001, J BIOL CHEM, V276, P11072, DOI 10.1074/jbc.M010862200; Li RK, 2000, J BIOL CHEM, V275, P27551; Meir A, 1999, PHYSIOL REV, V79, P1019, DOI 10.1152/physrev.1999.79.3.1019; NARAHASHI T, 1964, J GEN PHYSIOL, V47, P965, DOI 10.1085/jgp.47.5.965; NARAHASHI T, 1960, AM J PHYSIOL, V198, P934, DOI 10.1152/ajplegacy.1960.198.5.934; Nicholson GM, 1996, TOXICON, V34, P1443, DOI 10.1016/S0041-0101(96)00089-X; NICHOLSON GM, 1994, PFLUG ARCH EUR J PHY, V428, P400, DOI 10.1007/BF00724524; Nicholson GM, 1998, PFLUG ARCH EUR J PHY, V436, P117, DOI 10.1007/s004240050612; Norton RS, 1998, TOXICON, V36, P1573, DOI 10.1016/S0041-0101(98)00149-4; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Peng K, 2001, TOXICON, V39, P491, DOI 10.1016/S0041-0101(00)00150-1; Penzotti JL, 1998, BIOPHYS J, V75, P2647, DOI 10.1016/S0006-3495(98)77710-0; Porreca F, 1999, P NATL ACAD SCI USA, V96, P7640, DOI 10.1073/pnas.96.14.7640; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; ROY ML, 1992, J NEUROSCI, V12, P2104; Sampo B, 2000, P NATL ACAD SCI USA, V97, P3666, DOI 10.1073/pnas.97.7.3666; SATO K, 1991, J BIOL CHEM, V266, P16989; Shon KJ, 1998, J NEUROSCI, V18, P4473; Shu Q, 1999, J PEPT RES, V53, P486, DOI 10.1034/j.1399-3011.1999.00039.x; Strachan LC, 1999, J PHARMACOL EXP THER, V288, P379; Waxman SG, 1999, PAIN, pS133, DOI 10.1016/S0304-3959(99)00147-5; Waxman SG, 1999, P NATL ACAD SCI USA, V96, P7635, DOI 10.1073/pnas.96.14.7635; Wu J, 1997, PROTEIN SCI, V6, P391; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANAGAWA Y, 1988, BIOCHEMISTRY-US, V27, P6256, DOI 10.1021/bi00417a009; ZHANG DG, 1993, J PROTEIN CHEM, V12, P735, DOI 10.1007/BF01024931	39	129	145	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47564	47571		10.1074/jbc.M204063200	http://dx.doi.org/10.1074/jbc.M204063200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12228241	hybrid			2022-12-25	WOS:000179663700095
J	Dode, L; Vilsen, B; Van Baelen, K; Wuytack, F; Clausen, JD; Andersen, JP				Dode, L; Vilsen, B; Van Baelen, K; Wuytack, F; Clausen, JD; Andersen, JP			Dissection of the functional differences between sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) 1 and 3 isoforms by steady-state and transient kinetic analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; CALCIUM-PUMP; SKELETAL-MUSCLE; DEPENDENT RELAXATION; TISSUE DISTRIBUTION; SMOOTH-MUSCLE; CDNA CLONING; CA2+ PUMPS	Steady-state and transient-kinetic studies were conducted to characterize the overall and partial reactions of the Ca2+-transport cycle mediated by the human sarco(endo)plasmic reticulum Ca2+-ATPase 3 (SERCA3) isoforms: SERCA3a, SERCA3b, and SERCA3c. Relative to SERCA1a, all three human SERCA3 enzymes displayed a reduced apparent affinity for cytosolic Ca2+ in activation of the overall reaction due to a decreased E-2 to E1Ca2 transition rate and an increased rate of Ca2+ dissociation from E1Ca2. At neutral pH, the ATPase activity of the SERCA3 enzymes was not significantly enhanced upon permeabilization of the microsomal vesicles with calcium ionophore, indicating a difference from SERCA1a with respect to regulation of the lumenal Ca2+ level (either an enhanced efflux of lumenal Ca2+ through the pump in E-2 form or insensitivity to inhibition by lumenal Ca2+). Other differences from SERCA1a with respect to the overall ATPase reaction were an alkaline shift of the pH optimum, increased catalytic turnover rate at pH optimum (highest for SERCA3b, the isoform with the longest C terminus), and an increased sensitivity to inhibition by vanadate that disappeared under equilibrium conditions in the absence of Ca2+ and ATP. The transient-kinetic analysis traced several of the differences from SERCA1a to an enhancement of the rate of dephosphorylation of the E2P phosphoenzyme intermediate, which was most pronounced at alkaline pH and increased with the length of the alternatively spliced C terminus.	Univ Aarhus, Dept Physiol, DK-8000 Aarhus C, Denmark; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium	Aarhus University; University of Oxford; Wellcome Centre for Human Genetics; KU Leuven	Andersen, JP (corresponding author), Univ Aarhus, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk		Andersen, Jens Peter/0000-0003-0654-4300; Vilsen, Bente/0000-0002-4727-9382				ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; Andersen JP, 1998, TRENDS CARDIOVAS MED, V8, P41, DOI 10.1016/S1050-1738(97)00121-7; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; ANGER M, 1993, FEBS LETT, V334, P45, DOI 10.1016/0014-5793(93)81677-R; BabaAissa F, 1996, MOL BRAIN RES, V41, P169, DOI 10.1016/0169-328X(96)00088-5; BAGINSKI ES, 1967, CLIN CHEM, V13, P326; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BISHOP JE, 1988, J BIOL CHEM, V263, P1886; Bobe R, 1998, FEBS LETT, V423, P259, DOI 10.1016/S0014-5793(98)00106-9; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Cornish-Bowden A, 2001, FUNDAMENTALS ENZYME; deMeis L, 1996, BBA-BIOENERGETICS, V1275, P105, DOI 10.1016/0005-2728(96)00058-8; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; Dode L, 1996, BIOCHEM J, V318, P689, DOI 10.1042/bj3180689; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; FORGE V, 1993, J BIOL CHEM, V268, P10953; Gelebart P, 2002, J BIOL CHEM, V277, P26310, DOI 10.1074/jbc.M201747200; GERDES U, 1983, BIOCHIM BIOPHYS ACTA, V734, P191, DOI 10.1016/0005-2736(83)90117-7; GOULD GW, 1986, BIOCHEM J, V237, P217, DOI 10.1042/bj2370217; HACK N, 1988, BIOCHEM J, V250, P355, DOI 10.1042/bj2500355; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; Kao J, 1999, AM J PHYSIOL-LUNG C, V277, pL264, DOI 10.1152/ajplung.1999.277.2.L264; Legrand G, 2001, J BIOL CHEM, V276, P47608, DOI 10.1074/jbc.M107011200; Liu LH, 1997, J BIOL CHEM, V272, P30538, DOI 10.1074/jbc.272.48.30538; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Martin V, 2002, J BIOL CHEM, V277, P24442, DOI 10.1074/jbc.M202011200; Martin V, 2000, HYPERTENSION, V35, P91, DOI 10.1161/01.HYP.35.1.91; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Mitidieri F, 1999, J BIOL CHEM, V274, P28344, DOI 10.1074/jbc.274.40.28344; ORLOWSKI S, 1988, J BIOL CHEM, V263, P17576; Ozog A, 1998, FEBS LETT, V427, P349, DOI 10.1016/S0014-5793(98)00464-5; PAPP B, 1993, BIOCHEM J, V295, P685, DOI 10.1042/bj2950685; PAPP B, 1991, J BIOL CHEM, V266, P14593; Paschen W, 2001, CELL CALCIUM, V29, P1, DOI 10.1054/ceca.2000.0162; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Poch E, 1998, AM J PHYSIOL-CELL PH, V275, pC1449, DOI 10.1152/ajpcell.1998.275.6.C1449; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1442; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Sorensen TLM, 2000, J BIOL CHEM, V275, P28954, DOI 10.1074/jbc.M004072200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Varadi A, 1999, DIABETOLOGIA, V42, P1240, DOI 10.1007/s001250051298; Varadi A, 1996, BIOCHEM J, V319, P521, DOI 10.1042/bj3190521; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P10613, DOI 10.1021/bi00499a006; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Wuytack F, 1995, BIOSCIENCE REP, V15, P299, DOI 10.1007/BF01788362; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; YU X, 1994, J BIOL CHEM, V269, P16656; Zhang YL, 1995, GENOMICS, V30, P415, DOI 10.1006/geno.1995.1259	61	80	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45579	45591		10.1074/jbc.M207778200	http://dx.doi.org/10.1074/jbc.M207778200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12207029	hybrid			2022-12-25	WOS:000179404800124
J	McCudden, CR; James, KA; Hasilo, C; Wagner, GF				McCudden, CR; James, KA; Hasilo, C; Wagner, GF			Characterization of mammalian stanniocalcin receptors - Mitochondrial targeting of ligand and receptor for regulation of cellular metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; OVARIAN STANNIOCALCIN; MESSENGER-RNA; RAT-KIDNEY; HORMONE; CLONING; LOCALIZATION; CELLS; IDENTIFICATION; PROTEIN	The polypeptide hormone stanniocalcin (STC) is widely expressed in mammalian tissues. STC acts locally in kidney and gut to modulate calcium and phosphate excretion, and its overexpression in mice results in high serum phosphate, dwarfism, and increased metabolic rate. STC has also been linked to cancer, pregnancy, lactation, angiogenesis, organogenesis, cerebral ischemia, and hypertonic stress. In this report we have characterized the STC receptor and the functional targeting of ligand and receptor to mitochondria. For receptor binding analysis, a stanniocalcin-alkaline phosphatase fusion protein was engineered. Subsequent binding assays using the fusion protein indicated that kidney and liver contained the highest number of binding sites with affinities of 0.8 and 0.25 nm, respectively. Intriguingly, purified mitochondria from both tissues yielded similar high affinity binding sites. Fractionation analysis revealed that the majority of binding sites were localized to the inner mitochondrial membrane. In further studies, we characterized the time course of STC-alkaline phosphatase fusion protein sequestration by intact mitochondria. In situ ligand binding also revealed discrete, displaceable, binding to plasma membranes and mitochondria of nephron cells and liver hepatocytes. The existence of mitochondrial receptors prompted a similar search for the ligand. Immunogold electron microscopy revealed that STC was preferentially concentrated in the mitochondria of all nephron segments targeted by STC. Subcellular fractionation revealed that >90% of cellular STC immunoreactivity was mitochondrial, confined to the inner matrix, and similar in size to recombinant STC (50 kDa). In functional studies, recombinant STC had concentration-dependent stimulatory effects on electron transfer by sub-mitochondrial particles. Collectively the evidence implies a role for STC in cell metabolism.	Univ Western Ontario, Fac Med & Dent, Dept Physiol, London, ON N6A 5C1, Canada; Univ Western Ontario, Fac Sci, Dept Biol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Wagner, GF (corresponding author), Univ Western Ontario, Fac Med & Dent, Dept Physiol, London, ON N6A 5C1, Canada.	graham.wagner@fmd.uwo.ca		McCudden, Christopher/0000-0002-4172-4641				Amemiya Y, 2002, MOL CELL ENDOCRINOL, V188, P141, DOI 10.1016/S0303-7207(01)00741-9; BERGERON JJM, 1978, J BIOL CHEM, V253, P4058; Cadenas E, 2000, FREE RADICAL RES, V33, P747, DOI 10.1080/10715760000301271; CHANG ACM, 1995, MOL CELL ENDOCRINOL, V112, P241, DOI 10.1016/0303-7207(95)03601-3; Chang ACM, 1996, MOL CELL ENDOCRINOL, V124, P185, DOI 10.1016/S0303-7207(96)03929-9; Chen WJ, 2001, J EXP MED, V194, P439, DOI 10.1084/jem.194.4.439; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; Clausmeyer S, 1999, CIRC RES, V84, P337, DOI 10.1161/01.RES.84.3.337; De Niu P, 2000, MOL CELL ENDOCRINOL, V162, P131, DOI 10.1016/S0303-7207(00)00199-4; De Niu P, 1998, MOL CELL ENDOCRINOL, V137, P155, DOI 10.1016/S0303-7207(97)00243-8; Deol HK, 2000, ENDOCRINOLOGY, V141, P3412, DOI 10.1210/en.141.9.3412; DUNAIF AE, 1982, ENDOCRINOLOGY, V110, P1465, DOI 10.1210/endo-110-5-1465; Filvaroff EH, 2002, ENDOCRINOLOGY, V143, P3681, DOI 10.1210/en.2001-211424; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Flanagan JG, 2000, METHOD ENZYMOL, V327, P198, DOI 10.1016/S0076-6879(00)27277-7; Fujiwara Y, 2000, INT J ONCOL, V16, P799; Graham J M, 1993, Methods Mol Biol, V19, P19; Haddad M, 1996, ENDOCRINOLOGY, V137, P2113, DOI 10.1210/en.137.5.2113; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; Kriz W, 1992, KIDNEY PHYSL PATHOPH, P707; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; LU MQ, 1994, AM J PHYSIOL-REG I, V267, pR1356, DOI 10.1152/ajpregu.1994.267.5.R1356; Madsen KL, 1998, AM J PHYSIOL-GASTR L, V274, pG96, DOI 10.1152/ajpgi.1998.274.1.G96; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; McCudden CR, 2001, BIOL REPROD, V65, P763, DOI 10.1095/biolreprod65.3.763; McCudden CR, 2001, J ENDOCRINOL, V171, P33, DOI 10.1677/joe.0.1710033; Miura W, 2000, APMIS, V108, P367, DOI 10.1034/j.1600-0463.2000.d01-70.x; MORRE JD, 1971, METHOD ENZYMOL, P648; Nelson AE, 1996, MOL CELL ENDOCRINOL, V124, P17, DOI 10.1016/S0303-7207(96)03928-7; Olsen HS, 1996, P NATL ACAD SCI USA, V93, P1792, DOI 10.1073/pnas.93.5.1792; RAO CV, 1973, BIOCHIM BIOPHYS ACTA, V313, P372, DOI 10.1016/0304-4165(73)90037-8; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; Sheikh-Hamad D, 2000, AM J PHYSIOL-RENAL, V278, pF417, DOI 10.1152/ajprenal.2000.278.3.F417; Stasko SE, 2001, MOL CELL ENDOCRINOL, V174, P145, DOI 10.1016/S0303-7207(00)00394-4; Stasko SE, 2001, DEV DYNAM, V220, P49, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1086>3.0.CO;2-5; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Varghese R, 1998, ENDOCRINOLOGY, V139, P4714, DOI 10.1210/en.139.11.4714; Varghese R, 2002, ENDOCRINOLOGY, V143, P868, DOI 10.1210/en.143.3.868; Wagner GF, 1997, J BONE MINER RES, V12, P165, DOI 10.1359/jbmr.1997.12.2.165; Wagner Graham F., 1994, P273; Wong CKC, 1998, J ENDOCRINOL, V158, P183, DOI 10.1677/joe.0.1580183; Wong CKC, 2002, J ENDOCRINOL, V173, P199, DOI 10.1677/joe.0.1730199; Wrutniak-Cabello C, 2001, J MOL ENDOCRINOL, V26, P67, DOI 10.1677/jme.0.0260067; Zhang JL, 1998, PROTEIN EXPRES PURIF, V12, P390, DOI 10.1006/prep.1997.0857; Zhang KZ, 2000, P NATL ACAD SCI USA, V97, P3637, DOI 10.1073/pnas.070045897	47	102	107	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45249	45258		10.1074/jbc.M205954200	http://dx.doi.org/10.1074/jbc.M205954200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12223480	hybrid			2022-12-25	WOS:000179404800085
J	Song, L; De Sarno, P; Jope, RS				Song, L; De Sarno, P; Jope, RS			Central role of glycogen synthase kinase-3 beta in endoplasmic reticulum stress-induced caspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PEPTIDE; PROTEIN-KINASE-B; SH-SY5Y NEUROBLASTOMA-CELLS; GROWTH-FACTOR WITHDRAWAL; HIPPOCAMPAL-NEURONS; SIGNALING PATHWAY; SUBCELLULAR-DISTRIBUTION; NUCLEAR ACCUMULATION; MUTANT PRESENILIN-1; CALCIUM HOMEOSTASIS	Stress of the endoplasmic reticulum (ER), which is associated with many neurodegenerative conditions, can lead to the elimination of affected cells by apoptosis through only partially understood mechanisms. Thapsigargin, which causes ER stress by inhibiting the ER Ca2+-ATPase, was found to not only activate the apoptosis effector caspase-3 but also to cause a large and prolonged increase in the activity of glycogen synthase kinase-3beta (GSK3beta). Activation of GSK3beta was obligatory for thapsigargin-induced activation of caspase-3, because inhibition of GSK3beta by expression of dominant-negative GSK3beta or by the GSK3beta inhibitor lithium blocked caspase-3 activation. Thapsigargin treatment activated GSK3beta by inducing dephosphorylation of phospho-Ser-9 of GSK3beta, a phosphorylation that normally maintains GSK3beta inactivated. Caspase-3 activation induced by thapsigargin was blocked by increasing the phosphorylation of Ser-9-GSK3beta with insulin-like growth factor-1 or with the phosphatase inhibitors okadaic acid and calyculin A, but the calcineurin inhibitors FK506 and cyclosporin A were ineffective. Insulin-like growth factor-1, okadaic acid, calyculin A, and lithium also protected cells from two other inducers of ER stress, tunicamycin and brefeldin A. Thus, ER stress activates GSK3beta through dephosphorylation of phospho-Ser-9, a prerequisite for caspase-3 activation, and this process is amenable to pharmacological intervention.	Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Jope, RS (corresponding author), Univ Alabama, Dept Psychiat, Sparks Ctr 1057, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038752, R56MH038752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037768] Funding Source: NIH RePORTER; NIMH NIH HHS [MH38752] Funding Source: Medline; NINDS NIH HHS [NS37768] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alvarez G, 1999, FEBS LETT, V453, P260, DOI 10.1016/S0014-5793(99)00685-7; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Carmichael J, 2002, J BIOL CHEM, V277, P33791, DOI 10.1074/jbc.m204861200; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; Culbert AA, 2001, FEBS LETT, V507, P288, DOI 10.1016/S0014-5793(01)02990-8; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Elyaman W, 2002, EUR J NEUROSCI, V15, P651, DOI 10.1046/j.1460-9568.2002.01899.x; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; FURUYA Y, 1994, CANCER RES, V54, P6167; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; Guo Q, 1999, J NEUROCHEM, V72, P1019, DOI 10.1046/j.1471-4159.1999.0721019.x; Hall JL, 2001, DIABETES, V50, P1171, DOI 10.2337/diabetes.50.5.1171; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Hetman M, 2000, J NEUROSCI, V20, P2567; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Imahori K, 1997, J BIOCHEM, V121, P179; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Johnson Gail V. W., 1998, Alzheimer's Disease Review, V3, P125; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; King TD, 2001, BRAIN RES, V919, P106, DOI 10.1016/S0006-8993(01)03005-0; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kurihara S, 2000, ENDOCR J, V47, P739, DOI 10.1507/endocrj.47.739; LAM LK, 1994, J BIOL CHEM, V91, P6569; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Lotem J, 1999, P NATL ACAD SCI USA, V96, P12016, DOI 10.1073/pnas.96.21.12016; Maggirwar SB, 1999, J NEUROCHEM, V73, P578, DOI 10.1046/j.1471-4159.1999.0730578.x; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mora A, 2002, CELL SIGNAL, V14, P557, DOI 10.1016/S0898-6568(01)00282-0; Mora A, 2001, J NEUROCHEM, V78, P199, DOI 10.1046/j.1471-4159.2001.00410.x; Mukerjee N, 2000, ARCH BIOCHEM BIOPHYS, V379, P337, DOI 10.1006/abbi.2000.1889; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nath R, 1997, BIOCHEM MOL BIOL INT, V43, P197; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; Pap M, 2002, MOL CELL BIOL, V22, P578, DOI 10.1128/MCB.22.2.578-586.2002; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Pei JJ, 1997, J NEUROPATH EXP NEUR, V56, P70, DOI 10.1097/00005072-199701000-00007; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Sato N, 2001, J BIOL CHEM, V276, P2108, DOI 10.1074/jbc.M006886200; Schneider I, 2001, J BIOL CHEM, V276, P11539, DOI 10.1074/jbc.M010977200; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shiurba RA, 1996, BRAIN RES, V737, P119, DOI 10.1016/0006-8993(96)00717-2; Somervaille TCP, 2001, BLOOD, V98, P1374, DOI 10.1182/blood.V98.5.1374; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TAKASHIMA A, 1995, NEUROSCI LETT, V198, P83, DOI 10.1016/0304-3940(95)11964-X; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tong HY, 2002, CIRC RES, V90, P377, DOI 10.1161/01.RES.0000012567.95445.55; Tong N, 2001, EUR J NEUROSCI, V13, P1913, DOI 10.1046/j.0953-816x.2001.01572.x; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wei H, 2001, NEUROSCIENCE, V106, P603, DOI 10.1016/S0306-4522(01)00311-6; Wei HF, 2000, EUR J PHARMACOL, V392, P117, DOI 10.1016/S0014-2999(00)00127-8; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Yamaguchi H, 1996, ACTA NEUROPATHOL, V92, P232, DOI 10.1007/s004010050513; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	87	246	264	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44701	44708		10.1074/jbc.M206047200	http://dx.doi.org/10.1074/jbc.M206047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12228224	hybrid			2022-12-25	WOS:000179404800015
J	Cheng, F; Mani, K; van den Born, J; Ding, K; Belting, M; Fransson, LA				Cheng, F; Mani, K; van den Born, J; Ding, K; Belting, M; Fransson, LA			Nitric oxide-dependent processing of heparan sulfate in recycling S-nitrosylated glypican-1 takes place in caveolin-1-containing endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-UNSUBSTITUTED GLUCOSAMINE; HUMAN LUNG FIBROBLASTS; NUCLEAR-LOCALIZATION; ENDOTHELIAL-CELLS; MONOCLONAL-ANTIBODY; SKIN FIBROBLASTS; PLASMA-MEMBRANE; CORE PROTEIN; BREFELDIN-A; PROTEOGLYCANS	We have previously demonstrated intracellular degradation of the heparan sulfate side chains in recycling glypican-1 by heparanase and by deaminative cleavage at N-unsubstituted glucosamine with nitric oxide derived from intrinsic nitrosothiols (see Ding, K., Mani, K., Cheng, F., Belting, M. and Fransson, L.-A (2002) J. Biol. Chem. 277, 33353- 33360). To determine where and in what order events take place, we have visualized, by using confocal laser-scanning immunofluorescence microscopy, glypican-1 variants in unperturbed cells or arrested at various stages of processing. In unperturbed proliferating cells, glypican-1 was partly S-nitrosylated. Intracellular glypican-1 was enriched in endosomes, colocalized significantly with GM-1 ganglioside, caveolin-1, and Rab9-positive endosomes, and carried side chains rich in N-unsubstituted glucosamine residues. However, such residues were scarce in cell surface glypican-1. Brefeldin A-arrested glypican-1, which was non-S-nitrosylated and carried side chains rich in N-unsubstituted glucosamines, colocalized extensively with caveolin-1 but not with Rab9. Suramin, which inhibits heparanase, induced the appearance of S-nitrosylated glypican-1 in caveolin-l-rich compartments. Inhibition of deaminative cleavage did not prevent heparanase from generating heparan sulfate oligosaccharides that colocalized strongly with caveolin-1. Growth-quiescent cells displayed extensive NO-dependent deaminative cleavage of heparan sulfate-generating anhydromannose-terminating fragments that were partly associated with acidic vesicles. Proliferating cells generated such fragments during polyamine uptake. We conclude that recycling glypican-1 that is associated with caveolin-1-containing endosomes undergoes sequential N-desulfation/N-deacetylation, heparanase cleavage, S-nitrosylation, NO release, and deaminative cleavage of its side chains in conjunction with polyamine uptake.	Lund Univ, Dept Cell & Mol Biol, SE-22184 Lund, Sweden; Free Univ Amsterdam, Dept Cell Biol, NL-1081 BT Amsterdam, Netherlands	Lund University; Vrije Universiteit Amsterdam	Fransson, LA (corresponding author), Lund Univ, Dept Cell & Mol Biol, BMC C13, SE-22184 Lund, Sweden.	lars-ake.fransson@medkem.lu.se		Mani, Katrin/0000-0002-1821-0634; Belting, Mattias/0000-0003-1585-5434				Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030; Belting M, 2002, P NATL ACAD SCI USA, V99, P371, DOI 10.1073/pnas.012346499; Belting M, 1999, J BIOL CHEM, V274, P19375, DOI 10.1074/jbc.274.27.19375; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brown J, 2000, LAB INVEST, V80, P37, DOI 10.1038/labinvest.3780006; Chatterjee S, 2001, CELL MOL LIFE SCI, V58, P1969, DOI 10.1007/PL00000831; Chen RL, 2001, J BIOL CHEM, V276, P7507, DOI 10.1074/jbc.M008283200; Cheng F, 2001, J CELL BIOCHEM, V83, P597, DOI 10.1002/jcb.1254; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DEBOECK H, 1987, BIOCHEM J, V247, P765, DOI 10.1042/bj2470765; Ding K, 2002, J BIOL CHEM, V277, P33353, DOI 10.1074/jbc.M203383200; Ding K, 2001, J BIOL CHEM, V276, P46779, DOI 10.1074/jbc.M105419200; Ding K, 2001, J BIOL CHEM, V276, P3885, DOI 10.1074/jbc.M005238200; Dirks WG, 1999, IN VITRO CELL DEV-AN, V35, P558; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fansson LA, 2000, MATRIX BIOL, V19, P367, DOI 10.1016/S0945-053X(00)00083-4; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Filmus J, 2001, GLYCOBIOLOGY, V11, p19R, DOI 10.1093/glycob/11.3.19R; Fivaz M, 2002, EMBO J, V21, P3989, DOI 10.1093/emboj/cdf398; FRANSSON L, 1995, GLYCOBIOLOGY, V5, P407, DOI 10.1093/glycob/5.4.407; FRANSSON LA, 1983, J BIOL CHEM, V258, P4342; FRANSSON LA, 1982, CARBOHYD RES, V110, P127, DOI 10.1016/0008-6215(82)85031-3; Gagliardi ART, 1998, CANCER LETT, V125, P97, DOI 10.1016/S0304-3835(97)00496-5; Giraldez AJ, 2002, DEV CELL, V2, P667, DOI 10.1016/S1534-5807(02)00180-6; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Huang SS, 1997, FEBS LETT, V416, P297, DOI 10.1016/S0014-5793(97)01213-1; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Leteux C, 2001, J BIOL CHEM, V276, P12539, DOI 10.1074/jbc.M010291200; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Mani K, 2000, GLYCOBIOLOGY, V10, P577, DOI 10.1093/glycob/10.6.577; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; Murakami M, 2000, BBA-MOL CELL BIOL L, V1488, P159, DOI 10.1016/S1388-1981(00)00118-9; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; PEJLER G, 1988, J BIOL CHEM, V263, P5197; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Razani B, 2001, J BIOL CHEM, V276, P38121; Richardson TP, 2001, J CELL SCI, V114, P1613; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Spillmann D, 2001, BIOCHIMIE, V83, P811, DOI 10.1016/S0300-9084(01)01290-1; Stubauer G, 1999, J BIOL CHEM, V274, P28128, DOI 10.1074/jbc.274.40.28128; Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200; TANABE H, 1999, TISSUE CULT RES COMM, V18, P329, DOI DOI 10.11418/JTCA1981.18.4_329; THORENS B, 1993, J CELL BIOL, V123, P1687, DOI 10.1083/jcb.123.6.1687; Tumova S, 1999, BIOCHEM J, V337, P471, DOI 10.1042/0264-6021:3370471; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; WERMUTH B, 1982, METHOD ENZYMOL, V89, P181	60	64	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44431	44439		10.1074/jbc.M205241200	http://dx.doi.org/10.1074/jbc.M205241200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12226079	hybrid			2022-12-25	WOS:000179272000114
J	Lin, DH; Sterling, H; Lerea, KM; Giebisch, G; Wang, WH				Lin, DH; Sterling, H; Lerea, KM; Giebisch, G; Wang, WH			Protein kinase C (PKC)-induced phosphorylation of ROMK1 is essential for the surface expression of ROMK1 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; TYROSINE-PHOSPHATASE; POTASSIUM CHANNEL; GLIBENCLAMIDE; MODULATION; MECHANISM; CLONING; KIDNEY	We carried out in vitro phosphorylation assays to determine whether ROMK1 is a substrate of protein kinase C (PKC) and used the two-electrode voltage clamp method to investigate the role of serine residues 4, 183, and 201, the three putative PKC phosphorylation sites, in the regulation of ROMK1 channel activity. Incubation of the purified His-tagged ROMK1 protein with PKC and radiolabeled ATP resulted in P-32 incorporation into ROMK1 detected by autoradiography. Moreover, the in vitro phosphorylation study of three synthesized peptides corresponding to amino acids 1-16, 174-189, and 196-211 of ROMK1. revealed that serine residues 4 and 201 of ROMK1 were the two main PKC phosphorylation sites. In contrast, (32)p incorporation of peptide 174-189 was absent. In vitro phosphorylation studies with ROMK1 mutants, R1S4/NKA, R1S4/183A, and RlS183/201A, demonstrated that the phosphorylation levels of R1S4/201A were significantly lower than those of the other two mutants. Also, the Ba2+-sensitive K+ current in oocytes injected with green fluorescent protein (GFP)-R1S4/201A was only 5% of that in oocytes injected with wild type GFP-ROMK1. In contrast, the K+ current in oocytes injected with GFP-ROMK1 mutants containing either serine residue 4 or 201 was similar to those injected with wild type ROMK1. Confocal microscope imaging shows that the surface expression of the K+ channels was significantly diminished in oocytes injected with R1S4/201A and completely absent in oocytes injected with R1S4/183/201A. Furthermore, the biotin labeling technique confirmed that the membrane fraction of ROMK channels was almost absent in HEK293 cells transfected with either R1S4/201A or R1S4/183/201A. However, when serine residues 4 and 201 were mutated to aspartate, the K+ currents and the surface expression were completely restored. Finally, addition of calphostin C in the incubation medium significantly decreased the K+ current in comparison with that under control conditions. Biotin labeling technique further indicated that inhibition of PKC decreases the surface ROMK1 expression in human embryonic kidney (HEK) cells transfected with ROMK1. We conclude that ROMK1 is a substrate of PKC and that serine residues 4 and 201 are the two main PKC phosphorylation sites that are essential for the expression of ROMK1 in the cell surface.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; New York Med Coll, Dept Anat & Cell Biol, Valhalla, NY 10595 USA; Yale Univ, Dept Cellular & Mol Physiol, Sch Med, New Haven, CT 06511 USA	New York Medical College; New York Medical College; Yale University	Wang, WH (corresponding author), New York Med Coll, Dept Pharmacol, BSB Rm 537, Valhalla, NY 10595 USA.	wenhui_wang@nymc.edu	Lerea, Ken/GWU-8597-2022		NIDDK NIH HHS [R01 DK047402, DK 47402, DK 54983, R01 DK047402-13, R01 DK054983-08, R01 DK054983] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054983, R01DK047402, R29DK047402] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; CHEPILKO S, 1995, AM J PHYSIOL-CELL PH, V268, pC389, DOI 10.1152/ajpcell.1995.268.2.C389; Dong K, 2001, J BIOL CHEM, V276, P44347, DOI 10.1074/jbc.M108072200; FRINDT G, 1987, AM J PHYSIOL, V252, pF458, DOI 10.1152/ajprenal.1987.252.3.F458; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Lin DH, 2002, AM J PHYSIOL-RENAL, V283, pF671, DOI 10.1152/ajprenal.00160.2002; Liou HH, 1999, P NATL ACAD SCI USA, V96, P5820, DOI 10.1073/pnas.96.10.5820; Macica CM, 1996, AM J PHYSIOL-RENAL, V271, pF588, DOI 10.1152/ajprenal.1996.271.3.F588; Macica CM, 1998, AM J PHYSIOL-RENAL, V274, pF175, DOI 10.1152/ajprenal.1998.274.1.F175; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; McNicholas CM, 1997, AM J PHYSIOL-RENAL, V273, pF843, DOI 10.1152/ajprenal.1997.273.5.F843; Mennitt PA, 1997, J AM SOC NEPHROL, V8, P1823; Moral Z, 2001, J BIOL CHEM, V276, P7156, DOI 10.1074/jbc.M008671200; Morita T, 1997, AM J PHYSIOL-RENAL, V273, pF615, DOI 10.1152/ajprenal.1997.273.4.F615; PALMER LG, 1994, J GEN PHYSIOL, V104, P693, DOI 10.1085/jgp.104.4.693; Palmer LG, 1997, AM J PHYSIOL-RENAL, V273, pF404, DOI 10.1152/ajprenal.1997.273.3.F404; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; STANTON BA, 1992, HDB PHYSL RENAL PHYS, P813; Sterling H, 2002, J BIOL CHEM, V277, P4317, DOI 10.1074/jbc.M109739200; WANG WH, 1993, J GEN PHYSIOL, V101, P673, DOI 10.1085/jgp.101.5.673; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Wei Y, 2000, J BIOL CHEM, V275, P20502, DOI 10.1074/jbc.M000783200; WODA CB, 2000, AM J PHYSIOL, V280, pF786; Xu JZ, 1997, AM J PHYSIOL-RENAL, V273, pF739, DOI 10.1152/ajprenal.1997.273.5.F739; Yao XQ, 1996, J CLIN INVEST, V97, P2525, DOI 10.1172/JCI118700; ZHEN WZ, 2001, J AM SOC NEPHROL, V12, pA45	33	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44278	44284		10.1074/jbc.M203702200	http://dx.doi.org/10.1074/jbc.M203702200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12221079	hybrid, Green Accepted			2022-12-25	WOS:000179272000097
J	Mulligan, C; Rochford, J; Denyer, G; Stephens, R; Yeo, G; Freeman, T; Siddle, K; O'Rahilly, S				Mulligan, C; Rochford, J; Denyer, G; Stephens, R; Yeo, G; Freeman, T; Siddle, K; O'Rahilly, S			Microarray analysis of insulin and insulin-like growth factor-1 (IGF-1) receptor signaling reveals the selective up-regulation of the mitogen heparin-binding EGF-like growth factor by IGF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; CYTOPLASMIC DOMAINS; GLYCOGEN-SYNTHESIS; WOUND FLUID; EXPRESSION; GENE; PHOSPHORYLATION; CELLS; FIBROBLASTS; HEPATOCYTES	Insulin and insulin-like growth factor-1 (IGF-1) act through highly homologous receptors that engage similar intracellular signaling pathways, yet these hormones serve largely distinct physiological roles in the control of metabolism and growth, respectively. In an attempt to uncover the molecular mechanisms underlying their divergent functions, we compared insulin receptor (IR) and IGF-1 receptor (IGF-IR) regulation of gene expression by microarray analysis, using 3T3-LI cells expressing either TrkC/IR or TrkC/IGF-IR chimeric receptors to ensure the highly selective activation of each receptor tyrosine kinase. Following stimulation of the chimeric receptors for 4 h, we detected 11 genes to be differentially regulated, of which 10 were up-regulated to a greater extent by the IGF-1R. These included genes involved in adhesion, transcription, transport, and proliferation. The expression of mRNA encoding heparin-binding epidermal growth factor-like growth factor (HB-EGF), a potent mitogen, was markedly increased by IGF-1R but not IR activation. This effect was dependent on MAPK, but not phosphatidylinositol 3-kinase, and did not require an autocrine loop through the epidermal growth factor receptor. HB-EGF mitogenic activity was detectable in the medium of 3T3-Ll preadipocytes expressing activated IGF-1R but not IR, indicating that the transcriptional response is accompanied by a parallel increase in mature HB-EGF protein. The differential abilities of the IR and IGF-1R tyrosine kinases to stimulate the synthesis and release of a growth factor may provide, at least in part, an explanation for the greater role of the IGF-1R in the control of cellular proliferation.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; MRC Human Genome Mapping Programme RC, Hinxton CB10 1SB, England; Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Sydney; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	O'Rahilly, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Hills Rd, Cambridge CB2 2QR, England.		denyer, gareth/E-3437-2010; O'Rahilly, Stephen/ABF-6509-2020	O'Rahilly, Stephen/0000-0003-2199-4449; Yeo, Giles See How/0000-0001-8823-3615; Rochford, Justin/0000-0002-5020-4939				Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; Blakesley VA, 1996, ENDOCRINOLOGY, V137, P410, DOI 10.1210/en.137.2.410; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; DEMEYTS P, 1995, METABOLISM, V44, P2, DOI 10.1016/0026-0495(95)90214-7; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; Dupont J, 2001, J BIOL CHEM, V276, P26699, DOI 10.1074/jbc.M102664200; Frade JN, 1996, DEVELOPMENT, V122, P2497; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; ITO N, 1994, BIOCHEM BIOPH RES CO, V198, P25, DOI 10.1006/bbrc.1994.1004; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; KallooHosein HE, 1997, J BIOL CHEM, V272, P24325, DOI 10.1074/jbc.272.39.24325; KOBRIN MS, 1994, BIOCHEM BIOPH RES CO, V202, P1705, DOI 10.1006/bbrc.1994.2131; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; Le Bellego F, 2002, J ENDOCRINOL, V172, P45, DOI 10.1677/joe.0.1720045; Li SW, 1996, J BIOL CHEM, V271, P12254, DOI 10.1074/jbc.271.21.12254; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Marikovsky M, 1996, J INVEST DERMATOL, V106, P616, DOI 10.1111/1523-1747.ep12345413; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Park BC, 1999, BIOCHEMISTRY-US, V38, P7517, DOI 10.1021/bi9830718; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; Sugden MC, 2001, BIOCHEM SOC T, V29, P272, DOI 10.1042/0300-5127:0290272; TARTARE S, 1994, J BIOL CHEM, V269, P11449; Urso B, 1999, J BIOL CHEM, V274, P30864, DOI 10.1074/jbc.274.43.30864; Urso B, 2001, CELL SIGNAL, V13, P279, DOI 10.1016/S0898-6568(01)00130-9; ZAPF A, 1994, ENDOCRINOLOGY, V134, P2445, DOI 10.1210/en.134.6.2445	32	47	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42480	42487		10.1074/jbc.M206206200	http://dx.doi.org/10.1074/jbc.M206206200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12213819	hybrid			2022-12-25	WOS:000179081200009
J	Rui, HL; Fan, E; Zhou, HM; Xu, Z; Zhang, Y; Lin, SC				Rui, HL; Fan, E; Zhou, HM; Xu, Z; Zhang, Y; Lin, SC			SUMO-1 modification of the C-terminal KVEKVD of axin is required for JNK activation but has no effect on Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; KAPPA-B-ALPHA; F-BOX PROTEIN; BETA-CATENIN; NEGATIVE REGULATOR; FUNCTIONAL INTERACTION; KINASE ACTIVATION; BINDING PROTEIN; NUCLEAR-BODIES; PATHWAY	Axin is a multifunctional protein, regulating Wnt signaling and the c-Jun N-terminal/stress-activated protein kinase (JNK/SAPK) pathway as well as tumorigenesis. In the present study, we found that Axin interacts with three SUMO-1 (small ubiquitin-related modifier) conjugating enzymes 3 (E3), PIAS1, PIASxbeta, and PIASy. The extreme C-terminal six amino acid residues of Axin are critical for the Axin/E3 interaction as deletion of the six residues (AxinDeltaC6) completely abolished the ability of Axin to interact with E3 enzymes. AxinDeltaC6 also failed to activate JNK although it was intact in both its interaction with MEKK1 and homodimerization. Consistent with the presence of a doublet of the KV(E/D) sumoylation consensus motif at the C-terminal end (KVEKVD), we found that Axin is heavily sumoylated. Deletion of the C-terminal six amino acids drastically reduced sumoylation, indicating that the C-terminal six amino acids stretch is the main sumoylation site for Axin. Sumoylation-defective mutants failed to activate JNK but effectively destabilized beta-catenin and attenuated LEF1 transcriptional activity. In addition, we show that dominant negative Axin mutants blocked PIAS-mediated JNK activation, in accordance with the requirement of sumoylation for Axin-mediated JNK activation. Taken together, we demonstrate that sumoylation plays a role for Axin to function in the JNK pathway.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Tsing Hua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China	Hong Kong University of Science & Technology; Tsinghua University	Lin, SC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.		Lin, SC/G-4666-2010; Xu, Zhen/P-3029-2014; Rui, Hongliang/GNM-9930-2022	Xu, Zhen/0000-0002-2190-3861; Rui, Hongliang/0000-0002-7584-9610; Zhang, Yi/0000-0003-2785-1780				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Kadoya T, 2002, MOL CELL BIOL, V22, P3803, DOI 10.1128/MCB.22.11.3803-3819.2002; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Neo SY, 2000, BIOCHEM BIOPH RES CO, V272, P144, DOI 10.1006/bbrc.2000.2751; Nishida T, 2001, J BIOL CHEM, V276, P39060, DOI 10.1074/jbc.M103955200; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Polakis P, 2000, GENE DEV, V14, P1837; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P2851, DOI 10.1074/jbc.274.5.2851; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2002, J BIOL CHEM, V277, P17706, DOI 10.1074/jbc.M111982200; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	50	71	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42981	42986		10.1074/jbc.M208099200	http://dx.doi.org/10.1074/jbc.M208099200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12223491	hybrid			2022-12-25	WOS:000179081200073
J	Stevenson-Paulik, J; Odom, AR; York, JD				Stevenson-Paulik, J; Odom, AR; York, JD			Molecular and biochemical characterization of two plant inositol polyphosphate 6-/3-/5-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMATURE SOYBEAN SEEDS; MESSENGER-RNA EXPORT; 1,3,4,5,6-PENTAKISPHOSPHATE 2-KINASE; 1,3,4-TRISPHOSPHATE 5/6-KINASE; 1,4,5-TRISPHOSPHATE 3-KINASE; SACCHAROMYCES-CEREVISIAE; HEXAKISPHOSPHATE KINASE; MULTIKINASE; IDENTIFICATION; TRISPHOSPHATE	Despite the high deposition of inositol hexakisphosphate (IP6), also known as phytate or phytin, in certain plant tissues little is known at the molecular level about the pathway(s) involved in its production. In budding yeast, IP6 synthesis occurs through the sequential phosphorylation of I(1,4,5)P, by two gene products, Ipk2 and Ipk1, a IP3/IP4 dual-specificity 6-/3-kinase and an inositol 1,3,4,5,6-pentakisphosphate 2-kinase, respectively. Here we report the identification and characterization of two inositol polyphosphate kinases from Arabidopsis thaliana, designated AtIpk2alpha and AtIpk2beta that are encoded by distinct genes on chromosome 5 and that are ubiquitously expressed in mature tissue. The primary structures of AtIpk2alpha and AtIpk2beta are 70% identical to each other and 12-18% identical to Ipk2s from yeast and mammals. Similar to yeast Ipk2, purified recombinant AtIpk2alpha and AtIpk2beta have 6-/3-kinase activities that sequentially phosphorylate 1(1,4,5)P-3 to generate I(1,3,4,5,6)P-5 predominantly via an 1(1,4,5,6)P-4 intermediate. While 1(1,3,4,5)P-4 is a substrate for the plant Ipk2s, it does not appear to be a detectable product of the IP3 reaction. Additionally, we report that the plant and yeast Ipk2 have a novel 5-kinase activity toward I(1,3,4,6)P-4 and I(1,2,3,4,6)P-5, which would allow these proteins to participate in at least two proposed pathways in the synthesis of IP6. Heterologous expression of either plant isoform in an ipk2 mutant yeast strain restores IP4 and IP5 production in vivo and rescues its temperature-sensitive growth defects. Collectively our results provide a molecular basis for the synthesis of higher inositol polyphosphates in plants through multiple routes and indicate that the 6-/3-/5-kinase activities found in plant extracts may be encoded by the IPK2 gene class.	Duke Univ, Dept Pharmacol, Howard Hughes Med Inst, Med Ctr, Durham, NC 27710 USA; Duke Univ, Dept Canc Biol, Howard Hughes Med Inst, Med Ctr, Durham, NC 27710 USA; Duke Univ, Dept Biochem, Howard Hughes Med Inst, Med Ctr, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	York, JD (corresponding author), Duke Univ, Dept Pharmacol, Howard Hughes Med Inst, Med Ctr, Durham, NC 27710 USA.	yorkj@duke.edu	John, Audrey Odom/AAF-1300-2019	John, Audrey Odom/0000-0001-8395-8537	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-55672] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berdy SE, 2001, PLANT PHYSIOL, V126, P801, DOI 10.1104/pp.126.2.801; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brearley CA, 1996, BIOCHEM J, V314, P227, DOI 10.1042/bj3140227; CHATTAWAY JA, 1992, PLANTA, V187, P542, DOI 10.1007/BF00199975; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; COMMUNI D, 1995, CELL SIGNAL, V7, P643, DOI 10.1016/0898-6568(95)00035-N; Dubois E, 2002, J BIOL CHEM, V277, P23755, DOI 10.1074/jbc.M202206200; Ho MWY, 2002, CURR BIOL, V12, P477, DOI 10.1016/S0960-9822(02)00713-3; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Ives EB, 2000, J BIOL CHEM, V275, P36575, DOI 10.1074/jbc.M007586200; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Loewus FA, 2000, PLANT SCI, V150, P1, DOI 10.1016/S0168-9452(99)00150-8; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Phillippy BQ, 1998, PLANT PHYSIOL, V116, P291, DOI 10.1104/pp.116.1.291; PHILLIPPY BQ, 1994, J BIOL CHEM, V269, P28393; RABOY V, 1990, PLANT BIOL, V9, P55; Raboy V, 1996, Subcell Biochem, V26, P257; Raboy V, 2001, TRENDS PLANT SCI, V6, P458, DOI 10.1016/S1360-1385(01)02104-5; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; Schell MJ, 1999, FEBS LETT, V461, P169, DOI 10.1016/S0014-5793(99)01462-3; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Togashi S, 1997, BIOCHEM J, V326, P221, DOI 10.1042/bj3260221; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; Wilson MP, 1997, BIOCHEM BIOPH RES CO, V232, P678, DOI 10.1006/bbrc.1997.6355; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; Zhang T, 2001, FEBS LETT, V494, P208, DOI 10.1016/S0014-5793(01)02351-1	35	100	115	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42711	42718		10.1074/jbc.M209112200	http://dx.doi.org/10.1074/jbc.M209112200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12226109	hybrid			2022-12-25	WOS:000179081200038
J	Wang, JW; Barsky, LW; Shum, CH; Jong, A; Weinberg, KI; Collins, SJ; Triche, TJ; Wu, LT				Wang, JW; Barsky, LW; Shum, CH; Jong, A; Weinberg, KI; Collins, SJ; Triche, TJ; Wu, LT			Retinoid-induced G(1) arrest and differentiation activation are associated with a switch to cyclin-dependent kinase-activating kinase hypophosphorylation of retinoic acid receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIH; ACUTE PROMYELOCYTIC LEUKEMIA; DOMINANT-NEGATIVE ACTIVITY; CAK ASSEMBLY FACTOR; RAR-ALPHA; CELL-CYCLE; GRANULOCYTIC DIFFERENTIATION; SUBSTRATE-SPECIFICITY; INHIBITOR P27(KIP1); FUNCTIONS AF-1	Cell cycle G(1) exit is a critical stage where cells commonly commit to proliferate or to differentiate, but the biochemical events that regulate the proliferation/differentiation (P/D) transition at G(1) exit are presently unclear. We previously showed that MAT1 (menage a trois 1), an assembly factor and targeting subunit of the cyclin-dependent kinase (CDK)-activating kinase (CAK), modulates CAK activities to regulate G(1) exit. Here we find that the retinoid-induced G(1) arrest and differentiation activation of cultured human leukemic cells are associated with a switch to CAK hypophosphorylation of retinoic acid receptor alpha (RARalpha) from CAK hyperphosphorylation of RARa. The switch to CAK hypophosphorylation of RARa is accompanied by decreased MAT1 expression and MAT1. fragmentation that occurs in the differentiating cells through the all-trans-retinoic acid (ATRA)-mediated proteasome degradation pathway. Because HL60R cells that harbor a truncated ligand-dependent AF-2 domain of RARalpha do not demonstrate any changes in MAT1 levels or CAK phosphorylation of RARalpha following ATRA stimuli, these biochemical changes appear to be mediated directly through RARalpha. These studies indicate that significant changes in MAT1. levels and CAK activities on RARalpha phosphorylation accompany the ATRA-induced G(1) arrest and differentiation activation, which provide new insights to explore the inversely coordinated P/D transition at G(1) exit.	Univ So Calif, Dept Pathol, Childrens Hosp Los Angeles, Keck Sch Med,Res Inst, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Res Inst, Div Res Immunol Bone Marrow Transplant, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Res Inst, Div Hematol Oncol, Los Angeles, CA 90027 USA; Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA; Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; Children's Hospital Los Angeles; Fred Hutchinson Cancer Center; University of Southern California	Wu, LT (corresponding author), Univ So Calif, Dept Pathol, Childrens Hosp Los Angeles, Keck Sch Med,Res Inst, Mail Stop 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.							Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Ohnuma S, 2001, CURR OPIN NEUROBIOL, V11, P66, DOI 10.1016/S0959-4388(00)00175-6; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROBERTSON KA, 1992, BLOOD, V80, P1885; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Rossi DJ, 2001, EMBO J, V20, P2844, DOI 10.1093/emboj/20.11.2844; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Slack JL, 2000, ANN HEMATOL, V79, P227, DOI 10.1007/s002770050585; Studzinski GP, 1999, INT REV CYTOL, V189, P1, DOI 10.1016/S0074-7696(08)61384-4; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; Wu LT, 2001, MOL CELL BIOL, V21, P260, DOI 10.1128/MCB.21.1.260-270.2001; Wu LT, 1999, J BIOL CHEM, V274, P5564, DOI 10.1074/jbc.274.9.5564; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; YEE A, 1995, CANCER RES, V55, P6058; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	47	41	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43369	43376		10.1074/jbc.M206792200	http://dx.doi.org/10.1074/jbc.M206792200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12213824	hybrid			2022-12-25	WOS:000179081200121
J	Delgado, M; Leceta, J; Ganea, D				Delgado, M; Leceta, J; Ganea, D			Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells	FASEB JOURNAL			English	Article						VIP; PACAP; neuroimmunomodulation; memory T cells; apoptosis	T-CELLS; FAS LIGAND; INDUCED APOPTOSIS; VIP; EXPRESSION; LYMPHOCYTES; DEATH; NEUROPEPTIDES; TRANSCRIPTION; MACROPHAGES	Functionally active effector T cells are generated through clonal expansion. Most effector T cells are later eliminated, whereas a small number survive and differentiate into memory T cells. The mechanisms by which some effector T cells escape apoptosis and become memory T cells are not understood. Neuropeptides such as the vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) inhibit antigen-induced apoptosis of CD4 T cells. By using an in vivo long-term experimental model, in which CD4 T cells from TRC-transgenic mice were transferred into hosts, we demonstrate that VIP and PACAP induce the survival and/or generation of antigen-specific CD4 T cells with a memory Th2 phenotype. This was confirmed by the fact that transgenic CD4 T cells were recovered only from mice that received Th2, but not Th1 effector cells, in the presence of VIP or PACAP. In vitro, VIP/PACAP support the survival of Th2, but not Th1, cell lines through an inhibition of antigen-induced apoptosis. The role of neuropeptides in the biased development of Th2 memory cells is particularly relevant in view of the immune deviation existing in immune-privileged sites such as the brain and eye, where Th2, but not Th1, responses occur in nonpathological conditions.	Univ Complutense, Fac Biol, Dept Biol Celular, E-28040 Madrid, Spain; Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA	Complutense University of Madrid; Rutgers State University Newark; Rutgers State University New Brunswick	Delgado, M (corresponding author), Univ Complutense, Sch Biol, Dept Cell Biol, E-28040 Madrid, Spain.	mariodm@bio.ucm.es	Leceta, Javier/H-6940-2017; Delgado, Mario/P-1524-2016	Leceta, Javier/0000-0003-4845-0046; Delgado, Mario/0000-0003-1893-5982				Bellinger DL, 1996, ADV NEUROIMMUNOL, V6, P5, DOI 10.1016/S0960-5428(96)00008-3; Cerwenka A, 1996, J IMMUNOL, V156, P459; Delgado M, 2000, J IMMUNOL, V164, P1200, DOI 10.4049/jimmunol.164.3.1200; Delgado M, 1999, ANN NY ACAD SCI, V897, P401, DOI 10.1111/j.1749-6632.1999.tb07909.x; Delgado M, 1999, J NEUROIMMUNOL, V96, P167, DOI 10.1016/S0165-5728(99)00023-5; Delgado M, 2001, J IMMUNOL, V166, P2907, DOI 10.4049/jimmunol.166.5.2907; Delgado M, 1999, J IMMUNOL, V163, P3629; Delgado M, 2001, J IMMUNOL, V166, P1028, DOI 10.4049/jimmunol.166.2.1028; Delgado M, 2000, J IMMUNOL, V165, P114, DOI 10.4049/jimmunol.165.1.114; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; Ganea D, 2001, ARCH IMMUNOL THER EX, V49, P101; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; Gomariz RP, 2001, CURR PHARM DESIGN, V7, P89, DOI 10.2174/1381612013398374; Harling-Berg CJ, 1999, J NEUROIMMUNOL, V101, P111, DOI 10.1016/S0165-5728(99)00130-7; Harmar AJ, 1998, PHARMACOL REV, V50, P265; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Leceta J, 1996, ADV NEUROIMMUNOL, V6, P29, DOI 10.1016/S0960-5428(96)00001-0; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Martinez C, 1999, J NEUROIMMUNOL, V93, P126, DOI 10.1016/S0165-5728(98)00216-1; MCCORMACK JE, 1993, J IMMUNOL, V150, P3785; POWERS GD, 1988, J IMMUNOL, V140, P3352; Pozo D, 2000, IMMUNOL TODAY, V21, P7, DOI 10.1016/S0167-5699(99)01525-X; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; Streilein JW, 2000, ANN NY ACAD SCI, V917, P297; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; Takahashi M, 1999, CLIN EXP IMMUNOL, V116, P231; Wang HY, 2000, J NEUROIMMUNOL, V104, P68, DOI 10.1016/S0165-5728(99)00244-1; WEINBERG AD, 1990, J IMMUNOL, V144, P1800; ZHANG XH, 1995, J EXP MED, V182, P699, DOI 10.1084/jem.182.3.699; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837; Zheng LX, 1998, J IMMUNOL, V160, P763	34	57	63	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1844	+		10.1096/fj.02-0248fje	http://dx.doi.org/10.1096/fj.02-0248fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223451				2022-12-25	WOS:000181189100002
J	Kogerman, P; Krause, D; Rahnama, F; Kogerman, L; Unden, AB; Zaphiropoulos, PG; Toftgard, R				Kogerman, P; Krause, D; Rahnama, F; Kogerman, L; Unden, AB; Zaphiropoulos, PG; Toftgard, R			Alternative first exons of PTCH1 are differentially regulated in vivo and may confer different functions to the PTCH1 protein	ONCOGENE			English	Article						PTCH1 tumour suppressor gene; alternative first exons; SHH; Smoh	BASAL-CELL CARCINOMA; STEROL-SENSING DOMAIN; SONIC HEDGEHOG; HUMAN HOMOLOG; VESICULAR TRAFFICKING; SOMATIC MUTATIONS; PATCHED PROTEIN; GENE; RECEPTOR; REGION	The PTCH1 gene is a human tumour suppressor gene frequently mutated in basal cell carcinoma (BCC) and several other tumour types. It encodes a receptor for soluble factors of the hedgehog family. Binding of hedgehog to the receptor relieves its inhibitory action on the transmembrane co-receptor Smoh. In this study we describe alternative first exons of the PTCH1 tumour suppressor gene and show that they are differentially regulated in normal tissues, exon 1B being expressed at very low levels and the major mRNA species containing exon 1 or 1A. Exon 1B transcripts were found to be specifically upregulated in nodular BCCs. The different PTCH1 transcripts all encode proteins that interact with Smoh in doubly transfected cells. Furthermore, functional assays demonstrated that whereas all PTCH1 isoforms can inhibit the activity of SHH, only the PTCH1B isoform is capable of fully inhibiting Smoh activity. The results indicate that in tumour cells the PTCH1B promoter is specifically activated and importantly, that the N-terminal part of PTCH1 including exon 1B is required for full inhibition of Smoh signaling but not for physical interaction with Smoh.	Karolinska Inst, Novum, Dept Biosci, Huddinge, Sweden; Tallinn Univ Technol, NICPB, EE-200108 Tallinn, Estonia; Tallinn Univ Technol, Gene Technol Ctr, EE-200108 Tallinn, Estonia	Karolinska Institutet; National Institute of Chemical Physics & Biophysics (NICPB); Tallinn University of Technology; Tallinn University of Technology	Toftgard, R (corresponding author), Karolinska Inst, Novum, Dept Biosci, Huddinge, Sweden.	Rune.Toftgard@cnt.ki.se	Kogerman, Priit/B-6333-2008	Zaphiropoulos, Peter/0000-0003-4298-3861				Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Incardona JP, 2000, P NATL ACAD SCI USA, V97, P12044, DOI 10.1073/pnas.220251997; Ingham PW, 2000, CURR BIOL, V10, P1315, DOI 10.1016/S0960-9822(00)00755-7; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 2000, MOL CELL, V6, P467, DOI 10.1016/S1097-2765(00)00045-9; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Martin V, 2001, CURR BIOL, V11, P601, DOI 10.1016/S0960-9822(01)00178-6; McGarvey TW, 1998, ONCOGENE, V17, P1167, DOI 10.1038/sj.onc.1202045; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; RUIZ I, 1997, CELL, V90, P193; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Strutt H, 2001, CURR BIOL, V11, P608, DOI 10.1016/S0960-9822(01)00179-8; Unden AB, 1997, CANCER RES, V57, P2336; Vorechovsky I, 1997, CANCER RES, V57, P4677; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wang XQ, 2001, J BIOL CHEM, V276, P1311, DOI 10.1074/jbc.M005191200; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Zaphiropoulos PG, 1996, DNA CELL BIOL, V15, P1049, DOI 10.1089/dna.1996.15.1049	22	54	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6007	6016		10.1038/sj.onc.1205865	http://dx.doi.org/10.1038/sj.onc.1205865			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203113				2022-12-25	WOS:000177671300004
J	Wu, CG; Forgues, M; Siddique, S; Farnsworth, J; Velerie, K; Wang, XW				Wu, CG; Forgues, M; Siddique, S; Farnsworth, J; Velerie, K; Wang, XW			SAGE transcript profiles of normal primary human hepatocytes expressing oncogenic hepatitis B virus X protein	FASEB JOURNAL			English	Article						liver cancer; Megarray; nuclear export signal	GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; SERIAL ANALYSIS; LIVER-CANCER; HEPATOCARCINOGENESIS; INFECTION; LOCALIZATION; ETIOLOGY; COMPLEX	Hepatitis B virus (HBV) is a major risk factor for hepatocellular carcinoma (HCC). HBV encodes an oncogenic HBx gene that functions as a transcriptional coactivator of multiple cellular genes. To understand the role(s) of HBx in the early genesis of HCC, we systematically analyzed gene expression profiles by serial analysis of gene expression (SAGE) in freshly isolated human primary hepatocytes infected with a replication-defective adenovirus containing HBx. A total of 19,501 sequence tags (representing 1443 unique transcripts) were analyzed, which provide a distribution of a transcriptome characteristic of normal hepatocytes and a profile associated with HBx expression. Examples of the targeted genes were confirmed by the Megarray analysis with a significant correlation between quantitative SAGE and Megarray (r = 0.8, P < 0.005). In HBx-expressing hepatocytes, a total of 57 transcripts (3.9%) were induced, and 46 transcripts (3.3%) were repressed by more than fivefold. Interestingly, most of the HBx-up-regulated transcripts can be clustered into three major classes, including genes that encode ribosomal proteins, transcription factors with zinc-finger motifs, and proteins associated with protein degradation pathways. These results suggest that HBx may function as a major regulator in common cellular pathways that, in turn, regulate protein synthesis, gene transcription, and protein degradation.	NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; US FDA, Div Hematol, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); Virginia Commonwealth University	Wang, XW (corresponding author), NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, 37 Convent Dr,MSC 4255,Bldg 37,Room 2C25, Bethesda, MD 20892 USA.	xin_wei_wang@nih.gov	Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Andrisani OM, 1999, INT J ONCOL, V15, P373; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bradley DW, 1999, P ASSOC AM PHYSICIAN, V111, P588, DOI 10.1046/j.1525-1381.1999.t01-1-99240.x; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; CASELMANN WH, 1995, J HEPATOL, V22, P34; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; Forgues M, 2001, J BIOL CHEM, V276, P22797, DOI 10.1074/jbc.M101259200; Heinrich JM, 2001, J IMMUNOL, V167, P1624, DOI 10.4049/jimmunol.167.3.1624; Hoare J, 2001, J MED VIROL, V64, P419, DOI 10.1002/jmv.1067; Hough CD, 2000, CANCER RES, V60, P6281; KAWAMATA H, 1995, INT J CANCER, V63, P680, DOI 10.1002/ijc.2910630513; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; LAI WS, 1995, J BIOL CHEM, V270, P25266, DOI 10.1074/jbc.270.42.25266; Maddrey WC, 2000, J MED VIROL, V61, P362, DOI 10.1002/1096-9071(200007)61:3&lt;362::AID-JMV14&gt;3.0.CO;2-I; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Robinson WS, 1999, MICROBES AND MALIGNANCY, P232; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Song J, 2001, J BIOL CHEM, V276, P19897, DOI 10.1074/jbc.M010658200; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Vernon E, 2001, MOL CELL NEUROSCI, V17, P637, DOI 10.1006/mcne.2000.0960; Wu CG, 1996, BBA-MOL BASIS DIS, V1315, P169, DOI 10.1016/0925-4439(95)00117-4; Wu CG, 1997, CARCINOGENESIS, V18, P47, DOI 10.1093/carcin/18.1.47; Wu CG, 2001, ONCOGENE, V20, P3674, DOI 10.1038/sj.onc.1204481; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V269, P110, DOI 10.1006/bbrc.2000.2272; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P339, DOI 10.1046/j.1440-1746.2000.02166.x; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Zhang ZS, 2000, J BIOL CHEM, V275, P15157, DOI 10.1074/jbc.M910378199; Zhou W, 1998, CANCER EPIDEM BIOMAR, V7, P109; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	39	26	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10					1665	+		10.1096/fj.02-0074fje	http://dx.doi.org/10.1096/fj.02-0074fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207007				2022-12-25	WOS:000177814000019
J	Rebuffat, AG; Nawrocki, AR; Nielsen, PE; Bernasconi, AG; Bernal-Mendez, E; Frey, BM; Frey, FJ				Rebuffat, AG; Nawrocki, AR; Nielsen, PE; Bernasconi, AG; Bernal-Mendez, E; Frey, BM; Frey, FJ			Gene delivery by a steroid-peptide nucleic acid conjugate	FASEB JOURNAL			English	Article						nonviral; peptide nucleic acid; glucocorticosteroid; glucocorticoid receptor	ESTROGEN-RECEPTOR-BETA; PLASMID DNA; GLUCOCORTICOID RECEPTOR; STRAND DISPLACEMENT; PROSTATE-CANCER; BREAST-CANCER; LIVING CELLS; EXPRESSION; PNA; BINDING	We previously introduced a method called steroid-mediated gene delivery (SMGD), which uses steroid receptors as shuttles to facilitate the nuclear uptake of transfected DNA. Here, we describe a SMGD strategy with peptide nucleic acids (PNAs) that allowed linkage of a steroid molecule to a defined position in a plasmid without disturbing its gene expression. We synthesized and tested several bifunctional steroid derivatives [patent in process of nationalization] and finally selected the compound named DEX-bisPNA, a molecule consisting of a dexamethasone moiety linked to a PNA clamp (bisPNA) through a 30-atom chemical spacer. Dex-bisPNA binds to the glucocorticoid receptor (GR) as well as to reporter plasmids containing the corresponding PNA binding sites, translocates the GR from the cytoplasm into the nucleus, and increases the delivery of plasmid to the nucleus, resulting in enhanced GR-dependent expression of the reporter gene. The SMGD effect was more pronounced in growth-arrested cells than in proliferating cells. The specificity for the GR was shown by the reversion of the SMGD effect in the presence of dexamethasone as well as an enhanced expression in GR-positive cells but not in GR-negative cells. Thus, SMGD with PNA is a promising strategy for nonviral gene delivery into target tissues expressing specific steroid receptors.	Univ Bern, Div Nephrol & Hypertens, Dept Med, CH-3010 Bern, Switzerland; Univ Bern, Div Nephrol & Hypertens, Dept Clin Res, CH-3010 Bern, Switzerland; Univ Bern, Dept Chem, CH-3010 Bern, Switzerland; Univ Copenhagen, Panum Inst, Dept B, Ctr Biomol Recognit,IMBG, DK-2200 Copenhagen N, Denmark	University of Bern; University of Bern; University of Bern; University of Copenhagen	Frey, FJ (corresponding author), Univ Bern, Div Nephrol & Hypertens, Dept Med, Freiburgstr 15, CH-3010 Bern, Switzerland.	felix.frey@insel.ch						ACEDO M, 1995, BIOORG MED CHEM LETT, V5, P1577, DOI 10.1016/0960-894X(95)00274-W; AKNER G, 1995, J STEROID BIOCHEM, V52, P1, DOI 10.1016/0960-0760(94)00155-F; Becker K, 1999, HUM GENE THER, V10, P2559, DOI 10.1089/10430349950016898; Bernasconi A, 2001, TETRAHEDRON LETT, V42, P6511, DOI 10.1016/S0040-4039(01)01291-6; BERNASCONI AG, 2001, THESIS U BERN, P1; Boulikas T., 1998, GENE THER MOL BIOL, V1, P713; Branden LJ, 1999, NAT BIOTECHNOL, V17, P784, DOI 10.1038/11726; Brinkmann AO, 2000, NAT MED, V6, P628, DOI 10.1038/76194; Brunner S, 2000, GENE THER, V7, P401, DOI 10.1038/sj.gt.3301102; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; Cheng PW, 1996, HUM GENE THER, V7, P275, DOI 10.1089/hum.1996.7.3-275; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHRISTENSEN L, 1995, J PEPT SCI, V1, P175, DOI DOI 10.1002/PSC.310010304; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; DEMIDOV VV, 1995, P NATL ACAD SCI USA, V92, P2637, DOI 10.1073/pnas.92.7.2637; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1995, NUCLEIC ACIDS RES, V23, P217, DOI 10.1093/nar/23.2.217; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P9677, DOI 10.1021/ja00050a068; FUNDER JW, 1973, ENDOCRINOLOGY, V92, P1005, DOI 10.1210/endo-92-4-1005; FUNDER JW, 1992, SEMIN NEPHROL, V12, P6; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBERG ME, 1997, CURR PROT MOL BIOL, V1; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; HOUSLEY PR, 1989, BIOCHEM BIOPH RES CO, V164, P480, DOI 10.1016/0006-291X(89)91745-2; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Kersten S, 2001, FASEB J, V15, P1971, DOI 10.1096/fj.01-0147com; Kuhn H, 1998, NUCLEIC ACIDS RES, V26, P582, DOI 10.1093/nar/26.2.582; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867; Liang KW, 2000, MOL THER, V1, P236, DOI 10.1006/mthe.2000.0043; Ma Haiching, 2001, Current Pharmaceutical Biotechnology, V2, P1, DOI 10.2174/1389201013378770; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mesika A, 2001, MOL THER, V3, P653, DOI 10.1006/mthe.2001.0312; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MONDER C, 1991, FASEB J, V5, P3047, DOI 10.1096/fasebj.5.15.1743437; Mortimer I, 1999, GENE THER, V6, P403, DOI 10.1038/sj.gt.3300837; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1999, PEPTIDE NUCL ACIDS P, P253; Nielsen Peter E., 1994, Journal of Molecular Recognition, V7, P165, DOI 10.1002/jmr.300070303; Nishikawa M, 2001, HUM GENE THER, V12, P861, DOI 10.1089/104303401750195836; Odermatt A, 2001, J BIOL CHEM, V276, P28484, DOI 10.1074/jbc.M100374200; Pampinella F, 2002, MOL THER, V5, P161, DOI 10.1006/mthe.2002.0528; Perales JC, 1997, J BIOL CHEM, V272, P7398, DOI 10.1074/jbc.272.11.7398; Pratt WB, 2001, TRENDS PLANT SCI, V6, P54, DOI 10.1016/S1360-1385(00)01843-4; Rebuffat A, 2001, NAT BIOTECHNOL, V19, P1155, DOI 10.1038/nbt1201-1155; Reid P, 1999, INVEST NEW DRUG, V17, P271, DOI 10.1023/A:1006344807086; Sebestyen MG, 1998, NAT BIOTECHNOL, V16, P80, DOI 10.1038/nbt0198-80; Speirs V, 1999, CANCER RES, V59, P5421; Vacik J, 1999, GENE THER, V6, P1006, DOI 10.1038/sj.gt.3300924; Veselkov AG, 1996, NUCLEIC ACIDS RES, V24, P2483, DOI 10.1093/nar/24.13.2483; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; Ward CM, 2000, CURR OPIN MOL THER, V2, P182; Wei P, 1998, J STEROID BIOCHEM, V64, P1, DOI 10.1016/S0022-1759(97)89907-3; Zelphati O, 1999, HUM GENE THER, V10, P15, DOI 10.1089/10430349950019156; Zelphati O, 2000, BIOTECHNIQUES, V28, P304, DOI 10.2144/00282rr01	58	46	53	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					1426	+		10.1096/fj.01-0706fje	http://dx.doi.org/10.1096/fj.01-0706fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205036				2022-12-25	WOS:000177813100019
J	Werz, O; Burkert, E; Fischer, L; Szellas, D; Dishart, D; Samuelsson, B; Radmark, O; Steinhilber, D				Werz, O; Burkert, E; Fischer, L; Szellas, D; Dishart, D; Samuelsson, B; Radmark, O; Steinhilber, D			Extracellular signal-regulated kinases phosphorylate 5-lipoxygenase and stimulate 5-lipoxygenase product formation in leukocytes	FASEB JOURNAL			English	Article						arachidonic acid; leukotriene; p38 MAP kinase	ACTIVATED PROTEIN-KINASE; CYTOSOLIC PHOSPHOLIPASE A(2); ARACHIDONIC-ACID RELEASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; MYELIN BASIC-PROTEIN; HUMAN-NEUTROPHILS; LEUKOTRIENE SYNTHESIS; SUBSTRATE RECOGNITION; CHEMOTACTIC FACTOR; HUMAN EOSINOPHILS	5-Lipoxygenase (5-LO) is the key enzyme in the biosynthesis of proinflammatory leukotrienes. Here, we demonstrate that extracellular signal-regulated kinases (ERKs) can phosphorylate 5-LO in vitro. Efficient phosphorylation required the presence of unsaturated fatty acids and was abolished when Ser-663 was mutated to alanine. In intact HeLa cells stimulated with arachidonic acid (AA), impaired 5-LO product formation was evident in cells expressing the S663A-5-LO mutant compared with cells expressing wild-type 5-LO. For Mono Mac 6 cells, priming with phorbol myristate acetate (PMA) before stimulation with ionophore was required for ERK1/2 activation and efficient 5-LO phosphorylation, in parallel with substantial AA release and 5-LO product formation. Inhibition of PKC by GF109203x or MEK1/2 by U0126 (or PD98059) abolished the 5-LO up-regulation effects of PMA. In contrast, these inhibitors failed to suppress 5-LO product formation induced by stimuli such as AA plus ionophore, which apparently do not involve the ERK1/2 pathway. Based on inhibitor studies, ERKs are also involved in AA-stimulated 5-LO product formation in PMNL, whereas a role for ERKs is not apparent in 5-LO activation induced by ionophore or cell stress. Finally, the data suggest that ERKs and p38 MAPK-regulated MAPKAPKs can act in conjunction to stimulate 5-LO by phosphorylation.	Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60439 Frankfurt, Germany; Karolinska Inst, Div Physiol Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Goethe University Frankfurt; Karolinska Institutet	Werz, O (corresponding author), Goethe Univ Frankfurt, Inst Pharmaceut Chem, Marie Curie Str 9, D-60439 Frankfurt, Germany.	o.werz@pharmchem.uni-frankfurt.de	Steinhilber, Dieter/J-3221-2012					Ahamed J, 2002, J BIOL CHEM, V277, P22685, DOI 10.1074/jbc.M110210200; Bates ME, 2000, J BIOL CHEM, V275, P10968, DOI 10.1074/jbc.275.15.10968; Boden SE, 2000, INT J BIOCHEM CELL B, V32, P1069, DOI 10.1016/S1357-2725(00)00049-2; Boden SE, 2001, MOL PHARMACOL, V60, P267, DOI 10.1124/mol.60.2.267; BRUNGS M, 1995, P NATL ACAD SCI USA, V92, P107, DOI 10.1073/pnas.92.1.107; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; Caporale T, 1998, APPL ECON LETT, V5, P165, DOI 10.1080/758521375; Chang LC, 2001, J LEUKOCYTE BIOL, V69, P659; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Elzi DJ, 2001, AM J PHYSIOL-CELL PH, V281, pC350; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; HAMMARBERG T, 1995, EUR J BIOCHEM, V230, P401; Hammarberg T, 1999, BIOCHEMISTRY-US, V38, P4441, DOI 10.1021/bi9824700; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Lepley RA, 1998, ARCH BIOCHEM BIOPHYS, V356, P71, DOI 10.1006/abbi.1998.0744; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Lepley RA, 1996, ARCH BIOCHEM BIOPHYS, V331, P141, DOI 10.1006/abbi.1996.0292; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; NACCACHE PH, 1989, BRIT J PHARMACOL, V97, P461, DOI 10.1111/j.1476-5381.1989.tb11973.x; NACCACHE PH, 1979, SCIENCE, V203, P461, DOI 10.1126/science.760200; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; Provost P, 2001, J BIOL CHEM, V276, P16520, DOI 10.1074/jbc.M011205200; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Radmark OP, 2000, AM J RESP CRIT CARE, V161, pS11, DOI 10.1164/ajrccm.161.supplement_1.ltta-3; ROUZER CA, 1986, FEBS LETT, V204, P293, DOI 10.1016/0014-5793(86)80831-6; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHATZMUNDING M, 1991, EUR J BIOCHEM, V197, P487, DOI 10.1111/j.1432-1033.1991.tb15936.x; Surette ME, 1999, MOL PHARMACOL, V56, P1055, DOI 10.1124/mol.56.5.1055; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 1996, EUR J BIOCHEM, V242, P90, DOI 10.1111/j.1432-1033.1996.0090r.x; Werz O, 2002, J BIOL CHEM, V277, P14793, DOI 10.1074/jbc.M111945200; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; Werz O, 2001, BLOOD, V97, P2487, DOI 10.1182/blood.V97.8.2487; Werz O, 2001, J LEUKOCYTE BIOL, V70, P830; Werz O, 1996, PHARMAZIE, V51, P893; WHITE JR, 1983, BIOCHEM BIOPH RES CO, V113, P44, DOI 10.1016/0006-291X(83)90429-1; Zhu XD, 2001, J IMMUNOL, V167, P461, DOI 10.4049/jimmunol.167.1.461	52	114	117	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1441	+		10.1096/fj.01-0909fje	http://dx.doi.org/10.1096/fj.01-0909fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205041				2022-12-25	WOS:000177813100018
J	van Rooij, E; Doevendans, PA; de Theije, CC; Babiker, FA; Molkentin, JD; De Windt, LJ				van Rooij, E; Doevendans, PA; de Theije, CC; Babiker, FA; Molkentin, JD; De Windt, LJ			Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; JUN NH2-TERMINAL KINASE; CARDIAC-HYPERTROPHY; NF-ATC; HEART-FAILURE; MUSCLE-CELLS; IN-VIVO; TARGETED INHIBITION; SIGNALING PATHWAYS; NEGATIVE REGULATOR	The calcium-activated phosphatase calcineurin has been implicated as a critical intracellular signal transducer of cardiomyocyte hypertrophy. Although previous data suggested the nuclear factor of activated T-cells (NFAT) as its sole transcriptional effector, the absolute requirement of NFAT as a mediator of calcineurin signaling has not been examined in the heart. We therefore investigated the expression and activation profile of NFAT genes in the heart. Four members (NFATc1-c4) are expressed in cardiomyocytes, elicit nuclear translocation upon calcineurin activation, and are able to drive transactivation of cardiac promoter luciferase constructs. To define the necessary function of NFAT factors as hypertrophic transducers, a dominant negative NFAT construct was created, encompassing part of the N-terminal region of NFATc4 containing a conserved calcineurin-binding motif. Cotransfection of this construct dose-dependently abrogated promoter activation, irrespective of the NFAT isoform used, whereas a control construct with the calcineurin-binding motif mutated displayed no such effects. Adenoviral gene transfer of dominant negative NFAT rendered cardiomyocytes resistant toward all aspects of calcineurin or agonist-induced cardiomyocyte hypertrophy, whereas adenoviral gene transfer of the control construct had no discernable effect on these parameters. These results indicate that multiple NFAT isoforms are expressed in cardiomyocytes where they function as necessary transducers of calcineurin in facilitating cardiomyocyte hypertrophy.	Univ Hosp, Dept Cardiol, Inst Cardiovasc Res, NL-6202 AZ Maastricht, Netherlands; Interuniv Cardiol Inst Netherlands, NL-3501 DG Utrecht, Netherlands; Childrens Hosp, Med Ctr, Dept Pediat, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	Maastricht University; Interuniversity Cardiology Institute of the Netherlands; Utrecht University; Cincinnati Children's Hospital Medical Center	De Windt, LJ (corresponding author), Univ Hosp, Dept Cardiol, Inst Cardiovasc Res, P Debeyelaan 25,POB 5800, NL-6202 AZ Maastricht, Netherlands.		de Windt, Leon/AAO-6395-2020	de Windt, Leon/0000-0002-7793-2856; Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL060562, T32HL007382, R01HL060562] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07382, HL60562] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Bueno OF, 2002, CARDIOVASC RES, V53, P806, DOI 10.1016/S0008-6363(01)00493-X; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Chuvpilo S, 1999, J IMMUNOL, V162, P7294; Cleland JGF, 2001, EUR HEART J, V22, P623, DOI 10.1053/euhj.2000.2493; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; De Windt LJ, 2001, P NATL ACAD SCI USA, V98, P3322, DOI 10.1073/pnas.031371998; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; DeWindt LJ, 1997, J MOL CELL CARDIOL, V29, P2095, DOI 10.1006/jmcc.1997.0444; Friday BB, 2001, J CELL SCI, V114, P303; Garcia-Cozar FJ, 1998, J BIOL CHEM, V273, P23877, DOI 10.1074/jbc.273.37.23877; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Hautala N, 2002, PFLUG ARCH EUR J PHY, V443, P362, DOI 10.1007/s004240100699; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Imamura R, 1998, J IMMUNOL, V161, P3455; Kakita T, 2001, CIRC RES, V88, P1239, DOI 10.1161/hh1201.091794; Kegley KM, 2001, DEV BIOL, V232, P115, DOI 10.1006/dbio.2001.0179; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Lim HW, 2000, CIRCULATION, V101, P2431, DOI 10.1161/01.CIR.101.20.2431; Lorell BH, 2000, CIRCULATION, V102, P470; Luo C, 1996, J EXP MED, V184, P141, DOI 10.1084/jem.184.1.141; Marttila M, 2001, ENDOCRINOLOGY, V142, P4693, DOI 10.1210/en.142.11.4693; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 2000, CIRC RES, V87, P731, DOI 10.1161/01.RES.87.9.731; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Schaap FG, 1999, CIRC RES, V85, P329, DOI 10.1161/01.RES.85.4.329; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Suzuki E, 2002, CIRC RES, V90, P1004, DOI 10.1161/01.RES.0000017629.70769.CC; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WILKINSON BJ, MOL CELL BIOL, V22, P7603; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2; Zou YZ, 2001, CIRCULATION, V104, P97, DOI 10.1161/01.CIR.104.1.97	61	96	100	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48617	48626		10.1074/jbc.M206532200	http://dx.doi.org/10.1074/jbc.M206532200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12226086	hybrid			2022-12-25	WOS:000179789600085
J	Shen, MR; Chou, CY; Hsu, KF; Ellory, JC				Shen, MR; Chou, CY; Hsu, KF; Ellory, JC			Osmotic shrinkage of human cervical cancer cells induces an extracellular Cl--dependent nonselective cation channel, which requires p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLECTING DUCT CELLS; ACTIVATED PROTEIN-KINASES; ENDOTHELIAL-CELLS; VOLUME REGULATION; HYPERTONICITY; CONDUCTANCE; MECHANISMS; EXPRESSION; PATHWAYS; STRESS	This study is to integrate a functional role of nonselective cation (NSC) channels into a model of volume regulation on osmotic shrinkage for human cervical cancer cells. Application of a hypertonic solution (400 mosm kg(-1)) induced cell shrinkage, which was accompanied by a 7-fold increase of inward currents at -80 mV from -4.1 +/- 0.4 pA pF(-1) to -29 +/- 1.1 pA pF(-1) (n = 36,p < 0.001). There is a good correlation of channel activity and cell volume changes. Replacement of bath Na+ by K+, Cs+, Li+, or Rb+ did not affect the stimulated inward current significantly, but replacement by Ca2+, Ba2+, or the impermeable cation N-methyl-D-glucamine abolished the inward current; this demonstrates that the shrinkage-induced currents discriminate poorly between monovalent cations but are not carried by divalent cations. Replacement of extracellular Cl- by gluconate abolished the shrinkage-induced currents in a concentration-dependent manner without changing the reversal potential. Gadolinium (Gd3+) inhibited the stimulated current, whereas bumetanide and amiloride had no inhibitory effect. Cell shrinkage triggered mitogen-activated protein (MAP) kinase cascades leading to the activation of MAP/extracellular signal-regulated kinase 1/2 (ERK1/2) kinase (MEK1/2), and p38 kinase. Interference with p38 MAPK by either the specific inhibitor (SB202190), or a dominant-negative mutant profoundly suppressed the activation of the shrinkage-induced NSC channels. In contrast, the regulatory mechanism of shrinkage-induced NSC channels was independent of the volume-responsive MEK1/2 signaling pathway. More importantly, the cell volume response to hypertonicity was inhibited significantly in p38 dominant-negative mutant or by SB202190. Therefore, p38 MAPK is critically involved in the activation of a shrinkage-induced NSC channel, which plays an important role in the volume regulation of human cervical cancer cells.	Natl Cheng Kung Univ, Coll Med, Dept Obstet & Gynecol, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 704, Taiwan; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	National Cheng Kung University; National Cheng Kung University; University of Oxford	Shen, MR (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan.		Hsu, Keng-Fu/C-1441-2009					Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; Bohmer C, 2001, FEBS LETT, V494, P125, DOI 10.1016/S0014-5793(01)02303-1; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHAN HC, 1992, SCIENCE, V257, P669, DOI 10.1126/science.1379742; Chang MY, 1999, EXP CELL RES, V248, P589, DOI 10.1006/excr.1999.4436; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Fisher AB, 2001, AM J PHYSIOL-LUNG C, V281, pL529, DOI 10.1152/ajplung.2001.281.3.L529; GRAY MA, 1990, BIOCHIM BIOPHYS ACTA, V1029, P33, DOI 10.1016/0005-2736(90)90433-O; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354; KAWAHARA K, 1991, AM J PHYSIOL, V260, pF27, DOI 10.1152/ajprenal.1991.260.1.F27; Koch JP, 2000, J MEMBRANE BIOL, V177, P231, DOI 10.1007/s002320010006; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; Muraki K, 2001, J PHYSIOL-LONDON, V537, P431, DOI 10.1111/j.1469-7793.2001.00431.x; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Nelson DJ, 1996, AM J PHYSIOL-CELL PH, V270, pC179, DOI 10.1152/ajpcell.1996.270.1.C179; Niggel J, 2000, J MEMBRANE BIOL, V174, P121, DOI 10.1007/s002320001037; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; OKADA Y, 1997, AM J PHYSIOL, V273, P755; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Reifarth FW, 1999, BBA-BIOMEMBRANES, V1417, P63, DOI 10.1016/S0005-2736(98)00257-0; Roger F, 1999, J BIOL CHEM, V274, P34103, DOI 10.1074/jbc.274.48.34103; ROSS PE, 1995, J GEN PHYSIOL, V106, P415, DOI 10.1085/jgp.106.3.415; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Shen MR, 2002, J BIOL CHEM, V277, P15592, DOI 10.1074/jbc.M111043200; Shen MR, 2002, PFLUG ARCH EUR J PHY, V444, P276, DOI 10.1007/s00424-002-0811-3; Shen MR, 2001, J PHYSIOL-LONDON, V537, P347, DOI 10.1111/j.1469-7793.2001.00347.x; Shen MR, 2000, J PHYSIOL-LONDON, V529, P385, DOI 10.1111/j.1469-7793.2000.00385.x; Urbach V, 1999, J MEMBRANE BIOL, V168, P29, DOI 10.1007/s002329900495; VOLK T, 1995, P NATL ACAD SCI USA, V92, P8478, DOI 10.1073/pnas.92.18.8478; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199	38	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45776	45784		10.1074/jbc.M207993200	http://dx.doi.org/10.1074/jbc.M207993200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12226098	hybrid			2022-12-25	WOS:000179529300010
J	Jung, J; Lee, SY; Hwang, SW; Cho, H; Shin, J; Kang, YS; Kim, S; Oh, L				Jung, J; Lee, SY; Hwang, SW; Cho, H; Shin, J; Kang, YS; Kim, S; Oh, L			Agonist recognition sites in the cytosolic tails of vanilloid receptor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; NONSELECTIVE CATION CHANNEL; ACTIVATED ION-CHANNEL; CAPSAICIN-RECEPTOR; PAIN PATHWAY; BINDING; DOMAIN; HEAT; ACID; HYPERALGESIA	Vanilloid receptor 1 (VR1), a ligand-gated ion channel activated by vanilloids, acid, and heat, is a molecular detector that integrates multiple modes of pain. Although the function and the biophysical properties of the channel are now known, the regions of VR1 that recognize ligands are largely unknown. By the stepwise deletion of VR1 and by chimera construction using its capsaicin-insensitive homologue, VRL1, we localized key amino acids, Arg-114 and Glu-761, in the N- and C-cytosolic tails, respectively, that determine ligand binding. Point mutations of the two key residues resulted in a loss of sensitivity to capsaicin and a concomitant loss of specific binding to [H-3]resiniferatoxin, a potent vanilloid. Furthermore, changes in the charges of the two amino acids blocked capsaicin-sensitive currents and ligand binding without affecting current responses to heat. Thus, these two regions in the cytoplasmic tails of VR1 provide structural elements for its hydrophilic interaction with vanilloids and might constitute a long-suspected binding pocket.	Seoul Natl Univ, Coll Pharm, Sensory Res Ctr, Creat Res Initiat,Kwanak Gu, Seoul 151742, South Korea; Seoul Natl Univ, Coll Pharm, Ctr Aminoacyl tRNA Synthetase Network, Creat Res Initiat,Kwanak Gu, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Oh, L (corresponding author), Seoul Natl Univ, Coll Pharm, Sensory Res Ctr, Creat Res Initiat,Kwanak Gu, Shinlim 9 Dong, Seoul 151742, South Korea.		Kim, Sunghoon/AAE-8314-2020	Hwang, Sun Wook/0000-0001-8460-7480				Acs G, 1996, MOL BRAIN RES, V35, P173, DOI 10.1016/0169-328X(95)00204-6; BEVAN S, 1990, TRENDS PHARMACOL SCI, V11, P330; BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Gunthorpe NJ, 2001, PFLUG ARCH EUR J PHY, V442, P668; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jung J, 1999, J NEUROSCI, V19, P529; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Kuzhikandathil EV, 2001, J NEUROSCI, V21, P8697, DOI 10.1523/JNEUROSCI.21-22-08697.2001; LAMOTTE RH, 1978, J NEUROPHYSIOL, V41, P509, DOI 10.1152/jn.1978.41.2.509; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; MEYER RA, 1981, SCIENCE, V213, P1527, DOI 10.1126/science.7280675; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Oh U, 1996, J NEUROSCI, V16, P1659; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Shin J, 2002, P NATL ACAD SCI USA, V99, P10150, DOI 10.1073/pnas.152002699; Shin JS, 2001, NEUROSCI LETT, V299, P135, DOI 10.1016/S0304-3940(00)01777-8; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; SZALLASI A, 1992, J PHARMACOL EXP THER, V262, P883; Szallasi A, 1999, MOL PHARMACOL, V56, P581, DOI 10.1124/mol.56.3.581; SZALLASI A, 1990, BRAIN RES, V524, P106, DOI 10.1016/0006-8993(90)90498-Z; Szallasi A, 1999, PHARMACOL REV, V51, P159; SZOLCSANYI J, 1975, ARZNEIMITTEL-FORSCH, V25, P1877; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; WALPOLE CSJ, 1993, J MED CHEM, V36, P2373, DOI 10.1021/jm00068a015; WALPOLE CSJ, 1993, CAPSAICIN STUDY PAIN; Welch JM, 2000, P NATL ACAD SCI USA, V97, P13889, DOI 10.1073/pnas.230146497; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	41	133	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44448	44454		10.1074/jbc.M207103200	http://dx.doi.org/10.1074/jbc.M207103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228246	hybrid			2022-12-25	WOS:000179272000116
J	Zhang, YB; Wu, XH; Guo, DY; Rechkoblit, O; Taylor, JS; Geacintov, NE; Wang, ZG				Zhang, YB; Wu, XH; Guo, DY; Rechkoblit, O; Taylor, JS; Geacintov, NE; Wang, ZG			Lesion bypass activities of human DNA polymerase mu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; TRANSLESION SYNTHESIS; MAMMALIAN-CELLS; SYNTHESIS PAST; THYMINE DIMER; UV-LIGHT; MUTAGENESIS; ADDUCTS	DNA polymerase mu (Polmu) is a newly discovered member of the polymerase X family with unknown cellular function. The understanding of Polmu function should be facilitated by an understanding of its biochemical activities. By using purified human Polmu for biochemical analyses, we discovered the lesion bypass activities of this polymerase in response to several types of damage. When it encountered a template 8-oxoguanine, abasic site, or 1,N-6-ethenoadenine, purified human Polmu efficiently bypassed the lesion. Even bulky DNA adducts such as N-2-acetylaminofluorene-adducted guanine, (+)-and (-)-trans-anti-benzo[a]pyrene-N-2-dG were unable to block the polymerase activity of human Polmu. Bypass of these simple base damage and bulky adducts was predominantly achieved by human Polmu through a deletion mechanism. The Polmu specificity of nueleotide incorporation indicates that the deletion resulted from primer realignment before translesion synthesis. Purified human Polmu also effectively bypassed a template cis-syn TT dimer. However, this bypass was achieved in a mainly error-free manner with AA incorporation opposite the TT dimer. These results provide new insights into the biochemistry of human Polmu and show that efficient translesion synthesis activity is not strictly confined to the Y family polymerases.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; NYU, Dept Chem, New York, NY 10003 USA; Washington Univ, Dept Chem, St Louis, MO 63130 USA	University of Kentucky; New York University; Washington University (WUSTL)	Wang, ZG (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.		Zhang, Yanbin/F-2998-2011; Taylor, John-Stephen/AAA-3218-2020	Zhang, Yanbin/0000-0002-7263-5510; Taylor, John-Stephen/0000-0002-8615-7257; Rechkoblit, Olga/0000-0003-4270-7242	NATIONAL CANCER INSTITUTE [R01CA040463, R01CA020851, R37CA040463, R01CA092528] Funding Source: NIH RePORTER; NCI NIH HHS [CA92528, CA40463, CA20851] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; BENTOLILA LA, 1995, EMBO J, V14, P4221, DOI 10.1002/j.1460-2075.1995.tb00096.x; CHANG LMS, 1986, CRC CR REV BIOCH MOL, V21, P27, DOI 10.3109/10409238609113608; Cleaver JE, 2000, J DERMATOL SCI, V23, P1, DOI 10.1016/S0923-1811(99)00088-2; COSMAN M, 1990, CARCINOGENESIS, V11, P1667, DOI 10.1093/carcin/11.9.1667; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Duvauchelle JB, 2002, NUCLEIC ACIDS RES, V30, P2061, DOI 10.1093/nar/30.9.2061; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; GEACINTOV NE, 1991, CARCINOGENESIS, V12, P2099, DOI 10.1093/carcin/12.11.2099; GENTIL A, 1992, J MOL BIOL, V227, P981, DOI 10.1016/0022-2836(92)90513-J; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Guo DY, 2001, NUCLEIC ACIDS RES, V29, P2875, DOI 10.1093/nar/29.13.2875; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Levine RL, 2000, CANCER RES, V60, P4098; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McGregor WG, 1999, MOL CELL BIOL, V19, P147; Moriya M, 1996, BIOCHEMISTRY-US, V35, P16646, DOI 10.1021/bi9608875; Nelson JR, 2000, MOL MICROBIOL, V37, P549, DOI 10.1046/j.1365-2958.2000.01997.x; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Rajpal DK, 2000, MUTAT RES-DNA REPAIR, V461, P133, DOI 10.1016/S0921-8777(00)00047-1; Rechkoblit O, 1999, BIOCHEMISTRY-US, V38, P11834, DOI 10.1021/bi990614k; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Shibutani S, 1998, BIOCHEMISTRY-US, V37, P12034, DOI 10.1021/bi981059+; SMITH CA, 1993, J BIOL CHEM, V268, P11143; Wang Z, 2001, Mol Interv, V1, P269; Wang ZG, 2001, MUTAT RES-DNA REPAIR, V486, P59, DOI 10.1016/S0921-8777(01)00089-1; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; Zhang YB, 2002, DNA REPAIR, V1, P559, DOI 10.1016/S1568-7864(02)00055-1; Zhang YB, 2001, MOL CELL BIOL, V21, P7995, DOI 10.1128/MCB.21.23.7995-8006.2001; Zhang YB, 2001, NUCLEIC ACIDS RES, V29, P928, DOI 10.1093/nar/29.4.928	42	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44582	44587		10.1074/jbc.M207297200	http://dx.doi.org/10.1074/jbc.M207297200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12228225	hybrid			2022-12-25	WOS:000179272000131
J	Bera, AK; Chatav, M; Akabas, MH				Bera, AK; Chatav, M; Akabas, MH			GABA(A) receptor M2-M3 loop secondary structure and changes in accessibility during channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING SEGMENT; NICOTINIC ACETYLCHOLINE-RECEPTOR; TRANSMEMBRANE ALPHA-HELICES; GATED CHLORIDE CHANNEL; ION CHANNELS; M2 SEGMENT; GLYCINE RECEPTORS; LINING RESIDUES; LIGAND-BINDING; A RECEPTORS	The gamma-aminobutyric acid type A (GABA(A)) receptor M2-M3 loop structure and its role in gating were investigated using the substituted cysteine accessibility method. Residues from alpha(1)Arg-273 to alpha(1)Ile-289 were mutated to cysteine, one at a time. MTSET' or MTSES(-)reacted with all mutants from alpha(1)R273C to alpha(1)Y281C, except alpha(1)P277C, in the absence and presence of GABA. The MTSET' closed-state reaction rate was >1000 liters/ mol-s at alpha(1)N274C, alpha(1)S275C, alpha(1)K278C, and alpha(1)Y281C and was <300 liters/mol-s at alpha(1)R273C, alpha(1)L276C, alpha(1)V279C, alpha(1)A280C, and alpha(1)A284C. These two groups of residues lie on opposite sides of an alpha-helix. The fast reacting group lies on a continuation of the M2 segment channel-lining helix face. This suggests that the M2 segment alpha-helix extends about two helical turns beyond alpha(1)N274 (20'), aligned with the extracellular ring of charge. At alpha(1)S275C, alpha(1)V279C, alpha(1)A280C, and alpha(1)A284C the reaction rate was faster in the presence of GABA. The reagents had no functional effect on the mutants from alA282C to alpha(1)I289C, except alpha(1)A284C. Access may be sterically hindered possibly by close interaction with the extracellular domain. We suggest that the M2 segment alpha-helix extends beyond the predicted extracellular end of the M2 segment and that gating induces a conformational change in and/or around the N-terminal half of the M2-M3 loop. Implications for coupling ligand-evoked conformational changes in the extracellular domain to channel gating in the membrane-spanning domain are discussed.	Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Akabas, MH (corresponding author), Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Bera, Amal Kanti/0000-0003-0362-5578; Akabas, Myles/0000-0001-8781-7846	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM063266, P01GM061925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030808] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61925, GM63266] Funding Source: Medline; NINDS NIH HHS [NS30808] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Boileau AJ, 1999, J NEUROSCI, V19, P10213; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; BROWN KA, 1993, P NATL ACAD SCI USA, V90, P11753, DOI 10.1073/pnas.90.24.11753; CamposCaro A, 1996, P NATL ACAD SCI USA, V93, P6118, DOI 10.1073/pnas.93.12.6118; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; Davies M, 2001, J NEUROCHEM, V79, P55, DOI 10.1046/j.1471-4159.2001.00527.x; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; Grosman C, 2000, J GEN PHYSIOL, V116, P327, DOI 10.1085/jgp.116.3.327; Horenstein J, 1998, MOL PHARMACOL, V53, P870; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KIENKER P, 1994, BIOPHYS J, V66, P325, DOI 10.1016/S0006-3495(94)80781-7; Klausberger T, 2000, J BIOL CHEM, V275, P8921, DOI 10.1074/jbc.275.12.8921; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; Le Novere N, 1999, BIOPHYS J, V76, P2329, DOI 10.1016/S0006-3495(99)77390-X; Le Novere N, 1999, NUCLEIC ACIDS RES, V27, P340, DOI 10.1093/nar/27.1.340; Lewis TM, 1998, J PHYSIOL-LONDON, V507, P25, DOI 10.1111/j.1469-7793.1998.025bu.x; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; Lynch JW, 2001, J NEUROSCI, V21, P2589, DOI 10.1523/JNEUROSCI.21-08-02589.2001; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; Nilsson I, 1998, J MOL BIOL, V284, P1185, DOI 10.1006/jmbi.1998.2219; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; O'Shea SM, 2000, J BIOL CHEM, V275, P22764, DOI 10.1074/jbc.M001299200; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Ranganathan R, 2000, NATURE, V408, P470, DOI 10.1038/35044083; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Rovira JC, 1999, PFLUG ARCH EUR J PHY, V439, P86, DOI 10.1007/s004240051131; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; Sieghart W, 1999, NEUROCHEM INT, V34, P379, DOI 10.1016/S0197-0186(99)00045-5; Sigel E, 1999, J NEUROCHEM, V73, P1758, DOI 10.1046/j.1471-4159.1999.731758.x; Taylor PM, 2000, J NEUROSCI, V20, P1297; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Vassilatis DK, 1997, J MOL EVOL, V44, P501, DOI 10.1007/PL00006174; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; Wang CT, 1999, BIOPHYS J, V77, P691, DOI 10.1016/S0006-3495(99)76924-9; Williams DB, 2000, MOL PHARMACOL, V58, P1129, DOI 10.1124/mol.58.5.1129; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m	53	82	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43002	43010		10.1074/jbc.M206321200	http://dx.doi.org/10.1074/jbc.M206321200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12226083	hybrid			2022-12-25	WOS:000179081200076
J	Feng, B; Tabas, I				Feng, B; Tabas, I			ABCAl-mediated cholesterol efflux is defective in free cholesterol-loaded macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; ACYL-COENZYME-A; HUMAN ATHEROSCLEROTIC PLAQUES; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; J774 MACROPHAGES; PLASMA-MEMBRANE; TANGIER-DISEASE; UP-REGULATION; CELLS	In advanced atherosclerosis, macrophage foam cells progressively accumulate large amounts of unesterified or "free" cholesterol (FC), a process that is thought to contribute to foam cell death and lesional necrosis. The cellular consequences of early FC accumulation, including those that lead to further FC accumulation, are poorly understood. In this context, we show that cholesterol and phospholipid efflux mediated by ABCA1, which is initially induced in the cholesterol-loaded macrophage, was inhibited by similar to80% in pre-toxic FC-loaded macrophages. Cholesterol efflux to HDL2, which is mediated by a non-ABCA1 pathway, was inhibited by only similar to20% in FC-loaded macrophages. FC loading led to decreased levels of ABCA1 protein via increased degradation of ABCA1, and not by decreased transcription or translation of AbcA1 mRNA. The decrease in ABCA1 protein occurred relatively early and was not prevented by caspase inhibitors, indicating that it was not a consequence of FC-induced apoptosis. However, inhibition of proteasomal function by lactacystin largely prevented the degradation of ABCA1 Importantly, the FC-induced decrease in ABCA1 function and protein was almost entirely prevented in macrophages that had partial deficiency of npc1 or were exposed to nanomolar concentrations of U18666A, both of which lead to defective cholesterol trafficking to the endoplasmic reticulum, but leave trafficking to the plasma membrane largely intact. Thus, a relatively early event during FC loading of macrophages is increased degradation of ABCA1, which appears to require trafficking of cholesterol to a peripheral cellular site, but not bulk trafficking of excess cholesterol to the plasma membrane. These findings provide new insight into the post-translational regulation of ABCA1 and the pathobiology of the FC-loaded macrophage.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University; Columbia University	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.				NHLBI NIH HHS [HL-54591] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P630, DOI 10.1161/01.ATV.0000014804.35824.DA; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Attie AD, 2001, J LIPID RES, V42, P1717; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Bauriedel G, 1997, Z KARDIOL, V86, P902, DOI 10.1007/s003920050130; BERBERIAN PA, 1990, AM J PATHOL, V136, P71; Blom TS, 2001, BIOCHEMISTRY-US, V40, P14635, DOI 10.1021/bi0156714; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Fazio S, 2001, J CLIN INVEST, V107, P163, DOI 10.1172/JCI10310; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; Gillotte-Taylor K, 2002, J BIOL CHEM, V277, P11811, DOI 10.1074/jbc.M108268200; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Kellner-Weibel G, 1999, ATHEROSCLEROSIS, V146, P309, DOI 10.1016/S0021-9150(99)00155-0; Kolodgie FD, 2000, AM J PATHOL, V157, P1259, DOI 10.1016/S0002-9440(10)64641-X; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Leventhal AR, 2001, J BIOL CHEM, V276, P44976, DOI 10.1074/jbc.M106455200; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Mitchinson MJ, 1996, CURR OPIN LIPIDOL, V7, P324, DOI 10.1097/00041433-199610000-00011; Mori M, 2001, J LIPID RES, V42, P1771; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2001, J LIPID RES, V42, P1173; RAPP JH, 1983, J LIPID RES, V24, P1329; RINNINGER F, 1995, BBA-LIPID LIPID MET, V1255, P141, DOI 10.1016/0005-2760(94)00228-Q; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; Schmitz Gerd, 2002, Curr Atheroscler Rep, V4, P243, DOI 10.1007/s11883-002-0026-2; SHIO H, 1979, LAB INVEST, V41, P160; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; Tabas I, 2000, BBA-MOL CELL BIOL L, V1529, P164, DOI 10.1016/S1388-1981(00)00146-3; Tall AR, 2000, J CLIN INVEST, V106, P1205, DOI 10.1172/JCI11538; Tang W, 1999, BBA-MOL CELL BIOL L, V1437, P301, DOI 10.1016/S1388-1981(99)00023-2; Underwood KW, 1996, J LIPID RES, V37, P1556; van Dam MJ, 2002, LANCET, V359, P37, DOI 10.1016/S0140-6736(02)07277-X; Van Eck M, 2002, P NATL ACAD SCI USA, V99, P6298, DOI 10.1073/pnas.092327399; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200; Zhang DJ, 2000, J BIOL CHEM, V275, P35368, DOI 10.1074/jbc.M007099200; Zhang DJ, 2001, CIRCULATION, V104, P45; Zheng P, 2001, BBA-MOL CELL BIOL L, V1534, P121, DOI 10.1016/S1388-1981(01)00183-4	56	122	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43271	43280		10.1074/jbc.M207532200	http://dx.doi.org/10.1074/jbc.M207532200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12215451	hybrid			2022-12-25	WOS:000179081200110
J	Somalinga, BR; Roy, RP				Somalinga, BR; Roy, RP			Volume exclusion effect as a driving force for reverse proteolysis - Implications for polypeptide assemblage in a macromolecular crowded milieu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-ASSOCIATION; PEPTIDE LIGATION; FRAGMENTS; THERMOLYSIN; PROTEINS; SEMISYNTHESIS; KINETICS; MEDIA; CELL	Macromolecular crowding, in principle, should affect any reaction that is accompanied by significant reduction in excluded volume. Here we have examined the influence of crowding on reverse proteolysis. We show that proteosynthesis of a polypeptide product with an interacting folding motif such as coiled coil is facilitated in crowded media as a consequence of the volume exclusion effect. Further, we demonstrate that crowding could also effect the conversion of a noncovalent protein complex (fragment complementing protein) obtained by limited proteolysis to the native covalent form, but only if the formation of the native protein results in large compaction leading to a substantial volume exclusion effect. Subtilisin-catalyzed reformation of native triosephosphate isomerase (TIM) from multiple fragments is facilitated by crowding. However, a single nick in ribonuclease S (RNase S) could not be ligated under similar conditions. The failure of generation of RNase A from RNase S is consistent with the fact that the crystal structure of the two forms are almost superimposable, and hence no significant difference of volume exclusion exists between reactant (RNase S) and product (RNase A). In contrast, considerable compaction, and consequently large reduction in excluded volume, is attained through the assembly of a TIM barrel structure. Taken together, these results have implications for both in vitro as well as in vivo polypeptide assemblage by reverse proteolysis.	Natl Inst Immunol, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Roy, RP (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.							Boon CL, 2000, PROTEIN SCI, V9, P1011, DOI 10.1110/ps.9.5.1011; BORSOOK H, 1953, ADV PROTEIN CHEM, V8, P127, DOI 10.1016/S0065-3233(08)60092-3; CHAIKEN IM, 1981, CRC CR REV BIOCH MOL, V11, P255, DOI 10.3109/10409238109108703; CROOK EM, 1960, BIOCHEM J, V74, P234, DOI 10.1042/bj0740234; DEFILIPPIS V, 1990, INT J PEPT PROT RES, V35, P219; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; FRUTON JS, 1982, ADV ENZYMOL RAMB, V53, P239; HOMANDBERG GA, 1979, BIOCHEMISTRY-US, V18, P586, DOI 10.1021/bi00571a006; Kumaran S, 1997, PROTEIN SCI, V6, P2233; Kumaran S, 2000, PROTEIN SCI, V9, P734; LINDNER R, 1995, BIOPHYS CHEM, V57, P15, DOI 10.1016/0301-4622(95)00063-4; MATTHEWS JM, 1995, BIOCHEMISTRY-US, V34, P6805, DOI 10.1021/bi00020a027; MIN W, 1994, NAT STRUCT BIOL, V1, P502, DOI 10.1038/nsb0894-502; Minton AP, 1997, CURR OPIN BIOTECH, V8, P65, DOI 10.1016/S0958-1669(97)80159-0; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Minton AP, 2000, CURR BIOL, V10, pR97, DOI 10.1016/S0960-9822(00)00301-8; MONERA OD, 1993, J BIOL CHEM, V268, P19218; PARR GR, 1981, J BIOL CHEM, V256, P125; Ray SS, 1999, CHEM BIOL, V6, P625, DOI 10.1016/S1074-5521(99)80114-8; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; RICHARDS FREDERIC M., 1955, COMPT REND TRAV LAB CARLSBERG SER CHIM, V29, P322; Rivas G, 1999, BIOCHEMISTRY-US, V38, P9379, DOI 10.1021/bi990355z; Rivas G, 2001, P NATL ACAD SCI USA, V98, P3150, DOI 10.1073/pnas.051634398; Snyder R, 1975, Methods Enzymol, V41, P430; Srinivasulu S, 2002, PROTEIN SCI, V11, P1384, DOI 10.1110/ps.0201302; TANIUCHI H, 1977, J BIOL CHEM, V252, P125; TITANI K, 1972, BIOCHEMISTRY-US, V11, P2427, DOI 10.1021/bi00763a007; van den Berg B, 2000, EMBO J, V19, P3870, DOI 10.1093/emboj/19.15.3870; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; VOGEL K, 1994, J AM CHEM SOC, V116, P11164; WALLACE CJA, 1995, CURR OPIN BIOTECH, V6, P403, DOI 10.1016/0958-1669(95)80069-7; Zhou HX, 2001, BIOCHEMISTRY-US, V40, P11289, DOI 10.1021/bi0155504; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	36	29	30	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43253	43261		10.1074/jbc.M207974200	http://dx.doi.org/10.1074/jbc.M207974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12207031	hybrid			2022-12-25	WOS:000179081200108
J	Vilhardt, F; Plastre, O; Sawada, M; Suzuki, K; Wiznerowicz, M; Kiyokawa, E; Trono, D; Krause, KH				Vilhardt, F; Plastre, O; Sawada, M; Suzuki, K; Wiznerowicz, M; Kiyokawa, E; Trono, D; Krause, KH			The HIV-1 Nef protein and phagocyte NADPH oxidase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; IMMUNODEFICIENCY-VIRUS TYPE-1; SUPEROXIDE-PRODUCTION; CYTOSOLIC COMPONENTS; MICROGLIAL CELLS; MEMBRANE; RAC1; BINDING; KINASE; VAV	Nef, a multifunctional HIV protein, activates the Vav/ Rac/p21-activated kinase (PAK) signaling pathway. Given the potential role of this pathway in the activation of the phagocyte NADPH oxidase, we have investigated the effect of the HIV-1 Nef protein on the phagocyte respiratory burst. Microglia (cell line and primary culture) were transduced with lentiviral expression vectors. Expression of Nef did not activate the NADPH oxidase by itself but led to a massive enhancement of the responses to a variety of stimuli (Ca2+ ionophore, formyl peptide, endotoxin). These effects were not caused by up-regulation of phagocyte NADPH oxidase subunits. Nef mutants lacking motifs involved in the interaction with Vav and PAK failed to reproduce the effects of wild type Nef, suggesting a role for the Vav/Rac/PAK signaling pathway. The following results suggest a key role for Rac in the priming effect of Nef. (i) Inactivation of Rac by Clostridium difficile toxin B abolished the Nef effect. (ii) The fraction of activated Rac1 was increased in Nef-transduced cells, and (iii) the dominant positive Rac1(V12) mutant mimicked the effect of Nef. These results are to our knowledge the first analysis of the effect of Rac activation on the NADPH oxidase in intact phagocytes. Rac activation is not sufficient to stimulate the phagocyte NADPH oxidase; however, it markedly enhances the NADPH oxidase response to other stimuli.	Univ Hosp Geneva, Dept Geriatr, Biol Ageing Lab, CH-1225 Geneva, Switzerland; Fujita Hlth Univ, Inst Comprehens Med Sci, Joint Res Div Therapies Intractable Dis, Aichi 4701192, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Tokyo 3320012, Japan; NIID, Natl Inst Infect Dis, NIH, Shinjuku Ku, Tokyo 8640, Japan; Univ Geneva, Fac Med, Dept Genet & Microbiol, CH-1211 Geneva, Switzerland	University of Geneva; Fujita Health University; Japan Science & Technology Agency (JST); National Institute of Health Sciences - Japan; National Institute of Infectious Diseases (NIID); University of Geneva	Vilhardt, F (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Anat, Struct Cell Biol Unit, Bldg 18-4,Blegdamsvej 3A, DK-2200 Copenhagen N, Denmark.	fvilhardt@hotmail.com	Krause, Karl-Heinz/E-8030-2011; Vilhardt, Frederik/AAX-4766-2021	Krause, Karl-Heinz/0000-0002-9033-6768; Vilhardt, Frederik/0000-0001-8604-7165				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Ahmed S, 1998, J BIOL CHEM, V273, P15693, DOI 10.1074/jbc.273.25.15693; Aiken C, 1996, VIROLOGY, V217, P293, DOI 10.1006/viro.1996.0116; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; Bal-Price A, 2002, J NEUROCHEM, V80, P73, DOI 10.1046/j.0022-3042.2001.00675.x; Biggs TE, 1999, J MOL BIOL, V290, P21, DOI 10.1006/jmbi.1999.2849; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOKOCH GM, 1992, J CLIN INVEST, V89, P402, DOI 10.1172/JCI115599; Boquet P, 2001, TOXICON, V39, P1673, DOI 10.1016/S0041-0101(01)00154-4; Brigino E, 1997, P NATL ACAD SCI USA, V94, P3178, DOI 10.1073/pnas.94.7.3178; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; Cool RH, 1998, BIOCHEM J, V332, P5, DOI 10.1042/bj3320005; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Foti M, 1999, J BIOL CHEM, V274, P34765, DOI 10.1074/jbc.274.49.34765; FoyouziYoussefi R, 1997, BIOCHEM J, V322, P709, DOI 10.1042/bj3220709; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Inoue H, 1999, GLIA, V28, P265, DOI 10.1002/(SICI)1098-1136(199912)28:3<265::AID-GLIA10>3.0.CO;2-F; Johnson JL, 1998, J BIOL CHEM, V273, P35147, DOI 10.1074/jbc.273.52.35147; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; JORDAN CA, 1991, J VIROL, V65, P736, DOI 10.1128/JVI.65.2.736-742.1991; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kanzawa T, 2000, J NEUROSCI RES, V62, P383, DOI 10.1002/1097-4547(20001101)62:3<383::AID-JNR8>3.0.CO;2-6; Karnoub AE, 2001, MOL CELL BIOL, V21, P2847, DOI 10.1128/MCB.21.8.2847-2857.2001; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; Lu XB, 1996, CURR BIOL, V6, P1677, DOI 10.1016/S0960-9822(02)70792-6; MALY FE, 1994, J BIOL CHEM, V269, P18743; Marsh JW, 1999, ARCH BIOCHEM BIOPHYS, V365, P192, DOI 10.1006/abbi.1999.1208; Movilla N, 2001, ONCOGENE, V20, P8057, DOI 10.1038/sj.onc.1205000; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; PARK JW, 1992, J BIOL CHEM, V267, P17327; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Salmon P, 2000, BLOOD, V96, P3392; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sankarapandi S, 1998, ARCH BIOCHEM BIOPHYS, V353, P312, DOI 10.1006/abbi.1998.0658; SAWAI ET, 1995, J BIOL CHEM, V270, P15307, DOI 10.1074/jbc.270.25.15307; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Swingler S, 1999, NAT MED, V5, P997, DOI 10.1038/12433; WANG JF, 1993, ARCH BIOCHEM BIOPHYS, V304, P189, DOI 10.1006/abbi.1993.1338; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3; Xie Z, 2002, J NEUROSCI, V22, P3484; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	67	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42136	42143		10.1074/jbc.M200862200	http://dx.doi.org/10.1074/jbc.M200862200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12207012	hybrid, Green Published			2022-12-25	WOS:000178985300105
J	Takino, T; Yoshioka, K; Miyamori, H; Yamada, KM; Sato, H				Takino, T; Yoshioka, K; Miyamori, H; Yamada, KM; Sato, H			A scaffold protein in the c-Jun N-terminal kinase signaling pathway is associated with focal adhesion kinase and tyrosine-phosphorylated	ONCOGENE			English	Article						FAK; JSAP1; Src; tyrosine phosphorylation	PROMOTED CELL-MIGRATION; SRC FAMILY KINASES; NH2-TERMINAL KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; V-SRC; P130(CAS); FIBRONECTIN; ACTIVATION; AUTOPHOSPHORYLATION; INVOLVEMENT	Focal adhesion kinase (FAK) becomes activated and tyrosine-phosphorylated in response to cell adhesion to extracellular matrix proteins in a variety of cell types, and associates with a number of signaling molecules, structural proteins, and beta integrin cytoplasmic domains. Here we demonstrated that c-Jun N-terminal kinase (JNK)/stress activated protein kinase-associated protein 1 (JSAP1), a scaffold factor in the mitogen-activated protein kinase (MAPK) cascades, forms a complex with the N-terminus of FAK. The complex formation was further stimulated by c-Src, in which JSAP1 was tyrosine-phosphorylated and other FAK/Src signaling molecules were recruited. Fibronectin (FN) stimulation of cells expressing JSAP1 induced its tyrosine phosphorylation concomitant with association with FAK. Expression of JSAP1 in Hela cells facilitated formation of well-organized focal contacts and actin stress fibers, and promoted cell spreading onto FN. Taken together, these results suggest that JSAP1 is involved an integrin-mediated signaling pathway through FAK/Src by recruiting other signaling molecules, resulting in promotion of cell spreading onto FN.	Kanazawa Univ, Canc Res Inst, Div Mol Virol & Oncol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Div Cell Cycle Regulat, Kanazawa, Ishikawa 9200934, Japan; Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	Kanazawa University; Kanazawa University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Takino, T (corresponding author), Kanazawa Univ, Canc Res Inst, Div Mol Virol & Oncol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.		SATO, Hiroshi/D-8454-2015; TAKINO, Takahisa/D-8460-2015	Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000524, ZIADE000525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000525, Z01DE000524] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Ito M, 1999, MOL CELL BIOL, V19, P7539; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Verhey KJ, 2001, TRENDS BIOCHEM SCI, V26, P545, DOI 10.1016/S0968-0004(01)01931-4; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Vuori K, 1996, MOL CELL BIOL, V16, P2606; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697	28	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6488	6497		10.1038/sj.onc.1205840	http://dx.doi.org/10.1038/sj.onc.1205840			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226752	Green Submitted			2022-12-25	WOS:000177925300009
J	Im, E; von Lintig, FC; Chen, J; Zhuang, SH; Qui, WS; Chowdhury, S; Worley, PF; Boss, GR; Pilz, RB				Im, E; von Lintig, FC; Chen, J; Zhuang, SH; Qui, WS; Chowdhury, S; Worley, PF; Boss, GR; Pilz, RB			Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells	ONCOGENE			English	Article						Rheb; B-Raf kinase; MAP kinase; mammalian cells	EPIDERMAL GROWTH-FACTOR; SMALL GTPASES; A-RAF; PROTEIN; IDENTIFICATION; GENE; FIBROBLASTS; PATHWAY; YEAST; CAMP	Rheb (Ras homolog enriched in brain) is a member of the Ras family of proteins, and is in the immediate Ras/Rap/Ral subfamily. We found in three different mammalian cell lines that Rheb was highly activated, to levels much higher than for Ras or Rap 1, and that Rheb's activation state was unaffected by changes in growth conditions. Rheb's high activation was not secondary to unique glycine to arginine, or glycine to serine substitutions at positions 14 and 15, corresponding to Ras residues 12 and 13, since Rheb R14G and R14G, S15G mutants had similarly high activation levels as wild type Rheb. These data are consistent with earlier work which showed that purified Rheb has similar GTPase activity as Ras, and suggest a relative intracellular deficiency of Rheb GTPase activating proteins (GAPs) compared to Rheb activators. Further evidence for relatively low intracellular GAP activity was that increased Rheb expression led to a marked increase in Rheb activation. Rheb, like Ras and Rap1, bound B-Raf kinase, but in contrast to Ras and Rap 1, Rheb inhibited B-Raf kinase activity and prevented B-Raf-dependent activation of the transcription factor Elk-l. Thus, Rheb appears to be a unique member of the Ras/Rap/Ral subfamily, and in mammatian systems may serve to regulate B-Raf kinase activity.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Johns Hopkins University; Johns Hopkins University	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL CANCER INSTITUTE [R21CA081115, R21CA076968] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NCI NIH HHS [CA81115, CA76968] Funding Source: Medline; NIGMS NIH HHS [GM55586] Funding Source: Medline; NIMH NIH HHS [MH53608] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Dupuy AJ, 2001, J BIOL CHEM, V276, P11804, DOI 10.1074/jbc.M008970200; EYCHENE A, 1995, ONCOGENE, V10, P1159; Gromov PS, 1995, FEBS LETT, V377, P221, DOI 10.1016/0014-5793(95)01349-0; Guha A, 1996, ONCOGENE, V12, P507; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kuroda S, 1996, J BIOL CHEM, V271, P14680, DOI 10.1074/jbc.271.25.14680; Mach KE, 2000, GENETICS, V155, P611; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Mizuki N, 1996, GENOMICS, V34, P114, DOI 10.1006/geno.1996.0248; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Papin C, 1996, ONCOGENE, V12, P2213; PAPIN C, 1995, ONCOGENE, V10, P1647; Pilz RB, 1997, CELL GROWTH DIFFER, V8, P53; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; TIAN W, 2000, AM J PHYSIOL, V278, P372; Urano J, 2001, METHOD ENZYMOL, V333, P217; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; von Lintig FC, 2000, ONCOGENE, V19, P4029, DOI 10.1038/sj.onc.1203741; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921	43	107	112	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6356	6365		10.1038/sj.onc.1205792	http://dx.doi.org/10.1038/sj.onc.1205792			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214276				2022-12-25	WOS:000177829000012
J	Grazide, S; Maestre, N; Veldman, RJ; Bezombes, C; Maddens, S; Levade, T; Laurent, G; Jaffrezou, JP				Grazide, S; Maestre, N; Veldman, RJ; Bezombes, C; Maddens, S; Levade, T; Laurent, G; Jaffrezou, JP			Ara-C- and daunorubicin-induced recruitment of Lyn in sphingomyelinase-enriched membrane rafts	FASEB JOURNAL			English	Article						1-beta-D-arabinofuranosylcytosine; ceramide; apoptosis; Lyn kinase	INTERNUCLEOSOMAL DNA FRAGMENTATION; NEUTRAL SPHINGOMYELINASE; TYROSINE PHOSPHORYLATION; CERAMIDE GENERATION; INDUCED APOPTOSIS; PROTEIN; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; KINASE; ASSOCIATION; HYDROLYSIS	Induction of apoptosis by DNA-damaging agents such as 1-beta-D-arabinofuranosylcytosine (AraC) includes the activation of Lyn protein tyrosine kinase. We have previously established that Ara-C-induced activation of Lyn results in its binding to a neutral sphingomyelinase (SMase) and is requisite for its stimulation and the induction of apoptosis in U937 cells. However, the spacio-temporal organization of these events is unclear. This study demonstrates that part of the total cellular SMase activity is sequestered in sphingomyelin-enriched plasma membrane microdomains (rafts). Under Ara-C and daunorubicin (DNR) treatment, Lyn is rapidly activated and translocated into rafts. The compartmentalization of Lyn (as well as neutral SMase activation and apoptosis) induced by these drugs was blocked by the tyrosine kinase inhibitor herbimycin A and raft disruption. In conclusion, this study establishes that DNA-damaging agents such as AraC and DNR rapidly induce Lyn activation and its translocation into membrane rafts. This in turn leads to neutral SMase activation and raft-associated sphingomyelin hydrolysis with the concomitant generation of the proapoptotic lipid second messenger, ceramide. The apparent topological partitioning between DNA damage and apoptosis signaling (integrated into specialized plasma membrane domains) is discussed.	Inst Claudius Regaud, INSERM, E9910, F-31052 Toulouse, France; CHU Rangueil, INSERM, U466, Lab Biochim Med, F-31403 Toulouse, France; CHU Purpan, Hematol Serv, F-31059 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Jaffrezou, JP (corresponding author), Inst Claudius Regaud, INSERM, E9910, 20 Rue Pont St Pierre, F-31052 Toulouse, France.	jaffrezou@icr.fnclcc.fr	Levade, Thierry/O-8948-2014; Bezombes, christine/X-8479-2019; Bezombes, Christine/AAC-1724-2020; Bezombes, Christine/G-2743-2017	Bezombes, christine/0000-0003-4079-4872; 				Andrieu N, 1996, EUR J BIOCHEM, V236, P738, DOI 10.1111/j.1432-1033.1996.00738.x; Bettaieb A, 1996, BLOOD, V88, P1465, DOI 10.1182/blood.V88.4.1465.bloodjournal8841465; Bezombes C, 2001, FASEB J, V15, P1583, DOI 10.1096/fj.00-0787fje; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bodin S, 2001, BIOCHEMISTRY-US, V40, P15290, DOI 10.1021/bi0109313; Bradshaw CD, 1996, BIOCHEM MOL BIOL INT, V40, P709; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHABNER BA, 1989, CANC PRINCIPALS PRAC, P154; CHENG HC, 1991, J BIOL CHEM, V266, P17919; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; FRAM RJ, 1982, CANCER RES, V42, P4050; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; GUNJI H, 1991, CANCER RES, V51, P741; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAFFREZOU JP, 2002, PHOSPHOLID METABOLIS, V36, P269; Laurent G, 2001, BLOOD, V98, P913, DOI 10.1182/blood.V98.4.913; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; MYERS CE, 1990, CANC CHEMOTHERAPY PR, P356; QuilletMary A, 1996, LEUKEMIA, V10, P417; Sampath D, 2000, CANCER RES, V60, P6408; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STRUM JC, 1994, J BIOL CHEM, V269, P15493; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; Usami I, 1998, BIOCHEM PHARMACOL, V55, P185, DOI 10.1016/S0006-2952(97)00429-2; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041	40	37	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1685	+		10.1096/fj.01-0794fje	http://dx.doi.org/10.1096/fj.01-0794fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206990				2022-12-25	WOS:000177814000006
J	Yogev-Falach, M; Amit, T; Bar-Am, O; Weinstock, M; Youdim, MBH				Yogev-Falach, M; Amit, T; Bar-Am, O; Weinstock, M; Youdim, MBH			The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline	FASEB JOURNAL			English	Article						alpha-secretase; acetylcholinesterase inhibitors; signal transduction; Alzheimer's disease	ALPHA-SECRETASE CLEAVAGE; OXIDASE-B INHIBITOR; ANTI-PARKINSON DRUG; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; BETA-PROTEIN; CONVERTING-ENZYME; BRAIN; PHOSPHORYLATION; RIVASTIGMINE	Two novel neuroprotective cholinesterase (ChE) inhibitors, TV3326, (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate, and TV3279, (N-propargyl-(3S) aminoindan-5-yl)ethyl methyl carbamate, were derived from rasagiline for the treatment of Alzheimer's disease (AD). TV3326 also inhibits monoamine oxidase (MAO)-A and -B, whereas its S-isomer, TV3279, lacks MAO inhibitory activity. The action of these drugs in the regulation of amyloid precursor protein (APP) processing, using rat PC12 and human SH-SY5Y neuroblastoma cells, was examined. Both isomers stimulated the release of the non-amyloidogenic alpha-secretase form of soluble APP (sAPP) from these cell lines. The increases in sAPP induced by TV3326 and TV3279, were dose-dependent (0.1-100 muM) and blocked by the hydroxamic acid-based metalloprotease inhibitor, Ro31-9790, suggesting mediation via alpha-secretase activity. Using several signal transduction inhibitors, we identified the involvement of protein kinase C (PKC), mitogen-activated protein (MAP) kinase, and tyrosine kinase-dependent pathways in the enhancement of sAPP release by TV3326 and TV3279. In addition, both drugs directly induced the phosphorylation of p44 and p42 MAP kinase, which was abolished by the specific inhibitors of MAP kinase activation, PD98059 and U0126. These data suggest a novel pharmacological mechanism whereby these ChE inhibitors regulate the secretory processes of APP via activation of the MAP kinase pathway.	Technion Israel Inst Technol, Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Eve Topf Ctr Neurodegenerat Dis, Haifa, Israel; Technion Israel Inst Technol, Fac Med, NPF Ctr Neurodegenerat Dis, Haifa, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91010 Jerusalem, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Pharmacol, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il						Abu-Raya S, 1999, J NEUROSCI RES, V58, P456, DOI 10.1002/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bejar C, 1999, EUR J PHARMACOL, V383, P231, DOI 10.1016/S0014-2999(99)00643-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DAVIES B, 1993, CANCER RES, V53, P2087; DAVISSALINAS J, 1994, J BIOL CHEM, V269, P22623; Desai A, 2001, Expert Opin Pharmacother, V2, P653, DOI 10.1517/14656566.2.4.653; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finberg J P, 1999, Adv Neurol, V80, P495; Finberg JPM, 1998, NEUROREPORT, V9, P703; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Giacobini E, 1998, NEUROCHEM INT, V32, P413, DOI 10.1016/S0197-0186(97)00124-1; Giacobini E, 1996, ANN NY ACAD SCI, V777, P393, DOI 10.1111/j.1749-6632.1996.tb34451.x; Gouras GK, 2000, P NATL ACAD SCI USA, V97, P1202, DOI 10.1073/pnas.97.3.1202; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; HUNG AY, 1993, J BIOL CHEM, V268, P22959; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Krall WJ, 1999, ANN PHARMACOTHER, V33, P441, DOI 10.1345/aph.18211; Lamb HM, 2001, PHARMACOECONOMICS, V19, P303, DOI 10.2165/00019053-200119030-00008; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LeBlanc AC, 1998, J NEUROSCI, V18, P2907; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; Maruyama W, 2001, ANN NY ACAD SCI, V939, P320; Maruyama W, 2001, J NEUROCHEM, V78, P727, DOI 10.1046/j.1471-4159.2001.00448.x; MARUYAMA W, 2002, IN PRESS NEUROSCI LE; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Mills J, 1997, J NEUROSCI, V17, P9415; MORI F, 1995, NEUROREPORT, V6, P633, DOI 10.1097/00001756-199503000-00012; Morimoto T, 1998, J NEUROSCI RES, V51, P185, DOI 10.1002/(SICI)1097-4547(19980115)51:2<185::AID-JNR7>3.0.CO;2-9; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; NITSCH RM, 1993, ANN NY ACAD SCI, V695, P122, DOI 10.1111/j.1749-6632.1993.tb23039.x; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Pakaski M, 2001, NEUROCHEM INT, V38, P219, DOI 10.1016/S0197-0186(00)00091-7; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Racchi M, 1999, J NEUROCHEM, V72, P2464, DOI 10.1046/j.1471-4159.1999.0722464.x; Racchi M, 2001, MOL PSYCHIATR, V6, P520, DOI 10.1038/sj.mp.4000878; Rossner S, 2000, EUR J NEUROSCI, V12, P3191, DOI 10.1046/j.1460-9568.2000.00211.x; Savage MJ, 1998, J NEUROSCI, V18, P1743; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMALL DH, 1994, J NEUROSCI, V14, P2117; Solano DC, 2000, FASEB J, V14, P1015, DOI 10.1096/fasebj.14.7.1015; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Vincent B, 2001, J BIOL CHEM, V276, P37743; Weinstock M, 1999, CNS DRUGS, V12, P307, DOI 10.2165/00023210-199912040-00005; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.3.CO;2-Q; Weinstock M, 2001, ANN NY ACAD SCI, V939, P148; WEINSTOCK M, 2000, J NEURAL TRANSM-SUPP, V60, pS157; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Youdim MBH, 2001, BRIT J PHARMACOL, V132, P500, DOI 10.1038/sj.bjp.0703826; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; YOUDIM MBH, 1999, NEUROSCI LETT, V54, pS45	80	107	111	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1674	+		10.1096/fj.02-0198fje	http://dx.doi.org/10.1096/fj.02-0198fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206996				2022-12-25	WOS:000177814000010
J	Ishizaka, S; Shiroi, A; Kanda, S; Yoshikawa, M; Tsujinoue, H; Kuriyama, S; Hasuma, T; Nakatani, K; Takahashi, K				Ishizaka, S; Shiroi, A; Kanda, S; Yoshikawa, M; Tsujinoue, H; Kuriyama, S; Hasuma, T; Nakatani, K; Takahashi, K			Development of hepatocytes from embryonic stem cells after transfection with the HNF-3 beta gene	FASEB JOURNAL			English	Article						ES cells; differentiation	LONG-TERM CULTURE; RAT HEPATOCYTES; IN-VITRO; GROWTH-FACTOR; LIVER; TRANSCRIPTION; EXPRESSION; DIFFERENTIATION; ORGANIZATION; MAINTENANCE	We have attempted to generate embryonic stem (ES) cell-derived hepatocytes expressing liver-specific functional properties by use of ES cell technology. It was found that ES cells are allowed to differentiate into hepatocytes possessing high metabolic activities when hepatocyte nuclear factor (HNF)-3beta-transfected ES cells are cultured in alpha-MEM medium supplemented with 10% fetal bovine serum (FBS) and fibroblast growth factor (FGF)-2 in the three-dimensional cell culture system at 5% CO2. The differentiated cells induced albumin, triacylglycerol, urea, and glycogen synthesis as well as further expression of metabolic proteins and serum factors as markers of hepatocytic differentiation for at least 4 months. The cells differentiated from HNF-3beta-transfected ES cells also had hepatocyte-like ultrastructural characteristics, including several endoplasmic reticula, mitochondrion, and glycogen. Our findings indicate that generation of hepatocytes maintaining high metabolic functions developed from mouse ES cells will facilitate the study of the basic mechanism for hepatogenesis and will certainly provide new opportunities for tissue transplantation.	Nara Med Univ, Program Tissue Engn, Kashihara, Nara 6348521, Japan; Nara Med Univ, Dept Parasitol, Kashihara, Nara 6348521, Japan; Nara Med Univ, Dept Internal Med 3, Kashihara, Nara 6348521, Japan; Osaka City Univ, Sch Med, Dept Biochem 2, Osaka 558, Japan; Osaka City Univ, Sch Med, Dept Anat, Osaka 558, Japan; Osaka Prefecture Coll Hlth Sci, Dept Anat & Physiol, Osaka, Japan	Nara Medical University; Nara Medical University; Nara Medical University; Osaka Metropolitan University; Osaka Metropolitan University	Ishizaka, S (corresponding author), Nara Med Univ, Program Tissue Engn, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.	ishizaka@naramed-u.ac.jp						Abe K, 1996, EXP CELL RES, V229, P27, DOI 10.1006/excr.1996.0340; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Chen HL, 1998, J BIOMED SCI, V5, P435, DOI 10.1007/BF02255932; CHEN LH, 1989, ANTICANCER RES, V9, P1069; CHIST B, BIOL CHEM HOPPE SEYL, V371, P395; DEJUAN C, 1992, EXP CELL RES, V202, P495, DOI 10.1016/0014-4827(92)90104-G; DEJUAN C, 1992, J CELL PHYSIOL, V152, P95, DOI 10.1002/jcp.1041520113; DIAMANTSTEIN T, 1982, INT ARCH ALLER A IMM, V68, P377, DOI 10.1159/000233129; DUERDEN JM, 1989, BIOCHEM J, V263, P937, DOI 10.1042/bj2630937; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Funatsu K, 2001, ARTIF ORGANS, V25, P194, DOI 10.1046/j.1525-1594.2001.025003194.x; Glicklis R, 2000, BIOTECHNOL BIOENG, V67, P344, DOI 10.1002/(SICI)1097-0290(20000205)67:3<344::AID-BIT11>3.0.CO;2-2; GUIGUET M, 1987, IN VITRO CELL DEV B, V23, P821; HALLETT CJ, 1971, CLIN CHIM ACTA, V35, P33, DOI 10.1016/0009-8981(71)90289-0; Halpner AD, 1998, ARCH BIOCHEM BIOPHYS, V359, P305, DOI 10.1006/abbi.1998.0914; Hamazaki T, 2001, FEBS LETT, V497, P15, DOI 10.1016/S0014-5793(01)02423-1; Holzinger A, 1998, FEBS LETT, V433, P179, DOI 10.1016/S0014-5793(98)00873-4; INOUE C, 1989, J BIOL CHEM, V264, P4747; Jover R, 1996, MOL PHARMACOL, V50, P474; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Kaibori M, 1998, HEPATOLOGY, V27, P1354, DOI 10.1002/hep.510270523; LANDRY J, 1985, J CELL BIOL, V101, P914, DOI 10.1083/jcb.101.3.914; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; LevinsonDushnik M, 1997, MOL CELL BIOL, V17, P3817, DOI 10.1128/MCB.17.7.3817; Li JX, 2000, GENE DEV, V14, P464; Marc N, 2000, EUR J BIOCHEM, V267, P963, DOI 10.1046/j.1432-1327.2000.01083.x; Mori T, 1997, BIOMATERIALS, V18, P947, DOI 10.1016/S0142-9612(97)00017-3; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Overturf K, 1999, AM J PATHOL, V155, P2135, DOI 10.1016/S0002-9440(10)65531-9; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PRUDDEN JF, 1970, AM J SURG, V119, P560, DOI 10.1016/0002-9610(70)90175-3; Puviani AC, 1999, INT J ARTIF ORGANS, V22, P778, DOI 10.1177/039139889902201112; Ranucci CS, 1999, TISSUE ENG, V5, P407, DOI 10.1089/ten.1999.5.407; ROSENBERG MR, 1982, IN VITRO CELL DEV B, V18, P775; Sakai Y, 1996, CELL TRANSPLANT, V5, pS41, DOI 10.1016/0963-6897(96)00037-1; SCHUDT C, 1979, EUR J BIOCHEM, V97, P155, DOI 10.1111/j.1432-1033.1979.tb13097.x; Shibata Y, 1998, J IMMUNOL, V161, P4283; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPAYD RW, 1978, CLIN CHEM, V24, P1343; STEWARD AR, 1985, MOL PHARMACOL, V27, P125; TONG JZ, 1992, EXP CELL RES, V200, P326, DOI 10.1016/0014-4827(92)90179-C; VANHARKEN DR, 1969, J BIOL CHEM, V244, P2278; Wang Q, 1998, AM J PHYSIOL-REG I, V275, pR1584, DOI 10.1152/ajpregu.1998.275.5.R1584; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yanagi K, 1998, ASAIO J, V44, pM436, DOI 10.1097/00002480-199809000-00022; Zaret KS, 2000, MECH DEVELOP, V92, P83, DOI 10.1016/S0925-4773(99)00326-3; ZHENG Q, 1990, PEDIATR RES, V32, P714	49	100	117	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1444	+		10.1096/fj.01-0806fje	http://dx.doi.org/10.1096/fj.01-0806fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205042	Bronze			2022-12-25	WOS:000177813100017
J	Piccioni, F; Pinton, P; Simeoni, S; Pozzi, P; Fascio, U; Vismara, G; Martini, L; Rizzuto, R; Poletti, A				Piccioni, F; Pinton, P; Simeoni, S; Pozzi, P; Fascio, U; Vismara, G; Martini, L; Rizzuto, R; Poletti, A			Androgen receptor with elongated polyglutamine tract forms aggregates that alter axonal trafficking and mitochondrial distribution in motoneuronal processes	FASEB JOURNAL			English	Article						triplet repeats; fast axonal transport; kinesin; neurodegeneration; spinal bulbar muscular atrophy	BULBAR MUSCULAR-ATROPHY; NEURONAL INTRANUCLEAR INCLUSIONS; EXPANDED-POLYGLUTAMINE; HUNTINGTONS-DISEASE; TRANSGENIC MICE; NUCLEAR INCLUSIONS; CAG REPEAT; CELL-DEATH; NEURODEGENERATIVE DISEASES; 5-ALPHA-REDUCTASE TYPE-2	The CAG/polyglutamine (polyGln)-related diseases include nine different members that together form the most common class of inherited neurodegenerative disorders; neurodegeneration is linked to the same type of mutation, found in unrelated genes, consisting of an abnormal expansion of a polyGln tract normally present in the wild-type proteins. Nuclear, cytoplasmic, or neuropil aggregates are detectable in CAG/polyGln-related diseases, but their role is still debated. Alteration of the androgen receptor (AR), one of these proteins, has been linked to spinal and bulbar muscular atrophy, an X-linked recessive disease characterized by motoneuronal death. By using immortalized motoneuronal cells (the neuroblastoma-spinal cord cell line NSC34), we analyzed neuropil aggregate formation and toxicity: green fluorescent protein-tagged wild-type or mutated ARs were cotransfected into NSC34 cells with a blue fluorescent protein tagged to mitochondria. Altered mitochondrial distribution was observed in neuronal processes containing aggregates; occasionally, neuropil aggregates and mitochondrial concentration corresponded to axonal swelling. Neuropil aggregates also impaired the distribution of the motor protein kinesin. These data suggest that neuropil aggregates may physically alter neurite transport and thus deprive neuronal processes of factors or components that are important for axonal and dendritic functions. The soma may then be affected, leading to neuronal dysfunctions and possibly to cell death.	Univ Milan, Ctr Excellence Study Treatment Neurodegenerat Dis, Ist Endocrinol, I-20133 Milan, Italy; Univ Ferrara, ICSI, I-44100 Ferrara, Italy; Univ Ferrara, TCCI, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Univ Milan, Dept Biol, Sect Zool, I-20133 Milan, Italy; Univ Milan, Interdisciplinary Ctr Adv Microscopy, I-20133 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Milan; University of Ferrara; University of Ferrara; University of Milan; University of Milan	Poletti, A (corresponding author), Univ Milan, Ctr Excellence Study Treatment Neurodegenerat Dis, Ist Endocrinol, Via Balzaretti 9, I-20133 Milan, Italy.	Angelo.Poletti@unimi.it	Pinton, Paolo/J-8025-2012; Rizzuto, Rosario/B-6312-2008; Poletti, Angelo/A-9016-2011	Pinton, Paolo/0000-0001-7108-6508; Poletti, Angelo/0000-0002-8883-0468; Rizzuto, Rosario/0000-0001-7044-5097	Telethon [1283] Funding Source: Medline	Telethon(Fondazione Telethon)		Abdullah AAR, 1998, HUM MOL GENET, V7, P379, DOI 10.1093/hmg/7.3.379; Adachi H, 2001, HUM MOL GENET, V10, P1039, DOI 10.1093/hmg/10.10.1039; Altschuler EL, 1997, J PEPT RES, V50, P73; Andrew SE, 1997, HUM MOL GENET, V6, P2005, DOI 10.1093/hmg/6.12.2005; Brooks BP, 1997, NEUROBIOL DIS, V3, P313, DOI 10.1006/nbdi.1997.0126; Butler R, 1998, HUM MOL GENET, V7, P121, DOI 10.1093/hmg/7.1.121; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; Choong CS, 1998, J MOL ENDOCRINOL, V21, P235, DOI 10.1677/jme.0.0210235; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Davies SW, 1998, LANCET, V351, P131, DOI 10.1016/S0140-6736(97)08360-8; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DURHAM HD, 1993, NEUROTOXICOLOGY, V14, P387; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Fischbeck KH, 2001, BRAIN RES BULL, V56, P161, DOI 10.1016/S0361-9230(01)00577-9; Fischbeck KH, 1997, J INHERIT METAB DIS, V20, P152, DOI 10.1023/A:1005344403603; Gallo JM, 2001, BRAIN RES BULL, V56, P209, DOI 10.1016/S0361-9230(01)00575-5; Gao TS, 1996, J STEROID BIOCHEM, V59, P9, DOI 10.1016/S0960-0760(96)00097-0; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; HARRY GJ, 1992, MOL NEUROBIOL, V6, P203; Hirakura Y, 2000, J NEUROSCI RES, V60, P490, DOI 10.1002/(SICI)1097-4547(20000515)60:4<490::AID-JNR7>3.0.CO;2-9; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hurd DD, 1996, GENETICS, V144, P1075; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Jones AL, 1997, J INHERIT METAB DIS, V20, P125, DOI 10.1023/A:1005340302695; KAZEMIESFARJANI P, 1995, HUM MOL GENET, V4, P523, DOI 10.1093/hmg/4.4.523; KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; LASPADA AR, 1992, NAT GENET, V2, P301, DOI 10.1038/ng1292-301; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Li H, 1999, HUM MOL GENET, V8, P1227, DOI 10.1093/hmg/8.7.1227; Li I, 1998, AM J PATHOL, V153, P695, DOI 10.1016/S0002-9440(10)65612-X; Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216; Lieberman AP, 1998, LANCET, V351, P884, DOI 10.1016/S0140-6736(05)70296-8; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Merry DE, 2001, BRAIN RES BULL, V56, P203, DOI 10.1016/S0361-9230(01)00594-9; Merry DE, 1998, HUM MOL GENET, V7, P693, DOI 10.1093/hmg/7.4.693; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; Monoi H, 2000, BIOPHYS J, V78, P2892, DOI 10.1016/S0006-3495(00)76830-5; Morrison PJ, 1998, CLIN GENET, V53, P276; Moulder KL, 1999, J NEUROSCI, V19, P705; Nagai Y, 1999, ANN NY ACAD SCI, V893, P192, DOI 10.1111/j.1749-6632.1999.tb07826.x; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; Onodera O, 1997, BIOCHEM BIOPH RES CO, V238, P599, DOI 10.1006/bbrc.1997.7337; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; PERUTZ M, 1994, PROTEIN SCI, V3, P1629, DOI 10.1002/pro.5560031002; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Piccioni F, 2001, BRAIN RES BULL, V56, P215, DOI 10.1016/S0361-9230(01)00652-9; Poletti A, 1998, ENDOCRINOLOGY, V139, P2171, DOI 10.1210/en.139.4.2171; Poletti A, 2001, J NEUROENDOCRINOL, V13, P353, DOI 10.1046/j.1365-2826.2001.00635.x; POLETTI A, 1999, RRD NEUROCHEMISTRY 2, V2, P507; Rigamonti D, 2001, J BIOL CHEM, V276, P14545, DOI 10.1074/jbc.C100044200; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Sculptoreanu A, 2000, MOL CELL BIOCHEM, V203, P23, DOI 10.1023/A:1007010020228; Simeoni S, 2000, HUM MOL GENET, V9, P133, DOI 10.1093/hmg/9.1.133; Singhrao SK, 1998, EXP NEUROL, V150, P213, DOI 10.1006/exnr.1998.6778; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Toyoshima I, 1998, J NEUROL SCI, V159, P38, DOI 10.1016/S0022-510X(98)00137-3; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; Yagishita S, 1997, PATHOL INT, V47, P1, DOI 10.1111/j.1440-1827.1997.tb04429.x; Zhang B, 1997, J CELL BIOL, V139, P1307, DOI 10.1083/jcb.139.5.1307; Zhao C, 2001, CELL, V105, P587, DOI 10.1016/S0092-8674(01)00363-4; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	79	88	91	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1418	+		10.1096/fj.01-1035fje	http://dx.doi.org/10.1096/fj.01-1035fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205033	Bronze			2022-12-25	WOS:000177813100010
